<?xml version="1.0" encoding="UTF-8"?>
<projectSnippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4246609/results/search/inn/results.xml">
   <result pre="calponin, and negative for expression of the estrogen receptor and" exact="progesterone" post="receptor. Based on the result, an ipsilateral selective neck"/>
   <result pre="(CK-H), CK8/CK18, p63, calponin, the estrogen receptor (ER) and the" exact="progesterone" post="receptor (PR). The patient experienced no complications during post-operative"/>
   <result pre="1) suggested that certain individuals with advanced SDC treated with" exact="trastuzumab" post="(an anti-HER2 monoclonal antibody) demonstrated promising results. Therefore, patients"/>
   <result pre="may benefit from targeted therapies using anti-HER2 monoclonal antibodies, including" exact="trastuzumab" post="and pertuzumab, or HER2 tyrosine kinase inhibitors, such as"/>
   <result pre="HER2 human epidermal growth factor receptor-2 ER estrogen receptor PR" exact="progesterone" post="receptor CK cytokeratin References References 1 Kleinsasser O Klein"/>
   <result pre="K Pitkin L Carcinoma ex pleomorphic adenoma successfully treated with" exact="trastuzumab" post="and radiotherapy Virchows Arch 461 Suppl 1 S144 2012"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4261061/results/search/inn/results.xml">
   <result pre="neither PRKACA nor PIM1 restored MAPK or PI3K activation after" exact="lapatinib" post="or trastuzumab treatment, but rather inactivated the pro-apoptotic protein"/>
   <result pre="nor PIM1 restored MAPK or PI3K activation after lapatinib or" exact="trastuzumab" post="treatment, but rather inactivated the pro-apoptotic protein BAD, thereby"/>
   <result pre="effects conferred by PRKACA and PIM1, and sensitized cells to" exact="lapatinib" post="treatment. These observations suggest that combined targeting of HER2"/>
   <result pre="associated with poor prognosis, and perturbation of HER2 signaling with" exact="trastuzumab" post="or lapatinib has led to clinical benefit in HER2-positive"/>
   <result pre="poor prognosis, and perturbation of HER2 signaling with trastuzumab or" exact="lapatinib" post="has led to clinical benefit in HER2-positive breast cancer"/>
   <result pre="that failed to achieve a pathological complete remission (pCR) after" exact="trastuzumab" post="plus docetaxel neoadjuvant chemotherapy from those that did achieve"/>
   <result pre="to achieve a pathological complete remission (pCR) after trastuzumab plus" exact="docetaxel" post="neoadjuvant chemotherapy from those that did achieve a pCR"/>
   <result pre="We validated our findings by performing dose titration curves for" exact="lapatinib" post="in the setting of ectopic PRKACA expression in three"/>
   <result pre="BT474, SKBr3, and ZR-75-30 cells propagated in the presence of" exact="lapatinib" post="( Fig. 1B). PRKACA expression also increased the viability"/>
   <result pre="( Fig. S4). By counting viable cells, we found that" exact="lapatinib" post="treatment of control cells expressing LACZ resulted in cell"/>
   <result pre="PRKACA expression interferes with lapatinib-induced apoptosis. We found that, indeed," exact="lapatinib" post="treatment induced caspase 3/7 cleavage, and this event was"/>
   <result pre="BT474). These findings indicate that PRKACA rescues HER2-amplified cells from" exact="lapatinib" post="treatment at least in part through the restoration of"/>
   <result pre="We then investigated mechanism(s) by which PRKACA conferred resistance to" exact="trastuzumab" post="and lapatinib treatment. Since HER2 is thought to signal"/>
   <result pre="investigated mechanism(s) by which PRKACA conferred resistance to trastuzumab and" exact="lapatinib" post="treatment. Since HER2 is thought to signal primarily through"/>
   <result pre="activation of these pathways in the presence of AEE788 or" exact="lapatinib" post="in BT474 cells transduced with a control ORF, LACZ."/>
   <result pre="dose-dependent manner in these cells in response to AEE788 and" exact="lapatinib" post="( Fig. 2A). Transduction of HRASV12 into BT474s prior"/>
   <result pre="AEE788 treatment and had no effect at the doses of" exact="lapatinib" post="tested. These observations may be the result of the"/>
   <result pre="BAD, and GSK3 in PRKACA-overexpressing cells in the context of" exact="trastuzumab" post="or lapatinib treatment. We found that phosphorylation of BAD"/>
   <result pre="GSK3 in PRKACA-overexpressing cells in the context of trastuzumab or" exact="lapatinib" post="treatment. We found that phosphorylation of BAD at ser112"/>
   <result pre="of BAD at ser112 and ser136 was strikingly diminished by" exact="lapatinib" post="treatment, and was also inhibited by trastuzumab treatment ("/>
   <result pre="strikingly diminished by lapatinib treatment, and was also inhibited by" exact="trastuzumab" post="treatment ( Fig. 2C). In contrast, exposure to lapatinib"/>
   <result pre="by trastuzumab treatment ( Fig. 2C). In contrast, exposure to" exact="lapatinib" post="or trastuzumab failed to affect the phosphorylation of β-catenin"/>
   <result pre="treatment ( Fig. 2C). In contrast, exposure to lapatinib or" exact="trastuzumab" post="failed to affect the phosphorylation of β-catenin or GSK3-beta"/>
   <result pre="by PRKACA overexpression, but were not decreased by exposure to" exact="lapatinib" post="or AEE788 ( Fig. 2C). Phosphorylation of BAD at"/>
   <result pre="of BAD at ser112 and ser136 in the setting of" exact="lapatinib" post="treatment was fully restored by PRKACA expression in BT474,"/>
   <result pre="not restore MAPK or PI3K signaling in the context of" exact="lapatinib" post="treatment, PRKACA expression in SKBr3 or ZR-75-30 cells failed"/>
   <result pre="mTOR, and p70-S6K ( Fig. 2D). These observations suggest that" exact="lapatinib" post="and trastuzumab exert some of their inhibitory effects on"/>
   <result pre="p70-S6K ( Fig. 2D). These observations suggest that lapatinib and" exact="trastuzumab" post="exert some of their inhibitory effects on HER2-positive cells"/>
   <result pre="activity of PRKACA was required for the observed phenotypes of" exact="lapatinib" post="resistance and BAD phosphorylation. Expression of a kinase-dead PRKACA"/>
   <result pre="( 30) failed to rescue ZR-75-30 or SKBr3 cells from" exact="lapatinib" post="treatment, whereas both a V5-tagged and untagged (closed) version"/>
   <result pre="PRKACA is required for the observed phenotypes of rescue from" exact="lapatinib" post="and of BAD phosphorylation. To confirm that the phenotypes"/>
   <result pre="PRKACA. Forskolin pre-treatment of ZR-75-30 cells resulted in resistance to" exact="lapatinib" post="treatment ( Fig. S5A) as well as restoration of"/>
   <result pre="found that high levels of PRKACA expression conferred resistance to" exact="lapatinib" post="and trastuzumab treatment, we wished to determine whether PRKACA"/>
   <result pre="high levels of PRKACA expression conferred resistance to lapatinib and" exact="trastuzumab" post="treatment, we wished to determine whether PRKACA is overexpressed"/>
   <result pre="shown ( Fig. 3C, panel e). She was treated with" exact="trastuzumab" post="plus vinorelbine, with an excellent response in both the"/>
   <result pre="with our functional data demonstrating that PRKACA confers resistance to" exact="trastuzumab" post="and lapatinib in HER2-amplified breast cancer cells, these observations"/>
   <result pre="functional data demonstrating that PRKACA confers resistance to trastuzumab and" exact="lapatinib" post="in HER2-amplified breast cancer cells, these observations strongly suggest"/>
   <result pre="cells, these observations strongly suggest that PRKACA overexpression contributes to" exact="trastuzumab" post="resistance in a subset of human breast cancers. The"/>
   <result pre="present in the metastatic disease is unknown. These patients received" exact="trastuzumab" post="and/or lapatinib-based treatment in the metastatic setting, and were"/>
   <result pre="therapy. We first confirmed that PIM1 rescues HER2-amplified cells from" exact="lapatinib" post="and trastuzumab treatment ( Fig. 4A and 4C). We"/>
   <result pre="first confirmed that PIM1 rescues HER2-amplified cells from lapatinib and" exact="trastuzumab" post="treatment ( Fig. 4A and 4C). We further found"/>
   <result pre="expression restores BAD phosphorylation at ser112 in the presence of" exact="lapatinib" post="( Fig. 4D) and also inhibits lapatinib-induced apoptosis ("/>
   <result pre="Indeed, we found that overexpression of BCL-XL rescues cells from" exact="lapatinib" post="treatment ( Fig. 4B, 4C). We therefore hypothesized that"/>
   <result pre="its own had no effect on cell viability, synergized with" exact="lapatinib" post="to cause increased cell death ( Fig. 4E and"/>
   <result pre="Furthermore, the addition of this drug also partially abrogated the" exact="lapatinib" post="rescue effect conferred by PRKACA, PIM1, and BCL-XL ("/>
   <result pre="hypothesis that activation of BCL-2/BCL-XL at least partially underlies the" exact="lapatinib" post="resistance conferred by PIM1 and PRKACA overexpression, and suggest"/>
   <result pre="the introduction of the anti-HER2 drugs trastuzumab, lapatinib, pertuzumab, and" exact="trastuzumab" post="emtansine, such cancers remain nearly universally fatal once metastasis"/>
   <result pre="of PKA, PRKAR2A, has been reported to confer resistance to" exact="trastuzumab" post="in HER2-amplified cells in vitro ( 37). Both PRKACA"/>
   <result pre="survival signaling through inactivation of BAD. We found that both" exact="lapatinib" post="and trastuzumab treatment of HER2-positive breast cancer cells results"/>
   <result pre="through inactivation of BAD. We found that both lapatinib and" exact="trastuzumab" post="treatment of HER2-positive breast cancer cells results in BAD"/>
   <result pre="therapy. Our finding that the BCL-XL/BCL-2 inhibitor ABT-263 synergizes with" exact="lapatinib" post="in HER2-amplified cells supports this hypothesis. Indeed, recent work"/>
   <result pre="work showed that blockade of this pathway also synergizes with" exact="tamoxifen" post="in ER-positive breast cancers, suggesting that co-targeting of BCL-XL/BCL-2"/>
   <result pre="and have demonstrated that PRKACA overexpression leads to resistance to" exact="trastuzumab" post="and lapatinib. We have also identified PIM1 as a"/>
   <result pre="C, followed by a change to media with or without" exact="puromycin" post="(pLKO) or blasticidin (pLX303 and pLX304). Puromycin doses were"/>
   <result pre="confirmed by sequencing. AEE788 was a generous gift from Novartis," exact="lapatinib" post="(Tykerb) was purchased from Selleck Chemicals, ABT-263 (Navitoclax) was"/>
   <result pre="Chemicals, ABT-263 (Navitoclax) was purchased from Toronto Research Chemicals, and" exact="trastuzumab" post="(Herceptin) was purchased from the Dana-Farber Cancer Institute pharmacy."/>
   <result pre="E Schwartzberg LS Arbushites MC Maltzman JD et al. Single-agent" exact="lapatinib" post="for HER2-overexpressing advanced or metastatic breast cancer that progressed"/>
   <result pre="Harris LN Fehrenbacher L et al. Efficacy and safety of" exact="trastuzumab" post="as a single agent in first-line treatment of HER2-overexpressing"/>
   <result pre="to tumor inhibition by trastuzumab, and loss of PTEN predicts" exact="trastuzumab" post="resistance in patients Cancer Cell 2004 8 6 2"/>
   <result pre="approach identifies the PI3K pathway as a major determinant of" exact="trastuzumab" post="resistance in breast cancer Cancer Cell 2007 10 12"/>
   <result pre="et al. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with" exact="trastuzumab" post="response and survival in patients with HER2-positive metastatic breast"/>
   <result pre="and tensin homolog or phosphoinositol-3 kinase activation and response to" exact="trastuzumab" post="or lapatinib in human epidermal growth factor receptor 2-overexpressing"/>
   <result pre="homolog or phosphoinositol-3 kinase activation and response to trastuzumab or" exact="lapatinib" post="in human epidermal growth factor receptor 2-overexpressing locally advanced"/>
   <result pre="J et al. Cyclin E amplification/overexpression is a mechanism of" exact="trastuzumab" post="resistance in HER2+ breast cancer patients Proc Natl Acad"/>
   <result pre="P Guo H Poh SB Brady SW et al. Combating" exact="trastuzumab" post="resistance by targeting SRC, a common node downstream of"/>
   <result pre="M Nijkamp W et al. Phosphatidylinositol 3-kinase hyperactivation results in" exact="lapatinib" post="resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor"/>
   <result pre="11035810 30 Iyer GH Moore MJ Taylor SS Consequences of" exact="lysine" post="72 mutation on the phosphorylation and activation state of"/>
   <result pre="Chan S Romieu CG Pienkowski T et al. Lapatinib plus" exact="capecitabine" post="for HER2-positive advanced breast cancer N Engl J Med"/>
   <result pre="Im SA Hegg R Im YH et al. Pertuzumab plus" exact="trastuzumab" post="plus docetaxel for metastatic breast cancer N Engl J"/>
   <result pre="Hegg R Im YH et al. Pertuzumab plus trastuzumab plus" exact="docetaxel" post="for metastatic breast cancer N Engl J Med 2012"/>
   <result pre="Tretiakova M Lin L et al. Phase II trial of" exact="temsirolimus" post="in patients with metastatic breast cancer Breast Cancer Res"/>
   <result pre="Moore JA Flores PR et al. Phase I/II study of" exact="trastuzumab" post="in combination with everolimus (RAD001) in patients with HER2-overexpressing"/>
   <result pre="et al. Phase I/II study of trastuzumab in combination with" exact="everolimus" post="(RAD001) in patients with HER2-overexpressing metastatic breast cancer who"/>
   <result pre="G Kane SE Protein kinase A activation confers resistance to" exact="trastuzumab" post="in human breast cancer cell lines Clin Cancer Res"/>
   <result pre="lapatinib. Cells were lentivirally-transduced with the indicated ORFs, treated with" exact="lapatinib" post="at the indicated doses, and cell viability was assessed"/>
   <result pre="transduced with LACZ or PRKACA constructs and subsequently treated with" exact="lapatinib" post="5 uM or DMSO. Viable cells were counted by"/>
   <result pre="Cells were transduced with the indicated ORFs. Two days later" exact="lapatinib" post="10 uM or DMSO was added, and caspase 3/7"/>
   <result pre="AKT signaling, but does restore BAD phosphorylation. A. AEE788 or" exact="lapatinib" post="treatment decreases p-ERK and p-AKT levels in HER2-amplified cells,"/>
   <result pre="each of the V5-tagged ORFs, as indicated. C. Lapatinib or" exact="trastuzumab" post="treatment results in loss of BAD phosphorylation, which is"/>
   <result pre="with the indicated pLX304 constructs, blasticidin selected, and treated with" exact="lapatinib" post="0.1 uM or trastuzumab 10 ug/ml for 24 h."/>
   <result pre="constructs, blasticidin selected, and treated with lapatinib 0.1 uM or" exact="trastuzumab" post="10 ug/ml for 24 h. Protein lysates were harvested"/>
   <result pre="CREB immunoblots were run on the same gel, but the" exact="lapatinib" post="and trastuzumab lanes were run in inverse orientation from"/>
   <result pre="were run on the same gel, but the lapatinib and" exact="trastuzumab" post="lanes were run in inverse orientation from the other"/>
   <result pre="restored by PRKACA overexpression in multiple HER2-positive cell lines after" exact="lapatinib" post="treatment. SKBr3 and ZR-75-30 cells were lentivirally-transduced with pLX304"/>
   <result pre="expressing LACZ or PRKACA, blasticidin selected, and then treated with" exact="lapatinib" post="0.1 uM or DMSO for 24 h prior to"/>
   <result pre="kinase activity of PRKACA is required to confer resistance against" exact="lapatinib" post="and for BAD phosphorylation. A closed (untagged) kinase-dead mutant"/>
   <result pre="as well as a LACZ control. Cells were treated with" exact="lapatinib" post="at the indicated doses or DMSO and viability was"/>
   <result pre="LAZ. After blasticidin selection cells were treated with DMSO or" exact="lapatinib" post="0.1 uM for 24 h. Protein lysates were harvested"/>
   <result pre="analysis with the indicated antibodies. C. PRKACA is overexpressed in" exact="trastuzumab" post="resistant human breast cancers. Immunohistochemical analysis for PRKACA expression"/>
   <result pre="Two days later they were treated with increasing doses of" exact="lapatinib" post="(left panel) or trastuzumab (right panel), and cell viability"/>
   <result pre="were treated with increasing doses of lapatinib (left panel) or" exact="trastuzumab" post="(right panel), and cell viability was assessed by ATP-based"/>
   <result pre="the V5-tagged ORFs. D. PIM1 restores BAD ser112 phosphorylation after" exact="lapatinib" post="treatment. ZR-75-30 cells were lentivirally-transduced with the indicated pLX304"/>
   <result pre="indicated pLX304 constructs, blasticidin selected, and treated with DMSO or" exact="lapatinib" post="0.1 uM for 24h. Protein lysates were harvested and"/>
   <result pre="antibodies. E. Pharmacological blockade of BCL-2 and BCL-XL synergizes with" exact="lapatinib" post="treatment and partially abrogates the rescue effect conferred by"/>
   <result pre="constructs, ZR-75-30 cells were treated with the indicated doses of" exact="lapatinib" post="and ABT-263 or DMSO. Cell viability was read out"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4293298/results/search/inn/results.xml">
   <result pre="patients, ie, a higher degree of estrogen receptor (ER) and" exact="progesterone" post="receptor expression (81% of patients ≥70 years of age"/>
   <result pre="therapy with chemotherapy. 37, 38 The first study 37 compared" exact="anastrozole" post="or exemestane for 3 months with doxorubicin plus paclitaxel"/>
   <result pre="chemotherapy. 37, 38 The first study 37 compared anastrozole or" exact="exemestane" post="for 3 months with doxorubicin plus paclitaxel for four"/>
   <result pre="study 37 compared anastrozole or exemestane for 3 months with" exact="doxorubicin" post="plus paclitaxel for four cycles in older postmenopausal patients"/>
   <result pre="compared anastrozole or exemestane for 3 months with doxorubicin plus" exact="paclitaxel" post="for four cycles in older postmenopausal patients with hormone"/>
   <result pre="(33% versus 24%, P=0.58). In the second study, 38 comparing" exact="epirubicin" post="plus cyclophosphamide for four cycles versus exemestane for 24"/>
   <result pre="24%, P=0.58). In the second study, 38 comparing epirubicin plus" exact="cyclophosphamide" post="for four cycles versus exemestane for 24 weeks, a"/>
   <result pre="study, 38 comparing epirubicin plus cyclophosphamide for four cycles versus" exact="exemestane" post="for 24 weeks, a greater clinical response rate with"/>
   <result pre="1.29), and BCS rate (relative risk 1.36). Anastrozole, letrozole, and" exact="exemestane" post="can be used ( Table 1). Continuing letrozole in"/>
   <result pre="letrozole, and exemestane can be used ( Table 1). Continuing" exact="letrozole" post="in responding patients beyond 3–4 months achieves a further"/>
   <result pre="exist concerning neoadjuvant chemotherapy in the geriatric setting. Chemotherapy and" exact="trastuzumab" post="seem to be interesting in fit elderly patients with"/>
   <result pre="neoadjuvant setting. One Phase II study compared concomitant versus sequential" exact="doxorubicin" post="and docetaxel 44 and reported similar objective clinical responses"/>
   <result pre="One Phase II study compared concomitant versus sequential doxorubicin and" exact="docetaxel" post="44 and reported similar objective clinical responses but more"/>
   <result pre="over BCS. 45, 46 Historically, primary endocrine therapy alone with" exact="tamoxifen" post="was prescribed as an alternative to surgery. 47 Nevertheless,"/>
   <result pre="endocrine therapy with aromatase inhibitors, which are more efficient than" exact="tamoxifen" post="in the elderly. The UK ESTEEM (Endocrine ± Surgical"/>
   <result pre="Therapy for EldErly women with Mammary cancer) trial comparing primary" exact="anastrozole" post="with surgery plus adjuvant anastrozole in women aged 75"/>
   <result pre="Mammary cancer) trial comparing primary anastrozole with surgery plus adjuvant" exact="anastrozole" post="in women aged 75 years or older with ER-positive"/>
   <result pre="women (mean age 83 years at diagnosis) evaluated remained on" exact="letrozole" post="alone, and at 3 years the median time to"/>
   <result pre="time to treatment failure had not been reached. In conclusion," exact="letrozole" post="alone may provide long-term disease control for elderly women"/>
   <result pre="between tumorectomy and modified radical mastectomy. 48 However, tumorectomy plus" exact="tamoxifen" post="is associated with improved time to distant progression 48"/>
   <result pre="adjuvant endocrine therapy is indicated. Aromatase inhibitors are preferred to" exact="tamoxifen" post="for their safety and efficacy. In a subgroup analysis"/>
   <result pre="recurrence. 104, 105 Elderly healthy patients completing 5 years of" exact="tamoxifen" post="should be considered for extended adjuvant therapy with letrozole."/>
   <result pre="Tamoxifen Alone or in Combination), 35.2% of women treated with" exact="anastrozole" post="developed joint symptoms. 109 These symptoms are a frequent"/>
   <result pre="110 In routine clinical practice, only 69% of women on" exact="anastrozole" post="remained adherent to this therapy. 111 In this regard,"/>
   <result pre="with a 1.5 times higher risk of bone fractures than" exact="tamoxifen" post="(from 0.9% to 11%). 113 All patients initiating aromatase"/>
   <result pre="the CALGB 49907 trial, standard adjuvant chemotherapy with CMF or" exact="doxorubicin" post="plus cyclophosphamide was superior to capecitabine alone in fit"/>
   <result pre="49907 trial, standard adjuvant chemotherapy with CMF or doxorubicin plus" exact="cyclophosphamide" post="was superior to capecitabine alone in fit patients over"/>
   <result pre="chemotherapy with CMF or doxorubicin plus cyclophosphamide was superior to" exact="capecitabine" post="alone in fit patients over 65 years. 124 Only"/>
   <result pre="65 years. 124 Only one Phase III trial compared adjuvant" exact="epirubicin" post="plus tamoxifen versus tamoxifen alone, but the difference in"/>
   <result pre="124 Only one Phase III trial compared adjuvant epirubicin plus" exact="tamoxifen" post="versus tamoxifen alone, but the difference in DFS did"/>
   <result pre="one Phase III trial compared adjuvant epirubicin plus tamoxifen versus" exact="tamoxifen" post="alone, but the difference in DFS did not reach"/>
   <result pre="a significant risk of recurrence, four cycles of non-pegylated liposomal" exact="doxorubicin" post="plus cyclophosphamide was feasible but had a certain impact"/>
   <result pre="risk of recurrence, four cycles of non-pegylated liposomal doxorubicin plus" exact="cyclophosphamide" post="was feasible but had a certain impact on social"/>
   <result pre="139 The other feasible regimen is four cycles of adjuvant" exact="docetaxel" post="plus cyclophosphamide. 140, 141 Docetaxel plus cyclophosphamide was compared"/>
   <result pre="cycles of adjuvant docetaxel plus cyclophosphamide. 140, 141 Docetaxel plus" exact="cyclophosphamide" post="was compared with doxorubicin plus cyclophosphamide in one study."/>
   <result pre="plus cyclophosphamide. 140, 141 Docetaxel plus cyclophosphamide was compared with" exact="doxorubicin" post="plus cyclophosphamide in one study. 142 In patients aged"/>
   <result pre="140, 141 Docetaxel plus cyclophosphamide was compared with doxorubicin plus" exact="cyclophosphamide" post="in one study. 142 In patients aged 65–74 years,"/>
   <result pre="cyclophosphamide in one study. 142 In patients aged 65–74 years," exact="docetaxel" post="plus cyclophosphamide was superior to standard doxorubicin plus cyclophosphamide"/>
   <result pre="one study. 142 In patients aged 65–74 years, docetaxel plus" exact="cyclophosphamide" post="was superior to standard doxorubicin plus cyclophosphamide in terms"/>
   <result pre="aged 65–74 years, docetaxel plus cyclophosphamide was superior to standard" exact="doxorubicin" post="plus cyclophosphamide in terms of DFS and OS. However,"/>
   <result pre="years, docetaxel plus cyclophosphamide was superior to standard doxorubicin plus" exact="cyclophosphamide" post="in terms of DFS and OS. However, older women"/>
   <result pre="regimen in patients aged 65–77 years is 5-fluorouracil, epirubicin, and" exact="cyclophosphamide" post="with pegfilgrastim support. 144 In conclusion, the chemoregimens possible"/>
   <result pre="patients aged 65–77 years is 5-fluorouracil, epirubicin, and cyclophosphamide with" exact="pegfilgrastim" post="support. 144 In conclusion, the chemoregimens possible are CMF"/>
   <result pre="conclusion, the chemoregimens possible are CMF (with precautions), anthracyclines plus" exact="cyclophosphamide" post="with a preference for liposomal anthracyclines, and docetaxel plus"/>
   <result pre="anthracyclines plus cyclophosphamide with a preference for liposomal anthracyclines, and" exact="docetaxel" post="plus cyclophosphamide. Capecitabine alone is not recommended. Primary prophylaxis"/>
   <result pre="(N-SAS BC07; ClinicalTrials.gov identifier NCT01104935), a randomized controlled trial evaluating" exact="trastuzumab" post="without chemotherapy as postoperative adjuvant therapy in women aged"/>
   <result pre="postmenopausal women, regardless of age. Aromatase inhibitors are superior to" exact="tamoxifen" post="and better tolerated. In first-line, anastrozole, 148, 149 letrozole,"/>
   <result pre="tolerated. In first-line, anastrozole, 148, 149 letrozole, 150, 151 and" exact="exemestane" post="152 have shown their superiority. In second-line, fulvestrant and"/>
   <result pre="151 and exemestane 152 have shown their superiority. In second-line," exact="fulvestrant" post="and anastrozole have been shown to be similar in"/>
   <result pre="exemestane 152 have shown their superiority. In second-line, fulvestrant and" exact="anastrozole" post="have been shown to be similar in terms of"/>
   <result pre="(Breast cancer trials of OraL EveROlimus)-2 trial, 154 addition of" exact="everolimus" post="to exemestane after progression on nonsteroidal aromatase inhibitors improved"/>
   <result pre="trials of OraL EveROlimus)-2 trial, 154 addition of everolimus to" exact="exemestane" post="after progression on nonsteroidal aromatase inhibitors improved PFS. Elderly"/>
   <result pre="had more on-treatment deaths. 154 One Phase II study compared" exact="letrozole" post="plus cyclophosphamide versus letrozole alone 155 and found an"/>
   <result pre="on-treatment deaths. 154 One Phase II study compared letrozole plus" exact="cyclophosphamide" post="versus letrozole alone 155 and found an overall response"/>
   <result pre="154 One Phase II study compared letrozole plus cyclophosphamide versus" exact="letrozole" post="alone 155 and found an overall response rate of"/>
   <result pre="of 71.9% in 57 patients randomly assigned to receive primary" exact="letrozole" post="and 87.7% in 57 patients randomly assigned to receive"/>
   <result pre="letrozole and 87.7% in 57 patients randomly assigned to receive" exact="letrozole" post="plus cyclophosphamide. Chemotherapy Chemotherapy is recommended in elderly women"/>
   <result pre="65 years and over. 156 In this context, pegylated liposomal" exact="doxorubicin" post="was proposed as an interesting alternative 138, 157 but"/>
   <result pre="of 2,000 mg/m 2 161, 162 and intravenous or oral" exact="vinorelbine" post="163, 164 appear to be acceptable monochemotherapies with good"/>
   <result pre="provided follow-up is sufficient. The 1,000 mg/m 2 twice daily" exact="capecitabine" post="dose is the standard since two toxic deaths occurred"/>
   <result pre="daily. Several studies have shown the efficacy and safety of" exact="paclitaxel" post="165– 167 and docetaxel 168– 170 in elderly patients."/>
   <result pre="shown the efficacy and safety of paclitaxel 165– 167 and" exact="docetaxel" post="168– 170 in elderly patients. Cardiovascular complications must be"/>
   <result pre="patients. Cardiovascular complications must be monitored with paclitaxel, 165 and" exact="docetaxel" post="was proposed to be initiated at 26 mg/m 2"/>
   <result pre="dose escalation in the event of no toxicity. 170 Finally," exact="eribulin" post="appears to be a good alternative in heavily pretreated"/>
   <result pre="tolerance. 171 Considering polychemotherapies ( Table 4), a combination of" exact="gemcitabine" post="and vinorelbine in elderly patients with anthracycline-pretreated and taxane-pretreated"/>
   <result pre="Considering polychemotherapies ( Table 4), a combination of gemcitabine and" exact="vinorelbine" post="in elderly patients with anthracycline-pretreated and taxane-pretreated metastatic BC"/>
   <result pre="by GERICO assessed the effect of an oral combination of" exact="capecitabine" post="and vinorelbine in patients with advanced breast, prostate, or"/>
   <result pre="assessed the effect of an oral combination of capecitabine and" exact="vinorelbine" post="in patients with advanced breast, prostate, or lung cancer."/>
   <result pre="women ranges between 7% and 20%. The major concern about" exact="trastuzumab" post="is its safety, given its nearly doubled risk of"/>
   <result pre="A multicenter, retrospective, observational Italian study reported that use of" exact="trastuzumab" post="with taxanes or vinorelbine was associated with a 67%"/>
   <result pre="Italian study reported that use of trastuzumab with taxanes or" exact="vinorelbine" post="was associated with a 67% response rate and a"/>
   <result pre="older patients (median age 69 years) showed improved PFS with" exact="pertuzumab" post="plus trastuzumab plus docetaxel. This chemotherapy regimen was safe,"/>
   <result pre="(median age 69 years) showed improved PFS with pertuzumab plus" exact="trastuzumab" post="plus docetaxel. This chemotherapy regimen was safe, with a"/>
   <result pre="with a higher incidence of grade 3 diarrhea in the" exact="pertuzumab" post="arm and more fatigue, asthenia, decreased appetite, vomiting, and"/>
   <result pre="fatigue, asthenia, decreased appetite, vomiting, and dysgeusia. 181 Trastuzumab and" exact="lapatinib" post="were also evaluated in combination with endocrine therapy, and"/>
   <result pre="agents, a meta-analysis 184 of the three randomized trials evaluating" exact="bevacizumab" post="as first-line treatment in HER2-negative, metastatic BC, ie, E2100"/>
   <result pre="NCT00448591), 186 and a large, multicenter, noninterventional German study, 187" exact="bevacizumab" post="was well tolerated with no increase in the incidence"/>
   <result pre="is a large (2,251 patients), international, open-label study assessing first-line" exact="bevacizumab" post="in combination with standard chemotherapy in HER2-negative metastatic BC."/>
   <result pre="patients aged ≥70 years. 189 Bevacizumab was combined with single-agent" exact="paclitaxel" post="in 46% of older patients. Only hypertension and proteinuria"/>
   <result pre="a randomized multicenter trial ( ClinicalTrials.gov identifier NCT0019301) comparing weekly" exact="docetaxel" post="and CMF in the treatment of women with high-risk"/>
   <result pre="A randomized controlled trial is currently recruiting participants to evaluate" exact="trastuzumab" post="without chemotherapy as a postoperative adjuvant therapy in HER2-positive"/>
   <result pre="participants ( ClinicalTrials.gov identifier NCT01597414). 192 This trial will compare" exact="pertuzumab" post="plus trastuzumab versus pertuzumab plus trastuzumab plus metronomic chemotherapy"/>
   <result pre="ClinicalTrials.gov identifier NCT01597414). 192 This trial will compare pertuzumab plus" exact="trastuzumab" post="versus pertuzumab plus trastuzumab plus metronomic chemotherapy in the"/>
   <result pre="NCT01597414). 192 This trial will compare pertuzumab plus trastuzumab versus" exact="pertuzumab" post="plus trastuzumab plus metronomic chemotherapy in the elderly with"/>
   <result pre="This trial will compare pertuzumab plus trastuzumab versus pertuzumab plus" exact="trastuzumab" post="plus metronomic chemotherapy in the elderly with HER2-positive metastatic"/>
   <result pre="After progression, patients will be given the option of receiving" exact="trastuzumab" post="emtansine. Concerning radiotherapy, a randomized Phase II trial is"/>
   <result pre="and the benefit is sometimes modest. Polychemotherapies are superior to" exact="capecitabine" post="alone. The chemoregimens possible are CMF (with precautions), anthracyclines"/>
   <result pre="alone. The chemoregimens possible are CMF (with precautions), anthracyclines plus" exact="cyclophosphamide" post="with a preference for liposomal anthracyclines, and docetaxel plus"/>
   <result pre="anthracyclines plus cyclophosphamide with a preference for liposomal anthracyclines, and" exact="docetaxel" post="plus cyclophosphamide. Trastuzumab should be prescribed in combination with"/>
   <result pre="22674146 39 collab: Imperial Cancer Clinical Research Unit Chemotherapy or" exact="letrozole" post="before surgery in treating postmenopausal women with breast cancer"/>
   <result pre="Kim YH Kim JS Meta-analysis of pre-operative aromatase inhibitor versus" exact="tamoxifen" post="in postmenopausal woman with hormone receptor-positive breast cancer Cancer"/>
   <result pre="al. Increase in response rate by prolonged treatment with neoadjuvant" exact="letrozole" post="Breast Cancer Res Treat 2009 113 1 145 151"/>
   <result pre="KD McCaskill-Stevens W Sisk J et al. Combination versus sequential" exact="doxorubicin" post="and docetaxel as primary chemotherapy for breast cancer: a"/>
   <result pre="W Sisk J et al. Combination versus sequential doxorubicin and" exact="docetaxel" post="as primary chemotherapy for breast cancer: a randomized pilot"/>
   <result pre="trial EORTC 10850 comparing modified radical mastectomy with tumorectomy plus" exact="tamoxifen" post="Eur J Cancer 2003 39 3 300 308 12565981"/>
   <result pre="in the elderly: a randomised clinical trial EORTC 10851 comparing" exact="tamoxifen" post="alone with modified radical mastectomy Eur J Cancer 2003"/>
   <result pre="Wyld L Reed MW Surgery, with or without tamoxifen, vs" exact="tamoxifen" post="alone for older women with operable breast cancer: Cochrane"/>
   <result pre="M Late follow-up of a randomized trial of surgery plus" exact="tamoxifen" post="versus tamoxifen alone in women aged over 70 years"/>
   <result pre="follow-up of a randomized trial of surgery plus tamoxifen versus" exact="tamoxifen" post="alone in women aged over 70 years with operable"/>
   <result pre="Ceccherini R Milani S et al. Tamoxifen alone versus adjuvant" exact="tamoxifen" post="for operable breast cancer of the elderly: long-term results"/>
   <result pre="RW Cheung KL A randomised trial of mastectomy only versus" exact="tamoxifen" post="for treating elderly patients with operable primary breast cancer"/>
   <result pre="FS Syed BM et al. A randomised trial of primary" exact="tamoxifen" post="versus mastectomy plus adjuvant tamoxifen in fit elderly women"/>
   <result pre="A randomised trial of primary tamoxifen versus mastectomy plus adjuvant" exact="tamoxifen" post="in fit elderly women with invasive breast carcinoma of"/>
   <result pre="Hughes KS Schnaper LA Berry D et al. Lumpectomy plus" exact="tamoxifen" post="with or without irradiation in women 70 years of"/>
   <result pre="Hughes KS Schnaper LA Bellon JR et al. Lumpectomy plus" exact="tamoxifen" post="with or without irradiation in women age 70 years"/>
   <result pre="J et al. Five versus more than five years of" exact="tamoxifen" post="therapy for breast cancer patients with negative lymph nodes"/>
   <result pre="Breast International Group (BIG) 1-98 Collaborative Group A comparison of" exact="letrozole" post="and tamoxifen in postmenopausal women with early breast cancer"/>
   <result pre="Group (BIG) 1-98 Collaborative Group A comparison of letrozole and" exact="tamoxifen" post="in postmenopausal women with early breast cancer N Engl"/>
   <result pre="adjusting for selective crossover show improved overall survival with adjuvant" exact="letrozole" post="compared with tamoxifen in the BIG 1-98 study J"/>
   <result pre="crossover show improved overall survival with adjuvant letrozole compared with" exact="tamoxifen" post="in the BIG 1-98 study J Clin Oncol 2011"/>
   <result pre="life in older women with early-stage breast cancer treated with" exact="letrozole" post="or placebo after 5 years of tamoxifen: NCIC CTG"/>
   <result pre="D Sun Z Coates AS et al. Letrozole compared with" exact="tamoxifen" post="for elderly patients with endocrine-responsive early breast cancer: the"/>
   <result pre="Z et al. Cognitive function in postmenopausal women receiving adjuvant" exact="letrozole" post="or tamoxifen for breast cancer in the BIG 1-98"/>
   <result pre="al. Cognitive function in postmenopausal women receiving adjuvant letrozole or" exact="tamoxifen" post="for breast cancer in the BIG 1-98 randomized trial"/>
   <result pre="Specific adverse events predict survival benefit in patients treated with" exact="tamoxifen" post="or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational"/>
   <result pre="in patients treated with tamoxifen or aromatase inhibitors: an international" exact="tamoxifen" post="exemestane adjuvant multinational trial analysis J Clin Oncol 2013"/>
   <result pre="patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen" exact="exemestane" post="adjuvant multinational trial analysis J Clin Oncol 2013 31"/>
   <result pre="et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and" exact="fluorouracil" post="and tamoxifen for elderly patients with breast cancer: the"/>
   <result pre="Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and" exact="tamoxifen" post="for elderly patients with breast cancer: the International Breast"/>
   <result pre="J Roché H et al. Disease-free survival advantage of weekly" exact="epirubicin" post="plus tamoxifen versus tamoxifen alone as adjuvant treatment of"/>
   <result pre="H et al. Disease-free survival advantage of weekly epirubicin plus" exact="tamoxifen" post="versus tamoxifen alone as adjuvant treatment of operable, node-positive,"/>
   <result pre="al. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus" exact="tamoxifen" post="alone as adjuvant treatment of operable, node-positive, elderly breast"/>
   <result pre="D Taira N Hara F et al. Feasibility study of" exact="docetaxel" post="with cyclophosphamide as adjuvant chemotherapy for Japanese breast cancer"/>
   <result pre="N Hara F et al. Feasibility study of docetaxel with" exact="cyclophosphamide" post="as adjuvant chemotherapy for Japanese breast cancer patients Jpn"/>
   <result pre="Jones S Holmes FA O’Shaughnessy J et al. Docetaxel with" exact="cyclophosphamide" post="is associated with an overall survival benefit compared with"/>
   <result pre="cyclophosphamide is associated with an overall survival benefit compared with" exact="doxorubicin" post="and cyclophosphamide: 7-year follow-up of US Oncology Research Trial"/>
   <result pre="of febrile neutropenia in patients with operable breast cancer receiving" exact="docetaxel" post="and cyclophosphamide J Clin Oncol 2009 27 26 e101"/>
   <result pre="neutropenia in patients with operable breast cancer receiving docetaxel and" exact="cyclophosphamide" post="J Clin Oncol 2009 27 26 e101 e102 19652050"/>
   <result pre="et al. Elderly cancer patients receiving chemotherapy benefit from first-cycle" exact="pegfilgrastim" post="Oncologist 2007 12 12 1416 1424 18165618 146 Brollo"/>
   <result pre="146 Brollo J Curigliano G Disalvatore D et al. Adjuvant" exact="trastuzumab" post="in elderly with HER-2 positive breast cancer: a systematic"/>
   <result pre="Sawaki M Tokudome N Mizuno T et al. Evaluation of" exact="trastuzumab" post="without chemotherapy as a post-operative adjuvant therapy in HER2-positive"/>
   <result pre="Buzdar A Nabholtz JM et al. Anastrozole is superior to" exact="tamoxifen" post="as first-line therapy in hormone receptor positive advanced breast"/>
   <result pre="J Buzdar A Robertson JF Thürlimann B Anastrozole (Arimidex) versus" exact="tamoxifen" post="as first-line therapy for advanced breast cancer in postmenopausal"/>
   <result pre="1689 12888362 150 Mouridsen H Chaudri-Ross HA Efficacy of first-line" exact="letrozole" post="versus tamoxifen as a function of age in postmenopausal"/>
   <result pre="150 Mouridsen H Chaudri-Ross HA Efficacy of first-line letrozole versus" exact="tamoxifen" post="as a function of age in postmenopausal women with"/>
   <result pre="Gershanovich M Sun Y et al. Phase III study of" exact="letrozole" post="versus tamoxifen as first-line therapy of advanced breast cancer"/>
   <result pre="Sun Y et al. Phase III study of letrozole versus" exact="tamoxifen" post="as first-line therapy of advanced breast cancer in postmenopausal"/>
   <result pre="Mature results of a randomized phase II multicenter study of" exact="exemestane" post="versus tamoxifen as first-line hormone therapy for postmenopausal women"/>
   <result pre="of a randomized phase II multicenter study of exemestane versus" exact="tamoxifen" post="as first-line hormone therapy for postmenopausal women with metastatic"/>
   <result pre="Howell A Pippen J Elledge RM et al. Fulvestrant versus" exact="anastrozole" post="for the treatment of advanced breast carcinoma: a prospectively"/>
   <result pre="HA 3rd Ito Y et al. Safety and efficacy of" exact="everolimus" post="with exemestane vs exemestane alone in elderly patients with"/>
   <result pre="Ito Y et al. Safety and efficacy of everolimus with" exact="exemestane" post="vs exemestane alone in elderly patients with HER2-negative, hormone"/>
   <result pre="et al. Safety and efficacy of everolimus with exemestane vs" exact="exemestane" post="alone in elderly patients with HER2-negative, hormone receptor-positive breast"/>
   <result pre="D Brizzi MP et al. Randomized phase II trial of" exact="letrozole" post="and letrozole plus low-dose metronomic oral cyclophosphamide as primary"/>
   <result pre="MP et al. Randomized phase II trial of letrozole and" exact="letrozole" post="plus low-dose metronomic oral cyclophosphamide as primary systemic treatment"/>
   <result pre="II trial of letrozole and letrozole plus low-dose metronomic oral" exact="cyclophosphamide" post="as primary systemic treatment in elderly breast cancer patients"/>
   <result pre="Cancer (EORTC) studies to evaluate the role of pegylated liposomal" exact="doxorubicin" post="(Caelyx) in the treatment of elderly patients with metastatic"/>
   <result pre="et al. Impact of geriatric risk factors on pegylated liposomal" exact="doxorubicin" post="tolerance and efficacy in elderly metastatic breast cancer patients:"/>
   <result pre="Basso U Roma A Brunello A et al. Bi-weekly liposomal" exact="doxorubicin" post="for advanced breast cancer in elderly women (≥70 years)"/>
   <result pre="et al. A randomized phase III study comparing pegylated liposomal" exact="doxorubicin" post="with capecitabine as first-line chemotherapy in elderly patients with"/>
   <result pre="A randomized phase III study comparing pegylated liposomal doxorubicin with" exact="capecitabine" post="as first-line chemotherapy in elderly patients with metastatic breast"/>
   <result pre="et al. Safety and efficacy of two different doses of" exact="capecitabine" post="in the treatment of advanced breast cancer in older"/>
   <result pre="Robieux I Galligioni E et al. Pharmacokinetics and tolerance of" exact="vinorelbine" post="in elderly patients with metastatic breast cancer Eur J"/>
   <result pre="A Cennamo G et al. Low-dose metronomic oral administration of" exact="vinorelbine" post="in the first-line treatment of elderly patients with metastatic"/>
   <result pre="Del Mastro L Perrone F Repetto L et al. Weekly" exact="paclitaxel" post="as first-line chemotherapy in elderly advanced breast cancer patients:"/>
   <result pre="Ten Tije AJ Smorenburg CH Seynaeve C et al. Weekly" exact="paclitaxel" post="as first-line chemotherapy for elderly patients with metastatic breast"/>
   <result pre="Hainsworth JD Burris HA 3rd Yardley DA et al. Weekly" exact="docetaxel" post="in the treatment of elderly patients with advanced breast"/>
   <result pre="R Wildiers H et al. Safety and efficacy of weekly" exact="docetaxel" post="in frail and/or elderly patients with metastatic breast cancer:"/>
   <result pre="MT Baker SD et al. Pharmacokinetics and toxicity of weekly" exact="docetaxel" post="in older patients Clin Cancer Res 2006 12 20"/>
   <result pre="Li H Cui Y Guo Q Gemcitabine in combination with" exact="vinorelbine" post="in elderly patients with anthracycline- and taxane-pretreated metastatic breast"/>
   <result pre="Retornaz F Joly F et al. Impact of an all-oral" exact="capecitabine" post="and vinorelbine combination regimen on functional status of elderly"/>
   <result pre="Joly F et al. Impact of an all-oral capecitabine and" exact="vinorelbine" post="combination regimen on functional status of elderly patients with"/>
   <result pre="Fu AZ et al. Risk of cardiovascular adverse events from" exact="trastuzumab" post="(Herceptin ®) in elderly persons with breast cancer: a"/>
   <result pre="Bernardi A Martoni A Zamagni C Tolerability and activity of" exact="trastuzumab" post="in elderly patients with HER2-overexpressing metastatic breast cancer Ann"/>
   <result pre="D et al. Multicenter analysis of activity and safety of" exact="trastuzumab" post="plus chemotherapy in advanced breast cancer in elderly women"/>
   <result pre="Kaufman B Mackey JR Clemens MR et al. Trastuzumab plus" exact="anastrozole" post="versus anastrozole alone for the treatment of postmenopausal women"/>
   <result pre="Mackey JR Clemens MR et al. Trastuzumab plus anastrozole versus" exact="anastrozole" post="alone for the treatment of postmenopausal women with human"/>
   <result pre="Pippen J Jr Pivot X et al. Lapatinib combined with" exact="letrozole" post="versus letrozole and placebo as first-line therapy for post-menopausal"/>
   <result pre="Jr Pivot X et al. Lapatinib combined with letrozole versus" exact="letrozole" post="and placebo as first-line therapy for post-menopausal hormone receptor-positive"/>
   <result pre="Schneeweiss A Verma S et al. Efficacy and safety of" exact="bevacizumab" post="in combination with docetaxel for the first-line treatment of"/>
   <result pre="et al. Efficacy and safety of bevacizumab in combination with" exact="docetaxel" post="for the first-line treatment of elderly patients with locally"/>
   <result pre="H Thomssen C et al. Tolerability and efficacy of first-line" exact="bevacizumab" post="plus chemotherapy in elderly patients with advanced breast cancer:"/>
   <result pre="F Klare P et al. Efficacy and safety of first-line" exact="bevacizumab" post="combined with paclitaxel according to age: subpopulation analysis of"/>
   <result pre="et al. Efficacy and safety of first-line bevacizumab combined with" exact="paclitaxel" post="according to age: subpopulation analysis of a large, multicenter,"/>
   <result pre="188 Smith IE Pierga JY Biganzoli L et al. First-line" exact="bevacizumab" post="plus taxane-based chemotherapy for locally recurrent or metastatic breast"/>
   <result pre="23 1 111 118 21444356 190 collab: Aventis Pharmaceuticals Weekly" exact="docetaxel" post="and CMF in the adjuvant treatment of elderly women"/>
   <result pre="191 collab: Comprehensive Support Project for Oncology Research Evaluation of" exact="trastuzumab" post="without chemotherapy as a postoperative adjuvant therapy in HER2"/>
   <result pre="Cataliotti L Buzdar AU Noguchi S et al. Comparison of" exact="anastrozole" post="versus tamoxifen as preoperative therapy in postmenopausal women with"/>
   <result pre="Buzdar AU Noguchi S et al. Comparison of anastrozole versus" exact="tamoxifen" post="as preoperative therapy in postmenopausal women with hormone receptor-positive"/>
   <result pre="Green H Stål O Bachmeier K et al. Pegylated liposomal" exact="doxorubicin" post="as first-line monotherapy in elderly women with locally advanced"/>
   <result pre="Lombardi D Corona G et al. Innovative schedule of oral" exact="idarubicin" post="in elderly patients with metastatic breast cancer: comprehensive results"/>
   <result pre="206 Feher O Vodvarka P Jassem J et al. First-line" exact="gemcitabine" post="versus epirubicin in postmenopausal women aged 60 or older"/>
   <result pre="O Vodvarka P Jassem J et al. First-line gemcitabine versus" exact="epirubicin" post="in postmenopausal women aged 60 or older with metastatic"/>
   <result pre="Vrdoljak E Gómez H et al. Efficacy and safety of" exact="ixabepilone" post="plus capecitabine in elderly patients with anthracycline-and taxane-pretreated metastatic"/>
   <result pre="Gómez H et al. Efficacy and safety of ixabepilone plus" exact="capecitabine" post="in elderly patients with anthracycline-and taxane-pretreated metastatic breast cancer"/>
   <result pre="H Wynendaele W Dirix L Kains JP Paridaens R Weekly" exact="paclitaxel" post="versus weekly docetaxel in elderly or frail patients with"/>
   <result pre="Dirix L Kains JP Paridaens R Weekly paclitaxel versus weekly" exact="docetaxel" post="in elderly or frail patients with metastatic breast carcinoma:"/>
   <result pre="A Bilancia D Romano R Manzione L Biweekly administration of" exact="gemcitabine" post="and vinorelbine as first line therapy in elderly advanced"/>
   <result pre="D Romano R Manzione L Biweekly administration of gemcitabine and" exact="vinorelbine" post="as first line therapy in elderly advanced breast cancer"/>
   <result pre="Fratino L Brunello A et al. Which benefit from adding" exact="gemcitabine" post="to vinorelbine in elderly (&amp;gt; or =70 years) women"/>
   <result pre="Brunello A et al. Which benefit from adding gemcitabine to" exact="vinorelbine" post="in elderly (&amp;gt; or =70 years) women with metastatic"/>
   <result pre="Addeo R Faiola V Guarrasi R et al. Liposomal pegylated" exact="doxorubicin" post="plus vinorelbine combination as first-line chemotherapy for metastatic breast"/>
   <result pre="Faiola V Guarrasi R et al. Liposomal pegylated doxorubicin plus" exact="vinorelbine" post="combination as first-line chemotherapy for metastatic breast cancer in"/>
   <result pre="J et al. Multicenter phase II study of pegylated liposomal" exact="doxorubicin" post="in combination with vinorelbine as first-line treatment in elderly"/>
   <result pre="phase II study of pegylated liposomal doxorubicin in combination with" exact="vinorelbine" post="as first-line treatment in elderly patients with metastatic breast"/>
   <result pre="69.6% Anastrozole (1 mg once daily for 3 months) versus" exact="tamoxifen" post="Cataliotti et al 200 PROACT trial 67.3 (48.7–91.5) Randomized,"/>
   <result pre="18% Letrozole (2 mg once daily for 4 months) versus" exact="tamoxifen" post="Eiermann et al 202 68 Multinational, randomized, double-blind, Phase"/>
   <result pre="(years) Study design and population Line Efficacy Toxicity Pegylated liposomal" exact="doxorubicin" post="40 mg/m 2 every 28 days Falandry et al"/>
   <result pre="(years) Study design and population Line Efficacy Toxicity PLD versus" exact="capecitabine" post="6 cycles of PLD (45 mg/m 2 every 4"/>
   <result pre="(45 mg/m 2 every 4 weeks) or 8 cycles of" exact="capecitabine" post="(1,000 mg/m 2 twice daily, days 1–14 every 3"/>
   <result pre="Comparable grade 3 AEs, no grade 4 AEs Epirubicin versus" exact="gemcitabine" post="Epirubicin 35 mg/m 2 or gemcitabine 1,200 mg/m 2"/>
   <result pre="4 AEs Epirubicin versus gemcitabine Epirubicin 35 mg/m 2 or" exact="gemcitabine" post="1,200 mg/m 2 on days 1, 8, and 15"/>
   <result pre="Multicenter, randomized, Phase III, 397 patients First line Superiority of" exact="epirubicin" post="TTP 6.1 versus 3.4 months, P=0.0001; OS 19.1 versus"/>
   <result pre="186 and 183 evaluable patients) Both well tolerated Ixabepilone plus" exact="capecitabine" post="versus capecitabine Ixabepilone 40 mg/m 2 every 3 weeks"/>
   <result pre="183 evaluable patients) Both well tolerated Ixabepilone plus capecitabine versus" exact="capecitabine" post="Ixabepilone 40 mg/m 2 every 3 weeks + oral"/>
   <result pre="capecitabine Ixabepilone 40 mg/m 2 every 3 weeks + oral" exact="capecitabine" post="(1,000 mg/m 2 twice each day), or capecitabine alone"/>
   <result pre="+ oral capecitabine (1,000 mg/m 2 twice each day), or" exact="capecitabine" post="alone (1,250 mg/m 2 twice each day) Vahdat et"/>
   <result pre="12.2 months Febrile neutropenia 10% (ixabepilone + capecitabine) Paclitaxel versus" exact="docetaxel" post="Weekly paclitaxel 80 mg/m 2 or weekly docetaxel 36"/>
   <result pre="Febrile neutropenia 10% (ixabepilone + capecitabine) Paclitaxel versus docetaxel Weekly" exact="paclitaxel" post="80 mg/m 2 or weekly docetaxel 36 mg/m 2"/>
   <result pre="Paclitaxel versus docetaxel Weekly paclitaxel 80 mg/m 2 or weekly" exact="docetaxel" post="36 mg/m 2 Beuselinck et al 208 Elderly or"/>
   <result pre="55.7 weeks versus 32 weeks More anemia and neurotoxicity for" exact="paclitaxel" post="and more edema and fatigue for docetaxel Abbreviations: ORR,"/>
   <result pre="and neurotoxicity for paclitaxel and more edema and fatigue for" exact="docetaxel" post="Abbreviations: ORR, objective response rate; PFS, progression-free survival; OS,"/>
   <result pre="(years) Study design and population Line Efficacy Toxicity Gemcitabine and" exact="vinorelbine" post="Vinorelbine 25 mg/m 2 IV and gemcitabine 1,000 mg/m"/>
   <result pre="Toxicity Gemcitabine and vinorelbine Vinorelbine 25 mg/m 2 IV and" exact="gemcitabine" post="1,000 mg/m 2 IV on days 1 and 8"/>
   <result pre="53% Grade 3/4 neutropenia 20% Vinorelbine 25 mg/m 2 plus" exact="gemcitabine" post="1,000 mg/m 2 on days 1 and 8, every"/>
   <result pre="grade 3 GI toxicity 25% Gemcitabine 1,000 mg/m 2 and" exact="vinorelbine" post="25 mg/m 2 on days 1 and 8 every"/>
   <result pre="4% One toxic death because of GI hemorrhage PLD plus" exact="vinorelbine" post="PLD 40 mg/m 2 plus vinorelbine 25 mg/m 2"/>
   <result pre="GI hemorrhage PLD plus vinorelbine PLD 40 mg/m 2 plus" exact="vinorelbine" post="25 mg/m 2 IV on day 1 and oral"/>
   <result pre="vinorelbine 25 mg/m 2 IV on day 1 and oral" exact="vinorelbine" post="60 mg/m 2 on day 15 Addeo et al"/>
   <result pre="8.8% PLD 40 mg/m 2 IV on day 1 and" exact="vinorelbine" post="30 mg/m 2 IV on days 1 and 15"/>
   <result pre="line ORR 36% TTP 4 months OS 24 months Oral" exact="capecitabine" post="and vinorelbine 6 cycles: capecitabine 750 mg/m 2 bid,"/>
   <result pre="36% TTP 4 months OS 24 months Oral capecitabine and" exact="vinorelbine" post="6 cycles: capecitabine 750 mg/m 2 bid, days 1–14"/>
   <result pre="months OS 24 months Oral capecitabine and vinorelbine 6 cycles:" exact="capecitabine" post="750 mg/m 2 bid, days 1–14 every 21 days"/>
   <result pre="on tolerance (capecitabine 1,000 mg/m 2 bid, days 1–14 and" exact="vinorelbine" post="60 mg/m 2, days 1 and 8) Rousseau et"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4303336/results/search/inn/results.xml">
   <result pre="important. Although the cardiac toxicity due to anthracyclines, radiotherapy, or" exact="trastuzumab" post="is well-documented, several issues need to be clarified and"/>
   <result pre="management of cardiac toxicities. Keywords adjuvant anthracyclines cardiac toxicity radiotherapy" exact="trastuzumab" post="Introduction Breast cancer is the most common cancer in"/>
   <result pre="toxicity in early breast cancer Anthracycline-based chemotherapy Anthracycline-based regimens, including" exact="epirubicin" post="or doxorubicin, have been the cornerstone of breast cancer"/>
   <result pre="of CRCD is different from the cardiac toxicity caused by" exact="trastuzumab" post="which will be discussed later in this review. A"/>
   <result pre="of anthracyclines in treated patients. These thresholds are differed between" exact="epirubicin" post="and doxorubicin since, at equimolar doses, epirubicin is less"/>
   <result pre="in treated patients. These thresholds are differed between epirubicin and" exact="doxorubicin" post="since, at equimolar doses, epirubicin is less cardiotoxic than"/>
   <result pre="are differed between epirubicin and doxorubicin since, at equimolar doses," exact="epirubicin" post="is less cardiotoxic than doxorubicin because of the lower"/>
   <result pre="doxorubicin since, at equimolar doses, epirubicin is less cardiotoxic than" exact="doxorubicin" post="because of the lower levels of secondary alcohol metabolites"/>
   <result pre="previously mentioned meta-analysis, the authors found that the use of" exact="epirubicin" post="significantly decreased the risks of both clinical and subclinical"/>
   <result pre="catheters, questionable cost-effectiveness) that limit its clinical use. Encapsulation of" exact="doxorubicin" post="into liposomes significantly reduces its distribution volume, diminishing its"/>
   <result pre="39 In the previously mentioned meta-analysis, liposomal compared to conventional" exact="doxorubicin" post="significantly decreased the risk of clinical and subclinical cardiotoxicity."/>
   <result pre="studies included in the meta-analysis investigated the role of liposomal" exact="doxorubicin" post="in patients with metastatic breast cancer. The role of"/>
   <result pre="in patients with metastatic breast cancer. The role of liposomal" exact="doxorubicin" post="in the adjuvant setting is still under investigation. Early"/>
   <result pre="under investigation. Early Phase II trials have found that liposomal" exact="doxorubicin" post="seems to be a feasible option for elderly patients,"/>
   <result pre="option for elderly patients, 40 and in concurrent administration with" exact="trastuzumab" post="41 as adjuvant treatment. Several randomized trials with the"/>
   <result pre="the aim of investigating the efficacy and safety of liposomal" exact="doxorubicin" post="in elderly early breast cancer populations are ongoing. Advances"/>
   <result pre="agent that is thought to decrease the cardiotoxic effect of" exact="doxorubicin" post="by blocking the generation of free radicals. In a"/>
   <result pre="meta-analysis of six randomized trials, of which only three examined" exact="dexrazoxane" post="use in a homogenous breast cancer population receiving initial"/>
   <result pre="in a homogenous breast cancer population receiving initial anthracycline-based therapy," exact="dexrazoxane" post="given with either doxorubicin or epirubicin significantly reduced the"/>
   <result pre="cancer population receiving initial anthracycline-based therapy, dexrazoxane given with either" exact="doxorubicin" post="or epirubicin significantly reduced the incidence of clinical and"/>
   <result pre="receiving initial anthracycline-based therapy, dexrazoxane given with either doxorubicin or" exact="epirubicin" post="significantly reduced the incidence of clinical and subclinical cardiotoxicity."/>
   <result pre="plus dexrazoxane. 38 Considering the lack of clinical data on" exact="dexrazoxane" post="in the adjuvant setting and the concerns about potential"/>
   <result pre="setting and the concerns about potential impact on antitumor efficacy," exact="dexrazoxane" post="is not recommended for use in early breast cancer."/>
   <result pre="about the higher risk for bradycardia and cardiac arrhythmias with" exact="paclitaxel" post="46 as well as higher risk for left ventricular"/>
   <result pre="mechanism of cardiac toxicity. 49 Indeed, the combination of bolus" exact="doxorubicin" post="and paclitaxel resulted in an unacceptably high risk of"/>
   <result pre="cardiac toxicity. 49 Indeed, the combination of bolus doxorubicin and" exact="paclitaxel" post="resulted in an unacceptably high risk of cardiac complications."/>
   <result pre="of cardiac complications. 50 On the contrary, the combination of" exact="epirubicin" post="and paclitaxel was feasible with respect to cardiac toxicity"/>
   <result pre="complications. 50 On the contrary, the combination of epirubicin and" exact="paclitaxel" post="was feasible with respect to cardiac toxicity as long"/>
   <result pre="to cardiac toxicity as long as the cumulative dose of" exact="epirubicin" post="did not exceed the threshold of 990 mg/m 2."/>
   <result pre="women, whereas aromatase inhibitors (AI) have demonstrated superiority compared with" exact="tamoxifen" post="in postmenopausal women. 54– 56 Tamoxifen is a selective"/>
   <result pre="the risk of cardiovascular events. 58 In a meta-analysis evaluating" exact="tamoxifen" post="and focusing on adverse effects, tamoxifen was associated with"/>
   <result pre="In a meta-analysis evaluating tamoxifen and focusing on adverse effects," exact="tamoxifen" post="was associated with a decreased risk of death from"/>
   <result pre="difference in cardiovascular deaths between the groups was observed but" exact="anastrozole" post="treatment was associated with an increase in mild to"/>
   <result pre="hypertension. 60 In another trial, 5 years of treatment with" exact="letrozole" post="were compared with tamoxifen or sequential treatment with both"/>
   <result pre="trial, 5 years of treatment with letrozole were compared with" exact="tamoxifen" post="or sequential treatment with both substances. After a median"/>
   <result pre="After a median follow-up of 51 months, patients treated with" exact="letrozole" post="had a higher incidence of cardiac events grade 3–5,"/>
   <result pre="events. 61 Similar results were seen in a study evaluating" exact="tamoxifen" post="or tamoxifen in sequence with exemestane, in which the"/>
   <result pre="Similar results were seen in a study evaluating tamoxifen or" exact="tamoxifen" post="in sequence with exemestane, in which the treatment group"/>
   <result pre="in sequence with exemestane, in which the treatment group with" exact="exemestane" post="had significantly more ischemic cardiac adverse events after a"/>
   <result pre="be observed in a large trial evaluating prolonged treatment with" exact="letrozole" post="or tamoxifen after completion of 5 years tamoxifen treatment."/>
   <result pre="in a large trial evaluating prolonged treatment with letrozole or" exact="tamoxifen" post="after completion of 5 years tamoxifen treatment. 63 In"/>
   <result pre="treatment with letrozole or tamoxifen after completion of 5 years" exact="tamoxifen" post="treatment. 63 In summary, AI seem to entail a"/>
   <result pre="minor increase in the risk of cardiac adverse events whereas" exact="tamoxifen" post="does not seem to entail any cardiac risks. In"/>
   <result pre="HER2-positive breast cancer in any treatment setting. The importance of" exact="trastuzumab" post="in HER2-positive breast cancer disease was first demonstrated in"/>
   <result pre="disease was first demonstrated in the metastatic setting, in which" exact="trastuzumab" post="changed the natural history of HER2-positive disease from a"/>
   <result pre="HER2-negative disease. 64 In the adjuvant setting, 1-year treatment with" exact="trastuzumab" post="offers substantial benefit in terms of both disease-free and"/>
   <result pre="high rate of 30% in cases of concomitant administration of" exact="trastuzumab" post="with anthracyclines. 66 These findings had a major impact"/>
   <result pre="well as treatment schedules with sequential use of anthracyclines and" exact="trastuzumab" post="instead of concomitant administration were adopted. 67 As a"/>
   <result pre="recovery of cardiac function. 31 The cardiac toxicity due to" exact="trastuzumab" post="is classified as type II CRCD. 31 One potential"/>
   <result pre="mechanism could explain both the higher risk for cardiotoxicity when" exact="trastuzumab" post="and anthracyclines are combined (the stress and damage caused"/>
   <result pre="by anthracyclines is increased) and the reversibility of cardiotoxicity with" exact="trastuzumab" post="withdrawal (the pathway is becoming functional again). 72 Several"/>
   <result pre="in the pathologic complete remission with the concurrent administration of" exact="trastuzumab" post="and epirubicin, 78 and considering the concerns about the"/>
   <result pre="the treatment of HER2-positive breast cancer: the tyrosine kinase inhibitor" exact="lapatinib" post="is approved in metastatic setting 85 and the monoclonal"/>
   <result pre="is approved in metastatic setting 85 and the monoclonal antibody" exact="pertuzumab" post="is approved in the neoadjuvant and metastatic setting. 86,"/>
   <result pre="two anti-HER2 agents has been evaluated. Lapatinib in combination with" exact="trastuzumab" post="has shown promising results as neoadjuvant 88 and metastatic"/>
   <result pre="promising results as neoadjuvant 88 and metastatic treatment, 89 while" exact="pertuzumab" post="has been approved only in combination with trastuzumab both"/>
   <result pre="89 while pertuzumab has been approved only in combination with" exact="trastuzumab" post="both as neoadjuvant and as metastatic treatment. Those two"/>
   <result pre="by investigators from the NSABP B-31 trial (trastuzumab versus no" exact="trastuzumab" post="in the adjuvant setting) to predict the absolute risk"/>
   <result pre="absolute risk of heart failure in individual patients who received" exact="trastuzumab" post="as adjuvant therapy. 96 However, the lack of independent"/>
   <result pre="mandatory for all the patients who are planned to receive" exact="trastuzumab" post="without any exceptions. 91, 92 At present, the most"/>
   <result pre="ESMO guidelines concerning the time intervals in cardiac monitoring during" exact="trastuzumab" post="therapy and the potential value of cardiac biomarkers in"/>
   <result pre="ASE/EACVI guidelines recommend cardiac monitoring 6 months after completion of" exact="trastuzumab" post="therapy only in patients who had previously received a"/>
   <result pre="trial dedicated to patients with breast cancer, the administration of" exact="nebivolol" post="(n=27) under anthracycline-based chemotherapy was associated with lower risk"/>
   <result pre="chemotherapy (34 of 50 patients had breast cancer) in which" exact="carvedilol" post="was compared to placebo, 129 and a larger trial"/>
   <result pre="90 patients with hematologic malignancies in which the combination of" exact="enalapril" post="and carvedilol was compared to nonintervention. 130 This latter"/>
   <result pre="with hematologic malignancies in which the combination of enalapril and" exact="carvedilol" post="was compared to nonintervention. 130 This latter trial (OVERCOME"/>
   <result pre="114 patients with various malignancies for randomization to placebo versus" exact="enalapril" post="20 mg daily for 1 year. The incidence of"/>
   <result pre="clinical evidence on the potential cardioprotective effect of ACE-i/ARB under" exact="trastuzumab" post="or radiation therapy. 139 However, this potential cardioprotective effect"/>
   <result pre="models. 140 However, a small study in patients treated with" exact="trastuzumab" post="found that the exercise training was not effective in"/>
   <result pre="account in trastuzumab-induced cardiac toxicity are the need to withhold" exact="trastuzumab" post="according to specific criteria (LVEF ≤44, or LVEF 45–49"/>
   <result pre="titration of cardiovascular medication and, if it returns to baseline," exact="trastuzumab" post="can be restarted in combination with cardiovascular medications. 91,"/>
   <result pre="patients. 91 Conclusion Adjuvant treatment with radiotherapy, anthracycline-based chemotherapy, and/or" exact="trastuzumab" post="are important parts of postoperative therapy for many women"/>
   <result pre="et al. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in" exact="doxorubicin" post="cardiotoxicity and prevention by dexrazoxane Cancer Res 2007 67"/>
   <result pre="DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by" exact="dexrazoxane" post="Cancer Res 2007 67 8839 8846 17875725 31 Ewer"/>
   <result pre="G Nielsen G Skovsgaard T Andersen PK New insight into" exact="epirubicin" post="cardiac toxicity: competing risks analysis of 1097 breast cancer"/>
   <result pre="39 Giotta F Lorusso V Maiello E et al. Liposomal-encapsulated" exact="doxorubicin" post="plus cyclophosphamide as first-line therapy in metastatic breast cancer:"/>
   <result pre="F Lorusso V Maiello E et al. Liposomal-encapsulated doxorubicin plus" exact="cyclophosphamide" post="as first-line therapy in metastatic breast cancer: a phase"/>
   <result pre="Jackisch C et al. Cardiac safety of adjuvant pegylated liposomal" exact="doxorubicin" post="with concurrent trastuzumab: a randomized phase II trial Ann"/>
   <result pre="Fang J Kim YJ Wong MK Wang P Codelivery of" exact="doxorubicin" post="and paclitaxel by cross-linked multilamellar liposome enables synergistic antitumor"/>
   <result pre="Kim YJ Wong MK Wang P Codelivery of doxorubicin and" exact="paclitaxel" post="by cross-linked multilamellar liposome enables synergistic antitumor activity Mol"/>
   <result pre="44 Slamon D Eiermann W Robert N et al. Adjuvant" exact="trastuzumab" post="in HER2-positive breast cancer N Engl J Med 2011"/>
   <result pre="Minotti G Anthracycline cardiotoxicity in breast cancer patients: synergism with" exact="trastuzumab" post="and taxanes Cardiovasc Toxicol 2007 7 67 71 17652806"/>
   <result pre="detailed evaluation of cardiac toxicity: a phase II study of" exact="doxorubicin" post="and one- or three-hour-infusion paclitaxel in patients with metastatic"/>
   <result pre="a phase II study of doxorubicin and one- or three-hour-infusion" exact="paclitaxel" post="in patients with metastatic breast cancer Clin Cancer Res"/>
   <result pre="1-98 Collaborative Group Thürlimann B Keshaviah A A comparison of" exact="letrozole" post="and tamoxifen in postmenopausal women with early breast cancer"/>
   <result pre="Group Thürlimann B Keshaviah A A comparison of letrozole and" exact="tamoxifen" post="in postmenopausal women with early breast cancer N Engl"/>
   <result pre="Kilburn LS Snowdon CF et al. Survival and safety of" exact="exemestane" post="versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane"/>
   <result pre="Snowdon CF et al. Survival and safety of exemestane versus" exact="tamoxifen" post="after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a"/>
   <result pre="Survival and safety of exemestane versus tamoxifen after 2–3 years’" exact="tamoxifen" post="treatment (Intergroup Exemestane Study): a randomised controlled trial Lancet"/>
   <result pre="58 Lin C Chen LS Kuo SJ Chen DR Adjuvant" exact="tamoxifen" post="influences the lipid profile in breast cancer patients Breast"/>
   <result pre="Col NF Meta-analysis of vascular and neoplastic events associated with" exact="tamoxifen" post="J Gen Intern Med 2003 18 11 937 947"/>
   <result pre="Trialists’ Group Buzdar A Howell A Comprehensive side-effect profile of" exact="anastrozole" post="and tamoxifen as adjuvant treatment for early-stage breast cancer:"/>
   <result pre="Buzdar A Howell A Comprehensive side-effect profile of anastrozole and" exact="tamoxifen" post="as adjuvant treatment for early-stage breast cancer: long-term safety"/>
   <result pre="events during adjuvant endocrine therapy for early breast cancer using" exact="letrozole" post="or tamoxifen: safety analysis of BIG 1-98 trial J"/>
   <result pre="outcomes with long-term follow-up: an updated analysis of the intergroup" exact="exemestane" post="study J Clin Oncol 2012 30 7 709 717"/>
   <result pre="PE Ingle JN Martino S et al. Randomized trial of" exact="letrozole" post="following tamoxifen as extended adjuvant therapy in receptor-positive breast"/>
   <result pre="JN Martino S et al. Randomized trial of letrozole following" exact="tamoxifen" post="as extended adjuvant therapy in receptor-positive breast cancer: updated"/>
   <result pre="of women with metastatic breast cancer by HER2 status and" exact="trastuzumab" post="treatment: an institutional-based review J Clin Oncol 2010 28"/>
   <result pre="Afonso SL Stefano EJ De Fendi LI Soares FV Adjuvant" exact="trastuzumab" post="in the treatment of her-2-positive early breast cancer: a"/>
   <result pre="Hudis C Pierri MK et al. Cardiac dysfunction in the" exact="trastuzumab" post="clinical trials experience J Clin Oncol 2002 20 5"/>
   <result pre="AA Engel JM Stankowski RV Cardiovascular toxicity associated with adjuvant" exact="trastuzumab" post="therapy: prevalence, patient characteristics, and risk factors Ther Adv"/>
   <result pre="of heart failure in breast cancer patients after anthracycline and" exact="trastuzumab" post="treatment: a retrospective cohort study J Natl Cancer Inst"/>
   <result pre="Schneeweiss A Chia S Hickish T et al. Pertuzumab plus" exact="trastuzumab" post="in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy"/>
   <result pre="AU Suman VJ Meric-Bernstam F et al. Fluorouracil, epirubicin, and" exact="cyclophosphamide" post="(FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus"/>
   <result pre="F et al. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by" exact="paclitaxel" post="plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75"/>
   <result pre="al. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus" exact="trastuzumab" post="versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab"/>
   <result pre="epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus" exact="paclitaxel" post="plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant"/>
   <result pre="cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus" exact="trastuzumab" post="followed by FEC-75 plus trastuzumab as neoadjuvant treatment for"/>
   <result pre="plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus" exact="trastuzumab" post="as neoadjuvant treatment for patients with HER2-positive breast cancer"/>
   <result pre="Suman VJ Davidson NE et al. Cardiac safety analysis of" exact="doxorubicin" post="and cyclophosphamide followed by paclitaxel with or without trastuzumab"/>
   <result pre="Davidson NE et al. Cardiac safety analysis of doxorubicin and" exact="cyclophosphamide" post="followed by paclitaxel with or without trastuzumab in the"/>
   <result pre="al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by" exact="paclitaxel" post="with or without trastuzumab in the North Central Cancer"/>
   <result pre="of doxorubicin and cyclophosphamide followed by paclitaxel with or without" exact="trastuzumab" post="in the North Central Cancer Treatment Group N9831 adjuvant"/>
   <result pre="Gross CP Incidence of heart failure or cardiomyopathy after adjuvant" exact="trastuzumab" post="therapy for breast cancer J Am Coll Cardiol 2012"/>
   <result pre="as risk factor for cardiotoxicity in breast cancer treated with" exact="trastuzumab" post="Anticancer Res 2013 33 6 2569 2576 23749910 84"/>
   <result pre="al. Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with" exact="trastuzumab" post="related cardiac toxicity and efficacy in a subgroup of"/>
   <result pre="Geyer CE Forster J Lindquist D et al. Lapatinib plus" exact="capecitabine" post="for HER2-positive advanced breast cancer N Engl J Med"/>
   <result pre="Baselga J Cortés J Kim SB et al. Pertuzumab plus" exact="trastuzumab" post="plus docetaxel for metastatic breast cancer N Engl J"/>
   <result pre="Cortés J Kim SB et al. Pertuzumab plus trastuzumab plus" exact="docetaxel" post="for metastatic breast cancer N Engl J Med 2012"/>
   <result pre="T Im YH et al. Efficacy and safety of neoadjuvant" exact="pertuzumab" post="and trastuzumab in women with locally advanced, inflammatory, or"/>
   <result pre="YH et al. Efficacy and safety of neoadjuvant pertuzumab and" exact="trastuzumab" post="in women with locally advanced, inflammatory, or early HER2-positive"/>
   <result pre="88 Valachis A Nearchou A Lind P Mauri D Lapatinib," exact="trastuzumab" post="or the combination added to preoperative chemotherapy for breast"/>
   <result pre="Burstein HJ Storniolo AM et al. Overall survival benefit with" exact="lapatinib" post="in combination with trastuzumab for patients with human epidermal"/>
   <result pre="et al. Overall survival benefit with lapatinib in combination with" exact="trastuzumab" post="for patients with human epidermal growth factor receptor 2-positive"/>
   <result pre="September 8, 2014 94 Perez EA Morgan JP Cardiotoxicity of" exact="trastuzumab" post="and other HER2-targeted agents collab: UpToDate Savarese DFM UpToDate"/>
   <result pre="of cardiac function in NSABP B-31, a randomized trial comparing" exact="doxorubicin" post="and cyclophosphamide followed by paclitaxel (ACP) with ACP plus"/>
   <result pre="function in NSABP B-31, a randomized trial comparing doxorubicin and" exact="cyclophosphamide" post="followed by paclitaxel (ACP) with ACP plus trastuzumab as"/>
   <result pre="B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by" exact="paclitaxel" post="(ACP) with ACP plus trastuzumab as adjuvant therapy for"/>
   <result pre="doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus" exact="trastuzumab" post="as adjuvant therapy for patients with node-positive, human epidermal"/>
   <result pre="Strain rate imaging detects early cardiac effects of pegylated liposomal" exact="doxorubicin" post="as adjuvant therapy in elderly patients with breast cancer"/>
   <result pre="before conventional measures in patients undergoing breast cancer treatment with" exact="trastuzumab" post="Am Heart J 2009 158 2 294 301 19619708"/>
   <result pre="epidermal growth factor receptor II-positive breast cancer treated with adjuvant" exact="trastuzumab" post="therapy J Am Coll Cardiol 2011 57 22 2263"/>
   <result pre="prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and" exact="trastuzumab" post="Circ Cardiovasc Imaging 2012 5 5 596 603 22744937"/>
   <result pre="from N9831, a phase III randomized trial of chemotherapy and" exact="trastuzumab" post="as adjuvant therapy for HER2-positive breast cancer J Clin"/>
   <result pre="Combined NT-pro-BNP and CW-Doppler ultrasound cardiac output monitoring (USCOM) in" exact="epirubicin" post="and liposomal doxorubicin therapy Int J Cardiol 2008 128"/>
   <result pre="CW-Doppler ultrasound cardiac output monitoring (USCOM) in epirubicin and liposomal" exact="doxorubicin" post="therapy Int J Cardiol 2008 128 3 316 325"/>
   <result pre="from the genotoxic and cytotoxic effects of the anticancer drugs" exact="doxorubicin" post="and etoposide Br J Pharmacol 2006 149 8 988"/>
   <result pre="genotoxic and cytotoxic effects of the anticancer drugs doxorubicin and" exact="etoposide" post="Br J Pharmacol 2006 149 8 988 997 17088865"/>
   <result pre="XZ Ran X Zong ZW et al. Protective effect of" exact="atorvastatin" post="on radiation-induced vascular endothelial cell injury in vitro J"/>
   <result pre="Acar Z Kale A Turgut M et al. Efficiency of" exact="atorvastatin" post="in the protection of anthracycline-induced cardiomyopathy J Am Coll"/>
   <result pre="Asanuma H Minamino T Sanada S et al. Beta-adrenoceptor blocker" exact="carvedilol" post="provides cardioprotection via an adenosine-dependent mechanism in ischemic canine"/>
   <result pre="127 Kim IM Tilley DG Chen J et al. Beta-blockers" exact="alprenolol" post="and carvedilol stimulate beta-arrestin-mediated EGFR transactivation Proc Natl Acad"/>
   <result pre="IM Tilley DG Chen J et al. Beta-blockers alprenolol and" exact="carvedilol" post="stimulate beta-arrestin-mediated EGFR transactivation Proc Natl Acad Sci U"/>
   <result pre="MG Ozkan M Gunebakmaz O et al. Protective effects of" exact="nebivolol" post="against anthracycline-induced cardiomyopathy: a randomized control study Int J"/>
   <result pre="N Basar E Ozdogru I et al. Protective effects of" exact="carvedilol" post="against anthracycline-induced cardiomyopathy J Am Coll Cardiol 2006 48"/>
   <result pre="Bosch X Rovira M Sitges M et al. Enalapril and" exact="carvedilol" post="for preventing chemotherapy-induced left ventricular systolic dysfunction in patients"/>
   <result pre="Network Administration of angiotensin-converting enzyme inhibitors and β-blockers during adjuvant" exact="trastuzumab" post="chemotherapy for nonmetastatic breast cancer: marker of risk or"/>
   <result pre="Tokudome T Mizushige K Noma T et al. Prevention of" exact="doxorubicin" post="(adriamycin)-induced cardiomyopathy by simultaneous administration of angiotensin-converting enzyme inhibitor"/>
   <result pre="M El-Missiry MA Potential protective role of angiotensin-converting enzyme inhibitors" exact="captopril" post="and enalapril against adriamycin-induced acute cardiac and hepatic toxicity"/>
   <result pre="MA Potential protective role of angiotensin-converting enzyme inhibitors captopril and" exact="enalapril" post="against adriamycin-induced acute cardiac and hepatic toxicity in rats"/>
   <result pre="cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and" exact="prednisolone" post="Cancer 2005 104 11 2492 2498 16247790 137 Dessì"/>
   <result pre="18 months, protective effects of the angiotensin II receptor blocker" exact="telmisartan" post="on Epirubin-induced inflammation and oxidative stress assessed by serial"/>
   <result pre="MJ Mackey JR Thompson RB Jones LW Paterson DI Adjuvant" exact="trastuzumab" post="induces ventricular remodeling despite aerobic exercise training Clin Cancer"/>
   <result pre="Clemons M Coté MA et al. Cardiac management during adjuvant" exact="trastuzumab" post="therapy: recommendations of the Canadian Trastuzumab Working Group Curr"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4307685/results/search/inn/results.xml">
   <result pre="In this study, 25 patients received chemotherapy of taxol and" exact="cisplatin" post="(TP) plus nimotuzumab, 55 patients received chemotherapy of TP"/>
   <result pre="finds out that in lung cancer, amplification of c-Met causes" exact="gefitinib" post="resistance by driving ERBB3-dependent activation of PI3K, a pathway"/>
   <result pre="amplification [ 17]. In the breast cancer, c-Met contributes to" exact="trastuzumab" post="resistance, as inhibition of c-Met sensitizes cells to trastuzumab-mediated"/>
   <result pre="Y Li J Jin M A phase II trial of" exact="paclitaxel" post="and cisplatin in patients with advanced squamous-cell carcinoma of"/>
   <result pre="J Jin M A phase II trial of paclitaxel and" exact="cisplatin" post="in patients with advanced squamous-cell carcinoma of the esophagus"/>
   <result pre="double-blind phase iii study of onartuzumab (MetMAb) in combination with" exact="erlotinib" post="versus erlotinib alone in patients who have received standard"/>
   <result pre="iii study of onartuzumab (MetMAb) in combination with erlotinib versus" exact="erlotinib" post="alone in patients who have received standard chemotherapy for"/>
   <result pre="Hyland C Park JO et al. MET amplification leads to" exact="gefitinib" post="resistance in lung cancer by activating ERBB3 signaling Science"/>
   <result pre="JK Carraway KL 3rd Sweeney C Met receptor contributes to" exact="trastuzumab" post="resistance of Her2-overexpressing breast cancer cells Cancer Res 2008"/>
   <result pre="Increased MET and HGF gene copy numbers are associated with" exact="trastuzumab" post="failure in HER2-positive metastatic breast cancer Br J Cancer"/>
   <result pre="S Christensen JG Weiser MR MET activation mediates resistance to" exact="lapatinib" post="inhibition of HER2-amplified gastric cancer cells Mol Cancer Ther"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4309158/results/search/inn/results.xml">
   <result pre="downstream signaling ( 37, 38). More specifically, TKIs such as" exact="erlotinib" post="take effect via reversible binding to the kinase catalytic"/>
   <result pre="auto-phosphorylation and downstream activation ( 39). Alternatively, mAbs, such as" exact="trastuzumab" post="( 40) and cetuximab ( 41), bind to the"/>
   <result pre="( 39). Alternatively, mAbs, such as trastuzumab ( 40) and" exact="cetuximab" post="( 41), bind to the extra-cellular segment of HER-family"/>
   <result pre="resistance has been a major issue. The primary efficacy of" exact="erlotinib" post="and gefitinib in malignancies harboring an EGFR/HER1 activating mutation"/>
   <result pre="been a major issue. The primary efficacy of erlotinib and" exact="gefitinib" post="in malignancies harboring an EGFR/HER1 activating mutation is well"/>
   <result pre="patients with advanced lung cancers that have become resistant to" exact="gefitinib" post="or erlotinib. AZD9291 and CO1686 inhibited both the activating"/>
   <result pre="(in only 3% of untreated patients) and developed resistance to" exact="gefitinib" post="by driving HER3-dependent activation of PI3K in a gefitinib-sensitive"/>
   <result pre="16). However, the majority of patients who initially responded to" exact="trastuzumab" post="showed partial or complete resistance and disease progression in"/>
   <result pre="progression in &amp;lt;1 year post treatment ( 18). Multiple mechanisms of" exact="trastuzumab" post="resistance have been reported ( 56) including constitutive activation"/>
   <result pre="which activated the PI3K/AKT and Ras/Raf/MAPK signaling cascades. In addition," exact="trastuzumab" post="only blocks HER2-mediated signaling, but it may not inhibit"/>
   <result pre="the opportunity for upstream blockade of external signaling; for example," exact="cetuximab" post="blockade to EGFR/HER1. Karapetis et al. ( 58) in"/>
   <result pre="al. ( 58) in a randomized trial of single agent" exact="cetuximab" post="vs. best supportive care showed that a k-ras mutation"/>
   <result pre="that a k-ras mutation was a predictor for resistance to" exact="cetuximab" post="in patients. Drugs that target molecules downstream of k-ras"/>
   <result pre="to EGFR/HER1 targeted therapy. Their study revealed that resistance to" exact="cetuximab" post="in metastatic colorectal cancer &quot;xenopatients&quot; (patient-derived xenografts) was frequently"/>
   <result pre="(formerly known as BMS 599626), HM781-36B, Canertinib (CI-1033), Nertinib (HKI272)," exact="afatinib" post="(BIBW2992), and dacomitinib (PF299804). Multi-target TKIs such as lapatinib"/>
   <result pre="(HKI272), afatinib (BIBW2992), and dacomitinib (PF299804). Multi-target TKIs such as" exact="lapatinib" post="(an inhibitor of HER1 and HER2) are already approved"/>
   <result pre="already entered phase II ( 67, 68), while dacomitinib and" exact="afatinib" post="have been extensively tested in a range of cancer"/>
   <result pre="currently undergoing Phase III studies ( 69). Accordingly, dacomitinib and" exact="afatinib" post="will be introduced in the sessions that follow and"/>
   <result pre="of dacomitinib in patients (pts) after failure of chemotherapy and" exact="erlotinib" post="(US) Stable disease was observed in 9/18 pts in"/>
   <result pre="pts with k-ras wild-type adenocarcinoma NSCLC refractory to chemotherapy and" exact="erlotinib" post="or gefitinib Dacomitinib ( n = 30) showed 35% progression-free survival"/>
   <result pre="k-ras wild-type adenocarcinoma NSCLC refractory to chemotherapy and erlotinib or" exact="gefitinib" post="Dacomitinib ( n = 30) showed 35% progression-free survival rate at"/>
   <result pre="2012 Phase II: observing efficacy of dacomitinib ( n = 94) vs." exact="erlotinib" post="( n = 94) in patients after failure of chemotherapy Dacomitinib"/>
   <result pre="after failure of chemotherapy Dacomitinib showed significantly longer PFS vs." exact="erlotinib" post="in the overall population (2.86 vs. 1.91 months, p = 0.012), with"/>
   <result pre="with cisplatin/paclitaxel and cisplatin/5-fluorourcial, respectively. No relevant PK interaction between" exact="afatinib" post="and the chemotherapeutic agents Advanced solid tumors ( 80)"/>
   <result pre="80) 2013 Phase I: pulsatile 3-day administration in combination with" exact="docetaxel" post="( n = 40) This combination showed 12.5% objective responses and"/>
   <result pre="22.5% durable stable disease. No drug–drug interactions were observed between" exact="afatinib" post="and docetaxel Advanced solid tumors ( 81) 2012 Phase"/>
   <result pre="stable disease. No drug–drug interactions were observed between afatinib and" exact="docetaxel" post="Advanced solid tumors ( 81) 2012 Phase II: efficacy"/>
   <result pre="Advanced solid tumors ( 81) 2012 Phase II: efficacy of" exact="afatinib" post="as first ( n = 61) or second line treatment ("/>
   <result pre="second line treatment patients showed objective response after treatment with" exact="afatinib" post="daily. The most common adverse events were diarrhea and"/>
   <result pre="EGFR mutations ( 82) 2012 Exploratory phase II: efficacy of" exact="afatinib" post="in patients with HER2 mutations ( n = 3) All three"/>
   <result pre="mutations ( 83) 2012 Phase II: efficacy and safety of" exact="afatinib" post="as second or third-line treatment ( n = 50) Afatinib achieved"/>
   <result pre="skin HER2-negative metastatic breast cancer ( 84) 2012 Phase IIb/III:" exact="afatinib" post="vs. placebo as third or fourth line treatment in"/>
   <result pre="p &amp;lt; 0.01). There was no significant difference in overall survival between" exact="afatinib" post="(10.8 months) and placebo group (12 months, p = 0.74) Advance NSCLC ("/>
   <result pre="group (12 months, p = 0.74) Advance NSCLC ( 85) 2012 Phase III:" exact="afatinib" post="vs. pemetrexed and cisplatin as first-line treatment in 345"/>
   <result pre="p = 0.74) Advance NSCLC ( 85) 2012 Phase III: afatinib vs." exact="pemetrexed" post="and cisplatin as first-line treatment in 345 patients (LUX-Lung"/>
   <result pre="NSCLC ( 85) 2012 Phase III: afatinib vs. pemetrexed and" exact="cisplatin" post="as first-line treatment in 345 patients (LUX-Lung 3) Afatinib"/>
   <result pre="( 86) 2013 Phase III: safety and efficacy of first-line" exact="afatinib" post="vs. gemcitabine/cisplatin in Asian patients with EGFR mutation (LUX-Lung"/>
   <result pre="EGFR/HER1 blocking TKIs were more common in dacomitinib compared with" exact="erlotinib" post="( 95). Phase II studies In two subsequent phase"/>
   <result pre="encouraging activity in patients after failure of prior chemotherapy and" exact="erlotinib" post="or gefitinib treatment ( 70, 71). A randomized Phase"/>
   <result pre="in patients after failure of prior chemotherapy and erlotinib or" exact="gefitinib" post="treatment ( 70, 71). A randomized Phase II trial"/>
   <result pre="progression-free survival (PFS) in patients receiving dacomitinib (2.86 months) compared to" exact="erlotinib" post="(1.91 months) ( 69). In two Phase II studies of"/>
   <result pre="( 98). Pre-clinical studies In cell-free in vitro kinase assays," exact="afatinib" post="potently inhibited wild-type EGFR (EC 50 = 0.5 nM), HER2 (14 nM), and"/>
   <result pre="whereas NCI-H1975, T854A transfected 293T, and BT474 were resistant to" exact="erlotinib" post="and/or gefitinib ( 98, 100). Furthermore, afatinib induced tumor"/>
   <result pre="T854A transfected 293T, and BT474 were resistant to erlotinib and/or" exact="gefitinib" post="( 98, 100). Furthermore, afatinib induced tumor regression in"/>
   <result pre="were resistant to erlotinib and/or gefitinib ( 98, 100). Furthermore," exact="afatinib" post="induced tumor regression in a broad spectrum of xenograft"/>
   <result pre="lung tumor with HER2 YVMA mutation, with superior activity over" exact="erlotinib" post="( 99, 101). In a panel of seven human"/>
   <result pre="In a panel of seven human pancreatic tumor cell lines," exact="afatinib" post="indicated greater efficacy in antiproliferation and signaling blockage (phosphorylation"/>
   <result pre="and AKT) ( 102). In vivo, daily administration of 15 mg/kg" exact="afatinib" post="showed potent antitumor activity in the BxPC-3 human pancreatic"/>
   <result pre="4. Phase I studies Several Phase I dose-escalation studies with" exact="afatinib" post="indicated that afatinib is well-tolerated ( 76– 79, 103)."/>
   <result pre="studies Several Phase I dose-escalation studies with afatinib indicated that" exact="afatinib" post="is well-tolerated ( 76– 79, 103). The recommended dose"/>
   <result pre="skin rash. A pharmacokinetic study in healthy male volunteers with" exact="afatinib" post="showed the main route of excretion is via feces,"/>
   <result pre="antitumor activity after treatment as first or second line with" exact="afatinib" post="daily 40 or 50 mg ( 82). Afatinib was more"/>
   <result pre="patients with less common mutations (39%) ( 82). In addition," exact="afatinib" post="indicated therapeutic activity in three patients with lung adenocarcinoma"/>
   <result pre="exhibited activating HER2 mutation in exon 20 ( 83). However," exact="afatinib" post="had limited activity in HER2-negative breast cancer ( 84)."/>
   <result pre="than four treatment courses. This indicated that further examination of" exact="afatinib" post="in patients should select population with EGFR/HER2 mutations or"/>
   <result pre="LUX-Lung 1 was a randomized, double-blind phase IIb/III study comparing" exact="afatinib" post="with placebo in 585 NSCLC patients after failure of"/>
   <result pre="for study entry. Accordingly, LUX-Lung 3 examined the efficacy of" exact="afatinib" post="compared with pemetrexed and cisplatin as first-line treatment for"/>
   <result pre="Accordingly, LUX-Lung 3 examined the efficacy of afatinib compared with" exact="pemetrexed" post="and cisplatin as first-line treatment for patients with advanced"/>
   <result pre="3 examined the efficacy of afatinib compared with pemetrexed and" exact="cisplatin" post="as first-line treatment for patients with advanced lung adenocarcinoma"/>
   <result pre="for patients with advanced lung adenocarcinoma harboring EGFR-activating mutations. Encouragingly," exact="afatinib" post="led to a prolonged PFS, more significantly with common"/>
   <result pre="Del19 and L858R mutations ( 86, 87). In July 2013," exact="afatinib" post="was approved for the first-line treatment of patients with"/>
   <result pre="both in vitro and in vivo showed ( 107) that" exact="gefitinib" post="(EGFR/HER1 TKI) used in combination with antimetabolites, either fluorouracil"/>
   <result pre="that gefitinib (EGFR/HER1 TKI) used in combination with antimetabolites, either" exact="fluorouracil" post="(5FU) or pemetrexed, had an antagonistic growth inhibitory effect"/>
   <result pre="had an antagonistic growth inhibitory effect in vitro. In contrast," exact="afatinib" post="both in vitro and in vivo was synergistic with"/>
   <result pre="synergistic with these drugs. In two phase I studies of" exact="afatinib" post="combination with chemotherapy, the MTD for afatinib was 20 mg"/>
   <result pre="I studies of afatinib combination with chemotherapy, the MTD for" exact="afatinib" post="was 20 mg with cisplatin/paclitaxel, 30 mg with cisplatin/5-fluorouracil, and 90 mg"/>
   <result pre="with cisplatin/paclitaxel, 30 mg with cisplatin/5-fluorouracil, and 90 mg for 3 days after" exact="docetaxel" post="in advanced solid tumors ( 80, 81). Both studies"/>
   <result pre="panHER inhibitor with promising lab data showing it synergizes with" exact="cisplatin" post="in vitro ( 108). This is believed to be"/>
   <result pre="in vitro ( 108). This is believed to be because" exact="cisplatin" post="inhibits key genes in cell survival when the EGFR"/>
   <result pre="CI-1033 has undergone a phase I trial in combination with" exact="docetaxel" post="in advanced solid tumor patients. It appeared to be"/>
   <result pre="( 109). CI-1033 has also been examined in combination with" exact="paclitaxel" post="and carboplatin in advanced NSCLC patients ( 110). Phase"/>
   <result pre="CI-1033 has also been examined in combination with paclitaxel and" exact="carboplatin" post="in advanced NSCLC patients ( 110). Phase I studies"/>
   <result pre="by the FDA for routine clinical use in combination with" exact="capecitabine" post="(prodrug of 5FU). This is on the basis of"/>
   <result pre="positive breast cancer (12.0 weeks in combination therapy vs. 8.4 weeks in" exact="lapatinib" post="alone) ( 111). Another approach to target the HER-family"/>
   <result pre="115). Currently, a Phase II clinical trial combining MM-111 with" exact="paclitaxel" post="and trastuzumab is being investigate ( 116). The development"/>
   <result pre="a Phase II clinical trial combining MM-111 with paclitaxel and" exact="trastuzumab" post="is being investigate ( 116). The development of bispecific"/>
   <result pre="A recent example showed an enhanced antitumor activity when HER-antibody" exact="trastuzumab" post="was combined with an EGFR TKI gefitinib or erlotinib"/>
   <result pre="activity when HER-antibody trastuzumab was combined with an EGFR TKI" exact="gefitinib" post="or erlotinib ( 117). Soft tissue sarcomas as a"/>
   <result pre="HER-antibody trastuzumab was combined with an EGFR TKI gefitinib or" exact="erlotinib" post="( 117). Soft tissue sarcomas as a novel target"/>
   <result pre="is also confirmed in clinical studies ( 121), showing that" exact="erlotinib" post="was not active in malignant peripheral nerve sheath tumors"/>
   <result pre="sheath tumors (MPNST), which are relatively resistant to chemotherapy. Similarly," exact="cetuximab" post="has minimal activity in EGFR positive advanced sarcoma ("/>
   <result pre="osteosarcoma patients with HER2 over-expression showed that blocking HER2 using" exact="trastuzumab" post="in combination with cytotoxic chemotherapy had no clinical benefit"/>
   <result pre="epidermal growth factor receptor T790M mutation during chronic exposure to" exact="gefitinib" post="in a non small cell lung cancer cell line"/>
   <result pre="Hyland C Park JO et al. MET amplification leads to" exact="gefitinib" post="resistance in lung cancer by activating ERBB3 signaling ."/>
   <result pre="mutations in EGFR mutant lung tumors with acquired resistance to" exact="gefitinib" post="or erlotinib . Proc Natl Acad Sci U S"/>
   <result pre="EGFR mutant lung tumors with acquired resistance to gefitinib or" exact="erlotinib" post=". Proc Natl Acad Sci U S A ("/>
   <result pre="factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to" exact="trastuzumab" post="resistance of breast cancer cells . Cancer Res ("/>
   <result pre="D et al. Inhibition of IGF1R activity enhances response to" exact="trastuzumab" post="in HER-2-positive breast cancer cells . Ann Oncol ("/>
   <result pre="Wakeling AE Ali S Weiss H et al. Mechanisms of" exact="tamoxifen" post="resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer"/>
   <result pre="M . Insulin-like growth factor-I receptor signaling and resistance to" exact="trastuzumab" post="(Herceptin). J Natl Cancer Inst ( 2001) 93( 24):"/>
   <result pre="D Tebbutt NC et al. K-ras mutations and benefit from" exact="cetuximab" post="in advanced colorectal cancer. N Engl J Med ("/>
   <result pre="models with EGFR and ERBB2 mutations that are resistant to" exact="gefitinib" post=". Cancer Res ( 2007) 67( 24): 11924– 32."/>
   <result pre="Y Greshock J Annan R et al. Novel mechanism of" exact="lapatinib" post="resistance in HER2-positive breast tumor cells: activation of AXL"/>
   <result pre="(PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus" exact="erlotinib" post="in patients with advanced non-small-cell lung cancer . J"/>
   <result pre="at least one prior chemotherapy regimen and prior treatment with" exact="erlotinib" post="(E): a two-arm, phase II trial . J Clin"/>
   <result pre="non-small cell lung cancer (NSCLC) refractory to chemotherapy (CT) and" exact="erlotinib" post="(E) or gefitinib (G): a phase (P) I/II study"/>
   <result pre="cancer (NSCLC) refractory to chemotherapy (CT) and erlotinib (E) or" exact="gefitinib" post="(G): a phase (P) I/II study . J Clin"/>
   <result pre="T Nakamura Y et al. Phase I study of continuous" exact="afatinib" post="(BIBW 2992) in patients with advanced non-small cell lung"/>
   <result pre="I, open-label, dose-escalation study of continuous once-daily oral treatment with" exact="afatinib" post="in patients with advanced solid tumors . Invest New"/>
   <result pre="study to assess the safety of continuous oral treatment with" exact="afatinib" post="in combination with two chemotherapy regimens: cisplatin plus paclitaxel"/>
   <result pre="oral treatment with afatinib in combination with two chemotherapy regimens:" exact="cisplatin" post="plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with"/>
   <result pre="with afatinib in combination with two chemotherapy regimens: cisplatin plus" exact="paclitaxel" post="and cisplatin plus 5-fluorouracil, in patients with advanced solid"/>
   <result pre="in combination with two chemotherapy regimens: cisplatin plus paclitaxel and" exact="cisplatin" post="plus 5-fluorouracil, in patients with advanced solid tumors ."/>
   <result pre="et al. Phase I study of pulsatile 3-day administration of" exact="afatinib" post="(BIBW 2992) in combination with docetaxel in advanced solid"/>
   <result pre="pulsatile 3-day administration of afatinib (BIBW 2992) in combination with" exact="docetaxel" post="in advanced solid tumors . Invest New Drugs ("/>
   <result pre="Galdermans D De Mey J et al. Clinical activity of" exact="afatinib" post="(BIBW 2992) in patients with lung adenocarcinoma with mutations"/>
   <result pre="A phase II trial to assess efficacy and safety of" exact="afatinib" post="in extensively pretreated patients with HER2-negative metastatic breast cancer"/>
   <result pre="al. LUX-Lung 3: a randomized, open-label, phase III study of" exact="afatinib" post="versus pemetrexed and cisplatin as first-line treatment for patients"/>
   <result pre="3: a randomized, open-label, phase III study of afatinib versus" exact="pemetrexed" post="and cisplatin as first-line treatment for patients with advanced"/>
   <result pre="randomized, open-label, phase III study of afatinib versus pemetrexed and" exact="cisplatin" post="as first-line treatment for patients with advanced adenocarcinoma of"/>
   <result pre="al. LUX-Lung 6: a randomized, open-label, phase III study of" exact="afatinib" post="(A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian"/>
   <result pre="al. The irreversible pan-HER inhibitor PF00299804 alone or combined with" exact="gemcitabine" post="has an antitumor effect in biliary tract cancer cell"/>
   <result pre="inhibits proliferation of HER2-amplified breast cancer cell lines resistant to" exact="trastuzumab" post="and lapatinib . Mol Cancer Ther ( 2012) 11("/>
   <result pre="of HER2-amplified breast cancer cell lines resistant to trastuzumab and" exact="lapatinib" post=". Mol Cancer Ther ( 2012) 11( 9): 1978–"/>
   <result pre="head and neck cancer models that exhibit low response to" exact="cetuximab" post=". PLoS One ( 2013) 8( 2): e56112. 10.1371/journal.pone.0056112"/>
   <result pre="Taylor I et al. Efficacy and safety of PF299804 versus" exact="erlotinib" post="(E): a global, randomized phase II trial in patients"/>
   <result pre="C et al. Target binding properties and cellular activity of" exact="afatinib" post="(BIBW 2992), an irreversible ErbB family blocker . J"/>
   <result pre="Evidence for epidermal growth factor receptor-enhanced chemosensitivity in combinations of" exact="cisplatin" post="and the new irreversible tyrosine kinase inhibitor CI-1033 ."/>
   <result pre="clinical and pharmacokinetic study of oral CI-1033 in combination with" exact="docetaxel" post="in patients with advanced solid tumors . Clin Cancer"/>
   <result pre="A phase I evaluation of oral CI-1033 in combination with" exact="paclitaxel" post="and carboplatin as first-line chemotherapy in patients with advanced"/>
   <result pre="I evaluation of oral CI-1033 in combination with paclitaxel and" exact="carboplatin" post="as first-line chemotherapy in patients with advanced non-small cell"/>
   <result pre="et al. Phase I dose escalation and pharmacokinetic study of" exact="lapatinib" post="in combination with trastuzumab in patients with advanced ErbB2-positive"/>
   <result pre="dose escalation and pharmacokinetic study of lapatinib in combination with" exact="trastuzumab" post="in patients with advanced ErbB2-positive breast cancer . J"/>
   <result pre="MM-111, a bispecific HER2 and HER3 antibody, synergistically combines with" exact="trastuzumab" post="and paclitaxel in preclincal models of gastric cancer ."/>
   <result pre="bispecific HER2 and HER3 antibody, synergistically combines with trastuzumab and" exact="paclitaxel" post="in preclincal models of gastric cancer . Cancer Res"/>
   <result pre="et al. Randomized open-label phase 2 study of MM-111 and" exact="paclitaxel" post="(PTX) with trastuzumab (TRAS) in patients with HER2-expressing carcinomas"/>
   <result pre="open-label phase 2 study of MM-111 and paclitaxel (PTX) with" exact="trastuzumab" post="(TRAS) in patients with HER2-expressing carcinomas of the distal"/>
   <result pre="al. PI3K pathway activation results in low efficacy of both" exact="trastuzumab" post="and lapatinib. BMC Cancer ( 2011) 11: 248. 10.1186/1471-2407-11-248"/>
   <result pre="Budd GT Schuetze SM et al. Phase II study of" exact="erlotinib" post="in metastatic or unresectable malignant peripheral nerve sheath tumors"/>
   <result pre="Thomas DG Lucas DR et al. Phase II trial of" exact="cetuximab" post="in patients with metastatic or locally advanced soft tissue"/>
   <result pre="Gorlick R Lipshultz SE et al. Phase II trial of" exact="trastuzumab" post="in combination with cytotoxic chemotherapy for treatment of metastatic"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4310719/results/search/inn/results.xml">
   <result pre="from a prespecified analysis of a Phase III study of" exact="everolimus" post="(Afinitor ®), a mammalian target of rapamycin (mTOR) inhibitor,"/>
   <result pre="a mammalian target of rapamycin (mTOR) inhibitor, in combination with" exact="exemestane" post="(Aromasin ®) in patients with visceral disease progressing after"/>
   <result pre="BCs are hormone receptor–positive (HR+) (either estrogen receptor [ER]–positive or" exact="progesterone" post="receptor–positive), 3 and a strong correlation between hormone status"/>
   <result pre="8– 10 For most premenopausal patients with HR+ ABC after" exact="tamoxifen" post="therapy, ovarian suppression or ablation in combination with endocrine"/>
   <result pre="those without previous exposure. 7 Treatment with third-generation AIs, including" exact="letrozole" post="(Femara ®; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA),"/>
   <result pre="letrozole (Femara ®; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA)," exact="anastrozole" post="(Arimidex ®; AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA), and"/>
   <result pre="anastrozole (Arimidex ®; AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA), and" exact="exemestane" post="(Aromasin ®; Pfizer Inc., New York, NY, USA), has"/>
   <result pre="with ABC with visceral metastases. For example, second-line treatment with" exact="anastrozole" post="vs megestrol acetate (Megace ®; Bristol-Myers Squibb Company, Princeton,"/>
   <result pre="with visceral metastases. For example, second-line treatment with anastrozole vs" exact="megestrol" post="acetate (Megace ®; Bristol-Myers Squibb Company, Princeton, NJ, USA)"/>
   <result pre="respectively, in patients without visceral metastases. 21 First-line treatment with" exact="anastrozole" post="vs tamoxifen in two Phase III trials showed a"/>
   <result pre="patients without visceral metastases. 21 First-line treatment with anastrozole vs" exact="tamoxifen" post="in two Phase III trials showed a CBR of"/>
   <result pre="patients without visceral disease. 21 Similarly, a comparative study of" exact="exemestane" post="vs anastrozole for patients with visceral disease reported a"/>
   <result pre="visceral disease. 21 Similarly, a comparative study of exemestane vs" exact="anastrozole" post="for patients with visceral disease reported a CBR of"/>
   <result pre="disease reported a CBR of 32% in patients treated with" exact="anastrozole" post="vs 38% in patients treated with exemestane. 28 However,"/>
   <result pre="success of this therapeutic strategy. 5, 29– 33 Responses with" exact="tamoxifen" post="are not durable, with mean response durations of only"/>
   <result pre="therapy. 59– 61 Other endocrine therapies The selective ER downregulator" exact="fulvestrant" post="(Faslodex ®; AstraZeneca Pharmaceuticals LP) is believed to delay"/>
   <result pre="signaling pathways. 42 Clinical studies have shown the effectiveness of" exact="fulvestrant" post="in patients resistant to either AI or tamoxifen treatment,"/>
   <result pre="effectiveness of fulvestrant in patients resistant to either AI or" exact="tamoxifen" post="treatment, including patients with visceral disease. 44– 46 The"/>
   <result pre="Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT) showed that" exact="fulvestrant" post="and exemestane had comparable efficacy and tolerability in patients"/>
   <result pre="Faslodex versus Exemestane Clinical Trial (EFECT) showed that fulvestrant and" exact="exemestane" post="had comparable efficacy and tolerability in patients with ABC"/>
   <result pre="and 27% of patients with visceral metastases treated with either" exact="fulvestrant" post="or exemestane, respectively. 24 A retrospective analysis of two"/>
   <result pre="24 A retrospective analysis of two Phase III studies comparing" exact="fulvestrant" post="and anastrozole reported a CBR of 38% and 37%,"/>
   <result pre="retrospective analysis of two Phase III studies comparing fulvestrant and" exact="anastrozole" post="reported a CBR of 38% and 37%, respectively, in"/>
   <result pre="endocrine therapy. 45 In a Phase III trial of two" exact="fulvestrant" post="doses (250 mg and 500 mg) in postmenopausal women"/>
   <result pre="progression after previous endocrine therapy, PFS was significantly longer with" exact="fulvestrant" post="500 mg than with fulvestrant 250 mg (hazard ratio:"/>
   <result pre="PFS was significantly longer with fulvestrant 500 mg than with" exact="fulvestrant" post="250 mg (hazard ratio: 0.80; 95% CI: 0.68–0.94). 46"/>
   <result pre="On the basis of these results, the approved dose of" exact="fulvestrant" post="was increased from 250 mg to 500 mg. In"/>
   <result pre="was significantly longer in patients with visceral disease treated with" exact="fulvestrant" post="500 mg than in those treated with fulvestrant 250"/>
   <result pre="treated with fulvestrant 500 mg than in those treated with" exact="fulvestrant" post="250 mg (hazard ratio: 0.86; 95% CI: 0.70–1.06), as"/>
   <result pre="CI: 0.57–0.92). mTOR inhibitors In preclinical studies, the mTOR inhibitor" exact="everolimus" post="(Afinitor ®; Novartis Pharmaceuticals Corporation) in combination with endocrine"/>
   <result pre="sensitivity. 62, 63 Two key clinical studies have shown that" exact="everolimus" post="significantly improved time to progression in patients with ER+"/>
   <result pre="time to progression in patients with ER+ metastatic BC undergoing" exact="everolimus" post="plus endocrine therapy for endocrine-resistant HR+ ABC. In the"/>
   <result pre="AIs, 53% of whom had visceral disease, the addition of" exact="everolimus" post="to tamoxifen delayed time to disease progression and improved"/>
   <result pre="of whom had visceral disease, the addition of everolimus to" exact="tamoxifen" post="delayed time to disease progression and improved OS. 56"/>
   <result pre="improved OS. 56 Time to progression was 8.6 months with" exact="everolimus" post="plus tamoxifen and was 4.5 months with tamoxifen alone,"/>
   <result pre="56 Time to progression was 8.6 months with everolimus plus" exact="tamoxifen" post="and was 4.5 months with tamoxifen alone, corresponding to"/>
   <result pre="months with everolimus plus tamoxifen and was 4.5 months with" exact="tamoxifen" post="alone, corresponding to a 46% reduction in the risk"/>
   <result pre="reduction in the risk of progression with the addition of" exact="everolimus" post="(hazard ratio: 0.54; 95% CI: 0.36–0.81). OS was not"/>
   <result pre="0.54; 95% CI: 0.36–0.81). OS was not reached for the" exact="everolimus" post="plus tamoxifen arm and was 32.9 months in the"/>
   <result pre="CI: 0.36–0.81). OS was not reached for the everolimus plus" exact="tamoxifen" post="arm and was 32.9 months in the tamoxifen-alone arm,"/>
   <result pre="Cancer Trials of Oral Everolimus-2 (BOLERO-2) study, the combination of" exact="everolimus" post="and exemestane was evaluated in 724 postmenopausal women with"/>
   <result pre="of Oral Everolimus-2 (BOLERO-2) study, the combination of everolimus and" exact="exemestane" post="was evaluated in 724 postmenopausal women with HR+ ABC"/>
   <result pre="PFS based on investigator assessment was 7.8 months in the" exact="everolimus" post="plus exemestane arm and 3.2 months in the placebo"/>
   <result pre="on investigator assessment was 7.8 months in the everolimus plus" exact="exemestane" post="arm and 3.2 months in the placebo plus exemestane"/>
   <result pre="plus exemestane arm and 3.2 months in the placebo plus" exact="exemestane" post="arm (hazard ratio: 0.45; 95% CI: 0.38–0.54; P&amp;lt;0.0001). 58,"/>
   <result pre="also observed based on independent central assessment (11.0 months with" exact="everolimus" post="and exemestane vs 4.1 months with placebo plus exemestane)."/>
   <result pre="based on independent central assessment (11.0 months with everolimus and" exact="exemestane" post="vs 4.1 months with placebo plus exemestane). In a"/>
   <result pre="analysis of the BOLERO-2 study, the efficacy and safety of" exact="everolimus" post="plus exemestane were evaluated according to the presence of"/>
   <result pre="the BOLERO-2 study, the efficacy and safety of everolimus plus" exact="exemestane" post="were evaluated according to the presence of visceral disease,"/>
   <result pre="with visceral metastases, median PFS was 6.8 months in the" exact="everolimus" post="plus exemestane arm and was 2.8 months in the"/>
   <result pre="metastases, median PFS was 6.8 months in the everolimus plus" exact="exemestane" post="arm and was 2.8 months in the placebo plus"/>
   <result pre="exemestane arm and was 2.8 months in the placebo plus" exact="exemestane" post="arm by local investigator assessment (hazard ratio: 0.47; 95%"/>
   <result pre="without visceral metastases, median PFS was 9.9 months in the" exact="everolimus" post="plus exemestane arm and 4.2 months in the placebo"/>
   <result pre="metastases, median PFS was 9.9 months in the everolimus plus" exact="exemestane" post="arm and 4.2 months in the placebo plus exemestane"/>
   <result pre="plus exemestane arm and 4.2 months in the placebo plus" exact="exemestane" post="arm (hazard ratio: 0.41; 95% CI: 0.31–0.55; P&amp;lt;0.05). Improvement"/>
   <result pre="ratio: 0.41; 95% CI: 0.31–0.55; P&amp;lt;0.05). Improvement in PFS with" exact="everolimus" post="plus exemestane was seen in all patients irrespective of"/>
   <result pre="95% CI: 0.31–0.55; P&amp;lt;0.05). Improvement in PFS with everolimus plus" exact="exemestane" post="was seen in all patients irrespective of Eastern Cooperative"/>
   <result pre="0 having a median PFS of 6.8 months in the" exact="everolimus" post="plus exemestane arm and 2.8 months with placebo plus"/>
   <result pre="a median PFS of 6.8 months in the everolimus plus" exact="exemestane" post="arm and 2.8 months with placebo plus exemestane. In"/>
   <result pre="metastases and an ECOG performance status of at least 1," exact="everolimus" post="more than tripled the median PFS compared with that"/>
   <result pre="tripled the median PFS compared with that of placebo plus" exact="exemestane" post="(6.8 vs 1.5 months). CBR was also significantly higher"/>
   <result pre="months). CBR was also significantly higher among patients treated with" exact="everolimus" post="plus exemestane than with placebo plus exemestane, and this"/>
   <result pre="was also significantly higher among patients treated with everolimus plus" exact="exemestane" post="than with placebo plus exemestane, and this effect was"/>
   <result pre="22.2%,). Patients with visceral disease had a similar CBR with" exact="everolimus" post="plus exemestane, independent of ECOG performance status. In these"/>
   <result pre="ECOG performance status. In these studies, the safety profile of" exact="everolimus" post="was consistent with that reported in previous studies. 56–"/>
   <result pre="fatigue, anorexia, and infection were more common among recipients of" exact="everolimus" post="plus tamoxifen than those who received tamoxifen alone. 56"/>
   <result pre="and infection were more common among recipients of everolimus plus" exact="tamoxifen" post="than those who received tamoxifen alone. 56 Most adverse"/>
   <result pre="among recipients of everolimus plus tamoxifen than those who received" exact="tamoxifen" post="alone. 56 Most adverse events (AEs) were grade 1/2,"/>
   <result pre="AEs. 57 The most common grade 3/4 AEs in the" exact="everolimus" post="plus exemestane arm were stomatitis (8% vs 1% with"/>
   <result pre="The most common grade 3/4 AEs in the everolimus plus" exact="exemestane" post="arm were stomatitis (8% vs 1% with placebo plus"/>
   <result pre="metastases. 8 The most common treatment-emergent AEs for patients receiving" exact="everolimus" post="plus exemestane with visceral vs nonvisceral disease were stomatitis"/>
   <result pre="The most common treatment-emergent AEs for patients receiving everolimus plus" exact="exemestane" post="with visceral vs nonvisceral disease were stomatitis (59% and"/>
   <result pre="an mTOR inhibitor to increase sensitivity to endocrine therapy with" exact="tamoxifen" post="or exemestane. In particular, the subanalysis of BOLERO-2 highlights"/>
   <result pre="life-threatening. 8 The ongoing Phase II study BOLERO-6 is evaluating" exact="everolimus" post="in combination with exemestane vs everolimus alone vs capecitabine"/>
   <result pre="Phase II study BOLERO-6 is evaluating everolimus in combination with" exact="exemestane" post="vs everolimus alone vs capecitabine alone, in advanced, recurrent,"/>
   <result pre="study BOLERO-6 is evaluating everolimus in combination with exemestane vs" exact="everolimus" post="alone vs capecitabine alone, in advanced, recurrent, or metastatic"/>
   <result pre="evaluating everolimus in combination with exemestane vs everolimus alone vs" exact="capecitabine" post="alone, in advanced, recurrent, or metastatic BC patients, after"/>
   <result pre="or metastatic BC patients, after progression or recurrence with previous" exact="letrozole" post="or anastrozole therapy ( ClinicalTrials.gov identifier: NCT01783444). Other mTOR"/>
   <result pre="BC patients, after progression or recurrence with previous letrozole or" exact="anastrozole" post="therapy ( ClinicalTrials.gov identifier: NCT01783444). Other mTOR inhibitors undergoing"/>
   <result pre="mTOR inhibitors undergoing clinical evaluation in advanced breast cancer include" exact="temsirolimus" post="and ridaforolimus, although data in the setting of endocrine"/>
   <result pre="ER-Positive HER2- Positive Mammary Carcinoma (TAnDEM) study, 207 patients received" exact="trastuzumab" post="(Herceptin ®; Genentech, Inc., South San Francisco, CA, USA)"/>
   <result pre="(Herceptin ®; Genentech, Inc., South San Francisco, CA, USA) plus" exact="anastrozole" post="or anastrozole alone as first- or second-line endocrine therapy"/>
   <result pre="Genentech, Inc., South San Francisco, CA, USA) plus anastrozole or" exact="anastrozole" post="alone as first- or second-line endocrine therapy for ABC."/>
   <result pre="endocrine therapy for ABC. 49 The patients received previous adjuvant" exact="tamoxifen" post="therapy or hormonal therapy for metastatic disease. The addition"/>
   <result pre="therapy or hormonal therapy for metastatic disease. The addition of" exact="trastuzumab" post="to anastrozole significantly increased PFS (hazard ratio: 0.63; 95%"/>
   <result pre="hormonal therapy for metastatic disease. The addition of trastuzumab to" exact="anastrozole" post="significantly increased PFS (hazard ratio: 0.63; 95% CI: 0.47–0.84;"/>
   <result pre="improvement was modest, with a PFS of 4.8 months, with" exact="trastuzumab" post="plus anastrozole and 2.4 months with anastrozole alone, and"/>
   <result pre="modest, with a PFS of 4.8 months, with trastuzumab plus" exact="anastrozole" post="and 2.4 months with anastrozole alone, and no significant"/>
   <result pre="4.8 months, with trastuzumab plus anastrozole and 2.4 months with" exact="anastrozole" post="alone, and no significant difference in OS between the"/>
   <result pre="this study. In another Phase III study, 1,286 patients received" exact="letrozole" post="plus lapatinib (Tykerb ®; GlaxoSmithKline, Research Triangle Park, NC,"/>
   <result pre="In another Phase III study, 1,286 patients received letrozole plus" exact="lapatinib" post="(Tykerb ®; GlaxoSmithKline, Research Triangle Park, NC, USA) or"/>
   <result pre="lapatinib (Tykerb ®; GlaxoSmithKline, Research Triangle Park, NC, USA) or" exact="letrozole" post="plus placebo as first-line treatment of HR+ metastatic BC,"/>
   <result pre="was allowed; however, previous neoadjuvant or adjuvant antiestrogen, AI, or" exact="trastuzumab" post="therapy was allowed if completed more than 1 year"/>
   <result pre="in patients with HR+ HER2− tumors with the addition of" exact="lapatinib" post="to letrozole (hazard ratio: 0.90; 95% CI: 0.77–1.05; P=0.188)."/>
   <result pre="with HR+ HER2− tumors with the addition of lapatinib to" exact="letrozole" post="(hazard ratio: 0.90; 95% CI: 0.77–1.05; P=0.188). In contrast,"/>
   <result pre="In contrast, in patients with HR+/HER2+ tumors, the addition of" exact="lapatinib" post="to letrozole significantly reduced the risk for disease progression"/>
   <result pre="in patients with HR+/HER2+ tumors, the addition of lapatinib to" exact="letrozole" post="significantly reduced the risk for disease progression vs letrozole"/>
   <result pre="to letrozole significantly reduced the risk for disease progression vs" exact="letrozole" post="plus placebo (hazard ratio: 0.71; 95% CI: 0.53–0.96; P=0.019),"/>
   <result pre="and 4 AEs was 23% and 5%, respectively, in the" exact="trastuzumab" post="plus anastrozole arm, and 15% and 1%, respectively, in"/>
   <result pre="AEs was 23% and 5%, respectively, in the trastuzumab plus" exact="anastrozole" post="arm, and 15% and 1%, respectively, in the anastrozole"/>
   <result pre="plus anastrozole arm, and 15% and 1%, respectively, in the" exact="anastrozole" post="alone arm. 49 In the Phase III study of"/>
   <result pre="anastrozole alone arm. 49 In the Phase III study of" exact="letrozole" post="plus lapatinib or letrozole plus placebo, the most common"/>
   <result pre="arm. 49 In the Phase III study of letrozole plus" exact="lapatinib" post="or letrozole plus placebo, the most common AEs were"/>
   <result pre="In the Phase III study of letrozole plus lapatinib or" exact="letrozole" post="plus placebo, the most common AEs were diarrhea, rash,"/>
   <result pre="50 Results from both studies suggest that the combination of" exact="lapatinib" post="or trastuzumab with anastrozole may provide some clinical benefit"/>
   <result pre="from both studies suggest that the combination of lapatinib or" exact="trastuzumab" post="with anastrozole may provide some clinical benefit in patients"/>
   <result pre="studies suggest that the combination of lapatinib or trastuzumab with" exact="anastrozole" post="may provide some clinical benefit in patients with HR+/HER2+"/>
   <result pre="that members of the EGF and IGF families can modulate" exact="tamoxifen" post="sensitivity and that increased expression of EGFR, HER2, and"/>
   <result pre="that increased expression of EGFR, HER2, and IGFR1 can elicit" exact="tamoxifen" post="resistance have led to clinical studies evaluating EGFR-targeted therapies"/>
   <result pre="Two Phase II studies evaluated the oral tyrosine kinase inhibitor" exact="gefitinib" post="(Iressa ®; AstraZeneca Pharmaceuticals LP) in combination with anastrozole"/>
   <result pre="inhibitor gefitinib (Iressa ®; AstraZeneca Pharmaceuticals LP) in combination with" exact="anastrozole" post="or tamoxifen vs anastrozole or tamoxifen alone, in patients"/>
   <result pre="(Iressa ®; AstraZeneca Pharmaceuticals LP) in combination with anastrozole or" exact="tamoxifen" post="vs anastrozole or tamoxifen alone, in patients with HR+"/>
   <result pre="AstraZeneca Pharmaceuticals LP) in combination with anastrozole or tamoxifen vs" exact="anastrozole" post="or tamoxifen alone, in patients with HR+ metastatic BC."/>
   <result pre="LP) in combination with anastrozole or tamoxifen vs anastrozole or" exact="tamoxifen" post="alone, in patients with HR+ metastatic BC. 51, 52"/>
   <result pre="during or after adjuvant therapy reported that the addition of" exact="gefitinib" post="to anastrozole significantly increased PFS (14.7 vs 8.4 months;"/>
   <result pre="after adjuvant therapy reported that the addition of gefitinib to" exact="anastrozole" post="significantly increased PFS (14.7 vs 8.4 months; hazard ratio:"/>
   <result pre="treatment discontinuation occurred in the combination arm than in the" exact="anastrozole" post="plus placebo arm (21% vs 4%). In contrast, the"/>
   <result pre="reported no significant improvement in PFS with the addition of" exact="gefitinib" post="to tamoxifen (hazard ratio: 0.84; 95% CI: 0.59–1.18). 51"/>
   <result pre="significant improvement in PFS with the addition of gefitinib to" exact="tamoxifen" post="(hazard ratio: 0.84; 95% CI: 0.59–1.18). 51 In this"/>
   <result pre="on these conflicting results, it has been suggested that prescribing" exact="gefitinib" post="or any other EGFR-tyrosine kinase inhibitor in combination with"/>
   <result pre="EGFR, HER2, and HER3 signaling, was initiated in combination with" exact="anastrozole" post="in HR+, HER2−, endocrine therapy–naïve ABC. 55 An interim"/>
   <result pre="Preclinical studies have shown synergistic activity with the CDK4/6 inhibitor" exact="palbociclib" post="(PD 0332991). 54 An ongoing two-part Phase II study"/>
   <result pre="ongoing two-part Phase II study is evaluating first-line therapy with" exact="palbociclib" post="in combination with letrozole or letrozole alone, in 66"/>
   <result pre="study is evaluating first-line therapy with palbociclib in combination with" exact="letrozole" post="or letrozole alone, in 66 patients with HR+ HER2−"/>
   <result pre="evaluating first-line therapy with palbociclib in combination with letrozole or" exact="letrozole" post="alone, in 66 patients with HR+ HER2− ABC. At"/>
   <result pre="data cutoff, PFS was significantly improved with the addition of" exact="palbociclib" post="to letrozole (hazard ratio: 0.38: 95% CI: 0.17–0.86; P=0.015)."/>
   <result pre="PFS was significantly improved with the addition of palbociclib to" exact="letrozole" post="(hazard ratio: 0.38: 95% CI: 0.17–0.86; P=0.015). The most"/>
   <result pre="ERα levels. 53 A Phase II, randomized, placebo-controlled study of" exact="exemestane" post="with or without entinostat in 130 postmenopausal women with"/>
   <result pre="had progressed during treatment with a nonsteroidal AI reported that" exact="exemestane" post="plus entinostat improved PFS compared with exemestane plus placebo"/>
   <result pre="AI reported that exemestane plus entinostat improved PFS compared with" exact="exemestane" post="plus placebo (4.3 vs 2.3 months) (hazard ratio: 0.73;"/>
   <result pre="CI: 0.50–1.07; P=0.055). Median OS improved from 28.1 months with" exact="exemestane" post="plus entinostat, compared with 19.8 months with exemestane plus"/>
   <result pre="months with exemestane plus entinostat, compared with 19.8 months with" exact="exemestane" post="plus placebo (hazard ratio: 0.59; 95% CI: 0.36–0.97; P=0.036)."/>
   <result pre="53 The most frequently reported AEs in the entinostat plus" exact="exemestane" post="group were fatigue, nausea, neutropenia, peripheral edema, vomiting, anemia,"/>
   <result pre="assessed as a secondary objective in the BOLERO-2 trial of" exact="everolimus" post="plus exemestane vs exemestane alone. 67 Results from this"/>
   <result pre="a secondary objective in the BOLERO-2 trial of everolimus plus" exact="exemestane" post="vs exemestane alone. 67 Results from this study showed"/>
   <result pre="objective in the BOLERO-2 trial of everolimus plus exemestane vs" exact="exemestane" post="alone. 67 Results from this study showed that everolimus"/>
   <result pre="vs exemestane alone. 67 Results from this study showed that" exact="everolimus" post="in combination with exemestane was associated with a longer"/>
   <result pre="Results from this study showed that everolimus in combination with" exact="exemestane" post="was associated with a longer time to definitive deterioration"/>
   <result pre="deterioration in global health-related QoL (HRQoL) than was placebo plus" exact="exemestane" post="alone. The median time to definitive deterioration in HRQoL"/>
   <result pre="time to definitive deterioration in HRQoL was 8.3 months with" exact="everolimus" post="plus exemestane and 5.8 months with placebo plus exemestane"/>
   <result pre="definitive deterioration in HRQoL was 8.3 months with everolimus plus" exact="exemestane" post="and 5.8 months with placebo plus exemestane (hazard ratio:"/>
   <result pre="with everolimus plus exemestane and 5.8 months with placebo plus" exact="exemestane" post="(hazard ratio: 0.74; P=0.0084). A subgroup analysis of various"/>
   <result pre="in HRQoL outcomes between treatment arms was found, indicating that" exact="everolimus" post="combined with exemestane provides clinical benefit without adversely affecting"/>
   <result pre="between treatment arms was found, indicating that everolimus combined with" exact="exemestane" post="provides clinical benefit without adversely affecting QoL. In a"/>
   <result pre="severe HRQoL decline with both treatments, whereas patients treated with" exact="everolimus" post="plus exemestane who did not drop out early had"/>
   <result pre="decline with both treatments, whereas patients treated with everolimus plus" exact="exemestane" post="who did not drop out early had stable HRQoL"/>
   <result pre="results from BOLERO-2 provide additional support for the benefit of" exact="everolimus" post="plus exemestane in patients with ABC in whom disease"/>
   <result pre="BOLERO-2 provide additional support for the benefit of everolimus plus" exact="exemestane" post="in patients with ABC in whom disease progressed after"/>
   <result pre="of the BOLERO-2 study have shown promising clinical benefit with" exact="everolimus" post="plus exemestane in HR+ ABC patients with visceral disease"/>
   <result pre="BOLERO-2 study have shown promising clinical benefit with everolimus plus" exact="exemestane" post="in HR+ ABC patients with visceral disease that progresses"/>
   <result pre="Henderson BE Breast cancer risk factors defined by estrogen and" exact="progesterone" post="receptor status: the multiethnic cohort study Am J Epidemiol"/>
   <result pre="Effect of visceral metastases on the efficacy and safety of" exact="everolimus" post="in postmenopausal women with advanced breast cancer: subgroup analysis"/>
   <result pre="et al. FACT: an open-label randomized phase III study of" exact="fulvestrant" post="and anastrozole in combination compared with anastrozole alone as"/>
   <result pre="FACT: an open-label randomized phase III study of fulvestrant and" exact="anastrozole" post="in combination compared with anastrozole alone as first-line therapy"/>
   <result pre="III study of fulvestrant and anastrozole in combination compared with" exact="anastrozole" post="alone as first-line therapy for patients with receptor-positive postmenopausal"/>
   <result pre="H Gershanovich M Sun Y et al. Superior efficacy of" exact="letrozole" post="versus tamoxifen as first-line therapy for postmenopausal women with"/>
   <result pre="M Sun Y et al. Superior efficacy of letrozole versus" exact="tamoxifen" post="as first-line therapy for postmenopausal women with advanced breast"/>
   <result pre="with metastatic breast cancer: efficacy and safety of treatment with" exact="ixabepilone" post="and other chemotherapeutic agents Clin Breast Cancer 2010 10"/>
   <result pre="Robertson JF Vergote I A review of the efficacy of" exact="anastrozole" post="in postmenopausal women with advanced breast cancer with visceral"/>
   <result pre="e28 24 Mauriac L Romieu G Bines J Activity of" exact="fulvestrant" post="versus exemestane in advanced breast cancer patients with or"/>
   <result pre="Mauriac L Romieu G Bines J Activity of fulvestrant versus" exact="exemestane" post="in advanced breast cancer patients with or without visceral"/>
   <result pre="Abreu P Winer EP Cameron DA A comparative study of" exact="exemestane" post="versus anastrozole in patients with postmenopausal breast cancer with"/>
   <result pre="Winer EP Cameron DA A comparative study of exemestane versus" exact="anastrozole" post="in patients with postmenopausal breast cancer with visceral metastases"/>
   <result pre="Johnston S Postmenopausal advanced breast cancer: options for therapy after" exact="tamoxifen" post="and aromatase inhibitors Breast 2006 15 5 584 594"/>
   <result pre="P Villedieu M Grisard E et al. Molecular characterization of" exact="anastrozole" post="resistance in breast cancer: pivotal role of the Akt/mTOR"/>
   <result pre="PS Haaland B Montero AJ Lopes G A meta-analysis of" exact="anastrozole" post="in combination with fulvestrant in the first line treatment"/>
   <result pre="AJ Lopes G A meta-analysis of anastrozole in combination with" exact="fulvestrant" post="in the first line treatment of hormone receptor positive"/>
   <result pre="Mauriac L et al. Double-blind, randomized placebo controlled trial of" exact="fulvestrant" post="compared with exemestane after prior nonsteroidal aromatase inhibitor therapy"/>
   <result pre="al. Double-blind, randomized placebo controlled trial of fulvestrant compared with" exact="exemestane" post="after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women"/>
   <result pre="Quaresma Albano J Gertler SZ Osborne CK Fulvestrant (Faslodex) versus" exact="anastrozole" post="for the second-line treatment of advanced breast cancer in"/>
   <result pre="et al. Results of the CONFIRM phase III trial comparing" exact="fulvestrant" post="250 mg with fulvestrant 500 mg in postmenopausal women"/>
   <result pre="the CONFIRM phase III trial comparing fulvestrant 250 mg with" exact="fulvestrant" post="500 mg in postmenopausal women with estrogen receptor-positive advanced"/>
   <result pre="Kaufman B Mackey JR Clemens MR et al. Trastuzumab plus" exact="anastrozole" post="versus anastrozole alone for the treatment of postmenopausal women"/>
   <result pre="Mackey JR Clemens MR et al. Trastuzumab plus anastrozole versus" exact="anastrozole" post="alone for the treatment of postmenopausal women with human"/>
   <result pre="Pippen J Jr Pivot X et al. Lapatinib combined with" exact="letrozole" post="versus letrozole and placebo as first-line therapy for postmenopausal"/>
   <result pre="Jr Pivot X et al. Lapatinib combined with letrozole versus" exact="letrozole" post="and placebo as first-line therapy for postmenopausal hormone receptor-positive"/>
   <result pre="Dirix LY et al. Gefitinib or placebo in combination with" exact="tamoxifen" post="in patients with hormone receptor-positive metastatic breast cancer: a"/>
   <result pre="Mangalik A et al. Phase II, randomized trial to compare" exact="anastrozole" post="combined with gefitinib or placebo in postmenopausal women with"/>
   <result pre="al. Phase II, randomized trial to compare anastrozole combined with" exact="gefitinib" post="or placebo in postmenopausal women with hormone receptor-positive metastatic"/>
   <result pre="B et al. Randomized phase II, double-blind, placebo-controlled study of" exact="exemestane" post="with or without entinostat in postmenopausal women with locally"/>
   <result pre="0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with" exact="letrozole" post="vs letrozole alone for first-line treatment of ER+/HER2− advanced"/>
   <result pre="cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs" exact="letrozole" post="alone for first-line treatment of ER+/HER2− advanced breast cancer"/>
   <result pre="the EGFR, HER2, HER3 signaling inhibitor AZD8931 in combination with" exact="anastrozole" post="(A) in women with endocrine therapy (ET) naive advanced"/>
   <result pre="C Cropet C et al. Randomized phase II trial of" exact="everolimus" post="in combination with tamoxifen in patients with hormone receptor-positive,"/>
   <result pre="al. Randomized phase II trial of everolimus in combination with" exact="tamoxifen" post="in patients with hormone receptor-positive, human epidermal growth factor"/>
   <result pre="Boccardo F Guglielmini P Parodi A Rubagotti A Chemotherapy versus" exact="tamoxifen" post="versus chemotherapy plus tamoxifen in node-positive, oestrogen receptor-positive breast"/>
   <result pre="Parodi A Rubagotti A Chemotherapy versus tamoxifen versus chemotherapy plus" exact="tamoxifen" post="in node-positive, oestrogen receptor-positive breast cancer patients. Very late"/>
   <result pre="RD et al. Timing of CMF chemotherapy in combination with" exact="tamoxifen" post="in postmenopausal women with breast cancer: role of endocrine"/>
   <result pre="WE Russell DH et al. Inhibition of mTOR activity restores" exact="tamoxifen" post="response in breast cancer cells with aberrant Akt Activity"/>
   <result pre="Yardley DA Noguchi S Pritchard KI et al. Everolimus plus" exact="exemestane" post="in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final"/>
   <result pre="Bondarenko I et al. Randomized phase III placebo-controlled trial of" exact="letrozole" post="plus oral temsirolimus as first-line endocrine therapy in postmenopausal"/>
   <result pre="al. Randomized phase III placebo-controlled trial of letrozole plus oral" exact="temsirolimus" post="as first-line endocrine therapy in postmenopausal women with locally"/>
   <result pre="of life of patients with advanced breast cancer treated with" exact="everolimus" post="plus exemestane versus placebo plus exemestane in the phase"/>
   <result pre="of patients with advanced breast cancer treated with everolimus plus" exact="exemestane" post="versus placebo plus exemestane in the phase 3, randomized,"/>
   <result pre="breast cancer treated with everolimus plus exemestane versus placebo plus" exact="exemestane" post="in the phase 3, randomized, controlled, BOLERO-2 trial Cancer"/>
   <result pre="Hille ET et al. Quality of life in relation to" exact="tamoxifen" post="or exemestane treatment in postmenopausal breast cancer patients: a"/>
   <result pre="et al. Quality of life in relation to tamoxifen or" exact="exemestane" post="treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane"/>
   <result pre="postmenopausal women with HR(+), HER2(−) advanced breast cancer treated with" exact="everolimus" post="plus exemestane versus exemestane monotherapy Curr Med Res Opin"/>
   <result pre="with HR(+), HER2(−) advanced breast cancer treated with everolimus plus" exact="exemestane" post="versus exemestane monotherapy Curr Med Res Opin 2013 29"/>
   <result pre="HER2(−) advanced breast cancer treated with everolimus plus exemestane versus" exact="exemestane" post="monotherapy Curr Med Res Opin 2013 29 11 1463"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4315003/results/search/inn/results.xml">
   <result pre="the cumulative randomized evidence for the efficacy and safety of" exact="lapatinib" post="combined with neoadjuvant therapy in human epidermal growth factor"/>
   <result pre="and neutropenia, were statistically more frequent in patients that received" exact="lapatinib" post="(RR, 2.46; 95% CI, 1.97–3.07; P&amp;lt;0.00001). The present analysis"/>
   <result pre="1.97–3.07; P&amp;lt;0.00001). The present analysis revealed that the addition of" exact="lapatinib" post="to neoadjuvant chemotherapy for HER2-positive breast cancer improves the"/>
   <result pre="of achieving a higher pCR rate, but the use of" exact="lapatinib" post="is associated with a higher risk of adverse events."/>
   <result pre="lapatinib is associated with a higher risk of adverse events." exact="lapatinib" post="breast cancer neoadjuvant meta-analysis Introduction Neoadjuvant chemotherapy for the"/>
   <result pre="neoadjuvant chemotherapy for the treatment of HER2-positive breast cancer patients," exact="trastuzumab" post="offers a substantial benefit in terms of pCR, with"/>
   <result pre="demonstrated by cell line and xenograft models ( 6, 7)," exact="lapatinib" post="blocks the activating signaling cascades in the MAPK and"/>
   <result pre="cell growth arrest or apoptosis. Clinical trials have demonstrated that" exact="lapatinib" post="is efficacious in HER2-positive metastatic breast cancer ( 8)."/>
   <result pre="therapeutic option to improve HER2 inhibition is the combination of" exact="lapatinib" post="and trastuzumab. The theoretical advantage of this combination is"/>
   <result pre="trials (RCTs) that have explored the potential advantages by using" exact="lapatinib" post="in the neoadjuvant setting have been previously reported ("/>
   <result pre="( 9– 12). To evaluate the efficacy and safety of" exact="lapatinib" post="combined with neoadjuvant therapy for the treatment of HER2-positive"/>
   <result pre="searched to avoid the exclusion of unpublished recent trials using" exact="lapatinib" post="in neoadjuvant chemotherapy. Finally, the reference lists of the"/>
   <result pre="identification; type and dose of chemotherapy; dose and duration of" exact="trastuzumab" post="therapy; and dose and duration of lapatinib therapy. Primary"/>
   <result pre="and duration of trastuzumab therapy; and dose and duration of" exact="lapatinib" post="therapy. Primary and secondary outcome measures, consisting of pCR,"/>
   <result pre="HR-positive was defined as immunohistochemical estrogen receptor level ≥10% or" exact="progesterone" post="receptor level ≥10%. Assessment of risk of bias Cochrane’s"/>
   <result pre="with HER2-positive breast cancer receiving trastuzumab-based chemotherapy versus combination of" exact="lapatinib" post="as neoadjuvant therapy. For each eligible study group, the"/>
   <result pre="The four trials were three-armed and compared the administration of" exact="trastuzumab" post="with the administration of lapatinib or a combination of"/>
   <result pre="and compared the administration of trastuzumab with the administration of" exact="lapatinib" post="or a combination of the two for neoadjuvant chemotherapy,"/>
   <result pre="of the two for neoadjuvant chemotherapy, with all regimens including" exact="paclitaxel" post="in the regimen. All trials reported the pCR rate"/>
   <result pre="and primary adverse events. To investigate the potential role of" exact="lapatinib" post="in neoadjuvant therapy, only the data from the trastuzumab-based"/>
   <result pre="the data from the trastuzumab-based chemotherapy arm, termed the no" exact="lapatinib" post="group, and the lapatinib plus trastuzumab-based chemotherapy arm, termed"/>
   <result pre="trastuzumab-based chemotherapy arm, termed the no lapatinib group, and the" exact="lapatinib" post="plus trastuzumab-based chemotherapy arm, termed the lapatinib group, were"/>
   <result pre="group, and the lapatinib plus trastuzumab-based chemotherapy arm, termed the" exact="lapatinib" post="group, were extracted. In total, 779 patients were included"/>
   <result pre="those, 388 patients had been randomly allocated to the no" exact="lapatinib" post="group and 391 to the lapatinib group. Risk of"/>
   <result pre="allocated to the no lapatinib group and 391 to the" exact="lapatinib" post="group. Risk of bias Two studies ( 9, 10)"/>
   <result pre="by Begg’s (P=0.216) and Egger’s (P=0.122) tests. Overall effect of" exact="lapatinib" post="on pCR All four trials, including 779 patients, included"/>
   <result pre="rate was 56.78% (222 out of 391 patients) in the" exact="lapatinib" post="group and 41.24% (160 out of 388 patients) in"/>
   <result pre="and 41.24% (160 out of 388 patients) in the no" exact="lapatinib" post="group (RR, 1.39; 95% CI, 1.20–1.60; P&amp;lt;0.0001). A subgroup"/>
   <result pre="status. The probability of pCR was significantly higher in the" exact="lapatinib" post="group compared with the no lapatinib group for HR-positive"/>
   <result pre="significantly higher in the lapatinib group compared with the no" exact="lapatinib" post="group for HR-positive (RR, 1.39; 95% CI, 1.12–1.72; P=0.002)"/>
   <result pre="and a lack of the necessary data. Overall effect of" exact="lapatinib" post="on the BCS rate and adverse events Data on"/>
   <result pre="patients that experienced primary adverse events was higher in the" exact="lapatinib" post="group compared with the no lapatinib group (RR 2.46;"/>
   <result pre="was higher in the lapatinib group compared with the no" exact="lapatinib" post="group (RR 2.46; 95% CI, 1.97–3.07; P&amp;lt;0.0001). The heterogeneity"/>
   <result pre="3.08; 95% CI, 1.35–7.02; P=0.007) was significantly higher in the" exact="lapatinib" post="group compared with the no lapatinib group. Despite there"/>
   <result pre="significantly higher in the lapatinib group compared with the no" exact="lapatinib" post="group. Despite there being no significant difference between the"/>
   <result pre="toxicity and neutropenia appeared to occur more frequently in the" exact="lapatinib" post="group ( Fig. 6). The pooled RRs for additional"/>
   <result pre="adverse events and the 95% CI for the use of" exact="lapatinib" post="in neoadjuvant chemotherapy versus the use of no lapatinib,"/>
   <result pre="present study, with the inclusion of all available RCTs regarding" exact="lapatinib" post="combined to neoadjuvant therapy, provides evidence that the addition"/>
   <result pre="combined to neoadjuvant therapy, provides evidence that the addition of" exact="lapatinib" post="to neoadjuvant chemotherapy in HER2-positive breast cancer patients results"/>
   <result pre="cancer were randomly allocated to the chemotherapy or chemotherapy plus" exact="trastuzumab" post="groups, demonstrated a doubling in the pCR rate in"/>
   <result pre="groups, demonstrated a doubling in the pCR rate in the" exact="trastuzumab" post="group compared with the chemotherapy group, and a strong"/>
   <result pre="pCR rate and event-free survival was also identified. The Taxol" exact="epirubicin" post="cyclophosphamide Herceptin neoadjuvant study reported a correlation between pCR"/>
   <result pre="rate and event-free survival was also identified. The Taxol epirubicin" exact="cyclophosphamide" post="Herceptin neoadjuvant study reported a correlation between pCR and"/>
   <result pre="or overall survival ( 17). According to these previous studies," exact="lapatinib" post="combined with neoadjuvant therapy is likely to improve disease-free"/>
   <result pre="The BCS rate demonstrated no statistically significant difference between the" exact="lapatinib" post="and no lapatinib groups in the present study. However,"/>
   <result pre="demonstrated no statistically significant difference between the lapatinib and no" exact="lapatinib" post="groups in the present study. However, the BCS rate"/>
   <result pre="dermatological toxicity ( 18), despite the recommended dosage reduction for" exact="lapatinib" post="( 19), the grade 3–4 diarrhea and dermatological toxicity"/>
   <result pre="were found to be statistically more frequent in patients receiving" exact="lapatinib" post="in the present study. Notably, the administration of lapatinib"/>
   <result pre="receiving lapatinib in the present study. Notably, the administration of" exact="lapatinib" post="in combination with trastuzumab did not result in an"/>
   <result pre="present study. Notably, the administration of lapatinib in combination with" exact="trastuzumab" post="did not result in an increased risk of cardiotoxicity."/>
   <result pre="to a previous meta-analysis assessing the administration neoadjuvant chemotherapy containing" exact="trastuzumab" post="compared with no trastuzumab, in which a low cardiotoxicity"/>
   <result pre="HER2 ( 20– 22). The previously reported neoadjuvant study of" exact="pertuzumab" post="and Herceptin in an early regimen evaluation trial of"/>
   <result pre="dual HER2 blockade using a combination of two anti-HER2 antibodies," exact="trastuzumab" post="and pertuzumab ( 23). This combination has also been"/>
   <result pre="blockade using a combination of two anti-HER2 antibodies, trastuzumab and" exact="pertuzumab" post="( 23). This combination has also been found to"/>
   <result pre="for HER2-positive metastatic breast cancer ( 24). Similar to pertuzumab," exact="lapatinib" post="demonstrates a complementary mechanism of action with trastuzumab, and"/>
   <result pre="agents ( 26, 27). The effectiveness of dual blockade with" exact="trastuzumab" post="and lapatinib has been demonstrated in the metastatic setting"/>
   <result pre="26, 27). The effectiveness of dual blockade with trastuzumab and" exact="lapatinib" post="has been demonstrated in the metastatic setting ( 28)."/>
   <result pre="30) compared the efficacy and safety of the addition of" exact="lapatinib" post="with the addition of trastuzumab, or a combination of"/>
   <result pre="available evidence, the present study revealed that the administration of" exact="lapatinib" post="in HER2-positive breast cancer in the neoadjuvant setting improves"/>
   <result pre="randomized trials should be conducted to elucidate the role of" exact="lapatinib" post="in neoadjuvant therapy in patients with HER2-positive breast cancer."/>
   <result pre="I Eidtmann H et al. NeoALTTO Study Team: Lapatinib with" exact="trastuzumab" post="for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label,"/>
   <result pre="L Eiermann W Semiglazov V et al. Neoadjuvant chemotherapy with" exact="trastuzumab" post="followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in"/>
   <result pre="V et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant" exact="trastuzumab" post="versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally"/>
   <result pre="GE et al. Pathologic complete response after neoadjuvant chemotherapy plus" exact="trastuzumab" post="predicts favorable survival in human epidermal growth factor receptor"/>
   <result pre="19 Dang C Lin N Moy B et al. Dose-dense" exact="doxorubicin" post="and cyclophosphamide followed by weekly paclitaxel with trastuzumab and"/>
   <result pre="C Lin N Moy B et al. Dose-dense doxorubicin and" exact="cyclophosphamide" post="followed by weekly paclitaxel with trastuzumab and lapatinib in"/>
   <result pre="B et al. Dose-dense doxorubicin and cyclophosphamide followed by weekly" exact="paclitaxel" post="with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is"/>
   <result pre="al. Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with" exact="trastuzumab" post="and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible"/>
   <result pre="doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and" exact="lapatinib" post="in HER2/neu-overexpressed/amplified breast cancer is not feasible because of"/>
   <result pre="T Im YH et al. Efficacy and safety of neoadjuvant" exact="pertuzumab" post="and trastuzumab in women with locally advanced, inflammatory, or"/>
   <result pre="YH et al. Efficacy and safety of neoadjuvant pertuzumab and" exact="trastuzumab" post="in women with locally advanced, inflammatory, or early HER2-positive"/>
   <result pre="J Kim SB et al. CLEOPATRA Study Group: Pertuzumab plus" exact="trastuzumab" post="plus docetaxel for metastatic breast cancer N Engl J"/>
   <result pre="SB et al. CLEOPATRA Study Group: Pertuzumab plus trastuzumab plus" exact="docetaxel" post="for metastatic breast cancer N Engl J Med 366"/>
   <result pre="Venkatesan N et al. Activity of the dual kinase inhibitor" exact="lapatinib" post="(GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells Cancer"/>
   <result pre="G Gillihan R et al. Different mechanisms for resistance to" exact="trastuzumab" post="versus lapatinib in HER2-positive breast cancers - role of"/>
   <result pre="R et al. Different mechanisms for resistance to trastuzumab versus" exact="lapatinib" post="in HER2-positive breast cancers - role of estrogen receptor"/>
   <result pre="Burstein HJ Storniolo AM et al. Overall survival benefit with" exact="lapatinib" post="in combination with trastuzumab for patients with human epidermal"/>
   <result pre="et al. Overall survival benefit with lapatinib in combination with" exact="trastuzumab" post="for patients with human epidermal growth factor receptor 2-positive"/>
   <result pre="Forero A et al. Multicenter phase II study of neoadjuvant" exact="lapatinib" post="and trastuzumab with hormonal therapy and without chemotherapy in"/>
   <result pre="et al. Multicenter phase II study of neoadjuvant lapatinib and" exact="trastuzumab" post="with hormonal therapy and without chemotherapy in patients with"/>
   <result pre="30 Valachis A Nearchou A Lind P Mauri D Lapatinib," exact="trastuzumab" post="or the combination added to preoperative chemotherapy for breast"/>
   <result pre="Correlation of molecular effects and pathologic complete response to preoperative" exact="lapatinib" post="and trastuzumab, separately and combined prior to neoadjuvant breast"/>
   <result pre="The risk of bias was low. CHER-LOB, chemotherapy, Herceptin and" exact="lapatinib" post="in operable breast cancer; NeoALTTO, Neo-adjuvant Lapatinib and/or Trastuzumab"/>
   <result pre="The pathological complete response rate was significantly higher in the" exact="lapatinib" post="group compared with the no lapatinib group for HR-positive"/>
   <result pre="significantly higher in the lapatinib group compared with the no" exact="lapatinib" post="group for HR-positive and −negative patients. M-H, Mantel-Haenszel; CI,"/>
   <result pre="CI, confidence interval; HR, hormone receptor; CHER-LOB, chemotherapy, Herceptin and" exact="lapatinib" post="in operable breast cancer; NeoALTTO, Neo-adjuvant Lapatinib and/or Trastuzumab"/>
   <result pre="CI, confidence interval; HR, hormone receptor; CHER-LOB, chemotherapy, Herceptin and" exact="lapatinib" post="in operable breast cancer; NeoALTTO, Neo-adjuvant Lapatinib and/or Trastuzumab"/>
   <result pre="+ T 2 mg/kg weekly 16 CHER-LOB, chemotherapy, Herceptin and" exact="lapatinib" post="in operable breast cancer; NeoALTTO, Neo-adjuvant Lapatinib and/or Trastuzumab"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4316710/results/search/inn/results.xml">
   <result pre="the ErbB2-positive breast cancer subtype where combination of anti-ErbB2, e.g.," exact="trastuzumab" post="with conventional chemotherapy, has drastically changed the patients' prognosis"/>
   <result pre="al., 2005). As well, combination of MAbs with TKIs, e.g.," exact="trastuzumab" post="plus anti-EGFR/anti-ErbB2 such as lapatinib or pertuzumab, revealed of"/>
   <result pre="of MAbs with TKIs, e.g., trastuzumab plus anti-EGFR/anti-ErbB2 such as" exact="lapatinib" post="or pertuzumab, revealed of clinical benefit for recurrent cancers"/>
   <result pre="or pertuzumab, revealed of clinical benefit for recurrent cancers following" exact="trastuzumab" post="treatment for instance (Geyer et al., 2006; Joensuu et"/>
   <result pre="versus placebo+trastuzumab+docetaxel (control arm) showed a survival improvement in the" exact="pertuzumab" post="arm and also demonstrated that ErbB2 marker is suited"/>
   <result pre="ErbB2-positive patients with early and metastatic breast cancer treated with" exact="trastuzumab" post="monotherapy, respectively (Harris et al., 2007; Wolff et al.,"/>
   <result pre="isoforms of the receptors not recognized by the inhibitor, e.g.," exact="trastuzumab" post="resistance in breast cancer has been associated with the"/>
   <result pre="the expression of a truncated p95-ErbB2 receptor isoform that lacks" exact="trastuzumab" post="antibody binding site; (iii) decreased MAb-induced cell-mediated cytotoxicity in"/>
   <result pre="of the MAb; and (iv) failure of MAb such as" exact="trastuzumab" post="to induce ErbB2 receptor shedding, internalization, and/or degradation by"/>
   <result pre="overcome resistance to anti-ErbB, e.g., combination of MAb such as" exact="trastuzumab" post="with lapatinib or pertuzumab, the use of ado-trastuzumabemtansine (T-DM1),"/>
   <result pre="to anti-ErbB, e.g., combination of MAb such as trastuzumab with" exact="lapatinib" post="or pertuzumab, the use of ado-trastuzumabemtansine (T-DM1), or combinations"/>
   <result pre="or pertuzumab, the use of ado-trastuzumabemtansine (T-DM1), or combinations of" exact="trastuzumab" post="with heat shock protein-90 (HSP90) inhibitors, PI3K inhibitors, and"/>
   <result pre="inhibitors, PI3K inhibitors, and immune checkpoint modulators in combination with" exact="trastuzumab" post="(Amiri-Kordestani et al., 2014). In contrast to cancer-associated somatic"/>
   <result pre="group reported the association of ErbB3 overexpression with resistance to" exact="tamoxifen" post="as well as to small molecule TKI in breast"/>
   <result pre="recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor," exact="pertuzumab" post=". Cancer Immunol. Immunother. 55, 717– 727. 10.1007/s00262-005-0058-x 16151804"/>
   <result pre="2014). First FDA Approval of neoadjuvant therapy for breast cancer:" exact="pertuzumab" post="for the treatment of patients with HER2-positive breast cancer"/>
   <result pre="Biomarker analyses in CLEOPATRA: a Phase III, placebo-controlled study of" exact="pertuzumab" post="in human epidermal growth factor receptor 2-positive, first-line metastatic"/>
   <result pre="Nanni I. et al. . ( 2011). Pharmacogenetic profiling and" exact="cetuximab" post="outcome in patients with advanced colorectal cancer . BMC"/>
   <result pre="models with EGFR and ERBB2 mutations that are resistant to" exact="gefitinib" post=". Cancer Res 67, 11924– 11932. 10.1158/0008-5472.CAN-07-1885 18089823 Fan"/>
   <result pre="Proudlove C. et al. ( 2015). Pertuzumab in combination with" exact="trastuzumab" post="and docetaxel for the treatment of her2-positive metastatic or"/>
   <result pre="et al. ( 2015). Pertuzumab in combination with trastuzumab and" exact="docetaxel" post="for the treatment of her2-positive metastatic or locally recurrent"/>
   <result pre="G. Pienkowski T. et al. . ( 2006). Lapatinib plus" exact="capecitabine" post="for HER2-positive advanced breast cancer. N. Engl. J. Med."/>
   <result pre="2014). Association between the HER2 Ile655Val polymorphism and response to" exact="trastuzumab" post="in women with operable primary breast cancer . Ann."/>
   <result pre="et al. . ( 2007). Predictors of resistance to preoperative" exact="trastuzumab" post="and vinorelbine for HER2-positive early breast cancer . Clin."/>
   <result pre=". ( 2007). Predictors of resistance to preoperative trastuzumab and" exact="vinorelbine" post="for HER2-positive early breast cancer . Clin. Cancer Res."/>
   <result pre="Kataja V. Asola R. et al. . ( 2006). Adjuvant" exact="docetaxel" post="or vinorelbine with or without trastuzumab for breast cancer."/>
   <result pre="Asola R. et al. . ( 2006). Adjuvant docetaxel or" exact="vinorelbine" post="with or without trastuzumab for breast cancer. N. Engl."/>
   <result pre=". ( 2006). Adjuvant docetaxel or vinorelbine with or without" exact="trastuzumab" post="for breast cancer. N. Engl. J. Med. 354, 809–"/>
   <result pre="Thor A. D. ( 2007). Downregulation of erbB3 abrogates erbB2-mediated" exact="tamoxifen" post="resistance in breast cancer cells . Int. J. Cancer"/>
   <result pre="of K-ras in metastatic colorectal cancer patients treated with single-agent" exact="cetuximab" post=". Clin. Cancer Res. 14, 7884– 7895. 10.1158/1078-0432.CCR-07-5165 19047118"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4322830/results/search/inn/results.xml">
   <result pre="report a case of a complete response to single agent" exact="trastuzumab" post="in a hemodialysis patient with metastatic Her2/neu overexpressed EMPD"/>
   <result pre="with several individual reports of favorable response to therapy with" exact="trastuzumab" post="and paclitaxel [ 13– 15]. A single report of"/>
   <result pre="individual reports of favorable response to therapy with trastuzumab and" exact="paclitaxel" post="[ 13– 15]. A single report of trastuzumab monotherapy"/>
   <result pre="trastuzumab and paclitaxel [ 13– 15]. A single report of" exact="trastuzumab" post="monotherapy in a woman with labial EMPD has been"/>
   <result pre="with metastatic EMPD of the scrotum treated with single agent" exact="trastuzumab" post="with a complete response. Targeted next generation sequencing (tNGS)"/>
   <result pre="compare them to mammary Paget disease (MPD). The use of" exact="trastuzumab" post="in hemodialysis patients is also discussed. 2. Case Presentation"/>
   <result pre="hemodialysis, it was decided to attempt to treat him with" exact="trastuzumab" post="monotherapy rather than initiating cytotoxic chemotherapy, with a loading"/>
   <result pre="undergoing periodic cardiac function analysis, the patient continues to receive" exact="trastuzumab" post="therapy without significant side effects. Of note, he was"/>
   <result pre="lymph nodes and bone, who underwent treatment with single agent" exact="trastuzumab" post="and achieved a complete response by RECIST criteria. Our"/>
   <result pre="of particular interest for two separate reasons: the use of" exact="trastuzumab" post="to treat HER2/neu positive EMPD and the use of"/>
   <result pre="trastuzumab to treat HER2/neu positive EMPD and the use of" exact="trastuzumab" post="in a hemodialysis patient. Furthermore, we were able to"/>
   <result pre="died of actual EMPD, with several receiving neoadjuvant chemotherapy with" exact="docetaxel" post="prior to surgery [ 9]. Interestingly, nine of the"/>
   <result pre="case reports includes cisplatin, 5-fluorouracil, mitomycin C, paclitaxel, docetaxel, and" exact="epirubicin" post="[ 19– 21]. More recently, it has been observed"/>
   <result pre="22, 23]. As a result two case reports of using" exact="trastuzumab" post="with paclitaxel and a single report of single agent"/>
   <result pre="As a result two case reports of using trastuzumab with" exact="paclitaxel" post="and a single report of single agent trastuzumab have"/>
   <result pre="trastuzumab with paclitaxel and a single report of single agent" exact="trastuzumab" post="have been presented [ 13, 14, 16]. One patient"/>
   <result pre="response to single agent trastuzumab. No report of single agent" exact="trastuzumab" post="in penoscrotal EMPD our knowledge has been presented and"/>
   <result pre="presented and herein we report a second dramatic response to" exact="trastuzumab" post="monotherapy in EMPD overall and the first in the"/>
   <result pre="acute myeloid leukemia and myelodysplastic syndrome. DNA methyltransferase inhibitors include" exact="azacitidine" post="and decitabine and this may be considered for an"/>
   <result pre="leukemia and myelodysplastic syndrome. DNA methyltransferase inhibitors include azacitidine and" exact="decitabine" post="and this may be considered for an EMPD patient"/>
   <result pre="FISH and who was treated initially with adriamycin, cyclophosphamide, and" exact="letrozole" post="[ 24]. Due to NGS, a genomic ERBB2 S210F"/>
   <result pre="mutation was found and the patient was successfully treated with" exact="lapatinib" post="and capecitabine. Thus, to further investigate molecular profiling of"/>
   <result pre="given the overexpression noted in the scrotal case. Finally, whether" exact="trastuzumab" post="can be safely used in someone with ESRD on"/>
   <result pre="with recurrent metastatic HER2 (3+) breast cancer was treated with" exact="trastuzumab" post="without development of significant adverse effects. A second patient"/>
   <result pre="significant adverse effects. A second patient with ESRD also received" exact="trastuzumab" post="in the adjuvant setting for invasive ductal carcinoma in"/>
   <result pre="and had clinical response without adverse effects. Serum concentrations of" exact="trastuzumab" post="were not monitored in either of these cases. Our"/>
   <result pre="in every metastatic EMPD patient with the subsequent use of" exact="trastuzumab" post="as first line therapy. The question remains whether the"/>
   <result pre="first line therapy. The question remains whether the addition of" exact="paclitaxel" post="or any other cytotoxic drugs adds to overall survival,"/>
   <result pre="as EMPD, delaying cytotoxic therapy in favor of single agent" exact="trastuzumab" post="may be prudent. In our patient on hemodialysis, trastuzumab"/>
   <result pre="agent trastuzumab may be prudent. In our patient on hemodialysis," exact="trastuzumab" post="was well tolerated and adds a third case in"/>
   <result pre="S. A case of metastatic extramammary Paget's disease responding to" exact="trastuzumab" post="plus paclitaxel combination therapy Case Reports in Dermatology 2011"/>
   <result pre="case of metastatic extramammary Paget's disease responding to trastuzumab plus" exact="paclitaxel" post="combination therapy Case Reports in Dermatology 2011 3 3"/>
   <result pre="Kamegashira A. et al. Metastatic extramammary Paget's disease treated with" exact="paclitaxel" post="and trastuzumab combination chemotherapy Journal of Dermatology 2009 36"/>
   <result pre="et al. Metastatic extramammary Paget's disease treated with paclitaxel and" exact="trastuzumab" post="combination chemotherapy Journal of Dermatology 2009 36 8 457"/>
   <result pre="Dramatic clinical response of relapsed metastatic extramammary Paget's disease to" exact="trastuzumab" post="monotherapy Case Reports in Dermatological Medicine 2012 2012 3"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4322880/results/search/inn/results.xml">
   <result pre="doi: 10.2147/OTT.S74110 ott-8-289 : Case Report Efficacy of nab-paclitaxel plus" exact="trastuzumab" post="in a long-surviving heavily pretreated HER2-positive breast cancer patient"/>
   <result pre="is of note for several reasons. First, the nab-paclitaxel plus" exact="trastuzumab" post="combination, despite several previous lines of treatment, some of"/>
   <result pre="progression-free survival reported in our case with the nab-paclitaxel plus" exact="trastuzumab" post="combination further confirms the efficacy and the favorable toxicity"/>
   <result pre="a possible activity on BM. In conclusion, weekly nab-paclitaxel plus" exact="trastuzumab" post="may represent a valuable option in the treatment of"/>
   <result pre="heavily pretreated patients. Keywords HER-2 breast cancer nab-paclitaxel brain metastases" exact="trastuzumab" post="long survivor Background Brain metastases (BMs) represent a major"/>
   <result pre="as a consequence of the success of trastuzumab-based therapy. Because" exact="trastuzumab" post="does not cross the blood–brain barrier (BBB) due to"/>
   <result pre="1– 3 Moreover, three distinct meta-analyses of the use of" exact="trastuzumab" post="in the adjuvant setting reported a higher incidence of"/>
   <result pre="revealed a luminal B HER2-positive BC estrogen receptor (ER): 70%;" exact="progesterone" post="receptor (PgR): 40%; ki-67 &amp;gt;25%; HER2: 3+ detected by"/>
   <result pre="disease stage, she underwent adjuvant chemotherapy with fluouracil, epirubicin, and" exact="cyclophosphamide" post="(FEC (90)) for six cycles, followed by locoregional radiotherapy"/>
   <result pre="with luteinizing hormone-releasing hormone (LHRH) analog + tamoxifen. No adjuvant" exact="trastuzumab" post="therapy was administered because of regulatory issues. In January"/>
   <result pre="lung and then she was put on first-line metastatic therapy" exact="docetaxel" post="(75 mg/m 2 of body surface area every 21"/>
   <result pre="2 of body surface area every 21 days) plus 3-weekly" exact="trastuzumab" post="(with a loading dose of 8 mg/kg, followed by"/>
   <result pre="was discontinued and in March 2011, she began treatment with" exact="lapatinib" post="1,250 mg daily plus capecitabine 1,000 mg/m 2 twice"/>
   <result pre="2011, she began treatment with lapatinib 1,250 mg daily plus" exact="capecitabine" post="1,000 mg/m 2 twice daily on days 1–14 every"/>
   <result pre="months, she experienced bone progressive disease in the pelvis. Thus," exact="lapatinib" post="therapy was switched to weekly trastuzumab plus vinorelbine (at"/>
   <result pre="in the pelvis. Thus, lapatinib therapy was switched to weekly" exact="trastuzumab" post="plus vinorelbine (at a dose of 25 mg/m 2"/>
   <result pre="pelvis. Thus, lapatinib therapy was switched to weekly trastuzumab plus" exact="vinorelbine" post="(at a dose of 25 mg/m 2 of body"/>
   <result pre="nab-paclitaxel at a dose of 125 mg/m 2, continuing weekly" exact="trastuzumab" post="beyond progression. Four courses of nab-paclitaxel/trastuzumab therapy were delivered,"/>
   <result pre="Despite this impressive clinical activity, concern has been expressed that" exact="trastuzumab" post="therapy may be associated with an increased frequency of"/>
   <result pre="retrospective studies reported that patients with HER2-overexpressing MBC who received" exact="trastuzumab" post="after diagnosis of BM survive longer, suggesting that continuation"/>
   <result pre="presence of an altered BBB. Given its small lipophilic molecule," exact="lapatinib" post="can cross the BBB, and drug penetration at significant"/>
   <result pre="demonstrated in resected BM of patients with MBC treated with" exact="lapatinib" post="plus capecitabine, suggesting that these drugs are capable of"/>
   <result pre="a heavily pretreated patient with the combination of nab-paclitaxel plus" exact="trastuzumab" post="is of note for several reasons. First, nab-paclitaxel plus"/>
   <result pre="trastuzumab is of note for several reasons. First, nab-paclitaxel plus" exact="trastuzumab" post="combination, despite several previous lines of treatment, some of"/>
   <result pre="of which were associated with known activity on BM (ie," exact="lapatinib" post="plus capecitabine), was the first systemic therapy not associated"/>
   <result pre="lengthy PFS reported in our case with the nab-paclitaxel plus" exact="trastuzumab" post="combination further confirms the efficacy and the favorable toxicity"/>
   <result pre="than previous lines of therapy. In conclusion, weekly nab-paclitaxel plus" exact="trastuzumab" post="may represent a valuable option in the treatment of"/>
   <result pre="with standard first-line therapy, which now is represented by the" exact="trastuzumab" post="+ pertuzumab + docetaxel combination. 22 In addition, the"/>
   <result pre="first-line therapy, which now is represented by the trastuzumab +" exact="pertuzumab" post="+ docetaxel combination. 22 In addition, the present case"/>
   <result pre="which now is represented by the trastuzumab + pertuzumab +" exact="docetaxel" post="combination. 22 In addition, the present case further confirms"/>
   <result pre="case further confirms the positive impact of the use of" exact="trastuzumab" post="beyond, as emerged in the GBG 26 trial. 23"/>
   <result pre="et al. Cardiotoxicity and incidence of brain metastases after adjuvant" exact="trastuzumab" post="for early breast cancer: the dark side of the"/>
   <result pre="Afonso SL Stefano EJ De Fendi LI Soares FV Adjuvant" exact="trastuzumab" post="in the treatment of her-2-positive early breast cancer: a"/>
   <result pre="recurrence in patients with HER2-positive breast cancer treated with adjuvant" exact="trastuzumab" post="Ann Oncol 2013 24 6 1526 1533 23463626 7"/>
   <result pre="RD et al. collab: HERA study team 2-year follow-up of" exact="trastuzumab" post="after adjuvant chemotherapy in HER2-positive breast cancer: a randomised"/>
   <result pre="Morikawa A Peereboom DM Thorsheim HR et al. Capecitabine and" exact="lapatinib" post="uptake in surgically resected brain metastases from metastatic breast"/>
   <result pre="Min M A phase II study of weekly nanoparticle albumin-bound" exact="paclitaxel" post="with or without trastuzumab in metastatic breast cancer Clin"/>
   <result pre="II study of weekly nanoparticle albumin-bound paclitaxel with or without" exact="trastuzumab" post="in metastatic breast cancer Clin Breast Cancer 2011 11"/>
   <result pre="A et al. Phase II trial of weekly nanoparticle albumin-bound" exact="paclitaxel" post="with carboplatin and trastuzumab as first-line therapy for women"/>
   <result pre="al. Phase II trial of weekly nanoparticle albumin-bound paclitaxel with" exact="carboplatin" post="and trastuzumab as first-line therapy for women with HER2-overexpressing"/>
   <result pre="II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and" exact="trastuzumab" post="as first-line therapy for women with HER2-overexpressing metastatic breast"/>
   <result pre="with solid tumors: disposition kinetics and pharmacology distinct from solvent-based" exact="paclitaxel" post="J Clin Pharmacol 2014 54 10 1097 1107 24719309"/>
   <result pre="Kim SB et al. collab: CLEOPATRA Study Group Pertuzumab plus" exact="trastuzumab" post="plus docetaxel for metastatic breast cancer N Engl J"/>
   <result pre="et al. collab: CLEOPATRA Study Group Pertuzumab plus trastuzumab plus" exact="docetaxel" post="for metastatic breast cancer N Engl J Med 2012"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4323263/results/search/inn/results.xml">
   <result pre="inguinal fat pad of mice (MFP) concurrently with a subcutaneous" exact="estradiol" post="pellet. Following growth of the tumor in passage 1"/>
   <result pre="NOD, nonobese diabetic; NR, not reported; PDX, patient-derived xenograft; PR," exact="progesterone" post="receptor; SCID, severe combined immunodeficiency; TNC, triple-negative cancer. aIrradiated"/>
   <result pre="BCL-W [ 66], was found to potentiate the response to" exact="docetaxel" post="in PDX models of triple-negative breast cancer [ 35],"/>
   <result pre="or the specific BCL-2 inhibitor ABT-199 markedly improved responsiveness to" exact="tamoxifen" post="[ 30]. These data indicated that targeting of BCL2"/>
   <result pre="one PDX line (23 T), the combination of ABT-199 with" exact="tamoxifen" post="resulted in complete remission. Interestingly, in another ER-positive model"/>
   <result pre="P-AKT were apparent and synergistic activity was observed between ABT-199," exact="tamoxifen" post="and mammalian target of rapamycin (mTOR) inhibition [ 30]."/>
   <result pre="tested two HER2/ERBB2-amplified PDX lines, one of which responded to" exact="trastuzumab" post="while the other did not [ 27]. Synergistic interactions"/>
   <result pre="while the other did not [ 27]. Synergistic interactions of" exact="trastuzumab" post="with docetaxel were reported to increase anti-tumor efficacy. Inhibitors"/>
   <result pre="other did not [ 27]. Synergistic interactions of trastuzumab with" exact="docetaxel" post="were reported to increase anti-tumor efficacy. Inhibitors of the"/>
   <result pre="PDX model derived from a patient who had relapsed after" exact="trastuzumab" post="therapy was unresponsive to trastuzumab, but showed tumor shrinkage"/>
   <result pre="unresponsive to trastuzumab, but showed tumor shrinkage in response to" exact="lapatinib" post="and superior regression with a combination of lapatinib and"/>
   <result pre="response to lapatinib and superior regression with a combination of" exact="lapatinib" post="and the mTORC1/2 inhibitor INK-128 [ 67]. Patient-derived xenograft"/>
   <result pre="of ER-positive breast cancer diagnoses respond to anti-estrogens such as" exact="tamoxifen" post="and aromatase inhibitors, their efficacy is limited by intrinsic"/>
   <result pre="to estrogen deprivation retained some sensitivity to tamoxifen. Resistance to" exact="tamoxifen" post="did not produce a universal molecular phenotype of endocrine"/>
   <result pre="signaling and acquired sensitivity to mTOR inhibition. The mTOR inhibitor" exact="everolimus" post="has been beneficial in the treatment of advanced breast"/>
   <result pre="to endocrine therapies [ 70]. In tamoxifen-resistant xenografts, treatment with" exact="everolimus" post="alone or in combination with tamoxifen resulted in a"/>
   <result pre="tamoxifen-resistant xenografts, treatment with everolimus alone or in combination with" exact="tamoxifen" post="resulted in a cytostatic response; in contrast to combined"/>
   <result pre="tamoxifen resulted in a cytostatic response; in contrast to combined" exact="fulvestrant" post="and everolimus, which resulted in significant regression [ 68]."/>
   <result pre="to create resistance models for preclinical research. Prolonged exposure to" exact="cisplatin" post="in high-grade serous ovarian cancer has led to the"/>
   <result pre="to the generation of platinum-resistant models [ 73], while continuous" exact="vemurafenib" post="treatment led to the development of a resistant BRAF-mutated"/>
   <result pre="of breast cancer, continuous treatment of HER2-amplified PDX models with" exact="trastuzumab" post="could provide a useful preclinical tool to eventually overcome"/>
   <result pre="breast cancers, which were found to be more responsive to" exact="tamoxifen" post="[ 80]. The targeted knockin of multiple human cytokine"/>
   <result pre="in stroma-related gene pathways predict poor survival and resistance to" exact="gemcitabine" post="in patients with pancreatic cancer Clin Cancer Res. 2011"/>
   <result pre="al. Preclinical and clinical studies of gamma secretase inhibitors with" exact="docetaxel" post="on human breast tumors Clin Cancer Res. 2013 19"/>
   <result pre="AS Sellers WR Pryer NK Levesque MP et al. Modelling" exact="vemurafenib" post="resistance in melanoma reveals a strategy to forestall drug"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4325954/results/search/inn/results.xml">
   <result pre="energy supply for fast growth. In many breast cancers, estrogen," exact="progesterone" post="and epidermal growth factor receptor-positive cells proliferate in response"/>
   <result pre="breast cancer are also the phenotypic drug targets; hormone (estrogen," exact="progesterone" post="and HER2) receptors are commonly overexpressed. This knowledge has"/>
   <result pre="general chemotherapy that induces DNA damage through agents such as" exact="cisplatin" post="which act to reduce the DNA damage repair response"/>
   <result pre="patients, is characterised by tumours that lack expression of ER," exact="progesterone" post="receptor and HER2/neu and is associated with a poor"/>
   <result pre="Irrespective of the target receptor for each of the inhibitors," exact="lapatinib" post="and trastuzumab (epidermal growth factor receptor; EGFR and/or EGFR2;"/>
   <result pre="the target receptor for each of the inhibitors, lapatinib and" exact="trastuzumab" post="(epidermal growth factor receptor; EGFR and/or EGFR2; HER2, respectively),"/>
   <result pre="apoptosis when PI3k is knocked down [ 24]. The bisphosphonate," exact="zoledronic acid," post="originally used for osteoporosis management, is now in clinical"/>
   <result pre="limit the application of many anti-cancer therapies. Acquired resistance to" exact="lapatinib" post="and trastuzumab frequently occurs in breast cancer patients, possibly"/>
   <result pre="application of many anti-cancer therapies. Acquired resistance to lapatinib and" exact="trastuzumab" post="frequently occurs in breast cancer patients, possibly as a"/>
   <result pre="present an opportunity for adjuvant therapy with drugs such as" exact="tamoxifen" post="that target ER. Similarly, upregulation of HER3 is induced"/>
   <result pre="suggestion that targeting of the PI3k/mTOR pathway in combination with" exact="trastuzumab" post="is beneficial in trastuzumab-resistant breast cancer [ 56]. The"/>
   <result pre="The transcription factor FOXO3a is a crucial cellular target of" exact="gefitinib" post="(Iressa) in breast cancer cells Mol Cancer Ther 2007"/>
   <result pre="R et al. Delineation of molecular mechanisms of sensitivity to" exact="lapatinib" post="in breast cancer cell lines using global gene expression"/>
   <result pre="H Busby R Lupu R CCN1, a candidate target for" exact="zoledronic acid" post="treatment in breast cancer Mol Cancer Ther 2011 10"/>
   <result pre="Taneja C Sofrygin O Kaura S Gnant M Cost-effectiveness of" exact="zoledronic acid" post="plus endocrine therapy in premenopausal women with hormone-responsive early"/>
   <result pre="predictors of endocrine therapy responsiveness-a randomized neoadjuvant trial comparison between" exact="anastrozole" post="and tamoxifen for the treatment of postmenopausal breast cancer"/>
   <result pre="endocrine therapy responsiveness-a randomized neoadjuvant trial comparison between anastrozole and" exact="tamoxifen" post="for the treatment of postmenopausal breast cancer BMC Cancer."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4330173/results/search/inn/results.xml">
   <result pre="a Chinese population. We investigated neoadjuvant chemotherapy treatment with either" exact="trastuzumab" post="or lapatinib in BC patients based on molecular factors"/>
   <result pre="population. We investigated neoadjuvant chemotherapy treatment with either trastuzumab or" exact="lapatinib" post="in BC patients based on molecular factors such as"/>
   <result pre="collected from these 326 BC patients (154 patients in the" exact="trastuzumab" post="arm and 172 patients in the lapatinib arm). For"/>
   <result pre="patients in the trastuzumab arm and 172 patients in the" exact="lapatinib" post="arm). For the validation study, serum samples were collected"/>
   <result pre="positivity including HER2 positivity, triple negative status, and ER and" exact="progesterone" post="receptor status. All tests comparing groups were 2-tailed, and"/>
   <result pre="treatment along with clinicopathological characteristics and pathological complete responses to" exact="trastuzumab" post="or lapatinib-based neoadjuvant therapy. Our subgroup analysis revealed that"/>
   <result pre="estrogen receptor; HER2, human epithelial growth factor receptor 2; PR," exact="progesterone" post="receptor; TNM, tumor-node-metastasis. Table 3 Prognosis of serum miR-21"/>
   <result pre="human epithelial growth factor receptor 2; HR, hazard ratio; PR," exact="progesterone" post="receptor; TNM, tumor-node-metastasis."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4331616/results/search/inn/results.xml">
   <result pre="patients with HER2-positive advanced or metastatic breast cancer treated with" exact="lapatinib" post="in combination with capecitabine: results from 51 Japanese patients"/>
   <result pre="demonstrated a significant improvement in time to progression (TTP) when" exact="lapatinib" post="was combined with capecitabine compared with capecitabine alone in"/>
   <result pre="in time to progression (TTP) when lapatinib was combined with" exact="capecitabine" post="compared with capecitabine alone in patients with HER2-positive advanced"/>
   <result pre="progression (TTP) when lapatinib was combined with capecitabine compared with" exact="capecitabine" post="alone in patients with HER2-positive advanced or metastatic breast"/>
   <result pre="advanced or metastatic breast cancer. In this clinical study of" exact="lapatinib" post="in combination with capecitabine, efficacy, safety, pharmacokinetics (PK) and"/>
   <result pre="breast cancer treated with prior trastuzumab. Methods Eligible women received" exact="lapatinib" post="1250 mg once daily and capecitabine 1000 mg/m 2"/>
   <result pre="Methods Eligible women received lapatinib 1250 mg once daily and" exact="capecitabine" post="1000 mg/m 2 twice daily on days 1 through"/>
   <result pre="for at least 24 weeks). Results Lapatinib in combination with" exact="capecitabine" post="was well tolerated in the 51 patients enrolled in"/>
   <result pre="%) and stomatitis (41 %). Conclusions Lapatinib in combination with" exact="capecitabine" post="in Japanese HER2-positive breast cancer patients was well tolerated."/>
   <result pre="EGF receptor family TKIs, such as lapatinib, compete intracellularly with" exact="adenosine" post="triphosphate for its receptor binding site and inhibit the"/>
   <result pre="overseas phase III study evaluating the efficacy and safety of" exact="lapatinib" post="in combination with capecitabine in women with HER2-positive advanced"/>
   <result pre="evaluating the efficacy and safety of lapatinib in combination with" exact="capecitabine" post="in women with HER2-positive advanced or metastatic breast cancer"/>
   <result pre="metastatic breast cancer (MBC) that progressed following prior therapy including" exact="trastuzumab" post="provided the evidence of the efficacy and safety for"/>
   <result pre="safety for this combination [ 3– 5]. Further studies evaluating" exact="lapatinib" post="and capecitabine have been reported in the past ["/>
   <result pre="this combination [ 3– 5]. Further studies evaluating lapatinib and" exact="capecitabine" post="have been reported in the past [ 6– 9];"/>
   <result pre="in Japanese patients with HER2-positive advanced or MBC treated with" exact="lapatinib" post="in combination with capecitabine. Patients and methods Study design"/>
   <result pre="or stable disease (SD) for at least 24 weeks] of" exact="lapatinib" post="in combination with capecitabine at the overseas recommended dosage"/>
   <result pre="for at least 24 weeks] of lapatinib in combination with" exact="capecitabine" post="at the overseas recommended dosage (i.e., lapatinib 1250 mg/day"/>
   <result pre="in combination with capecitabine at the overseas recommended dosage (i.e.," exact="lapatinib" post="1250 mg/day QD and capecitabine 2000 mg/m 2/day BID)"/>
   <result pre="the overseas recommended dosage (i.e., lapatinib 1250 mg/day QD and" exact="capecitabine" post="2000 mg/m 2/day BID) in Japanese patients with HER2-positive"/>
   <result pre="was to determine the safety, tolerability and PK parameters of" exact="lapatinib" post="given with capecitabine in the six patients enrolled. This"/>
   <result pre="the safety, tolerability and PK parameters of lapatinib given with" exact="capecitabine" post="in the six patients enrolled. This was done as"/>
   <result pre="as it was the first time Japanese patients had received" exact="lapatinib" post="in combination with capecitabine. If no major safety concerns"/>
   <result pre="Patients were excluded if they had had prior therapy with" exact="capecitabine" post="or an EGFR and/or HER2 inhibitor other than trastuzumab,"/>
   <result pre="for 14 days in every 21 days. Each dose of" exact="capecitabine" post="was 1000 mg/m 2. Subjects were treated until disease"/>
   <result pre="collected in ethylenediaminetetraacetic acid (EDTA) tubes] for the analysis of" exact="lapatinib" post="were drawn before dosing and 1, 2, 3, 4,"/>
   <result pre="day 14 and day 21: blood samples (2 ml for" exact="lapatinib" post="and 6 ml for capecitabine, 5-FU and FBAL) were"/>
   <result pre="5-FU and FBAL) were taken at two time points: before" exact="lapatinib" post="and the morning dose of capecitabine on day 14"/>
   <result pre="two time points: before lapatinib and the morning dose of" exact="capecitabine" post="on day 14 (for assay of lapatinib, capecitabine, 5-FU"/>
   <result pre="of lapatinib, capecitabine, 5-FU and FBAL) and before dosing of" exact="lapatinib" post="on day 21 (for assay of lapatinib). Blood plasma"/>
   <result pre="and trastuzumab. Most patients (78 %) had received their last" exact="trastuzumab" post="treatment less than 8 weeks prior to study enrollment."/>
   <result pre="PgR− 35 (69) Unknown 1 (2) ER estrogen receptor, PgR" exact="progesterone" post="receptor The median duration of lapatinib treatment was 182"/>
   <result pre="ER estrogen receptor, PgR progesterone receptor The median duration of" exact="lapatinib" post="treatment was 182 days and that of capecitabine was"/>
   <result pre="duration of lapatinib treatment was 182 days and that of" exact="capecitabine" post="was 128 days. The longest treatment period of lapatinib"/>
   <result pre="of capecitabine was 128 days. The longest treatment period of" exact="lapatinib" post="was 833 days. Tolerability and safety In part 1,"/>
   <result pre="the tolerability criteria. Based on these findings, the combination of" exact="lapatinib" post="with capecitabine established in earlier studies was also tolerable"/>
   <result pre="criteria. Based on these findings, the combination of lapatinib with" exact="capecitabine" post="established in earlier studies was also tolerable in Japanese"/>
   <result pre="to be a potential risk of HER2 target agents including" exact="lapatinib" post="and trastuzumab, occurred in three subjects (6 %). These"/>
   <result pre="and later resolved. Pharmacokinetics In part 1, following administration of" exact="lapatinib" post="in combination with capecitabine on day 14 ( n"/>
   <result pre="In part 1, following administration of lapatinib in combination with" exact="capecitabine" post="on day 14 ( n = 5), t max"/>
   <result pre="5-FU and approximately 3 h for FBAL (Table 3). Co-administered" exact="lapatinib" post="and capecitabine were rapidly absorbed, and plasma concentrations of"/>
   <result pre="approximately 3 h for FBAL (Table 3). Co-administered lapatinib and" exact="capecitabine" post="were rapidly absorbed, and plasma concentrations of lapatinib, capecitabine,"/>
   <result pre="5-FU and FBAL showed rapid increases. Plasma concentrations of lapatinib," exact="capecitabine" post="and 5-FU reached C max and then decreased in"/>
   <result pre="just under 2.5 h, which was longer than that of" exact="capecitabine" post="and 5-FU by approximately three-fold. Table 3 Pharmacokinetic parameters"/>
   <result pre="(range) In part 2, mean (standard deviation) pre-dose concentrations of" exact="lapatinib" post="were 1.07 (0.72) μg/ml on day 14 and 1.24"/>
   <result pre="day 21. At pre-dose on day 14, plasma concentrations of" exact="capecitabine" post="were below the limit of quantitation in most of"/>
   <result pre="Baseline serum concentration of HER2 ECD according to response to" exact="lapatinib" post="plus capecitabine. a Kaplan-Meier plots stratified by HER2 ECD"/>
   <result pre="level according to the clinical benefit Discussion In this study," exact="lapatinib" post="in combination with capecitabine was well tolerated in Japanese"/>
   <result pre="clinical benefit Discussion In this study, lapatinib in combination with" exact="capecitabine" post="was well tolerated in Japanese patients with HER2-positive MBC"/>
   <result pre="study, conducted outside of Japan, investigated the drug-drug interaction between" exact="capecitabine" post="and lapatinib [ 6]. The results suggested there were"/>
   <result pre="outside of Japan, investigated the drug-drug interaction between capecitabine and" exact="lapatinib" post="[ 6]. The results suggested there were no significant"/>
   <result pre="there were no significant changes in the PK of lapatinib," exact="capecitabine" post="and its metabolites, 5-FU and FBAL. The 90 %"/>
   <result pre="study of 19 subjects, the AUC and C max of" exact="capecitabine" post="were 5.64, 7.98 and 4.31, 7.98, respectively, whereas those"/>
   <result pre="those of FBAL were 16.3, 25.5 and 3.38, 4.65. The" exact="capecitabine" post="intervals were lower, whereas the FBAL intervals were higher"/>
   <result pre="confidence intervals) in the AUC and C max of another" exact="capecitabine" post="metabolite, 5-FU (90 % CI 0.520, 0.772), and of"/>
   <result pre="capecitabine metabolite, 5-FU (90 % CI 0.520, 0.772), and of" exact="lapatinib" post="(90 % CI 32.7, 63.2). Furthermore, the median t"/>
   <result pre="between the two populations. The pivotal overseas study reported that" exact="lapatinib" post="in combination with capecitabine would be a recommended treatment"/>
   <result pre="The pivotal overseas study reported that lapatinib in combination with" exact="capecitabine" post="would be a recommended treatment option for patients with"/>
   <result pre="HER2-positive MBC who had been previously treated with therapy including" exact="trastuzumab" post="[ 3, 4]. In this study report, the median"/>
   <result pre="reported a higher CBR in a Japanese population treated with" exact="lapatinib" post="monotherapy. By making comparisons with the previously reported overseas"/>
   <result pre="basal HER2+ tumors [ 13– 17]. From this study on" exact="lapatinib" post="and capecitabine given in a Japanese population, a correlation"/>
   <result pre="tumors [ 13– 17]. From this study on lapatinib and" exact="capecitabine" post="given in a Japanese population, a correlation between the"/>
   <result pre="suggesting no correlation with EGFR expression and a benefit from" exact="lapatinib" post="with paclitaxel [ 18]. There was no significant difference"/>
   <result pre="correlation with EGFR expression and a benefit from lapatinib with" exact="paclitaxel" post="[ 18]. There was no significant difference in TTP"/>
   <result pre="outcome of this study were consistent with previous reports on" exact="lapatinib" post="in combination with capecitabine. These findings confirm that this"/>
   <result pre="the results from clinical trials of the new HER2-targeting agents" exact="pertuzumab" post="and trastuzumab emtansine have been reported, and these agents"/>
   <result pre="from clinical trials of the new HER2-targeting agents pertuzumab and" exact="trastuzumab" post="emtansine have been reported, and these agents can be"/>
   <result pre="19, 20]. As stated in this and previous reports, the" exact="lapatinib" post="and capecitabine combination shows anti-tumor efficacy even in patients"/>
   <result pre="As stated in this and previous reports, the lapatinib and" exact="capecitabine" post="combination shows anti-tumor efficacy even in patients who have"/>
   <result pre="efficacy even in patients who have undergone heavy treatment. Thus," exact="lapatinib" post="and capecitabine should still be options for long-term treatment"/>
   <result pre="in patients who have undergone heavy treatment. Thus, lapatinib and" exact="capecitabine" post="should still be options for long-term treatment of breast"/>
   <result pre="HER2-positive breast cancer patients, the suitable clinical position of the" exact="lapatinib" post="and capecitabine combination needs to be clarified by further"/>
   <result pre="cancer patients, the suitable clinical position of the lapatinib and" exact="capecitabine" post="combination needs to be clarified by further evaluations including"/>
   <result pre="Chan S Romieu CG Pienkowski T et al. Lapatinib plus" exact="capecitabine" post="for HER2-positive advanced breast cancer N Engl J Med"/>
   <result pre="Romieu CG et al. A phase III randomized comparison of" exact="lapatinib" post="plus capecitabine versus capecitabine alone in women with advanced"/>
   <result pre="et al. A phase III randomized comparison of lapatinib plus" exact="capecitabine" post="versus capecitabine alone in women with advanced breast cancer"/>
   <result pre="A phase III randomized comparison of lapatinib plus capecitabine versus" exact="capecitabine" post="alone in women with advanced breast cancer that has"/>
   <result pre="Oliva C Newstat B Imwalle B Geyer CE Lapatinib plus" exact="capecitabine" post="in women with HER-2-positive advanced breast cancer: final survival"/>
   <result pre="Versola MJ et al. Phase I and pharmacokinetic study of" exact="lapatinib" post="in combination with capecitabine in patients with advanced solid"/>
   <result pre="Phase I and pharmacokinetic study of lapatinib in combination with" exact="capecitabine" post="in patients with advanced solid malignancies J Clin Oncol"/>
   <result pre="N et al. Treatment of HER2-positive metastatic breast cancer with" exact="lapatinib" post="and capecitabine in the lapatinib expanded access programme, including"/>
   <result pre="al. Treatment of HER2-positive metastatic breast cancer with lapatinib and" exact="capecitabine" post="in the lapatinib expanded access programme, including efficacy in"/>
   <result pre="HER2-positive metastatic breast cancer with lapatinib and capecitabine in the" exact="lapatinib" post="expanded access programme, including efficacy in brain metastases—the UK"/>
   <result pre="patients with brain metastases from HER2-positive breast cancer treated with" exact="lapatinib" post="and capecitabine Ann Oncol 2011 22 3 625 630"/>
   <result pre="brain metastases from HER2-positive breast cancer treated with lapatinib and" exact="capecitabine" post="Ann Oncol 2011 22 3 625 630 10.1093/annonc/mdq434 20724575"/>
   <result pre="Shao ZM Luo RC Wang XJ et al. Lapatinib plus" exact="capecitabine" post="in treating HER2-positive advanced breast cancer: efficacy, safety, and"/>
   <result pre="Arbushites M Koehler M Olivia C et al. Estrogen receptor," exact="progesterone" post="receptor, human epidermal growth factor receptor 2 (HER2), and"/>
   <result pre="(HER2), and epidermal growth factor receptor expression and benefit from" exact="lapatinib" post="in a randomized trial of paclitaxel with lapatinib or"/>
   <result pre="expression and benefit from lapatinib in a randomized trial of" exact="paclitaxel" post="with lapatinib or placebo as first-line treatment in HER2-negative"/>
   <result pre="benefit from lapatinib in a randomized trial of paclitaxel with" exact="lapatinib" post="or placebo as first-line treatment in HER2-negative or unknown"/>
   <result pre="Im SA Hegg R Im YH et al. Pertuzumab plus" exact="trastuzumab" post="plus docetaxel for metastatic breast cancer N Engl J"/>
   <result pre="Hegg R Im YH et al. Pertuzumab plus trastuzumab plus" exact="docetaxel" post="for metastatic breast cancer N Engl J Med 2012"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4332983/results/search/inn/results.xml">
   <result pre="site. PET imaging obtained 6 months after the initiation of" exact="lapatinib" post="showed evidence of a partial response to treatment, although"/>
   <result pre="and mammaglobin; negative for CK20, TTF-1, BRST-2 or estrogen or" exact="progesterone" post="receptors. The patient then received adjuvant radiation treatment to"/>
   <result pre="and EGFR, at a dose of 1500 mg daily. She tolerated" exact="lapatinib" post="without significant side effects. CT imaging after 2 months"/>
   <result pre="to this. She ultimately died approximately 10 months after starting" exact="lapatinib" post="and more than 4 years after original diagnosis. 3."/>
   <result pre="to, an agent targeted at Her-2 overexpression. In this case," exact="lapatinib" post="was chosen over other agents due to its CNS"/>
   <result pre="within the CNS without any systemic treatment. The patient tolerated" exact="lapatinib" post="well. Approximately 6 months after starting lapatinib, PET imaging"/>
   <result pre="CNS. As it was, she did not begin treatment with" exact="lapatinib" post="for more than 2 years from initial diagnosis of"/>
   <result pre="of FDA-approved agents targeted at Her-2 overexpression, including not only" exact="lapatinib" post="but trastuzumab (Herceptin), ado-trastuzumab emtansine (Kadcyla), and pertuzumab (Perjeta)."/>
   <result pre="agents targeted at Her-2 overexpression, including not only lapatinib but" exact="trastuzumab" post="(Herceptin), ado-trastuzumab emtansine (Kadcyla), and pertuzumab (Perjeta). Conflict of"/>
   <result pre="not only lapatinib but trastuzumab (Herceptin), ado-trastuzumab emtansine (Kadcyla), and" exact="pertuzumab" post="(Perjeta). Conflict of Interests The author declares that there"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4333494/results/search/inn/results.xml">
   <result pre="doi: 10.1038/bjc.2014.647 pmid: 25584488 : Clinical Study Effect of adjuvant" exact="trastuzumab" post="among patients treated with anti-HER2-based neoadjuvant therapy Adjuvant trastuzumab"/>
   <result pre="adjuvant trastuzumab among patients treated with anti-HER2-based neoadjuvant therapy Adjuvant" exact="trastuzumab" post="after pCR Gonzalez-Angulo A M 1 2 Parinyanitikul N"/>
   <result pre="visit http://creativecommons.org/licenses/by-nc-sa/3.0/ Abstract Purpose: To study the impact of adjuvant" exact="trastuzumab" post="among patients achieving a pathologic complete response (pCR) after"/>
   <result pre="cancer treated with trastuzumab-based NST were categorised according to adjuvant" exact="trastuzumab" post="administration and pCR status. Adjuvant trastuzumab became standard of"/>
   <result pre="categorised according to adjuvant trastuzumab administration and pCR status. Adjuvant" exact="trastuzumab" post="became standard of care in 2006, this was the"/>
   <result pre="used to estimate survival. A test for interaction between adjuvant" exact="trastuzumab" post="and pCR was completed. Findings: Of 589 patients, 203"/>
   <result pre="adjuvant trastuzumab. Among patients achieving a pCR, 31.3% received adjuvant" exact="trastuzumab" post="compared with 68.8% among those who did not achieve"/>
   <result pre="achieve a pCR ( P=0.0006). Among patients achieving pCR, adjuvant" exact="trastuzumab" post="did not further improve overall survival (OS) or relapse-free"/>
   <result pre="(RFS) ( P=0.35 and P=0.93, respectively). Any benefit of adjuvant" exact="trastuzumab" post="in OS and RFS among patients without a pCR"/>
   <result pre="have excellent outcome regardless of whether they received adjuvant trastuzumab." exact="trastuzumab" post="neoadjuvant therapy pathologic complete response adjuvant therapy survival Neoadjuvant"/>
   <result pre="; Gianni et al, 2012 ). Although 1 year of" exact="trastuzumab" post="therapy is considered the standard of care today, several"/>
   <result pre="). A recent randomised trial comparing 6 months of adjuvant" exact="trastuzumab" post="therapy vs 1 year failed to show that 6"/>
   <result pre="1 year failed to show that 6 months of adjuvant" exact="trastuzumab" post="treatment was non-inferior to 12 months ( Pivot et"/>
   <result pre="( Pivot et al, 2013 ). The impact of adjuvant" exact="trastuzumab" post="among patients achieving a pCR after trastuzumab-based NST is"/>
   <result pre="therefore, aimed to evaluate the impact of completion of adjuvant" exact="trastuzumab" post="according to pCR status. Patients and methods A retrospective"/>
   <result pre="received trastuzumab-based NST from 2001 to 2012 were identified. Adjuvant" exact="trastuzumab" post="became standard of care in 2006; this was the"/>
   <result pre="main reason patients in our cohort did not receive adjuvant" exact="trastuzumab" post="in earlier years. Patients were classified according to whether"/>
   <result pre="Patients were classified according to whether they had received adjuvant" exact="trastuzumab" post="or not. Data were extracted on relevant prognostic factors"/>
   <result pre="status, race, histology, grade, lymphovascular invasion (LVI), oestrogen receptor status," exact="progesterone" post="receptor status, adjuvant radiation, and adjuvant endocrine therapy. pCR"/>
   <result pre="(yT0/is,N0). Patient characteristics were tabulated and compared between the adjuvant" exact="trastuzumab" post="vs no adjuvant trastuzumab groups using Chi-square test. Overall"/>
   <result pre="tabulated and compared between the adjuvant trastuzumab vs no adjuvant" exact="trastuzumab" post="groups using Chi-square test. Overall survival (OS) was measured"/>
   <result pre="Initially, a Cox proportional hazard model that included pCR, adjuvant" exact="trastuzumab" post="and the interaction between both covariates was tested. Because"/>
   <result pre="PH-FECH (paclitaxel 80 mg m −2 intravenously weekly for 12 weeks or" exact="paclitaxel" post="225 mg m −2 intravenously over 24 h every 3 weeks, followed"/>
   <result pre="weeks, followed by 4 cycles of FEC-75 (5-fluorouracil 500 mg m −2," exact="epirubicin" post="75 mg m −2, and cyclophosphamide 500 mg m −2) intravenously on day"/>
   <result pre="cycles of FEC-75 (5-fluorouracil 500 mg m −2, epirubicin 75 mg m −2, and" exact="cyclophosphamide" post="500 mg m −2) intravenously on day 1, every 3 weeks."/>
   <result pre="every 3 weeks. A loading dose of 4 mg kg −1 intravenously" exact="trastuzumab" post="was given on day 1 followed by 2 mg kg −1"/>
   <result pre="not receive adjuvant trastuzumab, and 480 (81.5%) patients received adjuvant" exact="trastuzumab" post="for 6 months to complete 1 year of therapy."/>
   <result pre="to complete 1 year of therapy. Patient characteristics by adjuvant" exact="trastuzumab" post="therapy are presented in Table 1. There were no"/>
   <result pre="a pCR. Among them, 73.9% of the patients received adjuvant" exact="trastuzumab" post="compared with 85.5% of patients not achieving a pCR"/>
   <result pre="93% for patients who did not or did receive adjuvant" exact="trastuzumab" post="( P=0.97); and the 5-year RFS estimates were 92%"/>
   <result pre="85% for patients who did not or did receive adjuvant" exact="trastuzumab" post="( P=0.33), respectively. When comparing patients who did not"/>
   <result pre="The Kaplan–Meier estimates of OS and RFS stratified by adjuvant" exact="trastuzumab" post="and pCR status are presented in Figure 1. On"/>
   <result pre="On multivariate analysis, there was no significant interaction between adjuvant" exact="trastuzumab" post="and pCR on OS ( P=0.32) or RFS ("/>
   <result pre="presentation, hormone receptor status, LVI and adjuvant endocrine therapy, adjuvant" exact="trastuzumab" post="had no significant impact on OS (HR=0.75; 95% CI=0.31–1.78;"/>
   <result pre="was undertaken to evaluate the impact of completion of adjuvant" exact="trastuzumab" post="in patients with HER2-positive disease treated at our institution"/>
   <result pre="had an excellent outcome regardless of whether they received adjuvant" exact="trastuzumab" post="or not. In our initial trastuzumab-based neoadjuvant study, patients"/>
   <result pre="or not. In our initial trastuzumab-based neoadjuvant study, patients received" exact="trastuzumab" post="for only 24 weeks during chemotherapy and did not"/>
   <result pre="only 24 weeks during chemotherapy and did not receive adjuvant" exact="trastuzumab" post="following local therapy because adjuvant trastuzumab was, at the"/>
   <result pre="did not receive adjuvant trastuzumab following local therapy because adjuvant" exact="trastuzumab" post="was, at the time, not part of the standard"/>
   <result pre="Buzdar et al, 2007 ). This practice was continued until" exact="trastuzumab" post="was approved in the adjuvant setting with the recommended"/>
   <result pre="cohort of patients available to evaluate the impact of adjuvant" exact="trastuzumab" post="among patients who achieved a pCR. A recently published"/>
   <result pre="including approximately 12 000 patients supporting the standard use of adjuvant" exact="trastuzumab" post="for 1 year. On the basis of the results"/>
   <result pre="FinHER study ( Joensuu et al, 2009 ), shorter adjuvant" exact="trastuzumab" post="regimens are being evaluated (9 weeks, 3 months, and"/>
   <result pre="the PHARE trial failed to show that 6 months of" exact="trastuzumab" post="is non-inferior to 12 months. Nevertheless, the cardiac safety"/>
   <result pre="might be less relevant given that dual anti-HER2 therapy with" exact="pertuzumab" post="and trastuzumab is now part of the new standard"/>
   <result pre="less relevant given that dual anti-HER2 therapy with pertuzumab and" exact="trastuzumab" post="is now part of the new standard of care."/>
   <result pre="; Gianni et al, 2014 ). The use of maintenance" exact="trastuzumab" post="to complete a year of therapy is considered standard,"/>
   <result pre="are available to support the use of pertuzumab, T-DM1, or" exact="lapatinib" post="in the adjuvant setting; further, the neoadjuvant studies adding"/>
   <result pre="lapatinib in the adjuvant setting; further, the neoadjuvant studies adding" exact="lapatinib" post="and pertuzumab only used these targeted therapies in the"/>
   <result pre="the adjuvant setting; further, the neoadjuvant studies adding lapatinib and" exact="pertuzumab" post="only used these targeted therapies in the pre-operative portion"/>
   <result pre="information on the reason a patient was prescribed further adjuvant" exact="trastuzumab" post="or not. Our results are hypothesis-generating and need to"/>
   <result pre="RD Piccart-Gebhart M collab: NeoALTTO Study Team 2012 Lapatinib with" exact="trastuzumab" post="for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label,"/>
   <result pre="Sahin AA Meric-Bernstam F 2012 Efficacy of neoadjuvant therapy with" exact="trastuzumab" post="concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast"/>
   <result pre="complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and" exact="epirubicin" post="chemotherapy: results of a randomized trial in human epidermal"/>
   <result pre="College of Surgeons Oncology Group, investigators 2013 Fluorouracil, epirubicin, and" exact="cyclophosphamide" post="(FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus"/>
   <result pre="Group, investigators 2013 Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by" exact="paclitaxel" post="plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75"/>
   <result pre="2013 Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus" exact="trastuzumab" post="versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab"/>
   <result pre="epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus" exact="paclitaxel" post="plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant"/>
   <result pre="cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus" exact="trastuzumab" post="followed by FEC-75 plus trastuzumab as neoadjuvant treatment for"/>
   <result pre="plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus" exact="trastuzumab" post="as neoadjuvant treatment for patients with HER2-positive breast cancer"/>
   <result pre="Ewer MS Buchholz TA Hortobagyi GN 2007 Neoadjuvant therapy with" exact="paclitaxel" post="followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent"/>
   <result pre="2007 Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and" exact="cyclophosphamide" post="chemotherapy and concurrent trastuzumab in human epidermal growth factor"/>
   <result pre="paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent" exact="trastuzumab" post="in human epidermal growth factor receptor 2-positive operable breast"/>
   <result pre="Steinseifer J Valagussa P Baselga J 2014 Neoadjuvant and adjuvant" exact="trastuzumab" post="in patients with HER2-positive locally advanced breast cancer (NOAH):"/>
   <result pre="Ross G Valagussa P 2012 Efficacy and safety of neoadjuvant" exact="pertuzumab" post="and trastuzumab in women with locally advanced, inflammatory, or"/>
   <result pre="Valagussa P 2012 Efficacy and safety of neoadjuvant pertuzumab and" exact="trastuzumab" post="in women with locally advanced, inflammatory, or early HER2-positive"/>
   <result pre="Study Team 2013 2 years versus 1 year of adjuvant" exact="trastuzumab" post="for HER2-positive breast cancer (HERA): an open-label, randomised controlled"/>
   <result pre="Leinonen M Isola J Kellokumpu-Lehtinen PL 2009 Fluorouracil, epirubicin, and" exact="cyclophosphamide" post="with either docetaxel or vinorelbine, with or without trastuzumab,"/>
   <result pre="J Kellokumpu-Lehtinen PL 2009 Fluorouracil, epirubicin, and cyclophosphamide with either" exact="docetaxel" post="or vinorelbine, with or without trastuzumab, as adjuvant treatments"/>
   <result pre="Mittendorf EA 2013 Pathologic complete response to neoadjuvant chemotherapy with" exact="trastuzumab" post="predicts for improved survival in women with HER2-overexpressing breast"/>
   <result pre="trial investigators 2013 6 months versus 12 months of adjuvant" exact="trastuzumab" post="for patients with HER2-positive early breast cancer (PHARE): a"/>
   <result pre="Loibl S 2011 Pathologic complete response after neoadjuvant chemotherapy plus" exact="trastuzumab" post="predicts favorable survival in human epidermal growth factor receptor"/>
   <result pre="( A) and RFS estimates ( B) according to adjuvant" exact="trastuzumab" post="use and pCR status. Table 1 Patient and tumour"/>
   <result pre="and tumour characteristics All patients ( N =589) No adjuvant" exact="trastuzumab" post="( N =109) Adjuvant trastuzumab ( N =480) N"/>
   <result pre="( N =589) No adjuvant trastuzumab ( N =109) Adjuvant" exact="trastuzumab" post="( N =480) N (%) N % N %"/>
   <result pre="0.98 (0.93, 0.99) 0.002 7 0.95 (0.9, 0.98) &amp;lt;0.0001 Adjuvant" exact="trastuzumab" post="No 109 11 0.91 (0.84, 0.95) 12 0.92 (0.85,"/>
   <result pre="CI P -value Hazard ratio 95% CI P -value Adjuvant" exact="trastuzumab" post="vs no 0.75 0.31–1.78 0.51 1.1 0.52–2.33 0.81 Year"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4335966/results/search/inn/results.xml">
   <result pre="7154 pre and postmenopausal women randomised to receive daily 20mg" exact="tamoxifen" post="( N = 3579) or matching placebo ( N"/>
   <result pre="= 3575) for five years [ 1]. They described how" exact="tamoxifen" post="reduced the incidence of all breast cancer overall by"/>
   <result pre="0.70). No differences in breast cancer mortality were seen (24" exact="tamoxifen" post="versus 27 placebo; odds ratio (OR) = 0.89 (0.49–1.60),"/>
   <result pre="St Gallen, Switzerland and colleagues assessed the survival advantage of" exact="anastrozole" post="compared to tamoxifen in lobular breast cancer in the"/>
   <result pre="and colleagues assessed the survival advantage of anastrozole compared to" exact="tamoxifen" post="in lobular breast cancer in the ABCSG-8 study. They"/>
   <result pre="in overall survival (OS) for invasive lobular cancer treated with" exact="anastrozole" post="compared to tamoxifen (HR 0.56, 95%CI 0.34–0.92) and this"/>
   <result pre="(OS) for invasive lobular cancer treated with anastrozole compared to" exact="tamoxifen" post="(HR 0.56, 95%CI 0.34–0.92) and this was replicated in"/>
   <result pre="on behalf of colleagues described a randomised comparison of adjuvant" exact="tamoxifen" post="(T) plus ovarian function suppression (OFS) versus tamoxifen in"/>
   <result pre="of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus" exact="tamoxifen" post="in premenopausal women with hormone receptor-positive (HR+) early breast"/>
   <result pre="women with HR+ BC were randomised to five years of" exact="tamoxifen" post="versus tamoxifen+OFS. After a median follow-up of 67 months,"/>
   <result pre="was 86.6% in the T+OFS group and 84.7% in the" exact="tamoxifen" post="group (HR = 0.83; 95% confidence interval (CI), 0.86–1.04;"/>
   <result pre="phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus" exact="fulvestrant" post="versus fulvestrant plus placebo in 168 patients with ER"/>
   <result pre="study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant versus" exact="fulvestrant" post="plus placebo in 168 patients with ER positive, aromatase"/>
   <result pre="CT presented results of a randomised phase II trial of" exact="fulvestrant" post="alone and then in combination with bortezomib (proteasome inhibitor)"/>
   <result pre="II trial of fulvestrant alone and then in combination with" exact="bortezomib" post="(proteasome inhibitor) in ER positive metastatic breast cancer resistant"/>
   <result pre="ER positive cancer resistant to AI were randomised either to" exact="fulvestrant" post="alone or to the combination of fulvestrant and bortezomib,"/>
   <result pre="randomised either to fulvestrant alone or to the combination of" exact="fulvestrant" post="and bortezomib, and a total of 118 women underwent"/>
   <result pre="after three months ( P = 0.056). The addition of" exact="bortezomib" post="to fulvestrant significantly reduced the rate of disease progression"/>
   <result pre="months ( P = 0.056). The addition of bortezomib to" exact="fulvestrant" post="significantly reduced the rate of disease progression (HR 0.73,"/>
   <result pre="or the median PFS did not improve. The combination of" exact="fulvestrant" post="to bortezomib was well tolerated with no grade 4"/>
   <result pre="median PFS did not improve. The combination of fulvestrant to" exact="bortezomib" post="was well tolerated with no grade 4 toxicity being"/>
   <result pre="being observed. This trial provides proof for the principle that" exact="bortezomib" post="may prevent or delay acquired resistance to endocrine therapy"/>
   <result pre="positive breast cancer. They demonstrated by subgroup analysis of the" exact="fulvestrant" post="500mg versus 250mg in endocrine patients of the CONFIRM"/>
   <result pre="endocrine patients of the CONFIRM trial [ 3] that high" exact="progesterone" post="receptor (PR) level was associated with improved progression free"/>
   <result pre="and protein levels of AP-2γ correlated with decreased response of" exact="fulvestrant" post="and 37 gene signatures were able to cluster patients"/>
   <result pre="able to cluster patients into good or poor responders to" exact="fulvestrant" post="forming the basis for future work. Professor John Robertson"/>
   <result pre="data from the phase II FIRST Study on 500 mg" exact="fulvestrant" post="versus anastrozole as first line endocrine monotherapy treatment for"/>
   <result pre="the phase II FIRST Study on 500 mg fulvestrant versus" exact="anastrozole" post="as first line endocrine monotherapy treatment for advanced breast"/>
   <result pre="postmenopausal ER positive patients were randomised either to 500 mg" exact="fulvestrant" post="or to 1 mg anastrozole. The overall survival HR"/>
   <result pre="0.70 (95% CI 0.50–0.98, P = 0.041). Median OS for" exact="fulvestrant" post="in this setting was 54.1 months versus 48.4 months"/>
   <result pre="in this setting was 54.1 months versus 48.4 months for" exact="anastrozole" post="(HR 0.70; 95% CI 0.50, 0.98; P = 0.041),"/>
   <result pre="0.50, 0.98; P = 0.041), demonstrating a survival advantage for" exact="fulvestrant" post="over its competitors. Clinical trials of targeted therapies The"/>
   <result pre="discussed the effect of sequential compared to concurrent treatment of" exact="pertuzumab" post="plus T-DM1 (monoclonal antibody therapy) in HER-2+ breast cancer"/>
   <result pre="to optimise scheduling and develop markers to predict response to" exact="pertuzumab" post="and trastuzumab emtansine (T-DM1). They concluded that in pre-clinical"/>
   <result pre="scheduling and develop markers to predict response to pertuzumab and" exact="trastuzumab" post="emtansine (T-DM1). They concluded that in pre-clinical testing cell"/>
   <result pre="They concluded that in pre-clinical testing cell lines, pre-treatment of" exact="pertuzumab" post="diminished T-DM1 efficacy when compared to concurrent combination treatment,"/>
   <result pre="diminished T-DM1 efficacy when compared to concurrent combination treatment, because" exact="pertuzumab" post="then T-DM1 has been shown to be antagonistic in"/>
   <result pre="a phase III double blind, placebo-controlled multicentre trial of daily" exact="everolimus" post="plus weekly trastuzumab and paclitaxel as first-line therapy in"/>
   <result pre="double blind, placebo-controlled multicentre trial of daily everolimus plus weekly" exact="trastuzumab" post="and paclitaxel as first-line therapy in women with HER-2+"/>
   <result pre="placebo-controlled multicentre trial of daily everolimus plus weekly trastuzumab and" exact="paclitaxel" post="as first-line therapy in women with HER-2+ advanced breast"/>
   <result pre="advanced breast cancer. The rationale for the BOLERO-1 trial is" exact="trastuzumab" post="resistance in HER-2+ breast cancer is because of the"/>
   <result pre="by seven months in the ER negative subpopulation (20 months" exact="everolimus" post="arm versus 13 months placebo arm, HR 0.66, P"/>
   <result pre="Higher rates of adverse events related deaths were reported for" exact="everolimus" post="(3.6% versus 0% with placebo) and all but one"/>
   <result pre="preliminary observation from BOLERO-3 [ 4] that treatment effect of" exact="everolimus" post="differs based on ER expression in patients with HER-2+"/>
   <result pre="the TBCRC023 trial, a randomised phase II neoadjuvant trial of" exact="lapatinib" post="combined with trastuzumab, with or without endocrine therapy for"/>
   <result pre="subtypes, PIK3CA mutation, and the degree of benefit from adjuvant" exact="trastuzumab" post="in NSABP-31 [ 5]. However, they were unable to"/>
   <result pre="and PAM50 intrinsic subtypes as biomarkers for differential response to" exact="trastuzumab" post="in NSABP B-31. This data suggest that results from"/>
   <result pre="breast cancer from a cohort of 636 patients treated with" exact="tamoxifen" post="monotherapy for five years and 10.4 years mean follow-up."/>
   <result pre="abstract on a randomised phase III trial comparing nanoparticle-based (nab)" exact="paclitaxel" post="with solvent-based paclitaxel as part of neoadjuvant chemotherapy in"/>
   <result pre="randomised phase III trial comparing nanoparticle-based (nab) paclitaxel with solvent-based" exact="paclitaxel" post="as part of neoadjuvant chemotherapy in 1200 patients with"/>
   <result pre="The team identified that whilst the side-effect profile of nab" exact="paclitaxel" post="was significantly higher than solvent based, the primary endpoint"/>
   <result pre="new targets (TNT) trial; a randomised phase III trial of" exact="carboplatin" post="as compared with docetaxel for patients with metastatic or"/>
   <result pre="a randomised phase III trial of carboplatin as compared with" exact="docetaxel" post="for patients with metastatic or recurrent locally advanced TNBC."/>
   <result pre="the subgroup of BRCA positive patients, who were significantly favouring" exact="carboplatin" post="( P = 0.03). Dr C Geyer on behalf"/>
   <result pre="III trial comparing six cycles of 5-fluorouracil (5-FU), epirubicin, and" exact="cyclophosphamide" post="(FEC) to four cycles of Adriamycin and cyclophosphamide (AC)"/>
   <result pre="epirubicin, and cyclophosphamide (FEC) to four cycles of Adriamycin and" exact="cyclophosphamide" post="(AC) in patients with node negative breast cancer. They"/>
   <result pre="E1199 trial: A phase II study of doxorubicin-cyclophosphamide followed by" exact="paclitaxel" post="or docetaxel given every three week or weekly in"/>
   <result pre="A phase II study of doxorubicin-cyclophosphamide followed by paclitaxel or" exact="docetaxel" post="given every three week or weekly in patients with"/>
   <result pre="between taxane and schedule ( P = 0.007), favouring one-weekly" exact="paclitaxel" post="( P = 0.011) and three weekly docetaxel ("/>
   <result pre="favouring one-weekly paclitaxel ( P = 0.011) and three weekly" exact="docetaxel" post="( P = 0.001) to the standard arm of"/>
   <result pre="( P = 0.001) to the standard arm of three-weekly" exact="paclitaxel" post="in DFS and OS. When evaluated by subtypes in"/>
   <result pre="OS. When evaluated by subtypes in exploratory analyses, the one-weekly" exact="paclitaxel" post="arm (but not the three-weekly docetaxel arm) was associated"/>
   <result pre="exploratory analyses, the one-weekly paclitaxel arm (but not the three-weekly" exact="docetaxel" post="arm) was associated with improved DFS ( P ="/>
   <result pre="German Breast Group presented the phase III ICE study: Adjuvant" exact="ibandronate" post="with or without capecitabine in elderly patients with moderate"/>
   <result pre="the phase III ICE study: Adjuvant ibandronate with or without" exact="capecitabine" post="in elderly patients with moderate or high-risk early breast"/>
   <result pre="identified no difference in DFS at five years for the" exact="ibandronate" post="+ capecitabine versus ibandronate alone groups respectively (78% versus"/>
   <result pre="difference in DFS at five years for the ibandronate +" exact="capecitabine" post="versus ibandronate alone groups respectively (78% versus 75%, P"/>
   <result pre="DFS at five years for the ibandronate + capecitabine versus" exact="ibandronate" post="alone groups respectively (78% versus 75%, P = 0.7)"/>
   <result pre="0.7) and grade 3/4 toxicities of less than 2% with" exact="capecitabine" post="except for hand-foot syndrome (6.8%). Prognostic indicators of adjuvant"/>
   <result pre="to non-LPBC but this was not replicated when chemotherapy and" exact="trastuzumab" post="were combined ( P = 0.79). Therefore, altering the"/>
   <result pre="CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly" exact="paclitaxel" post="(T) and trastuzumab (H) with or without lapatinib (L)"/>
   <result pre="a neoadjuvant phase III trial of weekly paclitaxel (T) and" exact="trastuzumab" post="(H) with or without lapatinib (L) for HER-2-positive breast"/>
   <result pre="of weekly paclitaxel (T) and trastuzumab (H) with or without" exact="lapatinib" post="(L) for HER-2-positive breast cancer, in which they identified"/>
   <result pre="gene signatures on pCR rates in TNBC after NACT +/-" exact="carboplatin" post="(Cb) or bevacizumab (Bev) by performing PAM50 subtype analysis"/>
   <result pre="pCR rates in TNBC after NACT +/- carboplatin (Cb) or" exact="bevacizumab" post="(Bev) by performing PAM50 subtype analysis on 367 pre-treatment"/>
   <result pre="of male breast cancer is treated by adjuvant endocrine therapy—mainly" exact="tamoxifen" post="(88%)– and the ER and PR status being prognostic"/>
   <result pre="25495490 3. Di Leo A et al. Final overall survival:" exact="fulvestrant" post="500 mg vs 250 mg in the randomized CONFIRM"/>
   <result pre="981 4 10.1038/nmeth.2603 23955771 7. Sparano JA et al. Weekly" exact="paclitaxel" post="in the adjuvant treatment of breast cancer N Engl"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4339844/results/search/inn/results.xml">
   <result pre="Abstract Intrinsic and acquired resistance to the monoclonal antibody drug" exact="trastuzumab" post="is a major problem in the treatment of HER2-positive"/>
   <result pre="was to detect genes and single nucleotide polymorphisms (SNPs) affecting" exact="trastuzumab" post="efficiency in cell culture. Three HER2-positive breast cancer cell"/>
   <result pre="resistance phenotypes were analyzed. We chose BT474 as model of" exact="trastuzumab" post="sensitivity, HCC1954 as model of intrinsic resistance, and BTR50,"/>
   <result pre="differential expression analyses on these cell lines with and without" exact="trastuzumab" post="treatment. Differentially expressed genes between the resistant cell lines"/>
   <result pre="to contribute to resistance. Differentially expressed genes between untreated and" exact="trastuzumab" post="treated BT474 are expected to contribute to drug efficacy."/>
   <result pre="removed genes that were also differentially expressed between untreated and" exact="trastuzumab" post="treated BTR50. We further searched for SNPs in the"/>
   <result pre="SNPs in the untreated cell lines which could contribute to" exact="trastuzumab" post="resistance. The analysis resulted in 54 differentially expressed candidate"/>
   <result pre="54 differentially expressed candidate genes that might be connected to" exact="trastuzumab" post="efficiency. 90% of 40 selected candidates were validated by"/>
   <result pre="CAV1, CYP1A2 and IGFBP3 were significantly higher expressed in the" exact="trastuzumab" post="treated than in the untreated BT474 cell line. GDF15,"/>
   <result pre="analyzed SNPs. These results contribute to a better understanding of" exact="trastuzumab" post="action and resistance mechanisms. Funding This work was supported"/>
   <result pre="and mortality rates [ 2, 3]. The humanized monoclonal antibody" exact="trastuzumab" post="targets specifically the extracellular domain of HER2 and is"/>
   <result pre="early breast cancer [ 4]. The improved outcome by adding" exact="trastuzumab" post="to chemotherapy for example is not completely understood. So"/>
   <result pre="cycle arrest and apoptosis or inhibition of tumor angiogenesis. Although" exact="trastuzumab" post="provides clinical benefit to women with HER2+ breast cancer,"/>
   <result pre="(VEGF). Corresponding therapeutic strategies to overcome or avoid resistance to" exact="trastuzumab" post="have been developed, and several new agents are in"/>
   <result pre="HER2-targeted therapies using small molecule tyrosine kinase inhibitors such as" exact="lapatinib" post="and HER2/HER3 antibodies such as pertuzumab [ 7]. However,"/>
   <result pre="kinase inhibitors such as lapatinib and HER2/HER3 antibodies such as" exact="pertuzumab" post="[ 7]. However, so far it is not possible"/>
   <result pre="so far it is not possible to predict prior to" exact="trastuzumab" post="treatment which patients will develop resistance. A need for"/>
   <result pre="A need for a better understanding of the mechanisms of" exact="trastuzumab" post="action and resistance persists. This study aims at detecting"/>
   <result pre="aims at detecting genes and single nucleotide polymorphisms (SNPs) affecting" exact="trastuzumab" post="efficiency in three cell lines with different resistance phenotypes."/>
   <result pre="in three cell lines with different resistance phenotypes. These include" exact="trastuzumab" post="sensitivity, intrinsic resistance due to a mutated PIK3CA gene,"/>
   <result pre="in breast cancer, could also contribute to novel strategies preventing" exact="trastuzumab" post="resistance. SNPs are the most common genetic variations and"/>
   <result pre="call our detected sequence variations, which are potentially related to" exact="trastuzumab" post="efficacy, ‘SNPs’ in the following. SNPs may unravel multifactorial"/>
   <result pre="to reveal SNPs in our candidate genes which might determine" exact="trastuzumab" post="efficiency in the untreated cell lines. Above that we"/>
   <result pre="and SNP analysis could help to predict the efficacy of" exact="trastuzumab" post="therapy. Consequently, the detection of corresponding genes and their"/>
   <result pre="(BT474, HCC1954 and BTR50) were chosen as model systems of" exact="trastuzumab" post="sensitivity (BT474 [ 6]), intrinsic (HCC1954 [ 6, 13])"/>
   <result pre="and acquired (BTR50) resistance. While HCC1954 is known to be" exact="trastuzumab" post="resistant due to a hotspot PIK3CA mutation (H1047R, PI3K"/>
   <result pre="cells (wild type, wt) in the presence of 50 μg" exact="trastuzumab" post="(Roche) for around six months. Parental cells (wt) were"/>
   <result pre="cultured in parallel to resistant ones without the addition of" exact="trastuzumab" post="( Fig. 1). Resistance of the cells to trastuzumab"/>
   <result pre="of trastuzumab ( Fig. 1). Resistance of the cells to" exact="trastuzumab" post="was verified by cell viability assays ( Fig. 2)."/>
   <result pre="markedly reduced the growth of BT474 (wt) cells compared to" exact="trastuzumab" post="resistant BT474 (BTR50) cells. Fig 1 Development of BTR50"/>
   <result pre="culturing parental BT474 cells in the presence of 20/50 μg" exact="trastuzumab" post="for around 6 months. Fig 2 BT474 cells have"/>
   <result pre="resistance to trastuzumab. (a) Proliferation rate of BT474 (parental) and" exact="trastuzumab" post="resistant BT474 (BTR50) cells treated with 20 μg/ml trastuzumab."/>
   <result pre="a luciferase-based viability assay. (b) Sensitivity of BT474 (parental) and" exact="trastuzumab" post="resistant BTR50 cells towards increasing concentrations of trastuzumab. Cell"/>
   <result pre="7 days of treatment. Cell viability assay and determination of" exact="trastuzumab" post="sensitivity For the measurement of cell viability, both parental"/>
   <result pre="For the measurement of cell viability, both parental BT474 and" exact="trastuzumab" post="resistant BTR50 cells were seeded in 96 well plates."/>
   <result pre="following the manufacturer’s instructions ( Fig. 2a). The sensitivity towards" exact="trastuzumab" post="was defined by treatment of both cell lines with"/>
   <result pre="by treatment of both cell lines with increasing concentrations of" exact="trastuzumab" post="and a subsequent measurement of cell viability after 7"/>
   <result pre="cultivated as described before. Cells were treated with 20 μg/ml" exact="trastuzumab" post="(Roche Diagnostics GmbH, Penzberg, Germany) or grown in full"/>
   <result pre="incubated in the standard media 24 h before addition of" exact="trastuzumab" post="or fresh full growth media. RNA sequencing Total RNA"/>
   <result pre="cancer cell lines BT474, HCC1954 and BTR50 with and without" exact="trastuzumab" post="treatment. In detail, five separate two-sample tests were performed"/>
   <result pre="to resistance. Next we tested for DE between untreated and" exact="trastuzumab" post="treated cells, i.e. each of the three cell lines"/>
   <result pre="cells, i.e. each of the three cell lines vs. its" exact="trastuzumab" post="treated version. The test for BT474 revealed 18 significant"/>
   <result pre="for BT474 revealed 18 significant genes which might contribute to" exact="trastuzumab" post="efficiency. To exclude false positives from the combined set"/>
   <result pre="that were also significant in the test for BTR50. No" exact="trastuzumab" post="effect was expected for the resistant cell line. The"/>
   <result pre="set. This way we discovered 54 genes that might determine" exact="trastuzumab" post="efficiency in HER2+ breast cancer cell lines. Annotation and"/>
   <result pre="Table. Results and Discussion mRNA profiling reveals genes associated with" exact="trastuzumab" post="efficiency The differential expression (DE) revealed by RNA-Seq analysis"/>
   <result pre="mainly based on literature support for association of genes with" exact="trastuzumab" post="efficiency or breast cancer. Six of the candidate genes"/>
   <result pre="gene set inferred by testing DE between BT474 and its" exact="trastuzumab" post="treated version. The whole subset consisted of eight genes."/>
   <result pre="CALCOCO1, CAV1, CYP1A2, IGFBP3, L1CAM) a significantly higher expression after" exact="trastuzumab" post="treatment of BT474 was validated apart from L1CAM. Of"/>
   <result pre="in BT474 was not validated. Upregulated genes in BT474 upon" exact="trastuzumab" post="treatment—indicators for drug sensitivity The validated candidate genes ALPP,"/>
   <result pre="Table. Fig 3 Fold Changes of DE genes (BT474 plus" exact="trastuzumab" post="vs. BT474). The barchart displays the log2 fold changes"/>
   <result pre="candidate genes, which significantly changed their expression in BT474 after" exact="trastuzumab" post="treatment. The positive values indicate an upregulation upon drug"/>
   <result pre="RT-qPCR analysis. 10.1371/journal.pone.0117818.t001 Table 1 Upregulated genes in BT474 upon" exact="trastuzumab" post="treatment. HGNC Symbol Description Log2 FC FDR ALPP alkaline"/>
   <result pre="results of the RNA-Seq data comparison between BT474 and its" exact="trastuzumab" post="treated version. It holds the description, log2 fold change"/>
   <result pre="The positive log2 fold changes indicate upregulated gene expression after" exact="trastuzumab" post="treatment. ALPP and CYP1A2 showed the highest FC, but"/>
   <result pre="and CYP1A2 showed the highest FC, but no association with" exact="trastuzumab" post="has been reported so far. ALPP encodes placental alkaline"/>
   <result pre="and CAV1 have already been reported in the context of" exact="trastuzumab" post="efficacy. Regarding CAV1 (caveolin 1), Sekhar et al. discovered"/>
   <result pre="cancer cells, CAV1 and caveolae deficiency might be preferable under" exact="trastuzumab" post="treatment [ 30]. Based on observations in the HER2+"/>
   <result pre="speculated that an attenuated ADCC effect might be contributing to" exact="trastuzumab" post="resistance. They found trastuzumab to be internalized and co-localized"/>
   <result pre="ADCC effect might be contributing to trastuzumab resistance. They found" exact="trastuzumab" post="to be internalized and co-localized with CAV1, mediating endocytosis"/>
   <result pre="by CAV1. Interestingly, in our study CAV1 was overexpressed upon" exact="trastuzumab" post="treatment in the sensitive cell line BT474. The RT-qPCR"/>
   <result pre="BT474, which was even stronger than the one in the" exact="trastuzumab" post="treated BT474 cell line ( S2 Table), underlining the"/>
   <result pre="drug efficacy. To further examine the role of CAV1 in" exact="trastuzumab" post="treatment, we analyzed its expression in public available data"/>
   <result pre="The original NeOAdjuvant Herceptin (NOAH) trial revealed the benefit of" exact="trastuzumab" post="addition to treatment with neoadjuvant chemotherapy in HER2+ breast"/>
   <result pre="doxorubicin/paclitaxel treatment followed by cyclophosphamide/methotrexate/fluorouracil. The remaining seven patients received" exact="trastuzumab" post="in addition for one year. CAV1 was differentially expressed"/>
   <result pre="(p &amp;lt; 0.05) with an approximately two-fold upregulation in the" exact="trastuzumab" post="treated group ( Fig. 4) supporting our observation. S1"/>
   <result pre="54 candidate genes. Fig 4 CAV1 expression is raised upon" exact="trastuzumab" post="treatment. The boxplot displays CAV1 gene expression (log2) of"/>
   <result pre="displays CAV1 gene expression (log2) of seven patients treated with" exact="trastuzumab" post="for one year in addition to neoadjuvant chemotherapy (red)"/>
   <result pre="hint at a positive association between its expression levels and" exact="trastuzumab" post="efficacy. The corresponding biological processes of the Gene Ontology"/>
   <result pre="signaling pathway and MAPK cascade. According to Dokmanovic et al.," exact="trastuzumab" post="enhanced IGFBP3 expression which in turn contributed to its"/>
   <result pre="inhibition [ 34]. They observed high IGFBP3 levels in the" exact="trastuzumab" post="sensitive cell lines SKBR3 and BT474 and explained the"/>
   <result pre="IGFBP2 and IGFBP3 were considered as potential predictive biomarkers for" exact="trastuzumab" post="resistance by them, since IGFBP3 interfered with IGF-I-mediated mitogenic"/>
   <result pre="IGFBP3 (rhIGFBP3) inhibited growth of HER2+ breast tumors and potentiated" exact="trastuzumab" post="activity [ 35]. They observed that IGF-IR activation countered"/>
   <result pre="35]. They observed that IGF-IR activation countered early effects of" exact="trastuzumab" post="on HER2 signaling via AKT and ERK1/2. Downregulated phosphorylation"/>
   <result pre="simultaneous blockade of HER2 and IGF-IR pathways via rhIGFBP3 plus" exact="trastuzumab" post="for HER2+ breast cancer patients. Lu et al. also"/>
   <result pre="et al. also reported a relation between IGF-IR signaling and" exact="trastuzumab" post="resistance in HER2+ breast cancer cell models [ 36]."/>
   <result pre="expressed in HCC1954 compared to BT474 and might contribute to" exact="trastuzumab" post="efficiency. Fig. 5 shows the log2 FC resulting from"/>
   <result pre="ones which have already been mentioned in the context of" exact="trastuzumab" post="efficacy, namely IL8, PTGS2, GDF15 and LCN2, all of"/>
   <result pre="them are speculated to participate in an inflammatory loop, mediating" exact="trastuzumab" post="resistance in HER2+ breast cancer by expanding the cancer"/>
   <result pre="results point to an important role of IL8 in driving" exact="trastuzumab" post="resistance via a hyperactive PI3K pathway. PTGS2 (cyclooxygenase prostaglandin-endoperoxide"/>
   <result pre="determining PTGS2 gene expression [ 40]. They further showed that" exact="trastuzumab" post="triggered HER2 protein depletion and mitigated the association between"/>
   <result pre="cancer, Gianni speculated that a combination of PTGS2 inhibitors with" exact="trastuzumab" post="may be efficient in high-risk patients [ 47]. Within"/>
   <result pre="cancer patients who have progressed after prior trastuzumab-based treatments with" exact="trastuzumab" post="and celecoxib, a PTGS2 inhibitor [ 48], which already"/>
   <result pre="Cho et al. suggested to combine the HIV protease inhibitor" exact="nelfinavir" post="and celecoxib or analogs to increase endoplasmic reticulum stress"/>
   <result pre="al. suggested to combine the HIV protease inhibitor nelfinavir and" exact="celecoxib" post="or analogs to increase endoplasmic reticulum stress and toxicity"/>
   <result pre="in human breast cancer cell lines that were resistant to" exact="trastuzumab" post="[ 50]. The background was that moderate activity of"/>
   <result pre="marginal association of abnormal copy number of PTGS2 with objective" exact="trastuzumab" post="response in metastatic breast cancer [ 51]. GDF15 (growth"/>
   <result pre="was overexpressed in HCC1954, too. Hence, it could contribute to" exact="trastuzumab" post="resistance as well. According to GO annotation, it is"/>
   <result pre="pathway. Indeed, Joshi et al. observed GDF15-mediated HER2 phosphorylation reducing" exact="trastuzumab" post="sensitivity of HER2+ breast cancer cells [ 52]. They"/>
   <result pre="of TGF- β receptor-Src-HER2 signaling crosstalk as a mechanism of" exact="trastuzumab" post="resistance. Another upregulated gene in HCC1954 was LCN2, encoding"/>
   <result pre="a common downstream effector molecule. Kumandan et al. observed that" exact="trastuzumab" post="inhibited the expression of LCN2 in SKBR3 cells. The"/>
   <result pre="feedback mechanism involving IL8 and LCN2, which could contribute to" exact="trastuzumab" post="resistance. Many of the remaining validated candidates which were"/>
   <result pre="1, member C1), a loss of expression and related decreased" exact="progesterone" post="catabolism, leading to decreased growth in the presence of"/>
   <result pre="this cell line. The keratin KRT5 (CK5) is related to" exact="progesterone" post="as well, since CK5+ cells were shown to lose"/>
   <result pre="BT474 compared to HCC1954 revealed a three-fold overexpression in the" exact="trastuzumab" post="treated version of BT474 compared to its untreated version"/>
   <result pre="EGFR/HER2 signaling pathway [ 78]. Collins et al. confirmed that" exact="trastuzumab" post="treatment upregulated ER transcriptional activity and TFF1 expression ["/>
   <result pre="[ 79]. However, they reported a mostly poor response to" exact="trastuzumab" post="treatment in HER2+ cells with co-expression of the steroid"/>
   <result pre="HCC1954 differs much more from BT474 than BTR50, and that" exact="trastuzumab" post="treatment hardly influences expression in this cell line ("/>
   <result pre="in the samples BT474, BTR50 and HCC1954 with and without" exact="trastuzumab" post="(T) treatment. Same colors denote that the samples belong"/>
   <result pre="and BT474+T vs. BT474. SNP analysis of genes associated with" exact="trastuzumab" post="efficiency We searched for SNPs in the three untreated"/>
   <result pre="gene candidates of the DE analysis on BT474 and its" exact="trastuzumab" post="treated version (ALPP, CALCOCO1, CAV1, CYP1A2, IGFBP3) as well"/>
   <result pre="vs. HCC1954 which were already reported in the context of" exact="trastuzumab" post="efficacy, namely GDF15, IL8, LCN2 and PTGS2. Additionally we"/>
   <result pre="study was to infer genes and corresponding variations, which influence" exact="trastuzumab" post="action in HER2+ breast cancer. Comparing gene expression in"/>
   <result pre="line models of different drug response characteristics with and without" exact="trastuzumab" post="treatment, we inferred 54 candidate genes. Most of them"/>
   <result pre="cancer but just a small proportion in the context of" exact="trastuzumab" post="action. The validated selection of the candidate genes was"/>
   <result pre="differentially expressed between the sensitive cell line BT474 and its" exact="trastuzumab" post="treated version, as well as between BT474 and the"/>
   <result pre="and LCN2, as those have already been reported to hinder" exact="trastuzumab" post="action. Interestingly, mechanisms involving the PI3K pathway have been"/>
   <result pre="IGFBP3, both of which have already been reported to influence" exact="trastuzumab" post="efficacy. While low CAV1 expression seems to support trastuzumab"/>
   <result pre="influence trastuzumab efficacy. While low CAV1 expression seems to support" exact="trastuzumab" post="action, high IGFBP3 levels are associated with trastuzumab sensitivity."/>
   <result pre="to support trastuzumab action, high IGFBP3 levels are associated with" exact="trastuzumab" post="sensitivity. We further detected that the intrinsically resistant cell"/>
   <result pre="BTR50, representing acquired resistance. HCC1954 was also influenced less by" exact="trastuzumab" post="treatment than BTR50. Thus, intrinsically resistant specimens seem to"/>
   <result pre="BTR50. Thus, intrinsically resistant specimens seem to respond less to" exact="trastuzumab" post="treatment than those which acquired resistance. This was supported"/>
   <result pre="as rs9340 of MAPK1. Those SNPs could likely contribute to" exact="trastuzumab" post="resistance. In general, some of the inferred SNPs are"/>
   <result pre="expressed genes as well as SNPs in the context of" exact="trastuzumab" post="resistance in different cell phenotypes. A high proportion of"/>
   <result pre="the role of these candidate genes or mutations in influencing" exact="trastuzumab" post="action. A deeper analysis of single candidates, supported by"/>
   <result pre="experiments, could reveal more detailed information about mechanisms leading to" exact="trastuzumab" post="resistance. Hence, our results provide a basis to improve"/>
   <result pre="of the 54 candidate genes from seven patients treated with" exact="trastuzumab" post="for one year in addition to neoadjuvant chemotherapy (red)"/>
   <result pre="al. ( 2010) Activated phosphoinositide 3-kinase/AKT signaling confers resistance to" exact="trastuzumab" post="but not lapatinib . Mol Cancer Ther 9( 6):"/>
   <result pre="Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not" exact="lapatinib" post=". Mol Cancer Ther 9( 6): 1489– 1502. doi:"/>
   <result pre="caveolin-1 as a potential causative factor in the generation of" exact="trastuzumab" post="resistance in breast cancer cells . J Cancer 4("/>
   <result pre="Lluch A , et al. ( 2010) Neoadjuvant chemotherapy with" exact="trastuzumab" post="followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in"/>
   <result pre="al. ( 2010) Neoadjuvant chemotherapy with trastuzumab followed by adjuvant" exact="trastuzumab" post="versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally"/>
   <result pre="Covington KR , et al. ( 2012) Phosphorylated and sumoylation-deficient" exact="progesterone" post="receptors drive proliferative gene signatures during breast cancer progression"/>
   <result pre="growth inhibition: implications for the development of predictive biomarkers for" exact="trastuzumab" post="resistance . Mol Cancer Ther 10( 6): 917– 928."/>
   <result pre="( 2001) Insulin-like growth factor-I receptor signaling and resistance to" exact="trastuzumab" post="(herceptin). J Natl Cancer Inst 93( 24): 1852– 1857."/>
   <result pre="al. ( 2012) Activation of an IL6 inflammatory loop mediates" exact="trastuzumab" post="resistance in HER2+ breast cancer by expanding the cancer"/>
   <result pre="MM , et al. ( 2004) Phase II study of" exact="celecoxib" post="and trastuzumab in metastatic breast cancer patients who have"/>
   <result pre="et al. ( 2004) Phase II study of celecoxib and" exact="trastuzumab" post="in metastatic breast cancer patients who have progressed after"/>
   <result pre="of chromosomes 1, 3, and 10 on patient response to" exact="trastuzumab" post="in metastatic breast cancer . Genes Chromosomes Cancer 46("/>
   <result pre="( 2011) Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces" exact="trastuzumab" post="sensitivity of HER2-overexpressing breast cancer cells . Biochem Pharmacol"/>
   <result pre="and AKR1C2 in breast cancer and their potential effect on" exact="progesterone" post="signaling . Cancer Res 64( 20): 7610– 7617. doi:"/>
   <result pre="expression of human kallikrein 10 in breast cancer tissue predicts" exact="tamoxifen" post="resistance . Br J Cancer 86( 11): 1790– 1796."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4341429/results/search/inn/results.xml">
   <result pre="most evident in &quot;triple-negative&quot; tumors [those without estrogen receptors (ER)," exact="progesterone" post="receptors (PR), and human epidermal growth factor receptor 2"/>
   <result pre="tumors had HER2− CTCs. A few studies have shown that" exact="trastuzumab" post="treatment is effective in eliminating HER2+ CTCs, including from"/>
   <result pre="EBC patients Patients randomized in 1:1 ratio to either the" exact="trastuzumab" post="arm or the observation arm. April 2017 CTC-CEC-AND (NCT02220556)"/>
   <result pre="BD Byskosh A Molteni A Duda RB . Estrogen and" exact="progesterone" post="receptor concordance between primary and recurrent breast cancer ."/>
   <result pre="Kasimir-Bauer S Loehberg CR et al. Comparison of estrogen and" exact="progesterone" post="receptor status of circulating tumor cells and the primary"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4342830/results/search/inn/results.xml">
   <result pre="patients who are HER2-positive receive targeted inhibitors to HER2, including" exact="trastuzumab" post="and lapatinib. While patients benefit from the use of"/>
   <result pre="Several recent studies indicate that activation of autophagy contributes to" exact="trastuzumab" post="and lapatinib resistance and demonstrate that impairing autophagy in"/>
   <result pre="studies indicate that activation of autophagy contributes to trastuzumab and" exact="lapatinib" post="resistance and demonstrate that impairing autophagy in breast cancer"/>
   <result pre="by serum deprivation for 24 h or with 100 nM" exact="lapatinib" post="(Santa Cruz) for 24 h prior to analysis by"/>
   <result pre="counter (Nexcelom). For autophagy, cells were treated with 100 uM" exact="chloroquine" post="(Sigma) for the indicated times and analyzed by Western"/>
   <result pre="the following day treated with vehicle (water) or 100 uM" exact="chloroquine" post="for 4 h. Resulting lysates were then immunoblotted for"/>
   <result pre="day, cells were treated with vehicle (water) or 100 uM" exact="chloroquine" post="for 4 h, fixed, and stained with DAPI. d"/>
   <result pre="following day treated with vehicle (water) or the autophagy inhibitor," exact="chloroquine" post="for 4 h. We used chloroquine because it is"/>
   <result pre="or the autophagy inhibitor, chloroquine for 4 h. We used" exact="chloroquine" post="because it is an autophagy inhibitor that impairs autophagic"/>
   <result pre="it is an autophagy inhibitor that impairs autophagic flux. Consequently," exact="chloroquine" post="treatment results in an accumulation of autophagosomes which incorporate"/>
   <result pre="which incorporate LC3BII, if autophagy is proceeding as expected. Following" exact="chloroquine" post="treatment of the Hunk WT and Hunk KO cells,"/>
   <result pre="WT cells, which had increased LC3BII levels in response to" exact="chloroquine" post="treatment (Fig. 1b), suggesting that in Hunk KO cells"/>
   <result pre="Hunk KO cells were transfected with GFP-LC3 and treated with" exact="chloroquine" post="the following day for 4 h. Cells were then"/>
   <result pre="exhibited a reduced number of GFP-LC3 puncta per cell under" exact="chloroquine" post="treatment conditions (Fig. 1c-IF, Fig. 1d-quantitation) indicating that loss"/>
   <result pre="HER2-positive breast cancer cells induces cell death in response to" exact="lapatinib" post="and alters autophagy response Because we previously demonstrated that"/>
   <result pre="inhibition, we treated control and HUNK shRNA-expressing BT474 cells with" exact="lapatinib" post="and measured caspase-3 activity. We found that indeed, HUNK"/>
   <result pre="day, cells were treated with vehicle (water) or 100 uM" exact="chloroquine" post="for 4 h and analyzed by immunoblotting for LC3BI"/>
   <result pre="day cells were treated with vehicle (DMSO) or 100 nM" exact="lapatinib" post="for 24 h. Cells treated with lapatinib plus chloroquine"/>
   <result pre="or 100 nM lapatinib for 24 h. Cells treated with" exact="lapatinib" post="plus chloroquine received 100 uM chloroquine for 4 h"/>
   <result pre="nM lapatinib for 24 h. Cells treated with lapatinib plus" exact="chloroquine" post="received 100 uM chloroquine for 4 h prior to"/>
   <result pre="h. Cells treated with lapatinib plus chloroquine received 100 uM" exact="chloroquine" post="for 4 h prior to lysis. Lysates were analyzed"/>
   <result pre="cell type were plated and the following day treated with" exact="chloroquine" post="for 4 h. Following, cells were assessed for levels"/>
   <result pre="saw an increase in LC3BII in control cells treated with" exact="chloroquine" post="but this did not occur in HUNK shRNA-expressing BT474"/>
   <result pre="an increase in LC3BII levels in control cells treated with" exact="lapatinib" post="(Fig. 2d, compare lane 1 to lane 2) but"/>
   <result pre="was not induced in HUNK shRNA BT474 cells treated with" exact="lapatinib" post="(Fig. 2d, compare lane 3 to lane 4). To"/>
   <result pre="of LC3BII processing, and thus possible diminished autophagy response to" exact="lapatinib" post="in HUNK shRNA cells, we additionally co-treated HUNK shRNA"/>
   <result pre="HUNK shRNA cells, we additionally co-treated HUNK shRNA cells with" exact="chloroquine" post="and lapatinib to assess LC3BII levels. Consistent with our"/>
   <result pre="cells, we additionally co-treated HUNK shRNA cells with chloroquine and" exact="lapatinib" post="to assess LC3BII levels. Consistent with our observations thus"/>
   <result pre="to assess LC3BII levels. Consistent with our observations thus far," exact="chloroquine" post="treatment did not result in an accumulation of LC3BII"/>
   <result pre="accumulation of LC3BII in HUNK shRNA cells also treated with" exact="lapatinib" post="(Fig. 2d, compare lane 4 to lane 5). Moreover,"/>
   <result pre="in LC3BII levels between HUNK shRNA cells treated with vehicle," exact="lapatinib" post="alone, and those cell that had been treated with"/>
   <result pre="alone, and those cell that had been treated with both" exact="lapatinib" post="and chloroquine (Fig. 2d, compare lanes 3, 4, and"/>
   <result pre="those cell that had been treated with both lapatinib and" exact="chloroquine" post="(Fig. 2d, compare lanes 3, 4, and 5), implying"/>
   <result pre="response by LC3B processing. JIMT-1 cells were isolated from a" exact="trastuzumab" post="resistant patient and are insensitive to HER2 and EGFR"/>
   <result pre="patient and are insensitive to HER2 and EGFR inhibitors including" exact="lapatinib" post="[ 18, 19]. We engineered JIMT-1 cells to express"/>
   <result pre="JIMT-1 cells were plated and treated the following day with" exact="chloroquine" post="for 4 h. Following, samples were evaluated for LC3BII"/>
   <result pre="day, cells were treated with vehicle (water) or 100 uM" exact="chloroquine" post="for 4 h and analyzed by immunoblotting for LC3BI"/>
   <result pre="HER2+ breast cancer because chronic application of HER2 inhibitors (i.e.," exact="trastuzumab" post="and lapatinib) has been shown to lead to the"/>
   <result pre="Lopez-Bonet E Martin-Castillo B Joven J Menendez JA The anti-malarial" exact="chloroquine" post="overcomes primary resistance and restores sensitivity to trastuzumab in"/>
   <result pre="The anti-malarial chloroquine overcomes primary resistance and restores sensitivity to" exact="trastuzumab" post="in HER2-positive breast cancer Sci Rep 2013 3 2469"/>
   <result pre="development of breast cancer resistance to the anti-HER2 monoclonal antibody" exact="trastuzumab" post="PLoS ONE 2009 4 7 e6251 10.1371/journal.pone.0006251 19606230 18."/>
   <result pre="Hemmila P Ilvesaro J Isola J Multiple molecular mechanisms underlying" exact="trastuzumab" post="and lapatinib resistance in JIMT-1 breast cancer cells Cancer"/>
   <result pre="Ilvesaro J Isola J Multiple molecular mechanisms underlying trastuzumab and" exact="lapatinib" post="resistance in JIMT-1 breast cancer cells Cancer Lett 2010"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4346363/results/search/inn/results.xml">
   <result pre="a complex and heterogeneous disease. Signaling by estrogen receptor (ER)," exact="progesterone" post="receptor (PR), and/or human EGF-like receptor 2 (HER2) is"/>
   <result pre="are classified by hormone receptor status, including estrogen receptor (ER)," exact="progesterone" post="receptor (PR), and human EGF-like receptor 2 (HER2) receptor"/>
   <result pre="standard treatment for ER + breast cancers. The development of" exact="trastuzumab" post="(Herceptin ®) treatment for HER2 + breast cancers provides"/>
   <result pre="will develop resistance to hormone therapy ( Table 3) or" exact="trastuzumab" post="treatment ( Table 4); 3) the development of clinical"/>
   <result pre="For HER2 + breast cancers, treatment with the targeted inhibitor" exact="trastuzumab" post="is the standard course. 45, 46 Even though trastuzumab"/>
   <result pre="inhibitor trastuzumab is the standard course. 45, 46 Even though" exact="trastuzumab" post="is effective, almost half of the breast cancer patients"/>
   <result pre="breast cancer patients that overexpress HER2 are either nonresponsive to" exact="trastuzumab" post="or develop resistance. 47– 49 There have been numerous"/>
   <result pre="resistance. 47– 49 There have been numerous mechanisms identified for" exact="trastuzumab" post="resistance, yet there is no clinical assay available to"/>
   <result pre="miRNAs or miRNA signatures that correlate with response to adjuvant" exact="tamoxifen" post="treatment. 60– 64 These signatures do not include any"/>
   <result pre="or ER + breast tumors. miRNAs in HER signaling and" exact="trastuzumab" post="resistance miR-125b, miR-134, miR-193a-5p, miR-199b-5p, miR-331-3p, miR-342-5p, and miR-744*"/>
   <result pre="other miRNAs, including miR-26, miR-30b, and miR-194, is upregulated upon" exact="trastuzumab" post="treatment in BT-474 and SK-BR-3 cells. 75, 76 Altered"/>
   <result pre="an intronic sequence. 78 High levels of miR-21 interfere with" exact="trastuzumab" post="treatment in BT-474, MDA-MB-453, and SK-BR-3 cells via inhibition"/>
   <result pre="HER2 + tumor tissues before and after neoadjuvant treatment with" exact="trastuzumab" post="are associated with poor response to treatment. 79 miR-221"/>
   <result pre="response to treatment. 79 miR-221 can also confer resistance to" exact="trastuzumab" post="treatment via PTEN in SK-BR-3 cells. 80 High levels"/>
   <result pre="miR-205 in serum before treatment correlated with response to neoadjuvant" exact="epirubicin" post="+ paclitaxel chemotherapy regimen in Stage II and III"/>
   <result pre="serum before treatment correlated with response to neoadjuvant epirubicin +" exact="paclitaxel" post="chemotherapy regimen in Stage II and III patients with"/>
   <result pre="samples before treatment correlated with complete pathologic response to neoadjuvant" exact="trastuzumab" post="treatment in patients with HER2 + breast tumors. 119"/>
   <result pre="in serum samples before treatment and the response to neoadjuvant" exact="trastuzumab" post="(or lapatinib) treatment in patients with HER2 + breast"/>
   <result pre="Kim C Wolmark N HER2 status and benefit from adjuvant" exact="trastuzumab" post="in breast cancer N Engl J Med 2008 358"/>
   <result pre="Cobleigh MA Tripathy D et al. Efficacy and safety of" exact="trastuzumab" post="as a single agent in first-line treatment of HER2-overexpressing"/>
   <result pre="Leva G Li M et al. MicroRNA-221/222 confers breast cancer" exact="fulvestrant" post="resistance by regulating multiple signaling pathways Oncogene 2011 30"/>
   <result pre="Downregulation of miR-221/222 enhances sensitivity of breast cancer cells to" exact="tamoxifen" post="through upregulation of TIMP3 Cancer Gene Ther 2014 21"/>
   <result pre="N Devaney A et al. MicroRNA signatures predict oestrogen receptor," exact="progesterone" post="receptor and HER2/neu receptor status in breast cancer Breast"/>
   <result pre="Spoelstra NS et al. Downregulation of miR-342 is associated with" exact="tamoxifen" post="resistant breast tumors Mol Cancer 2010 9 317 21172025"/>
   <result pre="miR-342 is associated with estrogen receptor-alpha expression and response to" exact="tamoxifen" post="in breast cancer Exp Ther Med 2013 5 3"/>
   <result pre="prolonged relapse-free time of primary oestrogen receptor-positive breast cancer following" exact="tamoxifen" post="treatment Eur J Cancer 2013 49 17 3598 3608"/>
   <result pre="Balwierz A et al. MicroRNA-519a is a novel oncomir conferring" exact="tamoxifen" post="resistance by targeting a network of tumour-suppressor genes in"/>
   <result pre="profiling of high-risk ER+ breast cancers from patients receiving adjuvant" exact="tamoxifen" post="mono-therapy: a DBCG study PLoS One 2012 7 5"/>
   <result pre="et al. Modulation of MicroRNA-194 and cell migration by HER2-targeting" exact="trastuzumab" post="in breast cancer PLoS One 2012 7 7 e41170"/>
   <result pre="Wang Y et al. Up-regulation of miR-21 mediates resistance to" exact="trastuzumab" post="therapy for breast cancer J Biol Chem 2011 286"/>
   <result pre="A subtype of breast cancer patients to neoadjuvant chemotherapy with" exact="epirubicin" post="plus paclitaxel PLoS One 2014 9 8 e104870 25137071"/>
   <result pre="of breast cancer patients to neoadjuvant chemotherapy with epirubicin plus" exact="paclitaxel" post="PLoS One 2014 9 8 e104870 25137071 119 Jung"/>
   <result pre="et al. Plasma microRNA 210 levels correlate with sensitivity to" exact="trastuzumab" post="and tumor presence in breast cancer patients Cancer 2012"/>
   <result pre="[23.5%], LN − [46.9%] vs LN + [51.8%]) treated with" exact="tamoxifen" post="monotherapy FFPE tissue TaqMan qRT-PCR (Thermo Fisher Scientific) Predicts"/>
   <result pre="FFPE tissue TaqMan qRT-PCR (Thermo Fisher Scientific) Predicts response to" exact="tamoxifen" post="and correlates with longer recurrence-free survival. 60 miR-19a, miR-205"/>
   <result pre="(Stage II [16.2%] vs Stage III [83.8%]) treated with neoadjuvant" exact="epirubicin" post="+ paclitaxel Serum SYBR-based qRT-PCR (Quantobio Technology) Predicts response"/>
   <result pre="[16.2%] vs Stage III [83.8%]) treated with neoadjuvant epirubicin +" exact="paclitaxel" post="Serum SYBR-based qRT-PCR (Quantobio Technology) Predicts response to epirubicin"/>
   <result pre="+ paclitaxel Serum SYBR-based qRT-PCR (Quantobio Technology) Predicts response to" exact="epirubicin" post="+ paclitaxel. 118 miR-30c 246 advanced-stage ER + cases"/>
   <result pre="cases (local recurrence [13%] vs distant recurrence [87%]) treated with" exact="tamoxifen" post="FFPE tissue TaqMan qRT-PCR (Thermo Fisher Scientific) Predicts response"/>
   <result pre="FFPE tissue TaqMan qRT-PCR (Thermo Fisher Scientific) Predicts response to" exact="tamoxifen" post="and correlates with longer progression-free survival. 61 miR-210 89"/>
   <result pre="(LN − [56%] vs LN + [38%]) treated with adjuvant" exact="tamoxifen" post="monotherapy FFPE tissue TaqMan qRT-PCR (Thermo Fisher Scientific) Correlates"/>
   <result pre="FFPE, formalin-fixed paraffin-embedded; LN, lymph node status; miRNA, microRNA; PR," exact="progesterone" post="receptor; HER2, human EGF-like receptor 2; qRT-PCR, quantitative real-time"/>
   <result pre="[84%] vs M1 [16%]) with neoadjuvant treatment (trastuzumab [50%] vs" exact="lapatinib" post="[50%]) Serum (pre- and post-neoadjuvant treatment) TaqMan qRT-PCR (Thermo"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4346691/results/search/inn/results.xml">
   <result pre="alone or in combination with a third drug such as" exact="epirubicin" post="or a taxane, constitutes the most effective treatment option"/>
   <result pre="Additional FDA approved 2nd line agents include docetaxel, paclitaxel, and" exact="irinotecan" post="[ 11– 14]. 3. Molecular Classification of Gastric Cancer"/>
   <result pre="13.8 months (95% CI 12–16 months) in those assigned to" exact="trastuzumab" post="plus chemotherapy compared with 11.1 months in those assigned"/>
   <result pre="stomach have higher HER2 expression [ 33]. The benefit of" exact="trastuzumab" post="was confined to those with IHC 2+/3+ and FISH"/>
   <result pre="with IHC 2+/3+ and FISH positivity. The practice of maintenance" exact="trastuzumab" post="and continuing trastuzumab until evidence of disease progression are"/>
   <result pre="and FISH positivity. The practice of maintenance trastuzumab and continuing" exact="trastuzumab" post="until evidence of disease progression are commonplace in the"/>
   <result pre="investigating this approach [ 36]. The development of resistance to" exact="trastuzumab" post="has prompted investigating alternative drugs which target HER2. Lapatinib"/>
   <result pre="downstream signaling [ 37]. The phase III TYTAN study compared" exact="paclitaxel" post="with or without lapatinib in HER2 positive gastric cancer"/>
   <result pre="The phase III TYTAN study compared paclitaxel with or without" exact="lapatinib" post="in HER2 positive gastric cancer in the second-line setting"/>
   <result pre="patients [ 38]. Median overall survival was 11 months with" exact="paclitaxel" post="plus lapatinib compared to 8.9 months with paclitaxel alone"/>
   <result pre="38]. Median overall survival was 11 months with paclitaxel plus" exact="lapatinib" post="compared to 8.9 months with paclitaxel alone ( P"/>
   <result pre="months with paclitaxel plus lapatinib compared to 8.9 months with" exact="paclitaxel" post="alone ( P = 0.1044). There was also no"/>
   <result pre="a phase III trial (JACOB) comparing pertuzumab/trastuzumab + chemotherapy to" exact="pertuzumab" post="+ chemotherapy [ 40]. Trastuzumab emtansine (T-DM1) is an"/>
   <result pre="[ 40]. Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate combining" exact="trastuzumab" post="and DM1 which is a cytotoxic/microtubule polymerization agent ["/>
   <result pre="cancers (20%) with EGFR amplification and overexpression can respond to" exact="cetuximab" post="therapy [ 46]. Cetuximab is a monoclonal antibody directed"/>
   <result pre="The EXPAND study was a phase III trial which studied" exact="capecitabine" post="and cisplatin with or without cetuximab in the first"/>
   <result pre="study was a phase III trial which studied capecitabine and" exact="cisplatin" post="with or without cetuximab in the first line setting"/>
   <result pre="III trial which studied capecitabine and cisplatin with or without" exact="cetuximab" post="in the first line setting in advanced gastric cancer"/>
   <result pre="(HR = 1.09, 95% CI 0.92–1.29, P = 0.32). Adding" exact="cetuximab" post="to this chemotherapy combination also did not improve overall"/>
   <result pre="the chemotherapy group was 11.3 months compared to chemotherapy +" exact="panitumumab" post="which was 8.8 months (HR = 1.37, 95% CI"/>
   <result pre="chemotherapy in gastric cancer [ 60, 61]. The failure of" exact="bevacizumab" post="to improve overall survival in the phase III AVAGAST"/>
   <result pre="cancer and those from European/American populations derived more benefit from" exact="bevacizumab" post="than other gastric cancer subtypes or patients from Asian/Pacific"/>
   <result pre="survival was 5.2 months (IQR 2.3–9.9) in patients in the" exact="ramucirumab" post="group and 3.8 months (IQR 1.7–7.1) in those in"/>
   <result pre="0.603–0.998; P = 0.047). The subsequently reported RAINBOW trial investigated" exact="paclitaxel" post="± ramucirumab in patients with metastatic GEJ or gastric"/>
   <result pre="= 0.047). The subsequently reported RAINBOW trial investigated paclitaxel ±" exact="ramucirumab" post="in patients with metastatic GEJ or gastric adenocarcinoma who"/>
   <result pre="was overall survival (OS). Median OS was 9.63 months for" exact="ramucirumab" post="+ paclitaxel compared to 7.36 months for paclitaxel alone"/>
   <result pre="survival (OS). Median OS was 9.63 months for ramucirumab +" exact="paclitaxel" post="compared to 7.36 months for paclitaxel alone (HR ="/>
   <result pre="months for ramucirumab + paclitaxel compared to 7.36 months for" exact="paclitaxel" post="alone (HR = 0.807, 95% CI 0.678–0.962, P ="/>
   <result pre="P = 0.017). Based on these results the combination of" exact="ramucirumab" post="+ paclitaxel is expected to become a standard of"/>
   <result pre="0.017). Based on these results the combination of ramucirumab +" exact="paclitaxel" post="is expected to become a standard of care treatment"/>
   <result pre="second-line setting for metastatic upper GI tumors. The success of" exact="ramucirumab" post="in the 2nd line setting has prompted its clinical"/>
   <result pre="prompted its clinical investigation in the first line setting. When" exact="ramucirumab" post="was combined with FOLFOX in the first-line setting, it"/>
   <result pre="[ 66]. Clinical trials investigating alternative combinations of chemotherapy with" exact="ramucirumab" post="in the first-line setting are ongoing. Prior to the"/>
   <result pre="was 6.8 months (95% CI 4.4–9.7 months). The addition of" exact="docetaxel" post="to sunitinib resulted in a higher objective response rate"/>
   <result pre="months (95% CI 4.4–9.7 months). The addition of docetaxel to" exact="sunitinib" post="resulted in a higher objective response rate (41.1% versus"/>
   <result pre="multitarget TKI of BRAF, VEGF, and PDGFR, was combined with" exact="oxaliplatin" post="in a phase II trial in patients who had"/>
   <result pre="a phase Ib study has been conducted combining BB1608 and" exact="paclitaxel" post="in advanced cancers and of 5 patients enrolled with"/>
   <result pre="migration, and invasion [ 72]. A phase II trial combined" exact="vismodegib" post="(SHH pathway inhibitor) with FOLFOX in patients with advanced"/>
   <result pre="in soft tissue sarcomas [ 77]. Cixutumumab was combined with" exact="paclitaxel" post="in metastatic esophageal/GE junction cancer in a randomized phase"/>
   <result pre="was not met with median PFS reaching 2.6 months for" exact="paclitaxel" post="alone and 2.3 months for paclitaxel + cixutumumab (90%"/>
   <result pre="reaching 2.6 months for paclitaxel alone and 2.3 months for" exact="paclitaxel" post="+ cixutumumab (90% CI 2–3.6 months, P = 0.72)."/>
   <result pre="dovitinib, a dual VEGF, and FGFR inhibitor, in combination with" exact="docetaxel" post="as second-line chemotherapy in gastric cancer [ 85]. 12."/>
   <result pre="progressed after 1-2 lines of chemotherapy were randomized to receive" exact="everolimus" post="or best supportive care (BSC). Median overall survival was"/>
   <result pre="supportive care (BSC). Median overall survival was 5.4 months with" exact="everolimus" post="and 4.3 months with BSC (HR = 0.90, 95%"/>
   <result pre="P = 0.124). There are also several ongoing trials comparing" exact="everolimus" post="with chemotherapy (paclitaxel, capecitabine, and oxaliplatin) [ 95, 96]."/>
   <result pre="Cunningham D. Starling N. Rao S. et al. Capecitabine and" exact="oxaliplatin" post="for advanced esophagogastric cancer The New England Journal of"/>
   <result pre="T. et al. Randomised, non-comparative phase II study of weekly" exact="docetaxel" post="with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric"/>
   <result pre="al. Randomised, non-comparative phase II study of weekly docetaxel with" exact="cisplatin" post="and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the"/>
   <result pre="study of weekly docetaxel with cisplatin and 5-fluorouracil or with" exact="capecitabine" post="in oesophagogastric cancer: the AGITG ATTAX trial British Journal"/>
   <result pre="Random assignment multicenter phase II study of modified docetaxel, cisplatin," exact="fluorouracil" post="(mDCF) versus DCF with growth factor support (GCSF) in"/>
   <result pre="Okines A. F. C. Papamichael D. et al. Docetaxel and" exact="irinotecan" post="as second-line therapy for advanced oesophagogastric cancer European Journal"/>
   <result pre="S. Boku N. Fukutomi A. Yoshino T. Onozawa Y. Weekly" exact="paclitaxel" post="as second-line chemotherapy for advanced or recurrent gastric cancer"/>
   <result pre="α gene amplification, intestinal type, poor prognosis and sensitivity to" exact="trastuzumab" post="Annals of Oncology 2005 16 2 273 278 10.1093/annonc/mdi064"/>
   <result pre="J. et al. 2 years versus 1 year of adjuvant" exact="trastuzumab" post="for HER2-positive breast cancer (HERA): an open-label, randomised controlled"/>
   <result pre="T. Kurokawa Y. et al. A phase II trial of" exact="trastuzumab" post="combined with irinotecan in patients with advanced HER2-positive chemo-refractory"/>
   <result pre="et al. A phase II trial of trastuzumab combined with" exact="irinotecan" post="in patients with advanced HER2-positive chemo-refractory gastric cancer: Osaka"/>
   <result pre="T. Xu R.-H. Chung H. C. et al. Lapatinib plus" exact="paclitaxel" post="versus paclitaxel alone in the second-line treatment of HER2-amplified"/>
   <result pre="R.-H. Chung H. C. et al. Lapatinib plus paclitaxel versus" exact="paclitaxel" post="alone in the second-line treatment of HER2-amplified advanced gastric"/>
   <result pre="recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor," exact="pertuzumab" post="Cancer Immunology, Immunotherapy 2006 55 6 717 727 10.1007/s00262-005-0058-x"/>
   <result pre="Marcelo Hoff P. Shen L. et al. Pertuzumab (P) with" exact="trastuzumab" post="(T) and chemotherapy (CTX) in patients (pts) with HER2-positive"/>
   <result pre="of gastric cancers with EGFR amplification and overexpression respond to" exact="cetuximab" post="therapy Scientific Reports 2013 3, article 2992 10.1038/srep02992 47"/>
   <result pre="Lordick F. Kang Y.-K. Chung H.-C. et al. Capecitabine and" exact="cisplatin" post="with or without cetuximab for patients with previously untreated"/>
   <result pre="Chung H.-C. et al. Capecitabine and cisplatin with or without" exact="cetuximab" post="for patients with previously untreated advanced gastric cancer (EXPAND):"/>
   <result pre="T. Chau I. Cunningham D. et al. Epirubicin, oxaliplatin, and" exact="capecitabine" post="with or without panitumumab for patients with previously untreated"/>
   <result pre="D. et al. Epirubicin, oxaliplatin, and capecitabine with or without" exact="panitumumab" post="for patients with previously untreated advanced oesophagogastric cancer (REAL3):"/>
   <result pre="S. Starling N. Cunningham D. et al. Matuzumab plus epirubicin," exact="cisplatin" post="and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine"/>
   <result pre="N. Cunningham D. et al. Matuzumab plus epirubicin, cisplatin and" exact="capecitabine" post="(ECX) compared with epirubicin, cisplatin and capecitabine alone as"/>
   <result pre="Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin," exact="cisplatin" post="and capecitabine alone as first-line treatment in patients with"/>
   <result pre="epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and" exact="capecitabine" post="alone as first-line treatment in patients with advanced oesophago-gastric"/>
   <result pre="I. et al. Rilotumumab in combination with epirubicin, cisplatin, and" exact="capecitabine" post="as first-line treatment for gastric or oesophagogastric junction adenocarcinoma:"/>
   <result pre="et al. Multicenter phase II study of irinotecan, cisplatin, and" exact="bevacizumab" post="in patients with metastatic gastric or gastroesophageal junction adenocarcinoma"/>
   <result pre="al. Survival analysis according to disease subtype in AVAGAST: first-line" exact="capecitabine" post="and cisplatin plus bevacizumab (bev) or placebo in patients"/>
   <result pre="analysis according to disease subtype in AVAGAST: first-line capecitabine and" exact="cisplatin" post="plus bevacizumab (bev) or placebo in patients (pts) with"/>
   <result pre="to disease subtype in AVAGAST: first-line capecitabine and cisplatin plus" exact="bevacizumab" post="(bev) or placebo in patients (pts) with advanced gastric"/>
   <result pre="al. RAINBOW: a global, phase III, randomized, double-blind study of" exact="ramucirumab" post="plus paclitaxel versus placebo plus paclitaxel in the treatment"/>
   <result pre="a global, phase III, randomized, double-blind study of ramucirumab plus" exact="paclitaxel" post="versus placebo plus paclitaxel in the treatment of metastatic"/>
   <result pre="randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus" exact="paclitaxel" post="in the treatment of metastatic gastroesophageal junction (GEJ) and"/>
   <result pre="Y.-K. Kang W. K. et al. Phase II study of" exact="sunitinib" post="as second-line treatment for advanced gastric cancer Investigational New"/>
   <result pre="J. Lee J. et al. Randomised phase II trial of" exact="docetaxel" post="and sunitinib in patients with metastatic gastric cancer who"/>
   <result pre="J. et al. Randomised phase II trial of docetaxel and" exact="sunitinib" post="in patients with metastatic gastric cancer who were previously"/>
   <result pre="R. Pericay C. et al. Multicenter phase II study of" exact="oxaliplatin" post="and sorafenib in advanced gastric adenocarcinoma after failure of"/>
   <result pre="C. et al. Multicenter phase II study of oxaliplatin and" exact="sorafenib" post="in advanced gastric adenocarcinoma after failure of cisplatin and"/>
   <result pre="oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of" exact="cisplatin" post="and fluoropyrimidine treatment. A GEMCAD study Investigational New Drugs"/>
   <result pre="study of the cancer stem cell inhibitor BBI608 administered with" exact="paclitaxel" post="in patients with advanced malignancies Journal of Clinical Oncology"/>
   <result pre="J. A. et al. A randomized phase II study of" exact="vismodegib" post="(V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX"/>
   <result pre="P. J. et al. E2208: randomized phase II study of" exact="paclitaxel" post="with or without the anti-IGF-IR antibody cixutumumab (IMC-A12) as"/>
   <result pre="phase I dose-escalation study of volasertib (BI 6727) combined with" exact="nintedanib" post="(BIBF 1120) in advanced solid tumors Journal of Clinical"/>
   <result pre="680 NCT02178956 EGFR inhibitors Panitumumab REAL-3 EOX with or without" exact="panitumumab" post="574 NCT00824785 Cetuximab EXPAND XP with or without cetuximab"/>
   <result pre="without panitumumab 574 NCT00824785 Cetuximab EXPAND XP with or without" exact="cetuximab" post="904 NCT00678535 Angiogenesis inhibitors Ramucirumab REGARD Ramucirumab versus BSC"/>
   <result pre="versus BSC 355 NCT00917384 Ramucirumab RAINBOW Paclitaxel with or without" exact="ramucirumab" post="665 NCT01170663 Regorafenib INTEGRATE Regorafenib versus BSC 150 Actrn12612000239864"/>
   <result pre="665 NCT01170663 Regorafenib INTEGRATE Regorafenib versus BSC 150 Actrn12612000239864 T-DM1:" exact="trastuzumab" post="emtansine; XP: cisplatin, capecitabine; XP-T: cisplatin, capecitabine; T: trastuzumab;"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4353460/results/search/inn/results.xml">
   <result pre="different treatment. Animals in group 1 received intraperitoneal doses of" exact="trastuzumab" post="(20 mg/kg), animal in group 2 received a mixture"/>
   <result pre="the tumors classified as negative or positive for estrogen and" exact="progesterone" post="receptors and EGFR and HER2 receptors [ 28]. The"/>
   <result pre="demonstrated that individually or the combination of anti-DCD antibodies and" exact="trastuzumab" post="caused a significant reduction of the number of cell"/>
   <result pre="Figure 7 Enhanced effect of anti-DCD rabbit polyclonal antibodies and" exact="trastuzumab" post="combination on growth and tumor formation of MDA-MB-361 cells"/>
   <result pre="column 2, 3 and 4) or presence of the antibodies" exact="trastuzumab" post="(20 mg/kg), a mixture of goat polyclonal anti-DCD antibodies"/>
   <result pre="each group) untreated or treated with weekly i.p. doses of" exact="trastuzumab" post="(20 mg/kg), a mixture of goat polyclonal anti-DCD antibodies"/>
   <result pre="malignant cells. Human breast cancer cells selected for resistance to" exact="trastuzumab" post="in vivo overexpress epidermal growth factor receptor and ErbB"/>
   <result pre="of various tumor cells to the EGFR/ErbB1 tyrosine kinase inhibitors" exact="erlotinib" post="and lapatinib. Conclusions Using gain-of-function and loss-of-function approaches we"/>
   <result pre="et al. Human breast cancer cells selected for resistance to" exact="trastuzumab" post="in vivo overexpress epidermal growth factor receptor and ErbB"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4353882/results/search/inn/results.xml">
   <result pre="% CI 1.5–25.6; p = 0.01] and the lack of" exact="trastuzumab" post="administration in the metastatic setting (Cohort A: HR 5.0,"/>
   <result pre="B. The presence of visceral metastases and the lack of" exact="trastuzumab" post="administration in the metastatic setting apparently increase the likelihood"/>
   <result pre="10]. However, owing to its high molecular weight, penetration of" exact="trastuzumab" post="into the central nervous system is extremely low, 1/420th"/>
   <result pre="11 Significant values marked in bold ER estrogen receptor, PR" exact="progesterone" post="receptor, HER2 human epidermal growth factor receptor 2 Pathology"/>
   <result pre="received induction chemotherapy and 87 % of patients were administered" exact="trastuzumab" post="in adjuvant or metastatic setting, usually in combination with"/>
   <result pre="usually in combination with chemotherapy. In 14 % of patients" exact="lapatinib" post="was administered at trastuzumab relapse. Follow-up from breast cancer"/>
   <result pre="chemotherapy. In 14 % of patients lapatinib was administered at" exact="trastuzumab" post="relapse. Follow-up from breast cancer diagnosis varied from 1"/>
   <result pre="without accompanying extracranial relapse. After BM, HER2 directed treatments included" exact="trastuzumab" post="(33 % of patients), lapatinib (15 %) and either"/>
   <result pre="BM, HER2 directed treatments included trastuzumab (33 % of patients)," exact="lapatinib" post="(15 %) and either used sequentially (4 %). Seventy"/>
   <result pre="dominant metastatic sites). Furthermore, more patients in this cohort received" exact="lapatinib" post="following failure of trastuzumab. The median time to diagnosis"/>
   <result pre="3, ER-negativity and less frequent use of endocrine treatment and" exact="trastuzumab" post="in the adjuvant and/or metastatic setting (Table 4). Additionally,"/>
   <result pre="0.72 Significant values marked in bold ER estrogen receptor, PR" exact="progesterone" post="receptor, HER2 human epidermal growth factor receptor 2 In"/>
   <result pre="% CI 1.5–25.6; p = 0.01) and the lack of" exact="trastuzumab" post="administration in the metastatic setting (HR 5.0, 95 %"/>
   <result pre="suggested increased risk of BM associated with the use of" exact="trastuzumab" post="[ 17]. The current study employed a high throughput"/>
   <result pre="visceral metastases. Furthermore, much more patients in this cohort received" exact="lapatinib" post="at trastuzumab relapse (32 %, compared to 14 %"/>
   <result pre="Furthermore, much more patients in this cohort received lapatinib at" exact="trastuzumab" post="relapse (32 %, compared to 14 % in Cohort"/>
   <result pre="Geyer et al. [ 21] showed that the addition of" exact="lapatinib" post="to capecitabine after progression on trastuzumab resulted in decreased"/>
   <result pre="al. [ 21] showed that the addition of lapatinib to" exact="capecitabine" post="after progression on trastuzumab resulted in decreased BM occurrence,"/>
   <result pre="that the addition of lapatinib to capecitabine after progression on" exact="trastuzumab" post="resulted in decreased BM occurrence, and preclinical studies show"/>
   <result pre="resulted in decreased BM occurrence, and preclinical studies show that" exact="lapatinib" post="prevents BMs formation by 53 % in a HER2-transfected"/>
   <result pre="HER2 enriched subtype [ 31– 34]. We also showed that" exact="trastuzumab" post="administration in the metastatic setting may reduce the risk"/>
   <result pre="to development of BM in HER2-positive patients who never received" exact="trastuzumab" post="[ 35, 36]. Conclusions We demonstrated that the presence"/>
   <result pre="that the presence of visceral metastases and the lack of" exact="trastuzumab" post="administration in the metastatic setting apparently increase the likelihood"/>
   <result pre="Wardley AM Incidence of cerebral metastases in patients treated with" exact="trastuzumab" post="for metastatic breast cancer Br J Cancer 2004 91"/>
   <result pre="B Heinemann V Characteristics of patients with brain metastases receiving" exact="trastuzumab" post="for HER2 overexpressing metastatic breast cancer Breast 2006 15"/>
   <result pre="M Elomaa I Isola J collab: FinHer Study Investigators Adjuvant" exact="docetaxel" post="or vinorelbine with or without trastuzumab for breast cancer"/>
   <result pre="I Isola J collab: FinHer Study Investigators Adjuvant docetaxel or" exact="vinorelbine" post="with or without trastuzumab for breast cancer N Engl"/>
   <result pre="FinHer Study Investigators Adjuvant docetaxel or vinorelbine with or without" exact="trastuzumab" post="for breast cancer N Engl J Med 2006 354"/>
   <result pre="A Crown J collab: Breast Cancer International Research Group Adjuvant" exact="trastuzumab" post="in HER2-positive breast cancer N Engl J Med 2011"/>
   <result pre="Willems A Bernhard H Harbeck N Heinemann V Ratio of" exact="trastuzumab" post="levels in serum and cerebrospinal fluid is altered in"/>
   <result pre="C Central nervous system metastases in breast cancer patients administered" exact="trastuzumab" post="Cancer Treat Rev 2005 31 312 318 10.1016/j.ctrv.2005.04.008 15979804"/>
   <result pre="Oliva C Rubin SD Stein S Cameron D Lapatinib plus" exact="capecitabine" post="for HER2-positive advanced breast cancer N Engl J Med"/>
   <result pre="Steinberg SM Merino MJ Rubin SD Steeg PS Effect of" exact="lapatinib" post="on the outgrowth of metastatic breast cancer cells to"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4358700/results/search/inn/results.xml">
   <result pre="subsequently inhibited signaling downstream of HER3. Consistent with these results," exact="perhexiline" post="inhibited breast cancer cell proliferation in vitro and tumor"/>
   <result pre="The novel approach used here led to the discovery that" exact="perhexiline" post="ablates HER3 expression, and offers an opportunity to identify"/>
   <result pre="Biologicals, Lawrenceville, GA, USA), 200 U/ml penicillin, and 50 ng/ml" exact="streptomycin" post="(Invitrogen, Grand Island, NY, USA). Cells were grown at"/>
   <result pre="microwell dishes (MatTek Cultureware, Ashland, MA, USA) were treated with" exact="dimethyl sulfoxide" post="(DMSO) or perhexiline for the indicated time at 37°C"/>
   <result pre="Ashland, MA, USA) were treated with dimethyl sulfoxide (DMSO) or" exact="perhexiline" post="for the indicated time at 37°C and followed by"/>
   <result pre="minutes. After washing out unbound antibodies, cells were incubated with" exact="perhexiline" post="or DMSO in culture medium at 37°C for 1"/>
   <result pre="grow for 24 hours and then treated with DMSO or" exact="perhexiline" post="for the indicated time at 37°C before fixation in"/>
   <result pre="complete growth medium. Cells were subsequently treated with DMSO or" exact="perhexiline" post="(10 μM) for the indicated time. Cell lysates were"/>
   <result pre="assays, cells cultured and treated as described were collected into" exact="glycerol" post="lysis buffer (50 mM Hepes, 250 mM NaCl, 0.5%"/>
   <result pre="with agarose-conjugated anti-HER3 antibody overnight, washed three times with the" exact="glycerol" post="lysis buffer, and subjected to Western blotting analysis. Western"/>
   <result pre="USA). For the dose–response assays, the cells were treated with" exact="perhexiline" post="ranging from 0.5 to 10 μM. To examine the"/>
   <result pre="0.5 to 10 μM. To examine the combinational effect of" exact="perhexiline" post="and lapatinib, the cells were treated with perhexiline and"/>
   <result pre="effect of perhexiline and lapatinib, the cells were treated with" exact="perhexiline" post="and lapatinib alone or in combination. For the MDA-MB-468"/>
   <result pre="perhexiline and lapatinib, the cells were treated with perhexiline and" exact="lapatinib" post="alone or in combination. For the MDA-MB-468 cells, the"/>
   <result pre="or in combination. For the MDA-MB-468 cells, the ratio of" exact="perhexiline" post="to lapatinib was 1:1. For the SK-BR-3, AU565, and"/>
   <result pre="combination. For the MDA-MB-468 cells, the ratio of perhexiline to" exact="lapatinib" post="was 1:1. For the SK-BR-3, AU565, and BT474 cells,"/>
   <result pre="Martin in the software CompuSyn. Testing the antitumor effect of" exact="perhexiline" post="in vivo All animal experiments were followed animal protocol"/>
   <result pre="on day 0. On day 7, oral gavage treatment with" exact="perhexiline" post="(0, 400 mg/kg) was initiated, and repeated for 5"/>
   <result pre="was used to analyze differences in tumor volumes at each" exact="perhexiline" post="concentration compared to vehicle control. Differences at P &amp;lt;0.05"/>
   <result pre="Library containing FDA and foreign regulatory agency-approved drugs, and discovered" exact="perhexiline" post="maleate (Figure 1B) induced HER3 receptor internalization (Figure 1A,"/>
   <result pre="no effect on HER3 localization (Figure 1A, panel v) suggesting" exact="perhexiline" post="operates through a mechanism independent of its ability to"/>
   <result pre="ability to inhibit CPT-1 [ 23]. Figure 1 Identification of" exact="perhexiline" post="as a novel agent that promotes HER3 internalization and"/>
   <result pre="cells expressing HER3ΔNLS2-YFP that were treated with DMSO, 10 μM" exact="perhexiline" post="for 30 minutes and 4 hours, and 20 μM"/>
   <result pre="intracellularly localized puncta of internalized HER3ΔNLS2-YFP receptors. (B) Structure of" exact="perhexiline" post="maleate. (C) Perhexiline induces dose-dependent downregulation of endogenous HER3"/>
   <result pre="lysates prepared from SK-BR-3 cells treated with different concentrations of" exact="perhexiline" post="for 8 hours were analyzed for the expression of"/>
   <result pre="control. (D) Quantification of HER3, HER2, EGFR protein expression following" exact="perhexiline" post="treatment. Western blots shown in (C) were quantified by"/>
   <result pre="endogenous HER3 in SK-BR-3 cells. Cells treated with 10 μM" exact="perhexiline" post="for the indicated time were analyzed for endogenous HER3,"/>
   <result pre="expression. (F) Quantification of HER3, HER2, EGFR protein expression following" exact="perhexiline" post="treatment. Western blots shown in (E) were quantified by"/>
   <result pre="quantified by normalizing to β-actin. CPT-1, mitochondrial carnitine palmitoyltransferase-1; DMSO," exact="dimethyl sulfoxide;" post="EGFR, epidermal growth factor receptor; HER3, human epidermal growth"/>
   <result pre="degradation of receptor proteins, we next examined the effect of" exact="perhexiline" post="on the level of endogenous HER3 receptors. As shown"/>
   <result pre="1C and D, treating SK-BR-3 cells with increasing concentrations of" exact="perhexiline" post="for 8 hours resulted in a dose-dependent downregulation of"/>
   <result pre="same family, including EGFR and HER2, were not affected by" exact="perhexiline" post="treatment (Figure 1C and D). Moreover, perhexiline (10 μM)-mediated"/>
   <result pre="not affected by perhexiline treatment (Figure 1C and D). Moreover," exact="perhexiline" post="(10 μM)-mediated downregulation of HER3 was observed after 30"/>
   <result pre="8-hour treatment (Figure 1E and F). A similar effect of" exact="perhexiline" post="on decreasing HER3 expression was detected in triple-negative breast"/>
   <result pre="surface-expressed HER3 and induces receptor ubiquitination Our data showed that" exact="perhexiline" post="stimulates HER3 internalization and degradation. To further prove that"/>
   <result pre="However, more internalized receptors were observed in cells treated with" exact="perhexiline" post="for 1 hour, and these internalized receptors formed larger"/>
   <result pre="and proteasome. (A) Cell surface-expressed Flag-HER3ΔNLS2 receptors are internalized upon" exact="perhexiline" post="treatment. HEK293 cells transfected with Flag-HER3ΔNLS2 were incubated with"/>
   <result pre="hour untreated (ii) or in the presence of DMSO or" exact="perhexiline" post="(10 μM) (iii, iv). Cells were fixed and localization"/>
   <result pre="(B) Perhexiline induces HER3 ubiquitination. MDA-MB-468 cells were treated with" exact="perhexiline" post="(10 μM) for the indicated time. The endogenous HER3"/>
   <result pre="or BFA1 (30 nM) in the absence or presence of" exact="perhexiline" post="(10 μM) for 8 hours. The endogenous HER3 was"/>
   <result pre="cells treated with DMSO (i to iii) or 10 μM" exact="perhexiline" post="(iv to vi) for 2 hours were fixed and"/>
   <result pre="in perhexiline-treated cells as yellow puncta marked by arrows. DMSO," exact="dimethyl sulfoxide;" post="EGFR, epidermal growth factor receptor; HER3, human epidermal growth"/>
   <result pre="human epidermal growth factor receptor 3. We next determined if" exact="perhexiline" post="induces HER3 degradation by promoting ubiquitination of the receptor."/>
   <result pre="the receptor. To this end, MDA-MB-468 cells were treated with" exact="perhexiline" post="over the time course of 2 hours, and endogenous"/>
   <result pre="HER3 receptors were immunoprecipitated from the cells. We found that" exact="perhexiline" post="treatment was accompanied by a rapid increase in the"/>
   <result pre="bafilomycin A1 (BFA1), a lysosome inhibitor (Figure 2C), suggesting that" exact="perhexiline" post="promotes both proteasome- and lysosome-dependent degradation of ubiquitinated HER3"/>
   <result pre="cytosol, and the nucleus in MDA-MB-468 cells, treating cells with" exact="perhexiline" post="resulted in the redistribution of endogenous HER3 to the"/>
   <result pre="expressing HER3-ΔNLS2-YFP were treated with DMSO (i to iii) or" exact="perhexiline" post="(iv to vi) and the internalized HER3-ΔNLS2-YFP receptors were"/>
   <result pre="the internalized HER3-ΔNLS2-YFP receptors were co-localized with lysosomes, confirming that" exact="perhexiline" post="induces HER3 degradation via the lysosome pathway (Figure S3"/>
   <result pre="and breast cancer cell proliferation To determine the effect of" exact="perhexiline" post="on HER3-mediated oncogenic signaling in breast cancer cells, serum-starved"/>
   <result pre="in breast cancer cells, serum-starved MDA-MB-468 cells were pretreated with" exact="perhexiline" post="and subsequently stimulated with NRGβ1. As shown in Figure"/>
   <result pre="and subsequently stimulated with NRGβ1. As shown in Figure 3A," exact="perhexiline" post="treatment significantly decreased NRGβ1-induced phosphorylation of Akt and ERK."/>
   <result pre="addition, MTS assays were performed to assess the effect of" exact="perhexiline" post="on cell proliferation. Results showed that NRGβ1 treatment resulted"/>
   <result pre="with HER3’s role in promoting tumor growth. Treating cells with" exact="perhexiline" post="decreased cell proliferation by 11.5% and 36.3% in serum-free"/>
   <result pre="MDA-MB-468 cells were cultured in the absence or presence of" exact="perhexiline" post="(10 μM) for 6 hours, and subsequently stimulated with"/>
   <result pre="or NRGβ1 (10 ng/ml) in the presence of DMSO or" exact="perhexiline" post="(2 μm). Cell growth was measured using the MTS"/>
   <result pre="the mean ± SEM (n = 3). The statistical significance between DMSO control and" exact="perhexiline" post="treatment in vehicle media or NRGβ1 media was analyzed"/>
   <result pre="group with only NRGβ1 treatment). BSA, bovine serum albumin; DMSO," exact="dimethyl sulfoxide;" post="ERK, extracellular signal-regulated protein kinase; HER3, human epidermal growth"/>
   <result pre="error of the mean. To further determine the effect of" exact="perhexiline" post="on breast cancer cell proliferation, MDA-MB-468 and SK-BR-3 cells"/>
   <result pre="MDA-MB-468 and SK-BR-3 cells were treated with different concentrations of" exact="perhexiline" post="for 72 hours in regular growth medium. Perhexiline treatment"/>
   <result pre="erlotinib) [ 12- 14], we next assessed the effect of" exact="perhexiline" post="combined with lapatinib, an agent commonly used to treat"/>
   <result pre="HER2-positive breast cancer. Treatment of MDA-MB-468 cells with 100 nM" exact="lapatinib" post="for 2 hours led to decreased phosphorylation and activation"/>
   <result pre="activation of HER3 and downstream Akt signaling (Figure 4C). However," exact="lapatinib" post="treatment after 36 hours led to the recovery of"/>
   <result pre="AKT phosphorylation, a result similar to the original report describing" exact="lapatinib" post="resistance mediated by HER3 (Figure 4C) [ 12]. In"/>
   <result pre="effective in cells treated with a combination of 5 μM" exact="perhexiline" post="and 100 nM lapatinib, suggesting that perhexiline can potentially"/>
   <result pre="of 5 μM perhexiline and 100 nM lapatinib, suggesting that" exact="perhexiline" post="can potentially be used to prevent the resistance to"/>
   <result pre="and SK-BR-3 (B) cells were treated with different concentrations of" exact="perhexiline" post="for 72 hours, and cell viability was measured using"/>
   <result pre="mean ± SEM of three independent experiments. (C) The synergistic effect of" exact="perhexiline" post="and lapatinib on inhibiting HER3-mediated Akt signaling. MDA-MB 468"/>
   <result pre="three independent experiments. (C) The synergistic effect of perhexiline and" exact="lapatinib" post="on inhibiting HER3-mediated Akt signaling. MDA-MB 468 cells treated"/>
   <result pre="HER3-mediated Akt signaling. MDA-MB 468 cells treated with 5 μM" exact="perhexiline" post="alone or in combination with 100 nM lapatinib for"/>
   <result pre="5 μM perhexiline alone or in combination with 100 nM" exact="lapatinib" post="for 2 or 36 hours. Cell lysates were analyzed"/>
   <result pre="well as total HER3 and Akt expression. (D-E) Perhexiline and" exact="lapatinib" post="synergistically inhibit MDA-MB-468 (D) and SK-BR-3 (E) cell growth."/>
   <result pre="(E) cell growth. Cells were treated with increasing concentrations of" exact="perhexiline" post="and lapatinib alone or in combination for 72 hours."/>
   <result pre="growth. Cells were treated with increasing concentrations of perhexiline and" exact="lapatinib" post="alone or in combination for 72 hours. MTS assays"/>
   <result pre="50%, 75%, 90% and 95% cells are killed, respectively. DMSO," exact="dimethyl sulfoxide;" post="HER3, human epidermal growth factor receptor 3; SEM, standard"/>
   <result pre="was then studied in MDA-MB-468 and SK-BR-3 cells. Combination of" exact="perhexiline" post="and lapatinib at each of the four indicated doses"/>
   <result pre="studied in MDA-MB-468 and SK-BR-3 cells. Combination of perhexiline and" exact="lapatinib" post="at each of the four indicated doses (1 to"/>
   <result pre="pronounced inhibition in cell proliferation compared to cells treated with" exact="perhexiline" post="or lapatinib alone in MDA-MB-468 cells (Figure 4D). Statistical"/>
   <result pre="in cell proliferation compared to cells treated with perhexiline or" exact="lapatinib" post="alone in MDA-MB-468 cells (Figure 4D). Statistical analysis of"/>
   <result pre="that combinational index (CI) values were less than 1, indicating" exact="perhexiline" post="synergistically enhances the antitumor effect of lapatinib. The combinational"/>
   <result pre="enhances the antitumor effect of lapatinib. The combinational effects of" exact="perhexiline" post="and lapatinib on SK-BR-3 cells also resulted in similar"/>
   <result pre="antitumor effect of lapatinib. The combinational effects of perhexiline and" exact="lapatinib" post="on SK-BR-3 cells also resulted in similar inhibition in"/>
   <result pre="lines, AU565 and BT474, to test the inhibitory effect of" exact="perhexiline" post="on cell proliferation, both alone and in combination with"/>
   <result pre="BT474 cell line was less robust. These data indicate that" exact="perhexiline" post="inhibits breast cancer cells growth and its inhibitory effect"/>
   <result pre="Perhexiline inhibits tumor growth in vivo The antitumor effect of" exact="perhexiline" post="was then studied in vivo. Triple-negative MDA-MB-468 cells were"/>
   <result pre="subcutaneously into SCID mice and 7 days later, oral gavage" exact="perhexiline" post="was initiated and dosed five times a week. As"/>
   <result pre="dosed five times a week. As shown in Figure 5A," exact="perhexiline" post="significantly inhibited the growth of MDA-MB-468 tumors. During the"/>
   <result pre="control tumors (Figure 5C-D). Taken together, these results indicated that" exact="perhexiline" post="inhibits tumor growth and HER3 signaling in vivo. Figure"/>
   <result pre="on day 0. On day 7, oral gavage treatment with" exact="perhexiline" post="(0, 400 mg/kg) was initiated, and repeated for 5"/>
   <result pre="fact that HER3 lacks active kinase activity. To our knowledge," exact="perhexiline" post="is the first small molecule identified that promotes selective"/>
   <result pre="HER3-mediated signaling by inducing receptor internalization. Consistent with this mechanism," exact="perhexiline" post="also inhibits breast cancer cell proliferation in vitro and"/>
   <result pre="in vitro and tumor growth in vivo and synergizes with" exact="lapatinib" post="to inhibit breast cancer cell growth. Increasing evidence has"/>
   <result pre="approved by the FDA for concurrent use in combination with" exact="trastuzumab" post="and docetaxel [ 25]. It provides a proof of"/>
   <result pre="the FDA for concurrent use in combination with trastuzumab and" exact="docetaxel" post="[ 25]. It provides a proof of concept of"/>
   <result pre="properties against the enzyme mitochondrial CPT-1. The plasma concentration of" exact="perhexiline" post="in humans within its therapeutic range is about 2"/>
   <result pre="is about 2 μM [ 28]. Distribution studies indicate that" exact="perhexiline" post="is preferentially distributed in tissues. For example in heart,"/>
   <result pre="is preferentially distributed in tissues. For example in heart, the" exact="perhexiline" post="concentration is at least 10-fold higher than in serum"/>
   <result pre="higher than in serum [ 19, 29]. The distribution of" exact="perhexiline" post="into tumors versus other tissues is unknown; the concentration"/>
   <result pre="into tumors versus other tissues is unknown; the concentration of" exact="perhexiline" post="in tumors needs to be determined. The anticancer properties"/>
   <result pre="in tumors needs to be determined. The anticancer properties of" exact="perhexiline" post="are not well known. It has been reported that"/>
   <result pre="perhexiline are not well known. It has been reported that" exact="perhexiline" post="has an effect on adriamycin-resistant human breast cancer cells."/>
   <result pre="effect on adriamycin-resistant human breast cancer cells. Simultaneous exposure to" exact="tamoxifen" post="or perhexiline decreased resistance to adriamycin in a clonogenic"/>
   <result pre="adriamycin-resistant human breast cancer cells. Simultaneous exposure to tamoxifen or" exact="perhexiline" post="decreased resistance to adriamycin in a clonogenic assay by"/>
   <result pre="[ 30]. Here, we report the anti-breast cancer properties of" exact="perhexiline" post="through HER3 degradation and HER3-mediated signaling inhibition. The synergistic"/>
   <result pre="degradation and HER3-mediated signaling inhibition. The synergistic inhibitory effect of" exact="perhexiline" post="with lapatinib on tumor growth may provide immediate therapeutic"/>
   <result pre="HER3-mediated signaling inhibition. The synergistic inhibitory effect of perhexiline with" exact="lapatinib" post="on tumor growth may provide immediate therapeutic benefits for"/>
   <result pre="breast cancer cells and tumors. As a clinically used drug," exact="perhexiline" post="may be administrated alone, or in combination with other"/>
   <result pre="with greater benefit to breast cancer patients. Clinical evaluation of" exact="perhexiline" post="and its improved derivatives may directly lead to a"/>
   <result pre="eliminating it from the cell membrane. Consistent with this mechanism," exact="perhexiline" post="inhibits HER3-mediated signaling as well as the growth of"/>
   <result pre="perhexiline-induced downregulation of endogenous HER3. Cells treated with 10 μM" exact="perhexiline" post="for the indicated time were analyzed for endogenous HER3"/>
   <result pre="control. (B) Quantification of HER3 and EGFR protein expression following" exact="perhexiline" post="treatment. Western blots shown in (A) were quantified by"/>
   <result pre="were quantified by normalizing to β-actin. (C) Dose-dependent effect of" exact="perhexiline" post="on HER3 expression. Cell lysates prepared from cells treated"/>
   <result pre="Cell lysates prepared from cells treated with different concentrations of" exact="perhexiline" post="for 8 hours were analyzed for the expression of"/>
   <result pre="EGFR. (D) Quantification of HER3 and EGFR protein expression following" exact="perhexiline" post="treatment. Western blots shown in (C) were quantified by"/>
   <result pre="were quantified by normalizing to β-actin. (E) Dose-dependent effect of" exact="perhexiline" post="on HER3 phosphorylation. Cell lysates prepared from cells treated"/>
   <result pre="Cell lysates prepared from cells treated with different concentrations of" exact="perhexiline" post="for 6 hours were analyzed for the phosphorylation of"/>
   <result pre="expressing HER3-ΔNLS2-YFP were treated with DMSO (i to iii) or" exact="perhexiline" post="(iv to vi) and co-localization of HER3ΔNLS2-YFP (green) with"/>
   <result pre="synergistically with lapatinib. (A and C) The antiproliferative effects of" exact="perhexiline" post="on AU565 (A) and BT474 (C) breast cancer cells."/>
   <result pre="breast cancer cells. Cells were treated with different concentrations of" exact="perhexiline" post="for 72 hours, and cell viability was measured using"/>
   <result pre="three independent experiments. (B and D) The synergistic effect of" exact="perhexiline" post="and lapatinib on inhibiting proliferation of AU565 (B) and"/>
   <result pre="experiments. (B and D) The synergistic effect of perhexiline and" exact="lapatinib" post="on inhibiting proliferation of AU565 (B) and BT474 (D)"/>
   <result pre="BT474 (D) cells. Cells were treated with increasing concentrations of" exact="perhexiline" post="and lapatinib alone or in combination for 72 hours."/>
   <result pre="cells. Cells were treated with increasing concentrations of perhexiline and" exact="lapatinib" post="alone or in combination for 72 hours. MTS assays"/>
   <result pre="serum albumin CI combinational index CPT-1 mitochondrial carnitine palmitoyltransferase-1 DMSO" exact="dimethyl sulfoxide" post="ED effective dose EGF epidermal growth factor EGFR epidermal"/>
   <result pre="of human breast cancer cell lines with acquired resistance to" exact="fulvestrant" post="Breast Cancer Res Treat 2009 114 263 75 10.1007/s10549-008-0011-8"/>
   <result pre="Bond MC Ren XR Lyerly HK et al. The anti-helminthic" exact="niclosamide" post="inhibits Wnt/Frizzled1 signaling Biochemistry 2009 48 10267 74 10.1021/bi9009677"/>
   <result pre="Krum H Systematic review of the efficacy and safety of" exact="perhexiline" post="in the treatment of ischemic heart disease Am J"/>
   <result pre="S Voss DW Northey DL Horowitz JD Relationship between plasma" exact="perhexiline" post="concentration and symptomatic status during short-term perhexiline therapy Ther"/>
   <result pre="Relationship between plasma perhexiline concentration and symptomatic status during short-term" exact="perhexiline" post="therapy Ther Drug Monit 1996 18 635 9 10.1097/00007691-199612000-00002"/>
   <result pre="to adriamycin in two human breast cancer cell lines with" exact="tamoxifen" post="or perhexiline maleate Cancer Chemother Pharmacol 1988 22 147"/>
   <result pre="in two human breast cancer cell lines with tamoxifen or" exact="perhexiline" post="maleate Cancer Chemother Pharmacol 1988 22 147 52 10.1007/BF00257313"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4359239/results/search/inn/results.xml">
   <result pre="and afatinib, the HER2 kinase inhibitor lapatinib, the EGFR-directed antibodies" exact="cetuximab" post="and panitumumab, and the HER2-targeted antibodies trastuzumab and pertuzumab."/>
   <result pre="the EGFR-directed antibodies cetuximab and panitumumab, and the HER2-targeted antibodies" exact="trastuzumab" post="and pertuzumab. Numerous other investigational agents targeting these receptors"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4359299/results/search/inn/results.xml">
   <result pre="for patients with either SCC or AC is chemotherapy with" exact="cisplatin" post="and 5-fluorouracil (5-FU) [ 9], and in combination with"/>
   <result pre="[ 9], and in combination with other agents such as" exact="oxaliplatin" post="[ 10] and irinotecan [ 11]. Unfortunately, the majority"/>
   <result pre="combination with other agents such as oxaliplatin [ 10] and" exact="irinotecan" post="[ 11]. Unfortunately, the majority of patients at advanced"/>
   <result pre="chronic inflammation and gastric tumorigenesis [ 92]. Targeted monoclonal antibodies," exact="panitumumab" post="(EGFR), pertuzumab (HER-2), ramucirumab (VEGFR-2), and onartuzumab (c-MET), are"/>
   <result pre="and gastric tumorigenesis [ 92]. Targeted monoclonal antibodies, panitumumab (EGFR)," exact="pertuzumab" post="(HER-2), ramucirumab (VEGFR-2), and onartuzumab (c-MET), are currently being"/>
   <result pre="tumorigenesis [ 92]. Targeted monoclonal antibodies, panitumumab (EGFR), pertuzumab (HER-2)," exact="ramucirumab" post="(VEGFR-2), and onartuzumab (c-MET), are currently being tested in"/>
   <result pre="of gastro-esophageal cancer [ 23]. In phase II clinical studies," exact="cetuximab" post="in combination with standard chemotherapy regimens significantly improved response"/>
   <result pre="junction (GEJ) cancer [ 24] or SCC [ 25]. However," exact="cetuximab" post="as a single agent has little clinical activity in"/>
   <result pre="randomized phase III clinical study concluded that the combination of" exact="cetuximab" post="with capecitabine and cisplatin had no additional clinical advantage"/>
   <result pre="III clinical study concluded that the combination of cetuximab with" exact="capecitabine" post="and cisplatin had no additional clinical advantage to chemotherapy"/>
   <result pre="study concluded that the combination of cetuximab with capecitabine and" exact="cisplatin" post="had no additional clinical advantage to chemotherapy alone in"/>
   <result pre="EGFR mAb, panitumumab, has been tested in combination with epirubicin," exact="oxaliplatin" post="and capecitabine in metastatic GEJ cancer patients in a"/>
   <result pre="panitumumab, has been tested in combination with epirubicin, oxaliplatin and" exact="capecitabine" post="in metastatic GEJ cancer patients in a randomized phase"/>
   <result pre="29]. The results from this study indicated that addition of" exact="panitumumab" post="to the chemotherapy does not increase overall survival. Several"/>
   <result pre="tested in upper gastrointestinal cancers. In a phase II study," exact="gefitinib" post="in combination with radiotherapy and chemotherapy in patients with"/>
   <result pre="survival [ 30]. However, in another phase II clinical trial," exact="gefitinib" post="alone has shown very minimal clinical activity in patients"/>
   <result pre="clinical outcome [ 31]. In a phase II clinical trial," exact="erlotinib" post="(TKI) in combination with concurrent chemotherapy and radiotherapy in"/>
   <result pre="clinical response [ 32]. In a separate phase II study," exact="erlotinib" post="as a single agent in patients with unresectable or"/>
   <result pre="[ 36, 37], led to the development and approval of" exact="trastuzumab" post="mAb to target HER-2 in breast tumors [ 38]."/>
   <result pre="HER-2 in breast tumors [ 38]. The initial success of" exact="trastuzumab" post="targeted therapy in breast cancer led to its investigation"/>
   <result pre="poor survival, respectively [ 39]. In a Japanese clinical study," exact="trastuzumab" post="in combination with capecitabine/cisplatin or 5-fluorouracil/cisplatin in patients with"/>
   <result pre="chemotherapy alone [ 40]. In a randomized phase III study," exact="pertuzumab" post="mAb, which is directed against HER-2, in combination with"/>
   <result pre="directed against HER-2, in combination with trastuzumab, 5-fluorouracil, capecitabine, and" exact="cisplatin" post="is currently investigated in patients with HER-2-positive metastatic gastric"/>
   <result pre="is currently ongoing to evaluate the efficacy and safety of" exact="trastuzumab" post="emtansine (T-DM1) compared to standard taxane treatment in patients"/>
   <result pre="breast cancer [ 41]. In a phase II clinical study," exact="lapatinib" post="alone in patients with EGFR- and/or HER-2-overexpressing esophageal AC"/>
   <result pre="a phase I clinical trial is currently ongoing to evaluate" exact="lapatinib" post="in combination with paclitaxel in patients with GEJ adenocarcinoma"/>
   <result pre="trial is currently ongoing to evaluate lapatinib in combination with" exact="paclitaxel" post="in patients with GEJ adenocarcinoma (NCT00313599). Mesenchymal-epithelial transition factor"/>
   <result pre="is currently investigated in combination with 5-fluorouracil, folinic acid, and" exact="oxaliplatin" post="(mFOLFOX6) in patients with metastatic HER2-negative and MET-positive gastric"/>
   <result pre="therapeutic target in esophageal cancers. In a phase III study," exact="bevacizumab" post="mAb, which binds to all isoforms of VEGF and"/>
   <result pre="colorectal carcinoma [ 52]. A phase II study revealed that" exact="bevacizumab" post="in combination with irinotecan and cisplatin relatively enhanced the"/>
   <result pre="A phase II study revealed that bevacizumab in combination with" exact="irinotecan" post="and cisplatin relatively enhanced the survival and clinical outcome"/>
   <result pre="II study revealed that bevacizumab in combination with irinotecan and" exact="cisplatin" post="relatively enhanced the survival and clinical outcome of patients"/>
   <result pre="a more recent phase II clinical trial, the combination of" exact="bevacizumab" post="with docetaxel, cisplatin, and fluorouracil improved response rate and"/>
   <result pre="clinical trial, the combination of bevacizumab with docetaxel, cisplatin, and" exact="fluorouracil" post="improved response rate and survival as compared to chemotherapy"/>
   <result pre="GEJ adenocarcinoma [ 55]. In a randomized phase III trial," exact="ramucirumab" post="monotherapy has improved survival in patients with advanced gastric"/>
   <result pre="patients with gastric or GEJ adenocarcinoma [ 57]. In addition," exact="sunitinib" post="is currently investigated in combination with chemotherapy (FOLFIRI) in"/>
   <result pre="esophageal cancers (NCT00891878, NCT00524186). Another TKI, sorafenib, in combination with" exact="docetaxel" post="and cisplatin improved the overall survival in patients with"/>
   <result pre="(NCT00891878, NCT00524186). Another TKI, sorafenib, in combination with docetaxel and" exact="cisplatin" post="improved the overall survival in patients with metastatic gastric"/>
   <result pre="GEJ adenocarcinoma [ 58]. However, in a phase II study," exact="sorafenib" post="as a single agent is being investigated in patients"/>
   <result pre="gastrointestinal cancers. Indeed, we found that MLN8237 in combination with" exact="cisplatin" post="or docetaxel significantly enhanced cell death in esophageal AC"/>
   <result pre="Indeed, we found that MLN8237 in combination with cisplatin or" exact="docetaxel" post="significantly enhanced cell death in esophageal AC xenograft mouse"/>
   <result pre="L Vokes EE Phase II trial of oxaliplatin, leucovorin and" exact="fluorouracil" post="in patients with advanced carcinoma of the esophagus Annals"/>
   <result pre="J Gonzalez G Kelsen DP Phase II trial of weekly" exact="irinotecan" post="plus cisplatin in advanced esophageal cancer Journal of clinical"/>
   <result pre="G Kelsen DP Phase II trial of weekly irinotecan plus" exact="cisplatin" post="in advanced esophageal cancer Journal of clinical oncology: official"/>
   <result pre="R Patterson SD Chang DD Wild-type KRAS is required for" exact="panitumumab" post="efficacy in patients with metastatic colorectal cancer Journal of"/>
   <result pre="C Moore MJ Zalcberg JR K-ras mutations and benefit from" exact="cetuximab" post="in advanced colorectal cancer The New England journal of"/>
   <result pre="Hicklin DJ Kang X Anti-epidermal growth factor receptor monoclonal antibody" exact="cetuximab" post="inhibits EGFR/HER-2 heterodimerization and activation International journal of oncology"/>
   <result pre="randomized phase II study of three standard chemotherapy regimens plus" exact="cetuximab" post="in metastatic esophageal and GE junction cancer Journal of"/>
   <result pre="E Fuchs CS A multicenter phase II trial of single-agent" exact="cetuximab" post="in advanced esophageal and gastric adenocarcinoma Annals of oncology:"/>
   <result pre="Gotte H Melezinkova H Moehler M et al. Capecitabine and" exact="cisplatin" post="with or without cetuximab for patients with previously untreated"/>
   <result pre="Moehler M et al. Capecitabine and cisplatin with or without" exact="cetuximab" post="for patients with previously untreated advanced gastric cancer (EXPAND):"/>
   <result pre="X Zhang X A pilot study of nimotuzumab combined with" exact="cisplatin" post="and 5-FU in patients with advanced esophageal squamous cell"/>
   <result pre="F Smith D Waters J et al. Epirubicin, oxaliplatin, and" exact="capecitabine" post="with or without panitumumab for patients with previously untreated"/>
   <result pre="J et al. Epirubicin, oxaliplatin, and capecitabine with or without" exact="panitumumab" post="for patients with previously untreated advanced oesophagogastric cancer (REAL3):"/>
   <result pre="perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance" exact="gefitinib" post="in locoregionally advanced esophagus and gastroesophageal junction cancer Journal"/>
   <result pre="LA Ives DI Rice TW A phase II trial of" exact="gefitinib" post="for recurrent or metastatic cancer of the esophagus or"/>
   <result pre="S Phase II study of concurrent chemoradiation in combination with" exact="erlotinib" post="for locally advanced esophageal carcinoma International journal of radiation"/>
   <result pre="Zaner KS Blanke CD Abbruzzese JL Phase II trial of" exact="erlotinib" post="in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127 Journal"/>
   <result pre="Tamura T Abe T Hatake K et al. Efficacy of" exact="trastuzumab" post="in Japanese patients with HER2-positive advanced gastric or gastroesophageal"/>
   <result pre="Raats JI et al. A phase III randomized comparison of" exact="lapatinib" post="plus capecitabine versus capecitabine alone in women with advanced"/>
   <result pre="et al. A phase III randomized comparison of lapatinib plus" exact="capecitabine" post="versus capecitabine alone in women with advanced breast cancer"/>
   <result pre="A phase III randomized comparison of lapatinib plus capecitabine versus" exact="capecitabine" post="alone in women with advanced breast cancer that has"/>
   <result pre="aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to" exact="crizotinib" post="Journal of clinical oncology: official journal of the American"/>
   <result pre="KS Loh E Rilotumumab in combination with epirubicin, cisplatin, and" exact="capecitabine" post="as first-line treatment for gastric or oesophagogastric junction adenocarcinoma:"/>
   <result pre="Mok T Lee C et al. MET amplification leads to" exact="gefitinib" post="resistance in lung cancer by activating ERBB3 signaling Science"/>
   <result pre="Kelsen DP Multicenter phase II study of irinotecan, cisplatin, and" exact="bevacizumab" post="in patients with metastatic gastric or gastroesophageal junction adenocarcinoma"/>
   <result pre="Kelsen DP Phase II study of modified docetaxel, cisplatin, and" exact="fluorouracil" post="with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma Journal"/>
   <result pre="Phase II study of modified docetaxel, cisplatin, and fluorouracil with" exact="bevacizumab" post="in patients with metastatic gastroesophageal adenocarcinoma Journal of clinical"/>
   <result pre="Lu DR Ruiz-Garcia A Sobrero A Phase II study of" exact="sunitinib" post="as second-line treatment for advanced gastric cancer Investigational new"/>
   <result pre="Catalano P Ansari RH Benson AB Phase II study of" exact="sorafenib" post="in combination with docetaxel and cisplatin in the treatment"/>
   <result pre="Benson AB Phase II study of sorafenib in combination with" exact="docetaxel" post="and cisplatin in the treatment of metastatic or advanced"/>
   <result pre="Phase II study of sorafenib in combination with docetaxel and" exact="cisplatin" post="in the treatment of metastatic or advanced gastric and"/>
   <result pre="Z Sehdev V Belkhiri A ABL regulation by AXL promotes" exact="cisplatin" post="resistance in esophageal cancer Cancer research 2013 73 331"/>
   <result pre="combination of alisertib, an investigational Aurora kinase A inhibitor, and" exact="docetaxel" post="promotes cell death and reduces tumor growth in preclinical"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4361905/results/search/inn/results.xml">
   <result pre="45 months after initial diagnosis. She was treated with intra-CSF" exact="trastuzumab" post="followed by intra-CSF liposomal cytarabine; however, the cancer progressed"/>
   <result pre="She was treated with CNS-directed radiotherapy (lumbosacral and cerebellar) and" exact="bevacizumab" post="plus vinorelbine. Rapid functional improvement occurred, and the patient"/>
   <result pre="significant improvement in neurological function combined with the prolonged response," exact="bevacizumab" post="alone or in combination with chemotherapy and CNS-directed radiotherapy"/>
   <result pre="a prolonged response to the combination of CNS-directed radiotherapy and" exact="bevacizumab" post="plus vinorelbine. Case Report A 29-year-old woman was diagnosed"/>
   <result pre="hormonal receptors. She initially received neoadjuvant chemotherapy [3 cycles of" exact="fluorouracil" post="(500 mg/m 2), epirubicin (100 mg/m 2) and cyclophosphamide"/>
   <result pre="received neoadjuvant chemotherapy [3 cycles of fluorouracil (500 mg/m 2)," exact="epirubicin" post="(100 mg/m 2) and cyclophosphamide (500 mg/m 2) every"/>
   <result pre="of fluorouracil (500 mg/m 2), epirubicin (100 mg/m 2) and" exact="cyclophosphamide" post="(500 mg/m 2) every 3 weeks] followed by 3"/>
   <result pre="mg/m 2) every 3 weeks] followed by 3 cycles of" exact="docetaxel" post="(100 mg/m 2 every 3 weeks) plus trastuzumab (6"/>
   <result pre="cycles of docetaxel (100 mg/m 2 every 3 weeks) plus" exact="trastuzumab" post="(6 mg/kg every 3 weeks for a total of"/>
   <result pre="Oncology Group-Performance Status (ECOG-PS) 1], and she was treated with" exact="docetaxel" post="(100 mg/m 2 every 3 weeks) plus trastuzumab (6"/>
   <result pre="treated with docetaxel (100 mg/m 2 every 3 weeks) plus" exact="trastuzumab" post="(6 mg/kg every 3 weeks) for 6 months followed"/>
   <result pre="(6 mg/kg every 3 weeks) for 6 months followed by" exact="trastuzumab" post="alone as maintenance therapy. Nine months later, she presented"/>
   <result pre="patient was enrolled in a phase I trial of intra-CSF" exact="trastuzumab" post="combined with intravenous trastuzumab (6 mg/kg every 3 weeks)"/>
   <result pre="a phase I trial of intra-CSF trastuzumab combined with intravenous" exact="trastuzumab" post="(6 mg/kg every 3 weeks) and oral capecitabine (2,000"/>
   <result pre="with intravenous trastuzumab (6 mg/kg every 3 weeks) and oral" exact="capecitabine" post="(2,000 mg twice a day for 2 weeks with"/>
   <result pre="deteriorated to 2. The patient was treated with intraventricular liposomal" exact="cytarabine" post="(50 mg every 14 days, for a total of"/>
   <result pre="every 14 days, for a total of 4 injections), oral" exact="lapatinib" post="(250 mg per day), intravenous trastuzumab (6 mg/kg every"/>
   <result pre="of 4 injections), oral lapatinib (250 mg per day), intravenous" exact="trastuzumab" post="(6 mg/kg every 3 weeks) and oral capecitabine (2,000"/>
   <result pre="day), intravenous trastuzumab (6 mg/kg every 3 weeks) and oral" exact="capecitabine" post="(2,000 mg twice a day for 2 weeks with"/>
   <result pre="discontinued. Bevacizumab (10 mg/kg every 2 weeks) in combination with" exact="vinorelbine" post="(80 mg/m 2) was initiated in conjunction with site-specific"/>
   <result pre="that the restoration of neurological function was secondary to systemic" exact="bevacizumab" post="plus vinorelbine administration since improvement was observed before the"/>
   <result pre="restoration of neurological function was secondary to systemic bevacizumab plus" exact="vinorelbine" post="administration since improvement was observed before the onset of"/>
   <result pre="proliferation. At present, there are only preliminary results of using" exact="bevacizumab" post="in the treatment of BC-related brain metastases [ 8,"/>
   <result pre="response in a single BC patient with LM treated with" exact="bevacizumab" post="and capecitabine. Additionally, there are reports of both the"/>
   <result pre="are reports of both the brain and LM responding to" exact="capecitabine" post="[ 14]. Labidi et al. [ 9] reported on"/>
   <result pre="a prolonged response in a BC-related LM patient treated with" exact="bevacizumab" post="and paclitaxel. The efficacy of paclitaxel in the CNS,"/>
   <result pre="LM patient treated with bevacizumab and paclitaxel. The efficacy of" exact="paclitaxel" post="in the CNS, like that of vinorelbine used in"/>
   <result pre="The efficacy of paclitaxel in the CNS, like that of" exact="vinorelbine" post="used in the current case, has been less frequently"/>
   <result pre="the limited CNS penetration. This suggests a primary role of" exact="bevacizumab" post="in the neurological and radiographic improvement seen in the"/>
   <result pre="weeks, 6 censored) [ 15]. Prospective studies are currently evaluating" exact="bevacizumab" post="in BC-related LM (NCT00924820, NCT01281696). Conclusion In radiographically bulky"/>
   <result pre="likely more active than intra-CSF therapy only. The combination of" exact="bevacizumab" post="and vinorelbine was safe and effective in our patient"/>
   <result pre="active than intra-CSF therapy only. The combination of bevacizumab and" exact="vinorelbine" post="was safe and effective in our patient notwithstanding its"/>
   <result pre="Alleviation of brain edema and restoration of functional independence by" exact="bevacizumab" post="in brain-metastatic breast cancer: a case report Breast Care"/>
   <result pre="Favier B Galy G Blay JY Guastalla JP Bevacizumab and" exact="paclitaxel" post="for breast cancer patients with central nervous system metastases:"/>
   <result pre="Schneider BP Krop IE Winer EP Phase II trial of" exact="carboplatin" post="(C) and bevacizumab (BEV) in patients (pts) with breast"/>
   <result pre="IE Winer EP Phase II trial of carboplatin (C) and" exact="bevacizumab" post="(BEV) in patients (pts) with breast cancer brain metastases"/>
   <result pre="YF Huang SM Shih TTF Cheng AL Bevacizumab, etoposide, and" exact="cisplatin" post="(BEEP) in brain metastases of breast cancer progressing from"/>
   <result pre="Camphausen K Yung WKA A pilot study of systemically administered" exact="bevacizumab" post="in patients with neoplastic meningitis: imaging, clinical, CSF, and"/>
   <result pre="at baseline (02.05.13; a), after 1 month of treatment with" exact="bevacizumab" post="plus vinorelbine at the end of posterior fossa irradiation"/>
   <result pre="(02.05.13; a), after 1 month of treatment with bevacizumab plus" exact="vinorelbine" post="at the end of posterior fossa irradiation (05.06.13; b),"/>
   <result pre="irradiation (05.06.13; b), and after 11.5 months of treatment with" exact="bevacizumab" post="plus vinorelbine (15.04.14; c)."/>
   <result pre="b), and after 11.5 months of treatment with bevacizumab plus" exact="vinorelbine" post="(15.04.14; c)."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4362606/results/search/inn/results.xml">
   <result pre="such as tyrosine kinase inhibitors and &quot;naked&quot; antibodies ( e.g." exact="trastuzumab" post="or cetuximab). Evidence for therapy efficacy of such agents"/>
   <result pre="and deparaffinized in xylene and hydrated through graded concentrations of" exact="ethanol" post="to distilled water. 23 EGFR-immunohistochemistry EGFR was assessed by"/>
   <result pre="peptides for therapy of neuroendocrine tumors 59, 60 ( e.g." exact="somatostatin" post="analogs such as 177Lu-Octreotate). There is potential for more"/>
   <result pre="indicate a possible value of HER2-targeted therapy (with for example" exact="lapatinib" post="and/or trastuzumab). 22 However, since then there has been"/>
   <result pre="Graaf WT de Korte MA Jonkman S et al. Indium-111-labeled" exact="trastuzumab" post="scintigraphy in patients with human epidermal growth factor receptor"/>
   <result pre="Bergström M et al. In vivo binding of [68Ga]-DOTATOC to" exact="somatostatin" post="receptors in neuroendocrine tumours--impact of peptide mass Nucl Med"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4363856/results/search/inn/results.xml">
   <result pre="hormone receptor positive breast cancer. In a phase II trial" exact="fulvestrant" post="was found to significantly improve progression free and overall"/>
   <result pre="fundamental question of whether an aromatase inhibitor was superior to" exact="tamoxifen" post="among premenopausal women with hormone receptor positive early stage"/>
   <result pre="of whether ovarian function suppression added benefit when combined with" exact="tamoxifen" post="among premenopausal women. Research efforts to refine the role"/>
   <result pre="receptor positive metastatic breast cancer to either 500 mg of" exact="fulvestrant" post="or anastrazole in the first line setting. The primary"/>
   <result pre="receptor positive metastatic breast cancer to either 500 mg of" exact="fulvestrant" post="or anastrzole. The second important question in the metastatic"/>
   <result pre="the adjuvant or metastatic setting to either 500 mg of" exact="fulvestrant" post="combined with the PI3Kinase inhibitor pictilisib or fulvestrant and"/>
   <result pre="mg of fulvestrant combined with the PI3Kinase inhibitor pictilisib or" exact="fulvestrant" post="and placebo. In the intent to treat population, the"/>
   <result pre="population, the authors reported that the addition of pictilisib to" exact="fulvestrant" post="was associated with a nonsignificant improvement in progression free"/>
   <result pre="inhibitors either in the adjuvant or metastatic setting to either" exact="fulvestrant" post="and bortezomib or fulvestrant alone. The authors reported that"/>
   <result pre="in the adjuvant or metastatic setting to either fulvestrant and" exact="bortezomib" post="or fulvestrant alone. The authors reported that the addition"/>
   <result pre="adjuvant or metastatic setting to either fulvestrant and bortezomib or" exact="fulvestrant" post="alone. The authors reported that the addition of bortezomib"/>
   <result pre="or fulvestrant alone. The authors reported that the addition of" exact="bortezomib" post="did not improve the median or 6 months progression"/>
   <result pre="positive early stage breast cancer were randomized to receive either" exact="tamoxifen" post="and ovarian function suppression or exemestane and ovarian function"/>
   <result pre="randomized to receive either tamoxifen and ovarian function suppression or" exact="exemestane" post="and ovarian function suppression. The combined analysis results revealed"/>
   <result pre="survival of 3.8% at 5 years favoring the group receiving" exact="exemestane" post="and ovarian function suppression. This year at SABCS we"/>
   <result pre="of the SOFT trial that randomized premenopausal women to either" exact="tamoxifen" post="alone, tamoxifen and ovarian function suppression or exemestane and"/>
   <result pre="SOFT trial that randomized premenopausal women to either tamoxifen alone," exact="tamoxifen" post="and ovarian function suppression or exemestane and ovarian function"/>
   <result pre="to either tamoxifen alone, tamoxifen and ovarian function suppression or" exact="exemestane" post="and ovarian function suppression.[ 5 6] Approximately, 1000 women"/>
   <result pre="to look at disease free survival among women who received" exact="tamoxifen" post="and tamoxifen plus ovarian function suppression. The authors reported"/>
   <result pre="at disease free survival among women who received tamoxifen and" exact="tamoxifen" post="plus ovarian function suppression. The authors reported that overall"/>
   <result pre="of 5.6 years the addition of ovarian function suppression to" exact="tamoxifen" post="did not benefit premenopausal women compared to tamoxifen alone"/>
   <result pre="suppression to tamoxifen did not benefit premenopausal women compared to" exact="tamoxifen" post="alone ( P = 0.10) indicating that some women"/>
   <result pre="P = 0.10) indicating that some women do well with" exact="tamoxifen" post="alone. In a preplanned analysis the authors further observed"/>
   <result pre="breast cancer free interval was 4.5% among women who received" exact="tamoxifen" post="and ovarian suppression and 7.7% among women who received"/>
   <result pre="tamoxifen and ovarian suppression and 7.7% among women who received" exact="exemestane" post="and ovarian suppression when compared to tamoxifen alone respectively."/>
   <result pre="women who received exemestane and ovarian suppression when compared to" exact="tamoxifen" post="alone respectively. Among premenopausal women who did not receive"/>
   <result pre="interval of 67.7%, 78.9%, 83.4% among women who received tamoxifen," exact="tamoxifen" post="plus ovarian function suppression and exmestane plus ovarian function"/>
   <result pre="risk of recurrence to warrant chemotherapy and who retain premenopausal" exact="estradiol" post="levels the addition of ovarian function suppression to tamoxifen"/>
   <result pre="premenopausal estradiol levels the addition of ovarian function suppression to" exact="tamoxifen" post="reduced risk of recurrence. The use of ovarian function"/>
   <result pre="40603 phase II trials that showed that the addition of" exact="carboplatin" post="to neoadjuvant chemotherapy increased pathological complete response rates among"/>
   <result pre="randomized patients with triple negative breast cancer who all received" exact="paclitaxel" post="to receive in addition either carboplatin or bevacizumab) were"/>
   <result pre="cancer who all received paclitaxel to receive in addition either" exact="carboplatin" post="or bevacizumab) were presented.[ 7] The investigators looked at"/>
   <result pre="positive metastatic breast cancer to either first line treatment with" exact="docetaxel" post="or single agent carboplatin were presented.[ 8] Primary end"/>
   <result pre="to either first line treatment with docetaxel or single agent" exact="carboplatin" post="were presented.[ 8] Primary end point was objective response,"/>
   <result pre="setting. Several new anti HER2 agents have been introduced including" exact="trastuzumab" post="emtansine (TDM-1), pertuzumab and lapatinib. Efforts are underway to"/>
   <result pre="anti HER2 agents have been introduced including trastuzumab emtansine (TDM-1)," exact="pertuzumab" post="and lapatinib. Efforts are underway to find ways to"/>
   <result pre="breast cancer who had not received prior chemotherapy to either" exact="trastuzumab" post="and paclitaxel or the same combination with everolimus.[ 10]"/>
   <result pre="who had not received prior chemotherapy to either trastuzumab and" exact="paclitaxel" post="or the same combination with everolimus.[ 10] The primary"/>
   <result pre="HER2 positive, hormone receptor negative breast cancer the addition of" exact="everolimus" post="resulted a 7 months improvement in progression free survival"/>
   <result pre="on trial design ( P = 0.044). The addition of" exact="everolimus" post="was associated with a higher rate of adverse event"/>
   <result pre="of adverse event related on treatment related deaths (3.6% for" exact="everolimus" post="vs. 0% for placebo). Another question that has been"/>
   <result pre="to receive either 12 weeks or 24 weeks of neoadjuvant" exact="trastuzumab" post="and lapatinib.[ 11] Patients with estrogen receptor positive disease"/>
   <result pre="randomized women with early stage breast cancer to receive neoadjuvant" exact="paclitaxel" post="followed by epirubicin, cyclophosphamide (EC) or abraxane, followed by"/>
   <result pre="stage breast cancer to receive neoadjuvant paclitaxel followed by epirubicin," exact="cyclophosphamide" post="(EC) or abraxane, followed by EC.[ 12] Patients with"/>
   <result pre="with HER 2 positive breast cancer in addition received neoadjuvant" exact="trastuzumab" post="and pertuzumab throughout the course of neoadjuvant chemotherapy. The"/>
   <result pre="2 positive breast cancer in addition received neoadjuvant trastuzumab and" exact="pertuzumab" post="throughout the course of neoadjuvant chemotherapy. The authors reported"/>
   <result pre="stage breast cancer to either four cycles of adjuvant adriamycin," exact="cyclophosphamide" post="(AC) or 6 cycles of adjuvant 5-FU, epirubicin, cyclophosphamide"/>
   <result pre="adriamycin, cyclophosphamide (AC) or 6 cycles of adjuvant 5-FU, epirubicin," exact="cyclophosphamide" post="(FEC) 100.[ 13] Following completion of chemotherapy patients with"/>
   <result pre="Following completion of chemotherapy patients with HER2 positive disease received" exact="trastuzumab" post="and those with hormone receptor positive disease received endocrine"/>
   <result pre="IM Kulyk SO et al. The cyclin-dependent kinase 4/6 inhibitor" exact="palbociclib" post="in combination with letrozole versus letrozole alone as first-line"/>
   <result pre="al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with" exact="letrozole" post="versus letrozole alone as first-line treatment of oestrogen receptor-positive,"/>
   <result pre="cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus" exact="letrozole" post="alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced"/>
   <result pre="Jasiówka M Hewson N et al. Fulvestrant 500 mg versus" exact="anastrozole" post="as first-line treatment for advanced breast cancer: Overall survival"/>
   <result pre="JJ Raptis G et al. Randomized phase II trial of" exact="fulvestrant" post="alone or in combination with bortezomib in hormone receptor-positive"/>
   <result pre="phase II trial of fulvestrant alone or in combination with" exact="bortezomib" post="in hormone receptor-positive metastatic breast cancer resistant to aromatase"/>
   <result pre="life (QoL) in the IBCSG SOFT trial: Adjuvant treatment with" exact="tamoxifen" post="(T) alone versus tamoxifen plus ovarian function suppression (OFS)"/>
   <result pre="IBCSG SOFT trial: Adjuvant treatment with tamoxifen (T) alone versus" exact="tamoxifen" post="plus ovarian function suppression (OFS) in premenopausal women with"/>
   <result pre="breast cancer (TNBC) after neoadjuvant chemotherapy (NACT) +/-carboplatin (Cb) or" exact="bevacizumab" post="(Bev): CALGB 40603/150709 (Alliance) S4-05 8 Tutt A Ellis"/>
   <result pre="al. The TNT trial: A randomized phase III trial of" exact="carboplatin" post="(C) compared with docetaxel (D) for patients with metastatic"/>
   <result pre="A randomized phase III trial of carboplatin (C) compared with" exact="docetaxel" post="(D) for patients with metastatic or recurrent locally advanced"/>
   <result pre="10 Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily" exact="everolimus" post="plus weekly trastuzumab and paclitaxel as first-line therapy in"/>
   <result pre="randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly" exact="trastuzumab" post="and paclitaxel as first-line therapy in women with HER2+"/>
   <result pre="placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and" exact="paclitaxel" post="as first-line therapy in women with HER2+ advanced breast"/>
   <result pre="al. TBCRC023: A randomized multicenter phase II neoadjuvant trial of" exact="lapatinib" post="plus trastuzumab, withendcorine therapy and without chemotherapy, for 12"/>
   <result pre="randomized phase III trial comparing neoadjuvant chemotherapy with weekly nanoparticle-based" exact="paclitaxel" post="with solventbased paclitaxel followed by anthracyline/cyclophosphamide for patients with"/>
   <result pre="trial comparing neoadjuvant chemotherapy with weekly nanoparticle-based paclitaxel with solventbased" exact="paclitaxel" post="followed by anthracyline/cyclophosphamide for patients with early breast cancer"/>
   <result pre="III trial comparing six cycles of 5-fluorouracil (5-FU), epirubicin, and" exact="cyclophosphamide" post="(FEC) to four cycles of adriamycin and cyclophosphamide (AC)"/>
   <result pre="epirubicin, and cyclophosphamide (FEC) to four cycles of adriamycin and" exact="cyclophosphamide" post="(AC) in patients (pts) with node-negative breast cancer S3-02"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4368842/results/search/inn/results.xml">
   <result pre="and transgenic mouse models [ 4, 5]. The anti-HER2 antibody" exact="trastuzumab" post="represents an effective, targeted therapy with significant efficacy in"/>
   <result pre="of HER2-positive breast and gastric cancer [ 6, 7]. Indeed," exact="trastuzumab" post="in combination with cisplatin and a fluoropyrimidine (capecitabine or"/>
   <result pre="gastric cancer [ 6, 7]. Indeed, trastuzumab in combination with" exact="cisplatin" post="and a fluoropyrimidine (capecitabine or 5-fluorouracil) has been approved"/>
   <result pre="improvement in median overall survival (OS) of 2.5 months with" exact="trastuzumab" post="plus chemotherapy treatment compared to chemotherapy alone, demonstrated in"/>
   <result pre="US Food and Drug Administration for selection of patients for" exact="trastuzumab" post="and pertuzumab therapy. HER2 chromogenic in situ hybridization CISH"/>
   <result pre="and Drug Administration for selection of patients for trastuzumab and" exact="pertuzumab" post="therapy. HER2 chromogenic in situ hybridization CISH was performed"/>
   <result pre="HER2 [ 13, 15– 18]. An early histology-independent trial using" exact="lapatinib" post="monotherapy for HER2-expressing tumors faced logistical challenges and showed"/>
   <result pre="F Bemis L Varella-Garcia M HER2 mutation and response to" exact="trastuzumab" post="therapy in non-small-cell lung cancer The New England Journal"/>
   <result pre="Zaks, T. Z. (2012). Target-specific, histology-independent, randomized discontinuation study of" exact="lapatinib" post="in patients with HER2-amplified solid tumors. Investigational New Drugs,"/>
   <result pre="B2225. (2008). Phase II, open-label study evaluating the activity of" exact="imatinib" post="in treating life-threatening malignancies known to be associated with"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4376930/results/search/inn/results.xml">
   <result pre="Breast cancer subtypes continue to be stratified histologically on oestrogen," exact="progesterone" post="and human epidermal growth factor-2 (HER2) receptor expression. HER2-positive"/>
   <result pre="field of HER2-positive disease, with the approval of trastuzumab, pertuzumab," exact="lapatinib" post="and trastuzumab emtansine (TDM-1). Recently, TDM-1 has been shown"/>
   <result pre="HER2-positive disease, with the approval of trastuzumab, pertuzumab, lapatinib and" exact="trastuzumab" post="emtansine (TDM-1). Recently, TDM-1 has been shown to improve"/>
   <result pre="to improve progression-free survival in HER2 MBC when compared to" exact="capecitabine" post="and lapatinib in clinical studies. Its main toxicities are"/>
   <result pre="progression-free survival in HER2 MBC when compared to capecitabine and" exact="lapatinib" post="in clinical studies. Its main toxicities are deranged liver"/>
   <result pre="these complexities, breast cancer is still traditionally classified by oestrogen," exact="progesterone" post="and human epidermal growth factor-2 (HER2) receptor expression ["/>
   <result pre="the treatment of MBC [ 7]. These include trastuzumab, lapatinib," exact="pertuzumab" post="and, most recently, trastuzumab emtansine (TDM-1; fig. 1). Since"/>
   <result pre="[ 7]. These include trastuzumab, lapatinib, pertuzumab and, most recently," exact="trastuzumab" post="emtansine (TDM-1; fig. 1). Since the introduction of trastuzumab"/>
   <result pre="recently, trastuzumab emtansine (TDM-1; fig. 1). Since the introduction of" exact="trastuzumab" post="for the management of MBC, the 2-year survival rates"/>
   <result pre="15]. Recently, the phase III EMILIA trial compared TDM-1 to" exact="capecitabine" post="and lapatinib in patients with HER2-positive MBC previously treated"/>
   <result pre="the phase III EMILIA trial compared TDM-1 to capecitabine and" exact="lapatinib" post="in patients with HER2-positive MBC previously treated with anthracycline,"/>
   <result pre="patients with HER2-positive MBC previously treated with anthracycline, taxane and" exact="trastuzumab" post="[ 16]. TDM-1 improved progression-free survival (PFS) when compared"/>
   <result pre="[ 16]. TDM-1 improved progression-free survival (PFS) when compared to" exact="capecitabine" post="and lapatinib (9.6 vs. 6.4 months, p &amp;lt; 0.0001)"/>
   <result pre="TDM-1 improved progression-free survival (PFS) when compared to capecitabine and" exact="lapatinib" post="(9.6 vs. 6.4 months, p &amp;lt; 0.0001) [ 16]."/>
   <result pre="grade 3 invasive ductal carcinoma that was oestrogen receptor positive," exact="progesterone" post="receptor negative and HER2 receptor positive. There was also"/>
   <result pre="proceeded to neo-adjuvant chemotherapy. The patient received 4 cycles of" exact="epirubicin" post="and cyclophosphamide followed by 4 cycles of accelerated paclitaxel."/>
   <result pre="neo-adjuvant chemotherapy. The patient received 4 cycles of epirubicin and" exact="cyclophosphamide" post="followed by 4 cycles of accelerated paclitaxel. The HER2-targeted"/>
   <result pre="followed by 4 cycles of accelerated paclitaxel. The HER2-targeted antibody" exact="trastuzumab" post="was added to her treatment regime along with the"/>
   <result pre="her treatment regime along with the initiation of the accelerated" exact="paclitaxel" post="component. On completion of her neo-adjuvant chemotherapy in May"/>
   <result pre="In the post-operative period, she underwent adjuvant radiotherapy, continued with" exact="trastuzumab" post="for 1 year and commenced adjuvant letrozole. In March"/>
   <result pre="biopsy-proven skin recurrence that was negative for the oestrogen and" exact="progesterone" post="receptor and positive for HER2. Imaging demonstrated no distant"/>
   <result pre="demonstrated no distant metastatic disease, and she was commenced on" exact="capecitabine" post="and lapatinib (first-line treatment for MBC). Her disease remained"/>
   <result pre="distant metastatic disease, and she was commenced on capecitabine and" exact="lapatinib" post="(first-line treatment for MBC). Her disease remained stable until"/>
   <result pre="chest wall soft tissue. Therefore, her treatment was changed to" exact="vinorelbine" post="and trastuzumab (second-line treatment for MBC), and repeat imaging"/>
   <result pre="soft tissue. Therefore, her treatment was changed to vinorelbine and" exact="trastuzumab" post="(second-line treatment for MBC), and repeat imaging in March"/>
   <result pre="demonstrated no measurable disease. At this juncture, the patient stopped" exact="vinorelbine" post="treatment and continued maintenance trastuzumab treatment alone. The response"/>
   <result pre="this juncture, the patient stopped vinorelbine treatment and continued maintenance" exact="trastuzumab" post="treatment alone. The response to treatment was short-lived, and"/>
   <result pre="and her chest wall disease recurred in June 2012, when" exact="vinorelbine" post="was again added to trastuzumab leading to stabilisation of"/>
   <result pre="recurred in June 2012, when vinorelbine was again added to" exact="trastuzumab" post="leading to stabilisation of her disease. In January 2013,"/>
   <result pre="In light of her progressive disease, treatment was changed to" exact="docetaxel" post="with ongoing maintenance trastuzumab (third-line treatment for MBC). Interval"/>
   <result pre="progressive disease, treatment was changed to docetaxel with ongoing maintenance" exact="trastuzumab" post="(third-line treatment for MBC). Interval imaging demonstrated response to"/>
   <result pre="her isolated liver metastasis with complete remission and continued maintenance" exact="trastuzumab" post="alone. The patient's chest wall disease progressed clinically in"/>
   <result pre="2013, and she was commenced on vertical dual blockade with" exact="lapatinib" post="and trastuzumab given in the absence of chemotherapy (fourth-line"/>
   <result pre="she was commenced on vertical dual blockade with lapatinib and" exact="trastuzumab" post="given in the absence of chemotherapy (fourth-line treatment for"/>
   <result pre="wall disease remained under good control and she continued on" exact="lapatinib" post="and trastuzumab. In April 2014, the patient showed further"/>
   <result pre="with HER2-directed therapy. In light of her progression on both" exact="trastuzumab" post="and lapatinib, she was treated with TDM-1 (fifth-line treatment"/>
   <result pre="for HER2-positive MBC have been approved, including the monoclonal antibodies" exact="trastuzumab" post="and pertuzumab, the dual tyrosine kinase inhibitor lapatinib, and"/>
   <result pre="TDM-1 is a unique antibody-drug conjugate combining the HER2-targeted antibody" exact="trastuzumab" post="and the cytotoxic moiety emtansine [ 20]. Trastuzumab inhibits"/>
   <result pre="MBC, TDM-1 demonstrated improved PFS compared to the combination of" exact="docetaxel" post="and trastuzumab (14.2 vs. 9.2 months) [ 14]. Similarly,"/>
   <result pre="demonstrated improved PFS compared to the combination of docetaxel and" exact="trastuzumab" post="(14.2 vs. 9.2 months) [ 14]. Similarly, TDM-1 demonstrated"/>
   <result pre="months) [ 14]. Similarly, TDM-1 demonstrated improved PFS compared to" exact="capecitabine" post="and lapatinib (9.6 vs. 6.4 months) as second-line treatment"/>
   <result pre="14]. Similarly, TDM-1 demonstrated improved PFS compared to capecitabine and" exact="lapatinib" post="(9.6 vs. 6.4 months) as second-line treatment of HER2-positive"/>
   <result pre="of women with metastatic breast cancer by HER2 status and" exact="trastuzumab" post="treatment: an institutional-based review J Clin Oncol 2010 28"/>
   <result pre="14 Hurvitz SA et al Phase II randomized study of" exact="trastuzumab" post="emtansine versus trastuzumab plus docetaxel in patients with human"/>
   <result pre="et al Phase II randomized study of trastuzumab emtansine versus" exact="trastuzumab" post="plus docetaxel in patients with human epidermal growth factor"/>
   <result pre="Phase II randomized study of trastuzumab emtansine versus trastuzumab plus" exact="docetaxel" post="in patients with human epidermal growth factor receptor 2-positive"/>
   <result pre="15 Krop IE et al A phase II study of" exact="trastuzumab" post="emtansine in patients with human epidermal growth factor receptor"/>
   <result pre="previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and" exact="capecitabine" post="J Clin Oncol 2012 30 3234 3241 22649126 16"/>
   <result pre="al Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of" exact="trastuzumab" post="and efficiently inhibits growth of lapatinib insensitive breast cancer"/>
   <result pre="mechanisms of action of trastuzumab and efficiently inhibits growth of" exact="lapatinib" post="insensitive breast cancer Breast Cancer Res Treat 2011 128"/>
   <result pre="for other HER family member proteins. The humanized monoclonal antibody" exact="pertuzumab" post="binds HER2 at a region distinct from that of"/>
   <result pre="pertuzumab binds HER2 at a region distinct from that of" exact="trastuzumab" post="and prevents HER2 dimerisation (A). Similarly, the humanized monoclonal"/>
   <result pre="and prevents HER2 dimerisation (A). Similarly, the humanized monoclonal antibody" exact="trastuzumab" post="binds HER2, leading to inhibition of downstream signaling in"/>
   <result pre="of HER1 and HER2 (C). The antibody-drug conjugate TDM-1 combines" exact="trastuzumab" post="linked to the microtubulin-disruptive agent emtansine (DM1). Trastuzumab binds"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4381292/results/search/inn/results.xml">
   <result pre="decisions are hormone receptor status including estrogen receptor alpha (ESR1/ER)," exact="progesterone" post="receptor (PGR/PR) or growth factor receptor status such as"/>
   <result pre="progression and poor prognosis. Targeted therapies for HER2-positive tumors include" exact="trastuzumab" post="or pertuzumab, anti-HER2 monoclonal antibodies [ 34, 35], lapatinib,"/>
   <result pre="inhibitor directed both to HER2 and HER1 [ 36] or" exact="trastuzumab" post="emtansine (T-DM1), an antibody-drug conjugate [ 37]. Triple-negative breast"/>
   <result pre="cancers [ 8, 44]. In HER2-positive breast cancer, treatment with" exact="trastuzumab" post="along with standard chemotherapy has significantly improved survival in"/>
   <result pre="such as PI3K/AKT are among various other factors contributing to" exact="trastuzumab" post="resistance in HER2-positive breast cancer [ 38]. Chemoresistant TNBC"/>
   <result pre="[ 98]. Through metabolomic analysis, Jain et al have identified" exact="glycine" post="as an important metabolite that promotes rapid cell proliferation"/>
   <result pre="ER- disease [ 88] MCF7 (ER+) GC-MS adriamycin Increase in" exact="glycerol" post="metabolism and decrease in glutathione biosynthesis [ 106] MDA-MB-231"/>
   <result pre="[ 89] MCF7 (ER+) and MDA-MB-231 (ER-) NMR curcumin +/-" exact="docetaxel" post="(dose- and time-response) Changes in glutathione metabolism, lipid metabolism,"/>
   <result pre="GC-MS None Changes in amino acids metabolism (glutamic acid, histidine," exact="proline" post="and tyrosine), glycolysis (lactate), phospholipid metabolism (choline) and fatty"/>
   <result pre="the antioxidant glutathione (GSH), a tripeptide of glutamate, cysteine and" exact="glycine" post="that is dependent on glutaminolysis [ 131]. High levels"/>
   <result pre="and confers resistance to anti-EGFR antibody therapy [ 134] and" exact="imatinib" post="[ 135]. Hexokinase II (HK2), localized to the outer"/>
   <result pre="American Pathologists guideline recommendations for immunohistochemical testing of estrogen and" exact="progesterone" post="receptors in breast cancer J. Clin. Oncol. 2010 28"/>
   <result pre="Jorns J.M. Healy P. Zhao L. Review of estrogen receptor," exact="progesterone" post="receptor, and HER-2/neu immunohistochemistry impacts on treatment for a"/>
   <result pre="N. Wickerham D.L. Fisher E.R. A randomized clinical trial evaluating" exact="tamoxifen" post="in the treatment of patients with node-negative breast cancer"/>
   <result pre="Morris C. Fulvestrant, formerly ICI 182,780, is as effective as" exact="anastrozole" post="in postmenopausal women with advanced breast cancer progressing after"/>
   <result pre="et al. Anastrozole, a potent and selective aromatase inhibitor, versus" exact="megestrol" post="acetate in postmenopausal women with advanced breast cancer: results"/>
   <result pre="randomised trial comparing 2.5 mg daily, 0.5 mg daily and" exact="aminoglutethimide" post="in postmenopausal women with advanced breast cancer. Letrozole International"/>
   <result pre="R. Sleeboom H.P. Janicke F. et al. Superior efficacy of" exact="letrozole" post="versus tamoxifen as first-line therapy for postmenopausal women with"/>
   <result pre="H.P. Janicke F. et al. Superior efficacy of letrozole versus" exact="tamoxifen" post="as first-line therapy for postmenopausal women with advanced breast"/>
   <result pre="Roman L. Pedrini J.L. Pienkowski T. Knott A. Pertuzumab plus" exact="trastuzumab" post="plus docetaxel for metastatic breast cancer N. Engl. J."/>
   <result pre="Pedrini J.L. Pienkowski T. Knott A. Pertuzumab plus trastuzumab plus" exact="docetaxel" post="for metastatic breast cancer N. Engl. J. Med. 2012"/>
   <result pre="Crown J. Chan A. Kaufman B. et al. Lapatinib plus" exact="capecitabine" post="for HER2-positive advanced breast cancer N. Engl. J. Med."/>
   <result pre="the clinical heterogeneity of estrogen receptor positive breast cancers and" exact="tamoxifen" post="response Crit. Rev. Oncol. Hematol. 2007 61 187 194"/>
   <result pre="Dakshanamurthy S. Clarke R. Tyrosine-phosphorylated caveolin-1 (Tyr-14) increases sensitivity to" exact="paclitaxel" post="by inhibiting BCL2 and BCLxL proteins via c-Jun N-terminal"/>
   <result pre="estrogen- and c-Myc-responsive genes and their relationship to response to" exact="tamoxifen" post="therapy in breast cancer PLoS One 2008 3 e2987"/>
   <result pre="cancer cells treated by curcumin alone and in association with" exact="docetaxel" post="PLoS One 2013 8 e57971 10.1371/journal.pone.0057971 23472124 92 Brauer"/>
   <result pre="C.B. Mootha V.K. Metabolite profiling identifies a key role for" exact="glycine" post="in rapid cancer cell proliferation Science 2012 336 1040"/>
   <result pre="cancer cells treated by curcumin alone and in association with" exact="docetaxel" post="PLoS One 2013 8 e57971 10.1371/journal.pone.0057971 23472124 110 Jager"/>
   <result pre="colon carcinoma cells: Correlation to drug resistance and influence of" exact="lonidamine" post="Clin. Cancer Res. 2000 6 1590 1597 10778993 129"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4385942/results/search/inn/results.xml">
   <result pre="of anti-apoptotic signaling by Kruppel-like factors 4 and 5 mediates" exact="lapatinib" post="resistance in breast cancer KLF4 and KLF5 mediate lapatinib"/>
   <result pre="mediates lapatinib resistance in breast cancer KLF4 and KLF5 mediate" exact="lapatinib" post="resistance Farrugia M K 1 2 Sharma S B"/>
   <result pre="and B-cell lymphoma-extra large (BCL-XL). Moreover, MCL1 was upregulated by" exact="lapatinib" post="in a KLF4/5-dependent manner, and enforced expression of MCL1"/>
   <result pre="distant metastasis-free survival (DMFS). Clinically approved HER2-targeted therapies such as" exact="lapatinib" post="and trastuzumab (Herceptin) have significantly improved the disease-free survival"/>
   <result pre="survival (DMFS). Clinically approved HER2-targeted therapies such as lapatinib and" exact="trastuzumab" post="(Herceptin) have significantly improved the disease-free survival (DFS) of"/>
   <result pre="in basal-like breast cancer models. 36, 37 We observed that" exact="lapatinib" post="treatment of HER2-amplified tumor cells resulted in the rapid"/>
   <result pre="factors. As shown by shRNA studies, in the presence of" exact="lapatinib" post="KLF4/5 coregulated the expression of myeloid leukemia cell 1"/>
   <result pre="of myeloid leukemia cell 1 (MCL1) and cooperated to confer" exact="lapatinib" post="resistance. Even in the absence of drug treatment, the"/>
   <result pre="and enforced expression of MCL1 was sufficient to rescue the" exact="lapatinib" post="sensitivity of KLF4/5-deficient cells. These results identify KLF4/5 as"/>
   <result pre="KLF4/5-deficient cells. These results identify KLF4/5 as inducible regulators of" exact="lapatinib" post="resistance through mediation of anti-apoptotic signaling. Results Klf4 and"/>
   <result pre="and median DMFS ( P=0.016). Endogenous KLF4/5 are induced by" exact="lapatinib" post="in breast cancer We next examined the transcript abundance"/>
   <result pre="expression with exposure to, or resistance to, HER2-targeted therapy. Interestingly," exact="lapatinib" post="promoted the expression of both the KLF4 and KLF5"/>
   <result pre="a previously described translation reporter, pMIR-Report-Luc-KLF4-FL, was actually decreased by" exact="lapatinib" post="treatment ( Figure 3e, left panel). 18 This decrease"/>
   <result pre="are consistent with lapatinib-mediated stabilization of the KLF4 protein. Therefore," exact="lapatinib" post="may function similarly to serum starvation to mediate a"/>
   <result pre="of the combined toxicity when cells were exposed to both" exact="lapatinib" post="and the protein synthesis inhibitor cycloheximide. Nevertheless, the results"/>
   <result pre="the protein synthesis inhibitor cycloheximide. Nevertheless, the results indicate that" exact="lapatinib" post="treatment of HER2-positive breast cancer cells can enhance KLF4"/>
   <result pre="transcriptional activity as indicated by miR-206 levels. Endogenous KLF4/5 mediate" exact="lapatinib" post="resistance in breast cancer Based on these results, we"/>
   <result pre="the BT474 and M6 models significantly sensitized the cells to" exact="lapatinib" post="treatment ( Figure 3f, right panels). Moreover, coreduction of"/>
   <result pre="studies, ectopic expression of KLF4/5 in M6 enhanced resistance to" exact="lapatinib" post="treatment ( Figure 3g). To further characterize their role"/>
   <result pre="we assessed mitochondrial membrane integrity (MMI) in these cells following" exact="lapatinib" post="exposure ( Figure 3h). Disruption of MMI is a"/>
   <result pre="step of the intrinsic pathway of apoptosis. Following 24 h of" exact="lapatinib" post="treatment, the single knockdown cell lines had reduced MMI"/>
   <result pre="next determined whether KLF4/5 contributed to malignant properties independently of" exact="lapatinib" post="exposure. Relative to the control, depletion of either KLF4"/>
   <result pre="phenotype. The intrinsic pathway of apoptosis is critical in both" exact="lapatinib" post="resistance and anoikis. 44 We therefore examined the association"/>
   <result pre="factors known to participate in apoptotic signaling. In response to" exact="lapatinib" post="or trastuzumab treatment, we observed induction of not only"/>
   <result pre="to participate in apoptotic signaling. In response to lapatinib or" exact="trastuzumab" post="treatment, we observed induction of not only KLF4/5 ("/>
   <result pre="increased in response to lapatinib, BCL2 levels were decreased upon" exact="trastuzumab" post="exposure, consistent with previous studies. 45 Despite the well-documented"/>
   <result pre="viable, lapatinib-sensitive KLF-depleted cells for analysis we used a reduced" exact="lapatinib" post="concentration of 250 nM. Although individual reduction of KLF4 or"/>
   <result pre="( Figure 5f). To validate the importance of MCL1 in" exact="lapatinib" post="resistance, we reduced MCL1 levels in BT474 cells using"/>
   <result pre="with the nontargeting control, siMCL1 cells demonstrated increased sensitivity to" exact="lapatinib" post="treatment. Similarly, a small molecule MCL1 inhibitor, UMI-77, yielded"/>
   <result pre="overexpression in KLF4/5 knockdown BT474 cells was sufficient to restore" exact="lapatinib" post="resistance ( Figure 5h). Discussion Targeted therapies have significantly"/>
   <result pre="HER2+ breast cancer, clinically approved therapies include the monoclonal antibodies" exact="trastuzumab" post="and pertuzumab and, for third- or fourth-line therapy of"/>
   <result pre="cancer, clinically approved therapies include the monoclonal antibodies trastuzumab and" exact="pertuzumab" post="and, for third- or fourth-line therapy of metastatic disease,"/>
   <result pre="progression of unresponsive tumors. 23, 24, 25, 26 Similar to" exact="lapatinib" post="and trastuzumab, it is likely that resistance mechanisms will"/>
   <result pre="improve clinical efficacy. Many studies support shared resistance mechanisms between" exact="lapatinib" post="and trastuzumab. 27, 28, 29, 30, 31, 32, 35"/>
   <result pre="either MCL1, BCL2 or BCL-XL significantly alters the efficacy of" exact="lapatinib" post="in HER2-amplified cells. 33, 35 In our study, the"/>
   <result pre="HER2-amplified cells. 33, 35 In our study, the KLFs mediated" exact="lapatinib" post="resistance in a cooperative manner, a result obtained in"/>
   <result pre="at 2500 r.p.m. for 1.5 h at 30 °C and selected in" exact="puromycin" post="(1.0  μg/ml). Immunoblot analysis Cell lysis, gel electrophoresis, transfer"/>
   <result pre="were used for each concentration of drug. Fresh media and" exact="lapatinib" post="was added to the cells after 48 h. Viable cell"/>
   <result pre="CA125123. We thank William Petros for the generous gift of" exact="trastuzumab" post="(MBRCC) and Fengju Chen (Baylor College of Medicine) for"/>
   <result pre="Chan S Romieu CG Pienkowski T et al. Lapatinib plus" exact="capecitabine" post="for HER2-positive advanced breast cancer N Engl J Med"/>
   <result pre="Im SA Hegg R Im YH et al. Pertuzumab plus" exact="trastuzumab" post="plus docetaxel for metastatic breast cancer N Engl J"/>
   <result pre="Hegg R Im YH et al. Pertuzumab plus trastuzumab plus" exact="docetaxel" post="for metastatic breast cancer N Engl J Med 2012"/>
   <result pre="to tumor inhibition by trastuzumab, and loss of PTEN predicts" exact="trastuzumab" post="resistance in patients Cancer Cell 2004 6 117 127"/>
   <result pre="approach identifies the PI3K pathway as a major determinant of" exact="trastuzumab" post="resistance in breast cancer Cancer Cell 2007 12 395"/>
   <result pre="M Nijkamp W et al. Phosphatidylinositol 3-kinase hyperactivation results in" exact="lapatinib" post="resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor"/>
   <result pre="et al. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with" exact="trastuzumab" post="response and survival in patients with HER2-positive metastatic breast"/>
   <result pre="and tensin homolog or phosphoinositol-3 kinase activation and response to" exact="trastuzumab" post="or lapatinib in human epidermal growth factor receptor 2-overexpressing"/>
   <result pre="homolog or phosphoinositol-3 kinase activation and response to trastuzumab or" exact="lapatinib" post="in human epidermal growth factor receptor 2-overexpressing locally advanced"/>
   <result pre="al. BikDD eliminates breast cancer initiating cells and synergizes with" exact="lapatinib" post="for breast cancer treatment Cancer Cell 2011 20 341"/>
   <result pre="Migliardi G et al. HER2-positive breast cancer cells resistant to" exact="trastuzumab" post="and lapatinib lose reliance upon HER2 and are sensitive"/>
   <result pre="et al. HER2-positive breast cancer cells resistant to trastuzumab and" exact="lapatinib" post="lose reliance upon HER2 and are sensitive to the"/>
   <result pre="upon HER2 and are sensitive to the multitargeted kinase inhibitor" exact="sorafenib" post="Breast Cancer Res Treat 2011 130 29 40 21153051"/>
   <result pre="SY Graham TR Dolan R et al. Combinatorial effects of" exact="lapatinib" post="and rapamycin in triple-negative breast cancer cells Mol Cancer"/>
   <result pre="D Chen C The induction of KLF5 transcription factor by" exact="progesterone" post="contributes to progesterone-induced breast cancer cell proliferation and dedifferentiation"/>
   <result pre="and P&amp;lt;0.05 was considered significant Figure 3 Endogenous KLF4/5 mediate" exact="lapatinib" post="resistance in breast cancer models. ( a) Levels of"/>
   <result pre="data. ( b) BT474 cells were treated with DMSO or" exact="lapatinib" post="for the indicated interval. Whole-cell lysate was analyzed by"/>
   <result pre="β-actin (bars, S.D.). ( c) BT474 cells were treated with" exact="trastuzumab" post="or sterile water for the indicated interval and whole-cell"/>
   <result pre="( d) KLF4/5 transcript levels were determined by qRT-PCR following" exact="lapatinib" post="exposure. Expression data were normalized using the housekeeping gene"/>
   <result pre="normalized Fluc activity in BT474 cells treated for 24 h with" exact="lapatinib" post="or DMSO (left panel). miR-206 levels were determined by"/>
   <result pre="(left panel). miR-206 levels were determined by qRT-PCR following 24-h" exact="lapatinib" post="exposure. Expression data were normalized using U6 snRNA (right"/>
   <result pre="shRNA construct, and the resulting cell populations were treated with" exact="lapatinib" post="for 96 h. For each cell population, cell viability relative"/>
   <result pre="via ATP-based luminescence assay (bars, S.D.). ( g) Similarly, the" exact="lapatinib" post="effect on the relative cell viability of M6 cells"/>
   <result pre="( h) To assess MMI, M6 cells were treated with" exact="lapatinib" post="for 24 h, stained with 250 nM of Mitotracker dye and"/>
   <result pre="expressing shCtl, shKLF4, shKLF5 or shKLF4/5. Cells were treated with" exact="lapatinib" post="for 24 h before preparation of cell extracts. * P&amp;lt;0.05;"/>
   <result pre="with DMSO, 1  μM lapatinib, sterile water or 10  μg/ml" exact="trastuzumab" post="for the indicated time intervals. BCL2, BCL-XL and MCL1"/>
   <result pre="was determined in BT474 cells. Cells were treated with 250 nM" exact="lapatinib" post="or DMSO for 24 h. For three independent experiments, the"/>
   <result pre="by siRNA and the resulting cell populations were treated with" exact="lapatinib" post="for 96 h. For each cell population, cell viability relative"/>
   <result pre="assay (paired t-test, two tailed; bars, S.D.). ( h) Similarly," exact="lapatinib" post="resistance was analyzed in KLF4/5 knockdown BT474 cells following"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4389676/results/search/inn/results.xml">
   <result pre="this article, unless otherwise stated. Abstract The clinical success of" exact="trastuzumab" post="in breast cancer taught us that appropriate tumor evaluation"/>
   <result pre="pertuzumab, T-DM1) and small molecule kinase inhibitors (that is, lapatinib," exact="neratinib" post="and afatinib) are the main strategies to target HER2"/>
   <result pre="[ 12]. Moreover, measurable clinical benefit is observed also when" exact="lapatinib" post="is administered as a single agent or in combination"/>
   <result pre="is administered as a single agent or in combination with" exact="paclitaxel" post="as first-line treatment [ 13, 14]. Recently, the antitumor"/>
   <result pre="activity of dual HER2 blockade (trastuzumab in combination with either" exact="lapatinib" post="or pertuzumab) was proven to be significantly superior to"/>
   <result pre="test the efficacy of anti-EGFR agents, such as the antibodies" exact="cetuximab" post="and panitumumab, in TNBC patients. In the metastatic setting,"/>
   <result pre="cetuximab and panitumumab, in TNBC patients. In the metastatic setting," exact="cetuximab" post="in combination with chemotherapy showed some promising activity ["/>
   <result pre="these patients. A small pilot study testing the efficacy of" exact="panitumumab" post="in combination with standard chemotherapy in TNBC patients in"/>
   <result pre="FISH reflex testing; 3+ was considered positive and eligible for" exact="trastuzumab" post="[ 29]. Despite the effort to standardize HER2 status"/>
   <result pre="shown to be both prognostic and predictive of response to" exact="trastuzumab" post="in HER2-positive tumors [ 36, 37]. Serum ECD values"/>
   <result pre="meta-analysis study [ 38] has combined the data of four" exact="trastuzumab" post="trials in metastatic breast cancer and showed that, from"/>
   <result pre="[ 110]. Recently, Genomic Health started reporting estrogen receptor (ER)," exact="progesterone" post="receptor (PR), and HER2 results separately in addition to"/>
   <result pre="determined by the HERmark assay correlated with clinical outcome of" exact="trastuzumab" post="therapy better than IHC or central FISH studies in"/>
   <result pre="suggesting that not all gene-amplified tumors overexpress the target of" exact="trastuzumab" post="[ 135]. Similarly, absolute HER2 quantification in an homogeneous"/>
   <result pre="triple quadrupole MS was predictive of a better response to" exact="trastuzumab" post="in both adjuvant and metastatic settings [ 136]. But"/>
   <result pre="level of HER2 amplification and outcome in patients treated with" exact="trastuzumab" post="has been proven only in the neoadjuvant setting ["/>
   <result pre="HER2-positive after central laboratory testing may still derive benefit from" exact="trastuzumab" post="[ 145, 146] and the complex relationship between HER2,"/>
   <result pre="145, 146] and the complex relationship between HER2, ER, and" exact="trastuzumab" post="sensitivity outlined by the study suggest that quantitative HER2"/>
   <result pre="and combination with other markers may be more predictive of" exact="trastuzumab" post="response [ 147]. Since dual HER2 blockade (trastuzumab combined"/>
   <result pre="[ 147]. Since dual HER2 blockade (trastuzumab combined with either" exact="pertuzumab" post="or lapatinib) is proving to be more effective than"/>
   <result pre="patients enrolled in the NeoALTTO trial, testing the activity of" exact="trastuzumab" post="in combination with lapatinib compared with single agent treatments,"/>
   <result pre="NeoALTTO trial, testing the activity of trastuzumab in combination with" exact="lapatinib" post="compared with single agent treatments, and a positive correlation"/>
   <result pre="of the mechanisms proposed for the synergy observed when combining" exact="lapatinib" post="and trastuzumab (at least in preclinical models) is the"/>
   <result pre="mechanisms proposed for the synergy observed when combining lapatinib and" exact="trastuzumab" post="(at least in preclinical models) is the stabilization and"/>
   <result pre="receptor kinase inhibition [ 149]. One may wonder, therefore, whether" exact="lapatinib" post="could sensitize tumors with relatively low levels of HER2"/>
   <result pre="the choice of therapy. Finally, HER-targeted therapeutic agents such as" exact="lapatinib" post="have been shown to stabilize/enhance the HER2-HER3 dimer in"/>
   <result pre="be of relevance. In fact, compensatory upregulation of HER3 upon" exact="lapatinib" post="treatment has been described both in preclinical models and"/>
   <result pre="EGFR antibody D38B1 did not appear to benefit from concurrent" exact="trastuzumab" post="in the N9831 trial using the fluorescence-based AQUA quantitative"/>
   <result pre="of tumors with high EGFR expression may better respond to" exact="lapatinib" post="or dual HER blockade compared with trastuzumab alone. The"/>
   <result pre="better respond to lapatinib or dual HER blockade compared with" exact="trastuzumab" post="alone. The absolute levels of EGFR may be predictive"/>
   <result pre="from the ALTTO adjuvant trial (comparing patients that received lapatinib," exact="trastuzumab" post="or the combination of the two agents) were recently"/>
   <result pre="message was that the combination was not significantly superior to" exact="trastuzumab" post="single agent in preventing relapses to therapy. These findings"/>
   <result pre="combination arm were not treated with a full dose of" exact="lapatinib" post="(for toxicity reasons). In a study where the 'control"/>
   <result pre="S Feyereislova A Dowsett M et al. 2-year follow-up of" exact="trastuzumab" post="after adjuvant chemotherapy in HER2-positive breast cancer: a randomised"/>
   <result pre="Chan S Romieu CG Pienkowski T et al. Lapatinib plus" exact="capecitabine" post="for HER2-positive advanced breast cancer N Engl J Med"/>
   <result pre="Aziz Z Nag S et al. Efficacy and safety of" exact="lapatinib" post="as first-line therapy for ErbB2-amplified locally advanced or metastatic"/>
   <result pre="Arbushites MC et al. Phase III, double-blind, randomized study comparing" exact="lapatinib" post="plus paclitaxel with placebo plus paclitaxel as first-line treatment"/>
   <result pre="et al. Phase III, double-blind, randomized study comparing lapatinib plus" exact="paclitaxel" post="with placebo plus paclitaxel as first-line treatment for metastatic"/>
   <result pre="double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus" exact="paclitaxel" post="as first-line treatment for metastatic breast cancer J Clin"/>
   <result pre="S de Azambuja E Aura C et al. Lapatinib with" exact="trastuzumab" post="for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label,"/>
   <result pre="Im SA Hegg R Im YH et al. Pertuzumab plus" exact="trastuzumab" post="plus docetaxel for metastatic breast cancer N Engl J"/>
   <result pre="Hegg R Im YH et al. Pertuzumab plus trastuzumab plus" exact="docetaxel" post="for metastatic breast cancer N Engl J Med 2012"/>
   <result pre="LM Liu MC et al. Efficacy and safety of neoadjuvant" exact="pertuzumab" post="and trastuzumab in women with locally advanced, inflammatory, or"/>
   <result pre="MC et al. Efficacy and safety of neoadjuvant pertuzumab and" exact="trastuzumab" post="in women with locally advanced, inflammatory, or early HER2-positive"/>
   <result pre="II study of the anti-epidermal growth factor receptor monoclonal antibody" exact="cetuximab" post="with cisplatin versus cisplatin alone in patients with metastatic"/>
   <result pre="of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with" exact="cisplatin" post="versus cisplatin alone in patients with metastatic triple-negative breast"/>
   <result pre="anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus" exact="cisplatin" post="alone in patients with metastatic triple-negative breast cancer J"/>
   <result pre="CX et al. TBCRC 001: randomized phase II study of" exact="cetuximab" post="in combination with carboplatin in stage IV triple-negative breast"/>
   <result pre="001: randomized phase II study of cetuximab in combination with" exact="carboplatin" post="in stage IV triple-negative breast cancer J Clin Oncol"/>
   <result pre="randomized phase II study of weekly irinotecan/carboplatin with or without" exact="cetuximab" post="in patients with metastatic breast cancer Breast Cancer Res"/>
   <result pre="Gligorov J et al. Multicentric neoadjuvant phase II study of" exact="panitumumab" post="combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast"/>
   <result pre="A Barnadas A Ojeda B Caranana V et al. Biweekly" exact="paclitaxel" post="plus gemcitabine in advanced breast cancer: phase II trial"/>
   <result pre="A Ojeda B Caranana V et al. Biweekly paclitaxel plus" exact="gemcitabine" post="in advanced breast cancer: phase II trial and predictive"/>
   <result pre="in clinical decision making: pooled analysis of four trials of" exact="trastuzumab" post="in metastatic breast cancer J Clin Oncol 2009 27"/>
   <result pre="in high HER2, ER negative breast cancer cell line induces" exact="trastuzumab" post="resistance Breast Cancer Res Treat 2010 122 685 697"/>
   <result pre="Sanyal M Shrivastav PS High throughput and sensitive determination of" exact="trazodone" post="and its primary metabolite, m-chlorophenylpiperazine, in human plasma by"/>
   <result pre="HER2 gene expression by the 21-gene RT-PCR assay and adjuvant" exact="trastuzumab" post="(H) benefit in NCCTG (Alliance) N9831 J Clin Oncol"/>
   <result pre="JM Bender R et al. Microarray-based determination of estrogen receptor," exact="progesterone" post="receptor, and HER2 receptor status in breast cancer Clin"/>
   <result pre="S Winslow J Jin X et al. Differential survival following" exact="trastuzumab" post="treatment based on quantitative HER2 expression and HER2 homodimers"/>
   <result pre="phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and" exact="trastuzumab" post="BMC Cancer 2014 14 326 24885187 133. Montemurro F"/>
   <result pre="C et al. Potential biomarkers of long-term benefit from single-agent" exact="trastuzumab" post="or lapatinib in HER2-positive metastatic breast cancer Mol Oncol"/>
   <result pre="al. Potential biomarkers of long-term benefit from single-agent trastuzumab or" exact="lapatinib" post="in HER2-positive metastatic breast cancer Mol Oncol 2014 8"/>
   <result pre="in situ hybridization-positive patients with metastatic breast cancer treated with" exact="trastuzumab" post="Cancer 2010 116 5168 5178 20661914 136. Nuciforo P"/>
   <result pre="chromosome 17 effect on patient outcome in the N9831 adjuvant" exact="trastuzumab" post="trial J Clin Oncol 2010 28 4307 4315 20697084"/>
   <result pre="and epidermal growth factor receptor mRNA and protein expression, and" exact="lapatinib" post="efficacy in women with metastatic breast cancer Clin Cancer"/>
   <result pre="with very high HER2 expression levels and possible resistance to" exact="trastuzumab" post="Ann Oncol 2011 22 2014 2020 21289364 142. Joensuu"/>
   <result pre="Kim C Wolmark N HER2 status and benefit from adjuvant" exact="trastuzumab" post="in breast cancer N Engl J Med 2008 358"/>
   <result pre="High HER2 expression correlates with response to the combination of" exact="lapatinib" post="and trastuzumab Clin Cancer Res 2015 21 569 576"/>
   <result pre="expression correlates with response to the combination of lapatinib and" exact="trastuzumab" post="Clin Cancer Res 2015 21 569 576 25467182 149."/>
   <result pre="et al. EGFR expression is associated with decreased benefit from" exact="trastuzumab" post="in the NCCTG N9831 (Alliance) trial Br J Cancer"/>
   <result pre="NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with" exact="lapatinib" post="alone (L), trastuzumab alone (T), their sequence (T→L), or"/>
   <result pre="comparing one year of anti-HER2 therapy with lapatinib alone (L)," exact="trastuzumab" post="alone (T), their sequence (T→L), or their combination (T+L)"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4391602/results/search/inn/results.xml">
   <result pre="significant predictive factor for response to HER2-targeted therapies such as" exact="trastuzumab" post="(Herceptin™), pertuzumab (Perjeta™), lapatinib (Tykerb™) or trastuzumab emtansine (T-DM1,"/>
   <result pre="factor for response to HER2-targeted therapies such as trastuzumab (Herceptin™)," exact="pertuzumab" post="(Perjeta™), lapatinib (Tykerb™) or trastuzumab emtansine (T-DM1, Kadcyla™) ["/>
   <result pre="response to HER2-targeted therapies such as trastuzumab (Herceptin™), pertuzumab (Perjeta™)," exact="lapatinib" post="(Tykerb™) or trastuzumab emtansine (T-DM1, Kadcyla™) [ 3- 6]."/>
   <result pre="therapies such as trastuzumab (Herceptin™), pertuzumab (Perjeta™), lapatinib (Tykerb™) or" exact="trastuzumab" post="emtansine (T-DM1, Kadcyla™) [ 3- 6]. Determination of the"/>
   <result pre="HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; PR," exact="progesterone" post="receptor. Comparison of HER2 results and various testing methods"/>
   <result pre="receptor 2; H2T, quantitative total HER2 expression by HERmark; PR," exact="progesterone" post="receptor. Cox proportional hazards multivariate analyses were then conducted"/>
   <result pre="IHC immunohistochemistry ISH in situ hybridization OS overall survival PR" exact="progesterone" post="receptor RF relative fluorescence Competing interests WH, YL and"/>
   <result pre="Conte P Miles D et al. Phase II trial of" exact="pertuzumab" post="and trastuzumab in patients with human epidermal growth factor"/>
   <result pre="Miles D et al. Phase II trial of pertuzumab and" exact="trastuzumab" post="in patients with human epidermal growth factor receptor 2-positive"/>
   <result pre="factor receptor 2-positive metastatic breast cancer that progressed during prior" exact="trastuzumab" post="therapy J Clin Oncol 2010 28 1138 44 10.1200/JCO.2009.24.2024"/>
   <result pre="Chan S Romieu CG Pienkowski T et al. Lapatinib plus" exact="capecitabine" post="for HER2-positive advanced breast cancer N Engl J Med"/>
   <result pre="HER2 and ESR1 mRNA expression levels and response to neoadjuvant" exact="trastuzumab" post="plus chemotherapy in patients with primary breast cancer Breast"/>
   <result pre="in situ hybridization-positive patients with metastatic breast cancer treated with" exact="trastuzumab" post="Cancer 2010 116 5168 78 10.1002/cncr.25430 20661914 17. Huang"/>
   <result pre="Kim C Wolmark N HER2 status and benefit from adjuvant" exact="trastuzumab" post="in breast cancer N Engl J Med 2008 358"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4394616/results/search/inn/results.xml">
   <result pre="MEK (GSK-1120212; trametinib), in addition to the standard of care" exact="trastuzumab" post="(Herceptin). The strategy used to identify effective combinations and"/>
   <result pre="the surface receptor HER2 and constitutive signaling. The monoclonal antibody" exact="trastuzumab" post="(Herceptin; Genentech/Roche, South San Francisco, CA) is standard of"/>
   <result pre="care Herceptin, the HER2-targeted small molecule tyrosine kinase inhibitor (TKI)" exact="lapatinib" post="(Tykerb, GSK), an antibody-based HER3 inhibitor MM-111, 7 and"/>
   <result pre="the HER2/HER3 complex with the combination of MM-111, Herceptin, and" exact="lapatinib" post="(MHL) was the most effective three-drug regimen when considering"/>
   <result pre="consistent with its established role in mediating both Herceptin and" exact="lapatinib" post="resistance 26 and the mechanism of action of MM-111"/>
   <result pre="in these genetically defined subpopulations. Simulations predicted that switching out" exact="lapatinib" post="in the MHL combination for an AKT inhibitor or"/>
   <result pre="single point mutations were sufficient to shift sensitivity from the" exact="lapatinib" post="to the AKTi-containing treatments. Also note that sensitivity to"/>
   <result pre="PI3K and MAPK activating mutations can be overcome by switching" exact="lapatinib" post="for AKT or MEK inhibitor-containing regimens, respectively. (a) In"/>
   <result pre="therapies, which can be overcome by switching the HER2 inhibitor" exact="lapatinib" post="for AKT or MEK inhibitors. Genomic profiles from primary"/>
   <result pre="drug screening, tumor growth was simulated over 2-week periods, with" exact="lapatinib" post="administered daily at 1250 mg and MM-111 weekly at 20 mg/kg,"/>
   <result pre="Wang X Zhou Q Gallo JM Preclinical pharmacokinetic/pharmacodynamic models of" exact="gefitinib" post="and the design of equivalent dosing regimens in EGFR"/>
   <result pre="nonclinical to clinical development: a case study of anticancer drug," exact="crizotinib" post="AAPS J 2012 15 354 366 ) 23250669 Harrold"/>
   <result pre="T Sliwkowski MX Claret FX Personalized drug combinations to overcome" exact="trastuzumab" post="resistance in HER2-positive breast cancer Biochim. Biophys. Acta 2014"/>
   <result pre="for the clinical development of a fixed-dose subcutaneous formulation of" exact="trastuzumab" post="CPT Pharmacometrics Syst. Pharmacol 2014 3 e87 25019376 Supporting"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4396883/results/search/inn/results.xml">
   <result pre="a considerable portion of the patients does not respond to" exact="trastuzumab" post="and the molecular mechanisms underlying the intrinsic resistance to"/>
   <result pre="expressing wild-type and fusion HER2. Finally, the anti-tumor efficacy of" exact="trastuzumab" post="was tested in NIH/3 T3 xenografts expressing the HER2"/>
   <result pre="oncogenic, lead to aberrant activation of HER2 kinase. Treatment with" exact="trastuzumab" post="inhibited tumor growth significantly in xenografts expressing MDK-HER2 fusion."/>
   <result pre="tumor growth significantly in xenografts expressing MDK-HER2 fusion. In contrast," exact="trastuzumab" post="had no effect on the growth of xenografts expressing"/>
   <result pre="kinase; pertuzumab, an antibody-blocking heterodimerization of HER2 with HER3; and" exact="trastuzumab" post="emtansine (T-DM1), which is trastuzumab conjugated with the antimitotic"/>
   <result pre="of HER2 with HER3; and trastuzumab emtansine (T-DM1), which is" exact="trastuzumab" post="conjugated with the antimitotic agent emtansine (DM1). The clinical"/>
   <result pre="20% of GC patients [ 9]. The anti-tumor activity of" exact="trastuzumab" post="as a single agent or in combination with cytotoxic"/>
   <result pre="improvement was achieved in HER2-positive metastatic GC patients treated with" exact="trastuzumab" post="plus cytotoxic agents [ 9, 13]. These results led"/>
   <result pre="[ 9, 13]. These results led to the approval of" exact="trastuzumab" post="as the first molecular targeted therapy for treating GC."/>
   <result pre="targeted therapy for treating GC. Despite the clinical benefits of" exact="trastuzumab" post="in the treatment of patients with HER2-positive GC or"/>
   <result pre="empty vector, and ZNF207-HER2 and MDK-HER2 fusions were treated with" exact="puromycin" post="(2 μg/ml) for two weeks. NIH/3 T3-resistant cells were"/>
   <result pre="To uncover the genetic aberrations that might confer resistance to" exact="trastuzumab" post="treatment in GC, we performed whole-transcriptome sequencing (RNAseq) on"/>
   <result pre="binding and responsiveness of the HER2 fusions to T-DM1 and" exact="trastuzumab" post="To determine whether the 5’ partners fused to a"/>
   <result pre="a truncated HER2 extracellular domain affects their binding ability to" exact="trastuzumab" post="in the two HER2 fusion variants, we used T-DM1"/>
   <result pre="in vivo efficacy study. We tested the anti-tumor efficacy of" exact="trastuzumab" post="in NIH/3 T3 xenografts expressing the ZNF207-HER2 or MDK-HER2"/>
   <result pre="expressing the ZNF207-HER2 or MDK-HER2 fusion variant. As expected, the" exact="trastuzumab" post="treatment resulted in significant tumor growth inhibition in the"/>
   <result pre="fusion (TGI = 2%) (Figures 7C), thus supporting the resistant mechanism to" exact="trastuzumab" post="in GC. Figure 7 Response of NIH/3T3 cells expressing"/>
   <result pre="assay. The error bars represent SD. B-C. Anti-tumor efficacy of" exact="trastuzumab" post="in xenograft models expressing the HER2 fusions. Nude mice"/>
   <result pre="MDK-HER2 (B) or ZNF207-HER2 fusion variant (C), were treated with" exact="trastuzumab" post="at 15 mg/kg biweekly and the tumor size was"/>
   <result pre="xenografts ectopically expressing MDK-HER2 but not ZNF207-HER2 were sensitive to" exact="trastuzumab" post=". Interestingly, the HER2 fusions were found to be"/>
   <result pre="ability to trastuzumab. Despite the overall survival benefit achieved with" exact="trastuzumab" post="in GC patients carrying HER2 amplification, a significant portion"/>
   <result pre="in BC; a truncated form of HER2, p95, lacking the" exact="trastuzumab" post="binding region [ 24, 25]; a splice variant that"/>
   <result pre="HER2 receptor, preventing disruption of HER2 homodimers upon binding by" exact="trastuzumab" post="[ 26]; In our study, we did not assess"/>
   <result pre="(PDGCX), which retains HER2-Δ16 (data not shown), responded well to" exact="trastuzumab" post="treatment, with a significant tumor regression being observed (data"/>
   <result pre="of clinical evidence of association between HER2-Δ16 and resistance to" exact="trastuzumab" post="in BC, as well as the lack of preclinical"/>
   <result pre="the lack of preclinical data on the anti-tumor efficacy of" exact="trastuzumab" post="in xenografts carrying HER2-Δ16 [ 26], our data suggest"/>
   <result pre="data suggest that HER2-Δ16 was not a resistance mechanism to" exact="trastuzumab" post="in GC when tested in the PDGCX model. Additional"/>
   <result pre="is needed to demonstrate its oncogenic activity and sensitivity to" exact="trastuzumab" post="or BRAF inhibitor, the findings suggest that BAIAP2L1-BRAF could"/>
   <result pre="available: lapatinib, an approved agent for HER2-positive BC patients, and" exact="afatinib" post="and neratinib, two irreversible kinase inhibitors, currently in phase"/>
   <result pre="trials for HER2-positive BC. The modulation of AKT signaling by" exact="lapatinib" post="in the cells expressing the HER2 fusions (Figure 5A)"/>
   <result pre="or MDK-HER2 showed to be sensitivity to lapatinib, afatinib, and" exact="neratinib" post="in vitro (data not shown) . Besides the functional"/>
   <result pre="explore the responsiveness of the HER2 fusions to combination of" exact="trastuzumab" post="with pertuzumab or chemotherapies may lead to additional insights"/>
   <result pre="responsiveness of the HER2 fusions to combination of trastuzumab with" exact="pertuzumab" post="or chemotherapies may lead to additional insights into the"/>
   <result pre="used for this study were collected prior the introduction of" exact="trastuzumab" post="to China, thus we lack evidence for clinical response"/>
   <result pre="trastuzuamb. Further studies on GC samples from patients treated with" exact="trastuzumab" post="at different stages will help to confirm the effect"/>
   <result pre="to the HER2-neutralizing antibody trastuzumab. The resistance of ZNF207-HER2 to" exact="trastuzumab" post="and the existence of the recurrent BRAF fusion variants"/>
   <result pre="diagnoses of HER 2-positive GC patients for more effective personalized" exact="trastuzumab" post="therapies and for future treatment options. Additional file LINK"/>
   <result pre="EGFR mutations in lung cancer: correlation with clinical response to" exact="gefitinib" post="therapy Science 2004 304 1497 500 10.1126/science.1099314 15118125 7."/>
   <result pre="IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to" exact="trastuzumab" post="Ann Oncol 2005 16 273 8 10.1093/annonc/mdi064 15668283 11."/>
   <result pre="H Moriya Y Mori K Tanaka Y Antitumor activity of" exact="trastuzumab" post="in combination with chemotherapy in human gastric cancer xenograft"/>
   <result pre="isoform of HER2 associated with locally disseminated breast cancer and" exact="trastuzumab" post="resistance Mol Cancer Ther 2009 8 2152 62 10.1158/1535-7163.MCT-09-0295"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4403678/results/search/inn/results.xml">
   <result pre="Pro1170 Ala polymorphism in HER2-neu is associated with risk of" exact="trastuzumab" post="cardiotoxicity Stanton Sasha E sestant2@uw.edu Ward Maureen M mmw2003@med.cornell.edu"/>
   <result pre="whether any of these particular polymorphisms were associated with increased" exact="trastuzumab" post="cardiotoxicity in a case–control study. Methods 140 subjects were"/>
   <result pre="HER2-neu positive breast cancer and more than 3 months of" exact="trastuzumab" post="therapy. Cases had either symptomatic CHF or a decline"/>
   <result pre="was no association between codon 665 and cardiotoxicity; however the" exact="proline" post="variant of amino acid 1170 was more likely than"/>
   <result pre="than the alanine variant to be found in cases with" exact="trastuzumab" post="cardiotoxicity (35% of case patients as compared to 17%"/>
   <result pre="of patients who are at increased risk of cardiotoxicity from" exact="trastuzumab" post="therapy. Her2/neu single nucleotide polymorphisms may be useful in"/>
   <result pre="and toxicity in cancer therapy [ 1]. The monoclonal antibody" exact="trastuzumab" post="has provided a critical directed therapy that has dramatically"/>
   <result pre="the HER2-neu receptor [ 2]. Prior to the advent of" exact="trastuzumab" post="therapy, patients with HER2 positive tumors had significantly worse"/>
   <result pre="compared with patients with HER2 negative tumors [ 3]. Although" exact="trastuzumab" post="is well tolerated, the major toxicity is cardiomyopathy, with"/>
   <result pre="4% developing signs of congestive heart failure following treatment with" exact="trastuzumab" post="as a single agent [ 4]. From a meta-analysis"/>
   <result pre="including 11,882 patients with early stage and metastatic breast cancer," exact="trastuzumab" post="therapy was associated with a 7.5% risk of LVEF"/>
   <result pre="2.13-fold and CHF was 4.19-fold compared with patients not receiving" exact="trastuzumab" post="[ 5]. When trastuzumab was used concurrently with anthracycline"/>
   <result pre="4.19-fold compared with patients not receiving trastuzumab [ 5]. When" exact="trastuzumab" post="was used concurrently with anthracycline chemotherapy the risk of"/>
   <result pre="non-anthracycline regimen was used [ 2, 4]. The risk of" exact="trastuzumab" post="cardiotoxicity was shown to be further increased in older"/>
   <result pre="older women, women with a decreased EF prior to starting" exact="trastuzumab" post="therapy, and women on an anti-hypertensive agent prior to"/>
   <result pre="therapy, and women on an anti-hypertensive agent prior to starting" exact="trastuzumab" post="[ 5]. The mechanism of trastuzumab cardiotoxicity is unknown."/>
   <result pre="agent prior to starting trastuzumab [ 5]. The mechanism of" exact="trastuzumab" post="cardiotoxicity is unknown. HER2/neu has been shown to be"/>
   <result pre="anthracyclines, including vacuolization and myocyte cell death, cardiac biopsies after" exact="trastuzumab" post="related cardiac dysfunction showed no structural changes [ 9]."/>
   <result pre="changes [ 9]. Whereas anthracycline toxicity is dose-dependent and irreversible," exact="trastuzumab" post="toxicity is not dose dependent and is reversible, and"/>
   <result pre="and is reversible, and patients can often be re-treated with" exact="trastuzumab" post="even after an initial LVEF decline if they are"/>
   <result pre="profiles, with the small molecule dual EGFR and HER2 inhibitor" exact="lapatinib" post="having much less cardiac toxicity than trastuzumab (0.2% CHF"/>
   <result pre="and HER2 inhibitor lapatinib having much less cardiac toxicity than" exact="trastuzumab" post="(0.2% CHF and 1.4% asymptomatic cardiac events) [ 9]."/>
   <result pre="the Val/Val and Val/Ile phenotypes in patients not treated with" exact="trastuzumab" post="(n = 816) were associated with worse disease free survival (hazard"/>
   <result pre="and distant disease free survival (HR = 1.9). However, when treated with" exact="trastuzumab" post="(n = 212) then the Val/Ile and Val/Val phenotypes were associated"/>
   <result pre="acid sequence may identify patients that are at risk for" exact="trastuzumab" post="cardiotoxicity, we conducted a case–control study to evaluate more"/>
   <result pre="any of 11 identified nonsynonomous HER2/neu SNPs are associated with" exact="trastuzumab" post="cardiotoxicity. Methods Study design Patients were recruited from the"/>
   <result pre="or cytologically (FISH amplification ratio ≥ 2) and history of treatment with" exact="trastuzumab" post="(in the adjuvant, metastatic, or neoadjuvant setting). Twenty-nine of"/>
   <result pre="of 10%) that resulted in at least temporary discontinuation of" exact="trastuzumab" post="and controls had to have received greater than 3"/>
   <result pre="controls had to have received greater than 3 months of" exact="trastuzumab" post="therapy without a decline in their LVEF. Sample processing"/>
   <result pre="centrifugation and PBMC DNA was extracted using phenol-chloroform extraction and" exact="ethanol" post="precipitation. DNA pellets were dried and resuspended in Tris/EDTA"/>
   <result pre="the patient population 140 patients with breast cancer treated with" exact="trastuzumab" post="were studied. There were 29 cases (patients who developed"/>
   <result pre="C to G that causes an amino acid change from" exact="proline" post="to alanine at codon 1170 in the carboxyterminus of"/>
   <result pre="polymorphism significantly predicted case (cardiotoxicity) vs. control (no-cardiotoxicity) status following" exact="trastuzumab" post="therapy (p = 0.046, adjusted OR = 2.60; 95% CI = 1.02 to 6.62) (Table"/>
   <result pre="CI = 1.02 to 6.62) (Table 5). Table 4 Increased cases of" exact="trastuzumab" post="cardiotoxicity with genotype Pro/Pro Codon 1170 Group Control Case"/>
   <result pre="LVEF, and age are all factors that can contribute to" exact="trastuzumab" post="toxicity [ 9], the similarities of these factors between"/>
   <result pre="these factors between the cases and controls suggest that the" exact="trastuzumab" post="cardiotoxicity can be associated with the SNP variants independent"/>
   <result pre="found that the Pro 1170 Ala polymorphism was associated with" exact="trastuzumab" post="cardiomyopathy. The Pro/Pro genotype was present more frequently in"/>
   <result pre="risk of cardiotoxicity. This is an important problem because when" exact="trastuzumab" post="is discontinued due to cardiac toxicity, it deprives patients"/>
   <result pre="of the Her2-neu receptor and is not part of the" exact="trastuzumab" post="binding site, the ligand binding domain, or the heterodimerization"/>
   <result pre="tyrosine residues that are phosphorylation sites for the kinase. Both" exact="proline" post="and alanine have non-polar side chains but proline has"/>
   <result pre="kinase. Both proline and alanine have non-polar side chains but" exact="proline" post="has a secondary amide structure which can allow more"/>
   <result pre="How this could alter downstream signaling and lead to increased" exact="trastuzumab" post="associated cardiotoxicity is unclear. Conclusion The Her2/neu polymorphism Pro"/>
   <result pre="Paton V Ashby M et al. Cardiac dysfunction in the" exact="trastuzumab" post="clinical trials experience J Clin Oncol 2002 20 5"/>
   <result pre="J Lu Y et al. Risk of cardiac dysfunction with" exact="trastuzumab" post="in breast cancer patients: a meta-analysis Cancer Treat Rev"/>
   <result pre="al. Association between the HER2 Ile655Val polymorphism and response to" exact="trastuzumab" post="in women with operable primary breast cancer Ann Oncol"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4404037/results/search/inn/results.xml">
   <result pre="of breast cancer subtypes by pathology-based biomarkers (e.g. estrogen receptor," exact="progesterone" post="receptor and HER2) vs genomic classifiers. They also refined"/>
   <result pre="and maintained pre-menopausal levels of estradiol, addition of OFS to" exact="tamoxifen" post="reduced the risk of recurrence. The magnitude of the"/>
   <result pre="patients [ 5]. In the TEXT trial, adjuvant treatment with" exact="exemestane" post="plus OFS, as compared with T plus OFS, significantly"/>
   <result pre="that led to broadly accepted standards of care such as" exact="tamoxifen" post="for hormone-receptor positive disease and chemotherapy for higher risk"/>
   <result pre="and lower expression of several luminal-related genes such as the" exact="progesterone" post="receptor (PR) [ 7]. Clinically, Luminal B tumours show"/>
   <result pre="highly specific CDK inhibitors have come into development. These include" exact="palbociclib" post="(PD-0332991), abemaciclib (LY2835219), and LEE011 all of which have"/>
   <result pre="Phase I/II study to evaluate the safety and efficacy of" exact="palbociclib" post="in combination with letrozole in the treatment of advanced"/>
   <result pre="evaluate the safety and efficacy of palbociclib in combination with" exact="letrozole" post="in the treatment of advanced ER+ breast cancer ["/>
   <result pre="p = 0.0004) confirming the preclinical observations that addition of" exact="palbociclib" post="to letrozole would improve efficacy in ER+/HER2− breast cancers."/>
   <result pre="0.0004) confirming the preclinical observations that addition of palbociclib to" exact="letrozole" post="would improve efficacy in ER+/HER2− breast cancers. This PFS"/>
   <result pre="adverse events being neutropenia and fatigue. Based on these data," exact="palbociclib" post="was designated a &quot;Breakthrough Therapy&quot; by the US FDA"/>
   <result pre="over 70% by using the double HER2 blockade either with" exact="trastuzumab" post="plus lapatinib or trastuzumab plus pertuzumab in addition to"/>
   <result pre="by using the double HER2 blockade either with trastuzumab plus" exact="lapatinib" post="or trastuzumab plus pertuzumab in addition to an 18–24"/>
   <result pre="the double HER2 blockade either with trastuzumab plus lapatinib or" exact="trastuzumab" post="plus pertuzumab in addition to an 18–24 weeks anthracycline/taxane"/>
   <result pre="HER2 blockade either with trastuzumab plus lapatinib or trastuzumab plus" exact="pertuzumab" post="in addition to an 18–24 weeks anthracycline/taxane based chemotherapy."/>
   <result pre="of the PIK3CA have a significantly lower pCR rate with" exact="trastuzumab" post="and lapatinib than those with wild-type PIK3CA [ 18]."/>
   <result pre="PIK3CA have a significantly lower pCR rate with trastuzumab and" exact="lapatinib" post="than those with wild-type PIK3CA [ 18]. However, it"/>
   <result pre="not show a major advantage for use of OFS +" exact="tamoxifen" post="compared to tamoxifen alone [ 6]. The joint SOFT/TEXT"/>
   <result pre="major advantage for use of OFS + tamoxifen compared to" exact="tamoxifen" post="alone [ 6]. The joint SOFT/TEXT analysis and ABCGS12"/>
   <result pre="potential benefits for OFS + AI compared with OFS +" exact="tamoxifen" post="[ 7]. Given the long natural history of endocrine-responsive"/>
   <result pre="in postmenopausal women. Treatment options for postmenopausal women include either" exact="tamoxifen" post="(Tam) or an aromatase inhibitor (AI) or a sequence"/>
   <result pre="with associated sexual dysfunction. In comparison to 5 years of" exact="tamoxifen" post="monotherapy, the incorporation of an AI into the treatment"/>
   <result pre="selectively predict early vs late recurrence, nor suggest treatment with" exact="tamoxifen" post="vs AI, nor determine who benefits from longer duration"/>
   <result pre="definition, all triple negative cancers do not have estrogen and" exact="progesterone" post="receptors and they are not amplified for HER2. As"/>
   <result pre="and pertuzumab, an anti-HER2 monoclonal antibody, which when coupled with" exact="trastuzumab" post="achieves a more thorough HER2 blockade, capitalizing on the"/>
   <result pre="different anti-HER2 in combination or in sequence with adjuvant chemotherapy:" exact="trastuzumab" post="or lapatinib alone, the sequence and the combination of"/>
   <result pre="in combination or in sequence with adjuvant chemotherapy: trastuzumab or" exact="lapatinib" post="alone, the sequence and the combination of the 2"/>
   <result pre="because of age is bad management: trials have shown that" exact="tamoxifen" post="alone in women over 70 is associated with both"/>
   <result pre="strongly suggest that older women with small breast cancers on" exact="tamoxifen" post="after surgery may gain little or nothing from adjuvant"/>
   <result pre="31 2783 2790 23816962 5. Pagani O et al. Adjuvant" exact="exemestane" post="with ovarian suppression in premenopausal breast cancer N Engl"/>
   <result pre="11. Finn RS et al. The cyclin-dependent kinase 4/6 inhibitor" exact="palbociclib" post="in combination with letrozole versus letrozole alone as first-line"/>
   <result pre="al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with" exact="letrozole" post="versus letrozole alone as first-line treatment of oestrogen receptor-positive,"/>
   <result pre="cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus" exact="letrozole" post="alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced"/>
   <result pre="Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without" exact="carboplatin" post="in human epidermal growth factor receptor 2-positive and triple-negative"/>
   <result pre="1086 1094 24055415 23. Schneeweiss A et al. Pertuzumab plus" exact="trastuzumab" post="in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4405013/results/search/inn/results.xml">
   <result pre="cytotoxicity (ADCC). In phase III ToGA trial, the addition of" exact="trastuzumab" post="to standard cisplatin and 5-fluorouracil improved overall survival from"/>
   <result pre="phase III ToGA trial, the addition of trastuzumab to standard" exact="cisplatin" post="and 5-fluorouracil improved overall survival from 11.1 to 13.8"/>
   <result pre="[ 23]. In phase III EXPAND trial, the addition of" exact="cetuximab" post="(chimeric monoclonal anti-EGFR antibody) to standard cisplatin and capecitabine"/>
   <result pre="the addition of cetuximab (chimeric monoclonal anti-EGFR antibody) to standard" exact="cisplatin" post="and capecitabine did not improve progression free survival in"/>
   <result pre="of cetuximab (chimeric monoclonal anti-EGFR antibody) to standard cisplatin and" exact="capecitabine" post="did not improve progression free survival in patients with"/>
   <result pre="24]. Similarly, in phase III REAL-3 trial, the addition of" exact="panitumumab" post="(fully humanized monoclonal anti-EGFR antibody) to epirubicin, oxaliplatin, and"/>
   <result pre="panitumumab (fully humanized monoclonal anti-EGFR antibody) to epirubicin, oxaliplatin, and" exact="capecitabine" post="did not improve overall survival in patients with advanced"/>
   <result pre="and HER-2. In phase III TYTAN trial, the addition of" exact="lapatinib" post="to weekly paclitaxel in second-line setting improved overall response"/>
   <result pre="phase III TYTAN trial, the addition of lapatinib to weekly" exact="paclitaxel" post="in second-line setting improved overall response rate in patients"/>
   <result pre="Phase III GRANITE-1 study evaluated the efficacy of mTOR inhibitor" exact="everolimus" post="compared to the best supportive care in patients with"/>
   <result pre="In this study, median survival was reportedly 5.39 months with" exact="everolimus" post="versus 4.34 months with placebo (HR = 0.90; 95%"/>
   <result pre="III AVAGAST and AVATAR studies have evaluated the addition of" exact="bevacizumab" post="(anti-VEGF-A monoclonal antibody) to first-line platinum-fluoropyrimidine chemotherapy in advanced"/>
   <result pre="progressed after previous chemotherapy. Median survival was 5.2 months with" exact="ramucirumab" post="versus 3.8 months with placebo (HR = 0.776; 95%"/>
   <result pre="the Food and Drug Administration (FDA) in United States approved" exact="ramucirumab" post="as second-line therapy for patients with advanced gastric cancer."/>
   <result pre="Lordick F. Kang Y.-K. Chung H.-C. et al. Capecitabine and" exact="cisplatin" post="with or without cetuximab for patients with previously untreated"/>
   <result pre="Chung H.-C. et al. Capecitabine and cisplatin with or without" exact="cetuximab" post="for patients with previously untreated advanced gastric cancer (EXPAND):"/>
   <result pre="T. Chau I. Cunningham D. et al. Epirubicin, oxaliplatin, and" exact="capecitabine" post="with or without panitumumab for patients with previously untreated"/>
   <result pre="D. et al. Epirubicin, oxaliplatin, and capecitabine with or without" exact="panitumumab" post="for patients with previously untreated advanced oesophagogastric cancer (REAL3):"/>
   <result pre="Xu R. H. Chung H. C. et al. Lapatinib plus" exact="paclitaxel" post="versus paclitaxel alone in the second-line treatment of HER2-amplified"/>
   <result pre="H. Chung H. C. et al. Lapatinib plus paclitaxel versus" exact="paclitaxel" post="alone in the second-line treatment of HER2-amplified advanced gastric"/>
   <result pre="Shen L. Li J. Xu J. et al. Bevacizumab plus" exact="capecitabine" post="and cisplatin in Chinese patients with inoperable locally advanced"/>
   <result pre="Li J. Xu J. et al. Bevacizumab plus capecitabine and" exact="cisplatin" post="in Chinese patients with inoperable locally advanced or metastatic"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4406526/results/search/inn/results.xml">
   <result pre="special emphasis on relevant clinical questions: treatment duration, sequence of" exact="trastuzumab" post="administration, toxicity, the role of anthracycline-based regimens, and optimal"/>
   <result pre="into consideration the development of modern anti-HER2 agents. breast neoplasm" exact="trastuzumab" post="neoadjuvant therapy adjuvant therapy antibodies, monoclonal, humanised Background Breast"/>
   <result pre="BC. In this article, the authors review the role of" exact="trastuzumab" post="in early-stage BC. Trastuzumab: clinical efficacy in the adjuvant"/>
   <result pre="the adjuvant setting In the adjuvant setting, anti-HER2-targeted therapy with" exact="trastuzumab" post="greatly contributed to improvement of clinical outcomes, as measured"/>
   <result pre="multicentre international trials were designed to assess the role of" exact="trastuzumab" post="treatment in high-risk early-stage BC patients, defined as node"/>
   <result pre="of eight trials (total 11991 patients) testing the benefit of" exact="trastuzumab" post="when added to adjuvant chemotherapy versus chemotherapy alone ["/>
   <result pre="ejection fraction (LVEF) decline (RR 1.83, 90% CI 1.36–2.47). Currently," exact="trastuzumab" post="is the only anti-HER2 drug that has demonstrated a"/>
   <result pre="has demonstrated a survival benefit in the adjuvant setting. Recently," exact="trastuzumab" post="was also prospectively tested in a cohort of patients"/>
   <result pre="negative disease (1.5% patients had N1mic) were treated with adjuvant" exact="paclitaxel" post="(80 mg weekly) plus trastuzumab (4 mg/kg loading dose"/>
   <result pre="N1mic) were treated with adjuvant paclitaxel (80 mg weekly) plus" exact="trastuzumab" post="(4 mg/kg loading dose followed for 2 mg/kg weekly)"/>
   <result pre="followed for 2 mg/kg weekly) for 12 weeks, followed by" exact="trastuzumab" post="(either 2mg/kg weekly or 6 mg/kg every three weeks)"/>
   <result pre="0.34; 95% CI 0.24–0.47) [ 15]. In the neoadjuvant setting," exact="trastuzumab" post="has been tested in combination with chemotherapy and other"/>
   <result pre="Table 2). The ‘first generation’ trials addressed the efficacy of" exact="trastuzumab" post="plus chemotherapy when compared to chemotherapy alone. The MD"/>
   <result pre="patients with stage II–IIIA invasive but non-inflammatory BC to either" exact="paclitaxel" post="followed by fluorouracil, epirubicin, and cyclophosphamide (FEC) with or"/>
   <result pre="non-inflammatory BC to either paclitaxel followed by fluorouracil, epirubicin, and" exact="cyclophosphamide" post="(FEC) with or without trastuzumab. The primary endpoint was"/>
   <result pre="of three years, no DFS events were recorded in the" exact="trastuzumab" post="arm, while in the arm without trastuzumab 94.7% (95%"/>
   <result pre="recorded in the trastuzumab arm, while in the arm without" exact="trastuzumab" post="94.7% (95% CI, 85.2–100%) were DFS-free at one year"/>
   <result pre="years (p = 0.041) (17). No patients receiving chemotherapy plus" exact="trastuzumab" post="developed clinical cardiac dysfunction or cardiac related deaths. The"/>
   <result pre="patients with locally advanced or inflammatory BC to either neoadjuvant" exact="trastuzumab" post="plus a chemotherapy regimen based on doxorubicin, paclitaxel, cyclophosphamide,"/>
   <result pre="a chemotherapy regimen based on doxorubicin, paclitaxel, cyclophosphamide, methotrexate, and" exact="fluorouracil" post="followed by adjuvant trastuzumab, or neoadjuvant chemotherapy only. It"/>
   <result pre="allocated to chemotherapy alone later received one year of adjuvant" exact="trastuzumab" post="after the final positive results of the trastuzumab arm."/>
   <result pre="of adjuvant trastuzumab after the final positive results of the" exact="trastuzumab" post="arm. With a median follow-up of three years, the"/>
   <result pre="arm. With a median follow-up of three years, the neoadjuvant" exact="trastuzumab" post="arm demonstrated a 41% event-free survival (EFS) improvement (HR"/>
   <result pre="primary endpoint. The pCR rate was also higher in the" exact="trastuzumab" post="arm (38% versus 19%, p = 0.001). Long term"/>
   <result pre="BC, from which 451 HER2-positive and 1058 HER2-negative, to receive" exact="epirubicin" post="and cyclophosphamide (EC) and then be randomly assigned to"/>
   <result pre="which 451 HER2-positive and 1058 HER2-negative, to receive epirubicin and" exact="cyclophosphamide" post="(EC) and then be randomly assigned to either docetaxel,"/>
   <result pre="cyclophosphamide (EC) and then be randomly assigned to either docetaxel," exact="docetaxel" post="plus capecitabine, or docetaxel followed by capecitabine. Those patients"/>
   <result pre="be randomly assigned to either docetaxel, docetaxel plus capecitabine, or" exact="docetaxel" post="followed by capecitabine. Those patients with HER2-positive BC further"/>
   <result pre="by capecitabine. Those patients with HER2-positive BC further received concomitant" exact="trastuzumab" post="for a total period of one year. A pCR"/>
   <result pre="endpoint) rate of 31.7% was observed in those patients receiving" exact="trastuzumab" post="(with HER2-positive disease). In comparison, only 15.7% of the"/>
   <result pre="of HER2-negative patients. These trials supported the current use of" exact="trastuzumab" post="in association with chemotherapy in the neoadjuvant setting. Subsequently,"/>
   <result pre="in the neoadjuvant setting. Subsequently, the ‘second generation’ trials compared" exact="trastuzumab" post="to other anti-HER2 agents or the added benefit of"/>
   <result pre="agents or the added benefit of other anti-HER2 agents to" exact="trastuzumab" post="plus chemotherapy. The GeparQuinto trial [ 21] performed a"/>
   <result pre="The GeparQuinto trial [ 21] performed a head-to-head comparison between" exact="trastuzumab" post="and lapatinib. This was a multicentre, open-label, phase III"/>
   <result pre="that randomly assigned 620 patients with locally advanced BC to" exact="epirubicin" post="plus cyclophosphamide and docetaxel with either trastuzumab or lapatinib."/>
   <result pre="assigned 620 patients with locally advanced BC to epirubicin plus" exact="cyclophosphamide" post="and docetaxel with either trastuzumab or lapatinib. The primary"/>
   <result pre="patients with locally advanced BC to epirubicin plus cyclophosphamide and" exact="docetaxel" post="with either trastuzumab or lapatinib. The primary endpoint was"/>
   <result pre="advanced BC to epirubicin plus cyclophosphamide and docetaxel with either" exact="trastuzumab" post="or lapatinib. The primary endpoint was the pCR rate,"/>
   <result pre="was the pCR rate, which was of 30.3% in the" exact="trastuzumab" post="arm, and of 22.7% in the lapatinib arm (OR"/>
   <result pre="30.3% in the trastuzumab arm, and of 22.7% in the" exact="lapatinib" post="arm (OR 0.68, 95% CI 0.47–0.97; p = 0.04)"/>
   <result pre="superior in the combination arm (46.7%, 90% CI 34.4–58.9%). The" exact="trastuzumab" post="only arm had a pCR of 25% (90% CI"/>
   <result pre="had a pCR of 25% (90% CI 13.1–36.9%) and the" exact="lapatinib" post="only arm 23.6% (90% 14.5–38.1%). The association lapatinib-trastuzumab was"/>
   <result pre="95% CI 43.1–59.5; versus 29·5%, 95% CI 22.4–37.5 in the" exact="trastuzumab" post="arm; p = 0·0001 for the difference). No significant"/>
   <result pre="for the difference). No significant difference was documented between the" exact="trastuzumab" post="and lapatinib arms (lapatinib pCR of 24.7%, 95% CI"/>
   <result pre="difference). No significant difference was documented between the trastuzumab and" exact="lapatinib" post="arms (lapatinib pCR of 24.7%, 95% CI 18.1–32.3; p"/>
   <result pre="the difference). The authors concluded that the dual inhibition with" exact="trastuzumab" post="and lapatinib might be a valid option in the"/>
   <result pre="The authors concluded that the dual inhibition with trastuzumab and" exact="lapatinib" post="might be a valid option in the neoadjuvant setting."/>
   <result pre="that tested the adjuvant use of the same combination of" exact="trastuzumab" post="plus lapatinib in the adjuvant setting (discussed ahead) ["/>
   <result pre="the adjuvant use of the same combination of trastuzumab plus" exact="lapatinib" post="in the adjuvant setting (discussed ahead) [ 24]. Other"/>
   <result pre="testing this combination are summarised in Table 2. Besides lapatinib," exact="trastuzumab" post="was also tested in combination with pertuzumab. The NeoSphere"/>
   <result pre="early, locally advanced, or inflammatory BC to four therapeutic groups:" exact="trastuzumab" post="plus docetaxel (group A), pertuzumab and trastuzumab plus docetaxel"/>
   <result pre="advanced, or inflammatory BC to four therapeutic groups: trastuzumab plus" exact="docetaxel" post="(group A), pertuzumab and trastuzumab plus docetaxel (group B),"/>
   <result pre="BC to four therapeutic groups: trastuzumab plus docetaxel (group A)," exact="pertuzumab" post="and trastuzumab plus docetaxel (group B), pertuzumab and trastuzumab"/>
   <result pre="four therapeutic groups: trastuzumab plus docetaxel (group A), pertuzumab and" exact="trastuzumab" post="plus docetaxel (group B), pertuzumab and trastuzumab (group C),"/>
   <result pre="groups: trastuzumab plus docetaxel (group A), pertuzumab and trastuzumab plus" exact="docetaxel" post="(group B), pertuzumab and trastuzumab (group C), and pertuzumab"/>
   <result pre="docetaxel (group A), pertuzumab and trastuzumab plus docetaxel (group B)," exact="pertuzumab" post="and trastuzumab (group C), and pertuzumab plus docetaxel (group"/>
   <result pre="A), pertuzumab and trastuzumab plus docetaxel (group B), pertuzumab and" exact="trastuzumab" post="(group C), and pertuzumab plus docetaxel (group D). After"/>
   <result pre="plus docetaxel (group B), pertuzumab and trastuzumab (group C), and" exact="pertuzumab" post="plus docetaxel (group D). After surgery, patients who received"/>
   <result pre="(group B), pertuzumab and trastuzumab (group C), and pertuzumab plus" exact="docetaxel" post="(group D). After surgery, patients who received docetaxel, further"/>
   <result pre="The trial revealed that patients treated with docetaxel, trastuzumab, and" exact="pertuzumab" post="(group B) had a more favourable pCR rate (45.8%,"/>
   <result pre="(45.8%, 95% CI 36.1–55.7) when compared with those treated with" exact="docetaxel" post="plus trastuzumab (group A, 29.0%, 95% CI 20.6–38.5; p"/>
   <result pre="CI 36.1–55.7) when compared with those treated with docetaxel plus" exact="trastuzumab" post="(group A, 29.0%, 95% CI 20.6–38.5; p = 0·014"/>
   <result pre="and 24.0% (15.8–33.7), respectively. In this study, the combination of" exact="trastuzumab" post="to pertuzumab did not increase cardiac toxicity. Besides showing"/>
   <result pre="(15.8–33.7), respectively. In this study, the combination of trastuzumab to" exact="pertuzumab" post="did not increase cardiac toxicity. Besides showing that the"/>
   <result pre="duration of therapy Only recently was the treatment duration of" exact="trastuzumab" post="more clearly established. The pivotal trials studying the role"/>
   <result pre="more clearly established. The pivotal trials studying the role of" exact="trastuzumab" post="in early BC used an empirical reference therapy duration"/>
   <result pre="FinHER trial [ 6] tested a shorter duration of adjuvant" exact="trastuzumab" post="in a subset of early BC patients with HER2-positive"/>
   <result pre="phase III trial, 1010 patients were randomly assigned to adjuvant" exact="docetaxel" post="or vinorelbine followed by FEC with or without nine"/>
   <result pre="trial, 1010 patients were randomly assigned to adjuvant docetaxel or" exact="vinorelbine" post="followed by FEC with or without nine cycles of"/>
   <result pre="followed by FEC with or without nine cycles of weekly" exact="trastuzumab" post="in the subset of HER2-positive breast cancer (232 patients,"/>
   <result pre="recurrence-free survival (RFS). At a median follow-up of 37 months," exact="trastuzumab" post="was an effective therapy (RFS HR 0.41, 95% CI"/>
   <result pre="0.16–1.08, p = 0.07). None of the women exposed to" exact="trastuzumab" post="had heart failure. The documented clinical improvement with the"/>
   <result pre="heart failure. The documented clinical improvement with the addition of" exact="trastuzumab" post="was similar to those trials with standard one-year therapy"/>
   <result pre="at least four cycles of chemotherapy and six months of" exact="trastuzumab" post="to continue trastuzumab for an additional period of six"/>
   <result pre="cycles of chemotherapy and six months of trastuzumab to continue" exact="trastuzumab" post="for an additional period of six months or to"/>
   <result pre="At a median follow-up of three-and-onehalf years, six months of" exact="trastuzumab" post="could not demonstrate non-inferiority (DFS HR 1.28, 95% CI"/>
   <result pre="by hormone-receptor status and timing of administration of chemotherapy and" exact="trastuzumab" post="(sequential or concomitant). The ER-negative cancers treated with sequential"/>
   <result pre="or concomitant). The ER-negative cancers treated with sequential chemotherapy and" exact="trastuzumab" post="had the worst two year DFS (89.8%, 95% CI"/>
   <result pre="of serious adverse events were documented; however early stopping of" exact="trastuzumab" post="because of cardiac toxicity was more common in the"/>
   <result pre="open-label phase III trial, besides comparing one year of adjuvant" exact="trastuzumab" post="with observation after standard adjuvant chemotherapy, also enrolled patients"/>
   <result pre="patients to a third arm treated with two years of" exact="trastuzumab" post="[ 27]. This trial was designed to detect DFS"/>
   <result pre="between subgroups. Interestingly, the hormone-receptor-negative subgroup receiving two years of" exact="trastuzumab" post="had a transient but not statistically significant improvement in"/>
   <result pre="adjuvant therapy is given to these patients (no hormone, nor" exact="trastuzumab" post="therapy). The authors argue that this finding is specially"/>
   <result pre="the cohort of hormone-receptor-negative patients receiving a second year of" exact="trastuzumab" post="closely resembles that of the hormone-receptor-positive groups. Regarding safety,"/>
   <result pre="these results the authors concluded that two years of adjuvant" exact="trastuzumab" post="has an unfavourable risk-benefit ratio. Grounded in the current"/>
   <result pre="ratio. Grounded in the current evidence, one year of adjuvant" exact="trastuzumab" post="remains the standard treatment duration. Anthracycline use and treatment"/>
   <result pre="regimens were used in the majority of the trials evaluating" exact="trastuzumab" post="in the adjuvant setting ( Table 1). As previously"/>
   <result pre="decline, was identified as a source of concern with adjuvant" exact="trastuzumab" post="therapy, which is aggravated with the use of anthracycline-based"/>
   <result pre="anthracycline-taxane containing chemotherapy regimen (AC-T), the same chemotherapy regimen plus" exact="trastuzumab" post="(AC-TH), or an anthracycline-free chemotherapy regimen containing docetaxel, carboplatin,"/>
   <result pre="(AC-TH), or an anthracycline-free chemotherapy regimen containing docetaxel, carboplatin, and" exact="trastuzumab" post="(TCH). In this trial, high risk was defined as"/>
   <result pre="studies demonstrating the same conclusion; and the uncertain benefit from" exact="carboplatin" post="when compared to anthracyclinetaxane based chemotherapy in HER2-positive BC."/>
   <result pre="BC. Whereas some of the pivotal trials opted to give" exact="trastuzumab" post="after chemotherapy (sequential approach), others preferred to administer trastuzumab"/>
   <result pre="give trastuzumab after chemotherapy (sequential approach), others preferred to administer" exact="trastuzumab" post="concurrent with paclitaxel ( Table 1). The NCCTG N9831"/>
   <result pre="chemotherapy (sequential approach), others preferred to administer trastuzumab concurrent with" exact="paclitaxel" post="( Table 1). The NCCTG N9831 study design evaluated"/>
   <result pre="this multicentre, open-label, phase III study, 2448 patients received adjuvant" exact="doxorubicin" post="and cyclophosphamide every three weeks for four cycles, and"/>
   <result pre="open-label, phase III study, 2448 patients received adjuvant doxorubicin and" exact="cyclophosphamide" post="every three weeks for four cycles, and they were"/>
   <result pre="then randomly assigned to receive one of three options: weekly" exact="paclitaxel" post="for 12 weeks (arm A), weekly paclitaxel plus sequential"/>
   <result pre="three options: weekly paclitaxel for 12 weeks (arm A), weekly" exact="paclitaxel" post="plus sequential weekly trastuzumab for 52 weeks (arm B),"/>
   <result pre="for 12 weeks (arm A), weekly paclitaxel plus sequential weekly" exact="trastuzumab" post="for 52 weeks (arm B), or weekly paclitaxel plus"/>
   <result pre="sequential weekly trastuzumab for 52 weeks (arm B), or weekly" exact="paclitaxel" post="plus concurrent trastuzumab for 12 weeks followed by weekly"/>
   <result pre="for 52 weeks (arm B), or weekly paclitaxel plus concurrent" exact="trastuzumab" post="for 12 weeks followed by weekly trastuzumab for 40"/>
   <result pre="paclitaxel plus concurrent trastuzumab for 12 weeks followed by weekly" exact="trastuzumab" post="for 40 weeks (arm C). The primary endpoint was"/>
   <result pre="= 954) to C (n = 949), those receiving concurrent" exact="trastuzumab" post="(arm C) presented a strong trend towards a reduction"/>
   <result pre="(1:1 ratio) to four cycles of FEC followed by weekly" exact="paclitaxel" post="plus trastuzumab or the reverse sequence, with continued trastuzumab"/>
   <result pre="to four cycles of FEC followed by weekly paclitaxel plus" exact="trastuzumab" post="or the reverse sequence, with continued trastuzumab during FEC."/>
   <result pre="weekly paclitaxel plus trastuzumab or the reverse sequence, with continued" exact="trastuzumab" post="during FEC. No significant differences in pCR in the"/>
   <result pre="outcome) were noted (56.5% versus 54.2% in the reverse sequence/concurrent" exact="trastuzumab" post="arm). Grade 3–4 neutropaenia, LVEF decline, fatigue, and neurosensory"/>
   <result pre="arm. Formulation differences The studies leading to the approval of" exact="trastuzumab" post="used an intravenous (IV) formulation of the drug. While"/>
   <result pre="used an intravenous (IV) formulation of the drug. While IV" exact="trastuzumab" post="has already been shown to be a cost-effective therapy"/>
   <result pre="five minutes), both every three weeks and in combination with" exact="docetaxel" post="times four followed by FEC times four (1:1 ratio"/>
   <result pre="ratio of C (trough) 1.33, 90% CI 1.24–1.44). Hence, SC" exact="trastuzumab" post="was considered non-inferior to the IV formulation after meeting"/>
   <result pre="the SC formulation [ 36]. Early predictors of response to" exact="trastuzumab" post="or other anti-HER2 therapies HER2 overexpression remains the only"/>
   <result pre="BC. In the metastatic setting, HER2 molecular imaging using 89Zirconium-labeled" exact="trastuzumab" post="is being tested as a noninvasive whole-body imaging technique"/>
   <result pre="of HER2-positive tumours using 89Zirconium-labeled trastuzumab. Other anti-HER2 therapies Despite" exact="trastuzumab" post="efficacy in the treatment of HER2-positive BC, tumour relapse"/>
   <result pre="with trastuzumab. The TEACH investigators addressed the role of adjuvant" exact="lapatinib" post="as a monotherapy in a randomised, placebo-controlled, phase III,"/>
   <result pre="phase III, and multinational trial that assigned 3161 women to" exact="lapatinib" post="or placebo (1:1 ratio). With a median follow-up of"/>
   <result pre="of almost four years, only a non-statistically significant trend towards" exact="lapatinib" post="was found in terms of DFS (HR 0.83, 95%"/>
   <result pre="p = 0.96). Lapatinib was also tested in association with" exact="trastuzumab" post="in non-metastatic BC in the ALTTO study, a randomised"/>
   <result pre="the study treatments. In Design 2B, a non-anthracycline regimen containing" exact="docetaxel" post="and carboplatin is given concurrently with study treatments’. Within"/>
   <result pre="treatments. In Design 2B, a non-anthracycline regimen containing docetaxel and" exact="carboplatin" post="is given concurrently with study treatments’. Within each of"/>
   <result pre="patients were randomised to receive one of the following treatments:" exact="trastuzumab" post="alone; lapatinib alone (until August 2011); trastuzumab followed by"/>
   <result pre="randomised to receive one of the following treatments: trastuzumab alone;" exact="lapatinib" post="alone (until August 2011); trastuzumab followed by lapatinib; or"/>
   <result pre="the following treatments: trastuzumab alone; lapatinib alone (until August 2011);" exact="trastuzumab" post="followed by lapatinib; or lapatinib in combination with trastuzumab."/>
   <result pre="lapatinib alone (until August 2011); trastuzumab followed by lapatinib; or" exact="lapatinib" post="in combination with trastuzumab. The primary endpoint was DFS."/>
   <result pre="study, there is no current support for the use of" exact="lapatinib" post="in the adjuvant setting. Pertuzumab is a recombinant humanised"/>
   <result pre="Its mechanism of action is considered complementary to that of" exact="trastuzumab" post="[ 42]. The CLEOPATRA trial [ 43] compared the"/>
   <result pre="[ 43] compared the progression-free-survival (PFS) between the combination of" exact="pertuzumab" post="plus trastuzumab plus docetaxel and the combination of placebo"/>
   <result pre="compared the progression-free-survival (PFS) between the combination of pertuzumab plus" exact="trastuzumab" post="plus docetaxel and the combination of placebo plus trastuzumab"/>
   <result pre="progression-free-survival (PFS) between the combination of pertuzumab plus trastuzumab plus" exact="docetaxel" post="and the combination of placebo plus trastuzumab plus docetaxel"/>
   <result pre="plus trastuzumab plus docetaxel and the combination of placebo plus" exact="trastuzumab" post="plus docetaxel in 808 patients with HER2-positive metastatic BC."/>
   <result pre="plus docetaxel and the combination of placebo plus trastuzumab plus" exact="docetaxel" post="in 808 patients with HER2-positive metastatic BC. In the"/>
   <result pre="months, this randomised, phase III trial demonstrated a benefit from" exact="pertuzumab" post="when compared to the placebo (OS HR 0.68, 95%"/>
   <result pre="The PERUSE (NCT01572038) and VELVET (NCT01565083) studies are currently testing" exact="pertuzumab" post="in metastatic BC in association with other chemotherapy regimens."/>
   <result pre="and TRYPHAENA trials [ 44], showed promising results in the" exact="pertuzumab" post="plus trastuzumab plus docetaxel association when compared to the"/>
   <result pre="trials [ 44], showed promising results in the pertuzumab plus" exact="trastuzumab" post="plus docetaxel association when compared to the same schema"/>
   <result pre="44], showed promising results in the pertuzumab plus trastuzumab plus" exact="docetaxel" post="association when compared to the same schema without pertuzumab."/>
   <result pre="the same schema without pertuzumab. Given the positive results of" exact="pertuzumab" post="in association with trastuzumab in the metastatic and neoadjuvant"/>
   <result pre="pertuzumab. Given the positive results of pertuzumab in association with" exact="trastuzumab" post="in the metastatic and neoadjuvant setting, this combination is"/>
   <result pre="placebo-controlled trial comparing the efficacy and safety of chemotherapy plus" exact="trastuzumab" post="and pertuzumab with that of chemotherapy plus trastuzumab and"/>
   <result pre="comparing the efficacy and safety of chemotherapy plus trastuzumab and" exact="pertuzumab" post="with that of chemotherapy plus trastuzumab and placebo as"/>
   <result pre="chemotherapy plus trastuzumab and pertuzumab with that of chemotherapy plus" exact="trastuzumab" post="and placebo as adjuvant therapy in patients with primary"/>
   <result pre="invasive DFS (IDFS). Trastuzumab emtansine (T-DM1) is a conjugate between" exact="trastuzumab" post="antibody and emtansine (DM1), a cytotoxic drug ( Table"/>
   <result pre="the metastatic setting, the EMILIA trial compared the combination of" exact="lapatinib" post="plus capecitabine versus T-DM1 in 991 patients with HER2-positive"/>
   <result pre="setting, the EMILIA trial compared the combination of lapatinib plus" exact="capecitabine" post="versus T-DM1 in 991 patients with HER2-positive BC previously"/>
   <result pre="T-DM1 in 991 patients with HER2-positive BC previously treated with" exact="trastuzumab" post="and a taxane in terms of PFS. This randomised,"/>
   <result pre="demonstrated an improvement from the T-DM1 arm when compared to" exact="lapatinib" post="plus capecitabine, not only in terms of PFS (9.6"/>
   <result pre="January 2013) compares the DFS (primary endpoint) between T-DM1 versus" exact="trastuzumab" post="as adjuvant therapy in patients with HER2-positive BC who"/>
   <result pre="(NCT01966471, started recruiting in January 2014) is comparing T-DM1 plus" exact="pertuzumab" post="to trastuzumab plus pertuzumab plus a taxane, both followed"/>
   <result pre="recruiting in January 2014) is comparing T-DM1 plus pertuzumab to" exact="trastuzumab" post="plus pertuzumab plus a taxane, both followed by an"/>
   <result pre="January 2014) is comparing T-DM1 plus pertuzumab to trastuzumab plus" exact="pertuzumab" post="plus a taxane, both followed by an anthracycline. The"/>
   <result pre="patients (1:1 ratio). Of note, the comparator arm (trastuzumab plus" exact="pertuzumab" post="plus a taxane) is not a standard of care"/>
   <result pre="Trastuzumab plus other anti-HER2 therapies (without chemotherapy) As previously discussed," exact="trastuzumab" post="significantly enhanced the clinical outcomes in patients with ‘high"/>
   <result pre="study questioned this ‘low risk’ assumption [ 9]. Yet, standard" exact="trastuzumab" post="plus chemotherapy regimens have well-documented toxicities, thus making the"/>
   <result pre="assigned patients with early, locally advanced, and inflammatory BC to" exact="trastuzumab" post="plus docetaxel or pertuzumab and trastuzumab plus docetaxel or"/>
   <result pre="with early, locally advanced, and inflammatory BC to trastuzumab plus" exact="docetaxel" post="or pertuzumab and trastuzumab plus docetaxel or pertuzumab and"/>
   <result pre="locally advanced, and inflammatory BC to trastuzumab plus docetaxel or" exact="pertuzumab" post="and trastuzumab plus docetaxel or pertuzumab and trastuzumab or"/>
   <result pre="and inflammatory BC to trastuzumab plus docetaxel or pertuzumab and" exact="trastuzumab" post="plus docetaxel or pertuzumab and trastuzumab or pertuzumab plus"/>
   <result pre="BC to trastuzumab plus docetaxel or pertuzumab and trastuzumab plus" exact="docetaxel" post="or pertuzumab and trastuzumab or pertuzumab plus docetaxel. The"/>
   <result pre="trastuzumab plus docetaxel or pertuzumab and trastuzumab plus docetaxel or" exact="pertuzumab" post="and trastuzumab or pertuzumab plus docetaxel. The pCR rates"/>
   <result pre="docetaxel or pertuzumab and trastuzumab plus docetaxel or pertuzumab and" exact="trastuzumab" post="or pertuzumab plus docetaxel. The pCR rates between arms"/>
   <result pre="pertuzumab and trastuzumab plus docetaxel or pertuzumab and trastuzumab or" exact="pertuzumab" post="plus docetaxel. The pCR rates between arms were 29%,"/>
   <result pre="note the low but significant proportion of patients receiving only" exact="trastuzumab" post="plus pertuzumab without chemotherapy that achieved a pCR (16.8%),"/>
   <result pre="low but significant proportion of patients receiving only trastuzumab plus" exact="pertuzumab" post="without chemotherapy that achieved a pCR (16.8%), which raised"/>
   <result pre="small minority of patients don’t benefit from chemotherapy when receiving" exact="trastuzumab" post="plus pertuzumab. This observation was especially valid for ER-negative"/>
   <result pre="prognosis. The preliminary data from combining new anti-HER2 therapies with" exact="trastuzumab" post="are exciting, and several large studies are underway to"/>
   <result pre="1659 72 10.1056/NEJMoa052306 16236737 4. Slamon D et al. Adjuvant" exact="trastuzumab" post="in HER2-positive breast cancer N Engl J Med 2011"/>
   <result pre="3744 52 10.1200/JCO.2014.55.5730 25332249 6. Joensuu H et al. Adjuvant" exact="docetaxel" post="or vinorelbine with or without trastuzumab for breast cancer"/>
   <result pre="10.1200/JCO.2014.55.5730 25332249 6. Joensuu H et al. Adjuvant docetaxel or" exact="vinorelbine" post="with or without trastuzumab for breast cancer N Engl"/>
   <result pre="H et al. Adjuvant docetaxel or vinorelbine with or without" exact="trastuzumab" post="for breast cancer N Engl J Med 2006 354"/>
   <result pre="10.1056/NEJMoa053028 16495393 7. Joensuu H et al. Fluorouracil, epirubicin, and" exact="cyclophosphamide" post="with either docetaxel or vinorelbine, with or without trastuzumab,"/>
   <result pre="Joensuu H et al. Fluorouracil, epirubicin, and cyclophosphamide with either" exact="docetaxel" post="or vinorelbine, with or without trastuzumab, as adjuvant treatments"/>
   <result pre="4 Cd006243 10.1002/14651858.CD006243.pub2 22513938 9. Tolaney SM et al. Adjuvant" exact="paclitaxel" post="and trastuzumab for node-negative, HER2-positive breast cancer N Engl"/>
   <result pre="10.1002/14651858.CD006243.pub2 22513938 9. Tolaney SM et al. Adjuvant paclitaxel and" exact="trastuzumab" post="for node-negative, HER2-positive breast cancer N Engl J Med"/>
   <result pre="10.1056/NEJMoa1406281 25564897 10. Campiglio M et al. Effect of adjuvant" exact="trastuzumab" post="treatment in conventional clinical setting: an observational retrospective multicenter"/>
   <result pre="12. Vaz-Luis I et al. Duration and toxicity of adjuvant" exact="trastuzumab" post="in older patients with early-stage breast cancer: a population-based"/>
   <result pre="complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and" exact="epirubicin" post="chemotherapy: results of a randomized trial in human epidermal"/>
   <result pre="10.1200/JCO.2005.07.032 15738535 17. Buzdar AU et al. Neoadjuvant therapy with" exact="paclitaxel" post="followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent"/>
   <result pre="al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and" exact="cyclophosphamide" post="chemotherapy and concurrent trastuzumab in human epidermal growth factor"/>
   <result pre="paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent" exact="trastuzumab" post="in human epidermal growth factor receptor 2–positive operable breast"/>
   <result pre="10.1158/1078-0432.CCR-06-1345 17200359 18. Gianni L et al. Neoadjuvant chemotherapy with" exact="trastuzumab" post="followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in"/>
   <result pre="L et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant" exact="trastuzumab" post="versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally"/>
   <result pre="10.1016/S0140-6736(09)61964-4 20113825 19. Gianni L et al. Neoadjuvant and adjuvant" exact="trastuzumab" post="in patients with HER2-positive locally advanced breast cancer (NOAH):"/>
   <result pre="10.1016/S1470-2045(14)70080-4 24657003 20. Untch M et al. Neoadjuvant treatment with" exact="trastuzumab" post="in HER2-positive breast cancer: results from the GeparQuattro study"/>
   <result pre="31 10.1200/JCO.2009.23.8451 20308670 21. Untch M et al. Lapatinib versus" exact="trastuzumab" post="in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44):"/>
   <result pre="95 10.1200/JCO.2011.39.0823 22493419 23. Baselga J et al. Lapatinib with" exact="trastuzumab" post="for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label,"/>
   <result pre="NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with" exact="lapatinib" post="alone (L), trastuzumab alone (T), their sequence (T→L), or"/>
   <result pre="comparing one year of anti-HER2 therapy with lapatinib alone (L)," exact="trastuzumab" post="alone (T), their sequence (T→L), or their combination (T+L)"/>
   <result pre="25. Gianni L et al. Efficacy and safety of neoadjuvant" exact="pertuzumab" post="and trastuzumab in women with locally advanced, inflammatory, or"/>
   <result pre="L et al. Efficacy and safety of neoadjuvant pertuzumab and" exact="trastuzumab" post="in women with locally advanced, inflammatory, or early HER2-positive"/>
   <result pre="X et al. 6 months versus 12 months of adjuvant" exact="trastuzumab" post="for patients with HER2-positive early breast cancer (PHARE): a"/>
   <result pre="A et al. 2 years versus 1 year of adjuvant" exact="trastuzumab" post="for HER2-positive breast cancer (HERA): an open-label, randomised controlled"/>
   <result pre="23871490 28. Perez EA et al. Cardiac safety snalysis of" exact="doxorubicin" post="and cyclophosphamide Followed by paclitaxel with or without trastuzumab"/>
   <result pre="Perez EA et al. Cardiac safety snalysis of doxorubicin and" exact="cyclophosphamide" post="Followed by paclitaxel with or without trastuzumab in the"/>
   <result pre="al. Cardiac safety snalysis of doxorubicin and cyclophosphamide Followed by" exact="paclitaxel" post="with or without trastuzumab in the North Central Cancer"/>
   <result pre="of doxorubicin and cyclophosphamide Followed by paclitaxel with or without" exact="trastuzumab" post="in the North Central Cancer Treatment Group N9831 Adjuvant"/>
   <result pre="al. Assessment of cardiac dysfunction in a randomized trial comparing" exact="doxorubicin" post="and cyclophosphamide followed by paclitaxel, with or without trastuzumab"/>
   <result pre="of cardiac dysfunction in a randomized trial comparing doxorubicin and" exact="cyclophosphamide" post="followed by paclitaxel, with or without trastuzumab as adjuvant"/>
   <result pre="comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without" exact="trastuzumab" post="as adjuvant therapy in node-positive, human epidermal growth factor"/>
   <result pre="10.1200/JCO.2012.42.0695 22614986 32. Perez EA et al. Sequential versus concurrent" exact="trastuzumab" post="in adjuvant chemotherapy for breast cancer J Clin Oncol"/>
   <result pre="10.1200/JCO.2011.36.7045 22042958 33. Buzdar AU et al. Fluorouracil, epirubicin, and" exact="cyclophosphamide" post="(FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus"/>
   <result pre="AU et al. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by" exact="paclitaxel" post="plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75"/>
   <result pre="al. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus" exact="trastuzumab" post="versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab"/>
   <result pre="epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus" exact="paclitaxel" post="plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant"/>
   <result pre="cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus" exact="trastuzumab" post="followed by FEC-75 plus trastuzumab as neoadjuvant treatment for"/>
   <result pre="plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus" exact="trastuzumab" post="as neoadjuvant treatment for patients with HER2-positive breast cancer"/>
   <result pre="Liberato NL Marchetti M Barosi G Cost effectiveness of adjuvant" exact="trastuzumab" post="in human epidermal growth factor receptor 2–positive breast cancer"/>
   <result pre="G et al. Subcutaneous versus intravenous administration of (neo) adjuvant" exact="trastuzumab" post="in patients with HER2-positive, clinical stage I–III breast cancer"/>
   <result pre="X et al. Preference for subcutaneous or intravenous administration of" exact="trastuzumab" post="in patients with HER2-positive early breast cancer (PrefHer): an"/>
   <result pre="42. Scheuer W et al. Strongly enhanced antitumor activity of" exact="trastuzumab" post="and pertuzumab combination treatment on HER2-positive human xenograft tumor"/>
   <result pre="W et al. Strongly enhanced antitumor activity of trastuzumab and" exact="pertuzumab" post="combination treatment on HER2-positive human xenograft tumor models Cancer"/>
   <result pre="6 10.1158/0008-5472.CAN-08-4597 19934333 43. Baselga J et al. Pertuzumab plus" exact="trastuzumab" post="plus docetaxel for metastatic breast cancer New Engl J"/>
   <result pre="19934333 43. Baselga J et al. Pertuzumab plus trastuzumab plus" exact="docetaxel" post="for metastatic breast cancer New Engl J Med 2012"/>
   <result pre="19 10.1056/NEJMoa1113216 22149875 44. Schneeweiss A et al. Pertuzumab plus" exact="trastuzumab" post="in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy"/>
   <result pre="61 10.1016/S0960-9776(11)70316-2 22015286 50. Gianni L et al. Treatment with" exact="trastuzumab" post="for 1 year after adjuvant chemotherapy in patients with"/>
   <result pre="of CALGB 40601: A neoadjuvant phase III trial of weekly" exact="paclitaxel" post="and trastuzumab with or without lapatinib for HER2-positive breast"/>
   <result pre="40601: A neoadjuvant phase III trial of weekly paclitaxel and" exact="trastuzumab" post="with or without lapatinib for HER2-positive breast cancer J"/>
   <result pre="III trial of weekly paclitaxel and trastuzumab with or without" exact="lapatinib" post="for HER2-positive breast cancer J Clin Oncol 2013 31"/>
   <result pre="analysis of a phase II 3-arm randomized trial of neoadjuvant" exact="trastuzumab" post="or lapatinib or the combination of trastuzumab and lapatinib,"/>
   <result pre="a phase II 3-arm randomized trial of neoadjuvant trastuzumab or" exact="lapatinib" post="or the combination of trastuzumab and lapatinib, followed by"/>
   <result pre="trial of neoadjuvant trastuzumab or lapatinib or the combination of" exact="trastuzumab" post="and lapatinib, followed by six cycles of docetaxel and"/>
   <result pre="combination of trastuzumab and lapatinib, followed by six cycles of" exact="docetaxel" post="and carboplatin with trastuzumab and/or lapatinib in patients with"/>
   <result pre="trastuzumab and lapatinib, followed by six cycles of docetaxel and" exact="carboplatin" post="with trastuzumab and/or lapatinib in patients with HER2+ breast"/>
   <result pre="lapatinib, followed by six cycles of docetaxel and carboplatin with" exact="trastuzumab" post="and/or lapatinib in patients with HER2+ breast cancer (TRIO-US"/>
   <result pre="by six cycles of docetaxel and carboplatin with trastuzumab and/or" exact="lapatinib" post="in patients with HER2+ breast cancer (TRIO-US B07) Cancer"/>
   <result pre="Rimawi MF et al. Multicenter phase II study of neoadjuvant" exact="lapatinib" post="and trastuzumab with hormonal therapy and without chemotherapy in"/>
   <result pre="et al. Multicenter phase II study of neoadjuvant lapatinib and" exact="trastuzumab" post="with hormonal therapy and without chemotherapy in patients with"/>
   <result pre="Correlation of molecular effects and pathologic complete response to preoperative" exact="lapatinib" post="and trastuzumab, separately and combined prior to neoadjuvant breast"/>
   <result pre="506 Table 1. Summary of results from major trials addressing" exact="trastuzumab" post="benefit in the adjuvant treatment of BC. Study Number"/>
   <result pre="BCIRG 006 trial ( ǂ) 3222/5 years • AC →" exact="docetaxel" post="• AC → docetaxel + trastuzumab → trastuzumab •"/>
   <result pre="ǂ) 3222/5 years • AC → docetaxel • AC →" exact="docetaxel" post="+ trastuzumab → trastuzumab • Docetaxel + carboplatin +"/>
   <result pre="years • AC → docetaxel • AC → docetaxel +" exact="trastuzumab" post="→ trastuzumab • Docetaxel + carboplatin + trastuzumab →"/>
   <result pre="AC → docetaxel • AC → docetaxel + trastuzumab →" exact="trastuzumab" post="• Docetaxel + carboplatin + trastuzumab → trastuzumab •"/>
   <result pre="AC → docetaxel + trastuzumab → trastuzumab • Docetaxel +" exact="carboplatin" post="+ trastuzumab → trastuzumab • HR 0.64, p &amp;lt;"/>
   <result pre="docetaxel + trastuzumab → trastuzumab • Docetaxel + carboplatin +" exact="trastuzumab" post="→ trastuzumab • HR 0.64, p &amp;lt; 0.001; 0.75,"/>
   <result pre="trastuzumab → trastuzumab • Docetaxel + carboplatin + trastuzumab →" exact="trastuzumab" post="• HR 0.64, p &amp;lt; 0.001; 0.75, p ="/>
   <result pre="years (DFS analysis at five years follow—up) • AC →" exact="paclitaxel" post="• AC → paclitaxel → trastuzumab Sequential arm •"/>
   <result pre="five years follow—up) • AC → paclitaxel • AC →" exact="paclitaxel" post="→ trastuzumab Sequential arm • HR 0.69, p &amp;lt;"/>
   <result pre="follow—up) • AC → paclitaxel • AC → paclitaxel →" exact="trastuzumab" post="Sequential arm • HR 0.69, p &amp;lt; 0.001 •"/>
   <result pre="NSABP B—31 trials ( ǂ) 4046/8.4 years • AC →" exact="paclitaxel" post="• AC → paclitaxel + trastuzumab → trastuzumab •"/>
   <result pre="ǂ) 4046/8.4 years • AC → paclitaxel • AC →" exact="paclitaxel" post="+ trastuzumab → trastuzumab • HR 0.60, p &amp;lt;"/>
   <result pre="years • AC → paclitaxel • AC → paclitaxel +" exact="trastuzumab" post="→ trastuzumab • HR 0.60, p &amp;lt; 0.001 •"/>
   <result pre="AC → paclitaxel • AC → paclitaxel + trastuzumab →" exact="trastuzumab" post="• HR 0.60, p &amp;lt; 0.001 • 62.3% versus"/>
   <result pre="four cycles standard chemotherapy • four cycles standard chemotherapy →" exact="trastuzumab" post="• HR 0.76, p &amp;lt; 0.001 • 72.2% versus"/>
   <result pre="50] FNCLCC—PACS04 trial ( §) 3010/3 years • FEC or" exact="epirubicin" post="plus docetaxel • FEC or epirubicin plus docetaxel →"/>
   <result pre="trial ( §) 3010/3 years • FEC or epirubicin plus" exact="docetaxel" post="• FEC or epirubicin plus docetaxel → trastuzumab •"/>
   <result pre="years • FEC or epirubicin plus docetaxel • FEC or" exact="epirubicin" post="plus docetaxel → trastuzumab • HR 0.86, p ="/>
   <result pre="FEC or epirubicin plus docetaxel • FEC or epirubicin plus" exact="docetaxel" post="→ trastuzumab • HR 0.86, p = 0.41 •"/>
   <result pre="epirubicin plus docetaxel • FEC or epirubicin plus docetaxel →" exact="trastuzumab" post="• HR 0.86, p = 0.41 • 77.9% versus"/>
   <result pre="51] FinHer trial ( ǂ) 232/5.1 years • Docetaxel or" exact="vinorelbine" post="→ FEC • Docetaxel or vinorelbine with trastuzumab →"/>
   <result pre="years • Docetaxel or vinorelbine → FEC • Docetaxel or" exact="vinorelbine" post="with trastuzumab → FEC • HR 0.65, p ="/>
   <result pre="Docetaxel or vinorelbine → FEC • Docetaxel or vinorelbine with" exact="trastuzumab" post="→ FEC • HR 0.65, p = 0.12 •"/>
   <result pre="chemotherapy and trastuzumab. § Sequential chemotherapy and trastuzumab. FEC–fluorouracil plus" exact="epirubicin" post="plus cyclophosphamide. AC–Doxorubicin plus cyclophosphamide. NR–not reported. NA–not applicable."/>
   <result pre="patients. Table 2. Summary of results from major trials addressing" exact="trastuzumab" post="benefit in the neoadjuvant treatment of BC. Study Number"/>
   <result pre="study 235 • CT (including combinations of doxorubicin, paclitaxel, cyclophosphamide," exact="methotrexate" post="and 5—fluorouracil) • CT + T 19 (NR) 38"/>
   <result pre="Untch et al (2010) [ 20] Trastuzumab versus or plus" exact="lapatinib" post="GeparQuinto 620 • EC + T → D +"/>
   <result pre="Holmes et al (2011) [ 56] Trastuzumab versus or plus" exact="pertuzumab" post="NeoSphere 417 NA • T + D • T"/>
   <result pre="plus cyclophosphamide; Cap–Capecitabine; C–Chemotherapy; D–Docetaxel; EC–Epirubicin plus cyclophosphamide; FEC–fluorouracil plus" exact="epirubicin" post="plus cyclophosphamide; L–Lapatinib; LHRHa–Luteinising Hormone Releasing Hormone agonist; NA–not"/>
   <result pre="overall survival (lack of proportional hazards) Table 4. Summary of" exact="pertuzumab" post="and trastuzumab emtansine (T-DM1) (neo)adjuvant phase III studies. Study"/>
   <result pre="(lack of proportional hazards) Table 4. Summary of pertuzumab and" exact="trastuzumab" post="emtansine (T-DM1) (neo)adjuvant phase III studies. Study Treatment setting"/>
   <result pre="Recruitment target and status APHINITY (NCT01358877) Adjuvant therapy Chemotherapy +" exact="pertuzumab" post="+ trastuzumab Chemotherapy + placebo + trastuzumab 4808; completed"/>
   <result pre="and status APHINITY (NCT01358877) Adjuvant therapy Chemotherapy + pertuzumab +" exact="trastuzumab" post="Chemotherapy + placebo + trastuzumab 4808; completed KATHERINE (NCT01772472)"/>
   <result pre="therapy Chemotherapy + pertuzumab + trastuzumab Chemotherapy + placebo +" exact="trastuzumab" post="4808; completed KATHERINE (NCT01772472) Adjuvant therapy post neoadjuvant therapy"/>
   <result pre="TDM1 Trastuzumab 1484; ongoing KAITLIN (NCT01966471) Adjuvant therapy TDM1 +" exact="pertuzumab" post="Trastuzumab + pertuzumab + taxane 2500; ongoing"/>
   <result pre="ongoing KAITLIN (NCT01966471) Adjuvant therapy TDM1 + pertuzumab Trastuzumab +" exact="pertuzumab" post="+ taxane 2500; ongoing"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4407294/results/search/inn/results.xml">
   <result pre="prognostic and predictive information to conventional biomarkers - estrogen receptor," exact="progesterone" post="receptor, and human epidermal growth factor receptor 2. Moreover,"/>
   <result pre="on the basis of the presence of estrogen receptor (ER)," exact="progesterone" post="receptor (PR), and HER2. At the molecular level, Perou"/>
   <result pre="HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; PR," exact="progesterone" post="receptor. In recent years, five novel gene expression prognostic"/>
   <result pre="studies with tumor specimens obtained from randomized clinical trials comparing" exact="tamoxifen" post="with or without chemotherapy [ 13]. The evaluation and"/>
   <result pre="for proliferation, luminal gene expression, estrogen receptor 1 ( ESR1)," exact="progesterone" post="receptor gene ( PGR), and HER2. Moreover, on the"/>
   <result pre="negative breast cancer (TNBC), and HR −/HER2 + who received" exact="trastuzumab" post="[ 15]. Interestingly, Glück and colleagues [ 16] investigated"/>
   <result pre="node-positive and -negative BC [ 10]. Prediction of benefit of" exact="tamoxifen" post="in pre-menopausal patients [ 9]. BC, breast cancer; CMF,"/>
   <result pre="the PI3K/AKT/mTOR and ER pathways. In particular, the mTOR inhibitor" exact="everolimus" post="(Afinitor) in combination with the aromatase inhibitor exemestane was"/>
   <result pre="mTOR inhibitor everolimus (Afinitor) in combination with the aromatase inhibitor" exact="exemestane" post="was shown to improve survival in patients with metastatic"/>
   <result pre="of a specific inhibitor of CDK 4/6 activity (palbociclib) to" exact="letrozole" post="compared with letrozole alone (20.2 versus 10.2 months). The"/>
   <result pre="inhibitor of CDK 4/6 activity (palbociclib) to letrozole compared with" exact="letrozole" post="alone (20.2 versus 10.2 months). The overall survival (OS)"/>
   <result pre="but was not statistically significant [ 23]. On these bases," exact="palbociclib" post="and other CDK 4/6 inhibitors, including LEE011 and abemaciclib,"/>
   <result pre="modifying enzymes have been developed, and the FDA has approved" exact="azacitidine" post="and decitabine for high-risk myelodysplastic syndrome and two histone"/>
   <result pre="have been developed, and the FDA has approved azacitidine and" exact="decitabine" post="for high-risk myelodysplastic syndrome and two histone deacetylase (HDAC)"/>
   <result pre="of ER through the recruitment of DNMT3B. On this basis," exact="azacitidine" post="and valproic acid (HDAC inhibitor) have been investigated in"/>
   <result pre="through the recruitment of DNMT3B. On this basis, azacitidine and" exact="valproic acid" post="(HDAC inhibitor) have been investigated in this setting and"/>
   <result pre="to improve PFS and OS when given in combination with" exact="exemestane" post="in patients with ER-positive advanced BC resistant to previous"/>
   <result pre="including the PI3K/AKT/mTOR, RAS/RAF/MEK/MAPK, and STAT pathways. The development of" exact="trastuzumab" post="has significantly improved the prognosis of patients with HER2-positive"/>
   <result pre="develop resistance and progressive disease. Several mechanisms of resistance to" exact="trastuzumab" post="have been identified: impaired access to HER2 by expression"/>
   <result pre="In the last few years, several therapeutic strategies for overcoming" exact="trastuzumab" post="resistance have been developed, including lapatinib, pertuzumab, and trastuzumab-DM1"/>
   <result pre="to choose which HER2-targeted therapy should be preferred. For instance," exact="lapatinib" post="is a dual HER1 (EGFR) and HER2 tyrosine kinase"/>
   <result pre="receiving T-DM1. On the other hand, in the group receiving" exact="lapatinib" post="and capecitabine, HER2 mRNA was not demonstrated to influence"/>
   <result pre="heterodimerization of HER2 with other HER family. Neoadjuvant BC (with" exact="trastuzumab" post="and docetaxel in locally advanced, inflammatory, or early stage"/>
   <result pre="HER2 with other HER family. Neoadjuvant BC (with trastuzumab and" exact="docetaxel" post="in locally advanced, inflammatory, or early stage BC -either"/>
   <result pre="stage BC -either &amp;gt;2 cm or node-positive) Metastatic BC (with" exact="trastuzumab" post="and docetaxel for first-line therapy) T-DM1 2013 Trastuzumab-like activity."/>
   <result pre="-either &amp;gt;2 cm or node-positive) Metastatic BC (with trastuzumab and" exact="docetaxel" post="for first-line therapy) T-DM1 2013 Trastuzumab-like activity. Metastatic BC"/>
   <result pre="epidermal growth factor receptor 2. Other potential strategies for overcoming" exact="trastuzumab" post="resistance include PI3K/AKT/mTOR pathway inhibitors, HER2 vaccines, inhibitors of"/>
   <result pre="has emerged as an attractive approach in order to overcome" exact="trastuzumab" post="resistance. Hsp90 is a ubiquitous molecular chaperone fundamental for"/>
   <result pre="tumor response have been observed with tanespimycin in combination with" exact="trastuzumab" post="in patients progressing on trastuzumab (NCT00773344) [ 32] and"/>
   <result pre="with tanespimycin in combination with trastuzumab in patients progressing on" exact="trastuzumab" post="(NCT00773344) [ 32] and more recently with single-agent ganetespib"/>
   <result pre="androgen blockade in this subgroup of patients [ 35]. Currently," exact="enzalutamide" post="and abiraterone are also under evaluation in phase II"/>
   <result pre="in this subgroup of patients [ 35]. Currently, enzalutamide and" exact="abiraterone" post="are also under evaluation in phase II studies in"/>
   <result pre="involvement of the immune system has been confirmed even in" exact="trastuzumab" post="antitumor activity. Recent evidence has demonstrated that TIL could"/>
   <result pre="subtype classifier for prognosis and prediction of benefit from adjuvant" exact="tamoxifen" post="Clin Cancer Res. 2012 18 4465 72 10.1158/1078-0432.CCR-12-0286 22711706"/>
   <result pre="IM, Kulyk SO et al. The cyclin-dependent kinase 4/6 inhibitor" exact="palbociclib" post="in combination with letrozole versus letrozole alone as first-line"/>
   <result pre="al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with" exact="letrozole" post="versus letrozole alone as first-line treatment of oestrogen receptor-positive,"/>
   <result pre="cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus" exact="letrozole" post="alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced"/>
   <result pre="PM et al. Randomized phase II, double-blind, placebo-controlled study of" exact="exemestane" post="with or without entinostat in postmenopausal women with locally"/>
   <result pre="(BM) and efficacy in EMILIA, a phase III study of" exact="trastuzumab" post="emtansine (TDM1) in HER2-positive metastatic breast cancer (MBC) [abstract]."/>
   <result pre="breast cancer: a phase II trial of tanespimycin (17-AAG) plus" exact="trastuzumab" post="in patients with HER2-positive metastatic breast cancer progressing on"/>
   <result pre="trastuzumab in patients with HER2-positive metastatic breast cancer progressing on" exact="trastuzumab" post="Clin Cancer Res. 2011 17 5132 9 10.1158/1078-0432.CCR-11-0072 21558407"/>
   <result pre="Liu MC Carey LA et al. Phase II trial of" exact="bicalutamide" post="in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast"/>
   <result pre="are prognostic in triple negative breast cancer and predictive for" exact="trastuzumab" post="benefit in early breast cancer: results from the FinHER"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4411474/results/search/inn/results.xml">
   <result pre="ΙΙΙA. She was treated with the combination of anthracycline and" exact="cyclophosphamide" post="for four courses, followed by four courses of paclitaxel"/>
   <result pre="and cyclophosphamide for four courses, followed by four courses of" exact="paclitaxel" post="with trastuzumab for one year. After 18 months of"/>
   <result pre="for four courses, followed by four courses of paclitaxel with" exact="trastuzumab" post="for one year. After 18 months of the first"/>
   <result pre="her therapy was started with the combination of anthracycline and" exact="cyclophosphamide" post="for four courses, followed by four courses of paclitaxel"/>
   <result pre="and cyclophosphamide for four courses, followed by four courses of" exact="paclitaxel" post="with trastuzumab for one year (17 courses of trastuzumab)."/>
   <result pre="for four courses, followed by four courses of paclitaxel with" exact="trastuzumab" post="for one year (17 courses of trastuzumab). Due to"/>
   <result pre="of AML has been especially reported for treated cases with" exact="cyclophosphamide" post="and anthracyclines and paclitaxel. In majority of these cases,"/>
   <result pre="case of Her-2 positive breast cancer and so treated with" exact="trastuzumab" post="for one year + irradiation on site of surgery"/>
   <result pre="of surgery and left axillary area and also treated with" exact="cyclophosphamide" post="and anthracyclines and paclitaxel. Adjuvant chemotherapy for breast cancer"/>
   <result pre="such as AML. As indicated in table 1, irradiation and" exact="cyclophosphamide" post="appear to be suspects of secondary AML incidence. Since"/>
   <result pre="cyclophosphamide appear to be suspects of secondary AML incidence. Since" exact="paclitaxel" post="is by itself leukemogenic, its effect may be augmented"/>
   <result pre="is by itself leukemogenic, its effect may be augmented by" exact="carboplatin" post="(REF). The interval between the alkylating agent exposure and"/>
   <result pre="a strongly possibility that addition of paclitaxel-therapy to irradiation and" exact="cyclophosphamide" post="will reduce interval period between two malignancies (breast cancer"/>
   <result pre="M Therapy-related acute myeloid leukemia with 11q23 abnormality due to" exact="paclitaxel" post="coexisting with bone marrow metastasis of breast cancer. Rinsho"/>
   <result pre="6 19352087 20 Arends J Urger C Excellent response to" exact="gemcitabine" post="in a massively pre-treated woman with extensive cutaneous involvement"/>
   <result pre="two malignancies 8 M2 56 ~53 cyclophosphamide, methothrexate, fluorouracil, radiation," exact="tamoxifene" post="The present study M2 37 18 anthracycline , cyclophosphamide,"/>
   <result pre="10 M2 44 28 docetaxel, doxorubicin, cyclophosphamide, lapatinib, radiotherapy, herceptin," exact="tamoxifen" post="11 M2 42 48 epirubicin, paclitaxel, cyclophosphamide, 5-fluorouracil, radiation"/>
   <result pre="11 M2 42 48 epirubicin, paclitaxel, cyclophosphamide, 5-fluorouracil, radiation therapy," exact="tamoxifene" post="12 M3 51 71 doxorubicin, cyclophosphamide, docetaxel, leuprorelin, tamoxifen,"/>
   <result pre="radiation therapy with (89) Sr injection 13 M3 36 24" exact="medroxyprogesterone" post="acetate, tamoxifen, radiotherapy 14 M3 43 9 - 15"/>
   <result pre="M3 43 9 - 15 M3 69 10 cyclophosphamide, doxorubicin," exact="paclitaxel" post="16 M5 56 36 radical mastectomy, radiotherapy, adriamycin, cyclophosphamide,"/>
   <result pre="50 48 alkylating agents, antitumor antibiotics, vincristine, etoposide, teniposide, Paclitaxel," exact="gemcitabine" post=""/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4413633/results/search/inn/results.xml">
   <result pre="cells with a pcMV6-TXNIP-expressing vector, and treated them with 0.5μM" exact="lapatinib" post="for 48 h. We found that TXNIP expression inhibited"/>
   <result pre="inhibited cell proliferation both in the presence and absence of" exact="lapatinib" post="(Figure 2D). Taken together, our results suggest that TXNIP"/>
   <result pre="SK-BR-3 cells. (D) Transfected cells were treated with 0.5 μM" exact="lapatinib" post="for 48 h, cell numbers were counted and cell"/>
   <result pre="SK-BR-3 cells were treated with 10 μg/ml cetuximab, 20 μg/ml" exact="trastuzumab" post="or 0.5 μM lapatinib. TXNIP and p27 mRNA levels"/>
   <result pre="blot analysis. As shown in Figure 3A and B, cetuximab," exact="trastuzumab" post="and lapatinib treatment induced TXNIP and p27 expression in"/>
   <result pre="As shown in Figure 3A and B, cetuximab, trastuzumab and" exact="lapatinib" post="treatment induced TXNIP and p27 expression in BT474 and"/>
   <result pre="expression in BT474 and SK-BR-3 cells at varying levels with" exact="lapatinib" post="causing the most significantly upregulation of TXNIP and p27"/>
   <result pre="and B) After treatment with 10 μg/ml cetuximab, 20 μg/ml" exact="trastuzumab" post="or 0.5 μM lapatinib, TXNIP and p27 protein and"/>
   <result pre="and SK-BR-3 cells along with 10 μg/ml cetuximab, 20 μg/ml" exact="trastuzumab" post="or 0.5 μM lapatinib. Cells were assayed 24 h"/>
   <result pre="expression [ 12]. As previously observed, the dual Her-1/2 inhibitor" exact="lapatinib" post="regulates p27 expression at the transcriptional as well as"/>
   <result pre="the post-translational level [ 9]. Meanwhile, we showed that cetuximab," exact="trastuzumab" post="and lapatinib treatment led to increased TXNIP and p27"/>
   <result pre="level [ 9]. Meanwhile, we showed that cetuximab, trastuzumab and" exact="lapatinib" post="treatment led to increased TXNIP and p27 expression in"/>
   <result pre="glucose deprivation and energetic stress [ 16]. Accordingly, treatment with" exact="lapatinib" post="is associated with increased expression of glucose deprivation response"/>
   <result pre="with the anti-Her-1 monoclonal antibody cetuximab, the anti-Her-2 monoclonal antibody" exact="trastuzumab" post="or the dual Her-1/2 inhibitor lapatinib, TXNIP mRNA and"/>
   <result pre="with 5% CO 2. Cetuximab (Erbitux; MerckKGaA, Darmstadt, Germany) and" exact="trastuzumab" post="(Herceptin, F. Hoffmann-La Roche, Basel, Switzerland) were dissolved in"/>
   <result pre="(Tykerb, GlaxoSmithKline, Research Triangle Park, NJ, USA) was dissolved in" exact="dimethyl sulfoxide" post="(dimethyl sulfoxide as a stock solution at 10mM) and"/>
   <result pre="stored at −20°C. BT474 and SK-BR-3 cells were treated with" exact="cetuximab" post="and trastuzumab at a final concentration of 10 μg/ml"/>
   <result pre="−20°C. BT474 and SK-BR-3 cells were treated with cetuximab and" exact="trastuzumab" post="at a final concentration of 10 μg/ml and 20"/>
   <result pre="culture medium, respectively. BT474 and SK-BR-3 cells were treated with" exact="lapatinib" post="at a final concentration of 0.5 μM in the"/>
   <result pre="well. After 14 days, the colonies were fixed with 70%" exact="ethanol" post="and stained with 0.1% crystal violet. Colonies larger than"/>
   <result pre="were transfected with pcMV6-vector TXNIP. The effects of 0.5 μM" exact="lapatinib" post="on cell proliferation were measured 48 h following initial"/>
   <result pre="thioredoxin-interacting protein expression differs in breast cancer-derived cells and regulates" exact="paclitaxel" post="IC50 Clinical cancer research : an official journal of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4423419/results/search/inn/results.xml">
   <result pre="HER2 extracellular domain. In resource-limited countries or populations, access to" exact="trastuzumab" post="is often limited by economic or logistic conditions ["/>
   <result pre="setting of having received chemotherapy +/− endocrine therapy but not" exact="trastuzumab" post="have not been fully described. We report here the"/>
   <result pre="are included in this analysis. Patients were randomized to oral" exact="lapatinib" post="or placebo, daily for 12 months or until disease"/>
   <result pre="( N = 699) had hormone receptor positive (HR+, estrogen (ER) and/or" exact="progesterone" post="receptor (PR)-positive) disease, and 44.5% ( N = 561) HR-negative disease"/>
   <result pre="chemotherapy; HR+, hormone receptor positive; ER+, estrogen receptor positive; PR+," exact="progesterone" post="receptor positive; ER-, estrogen receptor negative; HR-, hormone receptor"/>
   <result pre="positive; ER-, estrogen receptor negative; HR-, hormone receptor negative; PR-," exact="progesterone" post="receptor negative. In all centrally confirmed HER2+ placebo patients"/>
   <result pre="positive; HR-, hormone receptor negative; HR+, hormone receptor positive; PR-," exact="progesterone" post="receptor negative; PR+, progesterone receptor positive; TEACH, Tykerb evaluation"/>
   <result pre="negative; HR+, hormone receptor positive; PR-, progesterone receptor negative; PR+," exact="progesterone" post="receptor positive; TEACH, Tykerb evaluation after chemotherapy. The time-dependent"/>
   <result pre="those at the highest risk. As the relative effect of" exact="trastuzumab" post="is similar in patients with HR+ and HR- disease"/>
   <result pre="disease [ 13- 15] the absolute benefit of treatment with" exact="trastuzumab" post="is based on a patient’s absolute baseline risk. Therefore,"/>
   <result pre="show that HER2+ HR- will derive higher absolute treatment benefits from" exact="trastuzumab" post="treatment. Many countries worldwide with limited resources currently opt"/>
   <result pre="worldwide with limited resources currently opt not to provide adjuvant" exact="trastuzumab" post="at all because of economic reasons. Irrespective of the"/>
   <result pre="represented in this analysis, as, similar to the large adjuvant" exact="trastuzumab" post="trials [ 13, 18, 19], patients with small, low-risk"/>
   <result pre="novel interventions being considered. Based on the adjuvant data of" exact="trastuzumab" post="in HER2+ early BC, health care providers should strive"/>
   <result pre="early BC, health care providers should strive to ultimately provide" exact="trastuzumab" post="to all eligible patients. However, in health care settings"/>
   <result pre="positive HR+ hormone receptor positive HR- hormone receptor negative PR+" exact="progesterone" post="receptor positive PR- progesterone receptor negative TEACH Tykerb evaluation"/>
   <result pre="positive HR- hormone receptor negative PR+ progesterone receptor positive PR-" exact="progesterone" post="receptor negative TEACH Tykerb evaluation after chemotherapy Competing interests"/>
   <result pre="Afonso SL Stefano EJ De Fendi LI Soares FV Adjuvant" exact="trastuzumab" post="in the treatment of her-2-positive early breast cancer: a"/>
   <result pre="J Ejlertsen B Kaufmann M Boyle F et al. Adjuvant" exact="lapatinib" post="for women with early-stage HER2-positive breast cancer: a randomised,"/>
   <result pre="Hormone receptor status does not affect the clinical benefit of" exact="trastuzumab" post="therapy for patients with metastatic breast cancer Clin Breast"/>
   <result pre="EA, Rastogi P, Spielmann M, et al. Efficacy of adjuvant" exact="trastuzumab" post="compared with no trastuzumab for patients with HER2-positive breast"/>
   <result pre="M, et al. Efficacy of adjuvant trastuzumab compared with no" exact="trastuzumab" post="for patients with HER2-positive breast cancer and tumors ≤2"/>
   <result pre="cancer and tumors ≤2 cm: a meta-analysis of the randomized" exact="trastuzumab" post="trials. J Clin Oncol. 2014; 32:abstr 508. 16. Dressler"/>
   <result pre="Edgerton S Cowan D et al. HER2 and response to" exact="paclitaxel" post="in node-positive breast cancer N Engl J Med 2007"/>
   <result pre="analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without" exact="trastuzumab" post="in patients with HER2-positive breast cancer Proc Am Soc"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4424224/results/search/inn/results.xml">
   <result pre="study, positron emission tomography (PET) scanning after administration of radiolabelled" exact="lapatinib" post="was used to obtain direct evidence of cranial drug"/>
   <result pre="brain metastasis or without brain metastases underwent dynamic carbon-11 radiolabelled" exact="lapatinib" post="([ 11C]lapatinib)-PET. Less than 20 μg of [ 11C]lapatinib"/>
   <result pre="11C]lapatinib was administered before and after 8 days of oral" exact="lapatinib" post="(1,500 mg once daily). Radial arterial blood sampling was"/>
   <result pre="volume activity to the tissue signal was excluded to calculate" exact="lapatinib" post="uptake in normal brain and metastases. Partitioning of radioactivity"/>
   <result pre="( V T) was calculated and the tissue concentration of" exact="lapatinib" post="derived. Plasma lapatinib levels were measured and adverse events"/>
   <result pre="was calculated and the tissue concentration of lapatinib derived. Plasma" exact="lapatinib" post="levels were measured and adverse events noted. Results Six"/>
   <result pre="11C]lapatinib uptake in brain metastases. There was no difference in" exact="lapatinib" post="uptake between the baseline and day 8 scans, suggesting"/>
   <result pre="drug efflux proteins by therapeutic doses of lapatinib. Conclusions Increased" exact="lapatinib" post="uptake was observed in brain metastases but not in"/>
   <result pre="in contrast to the large monoclonal antibodies, the small molecule" exact="lapatinib" post="(Tykerb/Tyverb; GlaxoSmithKline, Brentford, UK; molecular weight: 581.07), an oral"/>
   <result pre="and Her-2 inhibitor, may cross the BBB. In addition, since" exact="lapatinib" post="is a P-glycoprotein (Pgp) and breast cancer resistance protein"/>
   <result pre="and breast cancer resistance protein (BCRP) substrate, therapeutic doses of" exact="lapatinib" post="may inhibit drug efflux by blocking Pgp/BCRP [ 4],"/>
   <result pre="the brain through an intact BBB. In order to evaluate" exact="lapatinib" post="access into normal brain and brain metastases, a positron"/>
   <result pre="positron emission tomography (PET) study was performed with carbon-11 radiolabelled" exact="lapatinib" post="([ 11C]lapatinib) in patients with Her-2-positive breast cancer. Further,"/>
   <result pre="in order to test our hypothesis that therapeutic doses of" exact="lapatinib" post="increase brain access into the brain and brain metastases,"/>
   <result pre="11C]lapatinib-PET imaging in patients before and after therapeutic doses of" exact="lapatinib" post="was performed. A schematic representation of our study hypothesis"/>
   <result pre="in normal brain would increase with therapeutic serum concentrations of" exact="lapatinib" post="due to the effect of lapatinib on drug efflux"/>
   <result pre="therapeutic serum concentrations of lapatinib due to the effect of" exact="lapatinib" post="on drug efflux pumps. Higher brain penetration in metastases"/>
   <result pre="previous radiotherapy or chemotherapy, respectively. Up to 1.5 mg of" exact="dexamethasone" post="was allowed whilst patients were on the imaging part"/>
   <result pre="and (ii) after 7 days of 1,500 mg of oral" exact="lapatinib" post="daily, starting on day 1 after completion of the"/>
   <result pre="8 PET scan started at 3 h post-dosing of oral" exact="lapatinib" post="to coincide with the known maximal plasma lapatinib level"/>
   <result pre="of oral lapatinib to coincide with the known maximal plasma" exact="lapatinib" post="level ( C max). Approval was obtained from the"/>
   <result pre="accommodate the [ 11C]lapatinib-PET scans, both the subjects started their" exact="lapatinib" post="therapy on time, as planned. Table 1 Patient demographics"/>
   <result pre="3-fluorophenylmagnesium bromide in tetrahydrofuran. The resulting acid was reduced with" exact="lithium" post="aluminium hydride, followed by iodination reaction in the presence"/>
   <result pre="intermediately purified by solid-phase extraction, before being reacted with the" exact="lapatinib" post="precursor in dimethylformamide in the presence of caesium carbonate."/>
   <result pre="Fully automated and good manufacturing process-compatible synthesis developed to label" exact="lapatinib" post="with radiolabelled carbon-11 in the benzylic position. [ 11C]Lapatinib"/>
   <result pre="iodide that was reacted in the last step with the" exact="lapatinib" post="precursor. 11C, carbon-11. PET scanning procedure and blood sampling"/>
   <result pre="hourly blood samples from 1 to 6 h after oral" exact="lapatinib" post="dosing were assessed on the day 8 scan. Radiation"/>
   <result pre="hospital treatment by their oncologist which in most instances was" exact="lapatinib" post="and capecitabine. Adverse events (AEs) were noted starting from"/>
   <result pre="curve to generate the required plasma parent input function. Plasma" exact="lapatinib" post="on day 8 Pharmacokinetic parameters were variable, spanning a"/>
   <result pre="bars) compared to day 8 (green bars). Minimal variability in" exact="lapatinib" post="uptake is seen in normal brain between subjects. AUC,"/>
   <result pre="between baseline and day 8 scans. Therefore, assuming equilibrium conditions," exact="lapatinib" post="concentrations in metastases between 300 and 2,000 ng/mL (0.52"/>
   <result pre="estimated by multiplying the PET V T by the plasma" exact="lapatinib" post="concentration on day 8. [ 11C]lapatinib uptake in other"/>
   <result pre="study, we have clearly demonstrated that there is uptake of" exact="lapatinib" post="in brain metastases that cannot be attributed to blood"/>
   <result pre="Morikawa et al . which showed a 60-fold variability of" exact="lapatinib" post="uptake (1 to 63 μM) in resected brain metastases"/>
   <result pre="μM) in resected brain metastases of four patients after oral" exact="lapatinib" post="[ 9]. Although the sevenfold variability (300 to 2,000"/>
   <result pre="metastases sampled, adequate fitting of kinetic models was obtained. Nevertheless," exact="lapatinib" post="concentrations in brain metastases in our study were comparable"/>
   <result pre="lines (0.025 to 5 μM) [ 4]. However, the variable" exact="lapatinib" post="uptake in metastases demonstrates the challenge posed by tumour"/>
   <result pre="to Morikawa et al., we were also able to evaluate" exact="lapatinib" post="uptake in normal brain and observed a consistent lack"/>
   <result pre="uptake in normal brain and observed a consistent lack of" exact="lapatinib" post="uptake in normal brain, in patients with and without"/>
   <result pre="to brain tissue uptake. Our hypothesis that therapeutic levels of" exact="lapatinib" post="[ 4] may increase lapatinib brain uptake by acting"/>
   <result pre="hypothesis that therapeutic levels of lapatinib [ 4] may increase" exact="lapatinib" post="brain uptake by acting as a substrate for drug"/>
   <result pre="brain and metastases. This would imply that the utility of" exact="lapatinib" post="as prophylactic therapy that aimed to exploit the study"/>
   <result pre="it is not possible (nor did we aim) to investigate" exact="lapatinib" post="access into normal brain in combination with other cytotoxic"/>
   <result pre="relative to areas of no uptake, we have established that" exact="lapatinib" post="uptake in brain metastases is mainly a result of"/>
   <result pre="normal brain was very minimal even at higher doses of" exact="lapatinib" post="suggesting that higher doses of lapatinib were unable to"/>
   <result pre="at higher doses of lapatinib suggesting that higher doses of" exact="lapatinib" post="were unable to block the drug efflux mechanisms, as"/>
   <result pre="breast cancer and is an unmet need [ 2]. Although" exact="lapatinib" post="and capecitabine in combination demonstrated activity in patients with"/>
   <result pre="and is an unmet need [ 2]. Although lapatinib and" exact="capecitabine" post="in combination demonstrated activity in patients with previously untreated"/>
   <result pre="study was unable to demonstrate the lack of superiority for" exact="lapatinib" post="over trastuzumab in the prevention of brain metastases ["/>
   <result pre="unable to demonstrate the lack of superiority for lapatinib over" exact="trastuzumab" post="in the prevention of brain metastases [ 16]. Therefore,"/>
   <result pre="metastases. PET scans were done after administration of carbon-11 radiolabelled" exact="lapatinib" post="to investigate intracranial lapatinib access. Lapatinib uptake was observed"/>
   <result pre="done after administration of carbon-11 radiolabelled lapatinib to investigate intracranial" exact="lapatinib" post="access. Lapatinib uptake was observed in brain metastasis, but"/>
   <result pre="in brain metastasis, but not in normal brain, suggesting that" exact="lapatinib" post="may have a role in the treatment of brain"/>
   <result pre="al. Phase I safety, pharmacokinetics, and clinical activity study of" exact="lapatinib" post="(GW572016), a reversible dual inhibitor of epidermal growth factor"/>
   <result pre="Samala R Balyan R Murphy CG et al. Capecitabine and" exact="lapatinib" post="uptake in surgically resected brain metastases from metastatic breast"/>
   <result pre="C Stemmler HJ et al. Multicenter phase II study of" exact="lapatinib" post="in patients with brain metastases from HER2-positive breast cancer"/>
   <result pre="Dieras V Cropet C Dalenc F et al. Lapatinib plus" exact="capecitabine" post="in patients with previously untreated brain metastases from HER2-positive"/>
   <result pre="Rubin SD Galvez-Peralta M Friedman R et al. Evaluation of" exact="lapatinib" post="and topotecan combination therapy: tissue culture, murine xenograft, and"/>
   <result pre="Galvez-Peralta M Friedman R et al. Evaluation of lapatinib and" exact="topotecan" post="combination therapy: tissue culture, murine xenograft, and phase I"/>
   <result pre="the central nervous system penetration of the tyrosine kinase inhibitor" exact="lapatinib" post="(N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016) Drug Metab Dispos 2009 37 2 439"/>
   <result pre="al. CEREBEL (EGF111438): a phase III, randomized, open-label study of" exact="lapatinib" post="plus capecitabine versus trastuzumab plus capecitabine in patients with"/>
   <result pre="(EGF111438): a phase III, randomized, open-label study of lapatinib plus" exact="capecitabine" post="versus trastuzumab plus capecitabine in patients with human epidermal"/>
   <result pre="phase III, randomized, open-label study of lapatinib plus capecitabine versus" exact="trastuzumab" post="plus capecitabine in patients with human epidermal growth factor"/>
   <result pre="randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus" exact="capecitabine" post="in patients with human epidermal growth factor receptor 2-positive"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4427936/results/search/inn/results.xml">
   <result pre="reduce the risk of cardiotoxicity: 1) The concomitant administration of" exact="dexrazoxane" post="with anthracylines; 2) The avoidance of anthracyclines where possible;"/>
   <result pre="dosing; and 4) The administration of anthracycline derivatives such as" exact="epirubicin" post="or liposomal-encapsulated doxorubicin instead of doxorubicin. In terms of"/>
   <result pre="The administration of anthracycline derivatives such as epirubicin or liposomal-encapsulated" exact="doxorubicin" post="instead of doxorubicin. In terms of management, one review"/>
   <result pre="chemotherapy agents include 0.14–48 % for anthracyclines (estimated risk for" exact="doxorubicin" post="dose &amp;gt; 400 mg/m [ 2] ranges from 0.14 % to"/>
   <result pre="cTnT • C-TnT can be used to assess cardioprotection using" exact="dexrazoxane" post="n 7 I: Cardiac markers • Published from 1983"/>
   <result pre="P: Cancer patients • 8 controlled trials • Doxorubicin vs" exact="epirubicin" post="• No difference in rate of clinical heart failure"/>
   <result pre="• No difference in rate of clinical heart failure between" exact="epirubicin" post="and doxorubicin (RR = 0.36; 95 % CI ="/>
   <result pre="difference in rate of clinical heart failure between epirubicin and" exact="doxorubicin" post="(RR = 0.36; 95 % CI = 0.12–1.11) y"/>
   <result pre="• Published from 1984 to 2004 • Doxorubicin vs liposomal-encapsulated" exact="doxorubicin" post="• Lower rate of clinical heart failure (RR ="/>
   <result pre="0.38, 95 % CI 0.24 to 0.59) associated with liposomal-encapsulated" exact="doxorubicin" post="compared with doxorubicin. C: Another anthracycline with the same"/>
   <result pre="ranged from 21 to 41 months • Epirubicin vs liposomal-encapsulated" exact="doxorubicin" post="• No significant difference in the occurrence of clinical"/>
   <result pre="in the occurrence of clinical and subclinical heart failure between" exact="epirubicin" post="and liposomal-encapsulated doxorubicin (RR = 1.13, 95 % CI"/>
   <result pre="of clinical and subclinical heart failure between epirubicin and liposomal-encapsulated" exact="doxorubicin" post="(RR = 1.13, 95 % CI 0.46 to 2.77,"/>
   <result pre="P: Cancer patients • 18 controlled trials • N-acetylcysteine Only" exact="dexrazoxane" post="showed a statistically significant cardioprotective effect (Heart failure RR"/>
   <result pre="in cardiac function determined using a diagnostic test) • Liposomal" exact="doxorubicin" post="vs doxorubicin (OR = 0.18; 95 % CI ="/>
   <result pre="function determined using a diagnostic test) • Liposomal doxorubicin vs" exact="doxorubicin" post="(OR = 0.18; 95 % CI = 0.08–0.38) •"/>
   <result pre="= 0.18; 95 % CI = 0.08–0.38) • Epirubicin vs" exact="doxorubicin" post="OR = 0.39 (95 % CI = 0.2–0.78) •"/>
   <result pre="= 0.39 (95 % CI = 0.2–0.78) • Anthracycline vs" exact="mitoxantrone" post="OR = 2.88 (95 % CI = 1.29–6.44) •"/>
   <result pre="2.88 (95 % CI = 1.29–6.44) • Dexrazoxane vs no" exact="dexrazoxane" post="OR = 0.21 (95 % CI = 0.13–0.33) •"/>
   <result pre="not reported • estramustine, • Similar rates of cardiotoxicity with" exact="estramustine" post="alone and medroxyprogesterone acetate plus epirubicin. C: Any comparison"/>
   <result pre="estramustine, • Similar rates of cardiotoxicity with estramustine alone and" exact="medroxyprogesterone" post="acetate plus epirubicin. C: Any comparison • 5-fluorouracil •"/>
   <result pre="Any comparison • 5-fluorouracil • Cardiotoxicity was less common with" exact="epirubicin" post="(11 %) than doxorubicin (48 %). O: Overall survival,"/>
   <result pre="• Cardiotoxicity was less common with epirubicin (11 %) than" exact="doxorubicin" post="(48 %). O: Overall survival, Disease-specific survival, PSA response,"/>
   <result pre="time to progression, pain response, toxicity, quality of life. •" exact="cyclophosphamide" post="• Doxorubicin combined with diethlystilbestrol was more cardiotoxic than"/>
   <result pre="cyclophosphamide • Doxorubicin combined with diethlystilbestrol was more cardiotoxic than" exact="doxorubicin" post="(7 % vs 1 %). • doxorubicin • mitoxantrone"/>
   <result pre="more cardiotoxic than doxorubicin (7 % vs 1 %). •" exact="doxorubicin" post="• mitoxantrone • docetaxel Prevention in children Bryant et"/>
   <result pre="than doxorubicin (7 % vs 1 %). • doxorubicin •" exact="mitoxantrone" post="• docetaxel Prevention in children Bryant et al. (2007)"/>
   <result pre="(7 % vs 1 %). • doxorubicin • mitoxantrone •" exact="docetaxel" post="Prevention in children Bryant et al. (2007) [ 35]"/>
   <result pre="a trial with 105 participants. • Fewer patients who received" exact="dexrazoxane" post="had elevations in troponin (21 % vs 50 %;"/>
   <result pre="Peak dose of anthracycline in one week = 25–90 mg/m2." exact="doxorubicin" post="treatment protocol was 300–420 mg/m2. O: survival Peak dose"/>
   <result pre="doxorubicin treatment protocol was 300–420 mg/m2. O: survival Peak dose" exact="doxorubicin" post="in 1 week 25–60 mg/m2 Tumour response cardiotoxicity Prevention"/>
   <result pre="that were all published in 2012. Anti-HER2 monotherapy (lapatinib or" exact="trastuzumab" post="or pertuzumab) • Pooled OR for CHF in patients"/>
   <result pre="• 5 RCT published in 2005 and 2006 Doxorubicin and" exact="cyclophosphamide" post="(AC) + paclitaxel (P). • Meta-analysis of 5 trials"/>
   <result pre="published in 2005 and 2006 Doxorubicin and cyclophosphamide (AC) +" exact="paclitaxel" post="(P). • Meta-analysis of 5 trials of adjuvant trastuzumab"/>
   <result pre="+ paclitaxel (P). • Meta-analysis of 5 trials of adjuvant" exact="trastuzumab" post="revealed a significant reduction in mortality (p &amp;lt; 0.00001),"/>
   <result pre="&amp;lt; 0.00001) and second tumours (p =0.007) compared with no" exact="trastuzumab" post="y 10 I: adjuvant trastuzumab • Length of follow-up"/>
   <result pre="(p =0.007) compared with no trastuzumab y 10 I: adjuvant" exact="trastuzumab" post="• Length of follow-up ranged from 9 to 60"/>
   <result pre="ranged from 9 to 60 months after randomisation Docetaxel or" exact="vinorelbine" post="+ fluorouracil, epirubicin and cyclophosphanide. • Increased cardiotoxicity including"/>
   <result pre="to 60 months after randomisation Docetaxel or vinorelbine + fluorouracil," exact="epirubicin" post="and cyclophosphanide. • Increased cardiotoxicity including symptomatic cardiac dysfunction"/>
   <result pre="including symptomatic cardiac dysfunction and asymptomatic decrease in LVEF with" exact="trastuzumab" post="compared to no trastuzumab C: any comparison Doxo, cyclo"/>
   <result pre="and asymptomatic decrease in LVEF with trastuzumab compared to no" exact="trastuzumab" post="C: any comparison Doxo, cyclo + trastuz. • The"/>
   <result pre="The likelihood of cardiac toxicity was 2.45 times higher for" exact="trastuzumab" post="compared with no trastuzumab (statistically significant heterogeneity) O: mortality,"/>
   <result pre="toxicity was 2.45 times higher for trastuzumab compared with no" exact="trastuzumab" post="(statistically significant heterogeneity) O: mortality, recurrance, metastases, second tumour"/>
   <result pre="mortality, recurrance, metastases, second tumour no breast cancer rate Docetaxel," exact="carboplatin" post="+ trastuz. Cardiac toxicity and brain metastases AC +"/>
   <result pre="follow-up was not reported in most trials • Comparison between" exact="mitoxantrone" post="and non-anti-tumour antibiotic regimen • Patients who received anthracyclines"/>
   <result pre="• The rate of cardiotoxicty was not reported in the" exact="mitoxantrone" post="comparison. Ferguson et al. 2007 [ 22] P: breast"/>
   <result pre="cardiotoxicity medical interventions • Phosphecreatine vs control treatment (vitamin C," exact="adenosine" post="tri-phosphate, vitamin E, oral co-enzyme Q10) Enalapril trial C:"/>
   <result pre="(RR 7.17, 95 % CI 1.71 to 30.17) associated with" exact="enalapril" post="• Higher occurrence of fatigue associated with enalapril (p"/>
   <result pre="associated with enalapril • Higher occurrence of fatigue associated with" exact="enalapril" post="(p = 0.013). Phosphocreatine trial • Length of follow-up"/>
   <result pre="patients treated with dual HER-2 blockade (pertuzumab plus trastuzumab, or" exact="trastuzumab" post="plus lapatanib) compared to monotherapy (lapatanib or trastuzumab or"/>
   <result pre="trastuzumab, or trastuzumab plus lapatanib) compared to monotherapy (lapatanib or" exact="trastuzumab" post="or pertuzumab) [ 24]. No statistically significant difference in"/>
   <result pre="second breast cancer systematic review focused on the anti-HER-2 medication" exact="trastuzumab" post="[ 23]. Meta-analysis indicated that the odds of developing"/>
   <result pre="were 2.45 times higher (95 % CI = 1.89–3.16) in subjects prescribed" exact="trastuzumab" post="[ 23]. However, overall mortality, recurrence and mortality rates"/>
   <result pre="different agents for which there were randomized controlled trials, only" exact="dexrazoxane" post="could be recommended for clinical practice [ 29]. Conflicting"/>
   <result pre="in the rate of cardiotoxicity as a result of different" exact="doxorubicin" post="peak doses [ 31]. A recently published review (2013)"/>
   <result pre="were included in this review. The two interventions tested were" exact="enalapril" post="and phosphocreatine. While the participants who received enalapril were"/>
   <result pre="tested were enalapril and phosphocreatine. While the participants who received" exact="enalapril" post="were less likely to experience decline in cardiac function,"/>
   <result pre="was not statistically significant ( p &amp;lt; 0.5). Moreover, participants who received" exact="enalapril" post="were more likely to experience hypotension, dizziness and fatigue."/>
   <result pre="reduce the risk of cardiotoxicity: 1) The concomitant administration of" exact="dexrazoxane" post="with anthracylines; 2) The administration of continuous anthracyclines, preferably"/>
   <result pre="dosing; and 3) The administration of anthracycline derivatives such as" exact="epirubicin" post="or liposomal-encapsulated doxorubicin instead of doxorubicin. In this context,"/>
   <result pre="The administration of anthracycline derivatives such as epirubicin or liposomal-encapsulated" exact="doxorubicin" post="instead of doxorubicin. In this context, it should be"/>
   <result pre="doxorubicin. In this context, it should be noted that while" exact="dexrazoxane" post="is listed in the relevant pharmaceutical benefits scheme in"/>
   <result pre="where cardiac risk before therapy is known), the use of" exact="doxorubicin" post="derivatives, a longer anthracycline infusion duration and concomitant administration"/>
   <result pre="Kerkela R et al. Cardiotoxicity associated with tyrosine kinase inhibitor" exact="sunitinib" post="Lancet 2007 370 2011 9 10.1016/S0140-6736(07)61865-0 18083403 11. Hutson"/>
   <result pre="Afonso SL Stefano EJ De Fendi LI Soares FV Adjuvant" exact="trastuzumab" post="in the treatment of her-2-positive early breast cancer: a"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4436450/results/search/inn/results.xml">
   <result pre="[ 2– 6]. A high prevalence of hypersensitivity reactions to" exact="cetuximab" post="have been reported in some areas of the United"/>
   <result pre="who had a hypersensitivity reaction to cetuximab, IgE antibodies against" exact="cetuximab" post="were present in serum before therapy [ 7– 10]."/>
   <result pre="α-1,3-galactose, which is present on the Fab portion of the" exact="cetuximab" post="heavy chain. The presence of such antibodies is predictive"/>
   <result pre="would help in minimizing the risk of anaphylaxis associated with" exact="cetuximab" post="[ 11]. 2.1. Standard Infusion Reactions (SIR) Nearly all"/>
   <result pre="10 and 30% occur during subsequent treatments. Rituximab, obinutuzumab, and" exact="trastuzumab" post="induce the highest incidence of SIR. In general, the"/>
   <result pre="the incidence of MoAb induced IR varies from 15–20% for" exact="cetuximab" post="(3% grade 3/4) and 40% for trastuzumab first infusion"/>
   <result pre="from 15–20% for cetuximab (3% grade 3/4) and 40% for" exact="trastuzumab" post="first infusion (&amp;lt;1% grade 3/4) to 77% for rituximab"/>
   <result pre="for trastuzumab first infusion (&amp;lt;1% grade 3/4) to 77% for" exact="rituximab" post="first infusion (10% grade 3/4). Infusion reactions are markedly"/>
   <result pre="respectively. The incidence of IR to the humanized MoAbs bevacizumab," exact="panitumumab" post="and nimotuzumabis is significantly lower at &amp;lt;3% (0.2% grade"/>
   <result pre="to each infusion of ramucirumab. Pharmacologic prophylaxis with antihistamines and" exact="acetaminophen" post="with or without a glucocorticoid is suggested for high-risk"/>
   <result pre="is suggested for high-risk agents (i.e., rituximab, first infusion of" exact="cetuximab" post="in a patient who resides in a high-risk area"/>
   <result pre="and mentation should rapidly occur. IV administration of 50 mg of" exact="diphenhydramine" post="and 650 mg of acetaminophen may provide symptomatic relief. Once"/>
   <result pre="occur. IV administration of 50 mg of diphenhydramine and 650 mg of" exact="acetaminophen" post="may provide symptomatic relief. Once symptoms have resolved, resumption"/>
   <result pre="be addressed. Patients with severe infusion reaction or anaphylaxis to" exact="cetuximab" post="can be safely switched to pannitumumab. The decision to"/>
   <result pre="third or fourth dose. The incidence of hypophysitis due to" exact="ipilimumab" post="has been reported to range from 0 to 17%"/>
   <result pre="TSH and free T4 and monitoring every 3 weeks during" exact="ipilimumab" post="treatment and every 2-3 months following completion. For patients"/>
   <result pre="patients with severe or life-threatening grade 3/4 AEs, treatment with" exact="ipilimumab" post="should be permanently discontinued and high doses of corticosteroids"/>
   <result pre="receive thyroid-blocking medications beginning at least 24 hours prior to" exact="tositumomab" post="and continued for 2 weeks after the therapeutic dose."/>
   <result pre="with specific MoAbs, including bevacizumab, trastuzumab, trastuzumabemtansine, pertuzumab, ofatumumab, and" exact="rituximab" post="[ 5, 22, 38, 45, 68, 69]. 4.1. Hypertension"/>
   <result pre="vascular homeostasis via mediation of the production of the vasodilator" exact="nitric oxide" post="and decrease of vascular resistance through the generation of"/>
   <result pre="antitumor activity [ 73]. The incidence rate of hypertension for" exact="ramucirumab" post="was lower than bevacizumab (all grades: 6%; grades 3/4:"/>
   <result pre="The incidence rate of hypertension for ramucirumab was lower than" exact="bevacizumab" post="(all grades: 6%; grades 3/4: 8%) [ 74]. 4.2."/>
   <result pre="thromboembolic events (ATEs) has been linked to the use of" exact="bevacizumab" post="and ramucirumab [ 23, 24, 28, 75]. The overall"/>
   <result pre="(ATEs) has been linked to the use of bevacizumab and" exact="ramucirumab" post="[ 23, 24, 28, 75]. The overall incidence of"/>
   <result pre="analysis of 1,745 patients, of whom 963 were treated with" exact="bevacizumab" post="(24% breast cancer), the incidence of thromboembolic events was"/>
   <result pre="incidence of thromboembolic events was 4% in patients treated with" exact="bevacizumab" post="plus chemotherapy, and 2% in those treated with chemotherapy"/>
   <result pre="incidence of high-grade CHF was 1.6% in patients treated with" exact="bevacizumab" post="and 0.4% in patients who did not receive this"/>
   <result pre="in LVEF occurred in 14% of patients, requiring discontinuation of" exact="trastuzumab" post="[ 22]. Endomyocardial biopsy was performed in a limited"/>
   <result pre="was performed in a limited number of patients exposed to" exact="trastuzumab" post="and demonstrated no significant abnormalities [ 31]. The incidence"/>
   <result pre="abnormalities [ 31]. The incidence of severe CHF in the" exact="trastuzumab" post="adjuvant studies is in the range of 1% to"/>
   <result pre="of median followup, all cases of severe CHF occurred during" exact="trastuzumab" post="treatment; however, the cardiac performance of the majority of"/>
   <result pre="cardiac performance of the majority of affected patients improved when" exact="trastuzumab" post="was withdrawn [ 32]. The incidence of CHF in"/>
   <result pre="32]. The incidence of CHF in older patients treated with" exact="trastuzumab" post="is expected to be higher than in the overall"/>
   <result pre="strategy to optimize the targeted treatment of breast cancer. The" exact="bevacizumab" post="plus trastuzumab combination was evaluated in 50 heavily pretreated"/>
   <result pre="optimize the targeted treatment of breast cancer. The bevacizumab plus" exact="trastuzumab" post="combination was evaluated in 50 heavily pretreated metastatic breast"/>
   <result pre="pertuzumab, cardiac dysfunction was seen in 4.5–14.5% of patients with" exact="pertuzumab" post="treatment and cardiac dysfunction was usually grade 1/2 ["/>
   <result pre="cardiac dysfunction was usually grade 1/2 [ 39]. Cardiotoxicity of" exact="pertuzumab" post="was usually reported in combination with trastuzumab and no"/>
   <result pre="39]. Cardiotoxicity of pertuzumab was usually reported in combination with" exact="trastuzumab" post="and no additive cardiotoxicity was reported with addition of"/>
   <result pre="trastuzumab and no additive cardiotoxicity was reported with addition of" exact="pertuzumab" post="to trastuzumab [ 38]. A phase II study evaluated"/>
   <result pre="no additive cardiotoxicity was reported with addition of pertuzumab to" exact="trastuzumab" post="[ 38]. A phase II study evaluated trastuzumab-DM1 in"/>
   <result pre="A total of 12,917 patients from 17 RCTs treated with" exact="bevacizumab" post="had a significantly increased risk of cerebrovascular events compared"/>
   <result pre="and 3.09 (95% CI, 1.36–6.99), respectively. Risk varied with the" exact="bevacizumab" post="dose, with RRs of 3.97 (95% CI, 2.15–7.36) and"/>
   <result pre="close serial monitoring of LVEF are warranted during therapy with" exact="bevacizumab" post="in older adults and those with a history of"/>
   <result pre="with impairment of wound healing. It is recommended to withhold" exact="ramucirumab" post="treatment prior to surgery. After surgery, clinical judgment dictates"/>
   <result pre="resume based on adequate wound healing. It is recommended that" exact="bevacizumab" post="should be discontinued at least 28 days prior to"/>
   <result pre="exclusion [ 16, 34, 35, 43, 78, 79]. Once again," exact="rituximab" post="is the most implicated MoAb, inducing a heterogeneous spectrum"/>
   <result pre="average, responsiveness to steroid therapy (delayed onset 15 days after" exact="methylprednisolone" post="infusion and favorable outcome with steroid therapy), rash and"/>
   <result pre="Interstitial lung disease (ILD) has been reported in treatment with" exact="cetuximab" post="and transtuzumab [ 16, 34]. Discontinuation of MoAb is"/>
   <result pre="The overall incidence of mild proteinuria in patients treated with" exact="bevacizumab" post="ranges from 21 to up to 63%, but grade"/>
   <result pre="The incidence is not higher in patients who receive shorter" exact="bevacizumab" post="infusions (i.e., 10 versus 90 minutes) [ 82, 83]."/>
   <result pre="10 versus 90 minutes) [ 82, 83]. The AEs of" exact="ramucirumab" post="were lower than bevacizumab, with only  5.1% of patients experiencing"/>
   <result pre="Other less common renal problems that have been reported with" exact="bevacizumab" post="include acute renal dysfunction and proliferative glomerulonephritis [ 27,"/>
   <result pre="dysfunction and proliferative glomerulonephritis [ 27, 83]. Temporary cessation of" exact="bevacizumab" post="is advised if protein excretion exceeds 2 g in 24"/>
   <result pre="are common gastrointestinal AEs of MoAbs. In a study of" exact="pertuzumab" post="monotherapy in patients with metastatic breast cancer, diarrhea of"/>
   <result pre="III comparison of best supportive care (BSC) with or without" exact="panitumumab" post="reported diarrhea of any grade in 21% of patients"/>
   <result pre="grade 3 or 4 diarrhea in studies of single agent" exact="cetuximab" post="have ranged from only 1.5 to 2% [ 17,"/>
   <result pre="perforation (GIP). GIP has been reported in patients treated with" exact="bevacizumab" post="for a variety of malignancies, and has occurred in"/>
   <result pre="response and prolonged survival in colorectal cancer patients treated with" exact="cetuximab" post="[ 86]. In the ASPECCT trial, Grade 3-4 skin"/>
   <result pre="Grade 3-4 skin AEs occurred in 62 patients (13%) given" exact="panitumumab" post="and 48 patients (10%) given cetuximab [ 19]. The"/>
   <result pre="62 patients (13%) given panitumumab and 48 patients (10%) given" exact="cetuximab" post="[ 19]. The skin AEs of nimotuzumab were very"/>
   <result pre="with Staphylococcus aureus) is not uncommon in patients treated with" exact="cetuximab" post="[ 17, 87]. Other less common specific cutaneous reactions"/>
   <result pre="been reported in a small number of patients treated with" exact="ipilimumab" post="for metastatic melanoma. Treatment options include topical antibiotics, topical"/>
   <result pre="is serious [ 57]. 8.3. Treatment Preventive/prophylactic management is recommended:" exact="hydrocortisone" post="1% combined with moisturizer, sunscreen, and doxycycline 100 mg bid"/>
   <result pre="management is recommended: hydrocortisone 1% combined with moisturizer, sunscreen, and" exact="doxycycline" post="100 mg bid for the first 6 weeks. Sunlight may"/>
   <result pre="exacerbate skin reactions (limit sun exposure). Treatment include the following:" exact="alclometasone" post="0.05% cream or fluocinonide 0.05% cream or clindamycin 1%,"/>
   <result pre="sun exposure). Treatment include the following: alclometasone 0.05% cream or" exact="fluocinonide" post="0.05% cream or clindamycin 1%, and doxycycline 100 mg bid"/>
   <result pre="0.05% cream or fluocinonide 0.05% cream or clindamycin 1%, and" exact="doxycycline" post="100 mg bid or minocycline 100 mg daily or isotretinoin at"/>
   <result pre="0.05% cream or clindamycin 1%, and doxycycline 100 mg bid or" exact="minocycline" post="100 mg daily or isotretinoin at low doses (20–30 mg/day) ["/>
   <result pre="1%, and doxycycline 100 mg bid or minocycline 100 mg daily or" exact="isotretinoin" post="at low doses (20–30 mg/day) [ 88]. 8.4. Mucositis/Stomatitis Mucositis"/>
   <result pre="Mucositis/Stomatitis Mucositis or stomatitis is a frequent oral complication for" exact="cetuximab" post="(grades 3/4: 0.9%). It mostly affects the nonkeratinized labial"/>
   <result pre="turnover time [ 17, 86]. Stomatitis has been reported with" exact="bevacizumab" post="(grades 1/2: 23%) [ 89]. Tositumomab has a higher"/>
   <result pre="89]. Tositumomab has a higher rate of severe mucositis than" exact="rituximab" post="(52 versus 18%) [ 50]. Other dermatologic toxicities include"/>
   <result pre="common [ 2, 3]. Hematologic events during ofatumumab (CD20-directed MoAb)," exact="brentuximab vedotin" post="(CD30-directed MoAb), and alemtuzumab (CD52-directed MoAb) treatment included anemia,"/>
   <result pre="events during ofatumumab (CD20-directed MoAb), brentuximab vedotin (CD30-directed MoAb), and" exact="alemtuzumab" post="(CD52-directed MoAb) treatment included anemia, neutropenia, and thrombocytopenia. Neutropenia"/>
   <result pre="Grade 3/4 bone marrow suppression may occur in treatment with" exact="brentuximab vedotin," post="as shown by neutropenia (20%), thrombocytopenia (8%), and anemia"/>
   <result pre="and anemia (6%) [ 52– 54]. Cytopenia in treatment with" exact="alemtuzumab" post="includes the following: lymphopenia (grades 3/4: 97%), neutropenia (77%;"/>
   <result pre="(PML) due to JC virus infection has been reported with" exact="rituximab" post="use, which may be fatal. Cases were reported in"/>
   <result pre="most cases were diagnosed within 12 months of the last" exact="rituximab" post="dose. Clinical findings included confusion/disorientation, motor weakness/hemiparesis, altered vision/speech,"/>
   <result pre="316 10.1097/01.all.0000173785.81024.33 15985812 5 Kimby E. Tolerability and safety of" exact="rituximab" post="(MabThera) Cancer Treatment Reviews 2005 31 6 456 473"/>
   <result pre="R. Joyce J. Jacobs S. A. Anaphylaxis after administration of" exact="ibritumomab" post="tiuxetan for follicular non-Hodgkin lymphoma Clinical Nuclear Medicine 2008"/>
   <result pre="Platts-Mills T. A. Commins S. P. Drug allergens and food—the" exact="cetuximab" post="and galactose- α-1, 3-galactose story Annals of Allergy, Asthma"/>
   <result pre="13 Sandhu A. Harford A. Singh P. Is thymoglobulin or" exact="rituximab" post="the cause of this serum sickness? A case report"/>
   <result pre="J. Flinn I. Jain V. et al. Therapeutic role of" exact="alemtuzumab" post="(Campath-1H) in patients who have failed fludarabine: results of"/>
   <result pre="D. Humblet Y. Siena S. et al. Cetuximab monotherapy and" exact="cetuximab" post="plus irinotecan in irinotecan-refractory metastatic colorectal cancer The New"/>
   <result pre="Y. Siena S. et al. Cetuximab monotherapy and cetuximab plus" exact="irinotecan" post="in irinotecan-refractory metastatic colorectal cancer The New England Journal"/>
   <result pre="M. Siena S. et al. Open-label phase III trial of" exact="panitumumab" post="plus best supportive care compared with best supportive care"/>
   <result pre="J. Peeters M. Kim T. W. et al. Panitumumab versus" exact="cetuximab" post="in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic"/>
   <result pre="al. Assessment of cardiac dysfunction in a randomized trial comparing" exact="doxorubicin" post="and cyclophosphamide followed by paclitaxel, with or without trastuzumab"/>
   <result pre="of cardiac dysfunction in a randomized trial comparing doxorubicin and" exact="cyclophosphamide" post="followed by paclitaxel, with or without trastuzumab as adjuvant"/>
   <result pre="comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without" exact="trastuzumab" post="as adjuvant therapy in node-positive, human epidermal growth factor"/>
   <result pre="Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor" exact="bevacizumab" post="in cancer patients: a meta-analysis The Journal of the"/>
   <result pre="heart failure risk in patients with breast cancer treated with" exact="bevacizumab" post="Journal of Clinical Oncology 2011 29 6 632 638"/>
   <result pre="E. Thompson L. C. et al. Bevacizumab with peri-operative epirubicin," exact="cisplatin" post="and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety"/>
   <result pre="L. C. et al. Bevacizumab with peri-operative epirubicin, cisplatin and" exact="capecitabine" post="(ECX) in localised gastro-oesophageal adenocarcinoma: a safety report Annals"/>
   <result pre="23108952 27 Gressett S. M. Shah S. R. Intricacies of" exact="bevacizumab" post="-induced toxicities and their management Annals of Pharmacotherapy 2009"/>
   <result pre="T. K. et al. A phase 2, single-arm study of" exact="ramucirumab" post="in patients with metastatic renal cell carcinoma with disease"/>
   <result pre="C. Cardiac risk associated with the receipt of anthracycline and" exact="trastuzumab" post="in a large nationwide cohort of older women with"/>
   <result pre="S. Gupta M. Wang B. et al. Clinical pharmacology of" exact="trastuzumab" post="emtansine (T-DM1): an antibody-drug conjugate in development for the"/>
   <result pre="Im Y. H. et al. Efficacy and safety of neoadjuvant" exact="pertuzumab" post="and trastuzumab in women with locally advanced, inflammatory, or"/>
   <result pre="H. et al. Efficacy and safety of neoadjuvant pertuzumab and" exact="trastuzumab" post="in women with locally advanced, inflammatory, or early HER2-positive"/>
   <result pre="P. Brice P. et al. Long-term efficacy and safety of" exact="alemtuzumab" post="in advanced primary cutaneous T-cell lymphomas British Journal of"/>
   <result pre="Elter T. Gercheva-Kyuchukova L. Pylylpenko H. et al. Fludarabine plus" exact="alemtuzumab" post="versus fludarabine alone in patients with previously treated chronic"/>
   <result pre="Gercheva-Kyuchukova L. Pylylpenko H. et al. Fludarabine plus alemtuzumab versus" exact="fludarabine" post="alone in patients with previously treated chronic lymphocytic leukaemia:"/>
   <result pre="et al. Phase III randomized intergroup trial of CHOP plus" exact="rituximab" post="compared with CHOP chemotherapy plus 131iodine-tositumomab for previously untreated"/>
   <result pre="L. J. et al. Phase III randomized study of rituximab/" exact="carmustine" post=", etoposide , cytarabine , and melphalan (BEAM) compared"/>
   <result pre="et al. Phase III randomized study of rituximab/ carmustine ," exact="etoposide" post=", cytarabine , and melphalan (BEAM) compared with iodine-131"/>
   <result pre="Phase III randomized study of rituximab/ carmustine , etoposide ," exact="cytarabine" post=", and melphalan (BEAM) compared with iodine-131 tositumomab /BEAM"/>
   <result pre="study of rituximab/ carmustine , etoposide , cytarabine , and" exact="melphalan" post="(BEAM) compared with iodine-131 tositumomab /BEAM with autologous hematopoietic"/>
   <result pre="etoposide , cytarabine , and melphalan (BEAM) compared with iodine-131" exact="tositumomab" post="/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse"/>
   <result pre="S. J. Coleman M. Leonard J. P. Cyclophosphamide, vincristine, and" exact="prednisone" post="followed by tositumomab and iodine-131-tositumomab in patients with untreated"/>
   <result pre="M. Leonard J. P. Cyclophosphamide, vincristine, and prednisone followed by" exact="tositumomab" post="and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma:"/>
   <result pre="D. et al. A phase I weekly dosing study of" exact="brentuximab vedotin" post="in patients with relapsed/refractory CD30-positive hematologic malignancies Clinical Cancer"/>
   <result pre="S. J. McDermott D. F. et al. Improved survival with" exact="ipilimumab" post="in patients with metastaticmelanoma The New England Journal of"/>
   <result pre="Costa L. Goldwasser F. et al. Randomized, double-blind study of" exact="denosumab" post="versus zoledronic acid in the treatment of bone metastases"/>
   <result pre="Goldwasser F. et al. Randomized, double-blind study of denosumab versus" exact="zoledronic acid" post="in the treatment of bone metastases in patients with"/>
   <result pre="remission, and long-term safety in patients with advanced melanoma receiving" exact="nivolumab" post="Journal of Clinical Oncology 2014 32 10 1020 1030"/>
   <result pre="E. V. Choueiri T. K. et al. Suppression of the" exact="nitric oxide" post="pathway in metastatic renal cell carcinoma patients receiving vascular"/>
   <result pre="T. K. et al. A phase 2, single-arm study of" exact="ramucirumab" post="in patients with metastatic renal cell carcinoma with disease"/>
   <result pre="events in patients with metastatic carcinoma treated with chemotherapy and" exact="bevacizumab" post="Journal of the National Cancer Institute 2007 99 1232"/>
   <result pre="et al. Thrombotic microangiopathy secondary to VEGF pathway inhibition by" exact="sunitinib" post="Nephrology Dialysis Transplantation 2009 24 2 682 685 10.1093/ndt/gfn657"/>
   <result pre="expression as a predictor of survival for first-line chemotherapy plus" exact="cetuximab" post="in patients with advanced non-small-cell lung cancer: analysis of"/>
   <result pre="I. Fehrenbacher L. et al. Phase II, randomized trial comparing" exact="bevacizumab" post="plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients"/>
   <result pre="L. et al. Phase II, randomized trial comparing bevacizumab plus" exact="fluorouracil" post="(FU)/leucovorin (LV) with FU/LV alone in patients with metastatic"/>
   <result pre="Wendtner C.-M. First-line treatment of chronic lymphocytic leukemia: role of" exact="alemtuzumab" post="Onco Targets and Therapy 2010 3 53 67 91"/>
   <result pre="X. Q. Feng F. Reversible posterior leukoencephalopathy syndrome induced by" exact="bevacizumab" post="plus chemotherapy in colorectal cancer World Journal of Gastroenterology"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4439018/results/search/inn/results.xml">
   <result pre="To our knowledge, no meta-analysis has evaluated HER2-targeted therapy including" exact="trastuzumab" post="emtansine (T-DM1) and pertuzumab for HER2-positive breast caner and"/>
   <result pre="meta-analysis has evaluated HER2-targeted therapy including trastuzumab emtansine (T-DM1) and" exact="pertuzumab" post="for HER2-positive breast caner and ranked the targeted treatments."/>
   <result pre="NST. Conclusions Overall, the regimen of T-DM1 as well as" exact="pertuzumab" post="in combination with trastuzumab and docetaxel is efficacious with"/>
   <result pre="regimen of T-DM1 as well as pertuzumab in combination with" exact="trastuzumab" post="and docetaxel is efficacious with fewer side effects as"/>
   <result pre="T-DM1 as well as pertuzumab in combination with trastuzumab and" exact="docetaxel" post="is efficacious with fewer side effects as compared with"/>
   <result pre="7]. With regard to the management of HER2-positive breast cancer," exact="trastuzumab" post="[ 8– 11], pertuzumab [ 12, 13], lapatinib ["/>
   <result pre="the management of HER2-positive breast cancer, trastuzumab [ 8– 11]," exact="pertuzumab" post="[ 12, 13], lapatinib [ 14, 15] are approved"/>
   <result pre="breast cancer, trastuzumab [ 8– 11], pertuzumab [ 12, 13]," exact="lapatinib" post="[ 14, 15] are approved as standard care for"/>
   <result pre="(ORR) compared with chemotherapy alone. The TDM4450g trial reported that" exact="trastuzumab" post="emtansine provides a better median PFS, by an increase"/>
   <result pre="median PFS, by an increase of 5 months, compared to" exact="trastuzumab" post="in combination with docetaxel in HER2-positive metastatic breast cancer"/>
   <result pre="increase of 5 months, compared to trastuzumab in combination with" exact="docetaxel" post="in HER2-positive metastatic breast cancer [ 17]. The targeting"/>
   <result pre="study, HER2-positive breast cancer patients received a regimen of combining" exact="pertuzumab" post="with trastuzumab and docetaxel, and demonstrated a significantly improvement"/>
   <result pre="breast cancer patients received a regimen of combining pertuzumab with" exact="trastuzumab" post="and docetaxel, and demonstrated a significantly improvement in overall"/>
   <result pre="overall survival compared with individuals who received a regimen of" exact="trastuzumab" post="in combination with placebo and docetaxel [ 12, 21]."/>
   <result pre="received a regimen of trastuzumab in combination with placebo and" exact="docetaxel" post="[ 12, 21]. In addition to the CLEOPATRA study,"/>
   <result pre="meta-analysis did not include the HER2-targeted agents of T-DM1 and" exact="pertuzumab" post="in the study [ 25]. Network meta-analysis is one"/>
   <result pre="relatively a better HER2-targeted treatment regimen among trastuzumab, pertuzumab, T-DM1," exact="lapatinib" post="in combination with standard treatment (chemotherapy or hormone therapy"/>
   <result pre="trastuzumab). Other therapies such as anthracycline, taxane, capecitabine, anastrozole, letrozole," exact="vinorelbine" post="without the addition of any-targeted agents were grouped as"/>
   <result pre="T-DM1; LC, lapatinib; HC, trastuzumab; NST, naïve standard treatments; PEHC," exact="pertuzumab" post="and trastuzumab; PEC, pertuzumab; LHC, lapatinib and trastuzumab. In"/>
   <result pre="naïve standard treatments; PEHC, pertuzumab and trastuzumab; PEC, pertuzumab; LHC," exact="lapatinib" post="and trastuzumab. In head-to-head comparisons, for OSR, the T-DM1"/>
   <result pre="Table). Discussion In our network meta-analysis, treatment with T-DM1 or" exact="pertuzumab" post="in combination with trastuzumab and docetaxel, outperformed other treatment"/>
   <result pre="network meta-analysis, treatment with T-DM1 or pertuzumab in combination with" exact="trastuzumab" post="and docetaxel, outperformed other treatment regimens, and the treatment"/>
   <result pre="other 6 regimens perhaps because of limited sample size. Adding" exact="pertuzumab" post="to standard treatment was previously found to be associated"/>
   <result pre="68]. Furthermore, risk of abnormal LVEF was greater with adding" exact="trastuzumab" post="to standard treatment than naïve standard treatment [ 69]."/>
   <result pre="our study supports that treatment with T-DM1 as well as" exact="pertuzumab" post="in combination with trastuzumab and docetaxel, currently is the"/>
   <result pre="treatment with T-DM1 as well as pertuzumab in combination with" exact="trastuzumab" post="and docetaxel, currently is the best targeted drug regimen"/>
   <result pre="breast cancer such as the comparable randomized trials that T-DM1+/-" exact="pertuzumab" post="versus standard treatment with or without T-MD1+/- pertuzumab, can"/>
   <result pre="T-DM1; LC, lapatinib; HC, trastuzumab; NST, naïve standard treatments; PEHC," exact="pertuzumab" post="and trastuzumab; PEC, pertuzumab; LHC, lapatinib and trastuzumab. (TIF)"/>
   <result pre="naïve standard treatments; PEHC, pertuzumab and trastuzumab; PEC, pertuzumab; LHC," exact="lapatinib" post="and trastuzumab. (TIF) LINK Click here for additional data"/>
   <result pre="Jensen AB , et al. Phase III randomized study comparing" exact="docetaxel" post="plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy"/>
   <result pre=", et al. Phase III randomized study comparing docetaxel plus" exact="trastuzumab" post="with vinorelbine plus trastuzumab as first-line therapy of metastatic"/>
   <result pre="al. Phase III randomized study comparing docetaxel plus trastuzumab with" exact="vinorelbine" post="plus trastuzumab as first-line therapy of metastatic or locally"/>
   <result pre="III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus" exact="trastuzumab" post="as first-line therapy of metastatic or locally advanced human"/>
   <result pre="Hegg R , Im YH , et al. Pertuzumab plus" exact="trastuzumab" post="plus docetaxel for metastatic breast cancer. The New England"/>
   <result pre=", Im YH , et al. Pertuzumab plus trastuzumab plus" exact="docetaxel" post="for metastatic breast cancer. The New England journal of"/>
   <result pre="VF , et al. Phase III trial of nonpegylated liposomal" exact="doxorubicin" post="in combination with trastuzumab and paclitaxel in HER2-positive metastatic"/>
   <result pre="Phase III trial of nonpegylated liposomal doxorubicin in combination with" exact="trastuzumab" post="and paclitaxel in HER2-positive metastatic breast cancer . Annals"/>
   <result pre="trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and" exact="paclitaxel" post="in HER2-positive metastatic breast cancer . Annals of oncology:"/>
   <result pre="Lambert-Falls R , Marcom PK , et al. Trastuzumab plus" exact="vinorelbine" post="or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the"/>
   <result pre="vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the" exact="trastuzumab" post="and vinorelbine or taxane study . Cancer. 2007; 110("/>
   <result pre="taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and" exact="vinorelbine" post="or taxane study . Cancer. 2007; 110( 5): 965–"/>
   <result pre="V , Campone M , et al. Pertuzumab, trastuzumab, and" exact="docetaxel" post="for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival"/>
   <result pre="W , Tong Z , et al. Randomized trial of" exact="lapatinib" post="versus placebo added to paclitaxel in the treatment of"/>
   <result pre="et al. Randomized trial of lapatinib versus placebo added to" exact="paclitaxel" post="in the treatment of human epidermal growth factor receptor"/>
   <result pre="Kaufmann M , Blohmer JU , et al. Lapatinib versus" exact="trastuzumab" post="in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44):"/>
   <result pre="Vinholes J , et al. Phase II randomized study of" exact="trastuzumab" post="emtansine versus trastuzumab plus docetaxel in patients with human"/>
   <result pre="et al. Phase II randomized study of trastuzumab emtansine versus" exact="trastuzumab" post="plus docetaxel in patients with human epidermal growth factor"/>
   <result pre="Phase II randomized study of trastuzumab emtansine versus trastuzumab plus" exact="docetaxel" post="in patients with human epidermal growth factor receptor 2-positive"/>
   <result pre="Liu MC , et al. Efficacy and safety of neoadjuvant" exact="pertuzumab" post="and trastuzumab in women with locally advanced, inflammatory, or"/>
   <result pre=", et al. Efficacy and safety of neoadjuvant pertuzumab and" exact="trastuzumab" post="in women with locally advanced, inflammatory, or early HER2-positive"/>
   <result pre=", et al. AVEREL: a randomized phase III Trial evaluating" exact="bevacizumab" post="in combination with docetaxel and trastuzumab as first-line therapy"/>
   <result pre="a randomized phase III Trial evaluating bevacizumab in combination with" exact="docetaxel" post="and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic"/>
   <result pre="phase III Trial evaluating bevacizumab in combination with docetaxel and" exact="trastuzumab" post="as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer"/>
   <result pre=", Gianni L , et al. Phase IIa trial of" exact="trastuzumab" post="emtansine with pertuzumab for patients with human epidermal growth"/>
   <result pre=", et al. Phase IIa trial of trastuzumab emtansine with" exact="pertuzumab" post="for patients with human epidermal growth factor receptor 2-positive,"/>
   <result pre="Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining" exact="pertuzumab" post="with trastuzumab and docetaxel in metastatic breast cancer ."/>
   <result pre="assessment in CLEOPATRA, a phase III study combining pertuzumab with" exact="trastuzumab" post="and docetaxel in metastatic breast cancer . Annals of"/>
   <result pre="CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and" exact="docetaxel" post="in metastatic breast cancer . Annals of oncology: official"/>
   <result pre="al. Pattern of rash, diarrhea, and hepatic toxicities secondary to" exact="lapatinib" post="and their association with age and response to neoadjuvant"/>
   <result pre="Randomized phase II trial of the efficacy and safety of" exact="trastuzumab" post="combined with docetaxel in patients with human epidermal growth"/>
   <result pre="trial of the efficacy and safety of trastuzumab combined with" exact="docetaxel" post="in patients with human epidermal growth factor receptor 2-positive"/>
   <result pre="G , et al. Randomized Phase II Trial of weekly" exact="paclitaxel" post="alone versus trastuzumab plus weekly paclitaxel as first-line therapy"/>
   <result pre="al. Randomized Phase II Trial of weekly paclitaxel alone versus" exact="trastuzumab" post="plus weekly paclitaxel as first-line therapy of patients with"/>
   <result pre="II Trial of weekly paclitaxel alone versus trastuzumab plus weekly" exact="paclitaxel" post="as first-line therapy of patients with Her-2 positive advanced"/>
   <result pre="Vaid A , Wardley A , et al. Trastuzumab plus" exact="anastrozole" post="versus anastrozole alone for the treatment of postmenopausal women"/>
   <result pre=", Wardley A , et al. Trastuzumab plus anastrozole versus" exact="anastrozole" post="alone for the treatment of postmenopausal women with human"/>
   <result pre="D , Thomssen C , et al. Higher efficacy of" exact="letrozole" post="in combination with trastuzumab compared to letrozole monotherapy as"/>
   <result pre=", et al. Higher efficacy of letrozole in combination with" exact="trastuzumab" post="compared to letrozole monotherapy as first-line treatment in patients"/>
   <result pre="Higher efficacy of letrozole in combination with trastuzumab compared to" exact="letrozole" post="monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive"/>
   <result pre="B , Imwalle B , Geyer CE . Lapatinib plus" exact="capecitabine" post="in women with HER-2-positive advanced breast cancer: final survival"/>
   <result pre="Romieu CG , Pienkowski T , et al. Lapatinib plus" exact="capecitabine" post="for HER2-positive advanced breast cancer. The New England journal"/>
   <result pre="L , Maltzman J , Johnston S . Lapatinib plus" exact="letrozole" post="as first-line therapy for HER-2+ hormone receptor-positive metastatic breast"/>
   <result pre="S , Dieras V , et al. Lapatinib combined with" exact="letrozole" post="versus letrozole and placebo as first-line therapy for postmenopausal"/>
   <result pre="Dieras V , et al. Lapatinib combined with letrozole versus" exact="letrozole" post="and placebo as first-line therapy for postmenopausal hormone receptor-positive"/>
   <result pre="MC , et al. Phase III, double-blind, randomized study comparing" exact="lapatinib" post="plus paclitaxel with placebo plus paclitaxel as first-line treatment"/>
   <result pre="et al. Phase III, double-blind, randomized study comparing lapatinib plus" exact="paclitaxel" post="with placebo plus paclitaxel as first-line treatment for metastatic"/>
   <result pre="double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus" exact="paclitaxel" post="as first-line treatment for metastatic breast cancer . Journal"/>
   <result pre="Hegg R , Im YH , et al. Pertuzumab plus" exact="trastuzumab" post="plus docetaxel for metastatic breast cancer. The New England"/>
   <result pre=", Im YH , et al. Pertuzumab plus trastuzumab plus" exact="docetaxel" post="for metastatic breast cancer. The New England journal of"/>
   <result pre="PA , Visscher DW , et al. Sequential versus concurrent" exact="trastuzumab" post="in adjuvant chemotherapy for breast cancer. Journal of clinical"/>
   <result pre=", Martin M , Press M , et al. Adjuvant" exact="trastuzumab" post="in HER2-positive breast cancer. The New England journal of"/>
   <result pre=", Kataja V , Asola R , et al. Adjuvant" exact="docetaxel" post="or vinorelbine with or without trastuzumab for breast cancer."/>
   <result pre="V , Asola R , et al. Adjuvant docetaxel or" exact="vinorelbine" post="with or without trastuzumab for breast cancer. The New"/>
   <result pre=", et al. Adjuvant docetaxel or vinorelbine with or without" exact="trastuzumab" post="for breast cancer. The New England journal of medicine."/>
   <result pre="Lu Y , et al. Risk of cardiac dysfunction with" exact="trastuzumab" post="in breast cancer patients: a meta-analysis. Cancer treatment reviews."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4439944/results/search/inn/results.xml">
   <result pre="endocrine agents used were third generation aromatase inhibitors (AIs), anastrozole," exact="letrozole" post="or exemestane. The investigated targeted agents were inhibitors of"/>
   <result pre="agents were inhibitors of tyrosine kinase receptors such as gefitinib," exact="imatinib" post="or trastuzumab/lapatinib, inhibitors of mTOR, such as everolimus, inhibitors"/>
   <result pre="in patients with HR-positive tumors 17. In the neoadjuvant setting," exact="tamoxifen" post="has historically been employed, but the third generation aromatase"/>
   <result pre="employed, but the third generation aromatase inhibitors (AIs), including letrozole," exact="anastrozole" post="and exemestane, have been shown to be significantly superior"/>
   <result pre="and exemestane, have been shown to be significantly superior to" exact="tamoxifen" post="in terms of overall response rate (RR) and achievement"/>
   <result pre="the overexpression of VEGF in tumor cells is responsible for" exact="tamoxifen" post="resistance 31. In this altered molecular milieu the inhibition"/>
   <result pre="the combination of an AI with anti-HER2 drugs, such as" exact="trastuzumab" post="or lapatinib, has been demonstrated to achieve longer progression"/>
   <result pre="Bolero-2 trial, the combination of everolimus, a mTOR inhibitor, and" exact="exemestane" post="resulted in an increased efficacy compared to exemestane alone"/>
   <result pre="inhibitor, and exemestane resulted in an increased efficacy compared to" exact="exemestane" post="alone in patients with HER2-negative advanced breast cancer who"/>
   <result pre="randomized controlled trial OR random OR randomized) AND (tamoxifen OR" exact="anastrozole" post="OR exemestane OR letrozole OR aromatase inhibitors OR fulvestrant"/>
   <result pre="trial OR random OR randomized) AND (tamoxifen OR anastrozole OR" exact="exemestane" post="OR letrozole OR aromatase inhibitors OR fulvestrant OR antiestrogens)&quot;."/>
   <result pre="random OR randomized) AND (tamoxifen OR anastrozole OR exemestane OR" exact="letrozole" post="OR aromatase inhibitors OR fulvestrant OR antiestrogens)&quot;. Further selection"/>
   <result pre="OR anastrozole OR exemestane OR letrozole OR aromatase inhibitors OR" exact="fulvestrant" post="OR antiestrogens)&quot;. Further selection was made by choosing &quot;clinical"/>
   <result pre="non-randomized, incorporating an AI as endocrine agent. In one study" exact="fulvestrant" post="was used as well 40. The table summarizes the"/>
   <result pre="in combination with AIs included inhibitors of TKRs, such as" exact="gefitinib" post="38- 40, imatinib 41, or trastuzumab/lapatinib 42; inhibitors of"/>
   <result pre="AIs included inhibitors of TKRs, such as gefitinib 38- 40," exact="imatinib" post="41, or trastuzumab/lapatinib 42; inhibitors of mTOR, such as"/>
   <result pre="imatinib 41, or trastuzumab/lapatinib 42; inhibitors of mTOR, such as" exact="everolimus" post="43; inhibitors of Cox-2, such as celecoxib 44, 45;"/>
   <result pre="mTOR, such as everolimus 43; inhibitors of Cox-2, such as" exact="celecoxib" post="44, 45; inhibitors of angiogenesis, such as bevacizumab 46."/>
   <result pre="such as celecoxib 44, 45; inhibitors of angiogenesis, such as" exact="bevacizumab" post="46. The details of the studies, with particular regard"/>
   <result pre="with HR-positive and EGFR-positive breast cancer were randomized to receive" exact="gefitinib" post="250 mg daily associated with anastrozole 1 mg daily"/>
   <result pre="were randomized to receive gefitinib 250 mg daily associated with" exact="anastrozole" post="1 mg daily (27 patients) or gefitinib alone (29"/>
   <result pre="daily associated with anastrozole 1 mg daily (27 patients) or" exact="gefitinib" post="alone (29 patients) for 4-6 weeks. The RR in"/>
   <result pre="in the combination group was 67%, not significantly different from" exact="gefitinib" post="alone (79%), although the combination was more effective in"/>
   <result pre="study does not provide information on the basal activity of" exact="anastrozole" post="given that the control arm was gefitinib. The second"/>
   <result pre="47% and 61% in the combination group (121 patients) and" exact="anastrozole" post="alone group (85 patients), respectively. However, the primary endpoint"/>
   <result pre="2 weeks could identify patients whose tumor was resistant to" exact="anastrozole" post="and that might be particularly sensitive to the added"/>
   <result pre="combination group was divided into a group of patients receiving" exact="gefitinib" post="250 mg daily for 16 weeks and a group"/>
   <result pre="and a group receiving placebo for 2 weeks, followed by" exact="gefitinib" post="250 mg daily for 14 weeks. The study failed"/>
   <result pre="and RR. The third study 40 examined the activity of" exact="gefitinib" post="250 mg daily associated with a potential more effective"/>
   <result pre="daily associated with a potential more effective endocrine treatment combining" exact="anastrozole" post="1 mg daily and fulvestrant 250 mg intramuscular monthly"/>
   <result pre="more effective endocrine treatment combining anastrozole 1 mg daily and" exact="fulvestrant" post="250 mg intramuscular monthly for 16 weeks. The study"/>
   <result pre="inhibitor of PDGFR and cKit, was studied in combination with" exact="letrozole" post="in a pilot study enrolling 13 women 41. Patients"/>
   <result pre="a pilot study enrolling 13 women 41. Patients received preoperatively" exact="imatinib" post="400 mg twice daily and letrozole 2.5 mg daily"/>
   <result pre="41. Patients received preoperatively imatinib 400 mg twice daily and" exact="letrozole" post="2.5 mg daily for 3 months. Three patients withdraw"/>
   <result pre="achieved a pCR. The dual block of HER2, obtained with" exact="trastuzumab" post="and lapatinib, was studied in 64 patients with locally"/>
   <result pre="patients with locally advanced HER2-positive breast cancer 42. Patients received" exact="trastuzumab" post="weekly (4 mg/kg loading, then 2 mg/kg) and lapatinib"/>
   <result pre="received trastuzumab weekly (4 mg/kg loading, then 2 mg/kg) and" exact="lapatinib" post="1000 mg daily for 12 weeks. Thirty-nine patients whose"/>
   <result pre="Thirty-nine patients whose tumors were HR-positive were also treated with" exact="letrozole" post="2.5 mg daily. The study primary endpoint was the"/>
   <result pre="a RR (referred to as non-pCR) of 46% in the" exact="letrozole" post="group. Moreover, given that only two patients experienced progression"/>
   <result pre="group, we can extrapolate that 54% of patients in the" exact="letrozole" post="group had SD. Inhibitors of mTOR A phase II,"/>
   <result pre="carried out to evaluate the rate of tumor response combining" exact="everolimus" post="and letrozole in the neoadjuvant treatment of postmenopausal women"/>
   <result pre="to evaluate the rate of tumor response combining everolimus and" exact="letrozole" post="in the neoadjuvant treatment of postmenopausal women with HR-positive"/>
   <result pre="with HR-positive breast cancer 43. One hundred thirty-eight patients received" exact="letrozole" post="2.5 mg plus everolimus 10 mg daily, while 132"/>
   <result pre="43. One hundred thirty-eight patients received letrozole 2.5 mg plus" exact="everolimus" post="10 mg daily, while 132 received letrozole plus placebo."/>
   <result pre="2.5 mg plus everolimus 10 mg daily, while 132 received" exact="letrozole" post="plus placebo. Treatment was administered for 16 weeks. The"/>
   <result pre="16 weeks. The RRs were 68.1% in patients treated with" exact="everolimus" post="and 59.1% in patients treated with placebo (p=0.062), a"/>
   <result pre="Ki67 index reduction (57% vs 30%, p&amp;lt;0.01). As expected, the" exact="everolimus" post="group had a higher incidence of grade 3 and"/>
   <result pre="patients). A pCR was reported in two patients treated with" exact="everolimus" post="and in one treated with placebo. Inhibitors of COX-2"/>
   <result pre="82 patients into 3 groups: group A (30 patients) received" exact="exemestane" post="25 mg daily and celecoxib 400 mg twice daily,"/>
   <result pre="group A (30 patients) received exemestane 25 mg daily and" exact="celecoxib" post="400 mg twice daily, group B (24 patients) received"/>
   <result pre="celecoxib 400 mg twice daily, group B (24 patients) received" exact="exemestane" post="25 mg daily, group C (28 patients) received letrozole"/>
   <result pre="received exemestane 25 mg daily, group C (28 patients) received" exact="letrozole" post="2.5 mg daily. The overall RRs were 58.6% for"/>
   <result pre="45 22 postmenopausal women were enrolled and treated with neoadjuvant" exact="exemestane" post="25 mg daily for 8 weeks, followed by exemestane"/>
   <result pre="neoadjuvant exemestane 25 mg daily for 8 weeks, followed by" exact="exemestane" post="25 mg daily and celecoxib 400 mg twice daily"/>
   <result pre="for 8 weeks, followed by exemestane 25 mg daily and" exact="celecoxib" post="400 mg twice daily for 8 weeks. The study"/>
   <result pre="expression of the aromatase enzyme, as well as estrogen receptor," exact="progesterone" post="receptor, HER2, Ki67, and COX-2 in the tumor before,"/>
   <result pre="tumor before, during, and after treatment. The study showed that" exact="progesterone" post="receptor and Ki67 significantly decreased by effect of the"/>
   <result pre="carried out to assess the activity of the combination of" exact="letrozole" post="and bevacizumab, a monoclonal antibody inhibiting VEGF, in the"/>
   <result pre="postmenopausal women with HR-positive breast cancer 46. Twenty-five patients received" exact="letrozole" post="2.5 mg daily and intravenous bevacizumab 15 mg/kg every"/>
   <result pre="46. Twenty-five patients received letrozole 2.5 mg daily and intravenous" exact="bevacizumab" post="15 mg/kg every 3 weeks. An objective clinical response"/>
   <result pre="showing an impressive increase of response was the one combining" exact="letrozole" post="and imatinib (RR 90%) 41. However, the study has"/>
   <result pre="impressive increase of response was the one combining letrozole and" exact="imatinib" post="(RR 90%) 41. However, the study has a very"/>
   <result pre="range of no benefit. However, the high RR observed combining" exact="imatinib" post="and AI suggests further investigation, advisably with a dose"/>
   <result pre="for the study on trastuzumab/lapatinib 42 and one study on" exact="gefitinib" post="38 in which the expression of HER2 and EGFR"/>
   <result pre="is probably one of the reasons for the benefit of" exact="everolimus" post="added to AIs in patients previously treated with AIs"/>
   <result pre="of celecoxib, a COX-2 inhibitor. The biological rationale to add" exact="celecoxib" post="to AIs is that breast cancer self-production of estrogen"/>
   <result pre="targeted agents. A significant reduction in Ki67 was observed adding" exact="gefitinib" post="38 or everolimus 43 to AI. Moreover, high rates"/>
   <result pre="significant reduction in Ki67 was observed adding gefitinib 38 or" exact="everolimus" post="43 to AI. Moreover, high rates of pCR were"/>
   <result pre="Soran A Wickerham DL Wolmark N Sequential preoperative or postoperative" exact="docetaxel" post="added to preoperative doxorubicin plus cyclophosphamide for operable breast"/>
   <result pre="Wolmark N Sequential preoperative or postoperative docetaxel added to preoperative" exact="doxorubicin" post="plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant"/>
   <result pre="Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus" exact="cyclophosphamide" post="for operable breast cancer: National Surgical Adjuvant Breast and"/>
   <result pre="Y Petrakova K Dube P de Oliveira CT Comparison of" exact="anastrozole" post="versus tamoxifen as preoperative therapy in postmenopausal women with"/>
   <result pre="K Dube P de Oliveira CT Comparison of anastrozole versus" exact="tamoxifen" post="as preoperative therapy in postmenopausal women with hormone receptor-positive"/>
   <result pre="R Iwase H Kamigaki S Takei H Noguchi S Neoadjuvant" exact="anastrozole" post="versus tamoxifen in patients receiving goserelin for premenopausal breast"/>
   <result pre="H Kamigaki S Takei H Noguchi S Neoadjuvant anastrozole versus" exact="tamoxifen" post="in patients receiving goserelin for premenopausal breast cancer (STAGE):"/>
   <result pre="H Noguchi S Neoadjuvant anastrozole versus tamoxifen in patients receiving" exact="goserelin" post="for premenopausal breast cancer (STAGE): a double-blind, randomised phase"/>
   <result pre="S Osborne CK Elledge RM HER-2 amplification, HER-1 expression, and" exact="tamoxifen" post="response in estrogen receptor-positive metastatic breast cancer: a southwest"/>
   <result pre="and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or" exact="tamoxifen" post="in breast cancer cells Mol Cancer Ther 2002 1"/>
   <result pre="WE Thottassery JV Kern FG Vascular endothelial growth factor reduces" exact="tamoxifen" post="efficacy and promotes metastatic colonization and desmoplasia in breast"/>
   <result pre="Wakeling AE Nicholson RI The antiepidermal growth factor receptor agent" exact="gefitinib" post="(ZD1839/Iressa) improves antihormone response and prevents development of resistance"/>
   <result pre="JM Roth RA Hidalgo M Inhibition of mTOR activity restores" exact="tamoxifen" post="response in breast cancer cells with aberrant Akt Activity"/>
   <result pre="Lehle M Feyereislova A Revil C Jones A Trastuzumab plus" exact="anastrozole" post="versus anastrozole alone for the treatment of postmenopausal women"/>
   <result pre="Feyereislova A Revil C Jones A Trastuzumab plus anastrozole versus" exact="anastrozole" post="alone for the treatment of postmenopausal women with human"/>
   <result pre="L Oliva C Stein S Pegram M Lapatinib combined with" exact="letrozole" post="versus letrozole and placebo as first-line therapy for postmenopausal"/>
   <result pre="C Stein S Pegram M Lapatinib combined with letrozole versus" exact="letrozole" post="and placebo as first-line therapy for postmenopausal hormone receptor-positive"/>
   <result pre="K Beresford E Ali S Slade MJ Coombes RC Preoperative" exact="gefitinib" post="versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor"/>
   <result pre="E Ali S Slade MJ Coombes RC Preoperative gefitinib versus" exact="gefitinib" post="and anastrozole in postmenopausal patients with oestrogen-receptor positive and"/>
   <result pre="S Slade MJ Coombes RC Preoperative gefitinib versus gefitinib and" exact="anastrozole" post="in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary"/>
   <result pre="P Dowsett M A phase II placebo-controlled trial of neoadjuvant" exact="anastrozole" post="alone or with gefitinib in early breast cancer J"/>
   <result pre="phase II placebo-controlled trial of neoadjuvant anastrozole alone or with" exact="gefitinib" post="in early breast cancer J Clin Oncol 2007 25"/>
   <result pre="R A phase II neoadjuvant trial of anastrozole, fulvestrant, and" exact="gefitinib" post="in patients with newly diagnosed estrogen receptor positive breast"/>
   <result pre="Osborne CK Chang JC Multicenter phase II study of neoadjuvant" exact="lapatinib" post="and trastuzumab with hormonal therapy and without chemotherapy in"/>
   <result pre="Chang JC Multicenter phase II study of neoadjuvant lapatinib and" exact="trastuzumab" post="with hormonal therapy and without chemotherapy in patients with"/>
   <result pre="Jonat W Rugo HS Phase II randomized study of neoadjuvant" exact="everolimus" post="plus letrozole compared with placebo plus letrozole in patients"/>
   <result pre="Rugo HS Phase II randomized study of neoadjuvant everolimus plus" exact="letrozole" post="compared with placebo plus letrozole in patients with estrogen"/>
   <result pre="study of neoadjuvant everolimus plus letrozole compared with placebo plus" exact="letrozole" post="in patients with estrogen receptor-positive breast cancer J Clin"/>
   <result pre="RM Brueggemeier RW Shapiro CL Phase II trial of neoadjuvant" exact="exemestane" post="in combination with celecoxib in postmenopausal women who have"/>
   <result pre="CL Phase II trial of neoadjuvant exemestane in combination with" exact="celecoxib" post="in postmenopausal women who have breast cancer Clin Breast"/>
   <result pre="JP Li Y LoBuglio AF Pilot trial of preoperative (neoadjuvant)" exact="letrozole" post="in combination with bevacizumab in postmenopausal women with newly"/>
   <result pre="AF Pilot trial of preoperative (neoadjuvant) letrozole in combination with" exact="bevacizumab" post="in postmenopausal women with newly diagnosed estrogen receptor- or"/>
   <result pre="bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or" exact="progesterone" post="receptor-positive breast cancer Clin Breast Cancer 2010 10 275"/>
   <result pre="Bottini A Generali D Petronini PG Overcoming acquired resistance to" exact="letrozole" post="by targeting the PI3K/AKT/mTOR pathway in breast cancer cell"/>
   <result pre="49 Chow LWC SY Jassem J Phase 3 study of" exact="temsirolimus" post="with letrozole or letrozole alone in postmenopausal women with"/>
   <result pre="LWC SY Jassem J Phase 3 study of temsirolimus with" exact="letrozole" post="or letrozole alone in postmenopausal women with locally advanced"/>
   <result pre="Jassem J Phase 3 study of temsirolimus with letrozole or" exact="letrozole" post="alone in postmenopausal women with locally advanced or metastatic"/>
   <result pre="Moore L Hayes DF Randomized phase III placebo-controlled trial of" exact="letrozole" post="plus oral temsirolimus as first-line endocrine therapy in postmenopausal"/>
   <result pre="DF Randomized phase III placebo-controlled trial of letrozole plus oral" exact="temsirolimus" post="as first-line endocrine therapy in postmenopausal women with locally"/>
   <result pre="al. Increased pathological complete response rate after a long-term neoadjuvant" exact="letrozole" post="treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer"/>
   <result pre="after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or" exact="progesterone" post="receptor-positive breast cancer Br J Cancer 2013 108 1587"/>
   <result pre="al. TBCRC023: A randomized multicenter phase II neoadjuvant trial of" exact="lapatinib" post="plus trastuzumab, with endcorine therapy and without chemotherapy, for"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4440424/results/search/inn/results.xml">
   <result pre="genotype is awaited. Keywords PI3K PIK3CA prognostic factor predictive factor" exact="trastuzumab" post="Introduction Molecularly based choice of care for solid tumors"/>
   <result pre="who had participated in randomized trials comparing adjuvant use of" exact="tamoxifen" post="for 1–3 years with observation failed to show any"/>
   <result pre="and predictive value of PIK3CA mutations in patients who received" exact="paclitaxel" post="alone or in combination with lapatinib in a prospective"/>
   <result pre="in patients who received paclitaxel alone or in combination with" exact="lapatinib" post="in a prospective randomized trial setting. 47 This study"/>
   <result pre="adverse prognostic factor for survival, but were not predictive for" exact="lapatinib" post="benefit. 47 This result should be interpreted with caution,"/>
   <result pre="therefore, PI3K gain-of-function mutations were hypothesized to cause resistance to" exact="trastuzumab" post="and other HER2-targeting drugs. A series of preclinical studies"/>
   <result pre="Results showed that mutant PIK3CA transfection resulted in resistance to" exact="trastuzumab" post="or lapatinib, a small-molecule HER2 inhibitor. 50, 51 Consistent"/>
   <result pre="lines with PIK3CA hot-spot mutations were significantly more resistant to" exact="trastuzumab" post="and CL-387,785, a small-molecule HER2 inhibitor, than those without"/>
   <result pre="themselves did not correlate with in vitro resistance to either" exact="trastuzumab" post="or lapatinib, PIK3CA mutations and/or PTEN-low cell lines as"/>
   <result pre="mutations and/or PTEN-low cell lines as a group correlated with" exact="trastuzumab" post="resistance, while still not affecting lapatinib sensitivity. 53 Trastuzumab"/>
   <result pre="a group correlated with trastuzumab resistance, while still not affecting" exact="lapatinib" post="sensitivity. 53 Trastuzumab in early breast cancer: adjuvant setting"/>
   <result pre="cancer patients who had been treated with cyclophosphamide, epirubicin, and" exact="fluorouracil" post="followed by 1 year’s trastuzumab in an adjuvant trial"/>
   <result pre="treated with cyclophosphamide, epirubicin, and fluorouracil followed by 1 year’s" exact="trastuzumab" post="in an adjuvant trial setting. 45 Results showed that"/>
   <result pre="all patients received perisurgical chemotherapy consisting of anthracycline-based combinations and" exact="docetaxel" post="and 1 year’s trastuzumab. Results showed better DFS in"/>
   <result pre="produced different results. These studies were randomized trials that compared" exact="trastuzumab" post="with no trastuzumab, which enables better distinction of the"/>
   <result pre="a prognostic factor from a predictive factor with regard to" exact="trastuzumab" post="benefit, compared to studies where all patients received trastuzumab."/>
   <result pre="patients with HER2-amplified tumors were randomized to either 9 weeks’" exact="trastuzumab" post="or control combined with chemotherapy, tumors were genotyped for"/>
   <result pre="39 The study found no clear difference in benefit from" exact="trastuzumab" post="therapy between PIK3CA-mutant and wild-type patients, 39 though the"/>
   <result pre="157; PIK3CA wild-type 123, PIK3CA-mutant 34) and the duration of" exact="trastuzumab" post="treatment was shorter than the current standard of 1"/>
   <result pre="a randomized Phase III trial that compared doxorubicin/cyclophosphamide followed by" exact="paclitaxel" post="with the same regimen combined with 1 year’s trastuzumab"/>
   <result pre="by paclitaxel with the same regimen combined with 1 year’s" exact="trastuzumab" post="starting from the paclitaxel phase. 55 Results showed that"/>
   <result pre="same regimen combined with 1 year’s trastuzumab starting from the" exact="paclitaxel" post="phase. 55 Results showed that the DFS benefit from"/>
   <result pre="paclitaxel phase. 55 Results showed that the DFS benefit from" exact="trastuzumab" post="in PIK3CA-mutant tumors (HR 0.44, 95% CI 0.24–0.82; P=0.009)"/>
   <result pre="55 suggesting a lack of predictive value for PIK3CA in" exact="trastuzumab" post="efficacy, consistent with the FinHER trial. Overall, it should"/>
   <result pre="has predictive value for a gain in DFS from adjuvant" exact="trastuzumab" post="therapy ( Table 2). Trastuzumab in early breast cancer:"/>
   <result pre="evaluated the influence of PIK3CA genotypes on p-CR rate when" exact="trastuzumab" post="was involved in neoadjuvant systemic therapy in HER2-positive patients."/>
   <result pre="independent neoadjuvant studies, in which all HER2-positive patients received either" exact="trastuzumab" post="or lapatinib or this combination plus anthracycline–taxane chemotherapy. 56"/>
   <result pre="studies, in which all HER2-positive patients received either trastuzumab or" exact="lapatinib" post="or this combination plus anthracycline–taxane chemotherapy. 56 Results showed"/>
   <result pre="patients treated with trastuzumab-containing regimens than in those treated with" exact="lapatinib" post="as the only HER2-targeted drug. Of note, this study"/>
   <result pre="cohort of 139 patients with HER2-positive metastatic cancer treated with" exact="trastuzumab" post="alone or in combination with chemotherapy, PIK3CA mutation was"/>
   <result pre="29 Lapatinib The predictive value of the PIK3CA genotype for" exact="lapatinib" post="is controversial from preclinical and clinical perspectives. In neoadjuvant"/>
   <result pre="lapatinib is controversial from preclinical and clinical perspectives. In neoadjuvant" exact="lapatinib" post="trials, as discussed earlier, the difference in clinical CR"/>
   <result pre="discussed earlier, the difference in clinical CR (c-CR) rate after" exact="lapatinib" post="treatment between PIK3CA-mutant and wild-type groups was trivial. 56,"/>
   <result pre="was trivial. 56, 57 In a Phase II trial of" exact="lapatinib" post="monotherapy in HER2-positive metastatic breast cancer, three PIK3CA-mutant patients"/>
   <result pre="findings, 53 the predictive value of the PIK3CA genotype for" exact="lapatinib" post="may not be as high as that for trastuzumab"/>
   <result pre="for lapatinib may not be as high as that for" exact="trastuzumab" post="( Table 2). Pertuzumab A biomarker study associated with"/>
   <result pre="a randomized Phase II study comparing three treatment arms involving" exact="pertuzumab" post="and trastuzumab in combination with chemotherapy, showed that patients"/>
   <result pre="Phase II study comparing three treatment arms involving pertuzumab and" exact="trastuzumab" post="in combination with chemotherapy, showed that patients carrying PIK3CA"/>
   <result pre="statistical significance. 59 This finding indicates that the addition of" exact="pertuzumab" post="may not be sufficient to overcome trastuzumab resistance caused"/>
   <result pre="the addition of pertuzumab may not be sufficient to overcome" exact="trastuzumab" post="resistance caused by PIK3CA mutations. The CLEOPATRA study was"/>
   <result pre="The CLEOPATRA study was a randomized Phase III trial comparing" exact="docetaxel" post="and trastuzumab with the same regimen combined with pertuzumab"/>
   <result pre="study was a randomized Phase III trial comparing docetaxel and" exact="trastuzumab" post="with the same regimen combined with pertuzumab for first-line"/>
   <result pre="comparing docetaxel and trastuzumab with the same regimen combined with" exact="pertuzumab" post="for first-line chemotherapy in HER2-positive recurrent or metastatic breast"/>
   <result pre="were recently published. 61 These showed that the addition of" exact="pertuzumab" post="to trastuzumab resulted in an improvement in progression-free survival"/>
   <result pre="published. 61 These showed that the addition of pertuzumab to" exact="trastuzumab" post="resulted in an improvement in progression-free survival in both"/>
   <result pre="genotype does not predict a benefit from the addition of" exact="pertuzumab" post="when trastuzumab is given as baseline treatment ( Table"/>
   <result pre="not predict a benefit from the addition of pertuzumab when" exact="trastuzumab" post="is given as baseline treatment ( Table 2). Endocrine"/>
   <result pre="in the absence of estrogen, and constitutively active AKT causes" exact="tamoxifen" post="resistance. 62 One study analyzed the correlation of the"/>
   <result pre="to neoadjuvant endocrine therapy consisting of either tamoxifen, letrozole, or" exact="exemestane" post="in three different clinical trials (n=235). Results showed that"/>
   <result pre="111 of 159 [70%]; P=0.0459). 41 The aforementioned study involving" exact="tamoxifen" post="and observation groups, however, failed to show a predictive"/>
   <result pre="predictive value of PIK3CA mutation measured with RFS from adjuvant" exact="tamoxifen" post="treatment. 38 Another study analyzing PIK3CA genotypes in tumors"/>
   <result pre="tumors from 447 ER-positive metastatic patients who had undergone first-line" exact="tamoxifen" post="treatment found no association of genotypes with treatment outcome"/>
   <result pre="36 Anti-PI3K pathway drugs As of today, the mTOR inhibitor" exact="everolimus" post="is the only drug targeting the PI3K pathway, which"/>
   <result pre="rate. 56, 57 It is unclear, however, whether or not" exact="trastuzumab" post="can be omitted in patients with HER2-positive/ PIK3CA-mutant tumors,"/>
   <result pre="impossible to conduct. Rather, the development of therapies to overcome" exact="trastuzumab" post="resistance by PIK3CA mutations is awaited. One potential solution"/>
   <result pre="be inapplicable to targeted therapies. Recently, the ALLTO trial comparing" exact="trastuzumab" post="and a trastuzumab plus lapatinib combination in an adjuvant"/>
   <result pre="targeted therapies. Recently, the ALLTO trial comparing trastuzumab and a" exact="trastuzumab" post="plus lapatinib combination in an adjuvant setting failed to"/>
   <result pre="Recently, the ALLTO trial comparing trastuzumab and a trastuzumab plus" exact="lapatinib" post="combination in an adjuvant setting failed to show an"/>
   <result pre="Parsons K et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by" exact="trastuzumab" post="and is effectively inhibited by the PI3K inhibitor GDC-0941"/>
   <result pre="et al. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with" exact="trastuzumab" post="response and survival in patients with HER2-positive metastatic breast"/>
   <result pre="association of PIK3CA mutations and PTEN loss with efficacy of" exact="trastuzumab" post="therapy in metastatic breast cancer Breast Cancer Res Treat"/>
   <result pre="with first-line treatment outcome for aromatase inhibitors but not for" exact="tamoxifen" post="Breast Cancer Res Treat 2013 139 1 39 49"/>
   <result pre="receptor 2, and insulin-like growth factor 1 receptor and adjuvant" exact="tamoxifen" post="resistance in postmenopausal breast cancer patients Breast Cancer Res"/>
   <result pre="et al. Somatic mutation profiling and associations with prognosis and" exact="trastuzumab" post="benefit in early breast cancer J Natl Cancer Inst"/>
   <result pre="HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and" exact="trastuzumab" post="Ann Oncol 2012 23 8 2034 2042 22172323 46"/>
   <result pre="factor receptor 2-positive metastatic breast cancer patients treated with first-line" exact="lapatinib" post="plus paclitaxel or paclitaxel alone Breast Cancer Res 2014"/>
   <result pre="2-positive metastatic breast cancer patients treated with first-line lapatinib plus" exact="paclitaxel" post="or paclitaxel alone Breast Cancer Res 2014 16 4"/>
   <result pre="breast cancer patients treated with first-line lapatinib plus paclitaxel or" exact="paclitaxel" post="alone Breast Cancer Res 2014 16 4 405 25056500"/>
   <result pre="approach identifies the PI3K pathway as a major determinant of" exact="trastuzumab" post="resistance in breast cancer Cancer Cell 2007 12 4"/>
   <result pre="M Scaltriti M et al. Phosphatidylinositol 3-kinase hyperactivation results in" exact="lapatinib" post="resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor"/>
   <result pre="L et al. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to" exact="trastuzumab" post="but not lapatinib Mol Cancer Ther 2010 9 6"/>
   <result pre="Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not" exact="lapatinib" post="Mol Cancer Ther 2010 9 6 1489 1502 20501798"/>
   <result pre="of PIK3CA mutations in HER2-positive breast cancer patients treated with" exact="trastuzumab" post="Br J Cancer 2013 108 9 1807 1809 23612454"/>
   <result pre="Baselga J Cortés J Kim SB et al. Pertuzumab plus" exact="trastuzumab" post="plus docetaxel for metastatic breast cancer N Engl J"/>
   <result pre="Cortés J Kim SB et al. Pertuzumab plus trastuzumab plus" exact="docetaxel" post="for metastatic breast cancer N Engl J Med 2012"/>
   <result pre="Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of" exact="pertuzumab" post="in human epidermal growth factor receptor 2-positive, first-line metastatic"/>
   <result pre="Park BH PIK3CA and KRAS mutations predict for response to" exact="everolimus" post="therapy: now that’s RAD001 J Clin Invest 2010 120"/>
   <result pre="Baselga J Bradbury I Eidtmann H et al. Lapatinib with" exact="trastuzumab" post="for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label,"/>
   <result pre="conclusion, but PIK3CA mutations were unlikely to predict benefit from" exact="lapatinib" post="therapy. Insufficient data for conclusion, but PIK3CA mutations were"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4444439/results/search/inn/results.xml">
   <result pre="increased risk of liver injury when treating with pazopanib, sunitinib," exact="lapatinib" post="and regorafenib. A meta-analysis published in 2013 showed that"/>
   <result pre="tests that allow one to assess liver function are the" exact="antipyrine" post="test, galactose elimination ability test, and bromsulphthalein clearance evaluation."/>
   <result pre="growth factor (VEGF) [ 18, 19]. Significant hepatotoxicity from using" exact="bevacizumab" post="has not been observed. Toxic injury of hepatocytes that"/>
   <result pre="However, there are publications that discuss the protective action of" exact="bevacizumab" post="in conjunction with chemotherapy. It is believed that it"/>
   <result pre="targeted therapy Aim Registration indications [ 18] Hepatotoxicity Monoclonal antibodies" exact="bevacizumab" post="VEGF colon cancer, rectum cancer, breast cancer, non-small-cell lung"/>
   <result pre="cancer, breast cancer, non-small-cell lung cancer, ovarian epithelial cancer –" exact="rituximab" post="membrane antigen CD 20 follicular lymphoma, diffuse large B-cell"/>
   <result pre="antigen CD 20 follicular lymphoma, diffuse large B-cell lymphoma –" exact="ipilimumab" post="CTLA-4 malignant melanoma + trastuzumab HER 2 breast cancer,"/>
   <result pre="diffuse large B-cell lymphoma – ipilimumab CTLA-4 malignant melanoma +" exact="trastuzumab" post="HER 2 breast cancer, stomach cancer + cetuximab EGFR"/>
   <result pre="melanoma + trastuzumab HER 2 breast cancer, stomach cancer +" exact="cetuximab" post="EGFR colon and rectum cancer, head and neck squamous"/>
   <result pre="and rectum cancer, head and neck squamous cell carcinoma –" exact="panitumumab" post="EGFR colon and rectum cancer – Kinase inhibitors erlotinib"/>
   <result pre="– panitumumab EGFR colon and rectum cancer – Kinase inhibitors" exact="erlotinib" post="EGFR non-small-cell lung cancer, pancreatic cancer + gefitinib EGFR"/>
   <result pre="Kinase inhibitors erlotinib EGFR non-small-cell lung cancer, pancreatic cancer +" exact="gefitinib" post="EGFR non-small-cell lung cancer + lapatinib EGFR, HER 2"/>
   <result pre="cancer, pancreatic cancer + gefitinib EGFR non-small-cell lung cancer +" exact="lapatinib" post="EGFR, HER 2 breast cancer +++ sorafenib RAF, VEGFR"/>
   <result pre="lung cancer + lapatinib EGFR, HER 2 breast cancer +++" exact="sorafenib" post="RAF, VEGFR type 1, 2 and 3, PDGFR, c-KIT"/>
   <result pre="2 and 3, PDGFR, c-KIT hepatocellular carcinoma, kidney cancer ++" exact="pazopanib" post="PDGFR, c-KIT, VEGFR type 1 and 2 renal cell"/>
   <result pre="renal cell carcinoma, some forms of soft tissue sarcoma +++" exact="sunitinib" post="VEGFR type 1 and 2, PDGFR, c-KIT, FLT-3, RET"/>
   <result pre="gastrointestinal stromal tumors, renal cell carcinoma, neuroendocrine pancreatic tumors +++" exact="imatinib" post="BCR-ABL, KIT, PDGFR chronic myeloid leukemia, acute lymphoblastic leukemia,"/>
   <result pre="or myeloproliferative disease, gastrointestinal stromal tumors, skin nodular fibrosarcoma ++" exact="temsirolimus" post="mTOR renal cell carcinoma, mantle cell lymphoma – everolimus"/>
   <result pre="++ temsirolimus mTOR renal cell carcinoma, mantle cell lymphoma –" exact="everolimus" post="mTOR breast cancer, pancreatic neuroendocrine tumors, renal cell carcinoma"/>
   <result pre="cancer, pancreatic neuroendocrine tumors, renal cell carcinoma – Proteasome inhibitor" exact="bortezomib" post="UP-S multiple myeloma + + single cases of hepatotoxicity"/>
   <result pre="triple blind study concluded that as a result of using" exact="ipilimumab" post="as monotherapy in 131 patients, there was an increase"/>
   <result pre="monoclonal human IgG2 antibody. The conditions necessary to treat with" exact="cetuximab" post="or panitumumab are proof of EGFR expression in tumor"/>
   <result pre="IgG2 antibody. The conditions necessary to treat with cetuximab or" exact="panitumumab" post="are proof of EGFR expression in tumor cells as"/>
   <result pre="the third and fourth stage as a result of using" exact="cetuximab" post="or panitumumab as monotherapy. In the case of treating"/>
   <result pre="and fourth stage as a result of using cetuximab or" exact="panitumumab" post="as monotherapy. In the case of treating with cetuximab"/>
   <result pre="or panitumumab as monotherapy. In the case of treating with" exact="cetuximab" post="or panitumumab in association with chemotherapy, hepatocyte damage can"/>
   <result pre="as monotherapy. In the case of treating with cetuximab or" exact="panitumumab" post="in association with chemotherapy, hepatocyte damage can occur, but"/>
   <result pre="disorders in liver function have been noted due to using" exact="erlotinib" post="as monotherapy [ 24]. However, in a third phase"/>
   <result pre="in a third phase trial which evaluated the effectiveness of" exact="erlotinib" post="in conjunction with gemcitabine in comparison to gemcitabine monotherapy"/>
   <result pre="trial which evaluated the effectiveness of erlotinib in conjunction with" exact="gemcitabine" post="in comparison to gemcitabine monotherapy in patients with locally"/>
   <result pre="effectiveness of erlotinib in conjunction with gemcitabine in comparison to" exact="gemcitabine" post="monotherapy in patients with locally advanced or disseminated pancreatic"/>
   <result pre="degree liver damage was observed in 11% of patients receiving" exact="erlotinib" post="compared to 8% of patients in the other group"/>
   <result pre="The group of tyrosine kinase inhibitors of EGFR also includes" exact="gefitinib" post="( Table 2). Gefitinib rarely causes an aminotransferase increase."/>
   <result pre="[ 26]. There are some reports which say that following" exact="gefitinib" post="which evoked hepatotoxicity with erlotinib may cause a decrease"/>
   <result pre="reports which say that following gefitinib which evoked hepatotoxicity with" exact="erlotinib" post="may cause a decrease in serum liver enzyme values"/>
   <result pre="many publications which report toxic drug-induced liver damage caused by" exact="sorafenib" post="[ 30]. In case of an increase in bilirubin"/>
   <result pre="double blind trial VEG105192 evaluated efficacy and safety when using" exact="pazopanib" post="in patients with advanced localized or disseminated renal clear"/>
   <result pre="drug toxicity. Fifty-three percent of patients who were treated with" exact="pazopanib" post="were diagnosed with increased ASPAT; however, the fourth degree"/>
   <result pre="The group of mTOR protein inhibitors (cytoplasmic serine-tyrosine kinase) includes" exact="temsirolimus" post="and everolimus ( Table 2). In the literature, there"/>
   <result pre="of mTOR protein inhibitors (cytoplasmic serine-tyrosine kinase) includes temsirolimus and" exact="everolimus" post="( Table 2). In the literature, there is no"/>
   <result pre="ALAT values in less than 10% of patients treated with" exact="sunitinib" post="and sorafenib, while the increases were present in more"/>
   <result pre="were present in more than 10% of patients treated with" exact="pazopanib" post="and mTOR inhibitors. Hyperbilirubinemia was diagnosed in over 10%"/>
   <result pre="due to the treatment with pazopanib. Similar warnings apply to" exact="sunitinib" post="and lapatinib. In March 2013 in the USA the"/>
   <result pre="lapatinib. In March 2013 in the USA the multikinase inhibitor" exact="regorafenib" post="was registered. Its use is linked to significant hepatotoxicity;"/>
   <result pre="(682 patients) was taking part in the trial concerning GIST" exact="imatinib" post="treatment, which was published in 2009 by De Matteo"/>
   <result pre="20 18345708 20 Zalinski S Bigourdan J Vauthey J Does" exact="bevacizumab" post="have a protective effect on hepatotoxicity induced by chemotherapy?"/>
   <result pre="F O'Day S McDermott D et al. Improved survival with" exact="ipilimumab" post="in patients with metastatic melanoma N Engl J Med"/>
   <result pre="Moore M Goldstein D Hamm J et al. Erlotinib plus" exact="gemcitabine" post="compared with gemcitabine alone in patients with advanced pancreatic"/>
   <result pre="D Hamm J et al. Erlotinib plus gemcitabine compared with" exact="gemcitabine" post="alone in patients with advanced pancreatic cancer: a phase"/>
   <result pre="W Shu YQ Wang ZX First-line single agent treatment with" exact="gefitinib" post="in patients with advanced non-small-cell lung cancer J Exp"/>
   <result pre="H Yamada T Igarashi S et al. Efficacy of low-dose" exact="erlotinib" post="against gefitinib-induced hepatotoxicity in a patient with lung adenocarcinoma"/>
   <result pre="HK Chan EC Mechanism-based inactivation of cytochrome P450 3A4 by" exact="lapatinib" post="Mol Pharmacol 2010 78 693 703 20624855 30 Fairfax"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4445592/results/search/inn/results.xml">
   <result pre="4445592 doi: 10.2147/BCTT.S61579 bctt-7-125 : Review The expanding role of" exact="pertuzumab" post="in the treatment of HER2-positive breast cancer Moya-Horno I"/>
   <result pre="inhibits HER2 by binding to a different HER2 epitope than" exact="trastuzumab" post="and represents a complementary mechanism of action to trastuzumab."/>
   <result pre="mechanism of action to trastuzumab. The efficacy and safety of" exact="pertuzumab" post="in combination with trastuzumab with or without chemotherapy have"/>
   <result pre="trastuzumab. The efficacy and safety of pertuzumab in combination with" exact="trastuzumab" post="with or without chemotherapy have been demonstrated in both"/>
   <result pre="Herein, we review the available data on the use of" exact="pertuzumab" post="for the treatment of patients with HER2-positive breast cancer."/>
   <result pre="for the treatment of patients with HER2-positive breast cancer. Keywords" exact="pertuzumab" post="anti-HER2 targeted therapies HER2-positive breast cancer Introduction Breast cancer"/>
   <result pre="licensed anti-HER2 agents: trastuzumab, lapatinib, and more recently, pertuzumab, and" exact="trastuzumab" post="emtansine (formerly known as T-DM1). Trastuzumab is a recombinant"/>
   <result pre="several mechanisms of action. The combination of systemic therapy with" exact="trastuzumab" post="has significantly altered the natural history of HER2-positive breast"/>
   <result pre="months. 5, 7, 8 Currently, taxanes (pacli-taxel and docetaxel) and" exact="vinorelbine" post="are the most common drugs used in combination with"/>
   <result pre="vinorelbine are the most common drugs used in combination with" exact="trastuzumab" post="for the first-line treatment of HER2-positive MBC. In postmenopausal"/>
   <result pre="HER-2-positive tumors treated with neoadjuvant chemotherapy, the addition of neoadjuvant" exact="trastuzumab" post="to taxanes and anthracyclines has also substantially improved the"/>
   <result pre="(pCR) and disease-free survival. 11, 12 Overview of pharmacology of" exact="pertuzumab" post="Pertuzumab is a recombinant humanized monoclonal antibody directed against"/>
   <result pre="a complementary mechanism of action to trastuzumab. The addition of" exact="pertuzumab" post="after progression to ongoing trastuzumab in xenografts synergistically increases"/>
   <result pre="to trastuzumab. The addition of pertuzumab after progression to ongoing" exact="trastuzumab" post="in xenografts synergistically increases tumor inhibition compared to trastuzumab"/>
   <result pre="ongoing trastuzumab in xenografts synergistically increases tumor inhibition compared to" exact="trastuzumab" post="treatment alone. 13 In combination with trastuzumab and docetaxel,"/>
   <result pre="inhibition compared to trastuzumab treatment alone. 13 In combination with" exact="trastuzumab" post="and docetaxel, pertuzumab improves PFS and OS versus trastuzumab"/>
   <result pre="trastuzumab treatment alone. 13 In combination with trastuzumab and docetaxel," exact="pertuzumab" post="improves PFS and OS versus trastuzumab and docetaxel in"/>
   <result pre="with trastuzumab and docetaxel, pertuzumab improves PFS and OS versus" exact="trastuzumab" post="and docetaxel in the phase III CLEOPATRA trial in"/>
   <result pre="and docetaxel, pertuzumab improves PFS and OS versus trastuzumab and" exact="docetaxel" post="in the phase III CLEOPATRA trial in first-line HER2-positive"/>
   <result pre="In a substudy of CLEOPATRA evaluating potential pharmacokinetic drug–drug interaction," exact="pertuzumab" post="showed no impact on the pharmacokinetics of trastuzumab or"/>
   <result pre="drug–drug interaction, pertuzumab showed no impact on the pharmacokinetics of" exact="trastuzumab" post="or docetaxel. 15 Pertuzumab is presented as a concentrated"/>
   <result pre="contains 420 mg of pertuzumab. The recommended initial dose of" exact="pertuzumab" post="is 840 mg administered as a 60-minute intravenous (iv)"/>
   <result pre="Efficacy, safety, and tolerability studies The efficacy and safety of" exact="pertuzumab" post="in combination with trastuzumab in MBC have been demonstrated"/>
   <result pre="studies The efficacy and safety of pertuzumab in combination with" exact="trastuzumab" post="in MBC have been demonstrated in two phase II"/>
   <result pre="approval by the US Food and Drug Administration (FDA) for" exact="pertuzumab" post="on June 8, 2012, for use in combination with"/>
   <result pre="pertuzumab on June 8, 2012, for use in combination with" exact="trastuzumab" post="and docetaxel for the treatment of patients with HER2-positive"/>
   <result pre="June 8, 2012, for use in combination with trastuzumab and" exact="docetaxel" post="for the treatment of patients with HER2-positive MBC who"/>
   <result pre="as an acceptable safety profile. As of August 1, 2013," exact="pertuzumab" post="received regulatory approval for the MBC indication in 53"/>
   <result pre="the MBC indication in 53 countries. Since the combination of" exact="pertuzumab" post="and trastuzumab showed significant OS benefit in the metastatic"/>
   <result pre="indication in 53 countries. Since the combination of pertuzumab and" exact="trastuzumab" post="showed significant OS benefit in the metastatic setting, the"/>
   <result pre="the metastatic setting, the FDA recently granted accelerated approval for" exact="pertuzumab" post="in combination with trastuzumab and docetaxel as neoadjuvant treatment"/>
   <result pre="FDA recently granted accelerated approval for pertuzumab in combination with" exact="trastuzumab" post="and docetaxel as neoadjuvant treatment for patients with HER2-positive"/>
   <result pre="granted accelerated approval for pertuzumab in combination with trastuzumab and" exact="docetaxel" post="as neoadjuvant treatment for patients with HER2-positive tumors greater"/>
   <result pre="an improvement in pCR in patients receiving pertuzumab, trastuzumab, and" exact="docetaxel" post="in both the NeoSphere and TRYPHAENA trials, but no"/>
   <result pre="blinded, phase III study comparing pertuzumab, trastuzumab, and chemotherapy to" exact="trastuzumab" post="and chemotherapy in the adjuvant treatment of patients with"/>
   <result pre="pertuzumab, trastuzumab, and chemotherapy in the early-stage setting. Efficacy of" exact="pertuzumab" post="in MBC The phase II BO17929 and TOC3487 trials"/>
   <result pre="of evaluating the efficacy and safety of the combination of" exact="pertuzumab" post="and trastuzumab without chemotherapy. In the BO17929 trial, the"/>
   <result pre="the efficacy and safety of the combination of pertuzumab and" exact="trastuzumab" post="without chemotherapy. In the BO17929 trial, the combination of"/>
   <result pre="trastuzumab without chemotherapy. In the BO17929 trial, the combination of" exact="pertuzumab" post="and trastuzumab showed a significant antitumor activity in 66"/>
   <result pre="chemotherapy. In the BO17929 trial, the combination of pertuzumab and" exact="trastuzumab" post="showed a significant antitumor activity in 66 patients, with"/>
   <result pre="this clinical benefit was a result of the combination of" exact="pertuzumab" post="and trastuzumab or pertuzumab alone, a cohort of 29"/>
   <result pre="benefit was a result of the combination of pertuzumab and" exact="trastuzumab" post="or pertuzumab alone, a cohort of 29 patients whose"/>
   <result pre="a result of the combination of pertuzumab and trastuzumab or" exact="pertuzumab" post="alone, a cohort of 29 patients whose disease was"/>
   <result pre="cohort of 29 patients whose disease was initially treated with" exact="pertuzumab" post="in monotherapy, with the addition of trastuzumab at the"/>
   <result pre="initially treated with pertuzumab in monotherapy, with the addition of" exact="trastuzumab" post="at the time of tumor progression, was recruited. The"/>
   <result pre="The results of the cohort of 29 patients treated with" exact="pertuzumab" post="in monotherapy were poor, with an RR of 3.4%,"/>
   <result pre="eleven patients evaluated. 19 The main data on efficacy of" exact="pertuzumab" post="in first-line treatment of HER2-positive MBC were obtained from"/>
   <result pre="a randomized, doubleblind, phase III study comparing placebo, trastuzumab, and" exact="docetaxel" post="versus pertuzumab, trastuzumab, and docetaxel for patients with HER2-"/>
   <result pre="study comparing placebo, trastuzumab, and docetaxel versus pertuzumab, trastuzumab, and" exact="docetaxel" post="for patients with HER2- positive MBC with no previous"/>
   <result pre="were central nervous system (CNS) metastases and previous exposure to" exact="doxorubicin" post="exceeding 360 mg/m 2. Patients received placebo/pertuzumab (840 mg"/>
   <result pre="iv loading dose, then 420 mg iv every 3 weeks)," exact="trastuzumab" post="(8 mg/kg iv loading dose, then 6 mg/kg iv"/>
   <result pre="loading dose, then 6 mg/kg iv every 3 weeks), and" exact="docetaxel" post="(75 mg/m 2 iv every 3 weeks, 100 mg/m"/>
   <result pre="mg/m 2 iv every 3 weeks if tolerated). Placebo/pertuzumab and" exact="trastuzumab" post="were administered until disease progression or unmanageable toxic effects."/>
   <result pre="until disease progression or unmanageable toxic effects. Dose reductions of" exact="pertuzumab" post="and trastuzumab were not allowed. The dose of docetaxel"/>
   <result pre="progression or unmanageable toxic effects. Dose reductions of pertuzumab and" exact="trastuzumab" post="were not allowed. The dose of docetaxel could be"/>
   <result pre="of pertuzumab and trastuzumab were not allowed. The dose of" exact="docetaxel" post="could be reduced by 25% to manage toxicity. At"/>
   <result pre="by 25% to manage toxicity. At least six cycles of" exact="docetaxel" post="were recommended. Fewer cycles of the drug were permitted"/>
   <result pre="trial, 406 were randomly assigned to receive placebo, trastuzumab, and" exact="docetaxel" post="(control group) and 402 received pertuzumab, trastuzumab, and docetaxel"/>
   <result pre="and docetaxel (control group) and 402 received pertuzumab, trastuzumab, and" exact="docetaxel" post="(pertuzumab group). The addition of pertuzumab to trastuzumab and"/>
   <result pre="received pertuzumab, trastuzumab, and docetaxel (pertuzumab group). The addition of" exact="pertuzumab" post="to trastuzumab and docetaxel provided a statistically significant improvement"/>
   <result pre="trastuzumab, and docetaxel (pertuzumab group). The addition of pertuzumab to" exact="trastuzumab" post="and docetaxel provided a statistically significant improvement in PFS"/>
   <result pre="docetaxel (pertuzumab group). The addition of pertuzumab to trastuzumab and" exact="docetaxel" post="provided a statistically significant improvement in PFS compared to"/>
   <result pre="statistically significant improvement in PFS compared to placebo, trastuzumab, and" exact="docetaxel" post="treatment. The median independently assessed PFS was increased by"/>
   <result pre="months in the control group to 18.5 months in the" exact="pertuzumab" post="group (hazard ratio [HR]: 0.62; 95% confidence interval [CI]:"/>
   <result pre="months in the control group and 16.9 months in the" exact="pertuzumab" post="group (HR: 0.62; 95% CI: 0.35–1.07). Among the 288"/>
   <result pre="months in the control group and 21.6 months in the" exact="pertuzumab" post="group (HR: 0.60; 95% CI: 0.43–0.83). Investigator-assessed median PFS"/>
   <result pre="months in the control group and 18.5 months in the" exact="pertuzumab" post="group (HR: 0.65; 95% CI: 0.54–0.78; P&amp;lt;0.001). The improvement"/>
   <result pre="in both the control (13.8 months versus 8.8 months) and" exact="pertuzumab" post="(21.8 months versus 12.5 months) groups. 20 At the"/>
   <result pre="analysis of OS showed a trend in favor of the" exact="pertuzumab" post="group, but this was not significant. After a follow-up"/>
   <result pre="the statistically significant improvement in OS in favor of the" exact="pertuzumab" post="group was maintained (HR: 0.68; 95% CI: 0.56–0.84; P=0.0002)."/>
   <result pre="months in the control group and 56.5 months in the" exact="pertuzumab" post="group, with difference of 15.7 months. The objective RR"/>
   <result pre="was 69.3% in the control group and 80.2% in the" exact="pertuzumab" post="group. The difference in RR was 10.8 percentage points"/>
   <result pre="between the control group (51 of 406, 12.6%) and the" exact="pertuzumab" post="group (55 of 402, 13.7%). The median time to"/>
   <result pre="months in the control group and 15.0 months in the" exact="pertuzumab" post="group (HR: 0.58; 95% CI: 0.39–0.85; P=0.0049). Median OS"/>
   <result pre="developed CNS metastases showed a trend in favor of the" exact="pertuzumab" post="group, being 26.3 months versus 34.4 months in the"/>
   <result pre="being 26.3 months versus 34.4 months in the control and" exact="pertuzumab" post="groups, respectively (HR: 0.66; 95% CI: 0.39–1.11). The difference"/>
   <result pre="have also found activity and tolerability for other regimens combining" exact="pertuzumab" post="and trastuzumab together with other active cytotoxics (paclitaxel and"/>
   <result pre="found activity and tolerability for other regimens combining pertuzumab and" exact="trastuzumab" post="together with other active cytotoxics (paclitaxel and vinorelbine). 24,"/>
   <result pre="phase IIIb trial PERUSE evaluating safety and efficacy of first-line" exact="pertuzumab" post="in combination with trastuzumab and a broader range of"/>
   <result pre="evaluating safety and efficacy of first-line pertuzumab in combination with" exact="trastuzumab" post="and a broader range of taxanes (investigator’s choice of"/>
   <result pre="of pertuzumab, trastuzumab, and a taxane. 26 The combination of" exact="pertuzumab" post="and T-DM1 in the treatment of patients with HER2-positive"/>
   <result pre="57% with no unexpected toxicities. 27 Further clinical trials of" exact="pertuzumab" post="plus other anti-HER2 therapies beyond trastuzumab in the treatment"/>
   <result pre="Further clinical trials of pertuzumab plus other anti-HER2 therapies beyond" exact="trastuzumab" post="in the treatment of patients with HER2-positive MBC are"/>
   <result pre="HER2-positive MBC are warranted. As commented before, the use of" exact="trastuzumab" post="and pertuzumab in trastuzumab-resistant patients has been explored in"/>
   <result pre="are warranted. As commented before, the use of trastuzumab and" exact="pertuzumab" post="in trastuzumab-resistant patients has been explored in phase II"/>
   <result pre="combination, a randomized phase III trial exploring the use of" exact="capecitabine" post="and trastuzumab with or without pertuzumab (the PHEREXA trial)"/>
   <result pre="randomized phase III trial exploring the use of capecitabine and" exact="trastuzumab" post="with or without pertuzumab (the PHEREXA trial) will define"/>
   <result pre="exploring the use of capecitabine and trastuzumab with or without" exact="pertuzumab" post="(the PHEREXA trial) will define the role of pertuzumab"/>
   <result pre="without pertuzumab (the PHEREXA trial) will define the role of" exact="pertuzumab" post="in trastuzumab-resistant patients. In view of these upcoming data,"/>
   <result pre="trastuzumab-based therapy without pertuzumab, a line of therapy containing both" exact="trastuzumab" post="and pertuzumab, with or without a cytotoxic agent (such"/>
   <result pre="and pertuzumab, with or without a cytotoxic agent (such as" exact="vinorelbine" post="or taxane), might be considered. Further research is needed"/>
   <result pre="determine the ideal strategy for anti-HER2 therapy sequence. Efficacy of" exact="pertuzumab" post="in EBC The approval by the FDA for pertuzumab"/>
   <result pre="of pertuzumab in EBC The approval by the FDA for" exact="pertuzumab" post="in the neoadjuvant setting is based on the results"/>
   <result pre="in diameter were randomized in a 1:1:1:1 ratio to receive" exact="trastuzumab" post="plus docetaxel, or pertuzumab and trastuzumab plus docetaxel, or"/>
   <result pre="in a 1:1:1:1 ratio to receive trastuzumab plus docetaxel, or" exact="pertuzumab" post="and trastuzumab plus docetaxel, or pertuzumab and trastuzumab, or"/>
   <result pre="1:1:1:1 ratio to receive trastuzumab plus docetaxel, or pertuzumab and" exact="trastuzumab" post="plus docetaxel, or pertuzumab and trastuzumab, or pertuzumab plus"/>
   <result pre="trastuzumab plus docetaxel, or pertuzumab and trastuzumab plus docetaxel, or" exact="pertuzumab" post="and trastuzumab, or pertuzumab plus docetaxel. Of the patients"/>
   <result pre="pertuzumab and trastuzumab plus docetaxel, or pertuzumab and trastuzumab, or" exact="pertuzumab" post="plus docetaxel. Of the patients who received pertuzumab plus"/>
   <result pre="trastuzumab, or pertuzumab plus docetaxel. Of the patients who received" exact="pertuzumab" post="plus trastuzumab and docetaxel, 45.8% (95% CI: 36.1–55.7) achieved"/>
   <result pre="pertuzumab plus docetaxel. Of the patients who received pertuzumab plus" exact="trastuzumab" post="and docetaxel, 45.8% (95% CI: 36.1–55.7) achieved pCR, compared"/>
   <result pre="(95% CI: 20.6–38.5) of patients who achieved pCR on the" exact="trastuzumab" post="plus docetaxel regimen ( P=0.0063). The TRYPHAENA was a"/>
   <result pre="20.6–38.5) of patients who achieved pCR on the trastuzumab plus" exact="docetaxel" post="regimen ( P=0.0063). The TRYPHAENA was a phase II,"/>
   <result pre="multi-center trial designed to evaluate the safety and tolerability of" exact="trastuzumab" post="and pertuzumab in combination with either anthracycline-based or carboplatin-based"/>
   <result pre="designed to evaluate the safety and tolerability of trastuzumab and" exact="pertuzumab" post="in combination with either anthracycline-based or carboplatin-based neoadjuvant chemotherapy."/>
   <result pre="receive six cycles of neoadjuvant therapy with FEC (fluorouracil/epirubicin/cyclophosphamide) plus" exact="trastuzumab" post="and pertuzumab followed by docetaxel, trastuzumab, and pertuzumab; or"/>
   <result pre="cycles of neoadjuvant therapy with FEC (fluorouracil/epirubicin/cyclophosphamide) plus trastuzumab and" exact="pertuzumab" post="followed by docetaxel, trastuzumab, and pertuzumab; or FEC followed"/>
   <result pre="followed by docetaxel, trastuzumab, and pertuzumab; or docetaxel, carboplatin, and" exact="trastuzumab" post="along with pertuzumab. Based on the assessment of pCR,"/>
   <result pre="was observed in patients who received pertuzumab, trastuzumab, docetaxel, and" exact="carboplatin" post="chemotherapy. Correlation of biomarker subgroups with the achievement of"/>
   <result pre="signals for other markers analyzed. 30 Safety and tolerability of" exact="pertuzumab" post="The initial safety data of pertuzumab were obtained from"/>
   <result pre="Safety and tolerability of pertuzumab The initial safety data of" exact="pertuzumab" post="were obtained from the phase II trials BO17929 and"/>
   <result pre="phase II trials BO17929 and TOC3487 evaluating the combination of" exact="pertuzumab" post="and trastuzumab without chemotherapy. In the BO17929 trial, the"/>
   <result pre="trials BO17929 and TOC3487 evaluating the combination of pertuzumab and" exact="trastuzumab" post="without chemotherapy. In the BO17929 trial, the combination of"/>
   <result pre="trastuzumab without chemotherapy. In the BO17929 trial, the combination of" exact="pertuzumab" post="and trastuzumab was well tolerated, and adverse events were"/>
   <result pre="chemotherapy. In the BO17929 trial, the combination of pertuzumab and" exact="trastuzumab" post="was well tolerated, and adverse events were mild or"/>
   <result pre="exposure to adjuvant trastuzumab, and all of them had had" exact="trastuzumab" post="for treatment of metastatic disease. Because cardiac safety was"/>
   <result pre="enrollment of 37 patients. 19 The main safety data of" exact="pertuzumab" post="were evaluated in patients who received at least one"/>
   <result pre="the drug in the CLEOPATRA trial. 14 The addition of" exact="pertuzumab" post="to trastuzumab and docetaxel was well tolerated, and the"/>
   <result pre="in the CLEOPATRA trial. 14 The addition of pertuzumab to" exact="trastuzumab" post="and docetaxel was well tolerated, and the adverse-event profile"/>
   <result pre="CLEOPATRA trial. 14 The addition of pertuzumab to trastuzumab and" exact="docetaxel" post="was well tolerated, and the adverse-event profile was generally"/>
   <result pre="profile was generally balanced between the control group and the" exact="pertuzumab" post="group. The most common adverse reactions reported in the"/>
   <result pre="pertuzumab group. The most common adverse reactions reported in the" exact="pertuzumab" post="group, compared to the control group, were diarrhea (66.8%"/>
   <result pre="slightly higher in the control group (16.4%) compared with the" exact="pertuzumab" post="group (14.5%), LVSD (all grades) being the most frequently"/>
   <result pre="frequently reported event (8.3% versus 4.4% in the control and" exact="pertuzumab" post="groups, respectively). Symptomatic LVSD occurred in a low proportion"/>
   <result pre="proportion of patients (1.8% versus 1.0% in the control and" exact="pertuzumab" post="groups, respectively) and had resolved at data cutoff in"/>
   <result pre="in 6.6% and 3.8% of patients in the control and" exact="pertuzumab" post="groups, respectively. Of these patients, 72% (control group) and"/>
   <result pre="were 18.4 weeks and 18.3 weeks in the control and" exact="pertuzumab" post="groups, respectively, representing approximately six cycles (HR: 0.97; 95%"/>
   <result pre="cycles (HR: 0.97; 95% CI: 0.81–1.16; P=0.7161). The addition of" exact="pertuzumab" post="to trastuzumab and docetaxel also prolonged the time to"/>
   <result pre="0.97; 95% CI: 0.81–1.16; P=0.7161). The addition of pertuzumab to" exact="trastuzumab" post="and docetaxel also prolonged the time to worsening of"/>
   <result pre="CI: 0.81–1.16; P=0.7161). The addition of pertuzumab to trastuzumab and" exact="docetaxel" post="also prolonged the time to worsening of breast cancer"/>
   <result pre="in the control group compared with 26.7 weeks in the" exact="pertuzumab" post="group (HR: 0.77; 95% CI: 0.64–0.93; P=0.0061). 32 In"/>
   <result pre="the NeoSphere trial, evaluating the efficacy and safety of neoadjuvant" exact="pertuzumab" post="in combination with trastuzumab and docetaxel in women with"/>
   <result pre="the efficacy and safety of neoadjuvant pertuzumab in combination with" exact="trastuzumab" post="and docetaxel in women with HER2-positive EBC, no substantial"/>
   <result pre="and safety of neoadjuvant pertuzumab in combination with trastuzumab and" exact="docetaxel" post="in women with HER2-positive EBC, no substantial differences in"/>
   <result pre="respect to cardiac function, of three neoadjuvant treatment regimens combining" exact="pertuzumab" post="with trastuzumab and either standard anthracycline- or platinum-based chemotherapy"/>
   <result pre="cardiac function, of three neoadjuvant treatment regimens combining pertuzumab with" exact="trastuzumab" post="and either standard anthracycline- or platinum-based chemotherapy for the"/>
   <result pre="chemotherapy for the treatment of HER2-positive EBC, the combination of" exact="trastuzumab" post="and pertuzumab was generally well tolerated regardless of whether"/>
   <result pre="the treatment of HER2-positive EBC, the combination of trastuzumab and" exact="pertuzumab" post="was generally well tolerated regardless of whether it was"/>
   <result pre="increase the rate of cardiac dysfunction observed in combinations of" exact="trastuzumab" post="plus standard chemotherapy. 29 A meta-analysis of six randomized"/>
   <result pre="or lapatinib) and anti-HER2 combination therapy (trastuzumab and pertuzumab, or" exact="trastuzumab" post="and lapatinib) with or without chemotherapy in breast cancer,"/>
   <result pre="0.88 (95% CI: 0.53–1.48; P=0.64), respectively. Discussion The addition of" exact="pertuzumab" post="to the combination of trastuzumab and docetaxel for the"/>
   <result pre="respectively. Discussion The addition of pertuzumab to the combination of" exact="trastuzumab" post="and docetaxel for the first-line treatment of patients with"/>
   <result pre="The addition of pertuzumab to the combination of trastuzumab and" exact="docetaxel" post="for the first-line treatment of patients with HER2-positive MBC"/>
   <result pre="advisable with the available data to restrict the indication of" exact="pertuzumab" post="to the subgroup of patients with visceral disease. The"/>
   <result pre="The majority of patients included in the CLEOPATRA trial were" exact="trastuzumab" post="naive, and if previously treated with trastuzumab (10% of"/>
   <result pre="CLEOPATRA trial were trastuzumab naive, and if previously treated with" exact="trastuzumab" post="(10% of patients), a 12-month disease-free interval was required."/>
   <result pre="patients who had previously received neoadjuvant or adjuvant chemotherapy with" exact="trastuzumab" post="indicates that the efficacy results are similar to those"/>
   <result pre="CLEOPATRA trial were all treated with docetaxel, the use of" exact="paclitaxel" post="or nab-paclitaxel with pertuzumab and trastuzumab is also reasonable,"/>
   <result pre="treated with docetaxel, the use of paclitaxel or nab-paclitaxel with" exact="pertuzumab" post="and trastuzumab is also reasonable, particularly for patients who"/>
   <result pre="docetaxel, the use of paclitaxel or nab-paclitaxel with pertuzumab and" exact="trastuzumab" post="is also reasonable, particularly for patients who might not"/>
   <result pre="other chemotherapy agents can be combined safely and effectively with" exact="trastuzumab" post="and pertuzumab, 25 the use of alternative regimens would"/>
   <result pre="evidence to make a strong recommendation for the use of" exact="pertuzumab" post="beyond first-line treatment of HER2-positive MBC, and T-DM1 should"/>
   <result pre="evidence for the safety and efficacy of the combination of" exact="pertuzumab" post="plus trastuzumab plus either a standard anthracycline-based, or platinum-based,"/>
   <result pre="the safety and efficacy of the combination of pertuzumab plus" exact="trastuzumab" post="plus either a standard anthracycline-based, or platinum-based, chemotherapy. The"/>
   <result pre="either a standard anthracycline-based, or platinum-based, chemotherapy. The approval of" exact="pertuzumab" post="in the neoadjuvant setting is based on demonstration of"/>
   <result pre="more complete blockade of the HER pathway in combination with" exact="trastuzumab" post="(dual blockade), resulting in augmented anticancer activity in patients"/>
   <result pre="Based on the available published data, candidates for treatment with" exact="pertuzumab" post="in combination with trastuzumab and docetaxel are those patients"/>
   <result pre="published data, candidates for treatment with pertuzumab in combination with" exact="trastuzumab" post="and docetaxel are those patients with HER2-positive MBC who"/>
   <result pre="candidates for treatment with pertuzumab in combination with trastuzumab and" exact="docetaxel" post="are those patients with HER2-positive MBC who have not"/>
   <result pre="seems reasonable to assume a certain degree of effectiveness of" exact="pertuzumab" post="also in those patients with a disease-free interval between"/>
   <result pre="might not be good candidates for docetaxel, the use of" exact="paclitaxel" post="or nab-paclitaxel with pertuzumab and trastuzumab is also reasonable"/>
   <result pre="candidates for docetaxel, the use of paclitaxel or nab-paclitaxel with" exact="pertuzumab" post="and trastuzumab is also reasonable for first-line treatment. In"/>
   <result pre="docetaxel, the use of paclitaxel or nab-paclitaxel with pertuzumab and" exact="trastuzumab" post="is also reasonable for first-line treatment. In combination with"/>
   <result pre="trastuzumab is also reasonable for first-line treatment. In combination with" exact="trastuzumab" post="and chemotherapy, pertuzumab has also shown substantial activity and"/>
   <result pre="reasonable for first-line treatment. In combination with trastuzumab and chemotherapy," exact="pertuzumab" post="has also shown substantial activity and good tolerability as"/>
   <result pre="HER2-positive EBC. Research is needed to address further indications of" exact="pertuzumab" post="beyond first-line treatment of patients with HER2-positive MBC and"/>
   <result pre="N et al. collab: Breast Cancer International Research Group Adjuvant" exact="trastuzumab" post="in HER2-positive breast cancer N Engl J Med 2011"/>
   <result pre="Randomized phase II trial of the efficacy and safety of" exact="trastuzumab" post="combined with docetaxel in patients with human epidermal growth"/>
   <result pre="trial of the efficacy and safety of trastuzumab combined with" exact="docetaxel" post="in patients with human epidermal growth factor receptor 2-positive"/>
   <result pre="E Bjerre K et al. Phase III randomized study comparing" exact="docetaxel" post="plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy"/>
   <result pre="K et al. Phase III randomized study comparing docetaxel plus" exact="trastuzumab" post="with vinorelbine plus trastuzumab as first-line therapy of metastatic"/>
   <result pre="al. Phase III randomized study comparing docetaxel plus trastuzumab with" exact="vinorelbine" post="plus trastuzumab as first-line therapy of metastatic or locally"/>
   <result pre="III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus" exact="trastuzumab" post="as first-line therapy of metastatic or locally advanced human"/>
   <result pre="S Pippen J Pivot X et al. Lapatinib combined with" exact="letrozole" post="versus letrozole and placebo as first-line therapy for postmenopausal"/>
   <result pre="J Pivot X et al. Lapatinib combined with letrozole versus" exact="letrozole" post="and placebo as first-line therapy for postmenopausal hormone receptor-positive"/>
   <result pre="Kaufman B Mackey JR Clemens MR et al. Trastuzumab plus" exact="anastrozole" post="versus anastrozole alone for the treatment of postmenopausal women"/>
   <result pre="Mackey JR Clemens MR et al. Trastuzumab plus anastrozole versus" exact="anastrozole" post="alone for the treatment of postmenopausal women with human"/>
   <result pre="complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and" exact="epirubicin" post="chemotherapy: results of a randomized trial in human epidermal"/>
   <result pre="L Eiermann W Semiglazov V et al. Neoadjuvant chemotherapy with" exact="trastuzumab" post="followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in"/>
   <result pre="V et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant" exact="trastuzumab" post="versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally"/>
   <result pre="T Thier M Scheuer W et al. Combination treatment with" exact="pertuzumab" post="and trastuzumab against Calu-3 human NSCLC xenograft tumors is"/>
   <result pre="M Scheuer W et al. Combination treatment with pertuzumab and" exact="trastuzumab" post="against Calu-3 human NSCLC xenograft tumors is superior to"/>
   <result pre="Kim SB et al. collab: CLEOPATRA Study Group Pertuzumab plus" exact="trastuzumab" post="plus docetaxel for metastatic breast cancer N Engl J"/>
   <result pre="et al. collab: CLEOPATRA Study Group Pertuzumab plus trastuzumab plus" exact="docetaxel" post="for metastatic breast cancer N Engl J Med 2012"/>
   <result pre="Kudaba I et al. Absence of pharmacokinetic drug-drug interaction of" exact="pertuzumab" post="with trastuzumab and docetaxel Anticancer Drugs 2013 24 10"/>
   <result pre="et al. Absence of pharmacokinetic drug-drug interaction of pertuzumab with" exact="trastuzumab" post="and docetaxel Anticancer Drugs 2013 24 10 1084 1092"/>
   <result pre="Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and" exact="docetaxel" post="Anticancer Drugs 2013 24 10 1084 1092 23969513 16"/>
   <result pre="Gelmon KA Verma S et al. Phase II trial of" exact="pertuzumab" post="and trastuzumab in patients with human epidermal growth factor"/>
   <result pre="Verma S et al. Phase II trial of pertuzumab and" exact="trastuzumab" post="in patients with human epidermal growth factor receptor 2-positive"/>
   <result pre="factor receptor 2-positive metastatic breast cancer that progressed during prior" exact="trastuzumab" post="therapy J Clin Oncol 2010 28 7 1138 1144"/>
   <result pre="JM Rosing DR et al. Cardiac toxicity and efficacy of" exact="trastuzumab" post="combined with pertuzumab in patients with human epidermal growth"/>
   <result pre="et al. Cardiac toxicity and efficacy of trastuzumab combined with" exact="pertuzumab" post="in patients with human epidermal growth factor receptor 2-positive"/>
   <result pre="Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of" exact="pertuzumab" post="in human epidermal growth factor receptor 2-positive, first-line metastatic"/>
   <result pre="SM Kim SB Cortés J et al. Pertuzumab, trastuzumab, and" exact="docetaxel" post="for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival"/>
   <result pre="analysis from the CLEOPATRA study of first-line pertuzumab, trastuzumab, and" exact="docetaxel" post="in patients with HER2-positive metastatic breast cancer Presented at:"/>
   <result pre="Iyengar N Datko F et al. Phase II study of" exact="paclitaxel" post="given once per week along with trastuzumab and pertuzumab"/>
   <result pre="II study of paclitaxel given once per week along with" exact="trastuzumab" post="and pertuzumab in patients with human epidermal growth factor"/>
   <result pre="of paclitaxel given once per week along with trastuzumab and" exact="pertuzumab" post="in patients with human epidermal growth factor receptor 2-positive"/>
   <result pre="Mastro L et al. A combination of pertuzumab, trastuzumab, and" exact="vinorelbine" post="for first-line treatment of patients with HER2-positive metastatic breast"/>
   <result pre="Diéras V Harbeck N et al. Phase II trial of" exact="trastuzumab" post="emtansine with pertuzumab for patients with human epidermal growth"/>
   <result pre="N et al. Phase II trial of trastuzumab emtansine with" exact="pertuzumab" post="for patients with human epidermal growth factor receptor 2-positive,"/>
   <result pre="T Im YH et al. Efficacy and safety of neoadjuvant" exact="pertuzumab" post="and trastuzumab in women with locally advanced, inflammatory, or"/>
   <result pre="YH et al. Efficacy and safety of neoadjuvant pertuzumab and" exact="trastuzumab" post="in women with locally advanced, inflammatory, or early HER2-positive"/>
   <result pre="Schneeweiss A Chia S Hickish T et al. Pertuzumab plus" exact="trastuzumab" post="in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy"/>
   <result pre="SM Ewer MS Cortés J et al. Cardiac tolerability of" exact="pertuzumab" post="plus trastuzumab plus docetaxel in patients with HER2-positive metastatic"/>
   <result pre="MS Cortés J et al. Cardiac tolerability of pertuzumab plus" exact="trastuzumab" post="plus docetaxel in patients with HER2-positive metastatic breast cancer"/>
   <result pre="J et al. Cardiac tolerability of pertuzumab plus trastuzumab plus" exact="docetaxel" post="in patients with HER2-positive metastatic breast cancer in CLEOPATRA:"/>
   <result pre="Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining" exact="pertuzumab" post="with trastuzumab and docetaxel in metastatic breast cancer Ann"/>
   <result pre="assessment in CLEOPATRA, a phase III study combining pertuzumab with" exact="trastuzumab" post="and docetaxel in metastatic breast cancer Ann Oncol 2013"/>
   <result pre="CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and" exact="docetaxel" post="in metastatic breast cancer Ann Oncol 2013 24 10"/>
   <result pre="9938 164 172 24529560 Table 1 Main clinical trials evaluating" exact="pertuzumab" post="in the treatment of HER2-positive breast cancer Trial reference"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4447178/results/search/inn/results.xml">
   <result pre="biliary cancers, and colorectal adenocarcinomas. Keywords colorectal cancer gastric cancer" exact="ramucirumab" post="pembrolizumab target therapy onartuzumab AMG 337 Introduction Significant studies"/>
   <result pre="stratification, update on the method for refining optimal candidates for" exact="sorafenib" post="in hepatocellular carcinoma (HCC), and discuss how to expand"/>
   <result pre="for the treatment of advanced melanoma after the failure of" exact="ipilimumab" post="administration or BRAF V600E-mutant melanoma in progression following BRAF"/>
   <result pre="results, a Phase III randomized trial that compares pembrolizumab to" exact="paclitaxel" post="in patients with recurrent or metastatic gastric or gastroesophageal"/>
   <result pre="entered the Phase II trial to explore the combination of" exact="trastuzumab" post="and chemotherapy in this setting. Patients were treated with"/>
   <result pre="were treated with three preoperative cycles of standard XELOX plus" exact="trastuzumab" post="(loading dose 8 mg/kg, instead of 6 mg/kg), followed"/>
   <result pre="of the same combination regimen and eventually 12 cycles of" exact="trastuzumab" post="monotherapy. The primary end point of the study was"/>
   <result pre="this biologically selected population and may promote the use of" exact="trastuzumab" post="in resectable gastric cancer patients. Significant advances in HCC,"/>
   <result pre="The REACH trial is a randomized Phase III study investigating" exact="ramucirumab" post="as a single agent for the treatment of advanced"/>
   <result pre="end point. In fact, median OS was 9.2 months for" exact="ramucirumab" post="vs 7.6 months for placebo. Interestingly the prespecified subgroup"/>
   <result pre="baseline alpha-fetoprotein (AFP) level might be a predictive marker for" exact="ramucirumab" post="efficacy. Among 250 patients with baseline AFP ≥400 ng/mL,"/>
   <result pre="P=0.0059) ( Table 1). Median OS was 7.8 months for" exact="ramucirumab" post="vs 4.2 months for placebo. Accordingly, in patients with"/>
   <result pre="AFP ≥1.5× the upper limit, OS was 8.6 months for" exact="ramucirumab" post="vs 5.7 months for placebo and the HR was"/>
   <result pre="baseline levels seemed to be correlated with clinical outcome during" exact="ramucirumab" post="treatment. Hopefully, the impact of this novel treatment approach"/>
   <result pre="that the antiangiogenic compound might induce an inhibition of endothelial" exact="nitric oxide" post="synthase (eNOS) activity by blocking the VEGFRs, with a"/>
   <result pre="the VEGFRs, with a consequent decrease of the production of" exact="nitric oxide," post="which is correlated with tumor angiogenesis, invasion, and metastasis."/>
   <result pre="mechanism of resistance, which is considered an escape pathway for" exact="sorafenib" post="activity. Nonetheless, dovitinib failed to prove superior to sorafenib"/>
   <result pre="for sorafenib activity. Nonetheless, dovitinib failed to prove superior to" exact="sorafenib" post="in the first-line treatment of HCC. In the Phase"/>
   <result pre="weeks for dovitinib and 36.7 weeks (23.3 weeks–49.3 weeks) for" exact="sorafenib" post="(HR: 1.27; 95% CI: 0.89–1.80). Palmer et al 25"/>
   <result pre="Phase II trial, time to progression (TTP) was similar between" exact="nintedanib" post="and sorafenib (TTP: 5.5 months vs 3.8 months; HR:"/>
   <result pre="trial, time to progression (TTP) was similar between nintedanib and" exact="sorafenib" post="(TTP: 5.5 months vs 3.8 months; HR: 1.05; 95%"/>
   <result pre="novel staging system for patients with advanced HCC treated with" exact="doxorubicin" post="drug-eluting beads transarterial chemoembolization. In the multivariate analysis, the"/>
   <result pre="of polymorphisms in the angiogenic pathway of HCC patients receiving" exact="sorafenib" post="should be integrated with already known data in this"/>
   <result pre="new antiangiogenic agents have been reported. Two studies suggested that" exact="ramucirumab" post="and famitinib might soon be added to the armamentarium"/>
   <result pre="metastatic CRC. The RAISE trial demonstrated that the addition of" exact="ramucirumab" post="to second-line FOLFIRI chemotherapy resulted in a significant delay"/>
   <result pre="study included 1,072 patients with metastatic disease randomly assigned to" exact="ramucirumab" post="(a human immunoglobulin G-1 monoclonal antibody that targets the"/>
   <result pre="alone (median OS: 13.3 months vs 11.7 months). In addition," exact="ramucirumab" post="reduced the risk of disease progression by 21% (HR:"/>
   <result pre="bedside&quot; is being pursued. The combination of the EGFR inhibitor" exact="panitumumab" post="with the BRAF inhibitor vemurafenib for BRAF-mutant metastatic CRC"/>
   <result pre="combination of the EGFR inhibitor panitumumab with the BRAF inhibitor" exact="vemurafenib" post="for BRAF-mutant metastatic CRC has shown interesting hints of"/>
   <result pre="of anti- BRAF monotherapy, a randomized Phase II trial of" exact="irinotecan" post="plus cetuximab with or without vemurafenib is also currently"/>
   <result pre="BRAF monotherapy, a randomized Phase II trial of irinotecan plus" exact="cetuximab" post="with or without vemurafenib is also currently ongoing. 41"/>
   <result pre="Phase II trial of irinotecan plus cetuximab with or without" exact="vemurafenib" post="is also currently ongoing. 41 Because another mechanism of"/>
   <result pre="inhibitor-refractory advanced CRC have been treated with the combination of" exact="lapatinib" post="and trastuzumab. 42 As expected from the literature, 43"/>
   <result pre="in rectal cancer. Conclusion In the era of targeted therapies," exact="trastuzumab" post="and ramucirumab are the only biologic therapy agents approved"/>
   <result pre="cancer. Conclusion In the era of targeted therapies, trastuzumab and" exact="ramucirumab" post="are the only biologic therapy agents approved for patients"/>
   <result pre="results. After several years of intense clinical and translational research," exact="sorafenib" post="still remains the only available therapeutic option for patients"/>
   <result pre="pancreatic cancers. MM-398, an investigational nanocompound consisting of the chemotherapeutic" exact="irinotecan" post="encapsulated in a liposomal sphere, and PF-04136309, a novel"/>
   <result pre="CRC biology and, correspondingly, of growth of complexity, famitinib and" exact="ramucirumab" post="will provide new options to patients with advanced disease."/>
   <result pre="aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to" exact="crizotinib" post="J Clin Oncol 2011 29 36 4803 4810 22042947"/>
   <result pre="Garcia Alfonso P et al. NEOHX study: perioperative treatment with" exact="trastuzumab" post="in combination with capecitabine and oxaliplatin (XELOX-T) in patients"/>
   <result pre="al. NEOHX study: perioperative treatment with trastuzumab in combination with" exact="capecitabine" post="and oxaliplatin (XELOX-T) in patients with HER-2 resectable stomach"/>
   <result pre="study: perioperative treatment with trastuzumab in combination with capecitabine and" exact="oxaliplatin" post="(XELOX-T) in patients with HER-2 resectable stomach or esophagogastric"/>
   <result pre="polymorphisms in relation to outcome in advanced HCC patients receiving" exact="sorafenib" post="J Clin Oncol 2015 33 suppl 3 abstr 230"/>
   <result pre="et al. Phase II study of front-line dovitinib (TKI258) versus" exact="sorafenib" post="in patients (Pts) with advanced hepatocellular carcinoma (HCC) J"/>
   <result pre="Randomized phase II trial comparing the efficacy and safety of" exact="nintedanib" post="versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)"/>
   <result pre="II trial comparing the efficacy and safety of nintedanib versus" exact="sorafenib" post="in patients with advanced hepatocellular carcinoma (HCC) J Clin"/>
   <result pre="of the patients with unresectable hepatocellular carcinoma (HCC) treated with" exact="doxorubicin" post="drug eluting beads transarterial chemoembolization (DEB TACE) J Clin"/>
   <result pre="III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus" exact="ramucirumab" post="(RAM) or placebo (PBO) in patients (pts) with metastatic"/>
   <result pre="carcinoma (CRC) progressive during or following first-line combination therapy with" exact="bevacizumab" post="(bev), oxaliplatin (ox), and a fluoropyrimidine (fp) J Clin"/>
   <result pre="progressive during or following first-line combination therapy with bevacizumab (bev)," exact="oxaliplatin" post="(ox), and a fluoropyrimidine (fp) J Clin Oncol 2015"/>
   <result pre="RD Cercek A O’Reilly EM et al. Pilot study of" exact="vemurafenib" post="and panitumumab combination therapy in patients with BRAF V600E"/>
   <result pre="A O’Reilly EM et al. Pilot study of vemurafenib and" exact="panitumumab" post="combination therapy in patients with BRAF V600E mutated metastatic"/>
   <result pre="O’Reilly EM et al. S1406: randomized phase II study of" exact="irinotecan" post="and cetuximab with or without vemurafenib in BRAF-mutant metastatic"/>
   <result pre="et al. S1406: randomized phase II study of irinotecan and" exact="cetuximab" post="with or without vemurafenib in BRAF-mutant metastatic colorectal cancer"/>
   <result pre="phase II study of irinotecan and cetuximab with or without" exact="vemurafenib" post="in BRAF-mutant metastatic colorectal cancer (mCRC) J Clin Oncol"/>
   <result pre="P=0.0059) Cheng et al 24 II, randomized First-line Dovitinib vs" exact="sorafenib" post="OS HR: 1.27; 95% CI: 0.89–1.80; P=ns Palmer et"/>
   <result pre="P=ns Palmer et al 25 II, randomized First-line Nintedanib vs" exact="sorafenib" post="TTP HR: 1.05; 95% CI: 0.63–1.76; P=ns Tabernero et"/>
   <result pre="P=ns Tabernero et al 34 III, randomized Second-line FOLFIRI +" exact="ramucirumab" post="vs FOLFIRI + placebo OS HR: 0.84; (95% CI:"/>
   <result pre="patients with baseline AFP ≥400 ng/mL might derive benefit from" exact="ramucirumab" post="treatment vs placebo (OS HR: 0.67, 95% CI: 0.51–0.90;"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4453607/results/search/inn/results.xml">
   <result pre="EGFR has been suggested to be a possible basis for" exact="trastuzumab" post="resistance. Methods: We analysed the clinical significance of EGFR"/>
   <result pre="cancers. In addition, we examined the correlations between EGFR overexpression," exact="trastuzumab" post="response and clinical outcome in 447 primary, and 112"/>
   <result pre="poor prognostic factor. However, EGFR overexpression was not associated with" exact="trastuzumab" post="response, progression-free survival or overall survival in the metastatic"/>
   <result pre="Epidermal growth factor receptor overexpression is a predictive factor for" exact="trastuzumab" post="response in HER2-positive primary breast cancer, but not in"/>
   <result pre="in metastatic breast cancer. breast carcinoma gene amplification EGFR HER2" exact="trastuzumab" post="immunohistochemistry Epidermal growth factor receptor (EGFR, ERBB1) expression has"/>
   <result pre="and EGFR/HER2 heterodimers. Application of the EGFR tyrosine kinase inhibitors," exact="erlotinib" post="and gefitinib, was associated with decreased phosphorylation of HER2,"/>
   <result pre="receptors through heterodimerisation is a plausible mechanism for resistance to" exact="trastuzumab" post="( Ritter et al, 2007 ). Actually, it was"/>
   <result pre="Ritter et al, 2007 ). Actually, it was shown that" exact="trastuzumab" post="is not able to block ligand-induced EGFR/HER2 and HER2/HER3"/>
   <result pre="al, 2004 ). However, the significance of EGFR overexpression for" exact="trastuzumab" post="response is not clear in clinical settings. Gori et"/>
   <result pre="overall survival of HER2-positive metastatic breast cancer patients treated with" exact="trastuzumab" post="( Gallardo et al, 2012 ). Epidermal growth factor"/>
   <result pre="In addition, we examined the correlation of EGFR expression with" exact="trastuzumab" post="response and clinical outcome in HER2-positive primary and metastatic"/>
   <result pre="HER2-positive primary breast cancer treated with chemotherapy and with adjuvant" exact="trastuzumab" post="for 1 year at Asan Medical Center from 2006"/>
   <result pre="was 112 cases of HER2-positive metastatic breast cancer treated with" exact="trastuzumab" post="at Seoul National University Bundang Hospital, Seoul National University"/>
   <result pre="other agents (i.e. gemcitabine, capecitabine, and vinorelbine) were combined with" exact="trastuzumab" post="in three cases. All cases were independently reviewed by"/>
   <result pre="of 0/1+ and 2+/3+ in three TMA cores). Oestrogen and" exact="progesterone" post="receptors were regarded as positive if there were at"/>
   <result pre="EGFR copy number (high polysomy and gene amplification). Assessment of" exact="trastuzumab" post="response for HER2-positive metastatic breast cancer Responses to trastuzumab-based"/>
   <result pre="progression was defined as the time from the initiation of" exact="trastuzumab" post="treatment to disease progression, and overall survival as the"/>
   <result pre="progression, and overall survival as the time from initiation of" exact="trastuzumab" post="treatment to patient's death from any cause. Statistical analysis"/>
   <result pre="poor disease-free survival. In the subgroup analyses, according to adjuvant" exact="trastuzumab" post="therapy, EGFR overexpression of 3+ was also an independent"/>
   <result pre="95% CI, 1.480–6.348; P=0.003) in the subgroup not receiving adjuvant" exact="trastuzumab" post="( n=209), but EGFR overexpression of 2+ or more"/>
   <result pre="outcome in HER2-positive primary breast cancer patients treated with adjuvant" exact="trastuzumab" post="In the second set, which comprised 447 HER2-positive primary"/>
   <result pre="comprised 447 HER2-positive primary breast cancer patients treated with adjuvant" exact="trastuzumab" post="for 1 year, EGFR expression data were not available"/>
   <result pre="or more, P&amp;lt;0.001; Supplementary Table S6). The clinical benefit of" exact="trastuzumab" post="treatment did not differ between the cases in which"/>
   <result pre="the identification of colorectal cancer patients eligible for treatment with" exact="cetuximab" post="or panitumumab, but any membranous staining or expression of"/>
   <result pre="growth factor receptor overexpression did not affect the response to" exact="trastuzumab" post="and progression-free survival in patients with HER2-positive metastatic breast"/>
   <result pre="survival. In this study, predictive value of EGFR overexpression for" exact="trastuzumab" post="response in metastatic setting seems to be different from"/>
   <result pre="receiving adjuvant trastuzuamb cannot be solely explained by resistance to" exact="trastuzumab" post="caused by EGFR overexpression. The utility of EGFR overexpression"/>
   <result pre="of the known interplay between EGFR and HER2, EGFR inhibitor" exact="gefitinib" post="has been tried in combination with trastuzuamb to treat"/>
   <result pre="; Somlo et al, 2012 ). However, this combination of" exact="gefitinib" post="and trastuzumab was not found to be more effective"/>
   <result pre="et al, 2012 ). However, this combination of gefitinib and" exact="trastuzumab" post="was not found to be more effective than traststuzumab"/>
   <result pre="been shown to be useful after previous treatments such as" exact="trastuzumab" post="in cases with progressive metastatic HER2-positive disease ( Geyer"/>
   <result pre="increased EGFR copy number as a positive predictive factor for" exact="lapatinib" post="response. In addition to lapatinib, other small-molecule inhibitors targeting"/>
   <result pre="lapatinib, other small-molecule inhibitors targeting ERBB family members, such as" exact="afatinib" post="and neratinib, are being investigated in ongoing trials in"/>
   <result pre="breast cancer, and it is also a predictive factor for" exact="trastuzumab" post="response in HER2-positive primary breast cancer, but not in"/>
   <result pre="study of combined blockade of the ErbB receptor network with" exact="trastuzumab" post="and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast"/>
   <result pre="combined blockade of the ErbB receptor network with trastuzumab and" exact="gefitinib" post="in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer Clin"/>
   <result pre="M 2005 Epidermal growth factor receptor gene and protein and" exact="gefitinib" post="sensitivity in non-small-cell lung cancer J Natl Cancer Inst"/>
   <result pre="2013 Epidermal growth factor receptor gene copy number may predict" exact="lapatinib" post="sensitivity in HER2-positive metastatic breast cancer Expert Opin Pharmacother"/>
   <result pre="and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with" exact="trastuzumab" post="resistance in HER2 breast carcinomas Br J Cancer 106"/>
   <result pre="C Rubin SD Stein S Cameron D 2006 Lapatinib plus" exact="capecitabine" post="for HER2-positive advanced breast cancer N Engl J Med"/>
   <result pre="clinical outcome in HER2-positive metastatic breast cancer patients treated with" exact="trastuzumab" post="Ann Oncol 20 648 654 19188134 Gradishar WJ 2013"/>
   <result pre="2013 Emerging approaches for treating HER2-positive metastatic breast cancer beyond" exact="trastuzumab" post="Ann Oncol 24 2492 2500 23827380 Gumuskaya B Alper"/>
   <result pre="american pathologists guideline recommendations for immunohistochemical testing of estrogen and" exact="progesterone" post="receptors in breast cancer J Oncol Pract 6 195"/>
   <result pre="Jung KH Park IA Park SY 2014 HER2 heterogeneity affects" exact="trastuzumab" post="responses and survival in patients with HER2-positive metastatic breast"/>
   <result pre="CL 2007 Human breast cancer cells selected for resistance to" exact="trastuzumab" post="in vivo overexpress epidermal growth factor receptor and ErbB"/>
   <result pre="phase I/II prospective, single arm trial of gefitinib, trastuzumab, and" exact="docetaxel" post="in patients with stage IV HER-2 positive metastatic breast"/>
   <result pre="overexpression in HER2-positive primary breast cancer patients treated with adjuvant" exact="trastuzumab" post=". EGFR overexpression defined as 3+ ( A and"/>
   <result pre="— — Positive 0.829 0.440–1.562 0.562 0.962 0.535–1.930 1.016 Adjuvant" exact="trastuzumab" post="Not received — — Received 0.804 0.212–3.048 0.748 1.289"/>
   <result pre="analyses for HER2-positive primary breast cancer patients treated with adjuvant" exact="trastuzumab" post="in the second set Multivariate analysis Model Variable Category"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4456592/results/search/inn/results.xml">
   <result pre="several other HER2/neu based targeted therapies are now available, including" exact="pertuzumab" post="and the antibody-drug conjugate ado-trastuzumab emtansine (Slamon et al."/>
   <result pre="assay (ELISA) (Lam et al. 2014). As the therapeutic antibody" exact="trastuzumab" post="was derived from mAb 4D5, this assay can potentially"/>
   <result pre="derived from mAb 4D5, this assay can potentially interfere with" exact="trastuzumab" post="in the serum. To circumvent this potential interference, we"/>
   <result pre="in order to detect sHER2 from serum samples of both" exact="trastuzumab" post="naïve and treated patients (Lam et al. 2012). In"/>
   <result pre="23.51 +/− 11.38 Median 21.32 Abbreviations: ER estrogen receptor, PR" exact="progesterone" post="receptor, sHER2, soluble human epidermal growth factor receptor 2."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4457853/results/search/inn/results.xml">
   <result pre="10] or as monotherapy after chemotherapy [ 11]. Since 2006," exact="trastuzumab" post="is also approved for use in adjuvant settings in"/>
   <result pre="disease [ 12]. According to current NCCN guidelines ( www.nccn.org)," exact="trastuzumab" post="is given in combination with adjuvant chemotherapy only. Preferred"/>
   <result pre="combination with adjuvant chemotherapy only. Preferred regimes for chemotherapy with" exact="trastuzumab" post="include Adriamycin, Cyclophosphamide, Paclitaxel, Docetaxel and Carboplatin. Numerous other"/>
   <result pre="between TOS and the outcome of recent clinical trials where" exact="trastuzumab" post="was used in combination with anthracycline- and taxane- based"/>
   <result pre="from http://clinicaltrials.gov and consisted of studies in which combinations included" exact="trastuzumab" post="either as an interaction partner or as a basis"/>
   <result pre="treatment. Several regimens included more than two agents, such as" exact="trastuzumab" post="and three additional drugs, A, B and C. Spearman's"/>
   <result pre="relative comparison. The examples in Table 3 list cases where" exact="trastuzumab" post="was combined with a cytotoxic drug (binary combination), or"/>
   <result pre="addition, the most potent single agent to be administered with" exact="trastuzumab" post="was also docetaxel. A few agents reached low scores"/>
   <result pre="with trastuzumab. But interestingly, some of these like cyclophosphamid and" exact="epirubicin" post="have achieved much higher scores when applied in complex"/>
   <result pre="of 1st of January 2013. Components in the combinations were" exact="lapatinib" post="(lap), fluorouracil (5fu), cyclophosphamid (cyc), epirubicin (epi), paclitaxel (pac),"/>
   <result pre="of January 2013. Components in the combinations were lapatinib (lap)," exact="fluorouracil" post="(5fu), cyclophosphamid (cyc), epirubicin (epi), paclitaxel (pac), pertuzumab (per),"/>
   <result pre="in the combinations were lapatinib (lap), fluorouracil (5fu), cyclophosphamid (cyc)," exact="epirubicin" post="(epi), paclitaxel (pac), pertuzumab (per), docetaxel (doc), carboplatin (car),"/>
   <result pre="combinations were lapatinib (lap), fluorouracil (5fu), cyclophosphamid (cyc), epirubicin (epi)," exact="paclitaxel" post="(pac), pertuzumab (per), docetaxel (doc), carboplatin (car), doxorubicin (dox),"/>
   <result pre="lapatinib (lap), fluorouracil (5fu), cyclophosphamid (cyc), epirubicin (epi), paclitaxel (pac)," exact="pertuzumab" post="(per), docetaxel (doc), carboplatin (car), doxorubicin (dox), gemcitabine (gem),"/>
   <result pre="fluorouracil (5fu), cyclophosphamid (cyc), epirubicin (epi), paclitaxel (pac), pertuzumab (per)," exact="docetaxel" post="(doc), carboplatin (car), doxorubicin (dox), gemcitabine (gem), carboplatin (car),"/>
   <result pre="cyclophosphamid (cyc), epirubicin (epi), paclitaxel (pac), pertuzumab (per), docetaxel (doc)," exact="carboplatin" post="(car), doxorubicin (dox), gemcitabine (gem), carboplatin (car), ixabepilone (ixa),"/>
   <result pre="epirubicin (epi), paclitaxel (pac), pertuzumab (per), docetaxel (doc), carboplatin (car)," exact="doxorubicin" post="(dox), gemcitabine (gem), carboplatin (car), ixabepilone (ixa), oxaliplatin (oxa)"/>
   <result pre="paclitaxel (pac), pertuzumab (per), docetaxel (doc), carboplatin (car), doxorubicin (dox)," exact="gemcitabine" post="(gem), carboplatin (car), ixabepilone (ixa), oxaliplatin (oxa) 2The scores"/>
   <result pre="pertuzumab (per), docetaxel (doc), carboplatin (car), doxorubicin (dox), gemcitabine (gem)," exact="carboplatin" post="(car), ixabepilone (ixa), oxaliplatin (oxa) 2The scores were computed"/>
   <result pre="docetaxel (doc), carboplatin (car), doxorubicin (dox), gemcitabine (gem), carboplatin (car)," exact="ixabepilone" post="(ixa), oxaliplatin (oxa) 2The scores were computed using the"/>
   <result pre="carboplatin (car), doxorubicin (dox), gemcitabine (gem), carboplatin (car), ixabepilone (ixa)," exact="oxaliplatin" post="(oxa) 2The scores were computed using the generalized TOS"/>
   <result pre="were implented in MATLAB R2014a. Published clinical trial data on" exact="trastuzumab" post="were collected from the ClinicalTrials database ( www.clinicaltrials.gov) using"/>
   <result pre="cabazitaxel, capecitabine, carboplatin, carmustine, chlorambucil, cladribine, cyclophosphamide, cytarabine, dacarbazine, daunorubicin," exact="daunorubicin" post="(liposomal), docetaxel, doxorubicin, epirubicin, estramustine, etoposide, fludarabine, fluorouracil, gemcitabine."/>
   <result pre="the world. Only 18 agents were studied in combination with" exact="trastuzumab" post="in 81 trials. The findings were narrowed to trials"/>
   <result pre="therapy was studied (n = 43). For trials in which" exact="trastuzumab" post="was studied in combination with more than one agent,"/>
   <result pre=", Geyer CE Jr. , et al. Four-year follow-up of" exact="trastuzumab" post="plus adjuvant chemotherapy for operable human epidermal growth factor"/>
   <result pre="A , Dowsett M , et al. 2-year follow-up of" exact="trastuzumab" post="after adjuvant chemotherapy in HER2-positive breast cancer: a randomised"/>
   <result pre="of women with metastatic breast cancer by HER2 status and" exact="trastuzumab" post="treatment: an institutional-based review . J Clin Oncol. 2010;"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4464713/results/search/inn/results.xml">
   <result pre="using immunohistochemical (IHC) detection of HER2, estrogen receptor- (ER) and" exact="progesterone" post="receptor (PR) expression has been suggested for invasive breast"/>
   <result pre="HercepTest©. As for hormone receptors (estrogen receptor alpha (ER) and" exact="progesterone" post="receptor (PR)), tumours with 10 % or more nuclei"/>
   <result pre="clinical trials testing the efficacy of HER2 targeting therapy with" exact="lapatinib" post="in DCIS patients (ClinicalTrials.gov NCT00555152 and NCT00857714, respectively). The"/>
   <result pre="published, however the trial results by Estevés et al. assessing" exact="lapatinib" post="in the pre-surgical setting reported significant inhibition of HER2"/>
   <result pre="38]. Further, other biomarker trials have assessed the effects of" exact="trastuzumab" post="in DCIS patients, among which, one trial has reported"/>
   <result pre="in terms of proliferation and apoptosis after a single-dose monotherapy" exact="trastuzumab" post="pre-surgically [ 39]. None of these studies have addressed"/>
   <result pre="DCIS. However, a currently recruiting phase III randomized trial prescribing" exact="trastuzumab" post="versus placebo concomitantly with radiotherapy, may shed light over"/>
   <result pre="Julian TB Geyer CE Jr Costantino JP et al. Adjuvant" exact="tamoxifen" post="reduces subsequent breast cancer in women with estrogen receptor-positive"/>
   <result pre="Marquez C Lopez Rios F et al. Molecular effects of" exact="lapatinib" post="in patients with HER2 positive ductal carcinoma in situ"/>
   <result pre="Hunt KK Symmans WF Biologic and immunologic effects of preoperative" exact="trastuzumab" post="for ductal carcinoma in situ of the breast Cancer"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4465168/results/search/inn/results.xml">
   <result pre="260 mg/m 2 every 3 weeks was superior to solvent-based" exact="paclitaxel" post="175 mg/m 2 every 3 weeks for the primary"/>
   <result pre="the National Comprehensive Cancer Network currently list the taxanes solvent-based" exact="paclitaxel" post="(sb-paclitaxel, Taxol; Bristol-Myers Squibb Co., Princeton, NJ, USA), docetaxel"/>
   <result pre="solvent-based paclitaxel (sb-paclitaxel, Taxol; Bristol-Myers Squibb Co., Princeton, NJ, USA)," exact="docetaxel" post="(Taxotere; sanofi-aventis US LLC, Bridgewater, NJ, USA), and nab-paclitaxel"/>
   <result pre="the treatment of recurrent and MBC [ 1]. sb-Paclitaxel and" exact="docetaxel" post="have demonstrated clinical benefit in the treatment of breast"/>
   <result pre="their chemical formulations have presented several limitations. Both sb-paclitaxel and" exact="docetaxel" post="require the use of solvents to enhance their solubility"/>
   <result pre="BASF Corporation, Florham Park, NJ, USA) and dehydrated ethanol, while" exact="docetaxel" post="is formulated using the solvent polysorbate 80), and these"/>
   <result pre="and dehydrated ethanol, while docetaxel is formulated using the solvent" exact="polysorbate" post="80), and these solvents have been associated with hypersensitivity"/>
   <result pre="dose-responsiveness pattern is most likely explained by the entrapment of" exact="paclitaxel" post="in solvent micelles [ 14, 15]. In patients with"/>
   <result pre="free and was designed to improve the therapeutic index of" exact="paclitaxel" post="(that is, to increase antitumor activity and reduce toxicities"/>
   <result pre="transport across endothelial cell monolayers and greater tumor delivery of" exact="paclitaxel" post="in preclinical models [ 17]. A phase I dose"/>
   <result pre="and resulting management costs were lower for nab-paclitaxel relative to" exact="docetaxel" post="and sb-paclitaxel [ 21]. The cost-effectiveness of nab-paclitaxel in"/>
   <result pre="treatment q3w in the adjuvant setting after standard administration of" exact="doxorubicin" post="plus cyclophosphamide (AC) [ 25]. Initial evidence suggested that"/>
   <result pre="in the adjuvant setting after standard administration of doxorubicin plus" exact="cyclophosphamide" post="(AC) [ 25]. Initial evidence suggested that a weekly"/>
   <result pre="first-line treatment for patients with MBC [ 29, 30]. A" exact="docetaxel" post="arm was also included. Patients treated with the higher"/>
   <result pre="qw 3/4, during the first 3 of 4 weeks; trastuz," exact="trastuzumab" post="Bevacizumab A recent phase II trial tested three schedules"/>
   <result pre="trial tested three schedules of nab-paclitaxel treatment in combination with" exact="bevacizumab" post="as first-line treatment for patients with MBC: nab-paclitaxel 130"/>
   <result pre="have explored a nab-paclitaxel regimen qw 3/4 in combination with" exact="bevacizumab" post="for treatment of MBC. A phase II study of"/>
   <result pre="II study of nab-paclitaxel 125 mg/m 2 qw 3/4 plus" exact="bevacizumab" post="demonstrated the feasibility of this schedule, although the incidence"/>
   <result pre="for Clinical Oncology [ 33]. A third arm of weekly" exact="ixabepilone" post="plus bevacizumab was also included, but the sb-paclitaxel plus"/>
   <result pre="Oncology [ 33]. A third arm of weekly ixabepilone plus" exact="bevacizumab" post="was also included, but the sb-paclitaxel plus bevacizumab arm"/>
   <result pre="ixabepilone plus bevacizumab was also included, but the sb-paclitaxel plus" exact="bevacizumab" post="arm was designated the control arm. Neither PFS (median"/>
   <result pre="Neither PFS (median 9.2 vs 10.6 months for nab-paclitaxel plus" exact="bevacizumab" post="vs sb-paclitaxel plus bevacizumab, respectively, P = 0.12) nor OS (27"/>
   <result pre="between the groups. Treatment with nab-paclitaxel 150 mg/m 2 plus" exact="bevacizumab" post="was associated with higher rates of grade 3/4 hematologic"/>
   <result pre="this nab-paclitaxel dose may be too high for combination with" exact="bevacizumab" post="in unselected patients with MBC. Human epidermal growth factor"/>
   <result pre="trial, nab-paclitaxel 125 mg/m 2 qw 3/4 with or without" exact="trastuzumab" post="demonstrated efficacy and a favorable safety profile for first-line"/>
   <result pre="schedule (weekly nab-paclitaxel 125 mg/m 2 qw 3/4) combined with" exact="lapatinib" post="1,250 mg daily for treatment of patients with HER2-positive"/>
   <result pre="reduced, with remaining patients given nab-paclitaxel 100 mg/m 2 and" exact="lapatinib" post="1,000 mg instead. Treatment resulted in an ORR of"/>
   <result pre="weekly nab-paclitaxel 100 mg/m 2 qw 3/4 in combination with" exact="lapatinib" post="is thus a feasible treatment in this patient population."/>
   <result pre="of 4 weeks; RCB, residual cancer burden; trastuz, trastuzumab; vin," exact="vinorelbine" post="In the neoadjuvant setting, the treatment goal is rapid"/>
   <result pre="each followed by epirubicin/cyclophosphamide. Patients with HER2-positive tumors also received" exact="trastuzumab" post="and pertuzumab throughout treatment. The pathological complete response (pCR)"/>
   <result pre="by epirubicin/cyclophosphamide. Patients with HER2-positive tumors also received trastuzumab and" exact="pertuzumab" post="throughout treatment. The pathological complete response (pCR) rate was"/>
   <result pre="setting, the S0800 phase II safety and efficacy trial evaluated" exact="bevacizumab" post="with nab-paclitaxel 100 mg/m 2 weekly followed by dose-dense"/>
   <result pre="inflammatory or locally advanced BC [ 37]. The addition of" exact="bevacizumab" post="resulted in a significantly higher pCR rate (primary endpoint"/>
   <result pre="% vs 28 %, P = 0.014). The 3-year OS for the" exact="bevacizumab" post="arm versus the nonbevacizumab arm was 87 % versus"/>
   <result pre="similar between groups (67 % and 65 % in the" exact="bevacizumab" post="and nonbevacizumab arms, respectively). Neoadjuvant treatment with four cycles"/>
   <result pre="nab-paclitaxel 260 mg/m 2 q2w for four cycles followed by" exact="vinorelbine" post="and trastuzumab. This treatment resulted in a high rate"/>
   <result pre="nab-paclitaxel 260 mg/m 2 plus bevacizumab, and, finally, treatment with" exact="bevacizumab" post="alone [ 44]. This study met its primary endpoint"/>
   <result pre="was low. Another phase II trial evaluated dose-dense AC plus" exact="pegfilgrastim" post="for four cycles, followed by either nab-paclitaxel 260 mg/m"/>
   <result pre="mg/m 2 q2w (cycles five to eight) [ 45]. Dose-dense" exact="bevacizumab" post="was administered with AC, nab-paclitaxel, or sb-paclitaxel, and then"/>
   <result pre="10 more cycles q3w. Despite a 44 % higher cumulative" exact="paclitaxel" post="dose for nab-paclitaxel compared with sb-paclitaxel ( P &amp;lt; 0.0001), the"/>
   <result pre="trial and with nab-paclitaxel 150 mg/m 2 qw 3/4 plus" exact="bevacizumab" post="in a phase III trial [ 29, 30, 33]."/>
   <result pre="treatment for MBC, nab-paclitaxel at 260 mg/m 2 q2w plus" exact="bevacizumab" post="for early-stage disease was feasible [ 31, 44, 45]."/>
   <result pre="question of whether a drug-drug interaction exists between nab-paclitaxel and" exact="bevacizumab" post="has not been examined. However, it is unlikely that"/>
   <result pre="combination since the US Food and Drug Administration approval of" exact="bevacizumab" post="for MBC has been withdrawn [ 46]. Patients who"/>
   <result pre="3/4 During the first 3 of 4 weeks sb-paclitaxel Solvent-based" exact="paclitaxel" post="Competing interests MM has participated in Celgene advisory boards"/>
   <result pre="CA Pratt CB Shuster JJ Relling MV Saturable pharmacokinetics and" exact="paclitaxel" post="pharmacodynamics in children with solid tumors J Clin Oncol"/>
   <result pre="L Lacatelli A et al. Nonlinear pharmacokinetics and metabolism of" exact="paclitaxel" post="and its pharmacokinetic/pharmacodynamic relationships in humans J Clin Oncol"/>
   <result pre="WJ Beijnen JH Cremophor EL causes (pseudo-) non-linear pharmacokinetics of" exact="paclitaxel" post="in patients Br J Cancer 1999 81 330 5"/>
   <result pre="van Tellingen O Nooijen WJ Beijnen JH Nonlinear pharmacokinetics of" exact="paclitaxel" post="in mice results from the pharmaceutical vehicle Cremophor EL"/>
   <result pre="Bruijn P Gelderblom H et al. Cremophor EL-mediated alteration of" exact="paclitaxel" post="distribution in human blood: clinical pharmacokinetic implications Cancer Res"/>
   <result pre="D Kornblith A Harris LN et al. Failure of higher-dose" exact="paclitaxel" post="to improve outcome in patients with metastatic breast cancer:"/>
   <result pre="Ci S Yang A et al. Increased antitumor activity, intratumor" exact="paclitaxel" post="concentrations, and endothelial cell transport of Cremophor-free, albumin-bound paclitaxel,"/>
   <result pre="cell transport of Cremophor-free, albumin-bound paclitaxel, ABI-007, compared with Cremophor-based" exact="paclitaxel" post="Clin Cancer Res 2006 12 1317 24 10.1158/1078-0432.CCR-05-1634 16489089"/>
   <result pre="pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of" exact="paclitaxel" post="Clin Cancer Res 2002 8 1038 44 12006516 19."/>
   <result pre="Bhar P et al. Phase III trial of nanoparticle albumin-bound" exact="paclitaxel" post="compared with polyethylated castor oil-based paclitaxel in women with"/>
   <result pre="trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based" exact="paclitaxel" post="in women with breast cancer J Clin Oncol 2005"/>
   <result pre="Cottrell W Spirovski B Hopkins S Economic analysis of albumin-bound" exact="paclitaxel" post="for the treatment of metastatic breast cancer J Oncol"/>
   <result pre="S Arpino G et al. An Italian cost-effectiveness analysis of" exact="paclitaxel" post="albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer"/>
   <result pre="An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional" exact="paclitaxel" post="for metastatic breast cancer patients: the COSTANza study Clinicoecon"/>
   <result pre="W nab-paclitaxel weekly or every 3 weeks compared to standard" exact="docetaxel" post="as first-line therapy in patients with metastatic breast cancer:"/>
   <result pre="al. Randomized phase III trial of weekly compared with every-3-weeks" exact="paclitaxel" post="for metastatic breast cancer, with trastuzumab for all HER-2"/>
   <result pre="weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with" exact="trastuzumab" post="for all HER-2 overexpressors and random assignment to trastuzumab"/>
   <result pre="with trastuzumab for all HER-2 overexpressors and random assignment to" exact="trastuzumab" post="or not in HER-2 nonoverexpressors: final results of Cancer"/>
   <result pre="S Jones V Perez EA Saphner T et al. Weekly" exact="paclitaxel" post="in the adjuvant treatment of breast cancer N Engl"/>
   <result pre="and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of" exact="paclitaxel" post="in patients with advanced nonhematologic malignancies J Clin Oncol"/>
   <result pre="Yu S et al. Superior efficacy of a Cremophor-free albumin-bound" exact="paclitaxel" post="compared with solvent-based paclitaxel in Chinese patients with metastatic"/>
   <result pre="Superior efficacy of a Cremophor-free albumin-bound paclitaxel compared with solvent-based" exact="paclitaxel" post="in Chinese patients with metastatic breast cancer Asia Pac"/>
   <result pre="Geister BV et al. Phase II study of weekly albumin-bound" exact="paclitaxel" post="for patients with metastatic breast cancer heavily pretreated with"/>
   <result pre="et al. Significantly longer progression-free survival with nab-paclitaxel compared with" exact="docetaxel" post="as first-line therapy for metastatic breast cancer J Clin"/>
   <result pre="A et al. Phase II trial of nab-paclitaxel compared with" exact="docetaxel" post="as first-line chemotherapy in patients with metastatic breast cancer:"/>
   <result pre="vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound" exact="paclitaxel" post="with bevacizumab as first-line chemotherapy for metastatic breast cancer"/>
   <result pre="2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with" exact="bevacizumab" post="as first-line chemotherapy for metastatic breast cancer Clin Breast"/>
   <result pre="al. Phase II trial of weekly nab-paclitaxel in combination with" exact="bevacizumab" post="as first-line treatment in metastatic breast cancer [abstract 1075]."/>
   <result pre="al. CALGB 40502/NCCTG N063H: randomized phase III trial of weekly" exact="paclitaxel" post="compared to weekly nanoparticle albumin bound nab-paclitaxel or ixabepilone ± bevacizumab"/>
   <result pre="Min M A phase II study of weekly nanoparticle albumin-bound" exact="paclitaxel" post="with or without trastuzumab in metastatic breast cancer Clin"/>
   <result pre="II study of weekly nanoparticle albumin-bound paclitaxel with or without" exact="trastuzumab" post="in metastatic breast cancer Clin Breast Cancer 2011 11"/>
   <result pre="Waterhouse DM Hagan MK et al. Phase II study evaluating" exact="lapatinib" post="in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer"/>
   <result pre="randomized phase III trial comparing neoadjuvant chemotherapy with weekly nanoparticle-based" exact="paclitaxel" post="with solvent-based paclitaxel followed by anthracycline/cyclophosphamide for patients with"/>
   <result pre="trial comparing neoadjuvant chemotherapy with weekly nanoparticle-based paclitaxel with solvent-based" exact="paclitaxel" post="followed by anthracycline/cyclophosphamide for patients with early breast cancer"/>
   <result pre="JR Perez EA et al. S0800: nab-paclitaxel, doxorubicin, cyclophosphamide, and" exact="pegfilgrastim" post="with or without bevacizumab in treating women with inflammatory"/>
   <result pre="al. S0800: nab-paclitaxel, doxorubicin, cyclophosphamide, and pegfilgrastim with or without" exact="bevacizumab" post="in treating women with inflammatory or locally advanced breast"/>
   <result pre="al. A phase II neoadjuvant trial of sequential nanoparticle albumin-bound" exact="paclitaxel" post="followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer Clin"/>
   <result pre="Grothusen J Melisko M et al. A feasibility study of" exact="bevacizumab" post="plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel"/>
   <result pre="of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound" exact="paclitaxel" post="in early-stage breast cancer Clin Cancer Res 2011 17"/>
   <result pre="J Paul D Vukelja S Clawson A Iglesias J Dose-dense" exact="doxorubicin" post="and cyclophosphamide followed by dose-dense albumin-bound paclitaxel plus bevacizumab"/>
   <result pre="D Vukelja S Clawson A Iglesias J Dose-dense doxorubicin and" exact="cyclophosphamide" post="followed by dose-dense albumin-bound paclitaxel plus bevacizumab is safe"/>
   <result pre="Iglesias J Dose-dense doxorubicin and cyclophosphamide followed by dose-dense albumin-bound" exact="paclitaxel" post="plus bevacizumab is safe as adjuvant therapy in patients"/>
   <result pre="Dose-dense doxorubicin and cyclophosphamide followed by dose-dense albumin-bound paclitaxel plus" exact="bevacizumab" post="is safe as adjuvant therapy in patients with early"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4467394/results/search/inn/results.xml">
   <result pre="Journals LLC pmcid: 4467394 pmid: 25691057 : Research Paper Combining" exact="lapatinib" post="and pertuzumab to overcome lapatinib resistance due to NRG1-mediated"/>
   <result pre="pmcid: 4467394 pmid: 25691057 : Research Paper Combining lapatinib and" exact="pertuzumab" post="to overcome lapatinib resistance due to NRG1-mediated signalling in"/>
   <result pre="25691057 : Research Paper Combining lapatinib and pertuzumab to overcome" exact="lapatinib" post="resistance due to NRG1-mediated signalling in HER2-amplified breast cancer"/>
   <result pre="of EGFR, HER2 and HER3 occurred within 24 hours of" exact="lapatinib" post="treatment after their initial dephosphorylation. This was associated with"/>
   <result pre="inhibits binding of NRG1 and other HER3 ligands. Addition of" exact="pertuzumab" post="to lapatinib further inhibited NRG1-induced signalling, which was not"/>
   <result pre="of NRG1 and other HER3 ligands. Addition of pertuzumab to" exact="lapatinib" post="further inhibited NRG1-induced signalling, which was not fully inhibited"/>
   <result pre="by either drug alone. In animal model, a combination of" exact="pertuzumab" post="to lapatinib induced a greater tumor regression than either"/>
   <result pre="drug alone. In animal model, a combination of pertuzumab to" exact="lapatinib" post="induced a greater tumor regression than either lapatinib or"/>
   <result pre="pertuzumab to lapatinib induced a greater tumor regression than either" exact="lapatinib" post="or pertuzumab monotherapy. This novel combination treatment may provide"/>
   <result pre="lapatinib induced a greater tumor regression than either lapatinib or" exact="pertuzumab" post="monotherapy. This novel combination treatment may provide a promising"/>
   <result pre="patients that will respond to this therapy requires further stratification." exact="lapatinib" post="pertuzumab resistance NRG1 HER2 INTRODUCTION The human epidermal growth"/>
   <result pre="that will respond to this therapy requires further stratification. lapatinib" exact="pertuzumab" post="resistance NRG1 HER2 INTRODUCTION The human epidermal growth factor"/>
   <result pre="antibodies (mAbs) and tyrosine kinase inhibitors (TKIs) [ 3]. Trastuzumab," exact="pertuzumab" post="(mAbs), trastuzumab emtansine (T-DM1, an antibody-drug conjugate) and lapatinib"/>
   <result pre="and tyrosine kinase inhibitors (TKIs) [ 3]. Trastuzumab, pertuzumab (mAbs)," exact="trastuzumab" post="emtansine (T-DM1, an antibody-drug conjugate) and lapatinib (TKI) were"/>
   <result pre="Trastuzumab, pertuzumab (mAbs), trastuzumab emtansine (T-DM1, an antibody-drug conjugate) and" exact="lapatinib" post="(TKI) were approved by the U.S. Food and Drug"/>
   <result pre="the HER signalling pathway [ 6, 7]. In preclinical studies," exact="pertuzumab" post="was found to inhibit NRG1-induced growth [ 8] and"/>
   <result pre="regression in NRG1-dependent xenograft model [ 9]. The combination of" exact="pertuzumab" post="and trastuzumab was shown to be synergistic in inhibiting"/>
   <result pre="NRG1-dependent xenograft model [ 9]. The combination of pertuzumab and" exact="trastuzumab" post="was shown to be synergistic in inhibiting the survival"/>
   <result pre="this combination has been shown to prolong PFS compared to" exact="trastuzumab" post="in metastatic breast cancer as first line treatment ["/>
   <result pre="the FDA has approved the use of the combination of" exact="pertuzumab" post="and trastuzumab with chemotherapy in metastatic breast cancer and"/>
   <result pre="has approved the use of the combination of pertuzumab and" exact="trastuzumab" post="with chemotherapy in metastatic breast cancer and early HER2-overexpressing"/>
   <result pre="with advanced HER2-positive breast cancer that have progressed after previous" exact="trastuzumab" post="containing regimens and its efficacy as a single targeted"/>
   <result pre="has been shown [ 16, 17]. Lapatinib in combination with" exact="trastuzumab" post="and chemotherapy has been reviewed in neoadjuvant studies such"/>
   <result pre="Recently, a meta-analysis of six randomised trials had concluded that" exact="lapatinib" post="in combination with chemotherapy achieved a lower pCR and"/>
   <result pre="a lower pCR and higher risk of toxicity compared to" exact="trastuzumab" post="with chemotherapy in the neoadjuvant setting [ 21]. Furthermore,"/>
   <result pre="Meeting found that, metastatic HER2-positive breast cancer patients who received" exact="lapatinib" post="and chemotherapy had shorter PFS than those receiving trastuzumab"/>
   <result pre="received lapatinib and chemotherapy had shorter PFS than those receiving" exact="trastuzumab" post="and chemotherapy [ 22]. Several models have been proposed"/>
   <result pre="Several models have been proposed to explain the resistance to" exact="lapatinib" post="in HER2-overexpressing breast cancer. Lapatinib derepresses FOXO3a, which stimulates"/>
   <result pre="reported that NRG1 autocrine stimulation of EGFR/HER3 signalling mediates acquired" exact="lapatinib" post="resistance [ 27], although the exact mechanism was not"/>
   <result pre="incurred by lapatinib. However, a novel combination of HER2-targeted therapies," exact="lapatinib" post="and pertuzumab, inhibited these NRG1-stimulated HER signalling pathways. The"/>
   <result pre="NRG1 expression To assess the acute response that may counteract" exact="lapatinib" post="inhibition, we treated two commonly used HER2-overexpressing breast cancer"/>
   <result pre="used HER2-overexpressing breast cancer cell lines, SK-BR-3 and BT-474, with" exact="lapatinib" post="for 24 hours. After 4 hours of lapatinib treatment,"/>
   <result pre="BT-474, with lapatinib for 24 hours. After 4 hours of" exact="lapatinib" post="treatment, the phosphorylation of EGFR, HER2 and HER3 in"/>
   <result pre="the HER signalling pathway, MAPK and Akt, were inhibited by" exact="lapatinib" post="after 1 hour, but started to recover after 24"/>
   <result pre="1 hour, but started to recover after 24 hours of" exact="lapatinib" post="treatment (Fig. 1A). In BT-474 cells, the dephosphorylation and"/>
   <result pre="1 Reactivation of HER receptors occurs within 24 hours of" exact="lapatinib" post="treatment, correlating with an increase in NRG1 expression (A)"/>
   <result pre="SK-BR-3 and (B) BT-474 cells were treated with 100 nM" exact="lapatinib" post="for the indicated times or DMSO solvent control before"/>
   <result pre="(D) BT-474 cells were treated with the indicated doses of" exact="lapatinib" post="or DMSO control for 8 hours. The mRNA expression"/>
   <result pre="(F) BT-474 cells were treated with the indicated concentrations of" exact="lapatinib" post="or DMSO control for 8 hours. Equal amount of"/>
   <result pre="****p&amp;lt;0.0001). Xia et al. (2013) reported a model of acquired" exact="lapatinib" post="resistance, in which EGFR/HER3 signalling was induced by NRG1"/>
   <result pre="NRG1 autocrine stimulation [ 27]. However, the short-term effect of" exact="lapatinib" post="on NRG1 expression was not shown. We hypothesised that"/>
   <result pre="as the downstream pathways during the first 24 hours of" exact="lapatinib" post="treatment could be mediated by NRG1. We showed that"/>
   <result pre="lapatinib treatment could be mediated by NRG1. We showed that" exact="lapatinib" post="treatment in 100 nM and 250 nM for 8"/>
   <result pre="increased significantly after the cells were treated with 250 nM" exact="lapatinib" post="for 8 hours (p&amp;lt;0.05) but not with 100 nM"/>
   <result pre="lapatinib for 8 hours (p&amp;lt;0.05) but not with 100 nM" exact="lapatinib" post="(Fig. 1D). We further confirmed that there was a"/>
   <result pre="small but statistically significant increase in NRG1 protein expression upon" exact="lapatinib" post="treatment using ELISA. In SK-BR-3 and BT-474 cells, both"/>
   <result pre="SK-BR-3 and BT-474 cells, both 100 nM and 250 nM" exact="lapatinib" post="increased NRG1 expression in the cell lysates (Fig. 1E"/>
   <result pre="low to be detected by ELISA (data not shown). Acquired" exact="lapatinib" post="resistance is mediated by HER3 ligands Since NRG1 level"/>
   <result pre="shown to be increased during the first 8 hours of" exact="lapatinib" post="treatment (Fig. 1E and F) and it has also"/>
   <result pre="F) and it has also been shown to mediate acquired" exact="lapatinib" post="resistance [ 27], we assessed the effect of HER3"/>
   <result pre="parental and lapatinib-resistant SK-BR-3 and BT-474 cells. SGP1 alone or" exact="lapatinib" post="alone reduced the cell number of the parental SK-BR-3"/>
   <result pre="control) (Fig. 2A and B). The addition of SGP1 to" exact="lapatinib" post="was more effective than lapatinib alone in the parental"/>
   <result pre="The addition of SGP1 to lapatinib was more effective than" exact="lapatinib" post="alone in the parental BT-474 cells and not SK-BR-3"/>
   <result pre="HER2-overexpressing breast cancer cell lines SK-BR-3 and BT-474 by chronic" exact="lapatinib" post="treatment up to the concentration of 250 nM over"/>
   <result pre="10 months. The resistant cell lines had reduced sensitivity to" exact="lapatinib" post="treatment ( Suppl. Fig. 1). In the resistant cells,"/>
   <result pre="resistant cells, there was an increase of cell number when" exact="lapatinib" post="was withdrawn in BT250LR cells (Fig. 2D) but not"/>
   <result pre="not in SK250LR cells (Fig. 2C). SGP1 with or without" exact="lapatinib" post="withdrawal could reduce the cell number significantly in both"/>
   <result pre="and other HER3 ligands. Figure 2 The inhibitory effect of" exact="lapatinib" post="and/or SGP1 on cell growth in parental and lapatinib-resistant"/>
   <result pre="and (D) BT250LR cells were seeded and maintained in continuous" exact="lapatinib" post="treatment the night before the experiment. On the next"/>
   <result pre="B) the untreated control or (C and D) continuous 250nM" exact="lapatinib" post="plus 20 μg/ml non-specific IgG control. At least three"/>
   <result pre="**p&amp;lt;0.01, ***p&amp;lt;0.001, ****p&amp;lt;0.0001). Exogenous NRG1 stimulation induces acquired resistance to" exact="lapatinib" post="To further confirm the role of NRG1 in mediating"/>
   <result pre="they were concurrently treated with lapatinib. In both cell lines," exact="lapatinib" post="decreased the cell number significantly (p&amp;lt;0.0001 compared to DMSO"/>
   <result pre="in both cell lines), but the addition of NRG1 to" exact="lapatinib" post="treatment recovered the cell number to the control level"/>
   <result pre="the cell number to the control level (p&amp;lt;0.0001 compared to" exact="lapatinib" post="alone in both cell lines) ( Suppl. Fig. 2A"/>
   <result pre="BT-474 cells from the inhibitory effect of lapatinib. Combination of" exact="lapatinib" post="and pertuzumab inhibits NRG1-induced signalling Although NRG1 autocrine signalling"/>
   <result pre="from the inhibitory effect of lapatinib. Combination of lapatinib and" exact="pertuzumab" post="inhibits NRG1-induced signalling Although NRG1 autocrine signalling was proposed"/>
   <result pre="was proposed to be one of the underlying mechanisms of" exact="lapatinib" post="resistance, no effective treatment option has been proposed ["/>
   <result pre="receptors [ 1]. This is supported by a report that" exact="lapatinib" post="could increase HER2/HER3 and EGFR/HER2 dimerisation [ 29]. Thus,"/>
   <result pre="inhibitor, pertuzumab, could inhibit NRG1-mediated HER receptor signalling induced by" exact="lapatinib" post="treatment [ 30]. In serum-free media, lapatinib inhibited phosphorylation"/>
   <result pre="signalling induced by lapatinib treatment [ 30]. In serum-free media," exact="lapatinib" post="inhibited phosphorylation of all HER receptors and the downstream"/>
   <result pre="3A and B). When the cells were stimulated by NRG1," exact="lapatinib" post="could still inhibit phosphorylation of EGFR and HER2; however,"/>
   <result pre="in phosphorylation of HER3, HER4, MAPK and Akt compared to" exact="lapatinib" post="alone. These results suggested that NRG1 stimulation could partially"/>
   <result pre="partially reverse the inhibition induced by lapatinib. We showed that" exact="pertuzumab" post="alone did not inhibit any HER receptors nor downstream"/>
   <result pre="and BT-474 cells; however, in the presence of NRG1 stimulation," exact="pertuzumab" post="inhibited phospho-EGFR, phospho-HER2 and phospho-HER4 (Fig. 3A and B)."/>
   <result pre="and phospho-HER4 (Fig. 3A and B). This result indicated that" exact="pertuzumab" post="inhibited as well as decreased NRG1-induced HER3 activation ligand-induced"/>
   <result pre="media for 24 hours before being treated with 100 nM" exact="lapatinib" post="and/or 20 μg/ml pertuzumab for 1 hour. DMSO and/or"/>
   <result pre="before being treated with 100 nM lapatinib and/or 20 μg/ml" exact="pertuzumab" post="for 1 hour. DMSO and/or 20 μg/ml non-specific IgG"/>
   <result pre="(D) BT-474 cells were treated with the indicated doses of" exact="lapatinib" post="or DMSO control, and 20 μg/ml pertuzumab or non-specific"/>
   <result pre="indicated doses of lapatinib or DMSO control, and 20 μg/ml" exact="pertuzumab" post="or non-specific human IgG control before the cells were"/>
   <result pre="When the cells were stimulated by NRG1, the combination of" exact="lapatinib" post="and pertuzumab inhibited phospho-HER3, phospho-HER4, phospho-Akt and phospho-MAPK more"/>
   <result pre="cells were stimulated by NRG1, the combination of lapatinib and" exact="pertuzumab" post="inhibited phospho-HER3, phospho-HER4, phospho-Akt and phospho-MAPK more than lapatinib"/>
   <result pre="and pertuzumab inhibited phospho-HER3, phospho-HER4, phospho-Akt and phospho-MAPK more than" exact="lapatinib" post="alone. Both phospho-HER3 and phospho-HER4 were inhibited to levels"/>
   <result pre="inhibited (Fig. 3B). This experiment showed that the combination of" exact="lapatinib" post="and pertuzumab could inhibit NRG1-stimulated HER signalling pathways, which"/>
   <result pre="3B). This experiment showed that the combination of lapatinib and" exact="pertuzumab" post="could inhibit NRG1-stimulated HER signalling pathways, which were not"/>
   <result pre="inhibited by either drug alone. Effect of the combination of" exact="lapatinib" post="and pertuzumab in vitro The additive effect of the"/>
   <result pre="either drug alone. Effect of the combination of lapatinib and" exact="pertuzumab" post="in vitro The additive effect of the combination of"/>
   <result pre="pertuzumab in vitro The additive effect of the combination of" exact="lapatinib" post="and pertuzumab on the inhibition of NRG1-stimulated HER signalling"/>
   <result pre="vitro The additive effect of the combination of lapatinib and" exact="pertuzumab" post="on the inhibition of NRG1-stimulated HER signalling suggested that"/>
   <result pre="anti-tumour activity. In total cell counting experiments, the combination of" exact="lapatinib" post="and pertuzumab (blue line) was shown to reduce total"/>
   <result pre="In total cell counting experiments, the combination of lapatinib and" exact="pertuzumab" post="(blue line) was shown to reduce total cell number"/>
   <result pre="line) was shown to reduce total cell number more than" exact="lapatinib" post="alone at any concentration (red line) and pertuzumab alone"/>
   <result pre="more than lapatinib alone at any concentration (red line) and" exact="pertuzumab" post="alone (green dashed line) in both SK-BR-3 and BT-474"/>
   <result pre="(Fig. 3C and D). The difference between the combination and" exact="lapatinib" post="alone was significant in both SK-BR-3 (p&amp;lt;0.001) and BT-474"/>
   <result pre="further confirmed by an apoptotic assay. Although the combination of" exact="lapatinib" post="and pertuzumab induced the highest percentage of apoptotic cells"/>
   <result pre="by an apoptotic assay. Although the combination of lapatinib and" exact="pertuzumab" post="induced the highest percentage of apoptotic cells in both"/>
   <result pre="cell lines, the change was only statistically significant compared to" exact="lapatinib" post="alone (+IgG control) in BT474 but not SK-BR-3 cells"/>
   <result pre="Fig. 4). However, the combination was significantly more effective than" exact="pertuzumab" post="alone in both cell lines. In order to further"/>
   <result pre="lapatinib-resistant cell lines as below. Effect of the combination of" exact="lapatinib" post="and pertuzumab in lapatinib-resistant cell lines The drug combination"/>
   <result pre="lines as below. Effect of the combination of lapatinib and" exact="pertuzumab" post="in lapatinib-resistant cell lines The drug combination was tested"/>
   <result pre="SK250LR and BT250LR to understand whether this could overcome acquired" exact="lapatinib" post="resistance. Pertuzumab slightly reduced cell number (p&amp;lt;0.01) compared to"/>
   <result pre="(p&amp;lt;0.01) compared to the DMSO (+ IgG control) only when" exact="lapatinib" post="was withdrawn in SK250LR cells but there was no"/>
   <result pre="significant difference between all other groups (Fig. 4A), indicating that" exact="pertuzumab" post="was not very effective in SK250LR cells. This is"/>
   <result pre="This is consistent with the apoptotic assay, which showed that" exact="pertuzumab" post="did not cause any change in the percentage of"/>
   <result pre="change in the percentage of apoptotic cells with or without" exact="lapatinib" post="in SK250LR cells (Fig. 4C and Suppl. Fig. 5A"/>
   <result pre="Suppl. Fig. 5A to F). In BT250LR cells, withdrawal of" exact="lapatinib" post="resulted in a statistically significant higher number of cell"/>
   <result pre="higher number of cell count compared to those with continuous" exact="lapatinib" post="treatment (p&amp;lt;0.0001, Fig. 4B). Pertuzumab significantly reduced cell number"/>
   <result pre="Pertuzumab significantly reduced cell number of BT250LR whether or not" exact="lapatinib" post="was present (both p&amp;lt;0.0001), which is consistent with the"/>
   <result pre="experiments showed that lapatinib-resistant cell line BT250LR was sensitive to" exact="pertuzumab" post="with or without continuous lapatinib treatment, but not SK250LR."/>
   <result pre="line BT250LR was sensitive to pertuzumab with or without continuous" exact="lapatinib" post="treatment, but not SK250LR. Figure 4 Effect of pertuzumab"/>
   <result pre="continuous lapatinib treatment, but not SK250LR. Figure 4 Effect of" exact="pertuzumab" post="with or without continuous lapatinib treatment in lapatinib-resistant cell"/>
   <result pre="SK250LR. Figure 4 Effect of pertuzumab with or without continuous" exact="lapatinib" post="treatment in lapatinib-resistant cell lines (A) SK250LR and (B)"/>
   <result pre="and (B) BT250LR cells were seeded and maintained in continuous" exact="lapatinib" post="treatment the night before the experiment. On the next"/>
   <result pre="In previous experiments, the resistant cells were continuously treated with" exact="lapatinib" post="until being seeded for cell counting experiments. To investigate"/>
   <result pre="SK250LR cell line not responding to the combined anti-HER2-targeted therapy," exact="lapatinib" post="was removed from the lapatinib-resistant cell lines for 7"/>
   <result pre="cells was compared to cells that were continuously treated with" exact="lapatinib" post="and untreated parental cells. In SK250LR cells, phospho-EGFR, phospho-HER2"/>
   <result pre="SK250LR cells, phospho-EGFR, phospho-HER2 and phospho-HER4 did not reactivate after" exact="lapatinib" post="was removed for 7 days (Fig. 5A). Furthermore, the"/>
   <result pre="counting experiments revealed that SK250LR cells were still insensitive to" exact="lapatinib" post="even after 7 days of lapatinib withdrawal (Fig. 5C)."/>
   <result pre="were still insensitive to lapatinib even after 7 days of" exact="lapatinib" post="withdrawal (Fig. 5C). HER3 and Akt were slightly rephosphorylated"/>
   <result pre="phosphorylation any of the HER receptors. Figure 5 Effect of" exact="lapatinib" post="withdrawal from lapatinib-resistant cell lines on their HER signalling"/>
   <result pre="from lapatinib-resistant cell lines on their HER signalling profile and" exact="lapatinib" post="sensitivity (A) SK250LR and (B) BT250LR cells were continuously"/>
   <result pre="and (B) BT250LR cells were continuously treated with 250 nM" exact="lapatinib" post="or had the drug withdrawn for 7 days before"/>
   <result pre="and (D) BT250LR were either continuously treated with 250 nM" exact="lapatinib" post="treatment (solid bars, Cont) or had withdrawal of the"/>
   <result pre="plates. Cells were then treated with DMSO or 250 nM" exact="lapatinib" post="for 3 days, and then trypsinised and counted. The"/>
   <result pre="of cell number was normalised to the cells treated with" exact="lapatinib" post="continuously and then no drug for 3 days (Cont-No"/>
   <result pre="cells, all the HER receptors and downstream proteins rephosphorylated after" exact="lapatinib" post="was removed for 7 days (Fig. 5B). The levels"/>
   <result pre="before and after 7D-lapatinib withdrawal. The reintroduction of 250 nM" exact="lapatinib" post="after 7 days of withdrawal (7DW-250 nM Lap) caused"/>
   <result pre="which was more than those which were continuously treated with" exact="lapatinib" post="(Cont-250 nM Lap) (Fig. 5D). This indicates that the"/>
   <result pre="the cells were only transiently adapted to lapatinib, and removing" exact="lapatinib" post="from BT250LR cell line reverted its resistance resulting in"/>
   <result pre="cell lines, it is suggested that BT250LR cells responded to" exact="pertuzumab" post="treatment because they were still dependent on the HER2"/>
   <result pre="being less sensitive to pertuzumab. Effect of the combination of" exact="lapatinib" post="and pertuzumab in vivo The anti-tumour efficacy of the"/>
   <result pre="sensitive to pertuzumab. Effect of the combination of lapatinib and" exact="pertuzumab" post="in vivo The anti-tumour efficacy of the drug combination"/>
   <result pre="xenograft model. In the clinical setting, a lower dose of" exact="lapatinib" post="has been used when combined with trastuzumab (+/− chemotherapy)"/>
   <result pre="lower dose of lapatinib has been used when combined with" exact="trastuzumab" post="(+/− chemotherapy) due to possible additional toxicity and expected"/>
   <result pre="efficacy. For example, in the neoALTTO trial, a 1500 mg" exact="lapatinib" post="dose was used for the lapatinib group but 1000"/>
   <result pre="trial, a 1500 mg lapatinib dose was used for the" exact="lapatinib" post="group but 1000 mg was used when combined with"/>
   <result pre="lapatinib group but 1000 mg was used when combined with" exact="trastuzumab" post="[ 20]. To demonstrate the additive effect of the"/>
   <result pre="size in this experiment (Fig. 6A). The results in the" exact="pertuzumab" post="treated group varied, with two tumour regressed but another"/>
   <result pre="was significantly different from the vehicle group (p&amp;lt;0.05) and the" exact="lapatinib" post="group (p&amp;lt;0.01). The above results suggested that the combination"/>
   <result pre="group (p&amp;lt;0.01). The above results suggested that the combination of" exact="lapatinib" post="and pertuzumab outperformed either monotherapy in vivo. Figure 6"/>
   <result pre="The above results suggested that the combination of lapatinib and" exact="pertuzumab" post="outperformed either monotherapy in vivo. Figure 6 Anti-tumour effect"/>
   <result pre="the indicated treatments. (Lapatinib: 50 mg/kg five times per week;" exact="pertuzumab" post="12 mg/kg loading dose followed by 6 mg/kg maintenance"/>
   <result pre="that of the vehicle control group (p&amp;lt;0.05) (Fig. 6B). Although" exact="trastuzumab" post="has been shown to downregulate HER2 [ 31], there"/>
   <result pre="[ 31], there was no decrease of HER2 level by" exact="lapatinib" post="or pertuzumab or their combination in vivo ( Suppl."/>
   <result pre="there was no decrease of HER2 level by lapatinib or" exact="pertuzumab" post="or their combination in vivo ( Suppl. Fig. 6)."/>
   <result pre="( Suppl. Fig. 7). DISCUSSION NRG1 has been implicated in" exact="lapatinib" post="resistance [ 27] as well as overcoming the inhibitory"/>
   <result pre="[ 27] as well as overcoming the inhibitory effect of" exact="gefitinib" post="[ 32] and trastuzumab [ 33] treatment in HER2-overexpressing"/>
   <result pre="as overcoming the inhibitory effect of gefitinib [ 32] and" exact="trastuzumab" post="[ 33] treatment in HER2-overexpressing breast cancer cells. Our"/>
   <result pre="that the NRG1 protein expression levels increased in response to" exact="lapatinib" post="treatment in HER2-overexpressing breast cancer cell lines, and lapatinib"/>
   <result pre="to lapatinib treatment in HER2-overexpressing breast cancer cell lines, and" exact="lapatinib" post="could not sustain its inhibition of HER receptor signalling."/>
   <result pre="of SPG1 antibody suggested that HER3 ligands may contribute to" exact="lapatinib" post="resistance. Moreover, we showed that pertuzumab could enhance response"/>
   <result pre="ligands may contribute to lapatinib resistance. Moreover, we showed that" exact="pertuzumab" post="could enhance response to lapatinib in BT-474 cells and"/>
   <result pre="resistance. Moreover, we showed that pertuzumab could enhance response to" exact="lapatinib" post="in BT-474 cells and xenograft models. A very recent"/>
   <result pre="demonstrate the role of NRG1 autocrine signalling in the acquired" exact="lapatinib" post="resistance, they combined the data of all patients receiving"/>
   <result pre="resistance, they combined the data of all patients receiving chemotherapy," exact="tamoxifen" post="or systematically untreated; therefore, this analysis could not address"/>
   <result pre="analysis could not address the association between NRG1 expression and" exact="lapatinib" post="response. To date, there is only one published clinical"/>
   <result pre="To date, there is only one published clinical trial involving" exact="lapatinib" post="(EGF104911) that measured NRG1 level in tumours by immunohistochemistry"/>
   <result pre="not mention any correlation between NRG1 and clinical benefits from" exact="lapatinib" post="monotherapy [ 34]. We propose for further studies to"/>
   <result pre="be done to validate NRG1 as a predictive biomarker for" exact="lapatinib" post="sensitivity. Since ADAM10 and 17 have been shown to"/>
   <result pre="shown to play a role in mediating acquired resistance to" exact="trastuzumab" post="through the shedding of HER ligands [ 33, 35],"/>
   <result pre="17 proteases as well as other HER ligands in mediating" exact="lapatinib" post="resistance in HER2-positive breast cancer. The addition of pertuzumab"/>
   <result pre="mediating lapatinib resistance in HER2-positive breast cancer. The addition of" exact="pertuzumab" post="to lapatinib inhibited the phosphorylation of HER3 and HER4,"/>
   <result pre="resistance in HER2-positive breast cancer. The addition of pertuzumab to" exact="lapatinib" post="inhibited the phosphorylation of HER3 and HER4, suggesting that"/>
   <result pre="important to assess the different dimerisation patterns in relation to" exact="lapatinib" post="treatment and resistance [ 36]. Since neratinib could overcome"/>
   <result pre="in relation to lapatinib treatment and resistance [ 36]. Since" exact="neratinib" post="could overcome trastuzumab resistance [ 37] and lapatinib resistance"/>
   <result pre="lapatinib treatment and resistance [ 36]. Since neratinib could overcome" exact="trastuzumab" post="resistance [ 37] and lapatinib resistance [ 27], it"/>
   <result pre="36]. Since neratinib could overcome trastuzumab resistance [ 37] and" exact="lapatinib" post="resistance [ 27], it will be interesting to assess"/>
   <result pre="it will be interesting to assess whether the combination of" exact="pertuzumab" post="and neratinib will also be additive in vitro and"/>
   <result pre="be interesting to assess whether the combination of pertuzumab and" exact="neratinib" post="will also be additive in vitro and in vivo"/>
   <result pre="were high in the tumours treated with the combination of" exact="lapatinib" post="and pertuzumab, suggesting HER4 may mediate the effect of"/>
   <result pre="in vessel perfusion and ADCC which could be induced by" exact="pertuzumab" post="[ 41]. Total cell counting and apoptotic assays showed"/>
   <result pre="cell line was not sensitive to the combination treatment of" exact="lapatinib" post="and pertuzumab. The innate resistance to pertuzumab may be"/>
   <result pre="combination treatment of lapatinib and pertuzumab. The innate resistance to" exact="pertuzumab" post="may be due to the permanent change in cell"/>
   <result pre="line was still dependent on HER2 signalling and responded to" exact="pertuzumab" post="treatment. Our data shows that the combination of lapatinib"/>
   <result pre="to pertuzumab treatment. Our data shows that the combination of" exact="lapatinib" post="and pertuzumab or pertuzumab alone may be effective in"/>
   <result pre="treatment. Our data shows that the combination of lapatinib and" exact="pertuzumab" post="or pertuzumab alone may be effective in a subset"/>
   <result pre="data shows that the combination of lapatinib and pertuzumab or" exact="pertuzumab" post="alone may be effective in a subset of lapatinib-resistant"/>
   <result pre="cell lines to further understand the difference mechanisms of acquired" exact="lapatinib" post="resistance. A recent report showed that anti-HER3 monoclonal antibody"/>
   <result pre="recent report showed that anti-HER3 monoclonal antibody was synergistic with" exact="lapatinib" post="in PC9ZD, a gefitinib-resistant lung cancer cell line which"/>
   <result pre="the NRG1/HER3 pathway was one of the mechanisms of acquired" exact="lapatinib" post="resistance in HER2-overexpressing breast cancer cell lines, this pathway"/>
   <result pre="and the effect of HER3 monoclonal antibodies in combination with" exact="lapatinib" post="in a larger panel of lapatinib-sensitive and innate-resistant breast"/>
   <result pre="consider other pathways which may affect HER receptor signalling and" exact="lapatinib" post="sensitivity. For example, a recent report showed that neurotensin"/>
   <result pre="affinity receptor (NTSR1) enhances EGFR, HER2, and HER3 activation, but" exact="lapatinib" post="could reduce the tumour growth of breast cancer cells"/>
   <result pre="cross-talk between neurotensinergic and the HER pathways in relation to" exact="lapatinib" post="sensitivity and resistance. It may also be useful to"/>
   <result pre="combinatorial drug screening approach to identify compensatory pathways that mediate" exact="lapatinib" post="resistance and to target them with other targeted agents"/>
   <result pre="to target them with other targeted agents in combination with" exact="lapatinib" post="to overcome its resistance and to achieve durable clinical"/>
   <result pre="to achieve durable clinical in order benefit [ 44]. Although" exact="lapatinib" post="plus pertuzumab may be a useful combination strategy for"/>
   <result pre="durable clinical in order benefit [ 44]. Although lapatinib plus" exact="pertuzumab" post="may be a useful combination strategy for anti-HER2 therapy,"/>
   <result pre="strategy for anti-HER2 therapy, it will require further comparison with" exact="trastuzumab" post="plus pertuzumab or trastuzumab plus lapatinib or the triple"/>
   <result pre="anti-HER2 therapy, it will require further comparison with trastuzumab plus" exact="pertuzumab" post="or trastuzumab plus lapatinib or the triple combination in"/>
   <result pre="it will require further comparison with trastuzumab plus pertuzumab or" exact="trastuzumab" post="plus lapatinib or the triple combination in preclinical models"/>
   <result pre="require further comparison with trastuzumab plus pertuzumab or trastuzumab plus" exact="lapatinib" post="or the triple combination in preclinical models and in"/>
   <result pre="treatments has changed. For metastatic breast cancer, the combination of" exact="pertuzumab" post="and trastuzumab with docetaxel chemotherapy is now recommended as"/>
   <result pre="changed. For metastatic breast cancer, the combination of pertuzumab and" exact="trastuzumab" post="with docetaxel chemotherapy is now recommended as the first-line"/>
   <result pre="metastatic breast cancer, the combination of pertuzumab and trastuzumab with" exact="docetaxel" post="chemotherapy is now recommended as the first-line treatment. T-DM1"/>
   <result pre="treatment since EMILIA trial showed that T-DM1 was superior to" exact="lapatinib" post="plus capecitabine in prolonging progression-free and overall survivals, and"/>
   <result pre="EMILIA trial showed that T-DM1 was superior to lapatinib plus" exact="capecitabine" post="in prolonging progression-free and overall survivals, and it caused"/>
   <result pre="less toxicity in HER2-positive breast cancer patients previously treated with" exact="trastuzumab" post="and a taxane [ 45]. This means that lapatinib"/>
   <result pre="with trastuzumab and a taxane [ 45]. This means that" exact="lapatinib" post="with capecitabine is increasingly being used as a third-line"/>
   <result pre="and a taxane [ 45]. This means that lapatinib with" exact="capecitabine" post="is increasingly being used as a third-line anti-HER2 treatment"/>
   <result pre="anti-HER2 treatment for metastatic breast cancer. Although we showed that" exact="pertuzumab" post="and lapatinib could potentially be useful in the setting"/>
   <result pre="for metastatic breast cancer. Although we showed that pertuzumab and" exact="lapatinib" post="could potentially be useful in the setting of lapatinib"/>
   <result pre="and lapatinib could potentially be useful in the setting of" exact="lapatinib" post="resistance, this is uncertain in the context of patients"/>
   <result pre="who have previously failed three lines of anti-HER2 treatments, namely" exact="pertuzumab" post="and trastuzumab with docetaxel followed by T-DM1 and lapatinib"/>
   <result pre="previously failed three lines of anti-HER2 treatments, namely pertuzumab and" exact="trastuzumab" post="with docetaxel followed by T-DM1 and lapatinib with capecitabine."/>
   <result pre="three lines of anti-HER2 treatments, namely pertuzumab and trastuzumab with" exact="docetaxel" post="followed by T-DM1 and lapatinib with capecitabine. This will"/>
   <result pre="namely pertuzumab and trastuzumab with docetaxel followed by T-DM1 and" exact="lapatinib" post="with capecitabine. This will needs to be tested in"/>
   <result pre="still be potentially useful for patients who have started on" exact="lapatinib" post="containing regimen first and have not had pertuzumab. In"/>
   <result pre="have not had pertuzumab. In summary, we have found that" exact="lapatinib" post="could not sustain the inhibition of HER receptor signalling."/>
   <result pre="ligands. The exogenous NRG1 stimulation diminished the inhibitory effect of" exact="lapatinib" post="in HER2-overexpressing cells. The addition of pertuzumab to lapatinib"/>
   <result pre="inhibitory effect of lapatinib in HER2-overexpressing cells. The addition of" exact="pertuzumab" post="to lapatinib inhibited NRG1-stimulated HER3 and HER4 signalling in"/>
   <result pre="of lapatinib in HER2-overexpressing cells. The addition of pertuzumab to" exact="lapatinib" post="inhibited NRG1-stimulated HER3 and HER4 signalling in both SK-BR-3"/>
   <result pre="BT250LR were generated by chronic exposure of increasing concentration of" exact="lapatinib" post="from 25 nM, 50 nM, 100 nM to 250"/>
   <result pre="then the cells were maintained in 250 nM lapatinib. Fresh" exact="lapatinib" post="was replaced every 3 days. Lapatinib was purchased from"/>
   <result pre="TWEEN80 (control for lapatinib) and PBSA (control for pertuzumab), b)" exact="lapatinib" post="and PBSA, c) TWEEN80 and pertuzumab, d) lapatinib and"/>
   <result pre="pertuzumab), b) lapatinib and PBSA, c) TWEEN80 and pertuzumab, d)" exact="lapatinib" post="and pertuzumab, and they received treatment for 3 weeks."/>
   <result pre="was compromised. The mice were euthanised by cardiac puncture under" exact="isoflurane" post="general anaesthesia and death confirmed by neck dislocation. Residual"/>
   <result pre="paraformaldehyde at 4°C for 48 hours and stored in 70%" exact="ethanol" post="at 4°C until being processed at the Oxford Centre"/>
   <result pre="5 minutes each. Then they were rehydrated twice with 100%" exact="ethanol" post="for another 5 minutes each, followed by 70% ethanol"/>
   <result pre="100% ethanol for another 5 minutes each, followed by 70%" exact="ethanol" post="for 5 minutes and finally tap water for 5"/>
   <result pre="10 Nahta R Hung MC Esteva FJ The HER-2-targeting antibodies" exact="trastuzumab" post="and pertuzumab synergistically inhibit the survival of breast cancer"/>
   <result pre="R Hung MC Esteva FJ The HER-2-targeting antibodies trastuzumab and" exact="pertuzumab" post="synergistically inhibit the survival of breast cancer cells Cancer"/>
   <result pre="Benyunes MC Ross G Swain SM Group CS Pertuzumab plus" exact="trastuzumab" post="plus docetaxel for metastatic breast cancer The New England"/>
   <result pre="Ross G Swain SM Group CS Pertuzumab plus trastuzumab plus" exact="docetaxel" post="for metastatic breast cancer The New England journal of"/>
   <result pre="V Bianchi G et al. Efficacy and safety of neoadjuvant" exact="pertuzumab" post="and trastuzumab in women with locally advanced, inflammatory, or"/>
   <result pre="G et al. Efficacy and safety of neoadjuvant pertuzumab and" exact="trastuzumab" post="in women with locally advanced, inflammatory, or early HER2-positive"/>
   <result pre="Podratz KC Slamon DJ Activity of the dual kinase inhibitor" exact="lapatinib" post="(GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells Cancer"/>
   <result pre="Raats JI et al. A phase III randomized comparison of" exact="lapatinib" post="plus capecitabine versus capecitabine alone in women with advanced"/>
   <result pre="et al. A phase III randomized comparison of lapatinib plus" exact="capecitabine" post="versus capecitabine alone in women with advanced breast cancer"/>
   <result pre="A phase III randomized comparison of lapatinib plus capecitabine versus" exact="capecitabine" post="alone in women with advanced breast cancer that has"/>
   <result pre="Berger M Oliva C Rubin SD et al. Lapatinib plus" exact="capecitabine" post="for HER2-positive advanced breast cancer The New England journal"/>
   <result pre="Horvath Z Coccia-Portugal M Domont J et al. Lapatinib with" exact="trastuzumab" post="for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label,"/>
   <result pre="21 Valachis A Nearchou A Lind P Mauri D Lapatinib," exact="trastuzumab" post="or the combination added to preoperative chemotherapy for breast"/>
   <result pre="phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with" exact="lapatinib" post="(L) or trastuzumab (T) as first-line therapy for women"/>
   <result pre="controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or" exact="trastuzumab" post="(T) as first-line therapy for women with HER2+ metastatic"/>
   <result pre="W Sathe GM Martin AM Gilmer TM Novel mechanism of" exact="lapatinib" post="resistance in HER2-positive breast tumor cells: activation of AXL"/>
   <result pre="Spector NL An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired" exact="lapatinib" post="resistance in HER2+ breast cancer models Breast cancer research"/>
   <result pre="Capala J Potential of PET to predict the response to" exact="trastuzumab" post="treatment in an ErbB2-positive human xenograft tumor model Journal"/>
   <result pre="Roxanis I Capala J Murphy G et al. ADAM10 mediates" exact="trastuzumab" post="resistance and is correlated with survival in HER2 positive"/>
   <result pre="Duffy MJ O'Donovan N Crown J et al. Neratinib overcomes" exact="trastuzumab" post="resistance in HER2 amplified breast cancer Oncotarget 2013 4"/>
   <result pre="Harris AL Kong A Nuclear HER4 mediates acquired resistance to" exact="trastuzumab" post="and is associated with poor outcome in HER2 positive"/>
   <result pre="B Endl J Hasmann M Strongly enhanced antitumor activity of" exact="trastuzumab" post="and pertuzumab combination treatment on HER2-positive human xenograft tumor"/>
   <result pre="J Hasmann M Strongly enhanced antitumor activity of trastuzumab and" exact="pertuzumab" post="combination treatment on HER2-positive human xenograft tumor models Cancer"/>
   <result pre="receptor 1 renders breast tumors aggressive yet highly responsive to" exact="lapatinib" post="and metformin in mice Oncotarget 2014 5 8235 51"/>
   <result pre="renders breast tumors aggressive yet highly responsive to lapatinib and" exact="metformin" post="in mice Oncotarget 2014 5 8235 51 25249538 43"/>
   <result pre="Steinberg SM Merino MJ Rubin SD Steeg PS Effect of" exact="lapatinib" post="on the outgrowth of metastatic breast cancer cells to"/>
   <result pre="Osborne CK Schiff R Reduced dose and intermittent treatment with" exact="lapatinib" post="and trastuzumab for potent blockade of the HER pathway"/>
   <result pre="Schiff R Reduced dose and intermittent treatment with lapatinib and" exact="trastuzumab" post="for potent blockade of the HER pathway in HER2/neu-overexpressing"/>
   <result pre="50 Friess T Scheuer W Hasmann M Combination treatment with" exact="erlotinib" post="and pertuzumab against human tumor xenografts is superior to"/>
   <result pre="T Scheuer W Hasmann M Combination treatment with erlotinib and" exact="pertuzumab" post="against human tumor xenografts is superior to monotherapy Clinical"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4467661/results/search/inn/results.xml">
   <result pre="Press pmcid: 4467661 doi: 10.2147/BCTT.S54414 bctt-7-147 : Review Profile of" exact="neratinib" post="and its potential in the treatment of breast cancer"/>
   <result pre="a new group of compounds that bind irreversibly to the" exact="adenosine" post="triphosphate binding pocket of HER receptors have been developed."/>
   <result pre="either as monotherapy or in combination with other drug(s). Keywords" exact="neratinib" post="HKI 272 pan-HER inhibitor irreversible tyrosine kinase inhibitor HER"/>
   <result pre="and it can also form potent homodimers. 10 Development of" exact="neratinib" post="to target HER family kinase activity Neratinib (HKI-272, Puma"/>
   <result pre="to the tyrosine kinase domain and inhibit its interaction with" exact="adenosine" post="triphosphate (ATP) in order to prevent receptor phosphorylation. A"/>
   <result pre="difficult due to different assay conditions. Earlier compounds such as" exact="erlotinib" post="(Tarceva ®) and gefitinib (Iressa ®), which are approved"/>
   <result pre="assay conditions. Earlier compounds such as erlotinib (Tarceva ®) and" exact="gefitinib" post="(Iressa ®), which are approved in non-small cell lung"/>
   <result pre="which are approved in non-small cell lung cancer (NSCLC), or" exact="lapatinib" post="(Tyverb), which is licensed for HER2-positive breast cancer, were"/>
   <result pre="specificity of the compound is achieved. It was shown that" exact="neratinib" post="did not significantly inhibit serine-threonine kinases such as AKT"/>
   <result pre="phenyl] amino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-, (2E)-, (2Z) -2-butenedioate (1:1). In comparison with EKB-569," exact="neratinib" post="has a lipophilic 2-pyridinylmethyl moiety at the para-position of"/>
   <result pre="three of the HER receptors, ie, EGFR, HER2, and HER4," exact="neratinib" post="is a pan-HER inhibitor. 11 Neratinib inhibits EGFR and"/>
   <result pre="and has indeed been shown previously. 26, 27 Efficacy of" exact="neratinib" post="in preclinical models As neratinib binds irreversibly to the"/>
   <result pre="previously. 26, 27 Efficacy of neratinib in preclinical models As" exact="neratinib" post="binds irreversibly to the ATP binding pocket of HER"/>
   <result pre="on receptor turnover. 11 Acute treatment with low doses of" exact="neratinib" post="led to a decrease of HER2 and EGFR phosphorylation"/>
   <result pre="to both EGFR and HER2, several studies have shown that" exact="neratinib" post="is more effective in HER2-positive breast cancers relative to"/>
   <result pre="panel of cell lines, we showed that the response to" exact="neratinib" post="was correlated with baseline HER2 and phosphorylated HER2 levels,"/>
   <result pre="levels, but not with EGFR levels in vitro. 26 Interestingly," exact="neratinib" post="decreased the activation of phosphatidylinositide 3-kinase and mitogen-activated protein"/>
   <result pre="have been correlated with response to neratinib. 29 In vivo," exact="neratinib" post="was shown to be more effective in decreasing xenograft"/>
   <result pre="the US Food and Drug Administration was the monoclonal antibody" exact="trastuzumab" post="(Herceptin ®), which targets domain IV of the extracellular"/>
   <result pre="cancer. 30– 33 However, de novo or acquired resistance to" exact="trastuzumab" post="is frequent and is still a subject of extensive"/>
   <result pre="38 or allosteric hindrance 39, 40 as mechanisms involved in" exact="trastuzumab" post="resistance. Interestingly, it was also reported that treatment with"/>
   <result pre="trastuzumab resistance. Interestingly, it was also reported that treatment with" exact="trastuzumab" post="led to an increased activation of other receptor tyrosine"/>
   <result pre="and c-Met. 41 In addition, we have previously shown that" exact="trastuzumab" post="induced an increase of ADAM10 and ADAM17 expression, which"/>
   <result pre="mechanism has also been reported in vitro with regard to" exact="lapatinib" post="resistance. 44, 45 As shown in Figure 3, neratinib"/>
   <result pre="to lapatinib resistance. 44, 45 As shown in Figure 3," exact="neratinib" post="targets tyrosine kinase activity at the intracellular domain of"/>
   <result pre="domain of the HER receptors (EGFR, HER2, and HER4), whereas" exact="trastuzumab" post="targets the extracellular domain of HER2. This difference in"/>
   <result pre="explain the improved response when both drugs are combined, since" exact="trastuzumab" post="can induce ligand-dependent activation of HER receptors, 42, 43"/>
   <result pre="can induce ligand-dependent activation of HER receptors, 42, 43 whereas" exact="neratinib" post="inhibits the phosphorylation and activity of HER receptors. Indeed,"/>
   <result pre="activity of HER receptors. Indeed, it has been shown that" exact="neratinib" post="can overcome trastuzumab resistance in vitro. 26 It was"/>
   <result pre="receptors. Indeed, it has been shown that neratinib can overcome" exact="trastuzumab" post="resistance in vitro. 26 It was reported that neratinib"/>
   <result pre="overcome trastuzumab resistance in vitro. 26 It was reported that" exact="neratinib" post="was able to suppress ligand-stimulated HER2–HER3 dimers and could"/>
   <result pre="antibody-dependent cellular cytotoxicity. 46 It has been shown that during" exact="trastuzumab" post="treatment and resistance, HER4 cleavage and its translocation to"/>
   <result pre="was associated with a poor prognosis. 27 However, cotreatment with" exact="neratinib" post="decreased trastuzumab-induced nuclear HER4 in vitro and in BT474"/>
   <result pre="In the same in vivo model, it was shown that" exact="trastuzumab" post="and neratinib treatment in combination was more effective than"/>
   <result pre="same in vivo model, it was shown that trastuzumab and" exact="neratinib" post="treatment in combination was more effective than either treatment"/>
   <result pre="combination was more effective than either treatment alone. 26 Additionally," exact="neratinib" post="was also shown to enhance response when added to"/>
   <result pre="al 28 point to the potential added benefit of using" exact="neratinib" post="as a combinational treatment option alongside other targeted treatments"/>
   <result pre="response to lapatinib, which was improved by the combination of" exact="lapatinib" post="with pertuzumab, an antibody binding to the HER2 dimerization"/>
   <result pre="thus be interesting to test whether NRG1 mediates resistance to" exact="neratinib" post="and whether pertuzumab could also enhance the response to"/>
   <result pre="to test whether NRG1 mediates resistance to neratinib and whether" exact="pertuzumab" post="could also enhance the response to neratinib. In addition,"/>
   <result pre="the response to neratinib. In addition, since the combination of" exact="trastuzumab" post="with new agent(s), including a heat shock protein 90"/>
   <result pre="synergistic, it will be interesting to test the combination of" exact="neratinib" post="with these new agents. However, more data will be"/>
   <result pre="clinical studies suggest that patients with CNS metastases who receive" exact="trastuzumab" post="have an increased overall survival compared with patients who"/>
   <result pre="who do not, it is well understood that penetration of" exact="trastuzumab" post="across the blood–brain barrier is inefficient. 50 Therefore, there"/>
   <result pre="actively extruding the drug compounds. Recent studies have shown that" exact="lapatinib" post="is a substrate as well as an inhibitor of"/>
   <result pre="an inhibitor of ABCB1, potentially explaining why brain concentrations of" exact="lapatinib" post="tend to be lower. 51 However, in contrast with"/>
   <result pre="tend to be lower. 51 However, in contrast with lapatinib," exact="neratinib" post="has been shown to reverse ABCB1-mediated chemoresistance 52 and"/>
   <result pre="unaltered by the presence of the ABCG2 transporter. 53 Moreover," exact="neratinib" post="could inhibit the function of this transporter at higher"/>
   <result pre="preliminary data from a clinical trial investigating the efficacy of" exact="neratinib" post="in HER2-positive breast cancer patients presenting with brain metastasis"/>
   <result pre="brain metastasis (ClinicalTrials.gov identifier NCT01494662, see Table 2) suggested that" exact="neratinib" post="could help to control disease in some HER2-positive breast"/>
   <result pre="HER2-negative breast cancer There is an interest in assessing whether" exact="neratinib" post="could also be effective in breast tumors with lower"/>
   <result pre="59 As the original HER2 positivity threshold was based on" exact="trastuzumab" post="response, it is unknown whether the threshold should be"/>
   <result pre="whether the threshold should be different for TKIs such as" exact="lapatinib" post="and neratinib, since there have been studies suggesting that"/>
   <result pre="with low HER2 by IHC may be more sensitive to" exact="lapatinib" post="than to trastuzumab. 60 The I-SPY2 trial suggested that"/>
   <result pre="suggested that HER2-negative patients may benefit from the addition of" exact="neratinib" post="to chemotherapy (see below). 61 Triple-negative breast cancer Triple"/>
   <result pre="breast cancers that lack expression of the estrogen receptor and" exact="progesterone" post="receptor as well as HER2 overexpression or gene amplification."/>
   <result pre="significant improvement in pathological complete response (pCR) when treated with" exact="neratinib" post="and chemotherapy in comparison with chemotherapy alone in the"/>
   <result pre="far show that the mechanisms of response and resistance to" exact="neratinib" post="and other EGFR inhibitors in TNBCs are not well"/>
   <result pre="biomarkers for use of EGFR inhibitors in TNBC. Role of" exact="neratinib" post="in treatment of tumors with EGFR, HER2, HER3, or"/>
   <result pre="with EGFR, HER2, HER3, or HER4 somatic mutations EGFR Previously," exact="erlotinib" post="and gefitinib have been found to be particularly effective"/>
   <result pre="HER2, HER3, or HER4 somatic mutations EGFR Previously, erlotinib and" exact="gefitinib" post="have been found to be particularly effective against NSCLCs"/>
   <result pre="ATP. 68 Two trials have demonstrated the clinical benefit of" exact="afatinib" post="in patients with lung cancer who had progressed on"/>
   <result pre="afatinib in patients with lung cancer who had progressed on" exact="erlotinib" post="or gefitinib. 69, 70 The recent results from the"/>
   <result pre="recent results from the LUX-Lung 3 trial showed superiority of" exact="afatinib" post="with regard to response rate and progression-free survival over"/>
   <result pre="afatinib with regard to response rate and progression-free survival over" exact="cisplatin" post="and pemetrexed as first-line agents in treatment-naïve patients with"/>
   <result pre="regard to response rate and progression-free survival over cisplatin and" exact="pemetrexed" post="as first-line agents in treatment-naïve patients with advanced adenocarcinoma"/>
   <result pre="adenocarcinoma of the lung and EGFR mutation. 71 Since then," exact="afatinib" post="has been approved for use in NSCLC with EGFR"/>
   <result pre="been approved for use in NSCLC with EGFR mutation. Since" exact="neratinib" post="is a similar compound to afatinib as an irreversible"/>
   <result pre="with EGFR mutation. Since neratinib is a similar compound to" exact="afatinib" post="as an irreversible TKI, there is an interest in"/>
   <result pre="an irreversible TKI, there is an interest in assessing whether" exact="neratinib" post="could be effective in solid tumors (including breast cancer)"/>
   <result pre="basis for the Basket Study (NCT01953926, see below). HER2 Similarly," exact="neratinib" post="could also be a treatment option for patients who"/>
   <result pre="resistant to lapatinib. 72 This provides the rationale for testing" exact="neratinib" post="in patients with HER2 mutations, including those with breast"/>
   <result pre="vivo growth. However, several HER3 or HER2 targeting agents, including" exact="trastuzumab" post="and lapatinib, were effective in targeting these mutants, 73"/>
   <result pre="lapatinib, were effective in targeting these mutants, 73 indicating that" exact="neratinib" post="may also have an effect. HER4 HER4 mutations have"/>
   <result pre="were sensitive to treatment with lapatinib. 74 As a result," exact="lapatinib" post="has been taken into clinical trials in melanoma, where"/>
   <result pre="more than two oncogenic somatic HER4 mutations will be offered" exact="lapatinib" post="monotherapy (NCT01264081). Being an irreversible pan-HER inhibitor, neratinib could"/>
   <result pre="be offered lapatinib monotherapy (NCT01264081). Being an irreversible pan-HER inhibitor," exact="neratinib" post="could probably inhibit HER4 activation more effectively than lapatinib,"/>
   <result pre="not been done. It will be interesting to assess whether" exact="neratinib" post="is effective in tumors with HER4 mutations, including melanoma"/>
   <result pre="75 Another group identified miR-630 deficiency as a cause of" exact="neratinib" post="resistance, at least partly due to its regulation of"/>
   <result pre="been shown to correspond with resistance to HER-targeting agents, including" exact="neratinib" post="in vitro. It was suggested that neuromedin U acts"/>
   <result pre="reactivation of HER3 and AKT phosphorylation after 24 hours of" exact="neratinib" post="treatment in HER2-positive breast cancer cells, although we did"/>
   <result pre="HER2, AKT, ERK, and other potential markers for response to" exact="neratinib" post="(see HER2-positive breast cancer section above). However, there are"/>
   <result pre="yet. So far, the I-SPY 2 trial has shown that" exact="neratinib" post="in addition to standard neoadjuvant chemotherapy may be beneficial"/>
   <result pre="also had a higher pCR rate with the addition of" exact="neratinib" post="(30% vs 17%). 64 In the same study, patients"/>
   <result pre="clinical trials will be needed to establish reliable biomarkers for" exact="neratinib" post="response and resistance. Clinical trials Neratinib is currently being"/>
   <result pre="Phase I dose-escalation study examined the safety and efficacy of" exact="neratinib" post="at doses of 40–400 mg daily in patients with"/>
   <result pre="mg daily in patients with solid tumors. The absorption of" exact="neratinib" post="was measured as median time to peak plasma concentration"/>
   <result pre="peak plasma concentration and area under the concentration–time curve for" exact="neratinib" post="increased in a dose-dependent manner from 40 to 320"/>
   <result pre="survival of 22.3 weeks in patients who had received prior" exact="trastuzumab" post="treatment; and a rate of 78% with a median"/>
   <result pre="The objective response rates were 24% in patients with prior" exact="trastuzumab" post="treatment and 56% in the trastuzumab-naïve cohort. 79 Similarly,"/>
   <result pre="79 Similarly, a Phase I/II study exploring the combination of" exact="neratinib" post="with vinorelbine in pretreated HER2-positive metastatic breast cancer showed"/>
   <result pre="a Phase I/II study exploring the combination of neratinib with" exact="vinorelbine" post="in pretreated HER2-positive metastatic breast cancer showed an objective"/>
   <result pre="showed an objective response of 8% in patients with prior" exact="lapatinib" post="and 41% in patients who had no prior lapatinib,"/>
   <result pre="the respective progression-free survival rates. 80 On the other hand," exact="neratinib" post="in combination with paclitaxel showed an overall response rate"/>
   <result pre="rates. 80 On the other hand, neratinib in combination with" exact="paclitaxel" post="showed an overall response rate of 71% in patients"/>
   <result pre="71% in patients who had not previously been treated with" exact="lapatinib" post="and 77% in those with prior lapatinib. 81 However,"/>
   <result pre="toxicity but it achieved a better response rate relative to" exact="neratinib" post="monotherapy. The overall response rate was 73% (95% confidence"/>
   <result pre="confidence interval 47.7–81.6). 81 Another study compared the combination of" exact="neratinib" post="with weekly paclitaxel and trastuzumab in heavily pretreated patients"/>
   <result pre="81 Another study compared the combination of neratinib with weekly" exact="paclitaxel" post="and trastuzumab in heavily pretreated patients with HER2-positive metastatic"/>
   <result pre="study compared the combination of neratinib with weekly paclitaxel and" exact="trastuzumab" post="in heavily pretreated patients with HER2-positive metastatic breast cancer"/>
   <result pre="to disease progression of 3.7 months. 82 The addition of" exact="neratinib" post="and/or trastuzumab to neoadjuvant paclitaxel followed by doxorubicin and"/>
   <result pre="progression of 3.7 months. 82 The addition of neratinib and/or" exact="trastuzumab" post="to neoadjuvant paclitaxel followed by doxorubicin and cyclophosphamide chemotherapy"/>
   <result pre="months. 82 The addition of neratinib and/or trastuzumab to neoadjuvant" exact="paclitaxel" post="followed by doxorubicin and cyclophosphamide chemotherapy is currently being"/>
   <result pre="addition of neratinib and/or trastuzumab to neoadjuvant paclitaxel followed by" exact="doxorubicin" post="and cyclophosphamide chemotherapy is currently being tested in a"/>
   <result pre="neratinib and/or trastuzumab to neoadjuvant paclitaxel followed by doxorubicin and" exact="cyclophosphamide" post="chemotherapy is currently being tested in a Phase II"/>
   <result pre="Neratinib in combination with the mammalian target of rapamycin inhibitor" exact="temsirolimus" post="was found to be tolerable and to be potentially"/>
   <result pre="(14%). 26 This dose-escalation study suggested a potential relationship between" exact="neratinib" post="dose/exposure and diarrhea, 78 but a follow-up study by"/>
   <result pre="or severity of diarrhea in healthy subjects who were given" exact="neratinib" post="either 240 mg once daily or 120 mg twice"/>
   <result pre="of antidiarrheal medication is now mandatory for all patients taking" exact="neratinib" post="in recent clinical trials, which has helped to reduce"/>
   <result pre="85 However, the possible long-term cardiac toxicity from addition of" exact="neratinib" post="to trastuzumab and/or chemotherapy will not be known until"/>
   <result pre="the possible long-term cardiac toxicity from addition of neratinib to" exact="trastuzumab" post="and/or chemotherapy will not be known until the ongoing"/>
   <result pre="ongoing clinical trials yield mature safety data. Ongoing trials Since" exact="neratinib" post="was often more potent than lapatinib in the preclinical"/>
   <result pre="data. Ongoing trials Since neratinib was often more potent than" exact="lapatinib" post="in the preclinical setting, there is interest in comparing"/>
   <result pre="Neratinib monotherapy has previously been compared with the combination of" exact="lapatinib" post="and capecitabine; however, this study could determine neither inferiority"/>
   <result pre="of neratinib. 86 Overall survival was slightly better in the" exact="lapatinib" post="+ capecitabine arm, but this difference was not statistically"/>
   <result pre="86 Overall survival was slightly better in the lapatinib +" exact="capecitabine" post="arm, but this difference was not statistically significant. 86"/>
   <result pre="but this difference was not statistically significant. 86 In addition," exact="neratinib" post="monotherapy may not be directly comparable with a combination"/>
   <result pre="monotherapy may not be directly comparable with a combination of" exact="lapatinib" post="and chemotherapy since the anti-HER2 treatment response could be"/>
   <result pre="enhanced by addition of concurrent chemotherapy. A subsequent study comparing" exact="neratinib" post="+ capecitabine with lapatinib + capecitabine in patients with"/>
   <result pre="addition of concurrent chemotherapy. A subsequent study comparing neratinib +" exact="capecitabine" post="with lapatinib + capecitabine in patients with HER2-positive metastatic"/>
   <result pre="concurrent chemotherapy. A subsequent study comparing neratinib + capecitabine with" exact="lapatinib" post="+ capecitabine in patients with HER2-positive metastatic breast cancer"/>
   <result pre="A subsequent study comparing neratinib + capecitabine with lapatinib +" exact="capecitabine" post="in patients with HER2-positive metastatic breast cancer who have"/>
   <result pre="is currently ongoing. The ExteNET trial is comparing extended adjuvant" exact="neratinib" post="vs placebo in HER2-positive patients with prior adjuvant trastuzumab."/>
   <result pre="is disease-free survival, which was increased by 33% in the" exact="neratinib" post="arm (hazard ratio 0.67, P=0.0046) compared with the placebo"/>
   <result pre="carcinoma in situ, there was a 37% improvement in the" exact="neratinib" post="arm compared with the placebo arm (hazard ratio 0.63,"/>
   <result pre="results, Puma Biotechnology is planning to apply for approval of" exact="neratinib" post="in the extended adjuvant setting in the first half"/>
   <result pre="half of 2015. 87 In view of the effect of" exact="neratinib" post="on HER receptor somatic mutations (see above), Puma Biotechnology"/>
   <result pre="Puma Biotechnology has started an open-label Phase II study of" exact="neratinib" post="in patients with solid tumors carrying somatic mutations of"/>
   <result pre="this compound should be used. Although most studies showed that" exact="neratinib" post="offers the greatest benefit to patients with HER2-positive breast"/>
   <result pre="data indicate that some HER2-negative patients may also benefit. Moreover," exact="neratinib" post="is now being tested in many solid tumors carrying"/>
   <result pre="or EGFR amplification. It will be interesting to see where" exact="neratinib" post="will be positioned in relation to other available HER-targeting"/>
   <result pre="A et al. Target binding properties and cellular activity of" exact="afatinib" post="(BIBW 2992), an irreversible ErbB family blocker J Pharmacol"/>
   <result pre="models with EGFR and ERBB2 mutations that are resistant to" exact="gefitinib" post="Cancer Res 2007 67 24 11924 11932 18089823 16"/>
   <result pre="Canonici A Gijsen M Mullooly M et al. Neratinib overcomes" exact="trastuzumab" post="resistance in HER2 amplified breast cancer Oncotarget 2013 4"/>
   <result pre="Kramer-Marek G et al. Nuclear HER4 mediates acquired resistance to" exact="trastuzumab" post="and is associated with poor outcome in HER2 positive"/>
   <result pre="et al. A genome-wide RNAi screen identifies novel targets of" exact="neratinib" post="sensitivity leading to neratinib and paclitaxel combination drug treatments"/>
   <result pre="RNAi screen identifies novel targets of neratinib sensitivity leading to" exact="neratinib" post="and paclitaxel combination drug treatments Mol Biosyst 2011 7"/>
   <result pre="identifies novel targets of neratinib sensitivity leading to neratinib and" exact="paclitaxel" post="combination drug treatments Mol Biosyst 2011 7 6 1974"/>
   <result pre="to tumor inhibition by trastuzumab, and loss of PTEN predicts" exact="trastuzumab" post="resistance in patients Cancer Cell 2004 6 2 117"/>
   <result pre="NT Hung MC Esteva FJ P27(kip1) downregulation is associated with" exact="trastuzumab" post="resistance in breast cancer cells Cancer Res 2004 64"/>
   <result pre="Szollosi J Nagy P Hyaluronan-induced masking of ErbB2 and CD44-enhanced" exact="trastuzumab" post="internalisation in trastuzumab resistant breast cancer Eur J Cancer"/>
   <result pre="P Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in" exact="trastuzumab" post="resistant breast cancer Eur J Cancer 2007 43 16"/>
   <result pre="JK Carraway KL 3rd Sweeney C Met receptor contributes to" exact="trastuzumab" post="resistance of Her2-overexpressing breast cancer cells Cancer Res 2008"/>
   <result pre="Feldinger K Generali D Kramer-Marek G et al. ADAM10 mediates" exact="trastuzumab" post="resistance and is correlated with survival in HER2 positive"/>
   <result pre="et al. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired" exact="lapatinib" post="resistance in HER2+ breast cancer models Breast Cancer Res"/>
   <result pre="45 Leung WY Roxanis I Sheldon H et al. Combining" exact="lapatinib" post="and pertuzumab to overcome lapatinib resistance due to NRG1-mediated"/>
   <result pre="WY Roxanis I Sheldon H et al. Combining lapatinib and" exact="pertuzumab" post="to overcome lapatinib resistance due to NRG1-mediated signaling in"/>
   <result pre="Sheldon H et al. Combining lapatinib and pertuzumab to overcome" exact="lapatinib" post="resistance due to NRG1-mediated signaling in HER2 amplified breast"/>
   <result pre="Cotter M et al. Comparative antiproliferative effects of iniparib and" exact="olaparib" post="on a panel of triple-negative and non-triple-negative breast cancer"/>
   <result pre="breast cancer: a phase II trial of tanespimycin (17-AAG) plus" exact="trastuzumab" post="in patients with HER2-positive metastatic breast cancer progressing on"/>
   <result pre="trastuzumab in patients with HER2-positive metastatic breast cancer progressing on" exact="trastuzumab" post="Clin Cancer Res 2011 17 15 5132 5139 21558407"/>
   <result pre="al. Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and" exact="neratinib" post="with the ABCG2 multidrug transporter: implications for the emergence"/>
   <result pre="Wefel JS et al. TBCRC 022: Phase II trial of" exact="neratinib" post="for patients (Pts) with human epidermal growth factor receptor"/>
   <result pre="Kim C Wolmark N HER2 status and benefit from adjuvant" exact="trastuzumab" post="in breast cancer N Engl J Med 2008 358"/>
   <result pre="Robidoux A Tang G Rastogi P et al. Evaluation of" exact="lapatinib" post="as a component of neoadjuvant therapy for HER2+operable breast"/>
   <result pre="of positive PB272 Phase II data from I-SPY 2 trial:" exact="neratinib" post="graduates from I-SPY 2 trial 2014 Available from: http://www.pumabiotechnology.com/pr20140407.html"/>
   <result pre="362 369 22967992 64 Carlson RH I-SPY 2 trial: neoadjuvant" exact="neratinib" post="improves pathologic complete response in HR-/HER2+ breast cancer Oncology"/>
   <result pre="PK et al. TBCRC 001: randomized phase II study of" exact="cetuximab" post="in combination with carboplatin in stage IV triple-negative breast"/>
   <result pre="001: randomized phase II study of cetuximab in combination with" exact="carboplatin" post="in stage IV triple-negative breast cancer J Clin Oncol"/>
   <result pre="II study of the anti-epidermal growth factor receptor monoclonal antibody" exact="cetuximab" post="with cisplatin versus cisplatin alone in patients with metastatic"/>
   <result pre="of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with" exact="cisplatin" post="versus cisplatin alone in patients with metastatic triple-negative breast"/>
   <result pre="anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus" exact="cisplatin" post="alone in patients with metastatic triple-negative breast cancer J"/>
   <result pre="&quot;never smokers&quot; and are associated with sensitivity of tumors to" exact="gefitinib" post="and erlotinib Proc Natl Acad Sci U S A"/>
   <result pre="and are associated with sensitivity of tumors to gefitinib and" exact="erlotinib" post="Proc Natl Acad Sci U S A 2004 101"/>
   <result pre="K et al. LUX-Lung 4: a phase II trial of" exact="afatinib" post="in patients with advanced non-small-cell lung cancer who progressed"/>
   <result pre="Yang JC Yamamoto N et al. Phase III study of" exact="afatinib" post="or cisplatin plus pemetrexed in patients with metastatic lung"/>
   <result pre="Yamamoto N et al. Phase III study of afatinib or" exact="cisplatin" post="plus pemetrexed in patients with metastatic lung adenocarcinoma with"/>
   <result pre="et al. Phase III study of afatinib or cisplatin plus" exact="pemetrexed" post="in patients with metastatic lung adenocarcinoma with EGFR mutations"/>
   <result pre="Ryan TE A genome-wide RNAi screen identifies novel targets of" exact="neratinib" post="resistance leading to identification of potential drug resistant genetic"/>
   <result pre="PM Bukowski RM et al. A phase I study with" exact="neratinib" post="(HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor,"/>
   <result pre="L Manso Sanchez L et al. Safety and efficacy of" exact="neratinib" post="(HKI-272) plus vinorelbine in the treatment of patients with"/>
   <result pre="L et al. Safety and efficacy of neratinib (HKI-272) plus" exact="vinorelbine" post="in the treatment of patients with ErbB2-positive metastatic breast"/>
   <result pre="81 Chow LW Xu B Gupta S et al. Combination" exact="neratinib" post="(HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic"/>
   <result pre="Xu B Gupta S et al. Combination neratinib (HKI-272) and" exact="paclitaxel" post="therapy in patients with HER2-positive metastatic breast cancer Br"/>
   <result pre="Abraham J Tan AR et al. Safety and efficacy of" exact="neratinib" post="in combination with weekly paclitaxel and trastuzumab in women"/>
   <result pre="al. Safety and efficacy of neratinib in combination with weekly" exact="paclitaxel" post="and trastuzumab in women with metastatic HER2-positive breast cancer:"/>
   <result pre="and efficacy of neratinib in combination with weekly paclitaxel and" exact="trastuzumab" post="in women with metastatic HER2-positive breast cancer: an NSABP"/>
   <result pre="Bahleda R Tolaney SM et al. Phase I study of" exact="neratinib" post="in combination with temsirolimus in patients with human epidermal"/>
   <result pre="et al. Phase I study of neratinib in combination with" exact="temsirolimus" post="in patients with human epidermal growth factor receptor 2-dependent"/>
   <result pre="crossover, placebo- and moxifloxacin-controlled study to assess the effects of" exact="neratinib" post="(HKI-272) on cardiac repolarization in healthy adult subjects Clin"/>
   <result pre="CE Jr et al. A phase two randomised trial of" exact="neratinib" post="monotherapy versus lapatinib plus capecitabine combination therapy in patients"/>
   <result pre="al. A phase two randomised trial of neratinib monotherapy versus" exact="lapatinib" post="plus capecitabine combination therapy in patients with HER2+ advanced"/>
   <result pre="phase two randomised trial of neratinib monotherapy versus lapatinib plus" exact="capecitabine" post="combination therapy in patients with HER2+ advanced breast cancer"/>
   <result pre="M Hatake K et al. Safety, efficacy and pharmacokinetics of" exact="neratinib" post="(HKI-272) in Japanese patients with advanced solid tumors: a"/>
   <result pre="from PubChem. 16– 21 Figure 3 Sites of interaction of" exact="trastuzumab" post="and neratinib with HER receptors. Abbreviations: ADAMs, A disintegrin"/>
   <result pre="16– 21 Figure 3 Sites of interaction of trastuzumab and" exact="neratinib" post="with HER receptors. Abbreviations: ADAMs, A disintegrin and metalloproteinases;"/>
   <result pre="receptor; TKR, tyrosine kinase receptor. Table 2 Clinical trials involving" exact="neratinib" post="in breast cancer NCT identifier Title Study participants Study"/>
   <result pre="design Patients (n) Objectives Status Reference NCT01423123 Combination of weekly" exact="paclitaxel" post="with neratinib and trastuzumab in women with metastatic HER2-positive"/>
   <result pre="(n) Objectives Status Reference NCT01423123 Combination of weekly paclitaxel with" exact="neratinib" post="and trastuzumab in women with metastatic HER2-positive breast cancer"/>
   <result pre="Status Reference NCT01423123 Combination of weekly paclitaxel with neratinib and" exact="trastuzumab" post="in women with metastatic HER2-positive breast cancer Women ≥18"/>
   <result pre="BC Open-label, non-randomized, single arm, Phase I 21 Safety/tolerability of" exact="neratinib" post="+ trastuzumab + paclitaxel Completed 82 NCT00708903 Study to"/>
   <result pre="non-randomized, single arm, Phase I 21 Safety/tolerability of neratinib +" exact="trastuzumab" post="+ paclitaxel Completed 82 NCT00708903 Study to examine the"/>
   <result pre="arm, Phase I 21 Safety/tolerability of neratinib + trastuzumab +" exact="paclitaxel" post="Completed 82 NCT00708903 Study to examine the effect of"/>
   <result pre="18–50 years Double-blind, randomized, Phase I 60 Pharmacokinetic/dynamic comparison of" exact="neratinib" post="vs placebo vs moxifloxacin Completed 85 NCT00146172 Study evaluating"/>
   <result pre="Phase I 60 Pharmacokinetic/dynamic comparison of neratinib vs placebo vs" exact="moxifloxacin" post="Completed 85 NCT00146172 Study evaluating HKI-272 in tumors Patients"/>
   <result pre="NCT00398567 Phase I/II study of HKI-272 (neratinib) in combination with" exact="trastuzumab" post="(Herceptin ®) in subjects with advanced breast cancer Patients"/>
   <result pre="NCT00445458 Phase I/II study of HKI-272 (neratinib) in combination with" exact="paclitaxel" post="(Taxol ®) in subjects with solid tumors and breast"/>
   <result pre="therapy (Part 1) or HER2-positive pathologically confirmed BC with prior" exact="trastuzumab" post="treatment Open-label, randomized, Phase I/II 115 Safety/efficacy (see title)"/>
   <result pre="Safety/efficacy (see title) Ongoing, not recruiting 81 NCT00777101 Study evaluating" exact="neratinib" post="vs lapatinib + capecitabine for ErbB2-positive advanced breast cancer"/>
   <result pre="title) Ongoing, not recruiting 81 NCT00777101 Study evaluating neratinib vs" exact="lapatinib" post="+ capecitabine for ErbB2-positive advanced breast cancer Women aged"/>
   <result pre="not recruiting 81 NCT00777101 Study evaluating neratinib vs lapatinib +" exact="capecitabine" post="for ErbB2-positive advanced breast cancer Women aged ≥18 years"/>
   <result pre="years with locally advanced or metastatic HER2-positive BC with prior" exact="trastuzumab" post="+ taxane Open-label, randomized, Phase II 233 Safety/efficacy (see"/>
   <result pre="recruiting 86 NCT02236000 A dose-escalation study evaluating the combination of" exact="trastuzumab" post="emtansine (T-DM1) with neratinib in women with metastatic HER2-positive"/>
   <result pre="dose-escalation study evaluating the combination of trastuzumab emtansine (T-DM1) with" exact="neratinib" post="in women with metastatic HER2-positive breast cancer Women aged"/>
   <result pre="Ongoing, not recruiting NCT00878709 ExteNET Study evaluating the effects of" exact="neratinib" post="after adjuvant trastuzumab in women with early stage breast"/>
   <result pre="NCT00878709 ExteNET Study evaluating the effects of neratinib after adjuvant" exact="trastuzumab" post="in women with early stage breast cancer Women aged"/>
   <result pre="aged ≥18 years with early stage HER2-positive BC with prior" exact="trastuzumab" post="Double-blind, randomized, Phase III 2,821 Efficacy (see title) Ongoing,"/>
   <result pre="title) Ongoing, not recruiting NCT00741260 Study evaluating the combination of" exact="neratinib" post="and capecitabine in solid tumors and breast cancer Women"/>
   <result pre="not recruiting NCT00741260 Study evaluating the combination of neratinib and" exact="capecitabine" post="in solid tumors and breast cancer Women aged ≥18"/>
   <result pre="a solid tumor not curable with available therapies for which" exact="neratinib" post="+ capecitabine is a reasonable treatment option (Part 1)"/>
   <result pre="tumor not curable with available therapies for which neratinib +" exact="capecitabine" post="is a reasonable treatment option (Part 1) and with"/>
   <result pre="or locally advanced BC that progressed on or following a" exact="trastuzumab" post="containing treatment Open-label, non-randomized, Phase I/II 105 Safety/efficacy (see"/>
   <result pre="Safety/efficacy (see title) Ongoing, not recruiting NCT00915018 NEFERTT Study evaluating" exact="neratinib" post="+ paclitaxel vs trastuzumab + paclitaxel in ErbB2-positive advanced"/>
   <result pre="title) Ongoing, not recruiting NCT00915018 NEFERTT Study evaluating neratinib +" exact="paclitaxel" post="vs trastuzumab + paclitaxel in ErbB2-positive advanced breast cancer"/>
   <result pre="not recruiting NCT00915018 NEFERTT Study evaluating neratinib + paclitaxel vs" exact="trastuzumab" post="+ paclitaxel in ErbB2-positive advanced breast cancer Women aged"/>
   <result pre="NCT00915018 NEFERTT Study evaluating neratinib + paclitaxel vs trastuzumab +" exact="paclitaxel" post="in ErbB2-positive advanced breast cancer Women aged ≥18 years"/>
   <result pre="or metastatic disease and no prior HER2 inhibitor other than" exact="trastuzumab" post="or lapatinib in the neoadjuvant or adjuvant setting Open-label,"/>
   <result pre="disease and no prior HER2 inhibitor other than trastuzumab or" exact="lapatinib" post="in the neoadjuvant or adjuvant setting Open-label, randomized, Phase"/>
   <result pre="adjuvant setting Open-label, randomized, Phase II 480 Safety/efficacy, comparison of" exact="neratinib" post="+ paclitaxel vs trastuzumab + paclitaxel Ongoing, not recruiting"/>
   <result pre="Open-label, randomized, Phase II 480 Safety/efficacy, comparison of neratinib +" exact="paclitaxel" post="vs trastuzumab + paclitaxel Ongoing, not recruiting NCT00706030 Study"/>
   <result pre="Phase II 480 Safety/efficacy, comparison of neratinib + paclitaxel vs" exact="trastuzumab" post="+ paclitaxel Ongoing, not recruiting NCT00706030 Study evaluating neratinib"/>
   <result pre="480 Safety/efficacy, comparison of neratinib + paclitaxel vs trastuzumab +" exact="paclitaxel" post="Ongoing, not recruiting NCT00706030 Study evaluating neratinib (HKI-272) in"/>
   <result pre="vs trastuzumab + paclitaxel Ongoing, not recruiting NCT00706030 Study evaluating" exact="neratinib" post="(HKI-272) in combination with vinorelbine in subjects with solid"/>
   <result pre="not recruiting NCT00706030 Study evaluating neratinib (HKI-272) in combination with" exact="vinorelbine" post="in subjects with solid tumors and metastatic breast cancer"/>
   <result pre="HER2- positive BC (current stage IV, Part 2) for which" exact="vinorelbine" post="+ neratinib is a reasonable treatment option and who"/>
   <result pre="BC (current stage IV, Part 2) for which vinorelbine +" exact="neratinib" post="is a reasonable treatment option and who had at"/>
   <result pre="(Part 2 only) Open-label, non-randomized, Phase I/II 92 Safety/efficacy of" exact="neratinib" post="+ vinorelbine, in Part 2 patients with or without"/>
   <result pre="+ vinorelbine, in Part 2 patients with or without prior" exact="lapatinib" post="were included Ongoing, not recruiting 80 NCT00300781 Study evaluating"/>
   <result pre="that progressed on trastuzumab, cohort 2 patients with no prior" exact="trastuzumab" post="Ongoing, not recruiting 79 NCT01008150 Phase II randomized trial"/>
   <result pre="79 NCT01008150 Phase II randomized trial evaluating neoadjuvant therapy with" exact="neratinib" post="and/ or trastuzumab followed by postoperative trastuzumab in women"/>
   <result pre="II randomized trial evaluating neoadjuvant therapy with neratinib and/ or" exact="trastuzumab" post="followed by postoperative trastuzumab in women with locally advanced"/>
   <result pre="neoadjuvant therapy with neratinib and/ or trastuzumab followed by postoperative" exact="trastuzumab" post="in women with locally advanced HER2-positive breast cancer Women"/>
   <result pre="BC without previous therapy with anthracyclines, taxanes, cyclophosphamide, trastuzumab, or" exact="neratinib" post="for any malignancy Open-label, randomized, Phase II 126 Safety/efficacy"/>
   <result pre="any malignancy Open-label, randomized, Phase II 126 Safety/efficacy (Three arms:" exact="neratinib" post="+ paclitaxel ± trastuzumab then doxorubicin and cyclophosphamide or"/>
   <result pre="Open-label, randomized, Phase II 126 Safety/efficacy (Three arms: neratinib +" exact="paclitaxel" post="± trastuzumab then doxorubicin and cyclophosphamide or paclitaxel +"/>
   <result pre="Phase II 126 Safety/efficacy (Three arms: neratinib + paclitaxel ±" exact="trastuzumab" post="then doxorubicin and cyclophosphamide or paclitaxel + trastuzumab then"/>
   <result pre="126 Safety/efficacy (Three arms: neratinib + paclitaxel ± trastuzumab then" exact="doxorubicin" post="and cyclophosphamide or paclitaxel + trastuzumab then doxorubicin and"/>
   <result pre="(Three arms: neratinib + paclitaxel ± trastuzumab then doxorubicin and" exact="cyclophosphamide" post="or paclitaxel + trastuzumab then doxorubicin and cyclophosphamide) Recruiting"/>
   <result pre="neratinib + paclitaxel ± trastuzumab then doxorubicin and cyclophosphamide or" exact="paclitaxel" post="+ trastuzumab then doxorubicin and cyclophosphamide) Recruiting NCT01494662 HKI-272"/>
   <result pre="paclitaxel ± trastuzumab then doxorubicin and cyclophosphamide or paclitaxel +" exact="trastuzumab" post="then doxorubicin and cyclophosphamide) Recruiting NCT01494662 HKI-272 for HER2-positive"/>
   <result pre="trastuzumab then doxorubicin and cyclophosphamide or paclitaxel + trastuzumab then" exact="doxorubicin" post="and cyclophosphamide) Recruiting NCT01494662 HKI-272 for HER2-positive breast cancer"/>
   <result pre="patients with measurable CNS disease who a) had no prior" exact="lapatinib" post="or b) had prior lapatinib Open-label, non-randomized, Phase II"/>
   <result pre="who a) had no prior lapatinib or b) had prior" exact="lapatinib" post="Open-label, non-randomized, Phase II 105 Efficacy (see patient cohorts)"/>
   <result pre="29 Efficacy study (see title) Recruiting NCT01808573 A study of" exact="neratinib" post="+ capecitabine vs lapatinib + capecitabine in patients with"/>
   <result pre="study (see title) Recruiting NCT01808573 A study of neratinib +" exact="capecitabine" post="vs lapatinib + capecitabine in patients with HER2-positive metastatic"/>
   <result pre="title) Recruiting NCT01808573 A study of neratinib + capecitabine vs" exact="lapatinib" post="+ capecitabine in patients with HER2-positive metastatic breast cancer"/>
   <result pre="NCT01808573 A study of neratinib + capecitabine vs lapatinib +" exact="capecitabine" post="in patients with HER2-positive metastatic breast cancer who have"/>
   <result pre="Phase III 600 Safety/efficacy (see title) Recruiting NCT01111825 Temsirolimus +" exact="neratinib" post="for patients with metastatic HER2-amplified or triple negative breast"/>
   <result pre="Patients aged ≥18 years with metastatic HER2-positive BC progressed on" exact="trastuzumab" post="or lapatinib or metastatic triple negative invasive adenocarcinoma who"/>
   <result pre="≥18 years with metastatic HER2-positive BC progressed on trastuzumab or" exact="lapatinib" post="or metastatic triple negative invasive adenocarcinoma who do not"/>
   <result pre="tyrosine kinase inhibitors; vs, versus. Table 3 Clinical trials involving" exact="neratinib" post="in other cancers NCT identifier Title Study subjects Study"/>
   <result pre="Objective Status Reference NCT01142063 A single dose bioequivalence study of" exact="neratinib" post="in healthy subjects Healthy patients, aged 18–55 years Phase"/>
   <result pre="NCT00860223 Study evaluating the potential effect of multiple doses of" exact="neratinib" post="on the pharmacokinetics of a single dose of digoxin"/>
   <result pre="of neratinib on the pharmacokinetics of a single dose of" exact="digoxin" post="Healthy patients, aged 18–50 years Open-label, non-randomized, Phase I"/>
   <result pre="Phase I 27 Pharmacokinetics study (see title) Completed NCT00380328 HKI-272" exact="ketoconazole" post="drug interaction study Healthy subjects, aged 18–50 years Open-label,"/>
   <result pre="evaluating the potential effect of rifampin on the pharmacokinetics of" exact="neratinib" post="Healthy subjects, aged 18–50 years Open-label, non-randomized, Phase I"/>
   <result pre="(see title) Completed NCT00814060 Study evaluating two tablet formulations of" exact="neratinib" post="(HKI-272) Healthy subjects, aged 18–50 years Open-label, randomized, Phase"/>
   <result pre="Completed 84 NCT00781430 Study evaluating the PK and safety of" exact="neratinib" post="in healthy subjects and subjects with chronic liver disease"/>
   <result pre="aged 18–65 years Open-label, non-randomized, Phase I 27 Pharmacokinetics of" exact="neratinib" post="in healthy subjects vs hepatically impaired patients/safety Completed NCT00958724"/>
   <result pre="healthy subjects vs hepatically impaired patients/safety Completed NCT00958724 Study evaluating" exact="neratinib" post="in combination with vinorelbine in subjects with advanced or"/>
   <result pre="impaired patients/safety Completed NCT00958724 Study evaluating neratinib in combination with" exact="vinorelbine" post="in subjects with advanced or metastatic solid tumors Patients"/>
   <result pre="tumor that is not curable with available therapies for which" exact="neratinib" post="+ vinorelbine is a reasonable treatment option Open-label, non-randomized,"/>
   <result pre="is not curable with available therapies for which neratinib +" exact="vinorelbine" post="is a reasonable treatment option Open-label, non-randomized, Phase I"/>
   <result pre="is not curable with available therapy for which HKI-272 +" exact="paclitaxel" post="is a reasonable treatment option Open-label, Phase I 10"/>
   <result pre="treatment option Open-label, Phase I 10 Safety and tolerability of" exact="neratinib" post="+ paclitaxel; pharmacokinetics and activity Completed NCT00266877 Study evaluating"/>
   <result pre="with or without an EGFR mutation that have progressed on" exact="erlotinib" post="or gefitinib C: previous smokers without prior EGFR TKI"/>
   <result pre="without an EGFR mutation that have progressed on erlotinib or" exact="gefitinib" post="C: previous smokers without prior EGFR TKI treatment Completed"/>
   <result pre="smokers without prior EGFR TKI treatment Completed NCT00838539 Study evaluating" exact="neratinib" post="in combination with temsirolimus in subjects with solid tumors"/>
   <result pre="TKI treatment Completed NCT00838539 Study evaluating neratinib in combination with" exact="temsirolimus" post="in subjects with solid tumors Patients aged ≥18 years"/>
   <result pre="I 21 Safety/efficacy (see title) Completed 89 NCT01956253 Single subject" exact="neratinib" post="in bladder cancer One patient with metastatic bladder cancer"/>
   <result pre="1 Response Ongoing, not recruiting NCT01827267 Neratinib with and without" exact="temsirolimus" post="for patients with HER2-activating mutations in NSCLC Patients aged"/>
   <result pre="mutant NSCLC without prior treatment with any investigational agent or" exact="neratinib" post="or mTOR inhibitor Open-label, randomized, Phase II 104 Safety/efficacy"/>
   <result pre="Safety/efficacy Ongoing, not recruiting NCT01960023 Safety and efficacy study of" exact="neratinib" post="and cetuximab to treat patients with quadruple wild-type metastatic"/>
   <result pre="not recruiting NCT01960023 Safety and efficacy study of neratinib and" exact="cetuximab" post="to treat patients with quadruple wild-type metastatic colorectal cancer"/>
   <result pre="title) Recruiting NCT01953926 Basket An open-label, Phase II study of" exact="neratinib" post="in patients with solid tumors with somatic human epidermal"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4467984/results/search/inn/results.xml">
   <result pre="tumors show amplification in DMs. However, these tumors respond to" exact="trastuzumab" post="in a similar fashion than those with amplification of"/>
   <result pre="in the series of samples from patients treated with adjuvant" exact="trastuzumab" post="was assessed by V. P. The HER2/centromere 17 probe"/>
   <result pre="manufacturer’s instructions. Cell Proliferation Cells were plated and treated with" exact="lapatinib" post="or T-DM1 at the described concentrations. At the indicated"/>
   <result pre="The analysis of 58 samples from HER2-amplified tumors treated with" exact="trastuzumab" post="plus chemotherapy prior to surgical resection (neoadjuvant treatment) showed"/>
   <result pre="cohorts of breast cancers patients treated with neoadjuvant or adjuvant" exact="trastuzumab" post="was determined as in Fig 1A and samples were"/>
   <result pre="2C). Thus, these results do not support that treatment with" exact="trastuzumab" post="results in loss of HER2 gene copies from tumors"/>
   <result pre="cohort of patients (n = 55) treated after surgery with" exact="trastuzumab" post="(adjuvant treatment). In agreement with the results in the"/>
   <result pre="used a PDX (PDX118, Fig 1) that is sensitive to" exact="trastuzumab" post="and to T-DM1 ( Fig 3A). After 75–125 days"/>
   <result pre="( Fig 3A). After 75–125 days of continuous treatment with" exact="trastuzumab" post="(10 mg/kg, biweekly), the tumors in five out of"/>
   <result pre="of six mice relapsed ( Fig 3B, TR stands for" exact="trastuzumab" post="resistant and S1 Fig) and their resistance to trastuzumab"/>
   <result pre="for trastuzumab resistant and S1 Fig) and their resistance to" exact="trastuzumab" post="was confirmed after re-implantation into new mice ( S2"/>
   <result pre="amplification pattern and gene copy number in tumors resistant to" exact="trastuzumab" post="or T-DM1. A, NOD/SCID mice (n = 8 per"/>
   <result pre="as indicated (red and green arrowheads indicate the administrations of" exact="trastuzumab" post="(10 mg/kg twice per week, i.p) and T-DM1 (15"/>
   <result pre="confidence intervals. B, Mice carrying PDX118 were chronically treated with" exact="trastuzumab" post="(left) or twice with T-DM1(right) and tumor volumes were"/>
   <result pre="and concluded that the downregulation of HER2 protein in the" exact="trastuzumab" post="and T-DM1 resistant tumors is not due to a"/>
   <result pre="of resistant cells (Fig 4A and 4B, LR stands for" exact="lapatinib" post="resistant). Analysis of two batches of resistant cells, generated"/>
   <result pre="amplification pattern and gene copy number in cells resistant to" exact="lapatinib" post="or T-DM1. A, Schematic showing the procedure to obtain"/>
   <result pre="vitro. Cultures from PDX118 were treated with increasing concentrations of" exact="lapatinib" post="or T-DM1 for 45 days. B, Parental PDX118 cell"/>
   <result pre="PDX118 cell cultures or cells selected in the presence of" exact="lapatinib" post="or T-DM1 as shown in A, in two independent"/>
   <result pre="DM respond in a similar fashion to neoadjuvant or adjuvant" exact="trastuzumab" post="( Fig 2). Furthermore, tumors with amplification in HSR"/>
   <result pre="resistant to trastuzumab. Mice carrying PDX118 were chronically treated with" exact="trastuzumab" post="and tumor volumes were calculated as in Fig 3A."/>
   <result pre="additional data file. S2 Fig Validation of PDXs resistant to" exact="trastuzumab" post="or T-DM1. Small pieces of the tumors that progressed"/>
   <result pre="or T-DM1. Small pieces of the tumors that progressed after" exact="trastuzumab" post="or T-DM1 treatment (see Fig 3B and S1 Fig)"/>
   <result pre="HER2 protein levels and gene amplification in PDXs resistant to" exact="trastuzumab" post="or T-DM1. Samples from the indicated tumor grafts were"/>
   <result pre="Lluch A , et al. ( 2010) Neoadjuvant chemotherapy with" exact="trastuzumab" post="followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in"/>
   <result pre="al. ( 2010) Neoadjuvant chemotherapy with trastuzumab followed by adjuvant" exact="trastuzumab" post="versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4469402/results/search/inn/results.xml">
   <result pre="patient had HER2/neu mutation and experienced a mixed response after" exact="lapatinib" post="therapy. The duration of response varied from 8+ to"/>
   <result pre="HER2/neu positive breast cancer: these include monoclonal antibodies such as" exact="trastuzumab" post="and pertuzumab, small molecule tyrosine kinase inhibitors like lapatinib,"/>
   <result pre="were Caucasian (Table 1). All had metastatic disease; seven received" exact="trastuzumab" post="either alone ( n = 2) or in combination"/>
   <result pre="with chemotherapy ( n = 5). Other HER2-directed therapies were" exact="lapatinib" post="and pertuzumab. One patient who received lapatinib had a"/>
   <result pre="HER2-directed therapies were lapatinib and pertuzumab. One patient who received" exact="lapatinib" post="had a mixed response; this patient had a HER2/neu"/>
   <result pre="cases had HER2/neu amplification or overexpression. In all these cases," exact="trastuzumab" post="was associated with partial response ( n = 4),"/>
   <result pre="months after surgical resection, which was again successfully salvaged with" exact="trastuzumab" post="(Fig. 1). Details regarding prior therapy administered, concurrent chemotherapy,"/>
   <result pre="cm liver mass ( arrow). b After 3 months of" exact="trastuzumab" post="and FOLFOX, the polypoid gallbladder mass is no longer"/>
   <result pre="with en bloc cholecystectomy and extended right hepatectomy, followed by" exact="capecitabine" post="and trastuzumab for 7 months. c After 6 months"/>
   <result pre="bloc cholecystectomy and extended right hepatectomy, followed by capecitabine and" exact="trastuzumab" post="for 7 months. c After 6 months of observation"/>
   <result pre="lymph nodes ( large arrowheads). After treatment with FOXFOX and" exact="trastuzumab" post="for 3 months, d a previously seen 1-cm retroperitoneal"/>
   <result pre="Thirteen months later, both nodules are stable after treatment with" exact="trastuzumab" post="Fig. 3 A 62-year-old female with recurrent metastatic gallbladder"/>
   <result pre="Best response 1 Bone, liver Nil IHC 3+ Trastuzumab Gemcitabine," exact="cisplatin" post="7 20 SD 2 Peritoneum, lung, liver Gemcitabine +"/>
   <result pre="+ cisplatin, capecitabine, FOLFOX ERBB2 NGS amplification Trastuzumab Gemcitabine +" exact="irinotecan" post="40 62 PR 5 Liver, LN Gemcitabine + cisplatin"/>
   <result pre="+ irinotecan 40 62 PR 5 Liver, LN Gemcitabine +" exact="cisplatin" post="ERBB2 NGS amplification Trastuzumab FOLFOX capecitabine 92 92 PR"/>
   <result pre="Liver, LN Gemcitabine + cisplatin ERBB2 NGS amplification Trastuzumab FOLFOX" exact="capecitabine" post="92 92 PR 6 Sternum, pleura, lung Gemcitabine, capecitabine"/>
   <result pre="FOLFOX capecitabine 92 92 PR 6 Sternum, pleura, lung Gemcitabine," exact="capecitabine" post="AMPLIFIED (FISH) Trastuzumab 168 178 PR 7 Retroperitoneal LN,"/>
   <result pre="Retroperitoneal LN, celiac LN Nil AMPLIFIED (FISH) Trastuzumab Gemcitabine +" exact="cisplatin" post="22+ 22+ PR 8 Retroperitoneal LN, supraclavicular LN Gemcitabine"/>
   <result pre="22+ PR 8 Retroperitoneal LN, supraclavicular LN Gemcitabine + capecitabine," exact="gemcitabine" post="+ cisplatin, pazopanib, dovitinib ERBB2 NGS amplification Trastuzumab +"/>
   <result pre="gemcitabine + cisplatin, pazopanib, dovitinib ERBB2 NGS amplification Trastuzumab +" exact="pertuzumab" post="Nil 8+ 8+ SD 9 Lungs, brain Gemcitabine +"/>
   <result pre="pertuzumab Nil 8+ 8+ SD 9 Lungs, brain Gemcitabine +" exact="cisplatin" post="radiation IHC 3+ Trastuzumab Paclitaxel capecitabine 72 96+ PR"/>
   <result pre="Lungs, brain Gemcitabine + cisplatin radiation IHC 3+ Trastuzumab Paclitaxel" exact="capecitabine" post="72 96+ PR HER2-positive tumors IHC 3+, FISH HER2/centromere"/>
   <result pre="gene and had received prior therapy with the FGFR-directed agents" exact="pazopanib" post="and dovitinib. Repeat biopsy after these therapies indicated that"/>
   <result pre="posterior to the left renal vein. After 2 months of" exact="trastuzumab" post="and pertuzumab, b the lymph node decreased to 1.2"/>
   <result pre="concurrent chemotherapy. In case of cholangiocarcinoma, no responses occurred from" exact="trastuzumab" post="therapy, unlike the case with gallbladder cancer. In all"/>
   <result pre="Liver, mediastinum, Lung Gemcitabine folfirinox Mutation (NGS) V777L Trastuzumab Gemcitabine," exact="docetaxel" post="19 29 PD 2 Liver, peritoneum, lung Gemcitabine +"/>
   <result pre="docetaxel 19 29 PD 2 Liver, peritoneum, lung Gemcitabine +" exact="cisplatin" post="ERBB2 amp NGS Trastuzumab FOLFOX 14 25 PD 3"/>
   <result pre="Trastuzumab 6 8 PD 5 Lung, liver, bones Gemcitabine +" exact="cisplatin" post="AMPLIFIED (FISH) Trastuzumab 10 12 PD HER2-positive tumors (IHC"/>
   <result pre="Amplification FGFR3-TACC3 fusion, TP53, CCNE1, MCL1, MYC SD Trastuzumab +" exact="pertuzumab" post="+8 +8 SD stable disease, PD progressive disease, MR"/>
   <result pre="for breast cancer [ 27– 29]. In gastric cancer, the" exact="trastuzumab" post="for gastric adenocarcinoma (ToGA) trial established the benefit of"/>
   <result pre="trastuzumab for gastric adenocarcinoma (ToGA) trial established the benefit of" exact="trastuzumab" post="in combination with a fluoropyrimidine plus cisplatin in a"/>
   <result pre="the benefit of trastuzumab in combination with a fluoropyrimidine plus" exact="cisplatin" post="in a randomized phase 3 trial of gastric cancer"/>
   <result pre="kinase domain). Two prior case reports have described responses with" exact="trastuzumab" post="in subjects with gallbladder cancer. In the first, a"/>
   <result pre="with gallbladder cancer. In the first, a 45-year-old woman received" exact="paclitaxel" post="and trastuzumab and a dramatic regression of her lung"/>
   <result pre="cancer. In the first, a 45-year-old woman received paclitaxel and" exact="trastuzumab" post="and a dramatic regression of her lung metastases occurred"/>
   <result pre="also with gallbladder cancer had a remarkable response to weekly" exact="paclitaxel" post="and trastuzumab, which persisted when trastuzumab was continued as"/>
   <result pre="remarkable response to weekly paclitaxel and trastuzumab, which persisted when" exact="trastuzumab" post="was continued as a single agent [ 32]. An"/>
   <result pre="addiction has been reported to be a mechanism leading to" exact="lapatinib" post="resistance in breast cancer [ 33]. However, to our"/>
   <result pre="for re-assessment of HER2/neu status in select cases. In contrast," exact="trastuzumab" post="was less effective in the case of cholangiocarcinoma and"/>
   <result pre="potentially respond to tyrosine kinase inhibitors like lapatinib, neratinib, and" exact="canertinib" post="[ 34]. HER2/neu-targeted therapy has also not proven to"/>
   <result pre="of efficacy is not known. Junttila et al. demonstrated that" exact="trastuzumab" post="disrupts ligand-independent ErbB2/ErbB3/PI3K complexes blocking AKT signaling; when PI3K"/>
   <result pre="kinase (PIK3CA) mutation, and PI3K pathway activation in sensitivity to" exact="trastuzumab" post="in HER2-positive breast cancer: a meta-analysis Curr Med Res"/>
   <result pre="Im SA Hegg R Im YH et al. Pertuzumab plus" exact="trastuzumab" post="plus docetaxel for metastatic breast cancer N Engl J"/>
   <result pre="Hegg R Im YH et al. Pertuzumab plus trastuzumab plus" exact="docetaxel" post="for metastatic breast cancer N Engl J Med 2012"/>
   <result pre="687 697 10.1016/S0140-6736(10)61121-X 20728210 31. Law LY Dramatic response to" exact="trastuzumab" post="and paclitaxel in a patient with human epidermal growth"/>
   <result pre="10.1016/S0140-6736(10)61121-X 20728210 31. Law LY Dramatic response to trastuzumab and" exact="paclitaxel" post="in a patient with human epidermal growth factor receptor"/>
   <result pre="S Marked radiographic response of a HER-2-overexpressing biliary cancer to" exact="trastuzumab" post="Cancer Manag Res. 2014 6 1 3 33. Azuma"/>
   <result pre="tumor cells: FGFR2 as a potential target for salvage after" exact="lapatinib" post="failure Biochem Biophys Res Commun 2011 407 1 219"/>
   <result pre="Friedman LS et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by" exact="trastuzumab" post="and is effectively inhibited by the PI3K inhibitor GDC-0941"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4470009/results/search/inn/results.xml">
   <result pre="kit, antipolyvalent, HRP/DAP) with blockage of internal peroxidase activity. Streptavidin" exact="biotin" post="peroxidase detection system was used, utilizing DAP as a"/>
   <result pre="also will improve patient outcome by introducing appropriate cases to" exact="trastuzumab" post="therapy. Available FREE in open access from: http://www.jpathinformatics.org/text.asp?2015/6/1/31/158066 References"/>
   <result pre="Wolff AC Hammond ME Hayes DF Re: Predictability of adjuvant" exact="trastuzumab" post="benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4471111/results/search/inn/results.xml">
   <result pre="CTCs despite disease stabilization or response to prior therapy, received" exact="lapatinib" post="1500 mg daily in monthly cycles, till disease progression"/>
   <result pre="= 0.018) but not among those with disease progression during" exact="lapatinib" post="treatment. No objective responses were observed. All CTC-positive patients"/>
   <result pre="30.6% (p = 0.03). Conclusions The above results indicate that" exact="lapatinib" post="is effective in decreasing HER2-positive CTCs in patients with"/>
   <result pre="No other anticancer treatment was allowed during the period of" exact="lapatinib" post="administration. All patients provided written informed consent in order"/>
   <result pre="(10 ml in EDTA) was obtained before the initiation of" exact="lapatinib" post="and monthly thereafter. To avoid cell contamination from the"/>
   <result pre="a pilot feasibility study designed to evaluate the effect of" exact="lapatinib" post="on HER2-positive CTC counts in patients with MBC who"/>
   <result pre="is a pilot study aiming to demonstrate the effect of" exact="lapatinib" post="on HER2-positive CTC counts. Since no prior experience exists"/>
   <result pre="metastatic setting Yes 20 90.9 No 2 9.1 Effect of" exact="lapatinib" post="on HER2-positive CTCs A median of 130 HER2-positive CTCs"/>
   <result pre="analysis after the end of the first cycle, treatment with" exact="lapatinib" post="was continued due to lack of clinical disease progression."/>
   <result pre="% change in HER2-positive CTC numbers in patients treated with" exact="lapatinib" post="(n = 20) after the completion of the first"/>
   <result pre="10.1371/journal.pone.0123683.t002 Table 2 Total CTCs and HER2-positive CTC counts during" exact="lapatinib" post="treatment and patient outcome. Patient no Baseline Post-1st Post-2nd"/>
   <result pre="the box shows the median value (Whiskers: Tukey). Effect of" exact="lapatinib" post="on CTCs according to outcome A total of 120"/>
   <result pre="in 10 (47.6%) ( Table 2); no objective responses to" exact="lapatinib" post="treatment were observed. Median PFS was 4.0 months (range,"/>
   <result pre="of Progression-Free-Survival (PFS) in patients with metaststic breast cancer receiving" exact="lapatinib" post="(n = 21). In patients with clinically stable disease,"/>
   <result pre="17, 28, 29]. We have previously demonstrated the effectiveness of" exact="trastuzumab" post="in eliminating CK-19 mRNA-positive CTCs in breast cancer patients"/>
   <result pre="[ 30]. In the current study we further demonstrate that" exact="lapatinib" post="is effective in decreasing HER2-positive CTC counts in patients"/>
   <result pre="the levels of HER2-positive CTCs was an early effect of" exact="lapatinib" post="treatment since by the end of the first treatment"/>
   <result pre="nadir CTC levels was 1 month (range, 1–5 months). Moreover," exact="lapatinib" post="effectively decreased CTC counts in 2 patients with HER2-positive"/>
   <result pre="could influence the effect of lapatinib. This finding suggests that" exact="lapatinib" post="can effectively target CTCs presenting resistance to trastuzumab. Similarly,"/>
   <result pre="target CTCs presenting resistance to trastuzumab. Similarly, in preclinical studies," exact="lapatinib" post="was effective against breast cancer with resistance to trastuzumab"/>
   <result pre="studies, lapatinib was effective against breast cancer with resistance to" exact="trastuzumab" post="[ 31] whereas, lapatinib added to capecitabine provided superior"/>
   <result pre="against breast cancer with resistance to trastuzumab [ 31] whereas," exact="lapatinib" post="added to capecitabine provided superior efficacy compar1ed to capecitabine"/>
   <result pre="with resistance to trastuzumab [ 31] whereas, lapatinib added to" exact="capecitabine" post="provided superior efficacy compar1ed to capecitabine alone in women"/>
   <result pre="whereas, lapatinib added to capecitabine provided superior efficacy compar1ed to" exact="capecitabine" post="alone in women with HER2-positive, MBC progressing after prior"/>
   <result pre="increased at the end-of-treatment sample. It has been shown that" exact="lapatinib" post="lacks efficacy in HER2-negative, EGFR-overexpressing inflammatory breast cancer ["/>
   <result pre="Thus, one could postulate that EGFR-positive/HER2-negative CTCs may contribute to" exact="lapatinib" post="resistance. No objective responses were observed in this cohort"/>
   <result pre="duration were evident in seven out of 21 patients. Similarly," exact="lapatinib" post="failed to induce clinical responses in patients with HER2-negative"/>
   <result pre="stabilization lasting for 8.5 months [ 35]. In these trials" exact="lapatinib" post="was administered in MBC patients progressing after prior treatment."/>
   <result pre="CTC. Finally, one could argue that the observed effect of" exact="lapatinib" post="on CTCs, does not necessarily imply that the drug"/>
   <result pre="surrogate marker of treatment efficacy [ 37]. The failure of" exact="lapatinib" post="to induce clinical responses in the present as well"/>
   <result pre="have previously shown that the administration of 6 cycles of" exact="trastuzumab" post="in patients with HER2-negative early breast cancer harbouring CK-19mRNA-positive"/>
   <result pre="cancer. In conclusion, the results of this study demonstrate that" exact="lapatinib" post="is effective in decreasing HER2-positive CTC counts in patients"/>
   <result pre="relevance of circulating CK-19 mRNA-positive cells detected during the adjuvant" exact="tamoxifen" post="treatment in patients with early breast cancer . Ann"/>
   <result pre="al. ( 2010) Activated phosphoinositide 3-kinase/AKT signaling confers resistance to" exact="trastuzumab" post="but not lapatinib . Mol Cancer Ther 9: 1489–"/>
   <result pre="Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not" exact="lapatinib" post=". Mol Cancer Ther 9: 1489– 1502. doi: 10.1158/1535-7163.MCT-09-1171"/>
   <result pre=", Romieu CG , et al. ( 2006) Lapatinib plus" exact="capecitabine" post="for HER2-positive advanced breast cancer. N Engl J Med"/>
   <result pre="factor receptor 2 (HER-2) in advanced inflammatory breast cancer with" exact="lapatinib" post="monotherapy . J Clin Oncol 26: 1066– 1072. doi:"/>
   <result pre="multicenter phase II clinical trial evaluating the activity of single-agent" exact="lapatinib" post="in patients with HER2-negative metastatic breast cancer and HER2-positive"/>
   <result pre="Avery M , et al. ( 2013) The efficacy of" exact="lapatinib" post="in metastatic breast cancer with HER2 non-amplified primary tumors"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4471791/results/search/inn/results.xml">
   <result pre="from a targeted therapy that uses the humanized monoclonal antibody" exact="trastuzumab" post="or the Her-2 kinase inhibitor lapatinib, the prognosis of"/>
   <result pre="of anthracycline-based and/or taxane-based chemotherapy after surgery. Hormone treatment with" exact="tamoxifen" post="or aromatase inhibitors was given to patients with hormone"/>
   <result pre="agreed to receive anti-Her-2 targeted therapy were treated with adjuvant" exact="trastuzumab" post="for 1 year at Harbin Medical University Cancer Hospital."/>
   <result pre=" Basal-like 79 ER, estrogen receptor; LNM, lymph node metastasis; PR," exact="progesterone" post="receptor. Follow up The clinical and pathological records of"/>
   <result pre="27 (34.2) ER, estrogen receptor; LNM, lymph node metastasis; PR," exact="progesterone" post="receptor. Prognostic significance of ribosome-binding protein 1 expression in"/>
   <result pre="2.790 0.828–9.395 0.098 P53 status  Positive/negative 0.514 0.202–1.306 0.162 Adjuvant" exact="trastuzumab" post=" Received/not received 0.414 0.176–0.978 0.044 RRBP1 expression   Positive/negative 2.667"/>
   <result pre="1.501–9.997 0.005 ER, estrogen receptor; LNM, lymph node metastasis; PR," exact="progesterone" post="receptor. Discussion Ribosome-binding protein 1 is an endoplasmic reticulum"/>
   <result pre="UPR is a possible means of overriding the effect of" exact="trastuzumab" post="in Her-2-positive cancer cells. 41 In this study, correlation"/>
   <result pre="survival in Her-2 positive patients. Thus, we hypothesized that UPR-caused" exact="trastuzumab" post="resistance might be the reason for poor prognosis in"/>
   <result pre="Venkatesan N et al. Activity of the dual kinase inhibitor" exact="lapatinib" post="(GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells Cancer"/>
   <result pre="American Pathologists guideline recommendations for immunohistochemical testing of estrogen and" exact="progesterone" post="receptors in breast cancer J Clin Oncol 2010 28"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4472207/results/search/inn/results.xml">
   <result pre="of patients treated on a phase III study of dose-dense" exact="gemcitabine" post="and cisplatin or dose-dense MVAC (methotrexate/vinblastine/doxorubicin hydrochloride/cisplatin) for metastatic"/>
   <result pre="treated on a phase III study of dose-dense gemcitabine and" exact="cisplatin" post="or dose-dense MVAC (methotrexate/vinblastine/doxorubicin hydrochloride/cisplatin) for metastatic UC, as"/>
   <result pre="for metastatic UC, as well as some patients treated with" exact="gemcitabine" post="and carboplatin 25. Formalin-fixed paraffin-embedded tissue (FFPE) was collected"/>
   <result pre="UC, as well as some patients treated with gemcitabine and" exact="carboplatin" post="25. Formalin-fixed paraffin-embedded tissue (FFPE) was collected from prior"/>
   <result pre="In vitro testing indicates that this mutation confers resistance to" exact="lapatinib" post="32. In addition, HER2 V777L has also been documented"/>
   <result pre="mutation in gastric and breast cancer, and remains sensitive to" exact="lapatinib" post="32. Although these molecular alterations have been identified in"/>
   <result pre="expression is increased in UC metastases 36. The addition of" exact="trastuzumab" post="to cytotoxic chemotherapy in patients with evidence of HER2"/>
   <result pre="designed to test safety and not efficacy 37. Single agent" exact="lapatinib" post="was tested in unselected second line patients, and did"/>
   <result pre="activity 38. An ongoing randomized phase III study of maintenance" exact="lapatinib" post="in UC patients with HER2 2 to 3+ IHC"/>
   <result pre="Duyster J Differential sensitivity of ERBB2 kinase domain mutations towards" exact="lapatinib" post="PLoS One 2011 6 e26760 22046346 collab: Cancer Genome"/>
   <result pre="lesion study evaluating effect of scheduling on response to intravesical" exact="gemcitabine" post="in recurrent stage Ta urothelial cell carcinoma of the"/>
   <result pre="Vaishampayan U Lara PN et al. Trastuzumab, paclitaxel, carboplatin, and" exact="gemcitabine" post="in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma:"/>
   <result pre="et al. A single-arm, multicenter, open-label phase 2 study of" exact="lapatinib" post="as the second-line treatment of patients with locally advanced"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4476721/results/search/inn/results.xml">
   <result pre="antigen (HLA)-DRB1*07:01. In order to investigate its mechanism, interaction of" exact="lapatinib" post="with HLA-DRB1*07:01 and its ligand peptide derived from tetanus"/>
   <result pre="toxoid, has been evaluated in vitro. Here we show that" exact="lapatinib" post="enhances binding of the ligand peptide to HLA-DRB1*07:01. Furthermore"/>
   <result pre="to HLA-DRB1*07:01. Furthermore in silico molecular dynamics analysis revealed that" exact="lapatinib" post="could change the β chain helix in the HLA-DRB1*07:01"/>
   <result pre="large part of the binding groove. These results indicate that" exact="lapatinib" post="affects the ligand binding to HLA-DRB1*07:01 and idiosyncratic lapatinib-induced"/>
   <result pre="or metastatic breast cancer. It is used in combination with" exact="capecitabine" post="for patients who have received previous therapy including an"/>
   <result pre="an anthracycline, a taxane and trastuzumab, and in combination with" exact="letrozole" post="for the treatment of postmenopausal women with hormone receptor–positive"/>
   <result pre="women with hormone receptor–positive breast cancer [ 1, 2]. Although" exact="lapatinib" post="has an acceptable safety profile in clinical settings, grade"/>
   <result pre="elevation during long-term treatment with the oral direct thrombin inhibitor" exact="ximelagatran" post="[ 7]. A competitive binding assay revealed that ximelagatran"/>
   <result pre="inhibitor ximelagatran [ 7]. A competitive binding assay revealed that" exact="ximelagatran" post="was able to preferentially compete for binding with a"/>
   <result pre="ximelagatran-induced hepatotoxicity. In this study, we evaluated the effect of" exact="lapatinib" post="on the binding of the known ligand peptides to"/>
   <result pre="known ligand peptides to HLA-DRB1*07:01 and DRB1*15:01 in vitro. Interestingly," exact="lapatinib" post="preferentially increased rather than competed the binding of ligand"/>
   <result pre="two other HLA-DRs to further assess the possible role of" exact="lapatinib" post="on HLA-peptide binding, which could lead to the mechanism"/>
   <result pre="were incubated with increasing concentrations of drugs (0.25–250 μM for" exact="lapatinib" post="and lumiracoxib and 2.5–2500 μM for amoxicillin) and biotinylated"/>
   <result pre="with increasing concentrations of drugs (0.25–250 μM for lapatinib and" exact="lumiracoxib" post="and 2.5–2500 μM for amoxicillin) and biotinylated control ligand"/>
   <result pre="into the volume were modeled as flexible. The structure of" exact="lapatinib" post="was obtained from DrugBank ( http://www.drugbank.ca/) and the CHARMM"/>
   <result pre="that is clinically related to DRB1*07:01 specific liver injury, and" exact="amoxicillin" post="and lumiracoxib, that are not related to it, on"/>
   <result pre="the test allele and DRB1*15:01 as the control allele). Interestingly," exact="lapatinib" post="increased TT peptide binding to HLA-DRB1*07:01 in a dose-dependent"/>
   <result pre="TT peptide binding to HLA-DRB1*07:01 in a dose-dependent manner, whereas" exact="amoxicillin" post="and lumiracoxib did not exhibit increment of peptide binding"/>
   <result pre="binding to HLA-DRB1*07:01 in a dose-dependent manner, whereas amoxicillin and" exact="lumiracoxib" post="did not exhibit increment of peptide binding for both"/>
   <result pre="for both alleles. These results indicate the observed effect is" exact="lapatinib" post="specific ( Fig 3). The enhancing effects of lapatinib"/>
   <result pre="is lapatinib specific ( Fig 3). The enhancing effects of" exact="lapatinib" post="were statistically significant ( P &amp;lt;0.05) for DRB1*07:01 at"/>
   <result pre="concentrations than for DRB1*15:01, which indicates the allele preference of" exact="lapatinib" post="for DRB1*07:01 over DRB1*15:01. Lapatinib did not exhibit any"/>
   <result pre="which is consistent with the previous report where addition of" exact="abacavir" post="did not shift the IC50 of ligand peptides ["/>
   <result pre="shift the IC50 of ligand peptides [ 12]. Amoxicillin and" exact="lumiracoxib" post="decreased the binding of ligand peptide to HLA-DRB1*07:01 significantly,"/>
   <result pre="incubation in the absence and presence of three drugs, lapatinib," exact="amoxicillin" post="and lumiracoxib are shown. Plots show mean ± s.d."/>
   <result pre="the absence and presence of three drugs, lapatinib, amoxicillin and" exact="lumiracoxib" post="are shown. Plots show mean ± s.d. of triplicates."/>
   <result pre="molecules in the absence of ligand peptides In all simulations," exact="lapatinib" post="remained bound in the binding groove throughout the entire"/>
   <result pre="in all simulations ( Fig 4b). The presence of a" exact="lapatinib" post="decreased the overall flexibility of the DRB1*01:01 and DRB1*07:01"/>
   <result pre="primary differences in three simulations are the binding pose of" exact="lapatinib" post="and the degree to which it alters the β"/>
   <result pre="by lapatinib. The blue envelope means the region occupied by" exact="lapatinib" post="at least half the MD frames. Specifically, the blue"/>
   <result pre="least half the MD frames. Specifically, the blue envelope around" exact="lapatinib" post="is the region occupied by lapatinib in at least"/>
   <result pre="the blue envelope around lapatinib is the region occupied by" exact="lapatinib" post="in at least 50% of the frames of the"/>
   <result pre="of the frames of the simulation. In the lapatinib-DRB1*01:01 system," exact="lapatinib" post="binds stably within the binding groove making good contacts"/>
   <result pre="good contacts in P1 and P4. The sulfonyl end of" exact="lapatinib" post="is unbound but stable. Bound lapatinib has a minimal"/>
   <result pre="The sulfonyl end of lapatinib is unbound but stable. Bound" exact="lapatinib" post="has a minimal impact on the configuration of the"/>
   <result pre="β chains ( Fig 5a– 5c). In the lapatinib-DRB1*07:01 system," exact="lapatinib" post="is relatively stationary except for a small flexible part"/>
   <result pre="groove can close in the apo form, the closing around" exact="lapatinib" post="indicates a stable interaction and suggests that lapatinib does"/>
   <result pre="closing around lapatinib indicates a stable interaction and suggests that" exact="lapatinib" post="does not interfere with the flexibility of the binding"/>
   <result pre="binding groove ( Fig 5d– 5f). In the lapatinib-DRB1*15:01 system," exact="lapatinib" post="does not shift locations from initial, but both ends"/>
   <result pre="HLA conformations by the end of the simulations. Although both" exact="lapatinib" post="and peptide contribute a relatively small percent of the"/>
   <result pre="similar in all simulations. Overall, the presence of peptide and" exact="lapatinib" post="slightly decreases the overall flexibility of three alleles compared"/>
   <result pre="panels. The placement of a peptide lying over the bound" exact="lapatinib" post="serves to reduce the mobility and flexibility of lapatinib"/>
   <result pre="bound lapatinib serves to reduce the mobility and flexibility of" exact="lapatinib" post="except for the lapatinib-DRB1*01:01-frame 3 system. Thus, these systems"/>
   <result pre="document. (c), (f), (i) and (l): The volume occupied by" exact="lapatinib" post="and peptide. The blue envelope outlines the 50% occupancy"/>
   <result pre="The HA peptide frame 2 binds over the top of" exact="lapatinib" post="and makes poor contact with P1 of DRB1*01:01. Lapatinib"/>
   <result pre="In frame 3, peptide also binds over the top of" exact="lapatinib" post="and its binding to P1-P4 of DRB1*01:01 seems to"/>
   <result pre="binding spans P1-P4, but despite starting in the P1 pocket," exact="lapatinib" post="pops out and is less stable than in frame"/>
   <result pre="the binding affinities to ligand peptides. With respect to DRB1*07:01," exact="lapatinib" post="lies across the bottom of the binding groove interacting"/>
   <result pre="and possibly descending into P4, which is similar to how" exact="lapatinib" post="behaved in the lapatinib-HLA system ( Fig 7g– 7i)."/>
   <result pre="behaved in the lapatinib-HLA system ( Fig 7g– 7i). Because" exact="lapatinib" post="is bound along a large part of the binding"/>
   <result pre="the α chain helix is maintained. With respect to DRB1*15:01," exact="lapatinib" post="lies across the bottom of the binding groove interacting"/>
   <result pre="unusual antigen presentation. In fact, it has been reported that" exact="abacavir" post="enhances binding of self-peptide LF9 (LSSPVTKSF) to the specific"/>
   <result pre="responses leading to toxicity [ 12]. Our study indicates that" exact="lapatinib" post="has a potential to enhance the binding of TT"/>
   <result pre="finding motivated us to predict the possible interaction mode of" exact="lapatinib" post="with HLA-DRs. A series of in silico studies indicated"/>
   <result pre="with HLA-DRs. A series of in silico studies indicated that" exact="lapatinib" post="lies across the bottom of the binding groove interacting"/>
   <result pre="to the case of abacavir. Illing et al. reported that" exact="abacavir" post="was bound to HLA-B*57:01 in an extended manner at"/>
   <result pre="base of the peptide binding groove and the presence of" exact="abacavir" post="within several binding pockets affects the nature of the"/>
   <result pre="peptide would clash with the cyclopentyl and purinyl moieties of" exact="abacavir" post="[ 19]. Considering the enhancing effect of abacavir on"/>
   <result pre="moieties of abacavir [ 19]. Considering the enhancing effect of" exact="abacavir" post="on the binding of LF9 peptide to HLA-B*57:01, the"/>
   <result pre="necessarily lead to the displacement of the ligand peptide. Moreover," exact="lapatinib" post="induced notable conformational change in the binding groove, adopting"/>
   <result pre="seem to occur in order to make better contact with" exact="lapatinib" post="even in the presence of ligand peptide. Therefore, this"/>
   <result pre="presence of ligand peptide. Therefore, this may be one reason" exact="lapatinib" post="enhanced the binding of the ligand peptide to DRB1*07:01"/>
   <result pre="also important. In summary, our in vitro experiments revealed that" exact="lapatinib" post="enhances binding of the ligand peptide to HLA-DRB1*07:01 preferentially."/>
   <result pre="Romieu CG , Pienkowski T , et al. Lapatinib plus" exact="capecitabine" post="for HER2-positive advanced breast cancer. N Engl J Med."/>
   <result pre="S , Dieras V , et al. Lapatinib combined with" exact="letrozole" post="versus letrozole and placebo as first-line therapy for postmenopausal"/>
   <result pre="Dieras V , et al. Lapatinib combined with letrozole versus" exact="letrozole" post="and placebo as first-line therapy for postmenopausal hormone receptor-positive"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4477383/results/search/inn/results.xml">
   <result pre="recently, a phase II trial investigating a regimen involving the" exact="irinotecan" post="showed a modest 30% response rate but with only"/>
   <result pre="41] Reports of some responses to hormonal agents, such as" exact="tamoxifen" post="exist, however ER positive patients who develop BCBM often"/>
   <result pre="to assess efficacy of anti-HER-2 therapy for BCBM include high-dose" exact="trastuzumab" post="as well as combination trastuzumab-emtansine, with the latter having"/>
   <result pre="target HER-2 positive tumors. These small molecule inhibitors such as" exact="lapatinib" post="target the kinase domains of epidermal growth factor receptor"/>
   <result pre="of epidermal growth factor receptor and HER-2. In preclinical studies," exact="lapatinib" post="has been shown to prevent progression of microscopic deposits"/>
   <result pre="the brain.[ 44] Geyer et al. found combination therapy of" exact="lapatinib" post="with capecitabine superior to capecitabine alone for treatment of"/>
   <result pre="44] Geyer et al. found combination therapy of lapatinib with" exact="capecitabine" post="superior to capecitabine alone for treatment of BM in"/>
   <result pre="al. found combination therapy of lapatinib with capecitabine superior to" exact="capecitabine" post="alone for treatment of BM in HER2-positive patients who"/>
   <result pre="In the recently reported RTOG 0320 trial, the addition of" exact="temozolomide" post="or erlotinib to WBRT plus SRS was not beneficial"/>
   <result pre="recently reported RTOG 0320 trial, the addition of temozolomide or" exact="erlotinib" post="to WBRT plus SRS was not beneficial (and possibly"/>
   <result pre="et al. Incidence of cerebral metastases in patients treated with" exact="trastuzumab" post="for metastatic breast cancer Br J Cancer 2004 91"/>
   <result pre="Brain metastases in HER2-positive breast cancer: The evolving role of" exact="lapatinib" post="Crit Rev Oncol Hematol 2010 75 110 21 20004109"/>
   <result pre="TBCRC 018: phase II study of iniparib in combination with" exact="irinotecan" post="to treat progressive triple negative breast cancer brain metastases"/>
   <result pre="Herring JM Vega-Valle E Feigenbaum L et al. Effect of" exact="lapatinib" post="on the outgrowth of metastatic breast cancer cells to"/>
   <result pre="Chan S Romieu CG Pienkowski T et al. Lapatinib plus" exact="capecitabine" post="for HER2-positive advanced breast cancer N Engl J Med"/>
   <result pre="Diéras V Cropet C Dalenc F et al. Lapatinib plus" exact="capecitabine" post="in patients with previously untreated brain metastases from HER2-positive"/>
   <result pre="therapy and stereotactic radiosurgery alone versus WBRT and SRS with" exact="temozolomide" post="or erlotinib for non-small cell lung cancer and 1"/>
   <result pre="stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or" exact="erlotinib" post="for non-small cell lung cancer and 1 to 3"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4479882/results/search/inn/results.xml">
   <result pre="effective antitumor strategy in preclinical HER2+ breast cancer models of" exact="trastuzumab" post="and lapatinib resistance. We developed and molecularly characterized in"/>
   <result pre="strategy in preclinical HER2+ breast cancer models of trastuzumab and" exact="lapatinib" post="resistance. We developed and molecularly characterized in vitro HER2+"/>
   <result pre="and molecularly characterized in vitro HER2+ models of resistance to" exact="trastuzumab" post="(SK TR), lapatinib (SK LR) and both (SK LTR)."/>
   <result pre="in vitro HER2+ models of resistance to trastuzumab (SK TR)," exact="lapatinib" post="(SK LR) and both (SK LTR). The cellular interactions"/>
   <result pre="and the synthetic G28UCM) with anti-HER2 signaling drugs (trastuzumab plus" exact="pertuzumab" post="and temsirolimus) were analyzed. Tumor growth inhibition after treatment"/>
   <result pre="were analyzed. Tumor growth inhibition after treatment with EGCG, pertuzumab," exact="temsirolimus" post="or the combination was evaluated in two in vivo"/>
   <result pre="HER2+ patient and another from a patient who relapsed on" exact="trastuzumab" post="and lapatinib-based therapy. SK TR, SK LR and SK"/>
   <result pre="SK LR and SK LTR. In vitro, anti-FASN compounds plus" exact="pertuzumab" post="showed synergistic interactions in lapatinib- and dual- resistant cells"/>
   <result pre="lapatinib- and dual- resistant cells and improved the results of" exact="pertuzumab" post="plus trastuzumab co-treatment. FASN inhibitors combined with temsirolimus displayed"/>
   <result pre="dual- resistant cells and improved the results of pertuzumab plus" exact="trastuzumab" post="co-treatment. FASN inhibitors combined with temsirolimus displayed the strongest"/>
   <result pre="results of pertuzumab plus trastuzumab co-treatment. FASN inhibitors combined with" exact="temsirolimus" post="displayed the strongest synergistic interactions in resistant cells. In"/>
   <result pre="to the antitumor activity of the combination of EGCG with" exact="pertuzumab" post="or temsirolimus, without signs of toxicity. We showed that"/>
   <result pre="fraction of HER2+ tumors display primary or acquired resistance to" exact="trastuzumab" post="[ 9]. Lapatinib, a small-molecule TKI targeting the intracellular"/>
   <result pre="[ 7]. Lapatinib is administered alone or in combination with" exact="trastuzumab" post="to abolish the activation of HER2-downstream pathway. But unfortunately,"/>
   <result pre="the activation of HER2-downstream pathway. But unfortunately, some tumors develop" exact="lapatinib" post="resistance and also resistance against the combination of both"/>
   <result pre="of both drugs [ 10]. The molecular mechanisms leading to" exact="trastuzumab" post="and lapatinib resistance has been extensively studied [ 11]."/>
   <result pre="drugs [ 10]. The molecular mechanisms leading to trastuzumab and" exact="lapatinib" post="resistance has been extensively studied [ 11]. These include"/>
   <result pre="in vivo conversion of HER2+ to HER2- carcinoma after neoadjuvant" exact="trastuzumab" post="[ 12], predominance of the constitutively active HER2 form"/>
   <result pre="breast cancer cells and on breast cancer cells resistant to" exact="trastuzumab" post="[ 29]. In this study, we have investigated the"/>
   <result pre="(EGCG) and G28UCM, as single agents or in combination with" exact="pertuzumab" post="and temsirolimus, in our developed trastuzumab (SK TR), lapatinib"/>
   <result pre="or in combination with pertuzumab and temsirolimus, in our developed" exact="trastuzumab" post="(SK TR), lapatinib (SK LR) and trastuzumab plus lapatinib"/>
   <result pre="with pertuzumab and temsirolimus, in our developed trastuzumab (SK TR)," exact="lapatinib" post="(SK LR) and trastuzumab plus lapatinib (SK TLR) resistant"/>
   <result pre="in our developed trastuzumab (SK TR), lapatinib (SK LR) and" exact="trastuzumab" post="plus lapatinib (SK TLR) resistant HER2+ breast cancer models."/>
   <result pre="developed trastuzumab (SK TR), lapatinib (SK LR) and trastuzumab plus" exact="lapatinib" post="(SK TLR) resistant HER2+ breast cancer models. In addition,"/>
   <result pre="another from a HER2+ patient who fail to respond to" exact="trastuzumab" post="and lapatinib therapies. Materials and Methods Cell culture and"/>
   <result pre="a HER2+ patient who fail to respond to trastuzumab and" exact="lapatinib" post="therapies. Materials and Methods Cell culture and development of"/>
   <result pre="L-glutamine, 1% sodium pyruvate, 100 U/mL penicillin, and 100 μg/mL" exact="streptomycin" post="(Gibco). Trastuzumab-resistant SK cells (SK TR) were developed by"/>
   <result pre="(SK TR) were developed by exposing SK cells continuously to" exact="trastuzumab" post="(Herceptin, Hoffmann-La Roche Pharma), starting with 1μM concentration for"/>
   <result pre="as we previously described [ 29]. Thus, cells resistant to" exact="trastuzumab" post="were maintained in 2 μM trastuzumab, a concentration at"/>
   <result pre="one month with an initial dose of 1.5 μM of" exact="lapatinib" post="(GW572016; Tykerb, GlaxoSmithKline) and after one month the dose"/>
   <result pre="(GW572016; Tykerb, GlaxoSmithKline) and after one month the dose of" exact="lapatinib" post="was increased up to 3 μM for 12 months"/>
   <result pre="at which SK parental cells were not viable. To develop" exact="lapatinib" post="plus trastuzumab resistant cells (SK LTR), SK LR were"/>
   <result pre="SK parental cells were not viable. To develop lapatinib plus" exact="trastuzumab" post="resistant cells (SK LTR), SK LR were co-cultured with"/>
   <result pre="trastuzumab resistant cells (SK LTR), SK LR were co-cultured with" exact="lapatinib" post="3 μM and trastuzumab 1μM and after one month"/>
   <result pre="LTR), SK LR were co-cultured with lapatinib 3 μM and" exact="trastuzumab" post="1μM and after one month in culture the dose"/>
   <result pre="1μM and after one month in culture the dose of" exact="trastuzumab" post="was increased up to 2 μM. Cells were co-cultured"/>
   <result pre="was increased up to 2 μM. Cells were co-cultured with" exact="lapatinib" post="and trastuzumab for 12 months. SK LTR cells were"/>
   <result pre="up to 2 μM. Cells were co-cultured with lapatinib and" exact="trastuzumab" post="for 12 months. SK LTR cells were mantained with"/>
   <result pre="months. SK LTR cells were mantained with 3 μM of" exact="lapatinib" post="and 2 μM of trastuzumab. Trastuzumab, lapatinib and trastuzumab"/>
   <result pre="3 μM of lapatinib and 2 μM of trastuzumab. Trastuzumab," exact="lapatinib" post="and trastuzumab plus lapatinib resistance was confirmed by dose-response"/>
   <result pre="of lapatinib and 2 μM of trastuzumab. Trastuzumab, lapatinib and" exact="trastuzumab" post="plus lapatinib resistance was confirmed by dose-response studies using"/>
   <result pre="and 2 μM of trastuzumab. Trastuzumab, lapatinib and trastuzumab plus" exact="lapatinib" post="resistance was confirmed by dose-response studies using the standard"/>
   <result pre="along with the corresponding concentrations of HER2 inhibitors (trastuzumab and" exact="pertuzumab" post="[2C4, Perjeta, Genentech]), FASN inhibitors (EGCG [Sigma] and 1,3-bis((3,4,5-thilhydroxybenzoil)oxy)naphthalene"/>
   <result pre="added to the cultures. Pertuzumab (5 μg/ml) was combined with" exact="trastuzumab" post="(20 μM) or FASN inhibitors (60 μM of EGCG"/>
   <result pre="EGCG or 5 μM of G28UCM) for 5 days. For" exact="temsirolimus" post="drug-combination experiments cells were treated for 2 days with"/>
   <result pre="(5–300 μM) or G28UCM (0.1–15 μM) plus fixed concentrations of" exact="temsirolimus" post="(0.05, 0.1, 0.5 and 1 μM). Same treatments were"/>
   <result pre="with both compounds alone. Interactions of G28UCM and EGCG with" exact="temsirolimus" post="were also evaluated by the isobologram method as we"/>
   <result pre="HER2+ breast cancer patient and HER2+ patient who relapsed after" exact="trastuzumab" post="and lapatinib-based treatment were orthotopically implanted into both inguinal"/>
   <result pre="control (vehicle alone 3d/wk), 30 mg/kg EGCG 3d/wk, 30 mg/kg" exact="pertuzumab" post="1d/w, 10 mg/kg temsirolimus 1d/w, or combination of EGCG"/>
   <result pre="30 mg/kg EGCG 3d/wk, 30 mg/kg pertuzumab 1d/w, 10 mg/kg" exact="temsirolimus" post="1d/w, or combination of EGCG + pertuzumab and EGCG"/>
   <result pre="1d/w, 10 mg/kg temsirolimus 1d/w, or combination of EGCG +" exact="pertuzumab" post="and EGCG + temsirolimus. Tumor xenografts were measured with"/>
   <result pre="by the above-mentioned committee, all surgery was performed under inhaled" exact="isoflurane" post="anesthesia, burprenorphine was administered as analgesic to mice after"/>
   <result pre="confirmed by at least three independent experiments. Results Characterization of" exact="trastuzumab" post="(SKTR), lapatinib (SKLR) and lapatinib plus trastuzumab-resistant (SKLTR) breast"/>
   <result pre="at least three independent experiments. Results Characterization of trastuzumab (SKTR)," exact="lapatinib" post="(SKLR) and lapatinib plus trastuzumab-resistant (SKLTR) breast cancer cells"/>
   <result pre="independent experiments. Results Characterization of trastuzumab (SKTR), lapatinib (SKLR) and" exact="lapatinib" post="plus trastuzumab-resistant (SKLTR) breast cancer cells As preclinical models"/>
   <result pre="with long-term (12 months) and high drug concentration exposure of" exact="trastuzumab" post="(SK TR), lapatinib (SK LR) and lapatinib plus trastuzumab"/>
   <result pre="months) and high drug concentration exposure of trastuzumab (SK TR)," exact="lapatinib" post="(SK LR) and lapatinib plus trastuzumab (SK LTR) ("/>
   <result pre="concentration exposure of trastuzumab (SK TR), lapatinib (SK LR) and" exact="lapatinib" post="plus trastuzumab (SK LTR) ( S1 Fig), following Nahta"/>
   <result pre="of trastuzumab (SK TR), lapatinib (SK LR) and lapatinib plus" exact="trastuzumab" post="(SK LTR) ( S1 Fig), following Nahta R et"/>
   <result pre="(SK TR) acquire the activating PIK3CA_E545K mutation and lapatinib- and" exact="lapatinib" post="plus trastuzumab-resistant cells (SK LR and SK LTR) acquire"/>
   <result pre="TBP constitutive gene. Then, ligands expression of trastuzumab-, lapatinib- and" exact="trastuzumab" post="plus lapatinib-resistant cells (SK TR, SK LR, SK LTR)"/>
   <result pre="to PI3K/AKT/mTOR and MAPK/ERK1/2 pathways. As shown in Fig 1B," exact="trastuzumab" post="resistant cells (SK TR) had a significant increase in"/>
   <result pre="and p-AKT compared to SK control cells. Cells resistant to" exact="lapatinib" post="(SK LR) showed a great increase in p-EGFR and"/>
   <result pre="was significantly up-regulated (more than 3-fold; p-value: 0. 012) in" exact="trastuzumab" post="resistant cells (SK TR) compared to SK control cells."/>
   <result pre="Fig 1E). In vitro cell growth interactions between HER2 inhibitors," exact="trastuzumab" post="and pertuzumab, in SK, SKTR, SKLR and SKLTR SK"/>
   <result pre="the effects of the HER2-dimerization inhibitor, pertuzumab, in comparison with" exact="trastuzumab" post="in resistant cells. As shown in Fig 2, 5"/>
   <result pre="resistant cells. As shown in Fig 2, 5 μg/ml of" exact="pertuzumab" post="and 20 μM of trastuzumab were needed to achieve"/>
   <result pre="Fig 2, 5 μg/ml of pertuzumab and 20 μM of" exact="trastuzumab" post="were needed to achieve 50% inhibition of cell proliferation"/>
   <result pre="TR, SK LR and SK LTR showed significant resistance to" exact="pertuzumab" post="and trastuzumab, compared with SK cells. Pertuzumab only reached"/>
   <result pre="SK LR and SK LTR, respectively. Similar inhibitory pattern displayed" exact="trastuzumab" post="in SK TR (19.9%; p-value: 0. 000), SK LR"/>
   <result pre="LTR (15.4%; p-value: 0. 000) cells. Fig 2 Pertuzumab plus" exact="trastuzumab" post="combination improves effects in SK and SKLTR. Cells were"/>
   <result pre="improves effects in SK and SKLTR. Cells were treated with" exact="trastuzumab" post="(20 μM), pertuzumab (5 μg/ml) and the combination of"/>
   <result pre="SK and SKLTR. Cells were treated with trastuzumab (20 μM)," exact="pertuzumab" post="(5 μg/ml) and the combination of both for 5"/>
   <result pre="in triplicate. Columns represent % of cell proliferation inhibition after" exact="trastuzumab" post="or pertuzumab exposure and bars SE. * (p ≤"/>
   <result pre="Columns represent % of cell proliferation inhibition after trastuzumab or" exact="pertuzumab" post="exposure and bars SE. * (p ≤ 0.05), **"/>
   <result pre="drugs administered alone (dashed line). Co-treatment of resistant cells with" exact="trastuzumab" post="plus pertuzumab did not increase cytotoxic effect in SK"/>
   <result pre="alone (dashed line). Co-treatment of resistant cells with trastuzumab plus" exact="pertuzumab" post="did not increase cytotoxic effect in SK TR (25.7%"/>
   <result pre="combined treatments ( p-value Pertuzumab : 0. 001 compared with" exact="pertuzumab" post="and p-value Trastuzumab : 0. 000 compared with trastuzumab)."/>
   <result pre="trastuzumab). In vitro cell growth interactions between FASN inhibitors and" exact="pertuzumab" post="in SK, SKTR, SKLR and SKLTR Since targeting only"/>
   <result pre="effect of EGCG and G28UCM alone and in combination with" exact="pertuzumab" post="in SK , SK TR, SK LR and SK"/>
   <result pre="in resistant cells ( S2 and S3 Figs). Results regarding" exact="pertuzumab" post="combinatory experiments with EGCG and G28UCM are shown in"/>
   <result pre="In SK LTR, monotreatments/combination ratio was 0.31. In this case," exact="pertuzumab" post="plus EGCG combination significantly improved effects of each treatment"/>
   <result pre="3; p-value compared with 1 : 0. 036). G28UCM plus" exact="pertuzumab" post="slightly improved EGCG plus pertuzumab inhibitory effects in SK"/>
   <result pre=": 0. 036). G28UCM plus pertuzumab slightly improved EGCG plus" exact="pertuzumab" post="inhibitory effects in SK TR cells (0.69 when combined"/>
   <result pre="EGCG case) ( Fig 3A). Fig 3 FASN inhibitors improve" exact="pertuzumab" post="and temsirolimus activity in parental and resistant cells. (a)"/>
   <result pre="( Fig 3A). Fig 3 FASN inhibitors improve pertuzumab and" exact="temsirolimus" post="activity in parental and resistant cells. (a) Cells were"/>
   <result pre="in parental and resistant cells. (a) Cells were treated with" exact="pertuzumab" post="(5 μg/ml) combined with EGCG (60 μM) or G28UCM"/>
   <result pre="each drug alone, ratio 1. (b) Cells were treated with" exact="temsirolimus" post="(0.05, 0.1, 0.5 and 1 μM) combined with EGCG"/>
   <result pre="from three independent experiments performed in triplicate and with several" exact="temsirolimus" post="concentrations. Dashed lines represent the effect of each drug"/>
   <result pre="the co-exposure of the FASN inhibitors, EGCG and G28UCM, with" exact="pertuzumab" post="in parental and resistant HER2+ breast cancer cells is"/>
   <result pre="agent. In vitro cell growth interactions between FASN inhibitors and" exact="temsirolimus" post="in SK, SKTR, SKLR and SKLTR In our resistant"/>
   <result pre="of inhibiting mTOR (temsirolimus) and FASN (EGCG) in combination with" exact="trastuzumab" post="and/or lapatinib. Temsirolimus or EGCG did not recovered trastuzumab"/>
   <result pre="with trastuzumab and/or lapatinib. Temsirolimus or EGCG did not recovered" exact="trastuzumab" post="and/or lapatinib sensitivity in resistant cells ( S3 Fig)."/>
   <result pre="and/or lapatinib. Temsirolimus or EGCG did not recovered trastuzumab and/or" exact="lapatinib" post="sensitivity in resistant cells ( S3 Fig). Therefore we"/>
   <result pre="Therefore we conducted experiments to evaluate the inhibitory effect of" exact="temsirolimus" post="(mTOR inhibitor) alone and in combination with anti-FASN compounds"/>
   <result pre="induced for co-treatment is shown in Fig 3B EGCG plus" exact="temsirolimus" post="ratio was similar in parental and resistant cells (from"/>
   <result pre="all significantly different from mono-treatments effect; graphed as 1). When" exact="temsirolimus" post="was combined with G28UCM, combinatorial effect was almost doubled"/>
   <result pre="TR, SK LR and SK LTR cells with EGCG and" exact="temsirolimus" post="resulted in a strong synergistic interaction index (0.84 &amp;lt;"/>
   <result pre="index (0.84 &amp;lt; Ix &amp;lt; 0.94). Combination of G28UCM plus" exact="temsirolimus" post="had an enhanced synergistic interaction index in parental and"/>
   <result pre="&amp;lt; 0.58), shown in S1 Table. Effects of EGCG plus" exact="temsirolimus" post="compared with mono-treatments and other combinations (EGCG plus pertuzumab"/>
   <result pre="plus temsirolimus compared with mono-treatments and other combinations (EGCG plus" exact="pertuzumab" post="and pertuzumab plus trastuzumab and/or lapatinib) on FASN and"/>
   <result pre="compared with mono-treatments and other combinations (EGCG plus pertuzumab and" exact="pertuzumab" post="plus trastuzumab and/or lapatinib) on FASN and mTOR expression"/>
   <result pre="mono-treatments and other combinations (EGCG plus pertuzumab and pertuzumab plus" exact="trastuzumab" post="and/or lapatinib) on FASN and mTOR expression were also"/>
   <result pre="in any treatment except in the case of EGCG plus" exact="temsirolimus" post="combination. EGCG plus temsirolimus completely abolished mTOR expression in"/>
   <result pre="in the case of EGCG plus temsirolimus combination. EGCG plus" exact="temsirolimus" post="completely abolished mTOR expression in SK TR, SK LR"/>
   <result pre="SK LTR resistant cells. These data show that co-exposure of" exact="temsirolimus" post="with FASN inhibitors, EGCG and G28UCM, display a more"/>
   <result pre="a single treatment. Antitumor activity of EGCG in combination with" exact="pertuzumab" post="and temsirolimus in HER2+ sensitive and resistant patient derived"/>
   <result pre="treatment. Antitumor activity of EGCG in combination with pertuzumab and" exact="temsirolimus" post="in HER2+ sensitive and resistant patient derived xenografts To"/>
   <result pre="our findings in vivo evaluating the antitumor activity of pertuzumab," exact="temsirolimus" post="and EGCG and the combination in a HER2+ PDX"/>
   <result pre="combination in a HER2+ PDX model (HER2-PDX) and in a" exact="trastuzumab" post="plus lapatinib-resistant HER2+ PDX (HER2-PDX R) model. Both PDX"/>
   <result pre="models ( S5 Fig). EGCG (30 mg/kg for 3d/w) and" exact="pertuzumab" post="(30 mg/kg/once weekly), as single agents, reduced tumor growth"/>
   <result pre="247.6 ± 45.0 mm 3 ( p-value: 0. 017), and" exact="pertuzumab" post="reduced to 301.0 ± 62.9 mm 3. Interestingly, superior"/>
   <result pre="and p-value vsPertu : 0. 010), compared with EGCG or" exact="pertuzumab" post="as single agents ( Fig 4A, left panel). Despite"/>
   <result pre="the HER2-PDX R model EGCG (30 mg/kg for 3d/w) and" exact="pertuzumab" post="(30 mg/kg/once weekly) also reduced tumor growth after 24"/>
   <result pre="was also superior (and more rapid) compared with EGCG and" exact="pertuzumab" post="as a single agents. Compared with the control group"/>
   <result pre="the control group (393.9 ± 95.5 mm 3), EGCG and" exact="pertuzumab" post="decreased tumor growth to 285.9 ± 36.5 mm 3"/>
   <result pre="± 34.5 mm 3, respectively. The combination of EGCG with" exact="pertuzumab" post="significantly reduced tumor growth up to 177.64 ± 34.5"/>
   <result pre="with control (C), EGCG (30 mg/kg, 3 days a week)," exact="pertuzumab" post="(30 mg/kg, 1 day a week) or the combination"/>
   <result pre="TUNEL fluorescent assay, was perfomed in control (C), EGCG (E)," exact="pertuzumab" post="(P) and combination (P+E) treated as in (A) tumors."/>
   <result pre="p-value: 0. 017). Despite the strong antitumor activity exhibited by" exact="temsirolimus" post="when used as a single agent (18.0 ± 15.1"/>
   <result pre="enhanced (day 21) by the addition of EGCG. Combination of" exact="temsirolimus" post="with EGCG not only reduced tumor ratio of growth,"/>
   <result pre="initial tumor volume (-8.2 ± 6.0 mm 3). In the" exact="trastuzumab" post="plus lapatinib-resistant HER2-PDX model EGCG treatment decreased the median"/>
   <result pre="( Fig 5A, left panel). In the HER2-PDX R model," exact="temsirolimus" post="significantly decreased tumor growth when used as a single"/>
   <result pre="EGCG (94.9 ± 33.1 mm 3). These results show that" exact="temsirolimus" post="could have a relevant effect in patients with HER2"/>
   <result pre="to anti-HER2 therapies, and combination with FASN-inhibitors could even assist" exact="temsirolimus" post="to achieve tumor depletion. Fig 5 EGCG, alone or"/>
   <result pre="with control (C), EGCG (30 mg/kg, 3 days a week)," exact="temsirolimus" post="(10 mg/kg, 1 day a week) or the combination"/>
   <result pre="TUNEL fluorescent assay, was perfomed in control (C), EGCG (E)," exact="temsirolimus" post="(T) and combination (T+E) treated as in (A) tumors."/>
   <result pre="assessed by fluorescent TUNEL assay (Figs 4B and 5B). EGCG," exact="pertuzumab" post="and temsirolimus used as single agents induced apoptosis in"/>
   <result pre="fluorescent TUNEL assay (Figs 4B and 5B). EGCG, pertuzumab and" exact="temsirolimus" post="used as single agents induced apoptosis in HER2-PDX (133±14"/>
   <result pre="TUNEL+ cells/mm 2) tumors. Combinatory treatments (pertuzumab plus EGCG and" exact="temsirolimus" post="plus EGCG) increased the apoptosis in HER2-PDX (933±40 TUNEL+"/>
   <result pre="In this study, animals treated with EGCG and also with" exact="pertuzumab" post="and temsirolimus (alone or in combination) were weighed daily"/>
   <result pre="study, animals treated with EGCG and also with pertuzumab and" exact="temsirolimus" post="(alone or in combination) were weighed daily to evaluate"/>
   <result pre="and fluid intake or body weight after treatment with EGCG," exact="pertuzumab" post="and temsirolimus alone or in combination (Figs 4C and"/>
   <result pre="intake or body weight after treatment with EGCG, pertuzumab and" exact="temsirolimus" post="alone or in combination (Figs 4C and 5C). Histological"/>
   <result pre="from the HER2-positive SKBr3 cells that are resistant to either" exact="trastuzumab" post="(SK TR), lapatinib (SK LR) or both (SK LTR)."/>
   <result pre="SKBr3 cells that are resistant to either trastuzumab (SK TR)," exact="lapatinib" post="(SK LR) or both (SK LTR). Some molecular mechanisms"/>
   <result pre="consequently activating the PI3K/AKT/mTOR pathway [ 6]. Conversely, our trastuzumab," exact="lapatinib" post="and trastuzumab plus lapatinib resistant models show a decrease"/>
   <result pre="the PI3K/AKT/mTOR pathway [ 6]. Conversely, our trastuzumab, lapatinib and" exact="trastuzumab" post="plus lapatinib resistant models show a decrease in HER3"/>
   <result pre="pathway [ 6]. Conversely, our trastuzumab, lapatinib and trastuzumab plus" exact="lapatinib" post="resistant models show a decrease in HER3 expression and"/>
   <result pre="several reports that show EGFR overexpression (and its ligands) in" exact="trastuzumab" post="resistant SKBr3 cells and in xenograft models of acquired"/>
   <result pre="trastuzumab resistant SKBr3 cells and in xenograft models of acquired" exact="trastuzumab" post="and lapatinib resistance [ 38– 40]. Even more, after"/>
   <result pre="SKBr3 cells and in xenograft models of acquired trastuzumab and" exact="lapatinib" post="resistance [ 38– 40]. Even more, after dual trastuzumab"/>
   <result pre="and lapatinib resistance [ 38– 40]. Even more, after dual" exact="trastuzumab" post="and lapatinib long-term exposure, our patented SK LTR ["/>
   <result pre="resistance [ 38– 40]. Even more, after dual trastuzumab and" exact="lapatinib" post="long-term exposure, our patented SK LTR [ 41] cells"/>
   <result pre="shown to be responsible of resistance to the EGFR inhibitor" exact="erlotinib" post="[ 43]. Our findings highlight that HER4 overexpression and"/>
   <result pre="and hyperactivation) have also been identified as resistant mechanisms to" exact="trastuzumab" post="and lapatinib therapies [ 14– 16]. In patients treated"/>
   <result pre="have also been identified as resistant mechanisms to trastuzumab and" exact="lapatinib" post="therapies [ 14– 16]. In patients treated with trastuzumab,"/>
   <result pre="PJ et al also reported PI3KCA mutations as responsible of" exact="lapatinib" post="resistance [ 15]. In this study, we have shown"/>
   <result pre="in order to maintain PI3K/AKT/ mTOR pathway activation in trastuzumab," exact="lapatinib" post="and also in a trastuzumab plus lapatinib resistant cells."/>
   <result pre="mTOR pathway activation in trastuzumab, lapatinib and also in a" exact="trastuzumab" post="plus lapatinib resistant cells. Lapatinib effects have been described"/>
   <result pre="activation in trastuzumab, lapatinib and also in a trastuzumab plus" exact="lapatinib" post="resistant cells. Lapatinib effects have been described to be"/>
   <result pre="with anti-FASN compounds (EGCG and the novel derivative G28UCM) plus" exact="pertuzumab" post="improved the effects of each drug alone in SK"/>
   <result pre="improved combinatorial effect of EGCG, producing much more synergism between" exact="temsirolimus" post="and G28UCM. We had previously shown that G28UCM improved"/>
   <result pre="and in HER2 samples of a patient who relapsed after" exact="trastuzumab" post="and lapatinib therapies (HER2-PDX R). Here, we report the"/>
   <result pre="HER2 samples of a patient who relapsed after trastuzumab and" exact="lapatinib" post="therapies (HER2-PDX R). Here, we report the validity of"/>
   <result pre="this approach clearly showing that the combination of EGCG with" exact="pertuzumab" post="and temsirolimus resulted in synergistic reduction of HER2-PDX and"/>
   <result pre="clearly showing that the combination of EGCG with pertuzumab and" exact="temsirolimus" post="resulted in synergistic reduction of HER2-PDX and HER2-PDX R"/>
   <result pre="seen in parental and resistant tumor samples treated with EGCG," exact="pertuzumab" post="and temsirolimus. As synergism in tumor reduction after combinatorial"/>
   <result pre="apoptosis has also been synergistically increased when combining EGCG with" exact="pertuzumab" post="or temsirolimus. These similar profiles in tumor growth reduction"/>
   <result pre="28, 37]. Apoptosis is also consistent with other studies of" exact="pertuzumab" post="in cells and mouse models [ 51, 52]. Temsirolimus"/>
   <result pre="been seen in different breast cancer cell lines treated with" exact="temsirolimus" post="[ 55]. In this study, we demonstrate that tumor"/>
   <result pre="vitro, encourages us to think that combining FASN inhibitors with" exact="temsirolimus" post="or pertuzumab could be one example of a potential"/>
   <result pre="us to think that combining FASN inhibitors with temsirolimus or" exact="pertuzumab" post="could be one example of a potential combinatorial available"/>
   <result pre="study, we have developed novel mono- and dual- long term" exact="trastuzumab" post="plus lapatinib resistant breast cancer models to find out"/>
   <result pre="have developed novel mono- and dual- long term trastuzumab plus" exact="lapatinib" post="resistant breast cancer models to find out new pharmacological"/>
   <result pre="data file. S1 Table Synergy analysis between FASN inhibitors and" exact="temsirolimus" post="in parental and resistant cells. Drug cytotoxicity was calculated"/>
   <result pre="(IC 50) when parental SKBr3 (SK) or trastuzumab-, lapatinib- and" exact="trastuzumab" post="plus lapatinib-resistant cells (SK TR, SK LR and SK"/>
   <result pre="independent experiments performed in triplicate. The interaction index (Ix) for" exact="temsirolimus" post="plus FASN inhibitors effect was calculated using isobologram analysis."/>
   <result pre="TR, ●) cells where both treated with increasing concentrations of" exact="trastuzumab" post="(1–30 μM) for 5 days. (b) SKBr3 (SK) parental"/>
   <result pre="LR, ●) cells where both treated with increasing concentrations of" exact="lapatinib" post="(2–30 μM) for 2 days. c, Lapatinib-resistant cells (SK"/>
   <result pre="for 2 days. c, Lapatinib-resistant cells (SK LR, ●) and" exact="trastuzumab" post="plus lapatinib-resistant SKBr3 (SK LTR, ●) cells where both"/>
   <result pre="(SK LTR, ●) cells where both treated with 3 μM" exact="lapatinib" post="plus increasing concentrations of trastuzumab (1–30 μM) for 5"/>
   <result pre="both treated with 3 μM lapatinib plus increasing concentrations of" exact="trastuzumab" post="(1–30 μM) for 5 days. Results are expressed as"/>
   <result pre="parental, trastuzumab-resistant SKBr3 (SK TR), lapatinib-resistant SKBr3 (SK LR) and" exact="lapatinib" post="plus trastuzumab-resistant SKBr3 (SK LTR) cells were treated with"/>
   <result pre="Click here for additional data file. S3 Fig EGCG and" exact="temsirolimus" post="improve trastuzumab, lapatinib and trastuzumab plus lapatinib treatment in"/>
   <result pre="additional data file. S3 Fig EGCG and temsirolimus improve trastuzumab," exact="lapatinib" post="and trastuzumab plus lapatinib treatment in parental and resistant"/>
   <result pre="file. S3 Fig EGCG and temsirolimus improve trastuzumab, lapatinib and" exact="trastuzumab" post="plus lapatinib treatment in parental and resistant cells. Apoptosis"/>
   <result pre="Fig EGCG and temsirolimus improve trastuzumab, lapatinib and trastuzumab plus" exact="lapatinib" post="treatment in parental and resistant cells. Apoptosis and induction"/>
   <result pre="b) trastuzumab-resistant SKBr3 (SK TR), lapatinib-resistant SKBr3 (SK LR) and" exact="lapatinib" post="plus trastuzumab-resistant SKBr3 (SK LTR) cells were treated with"/>
   <result pre="lapatinib plus trastuzumab-resistant SKBr3 (SK LTR) cells were treated with" exact="trastuzumab" post="(T; 2 μM), lapatinb (L; 3 μM), EGCG (250"/>
   <result pre="2 μM), lapatinb (L; 3 μM), EGCG (250 μM) and" exact="temsirolimus" post="(Temsi; 12 μM) for 12 and 24 hours. Control"/>
   <result pre="for additional data file. S4 Fig Effect of EGCG with" exact="pertuzumab" post="and temsirolimus combinations in parental and resistant cells. a)"/>
   <result pre="data file. S4 Fig Effect of EGCG with pertuzumab and" exact="temsirolimus" post="combinations in parental and resistant cells. a) SKBr3 (SK)"/>
   <result pre="SKBr3 (SK TR), c) lapatinib-resistant SKBr3 (SK LR) and d)" exact="lapatinib" post="plus trastuzumab-resistant SKBr3 (SK LTR) cells were treated with"/>
   <result pre="lapatinib plus trastuzumab-resistant SKBr3 (SK LTR) cells were treated with" exact="trastuzumab" post="(T; 2 μM), lapatinb (L; 3 μM), EGCG (250"/>
   <result pre="(T; 2 μM), lapatinb (L; 3 μM), EGCG (250 μM)," exact="pertuzumab" post="(5 μg/ml) and temsirolimus (Temsi; 12 μM) for 12"/>
   <result pre="(L; 3 μM), EGCG (250 μM), pertuzumab (5 μg/ml) and" exact="temsirolimus" post="(Temsi; 12 μM) for 12 and 24 hours. Control"/>
   <result pre="additional data file. S8 Fig EGCG, alone or combined with" exact="pertuzumab" post="and temsirolimus, does not induce kidney and lung toxicity"/>
   <result pre="providing samples from a HER2+ patient who relapsed after a" exact="trastuzumab" post="and lapatinib-based treatment. The authors thank Dr. Ramon Colomer"/>
   <result pre="LS , et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by" exact="trastuzumab" post="and is effectively inhibited by the PI3K inhibitor GDC-0941"/>
   <result pre="Romieu CG , Pienkowski T , et al. Lapatinib plus" exact="capecitabine" post="for HER2-positive advanced breast cancer. N Engl J Med."/>
   <result pre="Fu X , et al. Different mechanisms for resistance to" exact="trastuzumab" post="versus lapatinib in HER2-positive breast cancers—role of estrogen receptor"/>
   <result pre=", et al. Different mechanisms for resistance to trastuzumab versus" exact="lapatinib" post="in HER2-positive breast cancers—role of estrogen receptor and HER2"/>
   <result pre="MC , Hortobagyi GN . Molecular predictors of response to" exact="trastuzumab" post="and lapatinib in breast cancer. Nat Rev Clin Oncol."/>
   <result pre="Hortobagyi GN . Molecular predictors of response to trastuzumab and" exact="lapatinib" post="in breast cancer. Nat Rev Clin Oncol. 2010; 7("/>
   <result pre="to tumor inhibition by trastuzumab, and loss of PTEN predicts" exact="trastuzumab" post="resistance in patients . Cancer Cell. 2004; 6( 2):"/>
   <result pre="Nijkamp W , et al. Phosphatidylinositol 3-kinase hyperactivation results in" exact="lapatinib" post="resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor"/>
   <result pre="Nahta R , Esteva FJ . In vitro effects of" exact="trastuzumab" post="and vinorelbine in trastuzumab-resistant breast cancer cells . Cancer"/>
   <result pre=", Esteva FJ . In vitro effects of trastuzumab and" exact="vinorelbine" post="in trastuzumab-resistant breast cancer cells . Cancer Chemother Pharmacol."/>
   <result pre="in high HER2, ER negative breast cancer cell line induces" exact="trastuzumab" post="resistance . Breast Cancer Res Treat. 2010; 122( 3):"/>
   <result pre="et al. Human breast cancer cells selected for resistance to" exact="trastuzumab" post="in vivo overexpress epidermal growth factor receptor and ErbB"/>
   <result pre=", et al. High serum TGF-α predicts poor response to" exact="lapatinib" post="and capecitabine in HER2-positive breast cancer . Breast Cancer"/>
   <result pre="al. High serum TGF-α predicts poor response to lapatinib and" exact="capecitabine" post="in HER2-positive breast cancer . Breast Cancer Res Treat."/>
   <result pre="approach identifies the PI3K pathway as a major determinant of" exact="trastuzumab" post="resistance in breast cancer . Cancer Cell. 2007; 12("/>
   <result pre="A , Rocco I , et al. Ras-induced resistance to" exact="lapatinib" post="is overcome by MEK inhibition. Curr Cancer Drug Targets."/>
   <result pre=", Hung MC , Esteva FJ . The HER-2-targeting antibodies" exact="trastuzumab" post="and pertuzumab synergistically inhibit the survival of breast cancer"/>
   <result pre="MC , Esteva FJ . The HER-2-targeting antibodies trastuzumab and" exact="pertuzumab" post="synergistically inhibit the survival of breast cancer cells ."/>
   <result pre="Murono K , Nirei T , et al. Temsirolimus and" exact="chloroquine" post="cooperatively exhibit a potent antitumor effect against colorectal cancer"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4484424/results/search/inn/results.xml">
   <result pre="pmid: 25890497 : Research Paper The oncogenic receptor ErbB2 modulates" exact="gemcitabine" post="and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via"/>
   <result pre="diagnotic markers and efficient therapeutics. The fluorinated analog of deoxycytidine," exact="gemcitabine" post="and emerging FOLFIRINOX protocol (5-fluorouracil (5-FU), irinotecan/SN-38, oxaliplatin and"/>
   <result pre="of deoxycytidine, gemcitabine and emerging FOLFIRINOX protocol (5-fluorouracil (5-FU), irinotecan/SN-38," exact="oxaliplatin" post="and leucovorin) are the main chemotherapies to treat PDAC."/>
   <result pre="CAPAN-1 and CAPAN-2 cells led to an increased sensitivity to" exact="gemcitabine" post="and an increased resistance to irinotecan/SN-38 both in vitro"/>
   <result pre="chemotherapy response and allow stratification of patients eligible for either" exact="gemcitabine" post="or FOLFIRINOX treatment. ErbB2 pancreatic cancer gemcitabine FOLFIRINOX chemoresistance"/>
   <result pre="eligible for either gemcitabine or FOLFIRINOX treatment. ErbB2 pancreatic cancer" exact="gemcitabine" post="FOLFIRINOX chemoresistance INTRODUCTION Pancreatic adenocarcinoma (PDAC) is one of"/>
   <result pre="had increased toxicity. SN-38 which is the active metabolite of" exact="irinotecan" post="binds to the topoisomerase I thereby (i) inducing DNA"/>
   <result pre="the NF-κB pathway leading to decreased PC cell sensitivity to" exact="gemcitabine" post="[ 13]. Previous studies suggested the relationship of the"/>
   <result pre="the relationship of the ErbB2 receptor and chemotherapeutic sensitivity to" exact="lapatinib" post="eventually combined with SN-38 in other epithelial cancers ["/>
   <result pre="silencing leads to an increased sensitivity of PC cells to" exact="gemcitabine" post="via hCNT1/3 transporters. Moreover, ErbB2 silencing induces PC cell"/>
   <result pre="samples. RESULTS Loss of ErbB2 induces PDAC cell sensitivity to" exact="gemcitabine" post="and resistance to SN-38 We previously generated CAPAN-2 stable"/>
   <result pre="1B). Figure 1 ErbB2 deficient cells are more sensitive to" exact="gemcitabine" post="and resistant to SN-38 treatment A. mRNA expression of"/>
   <result pre="50 rates were measured after 72 h of gemcitabine, 5-FU," exact="oxaliplatin" post="or SN-38 irinotecan treatment in ErbB2-KD and control NT"/>
   <result pre="measured after 72 h of gemcitabine, 5-FU, oxaliplatin or SN-38" exact="irinotecan" post="treatment in ErbB2-KD and control NT cells. D. Survival"/>
   <result pre="arbitrarily reported to 1. FOX = 5-FU (1 μM) +" exact="oxaliplatin" post="(1 μM), FIRI = 5-FU + SN-38 (2 nM),"/>
   <result pre="in NT and ErbB2-KD CAPAN-2 cells. Cells were treated with" exact="gemcitabine" post="(100 nM) or SN-38 (20 nM) for 24 h."/>
   <result pre="CAPAN-2 cells were measured following transient siRNA-ErbB2 and treatment with" exact="gemcitabine" post="(F) or SN-38 (G) using the MTT assay. Measurement"/>
   <result pre="(G) using the MTT assay. Measurement of ErbB2-KD sensitivity to" exact="gemcitabine" post="was studied in CAPAN-2 cells. IC 50 showed that"/>
   <result pre="ErbB2 leads to an increased sensitivity of CAPAN-2 cells to" exact="gemcitabine" post="(ErbB2-KD = 11 ± 0.8 nM vs NT ="/>
   <result pre="0.6 μM vs NT = 2.96 ± 0.6 μM) or" exact="oxaliplatin" post="(ErbB2-KD = 2.14 ± 0.3 μM vs NT ="/>
   <result pre="μM) and a mild increase of sensitivity to SN-38, the" exact="irinotecan" post="active metabolite, (NT 1.08 ± 0.09 nM vs ErbB2-KD"/>
   <result pre="ErbB2-KD 1.46 ± 0.05 nM). Using different combinations of 5-FU," exact="oxaliplatin" post="and SN-38, we show that the lack of ErbB2"/>
   <result pre="alone (6-fold, p &amp;lt; 0.001) or combined with 5-FU (FIRI)," exact="oxaliplatin" post="(IRINOX) or both molecules (FIRINOX) (Figure 1D). H2A.X phosphorylated"/>
   <result pre="a mild increase of phospho-Ser139 H2A.X in ErbB2-KD cells following" exact="gemcitabine" post="treatment. By transient inhibition of ErbB2 using a siRNA"/>
   <result pre="siRNA approach, we observed a decrease of cell survival following" exact="gemcitabine" post="treatment of PC cells compared to control (Figure 1F)."/>
   <result pre="ErbB2 may be involved in mediating PDAC cell sensitivity to" exact="gemcitabine" post="and SN-38. In vitro ErbB2 silencing alters hCNT1 and"/>
   <result pre="level of hCNT1. Altogether, this suggests that ErbB2 inhibition promotes" exact="gemcitabine" post="sensitivity via hCNT1/3 transporters. Figure 2 hCNT1 and hCNT3"/>
   <result pre="sensitivity via hCNT1/3 transporters. Figure 2 hCNT1 and hCNT3 promote" exact="gemcitabine" post="sensitivity in ErbB2-KD cells A. mRNA expression of MRP3,"/>
   <result pre="compared to untreated control siRNA condition. ErbB2 and chemosensitivity to" exact="gemcitabine" post="and SN-38 in vivo In order to confirm in"/>
   <result pre="the effects of ErbB2 silencing on PC cell chemosensitivity to" exact="gemcitabine" post="and SN-38, SC xenografts with CAPAN-2 NT or ErbB2-KD"/>
   <result pre="alter the tumor volume of NT xenografts. On the contrary," exact="gemcitabine" post="reduced the tumor volume of ErbB-KD xenografts compared to"/>
   <result pre="in both NT and ErbB2-KD tumors was not altered by" exact="gemcitabine" post="or SN-38 treatment. We further evaluated apoptosis in xenografts"/>
   <result pre="TUNEL positive apoptotic cells in CAPAN-2-NT xenografts treated with either" exact="gemcitabine" post="or SN-38 (* p &amp;lt; 0.05) (Figure 4C). On"/>
   <result pre="Altogether, these results suggest that the loss of ErbB2 impairs" exact="gemcitabine" post="resistance and SN-38 sensitivity of CAPAN-2 PC cells in"/>
   <result pre="(Figure 4D). HCNT1 and MRP2 expression were not altered by" exact="gemcitabine" post="or SN-38 treatment (not shown). Figure 4 Loss of"/>
   <result pre="(not shown). Figure 4 Loss of ErbB2 mediates chemosensitivity to" exact="gemcitabine" post="and SN-38 resistance in vivo A. NT or ErbB2-KD"/>
   <result pre="MRP2 on extracted xenografted tumors. Altogether, these results suggest that" exact="gemcitabine" post="sensitivity could be related to hCNT1 overexpression in ErbB2-KD"/>
   <result pre="that the loss of ErbB2 sensitizes pancreatic cancer cells to" exact="gemcitabine" post="treatment. We also show that hCNT1 and hCNT3 expression"/>
   <result pre="work showed that ErbB2 inhibition improved the cytoxic effect of" exact="gemcitabine" post="in prostate cancer cells [ 17]. We had also"/>
   <result pre="in pancreatic cancer cells led to an increased sensitivity to" exact="gemcitabine" post="and an increased expression of hCNT1 correlated to cell"/>
   <result pre="an increase of SN-38 chemoresistance. In gastric cells, combination of" exact="trastuzumab" post="(monoclonal antibody targeting ErbB2) and SN-38 effects differ depending"/>
   <result pre="ErbB2) and SN-38 effects differ depending on the order of" exact="trastuzumab" post="and SN-38 administration. Sequential addition of SN-38 and trastuzumab"/>
   <result pre="of trastuzumab and SN-38 administration. Sequential addition of SN-38 and" exact="trastuzumab" post="increases the effectiveness of treatment while the reverse (trastuzumab"/>
   <result pre="of SN-38 cytotoxicity. Recently, p53 mutant has been associated with" exact="gemcitabine" post="chemoresistance in PDAC [ 20] highlighting the relevance of"/>
   <result pre="previously showed that NF-κB regulates the hCNT1 transporter and mediates" exact="gemcitabine" post="resistance [ 13]. NF-κB also transcriptionally represses the expression"/>
   <result pre="considered as a bad prognosis marker since they promote the" exact="irinotecan" post="therapeutic failure. In this work, we used subcutaneous xenografts"/>
   <result pre="show that ErbB2 expression in PC cells is associated with" exact="gemcitabine" post="resistance and SN-38 increased sensitivity (Figure 7). We propose"/>
   <result pre="marker of chemotherapy response to stratify patients eligible for either" exact="gemcitabine" post="or FOLFIRINOX treatment. Additional preclinical studies are requested to"/>
   <result pre="Figure 7 Proposed ErbB2-dependent mechanisms of PDAC cell chemosensitivity to" exact="gemcitabine" post="and SN-38 MATERIALS AND METHODS Cell culture CAPAN-1, CAPAN-2,"/>
   <result pre="were obtained following stable transfection of CAPAN-2 cells with pGeneClipTM" exact="puromycin" post="vector encoding ErbB2 ShRNA (SA BiosciencesTM) as previously described"/>
   <result pre="the medium was replaced by fresh medium containing gemcitabine, 5-FU," exact="oxaliplatin" post="or SN-38 at the determined concentration (range: 10 nM–20"/>
   <result pre="cell survival were used as follows: 5-FU at 1 μM," exact="oxaliplatin" post="at 1 μM and SN-38 at 20 nM. Quantitative"/>
   <result pre="cytotoxic assay, and left for 48 h at 37°C before" exact="gemcitabine" post="treatment (100 nM) or SN-38 (20 nM) for another"/>
   <result pre="Rivers, France). Once palpable tumors were developed (250 mm 3)," exact="gemcitabine" post="(15 mg/kg), SN-38 (40 mg/kg) or PBS (200 μl)"/>
   <result pre="Pere-Verge D Delbaldo C Assenat E et al. FOLFIRINOX versus" exact="gemcitabine" post="for metastatic pancreatic cancer N Engl J Med 2011"/>
   <result pre="Panetta JC Innocenti F Ratain MJ Pharmacogenetic pathway analysis of" exact="irinotecan" post="Clin Pharmacol Ther 2008 84 393 402 18418374 8"/>
   <result pre="E van Seuningen I Jonckheere N The MUC4 mucin mediates" exact="gemcitabine" post="resistance of human pancreatic cancer cells via the Concentrative"/>
   <result pre="Lenz HJ Ladner RD The dual EGFR/HER-2 tyrosine kinase inhibitor" exact="lapatinib" post="sensitizes colon and gastric cancer cells to the irinotecan"/>
   <result pre="inhibitor lapatinib sensitizes colon and gastric cancer cells to the" exact="irinotecan" post="active metabolite SN-38 Int J Cancer 2009 125 2957"/>
   <result pre="in androgen-independent human prostate cancer cells enhances cytotoxic effect by" exact="gemcitabine" post="in an androgen-reduced environment Cancer Lett 2009 285 58"/>
   <result pre="M Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to" exact="gemcitabine" post="Biochim Biophys Acta 2015 1853 89 100 25311384 21"/>
   <result pre="Martineau P Ychou M Robert B Gongora C Sorafenib overcomes" exact="irinotecan" post="resistance in colorectal cancer by inhibiting the ABCG2 drug-efflux"/>
   <result pre="Van Seuningen I Pigny P Tumour growth and resistance to" exact="gemcitabine" post="of pancreatic cancer cells are decreased by AP-2alpha overexpression"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4488128/results/search/inn/results.xml">
   <result pre="relative to healthy controls. Pathologic complete response (pCR) following neoadjuvant" exact="trastuzumab" post="and chemotherapy (T + C) is associated with decreased"/>
   <result pre="with larger resectable tumors often benefit from neoadjuvant administration of" exact="trastuzumab" post="and chemotherapy (T + C), with nearly 40–60 %"/>
   <result pre="pathologic stage, hormone receptor status, and time from completion of" exact="trastuzumab" post="(when applicable) Characteristic Treatment-naïve HER2 pos IBC (n ="/>
   <result pre="10 (45.5) 22 (55.0) 14 (56.0) Time from completion of" exact="trastuzumab" post="to study enrollment, number (%)  &amp;lt;6 months 18 (45.0)"/>
   <result pre="factor receptor overexpressing, IBC invasive breast cancer, T + C" exact="trastuzumab" post="and chemotherapy, AJCC American Joint Committee on Cancer, ER"/>
   <result pre="AJCC American Joint Committee on Cancer, ER estrogen receptor, PR" exact="progesterone" post="receptor Fig. 1 Consolidated Standards of Reporting Trials (CONSORT)"/>
   <result pre="callout boxes). Median follow up in the cohort treated with" exact="trastuzumab" post="and chemotherapy ( T + C) was 26 (IQR"/>
   <result pre="HER2 pos IBC (n = 22) and those treated with" exact="trastuzumab" post="and chemotherapy ( T + C) (n = 65);"/>
   <result pre="invasive breast cancer achieving pCR (n = 16) following neoadjuvant" exact="trastuzumab" post="and chemotherapy (T + C), compared with patients with"/>
   <result pre="AJCC American Joint Committee on Cancer, ER estrogen receptor, PR" exact="progesterone" post="receptor, AC/TH Adriamycin/Cytoxan/Taxol/Herceptin, BCS breast-conserving surgery, XRT radiotherapy Relevant"/>
   <result pre="in HER2 pos IBC patients with residual disease following neoadjuvant" exact="trastuzumab" post="and chemotherapy (NCT02061423) Subject Age, y HLA Race Menopausal"/>
   <result pre="HLA human leukocyte antigen (A2 yes/no), ER estrogen receptor, PR" exact="progesterone" post="receptor, T + C trastuzumab and chemotherapy, yp post-neoadjuvant"/>
   <result pre="yes/no), ER estrogen receptor, PR progesterone receptor, T + C" exact="trastuzumab" post="and chemotherapy, yp post-neoadjuvant pathologic stage, AC/TH Adriamycin/Cyclophosphamide/Taxol/Herceptin, MRM"/>
   <result pre="phosphate-buffered saline pCR pathologic complete response PMA phorbol-12-myristate 13-acetate PR" exact="progesterone" post="receptor PVDF polyvinylidene fluoride RT room temperature SFC spot-forming"/>
   <result pre="fluoride RT room temperature SFC spot-forming cells T + C" exact="trastuzumab" post="and chemotherapy Th1 T-helper type-1 TNF-α tumor necrosis factor-"/>
   <result pre="E Di Cosimo S Swaby RF et al. Lapatinib with" exact="trastuzumab" post="for HER2-positive early breast cancer (NeoALTTO): survival outcomes of"/>
   <result pre="A Lluch A Tjulandin S et al. Neoadjuvant chemotherapy with" exact="trastuzumab" post="followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in"/>
   <result pre="S et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant" exact="trastuzumab" post="versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally"/>
   <result pre="PA Huober J Tesch H et al. Neoadjuvant treatment with" exact="trastuzumab" post="in HER2-positive breast cancer: results from the GeparQuattro study"/>
   <result pre="R et al. Pathologic complete response after neoadjuvant chemotherapy plus" exact="trastuzumab" post="predicts favorable survival in human epidermal growth factor receptor"/>
   <result pre="AU et al. Pathologic complete response to neoadjuvant chemotherapy with" exact="trastuzumab" post="predicts for improved survival in women with HER2-overexpressing breast"/>
   <result pre="Barnadas A Calvo L Sanchez-Rovira P et al. Trastuzumab or" exact="lapatinib" post="with standard chemotherapy for HER2-positive breast cancer: results from"/>
   <result pre="V Fumagalli D et al. Tumor infiltrating lymphocytes (TILs) indicate" exact="trastuzumab" post="benefit in early-stage HER2-positive breast cancer Cancer Res 2013"/>
   <result pre="M Cellular adaptive immune system plays a crucial role in" exact="trastuzumab" post="clinical efficacy J Clin Oncol 2010 28 21 e369"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4491676/results/search/inn/results.xml">
   <result pre="(reviewed extensively in [ 123]). The mechanism of action of" exact="lenalidomide" post="is mediated through inhibition of the PP2A Cα subunit"/>
   <result pre="lines and xenograft models in nude mice [ 133]. In" exact="cisplatin" post="resistant mouse models, the modified compounds were tested and"/>
   <result pre="to demonstrate similar levels of tumour growth suppression compared to" exact="cisplatin" post="sensitive mouse models. The combination of minimal toxicity and"/>
   <result pre="to increase the efficacy of some well-known chemotherapy drugs including" exact="doxorubicin" post="in xenograft animal models of glioblastoma. In this situation,"/>
   <result pre="that is approved to treat patients with HER2 positive, metastatic," exact="trastuzumab" post="refractory breast cancer when used in combination with capecitabine"/>
   <result pre="metastatic, trastuzumab refractory breast cancer when used in combination with" exact="capecitabine" post="as it has been shown to prolong median survival"/>
   <result pre="as a contributory factor in the development of resistance to" exact="lapatinib" post="[ 138]. PP2A activity was found elevated in two"/>
   <result pre="lapatinib [ 138]. PP2A activity was found elevated in two" exact="lapatinib" post="resistant breast cancer cell lines. Both cell lines, as"/>
   <result pre="of PP2A in these cells resulted in increased sensitivity to" exact="lapatinib" post="( Figure 3). It was also demonstrated in this"/>
   <result pre="was also demonstrated in this study that treatment of a" exact="lapatinib" post="sensitive breast cancer cell line with the PP2A activator"/>
   <result pre="suggest that PP2A has potential as a novel biomarker of" exact="lapatinib" post="resistance and PP2A inhibition in combination with HER2 inhibition"/>
   <result pre="increases the sensitivity of breast cancer cells to the drug" exact="lapatinib" post="which has an anti-proliferative effect on cells [ 138]."/>
   <result pre="M. Zhang-Auberson L. et al. A placebo-controlled trial of oral" exact="fingolimod" post="in relapsing multiple sclerosis N. Engl. J. Med. 2010"/>
   <result pre="Stites T. Wu S. Holdbrook F. et al. Comparison of" exact="fingolimod" post="with interferon beta-1A in relapsing-remitting multiple sclerosis: A randomised"/>
   <result pre="Pohlmann H. Kappos L. collab: FTY720 D2201 Study Group Oral" exact="fingolimod" post="(FTY720) in multiple sclerosis two-year results of a phase"/>
   <result pre="J. Capra R. Gallo P. Izquierdo G. et al. Oral" exact="fingolimod" post="or intramuscular interferon for relapsing multiple sclerosis N. Engl."/>
   <result pre="FTY720 inhibits tumor growth and enhances the tumor-suppressive effect of" exact="topotecan" post="in neuroblastoma by interfering with the sphingolipid signaling pathway"/>
   <result pre="Lombardi A. Bianco R. Bianco C. et al. Sphingosine analog" exact="fingolimod" post="(FTY720) increases radiation sensitivity of human breast cancer cells"/>
   <result pre="Qi Y. Di W. Zhang P. Combination of FTY720 with" exact="cisplatin" post="exhibits antagonistic effects in ovarian cancer cells: Role of"/>
   <result pre="haplodeficiency in the selective suppression of deletion 5q MDS by" exact="lenalidomide" post="Proc. Natl. Acad. Sci. USA 2009 106 12974 12979"/>
   <result pre="a novel inhibitor of protein phosphatase 2A alone and with" exact="docetaxel" post="J. Clin. Oncol. 2014 32 TS2636 10.1200/JCO.2013.54.5228 136. Lu"/>
   <result pre="Crown J. Chan A. Kaufman B. et al. Lapatinib plus" exact="capecitabine" post="for HER2-positive advanced breast cancer N. Engl. J. Med."/>
   <result pre="W. Sathe G.M. Martin A.M. Gilmer T.M. Novel mechanism of" exact="lapatinib" post="resistance in HER2-positive breast tumor cells: Activation of AXL"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4494590/results/search/inn/results.xml">
   <result pre="Molecular therapies that target HER2 include the monoclonal anti-HER2 antibody" exact="trastuzumab" post="(Herceptin) and pertuzumab (Perjeta) (Genentech, South San Francisco, CA),"/>
   <result pre="target HER2 include the monoclonal anti-HER2 antibody trastuzumab (Herceptin) and" exact="pertuzumab" post="(Perjeta) (Genentech, South San Francisco, CA), and tyrosine kinase"/>
   <result pre="South San Francisco, CA), and tyrosine kinase inhibitors, such as" exact="lapatinib" post="(Tykerb) (GlaxoSmithKline, Middlesex, UK) [ 42]. As in primary"/>
   <result pre="42]. As in primary breast cancer, it is hypothesized that" exact="trastuzumab" post="functions by triggering the internalization and degradation of HER2"/>
   <result pre="HER2-positive tumors found to co-express SNAIL did not respond to" exact="trastuzumab" post="therapy [ 52], expression of TGF dependent proteins may"/>
   <result pre="52], expression of TGF dependent proteins may further contribute to" exact="trastuzumab" post="resistance and EMT [ 53]. Breast cancer is the"/>
   <result pre="in a cohort of metastatic breast cancer patients treated with" exact="trastuzumab" post="Cancer Chemother Pharmacol Montagna E Cancello G D'Agostino D"/>
   <result pre="261 269 39 2013 22727691 41 A systematic review of" exact="trastuzumab" post="and lapatinib in the treatment of women with brain"/>
   <result pre="39 2013 22727691 41 A systematic review of trastuzumab and" exact="lapatinib" post="in the treatment of women with brain metastases from"/>
   <result pre="8 12 5 2010 20847830 47 Efficacy and safety of" exact="trastuzumab" post="as a single agent in first-line treatment of HER2-overexpressing"/>
   <result pre="2010 20467795 52 Epithelial-to-mesenchymal transition (EMT) confers primary resistance to" exact="trastuzumab" post="(Herceptin) Cell Cycle Oliveras-Ferraros C Corominas-Faja B Cufí S"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4494975/results/search/inn/results.xml">
   <result pre="Clinical Research Paper Dual targeting of HER1/EGFR and HER2 with" exact="cetuximab" post="and trastuzumab in patients with metastatic pancreatic cancer after"/>
   <result pre="Paper Dual targeting of HER1/EGFR and HER2 with cetuximab and" exact="trastuzumab" post="in patients with metastatic pancreatic cancer after gemcitabine failure:"/>
   <result pre="cetuximab and trastuzumab in patients with metastatic pancreatic cancer after" exact="gemcitabine" post="failure: results of the &quot;THERAPY&quot;phase 1-2 trial Assenat Eric"/>
   <result pre="efficacy, we decided to simultaneously target HER1 and HER2 with" exact="trastuzumab" post="and cetuximab. Following promising preclinical results, we conducted a"/>
   <result pre="failure. In this single-arm, non-randomized, multicenter trial, patients received weekly" exact="cetuximab" post="(400mg/m², then 250mg/m²). They were sequentially included in two"/>
   <result pre="cetuximab (400mg/m², then 250mg/m²). They were sequentially included in two" exact="trastuzumab" post="dose levels: 3.0 or 4.0mg/kg, then 1.5 or 2.0mg/kg/weekly."/>
   <result pre="compliance issues. The higher dose level was defined as the" exact="trastuzumab" post="recommended dose. During phase 2 (n=39 patients), toxicities were"/>
   <result pre="were particularly detrimental because of the toxicity-response correlation. pancreatic cancer" exact="cetuximab" post="trastuzumab phase 1/2 antibody combination INTRODUCTION Pancreatic cancer is"/>
   <result pre="particularly detrimental because of the toxicity-response correlation. pancreatic cancer cetuximab" exact="trastuzumab" post="phase 1/2 antibody combination INTRODUCTION Pancreatic cancer is the"/>
   <result pre="deaths in 2009 [ 1]. Despite its modest clinical benefit," exact="gemcitabine" post="has been the only approved first-line treatment for advanced"/>
   <result pre="cancer for 15 years [ 2]. Combinations of fluorouracil, irinotecan," exact="oxaliplatin" post="and leucovorin (FOLFIRINOX), or gemcitabine and nab-paclitaxel are often"/>
   <result pre="2]. Combinations of fluorouracil, irinotecan, oxaliplatin and leucovorin (FOLFIRINOX), or" exact="gemcitabine" post="and nab-paclitaxel are often administered as first-line treatment to"/>
   <result pre="the chemotherapy efficacy, several studies have assessed the combination of" exact="gemcitabine" post="with targeted therapies; however, most regimens evaluated in phase"/>
   <result pre="one randomized trial [ 8] ( n=569 patients) that compared" exact="gemcitabine" post="alone or combined with erlotinib showed a modest, but"/>
   <result pre="( n=569 patients) that compared gemcitabine alone or combined with" exact="erlotinib" post="showed a modest, but significant OS increase in the"/>
   <result pre="showed a modest, but significant OS increase in the erlotinib+" exact="gemcitabine" post="arm (5.9 vs 6.2 months, P=0.025). The expression and"/>
   <result pre="efficacy. As part of a pilot study, the combination of" exact="trastuzumab" post="(TRA; anti-HER2 monoclonal antibody) and gemcitabine was well tolerated,"/>
   <result pre="study, the combination of trastuzumab (TRA; anti-HER2 monoclonal antibody) and" exact="gemcitabine" post="was well tolerated, but showed limited therapeutic benefit in"/>
   <result pre="(CET; anti-HER1 monoclonal antibody) was also assessed in combination with" exact="gemcitabine" post="in a phase 2 study that included 41 patients"/>
   <result pre="targeted. In a first preclinical study, we found that the" exact="trastuzumab" post="+ matuzumab (anti-HER1 antibody) combination was more efficient in"/>
   <result pre="CET combination had a better synergistic effect than TRA +" exact="erlotinib" post="or lapatinib alone in xenografted mice [ 21]. Here,"/>
   <result pre="had a better synergistic effect than TRA + erlotinib or" exact="lapatinib" post="alone in xenografted mice [ 21]. Here, we report"/>
   <result pre="chemotherapy treatment **  Adjuvant chemotherapy 2 (20%) 16 (42%)   with" exact="gemcitabine" post="2 (100%) 15 (94%)   with fluorouracil 0 - 1"/>
   <result pre="(20%) 16 (42%)   with gemcitabine 2 (100%) 15 (94%)   with" exact="fluorouracil" post="0 - 1 (6%)  Palliative chemotherapy 10 (100%) 32"/>
   <result pre="- 1 (6%)  Palliative chemotherapy 10 (100%) 32 (84%)   with" exact="gemcitabine" post="9 (90%) 20 (62%)   FOLFIRINOX 1 (10%) 0 -"/>
   <result pre="inclusion criterion of PS ≤ 1 ** All patients received" exact="gemcitabine" post="(adjuvant or palliative chemotherapy) In the phase 1 part,"/>
   <result pre="DISCUSSION This phase 1-2 trial confirms the feasibility of combining" exact="cetuximab" post="and trastuzumab for the treatment of patients with metastatic"/>
   <result pre="phase 1-2 trial confirms the feasibility of combining cetuximab and" exact="trastuzumab" post="for the treatment of patients with metastatic pancreatic adenocarcinoma"/>
   <result pre="be compared with those obtained with second-line palliative chemotherapy after" exact="gemcitabine" post="failure. In our study, 23 patients (48%) had already"/>
   <result pre="In another phase 3 randomized trial evaluating cisplatin/folinic acid/5-FU vs" exact="gemcitabine" post="as first- and second-line treatment for patients with metastatic"/>
   <result pre="study, 168 patients with pancreatic cancer and treated with combined" exact="erlotinib" post="and gemcitabine were classified in two groups (high and"/>
   <result pre="patients with pancreatic cancer and treated with combined erlotinib and" exact="gemcitabine" post="were classified in two groups (high and low severity),"/>
   <result pre="is in progress to determine whether administering escalating doses of" exact="cetuximab" post="in patients with no early skin toxicity could delay"/>
   <result pre="and are activated through dimerization, we tested the combination of" exact="cetuximab" post="(anti-EGFR/HER1) and trastuzumab (anti-HER2 antibody). Following promising preclinical results,"/>
   <result pre="through dimerization, we tested the combination of cetuximab (anti-EGFR/HER1) and" exact="trastuzumab" post="(anti-HER2 antibody). Following promising preclinical results, the aim of"/>
   <result pre="aim of this phase 1-2 trial was to determine the" exact="trastuzumab" post="recommended dose and to assess the combination safety and"/>
   <result pre="P et al. Improvements in survival and clinical benefit with" exact="gemcitabine" post="as first-line therapy for patients with advanced pancreas cancer:"/>
   <result pre="et al. Increased survival in pancreatic cancer with nab-paclitaxel plus" exact="gemcitabine" post="N Engl J Med 2013 369 1691 1703 24131140"/>
   <result pre="Buckels J a C. A double-blind placebo-controlled, randomised study comparing" exact="gemcitabine" post="and marimastat with gemcitabine and placebo as first line"/>
   <result pre="a C. A double-blind placebo-controlled, randomised study comparing gemcitabine and" exact="marimastat" post="with gemcitabine and placebo as first line therapy in"/>
   <result pre="A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with" exact="gemcitabine" post="and placebo as first line therapy in patients with"/>
   <result pre="Verslype C Neumann H et al. Phase III trial of" exact="gemcitabine" post="plus tipifarnib compared with gemcitabine plus placebo in advanced"/>
   <result pre="al. Phase III trial of gemcitabine plus tipifarnib compared with" exact="gemcitabine" post="plus placebo in advanced pancreatic cancer J Clin Oncol"/>
   <result pre="Shang A Cosaert J et al. Phase III trial of" exact="bevacizumab" post="in combination with gemcitabine and erlotinib in patients with"/>
   <result pre="et al. Phase III trial of bevacizumab in combination with" exact="gemcitabine" post="and erlotinib in patients with metastatic pancreatic cancer J"/>
   <result pre="Phase III trial of bevacizumab in combination with gemcitabine and" exact="erlotinib" post="in patients with metastatic pancreatic cancer J Clin Oncol"/>
   <result pre="Murawa P Walde D Wolff RA et al. Erlotinib plus" exact="gemcitabine" post="compared with gemcitabine alone in patients with advanced pancreatic"/>
   <result pre="D Wolff RA et al. Erlotinib plus gemcitabine compared with" exact="gemcitabine" post="alone in patients with advanced pancreatic cancer: a phase"/>
   <result pre="Rathore R Wolff R Tantravahi U et al. Herceptin and" exact="gemcitabine" post="for metastatic pancreatic cancers that overexpress HER-2/neu Cancer Invest"/>
   <result pre="Costanzo F Dapretto E Tonini G et al. Cetuximab plus" exact="gemcitabine" post="and cisplatin compared with gemcitabine and cisplatin alone in"/>
   <result pre="Dapretto E Tonini G et al. Cetuximab plus gemcitabine and" exact="cisplatin" post="compared with gemcitabine and cisplatin alone in patients with"/>
   <result pre="G et al. Cetuximab plus gemcitabine and cisplatin compared with" exact="gemcitabine" post="and cisplatin alone in patients with advanced pancreatic cancer:"/>
   <result pre="al. Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and" exact="cisplatin" post="alone in patients with advanced pancreatic cancer: a randomised,"/>
   <result pre="S Navarro-Teulon I Mach J-P Pèlegrin A Azria D Combined" exact="cetuximab" post="and trastuzumab are superior to gemcitabine in the treatment"/>
   <result pre="I Mach J-P Pèlegrin A Azria D Combined cetuximab and" exact="trastuzumab" post="are superior to gemcitabine in the treatment of human"/>
   <result pre="A Azria D Combined cetuximab and trastuzumab are superior to" exact="gemcitabine" post="in the treatment of human pancreatic carcinoma xenografts Ann"/>
   <result pre="with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or" exact="lapatinib" post="alone: implication of receptors' down-regulation and dimers' disruption Neoplasia"/>
   <result pre="Desseigne F Seitz JF Conroy T et al. Sorafenib and" exact="irinotecan" post="(NEXIRI) as second- or later-line treatment for patients with"/>
   <result pre="clinical outcome of patients with metastatic colorectal cancer treated with" exact="cetuximab" post="plus irinotecan J Clin Oncol 2009 27 1122 1129"/>
   <result pre="of patients with metastatic colorectal cancer treated with cetuximab plus" exact="irinotecan" post="J Clin Oncol 2009 27 1122 1129 19164213 26"/>
   <result pre="26 De P Hasmann M Leyland-Jones B Molecular determinants of" exact="trastuzumab" post="efficacy: What is their clinical relevance? Cancer Treat Rev"/>
   <result pre="P Chauffert B et al. Combination 5-fluorouracil, folinic acid and" exact="cisplatin" post="(LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in"/>
   <result pre="al. Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by" exact="gemcitabine" post="or the reverse sequence in metastatic pancreatic cancer: final"/>
   <result pre="metastatic colorectal cancer: Results of a phase I study of" exact="pertuzumab" post="plus cetuximab in cetuximab-refractory patients Invest New Drugs 2013"/>
   <result pre="cancer: Results of a phase I study of pertuzumab plus" exact="cetuximab" post="in cetuximab-refractory patients Invest New Drugs 2013 Available from"/>
   <result pre="non-randomized, feasibility/safety and efficacy study of the combination of everolimus," exact="cetuximab" post="and capecitabine in patients with advanced pancreatic cancer Invest"/>
   <result pre="and efficacy study of the combination of everolimus, cetuximab and" exact="capecitabine" post="in patients with advanced pancreatic cancer Invest New Drugs"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4495150/results/search/inn/results.xml">
   <result pre="oncogene (HER2-positive [HER2+]) and positivity for estrogen receptor (ER) or" exact="progesterone" post="receptor (PR) (referred to as hormone receptor-positive [HR +"/>
   <result pre="time to relapse [ 2, 3]. However, the introduction of" exact="trastuzumab" post="therapy has drastically altered this situation, significantly increasing outcomes"/>
   <result pre="diagnosis of metastasis, 214 patients received systemic chemotherapy as follows:" exact="paclitaxel" post="for 154 (63.4%) patients, anthracycline for 73 (30.0%), capecitabine"/>
   <result pre="follows: paclitaxel for 154 (63.4%) patients, anthracycline for 73 (30.0%)," exact="capecitabine" post="for 44 (18.1%), platinum for 41 (16.9%), vinorelbine for"/>
   <result pre="73 (30.0%), capecitabine for 44 (18.1%), platinum for 41 (16.9%)," exact="vinorelbine" post="for 30 (12.4%), and gemcitabine for 24 (9.9%). In"/>
   <result pre="(18.1%), platinum for 41 (16.9%), vinorelbine for 30 (12.4%), and" exact="gemcitabine" post="for 24 (9.9%). In addition, 87 (35.8%) patients received"/>
   <result pre="which tamoxifen, aromatase inhibitors (such as anastrozole, letrozole, exemestane), or" exact="goserelin" post="was used. Of 85 patients receiving anti-HER2 treatment, trastuzumab"/>
   <result pre="or goserelin was used. Of 85 patients receiving anti-HER2 treatment," exact="trastuzumab" post="or lapatinib was used. Eight patients were treated with"/>
   <result pre="was used. Of 85 patients receiving anti-HER2 treatment, trastuzumab or" exact="lapatinib" post="was used. Eight patients were treated with bevacizumab. Among"/>
   <result pre="patients was treatment targeting HER2. It should be noted that" exact="trastuzumab" post="and lapatinib are not covered by insurance in China,"/>
   <result pre="treatment targeting HER2. It should be noted that trastuzumab and" exact="lapatinib" post="are not covered by insurance in China, and most"/>
   <result pre="cancer patients who were HER2+, more HR– patients benefited from" exact="trastuzumab" post="treatment compared to HR+ patients. Our finding of greater"/>
   <result pre="patients with metastatic breast cancer in the present study. Though" exact="trastuzumab" post="can significantly improve the OS of breast cancer patients"/>
   <result pre="Gawor Z Potemski P Banach M Cardiac complications associated with" exact="trastuzumab" post="in the setting of adjuvant chemotherapy for breast cancer"/>
   <result pre="Gelber RD Jackisch C et al. Estimating the magnitude of" exact="trastuzumab" post="effects within patient subgroups in the HERA trial Ann"/>
   <result pre="81 24 Kaufman B Mackey JR Clemens MR Trastuzumab plus" exact="anastrozole" post="versus anastrozole alone for the treatment of postmenopausal women"/>
   <result pre="Kaufman B Mackey JR Clemens MR Trastuzumab plus anastrozole versus" exact="anastrozole" post="alone for the treatment of postmenopausal women with human"/>
   <result pre="of women with metastatic breast cancer by HER2 status and" exact="trastuzumab" post="treatment: an institutional-based review J Clin Oncol 2010 28"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4496366/results/search/inn/results.xml">
   <result pre="Shak S Stewart SJ Press M Efficacy and safety of" exact="trastuzumab" post="as a single agent in first-line treatment of HER2-overexpressing"/>
   <result pre="11 Hutchinson L Targeted therapies: Activated PI3K/AKT confers resistance to" exact="trastuzumab" post="but not lapatinib Nat Rev Clin Oncol 2010 7"/>
   <result pre="Targeted therapies: Activated PI3K/AKT confers resistance to trastuzumab but not" exact="lapatinib" post="Nat Rev Clin Oncol 2010 7 424 20700898 12"/>
   <result pre="MF Osborne CK Schiff R Different mechanisms for resistance to" exact="trastuzumab" post="versus lapatinib in HER2-positive breast cancers—role of estrogen receptor"/>
   <result pre="CK Schiff R Different mechanisms for resistance to trastuzumab versus" exact="lapatinib" post="in HER2-positive breast cancers—role of estrogen receptor and HER2"/>
   <result pre="SL O'Regan RM Nahta R Pharmacologic inhibition of mTOR improves" exact="lapatinib" post="sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab"/>
   <result pre="improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary" exact="trastuzumab" post="resistance Anticancer Agents Med Chem 2012 12 151 162"/>
   <result pre="Mok T Lee C et al. MET amplification leads to" exact="gefitinib" post="resistance in lung cancer by activating ERBB3 signaling Science"/>
   <result pre="Increased MET and HGF gene copy numbers are associated with" exact="trastuzumab" post="failure in HER2-positive metastatic breast cancer Br J Cancer"/>
   <result pre="S Christensen JG Weiser MR MET activation mediates resistance to" exact="lapatinib" post="inhibition of HER2-amplified gastric cancer cells Mol Cancer Ther"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4501549/results/search/inn/results.xml">
   <result pre="source are credited pone.0133072.pdf Abstract The humanized monoclonal antibody-drug conjugate" exact="trastuzumab" post="emtansine (T-DM1, Kadcyla) has been approved by the U.S."/>
   <result pre="low and moderate levels of caveolin-1, respectively, were treated with" exact="trastuzumab" post="or its conjugate T-DM1. Cell viability and molecular localizations"/>
   <result pre="T-DM1 also showed improved drug efficacy in BT-474 cells than" exact="trastuzumab" post="treatment. Caveolin-1 expression in these lines was manipulated by"/>
   <result pre="poor clinical outcome [ 1, 2]. The humanized monoclonal antibody," exact="trastuzumab" post="(Herceptin), binds to the extramembrane domain of HER-2 to"/>
   <result pre="of HER-2 dependent tumors. After several effective trials, in 2001," exact="trastuzumab" post="was approved by the Food and Drug Administration (FDA)"/>
   <result pre="[ 3]. Despite the success of this therapeutic treatment, naked" exact="trastuzumab" post="targeting of HER-2 expression in breast cancer is rarely"/>
   <result pre="effects of combination therapy: 27% of patients treated concurrently with" exact="trastuzumab" post="and anthracyclines, and 13% with trastuzumab and paclitaxed, had"/>
   <result pre="patients treated concurrently with trastuzumab and anthracyclines, and 13% with" exact="trastuzumab" post="and paclitaxed, had cardiotoxic side effects [ 8]. Recent"/>
   <result pre="clinical application in breast cancer treatment [ 11, 12] using" exact="trastuzumab" post="emtasime (trastuzumab-DM1; T-DM1), in which trastuzumab is conjugated through"/>
   <result pre="[ 11, 12] using trastuzumab emtasime (trastuzumab-DM1; T-DM1), in which" exact="trastuzumab" post="is conjugated through a stable thioether bond to the"/>
   <result pre="survival with less toxicity than the dual tyrosine kinase inhibitor" exact="lapatinib" post="plus capecitabine in patients with HER-2 positive advanced breast"/>
   <result pre="less toxicity than the dual tyrosine kinase inhibitor lapatinib plus" exact="capecitabine" post="in patients with HER-2 positive advanced breast cancer ["/>
   <result pre="with a patient population who had previously been treated with" exact="trastuzumab" post="and taxane, 228 (66%) of the 397 patients treated"/>
   <result pre="back to the membrane [ 30]. In a recent report," exact="trastuzumab" post="was demonstrated to colocalize with caveolin-1 in breast cancer"/>
   <result pre="31]. However, whether T-DM1 uses the same internalization mechanism as" exact="trastuzumab" post="is still unknown. Poor internalization has been considered an"/>
   <result pre="Eagle's Medium (DMEM) supplemented with 10% calf serum, penicillin, and" exact="streptomycin" post="(GIBCO-BRL, Gaithersberg, MD, USA) and were kept in an"/>
   <result pre="antibody internalization Cells grown on glass coverslips were incubated with" exact="trastuzumab" post="(10 μg/ml) or T-DM1 (1 μg/ml) at 37°C for"/>
   <result pre="BSA) at room temperature for 1 hr. The presence of" exact="trastuzumab" post="and T-DM1 was revealed by a Cy2-conjugated anti-human secondary"/>
   <result pre="10 6 cells/ml and incubated alone or in 10 μg/ml" exact="trastuzumab" post="(Herceptin, Roche Ltd., Basel, Swiss), 1 μg/ml T-DM1 (Kadcyla,"/>
   <result pre="1 μg/ml T-DM1 (Kadcyla, Roche Ltd., Basel, Swiss), or 1μg/ml" exact="paclitaxel" post="(Phyxol, Sinphar Ltd., I-Lan, Taiwan) for 72 hr ["/>
   <result pre="* P &amp;lt;0.05. CAV-1 indicates caveolin-1. Internalization and colocalization of" exact="trastuzumab" post="and T-DM1 with caveolin-1 in HER-2 positive breast cancer"/>
   <result pre="cancer cells MDA-MB-231, SKBR-3 and BT-474 cells were treated with" exact="trastuzumab" post="or T-DM1 for 30 min. Trastuzumab, T-DM1, and endogenous"/>
   <result pre="by immunofluorescence microscopy. Double immune staining micrographs demonstrated that neither" exact="trastuzumab" post="nor T-DM1 was present in MDA-MB-231 cells, which did"/>
   <result pre="membrane and cytosol; however, in BT-474 cells, most of the" exact="trastuzumab" post="and T-DM1 was localized only in the cell membrane"/>
   <result pre="Fig 3A and 3B, right lane). These results suggest that" exact="trastuzumab" post="and T-DM1 were bound to HER-2 positive cells, and"/>
   <result pre="bound to HER-2 positive cells, and that the internalization of" exact="trastuzumab" post="and T-DM1 was associated with caveolin-1 expression. Fig 3"/>
   <result pre="was associated with caveolin-1 expression. Fig 3 Caveolin-1 expression promoted" exact="trastuzumab" post="and T-DM1 internalization into the cells. MDA-MB-231, SKBR-3, and"/>
   <result pre="the cells. MDA-MB-231, SKBR-3, and BT-474 cells were incubated with" exact="trastuzumab" post="(A) or T-DM1 (B) for 30 minutes. Cells were"/>
   <result pre="positive SKBR3 cells, which have a high caveolin-1 expression, induced" exact="trastuzumab" post="and T-DM1 internalization into the cell and these were"/>
   <result pre="MDA-MB-231, SKBR-3, and BT-474 cells treated with trastuzumab, T-DM1, and" exact="paclitaxel" post="demonstrated that paclitaxel treatment caused the greatest cell toxicity"/>
   <result pre="BT-474 cells treated with trastuzumab, T-DM1, and paclitaxel demonstrated that" exact="paclitaxel" post="treatment caused the greatest cell toxicity in each of"/>
   <result pre="SKBR-3 was significantly more sensitive to T-DM1 when compared to" exact="trastuzumab" post="treatment ( Fig 4B, P &amp;lt;0.01). The cytotoxic efficacy"/>
   <result pre="P &amp;lt;0.01). The cytotoxic efficacy of T-DM1 was similar to" exact="paclitaxel" post="treatment ( Fig 4B). Fig 4 Caveolin-1 expressing HER-2"/>
   <result pre="T-DM1 treatment. MDA-MB-231, SKBR-3, and BT-474 cells were treated with" exact="trastuzumab" post="(10 μg/ml), T-DM1 (1 μg/ml) or paclitaxel (1 μg/ml)"/>
   <result pre="were treated with trastuzumab (10 μg/ml), T-DM1 (1 μg/ml) or" exact="paclitaxel" post="(1 μg/ml) for 72 hours. (A) phase contrast images"/>
   <result pre="phase contrast images and (B) cell survival graph showing that" exact="paclitaxel" post="causes cell toxicity in all cell types. SKBR-3 cells"/>
   <result pre="cells were most sensitive to T-DM1 treatment when compared to" exact="trastuzumab" post="treatment. (C) Western blot analysis of the pro-survival marker"/>
   <result pre="of caveolin-1 during tumor progression [ 45]. The efficacies of" exact="trastuzumab" post="and T-DM1 in breast cancer cell lines have been"/>
   <result pre="According to Barok's protocol [ 37], our data also showed" exact="trastuzumab" post="treatment had a similar efficacy on 72 hours treatment"/>
   <result pre="associated with caveolin-1 expression. Caveolin-1 has been shown to improve" exact="trastuzumab" post="internalization [ 31]. In this study, the role of"/>
   <result pre="HER-2 [ 32, 37]. Our results revealed effective cytotoxicity of" exact="paclitaxel" post="in the treatment of different breast cancer cells which"/>
   <result pre="expression in MDA-MB-231 and BT-474 cells when trastuzumab, T-DM1 and" exact="paclitaxel" post="treatment were compared. However, paclitaxel treatment showed significant reduction"/>
   <result pre="cells when trastuzumab, T-DM1 and paclitaxel treatment were compared. However," exact="paclitaxel" post="treatment showed significant reduction of Bcl-2 expression in MDA-MB-231"/>
   <result pre="&amp;lt;0.01) and BT-474 cells ( P &amp;lt;0.01) when compared to" exact="trastuzumab" post="treatment by t-test. Since the chemotherapeutic drugs of taxane"/>
   <result pre="in lysosomes [ 48]. Recently, the dominant opinion is that" exact="trastuzumab" post="causes the endocytic downregulation of HER-2 [ 49– 51]."/>
   <result pre="the cell and determines the drug efficacy. The action of" exact="trastuzumab" post="is dependent on HER-2 signaling through Src hyperactivation, which"/>
   <result pre="or compensatory HER-3 or IGF1-R activation, may be resistant to" exact="trastuzumab" post="treatment [ 55]. Our results, indeed, were consistent with"/>
   <result pre="Randomized phase II trial of the efficacy and safety of" exact="trastuzumab" post="combined with docetaxel in patients with human epidermal growth"/>
   <result pre="trial of the efficacy and safety of trastuzumab combined with" exact="docetaxel" post="in patients with human epidermal growth factor receptor 2-positive"/>
   <result pre="Gelmon K , Pond GR , et al. Pegylated liposomal" exact="doxorubicin" post="and trastuzumab in HER-2 overexpressing metastatic breast cancer: a"/>
   <result pre=", Pond GR , et al. Pegylated liposomal doxorubicin and" exact="trastuzumab" post="in HER-2 overexpressing metastatic breast cancer: a multicenter phase"/>
   <result pre="et al. Randomized phase III study of trastuzumab, paclitaxel, and" exact="carboplatin" post="compared with trastuzumab and paclitaxel in women with HER-2-overexpressing"/>
   <result pre="phase III study of trastuzumab, paclitaxel, and carboplatin compared with" exact="trastuzumab" post="and paclitaxel in women with HER-2-overexpressing metastatic breast cancer"/>
   <result pre="study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and" exact="paclitaxel" post="in women with HER-2-overexpressing metastatic breast cancer . J"/>
   <result pre=", Ashby M , et al. Cardiac dysfunction in the" exact="trastuzumab" post="clinical trials experience. J Clin Oncol. 2002; 20( 5):"/>
   <result pre="Vinholes J , et al. Phase II randomized study of" exact="trastuzumab" post="emtansine versus trastuzumab plus docetaxel in patients with human"/>
   <result pre="et al. Phase II randomized study of trastuzumab emtansine versus" exact="trastuzumab" post="plus docetaxel in patients with human epidermal growth factor"/>
   <result pre="Phase II randomized study of trastuzumab emtansine versus trastuzumab plus" exact="docetaxel" post="in patients with human epidermal growth factor receptor 2-positive"/>
   <result pre="of ErbB2 and the site of action of cancer therapeutics" exact="trastuzumab" post="and geldanamycin . Mol Biol Cell. 2004; 15( 12):"/>
   <result pre="caveolin-1 as a potential causative factor in the generation of" exact="trastuzumab" post="resistance in breast cancer cells . J Cancer. 2013;"/>
   <result pre="46 Gornstein E , Schwarz TL . The paradox of" exact="paclitaxel" post="neurotoxicity: Mechanisms and unanswered questions. Neuropharmacology. 2014; 76 Pt"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4501645/results/search/inn/results.xml">
   <result pre="has been associated with resistance to HER2-targeted therapies such as" exact="trastuzumab" post="and lapatanib ( 19– 22). Consistent with these observations,"/>
   <result pre="of HER2-amplified breast cancer by combining PI3K pathway inhibitors with" exact="trastuzumab" post="or lapatinib ( 7, 16, 23– 26). In this"/>
   <result pre="breast cancer by combining PI3K pathway inhibitors with trastuzumab or" exact="lapatinib" post="( 7, 16, 23– 26). In this study, we"/>
   <result pre="HER2 and HER3 ( 16, 24– 26). Likewise, resistance to" exact="trastuzumab" post="(Herceptin) has been associated with increased PI3K signalling, either"/>
   <result pre="Several clinical trials, combining PI3K/mTOR inhibitors with HER2 agents in" exact="trastuzumab" post="refactory patients have been initiated ( www.clinicaltrial.gov; NCT00736970, NCT01471847,"/>
   <result pre="have previously demonstrated that AZD5363 enhances the efficacy of both" exact="trastuzumab" post="and lapatinib in the KPL4 xenograft model which is"/>
   <result pre="demonstrated that AZD5363 enhances the efficacy of both trastuzumab and" exact="lapatinib" post="in the KPL4 xenograft model which is only partially"/>
   <result pre="which expresses high levels of p95HER2 and is resistant to" exact="trastuzumab" post="therapy. It is therefore suggested that the combination of"/>
   <result pre="signaling pathways in human cancer cells determines their response to" exact="everolimus" post="J Clin Invest 120 2858 2866 2010 10.1172/JCI37539 20664172"/>
   <result pre="to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor" exact="crizotinib" post="Lung Cancer 81 328 336 2013 10.1016/j.lungcan.2013.05.020 23809060 12"/>
   <result pre="to tumor inhibition by trastuzumab, and loss of PTEN predicts" exact="trastuzumab" post="resistance in patients Cancer Cell 6 117 127 2004"/>
   <result pre="approach identifies the PI3K pathway as a major determinant of" exact="trastuzumab" post="resistance in breast cancer Cancer Cell 12 395 402"/>
   <result pre="M Scaltriti M et al. Phosphatidylinositol 3-kinase hyperactivation results in" exact="lapatinib" post="resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4504492/results/search/inn/results.xml">
   <result pre="We accomplished this by measuring cellular and molecular responses to" exact="lapatinib" post="and the AKT inhibitors (AKT i) GSK690693 and GSK2141795"/>
   <result pre="wild type or mutant PIK3CA. We observed that combinations of" exact="lapatinib" post="plus AKT i were synergistic in HER2 +/PIK3CA mut"/>
   <result pre="15 cell lines after treatment with lapatinib, AKT i or" exact="lapatinib" post="+ AKT i to shed light on the underlying"/>
   <result pre="This revealed that p-S6RP levels were less well attenuated by" exact="lapatinib" post="in HER2 +/PIK3CA mut cells compared to HER2 +/PIK3CA"/>
   <result pre="mut cells compared to HER2 +/PIK3CA wt cells and that" exact="lapatinib" post="+ AKT i reduced p-S6RP levels to those achieved"/>
   <result pre="levels to those achieved in HER2 +/PIK3CA wt cells with" exact="lapatinib" post="alone. We also found that that compensatory up-regulation of"/>
   <result pre="p-HER3 and p-HER2 is blunted in PIK3CA mut cells following" exact="lapatinib" post="+ AKT i treatment. Responses of HER2 + SKBR3"/>
   <result pre="PIK3CA mutations act as downstream activators of AKT that blunt" exact="lapatinib" post="inhibition of downstream AKT signaling and that the effects"/>
   <result pre="the effects of PIK3CA mutations can be countered by combining" exact="lapatinib" post="with an AKT i. This combination does not confer"/>
   <result pre="AKT i. This combination does not confer substantial benefit beyond" exact="lapatinib" post="in HER2 +/PIK3CA wt cells. Funding This work was"/>
   <result pre="HER2/ERBB2/NEU) [ 7]. HER2-targeted drugs including the antibody based therapeutic" exact="trastuzumab" post="and the dual EGFR/HER2 tyrosine kinase inhibitor lapatinib have"/>
   <result pre="based therapeutic trastuzumab and the dual EGFR/HER2 tyrosine kinase inhibitor" exact="lapatinib" post="have improved outcomes for these patients in both the"/>
   <result pre="particularly when used in combination with chemotherapeutic agents such as" exact="capecitabine" post="or letrozole [ 9, 11, 12]. More recently, combinations"/>
   <result pre="used in combination with chemotherapeutic agents such as capecitabine or" exact="letrozole" post="[ 9, 11, 12]. More recently, combinations of lapatinib"/>
   <result pre="or letrozole [ 9, 11, 12]. More recently, combinations of" exact="lapatinib" post="with trastuzumab have been shown to be synergistic in"/>
   <result pre="[ 9, 11, 12]. More recently, combinations of lapatinib with" exact="trastuzumab" post="have been shown to be synergistic in both experimental"/>
   <result pre="signaling pathways [ 13, 14]. Sergina et al showed that" exact="lapatinib" post="induced inhibition of HER3 and PI3K-AKT signaling is transient"/>
   <result pre="signaling responses in the cell lines. Our study showed that" exact="lapatinib" post="in combination with AKT inhibitors was synergistic in HER2"/>
   <result pre="mutations stimulating AKT signaling downstream of HER2. In this model," exact="lapatinib" post="and AKT inhibitors are synergistic in HER2 +/PIK3CA mut"/>
   <result pre="suppress downstream AKT pathway activity that cannot be achieved using" exact="lapatinib" post="alone. Materials and Methods Cell Lines The cell lines"/>
   <result pre="vectors as a control. Cells were selected with 5 ug/ml" exact="puromycin" post="until all non-transduced control cells were killed. Transduced cells"/>
   <result pre="were killed. Transduced cells were then maintained in 2 ug/ml" exact="puromycin" post="until the time of drug treatment. Western Blotting Western"/>
   <result pre="(TGI) for both AKT inhibitors alone and in combination with" exact="lapatinib" post="are presented in Table 1 for GSK690693 and in"/>
   <result pre="AKT inhibitors showed responses that were correlated with response to" exact="lapatinib" post="alone (see S1 Fig). This is consistent with the"/>
   <result pre="with the notion that effective inhibition of PI3K-AKT signaling by" exact="lapatinib" post="in HER2 + cells is one of the major"/>
   <result pre="10.1371/journal.pone.0133219.t001 Table 1 Average GI 50 and TGI values for" exact="lapatinib" post="in 22 HER2 positive breast cancer cell lines. Cell"/>
   <result pre="0.038 0.027 0.098 0.070 We initially examined a combination of" exact="lapatinib" post="plus GSK690693 that was synergistic in some cell lines"/>
   <result pre="an inactivating PTEN mutation. This line showed responses to both" exact="lapatinib" post="and GSK690693, but has one of the lowest levels"/>
   <result pre="synergistic (in SUM190PT) and B. antagonistic (in AU565) interactions between" exact="lapatinib" post="(red curve) and GSK690693 (green curve) in breast cell"/>
   <result pre="show synergy with GSK2141795 and also displayed borderline significance with" exact="lapatinib" post="plus GSK690693. The reason for the differential responses to"/>
   <result pre="in levels of signaling pathway proteins induced by treatment with" exact="lapatinib" post="plus GSK69063 using Reverse Phase Protein Array (RPPA) analysis"/>
   <result pre="line did not show significant synergy with the combination of" exact="lapatinib" post="plus GSK690693 and has borderline levels of HER2 amplification."/>
   <result pre="level changes occurred in all cell lines following treatment with" exact="lapatinib" post="alone. These included down-regulation of phosphoproteins in the PI3K-AKT"/>
   <result pre="lines harboring PI3K mutations. C. Treatment with the combination of" exact="lapatinib" post="plus GSK690693 leads to down-regulation of the PI3K-AKT signaling"/>
   <result pre="treated with GSK690693 alone were similar to those observed with" exact="lapatinib" post="treatment, with several exceptions. Most notably, p-AKT (Ser473 and"/>
   <result pre="[ 35]. The treatment of lines with the combination of" exact="lapatinib" post="plus GSK690693 altered several protein levels in ways that"/>
   <result pre="may represent interplay between the inhibition of phosphorylation resulting from" exact="lapatinib" post="treatment and the loss of phosphatase activity as a"/>
   <result pre="Ser235 and Ser240 sites in both cell types. Unlike with" exact="lapatinib" post="monotherapy, there was little recovery over time, and the"/>
   <result pre="with GSK690693 alone, consistent with inhibition of MAPK signaling by" exact="lapatinib" post="( S3 Fig). Other changes that occurred only in"/>
   <result pre="that we observed by Western blotting. For example, treatment with" exact="lapatinib" post="lead to down-regulation of p-AKT (S473) p-ERK, and p-HER3,"/>
   <result pre="Expression of mutant PIK3CA is sufficient to induce synergy between" exact="lapatinib" post="and GSK690693 We explored the hypothesis that PIK3CA mutations"/>
   <result pre="PIK3CA mutations are causally linked to the synergistic response to" exact="lapatinib" post="plus GSK690693 by introducing PIK3CA hotspot mutations (E545K or"/>
   <result pre="treated cells). We treated the control and transfected cells with" exact="lapatinib" post="or lapatinib plus GSK690693 as described above. The presence"/>
   <result pre="We treated the control and transfected cells with lapatinib or" exact="lapatinib" post="plus GSK690693 as described above. The presence of either"/>
   <result pre="The presence of either PIK3CA mutant decreased the ability of" exact="lapatinib" post="to inhibit cell growth, diminished the lapatinib-induced down-regulation of"/>
   <result pre="baseline levels. The presence of the mutations also rendered the" exact="lapatinib" post="plus GSK690693 combination synergistic ( Fig 5B). As described"/>
   <result pre="response to lapatinib. Mutant harboring cells became more resistant to" exact="lapatinib" post="and the addition of GSK690693 countered the mutation-induced resistance."/>
   <result pre="cells. Thus, the synergy resulted from the mutation-induced decrease in" exact="lapatinib" post="sensitivity. We also performed an RPPA analysis of lapatinib"/>
   <result pre="in lapatinib sensitivity. We also performed an RPPA analysis of" exact="lapatinib" post="and DMSO time course treatments, this time in SKBR3"/>
   <result pre="pathway activity between the cells (data not shown). However, with" exact="lapatinib" post="treatment, there was a significantly greater down-regulation of PI3K"/>
   <result pre="( Fig 5C) and p-HER2 (not shown) in response to" exact="lapatinib" post="was significantly blunted in the mutant cells. Western blot"/>
   <result pre="of p-HER3 compared to PIK3CA WT cells following treatment with" exact="lapatinib" post="( Fig 5D). This supports the idea that the"/>
   <result pre="of p-AKT and p-S6RP at baseline, and diminished response to" exact="lapatinib" post="alone as measured by p-S6RP levels. Note that mutation"/>
   <result pre="E545K mutant, or H1047R mutant transduced SKBR3 cells treated with" exact="lapatinib" post="(red), GSK690693 (green), or a combination of the two"/>
   <result pre="two (blue). Introduction of mutations results in increased resistance to" exact="lapatinib" post="and synergistic interactions between lapatinib and GSK690693 (doses with"/>
   <result pre="results in increased resistance to lapatinib and synergistic interactions between" exact="lapatinib" post="and GSK690693 (doses with significant synergy are marked with"/>
   <result pre="while the control cell line shows the expected hyper-phosphorylation following" exact="lapatinib" post="treatment. D. Western blotting confirms the lack of recovery"/>
   <result pre="is an acceptable strategy since EGFR is also inhibited by" exact="lapatinib" post="and the protein phosphorylation kinetics of EGFR following lapatinib"/>
   <result pre="by lapatinib and the protein phosphorylation kinetics of EGFR following" exact="lapatinib" post="treatment mirrors those for HER2 and HER3 with an"/>
   <result pre="show diminished effects on p-S6 activity with increasing concentrations of" exact="lapatinib" post="monotherapy. Indeed, even when ERBB is completely inhibited, there"/>
   <result pre="ERBB tyrosine kinase receptor (EGFR/HER2) inhibition ( Fig 6B). With" exact="lapatinib" post="treatment alone, p-S6RP levels were reduced to near zero"/>
   <result pre="inhibited by 80% in wild type cells. In contrast, with" exact="lapatinib" post="monotherapy, even 100% inhibition of the receptor in PIK3CA"/>
   <result pre="is capable of explaining the synergistic effect of GSK690693 and" exact="lapatinib" post="within an otherwise unified dynamical model. The model supports"/>
   <result pre="model. The model supports the idea that the synergism between" exact="lapatinib" post="and GSK690693 results from the ability of GGSK690693 to"/>
   <result pre="activity in PIK3CA mutant cells that cannot be achieved using" exact="lapatinib" post="alone. Discussion Combination therapies promise to unlock the full"/>
   <result pre="Lapatinib and AKT i. We observed that the combination of" exact="lapatinib" post="with AKT inhibitors was synergistic predominantly in cells that"/>
   <result pre="observed between mutant and wild type cells in response to" exact="lapatinib" post="using both the cell line panel and the engineered"/>
   <result pre="a mutant form of PIK3CA resulted in decreased responsiveness to" exact="lapatinib" post="but led to synergistic interactions between lapatinib and GSK690693,"/>
   <result pre="decreased responsiveness to lapatinib but led to synergistic interactions between" exact="lapatinib" post="and GSK690693, which corresponded to increased baseline levels of"/>
   <result pre="and restoring the normal response to lapatinib. With respect to" exact="lapatinib" post="monotherapy, PI3K mutation status was not a major predictor"/>
   <result pre="alterations in the cells in response to the combination of" exact="lapatinib" post="plus GSK690693. Down-regulation of elements of the PI3K-AKT pathway"/>
   <result pre="mutant PIK3CA compared to their wild-type counterparts when treated with" exact="lapatinib" post="or alone. However, with the combination, there was much"/>
   <result pre="We speculate that in the absence of PI3K pathway mutations," exact="lapatinib" post="is sufficient to block the signal from the surface"/>
   <result pre="when used in combination with chemotherapeutic agents [ 9] or" exact="trastuzumab" post="[ 3, 4], but not as a monotherapy. It"/>
   <result pre="monotherapy. It is thought that much of the efficacy of" exact="lapatinib" post="occurs through the inhibition of the PI3K pathway, a"/>
   <result pre="that have suggested a potential role for combination therapies of" exact="lapatinib" post="with PI3K targeted therapeutic agents [ 16, 17, 22]."/>
   <result pre="MEK pathway proteins as well following an initial down-regulation after" exact="lapatinib" post="treatment. The mechanism that causes the antagonism we observed"/>
   <result pre="the antagonism we observed in the wild-type cell lines between" exact="lapatinib" post="and the AKT inhibitors is unclear, but is an"/>
   <result pre="lines. In conclusion, we observed a significant synergistic interaction between" exact="lapatinib" post="and AKT inhibitors in HER2 positive breast cancer cell"/>
   <result pre="our findings suggest that clinical trials treating breast cancer with" exact="lapatinib" post="in combination with AKT (e.g., NCT01245205) or PI3K inhibitors"/>
   <result pre="values calculated for: A GSK690693 and AKTi GSK2141795 and B" exact="lapatinib" post="and AKTi. (TIF) LINK Click here for additional data"/>
   <result pre="dose response curves for treated cells. Cells were treated with" exact="lapatinib" post="(red), GSK690693 (green), or a combination of the two"/>
   <result pre="with GSK690693 (upper panel) is blunted when the combination of" exact="lapatinib" post="plus GSK690693 is used (lower panel). (TIF) LINK Click"/>
   <result pre="al. Randomized study of Lapatinib alone or in combination with" exact="trastuzumab" post="in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer ."/>
   <result pre="Romieu CG , Pienkowski T , et al. Lapatinib plus" exact="capecitabine" post="for HER2-positive advanced breast cancer. N Engl J Med."/>
   <result pre="S , Dieras V , et al. Lapatinib combined with" exact="letrozole" post="versus letrozole and placebo as first-line therapy for postmenopausal"/>
   <result pre="Dieras V , et al. Lapatinib combined with letrozole versus" exact="letrozole" post="and placebo as first-line therapy for postmenopausal hormone receptor-positive"/>
   <result pre="D , Basso A , Moasser MM . Resistance to" exact="gefitinib" post="in PTEN-null HER-overexpressing tumor cells can be overcome through"/>
   <result pre="approach identifies the PI3K pathway as a major determinant of" exact="trastuzumab" post="resistance in breast cancer . Cancer Cell. 2007; 12("/>
   <result pre="and tensin homolog or phosphoinositol-3 kinase activation and response to" exact="trastuzumab" post="or lapatinib in human epidermal growth factor receptor 2-overexpressing"/>
   <result pre="homolog or phosphoinositol-3 kinase activation and response to trastuzumab or" exact="lapatinib" post="in human epidermal growth factor receptor 2-overexpressing locally advanced"/>
   <result pre="et al. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with" exact="trastuzumab" post="response and survival in patients with HER2-positive metastatic breast"/>
   <result pre="association of PIK3CA mutations and PTEN loss with efficacy of" exact="trastuzumab" post="therapy in metastatic breast cancer . Breast Cancer Res"/>
   <result pre="al. PI3K pathway activation results in low efficacy of both" exact="trastuzumab" post="and lapatinib. BMC Cancer. 2011; 11: 248 doi: 10.1186/1471-2407-11-248"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4506360/results/search/inn/results.xml">
   <result pre="A Phase I clinical trial combining liposomal doxorubicin, bevacizumab, and" exact="temsirolimus" post="(DAT) for patients with advanced cancers was designed to"/>
   <result pre="VEGF inhibitor bevacizumab, may overcome anthracycline resistance. However, resistance to" exact="bevacizumab" post="is also driven by upregulation of HIF-1α. Addition of"/>
   <result pre="been opened. This contrasts starkly with the rapid approval of" exact="crizotinib" post="for anaplastic lymphoma kinase gene–rearranged non-small cell lung cancer"/>
   <result pre="for anaplastic lymphoma kinase gene–rearranged non-small cell lung cancer (NSCLC);" exact="crizotinib" post="was approved approximately 2 years after its anticancer activity"/>
   <result pre="our Phase I experience with the combination of mTOR inhibitor" exact="sirolimus" post="and vorinostat in heavily pretreated patients with advanced cancer."/>
   <result pre="I experience with the combination of mTOR inhibitor sirolimus and" exact="vorinostat" post="in heavily pretreated patients with advanced cancer. Vorinostat is"/>
   <result pre="lymphoma refractory to standard therapies [ 12]. Novel HDAC inhibitors" exact="panobinostat" post="or mocetinostat demonstrated objective response rates of 27% in"/>
   <result pre="became the rationale for our Phase I clinical trial of" exact="sirolimus" post="and vorinostat. During the dose-escalation phase, we observed anticancer"/>
   <result pre="lymphoma generally have a poor clinical outcome, the combination of" exact="sirolimus" post="and vorinostat appears to be a promising treatment strategy."/>
   <result pre="have a poor clinical outcome, the combination of sirolimus and" exact="vorinostat" post="appears to be a promising treatment strategy. Interestingly, similar"/>
   <result pre="Oki et al in a trial of the combination of" exact="everolimus" post="and panobinostat in patients with relapsed or refractory lymphoma."/>
   <result pre="al in a trial of the combination of everolimus and" exact="panobinostat" post="in patients with relapsed or refractory lymphoma. In 14"/>
   <result pre="intolerance was higher (43% [13/30]) than in our trial of" exact="sirolimus" post="and vorinostat (4% [1/28]). The lower rate in our"/>
   <result pre="higher (43% [13/30]) than in our trial of sirolimus and" exact="vorinostat" post="(4% [1/28]). The lower rate in our study may"/>
   <result pre="among other factors, more flexible dosing and dose adjustments for" exact="sirolimus" post="and vorinostat, which are both FDA approved (although not"/>
   <result pre="both FDA approved (although not for Hodgkin lymphoma). Finally, the" exact="sirolimus" post="and vorinostat regimen has a relatively favorable cost compared"/>
   <result pre="approved (although not for Hodgkin lymphoma). Finally, the sirolimus and" exact="vorinostat" post="regimen has a relatively favorable cost compared to some"/>
   <result pre="vorinostat/sirolimus regimen is likely to drop even further when the" exact="vorinostat" post="patent protection expires in the near future, making this"/>
   <result pre="A final example is a phase I clinical trial of" exact="bevacizumab" post="in combination with an EGFR- or HER2-targeted agent. Preclinical"/>
   <result pre="These preclinical observations provided a rationale for combining anti-HER2 agents" exact="trastuzumab" post="and lapatinib with bevacizumab in patients with metastatic HER2-positive"/>
   <result pre="observations provided a rationale for combining anti-HER2 agents trastuzumab and" exact="lapatinib" post="with bevacizumab in patients with metastatic HER2-positive breast cancer"/>
   <result pre="a rationale for combining anti-HER2 agents trastuzumab and lapatinib with" exact="bevacizumab" post="in patients with metastatic HER2-positive breast cancer pretreated with"/>
   <result pre="TG Liang WS et al. Activity of the mTOR inhibitor" exact="sirolimus" post="and HDAC inhibitor vorinostat in heavily pretreated refractory Hodgkin"/>
   <result pre="al. Activity of the mTOR inhibitor sirolimus and HDAC inhibitor" exact="vorinostat" post="in heavily pretreated refractory Hodgkin lymphoma patients American Society"/>
   <result pre="J Kurzrock R Phase I study of the antiangiogenic antibody" exact="bevacizumab" post="and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal"/>
   <result pre="of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor" exact="temsirolimus" post="combined with liposomal doxorubicin: tolerance and biological activity Clin"/>
   <result pre="R A phase I trial of liposomal doxorubicin, bevacizumab, and" exact="temsirolimus" post="in patients with advanced gynecologic and breast malignancies Clin"/>
   <result pre="Koenig K Kurzrock R Responses to liposomal Doxorubicin, bevacizumab, and" exact="temsirolimus" post="in metaplastic carcinoma of the breast: biologic rationale and"/>
   <result pre="LM Forman SJ Fisher RI A phase 2 study of" exact="vorinostat" post="for treatment of relapsed or refractory Hodgkin lymphoma: Southwest"/>
   <result pre="RE Zhang J Ji Y Younes A The pan-deacetylase inhibitor" exact="panobinostat" post="induces cell death and synergizes with everolimus in Hodgkin"/>
   <result pre="The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with" exact="everolimus" post="in Hodgkin lymphoma cell lines Blood 2012 119 17"/>
   <result pre="Zhou S Feng L Younes A Phase I study of" exact="panobinostat" post="plus everolimus in patients with relapsed or refractory lymphoma"/>
   <result pre="Feng L Younes A Phase I study of panobinostat plus" exact="everolimus" post="in patients with relapsed or refractory lymphoma Clin Cancer"/>
   <result pre="Soft T and Bone Sarcoma G Safety and efficacy of" exact="imatinib" post="(STI571) in metastatic gastrointestinal stromal tumours: a phase I"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4506361/results/search/inn/results.xml">
   <result pre="LLC pmcid: 4506361 : Case Report Durable clinical benefit to" exact="trastuzumab" post="and chemotherapy in a patient with metastatic colon adenocarcinoma"/>
   <result pre="a TP 53 mutation in the metastatic lesion. Treatment with" exact="trastuzumab" post="with a chemotherapy backbone elicited stable disease/minor response in"/>
   <result pre="by comprehensive genomic profiling in metastatic colorectal adenocarcinoma. ERBB2 HER2" exact="trastuzumab" post="oxaliplatin colorectal adenocarcinoma CASE PRESENTATION A 39-year old female"/>
   <result pre="comprehensive genomic profiling in metastatic colorectal adenocarcinoma. ERBB2 HER2 trastuzumab" exact="oxaliplatin" post="colorectal adenocarcinoma CASE PRESENTATION A 39-year old female was"/>
   <result pre="as KRAS wild-type. Anti- EGFR combination treatment with FOLFIRI and" exact="cetuximab" post="was initiated and continued for 9 months until termination"/>
   <result pre="loss of function point mutation within TP53. Combination therapy of" exact="trastuzumab" post="with a backbone of capecitabine and oxaliplatin was started."/>
   <result pre="within TP53. Combination therapy of trastuzumab with a backbone of" exact="capecitabine" post="and oxaliplatin was started. The patient's performance status began"/>
   <result pre="Combination therapy of trastuzumab with a backbone of capecitabine and" exact="oxaliplatin" post="was started. The patient's performance status began to improve"/>
   <result pre="increased mobility and near complete resolution of symptoms. Of note," exact="oxaliplatin" post="was eliminated after 6 months of treatment. Imaging with"/>
   <result pre="reduced to a third of their initial values. Treatment with" exact="trastuzumab" post="continued for 12 months in total, after which time"/>
   <result pre="lung metastasis at baseline (A) and after 3 months of" exact="trastuzumab" post="and chemotherapy (B) Arrow indicates significantly regressed tumor burden."/>
   <result pre="and improved overall survival [ 14, 15]. The efficacy of" exact="trastuzumab" post="in breast and gastric cancers suggests by analogy that"/>
   <result pre="ERBB2 amplified left sided colorectal carcinoma and rectal carcinoma to" exact="trastuzumab" post="monotherapy [ 16, 17]. The relatively high copy number"/>
   <result pre="44 with HER2 overexpression [ 18]. Although preliminary, treatment with" exact="trastuzumab" post="and lapatinib in this sub group of ERBB2 amplified"/>
   <result pre="HER2 overexpression [ 18]. Although preliminary, treatment with trastuzumab and" exact="lapatinib" post="in this sub group of ERBB2 amplified cancer as"/>
   <result pre="exhausting prior guideline driven therapies, responded for 12 months to" exact="trastuzumab" post="with a XELOX backbone. Thus, this case illustrates a"/>
   <result pre="[ 24]. The current case of a patient treated with" exact="trastuzumab" post="and chemotherapy demonstrates a clear, durable, symptomatic, and radiographic"/>
   <result pre="and overall survival in HER2-positive advanced gastric cancer treated with" exact="trastuzumab" post="J Clin Oncol 2013 12 10 31 35 4445"/>
   <result pre="31 24311197 16 Sorscher SM Marked response to single agent" exact="trastuzumab" post="in a patient with metastatic HER-2 gene amplified rectal"/>
   <result pre="Siena S Sartore-Bianchi A Lonardi S et al. Trastuzumab and" exact="lapatinib" post="in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES"/>
   <result pre="D Mayer R Phase-II trial of 5-fluororuacil (5-FU), leucovorin (LV)," exact="oxaliplatin" post="(Ox), and trastuzumab (T) for patients with metastatic colorectal"/>
   <result pre="Phase-II trial of 5-fluororuacil (5-FU), leucovorin (LV), oxaliplatin (Ox), and" exact="trastuzumab" post="(T) for patients with metastatic colorectal cancer (CRC) refractory"/>
   <result pre="of HER-2/neu in advanced colorectal cancer limits the usefulness of" exact="trastuzumab" post="(Herceptin) and irinotecan as therapy. A phase II trial"/>
   <result pre="advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and" exact="irinotecan" post="as therapy. A phase II trial Cancer Invest 2004"/>
   <result pre="JH Kim TY Heo DS Bang Y-J Kim NK Single-agent" exact="capecitabine" post="in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4511219/results/search/inn/results.xml">
   <result pre="to 1 cm, the Panel endorsed a simplified regimen comprising" exact="paclitaxel" post="and trastuzumab without anthracycline as adjuvant therapy. For premenopausal"/>
   <result pre="cm, the Panel endorsed a simplified regimen comprising paclitaxel and" exact="trastuzumab" post="without anthracycline as adjuvant therapy. For premenopausal patients with"/>
   <result pre="Panel endorsed the role of ovarian function suppression with either" exact="tamoxifen" post="or exemestane for patients at higher risk. The Panel"/>
   <result pre="the role of ovarian function suppression with either tamoxifen or" exact="exemestane" post="for patients at higher risk. The Panel noted the"/>
   <result pre="TEXT trials clarifying the role of ovarian function suppression with" exact="tamoxifen" post="or exemestane in the endocrine treatment of premenopausal patients,"/>
   <result pre="clarifying the role of ovarian function suppression with tamoxifen or" exact="exemestane" post="in the endocrine treatment of premenopausal patients, and the"/>
   <result pre="patients have fewer recurrences while assigned AI than while assigned" exact="tamoxifen" post="during those periods when the treatments differed, although there"/>
   <result pre="comparing 5 years of an AI to the sequence of" exact="tamoxifen" post="followed by an AI. breast cancer subtypes Extensive genomic"/>
   <result pre="using more widely available immunohistochemical (IHC) tests for estrogen receptor," exact="progesterone" post="receptor together with IHC or in situ hybridization tests"/>
   <result pre="reflected in potential differences in predicting degree of response to" exact="trastuzumab" post="[ 46]. The difference between the hormone receptor-negative and"/>
   <result pre="breast cancer is important for choice of chemotherapy in that" exact="carboplatin" post="is as effective as docetaxel in basal-like but less"/>
   <result pre="choice of chemotherapy in that carboplatin is as effective as" exact="docetaxel" post="in basal-like but less so in other intrinsic subtypes"/>
   <result pre="54] in some studies, though not among patients treated with" exact="trastuzumab" post="in the N9831 trial [ 55]. Immune-related pathways Preclinical"/>
   <result pre="Targeting CDK 4/6 Palbociclib, a CDK 4/6 inhibitor, given with" exact="letrozole" post="showed superior clinical efficacy when compared with letrozole alone"/>
   <result pre="given with letrozole showed superior clinical efficacy when compared with" exact="letrozole" post="alone as first-line treatment in the PALOMA-1/TRIO-18 randomized phase"/>
   <result pre="high pCR rates to platinum salts [ 61, 62], and" exact="carboplatin" post="is significantly more active than doctaxel in patients with"/>
   <result pre="PI3K pathway The combination of the PIK3CA-alpha-specific inhibitor BYL719 and" exact="fulvestrant" post="appears synergistic in preclinical models [ 64]. Targeting the"/>
   <result pre="but substantial toxicity. Germline genetics In a small observational study," exact="tamoxifen" post="was associated with a reduced risk of contralateral breast"/>
   <result pre="Neoadjuvant systemic therapies An improved pCR rate was observed with" exact="carboplatin" post="for patients with triple-negative disease [ 75, 76]. Such"/>
   <result pre="observed in triple-negative breast cancer using nab-paclitaxel instead of solvent-based" exact="paclitaxel" post="[ 50]. pCR rates were higher in patients with"/>
   <result pre="breast cancer, either triple-negative or HER2-positive, who were treated with" exact="carboplatin" post="[ 77]. PIK3CA mutation was associated with inferior pCR"/>
   <result pre="The hazard ratio in ALTTO of 0.84 comparing dual-blockade with" exact="trastuzumab" post="alone [ 85] was much as expected [ 86]"/>
   <result pre="the dual-inhibition comparison and that involving the sequential administration of" exact="trastuzumab" post="and lapatinib. Surgery A large US population-based study of"/>
   <result pre="indicate that the combination of OFS (mainly using triptorelin) and" exact="tamoxifen" post="or OFS and AI should be considered for women"/>
   <result pre="indeed an adverse overall survival finding in ABCSG 12 using" exact="anastrozole" post="[ 100], patient preference and treatment tolerance should be"/>
   <result pre="and demonstrated that more intensive therapies such as OFS and" exact="exemestane" post="were particularly beneficial for patients at higher risk ["/>
   <result pre="been associated with poor breast cancer outcomes. The use of" exact="anastrozole" post="(but not letrozole) in the adjuvant or extended adjuvant"/>
   <result pre="incidence of cardiac toxicity following chemotherapy and anti-HER2 treatment with" exact="trastuzumab" post="did not increase with extended follow-up in the HERA"/>
   <result pre="110]. Adjuvant anti-HER2 therapy A phase II study of adjuvant" exact="paclitaxel" post="and trastuzumab, without anthracycline, showed excellent outcome in node-negative,"/>
   <result pre="Age was neither prognostic nor predictive for the impact of" exact="trastuzumab" post="in the HERA trial [ 91]. LHRH agonist therapy"/>
   <result pre="majority of the Panel would treat such a patient with" exact="tamoxifen" post="alone. The second scenario involved a 34-year-old patient with"/>
   <result pre="this patient, and a large majority would use this with" exact="exemestane" post="rather than tamoxifen. More generally, the Panel considered that"/>
   <result pre="for the use of an AI plus OFS rather than" exact="tamoxifen" post="plus OFS were (overwhelmingly) the involvement of four or"/>
   <result pre="decide to give OFS are you more likely to recommend" exact="tamoxifen" post="or an AI?’ with a majority favoring AI. The"/>
   <result pre="almost unanimous that some postmenopausal patients can be treated with" exact="tamoxifen" post="alone. However, virtually all Panel members regarded the involvement"/>
   <result pre="Panel was comfortable to contemplate switching from an AI to" exact="tamoxifen" post="after 2 years if necessary. The Panel was virtually"/>
   <result pre="5 years of adjuvant therapy had involved a switch from" exact="tamoxifen" post="to an AI. A clear majority was in favor"/>
   <result pre="of the Panel was willing to accept the combination of" exact="paclitaxel" post="and trastuzumab without anthracycline as a reasonable option for"/>
   <result pre="Panel was willing to accept the combination of paclitaxel and" exact="trastuzumab" post="without anthracycline as a reasonable option for stage 1"/>
   <result pre="not support dual HER2 blockade by the addition of either" exact="pertuzumab" post="or lapatinib to trastuzumab for postoperative adjuvant therapy. neoadjuvant"/>
   <result pre="dual HER2 blockade by the addition of either pertuzumab or" exact="lapatinib" post="to trastuzumab for postoperative adjuvant therapy. neoadjuvant cytotoxic chemotherapy"/>
   <result pre="blockade by the addition of either pertuzumab or lapatinib to" exact="trastuzumab" post="for postoperative adjuvant therapy. neoadjuvant cytotoxic chemotherapy for luminal"/>
   <result pre="the Panel supported dual anti-HER2 therapy with taxane, trastuzumab, and" exact="pertuzumab" post="as ‘an acceptable regimen’ for such patients. neoadjuvant systemic"/>
   <result pre="Panel was divided about the use of bisphosphonates such as" exact="zoledronic acid" post="or clodronate to improve disease-free survival. In postmenopausal patients,"/>
   <result pre="about the use of bisphosphonates such as zoledronic acid or" exact="clodronate" post="to improve disease-free survival. In postmenopausal patients, a slim"/>
   <result pre="not receiving LHRH and would not support the use of" exact="denosumab" post="as a substitute for bisphosphonates. elderly patients The Panel"/>
   <result pre="negative No systemic therapy  T1 b,c node negative Chemotherapy plus" exact="trastuzumab" post="Consider paclitaxel plus 12 months trastuzumab without anthracycline  Higher"/>
   <result pre="systemic therapy  T1 b,c node negative Chemotherapy plus trastuzumab Consider" exact="paclitaxel" post="plus 12 months trastuzumab without anthracycline  Higher T or"/>
   <result pre="node negative Chemotherapy plus trastuzumab Consider paclitaxel plus 12 months" exact="trastuzumab" post="without anthracycline  Higher T or N stage Anthracycline →"/>
   <result pre=" Higher T or N stage Anthracycline → taxane with concurrent" exact="trastuzumab" post="continued to 12 months Patients unsuitable for anthracycline may"/>
   <result pre="regimen, though cardiac contraindications to anthracycline may also argue against" exact="trastuzumab" post="[ 115] ER positive and HER2-positive As above plus"/>
   <result pre="5 years    Premenopausal other Tamoxifen 5–10 years or OFS plus" exact="tamoxifen" post="or OFS plus exemestane See criteria in papers ["/>
   <result pre="Tamoxifen 5–10 years or OFS plus tamoxifen or OFS plus" exact="exemestane" post="See criteria in papers [ 3, 4, 116]    Postmenopausal"/>
   <result pre="node-negative disease and T-size &amp;lt;2 cm, a nonanthracycline regimen comprising" exact="paclitaxel" post="and 1 year of trastuzumab is appropriate, while for"/>
   <result pre="cm, a nonanthracycline regimen comprising paclitaxel and 1 year of" exact="trastuzumab" post="is appropriate, while for more extensive disease treatment should"/>
   <result pre="and be followed by concurrent taxane and trastuzumab, with the" exact="trastuzumab" post="continued for a total of 1 year. Patients with"/>
   <result pre="Endocrine therapy for premenopausal patients at low risk should comprise" exact="tamoxifen" post="for 5 years, while those at higher risk should"/>
   <result pre="risk should be considered for OFS and the substitution of" exact="exemestane" post="for tamoxifen. In patients who have completed 5 years"/>
   <result pre="tamoxifen. In patients who have completed 5 years of adjuvant" exact="tamoxifen" post="therapy and are regarded as being at higher risk,"/>
   <result pre="therapy for a total of 10 years using either further" exact="tamoxifen" post="or, if the patient is clearly postmenopausal, an AI."/>
   <result pre="is clearly postmenopausal, an AI. For patients postmenopausal at presentation," exact="tamoxifen" post="alone may be suitable for those at lower risk"/>
   <result pre="O , Regan MM , Walley BA et al. Adjuvant" exact="exemestane" post="with ovarian suppression in premenopausal breast cancer. N Engl"/>
   <result pre="pathologic tumor response in early-stage breast cancer treated with neoadjuvant" exact="docetaxel" post="plus capecitabine with or without trastuzumab chemotherapy . Med"/>
   <result pre="response in early-stage breast cancer treated with neoadjuvant docetaxel plus" exact="capecitabine" post="with or without trastuzumab chemotherapy . Med Oncol 2014;"/>
   <result pre="cancer treated with neoadjuvant docetaxel plus capecitabine with or without" exact="trastuzumab" post="chemotherapy . Med Oncol 2014; 31: 163. 25186065 17"/>
   <result pre="Cheang MC , Martin M et al. Prognostic significance of" exact="progesterone" post="receptor-positive tumor cells within immunohistochemically defined luminal A breast"/>
   <result pre="distant recurrence risk in ER+ BC after 5 years of" exact="tamoxifen" post=". J Clin Oncol 2014; 32 (5s suppl): abstr"/>
   <result pre="Michelotti A et al. Effect of the gonadotropin-releasing hormone analogue" exact="triptorelin" post="on the occurrence of chemotherapy-induced early menopause in premenopausal"/>
   <result pre=", Chia S , Hickish T et al. Pertuzumab plus" exact="trastuzumab" post="in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy"/>
   <result pre="are prognostic in triple negative breast cancer and predictive for" exact="trastuzumab" post="benefit in early breast cancer: results from the FinHER"/>
   <result pre="S-TILs are associated with chemotherapy benefit but not associated with" exact="trastuzumab" post="benefit . Cancer Res 2015; 75: abstr S1-06. 56"/>
   <result pre=", Lang I et al. The cyclin-dependent kinase 4/6 inhibitor" exact="palbociclib" post="in combination with letrozole versus letrozole alone as first-line"/>
   <result pre="al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with" exact="letrozole" post="versus letrozole alone as first-line treatment of oestrogen receptor-positive,"/>
   <result pre="cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus" exact="letrozole" post="alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced"/>
   <result pre="LS et al. TNT: A randomized phase III trial of" exact="carboplatin" post="(C) compared with docetaxel (D) for patients with metastatic"/>
   <result pre="A randomized phase III trial of carboplatin (C) compared with" exact="docetaxel" post="(D) for patients with metastatic or recurrent locally advanced"/>
   <result pre=", Perou CM et al. Impact of the addition of" exact="carboplatin" post="and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense"/>
   <result pre="CM et al. Impact of the addition of carboplatin and/or" exact="bevacizumab" post="to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and"/>
   <result pre="of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week" exact="paclitaxel" post="followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete"/>
   <result pre="carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense" exact="doxorubicin" post="and cyclophosphamide on pathologic complete response rates in stage"/>
   <result pre="bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and" exact="cyclophosphamide" post="on pathologic complete response rates in stage II to"/>
   <result pre="G , Schneeweiss A , Loibl S et al. Neoadjuvant" exact="carboplatin" post="in patients with triple-negative and HER2-positive early breast cancer"/>
   <result pre="Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without" exact="carboplatin" post="in human epidermal growth factor receptor 2-positive and triple-negative"/>
   <result pre="Dieci M , Carbognin L et al. Activity of neoadjuvant" exact="lapatinib" post="plus trastuzumab for early breast cancer according to PIK3CA"/>
   <result pre=", Carbognin L et al. Activity of neoadjuvant lapatinib plus" exact="trastuzumab" post="for early breast cancer according to PIK3CA mutations: pathological"/>
   <result pre="al. Increased pathological complete response rate after a long-term neoadjuvant" exact="letrozole" post="treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer"/>
   <result pre="after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or" exact="progesterone" post="receptor-positive breast cancer . Br J Cancer 2013; 108:"/>
   <result pre=", Holmes AP , Piccart-Gebhart M et al. Lapatinib with" exact="trastuzumab" post="for HER2-positive early breast cancer (NeoALTTO): survival outcomes of"/>
   <result pre="NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with" exact="lapatinib" post="alone (L), trastuzumab alone (T), their sequence (T-&amp;gt;L), or"/>
   <result pre="comparing one year of anti-HER2 therapy with lapatinib alone (L)," exact="trastuzumab" post="alone (T), their sequence (T-&amp;gt;L), or their combination (T+L)"/>
   <result pre="et al. Zoledronic acid combined with adjuvant endocrine therapy of" exact="tamoxifen" post="versus anastrozol plus ovarian function suppression in premenopausal early"/>
   <result pre="M , Zhao F et al. Phase III comparison of" exact="tamoxifen" post="versus tamoxifen plus ovarian function suppression in premenopausal women"/>
   <result pre="Zhao F et al. Phase III comparison of tamoxifen versus" exact="tamoxifen" post="plus ovarian function suppression in premenopausal women with node-negative,"/>
   <result pre="life (QoL) in the IBCSG SOFT trial: adjuvant treatment with" exact="tamoxifen" post="(T) alone versus T plus ovarian function suppression (OFS)"/>
   <result pre="in the IBCSG TEXT and SOFT trials: adjuvant treatment with" exact="exemestane" post="(E) plus ovarian function suppression (OFS) versus tamoxifen (T)"/>
   <result pre="treatment with exemestane (E) plus ovarian function suppression (OFS) versus" exact="tamoxifen" post="(T) plus OFS in premenopausal women with hormone receptor-positive"/>
   <result pre="Cirrincione CT , Berry DA et al. Six cycles of" exact="doxorubicin" post="and cyclophosphamide or paclitaxel are not superior to four"/>
   <result pre=", Berry DA et al. Six cycles of doxorubicin and" exact="cyclophosphamide" post="or paclitaxel are not superior to four cycles as"/>
   <result pre="DA et al. Six cycles of doxorubicin and cyclophosphamide or" exact="paclitaxel" post="are not superior to four cycles as adjuvant chemotherapy"/>
   <result pre="SM , Barry WT , Dang CT et al. Adjuvant" exact="paclitaxel" post="and trastuzumab for node-negative, HER2-positive breast cancer. N Engl"/>
   <result pre="Barry WT , Dang CT et al. Adjuvant paclitaxel and" exact="trastuzumab" post="for node-negative, HER2-positive breast cancer. N Engl J Med"/>
   <result pre="D , Eiermann W , Robert N et al. Adjuvant" exact="trastuzumab" post="in HER2-positive breast cancer. N Engl J Med 2011;"/>
   <result pre=", Godwin J et al. Long-term effects of continuing adjuvant" exact="tamoxifen" post="to 10 years versus stopping at 5 years after"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4519046/results/search/inn/results.xml">
   <result pre="and (e) αv-H2-. Knockdown clones were maintained in 0.5 μg/ml" exact="puromycin" post="(Life Technologies, Eugene OR). SKBR3 and HCC1954, two non-transformed"/>
   <result pre="nude rats (rnu/rnu, 200–250g) were anesthetized with intraperitonial injection of" exact="ketamine" post="(60 mg/kg) and diazepam (7.5 mg/kg). Buprenorphine (0.1 mg/kg)"/>
   <result pre="were anesthetized with intraperitonial injection of ketamine (60 mg/kg) and" exact="diazepam" post="(7.5 mg/kg). Buprenorphine (0.1 mg/kg) was applied subcutaneously for"/>
   <result pre="prevalence of HER2 in brain metastases, anti-HER2 agents such as" exact="lapatinib" post="and trastuzumab have not yet found a role in"/>
   <result pre="HER2 in brain metastases, anti-HER2 agents such as lapatinib and" exact="trastuzumab" post="have not yet found a role in prevention or"/>
   <result pre="correlate with the patient’s response to HER2-targeted drugs (such as" exact="trastuzumab" post="or Trastuzumab-emtansine immunoconjugate) that requires binding the HER2 receptors"/>
   <result pre="support of this hypothesis, targeting αvβ6 integrin in combination with" exact="trastuzumab" post="was effective therapy even in trastuzumab-resistant tumor models ["/>
   <result pre="antibody to human alpha v integrins (intetumumab) in combination with" exact="docetaxel" post="and prednisone for the first-line treatment of patients with"/>
   <result pre="human alpha v integrins (intetumumab) in combination with docetaxel and" exact="prednisone" post="for the first-line treatment of patients with metastatic castration-resistant"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4524128/results/search/inn/results.xml">
   <result pre="ECOG Eastern Cooperative Oncology Group aOverlapped data bPaclitaxel in 1;" exact="paclitaxel" post="and trastuzumab in 1; methotrexate + 5-fluorouracil (5-FU) in 1; oxaliplatin + folinic"/>
   <result pre="Cooperative Oncology Group aOverlapped data bPaclitaxel in 1; paclitaxel and" exact="trastuzumab" post="in 1; methotrexate + 5-fluorouracil (5-FU) in 1; oxaliplatin + folinic acid + 5-FU in"/>
   <result pre="dose cisplatin + 5-FU in 1 cPaclitaxel in 2; methotrexate + 5-FU in 1;" exact="docetaxel" post="in 1; trastuzumab + lapatinib in 1 Concurrent chemotherapy was administered"/>
   <result pre="(33 %). The regimens were as follows: weekly paclitaxel, weekly" exact="paclitaxel" post="and trasutuzumab, methotrexate and 5-fluorouracil (5-FU), low-dose cisplatin and"/>
   <result pre="regimens were as follows: weekly paclitaxel, weekly paclitaxel and trasutuzumab," exact="methotrexate" post="and 5-fluorouracil (5-FU), low-dose cisplatin and 5-FU, and FOLFOX"/>
   <result pre="paclitaxel, weekly paclitaxel and trasutuzumab, methotrexate and 5-fluorouracil (5-FU), low-dose" exact="cisplatin" post="and 5-FU, and FOLFOX (oxaliplatin, folinic acid and 5-FU)."/>
   <result pre="Chemotherapy regimens after completion of RT were as follows: weekly" exact="paclitaxel" post="in two patients, methotrexate and 5-FU in one patient,"/>
   <result pre="of RT were as follows: weekly paclitaxel in two patients," exact="methotrexate" post="and 5-FU in one patient, trastuzumab and lapatinib in"/>
   <result pre="paclitaxel in two patients, methotrexate and 5-FU in one patient," exact="trastuzumab" post="and lapatinib in one patient, and docetaxel in one"/>
   <result pre="two patients, methotrexate and 5-FU in one patient, trastuzumab and" exact="lapatinib" post="in one patient, and docetaxel in one patient. Subsequent"/>
   <result pre="in one patient, trastuzumab and lapatinib in one patient, and" exact="docetaxel" post="in one patient. Subsequent chemotherapy was administrated to two"/>
   <result pre="P Sirzén F Noh SH collab: CLASSIC trial investigators Adjuvant" exact="capecitabine" post="and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC):"/>
   <result pre="F Noh SH collab: CLASSIC trial investigators Adjuvant capecitabine and" exact="oxaliplatin" post="for gastric cancer after D2 gastrectomy (CLASSIC): a phase"/>
   <result pre="10.1016/0049-3848(95)91519-Q 7495098 28. Born GV Aggregation of blood platelets by" exact="adenosine" post="diphosphate and its reversal Nature 1962 194 927 9"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4524286/results/search/inn/results.xml">
   <result pre="BT474 and HCC1954) in response to drug-treatment with HER2-inhibitors (lapatinib," exact="neratinib" post="or afatinib). Results Following 12 hours treatment with different"/>
   <result pre="the untreated cells, 16 proteins changed significantly in abundance following" exact="lapatinib" post="treatment (1 μM), 21 proteins changed significantly following neratinib"/>
   <result pre="following lapatinib treatment (1 μM), 21 proteins changed significantly following" exact="neratinib" post="treatment (150 nM) and 38 proteins changed significantly following"/>
   <result pre="neratinib treatment (150 nM) and 38 proteins changed significantly following" exact="afatinib" post="treatment (150 nM). Whereas following 24 hours treatment with"/>
   <result pre="afatinib treatment (150 nM). Whereas following 24 hours treatment with" exact="neratinib" post="(200 nM) 46 proteins changed significantly in abundance in"/>
   <result pre="accurately predicting drug sensitivity are urgently needed [ 3]. Lapatinib," exact="neratinib" post="and afatinib are tyrosine kinase inhibitors of HER2 and"/>
   <result pre="drug sensitivity are urgently needed [ 3]. Lapatinib, neratinib and" exact="afatinib" post="are tyrosine kinase inhibitors of HER2 and EGFR (epidermal"/>
   <result pre="HER2 [ 5] that has been approved in combination with" exact="capecitabine" post="for the treatment of refractory breast cancer [ 6]."/>
   <result pre="for the treatment of refractory breast cancer [ 6]. Although" exact="lapatinib" post="does not cross the blood–brain barrier, it can reach"/>
   <result pre="either as monotherapy or in combination [ 8, 9]. Both" exact="neratinib" post="and afatinib have the ability to penetrate the blood–brain"/>
   <result pre="monotherapy or in combination [ 8, 9]. Both neratinib and" exact="afatinib" post="have the ability to penetrate the blood–brain barrier and,"/>
   <result pre="as result of exposure to drug treatments such as lapatinib," exact="neratinib" post="and afatinib may provide novel drug targets for improved"/>
   <result pre="of exposure to drug treatments such as lapatinib, neratinib and" exact="afatinib" post="may provide novel drug targets for improved therapeutic action,"/>
   <result pre="a lack of studies investigating the proteomic profile of lapatinib," exact="neratinib" post="or afatinib response in breast cancer. To identify markers"/>
   <result pre="of studies investigating the proteomic profile of lapatinib, neratinib or" exact="afatinib" post="response in breast cancer. To identify markers which might"/>
   <result pre="tested routinely and were mycoplasma-free. Drug treatments were prepared in" exact="dimethyl sulfoxide" post="[(DMSO) Sigma-Aldrich, Germany] at a final concentration of 0.03"/>
   <result pre="final concentration of 0.03 % (v/v) and applied as follows" exact="lapatinib" post="1 μM (Sequoia Sciences, Saint Louis, MO, USA), 150"/>
   <result pre="1 μM (Sequoia Sciences, Saint Louis, MO, USA), 150 nM" exact="afatinib" post="(Sequoia Sciences, Saint Louis, MO, USA) and 150 nM"/>
   <result pre="Saint Louis, MO, USA) and 150 nM or 200 nM" exact="neratinib" post="(Sequoia Sciences, Saint Louis, MO, USA) for 12 or"/>
   <result pre="different concentrations employed for the three different drug treatments (afatinib," exact="neratinib" post="or lapatinib) were chosen to reflect published clinically relevant"/>
   <result pre="different in the BT474 cell line in response to afatinib," exact="neratinib" post="or lapatinib treatments and also in the breast cancer"/>
   <result pre="the BT474 cell line in response to afatinib, neratinib or" exact="lapatinib" post="treatments and also in the breast cancer cell lines"/>
   <result pre="breast cancer cell lines SKBR3 and HCC1954 in response to" exact="neratinib" post="treatments. Following analysis of the phenotypes using the software"/>
   <result pre="proteins differed in abundance respectively between the BT474 cell lines" exact="neratinib" post="or lapatinib-treated compared to untreated cells (Tables 2 and"/>
   <result pre="cells (Tables 2 and 3). In the comparison with the" exact="neratinib" post="treated cell lines 18 proteins demonstrated an increased abundance"/>
   <result pre="Of the 16 proteins identified in the comparison with the" exact="lapatinib" post="treated cell lines 11 proteins demonstrated an increased abundance"/>
   <result pre="different in the BT474 cell line in response to afatinib," exact="neratinib" post="or lapatinib treatments. The diagrams shows that 33, ten"/>
   <result pre="the BT474 cell line in response to afatinib, neratinib or" exact="lapatinib" post="treatments. The diagrams shows that 33, ten and eight"/>
   <result pre="that 33, ten and eight proteins identified respectively in afatinib," exact="neratinib" post="or lapatinib treated cell line were unique in each"/>
   <result pre="ten and eight proteins identified respectively in afatinib, neratinib or" exact="lapatinib" post="treated cell line were unique in each comparison. Two"/>
   <result pre="three comparisons, three and six were in common respectively between" exact="afatinib" post="and neratinib and between neratinib and lapatinib-treated cells. There"/>
   <result pre="three and six were in common respectively between afatinib and" exact="neratinib" post="and between neratinib and lapatinib-treated cells. There were no"/>
   <result pre="were in common respectively between afatinib and neratinib and between" exact="neratinib" post="and lapatinib-treated cells. There were no proteins common between"/>
   <result pre="neratinib and lapatinib-treated cells. There were no proteins common between" exact="afatinib" post="and lapatinib-treated cells. Table 1 38 proteins identified as"/>
   <result pre="Table 1 38 proteins identified as differentially expressed between the" exact="afatinib" post="treated BT474 cell line and the control following label-free"/>
   <result pre="16 proteins were up regulated in the cells treated with" exact="afatinib" post="(Table 1a) and 22 proteins were up regulated in"/>
   <result pre="Table 2 21 proteins identified as differentially expressed between the" exact="neratinib" post="treated BT474 cell line and the control following label-free"/>
   <result pre="Table 3 16 proteins identified as differentially expressed between the" exact="lapatinib" post="treated BT474 cell line and the control following label-free"/>
   <result pre="11 proteins were up regulated in the cells treated with" exact="lapatinib" post="(Table 3a) and five proteins were up regulated in"/>
   <result pre="of identified proteins with altered levels in response to afatinib," exact="lapatinib" post="or neratinib treatment compared to control in BT474 cell"/>
   <result pre="proteins with altered levels in response to afatinib, lapatinib or" exact="neratinib" post="treatment compared to control in BT474 cell line. The"/>
   <result pre="Table 4 23 proteins identified as differentially expressed between the" exact="neratinib" post="treated SKBR3 cell line and the control following label-free"/>
   <result pre="17 proteins were up regulated in the cells treated with" exact="neratinib" post="(Table 4a) and six proteins were up regulated in"/>
   <result pre="Table 5 46 proteins identified as differentially expressed between the" exact="neratinib" post="treated HCC1954 cell line and the control following label-free"/>
   <result pre="22 proteins were up regulated in the cells treated with" exact="neratinib" post="(Table 5a) and 24 proteins were up regulated in"/>
   <result pre="different cell lines (BT474, HCC1954 or SKBR3) in response to" exact="neratinib" post="treatments. The diagrams shows that 18, 42 and 18"/>
   <result pre="HCC1954, between HCC1954 and SKBR3 and between BT474 and SKBR3" exact="neratinib" post="treated cell lines. Fig. 2 Venn diagrams showing the"/>
   <result pre="number of identified proteins with altered levels in response to" exact="neratinib" post="treatment compared to control in BT474, SKBR3 and HCC1954"/>
   <result pre="comparisons between SKBR3 and HCC1954 cell lines both treated with" exact="neratinib" post="105 proteins demonstrated an increased abundance and 123 a"/>
   <result pre="the identified proteins with altered levels in response to afatinib," exact="lapatinib" post="or neratinib treatment compared to control in BT474 cell"/>
   <result pre="proteins with altered levels in response to afatinib, lapatinib or" exact="neratinib" post="treatment compared to control in BT474 cell line and"/>
   <result pre="compared to control in BT474 cell line and also in" exact="neratinib" post="treatment compared to control in HCC1954 and SKBR3 cell"/>
   <result pre="cell line, phosphoglycerate kinase 1 was down-regulated in response to" exact="afatinib" post="in BT474 cell line and in response to neratinib"/>
   <result pre="to afatinib in BT474 cell line and in response to" exact="neratinib" post="in HCC1954 cell line, but was up-regulated in response"/>
   <result pre="in HCC1954 cell line, but was up-regulated in response to" exact="neratinib" post="in SKBR3 cell line. Ubiquitin-like modifier-activating enzyme 1 and"/>
   <result pre="Q showed both an opposite abundance pattern in response to" exact="afatinib" post="in BT474 cell line and in response to neratinib"/>
   <result pre="to afatinib in BT474 cell line and in response to" exact="neratinib" post="in HCC1954 cell line. Details are presented in Table"/>
   <result pre="the identified proteins with altered levels in response to afatinib," exact="lapatinib" post="or neratinib treatment compared to control in BT474 cell"/>
   <result pre="proteins with altered levels in response to afatinib, lapatinib or" exact="neratinib" post="treatment compared to control in BT474 cell line and"/>
   <result pre="treatment compared to control in BT474 cell line and in" exact="neratinib" post="treatment compared to control in HCC1954 and SKBR3 cell"/>
   <result pre="HCC1954 and SKBR3 cell lines Protein Biological process a) BT474" exact="afatinib" post="vs untreated BT474 neratinib vs untreated BT474 lapatinib vs"/>
   <result pre="lines Protein Biological process a) BT474 afatinib vs untreated BT474" exact="neratinib" post="vs untreated BT474 lapatinib vs untreated SKBR3 neratinib vs"/>
   <result pre="a) BT474 afatinib vs untreated BT474 neratinib vs untreated BT474" exact="lapatinib" post="vs untreated SKBR3 neratinib vs untreated HCC1954 neratinib vs"/>
   <result pre="untreated BT474 neratinib vs untreated BT474 lapatinib vs untreated SKBR3" exact="neratinib" post="vs untreated HCC1954 neratinib vs untreated Trifunctional enzyme subunit"/>
   <result pre="untreated BT474 lapatinib vs untreated SKBR3 neratinib vs untreated HCC1954" exact="neratinib" post="vs untreated Trifunctional enzyme subunit alpha, mitochondrial fatty acid"/>
   <result pre="the proteomic response of three HER2-targeting tyrosine kinase inhibitors (lapatinib," exact="neratinib" post="and afatinib) in the overexpressing HER2 BT474 cell line."/>
   <result pre="breast cancer cell lines, we characterised the proteomic response to" exact="neratinib" post="treatment in two other overexpressing HER2 cell lines (HCC1954"/>
   <result pre="different cell lines) that had altered abundance in response to" exact="neratinib" post="treatment, namely, trifunctional enzyme subunit alpha, mitochondrial; lamina-associated polypeptide"/>
   <result pre="is involved in stress response was down-regulated in response to" exact="neratinib" post="treatment. These proteins were in common between BT474 and"/>
   <result pre="current study, we also investigated the protein response to lapatinib," exact="neratinib" post="or afatinib, emerging HER2-inhibitor in BT474 cell lines. Interestingly,"/>
   <result pre="were altered in abundance in two drugs treatments (afatinib and" exact="neratinib" post="or neratinib and lapatinib). All these proteins were up-regulated"/>
   <result pre="in abundance in two drugs treatments (afatinib and neratinib or" exact="neratinib" post="and lapatinib). All these proteins were up-regulated in response"/>
   <result pre="and myristoylated alanine-rich C-kinase substrate were down-regulated in response to" exact="neratinib" post="and lapatinib treatment, both proteins are involved in cell"/>
   <result pre="alanine-rich C-kinase substrate were down-regulated in response to neratinib and" exact="lapatinib" post="treatment, both proteins are involved in cell mobility. Interestingly,"/>
   <result pre="proteins showed a significant change in abundance in response to" exact="lapatinib" post="in SKBR3 cell line. Of these, inverted formin-2 was"/>
   <result pre="in our study in the BT474 cell line treated with" exact="lapatinib" post="and was down-regulated in response to drug treatments in"/>
   <result pre="and histone H3.1 were respectively identified as well in the" exact="neratinib" post="and afatinib treatment in BT474 cell line with a"/>
   <result pre="H3.1 were respectively identified as well in the neratinib and" exact="afatinib" post="treatment in BT474 cell line with a different abundance"/>
   <result pre="shock cognate 71 kDa (HSC70) protein was identified in the" exact="neratinib" post="treatment of the SKBR3 and HCC1954 cell lines and"/>
   <result pre="was altered in abundance in all three drugs treatments (lapatinib," exact="neratinib" post="or afatinib) in BT474 and in SKBR3 cell line"/>
   <result pre="is known that the use of HER2-targeted monoclonal antibodies like" exact="trastuzumab" post="increase the incidence of cardiac dysfunction. A significant reduction"/>
   <result pre="was firstly observed with the use of HER2-targeted small-molecule inhibitors" exact="lapatinib" post="and then further decreased incidences evident with the use"/>
   <result pre="and then further decreased incidences evident with the use of" exact="neratinib" post="and afatinib second-generation tyrosine kinase inhibitors [ 30]. The"/>
   <result pre="further decreased incidences evident with the use of neratinib and" exact="afatinib" post="second-generation tyrosine kinase inhibitors [ 30]. The higher abundance"/>
   <result pre="34] investigating proteins that are associated with the resistance to" exact="paclitaxel" post="in human breast cancer cells, an overexpression of hnRNP"/>
   <result pre="increased in abundance in one or more drugs treatments (lapatinib," exact="neratinib" post="or afatinib) in BT474 cell line. In particular the"/>
   <result pre="in two cell lines (BT474 and HCC1954) in response to" exact="neratinib" post="and in response to lapatinib in BT474 cell line."/>
   <result pre="and HCC1954) in response to neratinib and in response to" exact="lapatinib" post="in BT474 cell line. LAP2α is one of six"/>
   <result pre="abundance in the cell lines (SKBR3 and HCC1954) treated with" exact="neratinib" post="compared to the control. It is known that that"/>
   <result pre="treatment options. Similar data were also obtained in response to" exact="lapatinib" post="in SKBR3 cell line in a previous study from"/>
   <result pre="HER2-inhibitors drug treatments in HER2-overexpressing breast cancer cell lines, lapatinib," exact="neratinib" post="or afatinib in BT474 and in response to neratinib"/>
   <result pre="treatments in HER2-overexpressing breast cancer cell lines, lapatinib, neratinib or" exact="afatinib" post="in BT474 and in response to neratinib treatment in"/>
   <result pre="lapatinib, neratinib or afatinib in BT474 and in response to" exact="neratinib" post="treatment in two other cell lines (HCC1954 and SKBR3)."/>
   <result pre="al. Phase I safety, pharmacokinetics, and clinical activity study of" exact="lapatinib" post="(GW572016), a reversible dual inhibitor of epidermal growth factor"/>
   <result pre="Oliva C Newstat B Imwalle B Geyer CE Lapatinib plus" exact="capecitabine" post="in women with HER-2–positive advanced breast cancer: Final Survival"/>
   <result pre="X Munster PN New protein kinase inhibitors in breast cancer:" exact="afatinib" post="and neratinib Expert Opin Pharmacother 2014 15 9 1277"/>
   <result pre="PN New protein kinase inhibitors in breast cancer: afatinib and" exact="neratinib" post="Expert Opin Pharmacother 2014 15 9 1277 1288 10.1517/14656566.2014.913570"/>
   <result pre="BA Leister C Burns J Sonnichsen D Pharmacokinetics of oral" exact="neratinib" post="during co-administration of ketoconazole in healthy subjects Br J"/>
   <result pre="J Sonnichsen D Pharmacokinetics of oral neratinib during co-administration of" exact="ketoconazole" post="in healthy subjects Br J Clin Pharmacol 2011 71"/>
   <result pre="T Nakamura Y et al. Phase I study of continuous" exact="afatinib" post="(BIBW 2992) in patients with advanced non-small cell lung"/>
   <result pre="Straubinger RM et al. Determination of the proteomic response to" exact="lapatinib" post="treatment using a comprehensive and reproducible ion-current-based proteomics strategy"/>
   <result pre="of the proteins that are associated with the resistance to" exact="paclitaxel" post="in human breast cancer cells Mol BioSyst 2014 10"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4525792/results/search/inn/results.xml">
   <result pre="Potential Cardiac Toxicities Anthracyclines Anthracyclines such as doxorubicin, daunorubicin, and" exact="idarubicin" post="are used in the treatment of sarcomas, lymphomas, and"/>
   <result pre="of cardiotoxicity is thought to relate to the interaction between" exact="doxorubicin" post="and topoisomerase II, present on cardiac myocytes, resulting in"/>
   <result pre="may explain the mechanism of cardiotoxicity. 17 The use of" exact="trastuzumab" post="can result in the development of LVD, 18 with"/>
   <result pre="1–3 months. 19 The separation in timing of anthracycline and" exact="trastuzumab" post="administration can minimize toxicity. 3, 21 More recently, the"/>
   <result pre="for HER2-positive tumors has grown to include the combination of" exact="trastuzumab" post="with other agents such as lapatinib and pertuzumab with"/>
   <result pre="include the combination of trastuzumab with other agents such as" exact="lapatinib" post="and pertuzumab with the hopes of increasing efficacy in"/>
   <result pre="combination of trastuzumab with other agents such as lapatinib and" exact="pertuzumab" post="with the hopes of increasing efficacy in the setting"/>
   <result pre="evaluation should be individualized. 27 Microtubule-targeting agents Taxanes such as" exact="paclitaxel" post="and docetaxel are used in the treatment of advanced"/>
   <result pre="be individualized. 27 Microtubule-targeting agents Taxanes such as paclitaxel and" exact="docetaxel" post="are used in the treatment of advanced breast and"/>
   <result pre="early LVD and HF, 28 with a 5%–15% incidence with" exact="paclitaxel" post="and a 2.3%–8% reported incidence with docetaxel. 6 Interestingly,"/>
   <result pre="these agents have been shown to potentiate the cardiotoxicity of" exact="doxorubicin" post="through an increase in plasma levels and conversion to"/>
   <result pre="the treatment of multiple myeloma and non-Hodgkin’s lymphoma, 30 while" exact="carfilzomib" post="is used in the treatment of refractory or relapsing"/>
   <result pre="of smooth muscle cells, endothelial progenitor cells, and impaired endothelial" exact="nitric oxide" post="synthase activity, leading to coronary vasospasm. The incidence of"/>
   <result pre="kinase inhibitors Tyrosine kinase inhibitors such as sunitinib, imatinib, and" exact="lapatinib" post="affect cellular signal transduction, disrupting regulation of the cell"/>
   <result pre="the cell cycle, metabolism, transcription, and apoptosis. 36 Sunitinib and" exact="sorafenib" post="are nonselective agents that inhibit the VEGF pathway with"/>
   <result pre="patients. 7 In contrast to trastuzumab, another inhibitor or ErbB2," exact="lapatinib" post="is less car-diotoxic. 38 Because hypertension is a common"/>
   <result pre="the potential for cardiac toxicity with anthracyclines, platinum-based chemotherapy, and" exact="trastuzumab" post="however they do not provide specific guidelines for the"/>
   <result pre="Specific recommendations for withholding and resuming therapy with anthracyclines and" exact="trastuzumab" post="are outlined by the Food and Drug Administration agency."/>
   <result pre="al. Topoisomerase IIbeta mediated DNA double- strand breaks: implications in" exact="doxorubicin" post="cardiotoxicity and prevention by dexrazoxane Cancer Res 2007 67"/>
   <result pre="double- strand breaks: implications in doxorubicin cardiotoxicity and prevention by" exact="dexrazoxane" post="Cancer Res 2007 67 8839 46 17875725 9 Gottdiener"/>
   <result pre="prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and" exact="trastuzumab" post="Circ Cardiovasc Imaging 2012 5 596 603 22744937 13"/>
   <result pre="Multi-center randomized phase III study of the cardioprotective effect of" exact="dexrazoxane" post="(Cardioxane) in advanced/metastatic breast cancer patients treated with anthra-cycline-based"/>
   <result pre="Bosch X Rovira M Sitges M et al. Enalapril and" exact="carvedilol" post="for preventing chemotherapy-induced left ventricular systolic dysfunction in patients"/>
   <result pre="hemopathies: the OVERCOME trial (preventiOn of left ventricular dysfunction with" exact="enalapril" post="and carvedilol in patients submitted to intensive chemotherapy for"/>
   <result pre="OVERCOME trial (preventiOn of left ventricular dysfunction with enalapril and" exact="carvedilol" post="in patients submitted to intensive chemotherapy for the treatment"/>
   <result pre="Hudis C Pierri MK et al. Cardiac dysfunction in the" exact="trastuzumab" post="clinical trials experience J Clin Oncol 2002 20 1215"/>
   <result pre="heart failure risk in patients with breast cancer treated with" exact="bevacizumab" post="J Clin Oncol 2011 29 632 8 21205755 26"/>
   <result pre="Schulman P Bockorny B Bona R Severe heart failure after" exact="bortezomib" post="treatment in a patient with multiple myeloma: a case"/>
   <result pre="Ferrans VJ Deisseroth A Ziegler J Cardiotoxicity associated with high-dose" exact="cyclophosphamide" post="therapy Arch Intern Med 1981 141 758 63 7235784"/>
   <result pre="M Zielinski CC Vogl UM et al. Cardiac toxicity of" exact="sunitinib" post="and sorafenib in patients with metastatic renal cell carcinoma"/>
   <result pre="CC Vogl UM et al. Cardiac toxicity of sunitinib and" exact="sorafenib" post="in patients with metastatic renal cell carcinoma J Clin"/>
   <result pre="Yacobi R et al. Cardiotoxicity of the cancer therapeutic agent" exact="imatinib" post="mesylate Nat Med 2006 12 908 16 16862153 43"/>
   <result pre="2014 15 1063 93 52 FDA Drug Label for DOXIL-" exact="doxorubicin" post="hydrochloride injection, suspension, liposomal Available at: http://dailymed.nlm.nih.gov.ezproxy.hsclib.sunysb.edu/dailymed/drugInfo.cfm?setid=21d9c619-7e94-49e2-ac41-31e9ea96554a%3E 53 FDA"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4529453/results/search/inn/results.xml">
   <result pre="economic outcomes of alternative HER2 test strategies for guiding adjuvant" exact="trastuzumab" post="therapy Expert Rev Pharmacoecon Outcomes Res 2011 11 3"/>
   <result pre="N Jönsson B Rehnberg C Cost-effectiveness of HER2 testing and" exact="trastuzumab" post="therapy for metastatic breast cancer Acta Oncol 2008 47"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4533098/results/search/inn/results.xml">
   <result pre="molecule kinase inhibitors like lapatinib, and antibody-drug conjugate such as" exact="trastuzumab" post="emtansine have been developed. However, the therapeutic potential of"/>
   <result pre="properties compared to HER2 antibodies. It does not compete with" exact="trastuzumab" post="14 or pertuzumab 15 because the binding site of"/>
   <result pre="HER2 antibodies. It does not compete with trastuzumab 14 or" exact="pertuzumab" post="15 because the binding site of ZHER2 as shown"/>
   <result pre="structure of HER2/ZHER2 complex is different from the epitopes for" exact="trastuzumab" post="and pertuzumab determined previously 16- 18. ZHER2 does not"/>
   <result pre="HER2/ZHER2 complex is different from the epitopes for trastuzumab and" exact="pertuzumab" post="determined previously 16- 18. ZHER2 does not appear to"/>
   <result pre="Afterwards, the MTT solution was removed and 200 µL of" exact="dimethyl sulfoxide" post="(DMSO) was added to each well. The optical density"/>
   <result pre="between the key residues and HER2 remained. The numbers of" exact="glycine" post="residue needed to link the gaps between key residues"/>
   <result pre="between 3Å and 4Å which can be linked by one" exact="glycine" post="residue. The only exception is that Leu18 is 9.94"/>
   <result pre="Leu18 is 9.94 Å away from Asn24, and therefore three" exact="glycine" post="residues were required. Based on these calculations, a 32-mer"/>
   <result pre="buffer saline ICC immunocytochemistry PE phycoerythrin MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide DMSO" exact="dimethyl sulfoxide" post="OD optical density s.c. subcutaneously NIR Near-infrared. References 1"/>
   <result pre="on the wild-type and double mutant HIV-1 protease complexed with" exact="amprenavir" post="and two amprenavir-related inhibitors: mechanism for binding and drug"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4534500/results/search/inn/results.xml">
   <result pre="drugs have emerged. Various targeted therapies like erlotinib, trastuzumab, and" exact="cetuximab" post="have been approved in lung, breast, and colon cancers,"/>
   <result pre="together in most trials given their rarity. Combination chemotherapy involving" exact="cisplatin" post="and gemcitabine is the current standard of care in"/>
   <result pre="most trials given their rarity. Combination chemotherapy involving cisplatin and" exact="gemcitabine" post="is the current standard of care in the metastatic"/>
   <result pre="supported in a clinical trial comparing combination of 5-fluorouracil and" exact="etoposide" post="vs. best supportive care. The median OS in the"/>
   <result pre="clinical trial, demonstrated improvement in 6-month progression-free survival (PFS) favoring" exact="cisplatin" post="and gemcitabine compared to gemcitabine alone (8.0 vs. 4.0"/>
   <result pre="demonstrated improvement in 6-month progression-free survival (PFS) favoring cisplatin and" exact="gemcitabine" post="compared to gemcitabine alone (8.0 vs. 4.0 months) ["/>
   <result pre="6-month progression-free survival (PFS) favoring cisplatin and gemcitabine compared to" exact="gemcitabine" post="alone (8.0 vs. 4.0 months) [ 28]. ABC-02, a"/>
   <result pre="trial, showed an improvement in OS, with combination therapy of" exact="cisplatin" post="and gemcitabine (11.7 months) compared to gemcitabine alone (8.1"/>
   <result pre="an improvement in OS, with combination therapy of cisplatin and" exact="gemcitabine" post="(11.7 months) compared to gemcitabine alone (8.1 months) (hazard"/>
   <result pre="combination therapy of cisplatin and gemcitabine (11.7 months) compared to" exact="gemcitabine" post="alone (8.1 months) (hazard ratio (HR) 0.64, 95 %"/>
   <result pre="ABC-02 trial, in which 84 patients were randomized to either" exact="gemcitabine" post="alone or to the combination of cisplatin and gemcitabine"/>
   <result pre="randomized to either gemcitabine alone or to the combination of" exact="cisplatin" post="and gemcitabine [ 29]. A subsequent meta-analysis concluded that"/>
   <result pre="either gemcitabine alone or to the combination of cisplatin and" exact="gemcitabine" post="[ 29]. A subsequent meta-analysis concluded that BTC patients"/>
   <result pre="29]. A subsequent meta-analysis concluded that BTC patients treated with" exact="gemcitabine" post="combined with platinum agents (cisplatin or oxaliplatin) have better"/>
   <result pre="HER2 inhibitors tested in BTC cell lines in combination with" exact="gemcitabine" post="have shown promising activity [ 31], and they are"/>
   <result pre="Phase Arms NCT number Cetuximab EGFR antibody II Gemcitabine +" exact="oxaliplatin" post="with or without cetuximab NCT01267344 Afatinib EGFR inhibitor I"/>
   <result pre="Cetuximab EGFR antibody II Gemcitabine + oxaliplatin with or without" exact="cetuximab" post="NCT01267344 Afatinib EGFR inhibitor I Cisplatin + gemcitabine +"/>
   <result pre="or without cetuximab NCT01267344 Afatinib EGFR inhibitor I Cisplatin +" exact="gemcitabine" post="+ afatinib (single arm) NCT01679405 Cediranib VEGF inhibitor II"/>
   <result pre="cetuximab NCT01267344 Afatinib EGFR inhibitor I Cisplatin + gemcitabine +" exact="afatinib" post="(single arm) NCT01679405 Cediranib VEGF inhibitor II FOLFOX with"/>
   <result pre="Regorafenib (single arm) NCT02053376 Regorafenib Multikinase inhibitor I/II Gemcitabine +" exact="oxaliplatin" post="+ regorafenib (single arm) NCT02386397 Regorafenib Multikinase inhibitor II"/>
   <result pre="arm) NCT02053376 Regorafenib Multikinase inhibitor I/II Gemcitabine + oxaliplatin +" exact="regorafenib" post="(single arm) NCT02386397 Regorafenib Multikinase inhibitor II Regorafenib (single"/>
   <result pre="Pazopanib (single arm) NCT01855724 Pazopanib Multikinase inhibitor II Pazopanib +" exact="gemcitabine" post="(single arm) NCT01855724 Trametinib MEK inhibitor II Trametinib vs."/>
   <result pre="Trametinib (single arm) NCT01943864 Selumitinib MEK inhibitor II Cisplatin +" exact="gemcitabine" post="with or without selumitinib NCT02151084 Binimetinib MEK inhibitor I/II"/>
   <result pre="or without selumitinib NCT02151084 Binimetinib MEK inhibitor I/II Cisplatin +" exact="gemcitabine" post="+ binimetinib (single arm) NCT01828034 Vismodegib Hh pathway inhibitor"/>
   <result pre="41]. Several phase II trials have investigated the role of" exact="erlotinib" post="in the management of advanced BTC. Philip et al."/>
   <result pre="the small sample size [ 42]. Lubner et al. investigated" exact="erlotinib" post="in combination with bevacizumab, a vascular endothelial growth factor"/>
   <result pre="Lee et al. assessed the efficacy of the addition of" exact="erlotinib" post="to gemcitabine and oxaliplatin as first-line therapy for metastatic"/>
   <result pre="al. assessed the efficacy of the addition of erlotinib to" exact="gemcitabine" post="and oxaliplatin as first-line therapy for metastatic BTC. Two"/>
   <result pre="the efficacy of the addition of erlotinib to gemcitabine and" exact="oxaliplatin" post="as first-line therapy for metastatic BTC. Two hundred sixty-eight"/>
   <result pre="Korean patients were assigned in a 1:1 ratio to receive" exact="gemcitabine" post="and oxaliplatin with or without erlotinib. Median PFS was"/>
   <result pre="were assigned in a 1:1 ratio to receive gemcitabine and" exact="oxaliplatin" post="with or without erlotinib. Median PFS was 5.8 months"/>
   <result pre="erlotinib. Median PFS was 5.8 months in the chemotherapy plus" exact="erlotinib" post="group and 4.2 months in the chemotherapy alone group"/>
   <result pre="combination for patients with advanced BTC. However, the addition of" exact="erlotinib" post="did not produce a significant improvement in median PFS."/>
   <result pre="BTC, who were randomized to receive gemcitabine/oxaliplatin with or without" exact="cetuximab" post="in the first-line setting. Median PFS was 6.1 months"/>
   <result pre="Median PFS was 6.1 months (95 % CI 5.1–7.6) with" exact="cetuximab" post="and 5.5 months (95 % CI 3.7–6.6) without cetuximab,"/>
   <result pre="median OS was 11.0 months (95 % CI 9.1–13.7) with" exact="cetuximab" post="and 12.4 months (95 % CI 8.6–16.0) without cetuximab."/>
   <result pre="8.6–16.0) without cetuximab. Despite being well tolerated, the addition of" exact="cetuximab" post="to gemcitabine and oxaliplatin did not improve outcomes when"/>
   <result pre="cetuximab. Despite being well tolerated, the addition of cetuximab to" exact="gemcitabine" post="and oxaliplatin did not improve outcomes when used as"/>
   <result pre="being well tolerated, the addition of cetuximab to gemcitabine and" exact="oxaliplatin" post="did not improve outcomes when used as first-line treatment"/>
   <result pre="with or without cetuximab. Median PFS was 6.7 months with" exact="cetuximab" post="and 4.1 months without cetuximab ( p = 0.05), while median"/>
   <result pre="PFS was 6.7 months with cetuximab and 4.1 months without" exact="cetuximab" post="( p = 0.05), while median OS was 10.6 months with"/>
   <result pre="cetuximab ( p = 0.05), while median OS was 10.6 months with" exact="cetuximab" post="and 9.8 months without cetuximab ( p = 0.91). KRAS mutations,"/>
   <result pre="OS was 10.6 months with cetuximab and 9.8 months without" exact="cetuximab" post="( p = 0.91). KRAS mutations, detected in 36 % of"/>
   <result pre="PFS [ 47•]. Cetuximab was also evaluated in combination with" exact="gemcitabine" post="and capecitabine in the first-line setting, but ORR was"/>
   <result pre="47•]. Cetuximab was also evaluated in combination with gemcitabine and" exact="capecitabine" post="in the first-line setting, but ORR was only 17.6"/>
   <result pre="in advanced BTC phase II trials. Hezel et al. evaluated" exact="gemcitabine" post="and oxaliplatin in combination with panitumumab in KRAS wild-type"/>
   <result pre="BTC phase II trials. Hezel et al. evaluated gemcitabine and" exact="oxaliplatin" post="in combination with panitumumab in KRAS wild-type metastatic BTC."/>
   <result pre="Hezel et al. evaluated gemcitabine and oxaliplatin in combination with" exact="panitumumab" post="in KRAS wild-type metastatic BTC. ORR was 45 %,"/>
   <result pre="KRAS wild-type metastatic or unresectable BTC were randomized to receive" exact="gemcitabine" post="and oxaliplatin with or without panitumumab. No statistical significance"/>
   <result pre="metastatic or unresectable BTC were randomized to receive gemcitabine and" exact="oxaliplatin" post="with or without panitumumab. No statistical significance for median"/>
   <result pre="trend toward improved ORR and PFS in the arm with" exact="panitumumab" post="[ 50]. Jensen et al. looked at the regimen"/>
   <result pre="Jensen et al. looked at the regimen gemcitabine, oxaliplatin, and" exact="capecitabine" post="in combination with panitumumab in KRAS wild-type advanced BTC."/>
   <result pre="at the regimen gemcitabine, oxaliplatin, and capecitabine in combination with" exact="panitumumab" post="in KRAS wild-type advanced BTC. ORR was 33 %"/>
   <result pre="Sohal et al. reported data involving yet a different regimen," exact="gemcitabine" post="and irinotecan in combination with panitumumab. A promising ORR"/>
   <result pre="al. reported data involving yet a different regimen, gemcitabine and" exact="irinotecan" post="in combination with panitumumab. A promising ORR of 69"/>
   <result pre="phase II trials had small sample sizes, the role of" exact="panitumumab" post="in biliary tract cancers remains to be defined. HER2"/>
   <result pre="disease. All five cholangiocarcinoma patients had disease progression while on" exact="trastuzumab" post="as part of its treatment [ 55]. Lapatinib Lapatinib"/>
   <result pre="colorectal, lung, breast, renal, and ovarian. In addition to the" exact="bevacizumab" post="plus erlotinib trial described by Lubner et al. ["/>
   <result pre="breast, renal, and ovarian. In addition to the bevacizumab plus" exact="erlotinib" post="trial described by Lubner et al. [ 43], bevacizumab’s"/>
   <result pre="agents. Zhu et al. enrolled 35 patients who were given" exact="bevacizumab" post="followed by gemcitabine and oxaliplatin. Median PFS was 7.0"/>
   <result pre="al. enrolled 35 patients who were given bevacizumab followed by" exact="gemcitabine" post="and oxaliplatin. Median PFS was 7.0 months. FDG-PET scans"/>
   <result pre="regimen and recently presented data looking at gemcitabine, capecitabine, and" exact="bevacizumab" post="in patients with advanced BTC in the first-line setting."/>
   <result pre="II study [ 58, 62]. Subjects were randomized to receive" exact="cisplatin" post="and gemcitabine plus either cediranib or placebo. No statistically"/>
   <result pre="[ 58, 62]. Subjects were randomized to receive cisplatin and" exact="gemcitabine" post="plus either cediranib or placebo. No statistically significant difference"/>
   <result pre="median OS was 4.4 months [ 66]. Another trial involving" exact="sorafenib" post="was terminated early given that it failed to meet"/>
   <result pre="OS was 9 months [ 67]. Other trials have evaluated" exact="sorafenib" post="in combination with standard chemotherapy. Moehler et al. investigated"/>
   <result pre="sorafenib in combination with standard chemotherapy. Moehler et al. investigated" exact="gemcitabine" post="with either sorafenib or placebo in the first-line setting."/>
   <result pre="with standard chemotherapy. Moehler et al. investigated gemcitabine with either" exact="sorafenib" post="or placebo in the first-line setting. However, longer median"/>
   <result pre="longer median PFS and OS were actually seen in the" exact="gemcitabine" post="plus placebo arm [ 68]. A randomized, double-blinded, multicenter"/>
   <result pre="trial by Krege et al. comparing a combination of gemcitabine," exact="cisplatin" post="with either sorafenib or placebo found no significant difference"/>
   <result pre="et al. comparing a combination of gemcitabine, cisplatin with either" exact="sorafenib" post="or placebo found no significant difference in PFS and"/>
   <result pre="[ 69]. Finally, Lee et al. compared cisplatin, gemcitabine, and" exact="sorafenib" post="to historical data and showed no improvement in efficacy,"/>
   <result pre="phase II study, Yi et al. investigated the role of" exact="sunitinib" post="as a second-line treatment in advanced BTC. Only marginal"/>
   <result pre="not received any prior chemotherapy were randomized into three groups:" exact="vandetanib" post="monotherapy (V), vandetanib plus gemcitabine (V/G), and gemcitabine plus"/>
   <result pre="prior chemotherapy were randomized into three groups: vandetanib monotherapy (V)," exact="vandetanib" post="plus gemcitabine (V/G), and gemcitabine plus placebo (G/P). Median"/>
   <result pre="were randomized into three groups: vandetanib monotherapy (V), vandetanib plus" exact="gemcitabine" post="(V/G), and gemcitabine plus placebo (G/P). Median PFS was"/>
   <result pre="three groups: vandetanib monotherapy (V), vandetanib plus gemcitabine (V/G), and" exact="gemcitabine" post="plus placebo (G/P). Median PFS was 105 days (95"/>
   <result pre="G/P, respectively. This study did not demonstrate any superiority of" exact="vandetanib" post="alone or in association with gemcitabine when compared with"/>
   <result pre="demonstrate any superiority of vandetanib alone or in association with" exact="gemcitabine" post="when compared with gemcitabine alone [ 73•]. MEK pathway"/>
   <result pre="vandetanib alone or in association with gemcitabine when compared with" exact="gemcitabine" post="alone [ 73•]. MEK pathway In addition to targeting"/>
   <result pre="7.7 months [ 84]. In a phase II Australian study," exact="everolimus" post="was administered in the first-line setting in advanced BTC."/>
   <result pre="molecule inhibitor of ribonucleotide reductase was tested in combination with" exact="gemcitabine" post="in BTC. ORR was seen in 3 of the"/>
   <result pre="9 10.1016/j.ejso.2005.02.021 15922889 23. Valle J et al. Cisplatin plus" exact="gemcitabine" post="versus gemcitabine for biliary tract cancer N Engl J"/>
   <result pre="15922889 23. Valle J et al. Cisplatin plus gemcitabine versus" exact="gemcitabine" post="for biliary tract cancer N Engl J Med 2010"/>
   <result pre="Valle JW et al. Gemcitabine alone or in combination with" exact="cisplatin" post="in patients with advanced or metastatic cholangiocarcinomas or other"/>
   <result pre="M, et al., A randomized study of gemcitabine/cisplatin versus single-agent" exact="gemcitabine" post="in patients with biliary cancer. J Clin Oncol, 2009."/>
   <result pre="27(15_suppl: abstr #4579). 30. Yang R et al. Efficacy of" exact="gemcitabine" post="plus platinum agents for biliary tract cancers: a meta-analysis"/>
   <result pre="et al. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of" exact="gemcitabine" post="in biliary tract and gallbladder carcinomas BMC Cancer 2010"/>
   <result pre="12654182 42. Philip PA et al. Phase II study of" exact="erlotinib" post="in patients with advanced biliary cancer J Clin Oncol"/>
   <result pre="a multicenter phase II trial testing a combination of biweekly" exact="bevacizumab" post="and daily erlotinib in patients with unresectable biliary cancer:"/>
   <result pre="II trial testing a combination of biweekly bevacizumab and daily" exact="erlotinib" post="in patients with unresectable biliary cancer: a phase II"/>
   <result pre="7 10.1200/JCO.2010.28.4075 20530271 44.•• Lee J et al. Gemcitabine and" exact="oxaliplatin" post="with or without erlotinib in advanced biliary-tract cancer: a"/>
   <result pre="Lee J et al. Gemcitabine and oxaliplatin with or without" exact="erlotinib" post="in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase"/>
   <result pre="10.1016/S1470-2045(11)70301-1 22192731 45. Gruenberger B et al. Cetuximab, gemcitabine, and" exact="oxaliplatin" post="in patients with unresectable advanced or metastatic biliary tract"/>
   <result pre="8 10.1016/S1470-2045(10)70247-3 21071270 46.• Malka D et al. Gemcitabine and" exact="oxaliplatin" post="with or without cetuximab in advanced biliary-tract cancer (BINGO):"/>
   <result pre="Malka D et al. Gemcitabine and oxaliplatin with or without" exact="cetuximab" post="in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative"/>
   <result pre="al. A KRAS mutation status-stratified randomized phase II trial of" exact="gemcitabine" post="and oxaliplatin alone or in combination with cetuximab in"/>
   <result pre="KRAS mutation status-stratified randomized phase II trial of gemcitabine and" exact="oxaliplatin" post="alone or in combination with cetuximab in advanced biliary"/>
   <result pre="trial of gemcitabine and oxaliplatin alone or in combination with" exact="cetuximab" post="in advanced biliary tract cancer Ann Oncol 2015 26"/>
   <result pre="943 9 10.1093/annonc/mdv035 25632066 48. Rubovszky G et al. Cetuximab," exact="gemcitabine" post="and capecitabine in patients with inoperable biliary tract cancer:"/>
   <result pre="10.1093/annonc/mdv035 25632066 48. Rubovszky G et al. Cetuximab, gemcitabine and" exact="capecitabine" post="in patients with inoperable biliary tract cancer: a phase"/>
   <result pre="49. Hezel AF et al. Phase II study of gemcitabine," exact="oxaliplatin" post="in combination with panitumumab in KRAS wild-type unresectable or"/>
   <result pre="al. Phase II study of gemcitabine, oxaliplatin in combination with" exact="panitumumab" post="in KRAS wild-type unresectable or metastatic biliary tract and"/>
   <result pre="et al. A phase II, open-label, randomized clinical trial of" exact="panitumumab" post="plus gemcitabine and oxaliplatin (GEMOX) versus GEMOX alone as"/>
   <result pre="A phase II, open-label, randomized clinical trial of panitumumab plus" exact="gemcitabine" post="and oxaliplatin (GEMOX) versus GEMOX alone as first-line treatment"/>
   <result pre="II, open-label, randomized clinical trial of panitumumab plus gemcitabine and" exact="oxaliplatin" post="(GEMOX) versus GEMOX alone as first-line treatment in advanced"/>
   <result pre="51. Jensen LH et al. Phase II marker-driven trial of" exact="panitumumab" post="and chemotherapy in KRAS wild-type biliary tract cancer Ann"/>
   <result pre="Sohal DP et al. A phase II trial of gemcitabine," exact="irinotecan" post="and panitumumab in advanced cholangiocarcinoma Ann Oncol 2013 24"/>
   <result pre="et al. A phase II trial of gemcitabine, irinotecan and" exact="panitumumab" post="in advanced cholangiocarcinoma Ann Oncol 2013 24 12 3061"/>
   <result pre="56. Ramanathan RK et al. A phase II study of" exact="lapatinib" post="in patients with advanced biliary tree and hepatocellular cancer"/>
   <result pre="AX et al. Efficacy and safety of gemcitabine, oxaliplatin, and" exact="bevacizumab" post="in advanced biliary-tract cancers and correlation of changes in"/>
   <result pre="54 10.1016/S1470-2045(09)70333-X 19932054 60. Iyer RV, et al. Gemcitabine (G)," exact="capecitabine" post="(C) and bevacizumab (BV) in patients with advanced biliary"/>
   <result pre="60. Iyer RV, et al. Gemcitabine (G), capecitabine (C) and" exact="bevacizumab" post="(BV) in patients with advanced biliary cancers (ABC): final"/>
   <result pre="AB et al. SWOG 0514: a phase II study of" exact="sorafenib" post="in patients with unresectable or metastatic gallbladder carcinoma and"/>
   <result pre="51 10.1007/s10637-011-9719-0 21748296 68. Moehler M et al. Gemcitabine plus" exact="sorafenib" post="versus gemcitabine alone in advanced biliary tract cancer: a"/>
   <result pre="21748296 68. Moehler M et al. Gemcitabine plus sorafenib versus" exact="gemcitabine" post="alone in advanced biliary tract cancer: a double-blind placebo-controlled"/>
   <result pre="et al. Prospective randomized double-blind multicentre phase II study comparing" exact="gemcitabine" post="and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin"/>
   <result pre="Prospective randomized double-blind multicentre phase II study comparing gemcitabine and" exact="cisplatin" post="plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo"/>
   <result pre="double-blind multicentre phase II study comparing gemcitabine and cisplatin plus" exact="sorafenib" post="chemotherapy with gemcitabine and cisplatin plus placebo in locally"/>
   <result pre="II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with" exact="gemcitabine" post="and cisplatin plus placebo in locally advanced and/or metastasized"/>
   <result pre="comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and" exact="cisplatin" post="plus placebo in locally advanced and/or metastasized urothelial cancer:"/>
   <result pre="70. Lee JK et al. A phase II study of" exact="gemcitabine" post="and cisplatin plus sorafenib in patients with advanced biliary"/>
   <result pre="JK et al. A phase II study of gemcitabine and" exact="cisplatin" post="plus sorafenib in patients with advanced biliary adenocarcinomas Br"/>
   <result pre="al. A phase II study of gemcitabine and cisplatin plus" exact="sorafenib" post="in patients with advanced biliary adenocarcinomas Br J Cancer"/>
   <result pre="23900219 71. Kim A Balis FM Widemann BC Sorafenib and" exact="sunitinib" post="Oncologist 2009 14 8 800 5 10.1634/theoncologist.2009-0088 19648603 72."/>
   <result pre="72. Yi JH et al. A phase II study of" exact="sunitinib" post="as a second-line treatment in advanced biliary tract carcinoma:"/>
   <result pre="A et al. A randomized, multicenter, phase II study of" exact="vandetanib" post="monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine"/>
   <result pre="A randomized, multicenter, phase II study of vandetanib monotherapy versus" exact="vandetanib" post="in combination with gemcitabine versus gemcitabine plus placebo in"/>
   <result pre="II study of vandetanib monotherapy versus vandetanib in combination with" exact="gemcitabine" post="versus gemcitabine plus placebo in subjects with advanced biliary"/>
   <result pre="of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus" exact="gemcitabine" post="plus placebo in subjects with advanced biliary tract cancer:"/>
   <result pre="78. Bekaii-Saab T et al. Multi-institutional phase II study of" exact="selumetinib" post="in patients with metastatic biliary cancers J Clin Oncol"/>
   <result pre="al. A phase I trial of binimetinib in combination with" exact="gemcitabine" post="(G) and cisplatin (C) patients (pts) with untreated advanced"/>
   <result pre="I trial of binimetinib in combination with gemcitabine (G) and" exact="cisplatin" post="(C) patients (pts) with untreated advanced biliary cancer (ABC)."/>
   <result pre="24827133 85. Yeung YH, et al. Phase II study of" exact="everolimus" post="monotherapy as first-line treatment in advanced biliary tract cancer:"/>
   <result pre="89. ClinicalTrials.gov (NCT01546519). A study of the Hedgehog pathway inhibitor" exact="vismodegib" post="in patients with advanced solid malignancies including hepatocellular carcinoma"/>
   <result pre="Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus" exact="gemcitabine" post="in patients with advanced biliary tract cancer Cancer Chemother"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4535951/results/search/inn/results.xml">
   <result pre="multiple druggable targets. For drug repurposing, an EGFR/HER2 dual inhibitor" exact="lapatinib" post="was effective in PDX BL0440 (progression-free survival or PFS"/>
   <result pre="blot, immunohistochemical staining, or immunofluorescence staining. Mice were sacrificed through" exact="pentobarbital" post="overdose (180 mg/kg) or pentobarbital overdose (60 mg/kg) followed"/>
   <result pre="staining. Mice were sacrificed through pentobarbital overdose (180 mg/kg) or" exact="pentobarbital" post="overdose (60 mg/kg) followed by cervical dislocation. Statistical analysis"/>
   <result pre="carboplatin; gem: gemcitabine; PTX: paclitaxel; cis: cisplatin; MVAC: Methotrexate, vinblastine," exact="doxorubicin" post="(Adriamycin) and cisplatin. Morphological fidelity between patient tumors and"/>
   <result pre="NSG mice bearing PDX BL0269 or BL0440 were treated with" exact="lapatinib" post="or vehicle control. Both BL0269 and BL0440 expressed high"/>
   <result pre="Both BL0269 and BL0440 expressed high levels of HER2. Yet," exact="lapatinib" post="was ineffective in BL0269 with a progression-free survival (PFS)"/>
   <result pre="in the control group ( Fig 6A ). In contrast," exact="lapatinib" post="was very effective (PFS of 25.4 days versus 18.4"/>
   <result pre="median progression-free survival (PFS) of 13 days, a HER2 inhibitor" exact="lapatinib" post="and a Src inhibitor ponatinib had little effect in"/>
   <result pre="13 days, a HER2 inhibitor lapatinib and a Src inhibitor" exact="ponatinib" post="had little effect in suppressing tumor growth with a"/>
   <result pre="0.16) and 18 (p = 0.11) days, respectively. In contrast," exact="lapatinib" post="was very effective in BL0440 that expressed both HER2"/>
   <result pre="were treated with PBS control, BGJ398, or a Raf inhibitor" exact="sorafenib" post="plus a PIK3CA inhibitor BEZ235 combination. Compared to the"/>
   <result pre="Compared to the BGJ398 group, treatment of BGJ398-resistant PDX with" exact="sorafenib" post="and BEZ235 significantly prolonged PFS from 12 days to"/>
   <result pre="The first six PDXs were tested for sensitivity to cisplatin," exact="gemcitabine" post="or combination of both drugs. Only BL0440 was sensitive"/>
   <result pre="or combination of both drugs. Only BL0440 was sensitive to" exact="cisplatin" post="while only BL0269 and BL0479 were resistant to gemcitabine."/>
   <result pre="only BL0269 and BL0479 were resistant to gemcitabine. Resistance to" exact="cisplatin" post="could be overcome by gemcitabine, leaving four of these"/>
   <result pre="H1047R mutation of PIK3CA. Similar to lapatinib, a Src inhibitor" exact="ponatinib" post="was also ineffective (PFS of 18 versus 13 days"/>
   <result pre="combination of a PI3K/mTOR inhibitor BEZ235 and a Raf inhibitor" exact="sorafenib" post="significantly prolonged PFS from 12 day in the control"/>
   <result pre="effective chemotherapy drugs. We determined the PDX sensitivity to cisplatin," exact="gemcitabine" post="and the combination of these two drugs. This combination"/>
   <result pre="screened (10–12 mice per treatment group), five were resistant to" exact="cisplatin" post="and two were resistant to gemcitabine ( Fig 6C"/>
   <result pre="five were resistant to cisplatin and two were resistant to" exact="gemcitabine" post="( Fig 6C ). Consistent with our previous findings"/>
   <result pre="). Consistent with our previous findings that platinum agent and" exact="gemcitabine" post="achieved additive to synergistic anti-tumor activity [ 30], PDXs"/>
   <result pre="a wide range of response rates, from approximately 30% with" exact="trastuzumab" post="in breast cancer with HER2/Neu overexpression and/or gene amplification"/>
   <result pre="with HER2/Neu overexpression and/or gene amplification [ 32], 60% with" exact="vemurafenib" post="in melanoma with a BRAF mutation [ 33, 34],"/>
   <result pre="drugs were still effective in these pre-treated PDXs, such as" exact="cisplatin" post="in BL0440 and gemcitabine in BL0515. In addition, even"/>
   <result pre="in these pre-treated PDXs, such as cisplatin in BL0440 and" exact="gemcitabine" post="in BL0515. In addition, even when therapies are initially"/>
   <result pre=", Moore M , et al. ( 2000) Gemcitabine and" exact="cisplatin" post="versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or"/>
   <result pre="( 2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and" exact="cisplatin" post="in advanced or metastatic bladder cancer: results of a"/>
   <result pre="Pan CX ( 2010) Analysis of the cytotoxic activity of" exact="carboplatin" post="and gemcitabine combination. Anticancer Res 30: 4573– 4578. 21115908"/>
   <result pre="( 2010) Analysis of the cytotoxic activity of carboplatin and" exact="gemcitabine" post="combination. Anticancer Res 30: 4573– 4578. 21115908 31 Kim"/>
   <result pre="L , et al. ( 2002) Efficacy and safety of" exact="trastuzumab" post="as a single agent in first-line treatment of HER2-overexpressing"/>
   <result pre="Larkin J , et al. ( 2011) Improved survival with" exact="vemurafenib" post="in melanoma with BRAF V600E mutation. N Engl J"/>
   <result pre="et al. ( 2003) Imatinib compared with interferon and low-dose" exact="cytarabine" post="for newly diagnosed chronic-phase chronic myeloid leukemia . N"/>
   <result pre=", LObo C , et al. ( 2010) Nilotinib versus" exact="imatinib" post="for newly diagnosed chronic myeloid leukemia. N Engl J"/>
   <result pre="et al. ( 2005) Acquired resistance of lung adenocarcinomas to" exact="gefitinib" post="or erlotinib is associated with a second mutation in"/>
   <result pre="( 2005) Acquired resistance of lung adenocarcinomas to gefitinib or" exact="erlotinib" post="is associated with a second mutation in the EGFR"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4538762/results/search/inn/results.xml">
   <result pre="(&amp;lt;10 %), aromatase inhibitors (12 %) and taxanes (28 %);" exact="tamoxifen" post="and first generation chemotherapeutic regimens (e.g., anthracycline-based regimens) were"/>
   <result pre="based on clinicopathological criteria namely detection of the estrogen receptor," exact="progesterone" post="receptor, over expression or amplification of the HER2 oncogene"/>
   <result pre="the international guidelines in the NEMLs. Tamoxifen, anthracylines, CMF (cyclophosphamide," exact="methotrexate" post="and fluorouracil), CAF (cyclophosphamide, doxorubicin and fluorouracil) and AC"/>
   <result pre="NEMLs. Tamoxifen, anthracylines, CMF (cyclophosphamide, methotrexate and fluorouracil), CAF (cyclophosphamide," exact="doxorubicin" post="and fluorouracil) and AC (doxorubicin and cyclophosphamide) were well"/>
   <result pre="chemotherapeutic and hormonal therapy regimens in NEMLs (n = 75). CMF: cyclophosphamide," exact="methotrexate" post="and fluorouracil; CAF: cyclophosphamide, doxorubicin (adriamycin), fluorouracil, AC: doxorubicin"/>
   <result pre="in NEMLs (n = 75). CMF: cyclophosphamide, methotrexate and fluorouracil; CAF: cyclophosphamide," exact="doxorubicin" post="(adriamycin), fluorouracil, AC: doxorubicin and cyclophosphamide; EC: epirubicine and"/>
   <result pre="cyclophosphamide, methotrexate and fluorouracil; CAF: cyclophosphamide, doxorubicin (adriamycin), fluorouracil, AC:" exact="doxorubicin" post="and cyclophosphamide; EC: epirubicine and cyclophosphamide; CEF: cyclophosphamide, epirubicine"/>
   <result pre="EC: epirubicine and cyclophosphamide; CEF: cyclophosphamide, epirubicine and fluorouracil; DCa:" exact="docetaxel" post="and carboplatin; DC: docetaxel and cyclophosphamide; AIs: Aromatase Inhibitors"/>
   <result pre="CEF: cyclophosphamide, epirubicine and fluorouracil; DCa: docetaxel and carboplatin; DC:" exact="docetaxel" post="and cyclophosphamide; AIs: Aromatase Inhibitors A more detailed overview"/>
   <result pre="is illustrated in Additional file 1: Annex 3. Cyclophosphamide, methotrexate," exact="fluorouracil" post="and tamoxifen were found in over 75 % of"/>
   <result pre="in Additional file 1: Annex 3. Cyclophosphamide, methotrexate, fluorouracil and" exact="tamoxifen" post="were found in over 75 % of the NEMLs,"/>
   <result pre="were found in over 75 % of the NEMLs, and" exact="doxorubicin" post="and vinblastine in over 50 %. Of the HER2-targeted"/>
   <result pre="and vinblastine in over 50 %. Of the HER2-targeted therapies," exact="lapatinib" post="was completely absent and trastuzumab was selected in less"/>
   <result pre="%. Of the HER2-targeted therapies, lapatinib was completely absent and" exact="trastuzumab" post="was selected in less than 10 % of the"/>
   <result pre="countries (&amp;gt;70 %). Endocrine therapy was also well represented with" exact="tamoxifen" post="being included in 75 % of the NEMLs, whereas"/>
   <result pre="LMICs [ 39]. Due attention to the rational use of" exact="trastuzumab" post="will remain a concern even when inclusion in the"/>
   <result pre="to confirm these findings. Conclusion First generation chemotherapeutic agents and" exact="tamoxifen" post="were selected as essential medicines for breast cancer treatment"/>
   <result pre="N Pienkowski T Martin M Press M et al. Adjuvant" exact="trastuzumab" post="in HER2-positive breast cancer N Engl J Med 2011"/>
   <result pre="K Brent S Dyker A et al. The use of" exact="paclitaxel" post="in the management of early stage breast cancer Health"/>
   <result pre="Available at: http://erc.msh.org/dmpguide/index.cfm?search_cat=yes&amp;amp;display=yes&amp;amp;module=dmp. Accessed 1/12, 2014. 33. Jahanzeb M Adjuvant" exact="trastuzumab" post="therapy for HER2-positive breast cancer Clin Breast Cancer 2008"/>
   <result pre="34. Parkinson B Pearson SA Viney R Economic evaluations of" exact="trastuzumab" post="in HER2-positive metastatic breast cancer: a systematic review and"/>
   <result pre="Calleja-Hernandez MA Study of compliance with prescription information sheet of" exact="trastuzumab" post="prescriptions in a tertiary level hospital Farm Hosp 2012"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4538915/results/search/inn/results.xml">
   <result pre="specific therapies include expression of the estrogen receptor (ER) and" exact="progesterone" post="receptor (PR), which identify patients who benefit from adjuvant"/>
   <result pre="used alone or in addition to chemotherapy. In 1982, adjuvant" exact="tamoxifen" post="given for 2 years was shown to reduce the"/>
   <result pre="Aromatase inhibitors were subsequently shown to be more effective than" exact="tamoxifen" post="in postmenopausal women [ 34, 35]. In addition, extended"/>
   <result pre="be more effective than 5 years of therapy, including sequential" exact="tamoxifen" post="followed by an aromatase inhibitor [ 36], or tamoxifen"/>
   <result pre="sequential tamoxifen followed by an aromatase inhibitor [ 36], or" exact="tamoxifen" post="for up to 10 years [ 37]. Finally, in"/>
   <result pre="an aromatase inhibitor was shown to be more effective than" exact="tamoxifen" post="[ 38, 39]. Approximately 25 % of all breast"/>
   <result pre="several randomized trials demonstrated that addition of the anti-HER2 antibody" exact="trastuzumab" post="to adjuvant chemotherapy, either concurrently or sequentially, substantially decreased"/>
   <result pre="or high-risk node-negative breast cancer [ 40– 43]. Addition of" exact="trastuzumab" post="to sequential anthracycline/cyclophosphamide-taxane was associated with about a 3"/>
   <result pre="of cardiac toxicity [ 40– 42], while the combination of" exact="trastuzumab" post="with non-anthracycline regimens (e.g. carboplatin/docetaxel) was associated with lower"/>
   <result pre="have been expected to have higher recurrence rates without adjuvant" exact="trastuzumab" post="[ 44, 45]. Subsequent studies demonstrated that 1 year"/>
   <result pre="[ 44, 45]. Subsequent studies demonstrated that 1 year of" exact="trastuzumab" post="was more effective than 6 months [ 46], but"/>
   <result pre="[ 47]. The addition of the HER2 tyrosine kinase inhibitor" exact="lapatinib" post="did not improve outcomes when added to trastuzumab ["/>
   <result pre="kinase inhibitor lapatinib did not improve outcomes when added to" exact="trastuzumab" post="[ 48]. Adjuvant chemotherapy: first, second, and third generation"/>
   <result pre="generation regimen FECx4-Dx3, FECx4-weekly Tx8 Concurrent DAC Dose-dense ACx4-Tx4 ACx4-weekly" exact="paclitaxel" post="ACx4-docetaxel (q 3 weeks) *Adopted from Adjuvant online with"/>
   <result pre="51] CMF, Cyclophosphamide, methotrexate, 5-flourouracil; AC, Doxorubicin, cyclophosphamide; FEC50, 5-flourouracil," exact="epirubicin" post="(50 mg/m 2), cyclophosphamide; FEC100, 5-flourouracil, epirubicin (100 mg/m"/>
   <result pre="cyclophosphamide; FEC50, 5-flourouracil, epirubicin (50 mg/m 2), cyclophosphamide; FEC100, 5-flourouracil," exact="epirubicin" post="(100 mg/m 2), cyclophosphamide; DC, Docetaxel, cyclophosphamide; CAF, Cyclophosphamide,"/>
   <result pre="P = 0.03) CMF, Cyclophosphamide, methotrexate, 5-flourouracil; AC, Doxorubicin, cyclophosphamide; FEC50, 5-flourouracil," exact="epirubicin" post="(50 mg/m 2), cyclophosphamide; FEC100, 5-flourouracil, epirubicin (100 mg/m"/>
   <result pre="cyclophosphamide; FEC50, 5-flourouracil, epirubicin (50 mg/m 2), cyclophosphamide; FEC100, 5-flourouracil," exact="epirubicin" post="(100 mg/m 2), cyclophosphamide; DC, Docetaxel, cyclophosphamide; CAF, Cyclophosphamide,"/>
   <result pre="risk of this toxicity [ 56]. Epirubicin, an epimer of" exact="doxorubicin" post="differing in the orientation of the C4 hydroxyl group"/>
   <result pre="group on the sugar, is a less cardiotoxic anthracycline than" exact="doxorubicin" post="[ 57, 58]. Taxanes Paclitaxel was originally isolated from"/>
   <result pre="due to its scarcity and poor solubility. A formulation of" exact="paclitaxel" post="solubilized in Cremophor EL was eventually developed but was"/>
   <result pre="of acute hypersensitivity reactions and cumulative fluid retention associated with" exact="docetaxel" post="infusions [ 66]. A direct comparison of docetaxel with"/>
   <result pre="associated with docetaxel infusions [ 66]. A direct comparison of" exact="docetaxel" post="with paclitaxel in metastatic breast cancer showed greater efficacy"/>
   <result pre="docetaxel infusions [ 66]. A direct comparison of docetaxel with" exact="paclitaxel" post="in metastatic breast cancer showed greater efficacy for docetaxel"/>
   <result pre="with paclitaxel in metastatic breast cancer showed greater efficacy for" exact="docetaxel" post="but more toxicity [ 67], whereas a direct comparison"/>
   <result pre="but more toxicity [ 67], whereas a direct comparison of" exact="paclitaxel" post="with doxorubicin as first line therapy showed comparable efficacy"/>
   <result pre="toxicity [ 67], whereas a direct comparison of paclitaxel with" exact="doxorubicin" post="as first line therapy showed comparable efficacy [ 68]."/>
   <result pre="node positive patients after radical mastectomy to 12 cycles of" exact="cyclophosphamide" post="(100 mg/m 2 orally on days 1–14), methotrexate (40"/>
   <result pre="cycles of cyclophosphamide (100 mg/m 2 orally on days 1–14)," exact="methotrexate" post="(40 mg/m 2 IV on days 1 and 8),"/>
   <result pre="NSABP B-20 trial found that the addition of CMF to" exact="tamoxifen" post="improved 5-year DFS (HR, 0.65; P = 0.001) and OS (HR,"/>
   <result pre="of 4.7 % at 10 years [ 16]. Doxorubicin and" exact="cyclophosphamide" post="(AC) One of the first adjuvant trials evaluating doxorubicin"/>
   <result pre="and cyclophosphamide (AC) One of the first adjuvant trials evaluating" exact="doxorubicin" post="was NSABP B-11, which compared melphalan and 5-fluorouracil with"/>
   <result pre="first adjuvant trials evaluating doxorubicin was NSABP B-11, which compared" exact="melphalan" post="and 5-fluorouracil with or without doxorubicin in 697 non-tamoxifen"/>
   <result pre="NSABP B-11, which compared melphalan and 5-fluorouracil with or without" exact="doxorubicin" post="in 697 non-tamoxifen responsive patients (defined as women 50–59"/>
   <result pre="a trend to improved OS (HR, 0.74; P = 0.08) for the" exact="doxorubicin" post="arm [ 72]. In order to find a more"/>
   <result pre="with node-positive disease to AC (doxorubicin 60 mg/m 2 and" exact="cyclophosphamide" post="600 mg/m 2 every 3 weeks for four cycles)"/>
   <result pre="of AC, and superiority for AC compared with single agent" exact="paclitaxel" post="given every 2 or 3 weeks [ 75]. 5-Flourouracil,"/>
   <result pre="paclitaxel given every 2 or 3 weeks [ 75]. 5-Flourouracil," exact="epirubicin" post="(50 mg/m 2), and cyclophosphamide (FEC50) The French Adjuvant"/>
   <result pre="3 weeks [ 75]. 5-Flourouracil, epirubicin (50 mg/m 2), and" exact="cyclophosphamide" post="(FEC50) The French Adjuvant Study Group (FASG) compared epirubicin-based"/>
   <result pre="French Adjuvant Study Group (FASG) compared epirubicin-based chemoendocrine therapy with" exact="tamoxifen" post="alone in 457 postmenopausal women with ER-positive breast cancer"/>
   <result pre="76]. The chemotherapy regimen was FEC50 (5-fluorouracil 500 mg/m 2," exact="epirubicin" post="50 mg/m 2, cyclophosphamide 500 mg/m 2), which was"/>
   <result pre="was FEC50 (5-fluorouracil 500 mg/m 2, epirubicin 50 mg/m 2," exact="cyclophosphamide" post="500 mg/m 2), which was given every 3 weeks"/>
   <result pre="with tamoxifen. The 9-year DFS rates were 72 % with" exact="tamoxifen" post="and 84 % with FEC50-tamoxifen (HR, 0.46; P = 0.0008). The"/>
   <result pre="for OS (HR, 0.65; P = 0.07). Second generation chemotherapy regimens 5-Flourouracil," exact="epirubicin" post="(100 mg/m 2), and cyclophosphamide (FEC100) After randomized trials"/>
   <result pre="Second generation chemotherapy regimens 5-Flourouracil, epirubicin (100 mg/m 2), and" exact="cyclophosphamide" post="(FEC100) After randomized trials demonstrated a dose–response relationship for"/>
   <result pre="cyclophosphamide (FEC100) After randomized trials demonstrated a dose–response relationship for" exact="epirubicin" post="in metastatic breast cancer [ 58, 77], the FASG05"/>
   <result pre="metastatic breast cancer [ 58, 77], the FASG05 compared adjuvant" exact="fluorouracil" post="(500 mg/m 2) and cyclophosphamide (500 mg/m 2) with"/>
   <result pre="77], the FASG05 compared adjuvant fluorouracil (500 mg/m 2) and" exact="cyclophosphamide" post="(500 mg/m 2) with epirubicin given at 50 mg/m"/>
   <result pre="fluorouracil (500 mg/m 2) and cyclophosphamide (500 mg/m 2) with" exact="epirubicin" post="given at 50 mg/m 2 (FEC50) or 100 mg/m"/>
   <result pre="an acronym that is used to describe regimens in which" exact="cyclophosphamide" post="is administered orally for 14 days and doxorubicin and"/>
   <result pre="in which cyclophosphamide is administered orally for 14 days and" exact="doxorubicin" post="and 5-fluorouracil are given on days 1 and 8"/>
   <result pre="women with hormone-receptor positive, node-positive breast cancer to CAF plus" exact="tamoxifen" post="versus tamoxifen alone. DFS was superior for CAF plus"/>
   <result pre="hormone-receptor positive, node-positive breast cancer to CAF plus tamoxifen versus" exact="tamoxifen" post="alone. DFS was superior for CAF plus tamoxifen (HR,"/>
   <result pre="tamoxifen versus tamoxifen alone. DFS was superior for CAF plus" exact="tamoxifen" post="(HR, 0.76; P = 0.002), but OS was only marginally improved"/>
   <result pre="(risk ratio, 0.78; P = 0.0004) [ 16]. Sequential doxorubicin/cyclophosphamide followed by" exact="paclitaxel" post="(AC-T) Concurrent administration of paclitaxel and doxorubicin, two of"/>
   <result pre="16]. Sequential doxorubicin/cyclophosphamide followed by paclitaxel (AC-T) Concurrent administration of" exact="paclitaxel" post="and doxorubicin, two of the most active cytotoxic agents"/>
   <result pre="prohibitive cardiotoxicity due to a pharmacokinetic interaction resulting in greater" exact="doxorubicin" post="exposure [ 79]. In addition, mathematical modeling predicted that"/>
   <result pre="81]. Therefore, two phase 3 trials evaluated sequential administration of" exact="paclitaxel" post="after anthracycline-containing therapy (Table 3). CALGB 9344 employed a"/>
   <result pre="9344 employed a 2 × 2 factorial design evaluating escalating doses of" exact="doxorubicin" post="(60, 75, or 90 mg/m 2) in combination with"/>
   <result pre="doxorubicin (60, 75, or 90 mg/m 2) in combination with" exact="cyclophosphamide" post="(600 mg/m 2) every 21 days for four cycles,"/>
   <result pre="cycles, given alone, or followed sequentially by four cycles of" exact="paclitaxel" post="(175 mg/m 2 IV every 21 days) in 3,121"/>
   <result pre="After a median follow-up of 69 months, the addition of" exact="paclitaxel" post="was associated with improved DFS (HR, 0.83; P = 0.0023) and"/>
   <result pre="(HR, 0.83; P = 0.0023) and OS (HR, 0.82; P = 0.006). Escalation of" exact="doxorubicin" post="dose had no impact on outcomes [ 82]. In"/>
   <result pre="of 65 months, the sequential addition of four cycles of" exact="paclitaxel" post="(225 mg/m 2) to four cycles of AC in"/>
   <result pre="not OS (HR, 0.93; P = 0.46) [ 83]. Endocrine therapy with" exact="tamoxifen" post="was given after chemotherapy in the C9344 trial in"/>
   <result pre="from adjuvant chemotherapy in postmenopausal women with ER-positive disease when" exact="tamoxifen" post="is initiated sequentially following completion of chemotherapy [ 23]."/>
   <result pre="results of the C9344 study supported FDA approval of adjuvant" exact="paclitaxel" post="in the US. Sequential epirubicin followed by CMF The"/>
   <result pre="supported FDA approval of adjuvant paclitaxel in the US. Sequential" exact="epirubicin" post="followed by CMF The National Epirubicin Adjuvant Trial (NEAT)"/>
   <result pre="Adjuvant Trial (NEAT) and BR9601 trials evaluated the efficacy of" exact="epirubicin" post="followed by CMF. The BR9601 trial used a modified"/>
   <result pre="trial used a modified CMF regimen (cyclophosphamide 750 mg/m 2," exact="methotrexate" post="50 mg/m 2, and 5-flouorouracil 600 mg/m 2 on"/>
   <result pre="trial used classic CMF. Both trials compared four cycles of" exact="epirubicin" post="100 mg/m 2 every 3 weeks followed by four"/>
   <result pre="P &amp;lt;0.001) compared to CMF alone [ 84]. Docetaxel plus" exact="cyclophosphamide" post="The US Oncology Research phase III trial evaluated 1,016"/>
   <result pre="four 3-week cycles of AC (doxorubicin 60 mg/m 2 and" exact="cyclophosphamide" post="600 mg/m 2) or DC (docetaxel 75 mg/m 2"/>
   <result pre="600 mg/m 2) or DC (docetaxel 75 mg/m 2 and" exact="cyclophosphamide" post="600 mg/m 2) [ 85] (Table 3). After a"/>
   <result pre="(HR, 0.69; P = 0.032). Third generation chemotherapy regimens Docetaxel, doxorubicin, and" exact="cyclophosphamide" post="(DAC) Unlike paclitaxel, docetaxel does not have a major"/>
   <result pre="generation chemotherapy regimens Docetaxel, doxorubicin, and cyclophosphamide (DAC) Unlike paclitaxel," exact="docetaxel" post="does not have a major pharmacokinetic interaction with doxorubicin,"/>
   <result pre="88]. Two studies compared a combination of docetaxel, doxorubicin, and" exact="cyclophosphamide" post="(DAC) with FAC (Table 3). The Breast Cancer International"/>
   <result pre="0001 trial compared six cycles DAC (docetaxel 75 mg/m 2," exact="doxorubicin" post="50 mg/m 2, and cyclophosphamide 500 mg/m 2) with"/>
   <result pre="DAC (docetaxel 75 mg/m 2, doxorubicin 50 mg/m 2, and" exact="cyclophosphamide" post="500 mg/m 2) with FAC (5-fluorouracil 500 mg/m 2,"/>
   <result pre="cyclophosphamide 500 mg/m 2) with FAC (5-fluorouracil 500 mg/m 2," exact="doxorubicin" post="50 mg/m 2, and cyclophosphamide 500 mg/m 2) every"/>
   <result pre="FAC (5-fluorouracil 500 mg/m 2, doxorubicin 50 mg/m 2, and" exact="cyclophosphamide" post="500 mg/m 2) every 3 weeks as adjuvant treatment"/>
   <result pre="evaluated six 3-week cycles of FEC (5-fluorouracil 500 mg/m 2," exact="epirubicin" post="100 mg/m 2, and cyclophosphamide 500 mg/m 2) with"/>
   <result pre="FEC (5-fluorouracil 500 mg/m 2, epirubicin 100 mg/m 2, and" exact="cyclophosphamide" post="500 mg/m 2) with three cycles of FEC followed"/>
   <result pre="500 mg/m 2) with three cycles of FEC followed by" exact="docetaxel" post="(100 mg/m 2 every 3 weeks) for three cycles"/>
   <result pre="to four cycles of FEC followed by four cycles of" exact="docetaxel" post="(100 mg/m 2 every 3 weeks) versus a control"/>
   <result pre="choice of eight cycles of FEC (5-fluorouracil 600 mg/m 2," exact="epirubicin" post="60 mg/m 2, and cyclophosphamide 600 mg/m 2) or"/>
   <result pre="FEC (5-fluorouracil 600 mg/m 2, epirubicin 60 mg/m 2, and" exact="cyclophosphamide" post="600 mg/m 2) or epirubicin for four cycles followed"/>
   <result pre="epirubicin 60 mg/m 2, and cyclophosphamide 600 mg/m 2) or" exact="epirubicin" post="for four cycles followed by four cycles of CMF."/>
   <result pre="randomized to six cycles of FEC (5-fluorouracil 600 mg/m 2," exact="epirubicin" post="90 mg/m 2, and cyclophosphamide 600 mg/m 2) or"/>
   <result pre="FEC (5-fluorouracil 600 mg/m 2, epirubicin 90 mg/m 2, and" exact="cyclophosphamide" post="600 mg/m 2) or four cycles of FEC followed"/>
   <result pre="or four cycles of FEC followed by eight weekly doses" exact="paclitaxel" post="(100 mg/m 2 per week). After a median of"/>
   <result pre="per week). After a median of 66 months, the sequential" exact="paclitaxel" post="arm was associated with a reduced risk of recurrence"/>
   <result pre="3 weeks versus a dose-dense regimen every 2 weeks plus" exact="filgrastim" post="[ 97] (Table 3). At 36-month follow-up, the dose-dense"/>
   <result pre="chemotherapy arms than in the conventional chemotherapy arms. Sequential AC-weekly" exact="paclitaxel" post="or every 3 week docetaxel The ECOG E1199 trial"/>
   <result pre="conventional chemotherapy arms. Sequential AC-weekly paclitaxel or every 3 week" exact="docetaxel" post="The ECOG E1199 trial was designed to identify the"/>
   <result pre="analyses included a comparison of the standard every 3 week" exact="paclitaxel" post="arm (175 mg/m 2) for four cycles (P3 control"/>
   <result pre="mg/m 2) for four cycles (P3 control arm) with weekly" exact="paclitaxel" post="(80 mg/m 2) for 12 weeks (P1 arm), docetaxel"/>
   <result pre="weekly paclitaxel (80 mg/m 2) for 12 weeks (P1 arm)," exact="docetaxel" post="(100 mg/m 2) every 3 weeks for four cycles"/>
   <result pre="every 3 weeks for four cycles (D3 arm), or weekly" exact="docetaxel" post="(35 mg/m 2) for 12 weeks (D1 arm) ["/>
   <result pre="(HR, 0.79; P = 0.001 and HR, 0.86; P = 0.054, respectively). Although weekly" exact="paclitaxel" post="improved DFS and OS (HR, 0.69; P = 0.010 and HR,"/>
   <result pre="101]. Another trial found no difference in outcomes comparing weekly" exact="paclitaxel" post="(80 mg/m 2 for 12 doses) with biweekly paclitaxel"/>
   <result pre="weekly paclitaxel (80 mg/m 2 for 12 doses) with biweekly" exact="paclitaxel" post="given at a higher dose (175 mg/m 2 for"/>
   <result pre="AC, although there was more toxicity with biweekly higher dose" exact="paclitaxel" post="schedule [ 102]. Sequential versus concurrent taxane administration The"/>
   <result pre="administration The NSABP B30 trial addressed the question of whether" exact="docetaxel" post="is best given concurrently with or sequentially following doxorubicin"/>
   <result pre="whether docetaxel is best given concurrently with or sequentially following" exact="doxorubicin" post="[ 103]. The study included 5,351 patients with node-positive"/>
   <result pre="receive four cycles of AC followed by four cycles of" exact="docetaxel" post="(sequential AC-D), four cycles of doxorubicin and docetaxel (AD),"/>
   <result pre="by four cycles of docetaxel (sequential AC-D), four cycles of" exact="doxorubicin" post="and docetaxel (AD), or four cycles of doxorubicin, cyclophosphamide,"/>
   <result pre="cycles of docetaxel (sequential AC-D), four cycles of doxorubicin and" exact="docetaxel" post="(AD), or four cycles of doxorubicin, cyclophosphamide, and docetaxel"/>
   <result pre="and docetaxel (AD), or four cycles of doxorubicin, cyclophosphamide, and" exact="docetaxel" post="(concurrent DAC). After a median follow-up of 73 months,"/>
   <result pre="age, nodal status, tumor diameter or grade, ER expression, or" exact="tamoxifen" post="use, and breast cancer mortality was reduced on average"/>
   <result pre="if given. Patients with HER2-positive disease should also always receive" exact="trastuzumab" post="in combination with chemotherapy. Although data for adjuvant pertuzumab"/>
   <result pre="receive trastuzumab in combination with chemotherapy. Although data for adjuvant" exact="pertuzumab" post="is currently lacking, it is recommended by National Comprehensive"/>
   <result pre="hand, other expert panels do not recommend use of adjuvant" exact="pertuzumab" post="until results of the APHINITY trial (NCT01358877) become available"/>
   <result pre="[ 110], an adjuvant trial designed to determine whether adding" exact="pertuzumab" post="to adjuvant trastuzumab-chemotherapy regimen improves clinical outcomes. Table 4"/>
   <result pre="are incorporated into evidence-based guidelines [ 31] Endocrine therapy Adjuvant" exact="tamoxifen" post="reduces recurrence [ 32] and improve survival [ 12,"/>
   <result pre="and improve survival [ 12, 33] Five years of adjuvant" exact="tamoxifen" post="therapy more effective than shorter durations [ 13] The"/>
   <result pre="ER-positive tumors [ 15] Aromatase inhibitors are more effective than" exact="tamoxifen" post="in postmenopausal women [ 34, 35] Extended adjuvant therapy"/>
   <result pre="years more effective than 5 years of therapy, including sequential" exact="tamoxifen" post="followed by aromatase inhibitor [ 36], or tamoxifen for"/>
   <result pre="including sequential tamoxifen followed by aromatase inhibitor [ 36], or" exact="tamoxifen" post="for up to 10 years [ 37] Ovarian suppression"/>
   <result pre="an aromatase inhibitor was shown to be more effective than" exact="tamoxifen" post="in premenopausal women at high risk for recurrence ["/>
   <result pre="high risk for recurrence [ 38, 39] Anti-HER2 therapy Adjuvant" exact="trastuzumab" post="reduces the risk of recurrence when added to adjuvant"/>
   <result pre="or high-risk node-negative breast cancer [ 43] One year of" exact="trastuzumab" post="was more effective than 6 months [ 46], 2"/>
   <result pre="tyrosine kinase inhibitor did not improve outcomes when added to" exact="trastuzumab" post="[ 48] Abbreviations AC Doxorubicin and cyclophosphamide CAF Cyclophosphamide,"/>
   <result pre="when added to trastuzumab [ 48] Abbreviations AC Doxorubicin and" exact="cyclophosphamide" post="CAF Cyclophosphamide, doxorubicin, and 5-flourouracil CMF Cyclophosphamide, methotrexate, and"/>
   <result pre="5-flourouracil CMF Cyclophosphamide, methotrexate, and 5-fluorouracil DAC Docetaxel, doxorubicin, and" exact="cyclophosphamide" post="DC Docetaxel and cyclophosphamide DFS Disease-free survival EBCTCG Early"/>
   <result pre="and 5-fluorouracil DAC Docetaxel, doxorubicin, and cyclophosphamide DC Docetaxel and" exact="cyclophosphamide" post="DFS Disease-free survival EBCTCG Early Breast Cancer Trialists’ Collaborative"/>
   <result pre="United States Food and Drug Administration FEC50 5-Fluorouracil, epirubicin, and" exact="cyclophosphamide" post="HER2 Human epidermal growth factor receptor 2 HR Hazard"/>
   <result pre="American Pathologists guideline recommendations for immunohistochemical testing of estrogen and" exact="progesterone" post="receptors in breast cancer J Clin Oncol. 2010 28"/>
   <result pre="collab: Early Breast Cancer Trialists’ Collaborative Group Effects of adjuvant" exact="tamoxifen" post="and of cytotoxic therapy on mortality in early breast"/>
   <result pre="Cancer Intergroup of North America. Adjuvant chemotherapy and timing of" exact="tamoxifen" post="in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a"/>
   <result pre="Oncol 2007 25 5287 312 17954709 32. Controlled trial of" exact="tamoxifen" post="as adjuvant agent in management of early breast cancer,"/>
   <result pre="RD et al. Improved survival among patients treated with adjuvant" exact="tamoxifen" post="after mastectomy for early breast cancer Lancet. 1983 2"/>
   <result pre="AS Mouridsen H Mauriac L et al. A comparison of" exact="letrozole" post="and tamoxifen in postmenopausal women with early breast cancer"/>
   <result pre="H Mauriac L et al. A comparison of letrozole and" exact="tamoxifen" post="in postmenopausal women with early breast cancer N Engl"/>
   <result pre="Muss HB Piccart MJ et al. A randomized trial of" exact="letrozole" post="in postmenopausal women after five years of tamoxifen therapy"/>
   <result pre="trial of letrozole in postmenopausal women after five years of" exact="tamoxifen" post="therapy for early-stage breast cancer N Engl J Med."/>
   <result pre="Against Shorter (ATLAS) Collaborative Group. Long-term effects of continuing adjuvant" exact="tamoxifen" post="to 10 years versus stopping at 5 years after"/>
   <result pre="Láng I et al. International Breast Cancer Study Group. Adjuvant" exact="exemestane" post="with ovarian suppression in premenopausal breast cancer N Engl"/>
   <result pre="Kataja V Asola R et al. FinHer Study Investigators. Adjuvant" exact="docetaxel" post="or vinorelbine with or without trastuzumab for breast cancer"/>
   <result pre="Asola R et al. FinHer Study Investigators. Adjuvant docetaxel or" exact="vinorelbine" post="with or without trastuzumab for breast cancer N Engl"/>
   <result pre="FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without" exact="trastuzumab" post="for breast cancer N Engl J Med 2006 354"/>
   <result pre="Press M et al. Breast Cancer International Research Group. Adjuvant" exact="trastuzumab" post="in HER2-positive breast cancer N Engl J Med 2011"/>
   <result pre="CT Yardley DA Moy B Marcom PK et al. Adjuvant" exact="paclitaxel" post="and trastuzumab for node-negative, HER2-positive breast cancer N Engl"/>
   <result pre="DA Moy B Marcom PK et al. Adjuvant paclitaxel and" exact="trastuzumab" post="for node-negative, HER2-positive breast cancer N Engl J Med."/>
   <result pre="Sedlacek S Favret AM Gore I Jr et al. Adjuvant" exact="docetaxel" post="and cyclophosphamide plus trastuzumab in patients with HER2-amplified early"/>
   <result pre="Favret AM Gore I Jr et al. Adjuvant docetaxel and" exact="cyclophosphamide" post="plus trastuzumab in patients with HER2-amplified early stage breast"/>
   <result pre="Gore I Jr et al. Adjuvant docetaxel and cyclophosphamide plus" exact="trastuzumab" post="in patients with HER2-amplified early stage breast cancer: a"/>
   <result pre="PHARE trial investigators. 6 months versus 12 months of adjuvant" exact="trastuzumab" post="for patients with HER2-positive early breast cancer (PHARE): a"/>
   <result pre="Trial Study Team. 2 years versus 1 year of adjuvant" exact="trastuzumab" post="for HER2-positive breast cancer (HERA): an open-label, randomised controlled"/>
   <result pre="1978 1 35 9 373906 56. Sparano JA Use of" exact="dexrazoxane" post="and other strategies to prevent cardiomyopathy associated with doxorubicin-taxane"/>
   <result pre="Carter SK Howes AE Aston DA et al. Cardiotoxicity of" exact="epirubicin" post="and doxorubicin: assessment by endomyocardial biopsy Cancer Res. 1986"/>
   <result pre="et al. Phase III randomized study of fluorouracil, epirubicin, and" exact="cyclophosphamide" post="v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer:"/>
   <result pre="study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and" exact="cyclophosphamide" post="in advanced breast cancer: an Italian multicentre trial J"/>
   <result pre="Rocque GB Wilke LG Tevaarwerk AJ et al. Cytotoxicity of" exact="paclitaxel" post="in breast cancer is due to chromosome missegregation on"/>
   <result pre="I van Oosterom A et al. Coping with toxicities of" exact="docetaxel" post="(Taxotere) Ann Oncol. 1993 4 610 1 8103352 67."/>
   <result pre="L Lower E et al. Randomized phase III study of" exact="docetaxel" post="compared with paclitaxel in metastatic breast cancer J Clin"/>
   <result pre="et al. Randomized phase III study of docetaxel compared with" exact="paclitaxel" post="in metastatic breast cancer J Clin Oncol. 2005 23"/>
   <result pre="Phase III trial of doxorubicin, paclitaxel, and the combination of" exact="doxorubicin" post="and paclitaxel as front-line chemotherapy for metastatic breast cancer:"/>
   <result pre="trial of doxorubicin, paclitaxel, and the combination of doxorubicin and" exact="paclitaxel" post="as front-line chemotherapy for metastatic breast cancer: an intergroup"/>
   <result pre="reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and" exact="fluorouracil" post="in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results"/>
   <result pre="Becker HP Perez EA O'Regan R et al. Comparison of" exact="doxorubicin" post="and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for"/>
   <result pre="Perez EA O'Regan R et al. Comparison of doxorubicin and" exact="cyclophosphamide" post="versus single-agent paclitaxel as adjuvant therapy for breast cancer"/>
   <result pre="R et al. Comparison of doxorubicin and cyclophosphamide versus single-agent" exact="paclitaxel" post="as adjuvant therapy for breast cancer in women with"/>
   <result pre="Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with" exact="tamoxifen" post="alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast"/>
   <result pre="III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either" exact="doxorubicin" post="or epirubicin J Clin Oncol 1988 6 679 88"/>
   <result pre="comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or" exact="epirubicin" post="J Clin Oncol 1988 6 679 88 2895801 78."/>
   <result pre="78. collab: French Adjuvant Study Group Benefit of a high-dose" exact="epirubicin" post="regimen in adjuvant chemotherapy for node-positive breast cancer patients"/>
   <result pre="Fehrenbacher L Sedlacek SM Fisher B et al. Paclitaxel after" exact="doxorubicin" post="plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer:"/>
   <result pre="Sedlacek SM Fisher B et al. Paclitaxel after doxorubicin plus" exact="cyclophosphamide" post="as adjuvant chemotherapy for node-positive breast cancer: results from"/>
   <result pre="NEAT Investigators and the SCTBG. Epirubicin and cyclophosphamide, methotrexate, and" exact="fluorouracil" post="as adjuvant therapy for early breast cancer N Engl"/>
   <result pre="Blum JL Vukelja SJ McIntyre KJ et al. Docetaxel with" exact="cyclophosphamide" post="is associated with an overall survival benefit compared with"/>
   <result pre="cyclophosphamide is associated with an overall survival benefit compared with" exact="doxorubicin" post="and cyclophosphamide: 7-year follow-up of US Oncology Research Trial"/>
   <result pre="T et al. Phase II study of docetaxel, doxorubicin, and" exact="cyclophosphamide" post="as first-line chemotherapy for metastatic breast cancer J Clin"/>
   <result pre="Szanto J Martin M Chan S et al. Docetaxel and" exact="doxorubicin" post="compared with doxorubicin and cyclophosphamide as first-line chemotherapy for"/>
   <result pre="M Chan S et al. Docetaxel and doxorubicin compared with" exact="doxorubicin" post="and cyclophosphamide as first-line chemotherapy for metastatic breast cancer:"/>
   <result pre="S et al. Docetaxel and doxorubicin compared with doxorubicin and" exact="cyclophosphamide" post="as first-line chemotherapy for metastatic breast cancer: results of"/>
   <result pre="Schaefer PL Falkson CI Wood WC Phase II trial of" exact="doxorubicin" post="and docetaxel plus granulocyte colony-stimulating factor in metastatic breast"/>
   <result pre="Falkson CI Wood WC Phase II trial of doxorubicin and" exact="docetaxel" post="plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern"/>
   <result pre="et al. Breast Cancer International Research Group 001 Investigators. Adjuvant" exact="docetaxel" post="for node-positive breast cancer N Engl J Med 2005"/>
   <result pre="Ramos M Adrover E et al. GEICAM 9805 Investigators. Adjuvant" exact="docetaxel" post="for high-risk, node-negative breast cancer N Engl J Med"/>
   <result pre="Delozier T Serin D et al. Sequential adjuvant epirubicin-based and" exact="docetaxel" post="chemotherapy for node-positive breast cancer patients: the FNCLCC PACS"/>
   <result pre="al. UNICANCER Breast Group. Extended benefit from sequential administration of" exact="docetaxel" post="after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive"/>
   <result pre="from sequential administration of docetaxel after standard fluorouracil, epirubicin, and" exact="cyclophosphamide" post="regimen for node-positive breast cancer: the 8-year follow-up results"/>
   <result pre="S et al. TACT Trial Management Group; TACT Trialists. Sequential" exact="docetaxel" post="as adjuvant chemotherapy for early breast cancer (TACT): an"/>
   <result pre="Study Investigators. Randomized phase 3 trial of fluorouracil, epirubicin, and" exact="cyclophosphamide" post="alone or followed by Paclitaxel for early breast cancer"/>
   <result pre="S Jones V Perez EA Saphner T et al. Weekly" exact="paclitaxel" post="in the adjuvant treatment of breast cancer N Engl"/>
   <result pre="update of E1199: Phase III study of doxorubicin-cyclophosphamide followed by" exact="paclitaxel" post="or docetaxel given every 3 weeks or weekly in"/>
   <result pre="E1199: Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or" exact="docetaxel" post="given every 3 weeks or weekly in patients with"/>
   <result pre="J Semiglazov V Campone M et al. Pertuzumab, trastuzumab, and" exact="docetaxel" post="for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival"/>
   <result pre="Harvey V Eniu A Hegg R et al. Pertuzumab plus" exact="trastuzumab" post="in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy"/>
   <result pre="A et al. TRIO/BCIRG 001 investigators. Adjuvant docetaxel, doxorubicin, and" exact="cyclophosphamide" post="in node-positive breast cancer: 10-year follow-up of the phase"/>
   <result pre="A González S Calvo L et al. Fluorouracil, doxorubicin, and" exact="cyclophosphamide" post="(FAC) versus FAC followed by weekly paclitaxel as adjuvant"/>
   <result pre="Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly" exact="paclitaxel" post="as adjuvant therapy for high-risk, node-negative breast cancer: results"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4541732/results/search/inn/results.xml">
   <result pre="breast cancer, CTCs were also analyzed before and after first-line" exact="trastuzumab" post="therapy. Trastuzumab reduced the percentage of patients with full-length"/>
   <result pre="with early breast cancer [ 2]. The humanized monoclonal antibody" exact="trastuzumab" post="(Herceptin) was the first HER2-directed agent approved for clinical"/>
   <result pre="Moreover, many patients with metastatic disease do not respond to" exact="trastuzumab" post="therapy or develop refractory disease within 1 year of"/>
   <result pre="respectively. In addition, p95HER2 has been associated with resistance to" exact="trastuzumab" post="and with sensitivity to lapatinib [ 10]. Furthermore, it"/>
   <result pre="been associated with resistance to trastuzumab and with sensitivity to" exact="lapatinib" post="[ 10]. Furthermore, it was shown that trastuzumab was"/>
   <result pre="sensitivity to lapatinib [ 10]. Furthermore, it was shown that" exact="trastuzumab" post="was ineffective against in vivo tumor growth of T47D"/>
   <result pre="randomized phase II study showing that &quot;secondary adjuvant&quot; administration of" exact="trastuzumab" post="in HER2-negative patients with detectable HER2-positive CTCs after the"/>
   <result pre="lines were routinely checked every month for estrogen receptor (ER)," exact="progesterone" post="receptor (PR), HER2 and EGFR expression by immunofluorescence staining"/>
   <result pre="recommendations, slides were placed in xylene, absolute ethanol, 95 %" exact="ethanol" post="and water sequentially. After epitope retrieval, slides were stained"/>
   <result pre="%)   Unknown 4 (10.8 %) Abbreviations: ER estrogen receptor, PR" exact="progesterone" post="receptor, HER2 human epidermal growth factor receptor 2 HER2-positive"/>
   <result pre="+ + 0 0 2 Abbreviations: ER estrogen receptor, PR" exact="progesterone" post="receptor, HER2 human epidermal growth factor receptor 2, CTCs"/>
   <result pre="of metastatic breast cancer patients ( n = 14) after" exact="trastuzumab" post="administration. a Number of total CTCs per patient before"/>
   <result pre="of 14 patients before treatment and in four patients after" exact="trastuzumab" post="administration ( p = 0.035) (Fig. 4b). The p95HER2"/>
   <result pre="be detected in three and four patients before and after" exact="trastuzumab" post="administration, respectively (Fig. 4s). The percentage of CTCs that"/>
   <result pre="of p95HER2-positive CTCs per patient before and after treatment with" exact="trastuzumab" post="was 0 % and 22.92 %, respectively. In addition,"/>
   <result pre="attributed to a treatment-induced &quot;selection&quot; of the CK-positive/p95HER2-positive CTCs, since" exact="trastuzumab" post="is known to bind to the extracellular domain of"/>
   <result pre="CTCs, lacking the extracellular domain of the receptor, may &quot;escape&quot;" exact="trastuzumab" post="treatment. Finally, preliminary analysis of overall survival in metastatic"/>
   <result pre="of interest to investigate whether dual inhibition of HER2 with" exact="trastuzumab" post="and lapatinib is associated with a more effective eradication"/>
   <result pre="to investigate whether dual inhibition of HER2 with trastuzumab and" exact="lapatinib" post="is associated with a more effective eradication of both"/>
   <result pre="blood mononuclear cells PBS phosphate-buffered saline PFS progression-free survival PR" exact="progesterone" post="receptor RT-PCR reverse transcription polymerase chain reaction Galatea Kallergi"/>
   <result pre="Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of" exact="paclitaxel" post="and doxorubicin against HER2/neu overexpressing human breast cancer xenografts"/>
   <result pre="anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and" exact="doxorubicin" post="against HER2/neu overexpressing human breast cancer xenografts Cancer Res."/>
   <result pre="9. Gajria D Chandarlapaty S HER2-amplified breast cancer: mechanisms of" exact="trastuzumab" post="resistance and novel targeted therapies Expert Rev Anticancer Ther."/>
   <result pre="Yang W Li JF Sun SL Shou CC Effect of" exact="trastuzumab" post="on tumor cell lines shedding high or low level"/>
   <result pre="the absence of HER2 amplification: implications for efficacy of adjuvant" exact="trastuzumab" post="Cancer Res. 2013 73 1635 1646 10.1158/0008-5472.CAN-12-3349 23442322 28."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4542411/results/search/inn/results.xml">
   <result pre="to inhibit apoptosis in breast cancer cell lines treated with" exact="paclitaxel" post="through activation of the c-JUN N-terminal kinase pathway. 22"/>
   <result pre="Upregulation of MRP2 was reported to be involved in HIF-1α-mediated" exact="doxorubicin" post="efflux and resistance to doxorubicin in breast cancer cell"/>
   <result pre="to be involved in HIF-1α-mediated doxorubicin efflux and resistance to" exact="doxorubicin" post="in breast cancer cell lines. 53 Thus, hypoxia/HIF can"/>
   <result pre="vivo. 56 High levels of survivin expression also correlated with" exact="doxorubicin" post="resistance in a panel of organotypic human breast tumors."/>
   <result pre="inhibitor of glucose transporter GLUT1 and treatment with WZB117 and" exact="cisplatin" post="or paclitaxel can synergistically kill hypoxic lung cancer cells"/>
   <result pre="glucose transporter GLUT1 and treatment with WZB117 and cisplatin or" exact="paclitaxel" post="can synergistically kill hypoxic lung cancer cells in vitro"/>
   <result pre="a xenograft model. 59 Another GLUT1 inhibitor, phloretin, significantly enhances" exact="daunorubicin" post="effects by increasing daunorubicin-induced apoptosis under hypoxia and overcoming"/>
   <result pre="in the glycolytic pathway, the conversion of pyruvate and reduced" exact="nicotinamide" post="adenine dinucleotide to lactate and oxidized nicotinamide adenine dinucleotide,"/>
   <result pre="pyruvate and reduced nicotinamide adenine dinucleotide to lactate and oxidized" exact="nicotinamide" post="adenine dinucleotide, and has a critical role in tumor"/>
   <result pre="model. 62 Inhibition of LDHA by small molecule FX11 reduces" exact="adenosine" post="triphosphate (ATP) levels, induces oxidative stress and inhibits tumor"/>
   <result pre="progression in human lymphoma xenografts. 63 Importantly, combining FX11 with" exact="paclitaxel" post="promotes tumor regression in paclitaxel-resistant triple negative breast cancer"/>
   <result pre="is a well-known HIF target, the combination of FX11 and" exact="paclitaxel" post="may prove efficient against hypoxic tumors. PDH is responsible"/>
   <result pre="PDK3 upregulation significantly inhibited cell apoptosis and increased resistance to" exact="cisplatin" post="or paclitaxel in a cervical cancer cell line. 65"/>
   <result pre="significantly inhibited cell apoptosis and increased resistance to cisplatin or" exact="paclitaxel" post="in a cervical cancer cell line. 65 Knockdown of"/>
   <result pre="more pronounced under low oxygen concentration and the effect of" exact="bortezomib" post="specifically on hypoxic non-small cell lung tumors is currently"/>
   <result pre="colon carcinomas. 83 Inhibition of type I topoisomerase activity by" exact="topotecan" post="was also shown to downregulate HIF-1 expression in glioma"/>
   <result pre="glioma cells in vitro and in vivo. 84 More importantly," exact="topotecan" post="blocked HIF-1 synthesis in patients with advanced solid tumors"/>
   <result pre="patients with advanced solid tumors of different origin. 85 Currently," exact="topotecan" post="chemotherapy is used in the clinic for treatment of"/>
   <result pre="prodrugs are at various stages of clinical trial. The N-oxide" exact="tirapazamine" post="(TPZ) is the most studied hypoxia-activated prodrug. TPZ toxicity"/>
   <result pre="ERBB2-positive breast cancers. Activation of ERK signaling is required for" exact="lapatinib" post="resistance, as treatment with the MAPK/ERK kinase (MEK) inhibitor"/>
   <result pre="lapatinib resistance, as treatment with the MAPK/ERK kinase (MEK) inhibitor" exact="trametinib" post="reverses hypoxia-mediated lapatinib resistance. 121 Therefore, treatment of hypoxic"/>
   <result pre="treatment with the MAPK/ERK kinase (MEK) inhibitor trametinib reverses hypoxia-mediated" exact="lapatinib" post="resistance. 121 Therefore, treatment of hypoxic ERBB2-expressing breast tumors"/>
   <result pre="treatment of hypoxic ERBB2-expressing breast tumors with a combination of" exact="lapatinib" post="and MEK inhibitors may serve as a viable therapeutic"/>
   <result pre="of drugs that target VEGF or its receptor. Bevacizumab and" exact="ranibizumab" post="are two antibodies, targeting VEGF-A, used in antiangiogenic therapy."/>
   <result pre="et al. Survivin family proteins as novel molecular determinants of" exact="doxorubicin" post="resistance in organotypic human breast tumors Breast Cancer Res"/>
   <result pre="S et al. Glucose uptake inhibitor sensitizes cancer cells to" exact="daunorubicin" post="and overcomes drug resistance in hypoxia Cancer Chemother Pharmacol"/>
   <result pre="in combination with antiangiogenic therapy: a phase I trial of" exact="bortezomib" post="plus bevacizumab Oncotarget 2014 5 21 10280 10292 25373733"/>
   <result pre="with antiangiogenic therapy: a phase I trial of bortezomib plus" exact="bevacizumab" post="Oncotarget 2014 5 21 10280 10292 25373733 77 Kong"/>
   <result pre="Juwara L et al. Multihistology, target-driven pilot trial of oral" exact="topotecan" post="as an inhibitor of hypoxia-inducible factor-1α in advanced solid"/>
   <result pre="al. Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of" exact="sorafenib" post="and tanespimycin Clin Cancer Res 2010 16 14 3795"/>
   <result pre="breast cancer: a phase II trial of tanespimycin (17-AAG) plus" exact="trastuzumab" post="in patients with HER2-positive metastatic breast cancer progressing on"/>
   <result pre="trastuzumab in patients with HER2-positive metastatic breast cancer progressing on" exact="trastuzumab" post="Clin Cancer Res 2011 17 15 5132 5139 21558407"/>
   <result pre="LJ O’Sullivan B et al. Tirapazamine, cisplatin, and radiation versus" exact="cisplatin" post="and radiation for advanced squamous cell carcinoma of the"/>
   <result pre="Ramanathan RK et al. PR-104 a bioreductive pre-prodrug combined with" exact="gemcitabine" post="or docetaxel in a phase Ib study of patients"/>
   <result pre="et al. PR-104 a bioreductive pre-prodrug combined with gemcitabine or" exact="docetaxel" post="in a phase Ib study of patients with advanced"/>
   <result pre="791 808 9797688 121 Karakashev SV Reginato MJ Hypoxia/HIF1α induces" exact="lapatinib" post="resistance in ERBB2-positive breast cancer cells via regulation of"/>
   <result pre="et al, 90 Mode et al 91 Synthesis BEZ235, 2ME2," exact="topotecan" post="Karar et al, 81 Rapisarda et al, 84 Kummar"/>
   <result pre="et al, 82 Jeong et al 83 p300 interaction Chetomin," exact="bortezomib" post="Kung et al, 74 Shin et al, 75 Falchook"/>
   <result pre="97 DNA AQ4NE09 Williams et al 98 Angiogenesis VEGF-A Bevacizumab," exact="ranibizumab" post="Ellis and Hicklin 125 Abbreviations: 2ME2, 2-methoxyestradiol; mTOR, mammalian"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4546491/results/search/inn/results.xml">
   <result pre="12–16 65 3 ER/PR+ HR+ AC+T, post-mastectomy chest wall RT," exact="anastrozole" post="12–23 41 1 ER-PR-H2N- TNBC No chemotherapy because of"/>
   <result pre="ER+PR+H2N+ HR+ HER2+ AC × 6 cycles, TH, anastrozole, and" exact="zoledronic acid" post="12–37 41 6 ER-PR-H2N- TNBC 5-FU, epirubicin and cyclophosphamide"/>
   <result pre="anastrozole, and zoledronic acid 12–37 41 6 ER-PR-H2N- TNBC 5-FU," exact="epirubicin" post="and cyclophosphamide × 6 cycles, whole breast RT then"/>
   <result pre="zoledronic acid 12–37 41 6 ER-PR-H2N- TNBC 5-FU, epirubicin and" exact="cyclophosphamide" post="× 6 cycles, whole breast RT then MRM 2"/>
   <result pre="lung metastasis treated with surgery and docetaxel, then gemcitabine, then" exact="paclitaxel" post="(each drug for disease progression while on previous chemotherapy"/>
   <result pre="after lumpectomy Abbreviations: n/a: not available; ER: estrogen receptor; PR:" exact="progesterone" post="receptor; H2N: HER-2/neu; TNBC: triple negative breast cancer; AC:"/>
   <result pre="progesterone receptor; H2N: HER-2/neu; TNBC: triple negative breast cancer; AC:" exact="doxorubicin" post="and cyclophosphamide; AC+T: doxorubicin, cyclophosphamide, and docetaxel; 5-FU: fluorouracil;"/>
   <result pre="radiation therapy; ESRD: end-stage renal disease; DM: diabetes mellitus; TH:" exact="docetaxel" post="and trastuzumab (Herceptin); ACTH: doxorubicin and cyclophosphamide followed by"/>
   <result pre="ESRD: end-stage renal disease; DM: diabetes mellitus; TH: docetaxel and" exact="trastuzumab" post="(Herceptin); ACTH: doxorubicin and cyclophosphamide followed by paclitaxel and"/>
   <result pre="disease; DM: diabetes mellitus; TH: docetaxel and trastuzumab (Herceptin); ACTH:" exact="doxorubicin" post="and cyclophosphamide followed by paclitaxel and trastuzumab Re-occurring cancer"/>
   <result pre="diabetes mellitus; TH: docetaxel and trastuzumab (Herceptin); ACTH: doxorubicin and" exact="cyclophosphamide" post="followed by paclitaxel and trastuzumab Re-occurring cancer gene amplifications"/>
   <result pre="docetaxel and trastuzumab (Herceptin); ACTH: doxorubicin and cyclophosphamide followed by" exact="paclitaxel" post="and trastuzumab Re-occurring cancer gene amplifications in breast metastatic"/>
   <result pre="trastuzumab (Herceptin); ACTH: doxorubicin and cyclophosphamide followed by paclitaxel and" exact="trastuzumab" post="Re-occurring cancer gene amplifications in breast metastatic brain tumors"/>
   <result pre="CCND1 1 2.11 other daunorubicin, gemtuzumab DDR2 1 0.85 kinase" exact="regorafenib" post="ERBB2 2 1.83-2.54 kinase trastuzumab, lapatinib, erlotinib FGFR1 1"/>
   <result pre="1 0.85 kinase regorafenib ERBB2 2 1.83-2.54 kinase trastuzumab, lapatinib," exact="erlotinib" post="FGFR1 1 1.75 kinase sorafenib, dexamethasone JAK2 1 2.17"/>
   <result pre="1.83-2.54 kinase trastuzumab, lapatinib, erlotinib FGFR1 1 1.75 kinase sorafenib," exact="dexamethasone" post="JAK2 1 2.17 kinase ruxolitinib JAK3 1 0.81 kinase"/>
   <result pre="FGFR1 1 1.75 kinase sorafenib, dexamethasone JAK2 1 2.17 kinase" exact="ruxolitinib" post="JAK3 1 0.81 kinase tofacitinib, R-348 KDR 1 0.88"/>
   <result pre="1 0.81 kinase tofacitinib, R-348 KDR 1 0.88 kinase cabozantinib," exact="bevacizumab" post="KIT 2 0.86-0.88 transmembrane receptor dasatinib, sunitinib MUC1 2"/>
   <result pre="0.88 kinase cabozantinib, bevacizumab KIT 2 0.86-0.88 transmembrane receptor dasatinib," exact="sunitinib" post="MUC1 2 0.85-0.92 transcription regulator HuHMFG1 NTRK1 1 0.85"/>
   <result pre="MUC1 2 0.85-0.92 transcription regulator HuHMFG1 NTRK1 1 0.85 kinase" exact="regorafenib" post="PDGFRA 2 0.88-2.26 kinase sunitinib, pazopanib, imatinib PIK3CA 2"/>
   <result pre="1 0.85 kinase regorafenib PDGFRA 2 0.88-2.26 kinase sunitinib, pazopanib," exact="imatinib" post="PIK3CA 2 0.84-1.05 kinase SF1126, PX-866 RAF1 1 0.86"/>
   <result pre="2 0.84-1.05 kinase SF1126, PX-866 RAF1 1 0.86 kinase vemurafenib," exact="sorafenib" post="* Not a complete list. Comparing brain metastases with"/>
   <result pre="who contributed to this study – including ER, ERBB2/HER2 and" exact="progesterone" post="receptor (PR) status and treatments – is provided in"/>
   <result pre="3496 3502 12429640 8 Gluck S Castrellon A Lapatinib plus" exact="capecitabine" post="resolved human epidermal growth factor receptor 2-positive brain metastases"/>
   <result pre="Berger M Oliva C Rubin SD et al. Lapatinib plus" exact="capecitabine" post="for HER2-positive advanced breast cancer N Engl J Med"/>
   <result pre="A Blum JL et al. Multicenter phase II study of" exact="lapatinib" post="in patients with brain metastases from HER2-positive breast cancer"/>
   <result pre="and overall survival in HER2-positive advanced gastric cancer treated with" exact="trastuzumab" post="Journal of clinical oncology : official journal of the"/>
   <result pre="metastatic breast cancer patients who received chemotherapy with or without" exact="trastuzumab" post="Breast cancer 2014 37 Ithimakin S Day KC Malik"/>
   <result pre="the absence of HER2 amplification: implications for efficacy of adjuvant" exact="trastuzumab" post="Cancer research 2013 73 1635 1646 23442322 38 Salawu"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4548203/results/search/inn/results.xml">
   <result pre="as anti-angiogenic and pro-inflammatory, respectively. Examples of pro-angiogenic drugs are" exact="carvedilol" post="and urokinase. Examples of anti-inflammatory drugs are ACE inhibitors"/>
   <result pre="endothelial dysfunction in patients with PAD is characterized by impaired" exact="nitric oxide" post="signaling, excessive inflammation and diminished response to angiogenic factors"/>
   <result pre="NPR1, PF4, and SERPINE1. These drugs include mimosine targeting CCL2," exact="carvedilol" post="targeting NPPB, nitroprusside targeting NPR1, urokinase, reteplase, and drotrecogin"/>
   <result pre="SERPINE1. These drugs include mimosine targeting CCL2, carvedilol targeting NPPB," exact="nitroprusside" post="targeting NPR1, urokinase, reteplase, and drotrecogin alfa targeting SERPINE1."/>
   <result pre="urokinase, reteplase, and drotrecogin alfa targeting SERPINE1. The beta-blockers (e.g.," exact="carvedilol" post="in our prediction) in general have not been shown"/>
   <result pre="al., 2013). Infusion of recombinant-based plasminogen activator (e.g., reteplase) and" exact="urokinase" post="can clear blood clots and restore blood flow in"/>
   <result pre="PAD or CAD CCL2 Chemokine (C-C motif) ligand 2 Mimosine," exact="danazol" post="Potential indicator of atherosclerosis in PAD (Rull et al.,"/>
   <result pre="et al., 2013) NPR1 Natriuretic peptide receptor 1 Nitroprusside, nitroglycerin," exact="isosorbide dinitrate," post="amyl nitrite, erythrityl tetranitrate, nesiritide PF4 Platelet factor 4"/>
   <result pre="Natriuretic peptide receptor 1 Nitroprusside, nitroglycerin, isosorbide dinitrate, amyl nitrite," exact="erythrityl tetranitrate," post="nesiritide PF4 Platelet factor 4 Drotrecogin alfa PF4 level"/>
   <result pre="receptor 1 Nitroprusside, nitroglycerin, isosorbide dinitrate, amyl nitrite, erythrityl tetranitrate," exact="nesiritide" post="PF4 Platelet factor 4 Drotrecogin alfa PF4 level increasing"/>
   <result pre="of pro-inflammatory genes in Methods). The corresponding FDA-approved drugs include" exact="maraviroc" post="(an antiretroviral drug, a CCR5 inhibitor), bosentan (a dual"/>
   <result pre="FDA-approved drugs include maraviroc (an antiretroviral drug, a CCR5 inhibitor)," exact="bosentan" post="(a dual endothelin receptor antagonist that affects both endothelin"/>
   <result pre="B receptors, used in the treatment of pulmonary artery hypertension)," exact="sitaxentan" post="(endothelin A receptor antagonist, used in the treatment of"/>
   <result pre="receptor antagonist, used in the treatment of pulmonary artery hypertension)," exact="cetuximab" post="(EGFR antagonist, used in several types of cancer) and"/>
   <result pre="cetuximab (EGFR antagonist, used in several types of cancer) and" exact="imiquimod" post="(an immune response modulator, used for skin diseases including"/>
   <result pre="benazepril, enalapril, candoxatril, moexipril, lisinopril, perindopril, quinapril, rescinnamine, captopril, cilazapril," exact="spirapril" post="ACE inhibitor helping the walking ability in patients with"/>
   <result pre="et al., 2013) ADORA2B Adenosine A2b receptor Theophylline, adenosine, enprofylline," exact="defibrotide" post="AGTR1 Angiotensin II receptor, type 1 Valsartan, olmesartan, losartan,"/>
   <result pre="1 Valsartan, olmesartan, losartan, candesartan, eprosartan, telmisartan, irbesartan, forasartan, saprisartan," exact="tasosartan" post="Correlation between the increased AGTR1 and cardiovascular risk factors"/>
   <result pre="et al., 2011) AOC3 Amine oxidase, copper containing 3 Phenelzine," exact="hydralazine" post="C3 Complement component 3 Intravenous immunoglobulin C3 level in"/>
   <result pre="al., 2014) CNR1 Cannabinoid receptor 1 (brain) Dronabinol, nabilone, rimonabant," exact="dronabinol" post="EDNRA Endothelin receptor type A Bosentan, sitaxentan EGFR Epidermal"/>
   <result pre="Dronabinol, nabilone, rimonabant, dronabinol EDNRA Endothelin receptor type A Bosentan," exact="sitaxentan" post="EGFR Epidermal growth factor receptor Cetuximab, trastuzumab, lidocaine, gefitinib,"/>
   <result pre="Epidermal growth factor receptor Cetuximab, trastuzumab, lidocaine, gefitinib, erlotinib, lapatinib," exact="panitumumab" post="FCER1A Fc fragment of IgE, high affinity I, receptor"/>
   <result pre="affinity Ia, receptor (CD64) Cetuximab, etanercept, intravenous immunoglobulin, adalimumab, abciximab," exact="gemtuzumab ozogamicin," post="trastuzumab, rituximab, basiliximab, muromonab, ibritumomab, tositumomab, alemtuzumab, alefacept, efalizumab,"/>
   <result pre="affinity IIa, receptor (CD32) Cetuximab, etanercept, intravenous immunoglobulin, adalimumab, abciximab," exact="gemtuzumab ozogamicin," post="trastuzumab, rituximab, basiliximab, muromonab, ibritumomab, tositumomab, alemtuzumab, alefacept, efalizumab,"/>
   <result pre="basiliximab, muromonab, ibritumomab, tositumomab, alemtuzumab, alefacept, efalizumab, natalizumab, palivizumab, daclizumab," exact="bevacizumab" post="IL1B Interleukin 1, beta Minocycline, gallium nitrate, canakinumab IL6"/>
   <result pre="palivizumab, daclizumab, bevacizumab IL1B Interleukin 1, beta Minocycline, gallium nitrate," exact="canakinumab" post="IL6 Interleukin 6 Ginseng Phase III clinical trial targeting"/>
   <result pre="Interleukin 6 Ginseng Phase III clinical trial targeting IL-6 by" exact="tocilizumab" post="in cardiovascular disease (Ridker and Lüscher, 2014) LTA Lymphotoxin"/>
   <result pre="PDE5A phosphodiesterase 5A, cGMP-specific Sildenafil, theophylline, pentoxifylline, tadalafil, vardenafil, dipyridamole," exact="udenafil" post="PDE5 inhibition promotes ischemia-induced angiogenesis (Sahara et al., 2010)"/>
   <result pre="biloba PLA2G4A Phospholipase A2, group IVA (cytosolic, calcium-dependent) Fluticasone propionate," exact="quinacrine" post="PRKCA Protein kinase C, alpha Phosphatidylserine, vitamin E The"/>
   <result pre="2010) PTGER3 Prostaglandin E receptor 3 (subtype EP3) Bimatoprost, dinoprostone," exact="misoprostol" post="PTGS2 Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase)"/>
   <result pre="tenoxicam, lenalidomide, celecoxib, tolmetin, piroxicam, fenoprofen, diclofenac, sulindac, flurbiprofen, etodolac," exact="mefenamic acid," post="naproxen, sulfasalazine, phenylbutazone, meloxicam, carprofen, diflunisal, suprofen, salicyclic acid,"/>
   <result pre="acid, naproxen, sulfasalazine, phenylbutazone, meloxicam, carprofen, diflunisal, suprofen, salicyclic acid," exact="meclofenamic acid," post="acetylsalicylic acid, bromfenac, oxaprozin, ketoprofen, balsalazide, thalidomide, ibuprofen, lumiracoxib,"/>
   <result pre="sulfasalazine, phenylbutazone, meloxicam, carprofen, diflunisal, suprofen, salicyclic acid, meclofenamic acid," exact="acetylsalicylic acid," post="bromfenac, oxaprozin, ketoprofen, balsalazide, thalidomide, ibuprofen, lumiracoxib, magnesium salicylate,"/>
   <result pre="ibuprofen, lumiracoxib, magnesium salicylate, salicylate-sodium, salsalate, trisalicylate-choline, ginseng, antrafenine, antipyrine," exact="tiaprofenic acid," post="etoricoxib, niflumic acid, lornoxicam, nepafenac, gamma-homolinolenic acid, icosapent, ginseng,"/>
   <result pre="salicylate, salicylate-sodium, salsalate, trisalicylate-choline, ginseng, antrafenine, antipyrine, tiaprofenic acid, etoricoxib," exact="niflumic acid," post="lornoxicam, nepafenac, gamma-homolinolenic acid, icosapent, ginseng, thalidomide PTGS2 (COX2)"/>
   <result pre="acid, etoricoxib, niflumic acid, lornoxicam, nepafenac, gamma-homolinolenic acid, icosapent, ginseng," exact="thalidomide" post="PTGS2 (COX2) inhibition improves inflammation and endothelial dysfunction in"/>
   <result pre="et al., 2009) S100A12 S100 calcium binding protein A12 Olopatadine," exact="amlexanox" post="The potential biomarker for chronic arterial disease (Saito et"/>
   <result pre="PAD (Varela et al., 2015) TLR7 Toll-like receptor 7 Imiquimod," exact="hydroxychloroquine" post="TLR9 Toll-like receptor 9 Chloroquine, hydroxychloroquine TNF Tumor necrosis"/>
   <result pre="Toll-like receptor 7 Imiquimod, hydroxychloroquine TLR9 Toll-like receptor 9 Chloroquine," exact="hydroxychloroquine" post="TNF Tumor necrosis factor Etanercept, adalimumab, infliximab, chloroquine, thalidomide,"/>
   <result pre="factor Etanercept, adalimumab, infliximab, chloroquine, thalidomide, glucosamine, clenbuterol, pranlukast, amrinone," exact="thalidomide" post="Circulating TNF higher in PAD patients than control (Gardner"/>
   <result pre="Szubert et al., 2014 Nitroprusside NPR1 4 A source of" exact="nitric oxide," post="a potent peripheral vasodilator Hypertensive emergency Ziche et al.,"/>
   <result pre="drugs (Table 5). These drugs include antiplatelet (abciximab targeting FCGR1A," exact="acetylsalicylic acid" post="targeting PTGS2), monoclonal antibody (adalimumab targeintg TNF-alpha), immune suppressant"/>
   <result pre="immune suppressant (alefacept targeting FCGR1A and FCGR2A), ACE inhibitor (benazepril," exact="captopril" post="and enalapril), non-steroidal anti-inflammatory drug (NSAID, e.g., bromfenac, celecoxib,"/>
   <result pre="infections Leite et al., 2011 Aminosalicylic acid PTGS2 7 Inhibits" exact="folic acid" post="synthesis and synthesis of the cell wall component Tuberculosis"/>
   <result pre="orphan drug status. Details of hepatotoxicity of bosentan, ambrisentan, and" exact="sitaxentan" post="are reviewed in de Haro Miralles et al. ("/>
   <result pre="with PAD, currently there are no specific clinical trials for" exact="carvedilol" post="being compared to placebo or other beta-blockers in PAD"/>
   <result pre="involved in the inflammation pathway (Francisci et al., 2014). Therefore," exact="maraviroc" post="could have anti-inflammatory and anti-atherosclerosis effects, and become a"/>
   <result pre="microarrays from the human femoral artery in PAD. CCR5 inhibitor" exact="maraviroc" post="also blocks cell migration and metastasis, but not directly"/>
   <result pre="et al., 2014). Currently there are no clinical trials for" exact="maraviroc" post="in PAD patients. Limitations of computational drug repositioning approaches"/>
   <result pre="S. ( 2003). The anti-inflammatory effects of the phosphodiesterase inhibitor" exact="pentoxifylline" post="in the rat . Pharmacol. Res. 47, 331– 340."/>
   <result pre="R. Z. Hussain S. A. ( 2011). Anti-inflammatory activity of" exact="telmisartan" post="in rat models of experimentally-induced chronic inflammation: comparative study"/>
   <result pre="in rat models of experimentally-induced chronic inflammation: comparative study with" exact="dexamethasone" post=". Saudi Pharm. J. 19, 29– 34. 10.1016/j.jsps.2010.10.004 23960739"/>
   <result pre="2012). Attenuation of mouse somatic and emotional inflammatory pain by" exact="hydralazine" post="through scavenging acrolein and inhibiting neuronal activation . Pain"/>
   <result pre="Toft P. B. ( 2012). Treatment of orbital inflammation with" exact="rituximab" post="in Wegener's granulomatosis. Clin. Exp. Rheumatol. 30, S7– S10."/>
   <result pre="al. . ( 2003). Detection of the non-steroidal anti-inflammatory drug" exact="niflumic acid" post="in humans: a combined 19F-MRS in vivo and in"/>
   <result pre="J. Besson J. M. ( 1997). Potent anti-inflammatory/analgesic effects of" exact="lornoxicam" post="in comparison to other nsaids: a c-fos study in"/>
   <result pre="M. M. Maia L. C. ( 2009). The use of" exact="lidocaine" post="as an anti-inflammatory substance: a systematic review. J. Dent."/>
   <result pre="Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib," exact="valdecoxib" post="and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic"/>
   <result pre="Vandevanter D. R. et al. . ( 2015). Use of" exact="ibuprofen" post="to assess inflammatory biomarkers in induced sputum: implications for"/>
   <result pre="Whittem T. Bailey S. R. ( 2013). Effects of oral" exact="clenbuterol" post="on the clinical and inflammatory response to endotoxaemia in"/>
   <result pre="Rajpal R. K. et al. . ( 2011). Twice-daily, preservative-free" exact="ketorolac" post="0.45% for treatment of inflammation and pain after cataract"/>
   <result pre="Fox S. M. Johnston S. A. ( 1997). Use of" exact="carprofen" post="for the treatment of pain and inflammation in dogs."/>
   <result pre="E. et al. . ( 2014). Potential anti-inflammatory effects of" exact="maraviroc" post="in HIV-positive patients: a pilot study of inflammation, endothelial"/>
   <result pre="E. Lee J. et al. . ( 2008). Use of" exact="salsalate" post="to target inflammation in the treatment of insulin resistance"/>
   <result pre="A. Guidetti D. et al. . ( 2008). Thrombolysis with" exact="alteplase" post="3 to 4.5 hours after acute ischemic stroke. N."/>
   <result pre="A. Reddy K. S. ( 2013). Delayed allograft inflammation following" exact="alemtuzumab" post="induction for kidney transplantation. Clin. Transplant. 27, 772– 780."/>
   <result pre="Deniz Y. Reisner C. ( 2005). The anti-inflammatory effects of" exact="omalizumab" post="confirm the central role of IgE in allergic inflammation"/>
   <result pre="Smith N. Massanari M. Jimenez P. ( 2009). Effects of" exact="omalizumab" post="on markers of inflammation in patients with allergic asthma."/>
   <result pre="S. Jr. ( 2001). Inhibition of NF-kappa B activity by" exact="thalidomide" post="through suppression of IkappaB kinase activity . J. Biol."/>
   <result pre="in a canine model of chronic ischemic cardiomyopathy: comparison between" exact="carvedilol" post="and metoprolol . Basic Res. Cardiol. 108, 384. 10.1007/s00395-013-0384-7"/>
   <result pre="canine model of chronic ischemic cardiomyopathy: comparison between carvedilol and" exact="metoprolol" post=". Basic Res. Cardiol. 108, 384. 10.1007/s00395-013-0384-7 24072434 Lee"/>
   <result pre="Ade A. et al. . ( 2011). Anti-inflammatory properties of" exact="doxycycline" post="and minocycline in experimental models: an in vivo and"/>
   <result pre="et al. . ( 2011). Anti-inflammatory properties of doxycycline and" exact="minocycline" post="in experimental models: an in vivo and in vitro"/>
   <result pre="Panin N. et al. . ( 2012). Immunomodulatory activity of" exact="vardenafil" post="on induced lung inflammation in cystic fibrosis mice ."/>
   <result pre="Carvalho J. C. ( 2007). Anti-inflammatory and analgesic actions of" exact="etoricoxib" post="(an NSAID) combined with misoprostol. Inflammopharmacology 15, 175– 178."/>
   <result pre="Khalifa A. E. ( 2013). Anti-inflammatory and anti-oxidant activities of" exact="olmesartan" post="medoxomil ameliorate experimental colitis in rats . Toxicol. Appl."/>
   <result pre="et al. . ( 2007). Analgesic and anti-inflammatory effectiveness of" exact="nepafenac" post="0.1% for cataract surgery. Clin. Ophthalmol. 1, 527– 533."/>
   <result pre="Papapetropoulos A. ( 2007). cGMP-dependent and -independent angiogenesis-related properties of" exact="nitric oxide." post="Life Sci. 81, 1549– 1554. 10.1016/j.lfs.2007.09.014 17945311 Rahman S."/>
   <result pre="S. Parthasarathy S. Khan B. V. ( 2002). Effects of" exact="eprosartan" post="versus hydrochlorothiazide on markers of vascular oxidation and inflammation"/>
   <result pre="S. Khan B. V. ( 2002). Effects of eprosartan versus" exact="hydrochlorothiazide" post="on markers of vascular oxidation and inflammation and blood"/>
   <result pre="M. Brathwaite K. Zurier R. B. ( 1995). Effect of" exact="misoprostol" post="on acute and chronic inflammation. Am. J. Ther. 2,"/>
   <result pre="T. Hirata Y. Nagai R. ( 2010). A phosphodiesterase-5 inhibitor" exact="vardenafil" post="enhances angiogenesis through a protein kinase G-dependent hypoxia-inducible factor-1/vascular"/>
   <result pre="selected angiogenic and inflammatory markers in endometriosis before and after" exact="danazol" post="treatment . Reprod. Fertil. Dev. 26, 414– 420. 10.1071/RD12258"/>
   <result pre="C. G. Bar-Or R. Bar-Or D. ( 2007). Effects of" exact="danazol" post="on endothelial cell function and angiogenesis. Fertil. Steril. 88,"/>
   <result pre="Kukreja R. C. ( 2012). Anti-inflammatory and cardioprotective effects of" exact="tadalafil" post="in diabetic mice. PLoS ONE 7: e45243. 10.1371/journal.pone.0045243 23028874"/>
   <result pre="Ghosh S. Rioux K. ( 2011). Optimizing clinical use of" exact="mesalazine" post="(5-aminosalicylic acid) in inflammatory bowel disease . Therap. Adv."/>
   <result pre="Tolbert E. M. Dworkin L. D. ( 2007). Long-term, high-dosage" exact="candesartan" post="suppresses inflammation and injury in chronic kidney disease: nonhemodynamic"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4550185/results/search/inn/results.xml">
   <result pre="treatment. New combination regimens that target multiple pathways, such as" exact="everolimus" post="plus exemestane, have shown efficacy in elderly patients previously"/>
   <result pre="antigen Ki67): luminal A–like: low Ki67 expression, estrogen receptor–positive (ER+)," exact="progesterone" post="receptor–positive (PR+), and human epidermal growth factor receptor 2–negative"/>
   <result pre="AIs currently approved for use in advanced HR+ disease include" exact="anastrozole" post="(Arimidex ®), letrozole (Femara ®), and exemestane (Aromasin ®)."/>
   <result pre="for use in advanced HR+ disease include anastrozole (Arimidex ®)," exact="letrozole" post="(Femara ®), and exemestane (Aromasin ®). 44, 46, 48"/>
   <result pre="HR+ disease include anastrozole (Arimidex ®), letrozole (Femara ®), and" exact="exemestane" post="(Aromasin ®). 44, 46, 48 There are no clear"/>
   <result pre="a treatment class, AIs have demonstrated improved outcomes relative to" exact="tamoxifen" post="or other first-generation hormone agents. 59, 61 For patients"/>
   <result pre="For patients with both HR+ and HER2+ metastatic breast cancer," exact="lapatinib" post="(a dual HER2 and epidermal growth factor receptor inhibitor)"/>
   <result pre="in combination with letrozole. 62 A phase III trial of" exact="letrozole" post="plus lapatinib versus letrozole alone as first-line therapy showed"/>
   <result pre="with letrozole. 62 A phase III trial of letrozole plus" exact="lapatinib" post="versus letrozole alone as first-line therapy showed that the"/>
   <result pre="62 A phase III trial of letrozole plus lapatinib versus" exact="letrozole" post="alone as first-line therapy showed that the combination significantly"/>
   <result pre="endocrine inhibitor are currently under investigation. Trastuzumab in combination with" exact="anastrozole" post="was studied in a phase III trial in postmenopausal"/>
   <result pre="some of whom had previous exposure to endocrine therapy. Although" exact="anastrozole" post="alone improved time to progression (TTP) by 2.4 months,"/>
   <result pre="( P = 0.0007). 64 A phase III trial comparing" exact="letrozole" post="combined with trastuzumab to letrozole alone in patients with"/>
   <result pre="0.0007). 64 A phase III trial comparing letrozole combined with" exact="trastuzumab" post="to letrozole alone in patients with HR+/HER2+ metastatic breast"/>
   <result pre="A phase III trial comparing letrozole combined with trastuzumab to" exact="letrozole" post="alone in patients with HR+/HER2+ metastatic breast cancer, in"/>
   <result pre="cancer, in which approximately 40% of patients had received previous" exact="tamoxifen" post="therapy, showed that the median TTP with combination therapy"/>
   <result pre="combination therapy was 14.1 months compared with 3.3 months with" exact="letrozole" post="alone. 65 However, the therapeutic ratio for these combinations"/>
   <result pre="AI include switching to another endocrine therapy (including fulvestrant), or" exact="everolimus" post="plus exemestane (after anastrozole or letrozole only). 41, 58,"/>
   <result pre="switching to another endocrine therapy (including fulvestrant), or everolimus plus" exact="exemestane" post="(after anastrozole or letrozole only). 41, 58, 73, 74"/>
   <result pre="another endocrine therapy (including fulvestrant), or everolimus plus exemestane (after" exact="anastrozole" post="or letrozole only). 41, 58, 73, 74 Evidence from"/>
   <result pre="therapy (including fulvestrant), or everolimus plus exemestane (after anastrozole or" exact="letrozole" post="only). 41, 58, 73, 74 Evidence from clinical trials"/>
   <result pre="77 Other endocrine options after progression on an AI include" exact="fulvestrant" post="or tamoxifen. 78 Fulvestrant is a 17β-estradiol analog that"/>
   <result pre="setting, it has also demonstrated efficacy similar to that of" exact="tamoxifen" post="and anastrozole. 80, 81 A combined analysis of two"/>
   <result pre="breast cancer and disease progression during previous endocrine therapy found" exact="fulvestrant" post="250 mg to be noninferior to anastrozole. 84 When"/>
   <result pre="was considered by age in these studies, objective responses to" exact="fulvestrant" post="were seen in 22%–24% of patients aged &amp;lt;65 years"/>
   <result pre="and in 11%–16% of patients aged ≥65 years. 47 Additionally," exact="fulvestrant" post="(45% of patients in the Evaluation of Faslodex versus"/>
   <result pre="aged ≥65 years) has shown comparable efficacy and tolerability versus" exact="exemestane" post="in patients with advanced breast cancer after nonsteroidal AI"/>
   <result pre="nonsteroidal AI failure. 85 In a phase III study assessing" exact="fulvestrant" post="500 mg versus 250 mg in postmenopausal patients with"/>
   <result pre="endocrine therapy for advanced disease, a significant PFS benefit for" exact="fulvestrant" post="500 mg versus 250 mg was shown. 86 Of"/>
   <result pre="shown. 86 Of note, the last endocrine therapy prior to" exact="fulvestrant" post="was either an AI or antiestrogen, and a subgroup"/>
   <result pre="antiestrogen, and a subgroup analysis of the PFS benefit of" exact="fulvestrant" post="500 mg versus 250 mg based on this pretreatment"/>
   <result pre="not differ. At a final OS analysis of this study," exact="fulvestrant" post="500 mg was associated with a 19% reduction in"/>
   <result pre="US Food and Drug Administration (FDA) subsequently approved the high-dose" exact="fulvestrant" post="schedule as second-line therapy for postmenopausal women with HR+"/>
   <result pre="metastatic disease. 47 It has been hypothesized that coadministration of" exact="fulvestrant" post="with an AI may improve efficacy and delay the"/>
   <result pre="been mixed, with one study indicating that the combination of" exact="fulvestrant" post="plus anastrozole was superior to anastrozole alone, 88 while"/>
   <result pre="with one study indicating that the combination of fulvestrant plus" exact="anastrozole" post="was superior to anastrozole alone, 88 while others reported"/>
   <result pre="that the combination of fulvestrant plus anastrozole was superior to" exact="anastrozole" post="alone, 88 while others reported no advantage with the"/>
   <result pre="demonstrated efficacy with reasonable tolerability. 93 Recently, the mTOR inhibitor" exact="everolimus" post="in combination with exemestane was approved for the treatment"/>
   <result pre="tolerability. 93 Recently, the mTOR inhibitor everolimus in combination with" exact="exemestane" post="was approved for the treatment of postmenopausal women with"/>
   <result pre="postmenopausal women with advanced HR+/HER2− breast cancer after failure of" exact="anastrozole" post="or letrozole therapy, 45 based on the findings of"/>
   <result pre="with advanced HR+/HER2− breast cancer after failure of anastrozole or" exact="letrozole" post="therapy, 45 based on the findings of clinically meaningful"/>
   <result pre="≥65 years, and 164/724 were aged ≥70 years) showed that" exact="everolimus" post="and exemestane significantly improved median PFS (primary end point"/>
   <result pre="and 164/724 were aged ≥70 years) showed that everolimus and" exact="exemestane" post="significantly improved median PFS (primary end point of the"/>
   <result pre="improved median PFS (primary end point of the study) versus" exact="exemestane" post="alone in patients aged ≥70 years (median PFS: 6.77"/>
   <result pre="Similarly, the CBR in patients aged ≥70 years in the" exact="everolimus" post="plus exemestane group was greater compared with the exemestane-alone"/>
   <result pre="CBR in patients aged ≥70 years in the everolimus plus" exact="exemestane" post="group was greater compared with the exemestane-alone group (36%"/>
   <result pre="group (36% vs 23%). 95 The safety profile of combination" exact="everolimus" post="plus exemestane in patients aged ≥70 years was consistent"/>
   <result pre="vs 23%). 95 The safety profile of combination everolimus plus" exact="exemestane" post="in patients aged ≥70 years was consistent with the"/>
   <result pre="are preferred, including taxanes (paclitaxel, docetaxel), anthracyclines (doxorubicin, pegylated liposomal" exact="doxorubicin" post="[PLD]), capecitabine, gemcitabine, vinorelbine, or eribulin. 41 In a"/>
   <result pre="same efficacy observed in nonfrail/nonelderly patient cohorts. 97 Furthermore, weekly" exact="paclitaxel" post="is as effective as the newer chemotherapeutic agents ixabepilone"/>
   <result pre="weekly paclitaxel is as effective as the newer chemotherapeutic agents" exact="ixabepilone" post="and nab-paclitaxel, while demonstrating less toxicity. 98 PLD has"/>
   <result pre="cancer. On the basis of the success observed with the" exact="everolimus" post="plus exemestane combination, the use of mTOR inhibitors in"/>
   <result pre="the basis of the success observed with the everolimus plus" exact="exemestane" post="combination, the use of mTOR inhibitors in combination with"/>
   <result pre="continues to be explored in several ongoing phase II trials:" exact="everolimus" post="in combination with letrozole (NCT01698918), 101 with letrozole and"/>
   <result pre="in several ongoing phase II trials: everolimus in combination with" exact="letrozole" post="(NCT01698918), 101 with letrozole and lapatinib (NCT01499160), 102 and"/>
   <result pre="II trials: everolimus in combination with letrozole (NCT01698918), 101 with" exact="letrozole" post="and lapatinib (NCT01499160), 102 and with fulvestrant (NCT01797120 103;"/>
   <result pre="everolimus in combination with letrozole (NCT01698918), 101 with letrozole and" exact="lapatinib" post="(NCT01499160), 102 and with fulvestrant (NCT01797120 103; NCT00570921 104)."/>
   <result pre="(NCT01698918), 101 with letrozole and lapatinib (NCT01499160), 102 and with" exact="fulvestrant" post="(NCT01797120 103; NCT00570921 104). Other mTOR combinations have also"/>
   <result pre="postmenopausal women with HR+ advanced breast cancer in whom previous" exact="tamoxifen" post="and/or AI therapy was ineffective, sirolimus plus tamoxifen significantly"/>
   <result pre="cancer in whom previous tamoxifen and/or AI therapy was ineffective," exact="sirolimus" post="plus tamoxifen significantly improved TTP and response rates compared"/>
   <result pre="whom previous tamoxifen and/or AI therapy was ineffective, sirolimus plus" exact="tamoxifen" post="significantly improved TTP and response rates compared with tamoxifen"/>
   <result pre="plus tamoxifen significantly improved TTP and response rates compared with" exact="tamoxifen" post="alone in a phase II trial. 105 On the"/>
   <result pre="105 On the other hand, no benefit was observed when" exact="temsirolimus" post="was combined with letrozole versus letrozole alone in a"/>
   <result pre="hand, no benefit was observed when temsirolimus was combined with" exact="letrozole" post="versus letrozole alone in a phase III trial in"/>
   <result pre="benefit was observed when temsirolimus was combined with letrozole versus" exact="letrozole" post="alone in a phase III trial in postmenopausal women"/>
   <result pre="outcome. 106 Patients aged #65 years had longer PFS with" exact="letrozole" post="plus temsirolimus than with letrozole alone (median PFS: 9.0"/>
   <result pre="Patients aged #65 years had longer PFS with letrozole plus" exact="temsirolimus" post="than with letrozole alone (median PFS: 9.0 vs 5.6"/>
   <result pre="years had longer PFS with letrozole plus temsirolimus than with" exact="letrozole" post="alone (median PFS: 9.0 vs 5.6 months; hazard ratio:"/>
   <result pre="(NCT01633060) is evaluating the efficacy of BKM120 with or without" exact="fulvestrant" post="in postmenopausal women with HR+ HER2− locally advanced or"/>
   <result pre="BKM120 or BEZ235 (a novel pan-PI3K/mTOR inhibitor) in combination with" exact="letrozole" post="in HR+ metastatic breast cancer (NCT01248494). 111 Also in"/>
   <result pre="(ENCORE) 301] of entinostat (an HDAC inhibitor) in combination with" exact="exemestane" post="in patients with HR+ metastatic breast cancer that progressed"/>
   <result pre="trend for prolonged PFS in the combination arm compared with" exact="exemestane" post="alone. 114 Palbociclib (PD-0332991) is an orally bioavailable CDK"/>
   <result pre="PFS improved from 10 to 20 months in women receiving" exact="letrozole" post="plus palbociclib versus letrozole alone for first-line metastatic disease."/>
   <result pre="from 10 to 20 months in women receiving letrozole plus" exact="palbociclib" post="versus letrozole alone for first-line metastatic disease. 116 The"/>
   <result pre="to 20 months in women receiving letrozole plus palbociclib versus" exact="letrozole" post="alone for first-line metastatic disease. 116 The confirmatory larger"/>
   <result pre="reported. Based on the data from the phase II study," exact="palbociclib" post="was recently approved by the FDA for first-line use"/>
   <result pre="approved by the FDA for first-line use in combination with" exact="letrozole" post="in women with postmenopausal HR+ breast cancer who have"/>
   <result pre="breast cancer who have metastatic disease. Several other studies with" exact="palbociclib" post="are ongoing, including those that evaluate its use as"/>
   <result pre="endocrine therapy, 117 a phase II study in combination with" exact="anastrozole" post="(NCT01723774), 118 a phase III study in combination with"/>
   <result pre="anastrozole (NCT01723774), 118 a phase III study in combination with" exact="exemestane" post="(NCT02028507), 119 and three studies as first-line treatment in"/>
   <result pre="119 and three studies as first-line treatment in combination with" exact="letrozole" post="for HR+ advanced breast cancer (phases I/II, NCT00721409 120;"/>
   <result pre="the treatment of HER2− advanced breast cancer, in combination with" exact="letrozole" post="(phases I/II, NCT01872260 123; phase III, NCT01958021 124) or"/>
   <result pre="I/II, NCT01872260 123; phase III, NCT01958021 124) or added to" exact="everolimus" post="plus exemestane (phases I/II; NCT01857193 125). 101 Initial accelerated"/>
   <result pre="123; phase III, NCT01958021 124) or added to everolimus plus" exact="exemestane" post="(phases I/II; NCT01857193 125). 101 Initial accelerated approval for"/>
   <result pre="a clinically relevant therapeutic benefit. 21 Overall, however, analysis of" exact="bevacizumab" post="in elderly patients included in clinical trials indicates that"/>
   <result pre="recently reported Avastin THErapy for advaNced breAst cancer (ATHENA) trial," exact="bevacizumab" post="plus chemotherapy for first-line clinical use produced a median"/>
   <result pre="few novel combination therapies entering the treatment market, such as" exact="everolimus" post="plus exemestane, have shown good tolerability in elderly patients."/>
   <result pre="18 Brollo J Curigliano G Disalvatore D et al. Adjuvant" exact="trastuzumab" post="in elderly with HER-2 positive breast cancer: a systematic"/>
   <result pre="Owusu C Buist DS Field TS et al. Predictors of" exact="tamoxifen" post="discontinuation among older women with estrogen receptor-positive breast cancer"/>
   <result pre="AM Patient-centered experiences in breast cancer: predicting long-term adherence to" exact="tamoxifen" post="use Med Care 2007 45 5 431 9 17446829"/>
   <result pre="98 19192957 55 Mouridsen H Chaudri-Ross HA Efficacy of first-line" exact="letrozole" post="versus tamoxifen as a function of age in postmenopausal"/>
   <result pre="55 Mouridsen H Chaudri-Ross HA Efficacy of first-line letrozole versus" exact="tamoxifen" post="as a function of age in postmenopausal women with"/>
   <result pre="Pippen J Jr Pivot X et al. Lapatinib combined with" exact="letrozole" post="versus letrozole and placebo as first-line therapy for postmenopausal"/>
   <result pre="Jr Pivot X et al. Lapatinib combined with letrozole versus" exact="letrozole" post="and placebo as first-line therapy for postmenopausal hormone receptor-positive"/>
   <result pre="Kaufman B Mackey JR Clemens MR et al. Trastuzumab plus" exact="anastrozole" post="versus anastrozole alone for the treatment of postmenopausal women"/>
   <result pre="Mackey JR Clemens MR et al. Trastuzumab plus anastrozole versus" exact="anastrozole" post="alone for the treatment of postmenopausal women with human"/>
   <result pre="J Fasching PA Barsoum M et al. Higher efficacy of" exact="letrozole" post="in combination with trastuzumab compared to letrozole monotherapy as"/>
   <result pre="M et al. Higher efficacy of letrozole in combination with" exact="trastuzumab" post="compared to letrozole monotherapy as first-line treatment in patients"/>
   <result pre="Higher efficacy of letrozole in combination with trastuzumab compared to" exact="letrozole" post="monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive"/>
   <result pre="Saccani-Jotti G Smith IE et al. Changes in estrogen receptor," exact="progesterone" post="receptor, and pS2 expression in tamoxifen-resistant human breast cancer"/>
   <result pre="DA Camidge DR Oyee J Hirsch M Economic evaluation of" exact="fulvestrant" post="as an extra step in the treatment sequence for"/>
   <result pre="Lønning PE Bajetta E Murray R et al. Activity of" exact="exemestane" post="in metastatic breast cancer after failure of nonsteroidal aromatase"/>
   <result pre="G Garrone O Merlano M et al. Sequential treatment with" exact="exemestane" post="and non-steroidal aromatase inhibitors in advanced breast cancer Oncology"/>
   <result pre="Howell A Robertson JF Abram P et al. Comparison of" exact="fulvestrant" post="versus tamoxifen for the treatment of advanced breast cancer"/>
   <result pre="Robertson JF Abram P et al. Comparison of fulvestrant versus" exact="tamoxifen" post="for the treatment of advanced breast cancer in postmenopausal"/>
   <result pre="Robertson JF Llombart-Cussac A Rolski J et al. Activity of" exact="fulvestrant" post="500 mg versus anastrozole 1 mg as first-line treatment"/>
   <result pre="Rolski J et al. Activity of fulvestrant 500 mg versus" exact="anastrozole" post="1 mg as first-line treatment for advanced breast cancer:"/>
   <result pre="al. Double-blind, randomized trial comparing the efficacy and tolerability of" exact="fulvestrant" post="versus anastrozole in postmenopausal women with advanced breast cancer"/>
   <result pre="randomized trial comparing the efficacy and tolerability of fulvestrant versus" exact="anastrozole" post="in postmenopausal women with advanced breast cancer progressing on"/>
   <result pre="et al. Fulvestrant, formerly ICI 182,780, is as effective as" exact="anastrozole" post="in postmenopausal women with advanced breast cancer progressing after"/>
   <result pre="Mauriac L et al. Double-blind, randomized placebo controlled trial of" exact="fulvestrant" post="compared with exemestane after prior nonsteroidal aromatase inhibitor therapy"/>
   <result pre="al. Double-blind, randomized placebo controlled trial of fulvestrant compared with" exact="exemestane" post="after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women"/>
   <result pre="et al. Results of the CONFIRM phase III trial comparing" exact="fulvestrant" post="250 mg with fulvestrant 500 mg in postmenopausal women"/>
   <result pre="the CONFIRM phase III trial comparing fulvestrant 250 mg with" exact="fulvestrant" post="500 mg in postmenopausal women with estrogen receptor-positive advanced"/>
   <result pre="A Jerusalem G Petruzelka L et al. Final overall survival:" exact="fulvestrant" post="500 mg vs 250 mg in the randomized CONFIRM"/>
   <result pre="88 Mehta RS Barlow WE Albain KS et al. Combination" exact="anastrozole" post="and fulvestrant in metastatic breast cancer N Engl J"/>
   <result pre="RS Barlow WE Albain KS et al. Combination anastrozole and" exact="fulvestrant" post="in metastatic breast cancer N Engl J Med 2012"/>
   <result pre="et al. FACT: an open-label randomized phase III study of" exact="fulvestrant" post="and anastrozole in combination compared with anastro-zole alone as"/>
   <result pre="FACT: an open-label randomized phase III study of fulvestrant and" exact="anastrozole" post="in combination compared with anastro-zole alone as first-line therapy"/>
   <result pre="LS Ellis P et al. collab: SoFEA investigators Fulvestrant plus" exact="anastrozole" post="or placebo versus exemestane alone after progression on non-steroidal"/>
   <result pre="al. collab: SoFEA investigators Fulvestrant plus anastrozole or placebo versus" exact="exemestane" post="alone after progression on non-steroidal aromatase inhibitors in postmenopausal"/>
   <result pre="Yardley DA Noguchi S Pritchard KI et al. Everolimus plus" exact="exemestane" post="in postmenopausal patients with HR+ breast cancer: BOLERO-2 final"/>
   <result pre="HA 3rd Ito Y et al. Safety and efficacy of" exact="everolimus" post="with exemestane vs. exemestane alone in elderly patients with"/>
   <result pre="Ito Y et al. Safety and efficacy of everolimus with" exact="exemestane" post="vs. exemestane alone in elderly patients with HER2-negative, hormone"/>
   <result pre="et al. Safety and efficacy of everolimus with exemestane vs." exact="exemestane" post="alone in elderly patients with HER2-negative, hormone receptor-positive breast"/>
   <result pre="H Wynendaele W Dirix L Kains JP Paridaens R Weekly" exact="paclitaxel" post="versus weekly docetaxel in elderly or frail patients with"/>
   <result pre="Dirix L Kains JP Paridaens R Weekly paclitaxel versus weekly" exact="docetaxel" post="in elderly or frail patients with metastatic breast carcinoma:"/>
   <result pre="al. CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly" exact="paclitaxel" post="(P) compared to weekly nanoparticle bound nab-paclitaxel (NP) or"/>
   <result pre="paclitaxel (P) compared to weekly nanoparticle bound nab-paclitaxel (NP) or" exact="ixabepilone" post="(Ix) with or without bevacizumab (B) as first-line therapy"/>
   <result pre="nanoparticle bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without" exact="bevacizumab" post="(B) as first-line therapy for locally recurrent or metastatic"/>
   <result pre="et al. Impact of geriatric risk factors on pegy-lated liposomal" exact="doxorubicin" post="tolerance and efficacy in elderly metastatic breast cancer patients:"/>
   <result pre="et al. International Breast Cancer Study Group. Adjuvant pegylated liposomal" exact="doxorubicin" post="for older women with endocrine nonresponsive breast cancer who"/>
   <result pre="23453899 101 collab: Novartis Pharmaceuticals Open-label, phase II, study of" exact="everolimus" post="plus letrozole in postmenopausal women with ER+, HER2− metastatic"/>
   <result pre="collab: Novartis Pharmaceuticals Open-label, phase II, study of everolimus plus" exact="letrozole" post="in postmenopausal women with ER+, HER2− metastatic or locally"/>
   <result pre="Pharmaceuticals collab: GlaxoSmithKline GCC 0901 – study of how well" exact="letrozole" post="works in combination with lapatinib followed by an addition"/>
   <result pre="– study of how well letrozole works in combination with" exact="lapatinib" post="followed by an addition of everolimus in postmenopausal women"/>
   <result pre="works in combination with lapatinib followed by an addition of" exact="everolimus" post="in postmenopausal women with advanced endocrine resistant breast cancer"/>
   <result pre="[NLM Identifier: NCT01499160] 103 collab: PrECOG, LLC; Novartis Study of" exact="fulvestrant" post="+/− everolimus in post-menopausal, hormone-receptor + metastatic breast Ca"/>
   <result pre="NCT01499160] 103 collab: PrECOG, LLC; Novartis Study of fulvestrant +/−" exact="everolimus" post="in post-menopausal, hormone-receptor + metastatic breast Ca resistant to"/>
   <result pre="NCT01797120] 104 collab: Suleiman Massarweh collab: Novartis Study of combined" exact="fulvestrant" post="and everolimus in advanced/metastatic breast cancer after aromatase inhibitor"/>
   <result pre="collab: Suleiman Massarweh collab: Novartis Study of combined fulvestrant and" exact="everolimus" post="in advanced/metastatic breast cancer after aromatase inhibitor failure (BRE-43)"/>
   <result pre="Bhattacharyya GN Biswas J Singh JH et al. Reversal of" exact="tamoxifen" post="resistance (hormone resistance) by addition of sirolimus (mTOR inhibitor)"/>
   <result pre="al. Reversal of tamoxifen resistance (hormone resistance) by addition of" exact="sirolimus" post="(mTOR inhibitor) in metastatic breast cancer Presented at 2011"/>
   <result pre="Bondarenko I et al. Randomized phase III placebo-controlled trial of" exact="letrozole" post="plus oral temsirolimus as first-line endocrine therapy in postmenopausal"/>
   <result pre="al. Randomized phase III placebo-controlled trial of letrozole plus oral" exact="temsirolimus" post="as first-line endocrine therapy in postmenopausal women with locally"/>
   <result pre="collab: Novartis Pharmaceuticals Corp Phase III study of BKM120/placebo with" exact="fulvestrant" post="in postmenopausal patients with hormone receptor positive HER2− negative"/>
   <result pre="collab: Novartis Pharmaceuticals A Phase III study of BKM120 with" exact="fulvestrant" post="in patients with HR+,HER2−, AI treated, locally advanced or"/>
   <result pre="B et al. Randomized phase II, double-blind, placebo-controlled study of" exact="exemestane" post="with or without entinostat in postmenopausal women with locally"/>
   <result pre="et al. Phase 3, multicenter, randomized, double-blind placebo-controlled trial of" exact="fulvestrant" post="with or without PD-0332991 (palbociclib) + goserelin in women"/>
   <result pre="placebo-controlled trial of fulvestrant with or without PD-0332991 (palbociclib) +" exact="goserelin" post="in women with hormone receptor-positive, HER2-negative metastatic breast cancer"/>
   <result pre="JP Lang I et al. The cyclin-dependent kinase 4/6 inhibitor" exact="palbociclib" post="in combination with letrozole versus letrozole alone as first-line"/>
   <result pre="al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with" exact="letrozole" post="versus letrozole alone as first-line treatment of oestrogen receptor-positive,"/>
   <result pre="cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus" exact="letrozole" post="alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced"/>
   <result pre="Sanna G Pestrin M et al. Phase 2 study of" exact="palbociclib" post="(CDK 4/6 inhibitor) for ER positive, HER2− negative post-menopausal"/>
   <result pre="118 collab: Washington University School of Medicine PD 0332991 and" exact="anastrozole" post="for stage 2 or 3 estrogen receptor positive and"/>
   <result pre="Spanish Breast Cancer Research Group Pfizer Phase III study of" exact="palbociclib" post="(PD-0332991) in combination with exemestane versus chemotherapy (capecitabine) in"/>
   <result pre="Pfizer Phase III study of palbociclib (PD-0332991) in combination with" exact="exemestane" post="versus chemotherapy (capecitabine) in hormonal receptor (HR) positive/HER2 negative"/>
   <result pre="http://clinicaltrials.gov/show/NCT01709370 [NLM Identifier: NCT01709370] 122 collab: Pfizer A study of" exact="palbociclib" post="(PD-0332991) + letrozole vs letrozole for 1st line treatment"/>
   <result pre="NCT01709370] 122 collab: Pfizer A study of palbociclib (PD-0332991) +" exact="letrozole" post="vs letrozole for 1st line treatment of postmenopausal women"/>
   <result pre="collab: Pfizer A study of palbociclib (PD-0332991) + letrozole vs" exact="letrozole" post="for 1st line treatment of postmenopausal women with ER+/HER2−"/>
   <result pre="NCT01740427] 123 collab: Novartis Pharmaceuticals Study of LEE011, BYL719 and" exact="letrozole" post="in advanced ER+ breast cancer ClinicalTrials.gov [Internet] Bethesda, MD"/>
   <result pre="125 collab: Novartis Pharmaceuticals Phase Ib/II trial of LEE011 with" exact="everolimus" post="(RAD001) and exemestane in the treatment of ER+ Her2−"/>
   <result pre="Pharmaceuticals Phase Ib/II trial of LEE011 with everolimus (RAD001) and" exact="exemestane" post="in the treatment of ER+ Her2− advanced breast cancer"/>
   <result pre="127 Smith IE Pierga JY Biganzoli L et al. First-line" exact="bevacizumab" post="plus taxane-based chemotherapy for locally recurrent or metastatic breast"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4552740/results/search/inn/results.xml">
   <result pre="collection and the assay [ 9]. In patients treated with" exact="tamoxifen" post="for advanced disease, higher BCAR4 mRNA levels are associated"/>
   <result pre="12 13 estrogen receptor negative 14 15 positive 82 85" exact="progesterone" post="receptor negative 39 41 positive 57 59 ERBB2 0,"/>
   <result pre="were pooled and supplemented with BSA and 1 volume of" exact="glycerol" post="and were stored at -20°C. Western blot and immunoprecipitation"/>
   <result pre="had relapsed and converted to an ER-negative phenotype following 5-years-long" exact="tamoxifen" post="monotherapy [ 18, 17, 16, 15]. To rule out"/>
   <result pre="negative 10 (71) 4 (29) positive 76 (93) 6 (7)" exact="progesterone" post="receptor 0.521 a negative 34 (87) 5 (13) positive"/>
   <result pre="studies [ 29], all cell lines tested for sensitivity to" exact="lapatinib" post="were EGFR-negative, except UACC-893, which had minimal EGFR expression"/>
   <result pre="(ERBB2 0 to 1+, EGFR 0) was as sensitive to" exact="lapatinib" post="as UACC-893 (ERBB2 3+, EGFR 1+) ( Fig 4D)."/>
   <result pre="EGFR 1+) ( Fig 4D). The EC 50 values of" exact="lapatinib" post="were approximately 16- to 24-fold lower in IPH-926 and"/>
   <result pre="are presented. (D) Cells were exposed to various concentrations of" exact="lapatinib" post="for five days and cell proliferation was determined with"/>
   <result pre="manner [ 11, 9, 26]. The clinically approved ERBB2/EGFR inhibitor" exact="lapatinib" post="emerges as a potential therapeutic alternative for patients with"/>
   <result pre="an excellent biomarker to select patients with endocrine resistance for" exact="lapatinib" post="therapy. Currently a randomized phase III trial (NSABP B-47)"/>
   <result pre="B-47) of adjuvant therapy comparing chemotherapy alone to chemotherapy plus" exact="trastuzumab" post="in women with node-positive or high-risk node-negative HER2-low invasive"/>
   <result pre="of that study is to determine whether the addition of" exact="trastuzumab" post="to chemotherapy improves disease-free survival in women with resected"/>
   <result pre="taken into account when interpreting trials exploring the potential of" exact="lapatinib" post="to overcome endocrine treatment resistance ( https://clinicaltrials.gov/ct2/show/NCT00225758). The rationale"/>
   <result pre="such trials is primarily based on the inhibitory effects of" exact="lapatinib" post="on EGFR and HER2/ERBB2. Our findings suggest that beneficial"/>
   <result pre="EGFR and HER2/ERBB2. Our findings suggest that beneficial effects of" exact="lapatinib" post="could also be through inhibition of BCAR4 mediated effects,"/>
   <result pre="of BCAR4 mediated effects, Furthermore, a prospective clinical trial of" exact="lapatinib" post="in HER2-negative, BCAR4 positive tumors should be considered. Recently,"/>
   <result pre="of BCAR4, the region that is dispensable for induction of" exact="tamoxifen" post="resistance [ 8, 10]. Analysis of GEO expression data"/>
   <result pre=", Howell A , Dowsett M et al. Effect of" exact="anastrozole" post="and tamoxifen as adjuvant treatment for early-stage breast cancer:"/>
   <result pre="A , Dowsett M et al. Effect of anastrozole and" exact="tamoxifen" post="as adjuvant treatment for early-stage breast cancer: 10-year analysis"/>
   <result pre="J et al. Prognostic value of estrogen receptor alpha and" exact="progesterone" post="receptor conversion in distant breast cancer metastases . Cancer."/>
   <result pre="RS , Guerrero MS , Bouton AH . Pathways to" exact="tamoxifen" post="resistance. Cancer Lett. 2007; 256( 1): 1– 24. 17475399"/>
   <result pre="cancer antiestrogen resistance genes in human breast cancer progression and" exact="tamoxifen" post="resistance . J Clin Oncol. 2009; 27( 4): 542–"/>
   <result pre=", Dorssers LC . Functional screen for genes responsible for" exact="tamoxifen" post="resistance in human breast cancer cells . Mol Cancer"/>
   <result pre="JA , Dorssers LC et al. Relevance of BCAR4 in" exact="tamoxifen" post="resistance and tumour aggressiveness of human breast cancer ."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4553016/results/search/inn/results.xml">
   <result pre="stage, age and menopausal status, the oestrogen receptor (ER) and" exact="progesterone" post="receptor (PgR) status of the tumour, its proliferative capacity"/>
   <result pre="(QALYs) lost as a result of a patient not receiving" exact="trastuzumab" post="was also calculated. Lost productivity was based on the"/>
   <result pre="to FISH test, the patient would erroneously not be offered" exact="trastuzumab" post="treatment. 3 a-d) Widespread cytoplasmic reaction is seen in"/>
   <result pre="to FISH test and the patient would erroneously be offered" exact="trastuzumab" post="treatment. FISH, fluorescence in situ hybridisation IHC test results"/>
   <result pre="based on the 4.8 months’ additional life expectancy provided by" exact="trastuzumab" post="(median overall survival 25.1 months for chemotherapy + trastuzumab vs 20.3"/>
   <result pre="after 1 year of 16 % between patients treated with" exact="trastuzumab" post="and those who did not receive trastuzumab [ 7],"/>
   <result pre="patients treated with trastuzumab and those who did not receive" exact="trastuzumab" post="[ 7], 86 patients tested with an approved IVD"/>
   <result pre="in the treatment of HER2-positive breast cancer: the antibodies trastuzumab," exact="pertuzumab" post="and trastuzumab emtansine, and the tyrosine kinase inhibitor lapatinib."/>
   <result pre="treatment of HER2-positive breast cancer: the antibodies trastuzumab, pertuzumab and" exact="trastuzumab" post="emtansine, and the tyrosine kinase inhibitor lapatinib. However, the"/>
   <result pre="year, largely as a consequence of the correct use of" exact="trastuzumab" post="leading to avoidance of treatment costs associated with disease"/>
   <result pre="N, Pienkowski T, Martin M, Press M, et al. Adjuvant" exact="trastuzumab" post="in HER2-positive breast cancer. N Engl J Med. 2011;365:1273–83."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4558113/results/search/inn/results.xml">
   <result pre="respond even initially to these drugs, and the development of" exact="trastuzumab" post="and lapatinib resistance is an additional clinical problem ["/>
   <result pre="initially to these drugs, and the development of trastuzumab and" exact="lapatinib" post="resistance is an additional clinical problem [ 42]. This"/>
   <result pre="the number of new approved HER2 directed therapies such as" exact="pertuzumab" post="and TDM1, which can augment trastuzumab's effectiveness and/or overcome"/>
   <result pre="pertuzumab and TDM1, which can augment trastuzumab's effectiveness and/or overcome" exact="trastuzumab" post="resistance in HER2 positive breast cancer. Many breast cancers,"/>
   <result pre="breast cancers, particularly those that do not express estrogen receptor," exact="progesterone" post="receptor, or high levels of HER2 (i.e., triple negative"/>
   <result pre="with 5% FBS supplemented with 5μg/ml insulin (Gibco) and 1μg/ml" exact="hydrocortisone" post="(Sigma). MCF7 and Hs578t cell lines were cultured in"/>
   <result pre="0.1μg/ml cholera toxin (Sigma) and 100μg/ml each of penicillin and" exact="streptomycin" post="(Gibco), and the MCF10A/EGFR cell lines were cultured as"/>
   <result pre="cultured 8-21 days under treatment, and then fixed with 100%" exact="ethanol" post="and stained with 0.5% crystal violet (Sigma). Cell viability"/>
   <result pre="or AMPKαDN plasmid. Transformed bacteria were grown under selection on" exact="ampicillin" post="containing LB-agar plates. DNA was isolated from bacterial colonies"/>
   <result pre="at ~50% confluence were transfected with pBABE-puro-TdTomato and selected with" exact="puromycin" post="using previously described methods [ 47]. NOD-SCID mice (SKCCC"/>
   <result pre="JP et al. PIK3CA mutations and EGFR overexpression predict for" exact="lithium" post="sensitivity in human breast epithelial cells Cancer Biol Ther"/>
   <result pre="al. Phase I safety, pharmacokinetics, and clinical activity study of" exact="lapatinib" post="(GW572016), a reversible dual inhibitor of epidermal growth factor"/>
   <result pre="Romieu CG et al. A phase III randomized comparison of" exact="lapatinib" post="plus capecitabine versus capecitabine alone in women with advanced"/>
   <result pre="et al. A phase III randomized comparison of lapatinib plus" exact="capecitabine" post="versus capecitabine alone in women with advanced breast cancer"/>
   <result pre="A phase III randomized comparison of lapatinib plus capecitabine versus" exact="capecitabine" post="alone in women with advanced breast cancer that has"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4558136/results/search/inn/results.xml">
   <result pre="mesorectal excision (TME) followed by adjuvant chemotherapy with 5-FU and" exact="oxaliplatin" post="[ 5] and complete mesocolic excision (CME) as well"/>
   <result pre="treated with Fluoropyrimidine-based CTx and recently in the combination with" exact="irinotecan" post="or oxaliplatin. Due to non-specificity of this treatment, there"/>
   <result pre="unresectable colorectal liver metastases can be resected after response to" exact="cetuximab" post="based CTx leading to a better overall survival of"/>
   <result pre="(IHC 0, IHC 1+, IHC 2+/FISH-). These patients treated with" exact="trastuzumab" post="additionally to standard CTx benefited significantly from the individualized"/>
   <result pre="receptor represents an effective target for monoclonal antibodies such as" exact="trastuzumab" post="being approved for metastatic gastric cancer, pertuzumab [ 36]"/>
   <result pre="antibodies such as trastuzumab being approved for metastatic gastric cancer," exact="pertuzumab" post="[ 36] or antibody-drug-conjugates such as T-DM-1 [ 37]"/>
   <result pre="T-DM-1 [ 37] and for small tyrosine kinase inhibitors like" exact="lapatinib" post="[ 38] and afatinib [ 39]. Besides, also HER-3"/>
   <result pre="for small tyrosine kinase inhibitors like lapatinib [ 38] and" exact="afatinib" post="[ 39]. Besides, also HER-3 is considered as an"/>
   <result pre="simultaneously could have useful applications in metastastic CRC treatment. Although" exact="trastuzumab" post="is approved for HER-2 positive metastatic gastric cancer, clinical"/>
   <result pre="approved for HER-2 positive metastatic gastric cancer, clinical trials on" exact="trastuzumab" post="therapy for (metastatic) CRC are still lacking. In CRC,"/>
   <result pre="to KRAS mutation for response to an anti-EGFR therapy like" exact="cetuximab" post="in metastatic CRC. Dual inhibition with anti-EGFR antibodies (cetuximab"/>
   <result pre="regression of the tumor (−75%) in comparison to treatment with" exact="cetuximab" post="or lapatinib alone. Further analyses and clinical phase II"/>
   <result pre="the tumor (−75%) in comparison to treatment with cetuximab or" exact="lapatinib" post="alone. Further analyses and clinical phase II studies are"/>
   <result pre="cetuximab. Currently, a clinical study evaluates treatment with MM-121 plus" exact="cetuximab" post="versus MM-121 in combination with cetuximab plus irinotecan in"/>
   <result pre="treatment with MM-121 plus cetuximab versus MM-121 in combination with" exact="cetuximab" post="plus irinotecan in CRC ( http://ClinicalTrials.gov: NCT01451632). Another multicenter"/>
   <result pre="MM-121 plus cetuximab versus MM-121 in combination with cetuximab plus" exact="irinotecan" post="in CRC ( http://ClinicalTrials.gov: NCT01451632). Another multicenter study is"/>
   <result pre="to evaluate RG7116 alone (part A) or in combination with" exact="cetuximab" post="(part B) or erlotinib (part C) in patients with"/>
   <result pre="(part A) or in combination with cetuximab (part B) or" exact="erlotinib" post="(part C) in patients with metastatic and/or locally advanced"/>
   <result pre="II trial demonstrated with first results that the combination of" exact="trastuzumab" post="and lapatinib was effective in standard therapy refractory mCRCs"/>
   <result pre="demonstrated with first results that the combination of trastuzumab and" exact="lapatinib" post="was effective in standard therapy refractory mCRCs with HER-2"/>
   <result pre="Patients with a KRAS wild-typ status received the monoclonal antibody" exact="cetuximab" post="simultaneously to CTx protocols with doublets ( n ="/>
   <result pre="24 patients (12%). In 6 patients (3%), the application of" exact="cetuximab" post="additionally to bevacizumab had been performed. One patient received"/>
   <result pre="In 6 patients (3%), the application of cetuximab additionally to" exact="bevacizumab" post="had been performed. One patient received an additional third"/>
   <result pre="SB Yu CS et al. Oxaliplatin, fluorouracil, and leucovorin versus" exact="fluorouracil" post="and leucovorin as adjuvant chemotherapy for locally advanced rectal"/>
   <result pre="et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and" exact="oxaliplatin" post="in advanced colorectal cancer (CAIRO): a phase III randomised"/>
   <result pre="Xu B Qin XY Xu J Randomized controlled trial of" exact="cetuximab" post="plus chemotherapy for patients with KRAS wild-type unresectable colorectal"/>
   <result pre="Patient-reported outcomes from EMILIA, a randomized phase 3 study of" exact="trastuzumab" post="emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal"/>
   <result pre="a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus" exact="capecitabine" post="and lapatinib in human epidermal growth factor receptor 2-positive"/>
   <result pre="phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and" exact="lapatinib" post="in human epidermal growth factor receptor 2-positive locally advanced"/>
   <result pre="Caballero R Porras I Tibau A et al. Trastuzumab or" exact="lapatinib" post="with standard chemotherapy for HER2-positive breast cancer: results from"/>
   <result pre="prediction of clinical outcome for advanced colorectal cancer patients receiving" exact="irinotecan" post="and cetuximab Oncologist 2011 16 53 60 21212430 44"/>
   <result pre="clinical outcome for advanced colorectal cancer patients receiving irinotecan and" exact="cetuximab" post="Oncologist 2011 16 53 60 21212430 44 Baiocchi G"/>
   <result pre="of the epidermal growth factor receptor using the combination of" exact="cetuximab" post="and erlotinib: preclinical evaluation and results of the phase"/>
   <result pre="of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody" exact="cetuximab" post="Sci Transl Med 2011 3 99ra86 52 Schoeberl B"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4558503/results/search/inn/results.xml">
   <result pre="activation of the phosphoinositide 3-kinase-AKT pathway. The ERBB2 monoclonal antibody" exact="trastuzumab" post="(Herceptin) is an established therapeutic option, but de novo"/>
   <result pre="therapeutic option, but de novo and acquired therapeutic resistance to" exact="trastuzumab" post="is an important clinical problem. 5 Variations among signaling"/>
   <result pre="of ERBB2 can contribute to the development of resistance to" exact="trastuzumab" post="and other drugs targeting the ERBB2 pathway. The intracellular"/>
   <result pre="Pittsburgh, PA, USA) for 24 h and then transferred to 70%" exact="ethanol" post="before processing. Paraffin-embedded tissues were sectioned at 5  μm"/>
   <result pre="1179 1187 Pohlmann PR Mayer IA Mernaugh R Resistance to" exact="trastuzumab" post="in breast cancer Clin Cancer Res 2009 15 7479"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4558517/results/search/inn/results.xml">
   <result pre="the development of resistance to current HER2-targeted treatments such as" exact="trastuzumab" post="and lapatinib alternative therapeutic strategies are required. 18, 19"/>
   <result pre="of resistance to current HER2-targeted treatments such as trastuzumab and" exact="lapatinib" post="alternative therapeutic strategies are required. 18, 19 ATRA was"/>
   <result pre="increase in cell death when SKBR3 cells were treated with" exact="chloroquine" post="alone, but in combination with ATRA, a significant increase"/>
   <result pre="differentiation. To this end, we treated SKBR3 cells with ATRA," exact="chloroquine" post="or a combination thereof for 4 days and determined"/>
   <result pre="least when cells were treated with ATRA and 20  μM" exact="chloroquine" post="( Figure 6b, right panel). Similarly, depletion of ATG7"/>
   <result pre="during HER2-targeted therapy with lapatinib. On the one hand, combining" exact="lapatinib" post="with a pharmacological inhibitor of autophagy resulted in reduced"/>
   <result pre="Universidade de Vigo, Pontevedra, Spain). 3-MA (no. S2767)/BafA (B1793) and" exact="chloroquine" post="(no. C6628) were purchased from Sigma-Aldrich (Buchs, Switzerland) and"/>
   <result pre="DMEM/F12 supplemented with 5% FBS, 50 U/ml penicillin and 50  μg/ml" exact="streptomycin" post="in humidified atmosphere containing 5% CO 2 at 37 °C."/>
   <result pre="D Hung M-C Hortobagyi GN Molecular predictors of response to" exact="trastuzumab" post="and lapatinib in breast cancer Nat Rev Clin Oncol"/>
   <result pre="M-C Hortobagyi GN Molecular predictors of response to trastuzumab and" exact="lapatinib" post="in breast cancer Nat Rev Clin Oncol 2010 7"/>
   <result pre="Flora M Zanetti A et al. Synergistic antitumor activity of" exact="lapatinib" post="and retinoids on a novel subtype of breast cancer"/>
   <result pre="A et al. Autophagy inhibition augments the anticancer effects of" exact="epirubicin" post="treatment in anthracycline-sensitive and resistant triple negative breast cancer"/>
   <result pre="activity of SKBR3 cells treated with ATRA, increasing concentrations of" exact="chloroquine" post="or a combination thereof as indicated. Analysis as in"/>
   <result pre="for 4 days with 1  μM ATRA, increasing concentrations of" exact="chloroquine" post="or a combination thereof as indicated before western blot"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4567019/results/search/inn/results.xml">
   <result pre="both HER2 expression and phosphorylation. Trastuzumab (Tra) in combination with" exact="docetaxel" post="promoted cell growth inhibition, and treatment with Tra or"/>
   <result pre="66-year-old woman suffering from metastatic HER2-positive BC was treated with" exact="capecitabine" post="(Cape) (Chugai, Tokyo, Japan) and lapatinib (Lap) (Glaxo, Middlesex,"/>
   <result pre="BC was treated with capecitabine (Cape) (Chugai, Tokyo, Japan) and" exact="lapatinib" post="(Lap) (Glaxo, Middlesex, UK) followed by eribulin (Eizai, Tokyo,"/>
   <result pre="Tokyo, Japan) and lapatinib (Lap) (Glaxo, Middlesex, UK) followed by" exact="eribulin" post="(Eizai, Tokyo, Japan) plus Tra. Her disease remained clinically"/>
   <result pre="A 66-year-old woman with metastatic HER2-rich BC was treated with" exact="capecitabine" post="(Cape) and lapatinib (Lap) followed by eribulin plus trastuzumab"/>
   <result pre="with metastatic HER2-rich BC was treated with capecitabine (Cape) and" exact="lapatinib" post="(Lap) followed by eribulin plus trastuzumab (Tra). (B) A"/>
   <result pre="was treated with capecitabine (Cape) and lapatinib (Lap) followed by" exact="eribulin" post="plus trastuzumab (Tra). (B) A 68-year-old woman with Luminal/HER2"/>
   <result pre="with capecitabine (Cape) and lapatinib (Lap) followed by eribulin plus" exact="trastuzumab" post="(Tra). (B) A 68-year-old woman with Luminal/HER2 BC (stage"/>
   <result pre="For example, with respect to endocrine therapy, acquired resistance to" exact="tamoxifen" post="is associated with decreased ER positivity and increased HER2"/>
   <result pre="persists, despite the discovery of other anti-HER2 therapeutic agents, including" exact="pertuzumab" post="for inhibition of the HER2-HER3 heterodimer and Lap for"/>
   <result pre="CJ Billingham LJ Campbell FM et al. Estrogen receptor and" exact="progesterone" post="receptor as predictive biomarkers of response to endocrine therapy:"/>
   <result pre="to endocrine therapy: a prospectively powered pathology study in the" exact="tamoxifen" post="and exemestane adjuvant multinational trial J. Clin. Oncol 2011"/>
   <result pre="therapy: a prospectively powered pathology study in the tamoxifen and" exact="exemestane" post="adjuvant multinational trial J. Clin. Oncol 2011 29 1531"/>
   <result pre="of women with metastatic breast cancer by HER2 status and" exact="trastuzumab" post="Treatment: an institutional-based review J. Clin. Oncol 2009 28"/>
   <result pre="C Beryt M Pietras R Slamon DJ Rational combinations of" exact="trastuzumab" post="with chemotherapeutic drugs used in the treatment of breast"/>
   <result pre="Friedman LS et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by" exact="trastuzumab" post="and is effectively inhibited by the PI3K inhibitor GDC-0941"/>
   <result pre="8 e1000563 21203579 Lavaud P Andre F Strategies to overcome" exact="trastuzumab" post="resistance in HER2-overexpressing breast cancers: focus on new data"/>
   <result pre="Oliva C Newstat B Imwalle B Geyer CE Lapatinib plus" exact="capecitabine" post="in women with HER-2-positive advanced breast cancer: final survival"/>
   <result pre="Im SA Hegg R Im YH et al. Pertuzumab plus" exact="trastuzumab" post="plus docetaxel for metastatic breast cancer N. Engl. J."/>
   <result pre="Hegg R Im YH et al. Pertuzumab plus trastuzumab plus" exact="docetaxel" post="for metastatic breast cancer N. Engl. J. Med 2012"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4570757/results/search/inn/results.xml">
   <result pre="intravenous (IV) trastuzumab. Due to progressive CNS disease, intrathecal (IT)" exact="trastuzumab" post="was introduced to enhance HER-2+ therapy into the CSF"/>
   <result pre="leading to the patient’s respiratory compromise. In our patient, IT" exact="trastuzumab" post="immunotherapy improved prognosis and was an effective strategy to"/>
   <result pre="or alongside other anti-HER-2+ therapeutics with sufficient CNS penetration, IT" exact="trastuzumab" post="could extend the lifespan of patients with leptomeningeal and"/>
   <result pre="with leptomeningeal and CNS metastases. Keywords Antibody mediated immunotherapy Intrathecal" exact="trastuzumab" post="HER-2+ leptomeningeal CNS metastases Background Trastuzumab (Herceptin; Roche, Basel,"/>
   <result pre="inferior prognosis, resulting in shorter survival [ 1, 2]. However," exact="trastuzumab" post="has transformed HER-2+ breast cancer into one of the"/>
   <result pre="of the most treatable types of cancer. The efficacy of" exact="trastuzumab" post="partially relies on its immunologic ability to recruit natural"/>
   <result pre="4]. HER-2+ metastases can develop in areas where intravenous (IV)" exact="trastuzumab" post="has little to no penetration, particularly the central nervous"/>
   <result pre="tissue and are therefore more difficult lesions to treat. As" exact="trastuzumab" post="is highly effective against systemic HER-2+ breast cancer, a"/>
   <result pre="As a single-agent first line therapy for HER-2+ breast cancer," exact="trastuzumab" post="achieved a response rate of 25 –35 % [ 5]."/>
   <result pre="women with metastatic breast cancer who progressed after standard chemotherapy," exact="trastuzumab" post="yielded response rates of 15–18 % [ 6] as"/>
   <result pre="(NOAH, Neo-ALTTO) [ 10, 11] trials have demonstrated that combining" exact="trastuzumab" post="with standard chemotherapy reduces the risk of recurrence and"/>
   <result pre="standard of care. Given its demonstrated safety and efficacy, using" exact="trastuzumab" post="to target HER-2+ tumor cells that have spread to"/>
   <result pre="the prognosis for patients with LM metastases. Yet, intrathecal (IT)" exact="trastuzumab" post="has not been formally tested in a prospective fashion."/>
   <result pre="good antitumor activity for leptomeningeal metastases [ 12– 16], IT" exact="trastuzumab" post="is underutilized as a treatment modality for HER-2+ LM"/>
   <result pre="challenge remains: To implement an effective dose schedule of IT" exact="trastuzumab" post="in combination with other standard therapies to manage both"/>
   <result pre="metastatic HER-2+ systemic disease with IV trastuzumab. By initiating IT" exact="trastuzumab" post="in combination with modalities that can deliver anti-HER-2 therapy"/>
   <result pre="developed liver, lungs, lymph nodes, and skeletal metastases. She received" exact="gemcitabine" post="plus docetaxel, concurrent with IV trastuzumab and zoledronic acid."/>
   <result pre="skeletal metastases. She received gemcitabine plus docetaxel, concurrent with IV" exact="trastuzumab" post="and zoledronic acid. Subsequent scans showed significant response with"/>
   <result pre="She received gemcitabine plus docetaxel, concurrent with IV trastuzumab and" exact="zoledronic acid." post="Subsequent scans showed significant response with clinical remission. Table"/>
   <result pre="neurological symptoms and imaging na October-2010 Ommaya inserted Experimental IT" exact="trastuzumab" post="(5 mg flat dose per week) 12.3 January-2011 New"/>
   <result pre="c1 lesions Whole brain and spine radiation and increased IT" exact="trastuzumab" post="(10 mg per week) 12.6 July-2011 Worsening intramedullary c1"/>
   <result pre="12.6 July-2011 Worsening intramedullary c1 lesions One month of IT" exact="trastuzumab" post="(50–80 mg per week) and maximal dose of cyber"/>
   <result pre="stable thoracic and lumbar lesions Increased total dose of IT" exact="trastuzumab" post="(50–80 mg BIW, dose divided twice per week) administered"/>
   <result pre="for maintenance at 50 % of the weekly dose) and" exact="lapatinib" post="(750 mg, BID five days weekly), resulted in decreased"/>
   <result pre="August-2013 Removed ommaya 50 September-2013 New ommaya inserted Restarted IT" exact="trastuzumab" post="(40 mg per week) 50 October-2013 Worsening neurological symptoms"/>
   <result pre="(40 mg per week) 50 October-2013 Worsening neurological symptoms IT" exact="trastuzumab" post="50 mg (100 mg per week) 40 August-2014 Patient"/>
   <result pre="Cyberknife therapy for IAC tumors as well as treatment with" exact="lapatinib" post="(Tykerb; Glaxo-SmithKline, Philadelphia, PA) + capecitabine (Xeloda; Roche, Basel, Switzerland) resulted"/>
   <result pre="Research Protection Program (UCLA-OHRPP). Given the wide range of IT" exact="trastuzumab" post="dosages reported in the literature (flat dosing, ranging from"/>
   <result pre="however, a worsening intramedullary C1 lesion suggested that the IT" exact="trastuzumab" post="dosage might be inadequate to treat lesions inside of"/>
   <result pre="inside of the spinal cord. To treat worsening lesions, IT" exact="trastuzumab" post="was increased to 50–80 mg administered once per week"/>
   <result pre="dose of cyberknife therapy. The weekly dose escalation of IT" exact="trastuzumab" post="resulted in stable disease until March 2013, when the"/>
   <result pre="To further target intramedullary lesion, we implemented a pulsing oral" exact="lapatinib" post="regimen (750 mg) twice a day (BID) for five"/>
   <result pre="spinal cord. The increase in dosing and frequency of IT" exact="trastuzumab" post="was generally well tolerated, except for an episode of"/>
   <result pre="CSF that create LM, brain, and spinal cord lesions. IT" exact="trastuzumab" post="was effective in targeting extramedullary (LM) metastases. This resulted"/>
   <result pre="diagnosis of LM without treatment [ 18]. Given that IV" exact="trastuzumab" post="does not cross the blood–brain barrier or blood CSF"/>
   <result pre="not cross the blood–brain barrier or blood CSF barrier, IT" exact="trastuzumab" post="offers a direct approach to the leptomeninges. IT trastuzumab"/>
   <result pre="IT trastuzumab offers a direct approach to the leptomeninges. IT" exact="trastuzumab" post="immunotherapy delivers an optimal drug concentration to the CSF"/>
   <result pre="well tolerated compared to chemotherapy, such as IT methotrexate. IT" exact="methotrexate" post="can be associated with severe side effects including meningoencephalopathy,"/>
   <result pre="and marrow suppression [ 19]. Furthermore, dose escalation of IT" exact="trastuzumab" post="enabled disease management in our patient. When imaging revealed"/>
   <result pre="or when new neurological symptoms emerged, increasing the dose of" exact="trastuzumab" post="achieved subsequent stable scans and slowed the patient’s functional"/>
   <result pre="prevent this, we have administered up to 80 mg IT" exact="trastuzumab" post="weekly in divided doses (40 mg biweekly × 4 weeks) (Table"/>
   <result pre="lumbar puncture administration in addition to ommaya injection would allow" exact="trastuzumab" post="to reach the lumbar and thoracic LM areas more"/>
   <result pre="additional way to follow our patient’s LM/CNS progression. Although IT" exact="trastuzumab" post="treatment of extramedullary metastases has greatly extended the patient’s"/>
   <result pre="the CNS. In addition, the standard non-immunotherapeutic option using IT" exact="methotrexate" post="only has a median overall survival of approximately 2–7"/>
   <result pre="LM with standard IT chemotherapy [ 21]. In contrast, IT" exact="trastuzumab" post="immunotherapy could improve the prognosis of HER-2+ LM disease,"/>
   <result pre="is in sight. A phase I/II dose escalation of IT" exact="trastuzumab" post="(Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer;"/>
   <result pre="at the highest doses used (Phase I trial of intrathecal" exact="trastuzumab" post="in HER2 positive leptomeningeal metastases, 19th Annual Scientific Meeting"/>
   <result pre="on our experience, we predict that the high efficiency of" exact="trastuzumab" post="makes it a promising candidate to favorably impact the"/>
   <result pre="cancer. While its activity on extramedullary lesions is apparent, IT" exact="trastuzumab" post="alone isn’t adequate to prevent brain or intramedullary metastases."/>
   <result pre="progression, if its dose has not been maximally implemented. Moreover," exact="trastuzumab" post="could be combined with other antibody based therapies like"/>
   <result pre="trastuzumab could be combined with other antibody based therapies like" exact="pertuzumab" post="(Perjeta; Roche, Basel, Switzerland) to improve response rates mirroring"/>
   <result pre="exciting era of using immunotherapy for HER-2+ cancers. In particular," exact="trastuzumab" post="(Herceptin) has paved the way for HER-2+ breast cancer"/>
   <result pre="studies provide favorable evidence to support the conclusion that IT" exact="trastuzumab" post="extends the lives of women with HER-2+ LM metastases."/>
   <result pre="&amp;amp; Oncology whose translational research led to the discovery of" exact="trastuzumab" post="JB is Clinical Professor of Medicine at the Department"/>
   <result pre="Harris LN, Fehrenbacher L, et al. Efficacy and safety of" exact="trastuzumab" post="as a single agent in first-line treatment of HER2-overexpressing"/>
   <result pre="S, Feyereislova A, Dowsett M, et al. 2-year follow-up of" exact="trastuzumab" post="after adjuvant chemotherapy in HER2-positive breast cancer: a randomised"/>
   <result pre="et al. Randomized phase III study of trastuzumab, paclitaxel, and" exact="carboplatin" post="compared with trastuzumab and paclitaxel in women with HER-2-overexpressing"/>
   <result pre="phase III study of trastuzumab, paclitaxel, and carboplatin compared with" exact="trastuzumab" post="and paclitaxel in women with HER-2-overexpressing metastatic breast cancer."/>
   <result pre="study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and" exact="paclitaxel" post="in women with HER-2-overexpressing metastatic breast cancer. Journal of"/>
   <result pre="label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus" exact="paclitaxel" post="in women with HER2-positive primary breast cancer Cancer Res"/>
   <result pre="A, Lluch A, Tjulandin S, et al. Neoadjuvant chemotherapy with" exact="trastuzumab" post="followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in"/>
   <result pre="S, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant" exact="trastuzumab" post="versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally"/>
   <result pre="A, Bernhard H, Lassig D, et al. Application of intrathecal" exact="trastuzumab" post="(Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing"/>
   <result pre="M, Harbeck N, Laessig D, Herrmann KA, et al. Intrathecal" exact="trastuzumab" post="(Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic"/>
   <result pre="Laessig D, Herrmann KA, et al. Intrathecal trastuzumab (Herceptin) and" exact="methotrexate" post="for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a"/>
   <result pre="Walter S Meningeal carcinomatosis from breast cancer treated with intrathecal" exact="trastuzumab" post="Lancet Oncol 2006 7 9 778 80 10.1016/S1470-2045(06)70864-6 16945774"/>
   <result pre="10.1016/S1470-2045(06)70864-6 16945774 15. Laufman LR Forsthoefel KF Use of intrathecal" exact="trastuzumab" post="in a patient with carcinomatous meningitis Clin Breast Cancer"/>
   <result pre="Ropert S, Alexandre J, Lemare F, Goldwasser F. High-dose intrathecal" exact="trastuzumab" post="for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer."/>
   <result pre="Nayak, Eudocia Quant, Priya Kumthekar. Phase I trial of intrathecal" exact="trastuzumab" post="in HER2 positive leptomeningeal metastases. in Society for Neuro-Oncology."/>
   <result pre="Dieras V, Cropet C, Dalenc F, et al. Lapatinib plus" exact="capecitabine" post="in patients with previously untreated brain metastases from HER2-positive"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4574060/results/search/inn/results.xml">
   <result pre="source are credited pone.0138229.pdf Abstract Background The relative efficacy of" exact="lapatinib" post="vs. continuing trastuzumab beyond progression (TBP) in HER2-positive metastatic"/>
   <result pre="pone.0138229.pdf Abstract Background The relative efficacy of lapatinib vs. continuing" exact="trastuzumab" post="beyond progression (TBP) in HER2-positive metastatic breast cancer (MBC)"/>
   <result pre="this population based cohort study was to compare outcomes of" exact="lapatinib" post="vs. TBP in daily practice. Methods All HER2-positive MBC"/>
   <result pre="and Cox proportional hazards model. Results 64 patients received second-line" exact="lapatinib" post="and 93 TBP. The two treatment groups were similar"/>
   <result pre="and co-morbidity rates, but differed in proportion of prior adjuvant" exact="trastuzumab" post="(lapatinib: 29.7%, TBP: 16.1%, P = 0.043) and rates"/>
   <result pre="controlling for differences in age, adjuvant trastuzumab, duration of first-line" exact="trastuzumab" post="therapy, brain metastases, visceral metastases and hormonal treatment [Hazard"/>
   <result pre="who developed disease progression while on trastuzumab-containing therapy, treatment with" exact="trastuzumab" post="'beyond progression' (TBP) together with chemotherapy is feasible, safe"/>
   <result pre="FDA approval in 2007 was for use in combination with" exact="capecitabine" post="for the treatment of patients with HER2-overexpressing MBC who"/>
   <result pre="had received prior therapy including an anthracycline, a taxane, and" exact="trastuzumab" post="[ 7]. Current ASCO practice guidelines [ 8] and"/>
   <result pre="is not yet available, there is still a question whether" exact="trastuzumab" post="should remain the HER2-suppressing agent throughout multiple lines of"/>
   <result pre="of second-line therapy of HER2-positive MBC patients, treated with either" exact="lapatinib" post="or TBP. Patients and Methods Clalit Health Services (CHS)"/>
   <result pre="nearly 53% of the total population. Both TBP and second-line" exact="lapatinib" post="are available and reimbursed in Israel since January 2010."/>
   <result pre="HER2-positive MBC patients that started second-line anti-HER2 therapy with either" exact="lapatinib" post="or TBP, after a first-line protocol containing trastuzumab, between"/>
   <result pre="lines of therapy, were not available from the database. Since" exact="tamoxifen" post="and aromatase inhibitors are fully reimbursed in Israel for"/>
   <result pre="and ≥ 50), hormonal therapy (yes/no), prior adjuvant treatment with" exact="trastuzumab" post="(yes/no), duration of first-line metastatic trastuzumab therapy, brain metastases"/>
   <result pre="prior adjuvant treatment with trastuzumab (yes/no), duration of first-line metastatic" exact="trastuzumab" post="therapy, brain metastases prior to second-line therapy (yes/no) and"/>
   <result pre="had HER2-positive MBC were identified. Patients who did not receive" exact="trastuzumab" post="in their first-line protocol (n = 18) were excluded"/>
   <result pre="the final study population included 157 patients; 64 treated with" exact="lapatinib" post="and 93 with TBP ( S1 Data). The groups"/>
   <result pre="1), apart from a higher proportion of patients in the" exact="lapatinib" post="group that had received prior adjuvant trastuzumab (29.7% vs."/>
   <result pre="patients in the lapatinib group that had received prior adjuvant" exact="trastuzumab" post="(29.7% vs. 16.1%, P = 0.043) and more patients"/>
   <result pre="vs. 16.1%, P = 0.043) and more patients in the" exact="lapatinib" post="group that had brain metastases at initiation of second-line"/>
   <result pre="follow up time was 16.0 months. All 64 patients on" exact="lapatinib" post="were concurrently treated with capecitabine. Ninety one percent (58"/>
   <result pre="concurrently treated with capecitabine. Ninety one percent (58 patients) received" exact="capecitabine" post="for the whole duration of lapatinib therapy. The 93"/>
   <result pre="percent (58 patients) received capecitabine for the whole duration of" exact="lapatinib" post="therapy. The 93 patients treated with second-line trastuzumab received"/>
   <result pre="duration of lapatinib therapy. The 93 patients treated with second-line" exact="trastuzumab" post="received a variety of parallel therapies, 80% (74 patients)"/>
   <result pre="score (average) 3.39 3.10 NS b Duration of first-line metastatic" exact="trastuzumab" post="treatment (average, months) 11.4± 10.2 12.1± 11.1 NS b"/>
   <result pre="(average, months) 11.4± 10.2 12.1± 11.1 NS b Prior adjuvant" exact="trastuzumab" post="19 (29.7%) 15 (16.1%) 0.043 c Time to relapse"/>
   <result pre="(16.1%) 0.043 c Time to relapse after completion of adjuvant" exact="trastuzumab" post="(average, months) 15.7± 15.0 19.3± 17.9 NS a Hormonal"/>
   <result pre="Paclitaxel 21 (22.6%) Docetaxel 2 (2.2%) Gemcitabine 4 (4.3%) 5FU+" exact="cisplatin" post="1 (1.1%) Capecitabine 64 (100%) 6 (6.5%) Chemotherapy (total)"/>
   <result pre="(79.6%) There were altogether 87 deaths: 44 (68.8%) in the" exact="lapatinib" post="group and 43 (46.2%) in the trastuzumab group. Median"/>
   <result pre="(68.8%) in the lapatinib group and 43 (46.2%) in the" exact="trastuzumab" post="group. Median OS was 13.0 months for lapatinib (95%"/>
   <result pre="in the trastuzumab group. Median OS was 13.0 months for" exact="lapatinib" post="(95% CI: 9.5–16.5) and 31.0 months for TBP patients"/>
   <result pre="(HR = 0.54, P = 0.006). 10.1371/journal.pone.0138229.t003 Table 3 Second-line" exact="lapatinib" post="vs. trastuzumab univariate analysis. Variable Overall survival Lapatinib ("/>
   <result pre="0.54, P = 0.006). 10.1371/journal.pone.0138229.t003 Table 3 Second-line lapatinib vs." exact="trastuzumab" post="univariate analysis. Variable Overall survival Lapatinib ( N ="/>
   <result pre="Effect Hazard ratio 95% CI P value TBP vs. second-line" exact="lapatinib" post="0.63 0.40–0.99 0.045 Age ≥ 50 vs. &amp;lt;50 1.65"/>
   <result pre="Hormonal treatment *(yes vs. no) 0.54 0.34–0.84 0.006 Prior adjuvant" exact="trastuzumab" post="(yes vs. no) 1.19 0.70–2.02 0.511 Duration of first-line"/>
   <result pre="main between-group differences may have affected outcomes. Patients in the" exact="lapatinib" post="group were significantly more likely to have received adjuvant"/>
   <result pre="lapatinib group were significantly more likely to have received adjuvant" exact="trastuzumab" post="and more patients had prior brain metastases. This might"/>
   <result pre="prior brain metastases. This might suggest that patients in the" exact="lapatinib" post="group initially presented with a more aggressive disease and"/>
   <result pre="for TBP patients occurred despite the assumed potential activity of" exact="lapatinib" post="in patients with brain metastases [ 12]. Regulatory approval"/>
   <result pre="in patients with brain metastases [ 12]. Regulatory approval for" exact="lapatinib" post="as a second-line treatment of MBC patients following prior"/>
   <result pre="a second-line treatment of MBC patients following prior therapy with" exact="trastuzumab" post="was based on a phase III study which compared"/>
   <result pre="trastuzumab was based on a phase III study which compared" exact="capecitabine" post="alone against capecitabine plus lapatinib. The median time to"/>
   <result pre="on a phase III study which compared capecitabine alone against" exact="capecitabine" post="plus lapatinib. The median time to progression in the"/>
   <result pre="combination arm was 8 months vs. 4 months in the" exact="capecitabine" post="monotherapy arm (HR = 0.49, P &amp;lt; 0.001). Median"/>
   <result pre="with HER2-positive MBC who had progressed on trastuzumab, to either" exact="capecitabine" post="plus (continued) trastuzumab, or capecitabine monotherapy. Median time to"/>
   <result pre="progressed on trastuzumab, to either capecitabine plus (continued) trastuzumab, or" exact="capecitabine" post="monotherapy. Median time to progression was 8.2 months in"/>
   <result pre="months in the combination arm vs. 5.6 months in the" exact="capecitabine" post="monotherapy arm (HR = 0.69; P = 0.04). Median"/>
   <result pre="time to progression, its primary endpoint. It was hypothesized that" exact="trastuzumab" post="may act as a chemotherapy sensitizer, and when a"/>
   <result pre="the first published prospective, phase III, head-to-head comparison study of" exact="lapatinib" post="and trastuzumab in metastatic patients. Patients with brain metastases"/>
   <result pre="published prospective, phase III, head-to-head comparison study of lapatinib and" exact="trastuzumab" post="in metastatic patients. Patients with brain metastases were excluded"/>
   <result pre="and the design of the current study was that prior" exact="trastuzumab" post="for MBC was allowed in CEREBEL, but not required."/>
   <result pre="In fact, only 35% of the CEREBEL patients received prior" exact="trastuzumab" post="in the metastatic setting. In contrast to the aforementioned"/>
   <result pre="presents 'real-life' outcomes of patients who faced failure on first-line" exact="trastuzumab" post="and chemotherapy, including in patients who had already developed"/>
   <result pre="and with other increasing evidence showing less preferable outcomes with" exact="lapatinib" post="compared to trastuzumab in various breast cancer settings. Recently,"/>
   <result pre="increasing evidence showing less preferable outcomes with lapatinib compared to" exact="trastuzumab" post="in various breast cancer settings. Recently, Gelmon et al."/>
   <result pre="there was a trend for OS in favor of the" exact="trastuzumab" post="arm. Several limitations to the current analysis must be"/>
   <result pre="and dose density and intensity of the chemotherapies combined with" exact="trastuzumab" post="cannot be excluded. Besides, missing data on whether any"/>
   <result pre="'real world' practice is important in examining comparative effectiveness of" exact="lapatinib" post="and trastuzumab in the context of actual patient care."/>
   <result pre="practice is important in examining comparative effectiveness of lapatinib and" exact="trastuzumab" post="in the context of actual patient care. The results"/>
   <result pre="differences in prior brain metastases and rate of previous adjuvant" exact="trastuzumab" post="therapy. This study is hypothesis generating and results should"/>
   <result pre="et al. Safety of treatment of metastatic breast cancer with" exact="trastuzumab" post="beyond disease progression. J Clin Oncol. 2004; 22: 1063–"/>
   <result pre="positive metastatic breast cancer patients benefit from the use of" exact="trastuzumab" post="beyond disease progression? A mono-institutional experience and systemic review"/>
   <result pre="et al. FDA Drug Approval Summary: Lapatinib in combination with" exact="capecitabine" post="for previously treated metastatic breast cancer that overexpresses HER-2"/>
   <result pre="Stemmler HJ , et al. Multicenter phase II study of" exact="lapatinib" post="in patients with brain metastases from HER2- positive breast"/>
   <result pre="Romieu CG , Pienkowski T , et al. Lapatinib plus" exact="capecitabine" post="for HER2-positive advanced breast cancer. N Engl J Med."/>
   <result pre="B , Imwalle B , Geyer CE . Lapatinib plus" exact="capecitabine" post="in women with HER-2-positive advanced breast cancer: final survival"/>
   <result pre="al. CEREBEL (EGF111438): A phase III, randomized open-label study of" exact="lapatinib" post="plus capecitabine versus trastuzumab plus capecitabine in patients with"/>
   <result pre="(EGF111438): A phase III, randomized open-label study of lapatinib plus" exact="capecitabine" post="versus trastuzumab plus capecitabine in patients with human epidermal"/>
   <result pre="phase III, randomized open-label study of lapatinib plus capecitabine versus" exact="trastuzumab" post="plus capecitabine in patients with human epidermal growth factor"/>
   <result pre="randomized open-label study of lapatinib plus capecitabine versus trastuzumab plus" exact="capecitabine" post="in patients with human epidermal growth factor receptor 2-positive"/>
   <result pre="A , Di Leo A , et al. Lapatinib or" exact="trastuzumab" post="plus taxane therapy for human epidermal growth factor receptor"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4578850/results/search/inn/results.xml">
   <result pre="cancers that are low grade and oestrogen receptor (ER)- and" exact="progesterone" post="receptor (PR)-positive and human epidermal growth factor receptor 2"/>
   <result pre="the primary tumour and lymph nodes after neoadjuvant treatment. Is" exact="bevacizumab" post="a special case?: exploring the effect on the relationship"/>
   <result pre="for a ‘pure’ angiogenesis inhibition Reports of neo/adjuvant use of" exact="bevacizumab" post="in early breast cancer have produced added complexity when"/>
   <result pre="pCR rates and longer-term outcomes. In addition, two large adjuvant" exact="bevacizumab" post="trials, BEATRICE (TNBC) and ECOG Study E5103 (HER2-negative), show"/>
   <result pre="(HER2-negative), show no benefit from the addition of 12 months’" exact="bevacizumab" post="therapy to adjuvant chemotherapy [ 37, 38]. In our"/>
   <result pre="angiogenesis-independent micro-metastatic disease, particularly in the bone marrow. Whilst adjuvant" exact="bevacizumab" post="may delay the development of established metastatic disease during"/>
   <result pre="support this hypothesis because it demonstrates improved longer-term outcomes with" exact="bevacizumab" post="in the ER-positive group when both neoadjuvant and adjuvant"/>
   <result pre="only. This trial was completed just before the paradigm-shifting adjuvant" exact="trastuzumab" post="studies demonstrated the large benefit from adjuvant trastuzumab ["/>
   <result pre="paradigm-shifting adjuvant trastuzumab studies demonstrated the large benefit from adjuvant" exact="trastuzumab" post="[ 43, 44]. We must remember that in ALLTO"/>
   <result pre="therapy could improve on the impressive results of these initial" exact="trastuzumab" post="studies. These ‘second order’ trials are always going to"/>
   <result pre="large adjuvant trials. Fig. 4 Expected event-free survival curves for" exact="trastuzumab" post="as well as for the combination of trastuzumab and"/>
   <result pre="curves for trastuzumab as well as for the combination of" exact="trastuzumab" post="and lapatinib are shown based on the NeoALTTO results."/>
   <result pre="trastuzumab as well as for the combination of trastuzumab and" exact="lapatinib" post="are shown based on the NeoALTTO results. (Reproduced with"/>
   <result pre="already good. Both the BEATRICE and ALLTO adjuvant trials (of" exact="bevacizumab" post="and dual anti-HER2 therapy respectively) demonstrate Hatzis’ modelling, because"/>
   <result pre="A et al. Phase III trial evaluating the addition of" exact="paclitaxel" post="to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as"/>
   <result pre="al. Phase III trial evaluating the addition of paclitaxel to" exact="doxorubicin" post="followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or"/>
   <result pre="C Grybowicz L Vallier AL et al. Efficacy of neoadjuvant" exact="bevacizumab" post="added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide,"/>
   <result pre="Vallier AL et al. Efficacy of neoadjuvant bevacizumab added to" exact="docetaxel" post="followed by fluorouracil, epirubicin and cyclophosphamide, for women with"/>
   <result pre="Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil," exact="epirubicin" post="and cyclophosphamide, for women with HER2 negative early breast"/>
   <result pre="gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and" exact="paclitaxel" post="for women with high-risk early breast cancer (Neo-tAnGo): an"/>
   <result pre="PA et al. Survival after neoadjuvant chemotherapy with or without" exact="bevacizumab" post="or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)"/>
   <result pre="al. Survival after neoadjuvant chemotherapy with or without bevacizumab or" exact="everolimus" post="for HER2-negative primary breast cancer (GBG 44-GeparQuinto) Ann Oncol"/>
   <result pre="Jr, Liu Q, Robidoux A, et al. Neoadjuvant plus adjuvant" exact="bevacizumab" post="in early breast cancer (NSABP B-40 [NRG Oncology]): secondary"/>
   <result pre="A Tjulandin S Zambetti M et al. Neoadjuvant and adjuvant" exact="trastuzumab" post="in patients with HER2-positive locally advanced breast cancer (NOAH):"/>
   <result pre="PA Tesch H Eggemann H et al. Neoadjuvant chemotherapy and" exact="bevacizumab" post="for HER2-negative breast cancer N Engl J Med 2012"/>
   <result pre="CT Tolaney SM et al. Impact of the addition of" exact="carboplatin" post="and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense"/>
   <result pre="SM et al. Impact of the addition of carboplatin and/or" exact="bevacizumab" post="to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and"/>
   <result pre="of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week" exact="paclitaxel" post="followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete"/>
   <result pre="carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense" exact="doxorubicin" post="and cyclophosphamide on pathologic complete response rates in stage"/>
   <result pre="bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and" exact="cyclophosphamide" post="on pathologic complete response rates in stage II to"/>
   <result pre="S de Azambuja E Aura C et al. Lapatinib with" exact="trastuzumab" post="for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label,"/>
   <result pre="comparing one year of anti-HER2 therapy with Lapatinib alone (L)," exact="trastuzumab" post="alone (T), their sequence (T then L), or their"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4586465/results/search/inn/results.xml">
   <result pre="a triple-negative receptor status, with loss of estrogen receptor (ER)," exact="progesterone" post="receptor (PR) and HER-2. Thus, TNBC remains unresponsive to"/>
   <result pre="risk of cardiotoxicity. Similarly, while small-molecule RTK inhibitors, such as" exact="erlotinib" post="and lapatinib, are approved as single agents or in"/>
   <result pre="EC [ 33]. Based on data from the ToGA trial," exact="trastuzumab" post="was approved in 2010 for patients with HER-2-positive metastatic"/>
   <result pre="with chemotherapy [ 34, 35]. Additionally, the HER-2 targeted hmAb" exact="pertuzumab" post="has had significant clinical success in the treatment of"/>
   <result pre="success in the treatment of breast cancer when combined with" exact="trastuzumab" post="[ 36]; similar dual-targeting clinical trials are under way"/>
   <result pre="This observation led to the evaluation of the anti-HER-1 antibody" exact="cetuximab" post="in the clinical setting as single and combination treatments"/>
   <result pre="single and combination treatments [ 50, 51]. HER-1-targeting with hmAb" exact="cetuximab" post="performed poorly in metastatic breast cancer. However, further trials"/>
   <result pre="performed poorly in metastatic breast cancer. However, further trials combining" exact="cetuximab" post="with cisplatin showed significant success in phase II trials,"/>
   <result pre="in metastatic breast cancer. However, further trials combining cetuximab with" exact="cisplatin" post="showed significant success in phase II trials, establishing HER-1"/>
   <result pre="therapy has also demonstrated clinical success in gastric cancers. Notably," exact="lapatinib" post="produced synergistic antitumor effects in vitro when combined with"/>
   <result pre="phase III trial (ToGA) testing the combination of chemotherapy with" exact="trastuzumab" post="in HER-2 positive gastroesophageal cancers showed an increase in"/>
   <result pre="generally develop secondary resistance to monoclonal antibody regimens, such as" exact="trastuzumab" post="[ 62]; the development of resistance may be exacerbated"/>
   <result pre="[ 65]. Phase II clinical trials with the HER-1 inhibitor" exact="gefitinib" post="and the HER-2 hmAb trastuzumab failed to show a"/>
   <result pre="trials with the HER-1 inhibitor gefitinib and the HER-2 hmAb" exact="trastuzumab" post="failed to show a synergistic effect in patients with"/>
   <result pre="[ 66]. Further, the combination of the HER-1 kinase inhibitor" exact="erlotinib" post="and VEGF hmAb bevacizumab showed little therapeutic benefit in"/>
   <result pre="combination of the HER-1 kinase inhibitor erlotinib and VEGF hmAb" exact="bevacizumab" post="showed little therapeutic benefit in a phase II trial"/>
   <result pre="II trial of renal cell cancer. However, the HER-1 hmAb" exact="cetuximab" post="combined with the VEGF hmAb bevacizumab showed promising synergy"/>
   <result pre="However, the HER-1 hmAb cetuximab combined with the VEGF hmAb" exact="bevacizumab" post="showed promising synergy in preliminary data obtained in colorectal"/>
   <result pre="based on the crystallographic structures of the humanized monoclonal antibodies" exact="trastuzumab" post="and pertuzumab in complex with HER-2. Peptide synthesis was"/>
   <result pre="the crystallographic structures of the humanized monoclonal antibodies trastuzumab and" exact="pertuzumab" post="in complex with HER-2. Peptide synthesis was performed using"/>
   <result pre="FBS and other supplements were obtained from Invitrogen. Cetuximab and" exact="trastuzumab" post="were purchased from The James Cancer Hospital pharmacy of"/>
   <result pre="vessels (CD31). HER-2-266-296 and HER-2-597-626 were respectively designed from the" exact="pertuzumab" post="and trastuzumab binding sites of the HER-2 extracellular domain;"/>
   <result pre="HER-2-266-296 and HER-2-597-626 were respectively designed from the pertuzumab and" exact="trastuzumab" post="binding sites of the HER-2 extracellular domain; after synthesis,"/>
   <result pre="and measured proliferation using an MTT assay. Commercially available drugs" exact="trastuzumab" post="and cetuximab were used as a positive controls and"/>
   <result pre="proliferation using an MTT assay. Commercially available drugs trastuzumab and" exact="cetuximab" post="were used as a positive controls and rabbit and"/>
   <result pre="treatment alone (* p &amp;lt; 0.05). The commercially available drugs" exact="cetuximab" post="and trastuzumab were used as positive controls and showed"/>
   <result pre="(* p &amp;lt; 0.05). The commercially available drugs cetuximab and" exact="trastuzumab" post="were used as positive controls and showed higher levels"/>
   <result pre="or normal rabbit IgG was used as a negative control;" exact="trastuzumab" post="and cetuximab were positive controls. Values represent the mean"/>
   <result pre="rabbit IgG was used as a negative control; trastuzumab and" exact="cetuximab" post="were positive controls. Values represent the mean of at"/>
   <result pre="(Pierce, Rockford, IL, USA) were used as a negative control;" exact="cetuximab" post="and trastuzumab were positive controls. In EC cells, at"/>
   <result pre="IL, USA) were used as a negative control; cetuximab and" exact="trastuzumab" post="were positive controls. In EC cells, at a 100:1"/>
   <result pre="not significantly inhibit phosphorylation. This result is not surprising, as" exact="trastuzumab" post="binds to sub domain III of HER-2 but does"/>
   <result pre="single or combination treatments of peptide vaccine antibodies. Trastuzumab and" exact="cetuximab" post="were used as positive controls, and normal rabbit IgG"/>
   <result pre="luminometer. Normal rabbit IgG was used as a negative control;" exact="cetuximab" post="and trastuzumab were positive controls. Results are representative of"/>
   <result pre="rabbit IgG was used as a negative control; cetuximab and" exact="trastuzumab" post="were positive controls. Results are representative of two independent"/>
   <result pre="(** p &amp;lt; 0.001) ( Figure 4A). The combination of" exact="cetuximab" post="and trastuzumab also increased apoptosis significantly over single treatment"/>
   <result pre="&amp;lt; 0.001) ( Figure 4A). The combination of cetuximab and" exact="trastuzumab" post="also increased apoptosis significantly over single treatment of either"/>
   <result pre="EC patients in which HER-2 is overexpressed, normally treated with" exact="trastuzumab" post="in combination with cytotoxic chemotherapy have only modest survival"/>
   <result pre="importance of combination therapies in novel cancer treatment. Co-treatment with" exact="trastuzumab" post="and cetuximab has shown promising anti proliferative effects in"/>
   <result pre="combination therapies in novel cancer treatment. Co-treatment with trastuzumab and" exact="cetuximab" post="has shown promising anti proliferative effects in vitro in"/>
   <result pre="treatments. The HER-2-266 and HER-2-597 epitopes were created to mimic" exact="pertuzumab" post="and trastuzumab, respectively, and thus, exert their anti-tumor effects"/>
   <result pre="II and likely directly interferes with receptor dimerization, the HER-2-597" exact="trastuzumab" post="like epitope binds the c-terminal of the extracellular region"/>
   <result pre="and safer treatment option than current monoclonal antibody such as" exact="trastuzumab" post="or cetuximab. Current monoclonal antibody therapies are limited by"/>
   <result pre="Middleton G. Daniel F. Oates J. Norman A.R. Capecitabine and" exact="oxaliplatin" post="for advanced esophagogastric cancer N. Engl. J. Med. 2008"/>
   <result pre="Reimann J.D. Vassel A. A phase I/II dose-escalation trial of" exact="bevacizumab" post="in previously treated metastatic breast cancer Sem. Oncol. 2003"/>
   <result pre="llalpha gene amplification, intestinal type, poor prognosis and sensitivity to" exact="trastuzumab" post="Ann. Oncol. 2005 16 273 278 10.1093/annonc/mdi064 15668283 33."/>
   <result pre="J.M. Schneeweiss A. Knott A. et al. Pertuzumab, trastuzumab, and" exact="docetaxel" post="for HER2-positive metastatic breast cancer (cleopatra study): Overall survival"/>
   <result pre="A. et al. Tbcrc 001: Randomized phase ii study of" exact="cetuximab" post="in combination with carboplatin in stage iv triple-negative breast"/>
   <result pre="001: Randomized phase ii study of cetuximab in combination with" exact="carboplatin" post="in stage iv triple-negative breast cancer J. Clin. Oncol."/>
   <result pre="ii study of the anti-epidermal growth factor receptor monoclonal antibody" exact="cetuximab" post="with cisplatin versus cisplatin alone in patients with metastatic"/>
   <result pre="of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with" exact="cisplatin" post="versus cisplatin alone in patients with metastatic triple-negative breast"/>
   <result pre="anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus" exact="cisplatin" post="alone in patients with metastatic triple-negative breast cancer J."/>
   <result pre="and induction of survivin expression counteract the antitumor action of" exact="erlotinib" post="Cancer Res. 2006 66 10100 10111 10.1158/0008-5472.CAN-06-1684 17047074 55."/>
   <result pre="growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of" exact="gefitinib" post="(Iressa) in human breast cancer cells Breast Cancer Res."/>
   <result pre="Integrating molecular mechanisms and clinical evidence in the management of" exact="trastuzumab" post="resistant or refractory HER-2(+) metastatic breast cancer Oncologist 2011"/>
   <result pre="66. Moulder S.L. Arteaga C.L. A phase I/II trial of" exact="trastuzumab" post="and gefitinib in patients with metastatic breast cancer that"/>
   <result pre="S.L. Arteaga C.L. A phase I/II trial of trastuzumab and" exact="gefitinib" post="in patients with metastatic breast cancer that overexpresses HER2/neu"/>
   <result pre="et al. Randomized phase II trial of cetuximab, bevacizumab, and" exact="irinotecan" post="compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal"/>
   <result pre="phase II trial of cetuximab, bevacizumab, and irinotecan compared with" exact="cetuximab" post="and bevacizumab alone in irinotecan-refractory colorectal cancer: The bond-2"/>
   <result pre="trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and" exact="bevacizumab" post="alone in irinotecan-refractory colorectal cancer: The bond-2 study J."/>
   <result pre="Phillips G. Forni G. Morris J.C. Kaumaya P.T. Novel engineered" exact="trastuzumab" post="conformational epitopes demonstrate in vitro and in vivo antitumor"/>
   <result pre="P.T. Immunotherapy with HER-2 and VEGF peptide mimics plus metronomic" exact="paclitaxel" post="causes superior antineoplastic effects in transplantable and transgenic mouse"/>
   <result pre="Jang J. Thorner A.R. et al. Preexisting oncogenic events impact" exact="trastuzumab" post="sensitivity in ErbB2-amplified gastroesophageal adenocarcinoma J. Clin. Investig. 2014"/>
   <result pre="V. Condorelli D. Castorina S. In vitro antiproliferative effect of" exact="trastuzumab" post="(herceptin ®) combined with cetuximab (erbitux ®) in a"/>
   <result pre="In vitro antiproliferative effect of trastuzumab (herceptin ®) combined with" exact="cetuximab" post="(erbitux ®) in a model of human non-small cell"/>
   <result pre="factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to" exact="trastuzumab" post="resistance of breast cancer cells Cancer Res. 2005 65"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4586793/results/search/inn/results.xml">
   <result pre="with metastatic colorectal cancer [ 11, 12]. The benefit of" exact="cetuximab" post="and Panitumumab was limited to patients with RAS wild-type"/>
   <result pre="17]. More recently, Lapatinib has been used in combination with" exact="letrozole" post="(Femara) to treat postmenopausal women with Hormone receptor (HR)"/>
   <result pre="secondary target. These small molecule inhibitors include imatinib, sunitinib, sorafenib," exact="pazopanib" post="and nilotinib. Imatinib (Gleevec), a well-known inhibitor of the"/>
   <result pre="significant improvement of overall survival, many patients developed resistance to" exact="imatinib" post="[ 28]. Other drugs such as sunitinib, soratinib, pazopanib"/>
   <result pre="to imatinib [ 28]. Other drugs such as sunitinib, soratinib," exact="pazopanib" post="and nilotinib were used to target multiple RTK receptors"/>
   <result pre="[ 28]. Other drugs such as sunitinib, soratinib, pazopanib and" exact="nilotinib" post="were used to target multiple RTK receptors (e.g., PDGFR"/>
   <result pre="that renders the tyrosine kinase resistant to the inhibition of" exact="imatinib" post="[ 37, 38, 119]. Although newer c-Kit drugs have"/>
   <result pre=". This mutation is single-base missense substitution of valine with" exact="glutamic acid" post="at codon 600 (V600E) of the kinase domain and"/>
   <result pre="somatic mutation of AKT1 isoform associated with the substitution of" exact="glutamic acid" post="by a lysine at amino acid 17 (E17K) of"/>
   <result pre="isoform associated with the substitution of glutamic acid by a" exact="lysine" post="at amino acid 17 (E17K) of Akt1 have been"/>
   <result pre="Stewart S.J. Safety of treatment of metastatic breast cancer with" exact="trastuzumab" post="beyond disease progression J. Clin. Oncol. 2004 22 1063"/>
   <result pre="Thomas A. Tjulandin S. Zhang K. et al. Panitumumab versus" exact="cetuximab" post="in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic"/>
   <result pre="factor receptor exon 19 and exon 21 mutations treated with" exact="gefitinib" post="or erlotinib Clin. Cancer Res. 2006 12 839 844"/>
   <result pre="exon 19 and exon 21 mutations treated with gefitinib or" exact="erlotinib" post="Clin. Cancer Res. 2006 12 839 844 10.1158/1078-0432.CCR-05-1846 16467097"/>
   <result pre="G. Manikhas A. Kennedy M.J. et al. Lapatinib combined with" exact="letrozole" post="versus letrozole and placebo as first-line therapy for postmenopausal"/>
   <result pre="A. Kennedy M.J. et al. Lapatinib combined with letrozole versus" exact="letrozole" post="and placebo as first-line therapy for postmenopausal hormone receptor-positive"/>
   <result pre="Crown J. Chan A. Kaufman B. et al. Lapatinib plus" exact="capecitabine" post="for HER2-positive advanced breast cancer N. Engl. J. Med."/>
   <result pre="E. Adolf G.R. Target binding properties and cellular activity of" exact="afatinib" post="(BIBW 2992), an irreversible ErbB family blocker J. Pharmacol."/>
   <result pre="S. Garcia A.A. et al. A phase II study of" exact="afatinib" post="(BIBW 2992), an irreversible ErbB family blocker, in patients"/>
   <result pre="blocker, in patients with HER2-positive metastatic breast cancer progressing after" exact="trastuzumab" post="Breast Cancer Res. Treat. 2012 133 1057 1065 10.1007/s10549-012-2003-y"/>
   <result pre="Bjarnason G.A. et al. Overall survival and updated results for" exact="sunitinib" post="compared with interferon alfa in patients with metastatic renal"/>
   <result pre="Heinrich M.C. Morgan J.A. et al. Efficacy and safety of" exact="sunitinib" post="in patients with advanced gastrointestinal stromal tumour after failure"/>
   <result pre="Seynaeve C. Verweij J. Improved insight into resistance mechanisms to" exact="imatinib" post="in gastrointestinal stromal tumors: A basis for novel approaches"/>
   <result pre="M. Lee J. Davey B.B. von Mehren M. Evaluation of" exact="nilotinib" post="in advanced GIST previously treated with imatinib and sunitinib"/>
   <result pre="M. Evaluation of nilotinib in advanced GIST previously treated with" exact="imatinib" post="and sunitinib Cancer Chemother. Pharmacol. 2012 69 977 982"/>
   <result pre="of nilotinib in advanced GIST previously treated with imatinib and" exact="sunitinib" post="Cancer Chemother. Pharmacol. 2012 69 977 982 10.1007/s00280-011-1785-7 22119758"/>
   <result pre="H. Leutner C.C. Heinicke T. Hohenberger P. Acquired resistance to" exact="imatinib" post="in gastrointestinal stromal tumours caused by multiple KIT mutations"/>
   <result pre="gastrointestinal stromal tumors: Frequency, spectrum and in vitro sensitivity to" exact="imatinib" post="J. Clin. Oncol. 2005 23 5357 5364 10.1200/JCO.2005.14.068 15928335"/>
   <result pre="A multicenter phase 1 study of PX-866 in combination with" exact="docetaxel" post="in patients with advanced solid tumours Br. J. Cancer"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4588449/results/search/inn/results.xml">
   <result pre="in situ hybridization (FISH)/silver in situ hybridization (SISH) positive. Although" exact="trastuzumab" post="monotherapy has been reported to inhibit tumor growth and"/>
   <result pre="had previously received standard therapy, including trastuzumab, lapatinib, taxane, and" exact="capecitabine" post="prior to enrollment. Subjects with low expression level of"/>
   <result pre="single standard chemotherapy involving anthracycline, taxane, gemcitabine, capecitabine, vinorelbine, and" exact="cyclophosphamide" post="prior to enrollment. After the vaccination program, three subjects"/>
   <result pre="normal levels (from 43 to 12 ng/ml) after being treated with" exact="doxorubicin" post="+ cyclophosphamide and letrozole between weeks 8 and 24."/>
   <result pre="(from 43 to 12 ng/ml) after being treated with doxorubicin +" exact="cyclophosphamide" post="and letrozole between weeks 8 and 24. PR was"/>
   <result pre="to 12 ng/ml) after being treated with doxorubicin + cyclophosphamide and" exact="letrozole" post="between weeks 8 and 24. PR was observed due"/>
   <result pre="conventional anticancer therapies needs to be investigated. Certain chemotherapy involving" exact="gemcitabine" post="and cyclophosphamide was reported to diminish the immune suppressor"/>
   <result pre="therapies needs to be investigated. Certain chemotherapy involving gemcitabine and" exact="cyclophosphamide" post="was reported to diminish the immune suppressor function of"/>
   <result pre="study entry, and who completed standard therapies and progressed beyond" exact="trastuzumab" post="and lapatinib at least 4 weeks prior to enrollment"/>
   <result pre="and who completed standard therapies and progressed beyond trastuzumab and" exact="lapatinib" post="at least 4 weeks prior to enrollment met the"/>
   <result pre="patients were excluded if they received a cumulative dose of" exact="doxorubicin" post="&amp;gt; 360 mg/m 2 or epirubicin &amp;gt; 720 mg/m 2 by"/>
   <result pre="received a cumulative dose of doxorubicin &amp;gt; 360 mg/m 2 or" exact="epirubicin" post="&amp;gt; 720 mg/m 2 by the time of study entry"/>
   <result pre="8 weeks after the first injection. Particularly, anthracyclines such as" exact="doxorubicin" post="and epirubicin were prohibited during the 24 weeks follow-up"/>
   <result pre="after the first injection. Particularly, anthracyclines such as doxorubicin and" exact="epirubicin" post="were prohibited during the 24 weeks follow-up period. Also,"/>
   <result pre="epirubicin were prohibited during the 24 weeks follow-up period. Also," exact="trastuzumab" post="and herbal medicines that might affect immune system were"/>
   <result pre="Cook-Bruns, N and Barton, C ( 2004). Cardiotoxicity associated with" exact="trastuzumab" post="(Herceptin) therapy in the treatment of metastatic breast cancer"/>
   <result pre="human vascular endothelial growth factor receptor 2 in combination with" exact="gemcitabine" post="for patients with advanced pancreatic cancer . Cancer Sci"/>
   <result pre="cohort 2, and one subject in cohort 3 had received" exact="trastuzumab" post="as HER2-targeted agent. d Nine subjects had been treated"/>
   <result pre="d Nine subjects had been treated with combination regimens; 5-FU+cyclophosphamide+methotrexate," exact="cyclophosphamide" post="+doxorubicin, carboplatin+paclitaxel, capecitabine+vinorelbine, gemcitabine+vinorelbine, 5-FU+doxorubicin+cyclophosphamide, trastuzumab+paclitaxel, vinorelbine+gemcitabine, capecitabine+lapatinib, pazopanib+lapatinib,"/>
   <result pre="Hormone therapy: tamoxifen, exemestane, and letrozole, f Supportive therapy: goserelin," exact="zoledronic acid," post="and pamidronate. g One subject in cohort 1 (mitomycin"/>
   <result pre="j One subject in cohort 1 and 2 had received" exact="letrozole" post="hormone therapy. k Supportive therapy: methylprednisolone, pamidronate, and zoledronic"/>
   <result pre="received letrozole hormone therapy. k Supportive therapy: methylprednisolone, pamidronate, and" exact="zoledronic acid." post="Table 3 Adverse events Cohort 1 2 3 Number"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4589126/results/search/inn/results.xml">
   <result pre="pmcid: 4589126 doi: 10.2147/BTT.S62777 btt-9-093 : Review Clinical utility of" exact="ramucirumab" post="in advanced gastric cancer Chan Matthew MK 1 2"/>
   <result pre="will focus on the clinical utility and potential use of" exact="ramucirumab" post="in advanced gastric cancer. Keywords ramucirumab IMC-1121B gastric cancer"/>
   <result pre="and potential use of ramucirumab in advanced gastric cancer. Keywords" exact="ramucirumab" post="IMC-1121B gastric cancer vascular endothelial growth factor receptor-2 angiogenesis"/>
   <result pre="a platinum (cisplatin or oxaliplatin) and fluoropyrimidine (5-fluorouracil [5-FU] or" exact="capecitabine" post="or S-1 [Taiho Pharmaceutical Co., Ltd, Tokyo, Japan]) doublet,"/>
   <result pre="Japan]) doublet, or a triplet regimen with the addition of" exact="epirubicin" post="or docetaxel, provides a survival benefit and improved quality"/>
   <result pre="Cancer (ToGA) trial has shown that the anti-HER-2 monoclonal antibody," exact="trastuzumab" post="(Herceptin; Hoffman-La Roche Ltd., Basel, Switzerland), has a modest"/>
   <result pre="randomized, Phase III trials, demonstrating a modest survival benefit for" exact="docetaxel" post="or irinotecan monotherapy, as compared with best supportive care."/>
   <result pre="III trials, demonstrating a modest survival benefit for docetaxel or" exact="irinotecan" post="monotherapy, as compared with best supportive care. 18– 20"/>
   <result pre="of different second-line treatments. A Japanese trial that compared weekly" exact="paclitaxel" post="(80 mg/m 2 on Day [D] 1, D8, and"/>
   <result pre="and D15 and then every [q] 28 days [d]) versus" exact="irinotecan" post="(150 mg/m 2 on D1 and D15 and then"/>
   <result pre="chemotherapy, the TCOG GI-0801/BIRIP trial randomized 130 patients to combination" exact="cisplatin" post="(30 mg/m 2 on D1 and then q14d) plus"/>
   <result pre="cisplatin (30 mg/m 2 on D1 and then q14d) plus" exact="irinotecan" post="(60 mg/m 2 on D1 and then q14d) or"/>
   <result pre="irinotecan (60 mg/m 2 on D1 and then q14d) or" exact="irinotecan" post="alone (150 mg/m 2 on D1 and then q14d)."/>
   <result pre="mg/m 2 on D1 and then q14d). This showed that" exact="cisplatin" post="and irinotecan improved progression free survival (PFS) (3.8 vs"/>
   <result pre="on D1 and then q14d). This showed that cisplatin and" exact="irinotecan" post="improved progression free survival (PFS) (3.8 vs 2.8 months;"/>
   <result pre="advanced gastric cancer including epidermal growth factor receptor (EGFR) inhibitors," exact="cetuximab" post="(Erbitux; Merck Serono, Darmstadt, Germany) 24 and panitumumab (Vectibix;"/>
   <result pre="(EGFR) inhibitors, cetuximab (Erbitux; Merck Serono, Darmstadt, Germany) 24 and" exact="panitumumab" post="(Vectibix; Amgen Inc., Thousand Oaks, CA, USA), 25 and"/>
   <result pre="Inc., Thousand Oaks, CA, USA), 25 and the mTOR inhibitor," exact="everolimus" post="(Afinitor; Novartis International AG, Basel, Switzerland), 26 none of"/>
   <result pre="benefit in Phase III trials. A second-line Japanese/Korean study of" exact="irinotecan" post="with or without nimotuzumab is ongoing (NCT01813253). An OS"/>
   <result pre="second-line, Phase III trial of the HER-2 tyrosine kinase inhibitor," exact="lapatinib" post="(Tykerb; Glaxo-SmithKline plc, London, UK), in combination with pacli-taxel."/>
   <result pre="UK), in combination with pacli-taxel. 27 Phase III trials investigating" exact="trastuzumab" post="emtansine (Kadcyla TDM-1; Hoffman-La Roche Ltd) in the GATSBY"/>
   <result pre="(Kadcyla TDM-1; Hoffman-La Roche Ltd) in the GATSBY trial and" exact="pertuzumab" post="(Perjeta; Hoffman-La Roche Ltd) in the JACOB trial are"/>
   <result pre="Phase III study investigating a poly ADP ribose polymerase inhibitor" exact="olaparib" post="in combination with paclitaxel chemotherapy is ongoing (NCT01924533) following"/>
   <result pre="a poly ADP ribose polymerase inhibitor olaparib in combination with" exact="paclitaxel" post="chemotherapy is ongoing (NCT01924533) following Phase II data in"/>
   <result pre="in the second-line which showed an OS benefit in the" exact="olaparib" post="group. 30 Two studies that examined the role of"/>
   <result pre="olaparib group. 30 Two studies that examined the role of" exact="bevacizumab" post="(Avastin; Hoffman-La Roche Ltd) directed against the vascular endothelial"/>
   <result pre="was a large (n=774), multicenter, international, Phase III trial of" exact="capecitabine" post="and cisplatin chemotherapy with (n=387) or without (n=387) bevacizumab"/>
   <result pre="large (n=774), multicenter, international, Phase III trial of capecitabine and" exact="cisplatin" post="chemotherapy with (n=387) or without (n=387) bevacizumab (Avastin; Hoffman-La"/>
   <result pre="of capecitabine and cisplatin chemotherapy with (n=387) or without (n=387)" exact="bevacizumab" post="(Avastin; Hoffman-La Roche Ltd). This study showed a better"/>
   <result pre="5.3 months; HR: 0.8, 95% CI: 0.68–0.93, P=0.0037) in the" exact="bevacizumab" post="group. However, this study did not meet its primary"/>
   <result pre="is currently no role for anti-VEGF monoclonal antibodies such as" exact="bevacizumab" post="in advanced gastric cancer outside of clinical trials. Angiogenic"/>
   <result pre="sorafenib) Sunitinib (Sutent; Pfizer Inc., New York, NY, USA) and" exact="sorafenib" post="(Nexavar; Bayer AG, Leverkusen, Germany) are small molecule, multi-targeted,"/>
   <result pre="Phase II trial, for advanced gastric cancer, randomized patients to" exact="docetaxel" post="(60 mg/m 2 D1 and then q21d), with or"/>
   <result pre="(60 mg/m 2 D1 and then q21d), with or without" exact="sunitinib" post="(37.5 mg oral daily). This showed a higher objective"/>
   <result pre="mg oral twice daily) has been studied in combination with" exact="docetaxel" post="(75 mg/m 2 D1 and then q21d) and cisplatin"/>
   <result pre="with docetaxel (75 mg/m 2 D1 and then q21d) and" exact="cisplatin" post="(75 mg/m 2 D1 and then q21d) in a"/>
   <result pre="infusion over 60 minutes q2 weeks, the pharmacokinetic profile of" exact="ramucirumab" post="at steady state is characterized by a half-life of"/>
   <result pre="This study showed a safety profile that was similar to" exact="bevacizumab" post="with grade 3 adverse events that included hypertension, deep"/>
   <result pre="of 20 μg/mL was met. 58 Based on these studies," exact="ramucirumab" post="was evaluated at the 8 mg/kg dose q2 weeks"/>
   <result pre="dose q2 weeks in ongoing studies. Phase II studies of" exact="ramucirumab" post="in combination with paclitaxel and docetaxel in patients with"/>
   <result pre="ongoing studies. Phase II studies of ramucirumab in combination with" exact="paclitaxel" post="and docetaxel in patients with gastric cancer have been"/>
   <result pre="Phase II studies of ramucirumab in combination with paclitaxel and" exact="docetaxel" post="in patients with gastric cancer have been published in"/>
   <result pre="abstract form. 59, 60 These studies showed that co-administration of" exact="ramucirumab" post="with paclitaxel or docetaxel chemotherapy does not affect the"/>
   <result pre="59, 60 These studies showed that co-administration of ramucirumab with" exact="paclitaxel" post="or docetaxel chemotherapy does not affect the pharmacokinetics of"/>
   <result pre="These studies showed that co-administration of ramucirumab with paclitaxel or" exact="docetaxel" post="chemotherapy does not affect the pharmacokinetics of the chemotherapy"/>
   <result pre="2,400 mg/m 2 over 48 hours, and then q14d) plus" exact="ramucirumab" post="(8 mg/kg q14d) versus mFOLFOX6 plus placebo in first-line"/>
   <result pre="(HR: 1.08). 61 Disease control rate was better in the" exact="ramucirumab" post="group (85% vs 67%). Subgroup analysis by tumor site"/>
   <result pre="III studies There have been six Phase III trials of" exact="ramucirumab" post="completed to date including studies in breast cancer, hepatocellular"/>
   <result pre="cancer ( Table 2). The landmark REGARD trial (NCT00917384) of" exact="ramucirumab" post="was the first study of an anti-angiogenic targeted drug"/>
   <result pre="Phase III trial designed to evaluate the efficacy of second-line" exact="ramucirumab" post="monotherapy for advanced gastric cancer ( Table 3). Patients"/>
   <result pre="best supportive care and were randomized 2:1 to receive either" exact="ramucirumab" post="(8 mg/kg intravenous infusion q2 weeks) or placebo until"/>
   <result pre="used. The median treatment duration was 8 weeks in the" exact="ramucirumab" post="group and 6 weeks in the placebo group. There"/>
   <result pre="placebo group. There was an improvement in PFS in the" exact="ramucirumab" post="treated group (HR: 0.483, 95% CI: 0.376–0.620, P&amp;lt;0.0001) with"/>
   <result pre="CI: 0.376–0.620, P&amp;lt;0.0001) with median PFS of 2.1 months for" exact="ramucirumab" post="and 1.3 months for placebo. There was an improvement"/>
   <result pre="for placebo. There was an improvement in OS in the" exact="ramucirumab" post="treated group (HR: 0.776, 95% CI: 0.603–0.998, P=0.047) with"/>
   <result pre="P=0.047) with a median OS of 5.2 months for the" exact="ramucirumab" post="and 3.8 months for the placebo treated groups, respectively."/>
   <result pre="both groups. However, the disease control rate was higher for" exact="ramucirumab" post="(49%) than placebo (23%). The authors concluded that VEGFR-2"/>
   <result pre="placebo-controlled, Phase III trial designed to evaluate the use of" exact="paclitaxel" post="with or without ramucirumab in patients with previously treated"/>
   <result pre="designed to evaluate the use of paclitaxel with or without" exact="ramucirumab" post="in patients with previously treated advanced gastric cancer. 34"/>
   <result pre="or without an anthracycline). Six hundred and sixty-five patients received" exact="paclitaxel" post="(80 mg/m 2 on D1, D8, D15, and then"/>
   <result pre="used. The median treatment duration was 18.0 weeks in the" exact="paclitaxel" post="plus ramucirumab group and 12.0 weeks in the paclitaxel"/>
   <result pre="median treatment duration was 18.0 weeks in the paclitaxel plus" exact="ramucirumab" post="group and 12.0 weeks in the paclitaxel plus placebo"/>
   <result pre="the paclitaxel plus ramucirumab group and 12.0 weeks in the" exact="paclitaxel" post="plus placebo group. The median PFS was 4.4 months"/>
   <result pre="placebo group. The median PFS was 4.4 months for the" exact="paclitaxel" post="plus ramucirumab and 2.9 months for the paclitaxel plus"/>
   <result pre="The median PFS was 4.4 months for the paclitaxel plus" exact="ramucirumab" post="and 2.9 months for the paclitaxel plus placebo groups"/>
   <result pre="for the paclitaxel plus ramucirumab and 2.9 months for the" exact="paclitaxel" post="plus placebo groups (HR: 0.635, 95% CI: 0.536–0.752, P&amp;lt;0.0001)."/>
   <result pre="CI: 0.536–0.752, P&amp;lt;0.0001). The median OS was 9.6 months for" exact="paclitaxel" post="plus ramucirumab and 7.4 months for paclitaxel plus placebo"/>
   <result pre="P&amp;lt;0.0001). The median OS was 9.6 months for paclitaxel plus" exact="ramucirumab" post="and 7.4 months for paclitaxel plus placebo arms of"/>
   <result pre="9.6 months for paclitaxel plus ramucirumab and 7.4 months for" exact="paclitaxel" post="plus placebo arms of the study (HR: 0.807, 95%"/>
   <result pre="based on investigator-determined RECIST assessments, were both better in the" exact="paclitaxel" post="plus ramucirumab group. The RAINBOW trial is the largest"/>
   <result pre="investigator-determined RECIST assessments, were both better in the paclitaxel plus" exact="ramucirumab" post="group. The RAINBOW trial is the largest trial of"/>
   <result pre="to date. Although the median OS of patients treated with" exact="paclitaxel" post="plus ramucirumab in the RAINBOW trial was higher than"/>
   <result pre="Although the median OS of patients treated with paclitaxel plus" exact="ramucirumab" post="in the RAINBOW trial was higher than the median"/>
   <result pre="was higher than the median OS of patients treated with" exact="ramucirumab" post="monotherapy in the REGARD trial, the REGARD trial included"/>
   <result pre="not directly comparable, the additional benefit of adding chemotherapy to" exact="ramucirumab" post="as second-line therapy is not known and the optimal"/>
   <result pre="favorably with second-line studies of chemotherapy alone. Ongoing trials investigating" exact="ramucirumab" post="in advanced gastric cancer, outlined in Table 4, include"/>
   <result pre="Table 4, include an international, multicenter, Phase III trial of" exact="cisplatin" post="plus capecitabine with, or without, ramucirumab as first-line treatment"/>
   <result pre="include an international, multicenter, Phase III trial of cisplatin plus" exact="capecitabine" post="with, or without, ramucirumab as first-line treatment for gastric"/>
   <result pre="Phase III trial of cisplatin plus capecitabine with, or without," exact="ramucirumab" post="as first-line treatment for gastric cancer (NCT02314117). A summary"/>
   <result pre="gastric cancer (NCT02314117). A summary of Phase III trials of" exact="ramucirumab" post="in other tumor types are summarized in Table 2."/>
   <result pre="of patients with elevated baseline alpha-fetoprotein who received treatment with" exact="ramucirumab" post="for advanced HCC did show a survival benefit making"/>
   <result pre="survival benefit seen in HER-2 negative metastatic breast cancer, when" exact="ramucirumab" post="was added to first-line docetaxel chemotherapy, is due to"/>
   <result pre="negative metastatic breast cancer, when ramucirumab was added to first-line" exact="docetaxel" post="chemotherapy, is due to the choice of chemotherapy partner"/>
   <result pre="strategies for this tumor type. Safety and tolerability Toxicity Overall," exact="ramucirumab" post="is well tolerated ( Tables 5 and 6). In"/>
   <result pre="( Tables 5 and 6). In the REGARD trial of" exact="ramucirumab" post="versus placebo, the most frequent grade 3 or above"/>
   <result pre="vs &amp;lt;1%), or infusion-related reactions (0% vs 0%) associated with" exact="ramucirumab" post="use. More patients had to discontinue the drug due"/>
   <result pre="discontinue the drug due to an adverse event in the" exact="ramucirumab" post="group compared to placebo (10% vs 6%). In the"/>
   <result pre="to placebo (10% vs 6%). In the RAINBOW trial of" exact="paclitaxel" post="plus ramucirumab versus paclitaxel, the most frequent grade 3"/>
   <result pre="(10% vs 6%). In the RAINBOW trial of paclitaxel plus" exact="ramucirumab" post="versus paclitaxel, the most frequent grade 3 or above"/>
   <result pre="increased rate of treatment discontinuation or treatment-related death in the" exact="paclitaxel" post="plus ramucirumab group. Further safety and efficacy data based"/>
   <result pre="of treatment discontinuation or treatment-related death in the paclitaxel plus" exact="ramucirumab" post="group. Further safety and efficacy data based on the"/>
   <result pre="and efficacy data based on the real world use of" exact="ramucirumab" post="would be informative as this treatment has only a"/>
   <result pre="benefit. In particular, safety issues such as the use of" exact="ramucirumab" post="in patients with the primary tumor in-situ ought to"/>
   <result pre="97% of patients in the best supportive care (BSC) plus" exact="ramucirumab" post="group and 94% of patients in the BSC plus"/>
   <result pre="baseline quality of life data, only 48% of patients receiving" exact="ramucirumab" post="and 25% of patients receiving placebo had quality of"/>
   <result pre="reported stable or improved global quality of life in the" exact="ramucirumab" post="group, this was not statistically significant when compared with"/>
   <result pre="with the placebo treated group ( P=0.23). Patients in the" exact="ramucirumab" post="group maintained ECOG PS longer than the placebo group"/>
   <result pre="baseline quality of life data and 64% of patients receiving" exact="ramucirumab" post="plus paclitaxel and 61% of patients receiving placebo plus"/>
   <result pre="of life data and 64% of patients receiving ramucirumab plus" exact="paclitaxel" post="and 61% of patients receiving placebo plus paclitaxel had"/>
   <result pre="ramucirumab plus paclitaxel and 61% of patients receiving placebo plus" exact="paclitaxel" post="had end of treatment quality of life data. The"/>
   <result pre="meta-analyses of chemotherapy as well as Phase III studies of" exact="ramucirumab" post="would suggest that appropriate patients with good performance status"/>
   <result pre="fluoropyrimidine or platinum-based chemotherapy. Its approval was subsequently extended to" exact="ramucirumab" post="in combination with paclitaxel chemotherapy in November 2014 based"/>
   <result pre="Its approval was subsequently extended to ramucirumab in combination with" exact="paclitaxel" post="chemotherapy in November 2014 based on the results of"/>
   <result pre="the RAINBOW study. 62 In the absence of comparative studies," exact="ramucirumab" post="alone or in combination with paclitaxel provides an alternative"/>
   <result pre="absence of comparative studies, ramucirumab alone or in combination with" exact="paclitaxel" post="provides an alternative treatment option to docetaxel or irinotecan"/>
   <result pre="in combination with paclitaxel provides an alternative treatment option to" exact="docetaxel" post="or irinotecan chemotherapy in the second-line setting given the"/>
   <result pre="with paclitaxel provides an alternative treatment option to docetaxel or" exact="irinotecan" post="chemotherapy in the second-line setting given the similar modest"/>
   <result pre="effect profile. However, there have been no comparative trials of" exact="ramucirumab" post="versus chemotherapy and its routine use may be limited"/>
   <result pre="organ function, the more meaningful clinical benefit seen with using" exact="ramucirumab" post="in combination with paclitaxel chemotherapy in the second-line setting"/>
   <result pre="meaningful clinical benefit seen with using ramucirumab in combination with" exact="paclitaxel" post="chemotherapy in the second-line setting as shown in the"/>
   <result pre="with advanced gastric cancer. Second-line chemotherapy using a taxane or" exact="irinotecan" post="may be considered for patients with good ECOG PS"/>
   <result pre="with good ECOG PS who have advanced gastric cancer where" exact="ramucirumab" post="is not available. 18– 20 There is currently a"/>
   <result pre="HER-2 over-expressing advanced gastric cancers who have disease progression following" exact="trastuzumab" post="containing chemotherapy regimens remains unclear although clinical trials with"/>
   <result pre="gastric cancer. Future considerations may include investigating the use of" exact="ramucirumab" post="in the first-line setting, in combination with other chemotherapeutic"/>
   <result pre="further investigation given the positive OS data when combined with" exact="paclitaxel" post="that was not seen when ramucirumab was combined with"/>
   <result pre="data when combined with paclitaxel that was not seen when" exact="ramucirumab" post="was combined with mFOLFOX6. Therefore, the Phase III trial"/>
   <result pre="was combined with mFOLFOX6. Therefore, the Phase III trial of" exact="ramucirumab" post="in combination with cisplatin and capecitabine in first line"/>
   <result pre="Therefore, the Phase III trial of ramucirumab in combination with" exact="cisplatin" post="and capecitabine in first line is eagerly awaited. Dosage"/>
   <result pre="Phase III trial of ramucirumab in combination with cisplatin and" exact="capecitabine" post="in first line is eagerly awaited. Dosage and dose"/>
   <result pre="additional issues that may be examined as well as the" exact="ramucirumab" post="exposure-survival and ramucirumab exposure-safety relationship. Further post registration studies"/>
   <result pre="may be examined as well as the ramucirumab exposure-survival and" exact="ramucirumab" post="exposure-safety relationship. Further post registration studies may provide further"/>
   <result pre="and efficacy data based on the real world use of" exact="ramucirumab" post="that may not have been identified in the Phase"/>
   <result pre="3 Bang YJ Kim YW Yang HK et al. Adjuvant" exact="capecitabine" post="and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC):"/>
   <result pre="YJ Kim YW Yang HK et al. Adjuvant capecitabine and" exact="oxaliplatin" post="for gastric cancer after D2 gastrectomy (CLASSIC): a phase"/>
   <result pre="Cunningham D Starling N Rao S et al. Capecitabine and" exact="oxaliplatin" post="for advanced esophagogastric cancer N Engl J Med 2008"/>
   <result pre="trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either" exact="oxaliplatin" post="or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie"/>
   <result pre="Koizumi W Narahara H Hara T et al. S-1 plus" exact="cisplatin" post="versus S-1 alone for first-line treatment of advanced gastric"/>
   <result pre="Moiseyenko VM Tjulandin S et al. Phase III study of" exact="docetaxel" post="and cisplatin plus fluorouracil compared with cisplatin and fluorouracil"/>
   <result pre="Tjulandin S et al. Phase III study of docetaxel and" exact="cisplatin" post="plus fluorouracil compared with cisplatin and fluorouracil as first-line"/>
   <result pre="et al. Phase III study of docetaxel and cisplatin plus" exact="fluorouracil" post="compared with cisplatin and fluorouracil as first-line therapy for"/>
   <result pre="III study of docetaxel and cisplatin plus fluorouracil compared with" exact="cisplatin" post="and fluorouracil as first-line therapy for advanced gastric cancer:"/>
   <result pre="of docetaxel and cisplatin plus fluorouracil compared with cisplatin and" exact="fluorouracil" post="as first-line therapy for advanced gastric cancer: a report"/>
   <result pre="Yamamoto S Fukuda H et al. Fluorouracil versus combination of" exact="irinotecan" post="plus cisplatin versus S-1 in metastatic gastric cancer: a"/>
   <result pre="Fukuda H et al. Fluorouracil versus combination of irinotecan plus" exact="cisplatin" post="versus S-1 in metastatic gastric cancer: a randomised phase"/>
   <result pre="et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional" exact="fluorouracil" post="in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS"/>
   <result pre="PC Kretzschmar A Bichev D et al. Survival advantage for" exact="irinotecan" post="versus best supportive care as second-line chemotherapy in gastric"/>
   <result pre="Yasui H et al. Randomized, open-label, phase III study comparing" exact="irinotecan" post="with paclitaxel in patients with advanced gastric cancer without"/>
   <result pre="et al. Randomized, open-label, phase III study comparing irinotecan with" exact="paclitaxel" post="in patients with advanced gastric cancer without severe peritoneal"/>
   <result pre="23 Higuchi K Tanabe S Shimada K et al. Biweekly" exact="irinotecan" post="plus cisplatin versus irinotecan alone as second-line treatment for"/>
   <result pre="K Tanabe S Shimada K et al. Biweekly irinotecan plus" exact="cisplatin" post="versus irinotecan alone as second-line treatment for advanced gastric"/>
   <result pre="S Shimada K et al. Biweekly irinotecan plus cisplatin versus" exact="irinotecan" post="alone as second-line treatment for advanced gastric cancer: a"/>
   <result pre="Lordick F Kang YK Chung HC et al. Capecitabine and" exact="cisplatin" post="with or without cetuximab for patients with previously untreated"/>
   <result pre="Chung HC et al. Capecitabine and cisplatin with or without" exact="cetuximab" post="for patients with previously untreated advanced gastric cancer (EXPAND):"/>
   <result pre="T Chau I Cunningham D et al. Epirubicin, oxaliplatin, and" exact="capecitabine" post="with or without panitumumab for patients with previously untreated"/>
   <result pre="D et al. Epirubicin, oxaliplatin, and capecitabine with or without" exact="panitumumab" post="for patients with previously untreated advanced oesophagogastric cancer (REAL3):"/>
   <result pre="Satoh T Xu R-H Chung HC et al. Lapatinib plus" exact="paclitaxel" post="versus paclitaxel alone in the second-line treatment of HER2-amplified"/>
   <result pre="Xu R-H Chung HC et al. Lapatinib plus paclitaxel versus" exact="paclitaxel" post="alone in the second-line treatment of HER2-amplified advanced gastric"/>
   <result pre="Hoff P Tabernero J Shen L et al. P-0111 pertuzumab," exact="trastuzumab" post="and chemotherapy in HER2-positive metastatic gastric or gastro-oesophageal junction"/>
   <result pre="Bang Y Im S Lee K et al. Olaparib plus" exact="paclitaxel" post="in patients with recurrent or metastatic gastric cancer: a"/>
   <result pre="Shen L Li J Xu J et al. Bevacizumab plus" exact="capecitabine" post="and cisplatin in Chinese patients with inoperable locally advanced"/>
   <result pre="Li J Xu J et al. Bevacizumab plus capecitabine and" exact="cisplatin" post="in Chinese patients with inoperable locally advanced or metastatic"/>
   <result pre="H Muro K Van Cutsem E et al. Ramucirumab plus" exact="paclitaxel" post="versus placebo plus paclitaxel in patients with previously treated"/>
   <result pre="Cutsem E et al. Ramucirumab plus paclitaxel versus placebo plus" exact="paclitaxel" post="in patients with previously treated advanced gastric or gastro-oesophageal"/>
   <result pre="G Bonotto M Ongaro E et al. Critical appraisal of" exact="ramucirumab" post="(IMC-1121B) for cancer treatment: from benchside to clinical use"/>
   <result pre="J Lee J et al. Randomised phase II trial of" exact="docetaxel" post="and sunitinib in patients with metastatic gastric cancer who"/>
   <result pre="J et al. Randomised phase II trial of docetaxel and" exact="sunitinib" post="in patients with metastatic gastric cancer who were previously"/>
   <result pre="Powell M O’Dwyer PJ et al. Phase II study of" exact="sorafenib" post="in combination with docetaxel and cisplatin in the treatment"/>
   <result pre="et al. Phase II study of sorafenib in combination with" exact="docetaxel" post="and cisplatin in the treatment of metastatic or advanced"/>
   <result pre="Phase II study of sorafenib in combination with docetaxel and" exact="cisplatin" post="in the treatment of metastatic or advanced gastric and"/>
   <result pre="al. INTEGRATE: A randomized phase II double-blind placebo-controlled study of" exact="regorafenib" post="in refractory advanced oesophagogastric cancer (AOGC) – A study"/>
   <result pre="Garon EB Ciuleanu TE Arrieta O et al. Ramucirumab plus" exact="docetaxel" post="versus placebo plus docetaxel for second-line treatment of stage"/>
   <result pre="Arrieta O et al. Ramucirumab plus docetaxel versus placebo plus" exact="docetaxel" post="for second-line treatment of stage IV non-small-cell lung cancer"/>
   <result pre="a randomized placebo-controlled phase III trial evaluating the addition of" exact="ramucirumab" post="to first-line docetaxel chemotherapy in metastatic breast cancer J"/>
   <result pre="phase III trial evaluating the addition of ramucirumab to first-line" exact="docetaxel" post="chemotherapy in metastatic breast cancer J Clin Oncol 2015"/>
   <result pre="M et al. Phase I pharmacologic and biologic study of" exact="ramucirumab" post="(IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting"/>
   <result pre="et al. Phase II study evaluating the effect of concomitant" exact="ramucirumab" post="(IMC-1121B; RAM) on the pharmacokinetics (PK) of docetaxel (DOC)"/>
   <result pre="of concomitant ramucirumab (IMC-1121B; RAM) on the pharmacokinetics (PK) of" exact="docetaxel" post="(DOC) in patients (pts) with advanced malignant solid tumors"/>
   <result pre="et al. Phase II study evaluating the effect of concomitant" exact="ramucirumab" post="(IMC-1121B; RAM) on the pharmacokinetics (PK) of paclitaxel (PTX)"/>
   <result pre="of concomitant ramucirumab (IMC-1121B; RAM) on the pharmacokinetics (PK) of" exact="paclitaxel" post="(PTX) and the PK of RAM as monotherapy in"/>
   <result pre="32 Suppl 15S abstr 4004–256S 62 Ramucirumab in combination with" exact="paclitaxel" post="US Food and Drug Administration; US Department of Health"/>
   <result pre="vascular endothelial growth factor in four phase III trials evaluating" exact="bevacizumab" post="Clin Cancer Res 2013 19 929 937 23169435 Figure"/>
   <result pre="fluoropyrimidine-based chemotherapy  Thuss-Patience et al 20 Germany 40 BSC ±" exact="irinotecan" post="(250 mg/m 2 on D1 and then q21d, increasing"/>
   <result pre="(irinotecan 150 mg/m 2 on D1 and then q14d or" exact="docetaxel" post="60 mg/m 2 on D1 and then q21d) NA"/>
   <result pre="0.657, P=0.007  Ford et al 19 UK 168 BSC ±" exact="docetaxel" post="(75 mg/m 2 on D1 and then q21d) 7"/>
   <result pre="HR: 0.67, P=0.01  Hironaka et al 22 Japan 223 Weekly" exact="paclitaxel" post="(80 mg/m 2 on D1, D8, and D15 and"/>
   <result pre="on D1, D8, and D15 and then q28d) vs biweekly" exact="irinotecan" post="(150 mg/m 2 on D1 and D15 and then"/>
   <result pre="et al 23 Japan 130 Irinotecan (60 mg/m 2) +" exact="cisplatin" post="(30 mg/m 2) q2w vs irinotecan (150 mg/m 2"/>
   <result pre="(60 mg/m 2) + cisplatin (30 mg/m 2) q2w vs" exact="irinotecan" post="(150 mg/m 2 q2w) 22 vs 16 ( P=0.4975)"/>
   <result pre="q, every. Table 2 Summary of Phase III trials of" exact="ramucirumab" post="in other tumor types Trial ID Tumor Line n"/>
   <result pre="n Regimens Status NCT01168973 48 NSCLC Second 1,253 Ramucirumab +" exact="docetaxel" post="vs placebo + docetaxel Improved OS and PFS NCT01183780"/>
   <result pre="48 NSCLC Second 1,253 Ramucirumab + docetaxel vs placebo +" exact="docetaxel" post="Improved OS and PFS NCT01183780 50 Colon Second 1,050"/>
   <result pre="end point OS NCT00703326 49 Breast First 1,144 Ramucirumab +" exact="docetaxel" post="vs placebo + docetaxel Did not meet primary end"/>
   <result pre="49 Breast First 1,144 Ramucirumab + docetaxel vs placebo +" exact="docetaxel" post="Did not meet primary end point PFS Abbreviations: BSC,"/>
   <result pre="primary end point PFS Abbreviations: BSC, best supportive care; FOLFIRI," exact="fluorouracil" post="and irinotecan; HCC, hepatocellular carcinoma; NSCLC, non-small-cell lung cancer;"/>
   <result pre="PFS, progression free survival. Table 3 Summary of trials investigating" exact="ramucirumab" post="for advanced gastric cancer Trial ID Phase Line Indication"/>
   <result pre="NA NA NA NCT01253525 I Last Gastric 6 Ramucirumab +" exact="paclitaxel" post="NA NA NA NA NCT01515306 I Last Solid tumors"/>
   <result pre="NA NA NCT01515306 I Last Solid tumors 40 Ramucirumab +" exact="paclitaxel" post="NA NA NA NA NCT01567163 I Last Solid tumors"/>
   <result pre="NA NA NCT01567163 I Last Solid tumors 22 Ramucirumab +" exact="docetaxel" post="NA NA NA NA NCT01634555 I Last Solid tumors"/>
   <result pre="P=0.047 NCT01170663 (RAINBOW) 34 III Second Gastric 665 Ramucirumab +" exact="paclitaxel" post="(n=330) vs placebo + paclitaxel (n=335) 28 vs 16"/>
   <result pre="Second Gastric 665 Ramucirumab + paclitaxel (n=330) vs placebo +" exact="paclitaxel" post="(n=335) 28 vs 16 80 vs 64 4.4 vs"/>
   <result pre="7.4; HR: 0.807, P=0.0169 Abbreviations: BSC, best supportive care; FOLFIRI," exact="fluorouracil" post="and irinotecan; FOLFOX, fluorouracil and oxaliplatin; ORR, overall response"/>
   <result pre="Abbreviations: BSC, best supportive care; FOLFIRI, fluorouracil and irinotecan; FOLFOX," exact="fluorouracil" post="and oxaliplatin; ORR, overall response rate; DCR, disease control"/>
   <result pre="survival; NA, not available. Table 4 Ongoing clinical trials investigating" exact="ramucirumab" post="for advanced gastric cancer Trial ID Phase Line Intervention"/>
   <result pre="open 65 US study NCT02314117 III First line Cisplatin +" exact="capecitabine" post="± ramucirumab Recruiting 616 International Notes: a Group 1:"/>
   <result pre="US study NCT02314117 III First line Cisplatin + capecitabine ±" exact="ramucirumab" post="Recruiting 616 International Notes: a Group 1: capecitabine +"/>
   <result pre="capecitabine ± ramucirumab Recruiting 616 International Notes: a Group 1:" exact="capecitabine" post="+ cisplatin, group 2: S-1 + cisplatin, group 3:"/>
   <result pre="side effects occurring in at least 10% of patients on" exact="ramucirumab" post="plus paclitaxel, irrespective of causality Ramucirumab plus paclitaxel (n"/>
   <result pre="patients on ramucirumab plus paclitaxel, irrespective of causality Ramucirumab plus" exact="paclitaxel" post="(n =327) Placebo plus paclitaxel (n = 329) Grades"/>
   <result pre="irrespective of causality Ramucirumab plus paclitaxel (n =327) Placebo plus" exact="paclitaxel" post="(n = 329) Grades 1–2 Grade 3 Grade 4"/>
   <result pre="H, Muro K, Van Cutsem E, et al, Ramucirumab plus" exact="paclitaxel" post="versus placebo plus paclitaxel in patients with previously treated"/>
   <result pre="Cutsem E, et al, Ramucirumab plus paclitaxel versus placebo plus" exact="paclitaxel" post="in patients with previously treated advanced gastric or gastro-oesophageal"/>
   <result pre="(Phase III)  NCT01774786 JACOB III First XP-T with or without" exact="pertuzumab" post="780  NCT01450696 HELOISE III First XP-T (standard) vs XP-T"/>
   <result pre="Second Irinotecan ± nimotuzumab 400  NCT01924533 III Second Paclitaxel ±" exact="olaparib" post="500 Abbreviations: BSC, best supportive care; XP, cisplatin and"/>
   <result pre="Paclitaxel ± olaparib 500 Abbreviations: BSC, best supportive care; XP," exact="cisplatin" post="and capecitabine; T, trastuzumab; TDM-1, trastuzumab emtansine."/>
   <result pre="best supportive care; XP, cisplatin and capecitabine; T, trastuzumab; TDM-1," exact="trastuzumab" post="emtansine."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4589954/results/search/inn/results.xml">
   <result pre="the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant" exact="trastuzumab" post="benefit in Alliance N9831 Perez Edith A. (904) 953-0118"/>
   <result pre="Abstract Introduction The N9831 trial demonstrated the efficacy of adjuvant" exact="trastuzumab" post="for patients with human epidermal growth factor receptor 2"/>
   <result pre="and benefit from trastuzumab. Methods N9831 tested the addition of" exact="trastuzumab" post="to chemotherapy in stage I–III HER2-positive breast cancer. For"/>
   <result pre="breast cancer. For two of the arms of the trial," exact="doxorubicin" post="and cyclophosphamide followed by paclitaxel (AC-T) and doxorubicin and"/>
   <result pre="For two of the arms of the trial, doxorubicin and" exact="cyclophosphamide" post="followed by paclitaxel (AC-T) and doxorubicin and cyclophosphamide followed"/>
   <result pre="the arms of the trial, doxorubicin and cyclophosphamide followed by" exact="paclitaxel" post="(AC-T) and doxorubicin and cyclophosphamide followed by paclitaxel and"/>
   <result pre="the trial, doxorubicin and cyclophosphamide followed by paclitaxel (AC-T) and" exact="doxorubicin" post="and cyclophosphamide followed by paclitaxel and trastuzumab concurrent chemotherapy-trastuzumab"/>
   <result pre="doxorubicin and cyclophosphamide followed by paclitaxel (AC-T) and doxorubicin and" exact="cyclophosphamide" post="followed by paclitaxel and trastuzumab concurrent chemotherapy-trastuzumab (AC-TH), recurrence"/>
   <result pre="followed by paclitaxel (AC-T) and doxorubicin and cyclophosphamide followed by" exact="paclitaxel" post="and trastuzumab concurrent chemotherapy-trastuzumab (AC-TH), recurrence score (RS) and"/>
   <result pre="paclitaxel (AC-T) and doxorubicin and cyclophosphamide followed by paclitaxel and" exact="trastuzumab" post="concurrent chemotherapy-trastuzumab (AC-TH), recurrence score (RS) and HER2 mRNA"/>
   <result pre="was used to assess the association of HER2 expression with" exact="trastuzumab" post="benefit in preventing distant recurrence. Results Median follow-up was"/>
   <result pre="analysis, the association of HER2 expression by 21-gene assay with" exact="trastuzumab" post="benefit was marginally nonsignificant (nonlinear p = 0.057). In hormone receptor-positive"/>
   <result pre="were similar and high. Association of HER2 mRNA expression with" exact="trastuzumab" post="benefit as measured by time to distant recurrence was"/>
   <result pre="time to distant recurrence was nonsignificant. A consistent benefit of" exact="trastuzumab" post="irrespective of mHER2 levels was observed in patients with"/>
   <result pre="predictive markers for specific targeted therapies, including trastuzumab, pertuzumab, and" exact="lapatinib" post="[ 3, 4]. Reliable testing methodology is critical and"/>
   <result pre="13, 17]. Interestingly, both studies demonstrated the efficacy of adjuvant" exact="trastuzumab" post="added to chemoendocrine therapy not only for centrally assessed"/>
   <result pre="intratumoral heterogeneity. There is no firm evidence of a differential" exact="trastuzumab" post="benefit due to quantitative differences in HER2 gene copy,"/>
   <result pre="In two large randomized trials a similar benefit of adding" exact="trastuzumab" post="to adjuvant chemotherapy was observed for patients whose tumors"/>
   <result pre="19]. NSABP B-47 will ultimately illuminate whether the addition of" exact="trastuzumab" post="to chemotherapy improves invasive disease-free survival (DFS) in women"/>
   <result pre="quantitative RNA analysis of HER2 as predictor of benefit from" exact="trastuzumab" post="has not been reported prior to the study reported"/>
   <result pre="predictive of the magnitude of benefit from the addition of" exact="trastuzumab" post="to adjuvant chemotherapy in NCCTG (Alliance) N9831. The hypothesis"/>
   <result pre="was that increasing levels of expression are associated with increasing" exact="trastuzumab" post="benefit. A secondary objective was to evaluate the concordance"/>
   <result pre="Methods Patients The N9831 trial (the phase III trial of" exact="doxorubicin" post="and cyclophosphamide followed by weekly paclitaxel with or without"/>
   <result pre="The N9831 trial (the phase III trial of doxorubicin and" exact="cyclophosphamide" post="followed by weekly paclitaxel with or without trastuzumab as"/>
   <result pre="phase III trial of doxorubicin and cyclophosphamide followed by weekly" exact="paclitaxel" post="with or without trastuzumab as adjuvant treatment for women"/>
   <result pre="doxorubicin and cyclophosphamide followed by weekly paclitaxel with or without" exact="trastuzumab" post="as adjuvant treatment for women with HER2-overexpressing or -amplified"/>
   <result pre="(IRBs) [ 30]. The study had three arms: Arm A," exact="doxorubicin" post="and cyclophosphamide followed by weekly paclitaxel; Arm B, same"/>
   <result pre="30]. The study had three arms: Arm A, doxorubicin and" exact="cyclophosphamide" post="followed by weekly paclitaxel; Arm B, same as Arm"/>
   <result pre="tumor. Specimens were scored as per the instructions in the" exact="trastuzumab" post="package insert. A specimen with at least 10 %"/>
   <result pre="tumor tissue was deparaffinized using Shandon xylene substitute followed by" exact="ethanol" post="washes. RNA was extracted using Agencourt FormaPure kit (Beckman"/>
   <result pre="the association between HER2 expression level and the benefit of" exact="trastuzumab" post="for distant recurrence, comparing Arm C to Arm A."/>
   <result pre="to test for the significance of the ability to predict" exact="trastuzumab" post="benefit. Statistical power was prospectively estimated at ≥90 %"/>
   <result pre="status by RT-PCR, IHC or FISH and the benefit of" exact="trastuzumab" post="for distant recurrence. Kaplan-Meier estimates were generated for the"/>
   <result pre="%)  Unknown - 1 (&amp;lt;1 %) ER estrogen receptor, PR" exact="progesterone" post="receptor * p value from chi-square test for nominal"/>
   <result pre="of whom were also negative by central IHC. Prediction of" exact="trastuzumab" post="benefit by assessment of HER2 In the primary analysis,"/>
   <result pre="associated with the magnitude of benefit from the addition of" exact="trastuzumab" post="to adjuvant chemotherapy (nonlinear p = 0.057, Fig. 4). Hence, in"/>
   <result pre="centrally in 94 % of patients, the hypothesis of increasing" exact="trastuzumab" post="benefit with increasing HER2 mRNA expression was not supported."/>
   <result pre="mRNA expression was not supported. Fig. 4 Hazard ratio for" exact="trastuzumab" post="benefit as a continuous function of HER2 expression by"/>
   <result pre="nodes), overall and in different patient subsets. Hazard ratios for" exact="trastuzumab" post="benefit are depicted in a forest plot, along with"/>
   <result pre="intervals (Fig. 5). In all 901 patients, the addition of" exact="trastuzumab" post="halved the risk of distant recurrence (hazard ratio = 0.50, p &amp;lt; 0.001)."/>
   <result pre="stratified by HER2 status by RT-PCR, the hazard ratios for" exact="trastuzumab" post="treatment were 0.31 (95 % CI 0.09–0.83) for HER2-negative,"/>
   <result pre="for HER2-positive patients. There was a statistically significant benefit of" exact="trastuzumab" post="in patients who were HER2 negative by RT-PCR, and"/>
   <result pre="the 95 % confidence intervals for the hazard ratio for" exact="trastuzumab" post="benefit overlapped with the overall hazard ratio of 0.50."/>
   <result pre="For secondary endpoint DFS, there also was no association between" exact="trastuzumab" post="benefit and continuous HER2 by RT-PCR ( p = 0.21). In"/>
   <result pre="who were HER2 negative by RT-PCR, the hazard ratio for" exact="trastuzumab" post="treatment was 0.55 (95 % CI 0.26–1.12, p = 0.11). The"/>
   <result pre="0.55 (95 % CI 0.26–1.12, p = 0.11). The hazard ratios for" exact="trastuzumab" post="benefit were 0.81 (95 % CI 0.25–2.40) for HER2-equivocal,"/>
   <result pre="analyses of HER2 expression, hormone receptor status and prediction of" exact="trastuzumab" post="benefit Exploratory analyses were performed to evaluate the joint"/>
   <result pre="of ER expression and HER2 expression, assess the effect of" exact="trastuzumab" post="treatment by hormone receptor (HR) status, and the association"/>
   <result pre="receptor (HR) status, and the association between HER2 expression and" exact="trastuzumab" post="benefit by HR status. A scatterplot of ER expression"/>
   <result pre="consistent with the N9831 parent trial results, a statistically significant" exact="trastuzumab" post="benefit for distant recurrence was observed in both HR-positive"/>
   <result pre="RT-PCR (HR = 0.77, 95 % CI 0.59–0.997, p = 0.047). A statistically significant" exact="trastuzumab" post="benefit for DFS was observed in HR-positive patients ("/>
   <result pre="p = 0.051). Thus, HR status was neither prognostic nor predictive of" exact="trastuzumab" post="benefit for DRFI, but prognostic with some evidence of"/>
   <result pre="benefit for DRFI, but prognostic with some evidence of differential" exact="trastuzumab" post="benefit for DFS. In addition, the association between HER2"/>
   <result pre="addition, the association between HER2 expression level by RT-PCR and" exact="trastuzumab" post="benefit was evaluated separately in the HR-positive and HR-negative"/>
   <result pre="HER2 by RT-PCR was not associated with the magnitude of" exact="trastuzumab" post="benefit for distant recurrence (nonlinear p = 0.69, Additional file 5)."/>
   <result pre="there was a significant association between HER2 by RT-PCR and" exact="trastuzumab" post="benefit for distant recurrence in patients who were HR"/>
   <result pre="were HR positive by local IHC, the greatest benefit from" exact="trastuzumab" post="was observed in the lowest and highest quartiles of"/>
   <result pre="the recurrence score, and none were statistically significant predictors of" exact="trastuzumab" post="benefit. Discussion The primary aim of this prospectively designed"/>
   <result pre="predictive of the magnitude of benefit from the addition of" exact="trastuzumab" post="to adjuvant chemotherapy in NCCTG (Alliance) N9831. In this"/>
   <result pre="associated with the magnitude of benefit from the addition of" exact="trastuzumab" post="to adjuvant chemotherapy. Similarly, no association was observed for"/>
   <result pre="IHC or central FISH ratio. Thus, the hypothesis of increasing" exact="trastuzumab" post="benefit with increasing HER2 mRNA expression is not supported."/>
   <result pre="expression is not supported. In all patients, the addition of" exact="trastuzumab" post="approximately halved the risk of distant recurrence. This effect"/>
   <result pre="patients. In particular, there was a statistically significant benefit of" exact="trastuzumab" post="in patients who were HER2 negative by RT-PCR. Similarly,"/>
   <result pre="by RT-PCR. Similarly, there was a statistically significant benefit of" exact="trastuzumab" post="in patients who were HER2 negative by central FISH."/>
   <result pre="from trastuzumab. NSABP B-47 will determine whether the addition of" exact="trastuzumab" post="to chemotherapy improves outcome in women with resected node-positive"/>
   <result pre="reported as HER2-low by all HER2 testing performed. Statistically significant" exact="trastuzumab" post="benefit was observed in both the HR-positive and HR-negative"/>
   <result pre="measured by local IHC or RT-PCR [majority ER positive and/or" exact="progesterone" post="receptor (PR) positive]. Among tumors that were ER positive"/>
   <result pre="between HER2 and ER as determinants of clinical benefit from" exact="trastuzumab" post="added to adjuvant chemoendocrine therapy. There was a nonmonotonic"/>
   <result pre="therapy. There was a nonmonotonic association between HER2 mRNA and" exact="trastuzumab" post="benefit in the HR-positive subgroup. Surprisingly, the HER2 subgroup"/>
   <result pre="the HER2 subgroup with the least clinical benefit from adjuvant" exact="trastuzumab" post="actually had intermediately overexpressed—not the lowest—levels of HER2 mRNA,"/>
   <result pre="confidence intervals do not exclude a clinically important benefit of" exact="trastuzumab" post="for these intermediate expression levels. This finding of a"/>
   <result pre="This finding of a nonmonotonic interaction between HER2 expression and" exact="trastuzumab" post="benefit in patients with the highest levels of ESR1-associated"/>
   <result pre="there is a complex interaction between hormone therapy, chemotherapy and" exact="trastuzumab" post="benefit and tumor biology. These findings have prompted further"/>
   <result pre="other genes or gene groups will be better predictors of" exact="trastuzumab" post="benefit [ 51]. The secondary aim of this study"/>
   <result pre="included. Conclusions In summary, our data do not show that" exact="trastuzumab" post="benefit increases with increasing HER2 mRNA expression. They do"/>
   <result pre="kb) LINK Additional file 5: Figure S3. Hazard ratio for" exact="trastuzumab" post="benefit as a continuous function of HER2 expression by"/>
   <result pre="Surgical Adjuvant Breast and Bowel Project p17 polysomy 17 PR" exact="progesterone" post="receptor RS recurrence score RT-PCR reverse transcriptase polymerase chain"/>
   <result pre="Chan S Romieu CG Pienkowski T et al. Lapatinib plus" exact="capecitabine" post="for HER2-positive advanced breast cancer N Engl J Med."/>
   <result pre="chromosome 17 effect on patient outcome in the N9831 adjuvant" exact="trastuzumab" post="trial J Clin Oncol. 2010 28 4307 15 10.1200/JCO.2009.26.2154"/>
   <result pre="and epidermal growth factor receptor mRNA and protein expression, and" exact="lapatinib" post="efficacy in women with metastatic breast cancer Clin Cancer"/>
   <result pre="Kim C Wolmark N HER2 status and benefit from adjuvant" exact="trastuzumab" post="in breast cancer N Engl J Med. 2008 358"/>
   <result pre="CE Romond E Mejia-Mejia O et al. Benefit from adjuvant" exact="trastuzumab" post="may not be confined to patients with IHC 3+"/>
   <result pre="JR Kaufman PA Visscher DW et al. Sequential versus concurrent" exact="trastuzumab" post="in adjuvant chemotherapy for breast cancer J Clin Oncol."/>
   <result pre="of chromosomes 1, 3, and 10 on patient response to" exact="trastuzumab" post="in metastatic breast cancer Genes Chromosomes Cancer. 2007 46"/>
   <result pre="al. Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict" exact="docetaxel" post="chemosensitivity in breast cancer patients Breast Cancer Res Treat."/>
   <result pre="Gavin PG et al. Predicting degree of benefit from adjuvant" exact="trastuzumab" post="in NSABP trial B-31 J Natl Cancer Inst. 2013"/>
   <result pre="outcome in the North Central Cancer Treatment Group n9831 adjuvant" exact="trastuzumab" post="trial J Clin Oncol. 2015 33 701 8 10.1200/JCO.2014.57.6298"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4590321/results/search/inn/results.xml">
   <result pre="response and survival rates have been demonstrated with use of" exact="trastuzumab" post="in combination with standard chemotherapy in both early and"/>
   <result pre="in both early and advanced breast cancer. However, resistance to" exact="trastuzumab" post="may pose a major problem in the effective treatment"/>
   <result pre="been recently reported in clinical studies. Pertuzumab in combination with" exact="trastuzumab" post="and taxane is currently approved in the metastatic and"/>
   <result pre="been discussed. Keywords HER2 dual blockade neoadjuvant adjuvant breast cancer" exact="trastuzumab" post="Introduction Human epidermal growth factor receptor 2 (HER2) is"/>
   <result pre="activates antibody-dependent cellular toxicity (ADCC). 5, 6 The approval of" exact="trastuzumab" post="in 1998 has been a milestone in the treatment"/>
   <result pre="dimerization, and testing of irreversible dual HER1/2 inhibitors, such as" exact="afatinib" post="and neratinib. 11 For example, pertuzumab (Perjeta ®; Genentech)"/>
   <result pre="HER1/2 inhibitors, such as afatinib and neratinib. 11 For example," exact="pertuzumab" post="(Perjeta ®; Genentech) binds in sub-domain II of HER2"/>
   <result pre="Administration (FDA) approved as a first-line therapy in combination with" exact="trastuzumab" post="and chemotherapy in HER2-positive MBC and in the neoadjuvant"/>
   <result pre="reversibly binds in the HER2 and/or HER1 intracellular domain. Additionally," exact="lapatinib" post="leads to HER2 accumulation at the cell surface, augmenting"/>
   <result pre="approved in women with HER2+ MBC that has progressed after" exact="trastuzumab" post="treatment. 14 Trastuzumab emtansine (T-DM1, Kadcyla ®, Genentech) is"/>
   <result pre="emtansine (T-DM1, Kadcyla ®, Genentech) is a drug–antibody conjugate of" exact="trastuzumab" post="and a cytotoxic moiety (DM1 or mertansine, a microtubule"/>
   <result pre="is currently approved for advanced/MBC in patients previously treated with" exact="trastuzumab" post="and taxane therapy. 16 Novel agents such as afatinib"/>
   <result pre="with trastuzumab and taxane therapy. 16 Novel agents such as" exact="afatinib" post="and neratinib (oral irreversible pan-HER inhibitor) are also currently"/>
   <result pre="and taxane therapy. 16 Novel agents such as afatinib and" exact="neratinib" post="(oral irreversible pan-HER inhibitor) are also currently being investigated."/>
   <result pre="combinations of anti-HER agents, which may also help to overcome" exact="trastuzumab" post="resistance. 18– 21 Arpino et al 22 has demonstrated"/>
   <result pre="animal models that the three-drug combination of gefitinib, pertuzumab, and" exact="trastuzumab" post="is much more effective at eradicating HER2-overexpressing xenografts in"/>
   <result pre="Rimawi et al 23 that showed that the combination of" exact="lapatinib" post="and trastuzumab was also more effective in eradicating HER2-overexpressing"/>
   <result pre="al 23 that showed that the combination of lapatinib and" exact="trastuzumab" post="was also more effective in eradicating HER2-overexpressing xenografts. This"/>
   <result pre="study conducted by Black-well et al, 24 the combination of" exact="trastuzumab" post="and lapatinib improved the progression-free survival (PFS) and clinical"/>
   <result pre="by Black-well et al, 24 the combination of trastuzumab and" exact="lapatinib" post="improved the progression-free survival (PFS) and clinical benefit rate"/>
   <result pre="progression-free survival (PFS) and clinical benefit rate when compared to" exact="lapatinib" post="alone in patients with progression of MBC on prior"/>
   <result pre="in OS to 56.5 months in the pertuzumab, trastuzumab, and" exact="docetaxel" post="group versus 40.8 months in the trastuzumab and docetaxel"/>
   <result pre="pertuzumab, trastuzumab, and docetaxel group versus 40.8 months in the" exact="trastuzumab" post="and docetaxel group. Additionally, the PFS and duration of"/>
   <result pre="and docetaxel group versus 40.8 months in the trastuzumab and" exact="docetaxel" post="group. Additionally, the PFS and duration of response were"/>
   <result pre="the PFS and duration of response were prolonged in the" exact="pertuzumab" post="group, supporting the use of dual HER2 blockade in"/>
   <result pre="a relatively short period of time. In randomized neoadjuvant studies," exact="trastuzumab" post="and chemotherapy-containing regimens have led to improved pathological complete"/>
   <result pre="been reviewed in the following sections. Neoadjuvant trials Trastuzumab plus" exact="lapatinib" post="Efficacy The combination of trastuzumab and lapatinib in the"/>
   <result pre="sections. Neoadjuvant trials Trastuzumab plus lapatinib Efficacy The combination of" exact="trastuzumab" post="and lapatinib in the neoadjuvant setting has been studied"/>
   <result pre="trials Trastuzumab plus lapatinib Efficacy The combination of trastuzumab and" exact="lapatinib" post="in the neoadjuvant setting has been studied by multiple"/>
   <result pre="the combination for 6 weeks, followed by 12 weeks of" exact="paclitaxel" post="in addition to the assigned HER2 therapy prior to"/>
   <result pre="surgery, all patients received three cycles of 5-fluorouracil, epirubicin, and" exact="cyclophosphamide" post="(FEC), followed by the continuation of the initially assigned"/>
   <result pre="time of surgery, was significantly higher in patients treated with" exact="lapatinib" post="and trastuzumab than with trastuzumab alone (51.3% vs 29.5%;"/>
   <result pre="surgery, was significantly higher in patients treated with lapatinib and" exact="trastuzumab" post="than with trastuzumab alone (51.3% vs 29.5%; P=0.001), supporting"/>
   <result pre="higher in patients treated with lapatinib and trastuzumab than with" exact="trastuzumab" post="alone (51.3% vs 29.5%; P=0.001), supporting dual blockage of"/>
   <result pre="Also, no significant difference in pCR was seen between the" exact="lapatinib" post="and trastuzumab-alone groups (29.5% vs 24.7%). An improvement was"/>
   <result pre="breast and axilla in the dual therapy group compared to" exact="trastuzumab" post="alone (46.8% vs 27.6%; OR 2.39, P=0.0007) and improved"/>
   <result pre="partial response [PR]) at 6 weeks for both arms containing" exact="lapatinib" post="compared to trastuzumab (52.6% lapatinib alone, 67.1% combination, and"/>
   <result pre="at 6 weeks for both arms containing lapatinib compared to" exact="trastuzumab" post="(52.6% lapatinib alone, 67.1% combination, and 30.2% trastuzumab alone;"/>
   <result pre="weeks for both arms containing lapatinib compared to trastuzumab (52.6%" exact="lapatinib" post="alone, 67.1% combination, and 30.2% trastuzumab alone; P&amp;lt;0.0001). It"/>
   <result pre="compared to trastuzumab (52.6% lapatinib alone, 67.1% combination, and 30.2%" exact="trastuzumab" post="alone; P&amp;lt;0.0001). It is important to highlight that, during"/>
   <result pre="seen in patients who received dual blockade therapy versus either" exact="lapatinib" post="or trastuzumab alone. The best outcome was noted in"/>
   <result pre="patients who received dual blockade therapy versus either lapatinib or" exact="trastuzumab" post="alone. The best outcome was noted in patients with"/>
   <result pre="randomized phase II trial that also evaluated the combination of" exact="lapatinib" post="and trastuzumab therapy in HER2+ tumors in the preoperative"/>
   <result pre="II trial that also evaluated the combination of lapatinib and" exact="trastuzumab" post="therapy in HER2+ tumors in the preoperative setting. 33"/>
   <result pre="II–IIIA BC (n=121) were assigned to receive 12 weeks of" exact="paclitaxel" post="followed by four cycles of FEC given concurrently with"/>
   <result pre="paclitaxel followed by four cycles of FEC given concurrently with" exact="trastuzumab" post="(arm A), lapatinib (arm B), or the combination (arm"/>
   <result pre="four cycles of FEC given concurrently with trastuzumab (arm A)," exact="lapatinib" post="(arm B), or the combination (arm C) for 26"/>
   <result pre="in pCR (breast and axilla) with dual therapy compared to" exact="trastuzumab" post="or lapatinib alone (46.7% vs 25% vs 26.3%, respectively;"/>
   <result pre="(breast and axilla) with dual therapy compared to trastuzumab or" exact="lapatinib" post="alone (46.7% vs 25% vs 26.3%, respectively; P=0.019) demonstrating"/>
   <result pre="and Bowel Project B41 trial (NSABP-B41), investigated the combination of" exact="trastuzumab" post="and lapatinib and its effect on pCR when given"/>
   <result pre="Project B41 trial (NSABP-B41), investigated the combination of trastuzumab and" exact="lapatinib" post="and its effect on pCR when given with an"/>
   <result pre="study, 34 529 patients with HER2+ operable BC received neoadjuvant" exact="doxorubicin" post="and cyclophosphamide every 3 weeks for four cycles followed"/>
   <result pre="529 patients with HER2+ operable BC received neoadjuvant doxorubicin and" exact="cyclophosphamide" post="every 3 weeks for four cycles followed by weekly"/>
   <result pre="cyclophosphamide every 3 weeks for four cycles followed by weekly" exact="paclitaxel" post="for 12 weeks, concurrent with either weekly trastuzumab, lapatinib,"/>
   <result pre="trastuzumab, lapatinib, or the combination. Following surgery, all patients received" exact="trastuzumab" post="every 3 weeks for a total of 52 weeks"/>
   <result pre="pCR-breast + lymph nodes with combination anti-HER therapy compared to" exact="trastuzumab" post="alone (62% vs 52.5%, P=0.095, breast; and 60.2% vs"/>
   <result pre="Subgroup analysis showed that pCR improvement with the addition of" exact="lapatinib" post="to trastuzumab occurred mainly in clinically node-positive patients (47.2%"/>
   <result pre="showed that pCR improvement with the addition of lapatinib to" exact="trastuzumab" post="occurred mainly in clinically node-positive patients (47.2% vs 67.5%;"/>
   <result pre="reported in all three groups. However, fewer patients in the" exact="lapatinib" post="group achieved a clinical CR (69.9%) as compared to"/>
   <result pre="305 patients with Stage II–III HER2+ BC were assigned to" exact="paclitaxel" post="with trastuzumab alone or in combination with lapatinib for"/>
   <result pre="with Stage II–III HER2+ BC were assigned to paclitaxel with" exact="trastuzumab" post="alone or in combination with lapatinib for 16 weeks"/>
   <result pre="assigned to paclitaxel with trastuzumab alone or in combination with" exact="lapatinib" post="for 16 weeks prior to surgery. 35 The third"/>
   <result pre="weeks prior to surgery. 35 The third arm, consisting of" exact="lapatinib" post="and paclitaxel, was closed early due to negative efficacy"/>
   <result pre="36 Following surgery, all patients received four cycles of dose-dense" exact="doxorubicin" post="and cyclophosphamide followed by a recommended 1-year treatment of"/>
   <result pre="surgery, all patients received four cycles of dose-dense doxorubicin and" exact="cyclophosphamide" post="followed by a recommended 1-year treatment of trastuzumab. Numerically"/>
   <result pre="of pCR (breast) were observed in patients treated with combined" exact="trastuzumab" post="and lapatinib (51%) compared to trastuzumab alone (40%), but"/>
   <result pre="(breast) were observed in patients treated with combined trastuzumab and" exact="lapatinib" post="(51%) compared to trastuzumab alone (40%), but similar to"/>
   <result pre="patients treated with combined trastuzumab and lapatinib (51%) compared to" exact="trastuzumab" post="alone (40%), but similar to NSABP-B41, this difference was"/>
   <result pre="treated 140 women with Stage I–III HER2+ BC with either" exact="trastuzumab" post="alone, lapatinib alone, or the combination for 21 days"/>
   <result pre="women with Stage I–III HER2+ BC with either trastuzumab alone," exact="lapatinib" post="alone, or the combination for 21 days followed by"/>
   <result pre="the combination for 21 days followed by six cycles of" exact="docetaxel" post="and carboplatin with the assigned HER2 therapy. 37 The"/>
   <result pre="for 21 days followed by six cycles of docetaxel and" exact="carboplatin" post="with the assigned HER2 therapy. 37 The primary endpoint"/>
   <result pre="vs 40% DCT). Another smaller study evaluating pCR rates from" exact="lapatinib" post="and trastuzumab combination randomized 100 patients with Stage II–III"/>
   <result pre="DCT). Another smaller study evaluating pCR rates from lapatinib and" exact="trastuzumab" post="combination randomized 100 patients with Stage II–III HER2-positive BC"/>
   <result pre="with Stage II–III HER2-positive BC to 2 weeks of either" exact="lapatinib" post="alone (1,250 mg daily), trastuzumab alone, or the combination"/>
   <result pre="to 2 weeks of either lapatinib alone (1,250 mg daily)," exact="trastuzumab" post="alone, or the combination (with lapatinib reduced to 750"/>
   <result pre="alone (1,250 mg daily), trastuzumab alone, or the combination (with" exact="lapatinib" post="reduced to 750 mg daily), followed by 4 cycles"/>
   <result pre="(TBCRC) 006 trial investigated the role of the combination of" exact="trastuzumab" post="and lapatinib (plus letrozole in ER+ patients) without chemotherapy"/>
   <result pre="trial investigated the role of the combination of trastuzumab and" exact="lapatinib" post="(plus letrozole in ER+ patients) without chemotherapy in the"/>
   <result pre="the role of the combination of trastuzumab and lapatinib (plus" exact="letrozole" post="in ER+ patients) without chemotherapy in the neoadjuvant setting,"/>
   <result pre="30, 33, 38 evaluating the effect of the addition of" exact="lapatinib" post="to trastuzumab and neoadjuvant chemotherapy, pCR (breast and lymph"/>
   <result pre="38 evaluating the effect of the addition of lapatinib to" exact="trastuzumab" post="and neoadjuvant chemotherapy, pCR (breast and lymph nodes) rate"/>
   <result pre="pCR (breast and lymph nodes) rate was 38.36% in the" exact="trastuzumab" post="arm and 55.76% in the combination arm (OR 1.94;"/>
   <result pre="three trials that evaluated pCR (breast) for the combination of" exact="lapatinib" post="and trastuzumab resulted in a superior pCR rate of"/>
   <result pre="that evaluated pCR (breast) for the combination of lapatinib and" exact="trastuzumab" post="resulted in a superior pCR rate of 55.01% vs"/>
   <result pre="a study by Holmes et al, 38 the addition of" exact="lapatinib" post="to neoadjuvant chemotherapy resulted in a pCR (breast and"/>
   <result pre="the lapatinib-containing treatment arms. Of note, the concomitant administration of" exact="lapatinib" post="and docetaxel may have contributed to the higher number"/>
   <result pre="treatment arms. Of note, the concomitant administration of lapatinib and" exact="docetaxel" post="may have contributed to the higher number of diarrhea"/>
   <result pre="higher number of diarrhea and neutropenia cases seen in the" exact="lapatinib" post="arm. However, no major cardiac toxicities were observed in"/>
   <result pre="administered alone during the first 6 weeks, the toxicities of" exact="lapatinib" post="could be examined independent of chemotherapy. The majority of"/>
   <result pre="independent of chemotherapy. The majority of patients (78.8%) who received" exact="lapatinib" post="developed diarrhea (28% grade 3–4), 61.8% developed skin rash"/>
   <result pre="the NSABP-B41 trial, a lower percentage of patients in the" exact="lapatinib" post="group received the full planned course of docetaxel (including"/>
   <result pre="in the lapatinib group received the full planned course of" exact="docetaxel" post="(including lower mean cumulative dose) due to dose reductions"/>
   <result pre="duration of HER2 therapy or the mean cumulative dose of" exact="docetaxel" post="between the trastuzumab control and combination groups, suggesting that"/>
   <result pre="therapy or the mean cumulative dose of docetaxel between the" exact="trastuzumab" post="control and combination groups, suggesting that the addition of"/>
   <result pre="trastuzumab control and combination groups, suggesting that the addition of" exact="lapatinib" post="did not compromise delivery of standard agents. As predicted,"/>
   <result pre="occurred at a higher frequency in patients assigned to the" exact="lapatinib" post="arm in the CHER-LOB study. 33 The high occurrence"/>
   <result pre="necessitated a protocol amendment to reduce the starting dose of" exact="lapatinib" post="from 1,500 mg to 1,250 mg, and 1,000 mg"/>
   <result pre="exercised when interpreting the results of these studies. Trastuzumab plus" exact="pertuzumab" post="Efficacy Trastuzumab in combination with pertuzumab in the neoadjuvant"/>
   <result pre="these studies. Trastuzumab plus pertuzumab Efficacy Trastuzumab in combination with" exact="pertuzumab" post="in the neoadjuvant setting has also been evaluated ("/>
   <result pre="HER2+ BC to evaluate the efficacy of the combination of" exact="trastuzumab" post="plus pertuzumab. Patients were assigned to one of four"/>
   <result pre="Patients were assigned to one of four treatment arms: 1)" exact="trastuzumab" post="alone with docetaxel; 2) pertuzumab alone with docetaxel; 3)"/>
   <result pre="of four treatment arms: 1) trastuzumab alone with docetaxel; 2)" exact="pertuzumab" post="alone with docetaxel; 3) trastuzumab and pertuzumab with docetaxel;"/>
   <result pre="trastuzumab alone with docetaxel; 2) pertuzumab alone with docetaxel; 3)" exact="trastuzumab" post="and pertuzumab with docetaxel; or 4) trastuzumab and pertuzumab"/>
   <result pre="with docetaxel; 2) pertuzumab alone with docetaxel; 3) trastuzumab and" exact="pertuzumab" post="with docetaxel; or 4) trastuzumab and pertuzumab without chemotherapy"/>
   <result pre="with docetaxel; 3) trastuzumab and pertuzumab with docetaxel; or 4)" exact="trastuzumab" post="and pertuzumab without chemotherapy prior to breast surgery. 45"/>
   <result pre="3) trastuzumab and pertuzumab with docetaxel; or 4) trastuzumab and" exact="pertuzumab" post="without chemotherapy prior to breast surgery. 45 Postoperatively, all"/>
   <result pre="then went on to receive three cycles of FEC and" exact="trastuzumab" post="for a total of 1 year, with the addition"/>
   <result pre="for a total of 1 year, with the addition of" exact="docetaxel" post="only in the group who did not receive docetaxel"/>
   <result pre="of docetaxel only in the group who did not receive" exact="docetaxel" post="in the neoadjuvant setting. Results demonstrated that patients who"/>
   <result pre="the neoadjuvant setting. Results demonstrated that patients who were given" exact="pertuzumab" post="and trastuzumab plus docetaxel had a significantly improved pCR"/>
   <result pre="setting. Results demonstrated that patients who were given pertuzumab and" exact="trastuzumab" post="plus docetaxel had a significantly improved pCR (45.8%) compared"/>
   <result pre="demonstrated that patients who were given pertuzumab and trastuzumab plus" exact="docetaxel" post="had a significantly improved pCR (45.8%) compared with those"/>
   <result pre="had a significantly improved pCR (45.8%) compared with those given" exact="trastuzumab" post="with docetaxel (29%) or pertuzumab with docetaxel (24%; P=0.01)."/>
   <result pre="significantly improved pCR (45.8%) compared with those given trastuzumab with" exact="docetaxel" post="(29%) or pertuzumab with docetaxel (24%; P=0.01). These results"/>
   <result pre="(45.8%) compared with those given trastuzumab with docetaxel (29%) or" exact="pertuzumab" post="with docetaxel (24%; P=0.01). These results were considered practice-changing"/>
   <result pre="with those given trastuzumab with docetaxel (29%) or pertuzumab with" exact="docetaxel" post="(24%; P=0.01). These results were considered practice-changing and drove"/>
   <result pre="results were considered practice-changing and drove the FDA approval of" exact="pertuzumab" post="for neoadjuvant treatment of HER2+ BC. 45 Notably, the"/>
   <result pre="and lymph nodes was highest in the pertuzumab, trastuzumab, and" exact="docetaxel" post="arm (88%). 45 Long-term outcomes were recently reported at"/>
   <result pre="2015 ASCO annual meeting. Three-year PFS of those given combination" exact="trastuzumab" post="plus pertuzumab with docetaxel was 90%, compared to 86%"/>
   <result pre="annual meeting. Three-year PFS of those given combination trastuzumab plus" exact="pertuzumab" post="with docetaxel was 90%, compared to 86% in those"/>
   <result pre="Three-year PFS of those given combination trastuzumab plus pertuzumab with" exact="docetaxel" post="was 90%, compared to 86% in those given trastuzumab"/>
   <result pre="with docetaxel was 90%, compared to 86% in those given" exact="trastuzumab" post="with docetaxel (HR 0.69; 95% CI 0.34–1.40). HRs for"/>
   <result pre="was 90%, compared to 86% in those given trastuzumab with" exact="docetaxel" post="(HR 0.69; 95% CI 0.34–1.40). HRs for DFS and"/>
   <result pre="therapy, and therefore, results suggest that the benefit of adding" exact="pertuzumab" post="in the neoadjuvant setting may persist after surgery, although"/>
   <result pre="designed to investigate the tolerability of neoadjuvant treatment regimens combining" exact="pertuzumab" post="with H and either a standard anthracycline or platinum-based"/>
   <result pre="to either 1) six cycles of docetaxel, carboplatin, trastuzumab, and" exact="pertuzumab" post="(DCTP); 2) three cycles of FEC followed by three"/>
   <result pre="2) three cycles of FEC followed by three cycles of" exact="docetaxel" post="plus trastuzumab/pertuzumab (FEC → DTP); or 3) three cycles"/>
   <result pre="57.3%, and 66.2%, respectively. Following surgery, all patients received adjuvant" exact="trastuzumab" post="to complete a total of 1 year of therapy."/>
   <result pre="results, the researchers have been successful in &quot;graduating&quot; two drugs," exact="veliparib" post="and neratinib, from the study to accelerate drug development"/>
   <result pre="on responses seen thus far. 49, 50 The addition of" exact="neratinib" post="versus trastuzumab to neoadjuvant taxaneanthracycline was reported to have"/>
   <result pre="seen thus far. 49, 50 The addition of neratinib versus" exact="trastuzumab" post="to neoadjuvant taxaneanthracycline was reported to have an estimated"/>
   <result pre="patients. 49 Results of the I-SPY 2 trial regarding combination" exact="trastuzumab" post="plus pertuzumab and TDM1 plus pertuzumab are awaited. 48,"/>
   <result pre="Results of the I-SPY 2 trial regarding combination trastuzumab plus" exact="pertuzumab" post="and TDM1 plus pertuzumab are awaited. 48, 51 Adverse"/>
   <result pre="2 trial regarding combination trastuzumab plus pertuzumab and TDM1 plus" exact="pertuzumab" post="are awaited. 48, 51 Adverse events Regarding the overall"/>
   <result pre="48, 51 Adverse events Regarding the overall safety profile of" exact="trastuzumab" post="and pertuzumab in combination, both the NeoSphere 45 and"/>
   <result pre="Adverse events Regarding the overall safety profile of trastuzumab and" exact="pertuzumab" post="in combination, both the NeoSphere 45 and the TRYPHAENA"/>
   <result pre="ER− patients experienced increased pCR rates, despite the addition of" exact="letrozole" post="to ER+ tumors. 39 Increased pCR in ER− tumors"/>
   <result pre="was an impressive 18.9% and 24.8% difference in pCR between" exact="docetaxel" post="plus lapatinib and docetaxel alone in the ER+ group"/>
   <result pre="impressive 18.9% and 24.8% difference in pCR between docetaxel plus" exact="lapatinib" post="and docetaxel alone in the ER+ group and ER−"/>
   <result pre="and 24.8% difference in pCR between docetaxel plus lapatinib and" exact="docetaxel" post="alone in the ER+ group and ER− subgroups, respectively."/>
   <result pre="ER− subsets (77% in the combination group and 55% in" exact="trastuzumab" post="alone). 52 In the NeoSphere and TRYPHAENA studies, patients"/>
   <result pre="45, 47 Specifically in NeoSphere, the dual anti-HER2 therapy and" exact="docetaxel" post="arm resulted in a pCR rate of 63.2% in"/>
   <result pre="P=0.001) and ER− (ratio of 2.5; P=0.001) patients. In the" exact="trastuzumab" post="and lapatinib monotherapy arms, HER2 expression did not predict"/>
   <result pre="ER− (ratio of 2.5; P=0.001) patients. In the trastuzumab and" exact="lapatinib" post="monotherapy arms, HER2 expression did not predict for pCR"/>
   <result pre="one-third of HER2 positive tumors and is implicated in mediating" exact="trastuzumab" post="resistance. 12, 55– 57 A positive correlation of pCR"/>
   <result pre="of pCR with p95HER2 levels was noted only in the" exact="trastuzumab" post="arms. Expression of p95HER2 was mainly predictive for pCR"/>
   <result pre="mainly predictive for pCR in ER+ patients treated with either" exact="trastuzumab" post="or the combination of lapatinib plus trastuzumab, but did"/>
   <result pre="ER+ patients treated with either trastuzumab or the combination of" exact="lapatinib" post="plus trastuzumab, but did not predict for pCR in"/>
   <result pre="A (34%) or B (36%) subtypes. Among HER2-enriched, taxane plus" exact="trastuzumab" post="alone produced pCR rates in excess of 70%, which"/>
   <result pre="HER2+ breast tumors treated with chemotherapy alone or chemotherapy and" exact="trastuzumab" post="demonstrated no relationship with DFS. Nevertheless, presence of PTEN"/>
   <result pre="for CTC analysis in 51 (11%) patients (12 from the" exact="trastuzumab" post="arm, 19 from the lapatinib arm, and 20 from"/>
   <result pre="(11%) patients (12 from the trastuzumab arm, 19 from the" exact="lapatinib" post="arm, and 20 from the combination arm). 65 Patients"/>
   <result pre="new therapeutic agents and combination treatments. Adjuvant trials Trastuzumab plus" exact="lapatinib" post="Efficacy In the ALTTO trial, a phase III, multicenter"/>
   <result pre="ALTTO trial, a phase III, multicenter study, the efficacy of" exact="lapatinib" post="and trastuzumab combination was evaluated in the adjuvant setting."/>
   <result pre="a phase III, multicenter study, the efficacy of lapatinib and" exact="trastuzumab" post="combination was evaluated in the adjuvant setting. 36 A"/>
   <result pre="patients with operable HER2+ BC were randomized to receive either" exact="lapatinib" post="concurrently with trastuzumab, trastuzumab followed by lapatinib, lapatinib alone,"/>
   <result pre="BC were randomized to receive either lapatinib concurrently with trastuzumab," exact="trastuzumab" post="followed by lapatinib, lapatinib alone, or trastuzumab alone. The"/>
   <result pre="receive either lapatinib concurrently with trastuzumab, trastuzumab followed by lapatinib," exact="lapatinib" post="alone, or trastuzumab alone. The randomized anti-HER2 therapy was"/>
   <result pre="concurrently with trastuzumab, trastuzumab followed by lapatinib, lapatinib alone, or" exact="trastuzumab" post="alone. The randomized anti-HER2 therapy was introduced either after"/>
   <result pre="closed early in August 2011 due to demonstrated superiority of" exact="trastuzumab" post="over lapatinib alone, and those patients were allowed to"/>
   <result pre="in August 2011 due to demonstrated superiority of trastuzumab over" exact="lapatinib" post="alone, and those patients were allowed to cross over"/>
   <result pre="arm), 4-year invasive DFS was 88% in those receiving combination" exact="lapatinib" post="plus trastuzumab, compared to 86% in those receiving trastuzumab"/>
   <result pre="combination lapatinib plus trastuzumab, compared to 86% in those receiving" exact="trastuzumab" post="alone (HR 0.84; 97.5% CI 0.70–1.02; P=0.048). DFS was"/>
   <result pre="0.70–1.02; P=0.048). DFS was noted to be 87% in the" exact="trastuzumab" post="followed by lapatinib arm (HR 0.96; P=0.610). In a"/>
   <result pre="was noted to be 87% in the trastuzumab followed by" exact="lapatinib" post="arm (HR 0.96; P=0.610). In a pre-planned analysis, the"/>
   <result pre="In a pre-planned analysis, the non-inferiority of the combination of" exact="lapatinib" post="and trastuzumab vs trastuzumab alone could not be established"/>
   <result pre="pre-planned analysis, the non-inferiority of the combination of lapatinib and" exact="trastuzumab" post="vs trastuzumab alone could not be established (HR for"/>
   <result pre="the non-inferiority of the combination of lapatinib and trastuzumab vs" exact="trastuzumab" post="alone could not be established (HR for DFS 0.93;"/>
   <result pre="of analysis) were noted between the three arms (95% for" exact="trastuzumab" post="plus lapatinib, 95% for trastuzumab → lapatinib, and 94%"/>
   <result pre="the three arms (95% for trastuzumab plus lapatinib, 95% for" exact="trastuzumab" post="→ lapatinib, and 94% for trastuzumab alone). 36 The"/>
   <result pre="plus lapatinib, 95% for trastuzumab → lapatinib, and 94% for" exact="trastuzumab" post="alone). 36 The low rate of OS events in"/>
   <result pre="survival outcomes and the superiority of dual HER2 blockade over" exact="trastuzumab" post="alone, at least in the adjuvant setting. Further analysis"/>
   <result pre="(APHINITY) trial, a randomized, double-blind, placebo-controlled, two-arm study evaluating adjuvant" exact="pertuzumab" post="plus trastuzumab plus chemotherapy vs trastuzumab plus placebo plus"/>
   <result pre="a randomized, double-blind, placebo-controlled, two-arm study evaluating adjuvant pertuzumab plus" exact="trastuzumab" post="plus chemotherapy vs trastuzumab plus placebo plus chemotherapy. 66"/>
   <result pre="two-arm study evaluating adjuvant pertuzumab plus trastuzumab plus chemotherapy vs" exact="trastuzumab" post="plus placebo plus chemotherapy. 66 Until the results of"/>
   <result pre="trial are presented, we believe that the routine use of" exact="pertuzumab" post="in the adjuvant setting should at least be considered"/>
   <result pre="trial only 60%–78% of patients received &amp;gt;85% of the planned" exact="lapatinib" post="dose, whereas &amp;gt;90% received trastuzumab as planned. As expected,"/>
   <result pre="received &amp;gt;85% of the planned lapatinib dose, whereas &amp;gt;90% received" exact="trastuzumab" post="as planned. As expected, AEs such as diarrhea (75%"/>
   <result pre="In a phase II, single-arm trial, the tolerability of adjuvant" exact="lapatinib" post="plus trastuzumab was evaluated in 95 patients with stage"/>
   <result pre="phase II, single-arm trial, the tolerability of adjuvant lapatinib plus" exact="trastuzumab" post="was evaluated in 95 patients with stage I–III HER2+"/>
   <result pre="95 patients with stage I–III HER2+ BC. Patients received dose-dense" exact="doxorubicin" post="and cyclophosphamide followed by weekly docetaxel with trastuzumab and"/>
   <result pre="with stage I–III HER2+ BC. Patients received dose-dense doxorubicin and" exact="cyclophosphamide" post="followed by weekly docetaxel with trastuzumab and lapatinib for"/>
   <result pre="BC. Patients received dose-dense doxorubicin and cyclophosphamide followed by weekly" exact="docetaxel" post="with trastuzumab and lapatinib for 12 weeks and then"/>
   <result pre="received dose-dense doxorubicin and cyclophosphamide followed by weekly docetaxel with" exact="trastuzumab" post="and lapatinib for 12 weeks and then trastuzumab and"/>
   <result pre="doxorubicin and cyclophosphamide followed by weekly docetaxel with trastuzumab and" exact="lapatinib" post="for 12 weeks and then trastuzumab and lapatinib alone"/>
   <result pre="docetaxel with trastuzumab and lapatinib for 12 weeks and then" exact="trastuzumab" post="and lapatinib alone for an additional 40 weeks. In"/>
   <result pre="trastuzumab and lapatinib for 12 weeks and then trastuzumab and" exact="lapatinib" post="alone for an additional 40 weeks. In patients who"/>
   <result pre="diarrhea, despite active diarrhea management, and 43% had reductions in" exact="lapatinib" post="dose, necessitating early closure of the study. 67 Three"/>
   <result pre="patients (4%) had grade 2 unacceptable rash, which required a" exact="lapatinib" post="dose reduction. Three patients (3%) developed CHF, and six"/>
   <result pre="a randomized, phase II, single-arm trial, investigated the combination of" exact="lapatinib" post="plus trastuzumab with standard chemotherapy in the adjuvant setting."/>
   <result pre="phase II, single-arm trial, investigated the combination of lapatinib plus" exact="trastuzumab" post="with standard chemotherapy in the adjuvant setting. 68 Patients"/>
   <result pre="stages I–III HER2+ BC (109 patients) received four cycles of" exact="doxorubicin" post="and cyclophosphamide followed by 12 weeks of docetaxel, trastuzumab,"/>
   <result pre="HER2+ BC (109 patients) received four cycles of doxorubicin and" exact="cyclophosphamide" post="followed by 12 weeks of docetaxel, trastuzumab, and lapatinib,"/>
   <result pre="of docetaxel, trastuzumab, and lapatinib, and then 40 weeks of" exact="trastuzumab" post="and lapatinib. In regards to overall toxicity, grade 3–4"/>
   <result pre="and 2.7% of patients, respectively, at the initial dose of" exact="lapatinib" post="1,000 mg/day. Lapatinib was then reduced to 750 mg/day"/>
   <result pre="action. However, results obtained from trials utilizing the combination of" exact="trastuzumab" post="and pertuzumab actually demonstrated minimal cardiac toxicity with the"/>
   <result pre="results obtained from trials utilizing the combination of trastuzumab and" exact="pertuzumab" post="actually demonstrated minimal cardiac toxicity with the combination. 47,"/>
   <result pre="but one patient. Investigators from the TRYPHAENA trial concluded that" exact="pertuzumab" post="does not increase the rate of cardiac dysfunction compared"/>
   <result pre="does not increase the rate of cardiac dysfunction compared to" exact="trastuzumab" post="alone with standard chemotherapy in the neoadjuvant setting. 47,"/>
   <result pre="treatment arms, with no significant difference between groups treated with" exact="trastuzumab" post="alone compared to combination trastuzumab and pertuzumab. 45 In"/>
   <result pre="difference between groups treated with trastuzumab alone compared to combination" exact="trastuzumab" post="and pertuzumab. 45 In the overall treatment period, LVEF"/>
   <result pre="group and seven patients (4%) each in the single agent" exact="lapatinib" post="and trastuzumab groups. 34 Thus far, no CHF events"/>
   <result pre="seven patients (4%) each in the single agent lapatinib and" exact="trastuzumab" post="groups. 34 Thus far, no CHF events have been"/>
   <result pre="RC0639 trial was the cardiac safety of four cycles of" exact="doxorubicin" post="and cyclophosphamide followed by 12 weeks of docetaxel, trastuzumab,"/>
   <result pre="was the cardiac safety of four cycles of doxorubicin and" exact="cyclophosphamide" post="followed by 12 weeks of docetaxel, trastuzumab, and lapatinib,"/>
   <result pre="of docetaxel, trastuzumab, and lapatinib, and then 40 weeks of" exact="trastuzumab" post="and lapatinib. 68 Five patients (4.6%) in the study"/>
   <result pre="(NCCN Guidelines ®, version 2) recommend the use of neo-adjuvant" exact="pertuzumab" post="in combination with trastuzumab and taxane-based chemotherapy given sequentially"/>
   <result pre="2) recommend the use of neo-adjuvant pertuzumab in combination with" exact="trastuzumab" post="and taxane-based chemotherapy given sequentially with anthracyclines (doxorubicin and"/>
   <result pre="trastuzumab and taxane-based chemotherapy given sequentially with anthracyclines (doxorubicin and" exact="cyclophosphamide" post="or FEC). 76 Interestingly, these guidelines also suggest that"/>
   <result pre="that it may be reasonable to consider the use of" exact="pertuzumab" post="in the adjuvant setting (in a similar regimen as"/>
   <result pre="in the adjuvant setting. The first-line combination of TDM1 plus" exact="pertuzumab" post="and TDM1-alone arms, as tested in the phase III"/>
   <result pre="95% CI 0.73–1.13, P=31), but not superior outcomes compared to" exact="trastuzumab" post="and taxane (13.7 months) in patients with HER2+ MBC."/>
   <result pre="with HER2+ MBC. 77 The combination of pre-operative TDM1 and" exact="pertuzumab" post="is being actively investigated in the I-SPY 2 trial"/>
   <result pre="are currently investigating the combination of TDM1, lapatinib, and albumin-bound" exact="paclitaxel" post="compared with trastuzumab, lapatinib, and paclitaxel (clinical trial number"/>
   <result pre="TDM1, lapatinib, and albumin-bound paclitaxel compared with trastuzumab, lapatinib, and" exact="paclitaxel" post="(clinical trial number NCT02073487), and neratinib with/without trastuzumab in"/>
   <result pre="with trastuzumab, lapatinib, and paclitaxel (clinical trial number NCT02073487), and" exact="neratinib" post="with/without trastuzumab in the neoadjuvant setting (NSABP-FB7, clinical trial"/>
   <result pre="lapatinib, and paclitaxel (clinical trial number NCT02073487), and neratinib with/without" exact="trastuzumab" post="in the neoadjuvant setting (NSABP-FB7, clinical trial number NCT01008150)."/>
   <result pre="in pCR with dual HER2 blockade (trastuzumab plus lapatinib, or" exact="trastuzumab" post="plus pertuzumab); however, the magnitude of benefit was highly"/>
   <result pre="identify patients who may benefit from dual HER2 therapy vs" exact="trastuzumab" post="alone, allowing for a truly individualized treatment approach. Disclosure"/>
   <result pre="Parsons K et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by" exact="trastuzumab" post="and is effectively inhibited by the PI3K inhibitor GDC-0941"/>
   <result pre="N et al. collab: Breast Cancer International Research Group Adjuvant" exact="trastuzumab" post="in HER2-positive breast cancer N Engl J Med 2011"/>
   <result pre="Trial Study Team 2 years versus 1 year of adjuvant" exact="trastuzumab" post="for HER2-positive breast cancer (HERA): an open-label, randomised controlled"/>
   <result pre="AM Franco S et al. A phase II study of" exact="lapatinib" post="monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic"/>
   <result pre="CM Liu L Baudson NM Ory TL Spector NL Combining" exact="lapatinib" post="(GW572016), a small molecule inhibitor of ErbB1 and ErbB2"/>
   <result pre="Venkatesan N et al. Activity of the dual kinase inhibitor" exact="lapatinib" post="(GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells Cancer"/>
   <result pre="Wang YC et al. Reduced dose and intermittent treatment with" exact="lapatinib" post="and trastuzumab for potent blockade of the HER pathway"/>
   <result pre="et al. Reduced dose and intermittent treatment with lapatinib and" exact="trastuzumab" post="for potent blockade of the HER pathway in HER2/neu-overexpressing"/>
   <result pre="al. Randomized study of Lapatinib alone or in combination with" exact="trastuzumab" post="in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer J"/>
   <result pre="SB et al. collab: CLEOPATRA Study Group Pertuzumab, trastuzumab, and" exact="docetaxel" post="in HER2-positive metastatic breast cancer N Engl J Med"/>
   <result pre="GE et al. Pathologic complete response after neoadjuvant chemotherapy plus" exact="trastuzumab" post="predicts favorable survival in human epidermal growth factor receptor"/>
   <result pre="L Eiermann W Semiglazov V et al. Neoadjuvant chemotherapy with" exact="trastuzumab" post="followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in"/>
   <result pre="V et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant" exact="trastuzumab" post="versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally"/>
   <result pre="Eidtmann H et al. collab: NeoALTTO Study Team Lapatinib with" exact="trastuzumab" post="for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label,"/>
   <result pre="Azambuja E Holmes AP Piccart-Gebhart M et al. Lapatinib with" exact="trastuzumab" post="for HER2-positive early breast cancer (NeoALTTO): survival outcomes of"/>
   <result pre="of CALGB 40601: a neoadjuvant phase III trial of weekly" exact="paclitaxel" post="and trastuzumab with or without lapatinib for HER2-positive breast"/>
   <result pre="40601: a neoadjuvant phase III trial of weekly paclitaxel and" exact="trastuzumab" post="with or without lapatinib for HER2-positive breast cancer J"/>
   <result pre="III trial of weekly paclitaxel and trastuzumab with or without" exact="lapatinib" post="for HER2-positive breast cancer J Clin Oncol 2013 31"/>
   <result pre="NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with" exact="lapatinib" post="alone (L), trastuzumab alone (T), their sequence (T →"/>
   <result pre="comparing one year of anti-HER2 therapy with lapatinib alone (L)," exact="trastuzumab" post="alone (T), their sequence (T → L), or their"/>
   <result pre="analysis of a phase II 3-arm, randomized trial of neoadjuvant" exact="trastuzumab" post="or lapatinib or the combination of trastuzumab and lapatinib,"/>
   <result pre="a phase II 3-arm, randomized trial of neoadjuvant trastuzumab or" exact="lapatinib" post="or the combination of trastuzumab and lapatinib, followed by"/>
   <result pre="trial of neoadjuvant trastuzumab or lapatinib or the combination of" exact="trastuzumab" post="and lapatinib, followed by six cycles of docetaxel and"/>
   <result pre="combination of trastuzumab and lapatinib, followed by six cycles of" exact="docetaxel" post="and carboplatin with trastuzumab and/or lapatinib in patients with"/>
   <result pre="trastuzumab and lapatinib, followed by six cycles of docetaxel and" exact="carboplatin" post="with trastuzumab and/or lapatinib in patients with HER2 +"/>
   <result pre="lapatinib, followed by six cycles of docetaxel and carboplatin with" exact="trastuzumab" post="and/or lapatinib in patients with HER2 + breast cancer"/>
   <result pre="by six cycles of docetaxel and carboplatin with trastuzumab and/or" exact="lapatinib" post="in patients with HER2 + breast cancer (TRIO-US B07)"/>
   <result pre="Correlation of molecular effects and pathologic complete response to preoperative" exact="lapatinib" post="and trastuzumab, separately and combined prior to neoadjuvant breast"/>
   <result pre="Forero A et al. Multicenter phase II study of neoadjuvant" exact="lapatinib" post="and trastuzumab with hormonal therapy and without chemotherapy in"/>
   <result pre="et al. Multicenter phase II study of neoadjuvant lapatinib and" exact="trastuzumab" post="with hormonal therapy and without chemotherapy in patients with"/>
   <result pre="ER Abdel-Rasoul M et al. Neoadjuvant dual HER2-targeted therapy with" exact="lapatinib" post="and trastuzumab improves pathologic complete response in patients with"/>
   <result pre="M et al. Neoadjuvant dual HER2-targeted therapy with lapatinib and" exact="trastuzumab" post="improves pathologic complete response in patients with early stage"/>
   <result pre="al. Pattern of rash, diarrhea, and hepatic toxicities secondary to" exact="lapatinib" post="and their association with age and response to neoadjuvant"/>
   <result pre="MA Flood W et al. Phase III randomized trial of" exact="cisplatin" post="plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent"/>
   <result pre="Phase III randomized trial of cisplatin plus placebo compared with" exact="cisplatin" post="plus cetuximab in metastatic/recurrent head and neck cancer: an"/>
   <result pre="randomized trial of cisplatin plus placebo compared with cisplatin plus" exact="cetuximab" post="in metastatic/recurrent head and neck cancer: an Eastern Cooperative"/>
   <result pre="T Im YH et al. Efficacy and safety of neoadjuvant" exact="pertuzumab" post="and trastuzumab in women with locally advanced, inflammatory, or"/>
   <result pre="YH et al. Efficacy and safety of neoadjuvant pertuzumab and" exact="trastuzumab" post="in women with locally advanced, inflammatory, or early HER2-positive"/>
   <result pre="the phase II NeoSphere trial evaluating four cycles of neoadjuvant" exact="docetaxel" post="(D) and/or trastuzumab (T) and/or pertuzumab (P) J Clin"/>
   <result pre="NeoSphere trial evaluating four cycles of neoadjuvant docetaxel (D) and/or" exact="trastuzumab" post="(T) and/or pertuzumab (P) J Clin Oncol 2015 33"/>
   <result pre="four cycles of neoadjuvant docetaxel (D) and/or trastuzumab (T) and/or" exact="pertuzumab" post="(P) J Clin Oncol 2015 33 15 Suppl 505"/>
   <result pre="Schneeweiss A Chia S Hickish T et al. Pertuzumab plus" exact="trastuzumab" post="in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy"/>
   <result pre="Abstract S5–S02 51 Joensuu H Dual targeting of HER2 with" exact="lapatinib" post="and trastuzumab Lancet Oncol 2014 15 10 1050 1052"/>
   <result pre="51 Joensuu H Dual targeting of HER2 with lapatinib and" exact="trastuzumab" post="Lancet Oncol 2014 15 10 1050 1052 25130997 52"/>
   <result pre="CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly" exact="paclitaxel" post="and trastuzumab with or without lapatinib for HER2-positive breast"/>
   <result pre="(Alliance), a neoadjuvant phase III trial of weekly paclitaxel and" exact="trastuzumab" post="with or without lapatinib for HER2-positive breast cancer (BrCa)"/>
   <result pre="III trial of weekly paclitaxel and trastuzumab with or without" exact="lapatinib" post="for HER2-positive breast cancer (BrCa) J Clin Oncol 2014"/>
   <result pre="High HER2 expression correlates with response to the combination of" exact="lapatinib" post="and trastuzumab Clin Cancer Res 2015 21 3 569"/>
   <result pre="expression correlates with response to the combination of lapatinib and" exact="trastuzumab" post="Clin Cancer Res 2015 21 3 569 576 25467182"/>
   <result pre="and tensin homolog or phosphoinositol-3 kinase activation and response to" exact="trastuzumab" post="or lapatinib in human epidermal growth factor receptor 2-overexpressing"/>
   <result pre="homolog or phosphoinositol-3 kinase activation and response to trastuzumab or" exact="lapatinib" post="in human epidermal growth factor receptor 2-overexpressing locally advanced"/>
   <result pre="V Dieci MV Carbognin L et al. Activity of neoadjuvant" exact="lapatinib" post="(L) plus trastuzumab (T) for early breast cancer (EBC)"/>
   <result pre="Carbognin L et al. Activity of neoadjuvant lapatinib (L) plus" exact="trastuzumab" post="(T) for early breast cancer (EBC) according to PIK3CA"/>
   <result pre="al. Impact of PTEN protein expression on benefit from adjuvant" exact="trastuzumab" post="in early-stage human epidermal growth factor receptor 2-positive breast"/>
   <result pre="CM et al. Circulating tumor cells and response to neoadjuvant" exact="paclitaxel" post="and HER2-targeted therapy: a sub-study from the NeoALTTO phase"/>
   <result pre="66 collab: ClinicalTrialsgov [database on the Internet] A study of" exact="pertuzumab" post="in addition to chemotherapy and herceptin (trastuzumab) as adjuvant"/>
   <result pre="67 Dang C Lin N Moy B et al. Dose-dense" exact="doxorubicin" post="and cyclophosphamide followed by weekly paclitaxel with trastuzumab and"/>
   <result pre="C Lin N Moy B et al. Dose-dense doxorubicin and" exact="cyclophosphamide" post="followed by weekly paclitaxel with trastuzumab and lapatinib in"/>
   <result pre="B et al. Dose-dense doxorubicin and cyclophosphamide followed by weekly" exact="paclitaxel" post="with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is"/>
   <result pre="al. Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with" exact="trastuzumab" post="and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible"/>
   <result pre="doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and" exact="lapatinib" post="in HER2/neu-overexpressed/amplified breast cancer is not feasible because of"/>
   <result pre="et al. RC0639: phase II study of paclitaxel, trastuzumab, and" exact="lapatinib" post="as adjuvant therapy for early stage HER2-positive breast cancer"/>
   <result pre="analysis of cardiac safety in patients with cancer treated with" exact="pertuzumab" post="Ann Oncol 2012 23 3 791 800 21665955 71"/>
   <result pre="CH Eiermann W et al. Phase III, randomized study of" exact="trastuzumab" post="emtansine (T-DM1) {+/−} pertuzumab (P) vs trastuzumab + taxane"/>
   <result pre="al. Phase III, randomized study of trastuzumab emtansine (T-DM1) {+/−}" exact="pertuzumab" post="(P) vs trastuzumab + taxane (HT) for first-line treatment"/>
   <result pre="randomized study of trastuzumab emtansine (T-DM1) {+/−} pertuzumab (P) vs" exact="trastuzumab" post="+ taxane (HT) for first-line treatment of HER2-positive MBC:"/>
   <result pre="1 Summary of phase II and III trials using combination" exact="trastuzumab" post="plus lapatinib in the neoadjuvant setting for HER2 positive"/>
   <result pre="of phase II and III trials using combination trastuzumab plus" exact="lapatinib" post="in the neoadjuvant setting for HER2 positive breast cancer"/>
   <result pre="mg) → surgery B. T + L (1,000 mg) +" exact="letrozole" post="(ER +) → surgery &amp;gt;3 cm, or &amp;gt;2 cm"/>
   <result pre="been presented in the form of an abstract. Abbreviations: AC," exact="doxorubicin" post="and cyclophosphamide; ER, estrogen receptor; FEC, fluorouracil, epirubicin, cyclophosphamide;"/>
   <result pre="T, trastuzumab; HER2, human epidermal growth factor receptor 2; TL," exact="trastuzumab" post="and lapatinib; d, days; N, nodal stage. Table 2"/>
   <result pre="stage. Table 2 Summary of phase II trials using combination" exact="trastuzumab" post="plus pertuzumab in the neoadjuvant setting for HER2 positive"/>
   <result pre="2 Summary of phase II trials using combination trastuzumab plus" exact="pertuzumab" post="in the neoadjuvant setting for HER2 positive breast cancer"/>
   <result pre="LN) Rate of discontinuation ORR NeoSphere/II 45 A. T +" exact="docetaxel" post="→ surgery → FEC ×3 + T B.T +"/>
   <result pre="surgery → FEC ×3 + T B.T + P +" exact="docetaxel" post="→ surgery → FEC ×3 + T C. T"/>
   <result pre="×3 + T C. T + P → surgery →" exact="docetaxel" post="×4 + T → FEC ×3 + T D."/>
   <result pre="+ T → FEC ×3 + T D. P +" exact="docetaxel" post="→ surgery → FEC ×3 + T Stage II/III,"/>
   <result pre="88.0% C. 66.3% D. 73.9% TRYPHAENA/II 47 A. Carboplatin +" exact="docetaxel" post="+ T + P B. FEC → T +"/>
   <result pre="T + P B. FEC → T + P +" exact="docetaxel" post="C.FEC + T + P → T + P"/>
   <result pre="C.FEC + T + P → T + P +" exact="docetaxel" post="Stage II/III, including inflammatory cancer 225 patients ( A:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4591587/results/search/inn/results.xml">
   <result pre="lapatinib, the humanized monoclonal antibody pertuzumab, and the antibody–drug conjugate" exact="trastuzumab" post="emtansine (T-DM1). In addition to these therapies, other advances"/>
   <result pre="1997, the phase III trial that supported the licensure of" exact="trastuzumab" post="recruited patients with HER2-positive MBC (including patients with both"/>
   <result pre="in the metastatic setting. Median OS among patients who received" exact="trastuzumab" post="plus chemotherapy was 25.1 months compared with 20.3 months"/>
   <result pre="control arm (trastuzumab plus docetaxel) and 56.5 months in the" exact="pertuzumab" post="arm (pertuzumab plus trastuzumab plus docetaxel) [ 17]. This"/>
   <result pre="docetaxel) and 56.5 months in the pertuzumab arm (pertuzumab plus" exact="trastuzumab" post="plus docetaxel) [ 17]. This comparison across clinical trials,"/>
   <result pre="of women with metastatic breast cancer by HER2 status and" exact="trastuzumab" post="treatment: an institutional-based review J Clin Oncol 2010 28"/>
   <result pre="Im SA Hegg R Im YH et al. Pertuzumab plus" exact="trastuzumab" post="plus docetaxel for metastatic breast cancer N Engl J"/>
   <result pre="Hegg R Im YH et al. Pertuzumab plus trastuzumab plus" exact="docetaxel" post="for metastatic breast cancer N Engl J Med 2012"/>
   <result pre="J Semiglazov V Campone M et al. Pertuzumab, trastuzumab, and" exact="docetaxel" post="in HER2-positive metastatic breast cancer N Engl J Med"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4593385/results/search/inn/results.xml">
   <result pre="Four decades ago, the rise of hormonal therapy, such as" exact="tamoxifen" post="for breast cancer, has remarkably enhanced tissue selectivity and"/>
   <result pre="turn the malignant behaviors of leukemic cells [ 7]. Impressively," exact="imatinib" post="has been able to extend 5-year OS rate of"/>
   <result pre="thereby re-defining CML as a manageable disease [ 25]. Additionally," exact="imatinib" post="is also a potent antagonist of c-kit receptor tyrosine"/>
   <result pre="(GIST) [ 26]. In the pharmaceutical industry, the success of" exact="imatinib" post="evoked a huge wave of efforts to develop various"/>
   <result pre="following the light of the first BCR-ABL inhibitor, resistance to" exact="imatinib" post="is emerging as a major challenge in CML management."/>
   <result pre="gene were revealed to be the most common mechanism behind" exact="imatinib" post="resistance, and they associate with an advanced disease state"/>
   <result pre="disease state (accelerated or blast-phase CML). Imatinib works as an" exact="adenosine" post="triphosphate (ATP) mimetic compound, and it only binds to"/>
   <result pre="compound and, therefore, a loss of inhibitory potency. To address" exact="imatinib" post="resistance issue in CML, new-generation inhibitors, such as dasatinib,"/>
   <result pre="active conformation [ 7]. Likewise, in the case of GIST," exact="imatinib" post="resistance mainly results from mutations of the c- KIT"/>
   <result pre="KIT (exon 9) or PDGFRA (D842V). Moreover, secondary resistance to" exact="imatinib" post="appears approximately 2 years after the treatment, and it"/>
   <result pre="N822K plus exon 11 mutations. In response to these challenges," exact="sunitinib" post="and regorafenib have been developed to serve as second-"/>
   <result pre="exon 11 mutations. In response to these challenges, sunitinib and" exact="regorafenib" post="have been developed to serve as second- and third-generation"/>
   <result pre="monoclonal antibody cetuximab, and others [ 9]. Being less toxic," exact="gefitinib" post="and erlotinib have been reported to be superior to"/>
   <result pre="cetuximab, and others [ 9]. Being less toxic, gefitinib and" exact="erlotinib" post="have been reported to be superior to conventional cytotoxic"/>
   <result pre="EGFR mutations such as L858R ( EGFR addiction). In addition," exact="cetuximab" post="in combination with radiation in head and neck cancer"/>
   <result pre="the 2-year OS rate of the patients [ 13]. Additionally," exact="cetuximab" post="was approved for treating metastatic and chemotherapy-resistant colorectal cancer"/>
   <result pre="&quot;gatekeeper&quot; mutation, for which a currently available solution is combining" exact="cetuximab" post="with afatinid. However, an EGFR mutation S492R in colorectal"/>
   <result pre="a PFS of 10 months, the emergence of resistance to" exact="crizotinib" post="has been noticed as a challenge [ 14, 15]."/>
   <result pre="and L1196M have been reported as the molecular mode of" exact="crizotinib" post="resistance [ 14]. Moreover, alternative signaling activation, including EGFR"/>
   <result pre="antibody targeting the extracellular domain of the HER2 protein, and" exact="trastuzumab" post="plus chemotherapy has been accepted as the standard first-line"/>
   <result pre="first-line treatment for HER2-positive metastatic breast cancer (MBC). Application of" exact="trastuzumab" post="was revealed to confer extra-clinical benefits to HER2-positive breast"/>
   <result pre="majority of HER2-positive breast cancer patients would not respond to" exact="trastuzumab" post="without simultaneous cytotoxic therapy. It has been proposed that"/>
   <result pre="trastuzumab without simultaneous cytotoxic therapy. It has been proposed that" exact="trastuzumab" post="exerts clinical efficacy mainly through sensitizing tumor cells to"/>
   <result pre="its lack of the extracellular domain of HER2 targeted by" exact="trastuzumab" post="[ 16]. Moreover, enhanced HER2 dimerization resulting from PI3"/>
   <result pre="identified to play an important role in secondary resistance to" exact="trastuzumab" post="[ 2, 27]. To circumvent these problems, pertuzumab, a"/>
   <result pre="antibody, has been developed to disturb HER2/HER3 dimerization, thereby augmenting" exact="trastuzumab" post="activity [ 17]. In addition, trastuzumab emtansine, derived from"/>
   <result pre="HER2/HER3 dimerization, thereby augmenting trastuzumab activity [ 17]. In addition," exact="trastuzumab" post="emtansine, derived from covalently conjugating a cytotoxic compound with"/>
   <result pre="HER2, has been approved to treat HER2-positive breast cancer upon" exact="trastuzumab" post="failure [ 28]. Vascular endothelial growth factor (VEGF) antagonists"/>
   <result pre="also achieved clinical success [ 2]. Interestingly, the VEGFR inhibitors" exact="sunitinib" post="and vandetanib coincidentally inhibit c- KIT and rearranged during"/>
   <result pre="clinical success [ 2]. Interestingly, the VEGFR inhibitors sunitinib and" exact="vandetanib" post="coincidentally inhibit c- KIT and rearranged during transfection ("/>
   <result pre="stage, of which approximately 80% appear as the substitution of" exact="glutamic acid" post="(E) for valine (V) in codon 600, known as"/>
   <result pre="23]. In spite of an impressive RR of 50% with" exact="vemurafenib" post="and dabrafenib initially, acquired resistance to these drugs occurs"/>
   <result pre="spite of an impressive RR of 50% with vemurafenib and" exact="dabrafenib" post="initially, acquired resistance to these drugs occurs after approximately"/>
   <result pre="mutations [ 2]. In this light, combining the MEK inhibitor" exact="trametinib" post="with BRAF inhibitors in melanoma treatments has resulted better"/>
   <result pre="toxic profiles [ 34]. Impressively, the therapeutic response duration with" exact="nivolumab" post="has been extended beyond 2 years [ 23]. Conclusion"/>
   <result pre="and patients with more options to improve clinical outcomes. Although" exact="imatinib" post="has transformed CML into a manageable medical condition like"/>
   <result pre="Blasiak J Therapy of chronic myeloid leukemia: twilight of the" exact="imatinib" post="era? IRSN Oncol 2014 2014 596483 8. Heinrich MC"/>
   <result pre="kinase genotypes correlate with the biological and clinical activity of" exact="sunitinib" post="in imatinib resistant gastrointestinal stromal tumor J Clin Oncol"/>
   <result pre="correlate with the biological and clinical activity of sunitinib in" exact="imatinib" post="resistant gastrointestinal stromal tumor J Clin Oncol 2008 26"/>
   <result pre="Silletta M Santini D Tonini G The biological properties of" exact="cetuximab" post="Crit Rev Oncol Hematol 2008 68 93 106 10.1016/j.critrevonc.2008.07.006"/>
   <result pre="Conte P Miles D et al. Phase II trial of" exact="pertuzumab" post="and trastuzumab in patients with human epidermal growth factor"/>
   <result pre="Miles D et al. Phase II trial of pertuzumab and" exact="trastuzumab" post="in patients with human epidermal growth factor receptor 2-positive"/>
   <result pre="factor receptor 2-positive metastatic breast cancer that progressed during prior" exact="trastuzumab" post="therapy J Clin Oncol 2010 28 1138 1144 10.1200/JCO.2009.24.2024"/>
   <result pre="3096 10.1200/JCO.2010.33.2312 21383288 25. Druker BJ Perspectives on development of" exact="imatinib" post="and the future of cancer Nat Med 2009 15"/>
   <result pre="WJ Emerging approaches for treating HER2-positive metastatic breast cancer beyond" exact="trastuzumab" post="Ann Oncol 2013 24 2492 2500 10.1093/annonc/mdt217 23827380 29."/>
   <result pre="N Pienkowski T Martin M Press M et al. Adjuvant" exact="trastuzumab" post="in HER2-positive breast cancer N Engl J Med 2011"/>
   <result pre="Qian CN et al. Interleukin-8 mediates resistance to antiangiogenic agent" exact="sunitinib" post="in renal cell carcinoma Cancer Res 2010 70 1063"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4600684/results/search/inn/results.xml">
   <result pre="This profile includes the expression of the estrogen (ER) and" exact="progesterone" post="receptors (PR), decreased levels of cell proliferation markers ["/>
   <result pre="stage I, and no lymph node infiltration) and received adjuvant" exact="tamoxifen" post="treatment with or without radiation. A reduction in local"/>
   <result pre="in size, T1/T2), had undergone breast-conserving surgery, and received adjuvant" exact="tamoxifen" post="with or without radiotherapy. The local recurrence rate at"/>
   <result pre="rate at 5 years was 0.6% for the radiotherapy and" exact="tamoxifen" post="group and 7.7% for the tamoxifen monotherapy group. Fisher"/>
   <result pre="for the radiotherapy and tamoxifen group and 7.7% for the" exact="tamoxifen" post="monotherapy group. Fisher et al. [ 56] compared radiotherapy,"/>
   <result pre="tamoxifen monotherapy group. Fisher et al. [ 56] compared radiotherapy," exact="tamoxifen" post="therapy, and their combination in BC patients of all"/>
   <result pre="therapy In the 1980s and 1990s, nonrandomized studies showed that" exact="tamoxifen" post="itself was as effective as mastectomy in patients with"/>
   <result pre="mastectomy, but 57% in patients who had been treated with" exact="tamoxifen" post="alone [ 34 76 77]. The Cochrane review, which"/>
   <result pre="operable primary BCs (&amp;lt;5 cm) for both the mastectomy-alone and" exact="tamoxifen" post="monotherapy groups [ 79]. Johnston et al. [ 80]"/>
   <result pre="et al. [ 80] also reported that combining surgery with" exact="tamoxifen" post="in fit elderly people (≥70 years) conferred no advantage"/>
   <result pre="have shown an advantage of using surgery or surgery plus" exact="tamoxifen" post="compared to tamoxifen alone for better local control. Contradictory"/>
   <result pre="advantage of using surgery or surgery plus tamoxifen compared to" exact="tamoxifen" post="alone for better local control. Contradictory findings have also"/>
   <result pre="have also been reported, mainly no difference between surgery and" exact="tamoxifen" post="for local control. However, most studies agree that there"/>
   <result pre="Breast Cancer Trialists' Collaborative Group overview, 5-year adjuvant therapy with" exact="tamoxifen" post="in women of all ages with positive ER and"/>
   <result pre="of age [ 83]. In addition, the pivotal role of" exact="tamoxifen" post="in the hormonal management of elderly BC patients was"/>
   <result pre="International Breast Cancer Study Group Trial IV, wherein 1 year" exact="tamoxifen" post="delivery prolonged DFS and OS during a 21-years follow-up"/>
   <result pre="treatment with aromatase inhibitors (AIs) provides additional benefits compared to" exact="tamoxifen" post="treatment, but only a small proportion of the participants"/>
   <result pre="86 87]. The Breast International Group 1-98 study, which compared" exact="letrozole" post="treatment to tamoxifen therapy in a cohort of 8,010"/>
   <result pre="Breast International Group 1-98 study, which compared letrozole treatment to" exact="tamoxifen" post="therapy in a cohort of 8,010 patients (36% aged"/>
   <result pre="with a median follow-up time of 5 years, demonstrated that" exact="letrozole" post="was superior in terms of local and distant metastasis"/>
   <result pre="nonfracture adverse effects were observed in older patients in the" exact="letrozole" post="treatment arm, but no differences in thromboembolic or cardiac"/>
   <result pre="in Combination trial confirmed the above findings by showing that" exact="anastrozole" post="treatment improved DFS compared to tamoxifen therapy (hazard ratio,"/>
   <result pre="findings by showing that anastrozole treatment improved DFS compared to" exact="tamoxifen" post="therapy (hazard ratio, 0.75; p=0.01) and prolonged the time"/>
   <result pre="AIs was recently confirmed in two separate meta-analyses. First, upfront" exact="tamoxifen" post="monotherapy was compared with AIs, which resulted in a"/>
   <result pre="60. On the other hand, switching strategies (2-3 years of" exact="tamoxifen" post="then continuing with AIs) reduced BC recurrence rates in"/>
   <result pre="60 [ 94]. In addition, the MA.17 trial showed that" exact="letrozole" post="therapy after 5 years of tamoxifen treatment was superior"/>
   <result pre="MA.17 trial showed that letrozole therapy after 5 years of" exact="tamoxifen" post="treatment was superior to placebo in terms of DFS,"/>
   <result pre="all age groups [ 95 96]. The protective role of" exact="tamoxifen" post="against fractures has also been well documented in the"/>
   <result pre="has also been well documented in the older population. Five-year" exact="tamoxifen" post="administration in the adjuvant setting prevented 23 and 90"/>
   <result pre="nonvertebral (adjusted hazard ratio, 1.34) fractures than patients treated with" exact="tamoxifen" post="[ 99]. Patients aged over 75 with low bone"/>
   <result pre="Eidtmann et al. [ 101] recently confirmed the effectiveness of" exact="zoledronic acid" post="in preventing bone mineral loss in patients treated with"/>
   <result pre="mineral loss in patients treated with letrozole. Furthermore, treatment with" exact="tamoxifen" post="could result in a range of adverse effects, and"/>
   <result pre="their co-evaluation is significant, particularly for the elderly. More specifically," exact="tamoxifen" post="treatment in women aged 70-79 years increases the absolute"/>
   <result pre="cancer, thromboembolism, vaginal hemorrhage and hot flushes than that of" exact="tamoxifen" post="in any age group. However, arthralgia, myalgia, bone loss,"/>
   <result pre="should be treated with AIs upfront and then switched to" exact="tamoxifen" post="treatment. AIs can also be administered, beyond the first"/>
   <result pre="the first 5 years, in node-positive patients treated initially with" exact="tamoxifen" post="or for less than 5 years with AIs. No"/>
   <result pre="2 to 3 years of tamoxifen. As extended adjuvant treatment," exact="letrozole" post="and anastrozole could be used after 5 years of"/>
   <result pre="3 years of tamoxifen. As extended adjuvant treatment, letrozole and" exact="anastrozole" post="could be used after 5 years of tamoxifen ["/>
   <result pre="letrozole and anastrozole could be used after 5 years of" exact="tamoxifen" post="[ 104]. The American Society of Clinical Oncology guidelines"/>
   <result pre="of AIs as up-front therapy or as sequential treatment after" exact="tamoxifen" post="in postmenopausal women with hormone-responsive early BC, although the"/>
   <result pre="positive hormone receptor status is debated. A retrospective study compared" exact="tamoxifen" post="adjuvant monotherapy against a combination of tamoxifen and anthracycline-based"/>
   <result pre="retrospective study compared tamoxifen adjuvant monotherapy against a combination of" exact="tamoxifen" post="and anthracycline-based chemotherapy in BC patients (29.4% of patients"/>
   <result pre="et al. [ 47] documented that although low doses of" exact="epirubicin" post="and tamoxifen therapy versus tamoxifen alone improved DFS, but"/>
   <result pre="[ 47] documented that although low doses of epirubicin and" exact="tamoxifen" post="therapy versus tamoxifen alone improved DFS, but not OS"/>
   <result pre="that although low doses of epirubicin and tamoxifen therapy versus" exact="tamoxifen" post="alone improved DFS, but not OS in node-positive BC"/>
   <result pre="≥65 years. Adjuvant chemotherapy has historically included four cycles of" exact="doxorubicin" post="(adriamycin) and cyclophosphamide (AC) or six cycles of cyclophosphamide,"/>
   <result pre="chemotherapy has historically included four cycles of doxorubicin (adriamycin) and" exact="cyclophosphamide" post="(AC) or six cycles of cyclophosphamide, methotrexate, and 5-fluorouracil"/>
   <result pre="both AC and CMF were found to be superior to" exact="capecitabine" post="monotherapy in terms of both the relapse-free survival (85%"/>
   <result pre="worse natural history and poorer prognosis. Hence, the use of" exact="trastuzumab" post="in women with small breast tumors is an accepted"/>
   <result pre="Gallen 2015 consensus [ 74]. It is well documented that" exact="trastuzumab" post="adjuvant treatment for HER2+ BC patients, measured either by"/>
   <result pre="risk of local recurrence and death [ 74]. Furthermore, when" exact="trastuzumab" post="was combined with chemotherapy, it was shown to reduce"/>
   <result pre="to chemotherapy alone [ 29 120]. Therefore, combined chemotherapy and" exact="trastuzumab" post="administration should be used as adjuvant treatment in the"/>
   <result pre="St. Gallen 2015 consensus unanimously recognized the concurrent administration of" exact="trastuzumab" post="with paclitaxel over a 1-year period as a reasonable"/>
   <result pre="2015 consensus unanimously recognized the concurrent administration of trastuzumab with" exact="paclitaxel" post="over a 1-year period as a reasonable option for"/>
   <result pre="the panel favored anthracycline treatment followed by a taxane and" exact="trastuzumab" post="regimen [ 67]. The same panel accepted that the"/>
   <result pre="[ 15]. The major limiting factor and adverse effect of" exact="trastuzumab" post="is cardiotoxicity [ 118], resulting in a decreased left"/>
   <result pre="of age [ 70]. Although the incidence of cardiotoxicity in" exact="trastuzumab" post="monotherapy is only 5%, combination treatment with trastuzumab and"/>
   <result pre="cardiotoxicity in trastuzumab monotherapy is only 5%, combination treatment with" exact="trastuzumab" post="and anthracyclines dramatically increases this frequency to 25% ["/>
   <result pre="of cardiac toxicity, ESMO guidelines suggest the concurrent administration of" exact="trastuzumab" post="with a non-anthracycline-containing regimen and the avoidance of delivery"/>
   <result pre="receptor pathways. A multicenter, randomized phase III trial, recently documented" exact="lapatinib" post="as an accepted treatment option for trastuzumab-naive HER2-positive early-stage"/>
   <result pre="early-stage BC women who do not or cannot receive adjuvant" exact="trastuzumab" post="[ 122]. However, more data are needed to elucidate"/>
   <result pre="However, more data are needed to elucidate the role of" exact="lapatinib" post="in early-stage BC in elderly patients. CONCLUSION The management"/>
   <result pre="Van Praagh I et al. Disease-free survival advantage of weekly" exact="epirubicin" post="plus tamoxifen versus tamoxifen alone as adjuvant treatment of"/>
   <result pre="I et al. Disease-free survival advantage of weekly epirubicin plus" exact="tamoxifen" post="versus tamoxifen alone as adjuvant treatment of operable, node-positive,"/>
   <result pre="al. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus" exact="tamoxifen" post="alone as adjuvant treatment of operable, node-positive, elderly breast"/>
   <result pre="Cirrincione C McCormick B Shank B et al. Lumpectomy plus" exact="tamoxifen" post="with or without irradiation in women 70 years of"/>
   <result pre="in the elderly: a randomised clinical trial EORTC 10851 comparing" exact="tamoxifen" post="alone with modified radical mastectomy Eur J Cancer 2003"/>
   <result pre="Wyld L Reed MW Surgery, with or without tamoxifen, vs" exact="tamoxifen" post="alone for older women with operable breast cancer: cochrane"/>
   <result pre="RW Cheung KL A randomised trial of mastectomy only versus" exact="tamoxifen" post="for treating elderly patients with operable primary breast cancer-final"/>
   <result pre="SE Winterbottom L et al. A randomised trial of primary" exact="tamoxifen" post="versus mastectomy plus adjuvant tamoxifen in fit elderly women"/>
   <result pre="A randomised trial of primary tamoxifen versus mastectomy plus adjuvant" exact="tamoxifen" post="in fit elderly women with invasive breast carcinoma of"/>
   <result pre="Muss HB Piccart MJ et al. A randomized trial of" exact="letrozole" post="in postmenopausal women after five years of tamoxifen therapy"/>
   <result pre="trial of letrozole in postmenopausal women after five years of" exact="tamoxifen" post="therapy for early-stage breast cancer N Engl J Med"/>
   <result pre="Jassem J Delozier T et al. A randomized trial of" exact="exemestane" post="after two to three years of tamoxifen therapy in"/>
   <result pre="randomized trial of exemestane after two to three years of" exact="tamoxifen" post="therapy in postmenopausal women with primary breast cancer N"/>
   <result pre="adjusting for selective crossover show improved overall survival with adjuvant" exact="letrozole" post="compared with tamoxifen in the BIG 1-98 study J"/>
   <result pre="crossover show improved overall survival with adjuvant letrozole compared with" exact="tamoxifen" post="in the BIG 1-98 study J Clin Oncol 2011"/>
   <result pre="AS Mouridsen H Mauriac L et al. A comparison of" exact="letrozole" post="and tamoxifen in postmenopausal women with early breast cancer"/>
   <result pre="H Mauriac L et al. A comparison of letrozole and" exact="tamoxifen" post="in postmenopausal women with early breast cancer N Engl"/>
   <result pre="KN Thürlimann B Mouridsen H et al. Letrozole compared with" exact="tamoxifen" post="for elderly patients with endocrine-responsive early breast cancer: the"/>
   <result pre="Forbes JF Cuzick J Buzdar A et al. Effect of" exact="anastrozole" post="and tamoxifen as adjuvant treatment for early-stage breast cancer:"/>
   <result pre="Cuzick J Buzdar A et al. Effect of anastrozole and" exact="tamoxifen" post="as adjuvant treatment for early-stage breast cancer: 100-month analysis"/>
   <result pre="breast cancer outcomes in adjuvant trials of aromatase inhibitors versus" exact="tamoxifen" post="J Clin Oncol 2010 28 509 518 19949017 95"/>
   <result pre="NJ Muss HB Piccart MJ et al. Randomized trial of" exact="letrozole" post="following tamoxifen as extended adjuvant therapy in receptor-positive breast"/>
   <result pre="HB Piccart MJ et al. Randomized trial of letrozole following" exact="tamoxifen" post="as extended adjuvant therapy in receptor-positive breast cancer: updated"/>
   <result pre="D Zhao N Shepherd LE Goss PE Longer-term outcomes of" exact="letrozole" post="versus placebo after 5 years of tamoxifen in the"/>
   <result pre="Longer-term outcomes of letrozole versus placebo after 5 years of" exact="tamoxifen" post="in the NCIC CTG MA.17 trial: analyses adjusting for"/>
   <result pre="Llombart-Cussac A Davidson N Neven P et al. Efficacy of" exact="zoledronic acid" post="in postmenopausal women with early breast cancer receiving adjuvant"/>
   <result pre="Klijn JG et al. Anastrozole alone or in combination with" exact="tamoxifen" post="versus tamoxifen alone for adjuvant treatment of postmenopausal women"/>
   <result pre="et al. Anastrozole alone or in combination with tamoxifen versus" exact="tamoxifen" post="alone for adjuvant treatment of postmenopausal women with early"/>
   <result pre="Blum JL Vukelja SJ McIntyre KJ et al. Docetaxel with" exact="cyclophosphamide" post="is associated with an overall survival benefit compared with"/>
   <result pre="cyclophosphamide is associated with an overall survival benefit compared with" exact="doxorubicin" post="and cyclophosphamide: 7-year follow-up of US Oncology Research Trial"/>
   <result pre="J Ejlertsen B Kaufmann M Boyle F et al. Adjuvant" exact="lapatinib" post="for women with early-stage HER2-positive breast cancer: a randomised,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4602505/results/search/inn/results.xml">
   <result pre="anti-HER2 treatments, 1 such as lapatinib, 2 pertuzumab, 3 and" exact="trastuzumab" post="emtansine (T-DM1), 4 shows how increasingly important it is"/>
   <result pre="pNx, presenting the following immunophenotypic profile: estrogen receptor (ER) 90%," exact="progesterone" post="receptor (PR) 65%, Ki-67 3%, and HER2 (clone CB11)"/>
   <result pre="case as HER2 positive (score 3+) thus directly eligible for" exact="trastuzumab" post="therapy. Conversely, the DDISH did not evidence HER2 amplification."/>
   <result pre="= participant center, pN = lymph node status, PR =" exact="progesterone" post="receptor, pT = tumor size, RC = revising center,"/>
   <result pre="pT = tumor size, RC = revising center, T-DM1 =" exact="trastuzumab" post="emtansine. The authors have no funding and conflicts of"/>
   <result pre="Geyer CE Forster J Lindquist D et al. Lapatinib plus" exact="capecitabine" post="for HER2-positive advanced breast cancer. N Engl J Med"/>
   <result pre="J Kim SB et al. CLEOPATRA Study Group: Pertuzumab plus" exact="trastuzumab" post="plus docetaxel for metastatic breast cancer . N Engl"/>
   <result pre="SB et al. CLEOPATRA Study Group: Pertuzumab plus trastuzumab plus" exact="docetaxel" post="for metastatic breast cancer . N Engl J Med"/>
   <result pre="of prolonged fixation on the immunohistochemical evaluation of estrogen receptor," exact="progesterone" post="receptor, and HER2 expression in invasive breast cancer: a"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4609140/results/search/inn/results.xml">
   <result pre="1772 doi: 10.1186/s12885-015-1772-1 : Research Article Up-regulation of HER2 by" exact="gemcitabine" post="enhances the antitumor effect of combined gemcitabine and trastuzumab"/>
   <result pre="of HER2 by gemcitabine enhances the antitumor effect of combined" exact="gemcitabine" post="and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells"/>
   <result pre="by gemcitabine enhances the antitumor effect of combined gemcitabine and" exact="trastuzumab" post="emtansine treatment on pancreatic ductal adenocarcinoma cells Kan Shin"/>
   <result pre="a given agent, then combination therapy with that agent and" exact="trastuzumab" post="emtansine (T-DM1), a chemotherapeutic agent that is a conjugate"/>
   <result pre="including MIA PaCa-2, three showed increases in HER2 expression after" exact="gemcitabine" post="(GEM) treatment. The binding of T-DM1 to GEM-treated MIA"/>
   <result pre="The treatment of HER2-overexpressing breast or gastric cancer patients with" exact="trastuzumab" post="in combination with chemotherapeutic agents is being evaluated in"/>
   <result pre="PDAs widely express HER2 (10-82 %) [ 9– 13]. Although" exact="trastuzumab" post="treatment against human PDA cells has shown significant antitumor"/>
   <result pre="in vivo and in vitro studies, the combined treatment of" exact="gemcitabine" post="(GEM) or capecitabine with trastuzumab against metastatic PDA did"/>
   <result pre="in vitro studies, the combined treatment of gemcitabine (GEM) or" exact="capecitabine" post="with trastuzumab against metastatic PDA did not result in"/>
   <result pre="studies, the combined treatment of gemcitabine (GEM) or capecitabine with" exact="trastuzumab" post="against metastatic PDA did not result in improved progression-free"/>
   <result pre="15]. Trastuzumab emtansine (T-DM1) is a recently developed conjugate of" exact="trastuzumab" post="and DM1 (derivative of maytansine 1), a chemotherapeutic agent."/>
   <result pre="of trastuzumab, even if the tumor cells were resistant to" exact="trastuzumab" post="[ 18, 19]. In clinical studies, the antitumor effect"/>
   <result pre="of T-DM1 was found to be superior to those of" exact="lapatinib" post="and docetaxel in patients with HER2-positive advanced breast cancer"/>
   <result pre="was found to be superior to those of lapatinib and" exact="docetaxel" post="in patients with HER2-positive advanced breast cancer that was"/>
   <result pre="patients with HER2-positive advanced breast cancer that was resistant to" exact="trastuzumab" post="and taxanes [ 20]. One possible reason why trastuzumab"/>
   <result pre="to trastuzumab and taxanes [ 20]. One possible reason why" exact="trastuzumab" post="has not been applied as a treatment for PDA"/>
   <result pre="was purchased from Kyowa Hakko Kirin Co. (Tokyo, Japan), and" exact="oxaliplatin" post="(L-OHP) was purchased from Sigma-Aldrich (St. Louis, MO, USA)."/>
   <result pre="Trastuzumab was a gift from Chugai, Inc. (Tokyo, Japan), and" exact="trastuzumab" post="emtansine (T-DM1) was provided by Genentech Inc. (South San"/>
   <result pre="Triton X-100, 100 mM PMSF, 1 mg/ml leupeptin, 1 mg/ml" exact="aprotinin" post="and 0.9 M Na 3VO 4, and the protein"/>
   <result pre="Triton X-100, 100 mM PMSF, 1 mg/ml leupeptin, 1 mg/ml" exact="aprotinin" post="and 0.9 M Na 3VO 4. To quantify human"/>
   <result pre="surface HER2 expression by approximately 1.5-fold, and 10 μg/ml of" exact="oxaliplatin" post="(L-OHP) increased HER2 expression by approximately 2.5-fold (Fig. 3)."/>
   <result pre="-pretreated MIA PaCa-2 cells (100 ng/ml) was competitively inhibited when" exact="trastuzumab" post="was added to the culture (Fig. 5b). On the"/>
   <result pre="b GEM-treated (100 ng/ml) MIA PaCa-2 cells were incubated with" exact="trastuzumab" post="(0, 10, 30 or 100 μg/ml) in the presence"/>
   <result pre="numbers because of the limited degradation. T-DM1, a conjugate of" exact="trastuzumab" post="and emtansine, has shown promising results in breast cancer"/>
   <result pre="MIA PaCa-2 cells, and this effect was inhibited by competitive" exact="trastuzumab" post="treatment. Conversely, using a combined treatment of GEM and"/>
   <result pre="was a generous gift from Chugai, Inc. (Tokyo, Japan), and" exact="trastuzumab" post="emtansine (T-DM1) was kindly provided by Genentech Inc. (South"/>
   <result pre="Schwartz JD Steinhoff M Nauman C et al. Herceptin and" exact="gemcitabine" post="for metastatic pancreatic cancers that overexpress HER-2/neu Cancer Invest"/>
   <result pre="M Buechler P et al. Multicentre phase II trial of" exact="trastuzumab" post="and capecitabine in patients with HER2 overexpressing metastatic pancreatic"/>
   <result pre="P et al. Multicentre phase II trial of trastuzumab and" exact="capecitabine" post="in patients with HER2 overexpressing metastatic pancreatic cancer Br"/>
   <result pre="MR et al. Improvements in survival and clinical benefit with" exact="gemcitabine" post="as first-line therapy for patients with advanced pancreas cancer:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4612451/results/search/inn/results.xml">
   <result pre="SAC spindle assembly checkpoint TMA tissue microarray Introduction Taxanes (docetaxel," exact="paclitaxel" post="and cabazitaxel) are a family of anticancer agents which"/>
   <result pre="that decreased PRP4K protein level results in reduced sensitivity to" exact="paclitaxel" post="in both breast and ovarian cancer cell lines, and"/>
   <result pre="IGROV-1 and SK-BR-3 cells were treated with the kinase inhibitor" exact="lapatinib" post="for 48 h. In both cell lines, inhibition of"/>
   <result pre="SK-BR-3 cell lines were treated with 7.5 μM 0.1 μM" exact="lapatinib" post="(respectively) for 48 h to inhibit HER2 signaling. Total"/>
   <result pre="Knockdown of PRP4K decreases the sensitivity of cancer cells to" exact="paclitaxel" post="HER2 amplification has received a lot of attention for"/>
   <result pre="explore the role of PRP4K in the cellular response to" exact="paclitaxel" post="we employed an inducible knock-down system that could be"/>
   <result pre="doxycycline-inducible promoter. We found that the addition of 2 μg/ml" exact="doxycycline" post="to the culture media for 96 h led to"/>
   <result pre="clinical setting where patients are treated intravenously. Intravenous administration of" exact="paclitaxel" post="results in a brief spike in serum taxane levels,"/>
   <result pre="SK-BR-3 cells by pre-treating for 48 h with 0.1 μM" exact="lapatinib" post="( Fig. 2B ), cells showed decreased sensitivity to"/>
   <result pre="cellular resistance to paclitaxel. (A) Cell lines stably expressing a" exact="tetracycline" post="inducible shRNA targeting PRP4K were established using a lentiviral-based"/>
   <result pre="Hairpin expression was induced for 96 h with 2 μg/mL" exact="doxycycline" post="and PRP4K levels analyzed by Western blot analysis. Band"/>
   <result pre="to 1. ( B) PRP4K knock down was induced with" exact="doxycycline" post="for 96 h followed by paclitaxel treatment at the"/>
   <result pre="down was induced with doxycycline for 96 h followed by" exact="paclitaxel" post="treatment at the indicated concentrations for 90 min. Cell"/>
   <result pre="0.05. ( C) SK-BR-3 cells were treated with 0.1 μM" exact="lapatinib" post="for 48 h to decrease PRP4K expression. The cells"/>
   <result pre="to decrease PRP4K expression. The cells were then exposed to" exact="paclitaxel" post="at the indicated concentration for 90 min. Cell viability"/>
   <result pre="cells stably expressing a GFP-tagged histone H2B were treated with" exact="paclitaxel" post="for 90 min and then monitored via live-cell microscopy."/>
   <result pre="25 Thus, the decreased sensitivity of PRP4K knock-down cells to" exact="paclitaxel" post="arises from impaired SAC activity and mitotic slippage. Reduced"/>
   <result pre="several independent pools of cells cultured in increasing concentrations of" exact="paclitaxel" post="for 15 weeks, which resulted in separate populations of"/>
   <result pre="cells with increased resistance to chronic exposure to 10 nM" exact="paclitaxel" post="( Fig. 4A ). Six independent clones were isolated"/>
   <result pre="level. As shown in Figure 4A , all of the" exact="paclitaxel" post="resistant clones (PAXR1-PAXR6) express reduced levels of PRP4K, as"/>
   <result pre="patient diagnosed with high-grade serous ovarian cancer that had received" exact="paclitaxel" post="as part of their treatment regimen, and subsequently relapsed"/>
   <result pre="therapy. 34 The cell line which was isolated prior to" exact="paclitaxel" post="treatment (TOV1369) expressed a higher level of PRP4K ("/>
   <result pre="PRP4K levels are associated with the acquisition of resistance to" exact="paclitaxel" post="both in vitro and in vivo. Figure 4. PRP4K"/>
   <result pre="breast cancer cells were exposed to a sub-lethal concentration of" exact="paclitaxel" post="for 3 weeks. The concentration of paclitaxel in the"/>
   <result pre="sub-lethal concentration of paclitaxel for 3 weeks. The concentration of" exact="paclitaxel" post="in the growth media was tripled every 3 weeks"/>
   <result pre="that decreased PRP4K expression is associated with reduced sensitivity to" exact="paclitaxel" post="in vitro, that PRP4K is regulated by HER2 (a"/>
   <result pre="generated breast and ovarian cancer cell lines stably expressing a" exact="doxycycline" post="inducible hairpin targeting PRP4K. Across all 3 cell lines"/>
   <result pre="was decreased through inhibition of HER2 signaling, cellular sensitivity to" exact="paclitaxel" post="also decreased. Together, these data support the hypothesis that"/>
   <result pre="are administered in recent clinical trials showing efficacy of combined" exact="trastuzumab" post="or lapatinib treatment with taxanes; where treatment is initiated"/>
   <result pre="in recent clinical trials showing efficacy of combined trastuzumab or" exact="lapatinib" post="treatment with taxanes; where treatment is initiated with trastuzumab"/>
   <result pre="or lapatinib treatment with taxanes; where treatment is initiated with" exact="trastuzumab" post="or lapatinib being given concurrently with taxane treatments. 39,40"/>
   <result pre="treatment with taxanes; where treatment is initiated with trastuzumab or" exact="lapatinib" post="being given concurrently with taxane treatments. 39,40 It should"/>
   <result pre="better and patients exhibit fewer side-effects when treated periodically with" exact="trastuzumab" post="(given concurrently with taxane) rather than with chronic dosing"/>
   <result pre="Given our results, it is tempting to speculate that when" exact="lapatinib" post="is given daily the chronic exposure to drug may"/>
   <result pre="could provide a potential explanation for the increased efficacy of" exact="trastuzumab" post="periodic treatment over chronic lapatinib treatment regimes. How PRP4K"/>
   <result pre="for the increased efficacy of trastuzumab periodic treatment over chronic" exact="lapatinib" post="treatment regimes. How PRP4K contributes to taxane sensitivity may"/>
   <result pre="for splicing factors playing a role in taxane resistance; whereas" exact="paclitaxel" post="induced apoptosis has been clearly demonstrated to be dependent"/>
   <result pre="induce expression of the inducible TRIPZ PRP4K shRNA, 2 μg/mL" exact="doxycycline" post="was added to culture media for 96 h with"/>
   <result pre="Vitro Cell Viability Assay Paclitaxel (Sigma, T7402) was reconstituted in" exact="dimethyl sulfoxide" post="(DMSO) and diluted in growth media so that the"/>
   <result pre="that the DMSO concentration was 0.05% or less. To evaluate" exact="paclitaxel" post="response in vitro, 7 000 cells were plated in"/>
   <result pre="24 h prior to incubation with the indicated concentration of" exact="paclitaxel" post="for 90 min. Following acute paclitaxel treatment, the drug"/>
   <result pre="the indicated concentration of paclitaxel for 90 min. Following acute" exact="paclitaxel" post="treatment, the drug was removed and cells were allowed"/>
   <result pre="alamarBlue® reagent. To determine the effect of PRP4K knockdown on" exact="paclitaxel" post="response, cell lines stably expressing an shRNA were incubated"/>
   <result pre="lines stably expressing an shRNA were incubated with 2 μg/ml" exact="doxycycline" post="for 92 h prior to plating in the 96"/>
   <result pre="to plating in the 96 well plate, and maintained in" exact="doxycycline" post="for the remainder of the experiment. Statistical Analysis Survival"/>
   <result pre="16360716 6. Noguchi S . Predictive factors for response to" exact="docetaxel" post="in human breast cancers. Cancer Sci 2006; 97: 813-"/>
   <result pre="TA , et al. Microtubule-associated protein tau: a marker of" exact="paclitaxel" post="sensitivity in breast cancer. Proc Natl Acad Sci U"/>
   <result pre="M , Saya H , Ueno NT . Dependence of" exact="paclitaxel" post="sensitivity on a functional spindle assembly checkpoint. Cancer Res"/>
   <result pre="Ueno NT . Cyclin A-associated kinase activity is needed for" exact="paclitaxel" post="sensitivity. Mol Cancer Ther 2005; 4: 1039- 46; PMID:16020661;"/>
   <result pre=", Rosen PP , Norton L . HER2 overexpression and" exact="paclitaxel" post="sensitivity in breast cancer: therapeutic implications. Oncology 1997; 11:"/>
   <result pre="of advanced breast cancer patients randomly treated either with single-agent" exact="doxorubicin" post="or single-agent docetaxel . Breast Cancer Res Treat 2004;"/>
   <result pre="cancer patients randomly treated either with single-agent doxorubicin or single-agent" exact="docetaxel" post=". Breast Cancer Res Treat 2004; 86: 197- 206;"/>
   <result pre="D , et al. Her-2/neu gene amplification and response to" exact="paclitaxel" post="in patients with metastatic breast cancer . J Natl"/>
   <result pre=", Chap L , Juhos E , et al. Adjuvant" exact="docetaxel" post="for node-positive breast cancer. N Engl J Med 2005;"/>
   <result pre=", Ingle JN , et al. HER2 and response to" exact="paclitaxel" post="in node-positive breast cancer. N Engl J Med 2007;"/>
   <result pre="mitotic arrest and ceramide metabolism are determinants of sensitivity to" exact="paclitaxel" post="and other chemotherapeutic drugs . Cancer Cell 2007; 11:"/>
   <result pre=", Cole G Jr. , Schrump DS . Potentiation of" exact="paclitaxel" post="cytotoxicity in lung and esophageal cancer cells by pharmacologic"/>
   <result pre="G , Egorin MJ . Nonlinear pharmacokinetics and metabolism of" exact="paclitaxel" post="and its pharmacokinetic/pharmacodynamic relationships in humans . J Clin"/>
   <result pre="Burgues O , Carrasco E , et al. Trastuzumab or" exact="lapatinib" post="with standard chemotherapy for HER2-positive breast cancer: results from"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4612553/results/search/inn/results.xml">
   <result pre="risk factors for progression in HER2-positive breast cancer patients during" exact="trastuzumab" post="therapy. Material and methods The analysis included medical records"/>
   <result pre="included medical records of HER2(+) metastatic BC patients treated with" exact="trastuzumab" post="between 2006 and 2013. Results The most common site"/>
   <result pre="and 2013. Results The most common site of progression during" exact="trastuzumab" post="therapy were lungs 25 (39%), central nervous system (CNS)"/>
   <result pre="Metastases to lungs occurred also more often during therapy containing" exact="trastuzumab" post="with chemotherapy than trastuzumab alone 17/8 (58% vs. 41%),"/>
   <result pre="also more often during therapy containing trastuzumab with chemotherapy than" exact="trastuzumab" post="alone 17/8 (58% vs. 41%), p = 0.043. Central"/>
   <result pre="of cigarette smoking (liver metastases). metastatic breast cancer HER2 overexpression" exact="trastuzumab" post="risk factors metastasis location Introduction The HER2/neu (ERBB2) oncogene"/>
   <result pre="site of metastases for progression in HER2(+) BC patients during" exact="trastuzumab" post="therapy. Material and methods This retrospective study included medical"/>
   <result pre="medical records of 64 metastatic HER2(+) BC patients treated with" exact="trastuzumab" post="between 2006 and 2013 in the Cancer Center and"/>
   <result pre="in 8 patients. All patients were women. Inclusion criteria for" exact="trastuzumab" post="therapy were baseline left ventricular ejection fraction (LVEF) &amp;gt;"/>
   <result pre="stage according to TNM classification, surgical procedures, histology, estrogen and" exact="progesterone" post="receptor status, HER2 status and contralateral breast cancer were"/>
   <result pre="and pathology reports. Echocardiography was performed every 3 infusions during" exact="trastuzumab" post="therapy and also before and after the anthracycline-based chemotherapy."/>
   <result pre="beginning are shown in Table I. Thirty-three patients (52%) received" exact="trastuzumab" post="in combination with chemotherapy and the remaining 31 (48%)"/>
   <result pre="31 (48%) in monotherapy. The most frequently used cytostatics were" exact="paclitaxel" post="or vinorelbine. The median number of trastuzumab infusions was"/>
   <result pre="used cytostatics were paclitaxel or vinorelbine. The median number of" exact="trastuzumab" post="infusions was 19 (range 2-118). The duration of trastuzumab"/>
   <result pre="of trastuzumab infusions was 19 (range 2-118). The duration of" exact="trastuzumab" post="treatment ranged from 2 months to 7 years (mean"/>
   <result pre="40 58 6 45 7 8 2 Disease progression during" exact="trastuzumab" post="therapy occurred in 49 (76%) patients. Treatment discontinuation due"/>
   <result pre="Disease stagnation was observed in 9 (14%) patients. The best" exact="trastuzumab" post="therapy response (CR + PR) was observed in 10%"/>
   <result pre="45 22 31 The most common sites of progression during" exact="trastuzumab" post="therapy were lungs 25 (39%), central nervous system (CNS)"/>
   <result pre="Metastases to lungs occurred also more often during therapy containing" exact="trastuzumab" post="with chemotherapy than trastuzumab alone 17/8 (52% vs. 41%),"/>
   <result pre="also more often during therapy containing trastuzumab with chemotherapy than" exact="trastuzumab" post="alone 17/8 (52% vs. 41%), p = 0.043. Central"/>
   <result pre="of metastasis were more prone to develop CNS metastases during" exact="trastuzumab" post="therapy ( p = 0.178). There was observed a"/>
   <result pre="was a tendency to bone dissemination in patients who received" exact="trastuzumab" post="alone in comparison with combination therapy 11/6 (65% vs."/>
   <result pre="35%), p = 0.159. The presence of skin metastases during" exact="trastuzumab" post="therapy occurred nonsignificantly more often in patients above 65"/>
   <result pre="found in about 30% of patients [ 3, 4]. Although" exact="trastuzumab" post="improves survival in metastatic breast cancer patients with HER2"/>
   <result pre="[ 12, 13]. In the present paper, CNS dissemination during" exact="trastuzumab" post="therapy was found more frequently in postmenopausal patients but"/>
   <result pre="study to be a predictive factor for liver metastases during" exact="trastuzumab" post="therapy. In the analyzed group of patients, the most"/>
   <result pre="group of patients, the most frequent location of progression during" exact="trastuzumab" post="therapy was lungs. Disease dissemination to lungs was detected"/>
   <result pre="are no data evaluating risk factors for lung dissemination during" exact="trastuzumab" post="therapy. Bones are the most common site for metastatic"/>
   <result pre="diagnosis and bone dissemination was not presented. In some studies," exact="trastuzumab" post="was continued after disease progression due to a potential"/>
   <result pre="a statistically insignificant trend to improve survival for patients receiving" exact="trastuzumab" post="with multiple lines of systemic treatment [ 18]. In"/>
   <result pre="18]. In the studied group, patients with disease progression during" exact="trastuzumab" post="therapy did not continue therapy due to the reimbursement"/>
   <result pre="continue therapy due to the reimbursement system. Usually they received" exact="capecitabine" post="with lapatinib. Conclusions The best response to trastuzumab therapy"/>
   <result pre="they received capecitabine with lapatinib. Conclusions The best response to" exact="trastuzumab" post="therapy was observed in the patients with metastases to"/>
   <result pre="locoregional lymph nodes. The most frequent location of progression during" exact="trastuzumab" post="therapy was lungs and lymph nodes. Risk factors for"/>
   <result pre="inpatients with metastatic or locally advanced breast cancer treated with" exact="epirubicin" post="and docetaxel Ann Oncol 2001 12 353 356 11332148"/>
   <result pre="metastatic or locally advanced breast cancer treated with epirubicin and" exact="docetaxel" post="Ann Oncol 2001 12 353 356 11332148 10 Kennecke"/>
   <result pre="Bartsch R Wenzel C Hussian D et al. Analysis of" exact="trastuzumab" post="and chemotherapy in advanced breast cancer after the failure"/>
   <result pre="18 Cancello G Montagna E D'Agostino D et al. Continuing" exact="trastuzumab" post="beyond disease progression: outcomes analysis in patients with metastatic"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4619560/results/search/inn/results.xml">
   <result pre="Joint Committee on Cancer, ECOG Eastern Cooperative Oncology Group, PgR" exact="progesterone" post="receptor aMay reflect baseline characteristics before advanced breast cancer"/>
   <result pre="group of patients in each cohort received anti-HER2 therapy (ie," exact="lapatinib" post="or trastuzumab) despite being recorded as having HR +,"/>
   <result pre="Bevacizumab was the most commonly used targeted therapy, followed by" exact="trastuzumab" post="and lapatinib. Increased resource utilization resulted in approximately double"/>
   <result pre="HER2 status. Although the inclusion criteria stated HER2 − disease," exact="trastuzumab" post="and lapatinib were used in a small percentage of"/>
   <result pre="Although the inclusion criteria stated HER2 − disease, trastuzumab and" exact="lapatinib" post="were used in a small percentage of patients. It"/>
   <result pre="based the treatment on results from the EGF30008 trial of" exact="lapatinib" post="in combination with endocrine therapy [ 22]. In addition,"/>
   <result pre="M Sadeghi S Dieras V et al. Lapatinib combined with" exact="letrozole" post="versus letrozole and placebo as first-line therapy for postmenopausal"/>
   <result pre="S Dieras V et al. Lapatinib combined with letrozole versus" exact="letrozole" post="and placebo as first-line therapy for postmenopausal hormone receptor-positive"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4621756/results/search/inn/results.xml">
   <result pre="regression identified HER2 as a predictor protein for lapatinib, afatinib," exact="gefitinib" post="and erlotinib, which target HER2 or the EGF receptor,"/>
   <result pre="that could be modeled effectively include PI3K inhibitors, Akt inhibitors," exact="paclitaxel" post="and docetaxel, rapamycin, everolimus and temsirolimus, gemcitabine and vinorelbine."/>
   <result pre="effectively include PI3K inhibitors, Akt inhibitors, paclitaxel and docetaxel, rapamycin," exact="everolimus" post="and temsirolimus, gemcitabine and vinorelbine. Strikingly, this modeling approach"/>
   <result pre="inhibitors, Akt inhibitors, paclitaxel and docetaxel, rapamycin, everolimus and temsirolimus," exact="gemcitabine" post="and vinorelbine. Strikingly, this modeling approach with protein predictors"/>
   <result pre="guide their use. For example, levels of the estrogen or" exact="progesterone" post="receptor have been found to predict sensitivity to compounds"/>
   <result pre="growth factor receptor 2 ( HER2) predicts sensitivity to pertuzumab," exact="trastuzumab" post="and lapatinib. Additional biomarkers would be of significant value"/>
   <result pre="now used to characterize the expression of the estrogen receptor," exact="progesterone" post="receptor and HER2 proteins in breast cancer, suggesting that"/>
   <result pre="lasso regression identified HER2 as a predictor for sensitivity to" exact="everolimus" post="and temsirolimus, two derivatives of rapamycin. While the lasso"/>
   <result pre="identifies HER2 as a predictor for the two HER2 inhibitors," exact="afatinib" post="(BIBW2992) and lapatinib, and also for two of the"/>
   <result pre="(red symbols) have comparatively high drug sensitivity (vertical axes) for" exact="gefitinib" post="and lapatinib. Some cell lines with high sensitivity to"/>
   <result pre="gefitinib and lapatinib. Some cell lines with high sensitivity to" exact="gefitinib" post="do not over-express HER2 (blue symbols). Scatterplots for AG1478,"/>
   <result pre="gefitinib do not over-express HER2 (blue symbols). Scatterplots for AG1478," exact="afatinib" post="and erlotinib are similar to that of gefitinib, showing"/>
   <result pre="not over-express HER2 (blue symbols). Scatterplots for AG1478, afatinib and" exact="erlotinib" post="are similar to that of gefitinib, showing that over-expression"/>
   <result pre="fit the sensitivities of the cell lines to gefitinib, AG1478," exact="afatinib" post="and erlotinib, where the relation between sensitivity and HER2"/>
   <result pre="HER2 expression is not linear. The elastic net model for" exact="afatinib" post="contained nine predictor variables, compared to four in the"/>
   <result pre="lasso models. HER2 expression has a fairly high correlation with" exact="afatinib" post="sensitivity, 0.65, but the SLC7A5, BST2 and A2ML1 have"/>
   <result pre="1), rather than HER2, is the best predictor for erlotinib," exact="gefitinib" post="and AG1478. For each drug we found the best"/>
   <result pre="sense. For example, the model illustrated in Figure 3B for" exact="afatinib" post="included SLC7A (Q01650) and BST2 (Q10589) as predictors. Both"/>
   <result pre="cell lines to EGFR or HER2 blockers (AG1478, afatinib, erlotinib," exact="gefitinib" post="and lapatinib) were modeled effectively by both RPPA and"/>
   <result pre="predict the activity of PI3K inhibitors in patient samples. Rapamycin," exact="everolimus" post="and temsirolimus Rapamycin, everolimus and temsirolimus are related compounds"/>
   <result pre="activity of PI3K inhibitors in patient samples. Rapamycin, everolimus and" exact="temsirolimus" post="Rapamycin, everolimus and temsirolimus are related compounds that block"/>
   <result pre="PI3K inhibitors in patient samples. Rapamycin, everolimus and temsirolimus Rapamycin," exact="everolimus" post="and temsirolimus are related compounds that block the mammalian"/>
   <result pre="in patient samples. Rapamycin, everolimus and temsirolimus Rapamycin, everolimus and" exact="temsirolimus" post="are related compounds that block the mammalian target of"/>
   <result pre="in patients with ER+, HER2- breast cancer, in combination with" exact="exemestane" post="[ 27]. The cell line data suggests that HER2+"/>
   <result pre="from everolimus. Taxanes The sensitivities of the cell lines to" exact="paclitaxel" post="and docetaxel varied over smaller ranges than for rapamycin."/>
   <result pre="Taxanes The sensitivities of the cell lines to paclitaxel and" exact="docetaxel" post="varied over smaller ranges than for rapamycin. For both"/>
   <result pre="coefficient of determination ( Supplementary Information Figure 2). Paclitaxel and" exact="docetaxel" post="are similar chemically, hence it might be expected that"/>
   <result pre="As with rapamycin, the sensitivities of the cell lines to" exact="gemcitabine" post="and vinorelbine spanned approximately four orders of magnitude. If"/>
   <result pre="rapamycin, the sensitivities of the cell lines to gemcitabine and" exact="vinorelbine" post="spanned approximately four orders of magnitude. If this variation"/>
   <result pre="are highly sensitive to these drugs. The best model for" exact="gemcitabine" post="(R 2 = 0.77) appeared in the glycoprotein dataset,"/>
   <result pre="sulfatase) ( Supplementary Information Figure 2). The best model for" exact="vinorelbine" post="(R 2 = 0.85) was found in the MRM"/>
   <result pre="HER2. Figure 3 Comparison of predicted with observed sensitivities for" exact="afatinib" post="(BIBW2992). Observed values of the drug sensitivities are plotted"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4624825/results/search/inn/results.xml">
   <result pre="patient’s sequelae of CHF and venous thrombosis were complications of" exact="bortezomib" post="[ 2] and lenalidomide [ 3], respectively. Although the"/>
   <result pre="and venous thrombosis were complications of bortezomib [ 2] and" exact="lenalidomide" post="[ 3], respectively. Although the development of cardiomyopathy might"/>
   <result pre="age (&amp;gt;65 years for anthracyclines [ 27••], &amp;gt;80 years for" exact="trastuzumab" post="[ 28]), it is less clear whether there is"/>
   <result pre="ER endoplasmic reticulum, HTN hypertension, LV left ventricular dysfunction, NO" exact="nitric oxide," post="PH pulmonary hypertension, TK tyrosine kinase, TKI tyrosine kinase"/>
   <result pre="dysfunction also occurs but less common. Of the targeted agents," exact="trastuzumab" post="has been found to have a higher than expected"/>
   <result pre="more common with radiation therapy. Agents such as bleomycin, etoposide," exact="cisplatin" post="[ 37– 40], 5-fluorouracil (FU) [ 41– 44], as"/>
   <result pre="of arterial thromboembolism in patients treated with conventional chemotherapy and" exact="bevacizumab" post="as compared to patients treated with chemotherapy alone (3.8"/>
   <result pre="doses of anthracyclines (level IA: doxorubin &amp;gt;500 mg/m 2, liposomal" exact="doxorubicin" post="&amp;gt;900 mg/m 2; epirubicin &amp;gt;720 mg/m 2; mitoxantrone &amp;gt;120"/>
   <result pre="IA: doxorubin &amp;gt;500 mg/m 2, liposomal doxorubicin &amp;gt;900 mg/m 2;" exact="epirubicin" post="&amp;gt;720 mg/m 2; mitoxantrone &amp;gt;120 mg/m 2, idarubicin &amp;gt;90"/>
   <result pre="2, liposomal doxorubicin &amp;gt;900 mg/m 2; epirubicin &amp;gt;720 mg/m 2;" exact="mitoxantrone" post="&amp;gt;120 mg/m 2, idarubicin &amp;gt;90 mg/m 2); (2) LVEF"/>
   <result pre="mg/m 2; epirubicin &amp;gt;720 mg/m 2; mitoxantrone &amp;gt;120 mg/m 2," exact="idarubicin" post="&amp;gt;90 mg/m 2); (2) LVEF assessment (level IA, if"/>
   <result pre="et al. &quot;Real-world&quot; data on the efficacy and safety of" exact="lenalidomide" post="and dexamethasone in patients with relapsed/refractory multiple myeloma who"/>
   <result pre="&quot;Real-world&quot; data on the efficacy and safety of lenalidomide and" exact="dexamethasone" post="in patients with relapsed/refractory multiple myeloma who were treated"/>
   <result pre="Carter SK Howes AE Aston DA et al. Cardiotoxicity of" exact="epirubicin" post="and doxorubicin: assessment by endomyocardial biopsy Cancer Res 1986"/>
   <result pre="Paton V Ashby M et al. Cardiac dysfunction in the" exact="trastuzumab" post="clinical trials experience J Clin Oncol 2002 20 1215"/>
   <result pre="Kennedy BJ Severe vascular toxicity associated with vinblastine, bleomycin, and" exact="cisplatin" post="chemotherapy Cancer Chemother Pharmacol 1987 19 253 6 10.1007/BF00252982"/>
   <result pre="Acute vascular toxicity after combination chemotherapy with cisplatin, vinblastine, and" exact="bleomycin" post="for testicular cancer Eur Heart J 1988 9 552"/>
   <result pre="Fukuyama O Angina pectoris and therapy with cisplatin, vincristine, and" exact="bleomycin" post="Ann Intern Med 1989 111 342 3 10.7326/0003-4819-111-4-342 2474263"/>
   <result pre="S Olivenstein A et al. Continuous ambulatory ECG monitoring during" exact="fluorouracil" post="therapy: a prospective study J Clin Oncol 1989 7"/>
   <result pre="Patel T Hamm JT Hecht JR et al. Addition of" exact="bevacizumab" post="to bolus fluorouracil and leucovorin in first-line metastatic colorectal"/>
   <result pre="JT Hecht JR et al. Addition of bevacizumab to bolus" exact="fluorouracil" post="and leucovorin in first-line metastatic colorectal cancer: results of"/>
   <result pre="events in patients with metastatic carcinoma treated with chemotherapy and" exact="bevacizumab" post="J Natl Cancer Inst 2007 99 1232 9 10.1093/jnci/djm086"/>
   <result pre="L et al. Quality of life with defibrillator therapy or" exact="amiodarone" post="in heart failure N Engl J Med 2008 359"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4627342/results/search/inn/results.xml">
   <result pre="are credited. Abstract Lapatinib has been used in combination with" exact="capecitabine" post="or paclitaxel to treat patients with progressive HER2-overexpressing metastatic"/>
   <result pre="Abstract Lapatinib has been used in combination with capecitabine or" exact="paclitaxel" post="to treat patients with progressive HER2-overexpressing metastatic breast cancer"/>
   <result pre="of this combinational therapy. We found that the patients receiving" exact="lapatinib" post="and paclitaxel treatment showed a higher incidence of hepatobiliary"/>
   <result pre="combinational therapy. We found that the patients receiving lapatinib and" exact="paclitaxel" post="treatment showed a higher incidence of hepatobiliary system disorders"/>
   <result pre="a higher incidence of hepatobiliary system disorders than those receiving" exact="paclitaxel" post="alone. Lapatinib was shown to increase the accumulation of"/>
   <result pre="paclitaxel alone. Lapatinib was shown to increase the accumulation of" exact="doxorubicin" post="in ABCB1-overexpressing hepatocellular cancer cells and normal liver tissues"/>
   <result pre="altering the protein level of ABCB1. Pharmacokinetic studies revealed that" exact="lapatinib" post="could increase the systematic exposure of paclitaxel and doxorubicin."/>
   <result pre="studies revealed that lapatinib could increase the systematic exposure of" exact="paclitaxel" post="and doxorubicin. Moreover, the in vivo experiments showed that"/>
   <result pre="alanine aminotransferase and serious hepatocyte injury in the group of" exact="lapatinib" post="plus chemotherapeutic agent were significantly higher than those in"/>
   <result pre="those in the group of single chemotherapeutic agent such as" exact="paclitaxel" post="or doxorubicin. Our study thus revealed for the first"/>
   <result pre="dose adjustment may be needed to optimize the combination therapy." exact="lapatinib" post="ABC transporters hepatotoxicity pharmacokinetic INTRODUCTION ATP-binding cassette (ABC) transporters"/>
   <result pre="effect in various organs [ 6]. Previously, we showed that" exact="lapatinib" post="inhibited the function of ABC transporters (including ABCB1, ABCC1"/>
   <result pre="reported to protect again hepatotoxicity from anticancer drugs such as" exact="trabectedin" post="[ 10]. It follows that the accumulation of conventional"/>
   <result pre="drugs from the market because of severe hepatotoxicity, such as" exact="bithionol" post="cobalt salts, sulfathiazole and oxyphenisatin [ 11]. Liver is"/>
   <result pre="market because of severe hepatotoxicity, such as bithionol cobalt salts," exact="sulfathiazole" post="and oxyphenisatin [ 11]. Liver is the major site"/>
   <result pre="the mainstay treatment option for many cancers. Combination treatment of" exact="lapatinib" post="plus capecitabine or letrozole had been used in patients"/>
   <result pre="treatment option for many cancers. Combination treatment of lapatinib plus" exact="capecitabine" post="or letrozole had been used in patients with progressive"/>
   <result pre="for many cancers. Combination treatment of lapatinib plus capecitabine or" exact="letrozole" post="had been used in patients with progressive human epidermal"/>
   <result pre="A phase III study demonstrated that the combination treatment of" exact="lapatinib" post="and capecitabine significantly decreased the risk of disease progression"/>
   <result pre="III study demonstrated that the combination treatment of lapatinib and" exact="capecitabine" post="significantly decreased the risk of disease progression compared to"/>
   <result pre="were reported in patients who received the combination treatment of" exact="lapatinib" post="with paclitaxel, capecitabine or letrozole [ 17]. Other tyrosine"/>
   <result pre="patients who received the combination treatment of lapatinib with paclitaxel," exact="capecitabine" post="or letrozole [ 17]. Other tyrosine kinase inhibitors including"/>
   <result pre="received the combination treatment of lapatinib with paclitaxel, capecitabine or" exact="letrozole" post="[ 17]. Other tyrosine kinase inhibitors including imatinib, nilotinib,"/>
   <result pre="kinase inhibitors including imatinib, nilotinib, dasatinib, gefitinib, erlotinib, sorafenib, sunitinib," exact="pazopanib" post="have also been reported to cause hepatotoxicity [ 18]."/>
   <result pre="the increased incidence of hepatotoxicity during the combination treatment of" exact="lapatinib" post="with paclitaxel was associated with an increased accumulation of"/>
   <result pre="incidence of hepatotoxicity during the combination treatment of lapatinib with" exact="paclitaxel" post="was associated with an increased accumulation of the chemotherapeutic"/>
   <result pre="may facilitate the further optimization of the combination regimens composing" exact="lapatinib" post="and other chemotherapeutic drugs in clinic. RESULTS A higher"/>
   <result pre="of hepatotoxicity was observed in patients receiving combination therapy of" exact="lapatinib" post="and paclitaxel than those receiving paclitaxel alone From a"/>
   <result pre="was observed in patients receiving combination therapy of lapatinib and" exact="paclitaxel" post="than those receiving paclitaxel alone From a cohort of"/>
   <result pre="receiving combination therapy of lapatinib and paclitaxel than those receiving" exact="paclitaxel" post="alone From a cohort of 39 patients with HER2-overexpressing"/>
   <result pre="hyperbilirubinaemia. Furthermore, there was one patient in the group of" exact="lapatinib" post="and paclitaxel withdrawn from the treatment because of severe"/>
   <result pre="there was one patient in the group of lapatinib and" exact="paclitaxel" post="withdrawn from the treatment because of severe abnormal hepatic"/>
   <result pre="contrast, there were only 2 patients in the group of" exact="paclitaxel" post="alone showed grade 1 abnormal hepatic function. Therefore, the"/>
   <result pre="(paclitaxel plus lapatinib) group induced significantly more hepatotoxicity than the" exact="paclitaxel" post="alone treatment group. Table 1 Adverse events in the"/>
   <result pre="1/21 (4.76%) 1/21 (4.76%) 0/21 (0.00%) 2/21 (4.76%) Paclitaxel +" exact="lapatinib" post="4/18 (22.22%) 2/18 (11.11%) 4/18 (22.22%) * 7/18 (38.89%)"/>
   <result pre="test. * P &amp;lt; 0.05 for values versus those in" exact="paclitaxel" post="alone. Lapatinib increased doxorubicin accumulation in ABCB1-overexpressing hepatocellular carcinoma"/>
   <result pre="0.05 for values versus those in paclitaxel alone. Lapatinib increased" exact="doxorubicin" post="accumulation in ABCB1-overexpressing hepatocellular carcinoma cells in vitro We"/>
   <result pre="increased hepatotoxicity was associated with elevated drug accumulation induced by" exact="lapatinib" post="in the liver. In order to verify our conjecture,"/>
   <result pre="to verify our conjecture, we first investigated the effect of" exact="lapatinib" post="on increasing drug accumulation in a sensitive hepatocellular carcinoma"/>
   <result pre="1A. Lapatinib was found to enhance the cytotoxicity effect of" exact="doxorubicin" post="in HepG2/Adr cells in a concentration-dependent manner but not"/>
   <result pre="Compared with the parental HepG2 cells, the intracellular accumulation of" exact="doxorubicin" post="or an ABCB1 probe substrate rhodamine 123 in HepG2/Adr"/>
   <result pre="reduce intracellular substrate accumulation (Figure 1). The fluorescent index of" exact="doxorubicin" post="was increased by 1.85-, 2.15-, 3.10-fold in HepG2/Adr cell"/>
   <result pre="(Figure 1D and 1F). In contrast, the intracellular accumulations of" exact="doxorubicin" post="and rhodamine 123 were not altered in HepG2 cell"/>
   <result pre="cell in the presence of lapatinib. Figure 1 Effect of" exact="lapatinib" post="on the accumulations of doxorubicin and rhodamine 123 A."/>
   <result pre="lapatinib. Figure 1 Effect of lapatinib on the accumulations of" exact="doxorubicin" post="and rhodamine 123 A. The expression of ABCB1 in"/>
   <result pre="by Western blot. B. Lapatinib enhanced the cytotoxicity effect of" exact="doxorubicin" post="on ABCB1-overexpressing HepG2/Adr cells. C. D. E. F. The"/>
   <result pre="ABCB1-overexpressing HepG2/Adr cells. C. D. E. F. The accumulations of" exact="doxorubicin" post="and rhodamine 123 were measured by flow cytometric analysis"/>
   <result pre="done at least thrice. Since the increased accumulation effect of" exact="lapatinib" post="can be achieved either by antagonizing the drug efflux"/>
   <result pre="expression level of ABCB1. We next examined the effect of" exact="lapatinib" post="on the expression of ABCB1 at the mRNA and"/>
   <result pre="were not significantly altered in HepG2/Adr cells after treatment with" exact="lapatinib" post="for 24, 48 or 72 h. These results suggested"/>
   <result pre="for 24, 48 or 72 h. These results suggested that" exact="lapatinib" post="may increase intracellular accumulation of chemotherapeutic agents by inhibiting"/>
   <result pre="without altering the transporter expression level. Figure 2 Effect of" exact="lapatinib" post="on the expression of ABCB1 The protein level of"/>
   <result pre="set of data is shown in each panel. Lapatinib enhanced" exact="doxorubicin" post="accumulation in normal liver tissues To further understand the"/>
   <result pre="chemotherapeutical agent mediated-hepatotoxicity by lapatinib, we investigated the effect of" exact="lapatinib" post="on increasing drug accumulation in normal liver tissues obtained"/>
   <result pre="Importantly, we found that there was much more accumulation of" exact="doxorubicin" post="in human and mice liver tissues in the presence"/>
   <result pre="in human and mice liver tissues in the presence of" exact="lapatinib" post="than in the absence of lapatinib (Figure 3E). The"/>
   <result pre="in the presence of lapatinib than in the absence of" exact="lapatinib" post="(Figure 3E). The fluorescent index of doxorubicin was increased"/>
   <result pre="the absence of lapatinib (Figure 3E). The fluorescent index of" exact="doxorubicin" post="was increased by 2.64-fold in human liver tissues when"/>
   <result pre="2.64-fold in human liver tissues when incubated in 2.5 μM" exact="lapatinib" post="(Figure 3E). Similarly, the fluorescent index of doxorubicin was"/>
   <result pre="2.5 μM lapatinib (Figure 3E). Similarly, the fluorescent index of" exact="doxorubicin" post="was increased by 2.46-fold in Swiss mice liver tissues"/>
   <result pre="Swiss mice liver tissues in the presence of 2.5 μM" exact="lapatinib" post="(Figure 3E). Taken together, these results suggest that lapatinib"/>
   <result pre="μM lapatinib (Figure 3E). Taken together, these results suggest that" exact="lapatinib" post="could increase accumulation of ABCB1 substrate chemotherapeutical agents not"/>
   <result pre="normal liver cells. Figure 3 Expression levels of ABCB1 and" exact="doxorubicin" post="accumulation in normal liver tissues The mRNA level was"/>
   <result pre="The magnification is 400 ×. D. The absorption spectra for" exact="doxorubicin" post="(0.5 mg/ml) is detected by UV spectrophotometric method. E."/>
   <result pre="doxorubicin (0.5 mg/ml) is detected by UV spectrophotometric method. E." exact="lapatinib" post="increased the doxorubicin accumulation in normal liver tissues. All"/>
   <result pre="is detected by UV spectrophotometric method. E. lapatinib increased the" exact="doxorubicin" post="accumulation in normal liver tissues. All experiments were done"/>
   <result pre="were done at least thrice. Lapatinib altered the pharmacokinetics of" exact="paclitaxel" post="and doxorubicin in mice Co-administration of lapatinib and an"/>
   <result pre="at least thrice. Lapatinib altered the pharmacokinetics of paclitaxel and" exact="doxorubicin" post="in mice Co-administration of lapatinib and an anticancer drug"/>
   <result pre="the pharmacokinetics of paclitaxel and doxorubicin in mice Co-administration of" exact="lapatinib" post="and an anticancer drug may significantly elevate plasma concentrations"/>
   <result pre="side effect of the anticancer drugs [ 19, 20]. Since" exact="lapatinib" post="has been shown to inhibit ABCB1, we examined the"/>
   <result pre="shown to inhibit ABCB1, we examined the pharmacokinetic property of" exact="paclitaxel" post="and doxorubicin in mice in the presence or absence"/>
   <result pre="inhibit ABCB1, we examined the pharmacokinetic property of paclitaxel and" exact="doxorubicin" post="in mice in the presence or absence of lapatinib."/>
   <result pre="presence or absence of lapatinib. Our data indicated that the" exact="lapatinib" post="plus paclitaxel combination group showed a significantly longer T"/>
   <result pre="absence of lapatinib. Our data indicated that the lapatinib plus" exact="paclitaxel" post="combination group showed a significantly longer T 1/2β and"/>
   <result pre="greater area under concentration-time curve (AUC) than those in the" exact="paclitaxel" post="alone group (Figure 4A, Table 2). Moreover, a significantly"/>
   <result pre="a significantly slower plasma clearance (CL) was observed in the" exact="paclitaxel" post="plus lapatinib combination group (4.87 mL/h) than in the"/>
   <result pre="slower plasma clearance (CL) was observed in the paclitaxel plus" exact="lapatinib" post="combination group (4.87 mL/h) than in the paclitaxel alone"/>
   <result pre="paclitaxel plus lapatinib combination group (4.87 mL/h) than in the" exact="paclitaxel" post="alone group (8.35 mL/h) (Table 2). Similar results were"/>
   <result pre="(8.35 mL/h) (Table 2). Similar results were also observed for" exact="doxorubicin" post="in the presence or absence of lapatinib (Figure 4B,"/>
   <result pre="also observed for doxorubicin in the presence or absence of" exact="lapatinib" post="(Figure 4B, Table 2). These findings indicated that lapatinib"/>
   <result pre="of lapatinib (Figure 4B, Table 2). These findings indicated that" exact="lapatinib" post="could increase the systematic exposure of ABCB1 substrate chemotherapeutic"/>
   <result pre="(e.g. hepatotoxicity) from the chemotherapeutic agents. Figure 4 Effect of" exact="lapatinib" post="on pharmacokinetics of paclitaxel and doxorubicin A. B. Effect"/>
   <result pre="chemotherapeutic agents. Figure 4 Effect of lapatinib on pharmacokinetics of" exact="paclitaxel" post="and doxorubicin A. B. Effect of lapatinib on the"/>
   <result pre="Figure 4 Effect of lapatinib on pharmacokinetics of paclitaxel and" exact="doxorubicin" post="A. B. Effect of lapatinib on the profile of"/>
   <result pre="on pharmacokinetics of paclitaxel and doxorubicin A. B. Effect of" exact="lapatinib" post="on the profile of paclitaxel and doxorubicin pharmacokinetics in"/>
   <result pre="doxorubicin A. B. Effect of lapatinib on the profile of" exact="paclitaxel" post="and doxorubicin pharmacokinetics in mice. NIH mice were p.o."/>
   <result pre="B. Effect of lapatinib on the profile of paclitaxel and" exact="doxorubicin" post="pharmacokinetics in mice. NIH mice were p.o. administered with"/>
   <result pre="in mice. NIH mice were p.o. administered with or without" exact="lapatinib" post="(100 mg/kg) 1 h before i.v. administration of paclitaxel"/>
   <result pre="without lapatinib (100 mg/kg) 1 h before i.v. administration of" exact="paclitaxel" post="(18 mg/kg) or doxorubicin (10 mg/kg). HPLC analysis was"/>
   <result pre="1 h before i.v. administration of paclitaxel (18 mg/kg) or" exact="doxorubicin" post="(10 mg/kg). HPLC analysis was performed as described in"/>
   <result pre="in the triplicate determination. Table 2 The Pharmacokinetic parameters of" exact="paclitaxel" post="and doxorubicin were summarized in the presence or absence"/>
   <result pre="triplicate determination. Table 2 The Pharmacokinetic parameters of paclitaxel and" exact="doxorubicin" post="were summarized in the presence or absence of lapatinib"/>
   <result pre="and doxorubicin were summarized in the presence or absence of" exact="lapatinib" post="Group T 1/2β (h) Vd (mL) Clearance (mL/h) AUC0→4"/>
   <result pre="± 4.62 49.26 ± 5.52 1.42 ± 0.08 Paclitaxel +" exact="lapatinib" post="1.88 ± 0.21 * 13.22 ± 1.34 4.87 ±"/>
   <result pre="± 841.16 2956.42 ± 878.46 7.51 ± 1.08 Doxorubicin +" exact="lapatinib" post="15.50 ± 7.48 ## 2.28 ± 0. 64 1.95"/>
   <result pre="0.05 ** P &amp;lt; 0.01 for values versus those in" exact="paclitaxel" post="alone, respectively. ## P &amp;lt; 0.01 for values versus"/>
   <result pre="respectively. ## P &amp;lt; 0.01 for values versus those in" exact="doxorubicin" post="alone. Combination of lapatinib and paclitaxel/doxorubicin resulted in elevated"/>
   <result pre="0.01 for values versus those in doxorubicin alone. Combination of" exact="lapatinib" post="and paclitaxel/doxorubicin resulted in elevated hepatotoxicity in vivo The"/>
   <result pre="evaluate the potential hepatotoxic effect of the combination treatment of" exact="lapatinib" post="with paclitaxel or doxorubicin. Result of various hepatic function"/>
   <result pre="potential hepatotoxic effect of the combination treatment of lapatinib with" exact="paclitaxel" post="or doxorubicin. Result of various hepatic function markers were"/>
   <result pre="function markers were summarized in Table 3. The combination of" exact="lapatinib" post="and paclitaxel was found to increase ALT ( P"/>
   <result pre="were summarized in Table 3. The combination of lapatinib and" exact="paclitaxel" post="was found to increase ALT ( P &amp;lt; 0.05)"/>
   <result pre="0.05) and CRE ( P &amp;lt; 0.05) more significantly than" exact="paclitaxel" post="alone. Similarly, the combination of lapatinib and doxorubicin was"/>
   <result pre="0.05) more significantly than paclitaxel alone. Similarly, the combination of" exact="lapatinib" post="and doxorubicin was found to elevate BUN and UA"/>
   <result pre="significantly than paclitaxel alone. Similarly, the combination of lapatinib and" exact="doxorubicin" post="was found to elevate BUN and UA more remarkably"/>
   <result pre="was found to elevate BUN and UA more remarkably than" exact="doxorubicin" post="alone. Result from histopathological examination also revealed that the"/>
   <result pre="magnification × 400) A. Normal liver parenchyma; B. (group of" exact="lapatinib" post="alone) shows a similar histology to the normal group;"/>
   <result pre="a similar histology to the normal group; C. (group of" exact="paclitaxel" post="alone) shows mild liver damage: hepatocytes with hydropic changes"/>
   <result pre="and monocytes infiltration around the central vein; D. (group of" exact="doxorubicin" post="alone) shows mild central venous hyperemia, Hepatic cord disorder"/>
   <result pre="hyperemia, Hepatic cord disorder and vacuolar degeneration; E. (group of" exact="lapatinib" post="and paclitaxel) and F. (group of lapatinib and doxorubicin)"/>
   <result pre="E. (group of lapatinib and paclitaxel) and F. (group of" exact="lapatinib" post="and doxorubicin) show severe liver damage: severe inflammation with"/>
   <result pre="standard deviation in the triplicate determination. DISCUSSION The combination of" exact="lapatinib" post="and paclitaxel is an effective first-line therapy in patients"/>
   <result pre="in the triplicate determination. DISCUSSION The combination of lapatinib and" exact="paclitaxel" post="is an effective first-line therapy in patients with HER2-positive"/>
   <result pre="21, 22]. However, it has been reported that combination of" exact="lapatinib" post="and paclitaxel or capectiabine was associated with a higher"/>
   <result pre="However, it has been reported that combination of lapatinib and" exact="paclitaxel" post="or capectiabine was associated with a higher incidence of"/>
   <result pre="The mechanisms causing the increased hepatotoxicity in combination therapy of" exact="lapatinib" post="and paclitaxel are not well defined. In the present"/>
   <result pre="causing the increased hepatotoxicity in combination therapy of lapatinib and" exact="paclitaxel" post="are not well defined. In the present study, we"/>
   <result pre="more vulnerable to drug-induced hepatotoxicity upon treatment with combination of" exact="lapatinib" post="and substrate drugs of ABC transporters such as paclitaxel"/>
   <result pre="of lapatinib and substrate drugs of ABC transporters such as" exact="paclitaxel" post="and doxorubicin. To illustrate the potential mechanism, we found"/>
   <result pre="and doxorubicin. To illustrate the potential mechanism, we found that" exact="lapatinib" post="remarkably increased the accumulation of doxorubicin and rhodamine 123"/>
   <result pre="mechanism, we found that lapatinib remarkably increased the accumulation of" exact="doxorubicin" post="and rhodamine 123 in ABCB1-overexpressing hepatocellular carcinoma cells and"/>
   <result pre="carcinoma cells and normal liver tissues in concentration-dependent manners. However," exact="lapatinib" post="did not significantly increase the drug accumulation in the"/>
   <result pre="in the parental sensitive cells to the anticancer agents. Since" exact="lapatinib" post="did not alter the mRNA and protein expressions of"/>
   <result pre="chemotherapeutic drugs must be mediated by the inhibitory effect of" exact="lapatinib" post="on ABCB1 transport activity [ 7, 8]. The in"/>
   <result pre="the result of inhibiting ABCB1 function. As our study showed," exact="lapatinib" post="would likely exacerbate the hepatotoxic effects of paclitaxel or"/>
   <result pre="study showed, lapatinib would likely exacerbate the hepatotoxic effects of" exact="paclitaxel" post="or doxorubicin rather than reduce them. Our findings have"/>
   <result pre="lapatinib would likely exacerbate the hepatotoxic effects of paclitaxel or" exact="doxorubicin" post="rather than reduce them. Our findings have important implications"/>
   <result pre="Our findings have important implications for the clinical use of" exact="lapatinib" post="in combination with ABCB1 substrate anticancer drugs. Doxorubicin and"/>
   <result pre="breast cancer, are all ABCB1 substrates. Possible drug-drug interactions with" exact="lapatinib" post="may occur and cause severe hepatotoxicity. Therefore, evaluating genetic"/>
   <result pre="attracted a lot of attention recently. Early studies showed that" exact="gefitinib" post="enhanced the anticancer activity of irinotecan by inhibiting ABCB1"/>
   <result pre="Early studies showed that gefitinib enhanced the anticancer activity of" exact="irinotecan" post="by inhibiting ABCB1 and ABCG2 function, thereby increasing oral"/>
   <result pre="ABCG2 function, thereby increasing oral bioavailability and reducing clearance of" exact="topotecan" post="in mice [ 26, 27]. Co-administration of lapatinib and"/>
   <result pre="clearance of topotecan in mice [ 26, 27]. Co-administration of" exact="lapatinib" post="and irinotecan was also found to increase the area"/>
   <result pre="topotecan in mice [ 26, 27]. Co-administration of lapatinib and" exact="irinotecan" post="was also found to increase the area under the"/>
   <result pre="the plasma concentration-time curve of SN-38, the active metabolite of" exact="irinotecan" post="and ABCB1 substrate [ 28]. In a phase III"/>
   <result pre="metastatic breast cancer patients whose cancers had not responded to" exact="trastuzumab" post="or other therapies, superior therapeutic response were obtained by"/>
   <result pre="other therapies, superior therapeutic response were obtained by combination of" exact="lapatinib" post="and capecitabine, compared with capecitabine alone [ 29]. Moreover,"/>
   <result pre="were obtained by combination of lapatinib and capecitabine, compared with" exact="capecitabine" post="alone [ 29]. Moreover, lapatinib given in combination with"/>
   <result pre="lapatinib and capecitabine, compared with capecitabine alone [ 29]. Moreover," exact="lapatinib" post="given in combination with tamoxifen (substrate of ABCB1) was"/>
   <result pre="capecitabine alone [ 29]. Moreover, lapatinib given in combination with" exact="tamoxifen" post="(substrate of ABCB1) was also found to effectively inhibit"/>
   <result pre="was also found to effectively inhibit cell proliferation and restore" exact="tamoxifen" post="sensitivity in ER-positive and tamoxifen-resistant breast cancer [ 30]."/>
   <result pre="sensitivity in ER-positive and tamoxifen-resistant breast cancer [ 30]. While" exact="lapatinib" post="was also shown to provide clinical benefit when used"/>
   <result pre="the blood brain barrier [ 31]. Penetration of taxanes and" exact="vinorelbine" post="across the placenta was known to be regulated by"/>
   <result pre="known to be regulated by ABCB1. By inhibiting ABCB1, co-administration" exact="lapatinib" post="and paclitaxel has been shown to obscure the normal"/>
   <result pre="be regulated by ABCB1. By inhibiting ABCB1, co-administration lapatinib and" exact="paclitaxel" post="has been shown to obscure the normal development of"/>
   <result pre="avoided during pregnancy [ 32]. We have previously demonstrated that" exact="lapatinib" post="could reverse the ABC transporters-mediated MDR by inhibiting the"/>
   <result pre="study, we deliberately set out to investigate the pharmacokinetics of" exact="paclitaxel" post="and doxorubicin in the presence or absence of lapatinib."/>
   <result pre="deliberately set out to investigate the pharmacokinetics of paclitaxel and" exact="doxorubicin" post="in the presence or absence of lapatinib. In human"/>
   <result pre="of lapatinib. In human pharmacokinetic studies, the highest peak plasma" exact="lapatinib" post="concentration was roughly 3 μM and the half-life was"/>
   <result pre="of once-daily dosing [ 35, 36]. Therefore, the concentrations of" exact="lapatinib" post="investigated in our in vitro experiments are clinically relevant."/>
   <result pre="in vitro experiments are clinically relevant. Our result proved that" exact="lapatinib" post="significantly increased the exposure level of paclitaxel and doxorubicin"/>
   <result pre="result proved that lapatinib significantly increased the exposure level of" exact="paclitaxel" post="and doxorubicin in mice (Table 3). These suggest pharmacokinetics"/>
   <result pre="that lapatinib significantly increased the exposure level of paclitaxel and" exact="doxorubicin" post="in mice (Table 3). These suggest pharmacokinetics of conventional"/>
   <result pre="± 1.38 15.77 ± 1.78 14.12 ± 0.44 Paclitaxel +" exact="lapatinib" post="59.97 ± 26.72 * 107.10 ± 28.67 317.8±75.4 213.29"/>
   <result pre="22.19±15.00 84.71±11.08 440.27±78.04 * 112.3±6.91 1606.32±505.09 7.91±0.82 20.17±7.14 18.74±1.83 Doxorubicin+" exact="lapatinib" post="20.43±8.61 101.44±10.98 523.42±50.73 ** 113.85±18.66 1691.27±623.47 8.00±0.90 20.6±5.50 20.80±1.97"/>
   <result pre="liver could explain why the ALT level in group of" exact="lapatinib" post="and doxorubicin was not raised. From the above we"/>
   <result pre="explain why the ALT level in group of lapatinib and" exact="doxorubicin" post="was not raised. From the above we can conclude"/>
   <result pre="From the above we can conclude that the treatment of" exact="lapatinib" post="plus paclitaxel or doxorubicin could cause a severe liver"/>
   <result pre="above we can conclude that the treatment of lapatinib plus" exact="paclitaxel" post="or doxorubicin could cause a severe liver injury than"/>
   <result pre="can conclude that the treatment of lapatinib plus paclitaxel or" exact="doxorubicin" post="could cause a severe liver injury than the single-agent"/>
   <result pre="focal necrosis with extended exposure in the combination group of" exact="lapatinib" post="and paclitaxel or doxorubicin. In addition, we observed a"/>
   <result pre="with extended exposure in the combination group of lapatinib and" exact="paclitaxel" post="or doxorubicin. In addition, we observed a serious sinusoidal"/>
   <result pre="pathological changes are consistent with the cytotoxic effects induced by" exact="paclitaxel" post="and doxorubicin. The morphology of the liver injury induced"/>
   <result pre="and doxorubicin. The morphology of the liver injury induced by" exact="doxorubicin" post="is related to the hydropic degeneration, hemorrhage, heavy centrilobular"/>
   <result pre="in glycogen while the morphological changes in liver induced by" exact="paclitaxel" post="are inflammatory cell infiltrates and foci, sinusoidal expansion, vesicular"/>
   <result pre="doxorubicin) treatment at the dose tested. These results indicated that" exact="lapatinib" post="could exacerbate the liver injury induced by paclitaxel and"/>
   <result pre="indicated that lapatinib could exacerbate the liver injury induced by" exact="paclitaxel" post="and doxorubicin. It has been reported that doxorubicin and"/>
   <result pre="induced by paclitaxel and doxorubicin. It has been reported that" exact="doxorubicin" post="and paclitaxel could damage rat liver by inducing oxidative"/>
   <result pre="paclitaxel and doxorubicin. It has been reported that doxorubicin and" exact="paclitaxel" post="could damage rat liver by inducing oxidative stress ["/>
   <result pre="stress [ 39]. Further studies are needed to evaluate whether" exact="lapatinib" post="could enhance the effects of paclitaxel and doxorubicin through"/>
   <result pre="needed to evaluate whether lapatinib could enhance the effects of" exact="paclitaxel" post="and doxorubicin through promoting oxidative stress. In conclusion, the"/>
   <result pre="evaluate whether lapatinib could enhance the effects of paclitaxel and" exact="doxorubicin" post="through promoting oxidative stress. In conclusion, the present study"/>
   <result pre="the first time the hepatotoxicity caused by the co-administration of" exact="lapatinib" post="and paclitaxel/doxorubicin by both biochemical and histopathological evaluation. We"/>
   <result pre="paclitaxel/doxorubicin by both biochemical and histopathological evaluation. We showed that" exact="lapatinib" post="can increase the accumulation of chemotherapeutic agents especially ABCB1"/>
   <result pre="transporter inhibitor. Figure 6 Schematic illustration of the mechanism of" exact="lapatinib" post="promoting the cytotoxic effect of chemotherapeutic agent in liver"/>
   <result pre="in DMEM supplemented with 10% fetal bovine serum, 100 units/mL" exact="streptomycin" post="sulfate and 100 units/mL penicillin G sulfate, and maintained"/>
   <result pre="patients received the combination treatment (lapatinib 1500 mg daily plus" exact="paclitaxel" post="80 mg/m 2 every 3 days) and the control"/>
   <result pre="2 every 3 days) and the control group received only" exact="paclitaxel" post="(80 mg/m 2 every 3 days). The median age"/>
   <result pre="HepG2 and HepG2/Adr cells were exposed to different concentrations of" exact="lapatinib" post="(0.625, 1.25, 2.5 and 10 μM) for different periods"/>
   <result pre="periods (0, 24, 48 and 72 h) to test whether" exact="lapatinib" post="affected the expression of ABCB1. Western blot analysis was"/>
   <result pre="well in 96-well plates. After 24 h, different concentrations of" exact="doxorubicin" post="were added into the wells 1 h after lapatinib"/>
   <result pre="of doxorubicin were added into the wells 1 h after" exact="lapatinib" post="was added. After 68 h, MTT (5 mg/mL, 20"/>
   <result pre="CA, USA). Doxorubicin and rhodamine 123 accumulation The accumulation of" exact="doxorubicin" post="or rhodamine 123 in HepG2 and HepG2/Adr cells was"/>
   <result pre="as a positive control [ 42]. Ex vivo evaluation of" exact="doxorubicin" post="accumulation in patient liver tissues The fresh normal liver"/>
   <result pre="37°C. The tissues were incubated with the desired concentration of" exact="lapatinib" post="at 37°C for 1 h in the medium, and"/>
   <result pre="for 1 h in the medium, and then 10 μM" exact="doxorubicin" post="was added to the medium and further incubated for"/>
   <result pre="tissues lysis solution which contained 0.3 mol/l HCl and 60%" exact="ethanol" post="(1:1) and was homogenized at 4°C and then centrifuged"/>
   <result pre="and λ em 590 nm. Simultaneously, the standard curve of" exact="doxorubicin" post="was made with the same condition. The doxorubicin accumulation"/>
   <result pre="curve of doxorubicin was made with the same condition. The" exact="doxorubicin" post="accumulation in liver tissues (μg/g) was calculated according to"/>
   <result pre="1 and 2 of every week for 2 weeks); (2)" exact="lapatinib" post="alone (on day 1 and 2 of every week"/>
   <result pre="of every week for 2 weeks, p.o., 100 mg/kg); (3)" exact="paclitaxel" post="alone (on day 2 of every week for 2"/>
   <result pre="of every week for 2 weeks, i.v., 18 mg/kg); (4)" exact="paclitaxel" post="(i.v., 18 mg/kg) one hour after lapatinib on day"/>
   <result pre="18 mg/kg); (4) paclitaxel (i.v., 18 mg/kg) one hour after" exact="lapatinib" post="on day 2 of every week, (5) doxorubicin alone"/>
   <result pre="hour after lapatinib on day 2 of every week, (5)" exact="doxorubicin" post="alone (every three days for 2 weeks, i.v., 10"/>
   <result pre="(every three days for 2 weeks, i.v., 10 mg/kg); (6)" exact="doxorubicin" post="(i.v., 10 mg/kg) one hour after lapatinib (p.o., 100"/>
   <result pre="10 mg/kg); (6) doxorubicin (i.v., 10 mg/kg) one hour after" exact="lapatinib" post="(p.o., 100 mg/kg) every three days. The experimental animals"/>
   <result pre="The mice were randomly divided into four groups (paclitaxel alone," exact="doxorubicin" post="alone and their combination with lapatinib), each of which"/>
   <result pre="of 6 mice (three males and three females). For plasma" exact="paclitaxel" post="levels, mice were treated with either 100 mg/kg of"/>
   <result pre="paclitaxel levels, mice were treated with either 100 mg/kg of" exact="lapatinib" post="(p.o.) or vehicle on days 1 and 2 and"/>
   <result pre="day 2 all mice were injected with 18 mg/kg of" exact="paclitaxel" post="(10 mL/kg) via the caudal vein one hour after"/>
   <result pre="paclitaxel (10 mL/kg) via the caudal vein one hour after" exact="lapatinib" post="or vehicle. For plasma doxorubicin levels, mice were treated"/>
   <result pre="caudal vein one hour after lapatinib or vehicle. For plasma" exact="doxorubicin" post="levels, mice were treated with either 100 mg/kg of"/>
   <result pre="doxorubicin levels, mice were treated with either 100 mg/kg of" exact="lapatinib" post="(p.o.) or vehicle on days 1 and 2 and"/>
   <result pre="day 2 all mice were injected with 10 mg/kg of" exact="doxorubicin" post="(10 mL/kg) via the caudal vein one hour after"/>
   <result pre="doxorubicin (10 mL/kg) via the caudal vein one hour after" exact="lapatinib" post="or vehicle. Blood was collected from the retro-orbital plexus"/>
   <result pre="and stored at −80°C until analysis. The plasma levels of" exact="paclitaxel" post="and doxorubicin were analyzed by HPLC as previously described"/>
   <result pre="at −80°C until analysis. The plasma levels of paclitaxel and" exact="doxorubicin" post="were analyzed by HPLC as previously described (20). Pharmacokinetic"/>
   <result pre="Beijnen JH Schinkel AH P-glycoprotein (ABCB1) transports the primary active" exact="tamoxifen" post="metabolites endoxifen and 4-hydroxytamoxifen and restricts their brain penetration"/>
   <result pre="L Oliva C Stein S et al. Lapatinib combined with" exact="letrozole" post="versus letrozole and placebo as first-line therapy for postmenopausal"/>
   <result pre="C Stein S et al. Lapatinib combined with letrozole versus" exact="letrozole" post="and placebo as first-line therapy for postmenopausal hormone receptor-positive"/>
   <result pre="E. Hepatobiliary abnormalities in patients with metastatic cancer treated with" exact="lapatinib" post="Journal of clinical oncology : official journal of the"/>
   <result pre="M Abbey R A single-arm phase II trial of first-line" exact="paclitaxel" post="in combination with lapatinib in HER2-overexpressing metastatic breast cancer"/>
   <result pre="single-arm phase II trial of first-line paclitaxel in combination with" exact="lapatinib" post="in HER2-overexpressing metastatic breast cancer Oncology 2010 79 129"/>
   <result pre="Finn RS Press MF Phase III, double-blind, randomized study comparing" exact="lapatinib" post="plus paclitaxel with placebo plus paclitaxel as first-line treatment"/>
   <result pre="Press MF Phase III, double-blind, randomized study comparing lapatinib plus" exact="paclitaxel" post="with placebo plus paclitaxel as first-line treatment for metastatic"/>
   <result pre="double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus" exact="paclitaxel" post="as first-line treatment for metastatic breast cancer Journal of"/>
   <result pre="Preston A Martin AM Chi HD Wang L Lapatinib plus" exact="capecitabine" post="in treating HER2-positive advanced breast cancer: efficacy, safety, and"/>
   <result pre="PJ Gefitinib enhances the antitumor activity and oral bioavailability of" exact="irinotecan" post="in mice Cancer research 2004 64 7491 7499 15492275"/>
   <result pre="PJ Middleton MR A phase I and pharmacokinetic study of" exact="lapatinib" post="in combination with infusional 5-fluorouracil, leucovorin and irinotecan Annals"/>
   <result pre="study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and" exact="irinotecan" post="Annals of oncology : official journal of the European"/>
   <result pre="Berger M Oliva C Rubin SD et al. Lapatinib plus" exact="capecitabine" post="for HER2-positive advanced breast cancer The New England journal"/>
   <result pre="Blackwell K Chen S Slingerland J The dual ErbB1/ErbB2 inhibitor," exact="lapatinib" post="(GW572016), cooperates with tamoxifen to inhibit both cell proliferation-"/>
   <result pre="Slingerland J The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with" exact="tamoxifen" post="to inhibit both cell proliferation- and estrogen-dependent gene expression"/>
   <result pre="NL Phase I safety, pharmacokinetics, and clinical activity study of" exact="lapatinib" post="(GW572016), a reversible dual inhibitor of epidermal growth factor"/>
   <result pre="Oxidative stress induced in rat liver by anticancer drugs doxorubicin," exact="paclitaxel" post="and docetaxel Advances in medical sciences 2013 58 104"/>
   <result pre="induced in rat liver by anticancer drugs doxorubicin, paclitaxel and" exact="docetaxel" post="Advances in medical sciences 2013 58 104 111 23612702"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4627999/results/search/inn/results.xml">
   <result pre="years, data regarding the safety, efficacy, and survival benefit of" exact="eribulin" post="in clinical settings for the treatment of metastatic breast"/>
   <result pre="limited. This retrospective observational study investigated the survival benefit of" exact="eribulin" post="compared with conventional chemotherapy regimens in Japanese women with"/>
   <result pre="4 adverse events. Of the 293 patients analyzed, 66 received" exact="eribulin" post="(eribulin arm) and 227 received conventional chemotherapeutic agents excluding"/>
   <result pre="eribulin (eribulin arm) and 227 received conventional chemotherapeutic agents excluding" exact="eribulin" post="(noneribulin arm). The median OS from MBC diagnosis in"/>
   <result pre="(noneribulin arm). The median OS from MBC diagnosis in the" exact="eribulin" post="arm was 72.1 months (95 % CI 13.3–168.3) compared"/>
   <result pre="= 0.025]. No significant differences were noted in OS between" exact="eribulin" post="used as a first-/second-line or third-/&amp;gt;third-line treatment for MBC."/>
   <result pre="a first-/second-line or third-/&amp;gt;third-line treatment for MBC. No patient discontinued" exact="eribulin" post="therapy due to AEs. In the eribulin arm, grade"/>
   <result pre="No patient discontinued eribulin therapy due to AEs. In the" exact="eribulin" post="arm, grade 4 neutropenia and grade 3 febrile neutropenia"/>
   <result pre="routine clinical practice, with no unexpected grade 3/4 AEs. Interestingly," exact="eribulin" post="might be beneficial as any line therapy for ER+/HER2−"/>
   <result pre="women with MBC. Three phase II studies have demonstrated that" exact="eribulin" post="has potent anticancer activity with acceptable tolerability (Aogi et"/>
   <result pre="demonstrated a significant and clinically meaningful improvement in survival with" exact="eribulin" post="compared with the physician’s choice of treatment in women"/>
   <result pre="al. 2011). In another phase III randomized study (study 301)," exact="eribulin" post="showed a favorable improvement in overall survival (OS) compared"/>
   <result pre="OS compared with the controls. Moreover, the OS results for" exact="eribulin" post="were favorable in all population subgroups (Twelves et al."/>
   <result pre="et al. 2014). Based on the results of these studies," exact="eribulin" post="has been approved in the United States and certain"/>
   <result pre="two chemotherapeutic agents, including anthracycline- and taxane-based regimens. In Europe," exact="eribulin" post="has been approved for the treatment of MBC previously"/>
   <result pre="least one chemotherapy regimen. In Japan, on the other hand," exact="eribulin" post="has been approved for the treatment of patients with"/>
   <result pre="treated with chemotherapy regimens for MBC.A phase II study of" exact="eribulin" post="in Japanese patients with locally advanced disease or MBC"/>
   <result pre="well as previously treated with an anthracycline and a taxane," exact="eribulin" post="demonstrated an OS of 11.1 months, respectively (Aogi et"/>
   <result pre="retrospective and prospective studies have demonstrated the therapeutic benefits of" exact="eribulin" post="(Aogi et al. 2012; Cortes et al. 2010; Vahdat"/>
   <result pre="these findings to real-world settings remains to be explored. Although" exact="eribulin" post="has been clinically used as a treatment option in"/>
   <result pre="settings is not extensively documented. Moreover, the survival benefit of" exact="eribulin" post="over conventional chemotherapy is yet to be determined; thus,"/>
   <result pre="present study was conducted to investigate the survival benefit of" exact="eribulin" post="compared with conventional chemotherapy regimens in Japanese women with"/>
   <result pre="are presented in Table 1. The median age in both" exact="eribulin" post="and noneribulin arms was 54.0 years (range 27–77 and"/>
   <result pre="54.0 years (range 27–77 and 25–78 years, respectively). In the" exact="eribulin" post="arm, the median exposure to eribulin was 4.2 months,"/>
   <result pre="years, respectively). In the eribulin arm, the median exposure to" exact="eribulin" post="was 4.2 months, and the median relative dose intensity"/>
   <result pre="relative dose intensity was 47.4 %. The median duration of" exact="eribulin" post="treatment was 125 days, ranging from 2 to 454"/>
   <result pre="MBC 31 (47.0) 31 (47.0) – Taxane-based regimen prior to" exact="eribulin" post="40 (13.7) 40 (60.6) – CNS central nervous system,"/>
   <result pre="during the study period, of whom, 39 were from the" exact="eribulin" post="arm and 175 from the noneribulin arm. Kaplan–Meier survival"/>
   <result pre="the noneribulin arm. Kaplan–Meier survival curves for OS in the" exact="eribulin" post="and noneribulin arms are shown in Fig. 1. The"/>
   <result pre="MBC was 72.1 months (95 % CI 13.3–168.3) in the" exact="eribulin" post="arm compared with 43.3 months (95 % CI 9.1–202.0)"/>
   <result pre="in the noneribulin arm; OS was significantly prolonged in the" exact="eribulin" post="arm (HR: 0.67, 95 % CI 0.47–0.96; P ="/>
   <result pre="death from any cause. HR denotes hazard ratio for the" exact="eribulin" post="arm as compared with the noneribulin arm The influence"/>
   <result pre="each factor at a time. Based on the analyses, only" exact="eribulin" post="monotherapy significantly prolonged the OS (HR: 0.55, 95 %"/>
   <result pre="1.35, 95 % CI 1.01–1.82; P = 0.04) or a" exact="paclitaxel" post="+ gemcitabine combination regimen (HR: 2.79, 95 % CI"/>
   <result pre="% CI 1.01–1.82; P = 0.04) or a paclitaxel +" exact="gemcitabine" post="combination regimen (HR: 2.79, 95 % CI 1.34–5.79; P"/>
   <result pre="Vinorelbine monotherapy 37 37 (100.0) 1.15 0.76–1.73 0.51 Paclitaxel +" exact="bevacizumab" post="52 52 (57.7) 1.51 0.93–2.48 0.10 Docetaxel + capecitabine"/>
   <result pre="+ bevacizumab 52 52 (57.7) 1.51 0.93–2.48 0.10 Docetaxel +" exact="capecitabine" post="30 30 (96.7) 1.13 0.74–1.73 0.57 Paclitaxel + gemcitabine"/>
   <result pre="+ capecitabine 30 30 (96.7) 1.13 0.74–1.73 0.57 Paclitaxel +" exact="gemcitabine" post="10 10 (100.0) 2.79 1.34–5.79 0.01* CI confidence interval,"/>
   <result pre="characteristics of the patients and specific treatments at initiation of" exact="eribulin" post="on OS were analyzed. Prior use of an anthracycline-based"/>
   <result pre="use of an anthracycline-based regimen and duration of treatment with" exact="eribulin" post="were statistically significant clinical variables associated with prolonged OS"/>
   <result pre="significant differences were observed in OS with the use of" exact="eribulin" post="as first-, second-, third-, or beyond third-line treatment for"/>
   <result pre="MBC. Table 3 Prognostic factors for overall survival in the" exact="eribulin" post="arm Variables n HR 95 % CI P value"/>
   <result pre="for MBC 31 0.90 0.37–2.20 0.82 Taxane-based regimen prior to" exact="eribulin" post="28 1.41 0.63–3.14 0.40 Duration of eribulin treatment &amp;gt;median"/>
   <result pre="regimen prior to eribulin 28 1.41 0.63–3.14 0.40 Duration of" exact="eribulin" post="treatment &amp;gt;median (125 days) 33 0.45 0.21–0.94 0.03* CI"/>
   <result pre="ratio, MBC metastatic breast cancer Safety outcomes No patient discontinued" exact="eribulin" post="therapy due to adverse events. No grade 3 or"/>
   <result pre="(6.1 %) patients. None of these events was related to" exact="eribulin" post="according to the investigator. No other grade 3/4 hematological"/>
   <result pre="Discussion This retrospective observational study investigated the survival benefit of" exact="eribulin" post="compared with other conventional chemotherapy regimens in Japanese women"/>
   <result pre="present analyses revealed a prolonged OS in patients treated with" exact="eribulin" post="than in those treated with other chemotherapy regimens. In"/>
   <result pre="with other chemotherapy regimens. In addition, these analyses showed that" exact="eribulin" post="monotherapy provided a survival benefit with an efficacy that"/>
   <result pre="as a front- or late-line therapy. Moreover, no patient discontinued" exact="eribulin" post="therapy due to adverse events. The median OS for"/>
   <result pre="is significant, particularly in patients who had been treated with" exact="eribulin" post="for more than 125 days. Currently, no treatment standard"/>
   <result pre="(EMBRACE and study 301) (Twelves et al. 2014) suggest that" exact="eribulin" post="could prolong survival in patients with late-stage MBC, particularly"/>
   <result pre="those who have been heavily pretreated. In the present study," exact="eribulin" post="demonstrated a significant survival benefit in patients treated with"/>
   <result pre="in patients treated with an anthracycline-based regimen for MBC; thus," exact="eribulin" post="may be beneficial for patients who did not respond"/>
   <result pre="a third- or beyond third-line treatment, and the efficacy of" exact="eribulin" post="in these patients was comparable to those who received"/>
   <result pre="eribulin in these patients was comparable to those who received" exact="eribulin" post="as first- or second-line treatment. Taken together, eribulin might"/>
   <result pre="who received eribulin as first- or second-line treatment. Taken together," exact="eribulin" post="might be beneficial not only as a late-line but"/>
   <result pre="also as a front-line treatment for MBC. In certain countries," exact="eribulin" post="has been approved for the treatment of patients with"/>
   <result pre="chemotherapy regimens, including anthracycline- and taxane-based regimens; however, in Japan," exact="eribulin" post="has been approved for patients with inoperable or recurrent"/>
   <result pre="previous treatment history. The present study supports the indication of" exact="eribulin" post="use in Japan and demonstrates its potential as a"/>
   <result pre="several novel anti-HER2 therapeutic agents, including trastuzumab, lapatinib, pertuzumab, and" exact="trastuzumab" post="emtansine have been developed. Based on the Surveillance, Epidemiology,"/>
   <result pre="the results of the present study, the survival benefit of" exact="eribulin" post="was observed among the patients with ER+/HER2− MBC. A"/>
   <result pre="A subgroup analysis of the previous pooled analysis showed that" exact="eribulin" post="has a tendency to prolong OS which was not"/>
   <result pre="et al. 2014). These study results support the use of" exact="eribulin" post="as a potential therapeutic option for the treatment of"/>
   <result pre="of ER+/HER2− MBC; however, additional investigations on the benefits of" exact="eribulin" post="in such patients are warranted. In the present study,"/>
   <result pre="eribulin in such patients are warranted. In the present study," exact="eribulin" post="had an acceptable safety profile. Grade 3 and 4"/>
   <result pre="neuropathy, the most common adverse event leading to discontinuation of" exact="eribulin" post="therapy in EMBRACE, was not observed in the present"/>
   <result pre="observed in the present study. In addition, no patient discontinued" exact="eribulin" post="therapy due to adverse events. Based on the low"/>
   <result pre="adverse events and no treatment discontinuation, the safety profile of" exact="eribulin" post="in the present study may be considered more acceptable"/>
   <result pre="Twelves et al. 2014). The median relative dose intensity of" exact="eribulin" post="was 47.4 %, and the dose was modified to"/>
   <result pre="unwarranted toxicity at the physician’s discretion. Hence, the dose of" exact="eribulin" post="may be modified based on an individual patient’s needs"/>
   <result pre="present study which retrospectively investigated the efficacy and safety of" exact="eribulin" post="in Japanese women with ER+/HER2− MBC in routine clinical"/>
   <result pre="in routine clinical practice demonstrated a significant survival benefit of" exact="eribulin" post="in such patients, with a relatively lower dose intensity"/>
   <result pre="grade 3 and 4 adverse events. The survival benefit of" exact="eribulin" post="was regardless of the organs involved, previous treatment regimens,"/>
   <result pre="In addition, the median treatment duration and dose intensity of" exact="eribulin" post="were assessed. The primary efficacy measure assessed OS, which"/>
   <result pre="was November 30, 2014. OS curves for patients who received" exact="eribulin" post="(eribulin arm) and conventional chemotherapy excluding eribulin (noneribulin arm)"/>
   <result pre="patients who received eribulin (eribulin arm) and conventional chemotherapy excluding" exact="eribulin" post="(noneribulin arm) were estimated using the Kaplan–Meier method, and"/>
   <result pre="oncology breast cancer, version 2 2015) (e.g., TS-1 monotherapy and" exact="capecitabine" post="+ cyclophosphamide combination therapy) were excluded owing to the"/>
   <result pre="cancer, version 2 2015) (e.g., TS-1 monotherapy and capecitabine +" exact="cyclophosphamide" post="combination therapy) were excluded owing to the small number"/>
   <result pre="K Sasaki Y Takashima S A phase II study of" exact="eribulin" post="in Japanese patients with heavily pretreated metastatic breast cancer"/>
   <result pre="Allison MA Phase II study of the halichondrin B analog" exact="eribulin" post="mesylate in patients with locally advanced or metastatic breast"/>
   <result pre="breast cancer previously treated with an anthracycline, a taxane, and" exact="capecitabine" post="J Clin Oncol 2010 28 3922 3928 10.1200/JCO.2009.25.8467 20679609"/>
   <result pre="Dutcus CE Cortes J Phase III Open-label randomized study of" exact="eribulin" post="mesylate versus capecitabine in patients with locally advanced or"/>
   <result pre="J Phase III Open-label randomized study of eribulin mesylate versus" exact="capecitabine" post="in patients with locally advanced or metastatic breast cancer"/>
   <result pre="Olivo M He Y Kaufman PA Awada A Efficacy of" exact="eribulin" post="in women with metastatic breast cancer: a pooled analysis"/>
   <result pre="Cole PE Ashworth S Blum JL Phase II study of" exact="eribulin" post="mesylate, a halichondrin B analog, in patients with metastatic"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4631578/results/search/inn/results.xml">
   <result pre="subjected to total cerebral radiotherapy simultaneously with systemic therapy with" exact="trastuzumab" post="emtansine (T-DM1). Case study A 62-year-old female patient with"/>
   <result pre="of micrometastases in a lymph node, positivity for oestrogen and" exact="progesterone" post="receptors and a score of 3 + for the"/>
   <result pre="60 mg/m 2 of adriamycin and 600 mg/m 2 of" exact="cyclophosphamide" post="within a period of 2 months. Afterward, trastuzumab and"/>
   <result pre="2 of cyclophosphamide within a period of 2 months. Afterward," exact="trastuzumab" post="and paclitaxel were initiated, but the patient completed only"/>
   <result pre="cyclophosphamide within a period of 2 months. Afterward, trastuzumab and" exact="paclitaxel" post="were initiated, but the patient completed only two cycles,"/>
   <result pre="interrupted by an allergic reaction to taxane. The use of" exact="trastuzumab" post="and tamoxifen was continued for one year. Due to"/>
   <result pre="an allergic reaction to taxane. The use of trastuzumab and" exact="tamoxifen" post="was continued for one year. Due to bone pain"/>
   <result pre="product of the HER2 oncogene. Thus, treatment with radiotherapy and" exact="fulvestrant" post="associated with zoledronic acid was initiated and maintained for"/>
   <result pre="HER2 oncogene. Thus, treatment with radiotherapy and fulvestrant associated with" exact="zoledronic acid" post="was initiated and maintained for 4 months. With the"/>
   <result pre="progression, evidenced by an increase in the pain intensity, weekly" exact="docetaxel" post="was initiated, followed by capecitabine and lapatinib for a"/>
   <result pre="in the pain intensity, weekly docetaxel was initiated, followed by" exact="capecitabine" post="and lapatinib for a period of 1 month; however,"/>
   <result pre="pain intensity, weekly docetaxel was initiated, followed by capecitabine and" exact="lapatinib" post="for a period of 1 month; however, the symptoms"/>
   <result pre="the treatment with T-DM1, which was treated with 10 mg" exact="bromopride" post="orally 3× per day. In the fourth cycle, there"/>
   <result pre="weight. Due to this difficulty, approximately 10% of patients taking" exact="trastuzumab" post="exclusively as a treatment for metastatic breast cancer develop"/>
   <result pre="antibody for the extracellular region of the HER2 receptor –" exact="trastuzumab" post="– an antimicrotubule agent derived from maytansine – DM1"/>
   <result pre="connecting the two structures already mentioned. As for its mechanism," exact="trastuzumab" post="links to the HER2 receptor, allowing for the internalisation"/>
   <result pre="survival and lower toxicity in relation to the use of" exact="lapatinib" post="plus capecitabine in patients with advanced HER2-positive breast cancer"/>
   <result pre="lower toxicity in relation to the use of lapatinib plus" exact="capecitabine" post="in patients with advanced HER2-positive breast cancer in prior"/>
   <result pre="patients with advanced HER2-positive breast cancer in prior treatment with" exact="trastuzumab" post="and taxanes [ 13, 14]. While it has shown"/>
   <result pre="show controversies relating to the efficacy of treatment with isolated" exact="trastuzumab" post="in advanced breast cancer with cerebral metastasis. What has"/>
   <result pre="brain metastases from breast cancer treated with whole-brain radiotherapy and" exact="eribulin" post="mesylate Case Rep Oncol Med 2012 2012 Article ID"/>
   <result pre="with brain metastases from breast cancer in the pre-traztuzumab and" exact="trastuzumab" post="eras Radiat Oncol 2013 12 8 1 7 12."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4632920/results/search/inn/results.xml">
   <result pre="estrogen receptor-mitogen-activated protein kinases cross talk confer acquired resistance to" exact="lapatinib" post="Li Zhe 1 * Yang Sheng-Sheng 2 * Yin"/>
   <result pre="not used for commercial purposes. Abstract Background The efficacy of" exact="lapatinib" post="is limited by the development of acquired resistance. The"/>
   <result pre="estrogen receptor (ER) signaling compensatory activation in acquired resistance to" exact="lapatinib" post="in breast cancer cells BT474 and the related mechanism."/>
   <result pre="ER pathways in breast cancer cell BT474 after treatment with" exact="lapatinib" post="and the distinction between BT474 and rBT474. Methyl thiazolyl"/>
   <result pre="detect the proliferation of rBT474 and BT474 cells treated with" exact="lapatinib" post="and/or an ER inhibitor, fulvestrant, respectively. Results Lapatinib could"/>
   <result pre="of HER2 and induce expression of forkhead-box protein O3a and" exact="progesterone" post="receptor. Acquired resistant cell model rBT474 could grow in"/>
   <result pre="model. Conclusion ER signaling compensatory activation may partly contribute to" exact="lapatinib" post="acquired resistance in HER2-overexpressing/ERα-positive breast cancer cells, which might"/>
   <result pre="approved by the United States Food and Drug Administration after" exact="trastuzumab" post="(Herceptin, Roche, San Francisco, CA, USA). Lapatinib is also"/>
   <result pre="satisfactorily absorbed by oral administration. Clinical research has reported that" exact="lapatinib" post="can reduce the risk of brain metastases in breast"/>
   <result pre="the risk of brain metastases in breast cancer patients with" exact="trastuzumab" post="resistance. 2 Moreover, lapatinib has weak cardiotoxicity. However, like"/>
   <result pre="metastases in breast cancer patients with trastuzumab resistance. 2 Moreover," exact="lapatinib" post="has weak cardiotoxicity. However, like other molecular targeting drugs,"/>
   <result pre="studies have demonstrated an effective response of only 24% when" exact="lapatinib" post="was used alone, and a majority of treated patients"/>
   <result pre="efficiency of lapatinib, clarifying the mechanism of acquired resistance of" exact="lapatinib" post="is crucial. However, only a few studies have confirmed"/>
   <result pre="specific mechanism of compensatory activation of the ER pathway in" exact="lapatinib" post="drug resistance need to be further clarified. To explore"/>
   <result pre="need to be further clarified. To explore the influence of" exact="lapatinib" post="on the ER pathway, and to distinguish the differences"/>
   <result pre="established an acquired resistance model with a clinical concentration of" exact="lapatinib" post="in vitro. ER pathway activation was identified when there"/>
   <result pre="Culture Collection (Chinese Academy of Sciences, Shanghai, China). Lapatinib and" exact="fulvestrant" post="(Faslodex, Astra Zeneca, Wilmington DE, USA) were purchased from"/>
   <result pre="synthesized by Jierui Bioengineering Co., Ltd. (Shanghai, China) Establishment of" exact="lapatinib" post="acquired drug resistance model BT474 cells were cultured in"/>
   <result pre="cultured with RPMI 1640 medium with 10% FBS and 5 μM" exact="lapatinib" post="in 5% CO 2 at 37°C in an incubator."/>
   <result pre="TGC TGA TGT TGT TCT TT-3.′ The primer sequences of" exact="progesterone" post="receptor (PR) were as follows: forward primer, 5′-TTC ACC"/>
   <result pre="Apoptosis detection BT474 and rBT474 cells were disposed with 5 μM" exact="lapatinib" post="for six hours. Cells were then collected and washed"/>
   <result pre="The cells were divided into four groups: rBT474, rBT474 +" exact="fulvestrant" post="(10 nM), BT474, and BT474 + fulvestrant (10 nM). Each group"/>
   <result pre="groups: rBT474, rBT474 + fulvestrant (10 nM), BT474, and BT474 +" exact="fulvestrant" post="(10 nM). Each group had five duplicated wells. Both cells"/>
   <result pre="duplicated wells. Both cells were treated with different concentrations of" exact="lapatinib" post="for 48 hours. Then, 20 μl MTT (5 mg/ml) solution was"/>
   <result pre="at 37°C for four hours. Media was discarded and 150 μl" exact="dimethyl sulfoxide" post="(DMSO) was added to each well and then shaken"/>
   <result pre="previous described. 4 After tumors reached 200 mm3, treatment commenced with" exact="lapatinib" post="(100 mg/kg) by daily oral gavage and/or fulvestrant (5 mg/week) by"/>
   <result pre="treatment commenced with lapatinib (100 mg/kg) by daily oral gavage and/or" exact="fulvestrant" post="(5 mg/week) by subcutaneous injection. The short (a) and long"/>
   <result pre="the standard of statistical significance. Results The cell model of" exact="lapatinib" post="acquired resistance According to some clinical pharmacokinetic studies regarding"/>
   <result pre="2.70–6.49 μM). 5 In this study, mediums containing different concentrations of" exact="lapatinib" post="were applied to the incubation of BT474 for 21"/>
   <result pre="to the incubation of BT474 for 21 days (concentration of" exact="lapatinib" post="gradually increased from 0.25 μM to 5 μM). The lapatinib acquired"/>
   <result pre="(concentration of lapatinib gradually increased from 0.25 μM to 5 μM). The" exact="lapatinib" post="acquired resistance cell, rBT474, was obtained from the survival"/>
   <result pre="BT474 was observed under microscope after 24 hours of 5 μM" exact="lapatinib" post="treatment. However, the number of rBT474 cells had changed"/>
   <result pre="showed that the apoptosis rate of rBT474 treated with 5 μM" exact="lapatinib" post="for 12 hours (11.42 ± 3.67%) was remarkably lower"/>
   <result pre="resistance cells rBT47 (Fig.  1c). Figure 1 Identification of the" exact="lapatinib" post="acquired drug resistance model rBT474. (a) Comparison of the"/>
   <result pre="of BT474 and rBT474 under microscope after treatment with 5 μM" exact="lapatinib" post="for 24 hours. (b) The result of flow cytometry"/>
   <result pre="and human epidermal growth factor (HER)2 pathways were influenced by" exact="lapatinib" post="in BT474 cells The ERα pathway interacted with HER2."/>
   <result pre="ERα pathway interacted with HER2. To observe the impact of" exact="lapatinib" post="on the ERα pathway in breast cancer cells, HER2"/>
   <result pre="and FOXO3a increased (Fig.  2a, b). A higher concentration of" exact="lapatinib" post="activated PR and FOXO3, increasing their expression level ("/>
   <result pre="expression level ( P &amp;lt; 0.05). Figure 2 Impact of" exact="lapatinib" post="on the estrogen receptor (ER)α and human epidermal growth"/>
   <result pre="and protein level ( P &amp;lt; 0.05). Lap, lapatinib. ," exact="dimethyl sulfoxide" post="(DMSO); , Lap (0.5 μM); , Lap (1 μM). Difference in"/>
   <result pre="and BT474. (a) A comparison of rBT474 treated with 5 μM" exact="lapatinib" post="and untreated BT474 cells; the expression of ERα, PR,"/>
   <result pre="transcription. Inhibition of ERα pathway can reverse acquired resistance to" exact="lapatinib" post="Our results implied that the vicarious activation of the"/>
   <result pre="the ERα pathway is involved in the molecular mechanism of" exact="lapatinib" post="drug resistance. Thus, we inferred that using the ERα"/>
   <result pre="that using the ERα pathway inhibitor may recover sensitivity to" exact="lapatinib" post="in rBT474. Fulvestrant can degrade ERα effectively with no"/>
   <result pre="rBT474 were divided into two groups, one treated with 10 nM" exact="fulvestrant" post="and the other as the control, followed by treatment"/>
   <result pre="the control, followed by treatment with 0 μM, 0.5 μM, 1 μM, 5 μM" exact="lapatinib" post="and detection after 48 hours. As a result, the"/>
   <result pre="a result, the cell viability of rBT474 treated only with" exact="lapatinib" post="was decreased at the higher concentration (1 μM) and the"/>
   <result pre="rate of rBT474 remarkably decreased with the higher concentration of" exact="lapatinib" post="after treatment with 10 nM fulvestrant (43.96 ± 3.79%), notably"/>
   <result pre="with the higher concentration of lapatinib after treatment with 10 nM" exact="fulvestrant" post="(43.96 ± 3.79%), notably lower than the group without"/>
   <result pre="fulvestrant (43.96 ± 3.79%), notably lower than the group without" exact="fulvestrant" post="(77.84 ± 6.37%), P &amp;lt; 0.01. The cell viability"/>
   <result pre="0.01. The cell viability of BT474, after treatment with only" exact="lapatinib" post="or adding fulvestrant both saw a decrease in concentration"/>
   <result pre="viability of BT474, after treatment with only lapatinib or adding" exact="fulvestrant" post="both saw a decrease in concentration in a dose-dependent"/>
   <result pre="the cell viability of BT474 treated with a combination of" exact="lapatinib" post="and fulvestrant decreased more than the group with lapatinib"/>
   <result pre="viability of BT474 treated with a combination of lapatinib and" exact="fulvestrant" post="decreased more than the group with lapatinib alone, (14.58"/>
   <result pre="of lapatinib and fulvestrant decreased more than the group with" exact="lapatinib" post="alone, (14.58 ± 2.3% vs. 31.41 ± 1.7%), P"/>
   <result pre="vs. 31.41 ± 1.7%), P &amp;lt; 0.05 Treatment with both" exact="lapatinib" post="and fulvestrant had a remarkably synergistic inhibition on breast"/>
   <result pre="± 1.7%), P &amp;lt; 0.05 Treatment with both lapatinib and" exact="fulvestrant" post="had a remarkably synergistic inhibition on breast cancer cells"/>
   <result pre="cancer cells BT474 and rBT474, and enhanced the sensitivity to" exact="lapatinib" post="in rBT474. Figure 4 Effects of lapatinib and fulvestrant"/>
   <result pre="the sensitivity to lapatinib in rBT474. Figure 4 Effects of" exact="lapatinib" post="and fulvestrant on the growth of BT474 and rBT474."/>
   <result pre="to lapatinib in rBT474. Figure 4 Effects of lapatinib and" exact="fulvestrant" post="on the growth of BT474 and rBT474. The cell"/>
   <result pre="of BT474 and rBT474 were decreased markedly when treatment of" exact="lapatinib" post="and fulvestrant were combined; BT474 was more sensitive to"/>
   <result pre="and rBT474 were decreased markedly when treatment of lapatinib and" exact="fulvestrant" post="were combined; BT474 was more sensitive to both of"/>
   <result pre=", BT474+Ful. Double target treatment can prevent acquired resistance to" exact="lapatinib" post="in BT474 The rate of cell colony formation, as"/>
   <result pre="revealed the cloning number of the group treated with 1 μM" exact="lapatinib" post="and 10 nM fulvestrant was evidently lower than the other"/>
   <result pre="number of the group treated with 1 μM lapatinib and 10 nM" exact="fulvestrant" post="was evidently lower than the other groups treated with"/>
   <result pre="The rates of cell cloning demonstrate that treatment with both" exact="lapatinib" post="and fulvestrant can notably inhibit cell cloning of BT474"/>
   <result pre="of cell cloning demonstrate that treatment with both lapatinib and" exact="fulvestrant" post="can notably inhibit cell cloning of BT474 and might"/>
   <result pre="cell cloning of BT474 and might prevent acquired resistance to" exact="lapatinib" post="(Fig  5). Figure 5 The combination of lapatinib and"/>
   <result pre="resistance to lapatinib (Fig  5). Figure 5 The combination of" exact="lapatinib" post="and fulvestrant influenced the colony formation of BT474. In"/>
   <result pre="lapatinib (Fig  5). Figure 5 The combination of lapatinib and" exact="fulvestrant" post="influenced the colony formation of BT474. In a comparison"/>
   <result pre="of BT474. In a comparison of the effect of 0.1%" exact="dimethyl sulfoxide" post="(DMSO), 1 μM lapatinib, 10 nM fulvestrant and 1 μM lapatinib+ 10 nM"/>
   <result pre="the effect of 0.1% dimethyl sulfoxide (DMSO), 1 μM lapatinib, 10 nM" exact="fulvestrant" post="and 1 μM lapatinib+ 10 nM fulvestrant on BT474 colony formation,"/>
   <result pre="sulfoxide (DMSO), 1 μM lapatinib, 10 nM fulvestrant and 1 μM lapatinib+ 10 nM" exact="fulvestrant" post="on BT474 colony formation, the cloning number of 1 μM"/>
   <result pre="BT474 colony formation, the cloning number of 1 μM lapatinib, 10 nM" exact="fulvestrant" post="was evidently lower than the combination of DMSO, lapatinib,"/>
   <result pre="4.73%, and 70.33 ± 5.51%, respectively. Lapatinib and ER inhibitor" exact="fulvestrant" post="synergize against HER2-overexpressing xenografts We found that the upregulation"/>
   <result pre="we hypothesized that the addition of an ER inhibitor to" exact="lapatinib" post="would prevent or delay the development of drug resistance"/>
   <result pre="drug resistance and might further suppress tumor growth compared to" exact="lapatinib" post="alone. To test this, mice bearing BT474 xenografts were"/>
   <result pre="xenografts were randomized to therapy with vehicle controls (DMSO), lapatinib," exact="fulvestrant" post="or a combination of both drugs for 30 days."/>
   <result pre="the growth curve of the established BT474 xenografts (Fig.  6a)," exact="lapatinib" post="had a significant inhibition effect on tumor growth ("/>
   <result pre="( P &amp;lt; 0.05) in the labatinib only group, while" exact="fulvestrant" post="alone had little activity compared with the control mice"/>
   <result pre="from the xenograft growth curve. The tumor weight in the" exact="fulvestrant" post="group (0.22 ± 0.04 g) was a little lighter than"/>
   <result pre="no significant difference ( P &amp;gt; 0.05), while in the" exact="lapatinib" post="group, tumor weight (0.16 ± 0.13 g) was more significantly"/>
   <result pre="allocated to four treatment groups: vehicle (dimethyl sulfoxide [DMSO]) alone," exact="lapatinib" post="(100 mg/kg daily by orogastric gavage), fulvestran (5 mg/mice week by"/>
   <result pre="a molecular targeting drug to alter the HER2 gene. Fortunately," exact="trastuzumab" post="and lapatinib have been approved for clinical therapy. Lapatinib,"/>
   <result pre="targeting drug to alter the HER2 gene. Fortunately, trastuzumab and" exact="lapatinib" post="have been approved for clinical therapy. Lapatinib, as a"/>
   <result pre="efficient for trastuzumab-resistant breast cancer cells. The molecular weight of" exact="lapatinib" post="is small; therefore it can pass the blood-brain barrier,"/>
   <result pre="view of the mechanism of acquired drug resistance supports that" exact="lapatinib" post="is the most successful inhibitor of the HER2 pathway,"/>
   <result pre="of the HER2 and ERα pathways in the mechanism of" exact="lapatinib" post="acquired drug resistance; for example, a study found that"/>
   <result pre="cancer cells, BT474, as models to detect the influence of" exact="lapatinib" post="on HER2 and ER pathways. We found that lapatinb"/>
   <result pre="ERK; our results correspond with earlier studies. 22 In addition," exact="lapatinib" post="can induce the ERα pathway to be activated to"/>
   <result pre="Src and caveolin-1 were increased, and HER-2 was inhibited by" exact="lapatinib" post="long term to cause to Scr compensatory activation. This"/>
   <result pre="assays were used to show that the combined utilization of" exact="lapatinib" post="and fulvestrant could inhibit rBT474 cell proliferation, as well"/>
   <result pre="used to show that the combined utilization of lapatinib and" exact="fulvestrant" post="could inhibit rBT474 cell proliferation, as well as the"/>
   <result pre="results, we further confirmed that, in a mouse tumor model," exact="lapatinib" post="and fulvestrant are more efficient in inhibiting tumor growth"/>
   <result pre="further confirmed that, in a mouse tumor model, lapatinib and" exact="fulvestrant" post="are more efficient in inhibiting tumor growth than either"/>
   <result pre="against HER2 and ER pathways is effective therapy to prevent" exact="lapatinib" post="acquired drug resistance. In an in vivo trial, treatment"/>
   <result pre="vivo trial, treatment of HER2-positive xenografts with the combination of" exact="lapatinib" post="and a small molecule inhibitor of ER was more"/>
   <result pre="alone. ER signaling activation is suggested as a mechanism of" exact="lapatinib" post="resistance, indicating that the combination of HER2 and ER"/>
   <result pre="ER inhibition is a therapeutic strategy to prevent and/or overcome" exact="lapatinib" post="resistance in HER2-overexpressing breast cancer. Further in vivo or"/>
   <result pre="al. Phase I safety, pharmacokinetics, and clinical activity study of" exact="lapatinib" post="(GW572016), a reversible dual inhibitor of epidermal growth factor"/>
   <result pre="Nephew KP Estrogen receptor-alpha-interacting cytokeratins potentiate the antiestrogenic activity of" exact="fulvestrant" post="Cancer Biol Ther 2010 9 389 396 20061804 Pommier"/>
   <result pre="Doval DC Chavez MA et al. Efficacy and safety of" exact="lapatinib" post="as first-line therapy for ErbB2-amplified locally advanced or metastatic"/>
   <result pre="D Hung MC Hortobagyi GN Molecular predictors of response to" exact="trastuzumab" post="and lapatinib in breast cancer Nat Rev Clin Oncol"/>
   <result pre="MC Hortobagyi GN Molecular predictors of response to trastuzumab and" exact="lapatinib" post="in breast cancer Nat Rev Clin Oncol 2010 7"/>
   <result pre="M Scaltriti M et al. Phosphatidylinositol 3-kinase hyperactivation results in" exact="lapatinib" post="resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor"/>
   <result pre="L Greger J Shi H et al. Novel mechanism of" exact="lapatinib" post="resistance in HER2-positive breast tumor cells: Activation of AXL"/>
   <result pre="tumor cells: FGFR2 as a potential target for salvage after" exact="lapatinib" post="failure Biochem Biophys Res Commun 2011 407 219 224"/>
   <result pre="et al. Human breast cancer cells selected for resistance to" exact="trastuzumab" post="in vivo overexpress epidermal growth factor receptor and ErbB"/>
   <result pre="enhances estrogen-mediated signaling and tumor growth but does not confer" exact="tamoxifen" post="resistance Oncogene 2002 21 4000 4008 12037682 Todorovic-Rakovic N"/>
   <result pre="Edwards DP Regulation of signal transduction pathways by estrogen and" exact="progesterone" post="Annu Rev Physiol 2005 67 335 376 15709962"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4637019/results/search/inn/results.xml">
   <result pre="peucetius, with very potent antineoplastic activity [ 15]. In particular," exact="doxorubicin" post="and epirubicin are currently the cornerstone of treatment of"/>
   <result pre="very potent antineoplastic activity [ 15]. In particular, doxorubicin and" exact="epirubicin" post="are currently the cornerstone of treatment of many malignancies,"/>
   <result pre="It has been estimated that approximately 10% of patients receiving" exact="doxorubicin" post="or its derivatives will develop cardiac complications, even up"/>
   <result pre="species ( Figure 1) [ 27]. Consistent with this model," exact="doxorubicin" post="cardiotoxicity is prevented in mice knockout for the gene"/>
   <result pre="fibrosis is observed in hearts that have been exposed to" exact="doxorubicin" post="[ 36] and may impinge on both diastolic and—via"/>
   <result pre="been linked to late-onset LV dysfunction (milder than anthracyclines) is" exact="cisplatin" post="[ 1, 43]. Also, taxanes such as paclitaxel and"/>
   <result pre="anthracyclines) is cisplatin [ 1, 43]. Also, taxanes such as" exact="paclitaxel" post="and docetaxel are antimicrotubule agents that bind to tubulin,"/>
   <result pre="cisplatin [ 1, 43]. Also, taxanes such as paclitaxel and" exact="docetaxel" post="are antimicrotubule agents that bind to tubulin, thus impairing"/>
   <result pre="of patients, which was found to peak to 28% when" exact="trastuzumab" post="is coadministered with anthracyclines [ 56, 57]. In fact,"/>
   <result pre="release of troponin shown in sequential treatment with anthracyclines +" exact="trastuzumab" post="seems to be ascribed to the previous chemotherapy ["/>
   <result pre="there is evidence that it is relatively safe to readminister" exact="trastuzumab" post="after it has been discontinued and myocardial function has"/>
   <result pre="domain of HER2. Trastuzumab only disrupts ligand-independent HER2 signaling; conversely," exact="pertuzumab" post="interferes with the formation of ligand-induced HER2 heterodimers. Lapatinib"/>
   <result pre="affects both ligand-triggered and ligand-independent HER2 signaling [ 9]. Interestingly," exact="lapatinib" post="seems to be less toxic than trastuzumab. Data about"/>
   <result pre="be less toxic than trastuzumab. Data about the toxicity of" exact="pertuzumab" post="are limited [ 57]. Cardiotoxicity of HER2-targeting drugs has"/>
   <result pre="dysfunction. This is consistent with the increase in cardiotoxicity when" exact="trastuzumab" post="is associated with anthracyclines: trastuzumab enhances or even uncovers"/>
   <result pre="the increase in cardiotoxicity when trastuzumab is associated with anthracyclines:" exact="trastuzumab" post="enhances or even uncovers the damage caused by anthracyclines."/>
   <result pre="59]. Indeed, experimental studies have shown that neuregulin 1 modulates" exact="doxorubicin" post="damage in rat cardiomyocytes [ 14, 57, 63, 64]."/>
   <result pre="have to acknowledge antiangiogenic drugs. In particular, bevacizumab, sorafenib, and" exact="sunitinib" post="are now widely used in oncology; more recently, pazopanib"/>
   <result pre="and sunitinib are now widely used in oncology; more recently," exact="pazopanib" post="and vandetanib have also been approved by the US"/>
   <result pre="are now widely used in oncology; more recently, pazopanib and" exact="vandetanib" post="have also been approved by the US Food and"/>
   <result pre="of patients who have already received chemotherapy [ 79]. Instead," exact="sunitinib" post="and sorafenib, which are used in metastatic renal cancer"/>
   <result pre="other than the one of VEGF [ 10]. In particular," exact="sunitinib" post="inhibits more than 30 other receptor and nonreceptor tyrosine"/>
   <result pre="of these pathways in cardiovascular homeostasis. The higher incidence of" exact="sunitinib" post="cardiotoxicity is also explained by inhibition of off-target kinases,"/>
   <result pre="would occur due to myocyte dysfunction. In mice treated with" exact="sunitinib" post="and exposed to pressure load, Chu and colleagues ["/>
   <result pre="destruction of the normal mitochondrial architecture. Moreover, direct administration of" exact="sunitinib" post="on different myocardial preparations results in a dose-dependent inotropic"/>
   <result pre="92]. At clinically relevant concentrations in in vitro kinase assay," exact="sorafenib" post="inhibits at least 15 kinases, including VEGF receptor, PDGFR,"/>
   <result pre="[ 8, 10, 67]. The rate of cardiotoxicity associated with" exact="sorafenib" post="is not yet clear. Two meta-analysis, including almost 7000"/>
   <result pre="yet clear. Two meta-analysis, including almost 7000 patients treated with" exact="sunitinib" post="and 900 patients treated with sorafenib, found a 4.1%"/>
   <result pre="71] reported that 3 out of 14 patients treated with" exact="sorafenib" post="who experienced cardiac events showed abnormal EF. Interestingly, a"/>
   <result pre="[ 99]. 4.3. Other Type 2 Agents The BCR-ABL inhibitors," exact="imatinib" post="and dasatinib, are tyrosine kinase inhibitors used for treatment"/>
   <result pre="dysfunction in patients with breast cancer undergoing sequential therapy with" exact="doxorubicin" post="and trastuzumab, also showed that a marker of oxidative"/>
   <result pre="by androgens. Indeed, unpublished data from our laboratory show that" exact="testosterone" post="reduces the toxicity of doxorubicin in cultured cardiomyocytes. Finally,"/>
   <result pre="from our laboratory show that testosterone reduces the toxicity of" exact="doxorubicin" post="in cultured cardiomyocytes. Finally, it has to be acknowledged"/>
   <result pre="use of chemotherapy regimens not containing anthracyclines, administering anthracyclines and" exact="trastuzumab" post="sequentially rather than concurrently [ 44, 137, 140, 141],"/>
   <result pre="and, in the case of breast cancer, on anthracyclines +" exact="trastuzumab" post="[ 30, 146] and have been proposing dexrazoxane ["/>
   <result pre="anthracyclines + trastuzumab [ 30, 146] and have been proposing" exact="dexrazoxane" post="[ 147], ACE inhibitors [ 148], and statins ["/>
   <result pre="the mitochondrial dysfunction seen with anthracyclines [ 154]. Among β-blockers," exact="carvedilol" post="also has well-known antioxidant properties [ 155] and is"/>
   <result pre="properties [ 155] and is able to protect cells against" exact="doxorubicin" post="toxicity by reducing oxidative stress and apoptosis [ 156–"/>
   <result pre="19 5 529 542 1411651 21 Jain D. Cardiotoxicity of" exact="doxorubicin" post="and other anthracycline derivatives Journal of Nuclear Cardiology 2000"/>
   <result pre="drug dose as risk factors for late cardiotoxic effects of" exact="doxorubicin" post="therapy for childhood cancer The New England Journal of"/>
   <result pre="et al. Matrix metalloproteinase-2 and -9 are induced differently by" exact="doxorubicin" post="in H9c2 cells: the role of MAP kinases and"/>
   <result pre="J. Wong J. Iordanov M. Magun B. E. Doxorubicin and" exact="daunorubicin" post="induce processing and release of interleukin-1 β through activation"/>
   <result pre="44 Slamon D. Eiermann W. Robert N. et al. Adjuvant" exact="trastuzumab" post="in HER2-positive breast cancer The New England Journal of"/>
   <result pre="M. Osterwalder B. Incidence of cardiotoxicity with the oral fluoropyrimidine" exact="capecitabine" post="is typical of that reported with 5-fluorouracil Annals of"/>
   <result pre="shock protein 90 and ErbB2 in the cardiac response to" exact="doxorubicin" post="injury Cancer Research 2007 67 4 1436 1441 10.1158/0008-5472.can-06-3721"/>
   <result pre="C. C. Vogl U. M. et al. Cardiac toxicity of" exact="sunitinib" post="and sorafenib in patients with metastatic renal cell carcinoma"/>
   <result pre="Vogl U. M. et al. Cardiac toxicity of sunitinib and" exact="sorafenib" post="in patients with metastatic renal cell carcinoma Journal of"/>
   <result pre="R. Perry M. C. et al. Paclitaxel-carboplatin alone or with" exact="bevacizumab" post="for non-small-cell lung cancer The New England Journal of"/>
   <result pre="Holmes F. A. et al. Randomized phase III trial of" exact="capecitabine" post="compared with bevacizumab plus capecitabine in patients with previously"/>
   <result pre="et al. Randomized phase III trial of capecitabine compared with" exact="bevacizumab" post="plus capecitabine in patients with previously treated metastatic breast"/>
   <result pre="Randomized phase III trial of capecitabine compared with bevacizumab plus" exact="capecitabine" post="in patients with previously treated metastatic breast cancer Journal"/>
   <result pre="Kerkela R. et al. Cardiotoxicity associated with tyrosine kinase inhibitor" exact="sunitinib" post="The Lancet 2007 370 9604 2011 2019 10.1016/s0140-6736(07)61865-0 83"/>
   <result pre="C. M. Tannir N. et al. Heart failure associated with" exact="sunitinib" post="malate: a multitargeted receptor tyrosine kinase inhibitor Cancer 2008"/>
   <result pre="A. Srinivas S. Cardiotoxicity associated with the cancer therapeutic agent" exact="sunitinib" post="malate Annals of Oncology 2008 19 9 1613 1618"/>
   <result pre="G. Autorino R. Bruni G. et al. Cardiovascular toxicity following" exact="sunitinib" post="therapy in metastatic renal cell carcinoma: a multicenter analysis"/>
   <result pre="in patients with renal and nonrenal cell carcinoma treated with" exact="sunitinib" post="Journal of Clinical Oncology 2011 29 25 3450 3456"/>
   <result pre="with clinical outcome in colorectal cancer patients treated with first-line" exact="bevacizumab" post="Annals of Oncology 2009 20 2 227 230 10.1093/annonc/mdn637"/>
   <result pre="Yacobi R. et al. Cardiotoxicity of the cancer therapeutic agent" exact="imatinib" post="mesylate Nature Medicine 2006 12 8 908 916 10.1038/nm1446"/>
   <result pre="Congestive heart failure is a rare event in patients receiving" exact="imatinib" post="therapy Blood 2007 110 4 1233 1237 10.1182/blood-2007-01-070144 17449798"/>
   <result pre="epidermal growth factor receptor II-positive breast cancer treated with adjuvant" exact="trastuzumab" post="therapy Journal of the American College of Cardiology 2011"/>
   <result pre="Doppler and strain rate imaging in the early detection of" exact="trastuzumab" post="and anthracycline mediated cardiomyopathy Journal of the American Society"/>
   <result pre="before conventional measures in patients undergoing breast cancer treatment with" exact="trastuzumab" post="American Heart Journal 2009 158 2 294 301 10.1016/j.ahj.2009.05.031"/>
   <result pre="of radionuclide angiography and antimyosin immunoscintigraphy for risk assessment in" exact="epirubicin" post="cardiotoxicity Journal of Nuclear Cardiology 1997 4 6 502"/>
   <result pre="Lub-De Hooge M. N. Gietema J. A. et al. Indium-111-labeled" exact="trastuzumab" post="scintigraphy in patients with human epidermal growth factor receptor"/>
   <result pre="in patients with breast cancer treated with doxorubicin, taxanes, and" exact="trastuzumab" post="Journal of the American College of Cardiology 2014 63"/>
   <result pre="Bosch X. Rovira M. Sitges M. et al. Enalapril and" exact="carvedilol" post="for preventing chemotherapy-induced left ventricular systolic dysfunction in patients"/>
   <result pre="OVERCOME trial (prevention of left Ventricular dysfunction with Enalapril and" exact="carvedilol" post="in patients submitted to intensive Chemotherapy for the treatment"/>
   <result pre="Acar Z. Kale A. Turgut M. et al. Efficiency of" exact="atorvastatin" post="in the protection of anthracycline-induced cardiomyopathy Journal of the"/>
   <result pre="N. Basar E. Ozdogru I. et al. Protective effects of" exact="carvedilol" post="against anthracycline-induced cardiomyopathy Journal of the American College of"/>
   <result pre="effects of β-adrenergic receptor subtypes in myocytes and fibroblasts in" exact="doxorubicin" post="cardiomyopathy Journal of Molecular and Cellular Cardiology 2006 40"/>
   <result pre="781 789 10.1016/j.yjmcc.2011.06.019 21756913 155 Fonarow G. C. Role of" exact="carvedilol" post="controlled-release in cardiovascular disease Expert Review of Cardiovascular Therapy"/>
   <result pre="Watanabe K. Veeraveedu P. T. et al. Protective effect of" exact="carvedilol" post="on daunorubicin-induced cardiotoxicity and nephrotoxicity in rats Toxicology 2010"/>
   <result pre="W. Watanabe K. Veeraveedu P. T. et al. Effect of" exact="telmisartan" post="in limiting the cardiotoxic effect of daunorubicin in rats"/>
   <result pre="al. Effect of telmisartan in limiting the cardiotoxic effect of" exact="daunorubicin" post="in rats Journal of Pharmacy and Pharmacology 2010 62"/>
   <result pre="II receptor blocker, olmesartan, in limiting the cardiotoxic effect of" exact="daunorubicin" post="in rats Free Radical Research 2010 44 11 1369"/>
   <result pre="Napoli C. Prominent cardioprotective effects of third generation beta blocker" exact="nebivolol" post="against anthracycline-induced cardiotoxicity using the model of isolated perfused"/>
   <result pre="Das A. Hyder H. Kukreja R. C. Phosphodiesterase-5 inhibition with" exact="sildenafil" post="attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a"/>
   <result pre="apoptosis and left ventricular dysfunction in a chronic model of" exact="doxorubicin" post="cardiotoxicity Circulation 2005 111 13 1601 1610 10.1161/01.cir.0000160359.49478.c2 15811867"/>
   <result pre="kinase-overexpression improves myocardial energetics, contractile dysfunction and survival in murine" exact="doxorubicin" post="cardiotoxicity PLoS ONE 2013 8 10 10.1371/journal.pone.0074675 169 Wang"/>
   <result pre="fission through targeting apoptosis repressor with caspase recruitment domain in" exact="doxorubicin" post="cardiotoxicity Cell Death and Disease 2015 6 3 10.1038/cddis.2015.41"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4648606/results/search/inn/results.xml">
   <result pre="human epidermal growth factor 2-positive metastatic breast cancer patients receiving" exact="trastuzumab" post="therapy: a multicenter retrospective study Wang Yunchao 1 Sun"/>
   <result pre="were classified into four groups according to HR/HER2 status and" exact="trastuzumab" post="treatment: HER2+/HR+ patients with first-line trastuzumab treatment, HER2+/HR+ patients"/>
   <result pre="to HR/HER2 status and trastuzumab treatment: HER2+/HR+ patients with first-line" exact="trastuzumab" post="treatment, HER2+/HR+ patients with no trastuzumab treatment, HER2+/HR− patients"/>
   <result pre="HER2+/HR+ patients with first-line trastuzumab treatment, HER2+/HR+ patients with no" exact="trastuzumab" post="treatment, HER2+/HR− patients with first-line trastuzumab treatment, and HER2+/HR−"/>
   <result pre="HER2+/HR+ patients with no trastuzumab treatment, HER2+/HR− patients with first-line" exact="trastuzumab" post="treatment, and HER2+/HR− patients with no trastuzumab treatment. Kaplan–Meier"/>
   <result pre="patients with first-line trastuzumab treatment, and HER2+/HR− patients with no" exact="trastuzumab" post="treatment. Kaplan–Meier analysis, log-rank test, and multivariate analysis were"/>
   <result pre="HER2+/HR− disease, significant survival benefit was observed when treated with" exact="trastuzumab" post="(30 vs 21 months, P=0.000). However, in patients with"/>
   <result pre="vs 21 months, P=0.000). However, in patients with HER2+/HR+ disease," exact="trastuzumab" post="administration had a survival improvement trend but no significant"/>
   <result pre="HR status was an independent predictor of overall survival and" exact="trastuzumab" post="treatment had significantly decreased risk of death in HER2+/HR−"/>
   <result pre="with HER2-negative breast cancer patients, and anti-HER2 agents such as" exact="trastuzumab" post="in combination with chemotherapy are often a preferred first-line"/>
   <result pre="6, 12 Hormone receptors such as estrogen receptor (ER) and" exact="progesterone" post="receptor (PR) also regulate breast tumor cell proliferation and"/>
   <result pre="intensity. 23, 24 Another study revealed that HER2 heterogeneity affected" exact="trastuzumab" post="responses and survival in patients with HER2-positive metastatic breast"/>
   <result pre="still limited data on the influence of HR status on" exact="trastuzumab" post="treatment benefits in HER2-positive MBC. In the current study,"/>
   <result pre="retrospectively investigated the relationship of HR and HER2 status with" exact="trastuzumab" post="treatment and its effect on outcomes of patients with"/>
   <result pre="to the Declaration of Helsinki. Therapeutic regimen The patients received" exact="trastuzumab" post="at a loading dose of 8 mg/kg of body"/>
   <result pre="visceral metastases), initial number of metastases (single vs multiple metastases)," exact="trastuzumab" post="treatment (with trastuzumab treatment vs without). Univariate and multivariate"/>
   <result pre="number of metastases (single vs multiple metastases), trastuzumab treatment (with" exact="trastuzumab" post="treatment vs without). Univariate and multivariate Cox regression analyses"/>
   <result pre="206 (69.8%) patients. Approximately half of the women (52.5%) received" exact="trastuzumab" post="therapy and the median cycle of first-line trastuzumab-based therapy"/>
   <result pre="of first-line trastuzumab-based therapy was 6 (range 2–15). Women receiving" exact="trastuzumab" post="therapy and not receiving trastuzumab therapy were comparable in"/>
   <result pre="6 (range 2–15). Women receiving trastuzumab therapy and not receiving" exact="trastuzumab" post="therapy were comparable in demographic and baseline characteristics ("/>
   <result pre="Figure 2A). HER2+/HR+ and HER2+/HR− women receiving or not receiving" exact="trastuzumab" post="therapy were comparable in demographic and baseline characteristics ("/>
   <result pre="( Table 2). Among patients with HER2+/HR− disease, patients receiving" exact="trastuzumab" post="therapy showed markedly longer OS (median 30 months; 95%"/>
   <result pre="(median 30 months; 95% CI: 25.557–34.443) than those not receiving" exact="trastuzumab" post="therapy (median 21 months; 95% CI: 13.904–28.096) ( P=0.000)"/>
   <result pre="P=0.000) ( Figure 2B). However, in patients with HER2+/HR+ disease," exact="trastuzumab" post="administration showed longer OS (median 36 months; 95% CI:"/>
   <result pre="(median 36 months; 95% CI: 28.176–43.824) than those not receiving" exact="trastuzumab" post="therapy (median 30 months; 95% CI: 23.333–36.667), the difference"/>
   <result pre="months (95% CI: 9.200–10.800) ( Figure 3A). The addition of" exact="trastuzumab" post="therapy in HER2+/HR− women resulted in significantly longer PFS"/>
   <result pre="longer PFS (median 11 months; 95% CI: 9.363–12.637 vs no" exact="trastuzumab" post="therapy: median 6 months; 95% CI: 4.524–7.476) ( P=0.000)"/>
   <result pre="difference in PFS was also observed between HER2+/HR+ women receiving" exact="trastuzumab" post="therapy (median 13 months; 95% CI: 8.676–17.324) and those"/>
   <result pre="(median 13 months; 95% CI: 8.676–17.324) and those not receiving" exact="trastuzumab" post="therapy (median 10 months; 95% CI: 8.585–11.415) ( P=0.001)"/>
   <result pre="HR status (hazard ratio: 0.591, 95% CI: 0.406–0.860, P=0.006) and" exact="trastuzumab" post="therapy (hazard ratio: 0.478, 95% CI: 0.336–0.679, P=0.000) were"/>
   <result pre="I–III (hazard ratio: 0.247, 95% CI: 0.107–0.574, P=0.001) but not" exact="trastuzumab" post="therapy (hazard ratio: 0.709, 95% CI: 0.436–1.154, P=0.166) were"/>
   <result pre="in death risks for HR-positive women ( Table 4). Meanwhile," exact="trastuzumab" post="therapy (adjusted hazard ratio: 0.330, 95% CI: 0.195–0.556, P=0.000)"/>
   <result pre="non-visceral metastasis (hazard ratio: 0.702, 95% CI: 0.538–0.916, P=0.009), and" exact="trastuzumab" post="therapy (hazard ratio: 0.463, 95% CI: 0.350–0.611, P=0.000) were"/>
   <result pre="predictors of PFS of MBC patients ( Table 5) and" exact="trastuzumab" post="therapy was associated with more significant reduction in recurrence"/>
   <result pre="data from a retrospective study showed that the combination of" exact="trastuzumab" post="and chemotherapy gained different clinical outcomes in HER2-positive breast"/>
   <result pre="that HR status as an independent predictor of pCR and" exact="trastuzumab" post="therapy resulted in a smaller benefit in recurrence-free survival"/>
   <result pre="from a study on HR status and the benefit of" exact="trastuzumab" post="among MBC patients showed that high expression of ER"/>
   <result pre="(≥30% of tumor cells) was associated with reduced responsiveness to" exact="trastuzumab" post="plus chemotherapy, and when endocrine therapy was added to"/>
   <result pre="breast cancer, data on the influence of HR status on" exact="trastuzumab" post="treatment benefits in advanced HER2-positive breast cancer are limited."/>
   <result pre="the impact of HR status on the clinical outcome of" exact="trastuzumab" post="therapy for Chinese MBC patients. Our data showed that"/>
   <result pre="trastuzumab therapy for Chinese MBC patients. Our data showed that" exact="trastuzumab" post="administration resulted in a markedly longer OS with a"/>
   <result pre="HER2+/HR− women compared with HER2+/HR− women who did not receive" exact="trastuzumab" post="therapy. This survival benefit, however, was not observed in"/>
   <result pre="statistically significant reduction in risk of death when treated with" exact="trastuzumab" post="(hazard ratio: 0.330, 95% CI: 0.195–0.556, P=0.000). In our"/>
   <result pre="suggest that HR status modulates HER2-positive MBC patient response to" exact="trastuzumab" post="and HR status may be used to stratify MBC"/>
   <result pre="HR status may be used to stratify MBC patients for" exact="trastuzumab" post="therapy. Our findings partially disagreed with the retrospective study"/>
   <result pre="in three clinical trials and found that the addition of" exact="trastuzumab" post="therapy to chemotherapy significantly improved prognosis of patients with"/>
   <result pre="in anti-HER2 agent resistance. Wang et al showed that, following" exact="trastuzumab" post="and lapatinib treatment, the ER activity upregulated or dynamically"/>
   <result pre="agent resistance. Wang et al showed that, following trastuzumab and" exact="lapatinib" post="treatment, the ER activity upregulated or dynamically transitioned and"/>
   <result pre="near future. These findings partly support the clinical benefits of" exact="trastuzumab" post="therapy in HER2+/HR− breast cancer patients and imply that"/>
   <result pre="primary tumor characteristics; less than 20% of the patients received" exact="trastuzumab" post="therapy guided by biopsy data on metastatic lesions. The"/>
   <result pre="the study design. For example, among HER2-positive patients who received" exact="trastuzumab" post="therapy, the duration of trastuzumab as a first-line treatment"/>
   <result pre="among HER2-positive patients who received trastuzumab therapy, the duration of" exact="trastuzumab" post="as a first-line treatment and continuation after progression varied"/>
   <result pre="percentage of the HER2-positive breast cancer patients do not receive" exact="trastuzumab" post="therapy because of drug availability and cost issues. From"/>
   <result pre="of patients who may benefit less from the current &quot;standard&quot;" exact="trastuzumab" post="and chemotherapy treatment than the rest of the patients."/>
   <result pre="independent predictor of OS of HER2-positive MBC patients and that" exact="trastuzumab" post="therapy significantly improves OS of HER2+/HR− patients. The predictive"/>
   <result pre="and cause stratification by HR status of MBC patients for" exact="trastuzumab" post="therapy, which helps to optimize cost effectiveness of trastuzumab-based"/>
   <result pre="Yuan Z Peng R et al. HER2-positive breast cancer receiving" exact="trastuzumab" post="treatment obtain prognosis comparable with that of HER2-negative breast"/>
   <result pre="9 Slamon D Eiermann W Robert N et al. Adjuvant" exact="trastuzumab" post="in HER2-positive breast cancer N Engl J Med 2011"/>
   <result pre="MJ et al. 2 Years versus 1 year of adjuvant" exact="trastuzumab" post="for HER2-positive breast cancer (HERA): an open-label, randomised controlled"/>
   <result pre="LK Chen B Correlation of HER-2 status with estrogen and" exact="progesterone" post="receptors and histologic features in 3,655 invasive breast carcinomas"/>
   <result pre="Gelber RD Jackisch C et al. Estimating the magnitude of" exact="trastuzumab" post="effects within patient subgroups in the HERA trial Ann"/>
   <result pre="HJ Seo AN Kim EJ et al. HER2 heterogeneity affects" exact="trastuzumab" post="responses and survival in patients with HER2-positive metastatic breast"/>
   <result pre="High HER2 expression correlates with response to the combination of" exact="lapatinib" post="and trastuzumab Clin Cancer Res 2014 21 3 569"/>
   <result pre="expression correlates with response to the combination of lapatinib and" exact="trastuzumab" post="Clin Cancer Res 2014 21 3 569 576 25467182"/>
   <result pre="DA et al. NCCN Task Force Report: estrogen receptor and" exact="progesterone" post="receptor testing in breast cancer by immunohistochemistry J Natl"/>
   <result pre="American Pathologists guideline recommendations for immunohistochemical testing of estrogen and" exact="progesterone" post="receptors in breast cancer J Oncol Pract 2010 6"/>
   <result pre="T Im YH et al. Efficacy and safety of neoadjuvant" exact="pertuzumab" post="and trastuzumab in women with locally advanced, inflammatory, or"/>
   <result pre="YH et al. Efficacy and safety of neoadjuvant pertuzumab and" exact="trastuzumab" post="in women with locally advanced, inflammatory, or early HER2-positive"/>
   <result pre="Baselga J Bradbury I Eidtmann H et al. Lapatinib with" exact="trastuzumab" post="for HER2-positive early breast cancer (NeoALTTO): survival outcomes of"/>
   <result pre="Untch M Loibl S Bischoff J et al. Lapatinib versus" exact="trastuzumab" post="in combination with neoadjuvant anthracyclinetaxane-based chemotherapy (GeparQuinto, GBG 44):"/>
   <result pre="AU Suman VJ Meric-Bernstam F et al. Fluorouracil, epirubicin, and" exact="cyclophosphamide" post="(FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus"/>
   <result pre="F et al. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by" exact="paclitaxel" post="plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75"/>
   <result pre="al. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus" exact="trastuzumab" post="versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab"/>
   <result pre="epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus" exact="paclitaxel" post="plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant"/>
   <result pre="cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus" exact="trastuzumab" post="followed by FEC-75 plus trastuzumab as neoadjuvant treatment for"/>
   <result pre="plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus" exact="trastuzumab" post="as neoadjuvant treatment for patients with HER2-positive breast cancer"/>
   <result pre="Forero A et al. Multicenter phase II study of neoadjuvant" exact="lapatinib" post="and trastuzumab with hormonal therapy and without chemotherapy in"/>
   <result pre="et al. Multicenter phase II study of neoadjuvant lapatinib and" exact="trastuzumab" post="with hormonal therapy and without chemotherapy in patients with"/>
   <result pre="V Cossu RM et al. Hormone-receptor expression and activity of" exact="trastuzumab" post="with chemotherapy in HER2-positive advanced breast cancer patients Cancer"/>
   <result pre="Hormone receptor status does not affect the clinical benefit of" exact="trastuzumab" post="therapy for patients with metastatic breast cancer Clin Breast"/>
   <result pre="G Gillihan R et al. Different mechanisms for resistance to" exact="trastuzumab" post="versus lapatinib in HER2-positive breast cancers – role of"/>
   <result pre="R et al. Different mechanisms for resistance to trastuzumab versus" exact="lapatinib" post="in HER2-positive breast cancers – role of estrogen receptor"/>
   <result pre="receptor 2-positive and hormone receptor-positive breast cancer patients treated with" exact="trastuzumab" post="containing neoadjuvant chemotherapy BMC Cancer 2013 13 241 23679233"/>
   <result pre="53 Tolaney SM Barry WT Dang CT et al. Adjuvant" exact="paclitaxel" post="and trastuzumab for node-negative, HER2-positive breast cancer N Engl"/>
   <result pre="SM Barry WT Dang CT et al. Adjuvant paclitaxel and" exact="trastuzumab" post="for node-negative, HER2-positive breast cancer N Engl J Med"/>
   <result pre="Figure 2 Median overall survival (OS) regarding HR status and" exact="trastuzumab" post="treatment. Notes: ( A) Survival curve for all patients;"/>
   <result pre="all patients; ( B) survival curves for HR-negative patients regarding" exact="trastuzumab" post="treatment; and ( C) survival curves for HR-positive patients"/>
   <result pre="treatment; and ( C) survival curves for HR-positive patients regarding" exact="trastuzumab" post="treatment. Abbreviations: HER2, human epidermal growth factor receptor 2;"/>
   <result pre="Figure 3 Median progression-free survival (PFS) regarding HR status and" exact="trastuzumab" post="treatment. Notes: ( A) Survival curve for all patients;"/>
   <result pre="all patients; ( B) survival curves for HR-negative patients regarding" exact="trastuzumab" post="treatment; and ( C) survival curves for HR-positive patients"/>
   <result pre="treatment; and ( C) survival curves for HR-positive patients regarding" exact="trastuzumab" post="treatment. Abbreviations: HER2, human epidermal growth factor receptor 2;"/>
   <result pre="of the study population Variables All patients Trastuzumab therapy No" exact="trastuzumab" post="therapy Patients, n (%) 295 (100.0) 155 (52.5) 140"/>
   <result pre="invasive ductal carcinoma; IHC, immunohistochemistry; ILC, invasive lobular carcinoma; PR," exact="progesterone" post="receptor; TNM, tumor-node-metastasis. Table 2 Demographic and baseline characteristics"/>
   <result pre="baseline characteristics of HR-positive and HR-negative MBC patients according to" exact="trastuzumab" post="therapy Variables HR+ P-value HR− P-value Trastuzumab therapy Trastuzumab"/>
   <result pre="(0.514–1.037) 0.079 Single vs multiple metastases 0.776 (0.541–1.115) 0.170 With" exact="trastuzumab" post="in first-line treatment vs without 0.478 (0.336–0.679) 0.000 *"/>
   <result pre="vs multiple metastases 0.609 (0.363–1.023) 0.061 1.080 (0.640–1.824) 0.773 With" exact="trastuzumab" post="therapy vs without 0.709 (0.436–1.154) 0.166 * 0.330 (0.195–0.556)"/>
   <result pre="(0.819–1.504) 0.502 Non-visceral vs visceral metastases 0.702 (0.538–0.916) 0.009 With" exact="trastuzumab" post="in first-line treatment vs without 0.463 (0.350–0.611) 0.000 *"/>
   <result pre="vs visceral metastases 0.735 (0.507–1.066) 0.105 0.610 (0.410–0.907) 0.015 With" exact="trastuzumab" post="therapy vs without 0.556 (0.381–0.810) 0.002 * 0.369 (0.245–0.557)"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4648969/results/search/inn/results.xml">
   <result pre=": Phase I Studies Phase I and pharmacological trial of" exact="lapatinib" post="in combination with gemcitabine in patients with advanced breast"/>
   <result pre="Phase I and pharmacological trial of lapatinib in combination with" exact="gemcitabine" post="in patients with advanced breast cancer van der Noll"/>
   <result pre="Lapatinib has proven efficacy as monotherapy and in combination with" exact="capecitabine" post="in patients with metastatic breast cancer (MBC) overexpressing HER2"/>
   <result pre="and a favourable toxicity profile. In this phase I study" exact="lapatinib" post="and gemcitabine were combined. Methods Female patients with advanced"/>
   <result pre="favourable toxicity profile. In this phase I study lapatinib and" exact="gemcitabine" post="were combined. Methods Female patients with advanced BC were"/>
   <result pre="were combined. Methods Female patients with advanced BC were given" exact="lapatinib" post="once daily (QD) in 28-day cycles with gemcitabine administered"/>
   <result pre="were given lapatinib once daily (QD) in 28-day cycles with" exact="gemcitabine" post="administered on day 1, 8 and 15. Physical examinations,"/>
   <result pre="respectively) and rash (46 %). The maximum tolerated dose was" exact="lapatinib" post="1250 mg QD with gemcitabine 1000 mg/m 2. Lapatinib"/>
   <result pre="The maximum tolerated dose was lapatinib 1250 mg QD with" exact="gemcitabine" post="1000 mg/m 2. Lapatinib and gemcitabine PK did not"/>
   <result pre="1250 mg QD with gemcitabine 1000 mg/m 2. Lapatinib and" exact="gemcitabine" post="PK did not appear to be influenced by each"/>
   <result pre="a slightly increased toxicity profile compared to their respective monotherapies," exact="lapatinib" post="and gemcitabine can be safely combined while showing signs"/>
   <result pre="increased toxicity profile compared to their respective monotherapies, lapatinib and" exact="gemcitabine" post="can be safely combined while showing signs of anti-tumor"/>
   <result pre="an attractive target for inhibition, leading to the development of" exact="trastuzumab" post="(Herceptin®) [ 5]. This humanized, monoclonal antibody against HER2/neu"/>
   <result pre="[ 7]. Unfortunately, the majority of the patients treated with" exact="trastuzumab" post="tend to develop resistance to this drug within 1"/>
   <result pre="Anti-tumor activity may be regained by switching the combination of" exact="trastuzumab" post="and chemotherapy into trastuzumab plus another cytotoxic agent. However,"/>
   <result pre="regained by switching the combination of trastuzumab and chemotherapy into" exact="trastuzumab" post="plus another cytotoxic agent. However, development of new therapeutic"/>
   <result pre="However, development of new therapeutic strategies is needed to overcome" exact="trastuzumab" post="resistance [ 8]. Lapatinib is a dual tyrosine kinase"/>
   <result pre="shown anti-tumor activity in patients that had previously progressed on" exact="trastuzumab" post="[ 13]. Adding lapatinib to a chemotherapy regimen has"/>
   <result pre="patients that had previously progressed on trastuzumab [ 13]. Adding" exact="lapatinib" post="to a chemotherapy regimen has proven to increase its"/>
   <result pre="activity, as evidenced by the FDA and EMA approval of" exact="lapatinib" post="in combination with capecitabine for previously treated, metastatic, HER2-overexpressing"/>
   <result pre="the FDA and EMA approval of lapatinib in combination with" exact="capecitabine" post="for previously treated, metastatic, HER2-overexpressing breast cancer [ 14,"/>
   <result pre="study only showed increased diarrhea and rash when compared to" exact="capecitabine" post="alone, as was expected [ 16]. These encouraging results"/>
   <result pre="[ 16]. These encouraging results warrant further research into combining" exact="lapatinib" post="with other cytotoxic agents. Gemcitabine is a prodrug, which"/>
   <result pre="resulting in cell death [ 17]. The first approval for" exact="gemcitabine" post="was as a treatment modality for pancreatic cancer ["/>
   <result pre="cancer [ 18– 20]. Due to its favourable toxicity profile," exact="gemcitabine" post="can be combined with other anti-cancer treatments, which for"/>
   <result pre="cell lung cancer (NSCLC) and bladder cancer in combination with" exact="cisplatin" post="[ 21, 22]. Since gemcitabine has shown activity in"/>
   <result pre="bladder cancer in combination with cisplatin [ 21, 22]. Since" exact="gemcitabine" post="has shown activity in patients with metastatic breast cancer"/>
   <result pre="24], this study intended to investigate whether a combination of" exact="lapatinib" post="and gemcitabine could be a feasible treatment option for"/>
   <result pre="study intended to investigate whether a combination of lapatinib and" exact="gemcitabine" post="could be a feasible treatment option for women with"/>
   <result pre="alanine aminotransferase (ALAT) ≤ 2.5 × ULN and creatinine ≤ 1.5 × ULN); previously treated with" exact="trastuzumab" post="(in case of HER2-overexpression); no other investigational drugs within"/>
   <result pre="classified as a CYP3A4 inducer or inhibitor was allowed, since" exact="lapatinib" post="is a CYP3A4 substrate. Patients with a clinically significant"/>
   <result pre="dose (MTD), dose-limiting toxicities (DLTs) and optimal treatment schedule of" exact="lapatinib" post="combined with gemcitabine. Secondary objectives were to explore the"/>
   <result pre="Pharmacokinetic and pharmacodynamic analysis Plasma samples for the bioanalysis of" exact="lapatinib" post="were collected at predose and 30 min, 1, 2,"/>
   <result pre="15 and 29 (cycle 2 day 1). Plasma concentrations of" exact="lapatinib" post="were measured using a validated liquid chromatography/tandem mass spectrometry"/>
   <result pre="liquid chromatography/tandem mass spectrometry method [ 26]. Blood samples for" exact="gemcitabine" post="were collected prior to, at the end of infusion"/>
   <result pre="4, 8 and 24 h after start of infusion. Plasma" exact="gemcitabine" post="(2′,2′-difluorodeoxycytidine, dFdC) and its metabolite 2′,2′-difluorodeoxyuridine, dFdU) concentrations were"/>
   <result pre="received prior hormonal therapy, 64 % were previously treated with" exact="trastuzumab" post="and 88 % had received prior radiotherapy. HER2-overexpression was"/>
   <result pre="start of the first cycle, leading to an interruption of" exact="lapatinib" post="dosing and omission of gemcitabine infusions. Two patients showed"/>
   <result pre="leading to an interruption of lapatinib dosing and omission of" exact="gemcitabine" post="infusions. Two patients showed progression of disease after this"/>
   <result pre="cycle 2 was administered, albeit with a dose reduction of" exact="gemcitabine" post="with 25 % and lapatinib with 250 mg. Additionally,"/>
   <result pre="with a dose reduction of gemcitabine with 25 % and" exact="lapatinib" post="with 250 mg. Additionally, one DLT of grade 3"/>
   <result pre="observed at the highest dose-level explored, despite maximal support with" exact="loperamide" post="and ciprofloxacin. Lapatinib was interrupted and gemcitabine omitted. This"/>
   <result pre="maximal support with loperamide and ciprofloxacin. Lapatinib was interrupted and" exact="gemcitabine" post="omitted. This patient was not re-started on treatment. Table"/>
   <result pre="DLT, the MTD was set at dose-level 4, consisting of" exact="lapatinib" post="1250 mg QD (day 1–28) and gemcitabine 1000 mg/m"/>
   <result pre="4, consisting of lapatinib 1250 mg QD (day 1–28) and" exact="gemcitabine" post="1000 mg/m 2 (day 1, 8 and 15). This"/>
   <result pre="(18 and 15 %, respectively) and diarrhea (9 %). Interrupting" exact="lapatinib" post="dosing and omitting gemcitabine infusion improved the observed toxicities"/>
   <result pre="respectively) and diarrhea (9 %). Interrupting lapatinib dosing and omitting" exact="gemcitabine" post="infusion improved the observed toxicities and led to recovery"/>
   <result pre="was initially treated with metoclopramide, however, in more severe cases" exact="granisetron" post="was required. Diarrhea sometimes required treatment with loperamide. Rash"/>
   <result pre="all cases and responded to local treatment, such as with" exact="metronidazole" post="crème or systemic anti-histaminic treatment, such as with levocetirizine."/>
   <result pre="LVEF values. Pharmacokinetics PK parameters and plasma concentration-time curves of" exact="lapatinib" post="and gemcitabine (dFdC and dFdU) and intracellular concentrations of"/>
   <result pre="Pharmacokinetics PK parameters and plasma concentration-time curves of lapatinib and" exact="gemcitabine" post="(dFdC and dFdU) and intracellular concentrations of dFdCTP are"/>
   <result pre="0.8 (0.6–2.0) 1.9 (0.7–2.1) 2.0 (2.0–2.1) NA Pharmacokinetic parameters of" exact="lapatinib" post="and gemcitabine (dFdC, dFdU and dFdCTP) per dose-level Fig."/>
   <result pre="1.9 (0.7–2.1) 2.0 (2.0–2.1) NA Pharmacokinetic parameters of lapatinib and" exact="gemcitabine" post="(dFdC, dFdU and dFdCTP) per dose-level Fig. 1 Plasma"/>
   <result pre="and dFdCTP) per dose-level Fig. 1 Plasma concentration-time curves of" exact="lapatinib" post="( a), dFdC ( b), dFdU ( c) and"/>
   <result pre="time ( d) Lapatinib Plasma samples for the PK of" exact="lapatinib" post="were collected and analyzed in 28 patients. The PK"/>
   <result pre="were collected and analyzed in 28 patients. The PK of" exact="lapatinib" post="showed high interpatient variability (see Fig. 1a). The median"/>
   <result pre="weeks. Discussion In this phase I study, the combination of" exact="lapatinib" post="with gemcitabine did not result in unexpected toxicities. The"/>
   <result pre="In this phase I study, the combination of lapatinib with" exact="gemcitabine" post="did not result in unexpected toxicities. The MTD of"/>
   <result pre="unexpected toxicities. The MTD of the combination was defined at" exact="lapatinib" post="1250 mg QD (day 1–28) with gemcitabine 1000 mg/m"/>
   <result pre="was defined at lapatinib 1250 mg QD (day 1–28) with" exact="gemcitabine" post="1000 mg/m 2 (day 1, 8 and 15). The"/>
   <result pre="TRAEs were in line with toxicities that are observed with" exact="gemcitabine" post="and lapatinib monotherapy. Both frequency and severity of TRAEs"/>
   <result pre="in line with toxicities that are observed with gemcitabine and" exact="lapatinib" post="monotherapy. Both frequency and severity of TRAEs increased with"/>
   <result pre="patient who experienced grade 3 diarrhea despite maximal support with" exact="loperamide" post="and ciprofloxacin. This patient showed the highest exposure to"/>
   <result pre="loperamide and ciprofloxacin. This patient showed the highest exposure to" exact="lapatinib" post="out of all patients on study, which could explain"/>
   <result pre="diarrhea and rash (42 and 31 %, respectively, in the" exact="lapatinib" post="monotherapy phase I study) [ 10], were also observed"/>
   <result pre="combination (39, 55 and 52 %, respectively) when compared to" exact="gemcitabine" post="monotherapy (26, 39 and 31 %, respectively) [ 18]."/>
   <result pre="either of these agents alone. This resulted in a lower" exact="lapatinib" post="dose in the MTD of this study (1250 mg)"/>
   <result pre="recommended monotherapy dose of 1000 mg/m 2. The PK of" exact="lapatinib" post="showed high interpatient variability. The dose-normalized C max did"/>
   <result pre="between the different dose-levels. However, no sampling was done for" exact="lapatinib" post="alone thus no direct treatment comparisons could be made."/>
   <result pre="it difficult to draw definitive conclusions about the influence of" exact="gemcitabine" post="on lapatinib PK. Less variation was seen in the"/>
   <result pre="to draw definitive conclusions about the influence of gemcitabine on" exact="lapatinib" post="PK. Less variation was seen in the PK of"/>
   <result pre="lapatinib PK. Less variation was seen in the PK of" exact="gemcitabine" post="(dFdC) and its metabolite dFdU. For both dFdC and"/>
   <result pre="both dFdC and dFdU, PK appeared to be similar to" exact="gemcitabine" post="monotherapy [ 30], suggesting that co-administration of lapatinib did"/>
   <result pre="similar to gemcitabine monotherapy [ 30], suggesting that co-administration of" exact="lapatinib" post="did not influence gemcitabine PK. The measurement of dFdCTP"/>
   <result pre="[ 30], suggesting that co-administration of lapatinib did not influence" exact="gemcitabine" post="PK. The measurement of dFdCTP was performed in about"/>
   <result pre="were similar to those in literature with similar doses of" exact="gemcitabine" post="[ 31]. Although not the primary objective of this"/>
   <result pre="study HER2-expression was not an inclusion criterium. The combination of" exact="lapatinib" post="with gemcitabine (and oxaliplatin) has been investigated clinically before"/>
   <result pre="was not an inclusion criterium. The combination of lapatinib with" exact="gemcitabine" post="(and oxaliplatin) has been investigated clinically before in patients"/>
   <result pre="a phase I study in this population the MTD of" exact="lapatinib" post="with gemcitabine was set at 1500 mg and 1000"/>
   <result pre="I study in this population the MTD of lapatinib with" exact="gemcitabine" post="was set at 1500 mg and 1000 mg/m 2"/>
   <result pre="this patient population [ 33]. In a recent preclinical study" exact="lapatinib" post="was tested in combination with gemcitabine to investigate whether"/>
   <result pre="a recent preclinical study lapatinib was tested in combination with" exact="gemcitabine" post="to investigate whether these drugs showed synergistic or antagonistic"/>
   <result pre="no clear effect observed and thus the authors concluded that" exact="lapatinib" post="may not enhance the anti-tumor effects of gemcitabine in"/>
   <result pre="concluded that lapatinib may not enhance the anti-tumor effects of" exact="gemcitabine" post="in pancreatic cancer [ 34]. In contrast and consistent"/>
   <result pre="In contrast and consistent with our study, encouraging evidence of" exact="lapatinib" post="in combination with gemcitabine was demonstrated in a case"/>
   <result pre="with our study, encouraging evidence of lapatinib in combination with" exact="gemcitabine" post="was demonstrated in a case report of a female"/>
   <result pre="combination (lapatinib 1250 mg, later reduced to 1000 mg and" exact="gemcitabine" post="1000 mg/m 2) [ 35]. Overall, despite a slight"/>
   <result pre="in toxicity profile compared to their monotherapies, the combination of" exact="lapatinib" post="with gemcitabine appears to be a safe treatment regimen"/>
   <result pre="profile compared to their monotherapies, the combination of lapatinib with" exact="gemcitabine" post="appears to be a safe treatment regimen for patients"/>
   <result pre="the anti-tumor activity is comparable to the lapatinib/capecitabine combination, the" exact="lapatinib" post="combination with gemcitabine could be a new treatment modality"/>
   <result pre="is comparable to the lapatinib/capecitabine combination, the lapatinib combination with" exact="gemcitabine" post="could be a new treatment modality for these patients"/>
   <result pre="N Pienkowski T Martin M Press M et al. Adjuvant" exact="trastuzumab" post="in HER2-positive breast cancer N Engl J Med 2011"/>
   <result pre="8. Nahta R Esteva FJ HER2 therapy: molecular mechanisms of" exact="trastuzumab" post="resistance Breast Cancer Res 2006 8 215 10.1186/bcr1612 17096862"/>
   <result pre="al. Phase I safety, pharmacokinetics, and clinical activity study of" exact="lapatinib" post="(GW572016), a reversible dual inhibitor of epidermal growth factor"/>
   <result pre="S Rubin S et al. A phase II study of" exact="lapatinib" post="monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic"/>
   <result pre="E Schwartzberg LS Arbushites MC Maltzman JD et al. Single-agent" exact="lapatinib" post="for HER2-overexpressing advanced or metastatic breast cancer that progressed"/>
   <result pre="Ko C Sridhara R et al. FDA drug approval summary:" exact="lapatinib" post="in combination with capecitabine for previously treated metastatic breast"/>
   <result pre="et al. FDA drug approval summary: lapatinib in combination with" exact="capecitabine" post="for previously treated metastatic breast cancer that overexpresses HER-2"/>
   <result pre="Chan S Romieu CG Pienkowski T et al. Lapatinib plus" exact="capecitabine" post="for HER2-positive advanced breast cancer N Engl J Med"/>
   <result pre="MR et al. Improvements in survival and clinical benefit with" exact="gemcitabine" post="as first-line therapy for patients with advanced pancreas cancer:"/>
   <result pre="et al. Long-term survival results of a randomized trial comparing" exact="gemcitabine" post="plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in"/>
   <result pre="trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus" exact="cisplatin" post="in patients with bladder cancer J Clin Oncol 2005"/>
   <result pre="R Tomek S Vaclavik I Herscovici V et al. Single-agent" exact="gemcitabine" post="as second- and third-line treatment in metastatic breast cancer"/>
   <result pre="for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib," exact="sorafenib" post="and sunitinib in human plasma by liquid chromatography coupled"/>
   <result pre="quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and" exact="sunitinib" post="in human plasma by liquid chromatography coupled with tandem"/>
   <result pre="D Visseren-Grul CM Rosing H et al. Oral administration of" exact="gemcitabine" post="in patients with refractory tumors: a clinical and pharmacologic"/>
   <result pre="RS Wickremsinhe ER Perkins EJ et al. Quantitative analysis of" exact="gemcitabine" post="triphosphate in human peripheral blood mononuclear cells using weak"/>
   <result pre="A phase I clinical, plasma, and cellular pharmacology study of" exact="gemcitabine" post="J Clin Oncol 1991 9 491 498 1999720 31."/>
   <result pre="Whiting S Lopez CD Sun W et al. Lapatinib and" exact="gemcitabine" post="for metastatic pancreatic cancer Am J Clin Oncol 2011"/>
   <result pre="Kimura K Amano R et al. In vitro effects of" exact="lapatinib" post="with gemcitabine for pancreatic cancer cells Hepatogastroenterology 2013 60"/>
   <result pre="Amano R et al. In vitro effects of lapatinib with" exact="gemcitabine" post="for pancreatic cancer cells Hepatogastroenterology 2013 60 1484 1487"/>
   <result pre="a metastatic breast cancer patient treated with a combination of" exact="lapatinib" post="and gemcitabine Curr Oncol 2010 17 64 68 10.3747/co.v17i2.422"/>
   <result pre="breast cancer patient treated with a combination of lapatinib and" exact="gemcitabine" post="Curr Oncol 2010 17 64 68 10.3747/co.v17i2.422 20404981"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4650737/results/search/inn/results.xml">
   <result pre="J, Ejlertsen B, Kaufmann M, Boyle F et al. Adjuvant" exact="lapatinib" post="for women with early-stage HER2-positive breast cancer: a randomised,"/>
   <result pre="Rahmeh M et al. Activity of the dual kinase inhibitor" exact="lapatinib" post="(GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells ."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4650834/results/search/inn/results.xml">
   <result pre="al. (Lancet Oncol 14:461–71, 2013), with triple combination of pertuzumab," exact="trastuzumab" post="and docetaxel. Seven RCTs evaluated the OS of HER2-targeting"/>
   <result pre="Med 367:1783–91, 2012)). In the third-line setting, the association of" exact="lapatinib" post="and trastuzumab has demonstrated to improve OS to 4.5"/>
   <result pre="2012)). In the third-line setting, the association of lapatinib and" exact="trastuzumab" post="has demonstrated to improve OS to 4.5 months compared"/>
   <result pre="has demonstrated to improve OS to 4.5 months compared with" exact="lapatinib" post="alone (14 months vs. 9.5 months; Blackwell et al."/>
   <result pre="of patients with HER2+ mBC. The triple combination of docetaxel," exact="pertuzumab" post="and trastuzumab is associated with a survival extent of"/>
   <result pre="with HER2+ mBC. The triple combination of docetaxel, pertuzumab and" exact="trastuzumab" post="is associated with a survival extent of more than"/>
   <result pre="PFS T2 HR (95 % CI), p value Chemotherapy ± trastuzumab or" exact="lapatinib" post="Slamon 2001 Slamon et al. [ 1] 2001 Women"/>
   <result pre="mg/kg then 2 mg/kg every week until PD followed by" exact="trastuzumab" post="loading dose 4 mg/kg then 2 mg/kg every week + docetaxel"/>
   <result pre="of hormonal treatment for patients with hormone receptor–positive disease; prior" exact="trastuzumab" post="and/or taxane as neoadjuvant or adjuvant therapy were permitted"/>
   <result pre="days 1, 8, and 15 of a 28-day schedule or" exact="docetaxel" post="75 mg/m2 once every 3 weeks) for 24 weeks"/>
   <result pre="mg/m2 once every 3 weeks) for 24 weeks followed by" exact="lapatinib" post="(1,500 mg/d) until PD Trastuzumab + taxane (once per week [4"/>
   <result pre="maintenance] + docetaxel once every 3 weeks) for 24 weeks followed by" exact="trastuzumab" post="(6 mg/kg once every 3 weeks) until PD PFS"/>
   <result pre="p = 0.11 9.0 11.3 1.37 (1.13, 1.65), p &amp;lt; 0.001 Hormone therapy ± trastuzumab or" exact="lapatinib" post="TAnDEM Kaufman et al. [ 18] 2009 Postmenopausal women"/>
   <result pre="advanced or metastatic disease was allowed Lapatinib 1500 mg and" exact="letrozole" post="2.5 mg daily until PD Letrozole 2.5 mg daily"/>
   <result pre="mg daily until PD Letrozole 2.5 mg daily with matching" exact="lapatinib" post="placebo pill until PD PFS 111 108 33.3 32.3"/>
   <result pre="Carboplatin AUC = 6 + paclitaxel 175 mg/m2 every 3 weeks for six cycles" exact="trastuzumab" post="4 mg/kg loading dose, then 2 mg/kg weekly until"/>
   <result pre="if they had received prior platinum salt therapy, chemotherapy, or" exact="trastuzumab" post="for mBC Carboplatin AUC = 6 every 3 weeks for eight"/>
   <result pre="1.03), p = 0.083 16.1 14.5 0.84 (0.65, 1.08), p = 0.174 Chemotherapy + trastuzumab and" exact="pertuzumab" post="CLEOPATRA study Baselga et al. [ 13]; Swain et"/>
   <result pre="overall survival, PD progression of disease, PFS progression-free survival, PgR" exact="progesterone" post="receptor, RECIST Response Evaluation Criteria In Solid Tumors, T1"/>
   <result pre="not provided. OS overall survival, PFS progression-free survival Chemotherapy ± trastuzumab or" exact="lapatinib" post="The first RCT assessing a therapy against HER2 for"/>
   <result pre="HER2 evaluated the efficacy and safety of standard chemotherapy plus" exact="trastuzumab" post="versus standard chemotherapy alone (Slamon et al. [ 1])."/>
   <result pre="et al. [ 1]). In this study, the addition of" exact="trastuzumab" post="to chemotherapy was associated with longer OS (25.1 vs."/>
   <result pre="Inoue and colleagues evaluated the efficacy of sequential therapy with" exact="trastuzumab" post="monotherapy followed by trastuzumab plus docetaxel after disease progression"/>
   <result pre="the efficacy of sequential therapy with trastuzumab monotherapy followed by" exact="trastuzumab" post="plus docetaxel after disease progression versus upfront combination therapy"/>
   <result pre="of sequential therapy with trastuzumab monotherapy followed by trastuzumab plus" exact="docetaxel" post="after disease progression versus upfront combination therapy with trastuzumab"/>
   <result pre="plus docetaxel after disease progression versus upfront combination therapy with" exact="trastuzumab" post="and docetaxel as first-line therapy in patients with HER2+"/>
   <result pre="after disease progression versus upfront combination therapy with trastuzumab and" exact="docetaxel" post="as first-line therapy in patients with HER2+ metastatic BC."/>
   <result pre="BC. OS and PFS were significantly longer in the upfront" exact="trastuzumab" post="and docetaxel group (median values not reported for OS,"/>
   <result pre="and PFS were significantly longer in the upfront trastuzumab and" exact="docetaxel" post="group (median values not reported for OS, p = 0.04; median"/>
   <result pre="[ 16]). A trial evaluating the efficacy and safety of" exact="lapatinib" post="plus paclitaxel compared to placebo plus paclitaxel in patients"/>
   <result pre="A trial evaluating the efficacy and safety of lapatinib plus" exact="paclitaxel" post="compared to placebo plus paclitaxel in patients with newly"/>
   <result pre="and safety of lapatinib plus paclitaxel compared to placebo plus" exact="paclitaxel" post="in patients with newly diagnosed HER2+ metastatic BC showed"/>
   <result pre="newly diagnosed HER2+ metastatic BC showed that the addition of" exact="lapatinib" post="to paclitaxel significantly improved OS and PFS versus paclitaxel"/>
   <result pre="HER2+ metastatic BC showed that the addition of lapatinib to" exact="paclitaxel" post="significantly improved OS and PFS versus paclitaxel (27.8 vs."/>
   <result pre="of lapatinib to paclitaxel significantly improved OS and PFS versus" exact="paclitaxel" post="(27.8 vs. 20.5 months, p = 0.0124; 9.7 vs. 6.5 months,"/>
   <result pre="Chemotherapy + lapatinib versus chemotherapy + trastuzumab The MA.31 trial assessed the efficacy of" exact="lapatinib" post="versus trastuzumab combined with taxanes as first-line treatments for"/>
   <result pre="chemotherapy + trastuzumab The MA.31 trial assessed the efficacy of lapatinib versus" exact="trastuzumab" post="combined with taxanes as first-line treatments for HER2+ metastatic"/>
   <result pre="OS was not observed. Median PFS was 9.0 months with" exact="lapatinib" post="and 11.3 months with trastuzumab ( p = 0.001) (Gelmon et"/>
   <result pre="PFS was 9.0 months with lapatinib and 11.3 months with" exact="trastuzumab" post="( p = 0.001) (Gelmon et al. [ 31]). Hormone therapy ± trastuzumab"/>
   <result pre="( p = 0.001) (Gelmon et al. [ 31]). Hormone therapy ± trastuzumab or" exact="lapatinib" post="The TAnDEM study was the first phase III RCT"/>
   <result pre="the first phase III RCT combining a hormonal agent and" exact="trastuzumab" post="without chemotherapy as treatment for HER2/hormone receptor–copositive metastatic BC"/>
   <result pre="et al. [ 18]). Postmenopausal women were randomly assigned to" exact="anastrozole" post="with or without trastuzumab until progression; those receiving the"/>
   <result pre="Postmenopausal women were randomly assigned to anastrozole with or without" exact="trastuzumab" post="until progression; those receiving the monoclonal antibody in addition"/>
   <result pre="until progression; those receiving the monoclonal antibody in addition to" exact="anastrozole" post="experienced a non-statistically significant improvement in OS (28.5 vs."/>
   <result pre="factor receptor and the HER2 receptor, to the aromatase inhibitor" exact="letrozole" post="in women with hormone receptor-positive metastatic BC (Johnston et"/>
   <result pre="of 33.3 months and 8.2 months, respectively, in patients receiving" exact="lapatinib" post="plus letrozole and 32.3 months and 3.0 months, respectively,"/>
   <result pre="months and 8.2 months, respectively, in patients receiving lapatinib plus" exact="letrozole" post="and 32.3 months and 3.0 months, respectively, in patients"/>
   <result pre="and 32.3 months and 3.0 months, respectively, in patients receiving" exact="letrozole" post="( p = 0.113 and p = 0.019, respectively) (Johnston et al. ["/>
   <result pre="evaluating the clinical benefit and safety of the addition of" exact="carboplatin" post="to trastuzumab and paclitaxel versus trastuzumab and paclitaxel alone,"/>
   <result pre="clinical benefit and safety of the addition of carboplatin to" exact="trastuzumab" post="and paclitaxel versus trastuzumab and paclitaxel alone, reported no"/>
   <result pre="and safety of the addition of carboplatin to trastuzumab and" exact="paclitaxel" post="versus trastuzumab and paclitaxel alone, reported no difference in"/>
   <result pre="of the addition of carboplatin to trastuzumab and paclitaxel versus" exact="trastuzumab" post="and paclitaxel alone, reported no difference in OS (35.7"/>
   <result pre="addition of carboplatin to trastuzumab and paclitaxel versus trastuzumab and" exact="paclitaxel" post="alone, reported no difference in OS (35.7 vs. 32.2"/>
   <result pre="PFS (10.7 vs. 7.1 months, p = 0.03) with the inclusion of" exact="carboplatin" post="(Robert et al. [ 19]). The HERNATA study was"/>
   <result pre="al. [ 19]). The HERNATA study was designed to compare" exact="docetaxel" post="with vinorelbine, both associated with trastuzumab, as first-line therapy"/>
   <result pre="were of 38.8 months and 15.3 months, respectively, in the" exact="vinorelbine" post="plus trastuzumab group and 35.7 months and 12.4 months,"/>
   <result pre="38.8 months and 15.3 months, respectively, in the vinorelbine plus" exact="trastuzumab" post="group and 35.7 months and 12.4 months, respectively, in"/>
   <result pre="group and 35.7 months and 12.4 months, respectively, in the" exact="docetaxel" post="plus trastuzumab group ( p = 0.98 and p = 0.67) (Andersson et"/>
   <result pre="35.7 months and 12.4 months, respectively, in the docetaxel plus" exact="trastuzumab" post="group ( p = 0.98 and p = 0.67) (Andersson et al. ["/>
   <result pre="In the BCIRG 007 study, patients were randomly assigned to" exact="trastuzumab" post="plus docetaxel or trastuzumab plus carboplatin and docetaxel, but"/>
   <result pre="BCIRG 007 study, patients were randomly assigned to trastuzumab plus" exact="docetaxel" post="or trastuzumab plus carboplatin and docetaxel, but no statistically"/>
   <result pre="study, patients were randomly assigned to trastuzumab plus docetaxel or" exact="trastuzumab" post="plus carboplatin and docetaxel, but no statistically significant differences"/>
   <result pre="were randomly assigned to trastuzumab plus docetaxel or trastuzumab plus" exact="carboplatin" post="and docetaxel, but no statistically significant differences were found"/>
   <result pre="p = 0.57) (Valero et al. [ 22]). Since the addition of" exact="trastuzumab" post="to anthracyclines resulted in high incidence of cardiac toxicity"/>
   <result pre="Baselga and colleagues conducted a trial of first-line nonpegylated liposomal" exact="doxorubicin" post="plus trastuzumab and paclitaxel versus trastuzumab and paclitaxel alone"/>
   <result pre="colleagues conducted a trial of first-line nonpegylated liposomal doxorubicin plus" exact="trastuzumab" post="and paclitaxel versus trastuzumab and paclitaxel alone in patients"/>
   <result pre="a trial of first-line nonpegylated liposomal doxorubicin plus trastuzumab and" exact="paclitaxel" post="versus trastuzumab and paclitaxel alone in patients with HER2+"/>
   <result pre="of first-line nonpegylated liposomal doxorubicin plus trastuzumab and paclitaxel versus" exact="trastuzumab" post="and paclitaxel alone in patients with HER2+ metastatic BC"/>
   <result pre="nonpegylated liposomal doxorubicin plus trastuzumab and paclitaxel versus trastuzumab and" exact="paclitaxel" post="alone in patients with HER2+ metastatic BC (Slamon et"/>
   <result pre="a significant clinical improvement with the addition of nonpegylated liposomal" exact="doxorubicin" post="to the trastuzumab and paclitaxel regimen (Baselga et al."/>
   <result pre="improvement with the addition of nonpegylated liposomal doxorubicin to the" exact="trastuzumab" post="and paclitaxel regimen (Baselga et al. [ 14]). Chemotherapy + trastuzumab"/>
   <result pre="the addition of nonpegylated liposomal doxorubicin to the trastuzumab and" exact="paclitaxel" post="regimen (Baselga et al. [ 14]). Chemotherapy + trastuzumab and pertuzumab"/>
   <result pre="and paclitaxel regimen (Baselga et al. [ 14]). Chemotherapy + trastuzumab and" exact="pertuzumab" post="In the CLEOPATRA study, patients with HER2+ metastatic BC"/>
   <result pre="biological treatment for their metastatic disease were assigned to receive" exact="pertuzumab" post="plus trastuzumab and docetaxel or placebo plus trastuzumab and"/>
   <result pre="for their metastatic disease were assigned to receive pertuzumab plus" exact="trastuzumab" post="and docetaxel or placebo plus trastuzumab and docetaxel (Swain"/>
   <result pre="metastatic disease were assigned to receive pertuzumab plus trastuzumab and" exact="docetaxel" post="or placebo plus trastuzumab and docetaxel (Swain et al."/>
   <result pre="to receive pertuzumab plus trastuzumab and docetaxel or placebo plus" exact="trastuzumab" post="and docetaxel (Swain et al. [ 21]). Median OS"/>
   <result pre="pertuzumab plus trastuzumab and docetaxel or placebo plus trastuzumab and" exact="docetaxel" post="(Swain et al. [ 21]). Median OS in the"/>
   <result pre="docetaxel (Swain et al. [ 21]). Median OS in the" exact="pertuzumab" post="group was estimated to be 56.5 months, compared to"/>
   <result pre="the placebo ( p &amp;lt; 0.001); the PFS was 18.7 in the" exact="pertuzumab" post="group versus 12.4 months in the placebo group ("/>
   <result pre="curative intent or metastatic BC who had not received previous" exact="trastuzumab" post="or chemotherapy for the advanced stage of the disease"/>
   <result pre="et al. [ 32]). Patients were randomly assigned to daily" exact="everolimus" post="or placebo plus weekly trastuzumab and paclitaxel. OS analyses"/>
   <result pre="were randomly assigned to daily everolimus or placebo plus weekly" exact="trastuzumab" post="and paclitaxel. OS analyses are still in progress. The"/>
   <result pre="still in progress. The median PFS was 14.95 months with" exact="everolimus" post="and 14.49 months with placebo ( p = 0.1166) in the"/>
   <result pre="placebo ( p = 0.1166) in the full population; 20.27 months with" exact="everolimus" post="and 13.08 with placebo in the hormone receptor-negative population"/>
   <result pre="PFS T2 HR (95 % CI), p value Chemotherapy ± trastuzumab or" exact="lapatinib" post="Geyer 2006 Geyer et al. [ 26]; Cameron et"/>
   <result pre="treated with a minimum of an anthracycline, a taxane and" exact="trastuzumab" post="Lapatinib 1250 mg daily + capecitabine at a dose of 2000"/>
   <result pre="prior anthracycline and/or taxanes for (neo)adjuvant or metastatic disease. Prior" exact="trastuzumab" post="was allowed but not required Trastuzumab infusion of 6"/>
   <result pre="a loading dose of 8 mg/kg on day 1) and" exact="capecitabine" post="2500 mg/m2 per day on days 1 through 14,"/>
   <result pre="14, every 21 days Lapatinib 1250 mg once daily and" exact="capecitabine" post="2000 mg/m2 per day on days 1 through 14,"/>
   <result pre="trastuzumab-containing regimens Lapatinib 1000 mg daily in combination with intravenous" exact="trastuzumab" post="2 mg/kg weekly (after the initial 4 mg/kg loading"/>
   <result pre="[ 4] 2012 HER2-positive advanced breast cancer previously treated with" exact="trastuzumab" post="and a taxane T-DM1 3.6 mg/kg every 3 weeks"/>
   <result pre="two or more HER2-directed regimens in the advanced setting, including" exact="trastuzumab" post="and lapatinib, and previous taxane therapy in any setting"/>
   <result pre="advanced breast carcinoma who had previously received taxane therapy Daily" exact="everolimus" post="(5 mg/day) plus weekly trastuzumab (2 mg/kg) and vinorelbine"/>
   <result pre="previously received taxane therapy Daily everolimus (5 mg/day) plus weekly" exact="trastuzumab" post="(2 mg/kg) and vinorelbine (25 mg/m(2)) Placebo plus trastuzumab"/>
   <result pre="Daily everolimus (5 mg/day) plus weekly trastuzumab (2 mg/kg) and" exact="vinorelbine" post="(25 mg/m(2)) Placebo plus trastuzumab plus vinorelbine, in 3-week"/>
   <result pre="weekly trastuzumab (2 mg/kg) and vinorelbine (25 mg/m(2)) Placebo plus" exact="trastuzumab" post="plus vinorelbine, in 3-week cycles PFS 284 285 NA"/>
   <result pre="PFS progression-free survival, T1 treatment 1, T2 treatment 2, T-DM1" exact="trastuzumab" post="emtansine, TTP time to progression aCEREBEL was included in"/>
   <result pre="be noted that nearly 43 % of patients in the" exact="lapatinib" post="plus capecitabine arm (117 of 271 patients) and 45"/>
   <result pre="that nearly 43 % of patients in the lapatinib plus" exact="capecitabine" post="arm (117 of 271 patients) and 45 % of"/>
   <result pre="of 271 patients) and 45 % of patients in the" exact="trastuzumab" post="plus capecitabine arm (121 of 269 patients) had not"/>
   <result pre="patients) and 45 % of patients in the trastuzumab plus" exact="capecitabine" post="arm (121 of 269 patients) had not received prior"/>
   <result pre="03–05 study. OS overall survival, PFS progression-free survival Chemotherapy ± trastuzumab or" exact="lapatinib" post="The study by Geyer et al. [ 26], which"/>
   <result pre="progressed after trastuzumab-based therapy, who were randomly assigned to receive" exact="lapatinib" post="plus capecitabine or capecitabine alone, did not report results"/>
   <result pre="trastuzumab-based therapy, who were randomly assigned to receive lapatinib plus" exact="capecitabine" post="or capecitabine alone, did not report results on OS"/>
   <result pre="who were randomly assigned to receive lapatinib plus capecitabine or" exact="capecitabine" post="alone, did not report results on OS (Geyer et"/>
   <result pre="showed that the OS was 15.6 months in patients receiving" exact="lapatinib" post="plus capecitabine and 15.3 months in the capecitabine alone"/>
   <result pre="the OS was 15.6 months in patients receiving lapatinib plus" exact="capecitabine" post="and 15.3 months in the capecitabine alone group ("/>
   <result pre="patients receiving lapatinib plus capecitabine and 15.3 months in the" exact="capecitabine" post="alone group ( p = 0.177) (Cameron et al. [ 3]);"/>
   <result pre="a statistically significant improvement of PFS in patients that received" exact="capecitabine" post="with continuation of trastuzumab compared with those that received"/>
   <result pre="of PFS in patients that received capecitabine with continuation of" exact="trastuzumab" post="compared with those that received capecitabine alone (24.9 vs."/>
   <result pre="capecitabine with continuation of trastuzumab compared with those that received" exact="capecitabine" post="alone (24.9 vs. 20.6 months, p = 0.73; 8.2 vs. 5.6"/>
   <result pre="trial changed an oncology paradigm since it showed that continuing" exact="trastuzumab" post="beyond progression (associated with a different anticancer agent) was"/>
   <result pre="without central nervous system metastases were randomly assigned to receive" exact="lapatinib" post="plus capecitabine or trastuzumab plus capecitabine in the CEREBEL"/>
   <result pre="nervous system metastases were randomly assigned to receive lapatinib plus" exact="capecitabine" post="or trastuzumab plus capecitabine in the CEREBEL trial (Pivot"/>
   <result pre="metastases were randomly assigned to receive lapatinib plus capecitabine or" exact="trastuzumab" post="plus capecitabine in the CEREBEL trial (Pivot et al."/>
   <result pre="randomly assigned to receive lapatinib plus capecitabine or trastuzumab plus" exact="capecitabine" post="in the CEREBEL trial (Pivot et al. [ 28])."/>
   <result pre="metastatic disease. Nevertheless, approximately 43 % of patients in the" exact="lapatinib" post="plus capecitabine arm and 45 % of patients in"/>
   <result pre="Nevertheless, approximately 43 % of patients in the lapatinib plus" exact="capecitabine" post="arm and 45 % of patients in the trastuzumab"/>
   <result pre="plus capecitabine arm and 45 % of patients in the" exact="trastuzumab" post="plus capecitabine arm had not received prior treatment for"/>
   <result pre="arm and 45 % of patients in the trastuzumab plus" exact="capecitabine" post="arm had not received prior treatment for the metastatic"/>
   <result pre="disease (Pivot et al. [ 28]). PFS was longer with" exact="trastuzumab" post="plus capecitabine (8.1 vs. 6.6 months, p = 0.021), with no"/>
   <result pre="et al. [ 28]). PFS was longer with trastuzumab plus" exact="capecitabine" post="(8.1 vs. 6.6 months, p = 0.021), with no differences in"/>
   <result pre="22.7 months, p = 0.095) (Pivot et al. [ 28]). Lapatinib + trastuzumab or" exact="lapatinib" post="monotherapy In the EGF104900 study, patients with heavily pretreated"/>
   <result pre="heavily pretreated HER2+ metastatic BC were randomly assigned to receive" exact="lapatinib" post="plus trastuzumab or lapatinib monotherapy as a third-line anti-HER"/>
   <result pre="HER2+ metastatic BC were randomly assigned to receive lapatinib plus" exact="trastuzumab" post="or lapatinib monotherapy as a third-line anti-HER treatment (Blackwell"/>
   <result pre="BC were randomly assigned to receive lapatinib plus trastuzumab or" exact="lapatinib" post="monotherapy as a third-line anti-HER treatment (Blackwell et al."/>
   <result pre="a third-line anti-HER treatment (Blackwell et al. [ 5]). Combination" exact="lapatinib" post="plus trastuzumab significantly improved OS and PFS (14 vs."/>
   <result pre="anti-HER treatment (Blackwell et al. [ 5]). Combination lapatinib plus" exact="trastuzumab" post="significantly improved OS and PFS (14 vs. 9.5 months,"/>
   <result pre="(Blackwell et al. [ 5]). Trastuzumab emtansine (T-DM1) Lapatanib plus" exact="capecitabine" post="were further compared with trastuzumab emtansine (T-DM1) in the"/>
   <result pre="Trastuzumab emtansine (T-DM1) Lapatanib plus capecitabine were further compared with" exact="trastuzumab" post="emtansine (T-DM1) in the EMILIA trial that showed a"/>
   <result pre="had been treated with two or more HER2-directed regimens, including" exact="trastuzumab" post="and lapatinib, were randomized to receive T-DM1 or treatment"/>
   <result pre="et al. [ 23]). Patients were randomly assigned to daily" exact="everolimus" post="plus weekly trastuzumab and vinorelbine or to placebo plus"/>
   <result pre="23]). Patients were randomly assigned to daily everolimus plus weekly" exact="trastuzumab" post="and vinorelbine or to placebo plus trastuzumab and vinorelbine."/>
   <result pre="were randomly assigned to daily everolimus plus weekly trastuzumab and" exact="vinorelbine" post="or to placebo plus trastuzumab and vinorelbine. OS was"/>
   <result pre="everolimus plus weekly trastuzumab and vinorelbine or to placebo plus" exact="trastuzumab" post="and vinorelbine. OS was not mature and median PFS"/>
   <result pre="was not mature and median PFS was 7 months with" exact="everolimus" post="and 5.8 months with placebo ( p = 0.0067) (André et"/>
   <result pre="first-line treatment (Cardoso et al. [ 8]). The addition of" exact="lapatinib" post="to paclitaxel also results in a prolongation of 7"/>
   <result pre="(Cardoso et al. [ 8]). The addition of lapatinib to" exact="paclitaxel" post="also results in a prolongation of 7 months of"/>
   <result pre="in a prolongation of 7 months of OS compared with" exact="paclitaxel" post="alone, as well as the prolongation of PFS (Guan"/>
   <result pre="to a relevant clinical question through a head-to-head comparison between" exact="trastuzumab" post="and lapatinib (both combined with taxanes) as first-line treatments"/>
   <result pre="relevant clinical question through a head-to-head comparison between trastuzumab and" exact="lapatinib" post="(both combined with taxanes) as first-line treatments for HER2+"/>
   <result pre="breast cancer (Gelmon et al. [ 31]). Compared to trastuzumab," exact="lapatinib" post="was associated with a shorter PFS and a worse"/>
   <result pre="et al. [ 31]). These results support the use of" exact="trastuzumab" post="over lapatinib in patients with treatment-naïve HER2+ metastatic breast"/>
   <result pre="[ 31]). These results support the use of trastuzumab over" exact="lapatinib" post="in patients with treatment-naïve HER2+ metastatic breast cancer, and"/>
   <result pre="led to the prolongation of patients’ survival. The addition of" exact="trastuzumab" post="to the hormonal agent, anastrozole, was not associated with"/>
   <result pre="compared with anastrazole monotherapy (Kaufman et al. [ 18]). The" exact="lapatinib" post="plus letrozole combination increased PFS by 5 months when"/>
   <result pre="anastrazole monotherapy (Kaufman et al. [ 18]). The lapatinib plus" exact="letrozole" post="combination increased PFS by 5 months when compared with"/>
   <result pre="letrozole combination increased PFS by 5 months when compared with" exact="letrozole" post="monotherapy, but both regimens had similar OS (approximately 33"/>
   <result pre="OS (approximately 33 months) (Johnston et al. [ 17]). Adding" exact="carboplatin" post="to trastuzumab and taxane did not extend OS and"/>
   <result pre="33 months) (Johnston et al. [ 17]). Adding carboplatin to" exact="trastuzumab" post="and taxane did not extend OS and was associated"/>
   <result pre="[ 22]). The BOLERO-1 trial showed that the addition of" exact="everolimus" post="to trastuzumab and paclitaxel did not result in an"/>
   <result pre="The BOLERO-1 trial showed that the addition of everolimus to" exact="trastuzumab" post="and paclitaxel did not result in an improvement of"/>
   <result pre="trial showed that the addition of everolimus to trastuzumab and" exact="paclitaxel" post="did not result in an improvement of PFS in"/>
   <result pre="important prolongation of PFS (7.2 months) was only seen with" exact="everolimus" post="(versus placebo) when the analysis was restricted to hormone"/>
   <result pre="criteria for statistical significance (Hurwitz et al. [ 32]). Further," exact="everolimus" post="was associated with an increased risk for serious adverse"/>
   <result pre="is as relevant as efficacy results. Dual HER2 inhibition with" exact="trastuzumab" post="and pertuzumab, a HER2-targeted humanized monoclonal antibody that inhibits"/>
   <result pre="that inhibits dimerization, was more active than single inhibition with" exact="trastuzumab" post="(Swain et al. [ 2]). This therapeutic combination prolonged"/>
   <result pre="of metastatic BC in the second-line setting. When compared to" exact="lapatinib" post="plus capecitabine, T-DM1, an antibody-drug conjugate of trastuzumab and"/>
   <result pre="compared to lapatinib plus capecitabine, T-DM1, an antibody-drug conjugate of" exact="trastuzumab" post="and the chemotherapy drug DM1 (emtansine), extended the OS"/>
   <result pre="for almost 6 months in patients who had previously received" exact="trastuzumab" post="and a taxane (Verma et al. [ 4]). Additionally,"/>
   <result pre="treated with T-DM1 experienced less toxicity. Similarly, the addition of" exact="everolimus" post="to trastuzumab and vinorelbine in patients with trastuzumab-resistant and"/>
   <result pre="T-DM1 experienced less toxicity. Similarly, the addition of everolimus to" exact="trastuzumab" post="and vinorelbine in patients with trastuzumab-resistant and taxane-pretreated HER2+"/>
   <result pre="less toxicity. Similarly, the addition of everolimus to trastuzumab and" exact="vinorelbine" post="in patients with trastuzumab-resistant and taxane-pretreated HER2+ advanced BC"/>
   <result pre="improvement in PFS in this population. However, the addition of" exact="everolimus" post="was associated with a high incidence of serious adverse"/>
   <result pre="setting, a study demonstrated that treatment with dual HER2 blockade" exact="lapatinib" post="plus trastuzumab improved OS when compared with lapatinib (Blackwell"/>
   <result pre="study demonstrated that treatment with dual HER2 blockade lapatinib plus" exact="trastuzumab" post="improved OS when compared with lapatinib (Blackwell et al."/>
   <result pre="HER2 blockade lapatinib plus trastuzumab improved OS when compared with" exact="lapatinib" post="(Blackwell et al. [ 5]). However, treatment with lapatinib"/>
   <result pre="with lapatinib (Blackwell et al. [ 5]). However, treatment with" exact="lapatinib" post="plus trastuzumab was associated with higher rates of treatment"/>
   <result pre="(Blackwell et al. [ 5]). However, treatment with lapatinib plus" exact="trastuzumab" post="was associated with higher rates of treatment discontinuation and"/>
   <result pre="in patients with HER2+ metastatic BC who have previously received" exact="trastuzumab" post="and lapatinib (Krop et al. [ 27]). Patients treated"/>
   <result pre="with HER2+ metastatic BC who have previously received trastuzumab and" exact="lapatinib" post="(Krop et al. [ 27]). Patients treated with trastuzumab"/>
   <result pre="and lapatinib (Krop et al. [ 27]). Patients treated with" exact="trastuzumab" post="have higher risk of cardiotoxicity, mainly asymptomatic left ventricular"/>
   <result pre="34]). Yet, the rates of cardiac dysfunction were greatest when" exact="trastuzumab" post="was administered concomitantly with anthracyclines, and the most frequent"/>
   <result pre="order to minimize the risk, all candidates for treatment with" exact="trastuzumab" post="must undergo a baseline cardiac assessment, as well as"/>
   <result pre="dysfunction is justified given the improvement in OS associated with" exact="trastuzumab" post="(Seidman et al. [ 34]). Moreover, the most recently"/>
   <result pre="of brain metastasis as a first site of progression between" exact="lapatinib" post="plus capecitabine and trastuzumab plus capecitabine (Pivot et al."/>
   <result pre="metastasis as a first site of progression between lapatinib plus" exact="capecitabine" post="and trastuzumab plus capecitabine (Pivot et al. [ 28])."/>
   <result pre="a first site of progression between lapatinib plus capecitabine and" exact="trastuzumab" post="plus capecitabine (Pivot et al. [ 28]). The most"/>
   <result pre="site of progression between lapatinib plus capecitabine and trastuzumab plus" exact="capecitabine" post="(Pivot et al. [ 28]). The most likely explanation"/>
   <result pre="explanation for the data is that the beneficial effect of" exact="trastuzumab" post="on systemic disease extends the survival of patients to"/>
   <result pre="clinical trials may be used, assuming that the benefit of" exact="trastuzumab" post="is the same regardless of its partner agent (Pegram"/>
   <result pre="the outcome of patients with HER2+ metastatic BC. Integration of" exact="trastuzumab" post="led to about 6 months benefit in OS. More"/>
   <result pre="about 6 months benefit in OS. More recently, T-DM1 after" exact="trastuzumab" post="led to a further 6 months benefit in OS."/>
   <result pre="further 6 months benefit in OS. HER2 dual blockade with" exact="pertuzumab" post="and trastuzumab is associated with a survival extension to"/>
   <result pre="months benefit in OS. HER2 dual blockade with pertuzumab and" exact="trastuzumab" post="is associated with a survival extension to more than"/>
   <result pre="clinical trial of Slamon and colleagues evaluating the addition of" exact="trastuzumab" post="to chemotherapy, there has been an increase in OS"/>
   <result pre="J Semiglazov V Campone M et al. Pertuzumab, trastuzumab, and" exact="docetaxel" post="for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival"/>
   <result pre="Romieu CG et al. A phase III randomized comparison of" exact="lapatinib" post="plus capecitabine versus capecitabine alone in women with advanced"/>
   <result pre="et al. A phase III randomized comparison of lapatinib plus" exact="capecitabine" post="versus capecitabine alone in women with advanced breast cancer"/>
   <result pre="A phase III randomized comparison of lapatinib plus capecitabine versus" exact="capecitabine" post="alone in women with advanced breast cancer that has"/>
   <result pre="Sledge G Aktan G et al. Overall survival benefit with" exact="lapatinib" post="in combination with trastuzumab for patients with human epidermal"/>
   <result pre="et al. Overall survival benefit with lapatinib in combination with" exact="trastuzumab" post="for patients with human epidermal growth factor receptor 2-positive"/>
   <result pre="of women with metastatic breast cancer by HER2 status and" exact="trastuzumab" post="treatment: an institutional-based review J Clin Oncol 2010 28"/>
   <result pre="K Jensen AB et al. Phase III randomized study comparing" exact="docetaxel" post="plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy"/>
   <result pre="AB et al. Phase III randomized study comparing docetaxel plus" exact="trastuzumab" post="with vinorelbine plus trastuzumab as first-line therapy of metastatic"/>
   <result pre="al. Phase III randomized study comparing docetaxel plus trastuzumab with" exact="vinorelbine" post="plus trastuzumab as first-line therapy of metastatic or locally"/>
   <result pre="III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus" exact="trastuzumab" post="as first-line therapy of metastatic or locally advanced human"/>
   <result pre="Im SA Hegg R Im YH et al. Pertuzumab plus" exact="trastuzumab" post="plus docetaxel for metastatic breast cancer N Engl J"/>
   <result pre="Hegg R Im YH et al. Pertuzumab plus trastuzumab plus" exact="docetaxel" post="for metastatic breast cancer N Engl J Med 2012"/>
   <result pre="Semiglazov VF et al. Phase III trial of nonpegylated liposomal" exact="doxorubicin" post="in combination with trastuzumab and paclitaxel in HER2-positive metastatic"/>
   <result pre="Phase III trial of nonpegylated liposomal doxorubicin in combination with" exact="trastuzumab" post="and paclitaxel in HER2-positive metastatic breast cancer Ann Oncol"/>
   <result pre="trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and" exact="paclitaxel" post="in HER2-positive metastatic breast cancer Ann Oncol 2014 25"/>
   <result pre="Z Arpornwirat W Tong Z et al. Randomized trial of" exact="lapatinib" post="versus placebo added to paclitaxel in the treatment of"/>
   <result pre="et al. Randomized trial of lapatinib versus placebo added to" exact="paclitaxel" post="in the treatment of human epidermal growth factor receptor"/>
   <result pre="Y Masuda N et al. Randomized phase III trial of" exact="trastuzumab" post="monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus"/>
   <result pre="al. Randomized phase III trial of trastuzumab monotherapy followed by" exact="trastuzumab" post="plus docetaxel versus trastuzumab plus docetaxel as first-line therapy"/>
   <result pre="phase III trial of trastuzumab monotherapy followed by trastuzumab plus" exact="docetaxel" post="versus trastuzumab plus docetaxel as first-line therapy in patients"/>
   <result pre="trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus" exact="trastuzumab" post="plus docetaxel as first-line therapy in patients with HER2-positive"/>
   <result pre="trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus" exact="docetaxel" post="as first-line therapy in patients with HER2-positive metastatic breast"/>
   <result pre="M Sadeghi S Dieras V et al. Lapatinib combined with" exact="letrozole" post="versus letrozole and placebo as first-line therapy for postmenopausal"/>
   <result pre="S Dieras V et al. Lapatinib combined with letrozole versus" exact="letrozole" post="and placebo as first-line therapy for postmenopausal hormone receptor-positive"/>
   <result pre="Bapsy PP Vaid A Wardley A et al. Trastuzumab plus" exact="anastrozole" post="versus anastrozole alone for the treatment of postmenopausal women"/>
   <result pre="Vaid A Wardley A et al. Trastuzumab plus anastrozole versus" exact="anastrozole" post="alone for the treatment of postmenopausal women with human"/>
   <result pre="et al. Randomized phase III study of trastuzumab, paclitaxel, and" exact="carboplatin" post="compared with trastuzumab and paclitaxel in women with HER-2-overexpressing"/>
   <result pre="phase III study of trastuzumab, paclitaxel, and carboplatin compared with" exact="trastuzumab" post="and paclitaxel in women with HER-2-overexpressing metastatic breast cancer"/>
   <result pre="study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and" exact="paclitaxel" post="in women with HER-2-overexpressing metastatic breast cancer J Clin"/>
   <result pre="Florance A O’Rourke L Maltzman J Johnston S Lapatinib plus" exact="letrozole" post="as first-line therapy for HER-2+ hormone receptor-positive metastatic breast"/>
   <result pre="J Semiglazov V Campone M et al. Pertuzumab, trastuzumab, and" exact="docetaxel" post="in HER2-positive metastatic breast cancer N Engl J Med"/>
   <result pre="Minckwitz G et al. Multicenter phase III randomized trial comparing" exact="docetaxel" post="and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line"/>
   <result pre="et al. Multicenter phase III randomized trial comparing docetaxel and" exact="trastuzumab" post="with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for"/>
   <result pre="randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and" exact="trastuzumab" post="as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast"/>
   <result pre="al. Randomized study of Lapatinib alone or in combination with" exact="trastuzumab" post="in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer J"/>
   <result pre="Newstat B Imwalle B Geyer CE et al. Lapatinib plus" exact="capecitabine" post="in women with HER-2-positive advanced breast cancer: final survival"/>
   <result pre="Chan S Romieu CG Pienkowski T et al. Lapatinib plus" exact="capecitabine" post="for HER2-positive advanced breast cancer N Engl J Med"/>
   <result pre="al. CEREBEL (EGF111438): a phase III, randomized, open-label study of" exact="lapatinib" post="plus capecitabine versus trastuzumab plus capecitabine in patients with"/>
   <result pre="(EGF111438): a phase III, randomized, open-label study of lapatinib plus" exact="capecitabine" post="versus trastuzumab plus capecitabine in patients with human epidermal"/>
   <result pre="phase III, randomized, open-label study of lapatinib plus capecitabine versus" exact="trastuzumab" post="plus capecitabine in patients with human epidermal growth factor"/>
   <result pre="randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus" exact="capecitabine" post="in patients with human epidermal growth factor receptor 2-positive"/>
   <result pre="DG Manikhas A Di Leo A et al. Lapatinib or" exact="trastuzumab" post="plus taxane therapy for human epidermal growth factor receptor"/>
   <result pre="Shao Z Mano MS Neciosup SP et al. Combination of" exact="everolimus" post="with trastuzumab plus paclitaxel as first-line treatment for patients"/>
   <result pre="Mano MS Neciosup SP et al. Combination of everolimus with" exact="trastuzumab" post="plus paclitaxel as first-line treatment for patients with HER2-positive"/>
   <result pre="Neciosup SP et al. Combination of everolimus with trastuzumab plus" exact="paclitaxel" post="as first-line treatment for patients with HER2-positive advanced breast"/>
   <result pre="Paton V Ashby M et al. Cardiac dysfunction in the" exact="trastuzumab" post="clinical trials experience J Clin Oncol 2002 20 1215"/>
   <result pre="C Beryt M Pietras R Slamon DJ Rational combinations of" exact="trastuzumab" post="with chemotherapeutic drugs used in the treatment of breast"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4650980/results/search/inn/results.xml">
   <result pre="be presented. Most notably, HER2-targeted therapy with the monoclonal antibody" exact="trastuzumab" post="has proven beneficial in first-line therapy and has been"/>
   <result pre="pathway has also proven beneficial, and the VEGFR-targeted monoclonal antibody" exact="ramucirumab" post="is now approved for second-line therapy. In contrast to"/>
   <result pre="antibodies (mAbs), which recognize the extracellular domain of EGFR (cetuximab," exact="panitumumab" post="and nimotuzumab), and small molecule tyrosine kinase inhibitors (TKIs),"/>
   <result pre="data are from unselected GE-Ca patient populations. Anti-EGFR mAbs: cetuximab," exact="panitumumab" post="and nimotuzumab Cetuximab and panitumumab target the extracellular domain"/>
   <result pre="patient populations. Anti-EGFR mAbs: cetuximab, panitumumab and nimotuzumab Cetuximab and" exact="panitumumab" post="target the extracellular domain of EGFR and are currently"/>
   <result pre="is unclear at this time. Phase II trials of single-agent" exact="cetuximab" post="have shown minimal activity [ 25, 26]. However, multiple"/>
   <result pre="activity [ 25, 26]. However, multiple phase II studies of" exact="cetuximab" post="in combination with chemotherapy have shown promise, with median"/>
   <result pre="904 patients with metastatic GE-Ca to receive either placebo or" exact="cetuximab" post="in addition to cisplatin/capecitabine chemotherapy [ 33]. The primary"/>
   <result pre="toxicity. None of the endpoints differed significantly between placebo and" exact="cetuximab" post="groups (PFS ∼5 months, OS ∼10 months, RR 30%),"/>
   <result pre="cetuximab. Toxicity was similar except for increased rash in the" exact="cetuximab" post="group. The REAL-3 trial randomized 503 patients to receive"/>
   <result pre="REAL-3 trial randomized 503 patients to receive either placebo or" exact="panitumumab" post="in addition to epirubicin/oxaliplatin/capecitabine (EOX) chemotherapy. Dosing of oxaliplatin"/>
   <result pre="or panitumumab in addition to epirubicin/oxaliplatin/capecitabine (EOX) chemotherapy. Dosing of" exact="oxaliplatin" post="and capecitabine were attenuated in the panitumumab arm due"/>
   <result pre="in addition to epirubicin/oxaliplatin/capecitabine (EOX) chemotherapy. Dosing of oxaliplatin and" exact="capecitabine" post="were attenuated in the panitumumab arm due to the"/>
   <result pre="chemotherapy. Dosing of oxaliplatin and capecitabine were attenuated in the" exact="panitumumab" post="arm due to the increased toxicity observed in a"/>
   <result pre="resulted in early termination of the trial. Patients in the" exact="panitumumab" post="arm had an OS of 8.8 months, while those"/>
   <result pre="trial using an alternative chemotherapy regimen (docetaxel/oxaliplatin) with or without" exact="cetuximab" post="as first-line therapy for unselected patients with metastatic GE-Ca"/>
   <result pre="negative results, with a slight increase in RR in the" exact="cetuximab" post="arm (27% in chemo alone vs 38% with cetuximab)"/>
   <result pre="the phase II/III SCOPE1 trial that tested the addition of" exact="cetuximab" post="to cisplatin/5-FU chemoradiation for definitive treatment of localized GE-Ca."/>
   <result pre="cisplatin/5-FU chemoradiation for definitive treatment of localized GE-Ca. Again, the" exact="cetuximab" post="group experienced increased toxicity and had inferior outcomes, with"/>
   <result pre="the anti-EGFR antibodies in the treatment of GE-Ca. Anti-EGFR TKIs:" exact="gefitinib" post="and erlotinib The EGFR TKIs gefitinib and erlotinib have"/>
   <result pre="antibodies in the treatment of GE-Ca. Anti-EGFR TKIs: gefitinib and" exact="erlotinib" post="The EGFR TKIs gefitinib and erlotinib have been tested"/>
   <result pre="of GE-Ca. Anti-EGFR TKIs: gefitinib and erlotinib The EGFR TKIs" exact="gefitinib" post="and erlotinib have been tested in advanced GE-Ca, but"/>
   <result pre="Anti-EGFR TKIs: gefitinib and erlotinib The EGFR TKIs gefitinib and" exact="erlotinib" post="have been tested in advanced GE-Ca, but their benefits"/>
   <result pre="disease progression after first-line chemotherapy. Patients were randomized to single-agent" exact="gefitinib" post="500 mg daily or placebo. A non-significant improvement in PFS"/>
   <result pre="daily or placebo. A non-significant improvement in PFS (1.6 months" exact="gefitinib" post="vs 1.2 months placebo) was observed. More importantly, the"/>
   <result pre="between treatment groups (∼3.7 months). Odynophagia was improved in the" exact="gefitinib" post="group, but other symptoms were similar between groups. While"/>
   <result pre="could predict which patients were most likely to benefit from" exact="gefitinib" post="therapy [ 49]. The TRANS COG analysis evaluated the"/>
   <result pre="patients had evidence of CNG and appeared to benefit from" exact="gefitinib" post="with improved OS, PFS and disease control rate (DCR)."/>
   <result pre="control rate (DCR). Notably, 38% of CNG patients treated with" exact="gefitinib" post="survived 6 months, and 13% survived 12 months, which"/>
   <result pre="The authors concluded that EGFR CNG may predict benefit from" exact="gefitinib" post="and other EGFR-targeted therapies. While these results are provocative,"/>
   <result pre="they will need to be validated in additional studies before" exact="gefitinib" post="could be considered for standard clinical practice. EGF-targeted therapies:"/>
   <result pre="cancer, where four agents are currently approved: the mAbs trastuzumab," exact="trastuzumab" post="emtansine (T-DM1), pertuzumab; and the TKI lapatinib. Here, we"/>
   <result pre="new strategies that are currently under investigation. Anti-HER2 mAbs: trastuzumab," exact="trastuzumab" post="emtansine (T-DM1), and pertuzumab Trastuzumab is a mAb that"/>
   <result pre="currently under investigation. Anti-HER2 mAbs: trastuzumab, trastuzumab emtansine (T-DM1), and" exact="pertuzumab" post="Trastuzumab is a mAb that recognizes an extracellular epitope"/>
   <result pre="20% GEJ) were randomized to treatment with standard chemotherapy with" exact="cisplatin" post="and either intravenous 5-fluorouracil (5-FU) or oral capecitabine or"/>
   <result pre="chemotherapy with cisplatin and either intravenous 5-fluorouracil (5-FU) or oral" exact="capecitabine" post="or this doublet chemotherapy combined with trastuzumab. Trastuzumab was"/>
   <result pre="subsequent cycles. After six cycles of treatment, responding patients received" exact="trastuzumab" post="alone until disease progression. The complete RR (5%) and"/>
   <result pre="the addition of trastuzumab, as were both PFS (6.7 months" exact="trastuzumab" post="vs 5.5 months chemotherapy alone) and OS (13.8 months"/>
   <result pre="trastuzumab vs 5.5 months chemotherapy alone) and OS (13.8 months" exact="trastuzumab" post="vs 11.1 months chemotherapy alone). Importantly, trastuzumab was generally"/>
   <result pre="OS (13.8 months trastuzumab vs 11.1 months chemotherapy alone). Importantly," exact="trastuzumab" post="was generally well tolerated, and there were no differences"/>
   <result pre="IHC 3+) were the most likely subset to benefit from" exact="trastuzumab" post="treatment. In fact, there appeared to be no benefit"/>
   <result pre="FISH results. This landmark study led to the approval of" exact="trastuzumab" post="as first-line therapy in combination with chemotherapy for patients"/>
   <result pre="wide range of follow-up studies. In recent years, concerns over" exact="cisplatin" post="toxicity have led to an increased use of oxaliplatin-based"/>
   <result pre="3+. Capecitabine/oxaliplatin was given on a standard 21-day cycle, and" exact="trastuzumab" post="was given as in ToGA. Fifty-five patients were eligible"/>
   <result pre="single-arm phase II studies of S-1-based chemotherapy in combination with" exact="trastuzumab" post="were recently reported in abstract form. JACCRO GC-06 tested"/>
   <result pre="populations. Additional studies of different chemotherapy regimens in combination with" exact="trastuzumab" post="are ongoing including those with docetaxel and other chemotherapy"/>
   <result pre="regimens in combination with trastuzumab are ongoing including those with" exact="docetaxel" post="and other chemotherapy combinations (NCT01295086, NCT01364493, NCT02004769 and NCT01928290)."/>
   <result pre="provide further data on whether the safety and efficacy of" exact="trastuzumab" post="combinations can be expanded beyond cisplatin/5-FU. While trastuzumab improves"/>
   <result pre="efficacy of trastuzumab combinations can be expanded beyond cisplatin/5-FU. While" exact="trastuzumab" post="improves survival in HER2-positive GE-Ca, the results of ToGA"/>
   <result pre="ToGA were modest. There is theoretical concern that differences in" exact="trastuzumab" post="metabolism between breast cancer and GE-Ca patients may mean"/>
   <result pre="a patient who responded only after an increase in the" exact="trastuzumab" post="dose supports this concept [ 72], as do pharmacokinetic"/>
   <result pre="in the ToGA trial [ 59]. The question of optimal" exact="trastuzumab" post="dose is currently being addressed in the HELOISE trial"/>
   <result pre="study testing cisplatin/capecitabine in combination with standard-dose v s high-dose" exact="trastuzumab" post="in the first-line setting Given the success of trastuzumab"/>
   <result pre="high-dose trastuzumab in the first-line setting Given the success of" exact="trastuzumab" post="in the metastatic setting, ongoing trials are determining whether"/>
   <result pre="Safran et al . published a phase I/II study evaluating" exact="trastuzumab" post="in combination with chemoradiation for patients with resectable esophageal"/>
   <result pre="the role of neoadjuvant carboplatin/paclitaxel and radiation with or without" exact="trastuzumab" post="for patients with locally advanced, resectable HER2-positive esophageal or"/>
   <result pre="13 cycles, postoperatively. A similar trial, TOXAG (NCT01748773), is adding" exact="trastuzumab" post="to capecitabine/oxaliplatin chemoradiation. Building on the MAGIC trial, which"/>
   <result pre="another standard of care for resectable GE-Ca, current trials incorporating" exact="trastuzumab" post="into perioperative regimens are also underway [ 74]. The"/>
   <result pre="The NeoHX (NCT01130337) trial testing perioperative capecitabine/oxaliplatin in combination with" exact="trastuzumab" post="is ongoing, with the latest results after a median"/>
   <result pre="available [ 76]. T-DM1 is an antibody-drug conjugate that combines" exact="trastuzumab" post="with the microtubule polymerization inhibitor emtansine, which has been"/>
   <result pre="the phase I/II TRAX-HER2 (NCT01702558) trial will compare T-DM1 with" exact="capecitabine" post="vs T-DM1 alone. Mature data from these trials are"/>
   <result pre="from ToGA in combination with two different dosing schedules of" exact="pertuzumab" post="[ 79]. This study had primary endpoints of safety"/>
   <result pre="study trastuzumab/pertuzumab plus chemotherapy in the neoadjuvant setting. Anti-HER2 TKIs:" exact="lapatinib" post="and afatinib Anti-HER2 TKIs have been tested in HER2-positive"/>
   <result pre="plus chemotherapy in the neoadjuvant setting. Anti-HER2 TKIs: lapatinib and" exact="afatinib" post="Anti-HER2 TKIs have been tested in HER2-positive GE-Ca with"/>
   <result pre="trial of chemotherapy (capecitabine and oxaliplatin) combined with placebo or" exact="lapatinib" post="in the first-line treatment of advanced GE-Ca. This trial"/>
   <result pre="The results showed a non-significant trend towards benefit in the" exact="lapatinib" post="arm compared with the placebo (OS 12.2 vs 10.5"/>
   <result pre="study did not improve on the ToGA study, and thus" exact="trastuzumab" post="remains the standard of care in the first-line setting."/>
   <result pre="standard of care in the first-line setting. The role of" exact="lapatinib" post="in the second-line setting has also been addressed. The"/>
   <result pre="had clinical progression on first-line chemotherapy, to receive placebo or" exact="lapatinib" post="in combination with paclitaxel [ 81]. The majority (95%)"/>
   <result pre="first-line chemotherapy, to receive placebo or lapatinib in combination with" exact="paclitaxel" post="[ 81]. The majority (95%) of patients had not"/>
   <result pre="patients had not received previous HER2-targeted therapy. While those receiving" exact="lapatinib" post="had a statistically significant increase in RR (27% vs"/>
   <result pre="phase II trial (NCT01145404) randomized HER2 FISH+ patients to second-line" exact="capecitabine" post="with placebo or lapatinib. The primary endpoint of improved"/>
   <result pre="together, these trials show no benefit with the addition of" exact="lapatinib" post="to chemotherapy for patients with metastatic GE-Ca in either"/>
   <result pre="first- or second-line setting. There is currently no role for" exact="lapatinib" post="outside of a clinical trial. Afatinib is a small-molecule"/>
   <result pre="GE-Ca. Preclinical models using patient-derived HER2-positive tumor xenografts showed that" exact="afatinib" post="treatment led to tumor regression [ 84]. A phase"/>
   <result pre="to tumor regression [ 84]. A phase II study of" exact="afatinib" post="for GE-Ca that had progressed on trastuzumab showed that"/>
   <result pre="II study of afatinib for GE-Ca that had progressed on" exact="trastuzumab" post="showed that daily afatinib led to a disease stabilization"/>
   <result pre="for GE-Ca that had progressed on trastuzumab showed that daily" exact="afatinib" post="led to a disease stabilization rate of 40% in"/>
   <result pre="heavily treated population [ 84, 85]. Other trials are studying" exact="afatinib" post="in combination with trastuzumab or chemotherapy, including NCT01649271 (phase"/>
   <result pre="84, 85]. Other trials are studying afatinib in combination with" exact="trastuzumab" post="or chemotherapy, including NCT01649271 (phase I, first-line afatinib/trastuzumab), NCT01743365"/>
   <result pre="first-line afatinib/cisplatin/5-FU), NCT01522768 (phase II, second-line afatinib/trastuzumab after progression on" exact="trastuzumab" post="alone) and NCT02274012 and NCT02501603 (both phase II, second-line"/>
   <result pre="and NCT02501603 (both phase II, second-line afatinib/paclitaxel after progression on" exact="trastuzumab" post="alone). HER2 targeted therapies: conclusions In summary, targeted therapy"/>
   <result pre="GE-Ca, and ongoing studies will further clarify the role of" exact="trastuzumab" post="and other mAb-based therapies in both locally advanced and"/>
   <result pre="the VEGF/VEGFR pathway are available. mAb and related therapies include" exact="bevacizumab" post="[ 92], ramucirumab [ 93] and ziv-aflibercept [ 94]."/>
   <result pre="are available. mAb and related therapies include bevacizumab [ 92]," exact="ramucirumab" post="[ 93] and ziv-aflibercept [ 94]. VEGFR TKIs studied"/>
   <result pre="[ 94]. VEGFR TKIs studied in GE-Ca include regorafenib, sunitinib," exact="sorafenib" post="and apatinib. Anti-VEGF/VEGFR mAbs: bevacizumab, ramucirumab and ziv-aflibercept Bevacizumab"/>
   <result pre="GE-Ca include regorafenib, sunitinib, sorafenib and apatinib. Anti-VEGF/VEGFR mAbs: bevacizumab," exact="ramucirumab" post="and ziv-aflibercept Bevacizumab is a mAb targeting VEGF-A. The"/>
   <result pre="a mAb targeting VEGF-A. The preclinical and clinical efficacy of" exact="bevacizumab" post="in combination with chemotherapy in multiple tumor types led"/>
   <result pre="II study used a modified docetaxel/cisplatin/5-FU regimen in combination with" exact="bevacizumab" post="and showed even better results (albeit with significant toxicities):"/>
   <result pre="95]. These promising phase II results prompted further evaluation of" exact="bevacizumab" post="and chemotherapy in the phase III setting. The AVAGAST"/>
   <result pre="chemotherapy in the phase III setting. The AVAGAST trial evaluated" exact="bevacizumab" post="versus placebo in combination with cisplatin/capecitabine chemotherapy for first-line"/>
   <result pre="endpoint of OS was not improved (OS 12.1 months with" exact="bevacizumab" post="vs 10.1 months with placebo). Interestingly, both PFS and"/>
   <result pre="both PFS and RR were improved with the addition of" exact="bevacizumab" post="(PFS 6.7 vs 5.3 months and RR 46% vs"/>
   <result pre="ongoing study of interest is the MAGIC-B study, in which" exact="bevacizumab" post="is added to each cycle of perioperative ECX chemotherapy"/>
   <result pre="have recently been published and show that the addition of" exact="bevacizumab" post="does not result in unacceptable toxicity; efficacy results are"/>
   <result pre="are not yet available [ 98]. While additional studies of" exact="bevacizumab" post="and chemotherapy for advanced or metastatic GE-Ca are ongoing,"/>
   <result pre="of AVAGAST and AVATAR do not support the use of" exact="bevacizumab" post="outside of a clinical trial. Ramucirumab is a mAb"/>
   <result pre="REGARD trial randomized 355 advanced or metastatic gastric/GEJ patients to" exact="ramucirumab" post="alone (8 mg/kg IV every two weeks) or placebo as"/>
   <result pre="overall DCR was also improved at 49% for patients receiving" exact="ramucirumab" post="vs 23% for placebo. The drug was tolerable with"/>
   <result pre="significantly increased side effect. The modest improvement in OS with" exact="ramucirumab" post="was comparable to that seen in previous studies of"/>
   <result pre="for similar patient groups [ 100, 101]. The hypothesis that" exact="ramucirumab" post="combined with chemotherapy could improve on the results of"/>
   <result pre="a phase III, placebo-controlled trial that randomized 665 patients to" exact="paclitaxel" post="combined with either ramucirumab or placebo [ 102]. Just"/>
   <result pre="trial that randomized 665 patients to paclitaxel combined with either" exact="ramucirumab" post="or placebo [ 102]. Just as in REGARD, patients"/>
   <result pre="from the addition of angiogenesis inhibition. The OS favored the" exact="ramucirumab" post="group (9.6 vs 7.4 months with placebo) as did"/>
   <result pre="vs 2.9 months). The DCR was higher in those receiving" exact="ramucirumab" post="as well (80% vs 64%). Subgroup analysis showed that"/>
   <result pre="patients did not appear to benefit from the addition of" exact="ramucirumab" post="compared with patients from other parts of the world,"/>
   <result pre="Other ongoing second-line trials will test different dose schedules of" exact="ramucirumab" post="with paclitaxel (NCT02514551) or will combine ramucirumab with albumin-bound"/>
   <result pre="second-line trials will test different dose schedules of ramucirumab with" exact="paclitaxel" post="(NCT02514551) or will combine ramucirumab with albumin-bound nab-paclitaxel (NCT02317991)"/>
   <result pre="dose schedules of ramucirumab with paclitaxel (NCT02514551) or will combine" exact="ramucirumab" post="with albumin-bound nab-paclitaxel (NCT02317991) to see if these modifications"/>
   <result pre="Given these positive results, there is great interest in incorporating" exact="ramucirumab" post="into earlier lines of therapy. One study performed in"/>
   <result pre="in abstract form, evaluated the combination of 5-FU/leucovorin/oxaliplatin (FOLFOX) plus" exact="ramucirumab" post="in untreated patients with unresectable or metastatic GE-Ca (NCT01246960)"/>
   <result pre="tumor site did not markedly change the conclusion that adding" exact="ramucirumab" post="is not indicated in the first-line setting, at least"/>
   <result pre="combination with FOLFOX. The ongoing RAINFALL study (NCT02314117) is combining" exact="ramucirumab" post="or placebo with cisplatin/capecitabine as first-line therapy for patients"/>
   <result pre="and metastatic GE-Ca (NCT01747551). Given the discordant results seen with" exact="bevacizumab" post="and ramucirumab, it will be interesting to see if"/>
   <result pre="perforation, which may be more common than that seen with" exact="bevacizumab" post="[ 106]. Anti-VEGFR TKIs: sunitinib, sorafenib, regorafenib, and apatinib"/>
   <result pre="that have been extensively tested in GE-Ca. Two angiogenesis inhibitors," exact="sunitinib" post="and sorafenib, have been found to have clinical activity"/>
   <result pre="tumor (GIST), pancreatic neuroendocrine tumor (NET) and kidney cancer, while" exact="sorafenib" post="is approved for thyroid, liver and kidney cancers. Both"/>
   <result pre="have shown only modest activity with substantial toxicity. Sunitinib and" exact="sorafenib" post="have failed to show significant benefit in first- or"/>
   <result pre="as other growth factor receptors. It is very similar to" exact="sorafenib" post="and is thought to function as an angiogenesis inhibitor."/>
   <result pre="previously treated with one to two lines of chemotherapy to" exact="regorafenib" post="at 160 mg daily for 21 out of 28 days"/>
   <result pre="for patients on this trial was short (11.1 weeks for" exact="regorafenib" post="vs 3.9 weeks for placebo), but the difference was"/>
   <result pre="statistically significant. The OS showed a trend towards improvement with" exact="regorafenib" post="but did not reach significance (25 weeks for the"/>
   <result pre="regorafenib but did not reach significance (25 weeks for the" exact="regorafenib" post="vs 19.4 weeks for placebo). Regorafenib appeared to be"/>
   <result pre="on the trial. Other planned and ongoing trials are studying" exact="regorafenib" post="in metastatic GE-Ca including NCT02241720 (single-agent regorafenib in the"/>
   <result pre="trials are studying regorafenib in metastatic GE-Ca including NCT02241720 (single-agent" exact="regorafenib" post="in the second line), NCT01913639 (regorafenib/FOLFOX in the first"/>
   <result pre="trial (regorafenib/paclitaxel in the second line) and NCT02234180 (adjuvant single-agent" exact="regorafenib" post="after neoadjuvant chemotherapy and surgery for node-positive disease). The"/>
   <result pre="results of these studies will further define the role of" exact="regorafenib" post="in GE-Ca but, as in colorectal cancer, current studies"/>
   <result pre="of this agent including a randomized comparison of apatinib to" exact="docetaxel" post="in the third-line setting and two studies of apatinib"/>
   <result pre="for GE-Ca. The negative results seen with other agents including" exact="bevacizumab" post="are disappointing and indeed puzzling. Here, as in other"/>
   <result pre="to benefit [ 136]. Anti-MET TKIs; AMG 337, tivantinib, and" exact="crizotinib" post="While the data on onartuzumab and rilotumumab have been"/>
   <result pre="inhibits the MET tyrosine kinase. Preclinical experiments have shown that" exact="crizotinib" post="can inhibit the growth of MET-overexpressing gastric cancer cell"/>
   <result pre="140]. An exploratory analysis of a phase I trial of" exact="crizotinib" post="in solid tumor patients found that two of four"/>
   <result pre="GE-Ca had transient tumor shrinkage [ 128]. Other studies of" exact="crizotinib" post="in GE-Ca are ongoing including NCT02435108, a pilot study"/>
   <result pre="in GE-Ca are ongoing including NCT02435108, a pilot study testing" exact="crizotinib" post="as third-line therapy for MET-positive gastric cancer in Korea,"/>
   <result pre="MET-positive gastric cancer in Korea, and NCT02034981, which will test" exact="crizotinib" post="across multiple genetically defined tumor types including MET-amplified gastric"/>
   <result pre="remain far from having a ‘magic bullet’. Two targeted agents," exact="trastuzumab" post="and ramucirumab, are currently approved for treating advanced or"/>
   <result pre="KEYNOTE-061 (NCT02370498), which will study PD-1 blockade with pembrolizumab vs" exact="paclitaxel" post="in advanced GE-Ca, are underway. Also, early phase trials"/>
   <result pre="(OS) and progression-free survival (PFS) in the TRIO-013/LOGiC trial of" exact="lapatinib" post="(L) in combination with capecitabine plus oxaliplatin (CapeOx) ."/>
   <result pre="in the TRIO-013/LOGiC trial of lapatinib (L) in combination with" exact="capecitabine" post="plus oxaliplatin (CapeOx) . J Clin Oncol 2015; 33"/>
   <result pre="TRIO-013/LOGiC trial of lapatinib (L) in combination with capecitabine plus" exact="oxaliplatin" post="(CapeOx) . J Clin Oncol 2015; 33 ( Suppl"/>
   <result pre="Anti-EGFR monoclonal antibodies for treatment of colorectal cancers: development of" exact="cetuximab" post="and panitumumab . J Clin Pharmacol 2012; 52 :"/>
   <result pre="antibodies for treatment of colorectal cancers: development of cetuximab and" exact="panitumumab" post=". J Clin Pharmacol 2012; 52 : 128 –"/>
   <result pre="PC et al. A multicenter phase II trial of single-agent" exact="cetuximab" post="in advanced esophageal and gastric adenocarcinoma . Ann Oncol"/>
   <result pre="SA et al. Phase II study and biomarker analysis of" exact="cetuximab" post="combined with modified FOLFOX6 in advanced gastric cancer ."/>
   <result pre="Ryu MH et al. A prospective phase II study of" exact="cetuximab" post="in combination with XELOX (capecitabine and oxaliplatin) in patients"/>
   <result pre="F Luber B Lorenzen S et al. Cetuximab plus oxaliplatin/leucovorin/5-" exact="fluorouracil" post="in first-line metastatic gastric cancer: a phase II study"/>
   <result pre="T et al. Cetuximab with irinotecan, folinic acid and 5-" exact="fluorouracil" post="as first-line treatment in advanced gastroesophageal cancer: a prospective"/>
   <result pre="Fabio F Siena S et al. Phase II study of" exact="cetuximab" post="in combination with FOLFIRI in patients with untreated advanced"/>
   <result pre="32 Woll E Greil R Eisterer W et al. Oxaliplatin," exact="irinotecan" post="and cetuximab in advanced gastric cancer. A multicenter phase"/>
   <result pre="E Greil R Eisterer W et al. Oxaliplatin, irinotecan and" exact="cetuximab" post="in advanced gastric cancer. A multicenter phase II trial"/>
   <result pre="Lordick F Kang YK Chung HC et al. Capecitabine and" exact="cisplatin" post="with or without cetuximab for patients with previously untreated"/>
   <result pre="Chung HC et al. Capecitabine and cisplatin with or without" exact="cetuximab" post="for patients with previously untreated advanced gastric cancer (EXPAND):"/>
   <result pre="AF Ashley SE Cunningham D et al. Epirubicin, oxaliplatin, and" exact="capecitabine" post="with or without panitumumab for advanced esophagogastric cancer: dose-finding"/>
   <result pre="D et al. Epirubicin, oxaliplatin, and capecitabine with or without" exact="panitumumab" post="for advanced esophagogastric cancer: dose-finding study for the prospective"/>
   <result pre="T Chau I Cunningham D et al. Epirubicin, oxaliplatin, and" exact="capecitabine" post="with or without panitumumab for patients with previously untreated"/>
   <result pre="D et al. Epirubicin, oxaliplatin, and capecitabine with or without" exact="panitumumab" post="for patients with previously untreated advanced oesophagogastric cancer (REAL3):"/>
   <result pre="Richards D Kocs DM Spira AI et al. Results of" exact="docetaxel" post="plus oxaliplatin (DOCOX) +/- cetuximab in patients with metastatic"/>
   <result pre="Kocs DM Spira AI et al. Results of docetaxel plus" exact="oxaliplatin" post="(DOCOX) +/- cetuximab in patients with metastatic gastric and/or"/>
   <result pre="AI et al. Results of docetaxel plus oxaliplatin (DOCOX) +/-" exact="cetuximab" post="in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma:"/>
   <result pre="Du F Zheng Z Shi S et al. S-1 and" exact="cisplatin" post="with or without nimotuzumab for patients with untreated unresectable"/>
   <result pre="Hurt CN Falk S et al. Chemoradiotherapy with or without" exact="cetuximab" post="in patients with oesophageal cancer (SCOPE1): a multicentre, phase"/>
   <result pre="Hulshof MC et al. Preoperative chemoradiation therapy in combination with" exact="panitumumab" post="for patients with resectable esophageal cancer: the PACT study"/>
   <result pre="McCoy S Fenoglio-Preiser CM et al. Phase II trial of" exact="erlotinib" post="in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127 ."/>
   <result pre="M Beddard K et al. A phase II study of" exact="gefitinib" post="monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression,"/>
   <result pre="Predictive factors for outcome in a phase II study of" exact="gefitinib" post="in second-line treatment of advanced esophageal cancer patients ."/>
   <result pre="factor receptor copy number gain (EGFR CNG) and response to" exact="gefitinib" post="in esophageal cancer (EC): Results of a biomarker analysis"/>
   <result pre="of a biomarker analysis of a phase III trial of" exact="gefitinib" post="versus placebo (TRANS-COG) . J Clin Oncol 2014; 32"/>
   <result pre="58 Shiroiwa T Fukuda T Shimozuma K Cost-effectiveness analysis of" exact="trastuzumab" post="to treat HER2-positive advanced gastric cancer based on the"/>
   <result pre="trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either" exact="oxaliplatin" post="or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie"/>
   <result pre="C Kim JG et al. Multicenter phase II study of" exact="trastuzumab" post="in combination with capecitabine and oxaliplatin for advanced gastric"/>
   <result pre="al. Multicenter phase II study of trastuzumab in combination with" exact="capecitabine" post="and oxaliplatin for advanced gastric cancer . Eur J"/>
   <result pre="phase II study of trastuzumab in combination with capecitabine and" exact="oxaliplatin" post="for advanced gastric cancer . Eur J Cancer 2015;"/>
   <result pre="Cohen R Tournigand C et al. Efficacy and safety of" exact="trastuzumab" post="in combination with oxaliplatin and fluorouracil-based chemotherapy for patients"/>
   <result pre="et al. Efficacy and safety of trastuzumab in combination with" exact="oxaliplatin" post="and fluorouracil-based chemotherapy for patients with HER2- positive metastatic"/>
   <result pre="Nishikawa K et al. Mu lticenter phase II study of" exact="trastuzumab" post="with S-1 alone in elderly patients with HER-2 positive"/>
   <result pre="et al. A phase II trial of 5-weekly S-1 plus" exact="cisplatin" post="(CDDP) combination with trastuzumab (Tmab) for HER2-positive advanced gastric"/>
   <result pre="II trial of 5-weekly S-1 plus cisplatin (CDDP) combination with" exact="trastuzumab" post="(Tmab) for HER2-positive advanced gastric or esophagogastric junction (EGJ)"/>
   <result pre="126. 72 Kyi C Shah MA A case report of" exact="trastuzumab" post="dose in gastric cancer. J Gastrointest Oncol 2013; 4"/>
   <result pre="Akerman P et al. Phase I/II study of trastuzumab, paclitaxel," exact="cisplatin" post="and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma"/>
   <result pre="Garcia Alfonso P et al. NEOHX study: perioperative treatment with" exact="trastuzumab" post="in combination with capecitabine and oxaliplatin (XELOX-T) in patients"/>
   <result pre="al. NEOHX study: perioperative treatment with trastuzumab in combination with" exact="capecitabine" post="and oxaliplatin (XELOX-T) in patients with HER-2 resectable stomach"/>
   <result pre="study: perioperative treatment with trastuzumab in combination with capecitabine and" exact="oxaliplatin" post="(XELOX-T) in patients with HER-2 resectable stomach or esophagogastric"/>
   <result pre="SM Baselga J Kim SB et al. Pertuzumab, trastuzumab, and" exact="docetaxel" post="in HER2- positive metastatic breast cancer. . N Engl"/>
   <result pre="Iijima S Yorozu K et al. Pertuzumab in combination with" exact="trastuzumab" post="shows significantly enhanced antitumor activity in HER2-positive human gastric"/>
   <result pre="al. A phase IIa dose-finding and safety study of first-line" exact="pertuzumab" post="in combination with trastuzumab, capecitabine and cisplatin in patients"/>
   <result pre="and safety study of first-line pertuzumab in combination with trastuzumab," exact="capecitabine" post="and cisplatin in patients with HER2-positive advanced gastric cancer"/>
   <result pre="study of first-line pertuzumab in combination with trastuzumab, capecitabine and" exact="cisplatin" post="in patients with HER2-positive advanced gastric cancer . Br"/>
   <result pre="Bang Y Qin S et al. Lapatinib in combination with" exact="capecitabine" post="plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric,"/>
   <result pre="Qin S et al. Lapatinib in combination with capecitabine plus" exact="oxaliplatin" post="(CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or"/>
   <result pre="Satoh T Xu RH Chung HC et al. Lapatinib plus" exact="paclitaxel" post="versus paclitaxel alone in the second-line treatment of HER2-amplified"/>
   <result pre="Xu RH Chung HC et al. Lapatinib plus paclitaxel versus" exact="paclitaxel" post="alone in the second-line treatment of HER2-amplified advanced gastric"/>
   <result pre="S Riera Knorrenschild J Haag GM et al. Lapatinib versus" exact="lapatinib" post="plus capecitabine as second-line treatment in human epidermal growth"/>
   <result pre="Knorrenschild J Haag GM et al. Lapatinib versus lapatinib plus" exact="capecitabine" post="as second-line treatment in human epidermal growth factor receptor"/>
   <result pre="M Imtiaz T et al. A phase II study of" exact="afatinib" post="in patients (pts) with metastatic human epidermal growth factor"/>
   <result pre="G Ilson D et al. A phase II study of" exact="afatinib" post="in patients (pts) with metastatic human epidermal growth factor"/>
   <result pre="patients (pts) with metastatic human epidermal growth factor receptor (HER2)-positive" exact="trastuzumab" post="refractory esophagogastric (EG) cancer . J Clin Oncol 2015;"/>
   <result pre="et al. Multicenter phase II study of irinotecan, cisplatin, and" exact="bevacizumab" post="in patients with metastatic gastric or gastroesophageal junction adenocarcinoma"/>
   <result pre="Shen L Li J Xu J et al. Bevacizumab plus" exact="capecitabine" post="and cisplatin in Chinese patients with inoperable locally advanced"/>
   <result pre="Li J Xu J et al. Bevacizumab plus capecitabine and" exact="cisplatin" post="in Chinese patients with inoperable locally advanced or metastatic"/>
   <result pre="Langley RE Thompson LC et al. Bevacizumab with peri-operative epirubicin," exact="cisplatin" post="and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety"/>
   <result pre="Thompson LC et al. Bevacizumab with peri-operative epirubicin, cisplatin and" exact="capecitabine" post="(ECX) in localised gastro-oesophageal adenocarcinoma: a safety report ."/>
   <result pre="H Muro K Van Cutsem E et al. Ramucirumab plus" exact="paclitaxel" post="versus placebo plus paclitaxel in patients with previously treated"/>
   <result pre="Cutsem E et al. Ramucirumab plus paclitaxel versus placebo plus" exact="paclitaxel" post="in patients with previously treated advanced gastric or gastro-oesophageal"/>
   <result pre="al. A randomized, double-blind, placebo- controlled phase III study of" exact="cisplatin" post="plus a fluoropyrimidine with or without ramucirumab as first-line"/>
   <result pre="III study of cisplatin plus a fluoropyrimidine with or without" exact="ramucirumab" post="as first-line therapy in patients with metastatic gastric or"/>
   <result pre="Cutsem E Tabernero J Lakomy R et al. Addition of" exact="aflibercept" post="to fluorouracil, leucovorin, and irinotecan improves survival in a"/>
   <result pre="R et al. Addition of aflibercept to fluorouracil, leucovorin, and" exact="irinotecan" post="improves survival in a phase III randomized trial in"/>
   <result pre="Kang YK Kang WK et al. Phase II study of" exact="sunitinib" post="as second-line treatment for advanced gastric cancer. Invest New"/>
   <result pre="al. An open-label, multicentre biomarker-oriented AIO phase II trial of" exact="sunitinib" post="for patients with chemo-refractory advanced gastric cancer . Eur"/>
   <result pre="Schmitt JM Sommers SR Fisher W et al. Sunitinib plus" exact="paclitaxel" post="in patients with advanced esophageal cancer: a phase II"/>
   <result pre="J Lee J et al. Randomised phase II trial of" exact="docetaxel" post="and sunitinib in patients with metastatic gastric cancer who"/>
   <result pre="J et al. Randomised phase II trial of docetaxel and" exact="sunitinib" post="in patients with metastatic gastric cancer who were previously"/>
   <result pre="J Yang S et al. Phase I dose-finding study of" exact="sorafenib" post="with FOLFOX4 as first-line treatment in patients with unresectable"/>
   <result pre="JL Choi YH et al. Phase I dose-finding study of" exact="sorafenib" post="in combination with capecitabine and cisplatin as a first-line"/>
   <result pre="al. Phase I dose-finding study of sorafenib in combination with" exact="capecitabine" post="and cisplatin as a first-line treatment in patients with"/>
   <result pre="I dose-finding study of sorafenib in combination with capecitabine and" exact="cisplatin" post="as a first-line treatment in patients with advanced gastric"/>
   <result pre="N Fuse N et al. A phase I study of" exact="sorafenib" post="in combination with S-1 plus cisplatin in patients with"/>
   <result pre="phase I study of sorafenib in combination with S-1 plus" exact="cisplatin" post="in patients with advanced gastric cancer . Gastric Cancer"/>
   <result pre="R Pericay C et al. Multicenter phase II study of" exact="oxaliplatin" post="and sorafenib in advanced gastric adenocarcinoma after failure of"/>
   <result pre="C et al. Multicenter phase II study of oxaliplatin and" exact="sorafenib" post="in advanced gastric adenocarcinoma after failure of cisplatin and"/>
   <result pre="oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of" exact="cisplatin" post="and fluoropyrimidine treatment. A GEMCAD study . Invest New"/>
   <result pre="Powell M O'Dwyer PJ et al. Phase II study of" exact="sorafenib" post="in combination with docetaxel and cisplatin in the treatment"/>
   <result pre="et al. Phase II study of sorafenib in combination with" exact="docetaxel" post="and cisplatin in the treatment of metastatic or advanced"/>
   <result pre="Phase II study of sorafenib in combination with docetaxel and" exact="cisplatin" post="in the treatment of metastatic or advanced gastric and"/>
   <result pre="Reichardt P Kang YK et al. Efficacy and safety of" exact="regorafenib" post="for advanced gastrointestinal stromal tumours after failure of imatinib"/>
   <result pre="of regorafenib for advanced gastrointestinal stromal tumours after failure of" exact="imatinib" post="and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase"/>
   <result pre="for advanced gastrointestinal stromal tumours after failure of imatinib and" exact="sunitinib" post="(GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial"/>
   <result pre="INTEGRATE: A randomized phase II double- blind placebo-controlled study of" exact="regorafenib" post="in refractory advanced oesophagogastric cancer (AOGC)—A study by the"/>
   <result pre="aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to" exact="crizotinib" post=". J Clin Oncol 2011; 29 : 4803 –"/>
   <result pre="I et al. Rilotumumab in combination with epirubicin, cisplatin, and" exact="capecitabine" post="as first-line treatment for gastric or oesophagogastric junction adenocarcinoma:"/>
   <result pre="double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin," exact="cisplatin" post="and capecitabine (ECX) as first-line therapy in patients (pts)"/>
   <result pre="placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and" exact="capecitabine" post="(ECX) as first-line therapy in patients (pts) with advanced"/>
   <result pre="randomized, double-blind, placebo- controlled study of rilotumumab in combination with" exact="cisplatin" post="and capecitabine (CX) as first- line therapy for Asian"/>
   <result pre="placebo- controlled study of rilotumumab in combination with cisplatin and" exact="capecitabine" post="(CX) as first- line therapy for Asian patients (pts)"/>
   <result pre="et al. Antitumor action of the MET tyrosine kinase inhibitor" exact="crizotinib" post="(PF-02341066) in gastric cancer positive for MET amplification ."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4656949/results/search/inn/results.xml">
   <result pre="shown that biologics with specificity for VEGF A such as" exact="bevacizumab" post="and ranibizumab (a recombinant antibody and an antibody fragment,"/>
   <result pre="biologics with specificity for VEGF A such as bevacizumab and" exact="ranibizumab" post="(a recombinant antibody and an antibody fragment, respectively) or"/>
   <result pre="clinical trials. VEGF inhibitors such as pegaptanib sodium (Macugen™, OSI/Eyetech)," exact="ranibizumab" post="(Lucentis™, Genentech) and off-label bevacizumab (Avastin™, Genentech) are currently"/>
   <result pre="as pegaptanib sodium (Macugen™, OSI/Eyetech), ranibizumab (Lucentis™, Genentech) and off-label" exact="bevacizumab" post="(Avastin™, Genentech) are currently used for the treatment of"/>
   <result pre="of corneal neovascularization through topical, subconjunctival, and intraocular application of" exact="bevacizumab" post="and improving corneal transparency following corneal alkali burn injury"/>
   <result pre="basement membrane [ 12 , 13 ]. Subconjunctival administration of" exact="bevacizumab" post="induced an involution of new vessels, abolished inflammatory response"/>
   <result pre="return of corneal function [ 14 ]. Studies demonstrated that" exact="bevacizumab" post="is nontoxic to human corneal epithelial and fibroblast cells"/>
   <result pre="trigger NV in inflamed or ischemic tissues including the cornea,and" exact="bevacizumab" post="has been reported to inhibit NV formation in inflamed"/>
   <result pre="severe refractory uveitis after bone marrow transplants. Comparative studies between" exact="bevacizumab" post="and tacrolimus show that topical and subconjunctival tacrolimus application"/>
   <result pre="uveitis after bone marrow transplants. Comparative studies between bevacizumab and" exact="tacrolimus" post="show that topical and subconjunctival tacrolimus application may be"/>
   <result pre="studies between bevacizumab and tacrolimus show that topical and subconjunctival" exact="tacrolimus" post="application may be useful in reducing corneal NV and"/>
   <result pre="in reducing corneal NV and have comparable effects to subconjunctival" exact="bevacizumab" post="injection [ 21 ]. The topical administration of both"/>
   <result pre="bevacizumab injection [ 21 ]. The topical administration of both" exact="bevacizumab" post="and sunitinib (anti VEGF and anti PDGF) inhibits corneal"/>
   <result pre="[ 21 ]. The topical administration of both bevacizumab and" exact="sunitinib" post="(anti VEGF and anti PDGF) inhibits corneal neovascularization in"/>
   <result pre="rabbits. But vascular endothelial growth factor (VEGF) pathway blockade by" exact="bevacizumab" post="is not sufficient for a profound inhibition. Blocking both"/>
   <result pre="Blocking both VEGF and platelet-derived growth factor pathways by using" exact="sunitinib" post="is three times more effective [ 11 ]. Tocilizumab"/>
   <result pre="antiangiogenic effect was observed after subconjunctival injection of 2.5 mg" exact="tocilizumab" post="to an extent similar to that seen with 2.5"/>
   <result pre="with 2.5 mg bevacizumab, which indicates that subconjunctival application of" exact="tocilizumab" post="is effective for the inhibition of corneal neovascularization ["/>
   <result pre="weight of 48kD, making it approximately one-third the size of" exact="bevacizumab" post="and theoretically allowing a better corneal penetration; additionally, ranibizumab"/>
   <result pre="of bevacizumab and theoretically allowing a better corneal penetration; additionally," exact="ranibizumab" post="has been affinity-matured to optimize its VEGF-A binding potential."/>
   <result pre="to optimize its VEGF-A binding potential. These characteristics may enable" exact="ranibizumab" post="to treat corneal NV more effectively than bevacizumab ["/>
   <result pre="may enable ranibizumab to treat corneal NV more effectively than" exact="bevacizumab" post="[ 20 ]. Bevacizumab and ranibizumab have similar VEGF-binding"/>
   <result pre="NV more effectively than bevacizumab [ 20 ]. Bevacizumab and" exact="ranibizumab" post="have similar VEGF-binding characteristics because both drugs are related"/>
   <result pre="so that it binds VEGF-A with significantly higher affinity. Topical" exact="ranibizumab" post="1% is effective in the treatment of clinically stable"/>
   <result pre="change in invasion area suggests that the main outcome of" exact="ranibizumab" post="treatment is to induce the narrowing of blood vessels"/>
   <result pre="Experimental studies on rabbits demonstrated that early subconjunctival administration of" exact="ranibizumab" post="may successfully inhibit alkali-induced corneal neovascularization. Subconjunctival ranibizumab reduces"/>
   <result pre="administration of ranibizumab may successfully inhibit alkali-induced corneal neovascularization. Subconjunctival" exact="ranibizumab" post="reduces VEGF levels significantly not only in the cornea"/>
   <result pre="and the iris [ 18 ]. A comparative study of" exact="ranibizumab" post="and bevacizumab on corneal neovascularization in rabbits indicated that"/>
   <result pre="iris [ 18 ]. A comparative study of ranibizumab and" exact="bevacizumab" post="on corneal neovascularization in rabbits indicated that subconjunctival administrations"/>
   <result pre="of the treatment after the onset of NV. Early subconjunctival" exact="bevacizumab" post="administration (one day after injury) inhibited corneal NV more"/>
   <result pre="result in rabbit eyes with limbal insufficiency. Early and mid-point" exact="bevacizumab" post="injections inhibited epithelial alteration, the development of stromal opacity,"/>
   <result pre="[ 27 ]. Such coverage may decrease the effect of" exact="bevacizumab" post="on the regression of newly formed immature vessels. Pegaptanib"/>
   <result pre="controlling corneal neovascularization after corneal burn in rats. In addition," exact="bevacizumab" post="is more effective than ranibizumab and pegaptanib sodium. Ranibizumab"/>
   <result pre="burn in rats. In addition, bevacizumab is more effective than" exact="ranibizumab" post="and pegaptanib sodium. Ranibizumab and pegaptanib sodium had a"/>
   <result pre="alkali-induced corneal NV in rats. The inhibitory effects of topical" exact="regorafenib" post="were comparable to those of topical dexamethasone and bevacizumab"/>
   <result pre="effects of topical regorafenib were comparable to those of topical" exact="dexamethasone" post="and bevacizumab [ 23 ]. Monoclonal antibodies induce their"/>
   <result pre="topical regorafenib were comparable to those of topical dexamethasone and" exact="bevacizumab" post="[ 23 ]. Monoclonal antibodies induce their effect by"/>
   <result pre="process in ocular pathologies. Lapatinib used in the form of" exact="lapatinib" post="ditosylate, is an orally active drug for breast cancer"/>
   <result pre="treatment of experimental corneal neovascularization and suggested that systemically administered" exact="lapatinib" post="is more effective than systemically administered trastuzumab in preventing"/>
   <result pre="that systemically administered lapatinib is more effective than systemically administered" exact="trastuzumab" post="in preventing corneal neovascularization [ 31 ]. Antibody based"/>
   <result pre="VEGF-A189, and VEGF-A206. VEGF-A165 is the dominant proangiogenic isoform. Both" exact="bevacizumab" post="and ranibizumab use the same mechanisms and all inhibit"/>
   <result pre="VEGF-A206. VEGF-A165 is the dominant proangiogenic isoform. Both bevacizumab and" exact="ranibizumab" post="use the same mechanisms and all inhibit the VEGF-A"/>
   <result pre="the VEGF-A isoforms nonspecifically [ 28 ]. Nevertheless, differently from" exact="bevacizumab" post="and ranibizumab, pegaptanib does not inhibit all of the"/>
   <result pre="Javaloy J Alió JL Inhibition of corneal neovascularization by topical" exact="bevacizumab" post="(Anti-VEGF) and Sunitinib (Anti-VEGF and Anti-PDGF) in an animal"/>
   <result pre="I Weinberger D Kremer I Effect of subconjunctival and intraocular" exact="bevacizumab" post="injections on corneal neovascularization in a mouse model Curr"/>
   <result pre="VS Murthy RK Sharma RK Evaluation of cytotoxic effects of" exact="bevacizumab" post="on human corneal cells Cornea 2009 4 28 3"/>
   <result pre="Vergados I Douvali M Theodossiadis PG The effect of subconjunctival" exact="ranibizumab" post="on corneal and anterior segment neovascularization: study on an"/>
   <result pre="19 Kim EK Kong SJ Chung SK Comparative study of" exact="ranibizumab" post="and bevacizumab on corneal neovascularization in rabbits Cornea 2014"/>
   <result pre="EK Kong SJ Chung SK Comparative study of ranibizumab and" exact="bevacizumab" post="on corneal neovascularization in rabbits Cornea 2014 1 33"/>
   <result pre="R Corneal neovascularization and the utility of topical VEGF inhibition:" exact="ranibizumab" post="(Lucentis) vs bevacizumab (Avastin) Ocul Surf 2012 4 10"/>
   <result pre="and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs" exact="bevacizumab" post="(Avastin) Ocul Surf 2012 4 10 2 67 83"/>
   <result pre="2 3 22 Yoo AR Chung SK Effects of subconjunctival" exact="tocilizumab" post="versus bevacizumab in treatment ofcorneal neovascularization in rabbits Cornea"/>
   <result pre="22 Yoo AR Chung SK Effects of subconjunctival tocilizumab versus" exact="bevacizumab" post="in treatment ofcorneal neovascularization in rabbits Cornea 2014 10"/>
   <result pre="LP Chen CT Hu FR Mechanisms controlling the effects of" exact="bevacizumab" post="(avastin) on the inhibition of early but not late"/>
   <result pre="HC Lee JH Choi SK Lee D The effect of" exact="bevacizumab" post="versus ranibizumab in the treatment of corneal neovascularization: a"/>
   <result pre="JH Choi SK Lee D The effect of bevacizumab versus" exact="ranibizumab" post="in the treatment of corneal neovascularization: a preliminary study"/>
   <result pre="KT et al. The different effects of early and late" exact="bevacizumab" post="(Avastin) injection on inhibiting corneal neovascularization and conjunctivalization in"/>
   <result pre="Demir T Bulut H Akpolat N Turgut B Effects of" exact="lapatinib" post="and trastuzumab on vascular endothelial growth factor in experimental"/>
   <result pre="Bulut H Akpolat N Turgut B Effects of lapatinib and" exact="trastuzumab" post="on vascular endothelial growth factor in experimental corneal neovascularization"/>
   <result pre="C Franchini S Rama P Safety and efficacy of topical" exact="infliximab" post="in a mouse model of ocular surface scarring Invest"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4657380/results/search/inn/results.xml">
   <result pre="are some reports showing response of brain metastases to tamoxifen," exact="megestrol" post="acetate and aromatase inhibitors [ 56– 61]. Interestingly, tamoxifen"/>
   <result pre="tamoxifen, megestrol acetate and aromatase inhibitors [ 56– 61]. Interestingly," exact="tamoxifen" post="and its metabolites can achieve high concentrations in the"/>
   <result pre="For example, in patients without brain metastases, the ratio of" exact="trastuzumab" post="in plasma to trastuzumab in cerebrospinal fluid is &amp;gt;300:1"/>
   <result pre="without brain metastases, the ratio of trastuzumab in plasma to" exact="trastuzumab" post="in cerebrospinal fluid is &amp;gt;300:1 [ 64, 65]. The"/>
   <result pre="clinical studies have shown that the combination of chemotherapy with" exact="trastuzumab" post="improved survival, even after the development of brain metastases"/>
   <result pre="the treatment of HER2-positive brain metastases. As a single agent," exact="lapatinib" post="has shown response rates in the brain ranging from"/>
   <result pre="is observed in previously untreated patients, where the combination of" exact="lapatinib" post="and capecitabine produces an objective response rate of 65.9"/>
   <result pre="in previously untreated patients, where the combination of lapatinib and" exact="capecitabine" post="produces an objective response rate of 65.9 %, with"/>
   <result pre="as the first site of progression from 6 % with" exact="capecitabine" post="alone to 2 % with capecitabine and trastuzumab ("/>
   <result pre="from 6 % with capecitabine alone to 2 % with" exact="capecitabine" post="and trastuzumab ( P = 0.045) [ 79]. The"/>
   <result pre="% with capecitabine alone to 2 % with capecitabine and" exact="trastuzumab" post="( P = 0.045) [ 79]. The efficacy of"/>
   <result pre="trastuzumab ( P = 0.045) [ 79]. The efficacy of" exact="lapatinib" post="to prevent brain metastases was further tested in the"/>
   <result pre="HER2-positive metastatic breast cancer without CNS metastases were randomized to" exact="lapatinib" post="or trastuzumab in combination with capecitabine. The primary end"/>
   <result pre="breast cancer without CNS metastases were randomized to lapatinib or" exact="trastuzumab" post="in combination with capecitabine. The primary end point of"/>
   <result pre="arms for the incidence of CNS metastases (3 % for" exact="lapatinib" post="vs. 5 % for trastuzumab, P = 0.36), however"/>
   <result pre="0.36), however progression-free survival and overall survival were longer with" exact="trastuzumab" post="and capecitabine [ 80]. Despite the low incidence of"/>
   <result pre="progression-free survival and overall survival were longer with trastuzumab and" exact="capecitabine" post="[ 80]. Despite the low incidence of CNS metastases"/>
   <result pre="(T-DM1), a novel antibody–drug conjugate, improved overall survival compared with" exact="lapatinib" post="plus capecitabine in patients with previously treated HER2-positive metastatic"/>
   <result pre="novel antibody–drug conjugate, improved overall survival compared with lapatinib plus" exact="capecitabine" post="in patients with previously treated HER2-positive metastatic breast cancer"/>
   <result pre="experienced significant improvements in progression-free and overall survival with pertuzumab," exact="trastuzumab" post="and docetaxel compared with placebo, trastuzumab and docetaxel ["/>
   <result pre="improvements in progression-free and overall survival with pertuzumab, trastuzumab and" exact="docetaxel" post="compared with placebo, trastuzumab and docetaxel [ 63]. In"/>
   <result pre="overall survival with pertuzumab, trastuzumab and docetaxel compared with placebo," exact="trastuzumab" post="and docetaxel [ 63]. In this trial, an exploratory"/>
   <result pre="with pertuzumab, trastuzumab and docetaxel compared with placebo, trastuzumab and" exact="docetaxel" post="[ 63]. In this trial, an exploratory analysis of"/>
   <result pre="to development of CNS metastases was significantly prolonged in the" exact="pertuzumab" post="arm from 11.9 to 15 months ( P ="/>
   <result pre="with traditional chemotherapy combinations [ 86, 87]. A study evaluating" exact="cisplatin" post="with etoposide showed 38 % response rate in the"/>
   <result pre="chemotherapy combinations [ 86, 87]. A study evaluating cisplatin with" exact="etoposide" post="showed 38 % response rate in the brain ["/>
   <result pre="agent [ 89, 90]. However, when temozolamide was combined with" exact="cisplatin" post="had 40 % response rate [ 91], and showed"/>
   <result pre="91], and showed 18 % response rate when combined with" exact="capecitabine" post="[ 92]. The experience with single agent capecitabine is"/>
   <result pre="combined with capecitabine [ 92]. The experience with single agent" exact="capecitabine" post="is limited to mostly retrospective studies [ 93]. It"/>
   <result pre="area of great potential for future research. The use of" exact="bevacizumab" post="has shown good results in patients with glioblastoma and"/>
   <result pre="reported. One showed CNS response rate of 63 % for" exact="bevacizumab" post="and carboplatin; and the other one showed a response"/>
   <result pre="one showed a response rate of 60 % for bevacizumab," exact="etoposide" post="and cisplatin [ 94, 95]. It is important to"/>
   <result pre="a response rate of 60 % for bevacizumab, etoposide and" exact="cisplatin" post="[ 94, 95]. It is important to consider that"/>
   <result pre="to show an overall survival benefit with the use of" exact="bevacizumab" post="in metastatic breast cancer, which resulted in the US"/>
   <result pre="metastases [ 97]. Everolimus is being evaluated in combination with" exact="capecitabine" post="and lapatinib (NCT01783756) and in combination with vinorelbine and"/>
   <result pre="97]. Everolimus is being evaluated in combination with capecitabine and" exact="lapatinib" post="(NCT01783756) and in combination with vinorelbine and trastuzumab (NCT01305941)"/>
   <result pre="combination with capecitabine and lapatinib (NCT01783756) and in combination with" exact="vinorelbine" post="and trastuzumab (NCT01305941) in patients with HER2-positive brain metastases."/>
   <result pre="capecitabine and lapatinib (NCT01783756) and in combination with vinorelbine and" exact="trastuzumab" post="(NCT01305941) in patients with HER2-positive brain metastases. Given the"/>
   <result pre="NCT01332630 Phase II ANG1005 None NCT02048059 Phase II ANG1005 +" exact="trastuzumab" post="(if HER2-positive) None NCT01480583 Phase II Liposomal cytarabine +"/>
   <result pre="ANG1005 + trastuzumab (if HER2-positive) None NCT01480583 Phase II Liposomal" exact="cytarabine" post="+ high-dose methotrexate None NCT00992602 Phase II VEGF Bevacizumab"/>
   <result pre="(if HER2-positive) None NCT01480583 Phase II Liposomal cytarabine + high-dose" exact="methotrexate" post="None NCT00992602 Phase II VEGF Bevacizumab + carboplatin +"/>
   <result pre="+ high-dose methotrexate None NCT00992602 Phase II VEGF Bevacizumab +" exact="carboplatin" post="+ trastuzumab (if HER2-positive) None NCT01004172 Phase II Bevacizumab"/>
   <result pre="methotrexate None NCT00992602 Phase II VEGF Bevacizumab + carboplatin +" exact="trastuzumab" post="(if HER2-positive) None NCT01004172 Phase II Bevacizumab + etoposide"/>
   <result pre="+ trastuzumab (if HER2-positive) None NCT01004172 Phase II Bevacizumab +" exact="etoposide" post="+ cisplatin followed by WBRT WBRT alone NCT02185352 Phase"/>
   <result pre="(if HER2-positive) None NCT01004172 Phase II Bevacizumab + etoposide +" exact="cisplatin" post="followed by WBRT WBRT alone NCT02185352 Phase II Sorafenib"/>
   <result pre="II Sorafenib + WBRT None NCT01724606 Phase I Cabozantinib +" exact="trastuzumab" post="(if HER2-positive) None NCT02260531 Phase II Radiation WBRT +"/>
   <result pre="WBRT + oxygen NCT00083304 Phase III HER2-positive Chemotherapy Cabazitaxel +" exact="lapatinib" post="None NCT01934894 Phase II HER2 Lapatinib + WBRT WBRT"/>
   <result pre="Lapatinib + WBRT WBRT alone NCT01622868 Phase II Neratinib ±" exact="capecitabine" post="None NCT01494662 Phase II Afatinib ± vinorelbine Investigator’s choice"/>
   <result pre="II Neratinib ± capecitabine None NCT01494662 Phase II Afatinib ±" exact="vinorelbine" post="Investigator’s choice NCT01441596 Phase II T-DM1 + WBRT None"/>
   <result pre="II T-DM1 + WBRT None NCT02135159 Phase I ARRY-380 +" exact="trastuzumab" post="None NCT01921335 Phase I mTOR Everolimus + trastuzumab +"/>
   <result pre="ARRY-380 + trastuzumab None NCT01921335 Phase I mTOR Everolimus +" exact="trastuzumab" post="+ vinorelbine None NCT01305941 Phase II Everolimus + lapatinib"/>
   <result pre="trastuzumab None NCT01921335 Phase I mTOR Everolimus + trastuzumab +" exact="vinorelbine" post="None NCT01305941 Phase II Everolimus + lapatinib + capecitabine"/>
   <result pre="+ trastuzumab + vinorelbine None NCT01305941 Phase II Everolimus +" exact="lapatinib" post="+ capecitabine None NCT01783756 Phase Ib/II PI3K BKM120 +"/>
   <result pre="+ vinorelbine None NCT01305941 Phase II Everolimus + lapatinib +" exact="capecitabine" post="None NCT01783756 Phase Ib/II PI3K BKM120 + trastuzumab ±"/>
   <result pre="lapatinib + capecitabine None NCT01783756 Phase Ib/II PI3K BKM120 +" exact="trastuzumab" post="± capecitabine None NCT01132664 Phase Ib/II MET Tesevatinib +"/>
   <result pre="capecitabine None NCT01783756 Phase Ib/II PI3K BKM120 + trastuzumab ±" exact="capecitabine" post="None NCT01132664 Phase Ib/II MET Tesevatinib + trastuzumab None"/>
   <result pre="trastuzumab ± capecitabine None NCT01132664 Phase Ib/II MET Tesevatinib +" exact="trastuzumab" post="None NCT02154529 Phase Ib/IIa Radiation PCI None NCT00916877 Phase"/>
   <result pre="Radiation PCI None NCT00916877 Phase I PCI + taxane +" exact="trastuzumab" post="Taxane + trastuzumab NCT00639366 Phase III SRS + HER2"/>
   <result pre="NCT00916877 Phase I PCI + taxane + trastuzumab Taxane +" exact="trastuzumab" post="NCT00639366 Phase III SRS + HER2 directed therapy None"/>
   <result pre="directed therapy None NCT01924351 Phase II Triple-negative PI3K BKM120 +" exact="capecitabine" post="None NCT02000882 Phase II PARP Iniparib + irinotecan None"/>
   <result pre="BKM120 + capecitabine None NCT02000882 Phase II PARP Iniparib +" exact="irinotecan" post="None NCT01173497 Phase II Radiation PCI Observation NCT02448576 Phase"/>
   <result pre="OS Larsen M Longterm remission of multiple brain metastases with" exact="tamoxifen" post="J Neuro-oncol 1991 10 2 173 177 10.1007/BF00146879 58."/>
   <result pre="Dahrouge S Response of brain metastases from breast cancer to" exact="megestrol" post="acetate: a case report J Neuro-oncol 1995 24 3"/>
   <result pre="S, Puri T, Julka PK, Rath GK. Excellent response to" exact="letrozole" post="in brain metastases from breast cancer. Acta Neurochir. 2008;150(6):613–4"/>
   <result pre="case of brain metastases from breast cancer that responded to" exact="anastrozole" post="monotherapy Breast J 2009 15 4 435 437 10.1111/j.1524-4741.2009.00756.x"/>
   <result pre="Wester K Lonning PE Solheim E Ueland PM Distribution of" exact="tamoxifen" post="and metabolites into brain tissue and brain metastases in"/>
   <result pre="J Semiglazov V Campone M et al. Pertuzumab, trastuzumab, and" exact="docetaxel" post="in HER2-positive metastatic breast cancer N Engl J Med."/>
   <result pre="Come SE Ewend M et al. Phase II trial of" exact="lapatinib" post="for brain metastases in patients with human epidermal growth"/>
   <result pre="C Stemmler HJ et al. Multicenter phase II study of" exact="lapatinib" post="in patients with brain metastases from HER2-positive breast cancer"/>
   <result pre="N et al. Treatment of HER2-positive metastatic breast cancer with" exact="lapatinib" post="and capecitabine in the lapatinib expanded access programme, including"/>
   <result pre="al. Treatment of HER2-positive metastatic breast cancer with lapatinib and" exact="capecitabine" post="in the lapatinib expanded access programme, including efficacy in"/>
   <result pre="HER2-positive metastatic breast cancer with lapatinib and capecitabine in the" exact="lapatinib" post="expanded access programme, including efficacy in brain metastases–the UK"/>
   <result pre="patients with brain metastases from HER2-positive breast cancer treated with" exact="lapatinib" post="and capecitabine Ann Oncol Off J Eur Soc Med"/>
   <result pre="brain metastases from HER2-positive breast cancer treated with lapatinib and" exact="capecitabine" post="Ann Oncol Off J Eur Soc Med Oncol/ESMO. 2011"/>
   <result pre="Y Usami S et al. A phase II study of" exact="lapatinib" post="for brain metastases in patients with HER2-overexpressing breast cancer"/>
   <result pre="for brain metastases in patients with HER2-overexpressing breast cancer following" exact="trastuzumab" post="based systemic therapy and cranial radiotherapy: subset analysis of"/>
   <result pre="HER2-positive metastatic breast cancer patients with brain metastasis treated with" exact="lapatinib" post="and capecitabine: an open-label expanded access study in Korea"/>
   <result pre="Dieras V Cropet C Dalenc F et al. Lapatinib plus" exact="capecitabine" post="in patients with previously untreated brain metastases from HER2-positive"/>
   <result pre="Romieu CG et al. A phase III randomized comparison of" exact="lapatinib" post="plus capecitabine versus capecitabine alone in women with advanced"/>
   <result pre="et al. A phase III randomized comparison of lapatinib plus" exact="capecitabine" post="versus capecitabine alone in women with advanced breast cancer"/>
   <result pre="A phase III randomized comparison of lapatinib plus capecitabine versus" exact="capecitabine" post="alone in women with advanced breast cancer that has"/>
   <result pre="al. CEREBEL (EGF111438): a phase III, randomized, open-label study of" exact="lapatinib" post="plus capecitabine versus trastuzumab plus capecitabine in patients with"/>
   <result pre="(EGF111438): a phase III, randomized, open-label study of lapatinib plus" exact="capecitabine" post="versus trastuzumab plus capecitabine in patients with human epidermal"/>
   <result pre="phase III, randomized, open-label study of lapatinib plus capecitabine versus" exact="trastuzumab" post="plus capecitabine in patients with human epidermal growth factor"/>
   <result pre="randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus" exact="capecitabine" post="in patients with human epidermal growth factor receptor 2-positive"/>
   <result pre="Huober J Lu M et al. Trastuzumab emtansine (T-DM1) versus" exact="lapatinib" post="plus capecitabine in patients with HER2-positive metastatic breast cancer"/>
   <result pre="Lu M et al. Trastuzumab emtansine (T-DM1) versus lapatinib plus" exact="capecitabine" post="in patients with HER2-positive metastatic breast cancer and central"/>
   <result pre="F Fosser V Tonato M et al. Front-line chemotherapy with" exact="cisplatin" post="and etoposide for patients with brain metastases from breast"/>
   <result pre="V Tonato M et al. Front-line chemotherapy with cisplatin and" exact="etoposide" post="for patients with brain metastases from breast carcinoma, nonsmall"/>
   <result pre="Bamias A Carina M et al. Temozolomide (TMZ) combined with" exact="cisplatin" post="(CDDP) in patients with brain metastases from solid tumors:"/>
   <result pre="Francis D Arun B et al. Phase I study of" exact="capecitabine" post="in combination with temozolomide in the treatment of patients"/>
   <result pre="et al. Phase I study of capecitabine in combination with" exact="temozolomide" post="in the treatment of patients with brain metastases from"/>
   <result pre="Freedman RA, Sorensen AG, et al. Phase II trial of" exact="carboplatin" post="(C) and bevacizumab (BEV) in patients (pts) with breast"/>
   <result pre="AG, et al. Phase II trial of carboplatin (C) and" exact="bevacizumab" post="(BEV) in patients (pts) with breast cancer brain metastases"/>
   <result pre="LM, Yeh DC, Wu PF, et al. Bevacizumab, etoposide, and" exact="cisplatin" post="(BEEP) in brain metastases of breast cancer progressing from"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4657385/results/search/inn/results.xml">
   <result pre="2001) and also binds to the mutant receptor EGFRvIII. The" exact="cetuximab" post="promotes EGFR internalization ( Sunada et al., 1986). Panitumumab"/>
   <result pre="currently under evaluation for the treatment of cancer. Erlotinib or" exact="gefitinib" post="are the first-generation reversible EGFR-TKIs and are approved first-line"/>
   <result pre="with cell lines over-expressing EGFR and HER2 have shown that" exact="lapatinib" post="inhibits tyrosine phosphorylation in catalytic domain of EGFR and"/>
   <result pre="blocking ligand binding to EGFR in a manner similar to" exact="cetuximab" post="or by binding an epitope near the EGFR domain"/>
   <result pre="to HER2 receptor on an epitope different from that of" exact="trastuzumab" post="and with an affinity constant of 50 nM ("/>
   <result pre="M. et al. ( 2010). Randomized, phase III trial of" exact="panitumumab" post="with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4"/>
   <result pre="phase III trial of panitumumab with infusional fluorouracil, leucovorin, and" exact="oxaliplatin" post="(FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients"/>
   <result pre="al. ( 2012). Activation of an IL6 inflammatory loop mediates" exact="trastuzumab" post="resistance in HER2+ breast cancer by expanding the cancer"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4659935/results/search/inn/results.xml">
   <result pre="Supplementary Table 2). The patient was started on treatment with" exact="trastuzumab" post="and taxane-based chemotherapy, with a significant partial response ("/>
   <result pre="Supplementary Fig. 3). After induction chemotherapy, she was maintained on" exact="tamoxifen" post="and trastuzumab. After 19 months on treatment, she presented"/>
   <result pre="( Supplementary Fig. 4), which was resected (M2.1). Therapy with" exact="tamoxifen" post="and trastuzumab was continued and collection of plasma samples"/>
   <result pre="Fig. 4), which was resected (M2.1). Therapy with tamoxifen and" exact="trastuzumab" post="was continued and collection of plasma samples was initiated"/>
   <result pre="Supplementary Fig. 5). Treatment was switched to a combination of" exact="lapatinib" post="and capecitabine, resulting in stable disease for 12 months"/>
   <result pre="private mutations originating from each tumour site was calculated. During" exact="lapatinib" post="treatment, a rapid increase in the circulating abundance of"/>
   <result pre="cluster 5 increased in circulating prevalence with disease progression on" exact="lapatinib" post="treatment and 10/11 mutations in this cluster are private"/>
   <result pre="Fig. 2b and Supplementary Data 1). At the time of" exact="lapatinib" post="resistance, the most abundant private mutation in plasma was"/>
   <result pre="(28.2% AF) with its levels in plasma DNA increasing during" exact="lapatinib" post="treatment up to an AF of 12.2% at the"/>
   <result pre="an AF of 3.5% at the time of progression on" exact="trastuzumab" post="and tamoxifen (tumour cluster 8 and plasma cluster 4;"/>
   <result pre="of 3.5% at the time of progression on trastuzumab and" exact="tamoxifen" post="(tumour cluster 8 and plasma cluster 4; Fig. 2e)."/>
   <result pre="(tumour cluster 8 and plasma cluster 4; Fig. 2e). After" exact="lapatinib" post="treatment was started, the plasma levels dropped to AF"/>
   <result pre="minor tumour sub-clone that increased in size during treatment with" exact="tamoxifen" post="and trastuzumab, and then regressed on treatment with lapatinib."/>
   <result pre="has been associated with resistance to both endocrine therapy and" exact="trastuzumab" post="19 20. Discussion In this paper, we have presented"/>
   <result pre="approach identifies the PI3K pathway as a major determinant of" exact="trastuzumab" post="resistance in breast cancer . Cancer Cell 12, 395–"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4664841/results/search/inn/results.xml">
   <result pre="the anti-HER2 monoclonal antibody, trastuzumab, led to clinical trials of" exact="trastuzumab" post="in combination with systemic chemotherapy for the treatment of"/>
   <result pre="lapatanib ( n = 4). CPT-11 (350 mg/m 2) and" exact="bevacizumab" post="(10 mg/kg) were administered every 3 weeks for a"/>
   <result pre="a 6-week cycle (three patients) or every 2 weeks of" exact="bevacizumab" post="(10 mg/kg) and CPT-11 (125 mg/m 2) for a"/>
   <result pre="treated with 2000 cGy. After lumpectomy, she received radiation and" exact="cyclophosphamide" post="+ methotrexate + 5-fluorouracil chemotherapy. She had recurrence 6"/>
   <result pre="2000 cGy. After lumpectomy, she received radiation and cyclophosphamide +" exact="methotrexate" post="+ 5-fluorouracil chemotherapy. She had recurrence 6 years later"/>
   <result pre="22 February 2008, the US Food and Drug Administration approved" exact="bevacizumab" post="(Avastin; Genentech) plus paclitaxel as first-line therapy in patients"/>
   <result pre="US Food and Drug Administration approved bevacizumab (Avastin; Genentech) plus" exact="paclitaxel" post="as first-line therapy in patients with metastatic breast cancer"/>
   <result pre="HER2-positive node-positive or high-risk node-negative breast cancer comparing chemotherapy plus" exact="trastuzumab" post="with chemotherapy plus trastuzumab plus bevacizumab, otherwise known as"/>
   <result pre="node-negative breast cancer comparing chemotherapy plus trastuzumab with chemotherapy plus" exact="trastuzumab" post="plus bevacizumab, otherwise known as the BETH trial, is"/>
   <result pre="This case series illustrates that the combination of CPT-11 and" exact="bevacizumab" post="yielded a high radiographic response for the treatment of"/>
   <result pre="J Seidman AD Rosen PP Norton L HER2 overexpression and" exact="paclitaxel" post="sensitivity in breast cancer: therapeutic implications. Oncology 1997; 11:"/>
   <result pre="J et al. Predicting treatment response of malignant gliomas to" exact="bevacizumab" post="and irinotecan by imaging proliferation with [18F] fluorothymidine positron"/>
   <result pre="al. Predicting treatment response of malignant gliomas to bevacizumab and" exact="irinotecan" post="by imaging proliferation with [18F] fluorothymidine positron emission tomography:"/>
   <result pre="Reardon DA Quinn JA Rich JN et al. Bevacizumab plus" exact="irinotecan" post="in recurrent glioblastoma multiforme. J Clin Oncol 2007; 25:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4665969/results/search/inn/results.xml">
   <result pre="of the present study was to describe the use of" exact="pertuzumab" post="in Japan. A phase I clinical trial of pertuzumab"/>
   <result pre="of pertuzumab in Japan. A phase I clinical trial of" exact="pertuzumab" post="for HER2-positive metastatic breast cancer was first conducted in"/>
   <result pre="(study ID no. BO17929) and no phase II trial of" exact="pertuzumab" post="for Japanese patients has yet been conducted. A phase"/>
   <result pre="patients has yet been conducted. A phase III trial on" exact="pertuzumab" post="for metastatic breast cancer (CLEOPATRA study), which included 53"/>
   <result pre="cancer (CLEOPATRA study), which included 53 Japanese patients, revealed that" exact="pertuzumab" post="significantly prolonged progression-free and overall survival. However, the superiority"/>
   <result pre="prolonged progression-free and overall survival. However, the superiority of the" exact="pertuzumab" post="group was not verified in the subgroup analysis of"/>
   <result pre="initiated in November, 2013, to investigate the clinical effectiveness of" exact="pertuzumab" post="in Japanese patients. As of December, 2014, global trials"/>
   <result pre="in Japanese patients. As of December, 2014, global trials on" exact="pertuzumab" post="in the metastatic and adjuvant settings are currently ongoing."/>
   <result pre="Japanes Pharmaceutical and Medical Devices Agency approved the administration of" exact="pertuzumab" post="as second- or later-line treatment for HER2-positive metastatic breast"/>
   <result pre="HER2-positive metastatic breast cancer, as well as first-line treatment. Furthermore," exact="pertuzumab" post="may be used in combination with other chemotherapeutic agents,"/>
   <result pre="exception of docetaxel. The approval of the expanded use of" exact="pertuzumab" post="is likely to accelerate the market penetration of pertuzumab"/>
   <result pre="of pertuzumab is likely to accelerate the market penetration of" exact="pertuzumab" post="in Japan more quickly compared with other countries. pertuzumab"/>
   <result pre="of pertuzumab in Japan more quickly compared with other countries." exact="pertuzumab" post="trastuzumab human epidermal growth factor receptor 2 breast cancer"/>
   <result pre="pertuzumab in Japan more quickly compared with other countries. pertuzumab" exact="trastuzumab" post="human epidermal growth factor receptor 2 breast cancer clinical"/>
   <result pre="acts on the tyrosine kinase domain of HER2. Pertuzumab and" exact="trastuzumab" post="emtansine (T-DM1) were developed as new-generation anti-HER2 antibodies and"/>
   <result pre="of cancer cells ( 11, 13– 15). Similar to trastuzumab," exact="pertuzumab" post="has the function of antibody-dependent cell-mediated cytotoxity ( 16)."/>
   <result pre="has the function of antibody-dependent cell-mediated cytotoxity ( 16). Furthemore," exact="pertuzumab" post="and trastuzumab complementarily combine different domains (pertuzumab for domain"/>
   <result pre="function of antibody-dependent cell-mediated cytotoxity ( 16). Furthemore, pertuzumab and" exact="trastuzumab" post="complementarily combine different domains (pertuzumab for domain II and"/>
   <result pre="trastuzumab complementarily combine different domains (pertuzumab for domain II and" exact="trastuzumab" post="for domain IV) of the HER2 protein and strongly"/>
   <result pre="metastatic breast cancer (CLEOPATRA study), the patients received placebo plus" exact="trastuzumab" post="plus docetaxel (control group) or pertuzumab plus trastuzumab plus"/>
   <result pre="cancer (CLEOPATRA study), the patients received placebo plus trastuzumab plus" exact="docetaxel" post="(control group) or pertuzumab plus trastuzumab plus docetaxel (pertuzumab"/>
   <result pre="patients received placebo plus trastuzumab plus docetaxel (control group) or" exact="pertuzumab" post="plus trastuzumab plus docetaxel (pertuzumab group) as first-line treatment"/>
   <result pre="placebo plus trastuzumab plus docetaxel (control group) or pertuzumab plus" exact="trastuzumab" post="plus docetaxel (pertuzumab group) as first-line treatment until disease"/>
   <result pre="trastuzumab plus docetaxel (control group) or pertuzumab plus trastuzumab plus" exact="docetaxel" post="(pertuzumab group) as first-line treatment until disease progression or"/>
   <result pre="not be effectively managed ( 13). The findings demonstrated that" exact="pertuzumab" post="significantly prolonged progression-free survival (PFS), without increased cardiac toxicity."/>
   <result pre="the US Food and Drug Administration approved the use of" exact="pertuzumab" post="in combination with trastuzumab and docetaxel for the treatment"/>
   <result pre="Drug Administration approved the use of pertuzumab in combination with" exact="trastuzumab" post="and docetaxel for the treatment of patients with HER2-positive"/>
   <result pre="approved the use of pertuzumab in combination with trastuzumab and" exact="docetaxel" post="for the treatment of patients with HER2-positive metastatic breast"/>
   <result pre="anti-HER2 therapy. In March, 2013, the European Medicines Agency approved" exact="pertuzumab" post="under the same conditions. In Japan, pertuzumab was approved"/>
   <result pre="Medicines Agency approved pertuzumab under the same conditions. In Japan," exact="pertuzumab" post="was approved in August, 2013 for patients with HER2-positive"/>
   <result pre="of pertuzumab-related clinical trials and the specific conditions for using" exact="pertuzumab" post="in Japan. Phase I trials TOC2297g study The anti-HER2"/>
   <result pre="(origin of trastuzumab) ( 17). A phase I trial of" exact="pertuzumab" post="monotherapy for HER2-positive solid tumors (study ID no. TOC2297g)"/>
   <result pre="after standard therapy were recruited to a dose-escalation study of" exact="pertuzumab" post="(0.5–15 mg/kg) administered intravenously every 3 weeks. A total"/>
   <result pre="of 21 patients (including 3 patients with breast cancer) received" exact="pertuzumab" post="and 19 patients completed at least two cycles. The"/>
   <result pre="patients completed at least two cycles. The results demonstrated that" exact="pertuzumab" post="was well tolerated, had a pharmacokinetic profile supporting 3-week"/>
   <result pre="That study evaluated the toxicity, pharmacokinetics and antitumor activity of" exact="pertuzumab" post="in Japanese patients with HER2-positive solid tumors. Patients with"/>
   <result pre="therapy were administered 5, 10, 15, 20 and 25 mg/kg" exact="pertuzumab" post="intravenously, once every 3 weeks. A total of 18"/>
   <result pre="cancer) were enrolled and a total of 32 cycles of" exact="pertuzumab" post="were administered. The toxicities were generally acceptable. Grade 3"/>
   <result pre="of 25 mg/kg was not reached. The serum concentration of" exact="pertuzumab" post="slowly declined (terminal half-life of ~3 weeks). The area"/>
   <result pre="Phase II trials BO17929 study A phase II trial of" exact="pertuzumab" post="and trastuzumab in patients with HER2-positive metastatic breast cancer"/>
   <result pre="trials BO17929 study A phase II trial of pertuzumab and" exact="trastuzumab" post="in patients with HER2-positive metastatic breast cancer (study ID"/>
   <result pre="disease had progressed during prior trastuzumab-based therapy. The patients received" exact="trastuzumab" post="weekly or every 3 weeks, and pertuzumab every 3"/>
   <result pre="The patients received trastuzumab weekly or every 3 weeks, and" exact="pertuzumab" post="every 3 weeks. All 66 patients were assessable for"/>
   <result pre="disease. The median PFS was 5.5 months. The combination of" exact="pertuzumab" post="and trastuzumab was well tolerated, and the adverse events"/>
   <result pre="median PFS was 5.5 months. The combination of pertuzumab and" exact="trastuzumab" post="was well tolerated, and the adverse events were mild"/>
   <result pre="a result of cardiac-related adverse events. Therefore, the combination of" exact="pertuzumab" post="and trastuzumab was effective and well tolerated in patients"/>
   <result pre="of cardiac-related adverse events. Therefore, the combination of pertuzumab and" exact="trastuzumab" post="was effective and well tolerated in patients with HER2-positive"/>
   <result pre="metastatic breast cancer were randomly assigned to receive placebo plus" exact="trastuzumab" post="plus docetaxel (control group) or pertuzumab plus trastuzumab plus"/>
   <result pre="cancer were randomly assigned to receive placebo plus trastuzumab plus" exact="docetaxel" post="(control group) or pertuzumab plus trastuzumab plus docetaxel (pertuzumab"/>
   <result pre="to receive placebo plus trastuzumab plus docetaxel (control group) or" exact="pertuzumab" post="plus trastuzumab plus docetaxel (pertuzumab group) until disease progression"/>
   <result pre="placebo plus trastuzumab plus docetaxel (control group) or pertuzumab plus" exact="trastuzumab" post="plus docetaxel (pertuzumab group) until disease progression or until"/>
   <result pre="trastuzumab plus docetaxel (control group) or pertuzumab plus trastuzumab plus" exact="docetaxel" post="(pertuzumab group) until disease progression or until the development"/>
   <result pre="months in the control group and 18.5 months in the" exact="pertuzumab" post="group [hazard ratio (HR) for progression or death ="/>
   <result pre="overall survival (OS) exhibited a strong trend in favor of" exact="pertuzumab" post="plus trastuzumab plus docetaxel. The safety profile was generally"/>
   <result pre="(OS) exhibited a strong trend in favor of pertuzumab plus" exact="trastuzumab" post="plus docetaxel. The safety profile was generally similar between"/>
   <result pre="the control group, but had not been reached in the" exact="pertuzumab" post="group (HR=0.66, 95% CI: 0.52–0.84; P=0.0008) ( 21). The"/>
   <result pre="revealed a significant improvement in OS with pertuzumab, trastuzumab, and" exact="docetaxel" post="in patients with HER2-positive metastatic breast cancer compared with"/>
   <result pre="HER2-positive metastatic breast cancer compared with the control group (placebo," exact="trastuzumab" post="and docetaxel). Furthermore, the biomarker analyses in the CLEOPATRA"/>
   <result pre="was the only marker suitable for patient selection for the" exact="trastuzumab" post="plus pertuzumab-based regimen in HER2-positive metastatic breast cancer, and"/>
   <result pre="in Asian patients compared with patients from other regions, and" exact="docetaxel" post="dose escalations to 100 mg/m 2 were less frequent"/>
   <result pre="(PMDA) for drug approval in Japan. However, the superiority of" exact="pertuzumab" post="was not verified in terms of the PFS and"/>
   <result pre="that the baseline characteristics of the Japanese patients between the" exact="pertuzumab" post="group and the control group were not well-balanced due"/>
   <result pre="due to the limited number of the subgroup patients. The" exact="pertuzumab" post="group included more patients with visceral diseases or with"/>
   <result pre="study was planned to confirm the efficacy and safety of" exact="pertuzumab" post="combined with trastuzumab and docetaxel as first-line treatment in"/>
   <result pre="to confirm the efficacy and safety of pertuzumab combined with" exact="trastuzumab" post="and docetaxel as first-line treatment in Japanese patients with"/>
   <result pre="the efficacy and safety of pertuzumab combined with trastuzumab and" exact="docetaxel" post="as first-line treatment in Japanese patients with HER2-positive inoperable"/>
   <result pre="( 24). Neoadjuvant setting NEOSPHERE study The neoadjuvant study of" exact="pertuzumab" post="and trastuzumab in an early regimen evaluation (NEOSPHERE) is"/>
   <result pre="Neoadjuvant setting NEOSPHERE study The neoadjuvant study of pertuzumab and" exact="trastuzumab" post="in an early regimen evaluation (NEOSPHERE) is a randomised,"/>
   <result pre="loading dose, followed by 6 mg/kg every 3 weeks) plus" exact="docetaxel" post="(75 mg/m 2, escalating, if tolerated, to 100 mg/m"/>
   <result pre="tolerated, to 100 mg/m 2 every 3 weeks) (group A);" exact="pertuzumab" post="(loading dose 840 mg, followed by 420 mg every"/>
   <result pre="840 mg, followed by 420 mg every 3 weeks) and" exact="trastuzumab" post="plus docetaxel (group B); pertuzumab and trastuzumab (group C);"/>
   <result pre="followed by 420 mg every 3 weeks) and trastuzumab plus" exact="docetaxel" post="(group B); pertuzumab and trastuzumab (group C); and pertuzumab"/>
   <result pre="mg every 3 weeks) and trastuzumab plus docetaxel (group B);" exact="pertuzumab" post="and trastuzumab (group C); and pertuzumab plus docetaxel (group"/>
   <result pre="3 weeks) and trastuzumab plus docetaxel (group B); pertuzumab and" exact="trastuzumab" post="(group C); and pertuzumab plus docetaxel (group D). The"/>
   <result pre="plus docetaxel (group B); pertuzumab and trastuzumab (group C); and" exact="pertuzumab" post="plus docetaxel (group D). The primary endpoint was pathological"/>
   <result pre="(group B); pertuzumab and trastuzumab (group C); and pertuzumab plus" exact="docetaxel" post="(group D). The primary endpoint was pathological complete response."/>
   <result pre="the pathological complete response rate compared with the patients administered" exact="trastuzumab" post="plus docetaxel (no significant differences in tolerability). The tumors"/>
   <result pre="complete response rate compared with the patients administered trastuzumab plus" exact="docetaxel" post="(no significant differences in tolerability). The tumors in a"/>
   <result pre="a favorable safety profile. TRYPHAENA study The tolerability of pertuzumab," exact="trastuzumab" post="and anthracyclines in neoadjuvant breast cancer treatment (TRYPHAENA) is"/>
   <result pre="The patients were randomly assigned to one of three neoadjuvant" exact="pertuzumab" post="regimens: Arm A (3 cycles of 5-fluorouracil, epirubicin and"/>
   <result pre="three neoadjuvant pertuzumab regimens: Arm A (3 cycles of 5-fluorouracil," exact="epirubicin" post="and cyclophosphamide plus trastuzumab plus pertuzumab, followed by 3"/>
   <result pre="pertuzumab regimens: Arm A (3 cycles of 5-fluorouracil, epirubicin and" exact="cyclophosphamide" post="plus trastuzumab plus pertuzumab, followed by 3 cycles of"/>
   <result pre="Arm A (3 cycles of 5-fluorouracil, epirubicin and cyclophosphamide plus" exact="trastuzumab" post="plus pertuzumab, followed by 3 cycles of docetaxel plus"/>
   <result pre="cyclophosphamide plus trastuzumab plus pertuzumab, followed by 3 cycles of" exact="docetaxel" post="plus trastuzumab plus pertuzumab); Arm B (3 cycles of"/>
   <result pre="trastuzumab plus pertuzumab, followed by 3 cycles of docetaxel plus" exact="trastuzumab" post="plus pertuzumab); Arm B (3 cycles of 5-fluorouracil, epirubicin"/>
   <result pre="plus trastuzumab plus pertuzumab); Arm B (3 cycles of 5-fluorouracil," exact="epirubicin" post="and cyclophosphamide, followed by 3 cycles of docetaxel plus"/>
   <result pre="of 5-fluorouracil, epirubicin and cyclophosphamide, followed by 3 cycles of" exact="docetaxel" post="plus trastuzumab plus pertuzumab); and Arm C (6 cycles"/>
   <result pre="epirubicin and cyclophosphamide, followed by 3 cycles of docetaxel plus" exact="trastuzumab" post="plus pertuzumab); and Arm C (6 cycles of docetaxel"/>
   <result pre="plus trastuzumab plus pertuzumab); and Arm C (6 cycles of" exact="docetaxel" post="plus carboplatin plus trastuzumab plus pertuzumab). The primary endpoint"/>
   <result pre="plus pertuzumab); and Arm C (6 cycles of docetaxel plus" exact="carboplatin" post="plus trastuzumab plus pertuzumab). The primary endpoint was cardiac"/>
   <result pre="and Arm C (6 cycles of docetaxel plus carboplatin plus" exact="trastuzumab" post="plus pertuzumab). The primary endpoint was cardiac safety. The"/>
   <result pre="were consistent with those reported in previous studies of pertuzumab," exact="trastuzumab" post="and chemotherapy, either in combination or alone. Ongoing trials"/>
   <result pre="Ongoing trials (metastatic setting) MARIANNE study T-DM1 plus pertuzumab/pertuzumab-placebo vs." exact="trastuzumab" post="plus a taxane in patients with metastatic breast cancer"/>
   <result pre="conducted to evaluate the efficacy and safety of T-DM1 with" exact="pertuzumab" post="or T-DM1 with pertuzumab-placebo (blinded for pertuzumab) vs. the"/>
   <result pre="T-DM1 with pertuzumab-placebo (blinded for pertuzumab) vs. the combination of" exact="trastuzumab" post="plus a taxane (docetaxel or paclitaxel) in patients with"/>
   <result pre="endpoint for T-DM1-containing regimens. PERUSE study Pertuzumab in combination with" exact="trastuzumab" post="and a taxane as first-line treatment in patients with"/>
   <result pre="IIIb study conducted to evaluate the safety and tolerability of" exact="pertuzumab" post="in combination with trastuzumab and a taxane as first-line"/>
   <result pre="evaluate the safety and tolerability of pertuzumab in combination with" exact="trastuzumab" post="and a taxane as first-line treatment in patients with"/>
   <result pre="breast cancer ( 29). The patients are scheduled to receive" exact="pertuzumab" post="and trastuzumab plus a taxane every 3 weeks. The"/>
   <result pre="( 29). The patients are scheduled to receive pertuzumab and" exact="trastuzumab" post="plus a taxane every 3 weeks. The taxanes are"/>
   <result pre="is currently recruiting participants. VELVET study Pertuzumab in combination with" exact="trastuzumab" post="and vinorelbine as first-line treatment in patients with metastatic"/>
   <result pre="recruiting participants. VELVET study Pertuzumab in combination with trastuzumab and" exact="vinorelbine" post="as first-line treatment in patients with metastatic or locally"/>
   <result pre="II study conducted to assess the safety and efficacy of" exact="pertuzumab" post="administered in combination with trastuzumab and vinorelbine as first-line"/>
   <result pre="the safety and efficacy of pertuzumab administered in combination with" exact="trastuzumab" post="and vinorelbine as first-line treatment in patients with metastatic"/>
   <result pre="and efficacy of pertuzumab administered in combination with trastuzumab and" exact="vinorelbine" post="as first-line treatment in patients with metastatic or locally"/>
   <result pre="30). The patients are scheduled to receive 840 mg of" exact="pertuzumab" post="and 8 mg/kg of trastuzumab administered sequentially as separate"/>
   <result pre="to receive 840 mg of pertuzumab and 8 mg/kg of" exact="trastuzumab" post="administered sequentially as separate intravenous infusions on day 1"/>
   <result pre="cycle 2 onwards, the patients will receive 420 mg of" exact="pertuzumab" post="and 6 mg/kg of trastuzumab, administered either sequentially as"/>
   <result pre="This study is currently recruiting participants. PHEREXA study Combination of" exact="trastuzumab" post="and capecitabine with or without pertuzumab in patients with"/>
   <result pre="is currently recruiting participants. PHEREXA study Combination of trastuzumab and" exact="capecitabine" post="with or without pertuzumab in patients with HER2-positive metastatic"/>
   <result pre="PHEREXA study Combination of trastuzumab and capecitabine with or without" exact="pertuzumab" post="in patients with HER2-positive metastatic breast cancer (PHEREXA study"/>
   <result pre="to evaluate the efficacy and safety of a combination of" exact="trastuzumab" post="and capecitabine, with or without pertuzumab, in patients with"/>
   <result pre="I) ( 31). Eligibility requires progression during or following previous" exact="trastuzumab" post="therapy for metastatic disease. The study treatment is to"/>
   <result pre="enrolled in this study. PERTAIN study Pertuzumab in combination with" exact="trastuzumab" post="plus an aromatase inhibitor in patients with hormone receptor-positive"/>
   <result pre="II study conducted to evaluate the efficacy and safety of" exact="pertuzumab" post="in combination with trastuzumab plus an aromatase inhibitor in"/>
   <result pre="evaluate the efficacy and safety of pertuzumab in combination with" exact="trastuzumab" post="plus an aromatase inhibitor in the first-line treatment of"/>
   <result pre="be randomized to one of two treatment arms: Pertuzumab plus" exact="trastuzumab" post="plus aromatase inhibitor (Arm 1); or trastuzumab plus aromatase"/>
   <result pre="arms: Pertuzumab plus trastuzumab plus aromatase inhibitor (Arm 1); or" exact="trastuzumab" post="plus aromatase inhibitor (Arm 2). The patients may also"/>
   <result pre="The patients may also receive induction chemotherapy (a taxane, either" exact="docetaxel" post="or paclitaxel) at the investigator's discretion. The anticipated time"/>
   <result pre="is currently recruiting participants. JBCRG-M03 study Eribulin in combination with" exact="trastuzumab" post="and pertuzumab for advanced or recurrent HER2-positive breast cancer"/>
   <result pre="recruiting participants. JBCRG-M03 study Eribulin in combination with trastuzumab and" exact="pertuzumab" post="for advanced or recurrent HER2-positive breast cancer (JBCRG-M03 and"/>
   <result pre="II trial conducted in Japan to evaluate the usefulness of" exact="eribulin" post="in combination with trastuzumab and pertuzumab as first- or"/>
   <result pre="Japan to evaluate the usefulness of eribulin in combination with" exact="trastuzumab" post="and pertuzumab as first- or second-line therapy for patients"/>
   <result pre="evaluate the usefulness of eribulin in combination with trastuzumab and" exact="pertuzumab" post="as first- or second-line therapy for patients with advanced"/>
   <result pre="safety, OS, efficacy following prior use of pertuzumab, compliance to" exact="eribulin" post="and the efficacy of later therapy. This study is"/>
   <result pre="clinical study to confirm the superiority of the efficacy of" exact="pertuzumab" post="combined with trastuzumab and docetaxel compared with the control"/>
   <result pre="confirm the superiority of the efficacy of pertuzumab combined with" exact="trastuzumab" post="and docetaxel compared with the control group of the"/>
   <result pre="superiority of the efficacy of pertuzumab combined with trastuzumab and" exact="docetaxel" post="compared with the control group of the CLEOPATRA study"/>
   <result pre="(adjuvant setting) APHINITY study Pertuzumab in addition to chemotherapy and" exact="trastuzumab" post="as adjuvant therapy in patients with HER2-positive primary breast"/>
   <result pre="III study conducted to assess the safety and efficacy of" exact="pertuzumab" post="in addition to chemotherapy plus trastuzumab as adjuvant therapy"/>
   <result pre="safety and efficacy of pertuzumab in addition to chemotherapy plus" exact="trastuzumab" post="as adjuvant therapy in patients with operable HER2-positive primary"/>
   <result pre="35). The patients will be postoperatively randomized to receive either" exact="pertuzumab" post="or a placebo every 3 weeks for 1 year,"/>
   <result pre="addition to 6–8 cycles of chemotherapy and 1 year of" exact="trastuzumab" post="administered every 3 weeks. The anticipated time of the"/>
   <result pre="were enrolled in this study. KAITLIN study T-DM1 (Kadcyla) plus" exact="pertuzumab" post="(Perjeta) following anthracyclines in comparison with trastuzumab plus pertuzumab"/>
   <result pre="T-DM1 (Kadcyla) plus pertuzumab (Perjeta) following anthracyclines in comparison with" exact="trastuzumab" post="plus pertuzumab and a taxane following anthracyclines as adjuvant"/>
   <result pre="plus pertuzumab (Perjeta) following anthracyclines in comparison with trastuzumab plus" exact="pertuzumab" post="and a taxane following anthracyclines as adjuvant therapy in"/>
   <result pre="evaluate the efficacy and safety of T-DM1 in combination with" exact="pertuzumab" post="vs. trastuzumab in combination with pertuzumab and a taxane"/>
   <result pre="efficacy and safety of T-DM1 in combination with pertuzumab vs." exact="trastuzumab" post="in combination with pertuzumab and a taxane as adjuvant"/>
   <result pre="T-DM1 in combination with pertuzumab vs. trastuzumab in combination with" exact="pertuzumab" post="and a taxane as adjuvant therapy in patients with"/>
   <result pre="receive either 3.6 mg/kg of T-DM1 and 420 mg of" exact="pertuzumab" post="every 3 weeks or 6 mg/kg of trastuzumab every"/>
   <result pre="mg of pertuzumab every 3 weeks or 6 mg/kg of" exact="trastuzumab" post="every 3 weeks in combination with pertuzumab and a"/>
   <result pre="6 mg/kg of trastuzumab every 3 weeks in combination with" exact="pertuzumab" post="and a taxane. The anticipated time of HER2-targeted study"/>
   <result pre="study. Special status in Japan The unique circumstances related to" exact="pertuzumab" post="treatment in Japan differ from those in other countries."/>
   <result pre="in other countries. First, the PMDA allowed the use of" exact="pertuzumab" post="not only as first-line, but also as second- or"/>
   <result pre="with HER2-positive metastatic breast cancer. Moreover, Japanese physicians may use" exact="pertuzumab" post="for patients who previously received trastuzumab treatment in a"/>
   <result pre="Japanese physicians may use pertuzumab for patients who previously received" exact="trastuzumab" post="treatment in a metastatic setting. Therefore, the market penetration"/>
   <result pre="treatment in a metastatic setting. Therefore, the market penetration of" exact="pertuzumab" post="in Japan may be quicker compared with that in"/>
   <result pre="did not limit the chemotherapeutic agents to be administered with" exact="pertuzumab" post="and trastuzumab. The Japanese package insert states that the"/>
   <result pre="are selected. Japanese physicians may use chemotherapeutic agents other than" exact="docetaxel" post="(i.e., paclitaxel or eriburin) in clinical practice. As mentioned"/>
   <result pre="Japanese physicians may use chemotherapeutic agents other than docetaxel (i.e.," exact="paclitaxel" post="or eriburin) in clinical practice. As mentioned above, the"/>
   <result pre="eriburin) in clinical practice. As mentioned above, the study of" exact="eribulin" post="in combination with trastuzumab and pertuzumab for advanced or"/>
   <result pre="As mentioned above, the study of eribulin in combination with" exact="trastuzumab" post="and pertuzumab for advanced or recurrent HER2-positive breast cancer"/>
   <result pre="above, the study of eribulin in combination with trastuzumab and" exact="pertuzumab" post="for advanced or recurrent HER2-positive breast cancer (JBCRG-M03 study)"/>
   <result pre="of T-DM1 in September 2013, immediately following the approval of" exact="pertuzumab" post="by the PMDA, disrupted the treatment of patients with"/>
   <result pre="that T-DM1 should be used for patients who previously received" exact="trastuzumab" post="and taxane, based on the results of the EMILIA"/>
   <result pre="to several guidelines; however, the reverse sequence of administration of" exact="pertuzumab" post="regimens and T-DM1 is not prohibited. Furthermore, the appropriate"/>
   <result pre="not prohibited. Furthermore, the appropriate sequence of HER2-directed therapy, including" exact="lapatinib" post="regimens, trastuzumab regimens and T-DM1 for patients who had"/>
   <result pre="Furthermore, the appropriate sequence of HER2-directed therapy, including lapatinib regimens," exact="trastuzumab" post="regimens and T-DM1 for patients who had prior trastuzumab-based"/>
   <result pre="remains unclear. In conclusion, we reviewed certain clinical trials on" exact="pertuzumab" post="and outlined the special characteristics of pertuzumab use in"/>
   <result pre="clinical trials on pertuzumab and outlined the special characteristics of" exact="pertuzumab" post="use in Japan. Pertuzumab and T-DM1 may be used"/>
   <result pre="irrespective of the treatment history, and chemotherapeutic agents other than" exact="docetaxel" post="may be selected to be combined with pertuzumab. This"/>
   <result pre="et al. Herceptin Adjuvant (HERA) Trial Study Team: Treatment with" exact="trastuzumab" post="for 1 year after adjuvant chemotherapy in patients with"/>
   <result pre="Trial Study Team: 2 years versus 1 year of adjuvant" exact="trastuzumab" post="for HER2-positive breast cancer (HERA): An open-label, randomised controlled"/>
   <result pre="T Knott A et al. CLEOPATRA Study Group: Pertuzumab plus" exact="trastuzumab" post="plus docetaxel for metastatic breast cancer N Engl J"/>
   <result pre="A et al. CLEOPATRA Study Group: Pertuzumab plus trastuzumab plus" exact="docetaxel" post="for metastatic breast cancer N Engl J Med 366"/>
   <result pre="B Endl J Hasmann M Strongly enhanced antitumor activity of" exact="trastuzumab" post="and pertuzumab combination treatment on HER2-positive human xenograft tumor"/>
   <result pre="J Hasmann M Strongly enhanced antitumor activity of trastuzumab and" exact="pertuzumab" post="combination treatment on HER2-positive human xenograft tumor models Cancer"/>
   <result pre="McNally VA Ross GA et al. Phase II trial of" exact="pertuzumab" post="and trastuzumab in patients with human epidermal growth factor"/>
   <result pre="Ross GA et al. Phase II trial of pertuzumab and" exact="trastuzumab" post="in patients with human epidermal growth factor receptor 2-positive"/>
   <result pre="factor receptor 2-positive metastatic breast cancer that progressed during prior" exact="trastuzumab" post="therapy J Clin Oncol 28 1138 1144 2010 10.1200/JCO.2009.24.2024"/>
   <result pre="JM Schneeweiss A Knott A et al. Pertuzumab, trastuzumab, and" exact="docetaxel" post="for HER2-positive metastatic breast cancer (CLEOPATRA study): Overall survival"/>
   <result pre="Biomarker analyses in CLEOPATRA: A phase III, placebo-controlled study of" exact="pertuzumab" post="in human epidermal growth factor receptor 2-positive, first-line metastatic"/>
   <result pre="A Clark E Ross G Baselga J Safety profile of" exact="pertuzumab" post="with trastuzumab and docetaxel in patients from Asia with"/>
   <result pre="E Ross G Baselga J Safety profile of pertuzumab with" exact="trastuzumab" post="and docetaxel in patients from Asia with human epidermal"/>
   <result pre="G Baselga J Safety profile of pertuzumab with trastuzumab and" exact="docetaxel" post="in patients from Asia with human epidermal growth factor"/>
   <result pre="J Im SA et al. Efficacy and safety of neoadjuvant" exact="pertuzumab" post="and trastuzumab in women with locally advanced, inflammatory, or"/>
   <result pre="SA et al. Efficacy and safety of neoadjuvant pertuzumab and" exact="trastuzumab" post="in women with locally advanced, inflammatory, or early HER2-positive"/>
   <result pre="Seo JH Tsai YF Ratnayake J et al. Pertuzumab plus" exact="trastuzumab" post="in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy"/>
   <result pre="2278 2284 2013 10.1093/annonc/mdt182 23704196 27 ClinicalTrials.gov A study of" exact="trastuzumab" post="emtansine (T-DM1) plus pertuzumab/pertuzumab placebo versus trastuzumab [Herceptin] plus"/>
   <result pre="A study of trastuzumab emtansine (T-DM1) plus pertuzumab/pertuzumab placebo versus" exact="trastuzumab" post="[Herceptin] plus a taxane in patients with metastatic breast"/>
   <result pre="http://www.roche.com/media/store/releases/med-cor-2014-12-19.htm Accessed 4 2 2015 29 ClinicalTrials.gov A study of" exact="pertuzumab" post="in combination with Herceptin (trastuzumab) and a taxane in"/>
   <result pre="https://clinicaltrials.gov/ct2/show/NCT01572038 Accessed 4 2 2015 30 ClinicalTrials.gov A study of" exact="pertuzumab" post="in combination with Herceptin (trastuzumab) and vinorelbine in first"/>
   <result pre="A study of pertuzumab in combination with Herceptin (trastuzumab) and" exact="vinorelbine" post="in first line in patients with metastatic or locally"/>
   <result pre="2 2015 31 ClinicalTrials.gov A study of a combination of" exact="trastuzumab" post="and capecitabine with or without pertuzumab in patients with"/>
   <result pre="31 ClinicalTrials.gov A study of a combination of trastuzumab and" exact="capecitabine" post="with or without pertuzumab in patients with HER2-positive metastatic"/>
   <result pre="of a combination of trastuzumab and capecitabine with or without" exact="pertuzumab" post="in patients with HER2-positive metastatic breast cancer (PHEREXA) https://clinicaltrials.gov/ct2/show/NCT01026142"/>
   <result pre="https://clinicaltrials.gov/ct2/show/NCT01026142 Accessed 4 2 2015 32 ClinicalTrials.gov A study of" exact="pertuzumab" post="in combination with trastuzumab plus an aromatase inhibitor in"/>
   <result pre="2015 32 ClinicalTrials.gov A study of pertuzumab in combination with" exact="trastuzumab" post="plus an aromatase inhibitor in patients with hormone receptor-positive,"/>
   <result pre="2015 33 Japan Breast Cancer Research Group: A study of" exact="eribulin" post="in combination with trastuzumab and pertuzumab for advanced or"/>
   <result pre="Cancer Research Group: A study of eribulin in combination with" exact="trastuzumab" post="and pertuzumab for advanced or recurrent human epidermal growth"/>
   <result pre="Group: A study of eribulin in combination with trastuzumab and" exact="pertuzumab" post="for advanced or recurrent human epidermal growth factor receptor"/>
   <result pre="post-marketing clinical study to evaluate the efficacy and safety of" exact="pertuzumab" post="combined with trastuzumab and docetaxel as first line treatment"/>
   <result pre="to evaluate the efficacy and safety of pertuzumab combined with" exact="trastuzumab" post="and docetaxel as first line treatment in HER2- positive"/>
   <result pre="the efficacy and safety of pertuzumab combined with trastuzumab and" exact="docetaxel" post="as first line treatment in HER2- positive inoperable or"/>
   <result pre="http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-132321 Accessed 4 2 2015 35 ClinicalTrials.gov A study of" exact="pertuzumab" post="in addition to chemotherapy and Herceptin (trastuzumab) as adjuvant"/>
   <result pre="pertuzumab; T, trastuzumab; DTX, docetaxel; PTX, paclitaxel; X, capecitabine; T-DM1," exact="trastuzumab" post="emtansine; A, anthracycline-based chemotherapy; NS, no significant difference (only"/>
   <result pre="press release); PFS, progression-free survival. Table II. Clinical studies of" exact="pertuzumab" post="in Japan. Study name Treatment setting Study phase Study"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4666271/results/search/inn/results.xml">
   <result pre="and efficacy findings in an open-label, single-arm study of weekly" exact="paclitaxel" post="plus lapatinib as first-line therapy for Japanese women with"/>
   <result pre="findings in an open-label, single-arm study of weekly paclitaxel plus" exact="lapatinib" post="as first-line therapy for Japanese women with HER2-positive metastatic"/>
   <result pre="breast cancer (MBC). The efficacy, safety and pharmacokinetics (PK) of" exact="lapatinib" post="combined with paclitaxel (L+P) were investigated in this study,"/>
   <result pre="The efficacy, safety and pharmacokinetics (PK) of lapatinib combined with" exact="paclitaxel" post="(L+P) were investigated in this study, to establish clear"/>
   <result pre="in the second part. Eligible women were enrolled and received" exact="lapatinib" post="1500 mg once daily and paclitaxel 80 mg/m 2"/>
   <result pre="were enrolled and received lapatinib 1500 mg once daily and" exact="paclitaxel" post="80 mg/m 2 weekly for at least 6 cycles."/>
   <result pre="Japanese patients with HER2-positive MBC. Although the PK profiles of" exact="lapatinib" post="and paclitaxel influenced each other, the magnitudes were not"/>
   <result pre="with HER2-positive MBC. Although the PK profiles of lapatinib and" exact="paclitaxel" post="influenced each other, the magnitudes were not greatly different"/>
   <result pre="[ 3, 4]. One of the key combination regimens containing" exact="trastuzumab" post="is with taxane and is recommended by clinical practice"/>
   <result pre="the occurrence of brain metastases due to the inability of" exact="trastuzumab" post="to cross the intact blood–brain barrier. Cardiotoxicity has been"/>
   <result pre="first approved in the USA in 2006 in combination with" exact="capecitabine" post="for HER2-positive metastatic breast cancer (MBC) which persisted or"/>
   <result pre="cancer (MBC) which persisted or recurred after anthracycline, taxane and" exact="trastuzumab" post="treatment. The approved condition is the same worldwide, including"/>
   <result pre="such as trastuzumab, aromatase inhibitor and paclitaxel. Its combination with" exact="paclitaxel" post="is approved in some countries/regions as first-line treatment for"/>
   <result pre="countries/regions as first-line treatment for HER2-positive MBC patients in whom" exact="trastuzumab" post="is not appropriate. Lapatinib is a small molecule that"/>
   <result pre="metastatic brain lesions [ 12, 13]. This characteristic approach of" exact="lapatinib" post="led to the development of lapatinib in combination with"/>
   <result pre="This characteristic approach of lapatinib led to the development of" exact="lapatinib" post="in combination with paclitaxel as first-line therapy of HER2-positive"/>
   <result pre="lapatinib led to the development of lapatinib in combination with" exact="paclitaxel" post="as first-line therapy of HER2-positive MBC, as a replacement"/>
   <result pre="first-line therapy of HER2-positive MBC, as a replacement for the" exact="trastuzumab" post="regimens. The first Phase I study of a lapatinib"/>
   <result pre="the trastuzumab regimens. The first Phase I study of a" exact="lapatinib" post="and paclitaxel combination (L+P) in HER2-positive MBC patients was"/>
   <result pre="regimens. The first Phase I study of a lapatinib and" exact="paclitaxel" post="combination (L+P) in HER2-positive MBC patients was conducted outside"/>
   <result pre="was conducted outside Japan. This study demonstrated the tolerability of" exact="lapatinib" post="(1500 mg/day) in combination with both weekly paclitaxel 80"/>
   <result pre="tolerability of lapatinib (1500 mg/day) in combination with both weekly" exact="paclitaxel" post="80 mg/m 2 and with tri-weekly paclitaxel 135, 175,"/>
   <result pre="with both weekly paclitaxel 80 mg/m 2 and with tri-weekly" exact="paclitaxel" post="135, 175, 200 and 225 mg/m 2 [ 14]."/>
   <result pre="225 mg/m 2 [ 14]. Following this, the combination of" exact="lapatinib" post="(1500 mg/day) and tri-weekly paclitaxel (175 mg/m 2) as"/>
   <result pre="Following this, the combination of lapatinib (1500 mg/day) and tri-weekly" exact="paclitaxel" post="(175 mg/m 2) as first-line therapy was evaluated in"/>
   <result pre="regimen showed significant improvement in progression-free survival (PFS) compared to" exact="paclitaxel" post="monotherapy [hazard ratio (HR) = 0.49; 95 % confidence"/>
   <result pre="mainly conducted in China and South America, the combination of" exact="lapatinib" post="(1500 mg/day) with weekly paclitaxel (80 mg/m 2) as"/>
   <result pre="South America, the combination of lapatinib (1500 mg/day) with weekly" exact="paclitaxel" post="(80 mg/m 2) as first-line therapy was evaluated in"/>
   <result pre="overall survival (OS) of the combination was prolonged compared to" exact="paclitaxel" post="monotherapy (HR = 0.74; 95 % CI 0.58–0.94; p"/>
   <result pre="95 % CI 0.58–0.94; p = 0.0124). The combinations of" exact="lapatinib" post="(1250 mg/day) or trastuzumab either with paclitaxel or docetaxel"/>
   <result pre="p = 0.0124). The combinations of lapatinib (1250 mg/day) or" exact="trastuzumab" post="either with paclitaxel or docetaxel as first-line therapy for"/>
   <result pre="The combinations of lapatinib (1250 mg/day) or trastuzumab either with" exact="paclitaxel" post="or docetaxel as first-line therapy for HER2-positive MBC were"/>
   <result pre="of lapatinib (1250 mg/day) or trastuzumab either with paclitaxel or" exact="docetaxel" post="as first-line therapy for HER2-positive MBC were evaluated in"/>
   <result pre="results, reported in 2012, showed that the PFS of the" exact="lapatinib" post="combination was not significantly different compared with the trastuzumab"/>
   <result pre="the lapatinib combination was not significantly different compared with the" exact="trastuzumab" post="regimen [HR = 1.33 (95 % CI 1.06–1.67); p"/>
   <result pre="to investigate the tolerability, safety and pharmacokinetics (PK) of a" exact="lapatinib" post="1500 mg and weekly paclitaxel combination. Patients and methods"/>
   <result pre="and pharmacokinetics (PK) of a lapatinib 1500 mg and weekly" exact="paclitaxel" post="combination. Patients and methods Patients Eligible patients were Japanese"/>
   <result pre="with HER2-positive MBC who have not received prior chemotherapy or" exact="trastuzumab" post="for metastatic diseases. Six patients were enrolled in the"/>
   <result pre="given the standard treatment consisting of 6 cycles of weekly" exact="paclitaxel" post="80 mg/m 2 (for 3 weeks in a 4-week"/>
   <result pre="2 (for 3 weeks in a 4-week cycle) combined with" exact="lapatinib" post="1500 mg daily; the latter was given until disease"/>
   <result pre="or consent withdrawal. The investigators could chose to continue concurrent" exact="paclitaxel" post="administration for more cycles. For patients enrolled in Part"/>
   <result pre="administration for more cycles. For patients enrolled in Part 1," exact="lapatinib" post="was not given on day 1, but started on"/>
   <result pre="on day 1, but started on the following day, and" exact="paclitaxel" post="was not given on day 15, but was given"/>
   <result pre="purposes. If disease progression, unacceptable paclitaxel-related toxicities, or termination of" exact="lapatinib" post="occurred, then paclitaxel was terminated at any time during"/>
   <result pre="progression, unacceptable paclitaxel-related toxicities, or termination of lapatinib occurred, then" exact="paclitaxel" post="was terminated at any time during the study, even"/>
   <result pre="week during the combination treatment and at the discontinuation of" exact="paclitaxel" post="if it was decided to continue longer than 6"/>
   <result pre="it was decided to continue longer than 6 cycles. If" exact="paclitaxel" post="was discontinued at the sixth cycle, then safety assessment"/>
   <result pre="cycles during combination treatment and every 8 weeks while on" exact="lapatinib" post="monotherapy. Adverse events (AEs) were graded according to NCI-CTCAE"/>
   <result pre="and FISH at the central laboratory. Pharmacokinetics evaluation Pharmacokinetics of" exact="lapatinib" post="and/or paclitaxel were evaluated in all patients enrolled in"/>
   <result pre="at the central laboratory. Pharmacokinetics evaluation Pharmacokinetics of lapatinib and/or" exact="paclitaxel" post="were evaluated in all patients enrolled in Part 1"/>
   <result pre="days 1, 8 and 14: day 14 for PK of" exact="lapatinib" post="monotherapy, day 1 for paclitaxel monotherapy and day 8"/>
   <result pre="day 14 for PK of lapatinib monotherapy, day 1 for" exact="paclitaxel" post="monotherapy and day 8 for combination therapy. Plasma samples"/>
   <result pre="curve (AUC) from 0 to 24 h (AUC 0–24) of" exact="lapatinib" post="as well as C max, t max, half-life, AUC"/>
   <result pre="of whom 4 patients were positive for both ER and" exact="progesterone" post="receptor. Table 1 Baseline characteristics of intent-to-treat population Age,"/>
   <result pre="Based on diagnosis made by investigators ER estrogen receptor, PgR" exact="progesterone" post="receptor Tolerability and safety The median duration of lapatinib"/>
   <result pre="PgR progesterone receptor Tolerability and safety The median duration of" exact="lapatinib" post="treatment was 50.9 weeks (range 4–117 weeks). Toxicities other"/>
   <result pre="increased ALT and increased aspartate aminotransferase (AST). Dose interruptions of" exact="lapatinib" post="were reported in 10 patients, 73 times in total,"/>
   <result pre="reduction in one patient and of the dose interruptions of" exact="paclitaxel" post="in 10 patients. All 12 patients were withdrawn from"/>
   <result pre="response, SD stable disease Pharmacokinetics The plasma concentration–time profile of" exact="lapatinib" post="after repeated oral dosing of lapatinib 1500 mg with"/>
   <result pre="plasma concentration–time profile of lapatinib after repeated oral dosing of" exact="lapatinib" post="1500 mg with or without concomitant administration of paclitaxel"/>
   <result pre="of lapatinib 1500 mg with or without concomitant administration of" exact="paclitaxel" post="is shown in Fig. 3, and the plasma concentration–time"/>
   <result pre="shown in Fig. 3, and the plasma concentration–time profile of" exact="paclitaxel" post="after 1 h intravenous infusion of paclitaxel 80 mg/m"/>
   <result pre="concentration–time profile of paclitaxel after 1 h intravenous infusion of" exact="paclitaxel" post="80 mg/m 2 with or without concomitant administration of"/>
   <result pre="paclitaxel 80 mg/m 2 with or without concomitant administration of" exact="lapatinib" post="is shown in Fig. 4. Fig. 3 Plasma concentration–time"/>
   <result pre="shown in Fig. 4. Fig. 3 Plasma concentration–time profile of" exact="lapatinib" post="after dosing of lapatinib 1500 mg with or without"/>
   <result pre="Fig. 3 Plasma concentration–time profile of lapatinib after dosing of" exact="lapatinib" post="1500 mg with or without concomitant administration of paclitaxel"/>
   <result pre="of lapatinib 1500 mg with or without concomitant administration of" exact="paclitaxel" post="80 mg/m 2 Fig. 4 Plasma concentration–time profile of"/>
   <result pre="paclitaxel 80 mg/m 2 Fig. 4 Plasma concentration–time profile of" exact="paclitaxel" post="after dosing of paclitaxel 80 mg/m 2 with or"/>
   <result pre="Fig. 4 Plasma concentration–time profile of paclitaxel after dosing of" exact="paclitaxel" post="80 mg/m 2 with or without concomitant administration of"/>
   <result pre="paclitaxel 80 mg/m 2 with or without concomitant administration of" exact="lapatinib" post="1500 mg The geometric means of C max and"/>
   <result pre="The geometric means of C max and AUC (0–24) of" exact="lapatinib" post="were increased by 59 and 42 % under the"/>
   <result pre="lapatinib were increased by 59 and 42 % under the" exact="paclitaxel" post="80 mg/m 2 combination, in comparison to lapatinib alone."/>
   <result pre="under the paclitaxel 80 mg/m 2 combination, in comparison to" exact="lapatinib" post="alone. No change was observed in t max (Table"/>
   <result pre="The geometric means of C max and t max of" exact="paclitaxel" post="were not changed by combination with lapatinib; however, that"/>
   <result pre="by 23 % (Table 5). Table 4 Pharmacokinetic parameters of" exact="lapatinib" post="after repeat dosing with or without concomitant administration of"/>
   <result pre="lapatinib after repeat dosing with or without concomitant administration of" exact="paclitaxel" post="Parameter Lapatinib 1500 mg alone ( n = 6)"/>
   <result pre="mg alone ( n = 6) Lapatinib 1500 mg +" exact="paclitaxel" post="80 mg/m 2 ( n = 6) Ratio (90"/>
   <result pre="cMin and max dMedian difference Table 5 Pharmacokinetic parameters of" exact="paclitaxel" post="after dosing with or without concomitant administration of lapatinib"/>
   <result pre="of paclitaxel after dosing with or without concomitant administration of" exact="lapatinib" post="Parameter Paclitaxel 80 mg/m 2 alone ( n ="/>
   <result pre="alone ( n = 6) Paclitaxel 80 mg/m 2 +" exact="lapatinib" post="1500 mg ( n = 6) Ratio a (90"/>
   <result pre="cMin and max dMedian difference Discussion The tolerability of the" exact="lapatinib" post="(1500 mg/day) and weekly paclitaxel (80 mg/m 2) combination"/>
   <result pre="Discussion The tolerability of the lapatinib (1500 mg/day) and weekly" exact="paclitaxel" post="(80 mg/m 2) combination was confirmed in Japanese patients"/>
   <result pre="similar tolerability of this regimen [ 19]. Drug–drug interaction of" exact="lapatinib" post="and paclitaxel was found, as the AUC and C"/>
   <result pre="of this regimen [ 19]. Drug–drug interaction of lapatinib and" exact="paclitaxel" post="was found, as the AUC and C max of"/>
   <result pre="gastrectomy [ 19]. The interaction found in PK profiles of" exact="lapatinib" post="and paclitaxel is consistent regardless of the cancer type,"/>
   <result pre="19]. The interaction found in PK profiles of lapatinib and" exact="paclitaxel" post="is consistent regardless of the cancer type, and such"/>
   <result pre="and such interaction was considered to be the result of" exact="lapatinib" post="being a weak metabolism-dependent inhibitor of CYP3A4. The AEs"/>
   <result pre="clinical studies evaluating L+P and with known safety profiles of" exact="lapatinib" post="and paclitaxel given as monotherapy [ 14– 17]. The"/>
   <result pre="evaluating L+P and with known safety profiles of lapatinib and" exact="paclitaxel" post="given as monotherapy [ 14– 17]. The grade of"/>
   <result pre="17]. The grade of diarrhea was slightly worsened compared with" exact="lapatinib" post="monotherapy, which means that L+P would require more careful"/>
   <result pre="a significant PFS of a trastuzumab-containing regimen compared with a" exact="lapatinib" post="and taxane regimen [ 17]. Moreover, the results of"/>
   <result pre="taxane regimen [ 17]. Moreover, the results of a trastuzumab," exact="docetaxel" post="and pertuzumab tri-regimen became available after the results of"/>
   <result pre="[ 17]. Moreover, the results of a trastuzumab, docetaxel and" exact="pertuzumab" post="tri-regimen became available after the results of that global"/>
   <result pre="MBC worldwide [ 20]. As the new treatment of trastuzumab," exact="pertuzumab" post="and docetaxel tri-regimen became available for MBC and the"/>
   <result pre="[ 20]. As the new treatment of trastuzumab, pertuzumab and" exact="docetaxel" post="tri-regimen became available for MBC and the results of"/>
   <result pre="available for MBC and the results of direct comparison between" exact="lapatinib" post="and trastuzumab were confirmed, it is now proven to"/>
   <result pre="MBC and the results of direct comparison between lapatinib and" exact="trastuzumab" post="were confirmed, it is now proven to be difficult"/>
   <result pre="results that show the drug–drug interaction and PK interaction between" exact="lapatinib" post="and paclitaxel in Japanese patients with MBC. Although our"/>
   <result pre="show the drug–drug interaction and PK interaction between lapatinib and" exact="paclitaxel" post="in Japanese patients with MBC. Although our study does"/>
   <result pre="or the treatment strategy, it confirms that the combination of" exact="lapatinib" post="with paclitaxel is tolerable in Japanese patients with MBC."/>
   <result pre="treatment strategy, it confirms that the combination of lapatinib with" exact="paclitaxel" post="is tolerable in Japanese patients with MBC. Nevertheless, paclitaxel"/>
   <result pre="with paclitaxel is tolerable in Japanese patients with MBC. Nevertheless," exact="paclitaxel" post="remains a key drug in breast cancer therapies and"/>
   <result pre="drug in breast cancer therapies and many multiple-agent regimens with" exact="paclitaxel" post="have been evaluated worldwide. For this, it is considered"/>
   <result pre="adjuvant/neoadjuvant setting in which to evaluate combinations such as lapatinib," exact="paclitaxel" post="and trastuzumab are ongoing. There is no evidence to"/>
   <result pre="in which to evaluate combinations such as lapatinib, paclitaxel and" exact="trastuzumab" post="are ongoing. There is no evidence to recommend the"/>
   <result pre="ongoing. There is no evidence to recommend the use of" exact="lapatinib" post="in comparison to trastuzumab; however, our data can be"/>
   <result pre="all the study centers. This study was fully funded and" exact="lapatinib" post="was supplied by GlaxoSmithKline K.K. Conflict of interest Kenichi"/>
   <result pre="et al. Incidence of cerebral metastases in patients treated with" exact="trastuzumab" post="for metastatic breast cancer Br J Cancer 2004 91"/>
   <result pre="W et al. Characteristics of patients with brain metastases receiving" exact="trastuzumab" post="for HER2 overexpressing metastatic breast cancer Breast 2006 15"/>
   <result pre="brain metastases among patients with advanced breast cancer treated with" exact="trastuzumab" post="Acta Oncol 2006 45 196 201 10.1080/02841860500486630 16546866 11."/>
   <result pre="Geyer C Forster J Lindquist D et al. Lapatinib plus" exact="capecitabine" post="for HER2-positive advanced breast cancer N Engl J Med"/>
   <result pre="Carey LA Liu MC et al. Phase II trial of" exact="lapatinib" post="for brain metastases in patients with human epidermal growth"/>
   <result pre="study of the dual kinase inhibitor GW572016 in combination with" exact="paclitaxel" post="(EGF10009). J Clin Oncol 22(14S): (Abstract 2083) 15. Di"/>
   <result pre="Aziz Z et al. Phase III, double-blind, randomized study comparing" exact="lapatinib" post="plus paclitaxel with placebo plus paclitaxel as first-line treatment"/>
   <result pre="et al. Phase III, double-blind, randomized study comparing lapatinib plus" exact="paclitaxel" post="with placebo plus paclitaxel as first-line treatment for metastatic"/>
   <result pre="double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus" exact="paclitaxel" post="as first-line treatment for metastatic breast cancer J Clin"/>
   <result pre="Z Xu B DeSilvio ML et al. Randomized trial of" exact="lapatinib" post="versus placebo added to paclitaxel in the treatment of"/>
   <result pre="et al. Randomized trial of lapatinib versus placebo added to" exact="paclitaxel" post="in the treatment of human epidermal growth factor receptor"/>
   <result pre="phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with" exact="lapatinib" post="(L) or trastuzumab (T) as first-line therapy for women"/>
   <result pre="controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or" exact="trastuzumab" post="(T) as first-line therapy for women with HER2 +"/>
   <result pre="Satoh T Xu RH Chung HC et al. Lapatinib plus" exact="paclitaxel" post="versus paclitaxel alone in the second-line treatment of HER2-amplified"/>
   <result pre="Xu RH Chung HC et al. Lapatinib plus paclitaxel versus" exact="paclitaxel" post="alone in the second-line treatment of HER2-amplified advanced gastric"/>
   <result pre="Baselga J Cortes J Kim SB et al. Pertuzumab plus" exact="trastuzumab" post="plus docetaxel for metastatic breast cancer N Engl J"/>
   <result pre="Cortes J Kim SB et al. Pertuzumab plus trastuzumab plus" exact="docetaxel" post="for metastatic breast cancer N Engl J Med 2012"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4669075/results/search/inn/results.xml">
   <result pre="significant roles in the selection of patients for endocrine and" exact="trastuzumab" post="therapies. However, the initial treatment response is often followed"/>
   <result pre="cell surface receptor and stimulates a rapid generation of cyclic" exact="adenosine" post="monophosphate (cAMP). 36, 37 Subsequently, other reports of a"/>
   <result pre="reduces E2-stimulated endogenous pS2, cyclin D1, nuclear respiratory factor-1, and" exact="progesterone" post="receptor (PR) transcription. 44 Transfection with ERα46 changed the"/>
   <result pre="(SNCG), which binds to ERα66 or ERα36 depending on the" exact="estradiol" post="concentration. 57 SNCG is highly expressed in cancer cells"/>
   <result pre="the expression of SNCG. 57 Expression of SNCG also rendered" exact="tamoxifen" post="(TAM) resistance, consistent with the clinical observation that ERα36"/>
   <result pre="has been linked with resistance to the HER2-targeting monoclonal antibody" exact="trastuzumab" post="in metastatic BC, 133 but the impact of Δ16HER2"/>
   <result pre="sufficient to accelerate mammary tumorigenesis and improve the response to" exact="trastuzumab" post="(Herceptin®), a monoclonal antibody that interferes with the HER2"/>
   <result pre="SRC activation (pSRC). Clinically, HER2-positive BCs from patients who received" exact="trastuzumab" post="as an adjuvant therapy showed a positive correlation in"/>
   <result pre="expressing high pSRC or Δ16HER2 received the greatest benefit from" exact="trastuzumab" post="therapy with BC patients in an adjuvant setting. 134"/>
   <result pre="turn, results in significantly less or even no responsiveness to" exact="trastuzumab" post="as reported by Zhang et al. 133 Cittelly et"/>
   <result pre="the contribution of altered microRNA expression in Δ16HER2-mediated tumorigenesis and" exact="trastuzumab" post="resistance. Using a gene array strategy comparing microRNA expression"/>
   <result pre="p95-HER2 lacks the trastuzumab-binding site, its expression is associated with" exact="trastuzumab" post="resistance and poor prognosis but maintains sensitivity to the"/>
   <result pre="proliferate, migrate, and invade in vitro. They then developed a" exact="doxycycline" post="(DOX)-repressed CD44s BC xenograft model. 164 Although induction of"/>
   <result pre="and prevented recurrence in human BC xenografts after treatment with" exact="doxorubicin" post="and cyclophosphamide, demonstrating growth-promoting activities of CD44 in vivo."/>
   <result pre="X Wang ZY Estrogen receptor-α variant, ER-α36, is involved in" exact="tamoxifen" post="resistance and estrogen hypersensitivity Endocrinology 2013 154 1990 1998"/>
   <result pre="NS et al. Estrogen receptor alpha 46 is reduced in" exact="tamoxifen" post="resistant breast cancer cells and re-expression inhibits cell proliferation"/>
   <result pre="al. The HOXB7 protein renders breast cancer cells resistant to" exact="tamoxifen" post="through activation of the EGFR pathway Proc Natl Acad"/>
   <result pre="A Reddy KB Sarkar FH Functional role of miR-10b in" exact="tamoxifen" post="resistance of ER-positive breast cancer cells through down-regulation of"/>
   <result pre="Li H et al. MiR-873 regulates ERα transcriptional activity and" exact="tamoxifen" post="resistance via targeting CDK3 in breast cancer cells Oncogene"/>
   <result pre="non-receptor type 2 is associated with activation of AKT and" exact="tamoxifen" post="resistance in breast cancer Breast Cancer Res Treat 2015"/>
   <result pre="al. The role of microRNAs as predictors of response to" exact="tamoxifen" post="treatment in breast cancer patients Int J Mol Sci"/>
   <result pre="estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant" exact="tamoxifen" post="therapy J Clin Oncol 2008 26 3727 3734 18669459"/>
   <result pre="133 Zhang S Huang WC Li P et al. Combating" exact="trastuzumab" post="resistance by targeting SRC, a common node downstream of"/>
   <result pre="Activated d16HER2 homodimers and SRC kinase mediate optimal efficacy for" exact="trastuzumab" post="Cancer Res 2014 74 6248 6259 25164009 135 Cittelly"/>
   <result pre="oncogenic pathways to suppress HER2Δ16 mediated breast tumorigenesis and reverse" exact="trastuzumab" post="resistance PLoS One 2014 22 9 e114419 25532106 137"/>
   <result pre="138 Gajria D Chandarlapaty S HER2-amplified breast cancer: mechanisms of" exact="trastuzumab" post="resistance and novel targeted therapies Expert Rev Anticancer Ther"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4678619/results/search/inn/results.xml">
   <result pre="subtypes have shown low response rates. Moreover, standard chemotherapy using" exact="paclitaxel" post="and carboplatin has exhibited an approximately 70 % response"/>
   <result pre="shown low response rates. Moreover, standard chemotherapy using paclitaxel and" exact="carboplatin" post="has exhibited an approximately 70 % response rate in"/>
   <result pre="behavior [ 8– 10]. As an alternative to platinum drugs," exact="irinotecan" post="has been shown to be a promising candidate for"/>
   <result pre="phase II trial [ 13]. However, the combination therapy of" exact="irinotecan" post="plus cisplatin (CPT-P) failed to show efficacy. A recent"/>
   <result pre="trial [ 13]. However, the combination therapy of irinotecan plus" exact="cisplatin" post="(CPT-P) failed to show efficacy. A recent randomized phase"/>
   <result pre="to show efficacy. A recent randomized phase III trial of" exact="paclitaxel" post="plus carboplatin (TC) therapy versus irinotecan plus cisplatin (CPT-P)"/>
   <result pre="efficacy. A recent randomized phase III trial of paclitaxel plus" exact="carboplatin" post="(TC) therapy versus irinotecan plus cisplatin (CPT-P) was conducted"/>
   <result pre="phase III trial of paclitaxel plus carboplatin (TC) therapy versus" exact="irinotecan" post="plus cisplatin (CPT-P) was conducted by the Japanese Gynecologic"/>
   <result pre="trial of paclitaxel plus carboplatin (TC) therapy versus irinotecan plus" exact="cisplatin" post="(CPT-P) was conducted by the Japanese Gynecologic Oncology Group"/>
   <result pre="of ABCC3, which transports chemotherapeutic agents, has been associated with" exact="paclitaxel" post="resistance in breast cancer cell lines [ 16, 17]"/>
   <result pre="resistance in breast cancer cell lines [ 16, 17] and" exact="cisplatin" post="resistance in ovarian cancer cell lines [ 18] In"/>
   <result pre="by DNA microarray analysis. GPx3 suppression by RNA interference increased" exact="cisplatin" post="sensitivity by approximately 4-fold in CCC cell lines. Since"/>
   <result pre="approximately 4-fold in CCC cell lines. Since GPx3 suppression increased" exact="cisplatin" post="sensitivity of CCC cells, GPx3 may be a candidate"/>
   <result pre="components of the NER pathway and a key determinant of" exact="cisplatin" post="resistance. When we consider the role that it plays"/>
   <result pre="CCC might contribute to decreased cell proliferation and lead to" exact="cisplatin" post="resistance [ 42] Off target EGFR Function Epidermal growth"/>
   <result pre="cells [ 46]. Another study reported that EGFR inhibition increased" exact="cisplatin" post="efficacy in ovarian CCC cells [ 47]. Together, the"/>
   <result pre="mechanisms using which cancer cells elude the cytotoxic potential of" exact="cisplatin" post="before binding to cytoplasmic targets and DNA: (1) a"/>
   <result pre="cytoplasmic targets and DNA: (1) a reduced intracellular accumulation of" exact="cisplatin" post="and (2) an increased sequestration of cisplatin by glutathione,"/>
   <result pre="intracellular accumulation of cisplatin and (2) an increased sequestration of" exact="cisplatin" post="by glutathione, metallothioneins, and other cytoplasmic scavengers with nucleophilic"/>
   <result pre="reported, with significantly increased glutathione concentrations in cell lines after" exact="cisplatin" post="exposure [ 56]. Furthermore, a study of gene expression"/>
   <result pre="particular class of DNA polymerases [ 14]. The majority of" exact="cisplatin" post="lesions are removed from DNA by the nucleotide excision"/>
   <result pre="drug resistance against chemotherapeutic agents in CCC. Post-target resistance to" exact="cisplatin" post="may follow several alterations, including defects in signal transduction"/>
   <result pre="53, 61– 72]. Novel therapeutic modalities for CCC Paclitaxel plus" exact="carboplatin" post="combination therapy is currently the primary treatment strategy in"/>
   <result pre="growth factor (VEGF) receptor binding Efficacy A clinical trial of" exact="bevacizumab" post="addition to standard chemotherapy treatment in newly diagnosed advanced"/>
   <result pre="recurrent epithelial ovarian cancer (EOC). However, it remains unknown whether" exact="bevacizumab" post="is effective for the clinical treatment of clear cell"/>
   <result pre="Phase I and II studies show limited clincial benefits of" exact="sorafenib" post="in the treatment of EOC, both as monotherapy and"/>
   <result pre="as a useful therapy for patients with renal CCC. Therefore," exact="sorafenib" post="may be efficacious in the treatment of CCC Vascular"/>
   <result pre="recurrent ovarian cancer. Phase II and III trials indicate that" exact="pazopanib" post="may have a role in the treatment of some"/>
   <result pre="data demonstrates its efficacy in the treatment of CCC. However," exact="pazopanib" post="is regarded as useful in the treatment of renal"/>
   <result pre="patients Growth factor Epidermal growth factor receptor Gefitinib, erlotinib, and" exact="lapatinib" post="[ 78] Function Gefitinib is a tyrosine kinase inhibitor"/>
   <result pre="has no predictive or prognostic value in ovarian cancer. Although" exact="trastuzumab" post="is not useful for ovarian cancer, no studies have"/>
   <result pre="CCC. Further studies are needed to determine the efficacy of" exact="trastuzumab" post="in the treatment of ovarian CCC Insulin-like growth factor"/>
   <result pre="patients had sustained responses or stable disease, and treatment with" exact="imatinib" post="did not prolong progression-free survival DNA repair Poly ADP"/>
   <result pre="or -resistant recurrent ovarian cancer. Phase III clinical trial of" exact="olaparib" post="was initiated for patients with BRCA mutant ovarian cancer."/>
   <result pre="several solid tumors, including ovarian cancers, and the monoclonal antibody" exact="bevacizumab" post="has been shown to bind to VEGF, inhibit receptor"/>
   <result pre="(ICON7) and the Gynecologic Oncology Group (GOG) trials (GOG218) of" exact="bevacizumab" post="addition to standard chemotherapy in newly diagnosed advanced ovarian"/>
   <result pre="progression [ 84, 85]. In addition, efficacy and safety of" exact="bevacizumab" post="has been reported both in patients with platinum-sensitive and"/>
   <result pre="not been evaluated. Mabuchi et al. demonstrated the efficacy of" exact="bevacizumab" post="in in vitro and in vivo CCC models, which"/>
   <result pre="a few small clinical studies have reported the efficacy of" exact="sunitinib" post="for ovarian CCC [ 86]. Targeting the PI3K/AKT/mTOR signaling"/>
   <result pre="will be explored. Temsirolimus will be administered in combination with" exact="paclitaxel" post="and carboplatin for six cycles. For the maintenance phase,"/>
   <result pre="explored. Temsirolimus will be administered in combination with paclitaxel and" exact="carboplatin" post="for six cycles. For the maintenance phase, temsirolimus will"/>
   <result pre="paclitaxel and carboplatin for six cycles. For the maintenance phase," exact="temsirolimus" post="will be administered on days 1, 8, and 15"/>
   <result pre="enhanced AnxA4 expression was recently shown to increase chemoresistance to" exact="carboplatin" post="by contributing to extracellular efflux of the drug ["/>
   <result pre="AT-rich interactive domain-containing protein 1A CCC clear cell carcinoma CPT-P" exact="irinotecan" post="plus cisplatin EGFR epidermal growth factor receptor EOC epithelial"/>
   <result pre="domain-containing protein 1A CCC clear cell carcinoma CPT-P irinotecan plus" exact="cisplatin" post="EGFR epidermal growth factor receptor EOC epithelial ovarian cancer"/>
   <result pre="PFS progression-free survival PI3K phosphatidylinositol 3-kinases SAC serous adenocarcinoma TC" exact="paclitaxel" post="plus carboplatin VEGF vascular endothelial growth factor Authors’ contributions"/>
   <result pre="survival PI3K phosphatidylinositol 3-kinases SAC serous adenocarcinoma TC paclitaxel plus" exact="carboplatin" post="VEGF vascular endothelial growth factor Authors’ contributions SM, KY,"/>
   <result pre="Clarke-Pearson D Burger RA et al. Phase III trial of" exact="carboplatin" post="and paclitaxel compared with cisplatin and paclitaxel in patients"/>
   <result pre="Burger RA et al. Phase III trial of carboplatin and" exact="paclitaxel" post="compared with cisplatin and paclitaxel in patients with optimally"/>
   <result pre="al. Phase III trial of carboplatin and paclitaxel compared with" exact="cisplatin" post="and paclitaxel in patients with optimally resected stage III"/>
   <result pre="III trial of carboplatin and paclitaxel compared with cisplatin and" exact="paclitaxel" post="in patients with optimally resected stage III ovarian cancer:"/>
   <result pre="mucinous carcinoma of the ovary sensitive to combination chemotherapy with" exact="paclitaxel" post="and carboplatin? Proc Am Soc Clin Oncol 2003 22"/>
   <result pre="M Tsuda H Sagae S et al. Adjuvant chemotherapy with" exact="irinotecan" post="hydrochloride and cisplatin for clear cell carcinoma of the"/>
   <result pre="Sagae S et al. Adjuvant chemotherapy with irinotecan hydrochloride and" exact="cisplatin" post="for clear cell carcinoma of the ovary Oncol Rep"/>
   <result pre="D Inaba N et al. Randomized phase II trial of" exact="paclitaxel" post="plus carboplatin therapy versus irinotecan plus cisplatin therapy as"/>
   <result pre="N et al. Randomized phase II trial of paclitaxel plus" exact="carboplatin" post="therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy"/>
   <result pre="Randomized phase II trial of paclitaxel plus carboplatin therapy versus" exact="irinotecan" post="plus cisplatin therapy as first-line chemotherapy for clear cell"/>
   <result pre="II trial of paclitaxel plus carboplatin therapy versus irinotecan plus" exact="cisplatin" post="therapy as first-line chemotherapy for clear cell adenocarcinoma of"/>
   <result pre="J Martins I Kepp O et al. Molecular mechanisms of" exact="cisplatin" post="resistance Oncogene 2012 31 1869 1883 10.1038/onc.2011.384 21892204 15."/>
   <result pre="carcinoma of the ovary and its association with chemoresistance to" exact="carboplatin" post="Int J Cancer 2009 125 2316 2322 10.1002/ijc.24587 19598262"/>
   <result pre="KJ Barr MP The role of DNA repair pathways in" exact="cisplatin" post="resistant lung cancer Cancer Treat Rev 2014 40 1161"/>
   <result pre="deletion variant of epidermal growth factor receptor enhances invasiveness and" exact="cisplatin" post="resistance in epithelial ovarian cancer Carcinogenesis 2013 34 2639"/>
   <result pre="growth factor receptor underlying responsiveness of non-small-cell lung cancer to" exact="gefitinib" post="N Engl J Med 2004 350 2129 2139 10.1056/NEJMoa040938"/>
   <result pre="Takahashi K et al. Gefitinib (ZD1839) increases the efficacy of" exact="cisplatin" post="in ovarian cancer cells Cancer Biol Ther 2012 13"/>
   <result pre="receptor pathway analysis identifies amphiregulin as a key factor for" exact="cisplatin" post="resistance of human breast cancer cells J Biol Chem"/>
   <result pre="Sato S Kamazawa S Takahashi M et al. Mechanisms of" exact="cisplatin" post="resistance in clear cell carcinoma of the ovary Oncology."/>
   <result pre="possible novel treatment modality using recombinant monoclonal antibody against HER2," exact="trastuzumab" post="Jpn J Cancer Res 2002 93 1250 1257 10.1111/j.1349-7006.2002.tb01231.x"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4679405/results/search/inn/results.xml">
   <result pre="mdu486 : Original Articles: Breast Tumors Trastuzumab emtansine (T-DM1) versus" exact="lapatinib" post="plus capecitabine in patients with HER2-positive metastatic breast cancer"/>
   <result pre="Original Articles: Breast Tumors Trastuzumab emtansine (T-DM1) versus lapatinib plus" exact="capecitabine" post="in patients with HER2-positive metastatic breast cancer and central"/>
   <result pre="N. Lin, K. Blackwell et al. Efficacy and safety of" exact="trastuzumab" post="emtansine (T-DM1) versus lapatinib plus capecitabine in patients with"/>
   <result pre="et al. Efficacy and safety of trastuzumab emtansine (T-DM1) versus" exact="lapatinib" post="plus capecitabine in patients with human epidermal growth factor"/>
   <result pre="Efficacy and safety of trastuzumab emtansine (T-DM1) versus lapatinib plus" exact="capecitabine" post="in patients with human epidermal growth factor receptor 2-positive"/>
   <result pre="growth factor receptor 2-positive metastatic breast cancer was similar for" exact="trastuzumab" post="emtansine (T-DM1) and for capecitabine–lapatinib. In patients with treated,"/>
   <result pre="incidence of central nervous system (CNS) metastases after treatment with" exact="trastuzumab" post="emtansine (T-DM1) versus capecitabine–lapatinib (XL), and treatment efficacy among"/>
   <result pre="factor receptor 2 (HER2)-positive advanced breast cancer previously treated with" exact="trastuzumab" post="and a taxane were randomized to T-DM1 or XL"/>
   <result pre="several prospective trials, lapatinib—as a single agent or combined with" exact="capecitabine" post="(XL)—demonstrated some activity in HER2-positive CNS metastases [ 15–"/>
   <result pre="development of brain metastases [ 4, 5, 19– 21]. Although" exact="trastuzumab" post="is generally believed to be too large to cross"/>
   <result pre="using 89Zr-trastuzumab in patients with HER2-positive MBC has shown that" exact="trastuzumab" post="can access brain metastases, possibly due to a compromised"/>
   <result pre="drug conjugate composed of the cytotoxic agent DM1 conjugated to" exact="trastuzumab" post="via a stable linker, facilitates intracellular delivery of DM1"/>
   <result pre="as a single agent for HER2-positive MBC previously treated with" exact="trastuzumab" post="and a taxane. In the phase III EMILIA trial,"/>
   <result pre="progression of HER2-positive, unresectable, LABC or MBC previously treated with" exact="trastuzumab" post="and a taxane were randomized 1 : 1 to"/>
   <result pre="of 0 or 1. Prior exposure to T-DM1, lapatinib, or" exact="capecitabine" post="was not permitted. Patients received T-DM1 3.6 mg/kg i.v."/>
   <result pre="Patients received T-DM1 3.6 mg/kg i.v. every 21 days or" exact="capecitabine" post="1000 mg/m 2 orally twice-daily on days 1–14 of"/>
   <result pre="orally twice-daily on days 1–14 of each 21-day cycle and" exact="lapatinib" post="1250 mg orally once-daily on days 1–21. Treatment continued"/>
   <result pre="sites, prior anthracycline therapy, baseline ECOG PS, estrogen receptor and" exact="progesterone" post="receptor status, baseline disease measurability, menopausal status, prior anticancer"/>
   <result pre="status, baseline disease measurability, menopausal status, prior anticancer therapy, prior" exact="trastuzumab" post="therapy, and HER2 status by fluorescence in situ hybridization"/>
   <result pre="intent-to-treat; LVEF, left ventricular ejection fraction; N/A, not applicable; PR," exact="progesterone" post="receptor; T-DM1, trastuzumab emtansine; XL, capecitabine–lapatinib. Patients with baseline"/>
   <result pre="ventricular ejection fraction; N/A, not applicable; PR, progesterone receptor; T-DM1," exact="trastuzumab" post="emtansine; XL, capecitabine–lapatinib. Patients with baseline CNS metastases randomized"/>
   <result pre="at baseline who required a dose reduction of T-DM1 versus" exact="lapatinib" post="was similar [23.3% (10/43) versus 24.5% (12/49)]; however, 49.0%"/>
   <result pre="confidence interval; CNS, central nervous system; HR, hazard ratio; T-DM1," exact="trastuzumab" post="emtansine; XL, capecitabine – lapatinib. At data cutoff, there"/>
   <result pre="central nervous system; HR, hazard ratio; T-DM1, trastuzumab emtansine; XL," exact="capecitabine" post="– lapatinib. At data cutoff, there was a significant"/>
   <result pre="1.14, P = 0.865) was similar whether a patient received" exact="trastuzumab" post="plus capecitabine or XL [ 26]. In the current"/>
   <result pre="= 0.865) was similar whether a patient received trastuzumab plus" exact="capecitabine" post="or XL [ 26]. In the current analysis, the"/>
   <result pre="V Paul D et al. Multicenter phase II study of" exact="lapatinib" post="in patients with brain metastases from HER2-positive breast cancer"/>
   <result pre="Bachelot T Romieu G Campone M et al. Lapatinib plus" exact="capecitabine" post="in patients with previously untreated brain metastases from HER2-positive"/>
   <result pre="RA Ramakrishna N et al. A phase I study of" exact="lapatinib" post="with whole brain radiotherapy in patients with human epidermal"/>
   <result pre="patients with brain metastases from HER2-positive breast cancer treated with" exact="lapatinib" post="and capecitabine Ann Oncol 2011 22 625 630 20724575"/>
   <result pre="brain metastases from HER2-positive breast cancer treated with lapatinib and" exact="capecitabine" post="Ann Oncol 2011 22 625 630 20724575 19 Kirsch"/>
   <result pre="al. Survival after brain metastases from breast cancer in the" exact="trastuzumab" post="era J Clin Oncol 2005 23 2114 2116 15774813"/>
   <result pre="and re-irradiation in patients with metastatic breast cancer in the" exact="trastuzumab" post="era Radiat Oncol 2011 6 181 22204610 22 Dijkers"/>
   <result pre="al. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of" exact="trastuzumab" post="and efficiently inhibits growth of lapatinib insensitive breast cancer"/>
   <result pre="mechanisms of action of trastuzumab and efficiently inhibits growth of" exact="lapatinib" post="insensitive breast cancer Breast Cancer Res Treat 2011 128"/>
   <result pre="patients (pts) with HER2+ metastatic breast cancer (MBC), treated with" exact="lapatinib" post="plus capecitabine (LC) versus trastuzumab plus capecitabine (TC) 2012"/>
   <result pre="with HER2+ metastatic breast cancer (MBC), treated with lapatinib plus" exact="capecitabine" post="(LC) versus trastuzumab plus capecitabine (TC) 2012 Presented at"/>
   <result pre="breast cancer (MBC), treated with lapatinib plus capecitabine (LC) versus" exact="trastuzumab" post="plus capecitabine (TC) 2012 Presented at the European Society"/>
   <result pre="(MBC), treated with lapatinib plus capecitabine (LC) versus trastuzumab plus" exact="capecitabine" post="(TC) 2012 Presented at the European Society of Medical"/>
   <result pre="Press M et al. A phase III randomized comparison of" exact="lapatinib" post="plus capecitabine versus capecitabine alone in women with advanced"/>
   <result pre="et al. A phase III randomized comparison of lapatinib plus" exact="capecitabine" post="versus capecitabine alone in women with advanced breast cancer"/>
   <result pre="A phase III randomized comparison of lapatinib plus capecitabine versus" exact="capecitabine" post="alone in women with advanced breast cancer that has"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4682234/results/search/inn/results.xml">
   <result pre="tumors with EGFR overexpression. A phase II clinical study of" exact="erlotinib" post="(NCIC IND-148) for recurrent or metastatic endometrial carcinoma (EC)"/>
   <result pre="aim of this study was to re-examine the efficacy of" exact="erlotinib" post="in EC cells by utilizing in vitro and in"/>
   <result pre="and Ishikawa cells were used to evaluate the efficacy of" exact="erlotinib" post="in tumor cell lines expressing different EGFR levels. Furthermore,"/>
   <result pre="Ishikawa cells were implanted into athymic mice treated with either" exact="erlotinib" post="or trastuzumab. Results At our institution, 20.9 % of"/>
   <result pre="the proliferation of HEC-1A expressing high levels of EGFR, while" exact="trastuzumab" post="showed similar effect in Ishikawa cells dominantly expressing human"/>
   <result pre="expressing human epidermal growth factor receptor type2 (HER2). In vivo" exact="erlotinib" post="decreased tumor growth in mice xenografted with HEC-1A cells,"/>
   <result pre="anti-tumor effects in xenograft mice models. Our results suggest that" exact="erlotinib" post="continues to have clinical usefulness in specific cases, after"/>
   <result pre="Reagents Erlotinib (Abcam, Tokyo, Japan) was dissolved in DMSO, and" exact="pertuzumab" post="(Tyugai, Tokyo, Japan) was dissolved in distilled water for"/>
   <result pre="phosphate buffered saline (PBS) (stock solution: 20 ng/mL). DMEM (without" exact="phenol" post="red) and gentamicin sulfate (Geneticin) were purchased from Invitrogen"/>
   <result pre="(Carlsbad, CA, USA). DMEM/Ham’s nutrient mixture F-12 (1:1, vol/vol) (without" exact="phenol" post="red) was purchased from Sigma-Aldrich (St. Louis, MO, USA)."/>
   <result pre="supplemented with 5 % charcoal FBS. All media used were" exact="phenol" post="red free. Cells were incubated at 37 °C in"/>
   <result pre="the cells were treated with the pharmacological compounds (ErbB inhibitor:" exact="erlotinib" post="[EGFR tyrosine kinase inhibitor) and trastuzumab [HER-2 monoclonal antibody])"/>
   <result pre="pharmacological compounds (ErbB inhibitor: erlotinib [EGFR tyrosine kinase inhibitor) and" exact="trastuzumab" post="[HER-2 monoclonal antibody]) or transfected with siRNA, and incubated"/>
   <result pre="and 0.1 mL culture medium. Tumor-bearing mice were randomized into" exact="erlotinib" post="(1 mg, 3 mg, 10 mg, 30 mg/kg/day, intraperitoneal"/>
   <result pre="mg, 30 mg/kg/day, intraperitoneal (i.p.) for 5 days per week)," exact="pertuzumab" post="(1 mg, 3 mg, 10 mg/kg, i.p. twice per"/>
   <result pre="EC proliferation. In subsequent experiments, all cells were treated with" exact="erlotinib" post="(ERL: EGFR tyrosine kinase inhibitor) or trastuzumab (TRA: HER-2"/>
   <result pre="were treated with erlotinib (ERL: EGFR tyrosine kinase inhibitor) or" exact="trastuzumab" post="(TRA: HER-2 monoclonal antibody), and evaluated for ERK 1/2"/>
   <result pre="control ( P &amp;lt; 0.05). Fig. 5 Effect of ERK phosphorylation by" exact="erlotinib" post="or trastuzumab on proliferation in EC cell lines. a"/>
   <result pre="P &amp;lt; 0.05). Fig. 5 Effect of ERK phosphorylation by erlotinib or" exact="trastuzumab" post="on proliferation in EC cell lines. a All cells"/>
   <result pre="ERL (Fig. 6c). Fig. 6 Inhibition of tumor growth by" exact="erlotinib" post="(ERL) in vivo. Mice were implanted with Ishikawa ("/>
   <result pre="examined the molecular factors that underlie the variable responsiveness to" exact="erlotinib" post="in accordance with the expression levels of both EGFR"/>
   <result pre="variety of disease types. For HER2-positive patients with breast cancer," exact="trastuzumab" post="has significantly reduced the rate of recurrence [ 36]."/>
   <result pre="patients with non-small-cell lung cancer with poor prognosis [ 38]," exact="erlotinib" post="was beneficial in those patients in an EGFR-dependent way"/>
   <result pre="strongly effected by anti-EGFR drugs. Furthermore, the antitumor effects of" exact="erlotinib" post="against HEC-1A cells clearly inhibited tumor growth both in"/>
   <result pre="5b) and in vivo (Fig. 6b). On the other hand," exact="trastuzumab" post="did not reduce the tumor growth of Ishikawa cells"/>
   <result pre="(NCIC IND-148) has been largely considered to have concluded that" exact="erlotinib" post="is not a promising agent for recurrent or metastatic"/>
   <result pre="including progression and metastasis. However, the present data demonstrate that" exact="erlotinib" post="has efficacy in the treatment of endometrial cancers, which"/>
   <result pre="EC tumors will define patients who can be benefited by" exact="erlotinib" post="therapy. Conclusions Type I EC accounting for 80 %"/>
   <result pre="an EGFR tyrosine kinase inhibitor. In tumor xenograft mouse models," exact="erlotinib" post="clearly reduced the growth of tumors with high levels"/>
   <result pre="et al. Randomized phase III trial of whole-abdominal irradiation versus" exact="doxorubicin" post="and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic"/>
   <result pre="Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and" exact="cisplatin" post="chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group"/>
   <result pre="Yordan E Carson LF Evers C A randomized comparison of" exact="doxorubicin" post="alone versus doxorubicin plus cyclophosphamide in the management of"/>
   <result pre="LF Evers C A randomized comparison of doxorubicin alone versus" exact="doxorubicin" post="plus cyclophosphamide in the management of advanced or recurrent"/>
   <result pre="C A randomized comparison of doxorubicin alone versus doxorubicin plus" exact="cyclophosphamide" post="in the management of advanced or recurrent endometrial carcinoma:"/>
   <result pre="DuBeshter B Burger RA et al. Phase III trial of" exact="doxorubicin" post="with or without cisplatin in advanced endometrial carcinoma: a"/>
   <result pre="et al. Phase III trial of doxorubicin with or without" exact="cisplatin" post="in advanced endometrial carcinoma: a gynecologic oncology group study"/>
   <result pre="van der Burg ME Poveda A et al. Doxorubicin versus" exact="doxorubicin" post="and cisplatin in endometrial carcinoma: definitive results of a"/>
   <result pre="Burg ME Poveda A et al. Doxorubicin versus doxorubicin and" exact="cisplatin" post="in endometrial carcinoma: definitive results of a randomised study"/>
   <result pre="Reid GC Munkarah AR et al. Phase III trial of" exact="doxorubicin" post="plus cisplatin with or without paclitaxel plus filgrastim in"/>
   <result pre="Munkarah AR et al. Phase III trial of doxorubicin plus" exact="cisplatin" post="with or without paclitaxel plus filgrastim in advanced endometrial"/>
   <result pre="Phase III trial of doxorubicin plus cisplatin with or without" exact="paclitaxel" post="plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology"/>
   <result pre="trial of doxorubicin plus cisplatin with or without paclitaxel plus" exact="filgrastim" post="in advanced endometrial carcinoma: a Gynecologic Oncology Group Study"/>
   <result pre="Y et al. Expression of HER-2 affects patient survival and" exact="paclitaxel" post="sensitivity in endometrial cancer Br J Cancer 2010 103"/>
   <result pre="Dering J Ginther C Finn R et al. Activity of" exact="lapatinib" post="a novel HER2 and EGFR dual kinase inhibitor in"/>
   <result pre="Sakurada A Tsao MS et al. Phase II study of" exact="erlotinib" post="in recurrent or metastatic endometrial cancer: NCIC IND-148 J"/>
   <result pre="Thigpen JT Adler LM et al. Phase II trial of" exact="trastuzumab" post="in women with advanced or recurrent, HER2-positive endometrial carcinoma:"/>
   <result pre="Rahmeh M et al. Activity of the dual kinase inhibitor" exact="lapatinib" post="(GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells Cancer"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4687700/results/search/inn/results.xml">
   <result pre="Both of these alterations could explain the clinical failure of" exact="trastuzumab" post="55, 56, 57, 58, 59, 60. The Δ16HER‐2, a"/>
   <result pre="success 91. However, the efficacy of anti‐HER‐2 therapeutics such as" exact="trastuzumab" post="or small molecule HER‐2 TKI (lapatinib) is limited by"/>
   <result pre="a partial response to lapatinib, but showed no response to" exact="trastuzumab" post="alone. The mutation in this patient is analogue to"/>
   <result pre="harbour the T798M mutant alleles, acquired a resistance to both" exact="lapatinib" post="and trastuzumab alone. However, after the treatment of a"/>
   <result pre="T798M mutant alleles, acquired a resistance to both lapatinib and" exact="trastuzumab" post="alone. However, after the treatment of a simultaneous blockade"/>
   <result pre="and T798 in HER‐2 are critical residues, enable to determine" exact="lapatinib" post="sensitivity. Strong lapatinib resistance caused by L755S, L755P and"/>
   <result pre="HER‐2 are critical residues, enable to determine lapatinib sensitivity. Strong" exact="lapatinib" post="resistance caused by L755S, L755P and T798M, T798I have"/>
   <result pre="condition occurred after the treatment of other agents, such as" exact="gefitinib" post="or iressa, a selective epidermal growth factor receptor TKI,"/>
   <result pre="the ATP‐binding pocket was found, enabling these cells insensitive to" exact="gefitinib" post="104. Most HER‐2 mutations associated with lapatinib resistance locate"/>
   <result pre="cells insensitive to gefitinib 104. Most HER‐2 mutations associated with" exact="lapatinib" post="resistance locate in the ATP‐binding and hinge region. Herein,"/>
   <result pre="a conformation where the αC‐helix is fixed in to inhibit" exact="lapatinib" post="binding and influence the structure of the active state"/>
   <result pre="to the T790M mutation in EGFR. Another mechanism is that" exact="lapatinib" post="binds the inactive conformation preferentially, then incapable to bind"/>
   <result pre="interaction between Δ16HER‐2 and Src kinase. Treatment with single‐agent TKI" exact="dasatinib" post="overcame the resistance to trastuzumab, and suppressed tumourigenicity. In"/>
   <result pre="homolog (PTEN) may also contribute to the resistance 54. Surprisingly," exact="trastuzumab" post="was even identified to promote the growth and invasion"/>
   <result pre="cancer harbouring the expression of p95HER‐2 exhibit less response to" exact="trastuzumab" post="compared to patients without p95HER‐2. The lack of outer‐cell"/>
   <result pre="lack of outer‐cell attachment domain containing the binding site for" exact="trastuzumab" post="results in the failure of drug binding. Besides, actively"/>
   <result pre="signalling protein generated by ectopic expression of p95HER‐2, also promotes" exact="trastuzumab" post="resistance that has been demonstrated in preclinical and clinical"/>
   <result pre="that the applicability of anti‐HER‐2 agents, such as inhibitor combinations," exact="lapatinib" post="plus trastuzumab, or afatinib plus rapamycin, are the most"/>
   <result pre="anti‐HER‐2 agents, such as inhibitor combinations, lapatinib plus trastuzumab, or" exact="afatinib" post="plus rapamycin, are the most effective therapy in HER‐2‐mutant"/>
   <result pre="resistant to lapatinib, exhibited sensitivity to the irreversible HER‐2 inhibitor," exact="neratinib" post="23. All these findings validate that patients with HER‐2‐mutant"/>
   <result pre="to trastuzumab, but still sensitive to the TKI, such as" exact="lapatinib" post="53. In addition, some studies also reported that these"/>
   <result pre="possible biomarker to evaluate the efficacy of therapeutic regimens including" exact="lapatinib" post="and chemotherapy, and overcome the clinical failure of trastuzumab"/>
   <result pre="including lapatinib and chemotherapy, and overcome the clinical failure of" exact="trastuzumab" post="monotherapy. The effect of lapatinib, as single agents or"/>
   <result pre="revealed that tumours expressing these p95HER‐2 fragments, also respond to" exact="trastuzumab" post="plus chemotherapy, advocating that p95HER‐2 is also a predictive"/>
   <result pre="is also a predictive biomarker for the patients treated with" exact="trastuzumab" post="and chemotherapy 53. However, no inhibitors were directly targeted"/>
   <result pre="receptor and HER2 variants on receptor activity and inhibition by" exact="lapatinib" post=". Cancer Res. 2008; 68: 571– 9. 18199554 12"/>
   <result pre="E , Geers C , et al Clinical activity of" exact="afatinib" post="(BIBW 2992) in patients with lung adenocarcinoma with mutations"/>
   <result pre="Hitt R , Sebastian P , et al Effects of" exact="lapatinib" post="monotherapy: results of a randomised phase II study in"/>
   <result pre="growth factor receptor underlying responsiveness of non–small‐cell lung cancer to" exact="gefitinib" post=". N Engl J Med. 2004; 350: 2129– 39."/>
   <result pre="Morita S , Yatabe Y , et al Gefitinib versus" exact="cisplatin" post="plus docetaxel in patients with non‐small‐cell lung cancer harbouring"/>
   <result pre=", Yatabe Y , et al Gefitinib versus cisplatin plus" exact="docetaxel" post="in patients with non‐small‐cell lung cancer harbouring mutations of"/>
   <result pre="Biomarker analyses in CLEOPATRA: a phase III, placebo‐controlled study of" exact="pertuzumab" post="in human epidermal growth factor receptor 2–positive, first‐line metastatic"/>
   <result pre=", et al Effect of p95HER2/611CTF on the response to" exact="trastuzumab" post="and chemotherapy. J Natl Cancer Inst. 2014; 106: dju291."/>
   <result pre="isoform of HER2 associated with locally disseminated breast cancer and" exact="trastuzumab" post="resistance . Mol Cancer Ther. 2009; 8: 2152– 62."/>
   <result pre="Spector NL , Blackwell KL . Understanding the mechanisms behind" exact="trastuzumab" post="therapy for human epidermal growth factor receptor 2–positive breast"/>
   <result pre="KA , et al Acquired resistance of lung adenocarcinomas to" exact="gefitinib" post="or erlotinib is associated with a second mutation in"/>
   <result pre="et al Acquired resistance of lung adenocarcinomas to gefitinib or" exact="erlotinib" post="is associated with a second mutation in the EGFR"/>
   <result pre="domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor" exact="imatinib" post="(STI571) in chronic phase and blast crisis chronic myeloid"/>
   <result pre="P , Guo TH , et al Acquired resistance to" exact="imatinib" post="in gastrointestinal stromal tumor occurs through secondary gene mutation"/>
   <result pre="et al EXEL‐7647 inhibits mutant forms of ErbB2 associated with" exact="lapatinib" post="resistance and neoplastic transformation . Clin Cancer Res. 2008;"/>
   <result pre="al Breast cancer expressing the activated HER2/neu is sensitive to" exact="gefitinib" post="in vitro and in vivo and acquires resistance through"/>
   <result pre="L , Varella‐Garcia M . HER2 mutation and response to" exact="trastuzumab" post="therapy in non‐small‐cell lung cancer. N Engl J Med."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4687715/results/search/inn/results.xml">
   <result pre="blood marker S100A1 in detecting cardiotoxicity induced by chemotherapy agents;" exact="trastuzumab" post="and lapatinib, in normal rat heart. The rats were"/>
   <result pre="and L (n = 8, oral treatment with 100 mg/kg/day" exact="lapatinib" post="for 7 days). The activities of oxidative stress parameters"/>
   <result pre="of S100A1 with experiments performed on rats using chemotherapy agents;" exact="trastuzumab" post="and lapatinib, which have proven records of inducing cardiotoxicity"/>
   <result pre="randomly assigned to three groups: control (C, n = 8)," exact="trastuzumab" post="(T, n = 8) and lapatinib (L, n ="/>
   <result pre="(C, n = 8), trastuzumab (T, n = 8) and" exact="lapatinib" post="(L, n = 8) treatments. The control animals were"/>
   <result pre="8, anesthesia was induced by a single intraperitoneal injection of" exact="ketamine" post="and xylazine (50 and 5 mg/kg, respectively). The blood"/>
   <result pre="in the literature [ 21– 23]. But, those in the" exact="trastuzumab" post="and lapatinib treatment groups indicated substantial changes in the"/>
   <result pre="literature [ 21– 23]. But, those in the trastuzumab and" exact="lapatinib" post="treatment groups indicated substantial changes in the biochemistry of"/>
   <result pre="These results confirmed that exposure to the chemotherapy treatment drugs;" exact="trastuzumab" post="and lapatinib, indeed induced toxic injury through oxidative damage"/>
   <result pre="the troponinI, but negative for S100A1 level. Discussion Trastuzumab and" exact="lapatinib" post="are clinically approved drugs used for treating tumors in"/>
   <result pre="the changes in the activities of these markers indicated that" exact="trastuzumab" post="and lapatinib at the administered doses induce severe oxidative"/>
   <result pre="in the activities of these markers indicated that trastuzumab and" exact="lapatinib" post="at the administered doses induce severe oxidative damage in"/>
   <result pre="practice, as explained below. Conclusion and Future Work Treatment with" exact="trastuzumab" post="and lapatinib induces oxidative damage in myocardial tissue. The"/>
   <result pre="explained below. Conclusion and Future Work Treatment with trastuzumab and" exact="lapatinib" post="induces oxidative damage in myocardial tissue. The resulting cardiotoxicity"/>
   <result pre="direction by demonstrating the S100A1 response to cardiotoxicity induced by" exact="trastuzumab" post="and lapatinib in otherwise normal rats. In experimental investigations"/>
   <result pre="demonstrating the S100A1 response to cardiotoxicity induced by trastuzumab and" exact="lapatinib" post="in otherwise normal rats. In experimental investigations with S100A1"/>
   <result pre="biomarkers for early detection of cardiotoxicity after treatment with docetaxel," exact="doxorubicin" post="and cyclophosphamide . Biomarkers. 2015 5 18: 1– 6."/>
   <result pre="early detection of cardiotoxicity after treatment with docetaxel, doxorubicin and" exact="cyclophosphamide" post=". Biomarkers. 2015 5 18: 1– 6. doi: 10.3109/1354750x.2015.1040839"/>
   <result pre=", et al. Long-term cardiac safety and outcomes of dose-dense" exact="doxorubicin" post="and cyclophosphamide followed by paclitaxel and trastuzumab with and"/>
   <result pre="al. Long-term cardiac safety and outcomes of dose-dense doxorubicin and" exact="cyclophosphamide" post="followed by paclitaxel and trastuzumab with and without lapatinib"/>
   <result pre="safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by" exact="paclitaxel" post="and trastuzumab with and without lapatinib in patients with"/>
   <result pre="outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and" exact="trastuzumab" post="with and without lapatinib in patients with early breast"/>
   <result pre="and cyclophosphamide followed by paclitaxel and trastuzumab with and without" exact="lapatinib" post="in patients with early breast cancer . Cancer. 2013"/>
   <result pre="in patients with breast cancer treated with dose-dense chemotherapy incorporating" exact="trastuzumab" post="and lapatinib . Clin Cancer Res. 2011 5 15;"/>
   <result pre="with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and" exact="lapatinib" post=". Clin Cancer Res. 2011 5 15; 17( 10):"/>
   <result pre="prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and" exact="trastuzumab" post=". Circ Cardiovasc Imaging. 2012 9 1; 5( 5):"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4689767/results/search/inn/results.xml">
   <result pre="prognostic information. It is essential to study the estrogen receptor," exact="progesterone" post="receptor, and HER2. Ki-67 determination has high inter-observer variability"/>
   <result pre="The standard treatment for premenopausal women is 5 years of" exact="tamoxifen" post="(I, A) [ 30], but other alternatives should be"/>
   <result pre="A) [ 30], but other alternatives should be considered. Extending" exact="tamoxifen" post="beyond 5 years confers a significant reduction in risk"/>
   <result pre="but at the cost of greater toxicity [I, B]. Adjuvant" exact="exemestane" post="with ovarian suppression as compared with tamoxifen plus ovarian"/>
   <result pre="[I, B]. Adjuvant exemestane with ovarian suppression as compared with" exact="tamoxifen" post="plus ovarian suppression significantly reduced recurrence but did not"/>
   <result pre="cancer patients [ 33]. This combination is an alternative to" exact="tamoxifen" post="for patients at high risk of recurrence, at the"/>
   <result pre="toxicity [I, B]. EBCTCG and SOFT trials support that adjuvant" exact="tamoxifen" post="with GnRH analogues is not better but more toxic"/>
   <result pre="with GnRH analogues is not better but more toxic than" exact="tamoxifen" post="alone. This combination could be seen as an alternative"/>
   <result pre="[ 36]. For postmenopausal women, AIs are more effective than" exact="tamoxifen" post="[I, A] [ 37, 38]. There are no trials"/>
   <result pre="of platinum-based chemotherapy in TNBC is currently being evaluated. Neoadjuvant" exact="cisplatin" post="monotherapy in BRCA1 mutation-breast cancer patients is highly effective"/>
   <result pre="and a meta-analysis [ 43] have assessed the addition of" exact="carboplatin" post="to anthracyclines and taxane-based chemotherapy for TNBC. In the"/>
   <result pre="chemotherapy for TNBC. In the GeparSixto trial, the addition of" exact="carboplatin" post="significantly increased the pCR rate in TNBC patients treated"/>
   <result pre="increased the pCR rate in TNBC patients treated with weekly" exact="paclitaxel" post="and liposomal doxorubicin plus bevacizumab. Patients with both a"/>
   <result pre="rate in TNBC patients treated with weekly paclitaxel and liposomal" exact="doxorubicin" post="plus bevacizumab. Patients with both a BRCA1/2 and family"/>
   <result pre="in pCR. In the CALGB 40603 study, the addition of" exact="carboplatin" post="(at a dose of AUC every 3 weeks), to"/>
   <result pre="(at a dose of AUC every 3 weeks), to weekly" exact="paclitaxel" post="followed by AC every 2 weeks, increased the rate"/>
   <result pre="improved pCR was observed with Nab-paclitaxel compared to solvent-based weekly" exact="paclitaxel" post="(43 vs 34 %) in a head to head"/>
   <result pre="of HER2. The scientific evidence is definitive to recommend adjuvant" exact="trastuzumab" post="in node-positive and node-negative tumors sized &amp;gt;1 cm [I,"/>
   <result pre="in ER-negative disease (II, B) [ 47]. In most studies," exact="trastuzumab" post="was administered for 1 year. No additional benefit was"/>
   <result pre="further administration [I, A] [ 48]. Due to its cardiotoxicity," exact="trastuzumab" post="should not be routinely administered concomitantly with anthracyclines (I,"/>
   <result pre="effective than sequential treatment. Both AC followed by paclitaxel/docetaxel with" exact="trastuzumab" post="for 1 year commencing with the first dose of"/>
   <result pre="this group. However, in small, node-negative tumors, combination of single-agent" exact="paclitaxel" post="and trastuzumab provides excellent results [II B] [ 50]."/>
   <result pre="However, in small, node-negative tumors, combination of single-agent paclitaxel and" exact="trastuzumab" post="provides excellent results [II B] [ 50]. Trastuzumab may"/>
   <result pre="therapy. Neoadjuvant treatment for Her2-positive disease In the neoadjuvant setting," exact="trastuzumab" post="in combination with chemotherapy (taxane and anthracycline based) has"/>
   <result pre="outcomes. Dual antiHER2 blockade associated with chemotherapy (trastuzumab + lapatinib," exact="trastuzumab" post="+pertuzumab) has led to improvements in the pCR rate"/>
   <result pre="in the pCR rate when compared with chemotherapy associated with" exact="trastuzumab" post="agent, as shown in NEOSPHERE study. These data have"/>
   <result pre="Pöstlberger S Samonigg H Kwasny W et al. Tamoxifen and" exact="anastrozole" post="as a sequencing strategy: a randomized controlled trial in"/>
   <result pre="R Raina V et al. Long-term effects of continuing adjuvant" exact="tamoxifen" post="to 10 years versus stopping at 5 years after"/>
   <result pre="Bowden SJ, Perry P. aTTom: long-term effects of continuing adjuvant" exact="tamoxifen" post="to 10 years versus stopping at 5 years in"/>
   <result pre="BA Fleming GF Colleoni M Láng I et al. Adjuvant" exact="exemestane" post="with ovarian suppression in premenopausal breast cancer N Engl"/>
   <result pre="in combination: the immediate preoperative anastrozole, tamoxifen, or combined with" exact="tamoxifen" post="(IMPACT) multicenter double-blind randomized trial J Clin Oncol 2005"/>
   <result pre="S Salat C Denkert C Rezai M et al. Neoadjuvant" exact="carboplatin" post="in patients with triple-negative and Her2-positive early breast cancer"/>
   <result pre="CT Tolaney SM et al. Impact of the addition of" exact="carboplatin" post="and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense"/>
   <result pre="SM et al. Impact of the addition of carboplatin and/or" exact="bevacizumab" post="to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and"/>
   <result pre="of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week" exact="paclitaxel" post="followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete"/>
   <result pre="carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense" exact="doxorubicin" post="and cyclophosphamide on pathologic complete response rates in stage"/>
   <result pre="bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and" exact="cyclophosphamide" post="on pathologic complete response rates in stage II-III triple"/>
   <result pre="al. A randomized phase III trial comparing nanoparticle based (nab)" exact="paclitaxel" post="with solvent based paclitaxel as part of neoadjuvant chemotherapy"/>
   <result pre="III trial comparing nanoparticle based (nab) paclitaxel with solvent based" exact="paclitaxel" post="as part of neoadjuvant chemotherapy for patients with early"/>
   <result pre="Azambuja E Muehlbauer S Goldhirsch A et al. Treatment with" exact="trastuzumab" post="for 1 year after adjuvant chemotherapy in patients with"/>
   <result pre="TM et al. 2 years versus 1 year of adjuvant" exact="trastuzumab" post="for HER2-positive breast cancer (HERA): an open-label, randomised controlled"/>
   <result pre="N Pienkowski T Martin M Press M et al. Adjuvant" exact="trastuzumab" post="in HER2-positive breast cancer N Engl J Med 2011"/>
   <result pre="CT Yardley DA Moy B Marcom PK et al. Adjuvant" exact="paclitaxel" post="and trastuzumab for node-negative HER2-positive breast cancer N Engl"/>
   <result pre="DA Moy B Marcom PK et al. Adjuvant paclitaxel and" exact="trastuzumab" post="for node-negative HER2-positive breast cancer N Engl Med 2015"/>
   <result pre="A Lluch A Tjulandin S et al. Neoadjuvant chemotherapy with" exact="trastuzumab" post="followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in"/>
   <result pre="S et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant" exact="trastuzumab" post="versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally"/>
   <result pre="LM Liu MC et al. Efficacy and safety of neoadjuvant" exact="pertuzumab" post="and trastuzumab in women with locally advanced, inflammatory, or"/>
   <result pre="MC et al. Efficacy and safety of neoadjuvant pertuzumab and" exact="trastuzumab" post="in women with locally advanced, inflammatory, or early HER2-positive"/>
   <result pre="S de Azambuja E Aura C et al. Lapatinib with" exact="trastuzumab" post="for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label,"/>
   <result pre="NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with" exact="lapatinib" post="alone (L), trastuzumab alone (T), their sequence (T →"/>
   <result pre="comparing one year of anti-HER2 therapy with lapatinib alone (L)," exact="trastuzumab" post="alone (T), their sequence (T → L), or their"/>
   <result pre="Cirrincione CT Berry DA McCormick B et al. Lumpectomy plus" exact="tamoxifen" post="with or without irradiation in women age 70 years"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4689775/results/search/inn/results.xml">
   <result pre="of certainty: high; strength of recommendation: A). First-line treatment with" exact="trastuzumab" post="in combination with chemotherapy (especially taxanes), is associated to"/>
   <result pre="combinations seem inferior to the ones reached with chemotherapy plus" exact="trastuzumab" post="and, therefore, should be limited to low-risk patients (i.e.,"/>
   <result pre="there are no contraindications, should be a combination of docetaxel," exact="trastuzumab" post="and pertuzumab [ 18] (level of certainty: high; strength"/>
   <result pre="no contraindications, should be a combination of docetaxel, trastuzumab and" exact="pertuzumab" post="[ 18] (level of certainty: high; strength of recommendation:"/>
   <result pre="18] (level of certainty: high; strength of recommendation: A). Replacing" exact="docetaxel" post="with paclitaxel or vinorelbine may be considered in certain"/>
   <result pre="of certainty: high; strength of recommendation: A). Replacing docetaxel with" exact="paclitaxel" post="or vinorelbine may be considered in certain circumstances ["/>
   <result pre="high; strength of recommendation: A). Replacing docetaxel with paclitaxel or" exact="vinorelbine" post="may be considered in certain circumstances [ 19] (level"/>
   <result pre="completion of adjuvant trastuzumab, the combination of docetaxel, trastuzumab, and" exact="pertuzumab" post="may be considered; whereas with relapses of 6–12 months,"/>
   <result pre="anti-HER2 therapy, after progression during or following first-line treatment with" exact="trastuzumab" post="[ 20– 24] (level of certainty: high; strength of"/>
   <result pre="certainty: high; strength of recommendation: A). T-DM1 was superior to" exact="lapatinib" post="plus capecitabine (prior second-line standard) in terms of response"/>
   <result pre="strength of recommendation: A). T-DM1 was superior to lapatinib plus" exact="capecitabine" post="(prior second-line standard) in terms of response rate, PFS"/>
   <result pre="rate, PFS and OS in patients pretreated with either first-line" exact="trastuzumab" post="combinations or early relapses after trastuzumab adjuvant therapy ["/>
   <result pre="pretreated with either first-line trastuzumab combinations or early relapses after" exact="trastuzumab" post="adjuvant therapy [ 23]. T-DM1 is the preferred second-line"/>
   <result pre="(level of certainty: high; strength of recommendation: A). Lapatinib plus" exact="capecitabine" post="can be a good second-line option for patients with"/>
   <result pre="HER2-positive breast cancer previously treated with anti-HER2 therapy (including trastuzumab," exact="lapatinib" post="and pertuzumab), with or without chemotherapy (level of certainty:"/>
   <result pre="of certainty: high; strength of recommendation: A). The combination of" exact="lapatinib" post="plus trastuzumab in patients progressing on trastuzumab showed a"/>
   <result pre="high; strength of recommendation: A). The combination of lapatinib plus" exact="trastuzumab" post="in patients progressing on trastuzumab showed a higher PFS"/>
   <result pre="The combination of lapatinib plus trastuzumab in patients progressing on" exact="trastuzumab" post="showed a higher PFS and OS versus lapatinib alone."/>
   <result pre="progressing on trastuzumab showed a higher PFS and OS versus" exact="lapatinib" post="alone. The benefit was more notable in the sub-group"/>
   <result pre="Mechanism of action Class Agent Estrogen receptor blockage SERM Tamoxifen," exact="toremifene" post="Estrogen receptor downregulation SERD Fulvestrant Estrogen deprivation Ovarian ablation"/>
   <result pre="Ovarian ablation Surgery, radiation Ovarian suppression with GnRH Goserelin, triptorelin," exact="leuprolide" post="Aromatase inhibition NSAI Anastrozole, letrozole SAI Exemestane Unknown Progestins"/>
   <result pre="suppression with GnRH Goserelin, triptorelin, leuprolide Aromatase inhibition NSAI Anastrozole," exact="letrozole" post="SAI Exemestane Unknown Progestins Megestrol acetate, medroxyprogesterone acetate High-dose"/>
   <result pre="inhibition NSAI Anastrozole, letrozole SAI Exemestane Unknown Progestins Megestrol acetate," exact="medroxyprogesterone" post="acetate High-dose estrogens Diethylstilbestrol (DES) Mechanism of action SERM"/>
   <result pre="Premenopausal women First-line treatment: Ovarian ablation or suppression (OA) or" exact="tamoxifen" post="has similar results, the combination of OA plus tamoxifen"/>
   <result pre="or tamoxifen has similar results, the combination of OA plus" exact="tamoxifen" post="offers better results than OA alone and is considered"/>
   <result pre="strength of recommendation: A). Second-line treatment: For patients progressing on" exact="tamoxifen" post="or GnRH agonists, switching to the opposite is an"/>
   <result pre="combinations can be used in patients progressing on OA +" exact="tamoxifen" post="(level of certainty: low; strength of recommendation: B). A"/>
   <result pre="shown that the combination of ET (fulvestrant in postmenopausal women," exact="fulvestrant" post="plus OS in premenopausal women) and palbociclib improves PFS"/>
   <result pre="in postmenopausal women, fulvestrant plus OS in premenopausal women) and" exact="palbociclib" post="improves PFS vs ET alone. OA plus fulvestrant plus"/>
   <result pre="women) and palbociclib improves PFS vs ET alone. OA plus" exact="fulvestrant" post="plus palbociclib is, therefore, a second-line option for premenopausal"/>
   <result pre="palbociclib improves PFS vs ET alone. OA plus fulvestrant plus" exact="palbociclib" post="is, therefore, a second-line option for premenopausal women, although"/>
   <result pre="palbociclib is, therefore, a second-line option for premenopausal women, although" exact="palbociclib" post="is not yet available for prescription in Spain ["/>
   <result pre="strength of recommendation: A). Postmenopausal women First-line therapy (59) Anastrozole," exact="letrozole" post="and exemestane are superior to tamoxifen in PFS in"/>
   <result pre="recommendation: A). Postmenopausal women First-line therapy (59) Anastrozole, letrozole and" exact="exemestane" post="are superior to tamoxifen in PFS in patients without"/>
   <result pre="First-line therapy (59) Anastrozole, letrozole and exemestane are superior to" exact="tamoxifen" post="in PFS in patients without prior ET or only"/>
   <result pre="in PFS in patients without prior ET or only adjuvant" exact="tamoxifen" post="(level of certainty: high; strength of recommendation: A). Fulvestrant"/>
   <result pre="But this dose is now considered suboptimal. Recommended dose is" exact="fulvestrant" post="500 mg/monthly (level of certainty: high; strength of recommendation:"/>
   <result pre="of certainty: high; strength of recommendation: A). The combination of" exact="anastrozole" post="and fulvestrant (250 mg/monthly) versus anastrozole alone was explored"/>
   <result pre="high; strength of recommendation: A). The combination of anastrozole and" exact="fulvestrant" post="(250 mg/monthly) versus anastrozole alone was explored in two"/>
   <result pre="A). The combination of anastrozole and fulvestrant (250 mg/monthly) versus" exact="anastrozole" post="alone was explored in two randomized phase III trials,"/>
   <result pre="of recommendation: B). Fulvestrant (LD 500 mg) was superior to" exact="anastrozole" post="in PFS and OS according to a randomized phase"/>
   <result pre="strength of recommendation: B). Letrozol + Palbociclib is superior to" exact="letrozole" post="according to a randomized phase II trial (PFS). Data"/>
   <result pre="strength of recommendation: B). Fulvestrant 500 mg was superior to" exact="fulvestrant" post="250 mg in PFS and OS in patients with"/>
   <result pre="strength of recommendation: A). In patients treated with adjuvant AI," exact="fulvestrant" post="500 mg is also a good option (level of"/>
   <result pre="or modestly superior to progestins but much better tolerated and" exact="fulvestrant" post="250 mg was equivalent to anastrozole. In patients progressing"/>
   <result pre="equivalent to anastrozole. In patients progressing on a non-steroidal AI" exact="exemestane" post="and fulvestrant (250 mg) were equivalent. Fulvestrant 500 mg"/>
   <result pre="anastrozole. In patients progressing on a non-steroidal AI exemestane and" exact="fulvestrant" post="(250 mg) were equivalent. Fulvestrant 500 mg was superior"/>
   <result pre="(250 mg) were equivalent. Fulvestrant 500 mg was superior to" exact="fulvestrant" post="250 mg in PFS and OS in a phase"/>
   <result pre="50 % of patients with only adjuvant ET. Exemestane plus" exact="everolimus" post="was superior to exemestane in PFS (but not OS)"/>
   <result pre="with only adjuvant ET. Exemestane plus everolimus was superior to" exact="exemestane" post="in PFS (but not OS) in a phase III"/>
   <result pre="therapy for metastases (around 80 % of total). Palbociclib plus" exact="fulvestrant" post="was superior to fulvestrant in PFS in a phase"/>
   <result pre="80 % of total). Palbociclib plus fulvestrant was superior to" exact="fulvestrant" post="in PFS in a phase III trial. Palbociclib is"/>
   <result pre="yet available for prescription in Spain. Fulvestrant 500 mg or" exact="exemestane" post="+ everolimus is the best currently available option after"/>
   <result pre="for prescription in Spain. Fulvestrant 500 mg or exemestane +" exact="everolimus" post="is the best currently available option after progression to"/>
   <result pre="from prospective trials in patients with prior exposition to AI," exact="tamoxifen" post="fulvestrant and exemestane–everolimus. In cases where a positive effect"/>
   <result pre="prospective trials in patients with prior exposition to AI, tamoxifen" exact="fulvestrant" post="and exemestane–everolimus. In cases where a positive effect has"/>
   <result pre="therapy is not working any longer. Anthracyclines, taxanes, vinorelbine, capecitabine," exact="gemcitabine" post="and eribulin are available options. The choice of the"/>
   <result pre="not working any longer. Anthracyclines, taxanes, vinorelbine, capecitabine, gemcitabine and" exact="eribulin" post="are available options. The choice of the strategy and"/>
   <result pre="of certainty: high; strength of recommendation: A). The combination of" exact="bevacizumab" post="plus taxanes improves PFS and ORR, but not OS"/>
   <result pre="pretreated with adjuvant taxanes and anthracyclines, other options such as" exact="vinorelbine" post="[ 31, 32] and capecitabine [ 33] are also"/>
   <result pre="anthracyclines, other options such as vinorelbine [ 31, 32] and" exact="capecitabine" post="[ 33] are also appropriate first-line chemotherapy options (level"/>
   <result pre="in selected patients. Among them, capecitabine, vinorelbine, gemcitabine, nab-paclitaxel, liposomal" exact="doxorubicin" post="and eribulin are approved options and can be appropriate"/>
   <result pre="patients. Among them, capecitabine, vinorelbine, gemcitabine, nab-paclitaxel, liposomal doxorubicin and" exact="eribulin" post="are approved options and can be appropriate therapies ["/>
   <result pre="phase III trial in patients pretreated with taxanes and anthracyclines," exact="eribulin" post="was not superior to the current standard capecitabine in"/>
   <result pre="and anthracyclines, eribulin was not superior to the current standard" exact="capecitabine" post="in PFS or OS. In another phase III trial,"/>
   <result pre="capecitabine in PFS or OS. In another phase III trial," exact="eribulin" post="has shown a modest improvement in OS in patients"/>
   <result pre="of certainty: high; strength of recommendation: A). Considering these data," exact="capecitabine" post="is the most recommendable first option for HR-positive MBC"/>
   <result pre="for HR-positive MBC patients pretreated with taxanes and anthracyclines, while" exact="eribulin" post="can be administered after progression on capecitabine (level of"/>
   <result pre="and anthracyclines, while eribulin can be administered after progression on" exact="capecitabine" post="(level of certainty: high; strength of recommendation: A). Treatment"/>
   <result pre="pretreated with adjuvant taxanes and anthracyclines, other options such as" exact="vinorelbine" post="[ 31, 32] and capecitabine [ 33] are also"/>
   <result pre="anthracyclines, other options such as vinorelbine [ 31, 32] and" exact="capecitabine" post="[ 33] are also available (level of certainty: moderate;"/>
   <result pre="of certainty: moderate; strength of recommendation: B). The combination of" exact="bevacizumab" post="plus taxanes improves PFS and ORR, but not OS"/>
   <result pre="Despite the absence of phase III data, the combination of" exact="carboplatin" post="and gemcitabine has been accepted as an appropriate control"/>
   <result pre="absence of phase III data, the combination of carboplatin and" exact="gemcitabine" post="has been accepted as an appropriate control arm by"/>
   <result pre="trial in patients with both TNBC- and BRCA-associated metastatic tumors," exact="carboplatin" post="and docetaxel were similarly effective in the overall population"/>
   <result pre="patients with both TNBC- and BRCA-associated metastatic tumors, carboplatin and" exact="docetaxel" post="were similarly effective in the overall population [ 41]."/>
   <result pre="in the overall population [ 41]. Carboplatin was superior to" exact="docetaxel" post="in ORR and PFS in patients with BRCA-associated tumors"/>
   <result pre="quality of life is maintained. Capecitabine, vinorelbine, gemcitabine, nab-paclitaxel, liposomal" exact="doxorubicin" post="and eribulin are approved drugs and can be appropriate"/>
   <result pre="life is maintained. Capecitabine, vinorelbine, gemcitabine, nab-paclitaxel, liposomal doxorubicin and" exact="eribulin" post="are approved drugs and can be appropriate options ["/>
   <result pre="options [ 31, 33– 37]. In a phase III trial," exact="eribulin" post="was not superior to capecitabine in terms of PFS"/>
   <result pre="In a phase III trial, eribulin was not superior to" exact="capecitabine" post="in terms of PFS and OS in the overall"/>
   <result pre="the TNBC population the differences in OS were favorable to" exact="eribulin" post="[ 35]. As there are few effective treatment options"/>
   <result pre="of recommendation: A). In a large, randomized phase III study," exact="denosumab" post="was superior to zoledronic acid in delaying the time"/>
   <result pre="a large, randomized phase III study, denosumab was superior to" exact="zoledronic acid" post="in delaying the time to first squeletal-related event (SREs:"/>
   <result pre="significantly reduced the mean skeletal morbidity rate as compared with" exact="zoledronic acid." post="Therefore, denosumab is also an appropriate option, in conjunction"/>
   <result pre="mean skeletal morbidity rate as compared with zoledronic acid. Therefore," exact="denosumab" post="is also an appropriate option, in conjunction with anti-tumor"/>
   <result pre="cancer patients with bone metastases is unknown. The experience with" exact="zoledronic acid" post="and denosumab beyond two years of administration is very"/>
   <result pre="bone metastases is unknown. The experience with zoledronic acid and" exact="denosumab" post="beyond two years of administration is very limited (level"/>
   <result pre="L Wallwiener D Thomssen C et al. Higher efficacy of" exact="letrozole" post="in combination with trastuzumab compared to letrozole monotherapy as"/>
   <result pre="C et al. Higher efficacy of letrozole in combination with" exact="trastuzumab" post="compared to letrozole monotherapy as first-line treatment in patients"/>
   <result pre="Higher efficacy of letrozole in combination with trastuzumab compared to" exact="letrozole" post="monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive"/>
   <result pre="M Sadeghi S Dieras V et al. Lapatinib combined with" exact="letrozole" post="versus letrozole and placebo as first-line therapy for postmenopausal"/>
   <result pre="S Dieras V et al. Lapatinib combined with letrozole versus" exact="letrozole" post="and placebo as first-line therapy for postmenopausal hormone receptor-positive"/>
   <result pre="Bapsy PP Vaid A Wardley A et al. Trastuzumab plus" exact="anastrozole" post="versus anastrozole alone for the treatment of postmenopausal women"/>
   <result pre="Vaid A Wardley A et al. Trastuzumab plus anastrozole versus" exact="anastrozole" post="alone for the treatment of postmenopausal women with human"/>
   <result pre="J Semiglazov V Campone M et al. Pertuzumab, trastuzumab, and" exact="docetaxel" post="in HER2-positive metastatic breast cancer N Engl J Med"/>
   <result pre="Robb S, et al. 361pdinterim safety and efficacy of pertuzumab," exact="trastuzumab" post="and vinorelbine for first-line (1 l) treatment of patients"/>
   <result pre="et al. 361pdinterim safety and efficacy of pertuzumab, trastuzumab and" exact="vinorelbine" post="for first-line (1 l) treatment of patients (pts) with"/>
   <result pre="Chan S Romieu CG Pienkowski T et al. Lapatinib plus" exact="capecitabine" post="for HER2-positive advanced breast cancer N Engl J Med"/>
   <result pre="Sledge G Aktan G et al. Overall survival benefit with" exact="lapatinib" post="in combination with trastuzumab for patients with human epidermal"/>
   <result pre="et al. Overall survival benefit with lapatinib in combination with" exact="trastuzumab" post="for patients with human epidermal growth factor receptor 2-positive"/>
   <result pre="Pivot X Tomczak P et al. Phase III study of" exact="bevacizumab" post="plus docetaxel compared with placebo plus docetaxel for the"/>
   <result pre="Tomczak P et al. Phase III study of bevacizumab plus" exact="docetaxel" post="compared with placebo plus docetaxel for the first-line treatment"/>
   <result pre="III study of bevacizumab plus docetaxel compared with placebo plus" exact="docetaxel" post="for the first-line treatment of human epidermal growth factor"/>
   <result pre="Dickler M Cobleigh M Perez EA et al. Paclitaxel plus" exact="bevacizumab" post="versus paclitaxel alone for metastatic breast cancer N Engl"/>
   <result pre="Cobleigh M Perez EA et al. Paclitaxel plus bevacizumab versus" exact="paclitaxel" post="alone for metastatic breast cancer N Engl J Med"/>
   <result pre="double-blind, placebo-controlled, phase III trial of chemotherapy with or without" exact="bevacizumab" post="for first-line treatment of human epidermal growth factor receptor"/>
   <result pre="Tang L Ma Y Zhang F-C A systematic review of" exact="vinorelbine" post="for the treatment of breast cancer Breast J. 2013"/>
   <result pre="180 188 10.1111/tbj.12071 23320984 32. Aapro M Finek J Oral" exact="vinorelbine" post="in metastatic breast cancer: a review of current clinical"/>
   <result pre="126 10.1016/j.ctrv.2011.05.005 21742438 33. Chan A Verrill M Capecitabine and" exact="vinorelbine" post="in metastatic breast cancer Eur J Cancer 2009 45"/>
   <result pre="Velikova G, et al. Phase III open-label randomized study of" exact="eribulin" post="mesylate versus capecitabine in patients with locally advanced or"/>
   <result pre="al. Phase III open-label randomized study of eribulin mesylate versus" exact="capecitabine" post="in patients with locally advanced or metastatic breast cancer"/>
   <result pre="et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated" exact="doxorubicin" post="and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in"/>
   <result pre="Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and" exact="cyclophosphamide" post="compared with conventional doxorubicin and cyclophosphamide in a randomized,"/>
   <result pre="antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional" exact="doxorubicin" post="and cyclophosphamide in a randomized, multicenter trial of metastatic"/>
   <result pre="of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and" exact="cyclophosphamide" post="in a randomized, multicenter trial of metastatic breast cancer"/>
   <result pre="J et al. Efficacy and toxicity profile of pegylated liposomal" exact="doxorubicin" post="(Caelyx) in patients with advanced breast cancer Anticancer Drugs"/>
   <result pre="Y Garfield DH Wu J Huang O Shen K Both" exact="carboplatin" post="and bevacizumab improve pathological complete remission rate in neoadjuvant"/>
   <result pre="DH Wu J Huang O Shen K Both carboplatin and" exact="bevacizumab" post="improve pathological complete remission rate in neoadjuvant treatment of"/>
   <result pre="Neubauer M, et al. Phase III study of iniparib plus" exact="gemcitabine" post="and carboplatin versus gemcitabine and carboplatin in patients with"/>
   <result pre="et al. Phase III study of iniparib plus gemcitabine and" exact="carboplatin" post="versus gemcitabine and carboplatin in patients with metastatic triple-negative"/>
   <result pre="Phase III study of iniparib plus gemcitabine and carboplatin versus" exact="gemcitabine" post="and carboplatin in patients with metastatic triple-negative breast cancer."/>
   <result pre="study of iniparib plus gemcitabine and carboplatin versus gemcitabine and" exact="carboplatin" post="in patients with metastatic triple-negative breast cancer. J Clin"/>
   <result pre="al. The TNT trial: a randomized phase III trial of" exact="carboplatin" post="(C) compared with docetaxel (D) for patients with metastatic"/>
   <result pre="a randomized phase III trial of carboplatin (C) compared with" exact="docetaxel" post="(D) for patients with metastatic or recurrent locally advanced"/>
   <result pre="Tonkin K de Boer RH et al. Denosumab compared with" exact="zoledronic acid" post="for the treatment of bone metastases in patients with"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4694793/results/search/inn/results.xml">
   <result pre="underwent D2 resection, and were randomly assigned to receive adjuvant" exact="capecitabine" post="plus cisplatin (XP), or XP plus radiotherapy (XP/XRT/XP). Overall,"/>
   <result pre="resection, and were randomly assigned to receive adjuvant capecitabine plus" exact="cisplatin" post="(XP), or XP plus radiotherapy (XP/XRT/XP). Overall, the addition"/>
   <result pre="was 80% versus 70% for surgery alone. Finally, in a" exact="capecitabine" post="and oxaliplatin adjuvant study for stomach cancer (CLASSIC), a"/>
   <result pre="versus 70% for surgery alone. Finally, in a capecitabine and" exact="oxaliplatin" post="adjuvant study for stomach cancer (CLASSIC), a phase III"/>
   <result pre="underwent curative gastrectomy were randomly assigned to receive adjuvant chemotherapy" exact="capecitabine" post="plus intravenous oxaliplatin or surgery alone. The 3-year DFS"/>
   <result pre="were randomly assigned to receive adjuvant chemotherapy capecitabine plus intravenous" exact="oxaliplatin" post="or surgery alone. The 3-year DFS rates were 74%"/>
   <result pre="evaluation of new chemotherapy regimens, and the classical regimen of" exact="cisplatin" post="plus 5-FU (FP4w) remains the reference regimen. However, there"/>
   <result pre="and can replace infused 5-FU [ 17– 19]. S-1 plus" exact="oxaliplatin" post="(SOX) is regarded as a palliative standard first-line chemotherapy"/>
   <result pre="in Japan. A phase III study suggested that S-1 plus" exact="oxaliplatin" post="(SOX) was non-inferior to cisplatin plus S-1 (CS) in"/>
   <result pre="study suggested that S-1 plus oxaliplatin (SOX) was non-inferior to" exact="cisplatin" post="plus S-1 (CS) in terms of PFS and OS."/>
   <result pre="hematological and cardiovascular toxicity and may be an alternative to" exact="cisplatin" post="regimen (FLP) for the treatment of advanced GC ["/>
   <result pre="GC [ 21]. Furthermore, the combination of epirubicine, capecitabine, and" exact="oxaliplatin" post="(EOX) has been found to be as effective as"/>
   <result pre="ECF regimen [ 22]. In a phase III study of" exact="docetaxel" post="[ 23, 24], and in a study of weekly"/>
   <result pre="23, 24], and in a study of weekly administrations of" exact="paclitaxel" post="and irinotecan [ 25, 26], the potential for these"/>
   <result pre="and in a study of weekly administrations of paclitaxel and" exact="irinotecan" post="[ 25, 26], the potential for these treatments to"/>
   <result pre="ECF: epirubicin, cisplatin, 5-FU; DCF: docetaxel, cisplatin, 5-FU; FP4w: 5-FU," exact="cisplatin" post="every 4 weeks; FP3w: 5-FU, cisplatin every 3 weeks;"/>
   <result pre="cisplatin, 5-FU; FP4w: 5-FU, cisplatin every 4 weeks; FP3w: 5-FU," exact="cisplatin" post="every 3 weeks; EOX: epirubicin, oxaliplatin, capecitabine; ECX: epirubicin,"/>
   <result pre="that was approved by the Federal Drug Administration (FDA) was" exact="trastuzumab" post="in combination with chemotherapy (cisplatin plus either capecitabine or"/>
   <result pre="(FDA) was trastuzumab in combination with chemotherapy (cisplatin plus either" exact="capecitabine" post="or 5-FU). Currently, this treatment regimen is available in"/>
   <result pre="ERBB2-positive GC or GEJ that were treated with chemotherapy plus" exact="trastuzumab" post="compared to chemotherapy alone [ 27]. Patients that are"/>
   <result pre="distal gastric tumors [ 71]. In other studies, treatment with" exact="gefitinib" post="demonstrated biologic activity against EGFR, yet a comparable response"/>
   <result pre="response and OS rate was observed for the treatment with" exact="gefitinib" post="or erlotinib [ 72, 73]. Of the studies performed"/>
   <result pre="OS rate was observed for the treatment with gefitinib or" exact="erlotinib" post="[ 72, 73]. Of the studies performed for EGFR-targeting"/>
   <result pre="In a phase II study that evaluated the use of" exact="cetuximab" post="as a single agent for the treatment of patients"/>
   <result pre="survival period of 3.1 months [ 74]. In contrast, when" exact="cetuximab" post="was used as a first-line treatment in combination with"/>
   <result pre="open-label, randomized phase III trial that assessed the combination of" exact="cetuximab" post="with XP chemotherapy for patients with advanced stage gastric"/>
   <result pre="chemotherapy alone ( p = 0.32). Thus, the addition of" exact="cetuximab" post="to XP chemotherapy did not provide additional benefit to"/>
   <result pre="the first-line treatment of advanced stage GC patients. Matuzumab and" exact="panitumumab" post="are two other anti-EGFR monoclonal antibodies that have been"/>
   <result pre="the use of matuzumab in combination with 5-FU, leucovorin, and" exact="cisplatin" post="for the treatment of advanced stage GC patients was"/>
   <result pre="was low (26.7%) [ 81]. Similar findings were reported for" exact="panitumumab" post="in the REAL3 trial, a randomized multicenter phase III"/>
   <result pre="study where the clinical efficacy of an epirubicin, oxaliplatin, and" exact="capecitabine" post="(EOX) regimen with or without panitumumab was evaluated for"/>
   <result pre="an epirubicin, oxaliplatin, and capecitabine (EOX) regimen with or without" exact="panitumumab" post="was evaluated for the treatment of previously untreated advanced"/>
   <result pre="treatment of previously untreated advanced esophagogastric cancer. The addition of" exact="panitumumab" post="significantly reduced the median OS period from 11.3 months"/>
   <result pre="8.8 months (95% CI: 7.7-9.8) for the patients that received" exact="panitumumab" post="plus chemotherapy. Furthermore, EOX plus panitumumab was associated with"/>
   <result pre="the patients that received panitumumab plus chemotherapy. Furthermore, EOX plus" exact="panitumumab" post="was associated with increased grade 3 and 4 adverse"/>
   <result pre="reductions. The anti-EGFR phase III trials EXPAND and REAL-3, for" exact="cetuximab" post="and panitumumab respectively, failed to meet their primary endpoints,"/>
   <result pre="anti-EGFR phase III trials EXPAND and REAL-3, for cetuximab and" exact="panitumumab" post="respectively, failed to meet their primary endpoints, casting a"/>
   <result pre="disease [ 28]. To date, targeting of ERBB2-overexpressing tumors with" exact="trastuzumab" post="has been the most successful example of a targeted"/>
   <result pre="study, the efficacy of two first-line chemotherapy regimens consisting of" exact="trastuzumab" post="combined with standard chemotherapy (XC or 5-FU plus cisplatin)"/>
   <result pre="advanced, recurrent or metastatic ERBB2-positive gastric cancer. Patients in the" exact="trastuzumab" post="group had a longer OS period than those who"/>
   <result pre="chemotherapy alone (13.8 months vs. 11.1 months, respectively). Treatment with" exact="trastuzumab" post="also improved the median PFS period (6.7 months vs."/>
   <result pre="in a Phase II study that evaluated the use of" exact="trastuzumab" post="in combination with cisplatin in patients with untreated ERBB2-positive"/>
   <result pre="study that evaluated the use of trastuzumab in combination with" exact="cisplatin" post="in patients with untreated ERBB2-positive advanced gastric or gastroesophageal"/>
   <result pre="a recent phase III trial that combined the use of" exact="trastuzumab" post="with S-1 plus cisplatin, a response rate of 68%"/>
   <result pre="months, respectively [ 91]. Taken together, these results suggest that" exact="trastuzumab" post="represents a new therapeutic option for patients with ERBB2-positive"/>
   <result pre="trial is recruiting patients to evaluate a treatment regimen including" exact="trastuzumab" post="and LJM716, a ERBB3 protein inhibitor (NCT01602406) [ 92]."/>
   <result pre="acts by blocking autophosphorylation and downstream signaling. The combination of" exact="lapatinib" post="with paclitaxel showed anti-tumor activity as a second-line treatment"/>
   <result pre="blocking autophosphorylation and downstream signaling. The combination of lapatinib with" exact="paclitaxel" post="showed anti-tumor activity as a second-line treatment for patients"/>
   <result pre="to gene amplification, advanced stage GC patients was evaluated with" exact="lapatinib" post="combined with capecitabine and oxaliplatin (e.g., the XELOX regimen)"/>
   <result pre="advanced stage GC patients was evaluated with lapatinib combined with" exact="capecitabine" post="and oxaliplatin (e.g., the XELOX regimen) in 545 patients."/>
   <result pre="GC patients was evaluated with lapatinib combined with capecitabine and" exact="oxaliplatin" post="(e.g., the XELOX regimen) in 545 patients. PFS, but"/>
   <result pre="a phase I clinical trial to evaluate the combination the" exact="lapatinib" post="with trastuzumab in locally advanced or metastatic GC is"/>
   <result pre="I clinical trial to evaluate the combination the lapatinib with" exact="trastuzumab" post="in locally advanced or metastatic GC is in the"/>
   <result pre="patients with advanced stage GC receive a standard therapy of" exact="capecitabine" post="or 5-FU with cisplatin and trastuzumab. To date, the"/>
   <result pre="GC receive a standard therapy of capecitabine or 5-FU with" exact="cisplatin" post="and trastuzumab. To date, the role of lapatinib, alone"/>
   <result pre="trial, Avastin in Gastric Cancer (AVAGAST), the efficacy of adding" exact="bevacizumab" post="to a XP protocol for the first-line treatment of"/>
   <result pre="stage GC, the OS period for the patients that received" exact="ramucirumab" post="versus a placebo was 5.2 months and 3.8 months,"/>
   <result pre="P = 0.047) [ 103]. Furthermore, in the RAINBOW trial," exact="paclitaxel" post="plus ramucirumab versus paclitaxel plus placebo were compared for"/>
   <result pre="0.047) [ 103]. Furthermore, in the RAINBOW trial, paclitaxel plus" exact="ramucirumab" post="versus paclitaxel plus placebo were compared for the treatment"/>
   <result pre="103]. Furthermore, in the RAINBOW trial, paclitaxel plus ramucirumab versus" exact="paclitaxel" post="plus placebo were compared for the treatment of advanced,"/>
   <result pre="The results of this trial confirmed the survival advantage of" exact="ramucirumab" post="plus paclitaxel for the treatment of GC in non-Asian"/>
   <result pre="of this trial confirmed the survival advantage of ramucirumab plus" exact="paclitaxel" post="for the treatment of GC in non-Asian population ["/>
   <result pre="PFS of this cohort [ 105]. In a previous study," exact="sorafenib" post="treatment combined with chemotherapy resulted in a median OS"/>
   <result pre="successfully treat several cancer types [ 122, 123]. For GC," exact="everolimus" post="has been tested in phase II and III clinical"/>
   <result pre="[ 109, 124, 125]. In a recent phase II trial," exact="everolimus" post="demonstrated a response rate of 3.7% (2/44) and a"/>
   <result pre="a phase III GRANITE-1 study which evaluated the efﬁcacy of" exact="everolimus" post="compared to the best supportive care available for molecularly"/>
   <result pre="chemotherapy, improved survival was not significantly observed (5.39 months with" exact="everolimus" post="versus 4.34 months with placebo, HR, 0.90; 95% CI:"/>
   <result pre="P = 0.124) [ 127]. It is possible that since" exact="everolimus" post="only suppresses mTORC1, feedback activation of MAPK may limit"/>
   <result pre="feedback activation of MAPK may limit the anti-tumor potency of" exact="everolimus" post="[ 128]. Correspondingly, there are a few inhibitors that"/>
   <result pre="is an important biomarker for predicting the treatment response of" exact="everolimus" post="and AKT inhibitors [ 118, 131]. In contrast, the"/>
   <result pre="II study of rilotumumab in combination with epirubicin, cisplatin, and" exact="capecitabine" post="(ECX) for the treatment of advanced stage or metastatic"/>
   <result pre="intravenous infusion as a single agent or in combination with" exact="bevacizumab" post="in patients with advanced solid malignancies as part of"/>
   <result pre="conducted to evaluate combinations of tivantinib and FOLFOX, pazopanib, and" exact="bevacizumab" post="for the treatment of patients with GEJ and gastric"/>
   <result pre="167]. Other tyrosine kinase inhibitors that have been examined include" exact="cabozantinib" post="(XL184) and golvatinib (E7050). The former is a multikinase"/>
   <result pre="FLT3, and RET [ 168]. In 2012, the FDA approved" exact="cabozantinib" post="for the treatment of patients with metastatic medullary thyroid"/>
   <result pre="and VEGF-induced phosphorylation of VEGFR. When golvatinib in combination with" exact="gefitinib" post="was used to treat EGFR-mutated lung cancer cell lines,"/>
   <result pre="in combination with other targeted agents, including sorafenib, and with" exact="lenvatinib" post="(E7080) in patients with advanced stage malignancies, are ongoing."/>
   <result pre="development [ 208], while preclinical assays that combined chemotherapy with" exact="vismodegib" post="(GDC-0449, SMO inhibitor) to treat a subpopulation of CD44+"/>
   <result pre="clinical trial of patients with metastatic colorectal cancer, treatment with" exact="vismodegib" post="exhibited no incremental benefit in combination with FOLFOX ["/>
   <result pre="[ 212] or compared with standard FOLFOX or FOLFIRI plus" exact="bevacizumab" post="therapies [ 213]. Currently, the clinical roles of vismodegib,"/>
   <result pre="et al. [ 252], the porphyrin family of proteins, including" exact="verteporfin" post="(VP), hematoporphyrin, and protoporphyrin IX, were identified as YAP1"/>
   <result pre="Ahn YC Sohn I et al. Phase III trial comparing" exact="capecitabine" post="plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine"/>
   <result pre="Sohn I et al. Phase III trial comparing capecitabine plus" exact="cisplatin" post="versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in"/>
   <result pre="et al. Phase III trial comparing capecitabine plus cisplatin versus" exact="capecitabine" post="plus cisplatin with concurrent capecitabine radiotherapy in completely resected"/>
   <result pre="Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus" exact="cisplatin" post="with concurrent capecitabine radiotherapy in completely resected gastric cancer"/>
   <result pre="comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent" exact="capecitabine" post="radiotherapy in completely resected gastric cancer with D2 lymph"/>
   <result pre="W Lee JI Shin DB Ji J et al. Adjuvant" exact="capecitabine" post="plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC):"/>
   <result pre="JI Shin DB Ji J et al. Adjuvant capecitabine plus" exact="oxaliplatin" post="for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up"/>
   <result pre="Toh Y Nagaie T Takagi S et al. S-1 plus" exact="cisplatin" post="versus S-1 alone for first-line treatment of advanced gastric"/>
   <result pre="Imamura H Tsuda M et al. Phase III study comparing" exact="oxaliplatin" post="plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients"/>
   <result pre="et al. Phase III study comparing oxaliplatin plus S-1 with" exact="cisplatin" post="plus S-1 in chemotherapy-naive patients with advanced gastric cancer"/>
   <result pre="trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either" exact="oxaliplatin" post="or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie"/>
   <result pre="National Cancer Research Institute of the United K Capecitabine and" exact="oxaliplatin" post="for advanced esophagogastric cancer N Engl J Med 2008"/>
   <result pre="Marabotti C Van Cutsem E Group VS Clinical benefit with" exact="docetaxel" post="plus fluorouracil and cisplatin compared with cisplatin and fluorouracil"/>
   <result pre="Van Cutsem E Group VS Clinical benefit with docetaxel plus" exact="fluorouracil" post="and cisplatin compared with cisplatin and fluorouracil in a"/>
   <result pre="E Group VS Clinical benefit with docetaxel plus fluorouracil and" exact="cisplatin" post="compared with cisplatin and fluorouracil in a phase III"/>
   <result pre="Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with" exact="cisplatin" post="and fluorouracil in a phase III trial of advanced"/>
   <result pre="with docetaxel plus fluorouracil and cisplatin compared with cisplatin and" exact="fluorouracil" post="in a phase III trial of advanced gastric or"/>
   <result pre="L Wang K Bugat R Randomized phase III study comparing" exact="irinotecan" post="combined with 5-fluorouracil and folinic acid to cisplatin combined"/>
   <result pre="study comparing irinotecan combined with 5-fluorouracil and folinic acid to" exact="cisplatin" post="combined with 5-fluorouracil in chemotherapy naive patients with advanced"/>
   <result pre="Fujitani K et al. Randomized, open-label, phase III study comparing" exact="irinotecan" post="with paclitaxel in patients with advanced gastric cancer without"/>
   <result pre="et al. Randomized, open-label, phase III study comparing irinotecan with" exact="paclitaxel" post="in patients with advanced gastric cancer without severe peritoneal"/>
   <result pre="Colomer R Cortes-Funes H Jimeno A Phase II study of" exact="trastuzumab" post="and cisplatin as first-line therapy in patients with HER2-positive"/>
   <result pre="Cortes-Funes H Jimeno A Phase II study of trastuzumab and" exact="cisplatin" post="as first-line therapy in patients with HER2-positive advanced gastric"/>
   <result pre="Zaner KS Blanke CD Abbruzzese JL Phase II trial of" exact="erlotinib" post="in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127 J"/>
   <result pre="Predictive factors for outcome in a phase II study of" exact="gefitinib" post="in second-line treatment of advanced esophageal cancer patients J"/>
   <result pre="J Harrison R Jankowski J A phase II study of" exact="gefitinib" post="monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression,"/>
   <result pre="E Fuchs CS A multicenter phase II trial of single-agent" exact="cetuximab" post="in advanced esophageal and gastric adenocarcinoma Ann Oncol 2011"/>
   <result pre="Longobardi C Piana E Martoni AA Phase II study of" exact="cetuximab" post="in combination with FOLFIRI in patients with untreated advanced"/>
   <result pre="YJ Kim TY Phase II study and biomarker analysis of" exact="cetuximab" post="combined with modified FOLFOX6 in advanced gastric cancer Br"/>
   <result pre="Ryoo BY Kang YK A prospective phase II study of" exact="cetuximab" post="in combination with XELOX (capecitabine and oxaliplatin) in patients"/>
   <result pre="Park JO Sawaki A Celik I et al. Capecitabine and" exact="cisplatin" post="with or without cetuximab for patients with previously untreated"/>
   <result pre="Celik I et al. Capecitabine and cisplatin with or without" exact="cetuximab" post="for patients with previously untreated advanced gastric cancer (EXPAND):"/>
   <result pre="I study of matuzumab in combination with 5-fluorouracil, leucovorin and" exact="cisplatin" post="(PLF) in patients with advanced gastric and esophagogastric adenocarcinomas"/>
   <result pre="Doki Y Tsujinaka T Furukawa H Phase II study of" exact="trastuzumab" post="in combination with S-1 plus cisplatin in HER2-positive gastric"/>
   <result pre="Phase II study of trastuzumab in combination with S-1 plus" exact="cisplatin" post="in HER2-positive gastric cancer (HERBIS-1) Br J Cancer 2014"/>
   <result pre="Miwa H Qin SK Chung IJ et al. Lapatinib plus" exact="paclitaxel" post="versus paclitaxel alone in the second-line treatment of HER2-amplified"/>
   <result pre="Qin SK Chung IJ et al. Lapatinib plus paclitaxel versus" exact="paclitaxel" post="alone in the second-line treatment of HER2-amplified advanced gastric"/>
   <result pre="Li J Protsenko S et al. Lapatinib in combination with" exact="capecitabine" post="plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric,"/>
   <result pre="Protsenko S et al. Lapatinib in combination with capecitabine plus" exact="oxaliplatin" post="(CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or"/>
   <result pre="Cunningham D Rougier P Komatsu Y et al. Ramucirumab plus" exact="paclitaxel" post="versus placebo plus paclitaxel in patients with previously treated"/>
   <result pre="Komatsu Y et al. Ramucirumab plus paclitaxel versus placebo plus" exact="paclitaxel" post="in patients with previously treated advanced gastric or gastro-oesophageal"/>
   <result pre="P Ansari RH Benson AB 3rd Phase II study of" exact="sorafenib" post="in combination with docetaxel and cisplatin in the treatment"/>
   <result pre="AB 3rd Phase II study of sorafenib in combination with" exact="docetaxel" post="and cisplatin in the treatment of metastatic or advanced"/>
   <result pre="Phase II study of sorafenib in combination with docetaxel and" exact="cisplatin" post="in the treatment of metastatic or advanced gastric and"/>
   <result pre="Yoon D Ryu M Park Y Phase II study of" exact="everolimus" post="with biomarker exploration in patients with advanced gastric cancer"/>
   <result pre="of heavily pretreated metastatic gastric cancer with the mTOR inhibitor" exact="everolimus" post="(RAD001) in a patient with PIK3CA mutation and pS6"/>
   <result pre="an important role in chemoresistance of gastric cancer cells against" exact="etoposide" post="and doxorubicin induced cell death Int J Cancer 2008"/>
   <result pre="role in chemoresistance of gastric cancer cells against etoposide and" exact="doxorubicin" post="induced cell death Int J Cancer 2008 122 2"/>
   <result pre="KS Loh E Rilotumumab in combination with epirubicin, cisplatin, and" exact="capecitabine" post="as first-line treatment for gastric or oesophagogastric junction adenocarcinoma:"/>
   <result pre="Boyett JM Gilbertson RJ Curran T Phase I study of" exact="vismodegib" post="in children with recurrent or refractory medulloblastoma: a pediatric"/>
   <result pre="Wade JL et al. A randomized phase II study of" exact="vismodegib" post="(V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX"/>
   <result pre="Bray GL Low JA A randomized phase II trial of" exact="vismodegib" post="versus placebo with FOLFOX or FOLFIRI and bevacizumab in"/>
   <result pre="trial of vismodegib versus placebo with FOLFOX or FOLFIRI and" exact="bevacizumab" post="in patients with previously untreated metastatic colorectal cancer Clin"/>
   <result pre="Hasan T Pogue BW Pereira SP Phase I/II study of" exact="verteporfin" post="photodynamic therapy in locally advanced pancreatic cancer Br J"/>
   <result pre="D Mansoor W Crosby T et al. Epirubicin, oxaliplatin, and" exact="capecitabine" post="with or without panitumumab for patients with previously untreated"/>
   <result pre="T et al. Epirubicin, oxaliplatin, and capecitabine with or without" exact="panitumumab" post="for patients with previously untreated advanced oesophagogastric cancer (REAL3):"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4694855/results/search/inn/results.xml">
   <result pre="tumors [ 6]. Systemic therapies investigated in the past include" exact="cisplatin" post="[ 7], paclitaxel [ 8], combination of cisplatin plus"/>
   <result pre="Systemic therapies investigated in the past include cisplatin [ 7]," exact="paclitaxel" post="[ 8], combination of cisplatin plus vinorelbine [ 9]"/>
   <result pre="past include cisplatin [ 7], paclitaxel [ 8], combination of" exact="cisplatin" post="plus vinorelbine [ 9] and the combination of cisplatin,"/>
   <result pre="cisplatin [ 7], paclitaxel [ 8], combination of cisplatin plus" exact="vinorelbine" post="[ 9] and the combination of cisplatin, doxorubicin and"/>
   <result pre="cisplatin plus vinorelbine [ 9] and the combination of cisplatin," exact="doxorubicin" post="and cyclophosphamide [ 10]. Modest response rates can be"/>
   <result pre="vinorelbine [ 9] and the combination of cisplatin, doxorubicin and" exact="cyclophosphamide" post="[ 10]. Modest response rates can be achieved with"/>
   <result pre="EGFR [ 12], HER2 [ 13, 14], androgen, estrogen and" exact="progesterone" post="receptor protein expression by immunohistochemistry [ 15]; and PIK3CA"/>
   <result pre="are positive by immunohistochemistry [ 17]. Although targeted therapies with" exact="imatinib" post="[ 18], gefitinib [ 19], cetuximab [ 20], trastuzumab"/>
   <result pre="immunohistochemistry [ 17]. Although targeted therapies with imatinib [ 18]," exact="gefitinib" post="[ 19], cetuximab [ 20], trastuzumab [ 21] and"/>
   <result pre="Although targeted therapies with imatinib [ 18], gefitinib [ 19]," exact="cetuximab" post="[ 20], trastuzumab [ 21] and lapatinib [ 22]"/>
   <result pre="with imatinib [ 18], gefitinib [ 19], cetuximab [ 20]," exact="trastuzumab" post="[ 21] and lapatinib [ 22] have generally had"/>
   <result pre="gefitinib [ 19], cetuximab [ 20], trastuzumab [ 21] and" exact="lapatinib" post="[ 22] have generally had low response rates, these"/>
   <result pre="aberrations and were treated with appropriate targeting agents (trastuzumab and" exact="lapatinib" post="[ 23] or mTOR inhibitors [ 24], respectively), anecdotal"/>
   <result pre="in salivary tumors when genetic aberrations and therapies were matched:" exact="trastuzumab" post="and lapatinib for Her2-aberrant salivary tumors [ 23] or"/>
   <result pre="tumors when genetic aberrations and therapies were matched: trastuzumab and" exact="lapatinib" post="for Her2-aberrant salivary tumors [ 23] or mTOR inhibitors"/>
   <result pre="0.01) (Table 2). Anomalies in ERBB2 may be targeted with" exact="lapatinib" post="or trastuzumab [ 23, 30]. The second most common"/>
   <result pre="2). Anomalies in ERBB2 may be targeted with lapatinib or" exact="trastuzumab" post="[ 23, 30]. The second most common aberrations involved"/>
   <result pre="pathway is possibly targetable with CDK4/6 inhibitors such as with" exact="palbociclib" post="[ 33] and further investigation is warranted. Of interest,"/>
   <result pre="the role of PIK3CA mutation as a predictive biomarker for" exact="everolimus" post="or PI3K inhibitor response is controversial [ 44], the"/>
   <result pre="the PI3K pathway is potentially targetable with the mTOR inhibitor" exact="everolimus" post="[ 45]. Adding MEK inhibitors such as trametanib ["/>
   <result pre="C Palma SD Guzzo M Demicheli R Molinari R Cisplatin," exact="doxorubicin" post="and cyclophosphamide in advanced salivary gland carcinoma. A phase"/>
   <result pre="SD Guzzo M Demicheli R Molinari R Cisplatin, doxorubicin and" exact="cyclophosphamide" post="in advanced salivary gland carcinoma. A phase II trial"/>
   <result pre="SM Faquin WC Dayal Y Expression of androgen, estrogen, and" exact="progesterone" post="receptors in salivary gland tumors. Frequent expression of androgen"/>
   <result pre="Ho J Tsao MS et al. Phase II study of" exact="lapatinib" post="in recurrent or metastatic epidermal growth factor receptor and/or"/>
   <result pre="phosphatidylinositol 3-kinase pathway by blocking mammalian target of rapamycin with" exact="temsirolimus" post="J Clin Oncol 2011 29 e727 730 21844496 25"/>
   <result pre="Horvath Z Coccia-Portugal M Domont J et al. Lapatinib with" exact="trastuzumab" post="for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label,"/>
   <result pre="genotype and a PIK3CA mutation-related gene signature and response to" exact="everolimus" post="and letrozole in estrogen receptor positive breast cancer PLoS"/>
   <result pre="a PIK3CA mutation-related gene signature and response to everolimus and" exact="letrozole" post="in estrogen receptor positive breast cancer PLoS One 2013"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4694868/results/search/inn/results.xml">
   <result pre="Bild cohort. The expression of SERPINA1 can be suppressed by" exact="fulvestrant" post="and HER2 siRNA. Our results indicate that ER is"/>
   <result pre="of ER+ breast cancer is endocrine therapy using anti-estrogens like" exact="tamoxifen" post="or aromatase inhibitors (AIs). However, a significant number of"/>
   <result pre="key roles in endocrine-resistant breast cancer because the ER degrader," exact="fulvestrant" post="(ICI 182, 780), is able to suppress the expression"/>
   <result pre="regulated with E2 treatment and suppressed by the ER degrader," exact="fulvestrant" post="(ICI 182, 780) (Figure 4A). A search for SERPINA1"/>
   <result pre="ER pathway for proliferation, as indicated by the fact that" exact="fulvestrant" post="(ICI 182, 780) was able to partially suppress the"/>
   <result pre="co-expression of ER is known to result in a poor" exact="trastuzumab" post="response [ 46]. Previous studies have shown that in"/>
   <result pre="that a subset of these patients may not benefit from" exact="trastuzumab" post="[ 48]. Clinical data has shown that ER+/HER2+ patients"/>
   <result pre="TAnDEM (TrAstuzumab in Dual HER2 ER-positive Metastatic breast cancer) trials," exact="lapatinib" post="+ letrozole and trastuzumb + anastrozole were shown to"/>
   <result pre="in Dual HER2 ER-positive Metastatic breast cancer) trials, lapatinib +" exact="letrozole" post="and trastuzumb + anastrozole were shown to improve time"/>
   <result pre="Metastatic breast cancer) trials, lapatinib + letrozole and trastuzumb +" exact="anastrozole" post="were shown to improve time to progression versus AI"/>
   <result pre="analysis was reported by Delea et al. [ 52] that" exact="lapatinib" post="+ letrozole was not likely to be cost-effective than"/>
   <result pre="reported by Delea et al. [ 52] that lapatinib +" exact="letrozole" post="was not likely to be cost-effective than trastuzumab +"/>
   <result pre="lapatinib + letrozole was not likely to be cost-effective than" exact="trastuzumab" post="+ anastrozole. Therefore, for those ER+/HER2+ patients with high"/>
   <result pre="of women with metastatic breast cancer by HER2 status and" exact="trastuzumab" post="treatment: an institutional-based review J Clin Oncol 2010 28"/>
   <result pre="Quantitative ER and PgR assessment as predictors of benefit from" exact="lapatinib" post="in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast"/>
   <result pre="application and limitations of breast cancer cell lines to study" exact="tamoxifen" post="and aromatase inhibitor resistance J Steroid Biochem Mol Biol"/>
   <result pre="carcinoma in situ of the breast: frequency and implications for" exact="tamoxifen" post="therapy Modern pathology : an official journal of the"/>
   <result pre="HER2 and ESR1 mRNA expression levels and response to neoadjuvant" exact="trastuzumab" post="plus chemotherapy in patients with primary breast cancer Breast"/>
   <result pre="Remillard MY et al. Predicting degree of benefit from adjuvant" exact="trastuzumab" post="in NSABP trial B-31 J Natl Cancer Inst 2013"/>
   <result pre="Schayowitz A Goloubeva O Macedo L Brodie A Trastuzumab reverses" exact="letrozole" post="resistance and amplifies the sensitivity of breast cancer cells"/>
   <result pre="Wang Y Kane SE Chen S Improvement of sensitivity to" exact="tamoxifen" post="in estrogen receptor-positive and Herceptin-resistant breast cancer cells J"/>
   <result pre="Osborne CK Chang JC Multicenter phase II study of neoadjuvant" exact="lapatinib" post="and trastuzumab with hormonal therapy and without chemotherapy in"/>
   <result pre="Chang JC Multicenter phase II study of neoadjuvant lapatinib and" exact="trastuzumab" post="with hormonal therapy and without chemotherapy in patients with"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4695049/results/search/inn/results.xml">
   <result pre="insufficient to completely eradicate these heterogeneous tumors. The HER2-targeting agent" exact="trastuzumab" post="is only FDA-approved for use in patients whose tumors"/>
   <result pre="RUNX2 overexpressing MCF7 cells (doxycycline –) that were re-treated with" exact="doxycycline" post="(doxycycline +) to repress RUNX2 expression ( Supplementary Figure"/>
   <result pre="were grown in the presence (RUNX2-) or absence (RUNX2+) of" exact="doxycycline" post="and treated with 50 μM CADD522. In parallel, a"/>
   <result pre="2D) lowered TAZ nuclear levels within 24 hr (Figure 3E;" exact="doxycycline" post="–). However, CADD522 treatment of RUNX2 overexpressing MCF7 cells"/>
   <result pre="RUNX2 overexpressing MCF7 cells (doxycycline –) that were re-treated with" exact="doxycycline" post="(doxycycline +) to repress RUNX2 expression ( Supplementary Figure"/>
   <result pre="were grown in the presence (RUNX2–) or absence (RUNX2+) of" exact="doxycycline" post="for 3 days and starved 16 hr in D5030"/>
   <result pre="were grown in the presence (RUNX2–) or absence (RUNX2+) of" exact="doxycycline" post="for 3 days and then nutrient deprived in D5030"/>
   <result pre="produced by the Tet.OFF system even in the presence of" exact="doxycycline" post="(Figure 2D; Supplementary Figure S1A). Further, siRNA-targeted knockdown of"/>
   <result pre="were grown in the presence (RUNX2–) or absence (RUNX2+) of" exact="doxycycline" post="for 3 days. Cells were nutrient deprived for 16"/>
   <result pre="were grown in the presence (RUNX2-) or absence (RUNX2+) of" exact="doxycycline" post="for 3 days. Cells were then treated with 50"/>
   <result pre="sE-Cad. RUNX2 overexpressing MCF7 cells were grown in absence of" exact="doxycycline" post="and than transfected with TAZ siRNA#1 (Figure 3C) to"/>
   <result pre="activation [ 60]. RUNX2 overexpressing MCF7 cells were sensitive to" exact="lapatinib" post="treatment, with tumorsphere size reduced by 2.5-fold relative to"/>
   <result pre="were grown in the presence (RUNX2–) or absence (RUNX2+) of" exact="doxycycline" post="for 3 days and starved for 16 hr in"/>
   <result pre="Cells were then left untreated (yellow bars), or treated with" exact="lapatinib" post="(blue bars), or DMSO control (red bars) for 15"/>
   <result pre="G418 (100 μg/ml; Sigma), hygromycin B (200 μg/ml; Roche), and" exact="doxycycline" post="(2 μg/ml; Sigma) to repress RUNX2 expression (+Dox). To"/>
   <result pre="grown in the same media but in the absence of" exact="doxycycline" post="(−Dox) for 72 hours to achieve maximal RUNX2 protein"/>
   <result pre="presence (+Dox, RUNX2 negative) or absence (−Dox, RUNX2 positive) of" exact="doxycycline" post="for 3 days. Cells were then scraped and counted."/>
   <result pre="in the presence (RUNX2 negative) or absence (RUNX2 positive) of" exact="doxycycline" post="for 72 hr in full media as described above."/>
   <result pre="in the presence (RUNX2 negative) or absence (RUNX2 positive) of" exact="doxycycline" post="in minimal DMEM (Sigma, D5030) containing 0.1% BSA, 1%"/>
   <result pre="in the presence (RUNX2 negative) or absence (RUNX2 positive) of" exact="doxycycline" post="in minimal DMEM (Sigma, D5030) containing 0.1%BSA, 1% L-glutamine,"/>
   <result pre="in the presence (RUNX2 negative) or absence (RUNX2 positive) of" exact="doxycycline" post="for 3 days and then transfected with corresponding siRNA"/>
   <result pre="in the presence (RUNX2 negative) or absence (RUNX2 positive) of" exact="doxycycline" post="for 3 days and then transfected with TAZ siRNA"/>
   <result pre="in the presence (RUNX2 negative) or absence (RUNX2 positive) of" exact="doxycycline" post="for 3 days. RUNX2 transiently transfected T47D or HCC1428"/>
   <result pre="presence (+Dox, RUNX2 negative) or absence (−Dox, RUNX2 positive) of" exact="doxycycline" post="for 3 days and were then added to the"/>
   <result pre="in the presence (RUNX2 negative) or absence (RUNX2 positive) of" exact="doxycycline" post="in complete media. Cells were washed once with 1X"/>
   <result pre="the absence of HER2 amplification: implications for efficacy of adjuvant" exact="trastuzumab" post="Cancer Res 2013 73 1635 1646 23442322 7 Ferrari"/>
   <result pre="D Ellis MJ Frenkel B Opposing effects of Runx2 and" exact="estradiol" post="on breast cancer cell proliferation: in vitro identification of"/>
   <result pre="vitro identification of reciprocally regulated gene signature related to clinical" exact="letrozole" post="responsiveness Clin Cancer Res 2012 18 901 911 22147940"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4696215/results/search/inn/results.xml">
   <result pre="otherwise stated. Abstract Background nab-Paclitaxel is an albumin-bound formulation of" exact="paclitaxel" post="approved for the treatment of metastatic breast cancer (MBC)."/>
   <result pre="often (31.7 %) combined with targeted therapy (57.5 % with" exact="bevacizumab" post="and 23.9 % with trastuzumab or lapatinib). The median"/>
   <result pre="targeted therapy (57.5 % with bevacizumab and 23.9 % with" exact="trastuzumab" post="or lapatinib). The median duration of therapy was 128"/>
   <result pre="been reported in patients treated with solvent-based (sb) taxanes (ie," exact="paclitaxel" post="and docetaxel) [ 4– 6]. An albumin-bound formulation of"/>
   <result pre="paclitaxel and docetaxel) [ 4– 6]. An albumin-bound formulation of" exact="paclitaxel" post="(Abraxane®, nab-paclitaxel) was developed in an effort to overcome"/>
   <result pre="studies have shown that nab-paclitaxel delivers a 33 % higher" exact="paclitaxel" post="concentration to tumors and demonstrates enhanced transport across endothelial"/>
   <result pre="more rapid and greater tissue penetration and slower elimination of" exact="paclitaxel" post="[ 8]. nab-Paclitaxel was approved by the US Food"/>
   <result pre="first 3 of 4 weeks [qw 3/4]) were compared with" exact="docetaxel" post="100 mg/m 2 q3w for the treatment of chemotherapy-naive"/>
   <result pre="dose of nab-paclitaxel was a significantly more effective regimen than" exact="docetaxel" post="[ 13]. Median overall survival (OS) was 33.8 months"/>
   <result pre="dose regimens (100 and 101 mg/m 2/week, respectively), compared with" exact="docetaxel" post="(33 mg/m 2/week) [ 13]. The median time to"/>
   <result pre="to 22 days for nab-paclitaxel compared with 41 days for" exact="docetaxel" post="[ 13]. Table 1 Select clinical trials of nab-P"/>
   <result pre="First line ( N = 50) nab-P 125 mg/m 2 qw 2/3 + oral" exact="capecitabine" post="825 mg/m 2 twice daily on days 1 and"/>
   <result pre="First/second line ( N = 60) nab-P 125 mg/m 2 qw 3/4 + oral" exact="lapatinib" post="1250 mg daily 9.1 Median not reached 22 b"/>
   <result pre="Results of phase two trials of nab-paclitaxel in combination with" exact="gemcitabine" post="and oral capecitabine have demonstrated efficacy and favorable tolerability."/>
   <result pre="two trials of nab-paclitaxel in combination with gemcitabine and oral" exact="capecitabine" post="have demonstrated efficacy and favorable tolerability. The results of"/>
   <result pre="in combination with targeted agents such as bevacizumab, trastuzumab, and" exact="lapatinib" post="for the treatment of MBC [ 16– 21]. Clinical"/>
   <result pre="a combination therapy, targeted agents were often used (57.5 %" exact="bevacizumab" post="and 23.9 % trastuzumab or lapatinib). Bevacizumab combination was"/>
   <result pre="agents were often used (57.5 % bevacizumab and 23.9 %" exact="trastuzumab" post="or lapatinib). Bevacizumab combination was more often prescribed in"/>
   <result pre="was more often prescribed in first-line therapy with nab-paclitaxel vs" exact="trastuzumab" post="or lapatinib (81.0 vs 4.8 %). Trastuzumab combination therapy"/>
   <result pre="often prescribed in first-line therapy with nab-paclitaxel vs trastuzumab or" exact="lapatinib" post="(81.0 vs 4.8 %). Trastuzumab combination therapy was more"/>
   <result pre="51 81.0 53 64.6 45 39.5 149 57.5   Trastuzumab or" exact="lapatinib" post="3 4.8 14 17.1 45 39.5 62 23.9   Gemcitabine,"/>
   <result pre="when used in combination, nab-paclitaxel was most often given with" exact="bevacizumab" post="(58 %), and bevacizumab combination therapy was more often"/>
   <result pre="nab-paclitaxel was most often given with bevacizumab (58 %), and" exact="bevacizumab" post="combination therapy was more often initiated in the first"/>
   <result pre="20.8 months and 8.5 vs 6.7 months, respectively). In 2011," exact="bevacizumab" post="for the treatment of breast cancer was revoked by"/>
   <result pre="combination therapy use after 2011 and was likely due to" exact="bevacizumab" post="being revoked (data not shown). At this time it"/>
   <result pre="determine the efficacy and safety of nab-paclitaxel in combination with" exact="gemcitabine" post="or carboplatin in patients with triple-negative MBC [ 29]."/>
   <result pre="efficacy and safety of nab-paclitaxel in combination with gemcitabine or" exact="carboplatin" post="in patients with triple-negative MBC [ 29]. The common"/>
   <result pre="when used in combination, nab-paclitaxel was most often combined with" exact="bevacizumab" post="in first-line therapy. However, because the accelerated approval of"/>
   <result pre="bevacizumab in first-line therapy. However, because the accelerated approval of" exact="bevacizumab" post="for MBC was withdrawn due to the lack of"/>
   <result pre="OS advantage in the RIBBON-1 and AVADO trials [ 28]," exact="bevacizumab" post="is no longer used as standard therapy in MBC."/>
   <result pre="combination partners are being evaluated in patients with MBC, including" exact="gemcitabine" post="or carboplatin in patients with triple-negative MBC [ 29]."/>
   <result pre="are being evaluated in patients with MBC, including gemcitabine or" exact="carboplatin" post="in patients with triple-negative MBC [ 29]. Identification of"/>
   <result pre="Ci S Yang A et al. Increased antitumor activity, intratumor" exact="paclitaxel" post="concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel,"/>
   <result pre="cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based" exact="paclitaxel" post="Clin Cancer Res 2006 12 4 1317 24 10.1158/1078-0432.CCR-05-1634"/>
   <result pre="with solid tumors: disposition kinetics and pharmacology distinct from solvent-based" exact="paclitaxel" post="J Clin Pharmacol 2014 54 10 1097 107 10.1002/jcph.304"/>
   <result pre="Bhar P et al. Phase III trial of nanoparticle albumin-bound" exact="paclitaxel" post="compared with polyethylated castor oil-based paclitaxel in women with"/>
   <result pre="trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based" exact="paclitaxel" post="in women with breast cancer J Clin Oncol 2005"/>
   <result pre="et al. Significantly longer progression-free survival with nab-paclitaxel compared with" exact="docetaxel" post="as first-line therapy for metastatic breast cancer J Clin"/>
   <result pre="A et al. Phase II trial of nab-paclitaxel compared with" exact="docetaxel" post="as first-line chemotherapy in patients with metastatic breast cancer:"/>
   <result pre="of weekly nab (nanoparticle albuminbound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with" exact="gemcitabine" post="in patients with metastatic breast cancer (N0531) Ann Oncol"/>
   <result pre="Epperson AL Walker MS Phase II multicenter trial of albumin-bound" exact="paclitaxel" post="and capecitabine in first-line treatment of patients with metastatic"/>
   <result pre="Walker MS Phase II multicenter trial of albumin-bound paclitaxel and" exact="capecitabine" post="in first-line treatment of patients with metastatic breast cancer"/>
   <result pre="vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound" exact="paclitaxel" post="with bevacizumab as first-line chemotherapy for metastatic breast cancer"/>
   <result pre="2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with" exact="bevacizumab" post="as first-line chemotherapy for metastatic breast cancer Clin Breast"/>
   <result pre="C Leung E et al. Randomized phase III trial of" exact="paclitaxel" post="once per week compared with nanoparticle albumin bound nab-paclitaxel"/>
   <result pre="compared with nanoparticle albumin bound nab-paclitaxel once per week or" exact="ixabepilone" post="with bevacizumab as first-line chemotherapy for locally recurrent or"/>
   <result pre="nanoparticle albumin bound nab-paclitaxel once per week or ixabepilone with" exact="bevacizumab" post="as first-line chemotherapy for locally recurrent or metastatic breast"/>
   <result pre="Min M A phase II study of weekly nanoparticle albumin-bound" exact="paclitaxel" post="with or without trastuzumab in metastatic breast cancer Clin"/>
   <result pre="II study of weekly nanoparticle albumin-bound paclitaxel with or without" exact="trastuzumab" post="in metastatic breast cancer Clin Breast Cancer 2011 11"/>
   <result pre="Waterhouse DM Hagan MK et al. Phase II study evaluating" exact="lapatinib" post="in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer"/>
   <result pre="al. tnAcity: a phase II/III trial of weekly nab®-paclitaxel plus" exact="gemcitabine" post="or carboplatin vs gemcitabine/carboplatin as first-line treatment for triple-negative"/>
   <result pre="a phase II/III trial of weekly nab®-paclitaxel plus gemcitabine or" exact="carboplatin" post="vs gemcitabine/carboplatin as first-line treatment for triple-negative metastatic breast"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4700735/results/search/inn/results.xml">
   <result pre="kills tumor cells via antibody-dependent cellular cytotoxicity [ 9]. Since" exact="cetuximab" post="was introduced to the market in 2004 [ 10],"/>
   <result pre="the results between first-line treatment with a combination treatment of" exact="cetuximab" post="and other chemotherapy regimens and the use of a"/>
   <result pre="relatively lower toxicity. As a second-line treatment, combination regimens including" exact="cetuximab" post="are clearly advantageous in terms of reduced toxicity. However,"/>
   <result pre="clinical trials to investigate the effects of combination regimens including" exact="cetuximab" post="are ongoing [ 16]. Cetuximab in combination with capecitabine"/>
   <result pre="including cetuximab are ongoing [ 16]. Cetuximab in combination with" exact="capecitabine" post="and cisplatin in advanced esophagogastric cancer (EXPAND), a phase"/>
   <result pre="are ongoing [ 16]. Cetuximab in combination with capecitabine and" exact="cisplatin" post="in advanced esophagogastric cancer (EXPAND), a phase III clinical"/>
   <result pre="(EXPAND), a phase III clinical trial, evaluated the efficacy of" exact="cetuximab" post="in combination with capecitabine and cisplatin as a first-line"/>
   <result pre="clinical trial, evaluated the efficacy of cetuximab in combination with" exact="capecitabine" post="and cisplatin as a first-line treatment for advanced gastric"/>
   <result pre="evaluated the efficacy of cetuximab in combination with capecitabine and" exact="cisplatin" post="as a first-line treatment for advanced gastric cancer ["/>
   <result pre="were poor prognostic factors. In colon cancer, the efficacy of" exact="cetuximab" post="was increased in patients who carried wild-type KRAS; patients"/>
   <result pre="KRAS; patients who carried the mutant KRAS were resistant to" exact="cetuximab" post="treatment. However, the relationship between KRAS expression and treatment"/>
   <result pre="cancer patients has not been established. In contrast to cetuximab," exact="panitumumab" post="is a completely humanized monoclonal antibody. Panitumumab is beneficial"/>
   <result pre="treatment. In REAL3, a phase II/III clinical trial, treatment with" exact="panitumumab" post="combined with modified epirubicin, oxaliplatin, and capecitabine did not"/>
   <result pre="trial, treatment with panitumumab combined with modified epirubicin, oxaliplatin, and" exact="capecitabine" post="did not improve the condition of patients with esophageal,"/>
   <result pre="signal transducer and activator of transcription 3 (STAT3). In addition," exact="trastuzumab" post="induces antibody-dependent cytotoxicity by increasing the expression of the"/>
   <result pre="comprised the initial evidence to demonstrate that combination chemotherapy with" exact="trastuzumab" post="improves the survival rate of HER-2-positive advanced gastric cancer"/>
   <result pre="and randomly divided into two groups based on treatment with" exact="trastuzumab" post="plus chemotherapy (294 cases) and chemotherapy (290 cases). The"/>
   <result pre="cases). The results demonstrated that the efficacy endpoint in the" exact="trastuzumab" post="plus chemotherapy group significantly improved: 47 vs 35 %,"/>
   <result pre="HER-2, the median OS time was significantly increased in the" exact="trastuzumab" post="plus chemotherapy compared with the chemotherapy group (16.0 vs"/>
   <result pre="the European Medicines Agency (EMA) and the U.S. FDA approved" exact="trastuzumab" post="combined with either capecitabine or 5-FU and DDP to"/>
   <result pre="(EMA) and the U.S. FDA approved trastuzumab combined with either" exact="capecitabine" post="or 5-FU and DDP to treat metastatic gastric cancer"/>
   <result pre="Furthermore, the HELOISE trial is investigating the optimal dose of" exact="trastuzumab" post="in these patients. Pertuzumab is a recombinant humanized monoclonal"/>
   <result pre="which thereby inhibits downstream signaling pathways. The primary difference between" exact="pertuzumab" post="and trastuzumab is that the trastuzumab-induced inhibition of ligand-induced"/>
   <result pre="inhibits downstream signaling pathways. The primary difference between pertuzumab and" exact="trastuzumab" post="is that the trastuzumab-induced inhibition of ligand-induced dimerization is"/>
   <result pre="suggests that a broader range of individuals will benefit from" exact="pertuzumab" post="[ 21]. To date, there are no clinical reports"/>
   <result pre="date, there are no clinical reports regarding the use of" exact="pertuzumab" post="in the treatment of gastric cancer. However, a preclinical"/>
   <result pre="treatment of gastric cancer. However, a preclinical study demonstrated that" exact="pertuzumab" post="combined with trastuzumab enhanced the anticancer effect in an"/>
   <result pre="cancer. However, a preclinical study demonstrated that pertuzumab combined with" exact="trastuzumab" post="enhanced the anticancer effect in an HER2-positive gastric cancer"/>
   <result pre="JACOB, is ongoing to evaluate the efficacy and safety of" exact="pertuzumab" post="combined with trastuzumab and cisplatin and 5-FU/capecitabine treatment in"/>
   <result pre="to evaluate the efficacy and safety of pertuzumab combined with" exact="trastuzumab" post="and cisplatin and 5-FU/capecitabine treatment in HER2-positive metastatic gastric"/>
   <result pre="the efficacy and safety of pertuzumab combined with trastuzumab and" exact="cisplatin" post="and 5-FU/capecitabine treatment in HER2-positive metastatic gastric cancer or"/>
   <result pre="these cells to radiation [ 25]. However, the efficacy of" exact="gefitinib" post="in the treatment of gastroesophageal junction adenocarcinoma is not"/>
   <result pre="delE746-A750 or L858R, in esophagogastric junction adenocarcinoma [ 27]. Therefore," exact="gefitinib" post="is not primarily recommended for gastric cancer treatment. Erlotinib"/>
   <result pre="II clinical trial (SWOG 0127) and reported the effectiveness of" exact="erlotinib" post="for the treatment of gastroesophageal junction adenocarcinoma [ 28]."/>
   <result pre="TRIO-013/(LOGiC), a phase III clinical trial, compared the efficacy of" exact="capecitabine" post="and oxaliplatin with and without lapatinib to treat HER-2-positive"/>
   <result pre="phase III clinical trial, compared the efficacy of capecitabine and" exact="oxaliplatin" post="with and without lapatinib to treat HER-2-positive advanced gastric,"/>
   <result pre="compared the efficacy of capecitabine and oxaliplatin with and without" exact="lapatinib" post="to treat HER-2-positive advanced gastric, esophageal junction and gastroesophageal"/>
   <result pre="of lapatinib. Another phase III clinical trial, TyTAN, determined that" exact="lapatinib" post="combined with paclitaxel as a second-line regimen for advanced"/>
   <result pre="phase III clinical trial, TyTAN, determined that lapatinib combined with" exact="paclitaxel" post="as a second-line regimen for advanced gastric cancer in"/>
   <result pre="vs 8.9 months, respectively) or the mean PFS compared with" exact="paclitaxel" post="alone (5.4 vs 4.4 months, respectively) [ 31]. TyTAN"/>
   <result pre="(5.4 vs 4.4 months, respectively) [ 31]. TyTAN demonstrated that" exact="lapatinib" post="prolonged the survival of patients who received this second-line"/>
   <result pre="this conclusion was specific to HER-2-positive patients. The efficacy of" exact="lapatinib" post="for gastric cancer may not be as beneficial as"/>
   <result pre="as well as lapatinib-related treatment resistance. Studies have demonstrated that" exact="lapatinib" post="resistance may be associated with secondary HER-2 mutations, MET"/>
   <result pre="an increased median OS time and median PFS when administered" exact="lapatinib" post="and paclitaxel compared with paclitaxel alone [ 31]. The"/>
   <result pre="median OS time and median PFS when administered lapatinib and" exact="paclitaxel" post="compared with paclitaxel alone [ 31]. The subgroup analysis"/>
   <result pre="and median PFS when administered lapatinib and paclitaxel compared with" exact="paclitaxel" post="alone [ 31]. The subgroup analysis demonstrated that lapatinib"/>
   <result pre="with paclitaxel alone [ 31]. The subgroup analysis demonstrated that" exact="lapatinib" post="may provide a survival benefit to Chinese patients. Thus,"/>
   <result pre="[ 47] evaluated whether angiogenesis markers predicted the effects of" exact="bevacizumab" post="and determined that the efficacy of bevacizumab was related"/>
   <result pre="the effects of bevacizumab and determined that the efficacy of" exact="bevacizumab" post="was related to the baseline expression of VEGF-A and"/>
   <result pre="had failed first-line treatment demonstrated that best supportive care plus" exact="ramucirumab" post="significantly improved the OS, PFS, and disease control rate"/>
   <result pre="Another phase III clinical study demonstrated that the combination of" exact="ramucirumab" post="and chemotherapy markedly increased the OS, PFS and disease"/>
   <result pre="III clinical trials, the EMA and the U.S. FDA approved" exact="ramucirumab" post="as the second-line therapy for gastroesophageal junction and chemotherapy-failed"/>
   <result pre="effects. In a phase II clinical study, the combination of" exact="sunitinib" post="and docetaxel improved the objective remission rate (41.1 vs"/>
   <result pre="a phase II clinical study, the combination of sunitinib and" exact="docetaxel" post="improved the objective remission rate (41.1 vs 14.3 %,"/>
   <result pre="%, respectively) in patients with metastatic gastric cancer compared with" exact="docetaxel" post="alone [ 50]. Various phase І and II clinical"/>
   <result pre="II clinical trials have confirmed the safety and tolerability of" exact="sunitinib" post="combined with traditional chemotherapies; however, it clinical significance requires"/>
   <result pre="that included 44 patients with advanced gastric cancer indicated that" exact="sorafenib" post="combined with docetaxel and cisplatin was associated with a"/>
   <result pre="patients with advanced gastric cancer indicated that sorafenib combined with" exact="docetaxel" post="and cisplatin was associated with a 5.8 month median"/>
   <result pre="advanced gastric cancer indicated that sorafenib combined with docetaxel and" exact="cisplatin" post="was associated with a 5.8 month median PFS and"/>
   <result pre="П clinical trials regarding the efficacy of orafenib combined with" exact="oxaliplatin" post="and capecitabine are ongoing. Additional clinical trials are necessary"/>
   <result pre="trials regarding the efficacy of orafenib combined with oxaliplatin and" exact="capecitabine" post="are ongoing. Additional clinical trials are necessary to determine"/>
   <result pre="NF-κB signaling pathway. A phase II study demonstrated that the" exact="bortezomib" post="treatment efficacy was 66 %, which suggests that bortezomib"/>
   <result pre="the bortezomib treatment efficacy was 66 %, which suggests that" exact="bortezomib" post="is a feasible option for relapsed/refractory cancer [ 59]."/>
   <result pre="prognosis of gastric cancer [ 60– 63]. The MMP inhibitor" exact="marimastat" post="(BB-2516, TA-2516) exhibits anti-tumor activity in gastric cancer. Advanced"/>
   <result pre="in gastric cancer. Advanced gastric cancer patients also benefit from" exact="marimastat" post="because of its low hematological toxicity, which confirms the"/>
   <result pre="its low hematological toxicity, which confirms the clinical value of" exact="marimastat" post="for gastric cancer patients [ 64]. c-Met signaling pathway"/>
   <result pre="arrest [ 74]. However, a phase III clinical study of" exact="everolimus" post="in advanced gastric cancer patients who failed previous chemotherapy"/>
   <result pre="chemotherapy treatment demonstrated that there was no significant efficacy of" exact="everolimus" post="in gastric cancer [ 75]. Cyclooxygenase-2 (COX-2) inhibitors COX"/>
   <result pre="Lund P et al. Targeting CD137 enhances the efficacy of" exact="cetuximab" post="J Clin Invest 2014 124 2668 82 10.1172/JCI73014 24837434"/>
   <result pre="D Bleiberg H Santoro A et al. Cetuximab monotherapy and" exact="cetuximab" post="plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl"/>
   <result pre="H Santoro A et al. Cetuximab monotherapy and cetuximab plus" exact="irinotecan" post="in irinotecan-refractory metastatic colorectal cancer N Engl J Med"/>
   <result pre="Llimpe FL Ceccarelli C et al. Phase II study of" exact="cetuximab" post="in combination with FOLFIRI in patients with untreated advanced"/>
   <result pre="Falcone A Cascinu S et al. Phase II study of" exact="cetuximab" post="in combination with cisplatin and docetaxel in patients with"/>
   <result pre="et al. Phase II study of cetuximab in combination with" exact="cisplatin" post="and docetaxel in patients with untreated advanced gastric or"/>
   <result pre="Phase II study of cetuximab in combination with cisplatin and" exact="docetaxel" post="in patients with untreated advanced gastric or gastro-oesophageal junction"/>
   <result pre="AH Van Hazel GA Pavlakis N et al. Docetaxel plus" exact="cetuximab" post="as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG"/>
   <result pre="Shacham-Shmueli E Vrbanec D Plate S et al. FOLFOX4 plus" exact="cetuximab" post="administered weekly or every second week in the first-line"/>
   <result pre="Lim HY et al. A prospective phase II study of" exact="cetuximab" post="in combination with XELOX (capecitabine and oxaliplatin) in patients"/>
   <result pre="Salman P Oh SC Bodoky G et al. Capecitabine and" exact="cisplatin" post="with or without cetuximab for patients with previously untreated"/>
   <result pre="Bodoky G et al. Capecitabine and cisplatin with or without" exact="cetuximab" post="for patients with previously untreated advanced gastric cancer (EXPAND):"/>
   <result pre="D Okines AF Okines C et al. Epirubicin, oxaliplatin, and" exact="capecitabine" post="with or without panitumumab for patients with previously untreated"/>
   <result pre="C et al. Epirubicin, oxaliplatin, and capecitabine with or without" exact="panitumumab" post="for patients with previously untreated advanced oesophagogastric cancer (REAL3):"/>
   <result pre="human gastric cancer cell lines with HER2 amplification synergistically with" exact="cisplatin" post="Int J Oncol 2008 32 89 95 18097546 20."/>
   <result pre="Kurasawa M Ohta M et al. Pertuzumab in combination with" exact="trastuzumab" post="shows significantly enhanced antitumor activity in HER2-positive human gastric"/>
   <result pre="Hachiya T et al. Clinical outcomes in elderly patients administered" exact="gefitinib" post="as first-line treatment in epidermal growth factor receptor-mutated non-small-cell"/>
   <result pre="E Ohtsu A Doi T et al. Pharmacodynamic studies of" exact="gefitinib" post="in tumor biopsy specimens from patients with advanced gastric"/>
   <result pre="LA Ives DI Rice TW A phase II trial of" exact="gefitinib" post="for recurrent or metastatic cancer of the esophagus or"/>
   <result pre="KN Gao Q Chen LQ Lack of EGFR mutations benefiting" exact="gefitinib" post="treatment in adenocarcinoma of esophagogastric junction World J Surg"/>
   <result pre="Benedetti JK Baker AF et al. Phase II trial of" exact="erlotinib" post="in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127 J"/>
   <result pre="inhibits HER2-amplified human gastric cancer cells and is synergistic with" exact="trastuzumab" post="in vitro and in vivo Clin Cancer Res 2010"/>
   <result pre="Park JO Jeziorski K et al. Lapatinib in combination with" exact="capecitabine" post="plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric,"/>
   <result pre="Jeziorski K et al. Lapatinib in combination with capecitabine plus" exact="oxaliplatin" post="(CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or"/>
   <result pre="Sun GP Doi T Xu JM et al. Lapatinib plus" exact="paclitaxel" post="versus paclitaxel alone in the second-line treatment of HER2-amplified"/>
   <result pre="Doi T Xu JM et al. Lapatinib plus paclitaxel versus" exact="paclitaxel" post="alone in the second-line treatment of HER2-amplified advanced gastric"/>
   <result pre="S Christensen JG Weiser MR MET activation mediates resistance to" exact="lapatinib" post="inhibition of HER2-amplified gastric cancer cells Mol Cancer Ther"/>
   <result pre="et al. EXEL-7647 inhibits mutant forms of ErbB2 associated with" exact="lapatinib" post="resistance and neoplastic transformation Clin Cancer Res 2008 14"/>
   <result pre="P et al. Magnitude of benefit of the addition of" exact="bevacizumab" post="to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of"/>
   <result pre="et al. Phase II trial of carboplatin, paclitaxel, cetuximab, and" exact="bevacizumab" post="followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell"/>
   <result pre="II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by" exact="cetuximab" post="and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG"/>
   <result pre="of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and" exact="bevacizumab" post="in advanced nonsquamous non-small-cell lung cancer: SWOG S0536 J"/>
   <result pre="II, open-label, multicenter, pilot study of two docetaxel-based regimens plus" exact="bevacizumab" post="for the adjuvant treatment of subjects with node-positive or"/>
   <result pre="al. Bevacizumab combined with weekly paclitaxel, Pegylated liposomal doxorubicin, or" exact="topotecan" post="in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort"/>
   <result pre="X An updated meta-analysis of fatal adverse events caused by" exact="bevacizumab" post="therapy in cancer patients PLoS One 2014 9 10.1371/journal.pone.0089960"/>
   <result pre="Oh SC Bodoky G Shimada Y et al. Ramucirumab plus" exact="paclitaxel" post="versus placebo plus paclitaxel in patients with previously treated"/>
   <result pre="Shimada Y et al. Ramucirumab plus paclitaxel versus placebo plus" exact="paclitaxel" post="in patients with previously treated advanced gastric or gastro-oesophageal"/>
   <result pre="JO Yim DS et al. Randomised phase II trial of" exact="docetaxel" post="and sunitinib in patients with metastatic gastric cancer who"/>
   <result pre="DS et al. Randomised phase II trial of docetaxel and" exact="sunitinib" post="in patients with metastatic gastric cancer who were previously"/>
   <result pre="Puig M et al. A phase I, dose-finding study of" exact="sunitinib" post="combined with cisplatin and 5-fluorouracil in patients with advanced"/>
   <result pre="al. A phase I, dose-finding study of sunitinib combined with" exact="cisplatin" post="and 5-fluorouracil in patients with advanced gastric cancer Invest"/>
   <result pre="Khosravan R Lin X et al. Phase I study of" exact="sunitinib" post="plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer Invest"/>
   <result pre="P Ansari RH Benson AB 3rd Phase II study of" exact="sorafenib" post="in combination with docetaxel and cisplatin in the treatment"/>
   <result pre="AB 3rd Phase II study of sorafenib in combination with" exact="docetaxel" post="and cisplatin in the treatment of metastatic or advanced"/>
   <result pre="Phase II study of sorafenib in combination with docetaxel and" exact="cisplatin" post="in the treatment of metastatic or advanced gastric and"/>
   <result pre="GI Perkins EB et al. A phase I trial of" exact="vorinostat" post="and alvocidib in patients with relapsed, refractory, or poor"/>
   <result pre="EB et al. A phase I trial of vorinostat and" exact="alvocidib" post="in patients with relapsed, refractory, or poor prognosis acute"/>
   <result pre="M et al. Rilotumumab in combination with epirubicin, cisplatin, and" exact="capecitabine" post="as first-line treatment for gastric or oesophagogastric junction adenocarcinoma:"/>
   <result pre="double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin," exact="cisplatin" post="and capecitabine (ECX) as first-line therapy in patients (pts)"/>
   <result pre="placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and" exact="capecitabine" post="(ECX) as first-line therapy in patients (pts) with advanced"/>
   <result pre="T Tanai C Asahina H et al. Figitumumab combined with" exact="carboplatin" post="and paclitaxel in treatment-naive Japanese patients with advanced non-small"/>
   <result pre="C Asahina H et al. Figitumumab combined with carboplatin and" exact="paclitaxel" post="in treatment-naive Japanese patients with advanced non-small cell lung"/>
   <result pre="Randomized, phase III trial of first-line figitumumab in combination with" exact="paclitaxel" post="and carboplatin versus paclitaxel and carboplatin alone in patients"/>
   <result pre="III trial of first-line figitumumab in combination with paclitaxel and" exact="carboplatin" post="versus paclitaxel and carboplatin alone in patients with advanced"/>
   <result pre="of first-line figitumumab in combination with paclitaxel and carboplatin versus" exact="paclitaxel" post="and carboplatin alone in patients with advanced non-small-cell lung"/>
   <result pre="figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and" exact="carboplatin" post="alone in patients with advanced non-small-cell lung cancer J"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4703392/results/search/inn/results.xml">
   <result pre="we have investigated the effects of the three panHER-TKIs lapatinib," exact="canertinib" post="and afatinib on signal transduction cascade activation in SKBR3,"/>
   <result pre="investigated the effects of the three panHER-TKIs lapatinib, canertinib and" exact="afatinib" post="on signal transduction cascade activation in SKBR3, T47D and"/>
   <result pre="molecule-type inhibitors (TKIs) have been developed, and the HER2-specific antibody" exact="trastuzumab" post="has profoundly improved treatment outcome in HER2 overexpressing human"/>
   <result pre="are at least temporarily responsive to the reversible HER1/2 inhibitor" exact="lapatinib" post="[ 4]. This suggests that direct blockade of both"/>
   <result pre="extracellular domain of HER2 only. Moreover, retention of sensitivity of" exact="trastuzumab" post="resistant cells against the HER1/2 dual inhibitor also suggests"/>
   <result pre="have therefore investigated the effects of the reversible HER inhibitor" exact="lapatinib" post="and of the two novel potent irreversible HER-targeting drugs"/>
   <result pre="lapatinib and of the two novel potent irreversible HER-targeting drugs" exact="afatinib" post="(BIBW 2992) and canertinib (CI-1033) on downstream modulators of"/>
   <result pre="two novel potent irreversible HER-targeting drugs afatinib (BIBW 2992) and" exact="canertinib" post="(CI-1033) on downstream modulators of proliferation (STAT5, ERK 1/2,"/>
   <result pre="HER2 overexpressing models in vitro, including cell lines with acquired" exact="trastuzumab" post="resistance [ 4, 5]. Several phase III studies have"/>
   <result pre="phase III studies have now also confirmed the efficacy of" exact="lapatinib" post="in the metastatic setting when given in combination with"/>
   <result pre="and Methods Reagents Lapatinib was purchased from ChemieTek (Indianapolis, IN)," exact="afatinib" post="(BIBW 2992) was from Selleckchem (Houston, TX), and canertinib"/>
   <result pre="IN), afatinib (BIBW 2992) was from Selleckchem (Houston, TX), and" exact="canertinib" post="(CI-1033, PD-183805) was kindly provided by Pfizer (Groton, CT),"/>
   <result pre="with cell proliferation and apoptosis. Differential growth-inhibitory effects of lapatinib," exact="afatinib" post="and canertinib are dependent on the degree of HER2"/>
   <result pre="proliferation and apoptosis. Differential growth-inhibitory effects of lapatinib, afatinib and" exact="canertinib" post="are dependent on the degree of HER2 expression The"/>
   <result pre="of HER2 expression The growth-inhibitory effects of lapatinib, afatinib, and" exact="canertinib" post="on malignant human cell lines with differential HER2 protein"/>
   <result pre="the cell lines analyzed (lapatinib versus afatinib, p = 0.82;" exact="lapatinib" post="versus canertinib, p = 0.85; afatinib versus canertinib, p"/>
   <result pre="afatinib, p = 0.82; lapatinib versus canertinib, p = 0.85;" exact="afatinib" post="versus canertinib, p = 0.66). Fig 2 Dose-dependent growth"/>
   <result pre="2 Dose-dependent growth inhibition in response to 72h exposure to" exact="lapatinib" post="(a), canertinib (b), or afatinib (c) on malignant human"/>
   <result pre="growth inhibition in response to 72h exposure to lapatinib (a)," exact="canertinib" post="(b), or afatinib (c) on malignant human cell lines"/>
   <result pre="response to 72h exposure to lapatinib (a), canertinib (b), or" exact="afatinib" post="(c) on malignant human cell lines with no HER2"/>
   <result pre="(SKBR3). Means ± SD, n = 3. Effect of lapatinib," exact="afatinib" post="and canertinib on the inhibition of HER downstream signal"/>
   <result pre="± SD, n = 3. Effect of lapatinib, afatinib and" exact="canertinib" post="on the inhibition of HER downstream signal transduction pathways"/>
   <result pre="cells by using phosphotyrosine-specific Milliplex assays ( Fig 3). Lapatinib," exact="afatinib" post="and canertinib profoundly inhibited the phosphorylation of the proliferation-associated"/>
   <result pre="using phosphotyrosine-specific Milliplex assays ( Fig 3). Lapatinib, afatinib and" exact="canertinib" post="profoundly inhibited the phosphorylation of the proliferation-associated signaling effectors"/>
   <result pre="cell lines examined ( Fig 3). Fig 3 Effect of" exact="canertinib" post="(white bar), lapatinib (light grey bar) and afatinib (dark"/>
   <result pre="( Fig 3). Fig 3 Effect of canertinib (white bar)," exact="lapatinib" post="(light grey bar) and afatinib (dark grey bar) on"/>
   <result pre="Effect of canertinib (white bar), lapatinib (light grey bar) and" exact="afatinib" post="(dark grey bar) on activation (phosphorylation) of ERK/MAPK1/2, STAT3,"/>
   <result pre="in active caspase 3 was observed in response to 5μM" exact="canertinib" post="(6 vs. 2 hours, p = 0.03), whereas no"/>
   <result pre="not in T47 cells after 48 and 72h of 10μM" exact="canertinib" post="treatment (Figs 6 and 7). Accordingly, after densitometric scanning"/>
   <result pre="in both cell lines except in SKBR3 treated with 10μM" exact="canertinib" post="for 48h (OD cleavedPARP-1/OD full-length PARP-1 = 0.484) or"/>
   <result pre="when given for 72h (a) and time-dependent effect of 5μM" exact="canertinib" post="after 2 and 6 hours (b) on apoptosis as"/>
   <result pre="control. Means ± SD. Fig 6 Effect of the HER-TKI" exact="canertinib" post="on the expression of apoptosis-related PARP-1 cleavage products as"/>
   <result pre="roughly estimate protein loading. Fig 7 Effect of the HER-TKI" exact="canertinib" post="on the expression of apoptosis-related PARP-1 cleavage products as"/>
   <result pre="renders these tumors responsive to treatment with the monoclonal antibody" exact="trastuzumab" post="(Herceptin ®). However, the fact that the majority of"/>
   <result pre="broader target specificity. In contrast to earlier developments such as" exact="gefitinib" post="(Iressa, ZD1839) and erlotinib (Tarceva, OSI-774), which preferentially inhibit"/>
   <result pre="contrast to earlier developments such as gefitinib (Iressa, ZD1839) and" exact="erlotinib" post="(Tarceva, OSI-774), which preferentially inhibit EGFR/HER1 signaling, lapatinib (Tykerb,"/>
   <result pre="ZD1839) and erlotinib (Tarceva, OSI-774), which preferentially inhibit EGFR/HER1 signaling," exact="lapatinib" post="(Tykerb, GW572016) was the first clinically evaluated TKI, which"/>
   <result pre="to the development of second generation irreversible pan-HER-TKIs such as" exact="afatinib" post="and canertinib. Afatinib (Tomtovok, BIBW 2992) is an oral,"/>
   <result pre="arm open-label phase II study Lin et al. have explored" exact="afatinib" post="activity in HER2 overexpressing patients who had progressed after"/>
   <result pre="afatinib activity in HER2 overexpressing patients who had progressed after" exact="trastuzumab" post="treatment and found promising clinical activity [ 26]. Interestingly,"/>
   <result pre="+, ++, and +++ metastatic breast cancer. Not surprisingly, single-agent" exact="canertinib" post="did not show clinically meaningful activity in this setting,"/>
   <result pre="by recent findings by Trinks et al., who reported that" exact="canertinib" post="displays anti-proliferative and pro-apoptotic effects in HER2 devoid Jurkat"/>
   <result pre="used as negative control cells [ 23]. They showed that" exact="canertinib" post="was able to act as a multi-kinase inhibitor, which"/>
   <result pre="also affects Akt and ERK1/2. In their hands, treatment with" exact="canertinib" post="at increasing concentrations induced PARP-1 cleavage and activated caspase"/>
   <result pre="pro-apoptotic effect. They suggest that even in HER2 negative cells" exact="canertinib" post="is able to both downregulate proliferative signaling and activate"/>
   <result pre="[ 32– 36]. In summary, our data show that lapatinib," exact="afatinib" post="and canertinib exert HER2-dependent effects on proliferation and apoptosis"/>
   <result pre="36]. In summary, our data show that lapatinib, afatinib and" exact="canertinib" post="exert HER2-dependent effects on proliferation and apoptosis in vitro."/>
   <result pre="M , et al. Activity of the dual kinase inhibitor" exact="lapatinib" post="(GW572016) on Her2 overexpressing and trastuzumab- treated breast cancer"/>
   <result pre="inhibitors of the EGF receptor may circumvent acquired resistance to" exact="gefitinib" post=". Proc Natl Acad Sci USA. 2005; 102: 7665–"/>
   <result pre="cells with intrinsic resistance to the EGFR tyrosine kinase inhibitor" exact="gefitinib" post=". Breast Cancer Res Treat. 2007; 102: 275– 282."/>
   <result pre="Jönsson JI , et al. The pan-ErbB tyrosine kinase inhibitor" exact="canertinib" post="induces caspase-mediated cell death in human T-cell leukemia (Jurkat)"/>
   <result pre="A phase II trial to assess efficacy and safety of" exact="afatinib" post="in extensively pretreated patients with HER2-negative metastatic breast cancer"/>
   <result pre="Mendelson D , et al. A phase II study of" exact="afatinib" post="(BIBW 2992), an irreversible ErbB family blocker, in patients"/>
   <result pre="blocker, in patients with HER2-positive metastatic breast cancer progressing after" exact="trastuzumab" post=". Breast Cancer Res Treat. 2012; 133: 1057– 1065."/>
   <result pre="inhibits proliferation via ERKs and phosphatidyl-inositol 3-kinase activation but regulates" exact="urokinase" post="plasminogen activator independently of these pathways in metastatic mammary"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4706127/results/search/inn/results.xml">
   <result pre="Press pmcid: 4706127 doi: 10.2147/OTT.S68558 ott-9-075 : Review Profile of" exact="panitumumab" post="as first-line treatment in patients with wild-type KRAS metastatic"/>
   <result pre="this study, we review data to support the use of" exact="panitumumab" post="in combination with a chemotherapy backbone, in the first"/>
   <result pre="should be reserved for patients with RAS wild-type mCRC. Keywords" exact="panitumumab" post="metastatic colorectal cancer first-line RAS Introduction Colorectal cancer (CRC)"/>
   <result pre="in up to 5% of patients. 27 According to the" exact="cetuximab" post="label, premedication with antihistaminic drugs is recommended with the"/>
   <result pre="studies in xenografts from the A431 cell line showed that" exact="panitumumab" post="blocked activation of EGFR, prevented tumor formation, and eradicated"/>
   <result pre="EGFR, prevented tumor formation, and eradicated established tumors. 30 Since" exact="panitumumab" post="is fully humanized, premedication is not recommended per US"/>
   <result pre="apoptosis, and EGFR downregulation. 32 Safety data The safety of" exact="panitumumab" post="has been evaluated in different dose escalation studies. In"/>
   <result pre="studies. In the first study, four different dose levels of" exact="panitumumab" post="(from 1 to 2.5 mg/kg weekly) were evaluated in"/>
   <result pre="were identified. A Phase I trial tested different schedules of" exact="panitumumab" post="including: weekly panitumumab from 0.01 to 5 mg/kg, 6"/>
   <result pre="Phase I trial tested different schedules of panitumumab including: weekly" exact="panitumumab" post="from 0.01 to 5 mg/kg, 6 mg/kg every 2"/>
   <result pre="of activity in patients with CRC fueled interest in developing" exact="panitumumab" post="for this disease. Panitumumab and oxaliplatin schedules in first"/>
   <result pre="fueled interest in developing panitumumab for this disease. Panitumumab and" exact="oxaliplatin" post="schedules in first line mCRC The PRIME study (Panitumumab"/>
   <result pre="Metastatic colorectal cancer to determine Efficacy) showed improved PFS when" exact="panitumumab" post="was added to FOLFOX (folinic acid, 5-flurouracil, oxaliplatin) in"/>
   <result pre="allocated 1,183 patients in a 1:1 fashion to FOLFOX4 plus" exact="panitumumab" post="(6 mg/kg every 2 weeks) vs FOLFOX4 alone. The"/>
   <result pre="exon 2 wild-type KRAS patients enrolled in the FOLFOX4 plus" exact="panitumumab" post="arm (10 vs 8.6 months, hazard ratio [HR] =0.80;"/>
   <result pre="patients with exon 2 mutations enrolled in the FOLFOX4 plus" exact="panitumumab" post="arm (7.4 vs 9.2 months, HR =1.27, 95% CI:"/>
   <result pre="CI: 0.70–0.98, P=0.03) in exon 2 wild-type KRAS patients. Adding" exact="panitumumab" post="also increased RR in exon 2 wild-type KRAS patients"/>
   <result pre="in exon 2 wild-type KRAS patients with the addition of" exact="panitumumab" post="(10% vs 8%). A subset analysis, limited to patients"/>
   <result pre="rate of complete resection for patients in the FOLFOX plus" exact="panitumumab" post="arm, but it was not statistically significant (27.9 vs"/>
   <result pre="The PEAK study (Panitumumab Efficacy in combination with mFOLFOX6 Against" exact="bevacizumab" post="plus mFOLFOX6 in mCRC subjects with wild-type KRAS tumors)"/>
   <result pre="An early OS analysis (46% deaths reported) showed, in the" exact="panitumumab" post="arm, an improvement in OS (34.2 vs 24.3 months,"/>
   <result pre="exon 2 wild-type KRAS mCRC/other mutations in RAS in the" exact="panitumumab" post="arm were more likely to receive bevacizumab beyond progression"/>
   <result pre="RAS in the panitumumab arm were more likely to receive" exact="bevacizumab" post="beyond progression (50% vs 7%) as well as cytotoxic"/>
   <result pre="discussed in the &quot;Predictive biomarkers: patient stratification&quot; section. Panitumumab and" exact="irinotecan" post="schedules in first line mCRC No data are available"/>
   <result pre="data are available from Phase III randomized clinical trials testing" exact="panitumumab" post="in combination with irinotecan schedules in the first-line setting."/>
   <result pre="Phase III randomized clinical trials testing panitumumab in combination with" exact="irinotecan" post="schedules in the first-line setting. However, this regimen is"/>
   <result pre="in the second-line setting. In this study, the addition of" exact="panitumumab" post="to FOLFIRI in KRAS exon 2 wild-type resulted in"/>
   <result pre="patients (76%) in the best supportive care (BSC) group received" exact="panitumumab" post="postprogression. 38 Two Phase II studies have tested panitumumab"/>
   <result pre="received panitumumab postprogression. 38 Two Phase II studies have tested" exact="panitumumab" post="in combination with irinotecan schedules in the first line."/>
   <result pre="Two Phase II studies have tested panitumumab in combination with" exact="irinotecan" post="schedules in the first line. The first study tested"/>
   <result pre="irinotecan schedules in the first line. The first study tested" exact="panitumumab" post="at 2.5 mg/kg weekly in combination with either IFL"/>
   <result pre="PFS and OS. A second single-arm, Phase II study combined" exact="panitumumab" post="(6 mg/kg) with FOLFIRI every 2 weeks. 39 Mutations"/>
   <result pre="higher in the KRAS exon 2 wild-type subset. Panitumumab plus" exact="bevacizumab" post="in the first line Dual inhibition of EGFR and"/>
   <result pre="the first line Dual inhibition of EGFR and VEGF with" exact="cetuximab" post="and bevacizumab, in combination with irinotecan, resulted in an"/>
   <result pre="irinotecan, resulted in an improved RR and PFS compared to" exact="cetuximab" post="and bevacizumab in the BOND-2 study. 40 This was"/>
   <result pre="in an improved RR and PFS compared to cetuximab and" exact="bevacizumab" post="in the BOND-2 study. 40 This was a randomized"/>
   <result pre="both EGFR and VEGF in combination with fluoropyrimidines and either" exact="oxaliplatin" post="or irinotecan in the first-line treatment of 1,053 patients"/>
   <result pre="and VEGF in combination with fluoropyrimidines and either oxaliplatin or" exact="irinotecan" post="in the first-line treatment of 1,053 patients with mCRC."/>
   <result pre="endpoint was PFS. Regardless of KRAS status, the addition of" exact="panitumumab" post="was detrimental in this study in regards to both"/>
   <result pre="Grade 3 and 4 AEs were more frequent in the" exact="panitumumab" post="arm (90% vs 77% in oxaliplatin cohort and 90%"/>
   <result pre="more frequent in the panitumumab arm (90% vs 77% in" exact="oxaliplatin" post="cohort and 90% vs 63% in irinotecan cohort). Skin"/>
   <result pre="vs 77% in oxaliplatin cohort and 90% vs 63% in" exact="irinotecan" post="cohort). Skin toxicity, diarrhea, infections, pulmonary emboli, and deep"/>
   <result pre="and deep vein thrombosis were all more common in the" exact="panitumumab" post="arm. 41 A detrimental effect from adding cetuximab to"/>
   <result pre="in the panitumumab arm. 41 A detrimental effect from adding" exact="cetuximab" post="to CAPOX-bevacizumab was also observed in the Dutch Colorectal"/>
   <result pre="However, in the BOND study, a randomized clinical trial comparing" exact="cetuximab" post="monotherapy vs cetux-imab in combination with irinotecan in irinotecan"/>
   <result pre="clinical trial comparing cetuximab monotherapy vs cetux-imab in combination with" exact="irinotecan" post="in irinotecan refractory patients with mCRC, no correlation was"/>
   <result pre="comparing cetuximab monotherapy vs cetux-imab in combination with irinotecan in" exact="irinotecan" post="refractory patients with mCRC, no correlation was found between"/>
   <result pre="in the tumor and efficacy of cetuximab. Subsequently, responses to" exact="cetuximab" post="were seen in patients lacking EGFR expression. 21 Therefore,"/>
   <result pre="mCRC came from a randomized Phase III clinical trial testing" exact="panitumumab" post="vs BSC after progression following treatment with cytotoxic agents."/>
   <result pre="study endpoint was PFS. In KRAS exon 2 wild-type patients," exact="panitumumab" post="resulted in improved PFS (12.3 vs 7.3 weeks, HR"/>
   <result pre="contributed to diluting benefit in OS. A detrimental effect from" exact="panitumumab" post="in the KRAS mutant subset was not seen in"/>
   <result pre="patients with mCRC who progressed on standard fluoropyrimidines, oxaliplatin, and" exact="irinotecan" post="were randomized to cetuximab vs BSC. 44 KRAS exon"/>
   <result pre="progressed on standard fluoropyrimidines, oxaliplatin, and irinotecan were randomized to" exact="cetuximab" post="vs BSC. 44 KRAS exon 2 mutations were evaluated"/>
   <result pre="the study was OS. In KRAS exon 2 wild-type patients," exact="cetuximab" post="improved OS (9.5 vs 4.8 months, HR =0.55, P&amp;lt;0.001)"/>
   <result pre="patients randomized to the BSC arm crossed over and received" exact="cetuximab" post="therapy. 44 Similar to the panitumumab trial, cetuximab had"/>
   <result pre="crossed over and received cetuximab therapy. 44 Similar to the" exact="panitumumab" post="trial, cetuximab had no negative impact on PFS/OS in"/>
   <result pre="and received cetuximab therapy. 44 Similar to the panitumumab trial," exact="cetuximab" post="had no negative impact on PFS/OS in the KRAS"/>
   <result pre="A retrospective, pooled exploratory analysis of 579 patients treated with" exact="cetuximab" post="in different randomized trials showed a survival benefit from"/>
   <result pre="cetuximab in different randomized trials showed a survival benefit from" exact="cetuximab" post="in the subset of patients with KRAS G13D mCRC"/>
   <result pre="47 Indeed, a randomized Phase II study (ICECREAM) recently compared" exact="cetuximab" post="vs cetuximab plus irinotecan in mCRC. The trial included"/>
   <result pre="a randomized Phase II study (ICECREAM) recently compared cetuximab vs" exact="cetuximab" post="plus irinotecan in mCRC. The trial included RAS wild-type"/>
   <result pre="Phase II study (ICECREAM) recently compared cetuximab vs cetuximab plus" exact="irinotecan" post="in mCRC. The trial included RAS wild-type patients but"/>
   <result pre="The study failed to show any benefit from single agent" exact="cetuximab" post="in patients with KRAS G13D mCRC. 48 Therefore, NCCN"/>
   <result pre="to expanded RAS results showed that the benefit from adding" exact="panitumumab" post="was even larger in the RAS wild-type subset ("/>
   <result pre="=0.78, 95% CI: 0.62–0.99, P=0.04) ( Figure 2). However, when" exact="panitumumab" post="was added to FOLFOX4 in patients with a wild-type"/>
   <result pre="data prompted the FDA to issue a new label for" exact="panitumumab" post="on March 11, 2015, excluding from treatment patients whose"/>
   <result pre="still a trend toward increased PFS in patients treated with" exact="panitumumab" post="in the PRIME trial (PFS – HR =0.58, 95%"/>
   <result pre="have been sufficiently robust to evaluate the benefit of adding" exact="panitumumab" post="in this subset in the first line. Alternatively, it"/>
   <result pre="different EGFR mAb, was detrimental when added to fluoropyrimidines and" exact="oxaliplatin" post="in BRAF-positive patients with mCRC treated in the first"/>
   <result pre="improvement in outcomes in patients with BRAF-positive mCRC when either" exact="panitumumab" post="or cetuximab is added to standard therapy. 51, 52"/>
   <result pre="outcomes in patients with BRAF-positive mCRC when either panitumumab or" exact="cetuximab" post="is added to standard therapy. 51, 52 Consistent with"/>
   <result pre="for increased survival with FOLFOXIRI compared to FOLFIRI (irinotecan with" exact="fluorouracil" post="and folinic acid) in BRAF-positive patients, this difference was"/>
   <result pre="54 Ongoing studies are evaluating BRAF inhibitors in combination with" exact="cetuximab" post="and irinotecan or PI3K inhibitors in mCRC patients with"/>
   <result pre="studies are evaluating BRAF inhibitors in combination with cetuximab and" exact="irinotecan" post="or PI3K inhibitors in mCRC patients with these molecular"/>
   <result pre="from a dose escalation study with LGX-818 (BRAF inhibitor) plus" exact="cetuximab" post="with or without BYL-719 (PI3K inhibitor) in patients with"/>
   <result pre="additional RAS mutations. In RAS wild-type patients the addition of" exact="panitumumab" post="to FOLFOX resulted in improved PFS compared to FOLFOX"/>
   <result pre="to FOLFOX resulted in improved PFS compared to FOLFOX plus" exact="bevacizumab" post="(PFS 13 vs 9.5 months, HR =0.65, P=0.029). Similarly,"/>
   <result pre="as rates of R 0 resection (10% vs 8% for" exact="panitumumab" post="and bevacizumab, respectively). An exploratory analysis of responses from"/>
   <result pre="9.7–13.6] vs 8.5 [95% CI 6.3–9.3] months, P=0.0142) in the" exact="panitumumab" post="arm. These results are consistent with those seen in"/>
   <result pre="Therapy for Metastatic Colorectal Cancer) trial, which studied FOLFIRI with/without" exact="cetuximab" post="as first-line therapy, showed that the incidence of expanded"/>
   <result pre="was no negative effect seen in the CRYSTAL trial when" exact="cetuximab" post="was added to FOLFIRI in RAS-positive patients. The reasons"/>
   <result pre="activation. A retrospective analysis of patients with mCRC treated with" exact="cetuximab" post="across multiple centers in Europe suggested that PIK3CA mutations"/>
   <result pre="from the CO.17 study (a randomized Phase III study comparing" exact="cetuximab" post="vs BSC) arrived at different conclusions after analyzing the"/>
   <result pre="mCRC refractory to chemotherapy who were randomized to receive either" exact="panitumumab" post="or cetuximab. OS was the same in both arms"/>
   <result pre="OS was the same in both arms (10.4 months with" exact="panitumumab" post="vs 10.0 months with cetuximab) and AEs were similar"/>
   <result pre="AEs were similar with slightly greater skin toxicity in the" exact="panitumumab" post="arm although less infusion reactions (one patient vs nine"/>
   <result pre="although less infusion reactions (one patient vs nine in the" exact="cetuximab" post="arm). 68 As described above, the decreased incidence of"/>
   <result pre="the decreased incidence of infusion reactions is likely secondary to" exact="panitumumab" post="being a fully human monoclonal antibody. A small Phase"/>
   <result pre="antibody. A small Phase II trial showed no responses to" exact="panitumumab" post="in 20 patients with mCRC who had previously progressed"/>
   <result pre="S492R, S464L, G465R, and I491M) which may predict resistance to" exact="cetuximab" post="but not panitumumab, were recently identified. 70, 71 Retrospective"/>
   <result pre="samples from ASPECCT revealed that 16% of patients in the" exact="cetuximab" post="arm but only 1% of those in the panitumumab"/>
   <result pre="the cetuximab arm but only 1% of those in the" exact="panitumumab" post="arm developed EGFR S492R mutations. Those with EGFR S492R"/>
   <result pre="EGFR S492R mutations. Those with EGFR S492R mutations in the" exact="cetuximab" post="arm were also shown to have worse OS (11.9"/>
   <result pre="retrospective analysis in 64 patients with chemorefractory mCRC treated with" exact="cetuximab" post="plus chemotherapy showed a longer time to progression in"/>
   <result pre="tumor specimens collected during a Phase III trial that compared" exact="panitumumab" post="plus BSC vs BSC alone, failed to show that"/>
   <result pre="RR (35%) in patients with HER2-positive CRC patients treated with" exact="lapatinib" post="plus trastuzumab. HER2 was considered positive if tumor was"/>
   <result pre="Of note, single-agent pathway inhibition with BGJ398 (FGFR inhibitor) or" exact="imatinib" post="(PDGFR inhibitor) failed to show activity in these models"/>
   <result pre="tumor regressions were seen when these agents were combined with" exact="cetuximab" post="indicating that perhaps combination therapy will be needed for"/>
   <result pre="first-line randomized trials In the PRIME study, the addition of" exact="panitumumab" post="increased the incidence of AE. This had no impact"/>
   <result pre="of the patients discontinued treatment due to AEs in the" exact="panitumumab" post="arm. The distribution of grade 3–4 AE was similar"/>
   <result pre="similar regardless of KRAS status. The most common AE with" exact="panitumumab" post="was acneiform rash (37% and 31% for KRAS wild-type"/>
   <result pre="with Panitumumab) clinical trial shows that preemptive antibiotic treatment with" exact="doxycycline" post="decreases the incidence of grade ≥2 rash secondary to"/>
   <result pre="doxycycline decreases the incidence of grade ≥2 rash secondary to" exact="panitumumab" post="from 62% to 29%. 78 Similarly, the addition of"/>
   <result pre="panitumumab from 62% to 29%. 78 Similarly, the addition of" exact="panitumumab" post="increased the incidence of grade 3–4 diarrhea (18% vs"/>
   <result pre="(10% vs 3%). In the PEAK study, patients in the" exact="panitumumab" post="arm experienced AEs of any grade more frequently than"/>
   <result pre="AEs of any grade more frequently than those in the" exact="bevacizumab" post="arm (91% vs 83%); however, the percentage of patients"/>
   <result pre="3–4 AE was skin rash, 32% vs 2% in the" exact="panitumumab" post="vs bevacizumab group. Additional grade 3–4 AEs that were"/>
   <result pre="was skin rash, 32% vs 2% in the panitumumab vs" exact="bevacizumab" post="group. Additional grade 3–4 AEs that were increased in"/>
   <result pre="group. Additional grade 3–4 AEs that were increased in the" exact="panitumumab" post="arm included hypokalemia (11% vs 5%) and hypomagnesemia (7%"/>
   <result pre="5%) and hypomagnesemia (7% vs 0%). Conclusion The addition of" exact="panitumumab" post="to FOLFOX in first-line treatment resulted in improved RR,"/>
   <result pre="signaling pathways ( MET, FGFR1). 77 In randomized trials with" exact="panitumumab" post="in the first line, 17%–23% of KRAS exon 2"/>
   <result pre="important to note that expanded RAS analysis across trials testing" exact="cetuximab" post="has been done using different methods. Pyrosequencing was performed"/>
   <result pre="ICECREAM study reported recently showed no benefit from single agent" exact="cetuximab" post="in patients with KRAS G13D-positive disease. 48 These patients"/>
   <result pre="Lancet Oncol 2014 15 23 34 24314615 6 Modulation of" exact="fluorouracil" post="by leucovorin in patients with advanced colorectal cancer: evidence"/>
   <result pre="et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and" exact="oxaliplatin" post="in advanced colorectal cancer (CAIRO): a phase III randomised"/>
   <result pre="V von Weikersthal LF Decker T et al. FOLFIRI plus" exact="cetuximab" post="versus FOLFIRI plus bevacizumab as first-line treatment for patients"/>
   <result pre="Decker T et al. FOLFIRI plus cetuximab versus FOLFIRI plus" exact="bevacizumab" post="as first-line treatment for patients with metastatic colorectal cancer"/>
   <result pre="phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with" exact="bevacizumab" post="(BV) or cetuximab (CET) for patients (pts) with KRAS"/>
   <result pre="of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or" exact="cetuximab" post="(CET) for patients (pts) with KRAS wild-type (wt) untreated"/>
   <result pre="basis for inhibition of the epidermal growth factor receptor by" exact="cetuximab" post="Cancer Cell 2005 7 301 311 15837620 16 Citri"/>
   <result pre="M Peeters M et al. Wild-type KRAS is required for" exact="panitumumab" post="efficacy in patients with metastatic colorectal cancer J Clin"/>
   <result pre="E et al. EGFR FISH assay predicts for response to" exact="cetuximab" post="in chemotherapy refractory colorectal cancer patients Ann Oncol 2008"/>
   <result pre="number and clinical outcome of metastatic colorectal cancer treated with" exact="panitumumab" post="J Clin Oncol 2007 25 3238 3245 17664472 27"/>
   <result pre="factor receptor chimeric antibody C225 alone and in combination with" exact="cisplatin" post="J Clin Oncol 2000 18 904 914 10673534 28"/>
   <result pre="AS Crawford J et al. Dose and schedule study of" exact="panitumumab" post="monotherapy in patients with advanced solid malignancies Clin Cancer"/>
   <result pre="trial evaluating safety and pharmacokinetics of two dosing schedules of" exact="panitumumab" post="in patients with solid tumors Clin Colorectal Cancer 2009"/>
   <result pre="al. Final results from PRIME: randomized phase III study of" exact="panitumumab" post="with FOLFOX4 for first-line treatment of metastatic colorectal cancer"/>
   <result pre="et al. PEAK: a randomized, multicenter phase II study of" exact="panitumumab" post="plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab"/>
   <result pre="phase II study of panitumumab plus modified fluorouracil, leucovorin, and" exact="oxaliplatin" post="(mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously"/>
   <result pre="of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or" exact="bevacizumab" post="plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type"/>
   <result pre="al. An open-label, single-arm study assessing safety and efficacy of" exact="panitumumab" post="in patients with metastatic colorectal cancer refractory to standard"/>
   <result pre="39 Kohne CH Hofheinz R Mineur L et al. First-line" exact="panitumumab" post="plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer"/>
   <result pre="et al. Randomized phase II trial of cetuximab, bevacizumab, and" exact="irinotecan" post="compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal"/>
   <result pre="phase II trial of cetuximab, bevacizumab, and irinotecan compared with" exact="cetuximab" post="and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2"/>
   <result pre="trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and" exact="bevacizumab" post="alone in irinotecan-refractory colorectal cancer: the BOND-2 study J"/>
   <result pre="al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and" exact="panitumumab" post="compared with chemotherapy and bevacizumab alone for metastatic colorectal"/>
   <result pre="trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and" exact="bevacizumab" post="alone for metastatic colorectal cancer J Clin Oncol 2009"/>
   <result pre="J Koopman M Cats A et al. Chemotherapy, bevacizumab, and" exact="cetuximab" post="in metastatic colorectal cancer N Engl J Med 2009"/>
   <result pre="S Jonker DJ et al. K-ras mutations and benefit from" exact="cetuximab" post="in advanced colorectal cancer N Engl J Med 2008"/>
   <result pre="outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with" exact="cetuximab" post="JAMA 2010 304 1812 1820 20978259 47 Misale S"/>
   <result pre="Maughan TS Adams RA Smith CG et al. Addition of" exact="cetuximab" post="to oxaliplatin-based first-line combination chemotherapy for treatment of advanced"/>
   <result pre="of BRAF mutations in patients with advanced colorectal cancer receiving" exact="cetuximab" post="and panitumumab: a meta-analysis Eur J Cancer 2015 51"/>
   <result pre="Cremolini C Loupakis F Antoniotti C et al. FOLFOXIRI plus" exact="bevacizumab" post="versus FOLFIRI plus bevacizumab as first-line treatment of patients"/>
   <result pre="Antoniotti C et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus" exact="bevacizumab" post="as first-line treatment of patients with metastatic colorectal cancer:"/>
   <result pre="55 collab: Southwest Oncology Group S1406 Phase II study of" exact="irinotecan" post="and cetuximab with or without vemurafenib in BRAF mutant"/>
   <result pre="Southwest Oncology Group S1406 Phase II study of irinotecan and" exact="cetuximab" post="with or without vemurafenib in BRAF mutant metastatic colorectal"/>
   <result pre="Phase II study of irinotecan and cetuximab with or without" exact="vemurafenib" post="in BRAF mutant metastatic colorectal cancer Available from: https://www.clinicaltrials.gov/ct2/show/NCT02164916."/>
   <result pre="28, 2015 56 collab: Novartis Pharmaceuticals Study of LGX818 and" exact="cetuximab" post="or LGX818, BYL719, and cetuximab in BRAF mutant metastatic"/>
   <result pre="Pharmaceuticals Study of LGX818 and cetuximab or LGX818, BYL719, and" exact="cetuximab" post="in BRAF mutant metastatic colorectal cancer Available from: https://www.clinicaltrials.gov/ct2/show/NCT01719380."/>
   <result pre="of the selective BRAF V600 inhibitor encorafenib (LGX818) combined with" exact="cetuximab" post="with or without the α-specific PI3K inhibitor alpelisib (BYL719)"/>
   <result pre="M Hecht JR First-line treatment with modified FOLFOX6 (mFOLFOX6) +" exact="panitumumab" post="(pmab) or bevacizumab (bev) in wild-type (WT) RAS metastatic"/>
   <result pre="First-line treatment with modified FOLFOX6 (mFOLFOX6) + panitumumab (pmab) or" exact="bevacizumab" post="(bev) in wild-type (WT) RAS metastatic colorectal carcinoma (mCRC):"/>
   <result pre="E Lenz HJ Kohne CH et al. Fluorouracil, leucovorin, and" exact="irinotecan" post="plus cetuximab treatment and RAS mutations in col-orectal cancer"/>
   <result pre="HJ Kohne CH et al. Fluorouracil, leucovorin, and irinotecan plus" exact="cetuximab" post="treatment and RAS mutations in col-orectal cancer J Clin"/>
   <result pre="KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of" exact="cetuximab" post="plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective"/>
   <result pre="et al. PIK3CA, BRAF, and PTEN status and benefit from" exact="cetuximab" post="in the treatment of advanced colorectal cancer – results"/>
   <result pre="Price TJ Peeters M Kim TW et al. Panitumumab versus" exact="cetuximab" post="in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic"/>
   <result pre="in patients with KRAS wild-type colorectal cancer after progression on" exact="cetuximab" post="Oncologist 2012 17 14 22210091 70 Montagut C Dalmases"/>
   <result pre="the extracellular domain of the epidermal growth factor receptor conferring" exact="cetuximab" post="resistance in colorectal cancer Nat Med 2012 18 221"/>
   <result pre="G et al. Emergence of multiple EGFR extracellular mutations during" exact="cetuximab" post="treatment in colorectal cancer Clin Cancer Res 2015 21"/>
   <result pre="of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT:" exact="panitumumab" post="(pmab) vs. cetuximab (cmab) in pts with chemorefractory wild-type"/>
   <result pre="with EGFR S492R ectodomain mutations in ASPECCT: panitumumab (pmab) vs." exact="cetuximab" post="(cmab) in pts with chemorefractory wild-type KRAS exon 2"/>
   <result pre="al. Massively parallel tumor multigene sequencing to evaluate response to" exact="panitumumab" post="in a random-ized phase III study of metastatic colorectal"/>
   <result pre="EP Piperdi B et al. Skin toxicity evaluation protocol with" exact="panitumumab" post="(STEPP), a phase II, open-label, randomized trial evaluating the"/>
   <result pre="in patients with metastatic colorectal cancer (mCRC) treated first-line with" exact="cetuximab" post="plus FOLFOX4: new results from the OPUS study [abstr"/>
   <result pre="TK activation represented in ( C). ( D) Cetuximab and" exact="panitumumab" post="bind domain III of EGFR preventing untethering and subsequent"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4706528/results/search/inn/results.xml">
   <result pre="cancer phosphoinositide 3 kinase (PI3K)/Akt/ mammalian target of rapamycin (mTOR)" exact="everolimus" post="Introduction The phosphoinositide 3 kinase (PI3K)/Akt/mammalian target of rapamycin"/>
   <result pre="In addition, the PAM pathway has also been implicated in" exact="trastuzumab" post="resistance in HER2-overexpressing breast cancers 30 . As trastuzumab"/>
   <result pre="in trastuzumab resistance in HER2-overexpressing breast cancers 30 . As" exact="trastuzumab" post="blocks the signaling pathway upstream from PI3K, a downstream"/>
   <result pre="indicate that inhibitors of the pathway can act synergistically with" exact="trastuzumab" post="in resistant cells 31 - 34 . In triple"/>
   <result pre="sensitise basal-like breast cancer cells to DNA damaging agents, including" exact="cisplatin" post="38 , 39 , and to work synergistically with"/>
   <result pre="References Hormone receptor Positive, HER2 negative HORIZON study Temsirolimus +" exact="letrozole" post="vs. placebo + letrozole Phase III study, ABC, First-line"/>
   <result pre="HER2 negative HORIZON study Temsirolimus + letrozole vs. placebo +" exact="letrozole" post="Phase III study, ABC, First-line ( n=11,112) PFS: 8.9"/>
   <result pre="vs. 5.6 months ( P=0.003) 41 BOLERO-2 study Everolimus +" exact="exemestane" post="vs. placebo + exemestane Phase III study, ABC, relapsed"/>
   <result pre="P=0.003) 41 BOLERO-2 study Everolimus + exemestane vs. placebo +" exact="exemestane" post="Phase III study, ABC, relapsed or progressed on previous"/>
   <result pre="months ( P=0.14) 42 , 43 TAMRAD study Everolimus +" exact="tamoxifen" post="vs. tamoxifen Phase II randomised study; ABC; relapsed or"/>
   <result pre="P=0.14) 42 , 43 TAMRAD study Everolimus + tamoxifen vs." exact="tamoxifen" post="Phase II randomised study; ABC; relapsed or progressed on"/>
   <result pre="4.5 months ( P=0.002) 44 HER2 positive BOLERO-3 Everolimus +" exact="vinorelbine" post="+ trastuzumab vs. placebo + vinorelibine + trastuzumab Phase"/>
   <result pre="( P=0.002) 44 HER2 positive BOLERO-3 Everolimus + vinorelbine +" exact="trastuzumab" post="vs. placebo + vinorelibine + trastuzumab Phase III study,"/>
   <result pre="Everolimus + vinorelbine + trastuzumab vs. placebo + vinorelibine +" exact="trastuzumab" post="Phase III study, ABC, previous treatment with taxane, resistance"/>
   <result pre="Phase III study, ABC, previous treatment with taxane, resistance to" exact="trastuzumab" post="( n=569) PFS: 7.0 vs. 5.8 months ( P=0.0067);"/>
   <result pre="cancers but not in HR+ cancers 45 BOLERO-1 Everolimus +" exact="paclitaxel" post="+ trastuzumab vs. placebo + paclitaxel + trastuzumab Phase"/>
   <result pre="not in HR+ cancers 45 BOLERO-1 Everolimus + paclitaxel +" exact="trastuzumab" post="vs. placebo + paclitaxel + trastuzumab Phase III study,"/>
   <result pre="45 BOLERO-1 Everolimus + paclitaxel + trastuzumab vs. placebo +" exact="paclitaxel" post="+ trastuzumab Phase III study, ABC, first-line ( n=719)"/>
   <result pre="Everolimus + paclitaxel + trastuzumab vs. placebo + paclitaxel +" exact="trastuzumab" post="Phase III study, ABC, first-line ( n=719) PFS: 14.9"/>
   <result pre="inhibitor in breast cancer. The trial compared the combination of" exact="temsirolimus" post="plus letrozole to placebo plus letrozole, in the first-line"/>
   <result pre="breast cancer. The trial compared the combination of temsirolimus plus" exact="letrozole" post="to placebo plus letrozole, in the first-line setting in"/>
   <result pre="or progressed on nonsteroidal AI in a 2:1 ratio to" exact="exemestane" post="plus everolimus (10 mg) vs. exemestane plus placebo. The"/>
   <result pre="on nonsteroidal AI in a 2:1 ratio to exemestane plus" exact="everolimus" post="(10 mg) vs. exemestane plus placebo. The addition of"/>
   <result pre="a 2:1 ratio to exemestane plus everolimus (10 mg) vs." exact="exemestane" post="plus placebo. The addition of everolimus improved the PFS"/>
   <result pre="everolimus (10 mg) vs. exemestane plus placebo. The addition of" exact="everolimus" post="improved the PFS at central review to 10.6 months"/>
   <result pre="central review to 10.6 months compared to 4.1 months with" exact="exemestane" post="alone ( P&amp;lt;0.0001), and the PFS at local review"/>
   <result pre="results led to the FDA approval in August 2012 of" exact="everolimus" post="with exemestane in the treatment of postmenopausal women with"/>
   <result pre="to the FDA approval in August 2012 of everolimus with" exact="exemestane" post="in the treatment of postmenopausal women with HR+HER2− advanced"/>
   <result pre="with HR+HER2− advanced breast cancer after failure of treatment with" exact="letrozole" post="or anastrozole. The frequency of adverse events such as"/>
   <result pre="combination therapy compared to 26.6 months in the group receiving" exact="exemestane" post="and placebo ( P=0.14) 43 . The lack of"/>
   <result pre="control arm. In addition, blockade of the mTORC1 complex by" exact="everolimus" post="could have led to a negative intracellular feedback loop"/>
   <result pre="paradoxical activation of AKT. The higher rate of discontinuation of" exact="everolimus" post="due to an adverse event, 29% compared to 5%"/>
   <result pre="impacted treatment outcomes. The TAMRAD study evaluated the addition of" exact="everolimus" post="to tamoxifen in a phase II randomised study among"/>
   <result pre="outcomes. The TAMRAD study evaluated the addition of everolimus to" exact="tamoxifen" post="in a phase II randomised study among HR+/HER2−, AI-resistant"/>
   <result pre="study among HR+/HER2−, AI-resistant metastatic breast cancer patients. Addition of" exact="everolimus" post="significantly improved the clinical benefit rate (CBR) as well"/>
   <result pre="or secondary resistance to endocrine therapy obtained more benefit from" exact="everolimus" post="than patients with primary resistance. The differing results from"/>
   <result pre="the addition of an mTOR inhibitor, since the use of" exact="temsirolimus" post="in the first-line setting in the former study failed"/>
   <result pre="III study which randomised patients previously treated with taxane and" exact="trastuzumab" post="to everolimus 5 mg or placebo in combination with"/>
   <result pre="which randomised patients previously treated with taxane and trastuzumab to" exact="everolimus" post="5 mg or placebo in combination with vinorelbine and"/>
   <result pre="trastuzumab to everolimus 5 mg or placebo in combination with" exact="vinorelbine" post="and trastuzumab 45 , testing the hypothesis that the"/>
   <result pre="everolimus 5 mg or placebo in combination with vinorelbine and" exact="trastuzumab" post="45 , testing the hypothesis that the addition of"/>
   <result pre="trastuzumab 45 , testing the hypothesis that the addition of" exact="everolimus" post="could overcome trastuzumab resistance. The addition of everolimus improved"/>
   <result pre="testing the hypothesis that the addition of everolimus could overcome" exact="trastuzumab" post="resistance. The addition of everolimus improved the PFS from"/>
   <result pre="addition of everolimus could overcome trastuzumab resistance. The addition of" exact="everolimus" post="improved the PFS from 5.8 to 7.0 months (HR"/>
   <result pre="when HER2 but not ER is inhibited. The role of" exact="everolimus" post="in HER2+ breast cancer however remains unclear, especially with"/>
   <result pre="cancer however remains unclear, especially with the approved indications for" exact="trastuzumab" post="emtansine (TDM-1), lapatinib and pertuzumab. Of note, 28% of"/>
   <result pre="unclear, especially with the approved indications for trastuzumab emtansine (TDM-1)," exact="lapatinib" post="and pertuzumab. Of note, 28% of patients in the"/>
   <result pre="The BOLERO-1 study was a phase III randomised study evaluating" exact="everolimus" post="10 mg in combination with paclitaxel and trastuzumab in"/>
   <result pre="III randomised study evaluating everolimus 10 mg in combination with" exact="paclitaxel" post="and trastuzumab in HER2+ advanced breast cancer in the"/>
   <result pre="study evaluating everolimus 10 mg in combination with paclitaxel and" exact="trastuzumab" post="in HER2+ advanced breast cancer in the first-line setting,"/>
   <result pre="breast cancer in the first-line setting, testing the potential for" exact="everolimus" post="to circumvent trastuzumab resistance. The initial primary objective was"/>
   <result pre="the first-line setting, testing the potential for everolimus to circumvent" exact="trastuzumab" post="resistance. The initial primary objective was investigator-assessed PFS in"/>
   <result pre="not statistically improved at 14.9 months in the group receiving" exact="everolimus" post="compared to 14.5 months in the group receiving placebo"/>
   <result pre="a 7.2 months prolongation in PFS with the addition of" exact="everolimus" post="(20.3 vs. 13.1 months, P=0.0049) 46 , though the"/>
   <result pre="also a higher rate of adverse event-related on-treatment deaths with" exact="everolimus" post="(3.6% vs. 0%) mainly related to respiratory problems and"/>
   <result pre="proactive monitoring and early management of adverse events. The median" exact="everolimus" post="relative dose intensity of 0.54 (range, 0.03-1.00) compared with"/>
   <result pre="group also reflects the difficulty in administering 10 mg of" exact="everolimus" post="concurrently with weekly paclitaxel and trastuzumab. Triple negative breast"/>
   <result pre="difficulty in administering 10 mg of everolimus concurrently with weekly" exact="paclitaxel" post="and trastuzumab. Triple negative breast cancer (TNBC) Following the"/>
   <result pre="have been a few randomised trials studying the use of" exact="everolimus" post="in TNBC. The first, a phase II neoadjuvant study"/>
   <result pre="neoadjuvant study including 50 TNBC patients, tested the addition of" exact="everolimus" post="to weekly paclitaxel for 12 weeks, followed by fluorouracil,"/>
   <result pre="50 TNBC patients, tested the addition of everolimus to weekly" exact="paclitaxel" post="for 12 weeks, followed by fluorouracil, epirubicin and cyclophosphamide"/>
   <result pre="everolimus to weekly paclitaxel for 12 weeks, followed by fluorouracil," exact="epirubicin" post="and cyclophosphamide (FEC) every three weeks for four cycles."/>
   <result pre="weekly paclitaxel for 12 weeks, followed by fluorouracil, epirubicin and" exact="cyclophosphamide" post="(FEC) every three weeks for four cycles. A higher"/>
   <result pre="higher clinical response rate was showed in the arm including" exact="everolimus" post="(48% vs. 30%), but this did not reach statistical"/>
   <result pre="breast cancer showing no response after four cycles of neoadjuvant" exact="epirubicin" post="and cyclophosphamide (with or without bevacizumab) were randomised to"/>
   <result pre="showing no response after four cycles of neoadjuvant epirubicin and" exact="cyclophosphamide" post="(with or without bevacizumab) were randomised to receive either"/>
   <result pre="cyclophosphamide (with or without bevacizumab) were randomised to receive either" exact="paclitaxel" post="alone, or paclitaxel plus everolimus. pCR was achieved in"/>
   <result pre="without bevacizumab) were randomised to receive either paclitaxel alone, or" exact="paclitaxel" post="plus everolimus. pCR was achieved in 3.6% of patients"/>
   <result pre="everolimus. pCR was achieved in 3.6% of patients treated with" exact="paclitaxel" post="and everolimus versus 5.6% in the control arm ("/>
   <result pre="was achieved in 3.6% of patients treated with paclitaxel and" exact="everolimus" post="versus 5.6% in the control arm ( P=0.476), making"/>
   <result pre="setting, a randomised phase II trial evaluated the combination of" exact="paclitaxel" post="and bevacizumab with or without everolimus in 112 women"/>
   <result pre="randomised phase II trial evaluated the combination of paclitaxel and" exact="bevacizumab" post="with or without everolimus in 112 women with untreated"/>
   <result pre="evaluated the combination of paclitaxel and bevacizumab with or without" exact="everolimus" post="in 112 women with untreated metastatic HER2-negative breast cancer."/>
   <result pre="the higher toxicities and lower dose intensity achieved in the" exact="everolimus" post="arm 50 . The negative results from the studies"/>
   <result pre="in resistance to treatment. Biomarkers Although the clinical efficacy of" exact="everolimus" post="has been demonstrated in HR-positive and HER2-positive breast cancers,"/>
   <result pre="the BOLERO-2 study. A positive treatment effect in favour of" exact="everolimus" post="was detected across the various genetic marker subgroups. PIK3CA"/>
   <result pre="status was not predictive of increased benefit with addition of" exact="everolimus" post="to exemestane. However, women whose tumors had two or"/>
   <result pre="concomitant alterations in more than one oncogenic pathway may attenuate" exact="everolimus" post="efficacy 51 . One caveat to this biomarker subset"/>
   <result pre="beyond genomic alterations in the search for predictive biomarkers of" exact="everolimus" post="efficacy. Fifty-five primary tumor samples from the TAMRAD trial"/>
   <result pre="have an improvement in TTP with tamoxifen/everolimus therapy, compared with" exact="tamoxifen" post="alone, were patients with high p4EBP1 (a downstream effector"/>
   <result pre="who had progressed on prior AI use were randomised to" exact="fulvestrant" post="(500 mg monthly) with pictilisib (340 mg daily) or"/>
   <result pre="fulvestrant (500 mg monthly) with pictilisib (340 mg daily) or" exact="fulvestrant" post="with placebo. The preliminary results were presented at San"/>
   <result pre="Cancer Symposium 2014 54 ; the addition of pictilisib to" exact="fulvestrant" post="was associated with a non-statistically significant PFS increase from"/>
   <result pre="did not predict the benefit of addition of pictilisib to" exact="fulvestrant" post="either, but this was based on archived tumor specimens,"/>
   <result pre="with HR+/HER2- advanced breast cancer after progression on AI to" exact="fulvestrant" post="and buparlisib or fulvestrant and placebo; preliminary results may"/>
   <result pre="cancer after progression on AI to fulvestrant and buparlisib or" exact="fulvestrant" post="and placebo; preliminary results may soon be available. This"/>
   <result pre="been implicated in secondary resistance 64 . The combination of" exact="temsirolimus" post="and an anti-IGF-1 receptor antibody, cixutumumab, has been tested"/>
   <result pre="evaluated in the phase II trial of BYL719 together with" exact="everolimus" post="and exemestane (Clinicaltrials.gov no: NCT02077933). Rapalogues are postulated to"/>
   <result pre="the phase II trial of BYL719 together with everolimus and" exact="exemestane" post="(Clinicaltrials.gov no: NCT02077933). Rapalogues are postulated to have limited"/>
   <result pre="phase II study in two different dosing schedules together with" exact="fulvestrant" post="alone or fulvestrant and everolimus (Clinicaltrials.gov no: NCT02216786). More"/>
   <result pre="in two different dosing schedules together with fulvestrant alone or" exact="fulvestrant" post="and everolimus (Clinicaltrials.gov no: NCT02216786). More recently, preclinical data"/>
   <result pre="different dosing schedules together with fulvestrant alone or fulvestrant and" exact="everolimus" post="(Clinicaltrials.gov no: NCT02216786). More recently, preclinical data suggests that"/>
   <result pre="and PI3K inhibitors, such as the combination of LEE011 with" exact="fulvestrant" post="and BYL719 or BKM120 in postmenopausal women with advanced"/>
   <result pre="study is looking at the combination of LEE011, BYL719 and" exact="letrozole" post="(Clinicaltrials.gov no: NCT01872260). Toxicities PAM inhibitors are associated with"/>
   <result pre="of the monitoring and management guidelines are currently limited to" exact="everolimus" post="or mTOR inhibitors, as trials on other PAM inhibitors"/>
   <result pre=". Details on the management of adverse effects associated with" exact="everolimus" post="may also be obtained at http://www.global.afinitor.com and https://www.pharma.us.novartis.com/product/pi/pdf/afinitor.pdf. Table"/>
   <result pre="https://www.pharma.us.novartis.com/product/pi/pdf/afinitor.pdf. Table 3 Recommended monitoring guidelines for a patient on" exact="everolimus" post="Item Detailed guidelines Pre-treatment screening Screen baseline full blood"/>
   <result pre="avoid include moderate to strong inhibitors of cyp3a4 (e.g., ketoconazole," exact="clarithromycin" post="etc.) and moderate to strong inducers of CYP3A4 (e.g.,"/>
   <result pre="weeks initially The following toxicities are most commonly reported within" exact="everolimus" post="69 . Cutaneous and mucosal effects Stomatitis was the"/>
   <result pre="may also include the use of corticosteroid mouth rinses or" exact="everolimus" post="dose modifications ( Table 4 ). With appropriate management,"/>
   <result pre="everolimus dose modifications ( Table 4 ). With appropriate management," exact="everolimus" post="may be continued in some patients who experience stomatitis"/>
   <result pre="of this potentially life-threatening complication is crucial. Immunosuppression Patients on" exact="everolimus" post="can be predisposed to infections, including bacterial, fungal and"/>
   <result pre="setting of HR+/HER2− breast cancer at this present moment, with" exact="everolimus" post="approved for use in combination with exemestane after progression"/>
   <result pre="present moment, with everolimus approved for use in combination with" exact="exemestane" post="after progression on non-steroidal AIs. In HER2+ disease, benefit"/>
   <result pre="PAM pathway activation status also appears to be predictive of" exact="everolimus" post="efficacy. Monitoring and timely management of adverse effects are"/>
   <result pre="to tumor inhibition by trastuzumab, and loss of PTEN predicts" exact="trastuzumab" post="resistance in patients. Cancer Cell 2004; 6: 117- 127."/>
   <result pre="31 Nahta R. Pharmacological strategies to overcome HER2 cross-talk and" exact="trastuzumab" post="resistance. Curr Med Chem 2012; 19: 1065- 1075. 22229414"/>
   <result pre="et al. Preclinical testing of clinically applicable strategies for overcoming" exact="trastuzumab" post="resistance caused by PTEN deficiency. Clin Cancer Res 2007;"/>
   <result pre="Yue YC Chua CH Lim JY et al. Rapamycin synergizes" exact="cisplatin" post="sensitivity in basal-like breast cancer cells through up-regulation of"/>
   <result pre="Chow L et al. Randomized phase III placebo-controlled trial of" exact="letrozole" post="plus oral temsirolimus as first-line endocrine therapy in postmenopausal"/>
   <result pre="al. Randomized phase III placebo-controlled trial of letrozole plus oral" exact="temsirolimus" post="as first-line endocrine therapy in postmenopausal women with locally"/>
   <result pre="Pritchard KI Lebrun F Ito Y et al. Everolimus plus" exact="exemestane" post="for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast"/>
   <result pre="JM Freyer G et al. Randomized phase II trial of" exact="everolimus" post="in combination with tamoxifen in patients with hormone receptor-positive,"/>
   <result pre="al. Randomized phase II trial of everolimus in combination with" exact="tamoxifen" post="in patients with hormone receptor-positive, human epidermal growth factor"/>
   <result pre="Shao Z Mano MS Neciosup SP et al. Combination of" exact="everolimus" post="with trastuzumab plus paclitaxel as first-line treatment for patients"/>
   <result pre="Mano MS Neciosup SP et al. Combination of everolimus with" exact="trastuzumab" post="plus paclitaxel as first-line treatment for patients with HER2-positive"/>
   <result pre="Neciosup SP et al. Combination of everolimus with trastuzumab plus" exact="paclitaxel" post="as first-line treatment for patients with HER2-positive advanced breast"/>
   <result pre="al. Open-label randomized clinical trial of standard neoadjuvant chemotherapy with" exact="paclitaxel" post="followed by FEC versus the combination of paclitaxel and"/>
   <result pre="chemotherapy with paclitaxel followed by FEC versus the combination of" exact="paclitaxel" post="and everolimus followed by FEC in women with triple"/>
   <result pre="paclitaxel followed by FEC versus the combination of paclitaxel and" exact="everolimus" post="followed by FEC in women with triple receptor-negative breast"/>
   <result pre="M Eidtmann H Kittel K et al. Neoadjuvant chemotherapy with" exact="paclitaxel" post="and everolimus in breast cancer patients with non-responsive tumours"/>
   <result pre="H Kittel K et al. Neoadjuvant chemotherapy with paclitaxel and" exact="everolimus" post="in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide"/>
   <result pre="breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ±" exact="bevacizumab" post="- results of the randomised GeparQuinto study (GBG 44)."/>
   <result pre="Favret A, Morgan SK, Priego VM, et al. Everolimus with" exact="paclitaxel" post="plus bevacizumab as first-line therapy for HER2-negative metastatic breast"/>
   <result pre="Morgan SK, Priego VM, et al. Everolimus with paclitaxel plus" exact="bevacizumab" post="as first-line therapy for HER2-negative metastatic breast cancer (MBC):"/>
   <result pre="S, et al. Correlation of molecular alterations with efficacy of" exact="everolimus" post="in hormone receptor-positive, HER2-negative advanced breast cancer: results from"/>
   <result pre="evidence for mTORC1 activation marker as a predictive factor for" exact="everolimus" post="efficacy in advanced breast cancer. Ann Oncol 2015; 26:"/>
   <result pre="F, Tseng LM, Jerusalem TH, et al. Predictive biomarkers of" exact="everolimus" post="efficacy in HER2+ advanced breast cancer: Combined exploratory analysis"/>
   <result pre="phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus" exact="fulvestrant" post="vs fulvestrant plus placebo in patients with ER+, aromatase"/>
   <result pre="study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs" exact="fulvestrant" post="plus placebo in patients with ER+, aromatase inhibitor (AI)-resistant"/>
   <result pre="randomized studies of the oral pan-PI3K inhibitor buparlisib (BKM120) with" exact="fulvestrant" post="in postmenopausal women with HR+/HER2– locally advanced or metastatic"/>
   <result pre="phase I study of the AKT inhibitor (MK-2206) with concurrent" exact="trastuzumab" post="and lapatinib in patients with HER2-positive solid tumors. J"/>
   <result pre="study of the AKT inhibitor (MK-2206) with concurrent trastuzumab and" exact="lapatinib" post="in patients with HER2-positive solid tumors. J Clin Oncol"/>
   <result pre="A phase I/IB dose-escalation study of BEZ235 in combination with" exact="trastuzumab" post="in patients with PI3-kinase or PTEN altered HER2+ metastatic"/>
   <result pre="I trial of the IGF-1R antibody cixutumumab in combination with" exact="temsirolimus" post="in patients with metastatic breast cancer. Breast Cancer Res"/>
   <result pre="DN, Ravaud A, et al. Meta-analysis of stomatitis incidence in" exact="everolimus" post="(EVE) clinical studies and its relationship with efficacy. J"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4706584/results/search/inn/results.xml">
   <result pre="10.1007/s00280-015-2922-5 : Original Article Population pharmacokinetic and exposure–response analysis for" exact="trastuzumab" post="administered using a subcutaneous &quot;manual syringe&quot; injection or intravenously"/>
   <result pre="the population pharmacokinetics (PKs) of subcutaneous (SC) and intravenous (IV)" exact="trastuzumab" post="in early breast cancer (EBC), assess the impact of"/>
   <result pre="early breast cancer (EBC), assess the impact of covariates on" exact="trastuzumab" post="PK, and evaluate fixed (nonweight-based) dosing for the SC"/>
   <result pre="for the SC regimen administrated via handheld syringe. Methods Serum" exact="trastuzumab" post="concentrations from 595 patients with HER2-positive EBC in the"/>
   <result pre="HER2-positive EBC in the HannaH study (fixed 600 mg SC" exact="trastuzumab" post="or weight-based IV trastuzumab) were analyzed using nonlinear mixed-effects"/>
   <result pre="either regimen. Conclusion A fixed 600 mg SC dose of" exact="trastuzumab" post="provides the desired exposure, with steady-state trough concentrations (35–123"/>
   <result pre="metastatic breast cancer (MBC) (as monotherapy or in combination with" exact="pertuzumab" post="plus docetaxel, or with lapatinib, paclitaxel, docetaxel, or an"/>
   <result pre="aromatase inhibitor), and HER2-positive metastatic gastric cancer (in combination with" exact="capecitabine" post="or 5-fluorouracil and cisplatin) [ 3, 4]. The approved"/>
   <result pre="min without IV access, thereby increasing the overall convenience of" exact="trastuzumab" post="administration [ 5]. A 600 mg fixed SC dose"/>
   <result pre="and Uruguay) [ 4, 6]. This administration contains recombinant human" exact="hyaluronidase" post="(rHuPH20), which temporarily degrades hyaluronan at the injection site"/>
   <result pre="mL dosing volume [ 7]. The pharmacokinetics (PKs) of IV" exact="trastuzumab" post="were previously characterized in patients with HER2-positive MBC using"/>
   <result pre="linear clearance (CL) was sufficient to describe the PK of" exact="trastuzumab" post="[ 8, 9]. Body weight was an important covariate,"/>
   <result pre="dose for the HannaH study, a PopPK model for SC" exact="trastuzumab" post="was developed based on a phase I study (NCT00800436),"/>
   <result pre="HER2-positive EBC receiving single, weight-adjusted doses of SC and/or IV" exact="trastuzumab" post="[ 5]. A PopPK model consisting of a two-compartment"/>
   <result pre="the neoadjuvant–adjuvant setting, conducted to establish noninferiority of fixed-dose SC" exact="trastuzumab" post="with the approved weight-based IV q3w regimen [ 13]."/>
   <result pre="1:1 to receive eight cycles of neoadjuvant chemotherapy and concurrent" exact="trastuzumab" post="q3w, administered either IV (8 mg/kg loading dose, 6"/>
   <result pre="or SC (600 mg fixed dose). Following surgery, patients continued" exact="trastuzumab" post="q3w to complete 1 year of adjuvant therapy. C"/>
   <result pre="margin of −12.5 %. Thus, noninferiority of SC versus IV" exact="trastuzumab" post="was demonstrated for both endpoints. We present results from"/>
   <result pre="of this analysis were (1) to characterize the PopPK of" exact="trastuzumab" post="in the SC &quot;manual syringe&quot; injection and IV administrations,"/>
   <result pre="administrations, (2) to assess the effect of patient characteristics on" exact="trastuzumab" post="PK, (3) to explore the exposure–response relationship between PK,"/>
   <result pre="loading dose, 6 mg/kg IV maintenance dose; n = 298)" exact="trastuzumab" post="(Herceptin ®, F. Hoffmann-La Roche, Basel, Switzerland) q3w, for"/>
   <result pre="chemotherapy during the first eight presurgery cycles (neoadjuvant phase) and" exact="trastuzumab" post="monotherapy for the remaining ten post-surgery cycles (adjuvant phase)."/>
   <result pre="monotherapy for the remaining ten post-surgery cycles (adjuvant phase). SC" exact="trastuzumab" post="was injected with a manual handheld syringe over 5"/>
   <result pre="injected with a manual handheld syringe over 5 min; IV" exact="trastuzumab" post="was administered as an initial 90-min infusion with subsequent"/>
   <result pre="PK data included in the analysis Blood samples for serum" exact="trastuzumab" post="concentration were collected at peak (post-infusion) and trough (preinfusion)"/>
   <result pre="Terminology Criteria for Adverse Events (NCI-CTCAE V3.0) [ 15]. Serum" exact="trastuzumab" post="concentration assays Serum trastuzumab concentrations were determined using a"/>
   <result pre="Events (NCI-CTCAE V3.0) [ 15]. Serum trastuzumab concentration assays Serum" exact="trastuzumab" post="concentrations were determined using a validated receptor binding, enzyme-linked"/>
   <result pre="if they had at least one adequately documented dose of" exact="trastuzumab" post="and a corresponding PK sample. Records were excluded if"/>
   <result pre="selected based on potential clinical relevance and previous experience with" exact="trastuzumab" post="and other monoclonal antibodies. For CL, these were: patient"/>
   <result pre="patients, 595 of whom received at least one dose of" exact="trastuzumab" post="(297 patients in the SC arm and 298 patients"/>
   <result pre="dataset for PK model development contained 592 patients and 15,761" exact="trastuzumab" post="serum PK samples. A final sensitivity analysis, where all"/>
   <result pre="was modeled as a first-order process. PK parameter estimates for" exact="trastuzumab" post="(Table 1) were well defined (RSE &amp;lt; 39 %),"/>
   <result pre="residual error model. Table 1 Final population pharmacokinetic parameters for" exact="trastuzumab" post="Parameter Population estimate (% RSE) Between-subject variability (CV %)"/>
   <result pre="5). There was an acceptable level of shrinkage for all" exact="trastuzumab" post="PK parameters: 11.5 % for CL, 22.3 % for"/>
   <result pre="checks suggested that the model adequately describes the distribution of" exact="trastuzumab" post="PK concentrations. Fig. 1 Simulated and observed concentrations with"/>
   <result pre="( bottom) regimens. IV, intravenous; SC, subcutaneous. Circles are observed" exact="trastuzumab" post="serum concentrations; solid lines represent the median observed values;"/>
   <result pre="at low concentrations. Impact of patient characteristics and pathophysiology on" exact="trastuzumab" post="PK CL patient characteristics included: patient demographics (age, baseline"/>
   <result pre="analysis was performed to examine the influence of covariates on" exact="trastuzumab" post="exposure ( C min,ss and AUC ss) with the"/>
   <result pre="disease status (neoadjuvant vs. adjuvant) had statistically significant effects on" exact="trastuzumab" post="PK. Impact of body weight on exposure with SC"/>
   <result pre="Weight-adjusted dosing overcompensates for the effect of body weight on" exact="trastuzumab" post="PK and results in greater exposure in heavier patients."/>
   <result pre="xenograft efficacy models Impact of regimen on PK Typical predicted" exact="trastuzumab" post="concentration–time profiles were compared for three regimens: IV (8"/>
   <result pre="state (cycle 7, right panel), the SC regimen produced greater" exact="trastuzumab" post="concentrations than the IV regimens during the majority of"/>
   <result pre="≥3 AE) by body weight and exposure quartiles pCR IV" exact="trastuzumab" post="n = 263 SC trastuzumab n = 260 Patients"/>
   <result pre="and exposure quartiles pCR IV trastuzumab n = 263 SC" exact="trastuzumab" post="n = 260 Patients in subgroup ( n) Responders"/>
   <result pre="Missing 3 1 (33) 0 0 Grade ≥3 AEs IV" exact="trastuzumab" post="n = 298 SC trastuzumab n = 297 Patients"/>
   <result pre="0 Grade ≥3 AEs IV trastuzumab n = 298 SC" exact="trastuzumab" post="n = 297 Patients in subgroup ( n) Patients"/>
   <result pre="was evaluated in 595 female patients with HER2-positive EBC receiving" exact="trastuzumab" post="in the neoadjuvant and adjuvant settings in the phase"/>
   <result pre="using a population modeling approach. In addition, the relationship between" exact="trastuzumab" post="exposure, efficacy (pCR), and safety (grade ≥3 AEs) during"/>
   <result pre="analysis showing lack of a distinct relationship between C min,ss," exact="trastuzumab" post="regimen and route of administration, or body weight and"/>
   <result pre="of administration, or body weight and pCR or AUC ss," exact="trastuzumab" post="regimen and route of administration, or body weight with"/>
   <result pre="grade ≥3 AEs. In this PopPK analysis, SC and IV" exact="trastuzumab" post="serum concentration–time data were pooled together and described by"/>
   <result pre="[ 11]. As a result of the nonlinear elimination pathway," exact="trastuzumab" post="elimination is faster and the half-life shorter at low"/>
   <result pre="respectively. These values are comparable to those seen previously, where" exact="trastuzumab" post="PK of weekly IV administration was described using a"/>
   <result pre="impact of demographic and pathophysiological covariates on the PK of" exact="trastuzumab" post="was investigated. Baseline body weight and ALT were identified"/>
   <result pre="were identified as covariates that had statistically significant effects on" exact="trastuzumab" post="PK ( p &amp;lt; 0.001). Body weight was shown"/>
   <result pre="effect is consistent with the previously reported covariate relationships for" exact="trastuzumab" post="in patients with MBC [ 8]. Of note, higher"/>
   <result pre="analyses assessed the impact of body weight and ALT on" exact="trastuzumab" post="exposure and showed that while body weight had a"/>
   <result pre="showed that while body weight had a modest effect on" exact="trastuzumab" post="exposure, ALT had a minimal effect. In addition, body"/>
   <result pre="in linear CL. Although body weight had an impact on" exact="trastuzumab" post="exposure in the sensitivity analysis, the clinical trial simulations"/>
   <result pre="ATAs and AHAs) did not exhibit statistically significant effects on" exact="trastuzumab" post="PK. However, due to the low numbers of ADA-positive"/>
   <result pre="with HER2-positive EBC, a fixed dose of 600 mg SC" exact="trastuzumab" post="q3w provides the desired PK exposure, with steady-state trough"/>
   <result pre="the assessed patient covariates, including body weight, do not influence" exact="trastuzumab" post="PK to a magnitude that would require a dose"/>
   <result pre="of either body weight, exposure, or route of administration. Similar" exact="trastuzumab" post="exposure is expected in patients with MBC and supports"/>
   <result pre="Fox JA Nonclinical studies addressing the mechanism of action of" exact="trastuzumab" post="(Herceptin) Semin Oncol 1999 26 60 70 10482195 2."/>
   <result pre="JF Lieberman G Banken L Klein P Population pharmacokinetics of" exact="trastuzumab" post="in patients with HER2+ metastatic breast cancer Cancer Chemother"/>
   <result pre="L, Lennon S, Jorga K (2004) Population pharmacokinetic analysis of" exact="trastuzumab" post="(Herceptin) following long-term administration using different regimens. Population Approach"/>
   <result pre="for the clinical development of a fixed-dose subcutaneous formulation of" exact="trastuzumab" post="CPT: Pharmacometrics Syst Pharmacol 2014 3 e87 25019376 11."/>
   <result pre="Melichar B Jackisch C Subcutaneous versus intravenous administration of (neo)adjuvant" exact="trastuzumab" post="in patients with HER2-positive, clinical stage I-III breast cancer"/>
   <result pre="R Weber HA Ismael G Subcutaneous versus intravenous formulation of" exact="trastuzumab" post="for HER2-positive early breast cancer: updated results from the"/>
   <result pre="R Davis HM Serum albumin concentration: a predictive factor of" exact="infliximab" post="pharmacokinetics and clinical response in patients with ulcerative colitis"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4707213/results/search/inn/results.xml">
   <result pre="such as third-generation aromatase inhibitors; and target therapies such as" exact="trastuzumab" post="and lapatinib have exhibited greater treatment efficacy and yielded"/>
   <result pre="third-generation aromatase inhibitors; and target therapies such as trastuzumab and" exact="lapatinib" post="have exhibited greater treatment efficacy and yielded improved OS"/>
   <result pre="available for 48 patients; none of the HER2-positive patients received" exact="trastuzumab" post="therapy. All patients had bone metastasis (BM) and seven"/>
   <result pre="period in which EOMBC was diagnosed in the sample group," exact="trastuzumab" post="was not covered by the national health insurance program"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4708008/results/search/inn/results.xml">
   <result pre="treatment [ 31]. However, treatments that specifically target HER2 exist:" exact="trastuzumab" post="(herceptin) and lapatinib (tykerb). Trastuzumab binds to domain IV"/>
   <result pre="However, treatments that specifically target HER2 exist: trastuzumab (herceptin) and" exact="lapatinib" post="(tykerb). Trastuzumab binds to domain IV of the extracellular"/>
   <result pre="purchased from Sigma Chemical Co. These compounds were dissolved in" exact="dimethyl sulfoxide" post="(DMSO) and the final concentration of DMSO in the"/>
   <result pre="in RPMI 1640 medium containing 50 U/ml penicillin, 50 mg/ml" exact="streptomycin" post="and 10% foetal bovine serum (FBS; Welgene) at 37°C"/>
   <result pre="(1500 g ), the cells were fixed in cold 95%" exact="ethanol" post="with 0.5% Tween-20, and stored at -20°C for at"/>
   <result pre="1296 1298 15919761 57 Tolaney S.M. Krop I.E. Mechanisms of" exact="trastuzumab" post="resistance in breast cancer Anticancer Agents Med. Chem. 2009"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4708174/results/search/inn/results.xml">
   <result pre="for many years. Indeed, the Novartis mTOR complex 1 inhibitor" exact="everolimus" post="is now approved for several indications, demonstrating the potential"/>
   <result pre="setting. Hormone receptor-positive breast cancer The Phase III trial of" exact="everolimus" post="in combination with exemestane in ER-positive, HER2-negative advanced breast"/>
   <result pre="cancer The Phase III trial of everolimus in combination with" exact="exemestane" post="in ER-positive, HER2-negative advanced breast cancer (BOLERO-2; NCT00863655) demonstrated"/>
   <result pre="a recent Phase IB study of buparlisib in combination with" exact="letrozole" post="(a nonsteroidal aromatase inhibitor) has demonstrated the feasibility of"/>
   <result pre="has demonstrated the feasibility of combining a PI3K inhibitor with" exact="letrozole" post="in patients with ER-positive, HER2-negative metastatic breast cancer refractory"/>
   <result pre="In the pivotal Phase III BELLE-2 study of buparlisib and" exact="fulvestrant" post="(a selective ER downregulator) in patients with HR-positive, HER2-negative"/>
   <result pre="mid-2015. Preclinical data have demonstrated that buparlisib in combination with" exact="fulvestrant" post="can reverse resistance to mTOR inhibitors and/or fulvestrant (Novartis"/>
   <result pre="combination with fulvestrant can reverse resistance to mTOR inhibitors and/or" exact="fulvestrant" post="(Novartis data on file). Therefore, the Phase III BELLE-3"/>
   <result pre="file). Therefore, the Phase III BELLE-3 study of buparlisib and" exact="fulvestrant" post="is not using molecular preselection for enrollment, but mandates"/>
   <result pre="with PIK3CA alterations, and a subsequent study in combination with" exact="fulvestrant" post="in ER-positive metastatic breast cancer ( PIK3CA-altered and PIK3CA"/>
   <result pre="activity in PIK3CA-altered tumors treated with alpelisib alone or with" exact="fulvestrant" post="has been observed. 15, 16 Further analyses will reveal"/>
   <result pre="wild-type tumors are equally sensitive. The combination of alpelisib and" exact="fulvestrant" post="is being investigated in a Phase III trial in"/>
   <result pre="stratified based on PIK3CA mutation status, and randomized to receive" exact="fulvestrant" post="in combination with either alpelisib or placebo. Phase I"/>
   <result pre="placebo. Phase I studies are investigating alpelisib in combination with" exact="letrozole" post="or exemestane in HR-positive, locally advanced, and/or metastatic breast"/>
   <result pre="I studies are investigating alpelisib in combination with letrozole or" exact="exemestane" post="in HR-positive, locally advanced, and/or metastatic breast cancer (NCT01791478,"/>
   <result pre="of response. Phase I studies are also evaluating alpelisib plus" exact="paclitaxel" post="in locally advanced or metastatic, chemotherapy-naïve, HER2-negative breast cancer"/>
   <result pre="as well as the triplet combination of alpelisib, everolimus, and" exact="exemestane" post="in advanced breast cancer (NCT02077933). Enrollment for both studies"/>
   <result pre="determination of PI3K pathway activation status. A neoadjuvant study of" exact="letrozole" post="with or without buparlisib or alpelisib in HR-positive, HER2-negative"/>
   <result pre="HER2-positive breast cancer. 9 The Phase III trial of combined" exact="trastuzumab" post="and paclitaxel treatment with or without everolimus in HER2-positive"/>
   <result pre="cancer. 9 The Phase III trial of combined trastuzumab and" exact="paclitaxel" post="treatment with or without everolimus in HER2-positive advanced breast"/>
   <result pre="trial of combined trastuzumab and paclitaxel treatment with or without" exact="everolimus" post="in HER2-positive advanced breast cancer (BOLERO-1; NCT00876395), showed no"/>
   <result pre="of PI3K inhibitors in this indication. 17 Meanwhile, addition of" exact="everolimus" post="to trastuzumab and vinorelbine in women with HER2-positive metastatic"/>
   <result pre="inhibitors in this indication. 17 Meanwhile, addition of everolimus to" exact="trastuzumab" post="and vinorelbine in women with HER2-positive metastatic breast cancer"/>
   <result pre="this indication. 17 Meanwhile, addition of everolimus to trastuzumab and" exact="vinorelbine" post="in women with HER2-positive metastatic breast cancer in the"/>
   <result pre="patient population. 18 The CLEOPATRA study of pertuzumab, trastuzumab, and" exact="docetaxel" post="in first-line metastatic breast cancer (NCT00567190) established PIK3CA mutation"/>
   <result pre="a Phase II study of neoadjuvant buparlisib in combination with" exact="trastuzumab" post="and paclitaxel in HER2-positive breast cancer with or without"/>
   <result pre="II study of neoadjuvant buparlisib in combination with trastuzumab and" exact="paclitaxel" post="in HER2-positive breast cancer with or without PIK3CA mutations"/>
   <result pre="PI3K inhibitor. A Phase IB/II study has investigated buparlisib and" exact="trastuzumab" post="in relapsed HER2-positive breast cancer that has previously failed"/>
   <result pre="In the Phase IB part of the study, buparlisib and" exact="trastuzumab" post="were well tolerated, and preliminary signs of clinical activity"/>
   <result pre="and further analyses will assess the ability of buparlisib and" exact="trastuzumab" post="combinations to overcome trastuzumab resistance in patients with PIK3CA-activated"/>
   <result pre="assess the ability of buparlisib and trastuzumab combinations to overcome" exact="trastuzumab" post="resistance in patients with PIK3CA-activated and wild-type tumors. Buparlisib"/>
   <result pre="patients with PIK3CA-activated and wild-type tumors. Buparlisib in combination with" exact="lapatinib" post="is also being studied in a Phase IB/II trial"/>
   <result pre="IB/II trial in HER2-positive breast cancer that has failed following" exact="trastuzumab" post="therapy, again using the selective enrollment/target enrichment approach (NCT01589861)."/>
   <result pre="to be independent of PIK3CA mutation status. 23 Alpelisib and" exact="cetuximab" post="have demonstrated synergistic activity in HNSCC cell lines independently"/>
   <result pre="panel. PIK3CA amplifications and mutations are associated with resistance to" exact="cetuximab" post="therapy. 25 Therefore, a Phase II study is assessing"/>
   <result pre="Phase II randomized study is exploring buparlisib in combination with" exact="paclitaxel" post="(BERIL-1; NCT01852292); a Phase IB/II study is investigating alpelisib"/>
   <result pre="a Phase IB/II study is investigating alpelisib in combination with" exact="cetuximab" post="(NCT01602315); and a Phase I study of alpelisib with"/>
   <result pre="cetuximab (NCT01602315); and a Phase I study of alpelisib with" exact="paclitaxel" post="is also ongoing (NCT02051751). Early results from the study"/>
   <result pre="Early results from the study of alpelisib in combination with" exact="cetuximab" post="have demonstrated promising preliminary antitumor activity in patients with"/>
   <result pre="combinations. As such, buparlisib is being studied in combination with" exact="docetaxel" post="in second-line metastatic squamous NSCLC (NCT01911325), with provision of"/>
   <result pre="Preliminary results of a Phase IB study of buparlisib and" exact="gefitinib" post="demonstrated potential antitumor activity in EGFR TKI-resistant NSCLC (NCT01570296)."/>
   <result pre="be employed in a Phase II study of buparlisib and" exact="erlotinib" post="in advanced NSCLC that was previously sensitive to erlotinib"/>
   <result pre="and erlotinib in advanced NSCLC that was previously sensitive to" exact="erlotinib" post="(NCT01487265). Exploratory biomarker analyses will examine interactions between the"/>
   <result pre="Furthermore, synergistic activity was observed with buparlisib in combination with" exact="temozolomide" post="in PTEN-null GBM mouse xenografts. 3 Single-agent buparlisib has"/>
   <result pre="of the Phase IB/II studies of buparlisib in combination with" exact="carboplatin" post="or lomustine (NCT01934361) or with bevacizumab (NCT01349660) in patients"/>
   <result pre="Phase IB/II studies of buparlisib in combination with carboplatin or" exact="lomustine" post="(NCT01934361) or with bevacizumab (NCT01349660) in patients with recurrent"/>
   <result pre="buparlisib in combination with carboplatin or lomustine (NCT01934361) or with" exact="bevacizumab" post="(NCT01349660) in patients with recurrent GBM that has relapsed"/>
   <result pre="a Phase I trial of buparlisib with radiation therapy and" exact="temozolomide" post="in newly diagnosed GBM (NCT01473901). Archival tumor biopsies will"/>
   <result pre="H et al. Correlation of molecular alterations with efficacy of" exact="everolimus" post="in hormone receptor-positive, HER2-negative advanced breast cancer: results from"/>
   <result pre="to cancer phase IB study of pan-phosphoinositide-3-kinase inhibitor buparlisib with" exact="letrozole" post="in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic"/>
   <result pre="Hurvitz SA André F Jiang Z et al. Combination of" exact="everolimus" post="with trastuzumab plus paclitaxel as first-line treatment for patients"/>
   <result pre="André F Jiang Z et al. Combination of everolimus with" exact="trastuzumab" post="plus paclitaxel as first-line treatment for patients with HER2-positive"/>
   <result pre="Jiang Z et al. Combination of everolimus with trastuzumab plus" exact="paclitaxel" post="as first-line treatment for patients with HER2-positive advanced breast"/>
   <result pre="DJ Hurvitz SA Chen D et al. Predictive biomarkers of" exact="everolimus" post="efficacy in HER2+ advanced breast cancer: combined exploratory analysis"/>
   <result pre="Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of" exact="pertuzumab" post="in HER2-positive, first-line metastatic breast cancer (MBC) Poster presented"/>
   <result pre="Jerusalem G et al. Phase IB study of buparlisib plus" exact="trastuzumab" post="in patients with HER2-positive advanced or metastatic breast cancer"/>
   <result pre="lB/ll study of the PI3Kα inhibitor BYL719 in combination with" exact="cetuximab" post="in recurrent/metastatic squamous cell cancer of the head and"/>
   <result pre="I Sexton E Leblanc K Asselin E AKT involvement in" exact="cisplatin" post="chemoresistance of human uterine cancer cells Gynecol Oncol 2004"/>
   <result pre="pathway by PTEN reduction and PIK3CA mRNA amplification contributes to" exact="cisplatin" post="resistance in an ovarian cancer cell line Gynecol Oncol"/>
   <result pre="of a pan class I PI3K inhibitor buparlisib (BKM120) and" exact="gefitinib" post="(gef) in EGFR TKI-resistant NSCLC J Clin Oncol 2013"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4709394/results/search/inn/results.xml">
   <result pre="during pregnancy is necessary, the least harmful platinum preparation is" exact="cisplatin" post="(carboplatin is more toxic to the bones), while among"/>
   <result pre="(carboplatin is more toxic to the bones), while among anthracyclines," exact="doxorubicin" post="is recommended. The use of epirubicin and liposomal forms"/>
   <result pre="bones), while among anthracyclines, doxorubicin is recommended. The use of" exact="epirubicin" post="and liposomal forms of anthracyclines is more dangerous because"/>
   <result pre="The main risks to the foetus Plant alkaloids: vincristine, vinblastine," exact="vinorelbine" post="Preterm delivery, intrauterine growth restriction (IUGR) [ 67]. Defect"/>
   <result pre="68]. Anthracycline antibiotics: doxorubicin, daunorubicin, adriamycin, idarubicin, epirubicin, dactinomycine, bleomycin," exact="mitoxantrone" post="Mid-trimester miscarriage, transient neonatal neutropenia, and sepsis, IUGR ["/>
   <result pre="syndactyly, deficient growth and development [ 75– 77]. Cisplatin and" exact="carboplatin" post="Sensorineural hearing loss, respiratory distress syndrome [ 10, 78]."/>
   <result pre="of pregnancy (e.g. 4–6 cycles of AC or FAC regimens:" exact="doxorubicin" post="and cyclophosphamide or doxorubicin, cyclophosphamide, and fluorouracil). The risk"/>
   <result pre="(e.g. 4–6 cycles of AC or FAC regimens: doxorubicin and" exact="cyclophosphamide" post="or doxorubicin, cyclophosphamide, and fluorouracil). The risk for the"/>
   <result pre="pregnancy, and additionally because of the high teratogenic potential of" exact="tamoxifen" post="[ 31]. In women with locally advanced or metastatic"/>
   <result pre="overexpression of HER2, after failure of at least one chemotherapy," exact="lapatinib" post="(a small-molecule tyrosine kinase inhibitor of EGFR) can be"/>
   <result pre="Cancer Network) Clinical Practice Guidelines in Oncology, the use of" exact="trastuzumab" post="is contraindicated in pregnancy. In the literature on the"/>
   <result pre="contraindicated in pregnancy. In the literature on the use of" exact="trastuzumab" post="in pregnant women, few cases have been described. Treatment"/>
   <result pre="in pregnant women, few cases have been described. Treatment with" exact="trastuzumab" post="is associated with oligohydramnios (sometimes severe), lung aplasia, dysplastic"/>
   <result pre="patients treated with radiation therapy. However, in patients treated with" exact="cisplatin" post="alone administered once a week, the course of pregnancy"/>
   <result pre="non-pregnant women, the treatment of choice for preoperative chemotherapy is" exact="carboplatin" post="+ paclitaxel until foetal maturity [ 57, 58]. Colorectal"/>
   <result pre="the treatment of choice for preoperative chemotherapy is carboplatin +" exact="paclitaxel" post="until foetal maturity [ 57, 58]. Colorectal cancer Colorectal"/>
   <result pre="the first trimester of pregnancy [ 65]. The use of" exact="tropisetron" post="is discouraged: studies have shown teratogenic effects in animals."/>
   <result pre="discouraged: studies have shown teratogenic effects in animals. Granisetron and" exact="palonosetron" post="are rarely used in pregnancy. Analgesics (paracetamol, opioids, anti-inflammatory"/>
   <result pre="depression and foetal ductus arteriosus closure [ 66]. Bisphosphonates and" exact="somatostatin" post="should be postponed until after the delivery due to"/>
   <result pre="Elledge RM Ciocca DR Langone G McGuire WL Estrogen receptor," exact="progesterone" post="receptor, and HER2/neu protein in breast cancer from pregnant"/>
   <result pre="Delivery of a healthy baby after first-trimester maternal exposure to" exact="lapatinib" post="Clin Breast Cancer 2006 7 339 41 17092403 31"/>
   <result pre="8 16681782 41 Karam A Feldman N Holschneider CH Neoadjuvant" exact="cisplatin" post="and radical cesarean hysterectomy for cervical cancer in pregnancy"/>
   <result pre="Méndez LE Mueller A Salom E González-Quintero VH Paclitaxel and" exact="carboplatin" post="chemotherapy administered during pregnancy for advanced epithelial ovarian cancer"/>
   <result pre="SJ Reynolds JW Intrauterine growth retardation following third-trimester exposure to" exact="busulfan" post="Am J Obstet Gynecol 1977 129 111 2 268937"/>
   <result pre="J Foulon W Specific congenital malformations after exposure to cyclophosphamide," exact="epirubicin" post="and 5-fluorouracil during the first trimester of pregnancy Gynecol"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4717619/results/search/inn/results.xml">
   <result pre="as the first metastatic site were negative for estrogen and" exact="progesterone" post="receptor but frequently expressed CK5, nestin, and prominin-1 (CD133)."/>
   <result pre="thus no global consensus regarding the ideal treatment strategy. Although" exact="trastuzumab" post="is effective for treating HER2-positive breast cancer, it is"/>
   <result pre="in the brain. A study by Stemmler et al. examined" exact="trastuzumab" post="levels in serum and cerebrospinal fluid. Prior to radiotherapy,"/>
   <result pre="cerebrospinal fluid. Prior to radiotherapy, the median serum versus cerebrospinal" exact="trastuzumab" post="level ratio was 420:1. After the completion of radiotherapy,"/>
   <result pre="incidence of BM was reported in HER2-positive patients treated with" exact="trastuzumab" post="[ 22]. Data analysis showed that the enhanced risk"/>
   <result pre="Data analysis showed that the enhanced risk of BM after" exact="trastuzumab" post="treatment was due to an improved systemic control of"/>
   <result pre="an improved systemic control of the disease. The continuation of" exact="trastuzumab" post="treatment in patients with BM is beneficial; however, it"/>
   <result pre="the BBB. In findings from a mouse model, the average" exact="lapatinib" post="concentration in BM was only 10–20 % of that"/>
   <result pre="in a subset of brain lesions (17 %) did the" exact="lapatinib" post="concentration approach that of systemic metastases [ 23]. In"/>
   <result pre="23]. In HER2-positive breast cancer patients who progressed after WBRT," exact="lapatinib" post="monotherapy showed minor activity as a single agent ["/>
   <result pre="patients, only one partial response was observed. In another study," exact="lapatinib" post="monotherapy showed a response of 6 % [ 25]."/>
   <result pre="response of 6 % [ 25]. Interestingly, the addition of" exact="capecitabine" post="increased the response rates to 20 %. In the"/>
   <result pre="%. In the LANDSCAPE trial [ 25], the combination of" exact="lapatinib" post="and capecitabine administered prior to WBRT in newly diagnosed"/>
   <result pre="the LANDSCAPE trial [ 25], the combination of lapatinib and" exact="capecitabine" post="administered prior to WBRT in newly diagnosed HER2-positive BM"/>
   <result pre="%. A study in patients with resected BM found that" exact="capecitabine" post="and lapatinib penetrate to a significant although variable degree"/>
   <result pre="study in patients with resected BM found that capecitabine and" exact="lapatinib" post="penetrate to a significant although variable degree into the"/>
   <result pre="27]. These data do not support a better activity for" exact="lapatinib" post="compared with trastuzumab in the prevention of BM. Despite"/>
   <result pre="do not support a better activity for lapatinib compared with" exact="trastuzumab" post="in the prevention of BM. Despite these reports suggesting"/>
   <result pre="30], T-DM1 was associated with significantly improved OS compared with" exact="lapatinib" post="and capecitabine in patients with asymptomatic BM at baseline."/>
   <result pre="was associated with significantly improved OS compared with lapatinib and" exact="capecitabine" post="in patients with asymptomatic BM at baseline. The efficacy"/>
   <result pre="in patients with asymptomatic BM at baseline. The efficacy of" exact="bevacizumab" post="(a vascular endothelial growth factor (VEGF) antibody) in combination"/>
   <result pre="(37.1 %) [ 31]. Additionally, the combination of WBRT and" exact="bevacizumab" post="without chemotherapy showed some efficacy in a phase I"/>
   <result pre="of lesions with the highest permeability exhibited cytotoxic responses to" exact="paclitaxel" post="or doxorubicin [ 66]. Unfortunately, few approaches have been"/>
   <result pre="with the highest permeability exhibited cytotoxic responses to paclitaxel or" exact="doxorubicin" post="[ 66]. Unfortunately, few approaches have been attempted to"/>
   <result pre="cocultured with astrocytes, the tumor cells become more resistant to" exact="cisplatin" post="treatment. The protective function of astrocytes is dependent on"/>
   <result pre="brain metastases among patients with advanced breast cancer treated with" exact="trastuzumab" post="Acta Oncol 2006 45 196 201 10.1080/02841860500486630 16546866 5."/>
   <result pre="N et al. Management of patients with brain metastases receiving" exact="trastuzumab" post="treatment for metastatic breast cancer Onkologie 2011 34 304"/>
   <result pre="Willems A Bernhard H Harbeck N Heinemann V Ratio of" exact="trastuzumab" post="levels in serum and cerebrospinal fluid is altered in"/>
   <result pre="recurrence in patients with HER2-positive breast cancer treated with adjuvant" exact="trastuzumab" post="Ann Oncol 2013 24 1526 33 10.1093/annonc/mdt036 23463626 23."/>
   <result pre="Dieras V Cropet C Dalenc F et al. Lapatinib plus" exact="capecitabine" post="in patients with previously untreated brain metastases from HER2-positive"/>
   <result pre="Samala R Balyan R Murphy CG et al. Capecitabine and" exact="lapatinib" post="uptake in surgically resected brain metastases from metastatic breast"/>
   <result pre="al. CEREBEL (EGF111438): a phase III, randomized, open-label study of" exact="lapatinib" post="plus capecitabine versus trastuzumab plus capecitabine in patients with"/>
   <result pre="(EGF111438): a phase III, randomized, open-label study of lapatinib plus" exact="capecitabine" post="versus trastuzumab plus capecitabine in patients with human epidermal"/>
   <result pre="phase III, randomized, open-label study of lapatinib plus capecitabine versus" exact="trastuzumab" post="plus capecitabine in patients with human epidermal growth factor"/>
   <result pre="randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus" exact="capecitabine" post="in patients with human epidermal growth factor receptor 2-positive"/>
   <result pre="Huober J Lu M et al. Trastuzumab emtansine (T-DM1) versus" exact="lapatinib" post="plus capecitabine in patients with HER2-positive metastatic breast cancer"/>
   <result pre="Lu M et al. Trastuzumab emtansine (T-DM1) versus lapatinib plus" exact="capecitabine" post="in patients with HER2-positive metastatic breast cancer and central"/>
   <result pre="Campone M et al. REBECA: a phase I study of" exact="bevacizumab" post="and whole-brain radiation therapy for the treatment of brain"/>
   <result pre="Tseng LM Wu PF et al. Bevacizumab preconditioning followed by" exact="etoposide" post="and cisplatin is highly effective in treating brain metastases"/>
   <result pre="Wu PF et al. Bevacizumab preconditioning followed by etoposide and" exact="cisplatin" post="is highly effective in treating brain metastases of breast"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4717845/results/search/inn/results.xml">
   <result pre="Wan et al., 2004). Drugs that inhibit V600EBRAF, such as" exact="vemurafenib" post="and dabrafenib, or drugs that inhibit MEK such as"/>
   <result pre="vemurafenib and dabrafenib, or drugs that inhibit MEK such as" exact="trametinib" post="and cobimetinib can extend overall survival in melanoma patients"/>
   <result pre="dabrafenib, or drugs that inhibit MEK such as trametinib and" exact="cobimetinib" post="can extend overall survival in melanoma patients whose tumors"/>
   <result pre="samples from patients corresponding to tumor tissue before and after" exact="vemurafenib" post="treatment were analyzed. Samples were scored blind and a"/>
   <result pre="and incubated with various dilutions of PLX4720, BPTES, phenformin, buformin," exact="metformin" post="or 2DG for 72 h. Cell viability was determined"/>
   <result pre="than the parental cells to the biguanide mitochondrial poisons phenformin," exact="metformin" post="and buformin ( Supplemental Figure 1B). Thus BRAF inhibitor"/>
   <result pre="parental cells to the biguanide mitochondrial poisons phenformin, metformin and" exact="buformin" post="( Supplemental Figure 1B). Thus BRAF inhibitor resistant cells"/>
   <result pre="increased in melanomas from 7 patients who presented resistance to" exact="vemurafenib" post="(p = 0.03; Figure 1G, Supplemental Figure 2C), demonstrating"/>
   <result pre="demonstrating that PLX4720-resistant melanoma cell lines are more sensitive to" exact="metformin" post="and phenformin ( Yuan et al., 2013), our data"/>
   <result pre="PLX4720-resistant melanoma cell lines are more sensitive to metformin and" exact="phenformin" post="( Yuan et al., 2013), our data suggests that"/>
   <result pre="Ribas A. Survival in BRAF V600-mutant advanced melanoma treated with" exact="vemurafenib" post="N. Engl. J. Med. 366 2012 707 714 22356324"/>
   <result pre="O. Chen J. Wu Y. Price J.E. Tan M. Overcoming" exact="trastuzumab" post="resistance in breast cancer by targeting dysregulated glucose metabolism"/>
   <result pre="7 paired samples from patients before and after emergence of" exact="vemurafenib" post="resistance; *p &amp;lt; 0.05, and test (Wilcoxon Signed-Rank Test)."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4718910/results/search/inn/results.xml">
   <result pre="study of afatinib, an irreversible ErbB family blocker, added to" exact="letrozole" post="in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer"/>
   <result pre="patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on" exact="letrozole" post="Gunzer Katharina +33-231455002 k.gunzer@baclesse.unicancer.fr Joly Florence f.joly@baclesse.unicancer.fr Ferrero Jean-Marc"/>
   <result pre="assessing the efficacy and safety of the ErbB family blocker" exact="afatinib" post="combined with letrozole in estrogen receptor-positive metastatic breast cancer"/>
   <result pre="and safety of the ErbB family blocker afatinib combined with" exact="letrozole" post="in estrogen receptor-positive metastatic breast cancer (MBC) patients who"/>
   <result pre="receptor-positive metastatic breast cancer (MBC) patients who had progressed on" exact="letrozole" post="monotherapy. Adult females ( N = 28) received oral"/>
   <result pre="letrozole monotherapy. Adult females ( N = 28) received oral" exact="afatinib" post="(50 [ n = 7], 40 [ n ="/>
   <result pre="= 13] or 30 [ n = 8] mg/day) plus" exact="letrozole" post="2.5 mg/day in 28-day cycles until disease progression. Primary"/>
   <result pre="weeks of afatinib. At 16 weeks, four patients remained on" exact="afatinib" post="without progression; two of these were HER2 negative. Fifteen"/>
   <result pre="the most frequent adverse events. In this small, exploratory study," exact="afatinib" post="combined with letrozole was able to induce disease stabilization"/>
   <result pre="adverse events. In this small, exploratory study, afatinib combined with" exact="letrozole" post="was able to induce disease stabilization in 54 %"/>
   <result pre="patients with advanced solid tumors recommended a continuous dose of" exact="afatinib" post="50 mg once daily for the phase II setting"/>
   <result pre="with HER2-positive metastatic breast cancer (MBC) who had progressed following" exact="trastuzumab" post="treatment, with a median PFS of 15 weeks and"/>
   <result pre="et al. 2010). To further investigate the potential activity of" exact="afatinib" post="in MBC, we undertook a phase II exploratory study"/>
   <result pre="exploratory study to assess the efficacy, safety and pharmacokinetics of" exact="afatinib" post="in combination with letrozole in patients with ER-positive MBC"/>
   <result pre="the efficacy, safety and pharmacokinetics of afatinib in combination with" exact="letrozole" post="in patients with ER-positive MBC who had progressed on"/>
   <result pre="letrozole in patients with ER-positive MBC who had progressed on" exact="letrozole" post="monotherapy. Patients and methods Study design This was a"/>
   <result pre="This was a phase II, open-label, single-arm, multicenter trial of" exact="afatinib" post="added to letrozole in patients with ER-positive MBC who"/>
   <result pre="phase II, open-label, single-arm, multicenter trial of afatinib added to" exact="letrozole" post="in patients with ER-positive MBC who had progressed on"/>
   <result pre="letrozole in patients with ER-positive MBC who had progressed on" exact="letrozole" post="monotherapy. Patients continued to receive letrozole monotherapy during the"/>
   <result pre="who had progressed on letrozole monotherapy. Patients continued to receive" exact="letrozole" post="monotherapy during the 2-week screening period. The primary efficacy"/>
   <result pre="endpoint was progression-free rate at or after 16 weeks of" exact="afatinib" post="treatment. Progression was defined as the occurrence of any"/>
   <result pre="stage IIIB or IV ER-positive MBC. Patients had previously received" exact="letrozole" post="and had developed acquired resistance, defined as disease progression"/>
   <result pre="and had developed acquired resistance, defined as disease progression on" exact="letrozole" post="following previous response (PR or better, or SD for"/>
   <result pre="permitted. Patients with HER2-positive breast cancer could have received prior" exact="trastuzumab" post="in the adjuvant and metastatic setting. HER2 positivity was"/>
   <result pre="3 months prior to study entry. Treatment Patients received oral" exact="afatinib" post="once daily at a starting dose of 50 mg"/>
   <result pre="over repeated 28-day treatment cycles, with 2.5 mg of oral" exact="letrozole" post="daily until disease progression, withdrawal of consent or discontinuation"/>
   <result pre="intake. The protocol amendments were made as some patients receiving" exact="afatinib" post="50 or 40 mg experienced grade 3 cutaneous AEs"/>
   <result pre="AEs and diarrhea. As a result, the starting dose of" exact="afatinib" post="was reduced to 40 mg once-daily and then 30"/>
   <result pre="newly enrolled patients. At each starting dose, dose reduction of" exact="afatinib" post="in 10 mg decrements (to a minimum of 20"/>
   <result pre="afatinib. This analysis was supportive of the reduction of the" exact="afatinib" post="starting dose from 40 to 30 mg per day."/>
   <result pre="collected. Blood samples were drawn before and 2 h after" exact="letrozole" post="administration on day –14 and –7 during the first"/>
   <result pre="day –14 and –7 during the first 2 weeks of" exact="letrozole" post="monotherapy treatment. For quantification of letrozole and afatinib plasma"/>
   <result pre="first 2 weeks of letrozole monotherapy treatment. For quantification of" exact="letrozole" post="and afatinib plasma concentrations, blood samples were drawn on"/>
   <result pre="weeks of letrozole monotherapy treatment. For quantification of letrozole and" exact="afatinib" post="plasma concentrations, blood samples were drawn on day 1"/>
   <result pre="4 and 5) before and 2 h after administration of" exact="afatinib" post="and letrozole, and additionally at 1, 2, 4, 6,"/>
   <result pre="provide 80 % power to detect statistically significant evidence of" exact="afatinib" post="activity, based on the assumption of an underlying true"/>
   <result pre="entered the trial and received at least one dose of" exact="afatinib" post="(Fig. 1). Of the two patients who did not"/>
   <result pre="experienced SD ≥24 weeks as their best response to prior" exact="letrozole" post="therapy, with six patients (21 %) experiencing a PR,"/>
   <result pre="1 9 (32) ≥2 1 (4) Hormone therapy prior to" exact="letrozole" post="28 (100) Prior adjuvant radiotherapy Yes 16 (57) No"/>
   <result pre="endpoint (progression-free rate at 16 weeks) Afatinib 50 mg +" exact="letrozole" post="2.5 mg Afatinib 40 mg + letrozole 2.5 mg"/>
   <result pre="50 mg + letrozole 2.5 mg Afatinib 40 mg +" exact="letrozole" post="2.5 mg Afatinib 30 mg + letrozole 2.5 mg"/>
   <result pre="40 mg + letrozole 2.5 mg Afatinib 30 mg +" exact="letrozole" post="2.5 mg All afatinib doses Number of patients, n"/>
   <result pre="2.5 mg Afatinib 30 mg + letrozole 2.5 mg All" exact="afatinib" post="doses Number of patients, n (%) 7 (100.0) 13"/>
   <result pre="PD. Fig. 2 Duration of therapy by starting dose of" exact="afatinib" post="for patients who discontinued treatment (each bar represents one"/>
   <result pre="patients experienced an objective (complete or partial) tumor response to" exact="afatinib" post="plus letrozole treatment. Throughout the study, a best response"/>
   <result pre="an objective (complete or partial) tumor response to afatinib plus" exact="letrozole" post="treatment. Throughout the study, a best response of SD,"/>
   <result pre="(54 %). The incidence of SD was comparable across the" exact="afatinib" post="starting dose cohorts. Overall, six patients (21 %) experienced"/>
   <result pre="treatment. Of these six patients, the best response on prior" exact="letrozole" post="therapy was SD for five and PR for one"/>
   <result pre="have clinical benefit at 24 weeks. Best response to previous" exact="letrozole" post="treatment was PR in one patient and SD in"/>
   <result pre="30 mg afatinib, respectively. The longest duration of treatment with" exact="afatinib" post="and letrozole was 449 days. Duration of therapy, along"/>
   <result pre="afatinib, respectively. The longest duration of treatment with afatinib and" exact="letrozole" post="was 449 days. Duration of therapy, along with reasons"/>
   <result pre="with reasons for discontinuation, is shown by starting dose of" exact="afatinib" post="for all patients (Fig. 2). Median OS could not"/>
   <result pre="grade 5 AEs occurred, and only one patient who received" exact="afatinib" post="40 mg and letrozole 2.5 mg experienced a grade"/>
   <result pre="and only one patient who received afatinib 40 mg and" exact="letrozole" post="2.5 mg experienced a grade 4 AE (diarrhea). Fourteen"/>
   <result pre="leading to treatment discontinuation. Table 3 Treatment-related adverse events by" exact="afatinib" post="starting dose and reported as NCI CTCAE grades (patients"/>
   <result pre="grade ≥3 adverse event; treated set) Afatinib 50 mg +" exact="letrozole" post="2.5 mg, n = 7 Afatinib 40 mg +"/>
   <result pre="letrozole 2.5 mg, n = 7 Afatinib 40 mg +" exact="letrozole" post="2.5 mg, n = 13 Afatinib 30 mg +"/>
   <result pre="letrozole 2.5 mg, n = 13 Afatinib 30 mg +" exact="letrozole" post="2.5 mg, n = 8 All afatinib doses +"/>
   <result pre="30 mg + letrozole 2.5 mg, n = 8 All" exact="afatinib" post="doses + letrozole 2.5 mg, n = 28 n"/>
   <result pre="letrozole 2.5 mg, n = 8 All afatinib doses +" exact="letrozole" post="2.5 mg, n = 28 n (%) n (%)"/>
   <result pre="the seven patients (86 %) who initially received 50 mg" exact="afatinib" post="underwent protocol-specified dose reduction to 40 mg for a"/>
   <result pre="of 13 patients (62 %) who initially received 40 mg" exact="afatinib" post="underwent dose reduction to 30 mg. None of the"/>
   <result pre="None of the eight patients who received the 30 mg" exact="afatinib" post="starting dose required dose reduction. The frequency of AEs"/>
   <result pre="%) who experienced treatment-related rash, those receiving higher doses of" exact="afatinib" post="were more likely to experience grade 3 rash and"/>
   <result pre="Afatinib Table 4 shows the geometric mean pharmacokinetic parameters of" exact="afatinib" post="after multiple administrations of afatinib 30 mg or 40"/>
   <result pre="geometric mean pharmacokinetic parameters of afatinib after multiple administrations of" exact="afatinib" post="30 mg or 40 mg in combination with letrozole"/>
   <result pre="of afatinib 30 mg or 40 mg in combination with" exact="letrozole" post="2.5 mg. Inter-subject variability for maximum plasma concentration at"/>
   <result pre="over the dosing interval (AUC tau,ss) was moderate for the" exact="afatinib" post="40 mg dose group and high for the 30"/>
   <result pre="pharmacokinetic data available were sparse, and for the 50 mg" exact="afatinib" post="dose group there were insufficient data to perform any"/>
   <result pre="data to perform any descriptive statistics. Table 4 Summary of" exact="afatinib" post="pharmacokinetic parameters after multiple oral administrations of afatinib 40"/>
   <result pre="Summary of afatinib pharmacokinetic parameters after multiple oral administrations of" exact="afatinib" post="40 and 30 mg, with letrozole 2.5 mg Pharmacokinetic"/>
   <result pre="multiple oral administrations of afatinib 40 and 30 mg, with" exact="letrozole" post="2.5 mg Pharmacokinetic parameter (unit) Afatinib 40 mg Afatinib"/>
   <result pre="post-dose plasma concentrations were comparable for the screening period (without" exact="afatinib" post="administration) and the afatinib treatment period, indicating that there"/>
   <result pre="comparable for the screening period (without afatinib administration) and the" exact="afatinib" post="treatment period, indicating that there was no effect of"/>
   <result pre="afatinib treatment period, indicating that there was no effect of" exact="afatinib" post="on letrozole exposure (Fig. 3). In line with this,"/>
   <result pre="period, indicating that there was no effect of afatinib on" exact="letrozole" post="exposure (Fig. 3). In line with this, letrozole plasma"/>
   <result pre="afatinib on letrozole exposure (Fig. 3). In line with this," exact="letrozole" post="plasma concentrations appeared to be independent of the afatinib"/>
   <result pre="this, letrozole plasma concentrations appeared to be independent of the" exact="afatinib" post="dose level. Letrozole pharmacokinetic parameters on day 1 of"/>
   <result pre="on day 1 of cycle 4 were summarized over all" exact="afatinib" post="dose groups (geometric mean C max,ss was 135 ng/mL"/>
   <result pre="parameters was high. Fig. 3 Individual plasma concentration–time profiles of" exact="letrozole" post="after multiple oral administrations of 30, 40 or 50"/>
   <result pre="after multiple oral administrations of 30, 40 or 50 mg" exact="afatinib" post="Discussion This phase II study evaluated daily afatinib (30,"/>
   <result pre="50 mg afatinib Discussion This phase II study evaluated daily" exact="afatinib" post="(30, 40 or 50 mg/day) in combination with letrozole"/>
   <result pre="daily afatinib (30, 40 or 50 mg/day) in combination with" exact="letrozole" post="in ER-positive, hormone-refractory MBC. The attempt to overcome hormone"/>
   <result pre="MBC. The attempt to overcome hormone resistance, i.e. resistance to" exact="letrozole" post="by the addition of the ErbB Family inhibitor afatinib,"/>
   <result pre="agent. Of note, the duration of endocrine therapy prior to" exact="afatinib" post="treatment in those who did and did not achieve"/>
   <result pre="or acquired resistance, are being explored. Phase II trials investigating" exact="gefitinib" post="or erlotinib, two reversible EGFR TKIs, in combination with"/>
   <result pre="and 30 mg afatinib, respectively, demonstrating that the combination of" exact="afatinib" post="and letrozole may warrant further investigation for hormone-refractory MBC"/>
   <result pre="mg afatinib, respectively, demonstrating that the combination of afatinib and" exact="letrozole" post="may warrant further investigation for hormone-refractory MBC patients. Table"/>
   <result pre="et al. 2006) ER/PgR-positive MBC Hormone-sensitive population 150 Letrozole +" exact="erlotinib" post="Of 22 patients enrolled, 11/20 patients achieved clinical benefit"/>
   <result pre="et al. 2005) ER-positive MBC Hormone-refractory population 15 Anastrozole +" exact="gefitinib" post="No clinical benefit – Phase II (Cristofanilli et al."/>
   <result pre="No prior endocrine therapy and/or developed metastatic disease during/after adjuvant" exact="tamoxifen" post="93 a Anastrozole + gefitinib 14.7 Diarrhea 7 vs."/>
   <result pre="developed metastatic disease during/after adjuvant tamoxifen 93 a Anastrozole +" exact="gefitinib" post="14.7 Diarrhea 7 vs. 0 % Fatigue 5 vs."/>
   <result pre="MBC Patients with newly metastatic disease or recurring after adjuvant" exact="tamoxifen" post="206 b Tamoxifen + gefitinib 10.9 Diarrhea 4 vs."/>
   <result pre="disease or recurring after adjuvant tamoxifen 206 b Tamoxifen +" exact="gefitinib" post="10.9 Diarrhea 4 vs. 0 % Rash 4 vs."/>
   <result pre="% Tamoxifen + placebo 8.8 ER/PgR/HER2-positive MBC 37 Tamoxifen +" exact="gefitinib" post="6.7 – Tamoxifen + placebo 5.8 TAnDEM/phase III (Kaufman"/>
   <result pre="III (Kaufman et al. 2009) ER/PgR/HER2-positive MBC Previous treatment with" exact="tamoxifen" post="as adjuvant or hormonal therapy for MBC or anastrozole"/>
   <result pre="with tamoxifen as adjuvant or hormonal therapy for MBC or" exact="anastrozole" post="was permitted (begun up to 4 weeks before random"/>
   <result pre="up to 4 weeks before random assignment) 207 Anastrozole +" exact="trastuzumab" post="4.8 (independent assessment) Vomiting 3 vs. 1 % Hypertension"/>
   <result pre="trastuzumab, (completed &amp;gt;1 year before study entry) 219 Letrozole +" exact="lapatinib" post="8.2 Diarrhea 10 vs. &amp;lt;1 % Rash 1 vs."/>
   <result pre="(relapsed &amp;lt;6 months after stopping adjuvant tamoxifen) 200 Letrozole +" exact="lapatinib" post="8.3 – Letrozole + placebo 3.1 ER/PgR-positive HER2-negative MBC"/>
   <result pre="(ER H-score &amp;lt;160) (Finn et al. 2009) 207 Letrozole +" exact="lapatinib" post="13.6 Letrozole + placebo 6.6 eLEcTRA/phase III(Huober et al."/>
   <result pre="MBC First-line treatment; no prior hormone therapy 26 Letrozole +" exact="trastuzumab" post="14.1 Bone pain 4 vs. 7 % Dyspnea 0"/>
   <result pre="al. 2012) ER/PgR-positive HER2-negative MBC Aromatase inhibitor-resistant 111 Tamoxifen +" exact="everolimus" post="Clinical benefit rate = 61 % Stomatitis 11 vs."/>
   <result pre="2012) ER/PgR-positive advanced breast cancer Aromatase inhibitor-resistant 724 Exemestane +" exact="everolimus" post="6.9 Stomatitis 8 vs. 1 % Anemia 6 vs."/>
   <result pre="cancer, mTOR mammalian target of rapamycin, PFS progression-free survival, PgR" exact="progesterone" post="receptor, PR partial response, SD stable disease aStudy discontinued"/>
   <result pre="diagnosed metastatic disease or relapsed ≥1 year after stopping adjuvant" exact="tamoxifen" post="cPatients with centrally confirmed hormone receptor-positive, HER2-negative cancer (952"/>
   <result pre="progressing at 16 weeks. This observation is of interest because" exact="letrozole" post="combined with lapatinib, a reversible EGFR and HER2 TKI,"/>
   <result pre="demonstrated a statistically significant improvement in PFS when treated with" exact="letrozole" post="plus lapatinib (Finn et al. 2009). Targeting HER2 with"/>
   <result pre="statistically significant improvement in PFS when treated with letrozole plus" exact="lapatinib" post="(Finn et al. 2009). Targeting HER2 with the monoclonal"/>
   <result pre="(Finn et al. 2009). Targeting HER2 with the monoclonal antibody" exact="trastuzumab" post="and aromatase inhibitors such as anastrozole has also been"/>
   <result pre="with the monoclonal antibody trastuzumab and aromatase inhibitors such as" exact="anastrozole" post="has also been explored, and the mammalian target of"/>
   <result pre="been explored, and the mammalian target of rapamycin (mTOR) inhibitor" exact="everolimus" post="in combination with endocrine therapy represents another promising therapeutic"/>
   <result pre="with the side effects observed across the phase I dose-finding" exact="afatinib" post="monotherapy studies in patients with a variety of solid"/>
   <result pre="al. 2012). Data from phase I monotherapy studies indicated an" exact="afatinib" post="dose of 50 mg once daily to be the"/>
   <result pre="50 mg once daily to be the recommended dose for" exact="afatinib" post="development in subsequent phase II studies (Yap et al."/>
   <result pre="entered this phase II trial received a starting dose of" exact="afatinib" post="50 mg daily, with the option for dose reduction"/>
   <result pre="3 AEs. A notable proportion of patients initially treated with" exact="afatinib" post="50 mg in combination with letrozole experienced skin-associated AEs"/>
   <result pre="patients initially treated with afatinib 50 mg in combination with" exact="letrozole" post="experienced skin-associated AEs and diarrhea, requiring a dose reduction"/>
   <result pre="to AEs than patients who received 50 or 40 mg" exact="afatinib" post="doses. Overall, the combination of afatinib and letrozole appeared"/>
   <result pre="50 or 40 mg afatinib doses. Overall, the combination of" exact="afatinib" post="and letrozole appeared to result in skin-related AEs occurring"/>
   <result pre="40 mg afatinib doses. Overall, the combination of afatinib and" exact="letrozole" post="appeared to result in skin-related AEs occurring at greater"/>
   <result pre="in skin-related AEs occurring at greater intensity, when compared with" exact="afatinib" post="monotherapy. It is worth noting that at the time"/>
   <result pre="the toxicity profile of TKIs and their management. Co-administration of" exact="afatinib" post="with letrozole resulted in afatinib pharmacokinetic parameters that were"/>
   <result pre="profile of TKIs and their management. Co-administration of afatinib with" exact="letrozole" post="resulted in afatinib pharmacokinetic parameters that were comparable to"/>
   <result pre="and their management. Co-administration of afatinib with letrozole resulted in" exact="afatinib" post="pharmacokinetic parameters that were comparable to those observed during"/>
   <result pre="afatinib pharmacokinetic parameters that were comparable to those observed during" exact="afatinib" post="monotherapy (Yap et al. 2010; Eskens et al. 2008)."/>
   <result pre="2008). Letrozole plasma concentrations were also comparable with or without" exact="afatinib" post="administration and were within the ranges previously reported in"/>
   <result pre="2001; Dowsett 1999), indicating that there was no effect of" exact="afatinib" post="on letrozole exposure. Therefore, this study is a preliminary"/>
   <result pre="1999), indicating that there was no effect of afatinib on" exact="letrozole" post="exposure. Therefore, this study is a preliminary indication that"/>
   <result pre="letrozole exposure. Therefore, this study is a preliminary indication that" exact="afatinib" post="has no influence on the pharmacokinetics of letrozole and"/>
   <result pre="indication that afatinib has no influence on the pharmacokinetics of" exact="letrozole" post="and vice versa. However, the pharmacokinetic analysis was limited"/>
   <result pre="phase II exploratory observations presented here show that the once-daily" exact="afatinib" post="30 mg/letrozole 2.5 mg combination was able to induce"/>
   <result pre="MBC. An ongoing study (NCT02115048) is assessing the efficacy of" exact="afatinib" post="plus letrozole versus letrozole alone in first-line advanced ER-positive,"/>
   <result pre="ongoing study (NCT02115048) is assessing the efficacy of afatinib plus" exact="letrozole" post="versus letrozole alone in first-line advanced ER-positive, HER2-negative postmenopausal"/>
   <result pre="(NCT02115048) is assessing the efficacy of afatinib plus letrozole versus" exact="letrozole" post="alone in first-line advanced ER-positive, HER2-negative postmenopausal breast cancer"/>
   <result pre="expression. Conclusions In this small exploratory study, combination therapy with" exact="afatinib" post="and letrozole led to disease stabilization in 54 %"/>
   <result pre="In this small exploratory study, combination therapy with afatinib and" exact="letrozole" post="led to disease stabilization in 54 % of patients"/>
   <result pre="of patients with advanced hormone-refractory MBC who had progressed following" exact="letrozole" post="treatment. These findings warrant further evaluation to determine the"/>
   <result pre="irreversible inhibitor of EGFR/HER1 and HER2, to treatment continuation of" exact="letrozole" post="in estrogen receptor (ER)-positive metastatic breast cancer progressing on"/>
   <result pre="BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2, to" exact="letrozole" post="in estrogen receptor (ER)-positive metastatic breast cancer (mBC) progressing"/>
   <result pre="in estrogen receptor (ER)-positive metastatic breast cancer (mBC) progressing on" exact="letrozole" post="monotherapy. Poster presentation at 46th Annual Meeting of the"/>
   <result pre="J-M Freyer G et al. Randomized phase II trial of" exact="everolimus" post="in combination with tamoxifen in patients with hormone receptor–positive,"/>
   <result pre="al. Randomized phase II trial of everolimus in combination with" exact="tamoxifen" post="in patients with hormone receptor–positive, human epidermal growth factor"/>
   <result pre="Arena FP et al. Phase II, randomized trial to compare" exact="anastrozole" post="combined with gefitinib or placebo in postmenopausal women with"/>
   <result pre="al. Phase II, randomized trial to compare anastrozole combined with" exact="gefitinib" post="or placebo in postmenopausal women with hormone receptor-positive metastatic"/>
   <result pre="estrogen-receptor (ER)-low metastatic breast cancer (MBC) with the addition of" exact="lapatinib" post="to letrozole: Biomarker results of EGF30008. ASCO Meeting Abstracts"/>
   <result pre="L Wallwiener D Thomssen C et al. Higher efficacy of" exact="letrozole" post="in combination with trastuzumab compared to letrozole monotherapy as"/>
   <result pre="C et al. Higher efficacy of letrozole in combination with" exact="trastuzumab" post="compared to letrozole monotherapy as first-line treatment in patients"/>
   <result pre="Higher efficacy of letrozole in combination with trastuzumab compared to" exact="letrozole" post="monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive"/>
   <result pre="al. Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to" exact="tamoxifen" post="Nature 2008 456 663 666 10.1038/nature07483 19005469 Hurvitz SA"/>
   <result pre="M Sadeghi S Dieras V et al. Lapatinib combined with" exact="letrozole" post="versus letrozole and placebo as first-line therapy for postmenopausal"/>
   <result pre="S Dieras V et al. Lapatinib combined with letrozole versus" exact="letrozole" post="and placebo as first-line therapy for postmenopausal hormone receptor-positive"/>
   <result pre="Bapsy PP Vaid A Wardley A et al. Trastuzumab plus" exact="anastrozole" post="versus anastrozole alone for the treatment of postmenopausal women"/>
   <result pre="Vaid A Wardley A et al. Trastuzumab plus anastrozole versus" exact="anastrozole" post="alone for the treatment of postmenopausal women with human"/>
   <result pre="S Mendelson D et al. A phase II study of" exact="afatinib" post="(BIBW 2992), an irreversible ErbB family blocker, in patients"/>
   <result pre="blocker, in patients with HER2-positive metastatic breast cancer progressing after" exact="trastuzumab" post="Breast Cancer Res Treat 2012 133 1057 1065 10.1007/s10549-012-2003-y"/>
   <result pre="ZW Kommarreddy A Novielli N et al. The combination of" exact="letrozole" post="and trastuzumab as first or second-line biological therapy produces"/>
   <result pre="A Novielli N et al. The combination of letrozole and" exact="trastuzumab" post="as first or second-line biological therapy produces durable responses"/>
   <result pre="Muldowney N, Arteaga C (2006) A phase II trial of" exact="letrozole" post="plus erlotinib in post-menopausal women with hormone-sensitive metastatic breast"/>
   <result pre="Arteaga C (2006) A phase II trial of letrozole plus" exact="erlotinib" post="in post-menopausal women with hormone-sensitive metastatic breast cancer: preliminary"/>
   <result pre="al (2005) A phase II and biologic correlative study investigating" exact="anastrozole" post="in combination with gefitinib in post menopausal patients with"/>
   <result pre="II and biologic correlative study investigating anastrozole in combination with" exact="gefitinib" post="in post menopausal patients with estrogen receptor positive metastatic"/>
   <result pre="Negoro S Okamoto I Tsurutani J et al. Gefitinib versus" exact="cisplatin" post="plus docetaxel in patients with non-small-cell lung cancer harbouring"/>
   <result pre="Okamoto I Tsurutani J et al. Gefitinib versus cisplatin plus" exact="docetaxel" post="in patients with non-small-cell lung cancer harbouring mutations of"/>
   <result pre="Underhill C et al. Gefitinib or placebo in combination with" exact="tamoxifen" post="in patients with hormone receptor-positive metastatic breast cancer: a"/>
   <result pre="Effect of age and single versus multiple dose pharmacokinetics of" exact="letrozole" post="(Femara) in breast cancer patients Biopharm Drug Dispos 2001"/>
   <result pre="Florance A O’Rourke L Maltzman J Johnston S Lapatinib plus" exact="letrozole" post="as first-line therapy for HER-2+ hormone receptor-positive metastatic breast"/>
   <result pre="S et al. A phase II placebo-controlled trial of neoadjuvant" exact="anastrozole" post="alone or with gefitinib in early breast cancer J"/>
   <result pre="phase II placebo-controlled trial of neoadjuvant anastrozole alone or with" exact="gefitinib" post="in early breast cancer J Clin Oncol 2007 25"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4720061/results/search/inn/results.xml">
   <result pre="June 2011, and had available data on estrogen receptor (ER)," exact="progesterone" post="receptor (PR), and human epidermal growth factor 2 (HER2)"/>
   <result pre="no change, others have demonstrated changes in estrogen receptor (ER)," exact="progesterone" post="receptor (PR), and HER2 receptor status, as described in"/>
   <result pre="patients [ 15, 16]. The regimens included four cycles of" exact="doxorubicin" post="and cyclophosphamide, four cycles of doxorubicin and cyclophosphamide followed"/>
   <result pre="included four cycles of doxorubicin and cyclophosphamide, four cycles of" exact="doxorubicin" post="and cyclophosphamide followed by four cycles of either docetaxel"/>
   <result pre="cycles of doxorubicin and cyclophosphamide, four cycles of doxorubicin and" exact="cyclophosphamide" post="followed by four cycles of either docetaxel or paclitaxel,"/>
   <result pre="of doxorubicin and cyclophosphamide followed by four cycles of either" exact="docetaxel" post="or paclitaxel, six cycles of doxorubicin and docetaxel, four"/>
   <result pre="four cycles of either docetaxel or paclitaxel, six cycles of" exact="doxorubicin" post="and docetaxel, four cycles of paclitaxel and gemcitabine, and"/>
   <result pre="paclitaxel, six cycles of doxorubicin and docetaxel, four cycles of" exact="paclitaxel" post="and gemcitabine, and six cycles of paclitaxel, gemcitabine, and"/>
   <result pre="paclitaxel and gemcitabine, and six cycles of paclitaxel, gemcitabine, and" exact="trastuzumab" post="or lapatinib. Anti-HER2 therapy containing NAC was not yet"/>
   <result pre="of clinical trials [ 17, 18]. Anti-HER2 therapy consisted of" exact="trastuzumab" post="or lapatinib [ 19] for a total duration of"/>
   <result pre="trials [ 17, 18]. Anti-HER2 therapy consisted of trastuzumab or" exact="lapatinib" post="[ 19] for a total duration of 1 year,"/>
   <result pre="R Raina V et al. Long-term effects of continuing adjuvant" exact="tamoxifen" post="to 10 years versus stopping at 5 years after"/>
   <result pre="Nam BH et al. Primary systemic therapy with intermittent weekly" exact="paclitaxel" post="plus gemcitabine in patients with stage II and III"/>
   <result pre="et al. Primary systemic therapy with intermittent weekly paclitaxel plus" exact="gemcitabine" post="in patients with stage II and III breast cancer:"/>
   <result pre="et al. Phase II trial of preoperative paclitaxel, gemcitabine, and" exact="trastuzumab" post="combination therapy in HER2 positive stage II/III breast cancer:"/>
   <result pre="al. A phase Ib study of preoperative lapatinib, paclitaxel, and" exact="gemcitabine" post="combination therapy in women with HER2 positive early breast"/>
   <result pre="TN, triple negative. Table 3. Change in estrogen receptor and" exact="progesterone" post="receptor Allred scores after neoadjuvant chemotherapy Change (n=290) Decrease"/>
   <result pre="Values are presented as number (%). ER, estrogen receptor; PR," exact="progesterone" post="receptor. Table 4. Analysis of recurrence-free survival with clinical"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4720106/results/search/inn/results.xml">
   <result pre="with total mastectomy, axillary lymph-node dissection, and adjuvant chemotherapy with" exact="cyclophosphamide" post="plus doxorubicin. After the end of adjuvant trastuzumab therapy,"/>
   <result pre="chemotherapy with cyclophosphamide plus doxorubicin. After the end of adjuvant" exact="trastuzumab" post="therapy, she was diagnosed with panhypopituitarism due to pituitary"/>
   <result pre="form of breast cancer [ 1]; however, the introduction of" exact="trastuzumab" post="has significantly improved the poor prognosis of this population"/>
   <result pre="of HER2 [ 9], has demonstrated activity in combination with" exact="capecitabine" post="for treatment of HER2-positive metastatic breast cancer that progresses"/>
   <result pre="carcinoma of pT2N0M0, which was estrogen receptor positive (moderate, 10%)," exact="progesterone" post="receptor negative, and HER2-positive (2+ by immunohistochemistry and amplification"/>
   <result pre="fluorescence in situ hybridization). Four cycles of adjuvant chemotherapy with" exact="cyclophosphamide" post="600 mg/m 2 plus doxorubicin 60 mg/m 2 were"/>
   <result pre="cycles of adjuvant chemotherapy with cyclophosphamide 600 mg/m 2 plus" exact="doxorubicin" post="60 mg/m 2 were administered, followed by one year"/>
   <result pre="mg/m 2 were administered, followed by one year of adjuvant" exact="trastuzumab" post="and daily tamoxifen therapy. The patient presented with the"/>
   <result pre="administered, followed by one year of adjuvant trastuzumab and daily" exact="tamoxifen" post="therapy. The patient presented with the same symptoms—polydipsia, general"/>
   <result pre="and headache—1 month after completing the last cycle of adjuvant" exact="trastuzumab" post="therapy. Bitemporal hemianopsia was noted after her physical examination."/>
   <result pre="hormone replacement therapy (desmopressin acetate 50 μg twice a day," exact="prednisolone" post="7.5 mg a day, in divided doses every morning"/>
   <result pre="which clinically originated from the breast: estrogen receptor positive (30%)," exact="progesterone" post="receptor negative, HER2-positive (3+ by immunohistochemistry) ( Fig. 2)."/>
   <result pre="12 fractions) was applied ( Fig. 1B), followed by weekly" exact="paclitaxel" post="chemotherapy, but the patient was unable to finish the"/>
   <result pre="the patient was unable to finish the second cycle of" exact="paclitaxel" post="due to toxicity (grade 3 nausea, somnolence, and loss"/>
   <result pre="somnolence, and loss of memory). Lapatinib (1,250 mg daily) plus" exact="capecitabine" post="(2,000 mg/m 2 on days 1 through 14 of"/>
   <result pre="room with severe septic shock due to gastrointestinal toxicity of" exact="lapatinib" post="and capecitabine combination regimen. This was an expected adverse"/>
   <result pre="severe septic shock due to gastrointestinal toxicity of lapatinib and" exact="capecitabine" post="combination regimen. This was an expected adverse event of"/>
   <result pre="condition, her serum sodium level changed rapidly despite treatment with" exact="desmopressin" post="as panhypopituitarism originated from the metastatic brain lesion ("/>
   <result pre="ganglia ( Fig. 1C). Because a 20% dose reduction of" exact="capecitabine" post="still evoked adverse effects (general weakness and electrolyte imbalance),"/>
   <result pre="evoked adverse effects (general weakness and electrolyte imbalance), chemotherapy with" exact="lapatinib" post="alone was started. After 2 months of lapatinib monotherapy,"/>
   <result pre="chemotherapy with lapatinib alone was started. After 2 months of" exact="lapatinib" post="monotherapy, the follow-up MRI showed a decrease in the"/>
   <result pre="breast cancer metastasis. Brain metastasis developed despite previous treatment with" exact="trastuzumab" post="in early stage breast cancer. Recent studies have suggested"/>
   <result pre="in early stage breast cancer. Recent studies have suggested that" exact="trastuzumab" post="may not be active in the central nervous system"/>
   <result pre="diagnosed with pituitary metastasis [ 13, 14]. In this case," exact="trastuzumab" post="may have controlled the micro-metastasis of breast cancer after"/>
   <result pre="of brain metastasis from HER2-positive breast cancer in combination with" exact="capecitabine" post="[ 12]. It has low molecular weight, and therefore"/>
   <result pre="able to cross the blood-brain barrier [ 15]. Lapatinib and" exact="capecitabine" post="treatment are sometimes associated with grade 3 and grade"/>
   <result pre="adjustment of regimen can overcome these issues. Widespread use of" exact="trastuzumab" post="for treatment of HER2-positive breast cancer leaves patients with"/>
   <result pre="brain metastasis, the patient’s brain lesion is well controlled with" exact="lapatinib" post="monotherapy. Therefore, we suggest that lapatinib is beneficial for"/>
   <result pre="is well controlled with lapatinib monotherapy. Therefore, we suggest that" exact="lapatinib" post="is beneficial for improving the survival and quality of"/>
   <result pre="B Heinemann V Characteristics of patients with brain metastases receiving" exact="trastuzumab" post="for HER2 overexpressing metastatic breast cancer Breast 2006 15"/>
   <result pre="Chan S Romieu CG Pienkowski T et al. Lapatinib plus" exact="capecitabine" post="for HER2-positive advanced breast cancer N Engl J Med"/>
   <result pre="Romieu CG et al. A phase III randomized comparison of" exact="lapatinib" post="plus capecitabine versus capecitabine alone in women with advanced"/>
   <result pre="et al. A phase III randomized comparison of lapatinib plus" exact="capecitabine" post="versus capecitabine alone in women with advanced breast cancer"/>
   <result pre="A phase III randomized comparison of lapatinib plus capecitabine versus" exact="capecitabine" post="alone in women with advanced breast cancer that has"/>
   <result pre="Dieras V Cropet C Dalenc F et al. Lapatinib plus" exact="capecitabine" post="in patients with previously untreated brain metastases from HER2-positive"/>
   <result pre="had increased slightly (29 mm) 4 months after discontinuation of" exact="lapatinib" post="and capecitabine due to gastrointestinal sepsis (June 2013). (D)"/>
   <result pre="slightly (29 mm) 4 months after discontinuation of lapatinib and" exact="capecitabine" post="due to gastrointestinal sepsis (June 2013). (D) After re-starting"/>
   <result pre="capecitabine due to gastrointestinal sepsis (June 2013). (D) After re-starting" exact="lapatinib" post="monotherapy, the size of the enhancing mass decreased (25"/>
   <result pre="and it was stabilized after the tumor was controlled by" exact="lapatinib" post="(November 2013). Table 1. Blood and urine laboratory results"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4722889/results/search/inn/results.xml">
   <result pre="(MPM). It was reported that the tyrosine kinase inhibitor (TKI)" exact="lapatinib" post="enhanced trastuzumab-mediated antibody-dependent cellular cytotoxicity (ADCC) in HER2-positive breast"/>
   <result pre="was to explore the possibility of a TKI combined with" exact="trastuzumab" post="to enhance ADCC in MPM cells. Five MPM cell"/>
   <result pre="used to test the effects of TKIs targeting EGFR (gefitinib," exact="afatinib" post="and lapatinib) on cell proliferation and the expression of"/>
   <result pre="the HER family receptor. The combined effects of TKI with" exact="trastuzumab" post="on ADCC were evaluated using the LDH release assay."/>
   <result pre="cell lines, HER2 expression was upregulated by lapatinib, downregulated by" exact="afatinib" post="and unaffected by gefitinib. As expected, more trastuzumab bound"/>
   <result pre="downregulated by afatinib and unaffected by gefitinib. As expected, more" exact="trastuzumab" post="bound to MPM cells pretreated with lapatinib than untreated"/>
   <result pre="As expected, more trastuzumab bound to MPM cells pretreated with" exact="lapatinib" post="than untreated cells, resulting in the enhancement of trastuzumab-mediated"/>
   <result pre="both trastuzumab- and cetuximab-mediated ADCC. Of the three TKIs, only" exact="lapatinib" post="enhanced trastuzumab-mediated ADCC via the upregulation of HER2 expression"/>
   <result pre="HER2 expression in MPM cells, suggesting that sequential combination of" exact="lapatinib" post="and trastuzumab may be a promising strategy for MPM"/>
   <result pre="in MPM cells, suggesting that sequential combination of lapatinib and" exact="trastuzumab" post="may be a promising strategy for MPM treatment. malignant"/>
   <result pre="strategy for MPM treatment. malignant pleural mesothelioma antibody-dependent cellular cytotoxicity" exact="lapatinib" post="trastuzumab cetuximab Introduction Malignant pleural mesothelioma (MPM) is an"/>
   <result pre="for MPM treatment. malignant pleural mesothelioma antibody-dependent cellular cytotoxicity lapatinib" exact="trastuzumab" post="cetuximab Introduction Malignant pleural mesothelioma (MPM) is an aggressive"/>
   <result pre="MPM treatment. malignant pleural mesothelioma antibody-dependent cellular cytotoxicity lapatinib trastuzumab" exact="cetuximab" post="Introduction Malignant pleural mesothelioma (MPM) is an aggressive thoracic"/>
   <result pre="5). It was recently reported that a sequential combination of" exact="lapatinib" post="with trastuzumab enhanced trastuzumab-mediated antibody-dependent cellular cytotoxicity (ADCC) by"/>
   <result pre="was recently reported that a sequential combination of lapatinib with" exact="trastuzumab" post="enhanced trastuzumab-mediated antibody-dependent cellular cytotoxicity (ADCC) by upregulating HER2"/>
   <result pre="In the present study, we report that the dual EGFR/HER2-TKI" exact="lapatinib" post="may upregulate the expression of both EGFR and HER2,"/>
   <result pre="expression of both EGFR and HER2, while neither the EGFR-TKI" exact="gefitinib" post="nor the pan-HER-TKI afatinib demonstrate the same effect. Additionally,"/>
   <result pre="and HER2, while neither the EGFR-TKI gefitinib nor the pan-HER-TKI" exact="afatinib" post="demonstrate the same effect. Additionally, we have shown that"/>
   <result pre="afatinib demonstrate the same effect. Additionally, we have shown that" exact="lapatinib" post="enhanced both trastuzumab- and cetuximab-mediated ADCC in MPM cells"/>
   <result pre="MPM cells isolated from the patient. The sequential combination of" exact="lapatinib" post="with trastuzumab and/or cetuximab may prove to be a"/>
   <result pre="isolated from the patient. The sequential combination of lapatinib with" exact="trastuzumab" post="and/or cetuximab may prove to be a promising strategy"/>
   <result pre="the patient. The sequential combination of lapatinib with trastuzumab and/or" exact="cetuximab" post="may prove to be a promising strategy for MPM"/>
   <result pre="(both from Invitrogen, Carlsbad, CA, USA) and 50 U/ml penicillin" exact="streptomycin" post="(Sigma-Aldrich, St. Louis, MO, USA) at 37°C in a"/>
   <result pre="a humidified atmosphere with 5% CO 2. For cell culturing," exact="gefitinib" post="(Cayman Chemical, Ann Arbor, MI, USA), afatinib and lapatinib"/>
   <result pre="For cell culturing, gefitinib (Cayman Chemical, Ann Arbor, MI, USA)," exact="afatinib" post="and lapatinib (both from Selleckchem, Houston, TX, USA) were"/>
   <result pre="culturing, gefitinib (Cayman Chemical, Ann Arbor, MI, USA), afatinib and" exact="lapatinib" post="(both from Selleckchem, Houston, TX, USA) were dissolved in"/>
   <result pre="Houston, TX, USA) were dissolved in dimethylsulfoxide (DMSO) (Sigma-Aldrich). Rituximab," exact="trastuzumab" post="(both from Roche, Basel, Switzerland) and cetuximab (Merck Serono,"/>
   <result pre="(DMSO) (Sigma-Aldrich). Rituximab, trastuzumab (both from Roche, Basel, Switzerland) and" exact="cetuximab" post="(Merck Serono, Darmstadt, Germany) were dissolved in saline. Allophycocyanin"/>
   <result pre="Diego, CA, USA) were used for flow cytometry. Fluorescein (FITC)-conjugated" exact="trastuzumab" post="and FITC-conjugated rituximab were kindly provided by Professor Rolf"/>
   <result pre="were used for flow cytometry. Fluorescein (FITC)-conjugated trastuzumab and FITC-conjugated" exact="rituximab" post="were kindly provided by Professor Rolf Kiessling (Karolinska Institutet,"/>
   <result pre="flat-bottomed plates (Asahi Glass, Tokyo, Japan) with 0.01–10 µM afatinib," exact="gefitinib" post="or lapatinib in 100 µl of culture medium for"/>
   <result pre="(Asahi Glass, Tokyo, Japan) with 0.01–10 µM afatinib, gefitinib or" exact="lapatinib" post="in 100 µl of culture medium for 48 h,"/>
   <result pre="FlowJo software 6.4.7 (Tree Star, Ashland, OR, USA). Both FITC-conjugated" exact="trastuzumab" post="and cetuximab were used to evaluate the expression of"/>
   <result pre="6.4.7 (Tree Star, Ashland, OR, USA). Both FITC-conjugated trastuzumab and" exact="cetuximab" post="were used to evaluate the expression of the trastuzumab-binding"/>
   <result pre="the cetuximab-binding site, respectively, on the MPM cells, while FITC-conjugated" exact="rituximab" post="was used as an isotype control. Western blot analysis"/>
   <result pre="6-well plate and treated with DMSO or 1 µM of" exact="afatinib" post="or lapatinib for 24 h, for subsequent use as"/>
   <result pre="and treated with DMSO or 1 µM of afatinib or" exact="lapatinib" post="for 24 h, for subsequent use as target cells."/>
   <result pre="96-well U-bottom plate (BD Biosciences) with 100 ng/ml of trastuzumab," exact="cetuximab" post="or rituximab as irrelevant control, according to the manufacturer's"/>
   <result pre="plate (BD Biosciences) with 100 ng/ml of trastuzumab, cetuximab or" exact="rituximab" post="as irrelevant control, according to the manufacturer's protocol. After"/>
   <result pre="expression level was quite low ( Fig. 1). Lapatinib and" exact="afatinib" post="strongly inhibit the cell proliferation of MPM cell lines,"/>
   <result pre="strongly inhibit the cell proliferation of MPM cell lines, but" exact="gefitinib" post="does not The first-generation EGFR-TKI, gefitinib, is a powerful"/>
   <result pre="as T790M ( 10), while a second generation pan-HER inhibitor" exact="afatinib" post="overcame T790M in NSCLC cells ( 11). Lapatinib is"/>
   <result pre="MPM-p3 cells, were treated with various concentrations of TKIs. Both" exact="afatinib" post="and lapatinib clearly inhibited cell proliferation of MPM cells,"/>
   <result pre="were treated with various concentrations of TKIs. Both afatinib and" exact="lapatinib" post="clearly inhibited cell proliferation of MPM cells, while gefitinib"/>
   <result pre="and lapatinib clearly inhibited cell proliferation of MPM cells, while" exact="gefitinib" post="had a slight effect on cell proliferation of MPM"/>
   <result pre="MPM cells ( Fig. 2). Lapatinib upregulates HER2 expression while" exact="afatinib" post="downregulates HER2 expression in MPM cells We assessed whether"/>
   <result pre="of EGFR and HER2 was assessed by flow cytometry. Notably," exact="afatinib" post="downregulated the expression of EGFR in NCI-H28 and NCI-H2052"/>
   <result pre="downregulated the expression of HER2 in all cell lines, while" exact="lapatinib" post="clearly upregulated HER2 expression in all the cell lines."/>
   <result pre="HER2 expression in all the cell lines. In MPM-p3 cells," exact="afatinib" post="upregulated EGFR and downregulated HER2, while lapatinib upregulated expression"/>
   <result pre="In MPM-p3 cells, afatinib upregulated EGFR and downregulated HER2, while" exact="lapatinib" post="upregulated expression of both EGFR and HER2. Gefitinib had"/>
   <result pre="inhibited the phosphorylation of both EGFR and HER2. Notably, both" exact="afatinib" post="and lapatinib strongly and similarly inhibited the phosphorylation of"/>
   <result pre="phosphorylation of both EGFR and HER2. Notably, both afatinib and" exact="lapatinib" post="strongly and similarly inhibited the phosphorylation of EGFR and"/>
   <result pre="HER2 in both cell lines ( Fig. 4). Lapatinib enhances" exact="trastuzumab" post="binding with MPM cells, resulting in enhanced trastuzumab-mediated ADCC"/>
   <result pre="enhanced trastuzumab-mediated ADCC in MPM cell lines To evaluate whether" exact="lapatinib" post="enhances trastuzumab binding with tumor cells, we used FITC-conjugated"/>
   <result pre="ADCC in MPM cell lines To evaluate whether lapatinib enhances" exact="trastuzumab" post="binding with tumor cells, we used FITC-conjugated trastuzumab in"/>
   <result pre="lapatinib enhances trastuzumab binding with tumor cells, we used FITC-conjugated" exact="trastuzumab" post="in two MPM cell lines (NCI-H28 and NCI-H2052) in"/>
   <result pre="in two MPM cell lines (NCI-H28 and NCI-H2052) in which" exact="lapatinib" post="clearly upregulated HER2 expression for flow cytometry. In line"/>
   <result pre="cytometry. In line with our FACS data in Fig. 3," exact="lapatinib" post="upregulated the trastuzumab binding site in both NCI-H28 and"/>
   <result pre="with our FACS data in Fig. 3, lapatinib upregulated the" exact="trastuzumab" post="binding site in both NCI-H28 and NCI-H2052 cells ("/>
   <result pre="target cells treated with DMSO in both cell lines, while" exact="afatinib" post="did not enhance trastuzumab mediated-ADCC ( Fig. 5C and"/>
   <result pre="DMSO in both cell lines, while afatinib did not enhance" exact="trastuzumab" post="mediated-ADCC ( Fig. 5C and D). Lapatinib enhances trastuzumab"/>
   <result pre="enhance trastuzumab mediated-ADCC ( Fig. 5C and D). Lapatinib enhances" exact="trastuzumab" post="or cetuximab to bind with MPM cells from a"/>
   <result pre="mediated-ADCC ( Fig. 5C and D). Lapatinib enhances trastuzumab or" exact="cetuximab" post="to bind with MPM cells from a patient, resulted"/>
   <result pre="MPM, were assessed. Both EGFR and HER2 were upregulated by" exact="lapatinib" post="in MPM-p3 cells ( Fig. 3). In line with"/>
   <result pre="MPM-p3 cells ( Fig. 3). In line with these results," exact="lapatinib" post="upregulated both the cetuximab and trastuzumab binding sites ("/>
   <result pre="3). In line with these results, lapatinib upregulated both the" exact="cetuximab" post="and trastuzumab binding sites ( Fig. 6A and B),"/>
   <result pre="line with these results, lapatinib upregulated both the cetuximab and" exact="trastuzumab" post="binding sites ( Fig. 6A and B), resulting in"/>
   <result pre="and D). Discussion In the present study, we reported that" exact="lapatinib" post="enhanced trastuzumab-mediated ADCC in MPM cell lines as well"/>
   <result pre="in MPM patient cells, EGFR targeting therapy using first-generation EGFR-TKIs" exact="gefitinib" post="or erlotinib have failed to show any clinical benefits"/>
   <result pre="patient cells, EGFR targeting therapy using first-generation EGFR-TKIs gefitinib or" exact="erlotinib" post="have failed to show any clinical benefits in previously"/>
   <result pre="MPM cells, however, there are no reported clinical studies using" exact="trastuzumab" post="or lapatinib. Thus, targeting both EGFR and HER2 in"/>
   <result pre="mechanism behind the therapeutic potential of the anti-HER2 antibody drug" exact="trastuzumab" post="in HER2 overexpressing breast cancer cells is ADCC ("/>
   <result pre="crucial mechanism for the antitumor effects of anti-EGFR antibody drug" exact="cetuximab" post="in both NSCLC ( 15) and MPM cells ("/>
   <result pre="treatment of MPM. We have also shown that dual EGFR/HER2-TKI" exact="lapatinib" post="enhanced the expression of EGFR or HER2, however, the"/>
   <result pre="enhanced the expression of EGFR or HER2, however, the EGFR-TKI" exact="gefitinib" post="and pan-HER TKI afatinib did not enhance either receptor"/>
   <result pre="EGFR or HER2, however, the EGFR-TKI gefitinib and pan-HER TKI" exact="afatinib" post="did not enhance either receptor in MPM cells. Although"/>
   <result pre="results are in line with the recent studies showing that" exact="lapatinib" post="enhanced trastuzumab-mediated ADCC in breast cancer or gastrointestinal cancers"/>
   <result pre="are urgently required. Another important finding is that dual EGFR/HER2-TKI" exact="lapatinib" post="enhances both EGFR and HER2, while neither the EGFR-TKI"/>
   <result pre="lapatinib enhances both EGFR and HER2, while neither the EGFR-TKI" exact="gefitinib" post="nor pan-HER TKI afatinib have shown this effect. Our"/>
   <result pre="and HER2, while neither the EGFR-TKI gefitinib nor pan-HER TKI" exact="afatinib" post="have shown this effect. Our immunoblotting results show the"/>
   <result pre="HER2 were weakly inhibited by gefitinib, while strongly inhibited by" exact="afatinib" post="or lapatinib, suggesting that gefinitib had weaker effects on"/>
   <result pre="suggesting that gefinitib had weaker effects on EGFR/HER2 signaling than" exact="afatinib" post="or lapatinib in MPM cells. Notably, afatinib shows a"/>
   <result pre="gefinitib had weaker effects on EGFR/HER2 signaling than afatinib or" exact="lapatinib" post="in MPM cells. Notably, afatinib shows a similar effect"/>
   <result pre="EGFR/HER2 signaling than afatinib or lapatinib in MPM cells. Notably," exact="afatinib" post="shows a similar effect to that of lapatinib on"/>
   <result pre="cells. Notably, afatinib shows a similar effect to that of" exact="lapatinib" post="on both pEGFR and pHER2, but differed from that"/>
   <result pre="on both pEGFR and pHER2, but differed from that of" exact="lapatinib" post="on the expression of HER2. Rimawi et al showed"/>
   <result pre="on the expression of HER2. Rimawi et al showed that" exact="afatinib" post="monotherapy decreased the HER2 dimer in breast cancer tissue"/>
   <result pre="collected from patients ( 17). It was also reported that" exact="lapatinib" post="blocks the internalization of HER2, resulting in enhanced stabilization"/>
   <result pre="Based on these reported findings, the possible mechanism is that" exact="lapatinib" post="keeps homo- or heterodimers on the cell surface via"/>
   <result pre="internalization, resulting in the enhancement of HER2 expression. However, if" exact="afatinib" post="does not keep the dimerization, then HER2 may be"/>
   <result pre="and degradated. It is well known that the first-generation EGFR-TKIs" exact="gefitinib" post="and erlotinib exhibit a significant response in NSCLC cells"/>
   <result pre="It is well known that the first-generation EGFR-TKIs gefitinib and" exact="erlotinib" post="exhibit a significant response in NSCLC cells having the"/>
   <result pre="benefits for patients with MPM. In contrast, the second-generation EGFR-TKI" exact="afatinib" post="can inhibit EGFR signaling in NSCLC cells without EGFR"/>
   <result pre="such as the T790M mutation. According to our data, both" exact="afatinib" post="and lapatinib clearly inhibited the cell proliferation of MPM"/>
   <result pre="the T790M mutation. According to our data, both afatinib and" exact="lapatinib" post="clearly inhibited the cell proliferation of MPM cells, suggesting"/>
   <result pre="monotherapy. Additionally, we have shown in the present study that" exact="lapatinib" post="enhanced trastuzumab- or cetuximab-mediated ADCC while afatinib did not."/>
   <result pre="present study that lapatinib enhanced trastuzumab- or cetuximab-mediated ADCC while" exact="afatinib" post="did not. This suggests that lapatinib combined with trastuzumab"/>
   <result pre="or cetuximab-mediated ADCC while afatinib did not. This suggests that" exact="lapatinib" post="combined with trastuzumab and/or cetuximab is a very promising"/>
   <result pre="while afatinib did not. This suggests that lapatinib combined with" exact="trastuzumab" post="and/or cetuximab is a very promising strategy, as we"/>
   <result pre="did not. This suggests that lapatinib combined with trastuzumab and/or" exact="cetuximab" post="is a very promising strategy, as we can expect"/>
   <result pre="pursue optimal effect with least toxicity for MPM patients, and" exact="lapatinib" post="has been shown to be an ideal partner drug"/>
   <result pre="has been shown to be an ideal partner drug for" exact="cetuximab" post="or trastuzumab to enhance ADCC for MPM treatment. Acknowledgments"/>
   <result pre="shown to be an ideal partner drug for cetuximab or" exact="trastuzumab" post="to enhance ADCC for MPM treatment. Acknowledgments We thank"/>
   <result pre="Emri S Manegold C et al. Phase III study of" exact="pemetrexed" post="in combination with cisplatin versus cisplatin alone in patients"/>
   <result pre="et al. Phase III study of pemetrexed in combination with" exact="cisplatin" post="versus cisplatin alone in patients with malignant pleural mesothelioma"/>
   <result pre="Phase III study of pemetrexed in combination with cisplatin versus" exact="cisplatin" post="alone in patients with malignant pleural mesothelioma J Clin"/>
   <result pre="Testa JR Altomare DA Borden EC Phase II study of" exact="erlotinib" post="in patients with malignant pleural mesothelioma: A Southwest Oncology"/>
   <result pre="Kris MG Varmus H Acquired resistance of lung adenocarcinomas to" exact="gefitinib" post="or erlotinib is associated with a second mutation in"/>
   <result pre="Varmus H Acquired resistance of lung adenocarcinomas to gefitinib or" exact="erlotinib" post="is associated with a second mutation in the EGFR"/>
   <result pre="Crown J Chan A Kaufman B et al. Lapatinib plus" exact="capecitabine" post="for HER2-positive advanced breast cancer N Engl J Med"/>
   <result pre="receptor and HER2 variants on receptor activity and inhibition by" exact="lapatinib" post="Cancer Res 68 571 579 2008 10.1158/0008-5472.CAN-07-2404 18199554 14"/>
   <result pre="M Miyata M et al. Antibody-dependent cellular cytotoxicity mediated by" exact="cetuximab" post="against lung cancer cell lines Clin Cancer Res 13"/>
   <result pre="et al. A neoadjuvant, randomized, open-label phase II trial of" exact="afatinib" post="versus trastuzumab versus lapatinib in patients with locally advanced"/>
   <result pre="A neoadjuvant, randomized, open-label phase II trial of afatinib versus" exact="trastuzumab" post="versus lapatinib in patients with locally advanced HER2-positive breast"/>
   <result pre="randomized, open-label phase II trial of afatinib versus trastuzumab versus" exact="lapatinib" post="in patients with locally advanced HER2-positive breast cancer Clin"/>
   <result pre="NCI-H2052 cells were treated with DMSO or 1 µM of" exact="afatinib" post="or lapatinib for 24 h, then the binding site"/>
   <result pre="were treated with DMSO or 1 µM of afatinib or" exact="lapatinib" post="for 24 h, then the binding site of trastuzumab"/>
   <result pre="or lapatinib for 24 h, then the binding site of" exact="trastuzumab" post="was analyzed using FITC-conjugated trastuzumab. FITC-conjugate rituximab was used"/>
   <result pre="binding site of trastuzumab was analyzed using FITC-conjugated trastuzumab. FITC-conjugate" exact="rituximab" post="was used as an isotype control. Representative data of"/>
   <result pre="NCI-H2052 cells were treated with DMSO or 1 µM of" exact="lapatinib" post="or afatinib for 24 h, then trastuzumab-mediated antibody-dependent cellular"/>
   <result pre="were treated with DMSO or 1 µM of lapatinib or" exact="afatinib" post="for 24 h, then trastuzumab-mediated antibody-dependent cellular cytotoxicity (ADCC)"/>
   <result pre="MPM-p3 cells were treated with DMSO or 1 µM of" exact="lapatinib" post="for 24 h, then the binding site of (A)"/>
   <result pre="lapatinib for 24 h, then the binding site of (A)" exact="cetuximab" post="or (B) trastuzumab were analyzed using FITC-conjugated trastuzumab. FITC-conjugate"/>
   <result pre="h, then the binding site of (A) cetuximab or (B)" exact="trastuzumab" post="were analyzed using FITC-conjugated trastuzumab. FITC-conjugate rituximab was used"/>
   <result pre="cetuximab or (B) trastuzumab were analyzed using FITC-conjugated trastuzumab. FITC-conjugate" exact="rituximab" post="was used as an isotype control. Single experiments are"/>
   <result pre="MPM-p3 cells were treated with DMSO or 1 µM of" exact="lapatinib" post="for 24 h, both cetuximab-mediated (C) and trastuzumab-mediated (D),"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4728453/results/search/inn/results.xml">
   <result pre="bound to plasma proteins [ 20, 21]. Altered distribution of" exact="docetaxel" post="can be expected in the elderly patient who has"/>
   <result pre="[ 11, 12]. With only a small fraction excreted renally," exact="docetaxel" post="undergoes hepatic metabolism by CYP3A4 into inactive metabolites and"/>
   <result pre="and n = 20, respectively) documented a significant decrease in" exact="docetaxel" post="clearance with increasing age [ 29, 30]. A subsequent"/>
   <result pre="n = 601) supported this significant effect of aging on" exact="docetaxel" post="PK, although the observed decrease in clearance of 7%"/>
   <result pre="NSCLC 50 76 (75–86) Docetaxel: Docetaxel: Elderly received a lower" exact="doxorubicin" post="dose per protocol, resulting in a significantly lower AUC,"/>
   <result pre="others 37 51 (17–74) NA ≥70 y: Also reported that" exact="doxorubicin" post="CL of the distribution phase was significantly influenced by"/>
   <result pre="total group of 27 pts, of which 20 received iv" exact="vinorelbine" post="T ½: +6% &amp;lt;65 y; n = 6 AUC:"/>
   <result pre="( n = 23), increasing age was inversely associated with" exact="paclitaxel" post="elimination, showing a 50% lower clearance of unbound paclitaxel"/>
   <result pre="with paclitaxel elimination, showing a 50% lower clearance of unbound" exact="paclitaxel" post="in patients aged ≥70 years [ 39]. These results"/>
   <result pre="younger peers. It remains uncertain whether elderly patients treated with" exact="paclitaxel" post="in clinical practice have a similar PK profile compared"/>
   <result pre="recent large studies imply a small impact of age on" exact="paclitaxel" post="PK [ 40, 41, 42]. Given the high inter-"/>
   <result pre="41, 42]. Given the high inter- and intra-patient variability in" exact="paclitaxel" post="PK, it seems implausible that any potential age-related PK"/>
   <result pre="parent drug is excreted in the bile, while 30% of" exact="doxorubicin" post="is excreted as conjugates. Five to 12% of the"/>
   <result pre="found no influence of advanced age on the clearance of" exact="doxorubicin" post="[ 46, 47], although one of these studies noted"/>
   <result pre="the distribution phase of doxorubicin. This study showed that initial" exact="doxorubicin" post="concentrations were higher in the elderly patient due to"/>
   <result pre="a small, but significant inverse correlation between age and total" exact="doxorubicin" post="clearance [ 49]. These findings were supported by a"/>
   <result pre="65 breast cancer patients, showing a significant 9% decrease in" exact="doxorubicin" post="clearance per 10-year increase in age [ 50]. Overall,"/>
   <result pre="breast cancer patients, no relevant age-related differences in PK of" exact="epirubicin" post="were found. However, the number of elderly patients included"/>
   <result pre="on the contrary, a significant influence of increasing age on" exact="epirubicin" post="clearance was observed, although it should be noted that"/>
   <result pre="a study including 66 breast cancer patients, showing an increased" exact="epirubicin" post="maximum serum concentration with increasing age [ 54]. Based"/>
   <result pre="shows autoinduction after repeated administration [ 57]. Following intravenous administration," exact="cyclophosphamide" post="is primarily excreted as metabolites, while 10%–20% is excreted"/>
   <result pre="excreted in the bile. The impact of liver dysfunction on" exact="cyclophosphamide" post="PK remains unclear at present, with some reports showing"/>
   <result pre="no apparent impact of patient age on the clearance of" exact="cyclophosphamide" post="[ 47, 50]. 4.4. Vinca-Alkaloids 4.4.1. Vinorelbine (Intravenous) Vinorelbine"/>
   <result pre="clinical trials showed no correlation between age and elimination of" exact="vinorelbine" post="[ 61, 62, 63, 64, 65]. Gauvin and colleagues,"/>
   <result pre="Gauvin and colleagues, however, described a significant age-related decrease of" exact="vinorelbine" post="clearance in two clinical studies that exclusively included patients"/>
   <result pre="drug’s SmPC [ 68]. 4.4.2. Vinorelbine (Oral) Oral administration of" exact="vinorelbine" post="may be an attractive alternative to intravenous vinorelbine for"/>
   <result pre="administration of vinorelbine may be an attractive alternative to intravenous" exact="vinorelbine" post="for elderly patients, who are often affected by poor"/>
   <result pre="who are often affected by poor venous access. However, oral" exact="vinorelbine" post="has been associated with severe and potentially fatal neutropenia,"/>
   <result pre="71, 72]. The average bioavailability of the oral formulation of" exact="vinorelbine" post="ranges from 33%–43%, with linear elimination similar to the"/>
   <result pre="analyses suggested that increasing age has no clinically-relevant impact on" exact="vinorelbine" post="PK [ 63, 74, 75]. 4.5. Anti-Metabolites 4.5.1. 5-Fluorouracil"/>
   <result pre="are not necessary [ 84]. 4.5.2. Capecitabine After oral administration," exact="capecitabine" post="is sequentially converted to 5′-deoxy-5-fluorocytidine (DFCR) by hepatic carboxylesterase"/>
   <result pre="patients have a higher risk of developing severe toxicity with" exact="capecitabine" post="compared to intravenous 5-FU [ 85, 86]. Renal function"/>
   <result pre="dose reductions than their younger peers (51% vs. 39%) during" exact="capecitabine" post="treatment [ 88]. Although not formally advised, several studies"/>
   <result pre="99, 100, 101]. In one moderate-sized PK study, a lower" exact="capecitabine" post="clearance in elderly patients was found ( n ="/>
   <result pre="trials, showing no effect of age on the clearance of" exact="capecitabine" post="and its metabolites. Although a difference in absorption by"/>
   <result pre="having clinical relevance [ 101]. According to the drug’s SmPC," exact="capecitabine" post="should be used cautiously in elderly patients. EMA stated"/>
   <result pre="with subsequent studies showing no clinically-relevant effect of aging on" exact="capecitabine" post="PK. Still, elderly patients develop more pronounced toxicity from"/>
   <result pre="capecitabine PK. Still, elderly patients develop more pronounced toxicity from" exact="capecitabine" post="on average, potentially due to reduced organ function, and"/>
   <result pre="drug mainly undergoes renal excretion [ 104]. In clinical practice," exact="carboplatin" post="is dosed based on estimates of GFR, typically by"/>
   <result pre="106]. In a phase I study including 55 patients receiving" exact="carboplatin" post="dosed in mg/m 2, a significant increase in mean"/>
   <result pre="2, a significant increase in mean plasma ultrafiltrate AUC of" exact="carboplatin" post="was observed with increasing age [ 43]. In a"/>
   <result pre="more recent study ( n = 24), elderly patients received" exact="carboplatin" post="AUC 4 (mg/min/Ml) versus carboplatin AUC 5 in their"/>
   <result pre="= 24), elderly patients received carboplatin AUC 4 (mg/min/Ml) versus" exact="carboplatin" post="AUC 5 in their younger counterparts, as calculated with"/>
   <result pre="similar in both groups. Age was a significant predictor of" exact="carboplatin" post="clearance, showing a 31% mean clearance decrease in patients"/>
   <result pre="n = 22), lower creatinine clearance was significantly associated with" exact="cisplatin" post="maximum plasma concentrations (Cmax) [ 113]. Although the influence"/>
   <result pre="concentrations (Cmax) [ 113]. Although the influence of age on" exact="cisplatin" post="PK was not tested in this analysis, results could"/>
   <result pre="analysis, results could justify dose reductions or prolonged infusion of" exact="cisplatin" post="in elderly patients with an associated decreases in renal"/>
   <result pre="in roughly 25% of breast cancer patients. After intravenous administration," exact="trastuzumab" post="undergoes target-directed distribution and elimination by the reticuloendothelial system"/>
   <result pre="HER2-positive breast cancer in the early or advanced stage. While" exact="trastuzumab" post="is given as a three-weekly intravenous infusion in early-stage"/>
   <result pre="found to be a significant covariate on the relationship between" exact="trastuzumab" post="PK and the trastuzumab-associated decrease of left ventricular ejection"/>
   <result pre="of trastuzumab. Monitoring of cardiac function at baseline and during" exact="trastuzumab" post="treatment, however, is of substantial importance to keep a"/>
   <result pre="is also in agreement with data as described for the" exact="trastuzumab" post="antibody-drug conjugate T-DM1 (see below). 4.7.2. Trastuzumab Emtansine (Antibody-Drug"/>
   <result pre="(T-DM1) is a novel antibody-drug conjugate, which is composed of" exact="trastuzumab" post="coupled through a stable thioether linker to mertansine, an"/>
   <result pre="to trastuzumab. Yet, drug clearance of T-DM1 was faster than" exact="trastuzumab" post="clearance, which may be ascribed to the addition of"/>
   <result pre="studies revealed no influence of aging on the PK of" exact="trastuzumab" post="emtansine in large datasets [ 125, 126]. This is"/>
   <result pre="label stating that age has no clinically meaningful effect on" exact="trastuzumab" post="emtansine PK [ 121]. 4.8. Tubulin Inhibitors 4.8.1. Eribulin"/>
   <result pre="is predominantly excreted unchanged in the feces. Renal excretion of" exact="eribulin" post="mesylate was shown to be less than 10% ["/>
   <result pre="was provided. This analysis showed that the median clearance of" exact="eribulin" post="mesylate was not influenced by age [ 130]. 4.9."/>
   <result pre="[ 131]. The FDA’s SmPC stated that the clearance of" exact="everolimus" post="is not dependent on age [ 132]. Although this"/>
   <result pre="low solubility and first-pass metabolism by CYP3A4/5. After gastrointestinal absorption," exact="lapatinib" post="is highly protein bound (99%) to albumin and alpha-1-acid-glycoprotein."/>
   <result pre="as no data are available on the age-related PK of" exact="lapatinib" post="[ 137, 138, 139, 140]. Although no influence of"/>
   <result pre="evidence of absence&quot; of any association between patient age and" exact="lapatinib" post="PK, as no studies were available investigating the influence"/>
   <result pre="no studies were available investigating the influence of aging on" exact="lapatinib" post="PK [ 138]. 5. Discussion This article summarizes existing"/>
   <result pre="patient age to impact the PK of taxanes, anthracyclines, vinorelbine," exact="capecitabine" post="and platinum compounds. On the other side, potential PK"/>
   <result pre="to be clinically relevant in the case of docetaxel, doxorubicin," exact="vinorelbine" post="and capecitabine. Additional analysis of paclitaxel also implies no"/>
   <result pre="case of docetaxel, doxorubicin, vinorelbine and capecitabine. Additional analysis of" exact="paclitaxel" post="also implies no clinically-relevant PK differences in the elderly."/>
   <result pre="various covariates on the drug’s PK, including patient age. For" exact="eribulin" post="mesylate, trastuzumab emtansine and everolimus, these model-based analyses showed"/>
   <result pre="on the drug’s PK, including patient age. For eribulin mesylate," exact="trastuzumab" post="emtansine and everolimus, these model-based analyses showed no age-associated"/>
   <result pre="USA 2015 22. Clarke S.J. Rivory L.P. Clinical pharmacokinetics of" exact="docetaxel" post="Clin. Pharmacokinet. 1999 36 99 114 10.2165/00003088-199936020-00002 10092957 23."/>
   <result pre="Sekine I. et al. Comparison of pharmacokinetics and pharmacodynamics of" exact="docetaxel" post="and cisplatin in elderly and non-elderly patients: Why is"/>
   <result pre="et al. Comparison of pharmacokinetics and pharmacodynamics of docetaxel and" exact="cisplatin" post="in elderly and non-elderly patients: Why is toxicity increased"/>
   <result pre="McLachlan A.J. Blair E.Y.L. Rivory L.P. Population pharmacokinetics of weekly" exact="docetaxel" post="in patients with advanced cancer Br. J. Clin. Pharmacol."/>
   <result pre="S.D. Prospective evaluation of the pharmacokinetics and toxicity profile of" exact="docetaxel" post="in the elderly J. Clin. Oncol. 2005 23 1070"/>
   <result pre="M.G. Gomez J. et al. Pharmacokinetics and toxicity of weekly" exact="docetaxel" post="in older patients Clin. Cancer Res. 2006 12 6100"/>
   <result pre="Kamiya Y. Sekine I. Kunitoh H. Saijo N. Correlation between" exact="docetaxel" post="clearance and estimated cytochrome P450 activity by urinary metabolite"/>
   <result pre="Montay G. Rhodes G.R. Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for" exact="docetaxel" post="Investig. New Drugs 2001 19 163 169 10.1023/A:1010687017717 11392450"/>
   <result pre="Gianni L. Verweij J. Sparreboom A. Mechanism-based pharmacokinetic model for" exact="paclitaxel" post="J. Clin. Oncol. 2001 19 4065 4073 11600609 36."/>
   <result pre="and efficacy in phase II trials of 3-h infusions of" exact="paclitaxel" post="for patients 70 years of age or older and"/>
   <result pre="cancer treated with chemotherapy. A phase II study of weekly" exact="paclitaxel" post="Clin. Cancer Res. 2001 7 3942 3949 11751486 38."/>
   <result pre="Zomeren D.M. Seynaeve C. Sparreboom A. Altered clearance of unbound" exact="paclitaxel" post="in elderly patients with metastatic breast cancer Eur. J."/>
   <result pre="Jaehde U. Evaluation of a pharmacology-driven dosing algorithm of 3-weekly" exact="paclitaxel" post="using therapeutic drug monitoring: A pharmacokinetic-pharmacodynamic simulation study Clin."/>
   <result pre="al. Prospective evaluation of the relationship of patient age and" exact="paclitaxel" post="clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762)"/>
   <result pre="Koolen M.G. ten Bokkel Huinink W.W. et al. Pharmacokinetics of" exact="paclitaxel" post="and carboplatin in a dose-escalating and dose-sequencing study in"/>
   <result pre="ten Bokkel Huinink W.W. et al. Pharmacokinetics of paclitaxel and" exact="carboplatin" post="in a dose-escalating and dose-sequencing study in patients with"/>
   <result pre="Gillies H. James C.A. Harper P.G. Rubens R.D. Gender affects" exact="doxorubicin" post="pharmacokinetics in patients with normal liver biochemistry Cancer Chemother."/>
   <result pre="J. Hoerni B. Age dependence of the early-phase pharmacokinetics of" exact="doxorubicin" post="Cancer Res. 1983 43 4467 9 6871877 49. Li"/>
   <result pre="P.R. The effect of age on the early disposition of" exact="doxorubicin" post="Cancer Chemother. Pharmacol. 2003 51 395 402 12679882 50."/>
   <result pre="A. Sorio R. et al. Population pharmacokinetics and pharmacodynamics of" exact="doxorubicin" post="and cyclophosphamide in breast cancer patients: A study by"/>
   <result pre="R. et al. Population pharmacokinetics and pharmacodynamics of doxorubicin and" exact="cyclophosphamide" post="in breast cancer patients: A study by the EORTC-PAMM-NDDG"/>
   <result pre="E. Rose C. Nielsen O.S. et al. Multiple-dose pharmacokinetics of" exact="epirubicin" post="at four different dose levels: Studies in patients with"/>
   <result pre="Village, CO, USA 2015 58. Moore M.J. Clinical pharmacokinetics of" exact="cyclophosphamide" post="Clin. Pharmacokinet. 1991 20 194 208 10.2165/00003088-199120030-00002 2025981 59."/>
   <result pre="Crivellari D. Saracchini S. Monfardini S. Pharmacokinetics and tolerance of" exact="vinorelbine" post="in elderly patients with metastatic breast cancer Eur. J."/>
   <result pre="P. Population pharmacokinetics model and limited sampling strategy for intravenous" exact="vinorelbine" post="derived from phase I clinical trials Br. J. Clin."/>
   <result pre="B. Puozzo C. A simultaneous oral/intravenous population pharmacokinetic model for" exact="vinorelbine" post="Eur. J. Clin. Pharmacol. 2002 58 467 476 10.1007/s00228-002-0506-x"/>
   <result pre="L. Suttle A.B. Sullivan D.M. The absolute bioavailability of oral" exact="vinorelbine" post="in patients with solid tumors Cancer Chemother. Pharmacol. 2005"/>
   <result pre="Farlow D. Collins M. Rivory L.P. et al. Predictors of" exact="vinorelbine" post="pharmacokinetics and pharmacodynamics in patients with cancer J. Clin."/>
   <result pre="S. Astre C. Gomeni R. Bressolle F. Bayesian estimate of" exact="vinorelbine" post="pharmacokinetic parameters in elderly patients with advanced metastatic cancer"/>
   <result pre="F. A limited-sampling strategy to estimate individual pharmacokinetic parameters of" exact="vinorelbine" post="in elderly patients with advanced metastatic cancer Anticancer Drugs"/>
   <result pre="Y. Merrouche Y. Robinet G. Senac I. Puozzo C. Oral" exact="vinorelbine" post="pharmacokinetics and absolute bioavailability study in patients with solid"/>
   <result pre="R. Betticher D. Pless M. Pons J.T. et al. Oral" exact="vinorelbine" post="given as monotherapy to advanced, elderly NSCLC patients: A"/>
   <result pre="polymorphisms and haplotypes in DPYD and toxicity and efficacy of" exact="capecitabine" post="in advanced colorectal cancer Clin. Cancer Res. 2011 17"/>
   <result pre="Schneider M. Demard F. Influence of sex and age on" exact="fluorouracil" post="clearance J. Clin. Oncol. 1992 10 1171 1175 1607921"/>
   <result pre="Kim S.S. Koh Y.H. Park S.J. et al. Comparison of" exact="capecitabine" post="and 5-fluorouracil in chemoradiotherapy for locally advanced pancreatic cancer"/>
   <result pre="S.M. Kim Y.J. Kim D.W. Kang S.B. Lee J.S. Adjuvant" exact="capecitabine" post="chemotherapy using a tailored-dose strategy in elderly patients with"/>
   <result pre="Buzzoni R. Safety and efficacy of two different doses of" exact="capecitabine" post="in the treatment of advanced breast cancer in older"/>
   <result pre="Osborne S. Andre N. Waterkamp D. Saunders M.P. Bevacizumab plus" exact="capecitabine" post="versus capecitabine alone in elderly patients with previously untreated"/>
   <result pre="Andre N. Waterkamp D. Saunders M.P. Bevacizumab plus capecitabine versus" exact="capecitabine" post="alone in elderly patients with previously untreated metastatic colorectal"/>
   <result pre="O. Buzdar A. Osterwalder B. Multicenter, Phase II study of" exact="capecitabine" post="in taxane-pretreated metastatic breast carcinoma patients Cancer 2001 92"/>
   <result pre="D. Curé H. et al. Multicentre, phase II study evaluating" exact="capecitabine" post="monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast"/>
   <result pre="W. Wei M. Yang T. Wang Z. Qiu M. Low-dose" exact="capecitabine" post="adjuvant chemotherapy in elderly stage II/III colorectal cancer patients"/>
   <result pre="Blesch K.S. Steimer J.L. Population pharmacokinetics and concentration-effect relationships of" exact="capecitabine" post="metabolites in colorectal cancer patients Br. J. Clin. Pharmacol."/>
   <result pre="Roos B. et al. Bioequivalence of two tablet formulations of" exact="capecitabine" post="and exploration of age, gender, body surface area, and"/>
   <result pre="Steimer J.L. Population pharmacokinetic analysis of the major metabolites of" exact="capecitabine" post="J. Pharmacokinet. Pharmacodyn. 2002 29 25 47 10.1023/A:1015716617967 12194534"/>
   <result pre="P. Tubiana-Mathieu N. Rousseau A. Pharmacokinetics and exposure-effect relationships of" exact="capecitabine" post="in elderly patients with breast or colorectal cancer Cancer"/>
   <result pre="D. Raghavan D. Shields A.F. Gold P.J. Blanke C.D. Higher" exact="capecitabine" post="AUC in elderly patients with advanced colorectal cancer (SWOGS0030)"/>
   <result pre="Effect of age on systemic exposure and haematological toxicity of" exact="carboplatin" post="in advanced non-small cell lung cancer patients Basic Clin."/>
   <result pre="Taylor S. Repta A.J. Sternson L.A. Clinical kinetics on intact" exact="cisplatin" post="and some related species Clin. Pharmacol. Ther. 1981 29"/>
   <result pre="F. Shiraishi J. Katsumata N. The influence of ageing on" exact="cisplatin" post="pharmacokinetics in lung cancer patients with normal organ function"/>
   <result pre="A. Gaspard M.H. Dassonville O. Schneider M. Renal tolerance of" exact="cisplatin" post="in patients more than 80 years old J. Clin."/>
   <result pre="Budman D. DeMarco L. Schuster M. Lovecchio J. Use of" exact="cisplatin" post="for elderly patients Age Ageing 1992 21 202 204"/>
   <result pre="Castro J. Ordoñez A. González Barón M. Renal tolerance to" exact="cisplatin" post="in patients 70 years and older Am. J. Clin."/>
   <result pre="al. Randomized phase III trial of weekly compared with every-3-weeks" exact="paclitaxel" post="for metastatic breast cancer, with trastuzumab for all HER-2"/>
   <result pre="weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with" exact="trastuzumab" post="for all HER-2 overexpressors and random assignment to trastuzumab"/>
   <result pre="with trastuzumab for all HER-2 overexpressors and random assignment to" exact="trastuzumab" post="or not in HER-2 nonoverexpressors: Final results of Cancer"/>
   <result pre="H.A. Girish S. An integrated multiple-analyte pharmacokinetic model to characterize" exact="trastuzumab" post="emtansine (T-DM1) clearance pathways and to evaluate reduced pharmacokinetic"/>
   <result pre="M. Rimawi M. Conte P. et al. Population pharmacokinetics of" exact="trastuzumab" post="emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with"/>
   <result pre="Grünwald V. Thompson J.A. Figlin R.A. et al. Efficacy of" exact="everolimus" post="in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled"/>
   <result pre="R. Two-dose-level confirmatory study of the pharmacokinetics and tolerability of" exact="everolimus" post="in Chinese patients with advanced solid tumors J. Hematol."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4729711/results/search/inn/results.xml">
   <result pre="receptor antagonist Elevation of liver enzymes, oedema Molecular-targeted therapy Trastuzumab," exact="pertuzumab" post="Interferes with the HER2/neu receptor Cardiotoxicity, pulmonary toxicity Lapatinib"/>
   <result pre="cytotoxic drugs are taxanes (paclitaxel and docetaxel), cyclophosphamide, eribulin, capecitabine," exact="cisplatin" post="and anthracyclines (doxorubicin and epirubicin). Taxanes and anthracyclines are"/>
   <result pre="agents, called aromatase inhibitors (AIs), has shown superior efficacy to" exact="tamoxifen" post="in the metastatic, neoadjuvant and adjuvant settings in postmenopausal"/>
   <result pre="the metastatic, neoadjuvant and adjuvant settings in postmenopausal women. Anastrozole," exact="letrozole" post="and exemestane are the three most widely used of"/>
   <result pre="neoadjuvant and adjuvant settings in postmenopausal women. Anastrozole, letrozole and" exact="exemestane" post="are the three most widely used of these drugs."/>
   <result pre="surgery have been demonstrated in patients treated with AIs versus" exact="tamoxifen" post="[ 6]. Endocrine therapy has a better toxicity profile"/>
   <result pre="trials have demonstrated better disease-free survival with the addition of" exact="trastuzumab" post="in combination with standard first-line chemotherapy for the treatment"/>
   <result pre="single anti-HER2 agent [ 13]. The NCCN guidelines now recommend" exact="trastuzumab" post="and pertuzumab (in combination) in HER2-positive metastatic disease in"/>
   <result pre="agent [ 13]. The NCCN guidelines now recommend trastuzumab and" exact="pertuzumab" post="(in combination) in HER2-positive metastatic disease in combination with"/>
   <result pre="suggestive of pseudoprogression Fig. 3 82-year-old woman with estrogen and" exact="progesterone" post="receptor-positive breast cancer with bony metastases being treated with"/>
   <result pre="agents, including gadoxetate disodium (Eovist/Primovist; Bayer HealthCare, Leverkusen, Germany) and" exact="gadobenate dimeglumine" post="(MultiHance; Bracco Diagnostics Inc., Princeton, NJ, USA), are excreted"/>
   <result pre="T1-weighted MR image in venous phase after administration of intravenous" exact="gadopentetate dimeglumine" post="(Magnevist) shows ill-defined hyperenhancement in segment III of left"/>
   <result pre="image after whole-brain radiation and 2 months of therapy with" exact="lapatinib" post="shows significant interval decrease in size of enhancing lesion"/>
   <result pre="image before ( a) and after ( b) treatment with" exact="paclitaxel" post="shows interval appearance of patchy ground-glass opacities in upper"/>
   <result pre="associated with several cytotoxic breast cancer drugs including doxorubicin, docetaxel," exact="paclitaxel" post="and platinum agents. CT findings include colonic wall thickening"/>
   <result pre="to perforation, is another treatment complication most commonly associated with" exact="doxorubicin" post="and taxanes. Pneumatosis intestinalis may be observed with cyclophosphamide,"/>
   <result pre="and taxanes. Pneumatosis intestinalis may be observed with cyclophosphamide, doxorubicin," exact="cisplatin" post="and docetaxel [ 49]. Fluid retention, likely due to"/>
   <result pre="Pneumatosis intestinalis may be observed with cyclophosphamide, doxorubicin, cisplatin and" exact="docetaxel" post="[ 49]. Fluid retention, likely due to capillary protein"/>
   <result pre="within the bladder [ 52]. Hormones Patients receiving treatment with" exact="tamoxifen" post="have an increased prevalence of endometrial hyperplasia, endometrial polyps"/>
   <result pre="in women treated with tamoxifen. While the agonistic effects of" exact="tamoxifen" post="on estrogen receptors are beneficial in some tissues—for example,"/>
   <result pre="typically diffusely or partially echogenic. As many patients treated on" exact="tamoxifen" post="have endometrial thickening and underlying adenomyosis, poorly defined endometrial"/>
   <result pre="is useful for the characterization of endometrial abnormalities associated with" exact="tamoxifen" post="therapy [ 55]. Fig. 10 72-year-old woman with metastatic"/>
   <result pre="seen in up to 30 % of patients treated with" exact="tamoxifen" post="(Fig. 11), and can be present as early as"/>
   <result pre="discontinuation [ 57]. Risk factors for hepatic changes associated with" exact="tamoxifen" post="include preexisting conditions such as diabetes, obesity and hepatic"/>
   <result pre="a) and after ( b) 6 months of treatment with" exact="tamoxifen" post="shows diffuse hypodensity of liver parenchyma on image ("/>
   <result pre="MTTs have class-specific and drug-specific toxicities. m-TOR inhibitors such as" exact="everolimus" post="are associated with drug-induced pneumonitis manifesting radiologically as ground-glass"/>
   <result pre="after doxorubicin. The incidence of cardiac dysfunction in patients receiving" exact="trastuzumab" post="ranges from 2 to 28 % [ 61]. The"/>
   <result pre="to 28 % [ 61]. The most common manifestation of" exact="trastuzumab" post="cardiotoxicity is an asymptomatic decrease in left ventricular ejection"/>
   <result pre="who develop symptomatic cardiac failure [ 66]. Adverse effects of" exact="lapatinib" post="include fatigue, nausea, rash, diarrhoea, neutropenia, hepatotoxicity, interstitial lung"/>
   <result pre="image before ( a) and after ( b) treatment with" exact="trastuzumab" post="shows interval appearance of peripheral ground-glass opacities in right"/>
   <result pre="Cataliotti L Buzdar AU Noguchi S et al. Comparison of" exact="anastrozole" post="versus tamoxifen as preoperative therapy in postmenopausal women with"/>
   <result pre="Buzdar AU Noguchi S et al. Comparison of anastrozole versus" exact="tamoxifen" post="as preoperative therapy in postmenopausal women with hormone receptor-positive"/>
   <result pre="H Bono P Kataja V et al. Fluorouracil, epirubicin, and" exact="cyclophosphamide" post="with either docetaxel or vinorelbine, with or without trastuzumab,"/>
   <result pre="Kataja V et al. Fluorouracil, epirubicin, and cyclophosphamide with either" exact="docetaxel" post="or vinorelbine, with or without trastuzumab, as adjuvant treatments"/>
   <result pre="V Paul D et al. Multicenter phase ii study of" exact="lapatinib" post="in patients with brain metastases from HER2-positive breast cancer"/>
   <result pre="SM Kim SB Cortes J et al. Pertuzumab, trastuzumab, and" exact="docetaxel" post="for HER2-positive metastatic breast cancer (cleopatra study): overall survival"/>
   <result pre="HJ Kim GC Kim DK Sim YJ Clinical features of" exact="docetaxel" post="chemotherapy-related lymphedema Lymphat Res Biol 2014 12 197 202"/>
   <result pre="De Vries A Mactaggart P Nicol D Urological implications of" exact="cyclophosphamide" post="and ifosfamide Scand J Urol Nephrol 2008 42 309"/>
   <result pre="A Mactaggart P Nicol D Urological implications of cyclophosphamide and" exact="ifosfamide" post="Scand J Urol Nephrol 2008 42 309 317 10.1080/00365590701570953"/>
   <result pre="et al (2014) Radiation recall dermatitis and pneumonitis induced by" exact="trastuzumab" post="(herceptin ®). Int J Dermatol 53:e159–e160 61. Yeh ET"/>
   <result pre="Les D Sarzyczny-Slota D Nowara E Cardiac side effects of" exact="trastuzumab" post="in breast cancer patients—single center experiences Contemp Oncol (Pozn)"/>
   <result pre="Lenihan DJ Valero V et al. Long-term cardiac tolerability of" exact="trastuzumab" post="in metastatic breast cancer: the M.D. Anderson Cancer Center"/>
   <result pre="16908934 64. Perez EA Rodeheffer R Clinical cardiac tolerability of" exact="trastuzumab" post="J Clin Oncol 2004 22 322 329 10.1200/JCO.2004.01.120 14722042"/>
   <result pre="Azambuja E Holmes AP Piccart-Gebhart M et al. Lapatinib with" exact="trastuzumab" post="for HER2-positive early breast cancer (NeoALTTO): survival outcomes of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4730993/results/search/inn/results.xml">
   <result pre="3 Subsequent clinical trials confirmed these observations, 4– 6 and" exact="tamoxifen" post="is now the standard of care for both pre-"/>
   <result pre="1998, the codevelopment and FDA approval of the monoclonal antibody" exact="trastuzumab" post="(Herceptin, Roche/Genentech) and the immunohistochemistry (IHC) assay HercepTest (Dako"/>
   <result pre="(such as tumor grade and lymphovascular infiltration), estrogen receptor and" exact="progesterone" post="receptor status, and HER2 overexpression are collectively considered when"/>
   <result pre="American Society of Clinical Oncology (ASCO) guidelines 22 recommend that" exact="tamoxifen" post="therapy should be given to premenopausal women for a"/>
   <result pre="reduced recurrence and improved survival benefit with longer duration of" exact="tamoxifen" post="use. 23, 24 For postmenopausal women, 10 years total"/>
   <result pre="years total endocrine therapy is recommended, which consists of either" exact="tamoxifen" post="given for the full duration or 5 years tamoxifen"/>
   <result pre="either tamoxifen given for the full duration or 5 years" exact="tamoxifen" post="plus 5 years of an aromatase inhibitor. 22 For"/>
   <result pre="breast cancer, which lacks the expression of the estrogen receptor," exact="progesterone" post="receptor, and HER2, is an aggressive subgroup for which"/>
   <result pre="gene. Given the history of their use, estrogen receptor and" exact="progesterone" post="receptor testing is not considered companion diagnostics by the"/>
   <result pre="the effective treatment with aromatase inhibitors and the hormone modulators," exact="tamoxifen" post="and fulvestrant. Therefore, estrogen receptor and progesterone receptor testing"/>
   <result pre="the hormone modulators, tamoxifen and fulvestrant. Therefore, estrogen receptor and" exact="progesterone" post="receptor testing is included in the discussion below. Estrogen"/>
   <result pre="testing is included in the discussion below. Estrogen receptor and" exact="progesterone" post="receptor testing In normal breast tissue, estrogen and progesterone"/>
   <result pre="and progesterone receptor testing In normal breast tissue, estrogen and" exact="progesterone" post="are critical regulators of the growth and differentiation of"/>
   <result pre="the growth and differentiation of epithelial cells. Specifically, estrogen and" exact="progesterone" post="mediate their biological effects through binding to isoforms of"/>
   <result pre="isoforms of their respective steroid receptors, the estrogen receptor and" exact="progesterone" post="receptor. The estrogen receptor-α isoform is the most studied"/>
   <result pre="testing method for assessing the presence of the estrogen and" exact="progesterone" post="receptors in breast cancer. First standardized and validated by"/>
   <result pre="crucial component of the ASCO/CAP guideline is that estrogen and" exact="progesterone" post="receptor assays be considered positive if 1% or more"/>
   <result pre="low as 1% of tumor cells positive for estrogen and" exact="progesterone" post="staining derive benefit from endocrine therapy, this recommendation has"/>
   <result pre="a specific molecular target, in this case HER2. In 1998," exact="trastuzumab" post="and the Dako Denmark A/S companion diagnostic test, HercepTest,"/>
   <result pre="as a companion diagnostic to assess suitability for initiation of" exact="trastuzumab" post="treatment. HercepTest is the only companion diagnostic approved for"/>
   <result pre="IHC assessment for the presence of the estrogen receptor and" exact="progesterone" post="receptor, IHC testing for overexpression of HER2 is considered"/>
   <result pre="cells. As with IHC testing of the estrogen receptor and" exact="progesterone" post="receptor, variability in HER2 IHC may arise from preanalytical,"/>
   <result pre="(ie, Ki67 and CCNB1), estrogen regulation (ie, estrogen receptor and" exact="progesterone" post="receptor), HER2 amplification, and invasiveness. This assay is performed"/>
   <result pre="J Redmond C et al. A randomized clinical trial evaluating" exact="tamoxifen" post="in the treatment of patients with node-negative breast cancer"/>
   <result pre="C Brown A et al. Influence of tumor estrogen and" exact="progesterone" post="receptor levels on the response to tamoxifen and chemotherapy"/>
   <result pre="tumor estrogen and progesterone receptor levels on the response to" exact="tamoxifen" post="and chemotherapy in primary breast cancer J Clin Oncol"/>
   <result pre="et al. Treatment of primary breast cancer with chemotherapy and" exact="tamoxifen" post="N Engl J Med 1981 305 1 1 6"/>
   <result pre="Calster B Brouckaert O et al. Qualitative assessment of the" exact="progesterone" post="receptor and HER2 improves the Nottingham Prognostic Index up"/>
   <result pre="H Godwin J et al. Long-term effects of continuing adjuvant" exact="tamoxifen" post="to 10 years versus stopping at 5 years after"/>
   <result pre="23219286 24 Tormey DC Gray R Falkson HC Postchemotherapy adjuvant" exact="tamoxifen" post="therapy beyond five years in patients with lymph node-positive"/>
   <result pre="25 McArthur HL Mahoney KM Morris PG et al. Adjuvant" exact="trastuzumab" post="with chemotherapy is effective in women with small, node-negative,"/>
   <result pre="28 Slamon D Eiermann W Robert N et al. Adjuvant" exact="trastuzumab" post="in HER2-positive breast cancer N Engl J Med 2011"/>
   <result pre="Baselga J Cortes J Kim SB et al. Pertuzumab plus" exact="trastuzumab" post="plus docetaxel for metastatic breast cancer N Engl J"/>
   <result pre="Cortes J Kim SB et al. Pertuzumab plus trastuzumab plus" exact="docetaxel" post="for metastatic breast cancer N Engl J Med 2012"/>
   <result pre="Geyer CE Forster J Lindquist D et al. Lapatinib plus" exact="capecitabine" post="for HER2-positive advanced breast cancer N Engl J Med"/>
   <result pre="Clark GM Osborne CK McGuire WL Correlations between estrogen receptor," exact="progesterone" post="receptor, and patient characteristics in human breast cancer J"/>
   <result pre="DA et al. NCCN Task Force Report: Estrogen receptor and" exact="progesterone" post="receptor testing in breast cancer by immunohistochemistry J Natl"/>
   <result pre="American Pathologists guideline recommendations for immunohistochemical testing of estrogen and" exact="progesterone" post="receptors in breast cancer J Clin Oncol 2010 28"/>
   <result pre="L Eiermann W Semiglazov V et al. Neoadjuvant and adjuvant" exact="trastuzumab" post="in patients with HER2-positive locally advanced breast cancer (NOAH):"/>
   <result pre="17611206 48 Spector NL Blackwell KL Understanding the mechanisms behind" exact="trastuzumab" post="therapy for human epidermal growth factor receptor 2-positive breast"/>
   <result pre="prognostic assay in patients with early breast cancer treated with" exact="tamoxifen" post="Oncologist 2007 12 6 631 635 17602054 53 Paik"/>
   <result pre="node-negative and node-positive postmenopausal patients with breast cancer treated with" exact="anastrozole" post="or tamoxifen: a TransATAC study J Clin Oncol 2010"/>
   <result pre="Austrian breast and colorectal cancer study group 8 and arimidex," exact="tamoxifen" post="alone or in combination randomized trials using the PAM50"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4734963/results/search/inn/results.xml">
   <result pre="the benefit of EGFR inhibition (EXPAND [ 25] trial for" exact="cetuximab" post="and REAL-3 trial [ 26] for panitumumab as first-line"/>
   <result pre="25] trial for cetuximab and REAL-3 trial [ 26] for" exact="panitumumab" post="as first-line therapy); however, both trials failed to prove"/>
   <result pre="success of a clinical trial that investigated the effects of" exact="trastuzumab" post="targeting HER2 in HER2-overexpressed GC patients resulted in changes"/>
   <result pre="GC patients resulted in changes in clinical practice. Addition of" exact="trastuzumab" post="to chemotherapy as the first-line treatment of metastatic GC"/>
   <result pre="an updated survival analysis showed that the benefit of the" exact="trastuzumab" post="decreased over time, the difference in median overall survival"/>
   <result pre="concern, requiring further investigation to clarify the clinical benefit of" exact="trastuzumab" post="in HER2-overexpressing GC patients. Indeed, two first-line therapy trials"/>
   <result pre="trials are underway to investigate the effect of addition of" exact="pertuzumab" post="to a standard HER2 targeting regimen and the effect"/>
   <result pre="targeting regimen and the effect of two dose levels of" exact="trastuzumab" post="(JACOB and HELIOSE, respectively). The frequency of HER2 mutation"/>
   <result pre="GC, and the relationship between HER2 mutation and responsiveness to" exact="trastuzumab" post="has not yet been determined. Another clinically important issue"/>
   <result pre="that patients with MET amplification had a favorable response to" exact="crizotinib" post="(PF-02341066), a MET/anaplastic lymphoma kinase tyrosine kinase inhibitor ["/>
   <result pre="74]. Also, a phase II trial that showed efficacy of" exact="bevacizumab" post="for advanced gastro-esophageal cancer seemed to reinforce the success"/>
   <result pre="gastric cancer [ 75]. Despite initial enthusiasm regarding its use," exact="bevacizumab" post="combined with chemotherapy as a first-line therapy did not"/>
   <result pre="34] and REGARD [ 33] trials, which evaluated benefits of" exact="ramucirumab" post="(antibody targeting VEGFR2) as second-line and first-line therapies, respectively,"/>
   <result pre="VEGF-A and neuropilin-1 levels could be prognostic and predictive of" exact="bevacizumab" post="treatment in a non-Asian population [ 32]. Those findings"/>
   <result pre="83]. Thus, targeting this pathway with appropriate agents such as" exact="metformin" post="would inhibit cellular transformation and selectively kill cancer stem"/>
   <result pre="a recent report showed that patients with GC treated with" exact="metformin" post="for diabetes mellitus had better survival compared to those"/>
   <result pre="survival compared to those treated with diabetic medications other than" exact="metformin" post="[ 85]. GC stem cells express CD133, CD44, aldehyde"/>
   <result pre="11 Bang YJ Kim YW Yang HK et al. Adjuvant" exact="capecitabine" post="and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC):"/>
   <result pre="YJ Kim YW Yang HK et al. Adjuvant capecitabine and" exact="oxaliplatin" post="for gastric cancer after D2 gastrectomy (CLASSIC): a phase"/>
   <result pre="12 Noh SH Park SR Yang HK et al. Adjuvant" exact="capecitabine" post="plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC):"/>
   <result pre="SH Park SR Yang HK et al. Adjuvant capecitabine plus" exact="oxaliplatin" post="for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up"/>
   <result pre="Lordick F Kang YK Chung HC et al. Capecitabine and" exact="cisplatin" post="with or without cetuximab for patients with previously untreated"/>
   <result pre="Chung HC et al. Capecitabine and cisplatin with or without" exact="cetuximab" post="for patients with previously untreated advanced gastric cancer (EXPAND):"/>
   <result pre="T Chau I Cunningham D et al. Epirubicin, oxaliplatin, and" exact="capecitabine" post="with or without panitumumab for patients with previously untreated"/>
   <result pre="D et al. Epirubicin, oxaliplatin, and capecitabine with or without" exact="panitumumab" post="for patients with previously untreated advanced oesophagogastric cancer (REAL3):"/>
   <result pre="Satoh T Xu RH Chung HC et al. Lapatinib plus" exact="paclitaxel" post="versus paclitaxel alone in the second-line treatment of HER2-amplified"/>
   <result pre="Xu RH Chung HC et al. Lapatinib plus paclitaxel versus" exact="paclitaxel" post="alone in the second-line treatment of HER2-amplified advanced gastric"/>
   <result pre="aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to" exact="crizotinib" post="J Clin Oncol 2011 29 4803 10 22042947 29"/>
   <result pre="I et al. Rilotumumab in combination with epirubicin, cisplatin, and" exact="capecitabine" post="as first-line treatment for gastric or oesophagogastric junction adenocarcinoma:"/>
   <result pre="H Muro K Van Cutsem E et al. Ramucirumab plus" exact="paclitaxel" post="versus placebo plus paclitaxel in patients with previously treated"/>
   <result pre="Cutsem E et al. Ramucirumab plus paclitaxel versus placebo plus" exact="paclitaxel" post="in patients with previously treated advanced gastric or gastro-oesophageal"/>
   <result pre="results from a phase III, randomized, open-label, first-line study of" exact="gefitinib" post="versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell"/>
   <result pre="Janne PA Shaw AT Pereira JR et al. Selumetinib plus" exact="docetaxel" post="for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre,"/>
   <result pre="Gray R Perry MC et al. Paclitaxel-carboplatin alone or with" exact="bevacizumab" post="for non-small-cell lung cancer N Engl J Med 2006"/>
   <result pre="et al. Phase II study of modified docetaxel, cisplatin, and" exact="fluorouracil" post="with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma J"/>
   <result pre="Phase II study of modified docetaxel, cisplatin, and fluorouracil with" exact="bevacizumab" post="in patients with metastatic gastroesophageal adenocarcinoma J Clin Oncol"/>
   <result pre="85 Lee CK Jung M Jung I et al. Cumulative" exact="metformin" post="use and its impact on survival in gastric cancer"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4735094/results/search/inn/results.xml">
   <result pre="decisions are now guided by prognostic and predictive biomarkers [ER," exact="progesterone" post="receptor (PR) and HER2] which define 3 major therapeutic"/>
   <result pre="therapy Early setting Positive trial outcomes Additional 5 years of" exact="tamoxifen" post="(Davies et al. 2013; Gray et al. 2013) or"/>
   <result pre="tamoxifen (Davies et al. 2013; Gray et al. 2013) or" exact="letrozole" post="(Goss et al. 2005) in HR-positive populations Negative trial"/>
   <result pre="in HR-positive populations Negative trial outcomes An additional year of" exact="trastuzumab" post="in HER2-positive populations (Goldhirsch et al. 2013) Advanced setting"/>
   <result pre="for accelerated testing c Pertuzumab (Gianni et al. 2012, 2015)," exact="trastuzumab" post="plus FEC and paclitaxel (Buzdar et al. 2013) in"/>
   <result pre="Pertuzumab (Gianni et al. 2012, 2015), trastuzumab plus FEC and" exact="paclitaxel" post="(Buzdar et al. 2013) in HER2-positive NAT populations Trastuzumab"/>
   <result pre="(Buzdar et al. 2013) in HER2-positive NAT populations Trastuzumab plus" exact="lapatinib" post="(Baselga et al. 2012a; Robidoux et al. 2012) in"/>
   <result pre="et al. 2013) CT chemotherapy, ET endocrine therapy, FEC fluorouracil," exact="epirubicin" post="and cyclophosphamide, HER2 human epidermal growth factor receptor 2,"/>
   <result pre="pCR pathological complete response, T- D target-directed therapy, T- DM1" exact="trastuzumab" post="emtansine, TN triple negative aPatient selection is based on"/>
   <result pre="mTOR-inhibitor and ET (n = 2), or a HER2-inhibitor plus" exact="metformin" post="and ET (n = 1). Triple-negative/BRCA-positive In TN/BRCA-positive disease,"/>
   <result pre="3, 4.6 %), bisphosphonates (n = 3, 4.6 %), and" exact="metformin" post="(n = 3, 4.6 %). Some multi-class research was"/>
   <result pre="trial, showing a lack of improvement with the addition of" exact="lapatinib" post="to standard adjuvant targeted therapy, calls into question the"/>
   <result pre="Results from the APHINITY trial (NCT01358877), assessing the addition of" exact="pertuzumab" post="(rather than lapatinib) to adjuvant targeted therapy, will help"/>
   <result pre="micro-environment (bisphosphonates). Breakthroughs such as the addition of the mTOR-inhibitor" exact="everolimus" post="to exemestane in advanced BC resistant to prior non-steroidal"/>
   <result pre="Breakthroughs such as the addition of the mTOR-inhibitor everolimus to" exact="exemestane" post="in advanced BC resistant to prior non-steroidal aromatase-inhibitor therapy"/>
   <result pre="aromatase-inhibitor therapy (Baselga et al. 2012b) and the addition of" exact="palbociclib" post="to fulvestrant in patients with advanced BC progressing on"/>
   <result pre="(Baselga et al. 2012b) and the addition of palbociclib to" exact="fulvestrant" post="in patients with advanced BC progressing on prior ET"/>
   <result pre="FDA approval (Prowell and Pazdur 2012). Although the FDA approved" exact="pertuzumab" post="in the neoadjuvant setting, the results of the Neosphere"/>
   <result pre="14-gene signature to identify immune-enriched patients who preferentially respond to" exact="trastuzumab" post="therapy (Perez et al. 2014). Conclusions Target-directed research is"/>
   <result pre="4, 2013, are summarized in Table 3. Bone-modifying/remodeling agents and" exact="progesterone" post="were considered established due to their historical and widespread"/>
   <result pre="RANKL receptor activator of nuclear factor kappa-B ligand, T- DM1" exact="trastuzumab" post="emtansine, VEGF vascular endothelial growth factor To assess the"/>
   <result pre="poly(ADP-ribose) polymerase pCR pathological complete response PI3K phosphoinositide 3-kinase PR" exact="progesterone" post="receptor PK protein kinase T-DM1 ado-trastuzumab-emtansine TN triple-negative US"/>
   <result pre="K Kern KA Martin M Phase III randomized trial of" exact="sunitinib" post="versus capecitabine in patients with previously treated HER2-negative advanced"/>
   <result pre="KA Martin M Phase III randomized trial of sunitinib versus" exact="capecitabine" post="in patients with previously treated HER2-negative advanced breast cancer"/>
   <result pre="J Ciruelos Gil E Zubel A Groos J Cetuximab +" exact="cisplatin" post="in estrogen receptor-negative, progesterone receptor-negative, HER2-negative (triple-negative) metastatic breast"/>
   <result pre="Zubel A Groos J Cetuximab + cisplatin in estrogen receptor-negative," exact="progesterone" post="receptor-negative, HER2-negative (triple-negative) metastatic breast cancer: results of the"/>
   <result pre="Pusztai L Untch M Gelber RD Piccart-Gebhart M Lapatinib with" exact="trastuzumab" post="for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label,"/>
   <result pre="Clark E Benyunes MC Ross G Swain SM Pertuzumab plus" exact="trastuzumab" post="plus docetaxel for metastatic breast cancer N Engl J"/>
   <result pre="Benyunes MC Ross G Swain SM Pertuzumab plus trastuzumab plus" exact="docetaxel" post="for metastatic breast cancer N Engl J Med 2012"/>
   <result pre="placebo-controlled, phase III trial evaluating the efficacy and safety of" exact="bevacizumab" post="in combination with chemotherapy for second-line treatment of human"/>
   <result pre="Plourde PV Anastrozole, a potent and selective aromatase inhibitor, versus" exact="megestrol" post="acetate in postmenopausal women with advanced breast cancer: results"/>
   <result pre="Wolter JM Steinberg M Webster A Lee D Anastrozole versus" exact="megestrol" post="acetate in the treatment of postmenopausal women with advanced"/>
   <result pre="M McCall LM Ewer MS Hunt KK Fluorouracil, epirubicin, and" exact="cyclophosphamide" post="(FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus"/>
   <result pre="MS Hunt KK Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by" exact="paclitaxel" post="plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75"/>
   <result pre="KK Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus" exact="trastuzumab" post="versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab"/>
   <result pre="epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus" exact="paclitaxel" post="plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant"/>
   <result pre="cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus" exact="trastuzumab" post="followed by FEC-75 plus trastuzumab as neoadjuvant treatment for"/>
   <result pre="plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus" exact="trastuzumab" post="as neoadjuvant treatment for patients with HER2-positive breast cancer"/>
   <result pre="Stein S Geyer CE A phase III randomized comparison of" exact="lapatinib" post="plus capecitabine versus capecitabine alone in women with advanced"/>
   <result pre="Geyer CE A phase III randomized comparison of lapatinib plus" exact="capecitabine" post="versus capecitabine alone in women with advanced breast cancer"/>
   <result pre="A phase III randomized comparison of lapatinib plus capecitabine versus" exact="capecitabine" post="alone in women with advanced breast cancer that has"/>
   <result pre="CM Winer EP TBCRC 001: randomized phase II study of" exact="cetuximab" post="in combination with carboplatin in stage IV triple-negative breast"/>
   <result pre="001: randomized phase II study of cetuximab in combination with" exact="carboplatin" post="in stage IV triple-negative breast cancer J Clin Oncol"/>
   <result pre="subtype classifier for prognosis and prediction of benefit from adjuvant" exact="tamoxifen" post="Clin Cancer Res 2012 18 16 4465 4472 10.1158/1078-0432.CCR-12-0286"/>
   <result pre="29 May 2014 ClinicalTrials.gov (2014d) Tamoxifen citrate, letrozole, anastrozole, or" exact="exemestane" post="with or without chemotherapy in treating patients with invasive"/>
   <result pre="AU Forbes JF Prognostic value of a combined estrogen receptor," exact="progesterone" post="receptor, Ki-67, and human epidermal growth factor receptor 2"/>
   <result pre="M Wang Y Peto R Long-term effects of continuing adjuvant" exact="tamoxifen" post="to 10 years versus stopping at 5 years after"/>
   <result pre="of women with metastatic breast cancer by HER2 status and" exact="trastuzumab" post="treatment: an institutional-based review J Clin Oncol 2010 28"/>
   <result pre="V Forbes J Buzdar A Relationship between quantitative estrogen and" exact="progesterone" post="receptor expression and human epidermal growth factor receptor 2"/>
   <result pre="DL Fisher ER et al. A randomized clinical trial evaluating" exact="tamoxifen" post="in the treatment of patients with node-negative breast cancer"/>
   <result pre="J Ross G Valagussa P Efficacy and safety of neoadjuvant" exact="pertuzumab" post="and trastuzumab in women with locally advanced, inflammatory, or"/>
   <result pre="G Valagussa P Efficacy and safety of neoadjuvant pertuzumab and" exact="trastuzumab" post="in women with locally advanced, inflammatory, or early HER2-positive"/>
   <result pre="NOAH, a randomized phase III trial evaluating neoadjuvant chemotherapy with" exact="trastuzumab" post="(CT + H) followed by adjuvant H versus CT"/>
   <result pre="the phase II NeoSphere trial evaluating four cycles of neoadjuvant" exact="docetaxel" post="(D) and/or trastuzumab (T) and/or pertuzumab (P) ASCO Meet"/>
   <result pre="NeoSphere trial evaluating four cycles of neoadjuvant docetaxel (D) and/or" exact="trastuzumab" post="(T) and/or pertuzumab (P) ASCO Meet Abstr 2015 33"/>
   <result pre="four cycles of neoadjuvant docetaxel (D) and/or trastuzumab (T) and/or" exact="pertuzumab" post="(P) ASCO Meet Abstr 2015 33 15 suppl 505"/>
   <result pre="B Baselga J 2 years versus 1 year of adjuvant" exact="trastuzumab" post="for HER2-positive breast cancer (HERA): an open-label, randomised controlled"/>
   <result pre="JS Cameron DA Palmer MJ Pater JL Randomized trial of" exact="letrozole" post="following tamoxifen as extended adjuvant therapy in receptor-positive breast"/>
   <result pre="DA Palmer MJ Pater JL Randomized trial of letrozole following" exact="tamoxifen" post="as extended adjuvant therapy in receptor-positive breast cancer: updated"/>
   <result pre="Perry P Earl H aTTom: long-term effects of continuing adjuvant" exact="tamoxifen" post="to 10 years versus stopping at 5 years in"/>
   <result pre="L Chen G Oliva C Gomez H Randomized trial of" exact="lapatinib" post="versus placebo added to paclitaxel in the treatment of"/>
   <result pre="Gomez H Randomized trial of lapatinib versus placebo added to" exact="paclitaxel" post="in the treatment of human epidermal growth factor receptor"/>
   <result pre="Y Sano M Noguchi S Randomized phase III trial of" exact="trastuzumab" post="monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus"/>
   <result pre="S Randomized phase III trial of trastuzumab monotherapy followed by" exact="trastuzumab" post="plus docetaxel versus trastuzumab plus docetaxel as first-line therapy"/>
   <result pre="phase III trial of trastuzumab monotherapy followed by trastuzumab plus" exact="docetaxel" post="versus trastuzumab plus docetaxel as first-line therapy in patients"/>
   <result pre="trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus" exact="trastuzumab" post="plus docetaxel as first-line therapy in patients with HER2-positive"/>
   <result pre="trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus" exact="docetaxel" post="as first-line therapy in patients with HER2-positive metastatic breast"/>
   <result pre="randomized placebo controlled phase III trial evaluating the addition of" exact="ramucirumab" post="to first-line docetaxel chemotherapy in metastatic breast cancer. Cancer"/>
   <result pre="phase III trial evaluating the addition of ramucirumab to first-line" exact="docetaxel" post="chemotherapy in metastatic breast cancer. Cancer Res 73(24 Supplement):abstr"/>
   <result pre="Randomized phase II trial of the efficacy and safety of" exact="trastuzumab" post="combined with docetaxel in patients with human epidermal growth"/>
   <result pre="trial of the efficacy and safety of trastuzumab combined with" exact="docetaxel" post="in patients with human epidermal growth factor receptor 2-positive"/>
   <result pre="Wardley AM Chlistalla A Romieu G Phase III study of" exact="bevacizumab" post="plus docetaxel compared with placebo plus docetaxel for the"/>
   <result pre="Chlistalla A Romieu G Phase III study of bevacizumab plus" exact="docetaxel" post="compared with placebo plus docetaxel for the first-line treatment"/>
   <result pre="III study of bevacizumab plus docetaxel compared with placebo plus" exact="docetaxel" post="for the first-line treatment of human epidermal growth factor"/>
   <result pre="AP Langmuir V Rugo HS Randomized phase III trial of" exact="capecitabine" post="compared with bevacizumab plus capecitabine in patients with previously"/>
   <result pre="Rugo HS Randomized phase III trial of capecitabine compared with" exact="bevacizumab" post="plus capecitabine in patients with previously treated metastatic breast"/>
   <result pre="Randomized phase III trial of capecitabine compared with bevacizumab plus" exact="capecitabine" post="in patients with previously treated metastatic breast cancer J"/>
   <result pre="Perez EA Shenkier T Cella D Davidson NE Paclitaxel plus" exact="bevacizumab" post="versus paclitaxel alone for metastatic breast cancer N Engl"/>
   <result pre="Shenkier T Cella D Davidson NE Paclitaxel plus bevacizumab versus" exact="paclitaxel" post="alone for metastatic breast cancer N Engl J Med"/>
   <result pre="Gomez-Fernandez C Ganjei-Azar P Morales AR Immunohistochemistry of estrogen and" exact="progesterone" post="receptors reconsidered: experience with 5,993 breast cancers Am J"/>
   <result pre="randomized phase II study of weekly irinotecan/carboplatin with or without" exact="cetuximab" post="in patients with metastatic breast cancer Breast Cancer Res"/>
   <result pre="S Mamounas EP Kaufman PA Wolmark N Four-year follow-up of" exact="trastuzumab" post="plus adjuvant chemotherapy for operable human epidermal growth factor"/>
   <result pre="genes and clinical outcome in the NCCTG (Alliance) N9831 adjuvant" exact="trastuzumab" post="trial. J Clin Oncol 32(15 suppl):abstr 509 Perou CM"/>
   <result pre="between event-free survival and pathological complete response to neoadjuvant lapatinib," exact="trastuzumab" post="or their combination in HER2-positive breast cancer. Survival follow-up"/>
   <result pre="NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with" exact="lapatinib" post="alone (L), trastuzumab alone (T), their sequence (T →"/>
   <result pre="comparing one year of anti-HER2 therapy with lapatinib alone (L)," exact="trastuzumab" post="alone (T), their sequence (T → L), or their"/>
   <result pre="double-blind, placebo-controlled, phase III trial of chemotherapy with or without" exact="bevacizumab" post="for first-line treatment of human epidermal growth factor receptor"/>
   <result pre="Fehrenbacher L Bear HD Baez-Diaz L Kuebler JP Evaluation of" exact="lapatinib" post="as a component of neoadjuvant therapy for HER2 +"/>
   <result pre="E Ross G Benyunes MC Baselga J Pertuzumab, trastuzumab, and" exact="docetaxel" post="for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival"/>
   <result pre="23602601 collab: The Nolvadex Adjuvant Trial Organisation Controlled trial of" exact="tamoxifen" post="as single adjuvant agent in management of early breast"/>
   <result pre="Shak S Stewart SJ Press M Efficacy and safety of" exact="trastuzumab" post="as a single agent in first-line treatment of HER2-overexpressing"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4736909/results/search/inn/results.xml">
   <result pre="Binding with high affinity to the extracellular domain of HER2," exact="trastuzumab" post="interrupts HER2-mediated cell signaling pathways and cell cycle progression,"/>
   <result pre="of the FDA in October 2012. Trastuzumab in combination with" exact="capecitabine" post="or 5-fluorouracil and cisplatin is indicated for the treatment"/>
   <result pre="October 2012. Trastuzumab in combination with capecitabine or 5-fluorouracil and" exact="cisplatin" post="is indicated for the treatment of patients with HER2-positive"/>
   <result pre="1 : 1 ratio to two groups: one group received chemotherapy alone," exact="cisplatin" post="(80 mg/m 2) plus fluorouracil (800 mg/m 2, Qd × 5"/>
   <result pre="groups: one group received chemotherapy alone, cisplatin (80 mg/m 2) plus" exact="fluorouracil" post="(800 mg/m 2, Qd × 5 days), or capecitabine (1000 mg/m"/>
   <result pre="2) plus fluorouracil (800 mg/m 2, Qd × 5 days), or" exact="capecitabine" post="(1000 mg/m 2, bid × 14 days); the other group"/>
   <result pre="bid × 14 days); the other group received chemotherapy plus" exact="trastuzumab" post="(Herceptin, F. Hoffmann-La Roche, Basel, Switzerland, 6 mg/kg, q3w). The"/>
   <result pre="showed that the OS of the second group (which received" exact="trastuzumab" post="plus chemotherapy) was 13.8 months, 2.7 months longer than"/>
   <result pre="from 5.5 months to 6.7 months by the addition of" exact="trastuzumab" post="to chemotherapy (HR = 0.71, P = 0.002). A"/>
   <result pre="a landmark study of gastric cancer. Its results demonstrate that" exact="trastuzumab" post="plus chemotherapy can expand the overall survival of patients"/>
   <result pre="more than 1 year and prove the important role of" exact="trastuzumab" post="in gastric cancer therapy. An additional ToGA study on"/>
   <result pre="[ 6] and Japanese [ 7] patients also showed that" exact="trastuzumab" post="plus chemotherapy could improve the overall survival of patients"/>
   <result pre="were carried out to explore the efficacy and safety of" exact="trastuzumab" post="plus XELOX (capecitabine/oxaliplatin) [ 8] and SP (S-1/cisplatin) ["/>
   <result pre="event profiles were similar to ToGA. These results confirmed that" exact="trastuzumab" post="plus XELOX or SP can also treat gastric cancer"/>
   <result pre="kinase phosphorylation of homodimers or heterodimers of the two receptors," exact="lapatinib" post="blocks EGFR or HER2 signal transduction, thereby inhibiting cell"/>
   <result pre="evaluating the efficacy and safety of CapeOx in combination with" exact="lapatinib" post="(CapeOx+L) or placebo (CapeOx+P) as a first-line treatment for"/>
   <result pre="diarrhea and skin toxicity with CapeOx+L. These results indicate that" exact="lapatinib" post="combined with CapeOx as first-line treatment had no survival"/>
   <result pre="III clinical study that explored the efficacy and safety of" exact="lapatinib" post="in combination with chemotherapy to treat advanced HER2-positive gastric"/>
   <result pre="Two hundred sixty-one HER2-positive patients were randomly assigned to receive" exact="paclitaxel" post="(80 mg/m 2) alone or in combination with lapatinib (1500 mg)."/>
   <result pre="to receive paclitaxel (80 mg/m 2) alone or in combination with" exact="lapatinib" post="(1500 mg). The median OS, PFS, and time to progression"/>
   <result pre="between these two groups was similar. These results suggested that" exact="lapatinib" post="plus paclitaxel demonstrated activity in the second-line treatment of"/>
   <result pre="two groups was similar. These results suggested that lapatinib plus" exact="paclitaxel" post="demonstrated activity in the second-line treatment of patients with"/>
   <result pre="II clinical trial in Germany showed that the efficacy of" exact="lapatinib" post="plus capecitabine in patients with HER2-positive gastric cancer as"/>
   <result pre="trial in Germany showed that the efficacy of lapatinib plus" exact="capecitabine" post="in patients with HER2-positive gastric cancer as second-line treatment"/>
   <result pre="Neither LOGiC nor TyTAN research got positive results, probably because" exact="trastuzumab" post="has cell-mediated antibody-dependent cytotoxicity (ADCC) while lapatinib lacks it."/>
   <result pre="results, probably because trastuzumab has cell-mediated antibody-dependent cytotoxicity (ADCC) while" exact="lapatinib" post="lacks it. 3. Anti-VEGF Targeted Therapy Abnormal angiogenesis is"/>
   <result pre="III clinical trial designed to evaluate the efficacy of adding" exact="bevacizumab" post="to capecitabine-cisplatin in the first-line treatment of advanced gastric"/>
   <result pre="treated with chemotherapy (capecitabine, 1000 mg/m 2, bid, d1–14, q3w; plus" exact="cisplatin" post="80 mg/m 2, d1, q3w × 6 cycle, and bevacizumab"/>
   <result pre="plus cisplatin 80 mg/m 2, d1, q3w × 6 cycle, and" exact="bevacizumab" post="7.5 mg/kg) or placebo. Efficacy measures showed improvements with bevacizumab"/>
   <result pre="and bevacizumab 7.5 mg/kg) or placebo. Efficacy measures showed improvements with" exact="bevacizumab" post="and chemotherapy versus chemotherapy alone in the first-line treatment"/>
   <result pre="versus 37.4%; P = 0.0315). However, they observed that adding" exact="bevacizumab" post="to fluoropyrimidine-cisplatin only improved OS from 10.1 to 12.1"/>
   <result pre="0.73–1.03; P = 0.1002), without reaching its primary objective. Therefore," exact="bevacizumab" post="plus chemotherapy could not significantly improve the overall survival"/>
   <result pre="Another phase III AVATAR study from China also found that" exact="bevacizumab" post="combined with capecitabine/cisplatin chemotherapy did not significantly improve overall"/>
   <result pre="urgently needed to select more suitable gastric cancer patients for" exact="bevacizumab" post="treatment. We are looking forward to more in-depth basic"/>
   <result pre="Gastric Guide (2015 Edition) does not recommend the use of" exact="bevacizumab" post="in patients with advanced gastric cancer, although the FDA"/>
   <result pre="patients with advanced gastric cancer, although the FDA has approved" exact="bevacizumab" post="for the treatment of advanced colorectal cancer and advanced"/>
   <result pre="REGARD study [ 21], in April 2014, the FDA approved" exact="ramucirumab" post="(CYRAMZA, Eli Lilly) for the treatment of advanced gastric"/>
   <result pre="of advanced gastric or gastroesophageal junction adenocarcinoma that developed after" exact="fluorouracil" post="platinum therapy. Then, in November 2014, based on the"/>
   <result pre="based on the RAINBOW study [ 22], the FDA approved" exact="ramucirumab" post="plus paclitaxel for the treatment of advanced stomach or"/>
   <result pre="the RAINBOW study [ 22], the FDA approved ramucirumab plus" exact="paclitaxel" post="for the treatment of advanced stomach or gastroesophageal junction"/>
   <result pre="of advanced stomach or gastroesophageal junction adenocarcinoma that developed after" exact="fluorouracil" post="or platinum treatment. This is the only antiangiogenic drug"/>
   <result pre="23]. The REGARD study compared the efficacy and safety of" exact="ramucirumab" post="versus placebo in the treatment of advanced gastric cancer"/>
   <result pre="had cancer progression after chemotherapy, were randomly divided into a" exact="ramucirumab" post="group (8 mg/kg, every 2 weeks by iv) and a"/>
   <result pre="survival. The results showed that the median OS in the" exact="ramucirumab" post="group and the placebo group were 5.2 and 3.8"/>
   <result pre="P = 0.047), respectively. Hypertension was more common in the" exact="ramucirumab" post="group (16%), while hypertension in the control group affected"/>
   <result pre="cancer and esophageal and gastric adenocarcinoma, who failed first-line chemotherapy," exact="ramucirumab" post="is the first therapeutic monoclonal antibody used as a"/>
   <result pre="III RAINBOW study [ 22] found that the combination of" exact="ramucirumab" post="with paclitaxel significantly improved the overall survival of patients"/>
   <result pre="study [ 22] found that the combination of ramucirumab with" exact="paclitaxel" post="significantly improved the overall survival of patients with gastric"/>
   <result pre="failure of first-line chemotherapy treatment. Compared with treatment with paclitaxel," exact="ramucirumab" post="combined with paclitaxel can extend overall survival for 2.2"/>
   <result pre="chemotherapy treatment. Compared with treatment with paclitaxel, ramucirumab combined with" exact="paclitaxel" post="can extend overall survival for 2.2 months (9.6 months"/>
   <result pre="0.807, P = 0.017). Treatment of advanced gastric cancer with" exact="ramucirumab" post="alone or in combination with second-line paclitaxel has a"/>
   <result pre="gastric cancer with ramucirumab alone or in combination with second-line" exact="paclitaxel" post="has a certain curative effect [ 23]. Unfortunately, at"/>
   <result pre="at the 2014 ASCO annual meeting, it was reported that" exact="ramucirumab" post="combined with FOLFOX chemotherapy cannot improve the early cure"/>
   <result pre="or gastroesophageal junction were enrolled. For the patients treated with" exact="ramucirumab" post="combined with FOLFOX and ramucirumab monotherapy, the median PFS"/>
   <result pre="For the patients treated with ramucirumab combined with FOLFOX and" exact="ramucirumab" post="monotherapy, the median PFS was 6.4 months and 6.7"/>
   <result pre="AVAGAST study revealed that treatment of advanced gastric cancer with" exact="bevacizumab" post="combined with first-line capecitabine/cisplatin showed no survival benefit, and"/>
   <result pre="obtained in advanced gastric cancer patients receiving first-line treatment with" exact="ramucirumab" post="combined with the FOLFOX regimen. Molecular markers for screening"/>
   <result pre="phosphorylated and total VEGFR-2 proteins was found significantly decreased in" exact="regorafenib" post="treated mouse xenografts models, which were constructed by gastric"/>
   <result pre="cancer cells, so antiangiogenesis maybe the major driving force of" exact="regorafenib" post="when performing antitumor function in gastric cancer [ 28]."/>
   <result pre="gastric cancer [ 28]. To test the application value of" exact="regorafenib" post="in treatment of refractory advanced oesophagogastric cancer, a randomized,"/>
   <result pre="cancer in all enrolled patients was 85/147; at the endpoint," exact="regorafenib" post="group got significantly longer median PFS than placebo group"/>
   <result pre="lower ones. From the current research results, the prospect of" exact="regorafenib" post="application in the treatment of intractable patients who experienced"/>
   <result pre="issues: what is the keenly functional molecular targets answer to" exact="regorafenib" post="in advanced gastric cancer patients? And how to use"/>
   <result pre="of treatment of advanced gastric and gastroesophageal junction adenocarcinoma with" exact="cetuximab" post="combined with XP regimens (gemcitabine/cisplatin) [ 31]. A total"/>
   <result pre="patients were randomly divided into two groups receiving treatment with" exact="cetuximab" post="combined with XP regimens or XP regimens alone. PFS"/>
   <result pre="the treatment of advanced gastric cancer with the combination of" exact="cetuximab" post="and XP regimens does not have a survival benefit."/>
   <result pre="of treatment of advanced gastric and gastroesophageal junction adenocarcinoma with" exact="panitumumab" post="combined with a united EOC scheme (epirubicin/oxaliplatin/card capecitabine) ["/>
   <result pre="half-life, higher dose-effect rate, and less severe dermatological toxicity than" exact="cetuximab" post="[ 35]. Several clinical trials have been performed to"/>
   <result pre="with advanced gastric included 40 who received nimotuzumab 400 mg/week plus" exact="irinotecan" post="150 mg/m 2/biweekly, and the rest of patients were treated"/>
   <result pre="150 mg/m 2/biweekly, and the rest of patients were treated by" exact="irinotecan" post="150 mg/m 2/biweekly only. The results reflected that no difference"/>
   <result pre="358.5/229.5 days, resp.). A phase III trial of nimotuzumab and" exact="irinotecan" post="as a second line treatment with advanced cancer have"/>
   <result pre="low adverse events rate allows patients who received nimotuzumab plus" exact="irinotecan" post="to gain a well quality of life. Recently, another"/>
   <result pre="clinical phase II study explored the efficacy and safety of" exact="everolimus" post="in the treatment of advanced gastric cancer [ 39]."/>
   <result pre="gastric cancer patients with previous chemotherapy failure were treated with" exact="everolimus" post="(10 mg, oral), once a day, until disease progression. Despite"/>
   <result pre="alanine aminotransferase and decrease in lymphocytes. The conclusion is that" exact="everolimus" post="monotherapy has a good disease control rate for advanced"/>
   <result pre="international multicenter, double-blind, randomized phase III GRANITE-1 study found that" exact="everolimus" post="did not improve the survival of advanced gastric cancer"/>
   <result pre="with failed first- or second-line chemotherapy were randomized to receive" exact="everolimus" post="(10 mg/day) or placebo treatment. The main outcome was overall"/>
   <result pre="results demonstrated that the OS was 5.4 months for the" exact="everolimus" post="group and 4.3 months for the placebo group (HR"/>
   <result pre="1.7 months and 1.4 months (HR = 0.66) for the" exact="everolimus" post="and the placebo group, respectively. Grades 3-4 adverse reactions"/>
   <result pre="were observed in treated patients. Although the FDA has approved" exact="everolimus" post="for the treatment of advanced renal cell carcinomas that"/>
   <result pre="cancer patients (July, 2012) [ 42] for the use of" exact="everolimus" post="in the treatment of advanced gastric cancer; there is"/>
   <result pre="from the United States National Comprehensive Cancer Network (NCCN) recommended" exact="trastuzumab" post="(first line) and ramucirumab (second line) for the treatment"/>
   <result pre="National Comprehensive Cancer Network (NCCN) recommended trastuzumab (first line) and" exact="ramucirumab" post="(second line) for the treatment of advanced gastric cancer"/>
   <result pre="of patients with HER2-positive advanced gastric cancer, and treatment with" exact="trastuzumab" post="is now considered to be the standard first-line therapy."/>
   <result pre="or mTOR-targeted drugs in early clinical trials. Fortunately, the anti-VEGFR-2" exact="ramucirumab" post="and the VEGFR-2 small molecule inhibitor apatinib bring hope"/>
   <result pre="Sawaki A. Ohashi Y. Omuro Y. et al. Efficacy of" exact="trastuzumab" post="in Japanese patients with HER2-positive advanced gastric or gastroesophageal"/>
   <result pre="Kim J. G. et al. Multicenter phase II study of" exact="trastuzumab" post="in combination with capecitabine and oxaliplatin for advanced gastric"/>
   <result pre="al. Multicenter phase II study of trastuzumab in combination with" exact="capecitabine" post="and oxaliplatin for advanced gastric cancer European Journal of"/>
   <result pre="phase II study of trastuzumab in combination with capecitabine and" exact="oxaliplatin" post="for advanced gastric cancer European Journal of Cancer 2015"/>
   <result pre="Sugimoto N. Miwa H. et al. Phase II study of" exact="trastuzumab" post="in combination with S-1 plus cisplatin in HER2-positive gastric"/>
   <result pre="Phase II study of trastuzumab in combination with S-1 plus" exact="cisplatin" post="in HER2-positive gastric cancer (HERBIS-1) British Journal of Cancer"/>
   <result pre="inhibits HER2-amplified human gastric cancer cells and is synergistic with" exact="trastuzumab" post="in vitro and in vivo Clinical Cancer Research 2010"/>
   <result pre="J. Qin S. K. et al. Lapatinib in combination with" exact="capecitabine" post="plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric,"/>
   <result pre="S. K. et al. Lapatinib in combination with capecitabine plus" exact="oxaliplatin" post="(CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or"/>
   <result pre="T. Xu R.-H. Chung H. C. et al. Lapatinib plus" exact="paclitaxel" post="versus paclitaxel alone in the second-line treatment of HER2-amplified"/>
   <result pre="R.-H. Chung H. C. et al. Lapatinib plus paclitaxel versus" exact="paclitaxel" post="alone in the second-line treatment of HER2-amplified advanced gastric"/>
   <result pre="S. Knorrenschild J. R. Haag G. et al. Lapatinib versus" exact="lapatinib" post="plus capecitabine as second-line treatment in human epidermal growth"/>
   <result pre="J. R. Haag G. et al. Lapatinib versus lapatinib plus" exact="capecitabine" post="as second-line treatment in human epidermal growth factor receptor"/>
   <result pre="Shen L. Li J. Xu J. et al. Bevacizumab plus" exact="capecitabine" post="and cisplatin in Chinese patients with inoperable locally advanced"/>
   <result pre="Li J. Xu J. et al. Bevacizumab plus capecitabine and" exact="cisplatin" post="in Chinese patients with inoperable locally advanced or metastatic"/>
   <result pre="H. Muro K. Van Cutsem E. et al. Ramucirumab plus" exact="paclitaxel" post="versus placebo plus paclitaxel in patients with previously treated"/>
   <result pre="Cutsem E. et al. Ramucirumab plus paclitaxel versus placebo plus" exact="paclitaxel" post="in patients with previously treated advanced gastric or gastro-oesophageal"/>
   <result pre="Fashoyin-Aje I. Lemery S. J. et al. FDA approval summary:" exact="ramucirumab" post="for gastric cancer Clinical Cancer Research 2015 21 15"/>
   <result pre="safety of combination therapy with Endostar and S-1 combined with" exact="oxaliplatin" post="in advanced gastric cancer OncoTargets and Therapy 2013 6"/>
   <result pre="Reichardt P. Kang Y.-K. et al. Efficacy and safety of" exact="regorafenib" post="for advanced gastrointestinal stromal tumours after failure of imatinib"/>
   <result pre="of regorafenib for advanced gastrointestinal stromal tumours after failure of" exact="imatinib" post="and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase"/>
   <result pre="for advanced gastrointestinal stromal tumours after failure of imatinib and" exact="sunitinib" post="(GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial"/>
   <result pre="Ong R. Zopf D. Antitumor activity of the multikinase inhibitor" exact="regorafenib" post="in patient-derived xenograft models of gastric cancer Journal of"/>
   <result pre="al. INTEGRATE: a randomized phase II double-blind placebo-controlled study of" exact="regorafenib" post="(REG) in refractory advanced oesophagogastric cancer (AOGC)-a study by"/>
   <result pre="Lordick F. Kang Y.-K. Chung H.-C. et al. Capecitabine and" exact="cisplatin" post="with or without cetuximab for patients with previously untreated"/>
   <result pre="Chung H.-C. et al. Capecitabine and cisplatin with or without" exact="cetuximab" post="for patients with previously untreated advanced gastric cancer (EXPAND):"/>
   <result pre="T. Chau I. Cunningham D. et al. Epirubicin, oxaliplatin, and" exact="capecitabine" post="with or without panitumumab for patients with previously untreated"/>
   <result pre="D. et al. Epirubicin, oxaliplatin, and capecitabine with or without" exact="panitumumab" post="for patients with previously untreated advanced oesophagogastric cancer (REAL3):"/>
   <result pre="Y. et al. Randomized phase II trial of nimotuzumab plus" exact="irinotecan" post="versus irinotecan alone as second-line therapy for patients with"/>
   <result pre="al. Randomized phase II trial of nimotuzumab plus irinotecan versus" exact="irinotecan" post="alone as second-line therapy for patients with advanced gastric"/>
   <result pre="Du F. Zheng Z. Shi S. et al. S-1 and" exact="cisplatin" post="with or without nimotuzumab for patients with untreated unresectable"/>
   <result pre="K. Boku N. et al. Multicenter phase II study of" exact="everolimus" post="in patients with previously treated metastatic gastric cancer Journal"/>
   <result pre="I. et al. Rilotumumab in combination with epirubicin, cisplatin, and" exact="capecitabine" post="as first-line treatment for gastric or oesophagogastric junction adenocarcinoma:"/>
   <result pre="double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin," exact="cisplatin" post="and capecitabine (ECX) as first-line therapy in patients (pts)"/>
   <result pre="placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and" exact="capecitabine" post="(ECX) as first-line therapy in patients (pts) with advanced"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4738716/results/search/inn/results.xml">
   <result pre="subgroups is still based on the status of estrogen and" exact="progesterone" post="receptor (ER and PR) and human epidermal growth factor"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4739616/results/search/inn/results.xml">
   <result pre="[ 19]. Similarly, Bcl-2 inhibitors have been found to increase" exact="lapatinib" post="efficiency in HER2-positive cells [ 20]. Furthermore, targeting PI3K"/>
   <result pre="ABT-737, than parental cells. Moreover, the combination of ABT-737 and" exact="trastuzumab" post="was found to inhibit the growth of trastuzumab-resistant cells"/>
   <result pre="[ 4]. Similarly, the Akt inhibitor, triciribine, in combination with" exact="trastuzumab" post="caused a synergistic reduction of traztuzumab-resistant tumor growth ["/>
   <result pre="reduction of traztuzumab-resistant tumor growth [ 21]. The application of" exact="trastuzumab" post="along with a PI3K inhibitor, SF1126, also induced a"/>
   <result pre="cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and" exact="pertuzumab" post=". Clin Cancer Res 15: 4147– 4156. doi: 10.1158/1078-0432.CCR-08-2814"/>
   <result pre="( 2007) Preclinical testing of clinically applicable strategies for overcoming" exact="trastuzumab" post="resistance caused by PTEN deficiency . Clin Cancer Res"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4740402/results/search/inn/results.xml">
   <result pre="decline in contractile force for gefitinib, lapatinib, sunitinib, imatinib, sorafenib," exact="vandetanib" post="and lestaurtinib and no decline in contractile force for"/>
   <result pre="vandetanib and lestaurtinib and no decline in contractile force for" exact="erlotinib" post="and dasatinib after 96 hours of incubation. The decline"/>
   <result pre="lestaurtinib and no decline in contractile force for erlotinib and" exact="dasatinib" post="after 96 hours of incubation. The decline in contractile"/>
   <result pre="structural cardiotoxicity mediated by TKIs appeared when patients treated with" exact="imatinib" post="developed heart failure [ 4]. Histologically, mitochondrial abnormalities and"/>
   <result pre="in cultured cardiomyocytes and animal models provided further evidence that" exact="imatinib" post="was associated with mitochondrial insufficiency resulting in cytochrome c-release"/>
   <result pre="involved in the mechanism of toxicity [ 4, 5]. Morphologically" exact="imatinib" post="cardiotoxicity in rats was characterized by cytoplasmic vacuolization and"/>
   <result pre="of AMPK and RAF 1/BRAF as key cardiotoxic mechanisms for" exact="sunitinib" post="and sorafenib, respectively [ 7, 8]. Modulation of autophagy"/>
   <result pre="is challenging to demonstrate left ventricular dysfunction upon treatment with" exact="sunitinib" post="in the absence of pressure overload [ 7, 10]."/>
   <result pre="have proven to be useful to demonstrate ventricular dysfunction of" exact="sunitinib" post="and sorafenib [ 8] but species differences may limit"/>
   <result pre="to be useful to demonstrate ventricular dysfunction of sunitinib and" exact="sorafenib" post="[ 8] but species differences may limit wide-spread use."/>
   <result pre="1% penicillin/streptomycin (Gibco 15140), insulin (10 μg/mL, Sigma-Aldrich I9278) and" exact="aprotinin" post="(33 μg/mL, Sigma-Aldrich A1153) and was changed on Mondays,"/>
   <result pre="of TKIs TKIs were purchased from LC Laboratories (dasatinib D-3307," exact="erlotinib" post="E-4007, gefitinib G-4408, imatinib I-5508, lapatinib L-4899, lestaurtinib L-6307,"/>
   <result pre="TKIs were purchased from LC Laboratories (dasatinib D-3307, erlotinib E-4007," exact="gefitinib" post="G-4408, imatinib I-5508, lapatinib L-4899, lestaurtinib L-6307, sorafenib S-8599,"/>
   <result pre="purchased from LC Laboratories (dasatinib D-3307, erlotinib E-4007, gefitinib G-4408," exact="imatinib" post="I-5508, lapatinib L-4899, lestaurtinib L-6307, sorafenib S-8599, sunitinib S-8803,"/>
   <result pre="LC Laboratories (dasatinib D-3307, erlotinib E-4007, gefitinib G-4408, imatinib I-5508," exact="lapatinib" post="L-4899, lestaurtinib L-6307, sorafenib S-8599, sunitinib S-8803, vandetanib V-9402)"/>
   <result pre="erlotinib E-4007, gefitinib G-4408, imatinib I-5508, lapatinib L-4899, lestaurtinib L-6307," exact="sorafenib" post="S-8599, sunitinib S-8803, vandetanib V-9402) and solubilized in dimethyl"/>
   <result pre="gefitinib G-4408, imatinib I-5508, lapatinib L-4899, lestaurtinib L-6307, sorafenib S-8599," exact="sunitinib" post="S-8803, vandetanib V-9402) and solubilized in dimethyl sulfoxide (DMSO)."/>
   <result pre="imatinib I-5508, lapatinib L-4899, lestaurtinib L-6307, sorafenib S-8599, sunitinib S-8803," exact="vandetanib" post="V-9402) and solubilized in dimethyl sulfoxide (DMSO). Four logarithmically-diluted"/>
   <result pre="L-6307, sorafenib S-8599, sunitinib S-8803, vandetanib V-9402) and solubilized in" exact="dimethyl sulfoxide" post="(DMSO). Four logarithmically-diluted concentrations per TKI were analyzed (each"/>
   <result pre="concentrations of 10-100x total therapeutic plasma concentration (TPC). Exceptions were" exact="dasatinib" post="and lapatinib with maximal study concentrations of 250x and"/>
   <result pre="10-100x total therapeutic plasma concentration (TPC). Exceptions were dasatinib and" exact="lapatinib" post="with maximal study concentrations of 250x and 136xTPC, respectively."/>
   <result pre="lapatinib, vandetanib, lestaurtinib and 0.1% DMSO for dasatinib, gefitinib, sunitinib," exact="imatinib" post="and sorafenib). S1 Table lists the TKI concentrations used"/>
   <result pre="cell culture medium supernatant was performed in EHT medium containing" exact="phenol" post="red-free DMEM (Gibco, 11880–028). Medium was sampled after 48"/>
   <result pre="stable contractile force ( Fig 1A, S2 Fig). Erlotinib and" exact="dasatinib" post="were not associated with reduction in contractile force at"/>
   <result pre="reduction in contractile force at any concentration studied. In contrast," exact="gefitinib" post="(10 μM, 86xTPC), lapatinib (150 μM, 136xTPC), sunitinib (10"/>
   <result pre="at any concentration studied. In contrast, gefitinib (10 μM, 86xTPC)," exact="lapatinib" post="(150 μM, 136xTPC), sunitinib (10 μM, 50xTPC), imatinib (100"/>
   <result pre="In contrast, gefitinib (10 μM, 86xTPC), lapatinib (150 μM, 136xTPC)," exact="sunitinib" post="(10 μM, 50xTPC), imatinib (100 μM, 50xTPC), and sorafenib"/>
   <result pre="μM, 86xTPC), lapatinib (150 μM, 136xTPC), sunitinib (10 μM, 50xTPC)," exact="imatinib" post="(100 μM, 50xTPC), and sorafenib (100 μM, 15xTPC), vandetanib"/>
   <result pre="136xTPC), sunitinib (10 μM, 50xTPC), imatinib (100 μM, 50xTPC), and" exact="sorafenib" post="(100 μM, 15xTPC), vandetanib (10, 100 μM, 5xTPC, 50xTPC)"/>
   <result pre="50xTPC), imatinib (100 μM, 50xTPC), and sorafenib (100 μM, 15xTPC)," exact="vandetanib" post="(10, 100 μM, 5xTPC, 50xTPC) and lestaurtinib (1, 10,"/>
   <result pre="The decline occurred rapidly (after 2 hours of incubation) for" exact="vandetanib" post="(100 μM, 50xTPC), lestaurtinib (100 μM, 12xTPC) and sorafenib"/>
   <result pre="for vandetanib (100 μM, 50xTPC), lestaurtinib (100 μM, 12xTPC) and" exact="sorafenib" post="(100 μM, 15xTPC) and delayed for all other conditions"/>
   <result pre="prolongation of relaxation time with erlotinib. This could indicate that" exact="erlotinib" post="is inhibiting repolarising potassium channels since prolongation of repolarisation"/>
   <result pre="no increase in LDH activity was detected for dasatinib, erlotinib," exact="gefitinib" post="and sunitinib. After 48 hours, a significant and substantial"/>
   <result pre="a significant and substantial increase in LDH was determined for" exact="vandetanib" post="(100 μM, 50xTPC, 4.8 fold), lestaurtinib (100 μM, 12xTPC,"/>
   <result pre="50xTPC, 4.8 fold), lestaurtinib (100 μM, 12xTPC, 4.6 fold) and" exact="lapatinib" post="(150 μM, 136xTPC, 4.1 fold). LDH was modestly increased"/>
   <result pre="(150 μM, 136xTPC, 4.1 fold). LDH was modestly increased by" exact="sorafenib" post="(100 μM, 15xTPC, 1.8 fold) and lestaurtinib (10 μM,"/>
   <result pre="lestaurtinib (10 μM, 1.2xTPC, 1.5 fold) and slightly elevated by" exact="imatinib" post="(100 μM, 50xTPC, 1.3 fold). LDH elevations were accentuated"/>
   <result pre="than in controls ( S3 Fig). Compared to vehicle control," exact="lapatinib" post="(150 mM, 136xTPC, 1.1 fold), sunitinib (10 μM, 50xTPC,"/>
   <result pre="Compared to vehicle control, lapatinib (150 mM, 136xTPC, 1.1 fold)," exact="sunitinib" post="(10 μM, 50xTPC, 1.4 fold), lestaurtinib (100 μM, 12xTPC,"/>
   <result pre="μM, 50xTPC, 1.4 fold), lestaurtinib (100 μM, 12xTPC, 1.2 fold)," exact="sorafenib" post="(100 μM, 15xTPC, 2.1 fold) and vandetanib (100 μM,"/>
   <result pre="12xTPC, 1.2 fold), sorafenib (100 μM, 15xTPC, 2.1 fold) and" exact="vandetanib" post="(100 μM, 50xTPC, 1.5 fold) resulted in increased CK"/>
   <result pre="activity after 48 hours. After 96 hours lower concentrations of" exact="sunitinib" post="(1 μM, 2 fold), lestaurtinib (10μM, 2 fold, 1"/>
   <result pre="fold), lestaurtinib (10μM, 2 fold, 1 μM, 1.5 fold), and" exact="vandetanib" post="(10 μM, 2 fold) as well as gefitinib (10"/>
   <result pre="fold), and vandetanib (10 μM, 2 fold) as well as" exact="gefitinib" post="(10 μM, 86xTPC, 1.6 fold) and erlotinib (100 μM,"/>
   <result pre="as well as gefitinib (10 μM, 86xTPC, 1.6 fold) and" exact="erlotinib" post="(100 μM, 40xTPC, 1.7 fold, 10 μM, 1.6 fold)"/>
   <result pre="three groups. Dasatinib-treated EHTs did not differ from controls and" exact="erlotinib" post="(100 μM, 40xTPC)- and gefitinib (10 μM, 86xTPC)-treated EHTs"/>
   <result pre="not differ from controls and erlotinib (100 μM, 40xTPC)- and" exact="gefitinib" post="(10 μM, 86xTPC)-treated EHTs showed moderate alterations (lower cell"/>
   <result pre="erlotinib, reduction of cross-striation). In contrast, in the presence of" exact="imatinib" post="(100 μM, 50xTPC), lapatinib (150 μM, 136xTPC), sunitinib (10"/>
   <result pre="In contrast, in the presence of imatinib (100 μM, 50xTPC)," exact="lapatinib" post="(150 μM, 136xTPC), sunitinib (10 μM, 50xTPC), lestaurtinib (100"/>
   <result pre="presence of imatinib (100 μM, 50xTPC), lapatinib (150 μM, 136xTPC)," exact="sunitinib" post="(10 μM, 50xTPC), lestaurtinib (100 μM, 12xTPC), sorafenib (100"/>
   <result pre="μM, 136xTPC), sunitinib (10 μM, 50xTPC), lestaurtinib (100 μM, 12xTPC)," exact="sorafenib" post="(100 μM, 15xTPC) or vandetanib (100 μM, 50xTPC), the"/>
   <result pre="50xTPC), lestaurtinib (100 μM, 12xTPC), sorafenib (100 μM, 15xTPC) or" exact="vandetanib" post="(100 μM, 50xTPC), the cellular density and α-sarcomeric actin-positivity"/>
   <result pre="0.1% DMSO); (C) sarcomere with sarcomeric disarray, widened Z-band, (Zw," exact="imatinib" post="10 μM); (D) mutilamellar bodies (MB, imatinib 10 μM);"/>
   <result pre="widened Z-band, (Zw, imatinib 10 μM); (D) mutilamellar bodies (MB," exact="imatinib" post="10 μM); (E) mitochondria with structural defects (Md), vacuoles"/>
   <result pre="mitochondria with structural defects (Md), vacuoles and inclusion bodies (IB," exact="sunitinib" post="1 μM); (F) autophagy (A, vandetanib 10 μM), scale"/>
   <result pre="and inclusion bodies (IB, sunitinib 1 μM); (F) autophagy (A," exact="vandetanib" post="10 μM), scale bar 1 μm. Due to the"/>
   <result pre="sections of the second highest TKI concentrations were analyzed for" exact="gefitinib" post="(1 μM, 8.6xTPC), imatinib (10 μM, 5xTPC), lapatinib (15"/>
   <result pre="highest TKI concentrations were analyzed for gefitinib (1 μM, 8.6xTPC)," exact="imatinib" post="(10 μM, 5xTPC), lapatinib (15 μM, 13.6xTPC), sunitinib (1"/>
   <result pre="analyzed for gefitinib (1 μM, 8.6xTPC), imatinib (10 μM, 5xTPC)," exact="lapatinib" post="(15 μM, 13.6xTPC), sunitinib (1 μM, 5xTPC), lestaurtinib (10"/>
   <result pre="μM, 8.6xTPC), imatinib (10 μM, 5xTPC), lapatinib (15 μM, 13.6xTPC)," exact="sunitinib" post="(1 μM, 5xTPC), lestaurtinib (10 μM, 1.2xTPC), sorafenib (10"/>
   <result pre="μM, 13.6xTPC), sunitinib (1 μM, 5xTPC), lestaurtinib (10 μM, 1.2xTPC)," exact="sorafenib" post="(10 μM, 1.5xTPC) and vandetanib (10 μM, 5xTPC) and"/>
   <result pre="5xTPC), lestaurtinib (10 μM, 1.2xTPC), sorafenib (10 μM, 1.5xTPC) and" exact="vandetanib" post="(10 μM, 5xTPC) and the highest concentration for erlotinib"/>
   <result pre="and vandetanib (10 μM, 5xTPC) and the highest concentration for" exact="erlotinib" post="(100 μM, 40xTPC) and dasatinib (10 μM, 250xTPC). Important"/>
   <result pre="and the highest concentration for erlotinib (100 μM, 40xTPC) and" exact="dasatinib" post="(10 μM, 250xTPC). Important findings were sarcomeric -, Z-line—and"/>
   <result pre="LC3-II/I ratio. This increase was low and not significant for" exact="erlotinib" post="(10/100 μM; 0.4, 0.7). Moderate-strong effects were observed with"/>
   <result pre="erlotinib (10/100 μM; 0.4, 0.7). Moderate-strong effects were observed with" exact="dasatinib" post="(1/10 μM; 1.3, 2.6), gefitinib (1/10 μM; 0.7, 17.4),"/>
   <result pre="Moderate-strong effects were observed with dasatinib (1/10 μM; 1.3, 2.6)," exact="gefitinib" post="(1/10 μM; 0.7, 17.4), lapatinib (15/150 μM; 1.6, 74.7),"/>
   <result pre="dasatinib (1/10 μM; 1.3, 2.6), gefitinib (1/10 μM; 0.7, 17.4)," exact="lapatinib" post="(15/150 μM; 1.6, 74.7), sunitinib (1/10 μM; 0.6, 30.2),"/>
   <result pre="gefitinib (1/10 μM; 0.7, 17.4), lapatinib (15/150 μM; 1.6, 74.7)," exact="sunitinib" post="(1/10 μM; 0.6, 30.2), imatinib (10/100 μM; 1.5, 6.8)"/>
   <result pre="lapatinib (15/150 μM; 1.6, 74.7), sunitinib (1/10 μM; 0.6, 30.2)," exact="imatinib" post="(10/100 μM; 1.5, 6.8) and sorafenib (10/100 μM; 0.6,"/>
   <result pre="(1/10 μM; 0.6, 30.2), imatinib (10/100 μM; 1.5, 6.8) and" exact="sorafenib" post="(10/100 μM; 0.6, 6.6) resulting in significantly higher LC3-II/I"/>
   <result pre="concentration for each TKI. The strongest effects were demonstrated for" exact="vandetanib" post="(10/100 μM; 8.9, 20.0) and lestaurtinib (10/100 μM; 5.8,"/>
   <result pre="alterations, a time series for 96 hours was performed with" exact="sorafenib" post="(100 μM), imatinib (100 μM) and sunitinib (10 μM)."/>
   <result pre="series for 96 hours was performed with sorafenib (100 μM)," exact="imatinib" post="(100 μM) and sunitinib (10 μM). These three TKIs"/>
   <result pre="was performed with sorafenib (100 μM), imatinib (100 μM) and" exact="sunitinib" post="(10 μM). These three TKIs were chosen because all"/>
   <result pre="did not show incremental tendencies over time. In contrast, sorafenib," exact="imatinib" post="and sunitinib led to a substantial increase in sarcomeric"/>
   <result pre="show incremental tendencies over time. In contrast, sorafenib, imatinib and" exact="sunitinib" post="led to a substantial increase in sarcomeric disarray, damaged"/>
   <result pre="activity. The onset of these alterations was 24–48 hours for" exact="sorafenib" post="and imatinib and 96 hours for sunitinib. Quantitative analyses"/>
   <result pre="onset of these alterations was 24–48 hours for sorafenib and" exact="imatinib" post="and 96 hours for sunitinib. Quantitative analyses of these"/>
   <result pre="LC3-II/I ratio values of 1.6 and 2.0. In contrast, imatinib," exact="sorafenib" post="and sunitinib led to a shift and enhancement of"/>
   <result pre="values of 1.6 and 2.0. In contrast, imatinib, sorafenib and" exact="sunitinib" post="led to a shift and enhancement of the LC3"/>
   <result pre="96 hours of incubation under (vehicle) control conditions and with" exact="sorafenib" post="(100 μM), imatinib (100 μM) and sunitinib (10 μM)."/>
   <result pre="incubation under (vehicle) control conditions and with sorafenib (100 μM)," exact="imatinib" post="(100 μM) and sunitinib (10 μM). Mosaic TEM images"/>
   <result pre="conditions and with sorafenib (100 μM), imatinib (100 μM) and" exact="sunitinib" post="(10 μM). Mosaic TEM images are shown in S4–"/>
   <result pre="series (24 h-96 h) for vehicle control DMSO 0.1% (DMSO)," exact="sorafenib" post="(100 μM), imatinib (100 μM), and sunitinib (10 μM)"/>
   <result pre="h) for vehicle control DMSO 0.1% (DMSO), sorafenib (100 μM)," exact="imatinib" post="(100 μM), and sunitinib (10 μM) on heart cell"/>
   <result pre="DMSO 0.1% (DMSO), sorafenib (100 μM), imatinib (100 μM), and" exact="sunitinib" post="(10 μM) on heart cell EHTs. Arrows indicate cytoplasmatic"/>
   <result pre="in cardiac tissue done so far. Other interesting candidates like" exact="trastuzumab" post="were not included due to substantial differences in species"/>
   <result pre="but appeared safe with this assay. On the other hand," exact="gefitinib" post="is not considered cardiotoxic but was associated with a"/>
   <result pre="include species-specific differences in sensitivity. In fact, recent studies on" exact="dasatinib" post="cardiotoxicity in rat (H9c2) and human (induced pluripotent stem"/>
   <result pre="(10 μM), reduced contractility when incubated for 4 days. Similarly," exact="sunitinib" post="had already effects at 1 μM. The data suggest"/>
   <result pre="actin). An additional time series experiment was performed with sorafenib," exact="imatinib" post="and sunitinib. The experiments revealed that sarcomeric disarray and"/>
   <result pre="already established at the early time points (24–48 hours) for" exact="sorafenib" post="and imatinib, but needed 96 hours for sunitinib. This"/>
   <result pre="was maximally inhibited in EHTs in the presence of imatinib," exact="sorafenib" post="and sunitinib, already after 24 hours of incubation ("/>
   <result pre="evidence was provided in several different experimental models for sorafenib," exact="sunitinib" post="and imatinib [ 21– 26]. Hu et al. suggested"/>
   <result pre="provided in several different experimental models for sorafenib, sunitinib and" exact="imatinib" post="[ 21– 26]. Hu et al. suggested that this"/>
   <result pre="on physicochemical properties based on the observation that analogues of" exact="imatinib" post="without kinase inhibitory activity but similar physicochemical properties had"/>
   <result pre="decline in contractility was approximately parallel in the case of" exact="sunitinib" post="and imatinib, but not for sorafenib, where force declined"/>
   <result pre="C , et al. Cardiotoxicity of the cancer therapeutic agent" exact="imatinib" post="mesylate. Nat Med. 2006; 12: 908– 16. doi: 10.1038/nm1446"/>
   <result pre="potential limitations of animal models utilized in the development of" exact="trastuzumab" post="(Herceptin): A case study . Advanced Drug Delivery Reviews."/>
   <result pre="of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and" exact="sorafenib" post="on mitochondrial function in isolated rat heart mitochondria and"/>
   <result pre="of autophagy potentiates the antitumor effect of the multikinase inhibitor" exact="sorafenib" post="in hepatocellular carcinoma . Int J Cancer. 2012; 131:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4741577/results/search/inn/results.xml">
   <result pre="of mice with HER2-targeted immunotoxin (Fig. 6) or chemotherapy drug" exact="cisplatin" post="or their combination. Figure 6 Sequential in vivo images"/>
   <result pre="red bars). The combined treatment of tumors by 4D5scFv-ETA and" exact="cisplatin" post="slightly enhanced the anti-tumor effect (Fig. 7, green bars)."/>
   <result pre="for in vivo evaluation of anti-tumor efficacy of chemotherapeutic agent" exact="cisplatin" post="and novel HER2-targeted recombinant immunotoxin based on the scFv"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4741657/results/search/inn/results.xml">
   <result pre="Negative Initial stage IV Trastuzumab + Paclitaxel 38 Lapatinib +" exact="capecitabine" post="6 S413L (0.01) OS256 S72A (0.01) Negative Negative 9"/>
   <result pre="resistance to HER2-targeted therapies. Several mechanisms of resistance to both" exact="trastuzumab" post="and lapatinib have been identified in preclinical studies ["/>
   <result pre="HER2-targeted therapies. Several mechanisms of resistance to both trastuzumab and" exact="lapatinib" post="have been identified in preclinical studies [ 17– 23]."/>
   <result pre="the identification of a robust clinical or molecular predictor of" exact="trastuzumab" post="benefit, including HER2 itself, has proven challenging [ 26–"/>
   <result pre="Clark E Benyunes MC Ross G et al. Pertuzumab plus" exact="trastuzumab" post="plus docetaxel for metastatic breast cancer N Engl J"/>
   <result pre="Benyunes MC Ross G et al. Pertuzumab plus trastuzumab plus" exact="docetaxel" post="for metastatic breast cancer N Engl J Med 2012"/>
   <result pre="AR Voytko NL et al. The cyclin-dependent kinase 4/6 inhibitor" exact="palbociclib" post="in combination with letrozole versus letrozole alone as first-line"/>
   <result pre="al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with" exact="letrozole" post="versus letrozole alone as first-line treatment of oestrogen receptor-positive,"/>
   <result pre="cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus" exact="letrozole" post="alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced"/>
   <result pre="R Gilmer TM Delineation of molecular mechanisms of sensitivity to" exact="lapatinib" post="in breast cancer cell lines using global gene expression"/>
   <result pre="isoform of HER2 associated with locally disseminated breast cancer and" exact="trastuzumab" post="resistance Mol Cancer Ther 2009 8 2152 2162 19671734"/>
   <result pre="Arteaga CL Human breast cancer cells selected for resistance to" exact="trastuzumab" post="in vivo overexpress epidermal growth factor receptor and ErbB"/>
   <result pre="Ross GA Fumoleau P Gianni L Phase II trial of" exact="pertuzumab" post="and trastuzumab in patients with human epidermal growth factor"/>
   <result pre="Fumoleau P Gianni L Phase II trial of pertuzumab and" exact="trastuzumab" post="in patients with human epidermal growth factor receptor 2-positive"/>
   <result pre="factor receptor 2-positive metastatic breast cancer that progressed during prior" exact="trastuzumab" post="therapy J Clin Oncol 2010 28 1138 1144 20124182"/>
   <result pre="B Morandi P et al. Efficacy and safety of neoadjuvant" exact="pertuzumab" post="and trastuzumab in women with locally advanced, inflammatory, or"/>
   <result pre="P et al. Efficacy and safety of neoadjuvant pertuzumab and" exact="trastuzumab" post="in women with locally advanced, inflammatory, or early HER2-positive"/>
   <result pre="al. Impact of PTEN protein expression on benefit from adjuvant" exact="trastuzumab" post="in early-stage human epidermal growth factor receptor 2-positive breast"/>
   <result pre="chromosome 17 effect on patient outcome in the N9831 adjuvant" exact="trastuzumab" post="trial J Clin Oncol 2010 28 4307 4315 20697084"/>
   <result pre="Kim C Wolmark N HER2 status and benefit from adjuvant" exact="trastuzumab" post="in breast cancer N Engl J Med 2008 358"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4742525/results/search/inn/results.xml">
   <result pre="suggested before us[ 69]. Of note, the true effects of" exact="trastuzumab" post="on HER2-overexpressing breast cancer were discovered synchronously with the"/>
   <result pre=", et al. Phase II trial of modified FOLFOX6 and" exact="erlotinib" post="in patients with metastatic or advanced adenocarcinoma of the"/>
   <result pre=", Park JO , et al. MET amplification leads to" exact="gefitinib" post="resistance in lung cancer by activating ERBB3 signaling ."/>
   <result pre="S , Eichmann M , et al. Biomarker analysis of" exact="cetuximab" post="plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction"/>
   <result pre="Predictive factors for outcome in a phase II study of" exact="gefitinib" post="in second-line treatment of advanced esophageal cancer patients ."/>
   <result pre=", Baker AF , et al. Phase II trial of" exact="erlotinib" post="in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127 ."/>
   <result pre="A , Webb J , et al. Epirubicin, oxaliplatin, and" exact="capecitabine" post="with or without panitumumab for advanced esophagogastric cancer: dose-finding"/>
   <result pre=", et al. Epirubicin, oxaliplatin, and capecitabine with or without" exact="panitumumab" post="for advanced esophagogastric cancer: dose-finding study for the prospective"/>
   <result pre="D , Ruhstaller T , et al. Matuzumab plus epirubicin," exact="cisplatin" post="and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine"/>
   <result pre="Ruhstaller T , et al. Matuzumab plus epirubicin, cisplatin and" exact="capecitabine" post="(ECX) compared with epirubicin, cisplatin and capecitabine alone as"/>
   <result pre="Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin," exact="cisplatin" post="and capecitabine alone as first-line treatment in patients with"/>
   <result pre="epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and" exact="capecitabine" post="alone as first-line treatment in patients with advanced oesophago-gastric"/>
   <result pre="MA , et al. Combination of anti-HER3 antibody MM-121/SAR256212 and" exact="cetuximab" post="inhibits tumor growth in preclinical models of head and"/>
   <result pre="Obszynska J , et al. A phase II study of" exact="gefitinib" post="monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression,"/>
   <result pre="patients who received curative surgery followed by adjuvant 5-fluorouracil and" exact="cisplatin" post="chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4743179/results/search/inn/results.xml">
   <result pre="breast cancer whose disease had progressed on anthracyclines, taxanes, and" exact="capecitabine" post="to either physician choice of chemotherapy or the etirinotecan"/>
   <result pre="early stage triple-negative breast cancer who had received adriamycin and" exact="cyclophosphamide" post="(AC) to either ixabepilone or paclitaxel in the adjuvant"/>
   <result pre="cancer who had received adriamycin and cyclophosphamide (AC) to either" exact="ixabepilone" post="or paclitaxel in the adjuvant setting. The authors reported"/>
   <result pre="had received adriamycin and cyclophosphamide (AC) to either ixabepilone or" exact="paclitaxel" post="in the adjuvant setting. The authors reported disease free"/>
   <result pre="among those who received AC/paclitaxel thereby, demonstrating no advantage of" exact="ixabepilone" post="over paclitaxel in the adjuvant setting in this cohort."/>
   <result pre="who received AC/paclitaxel thereby, demonstrating no advantage of ixabepilone over" exact="paclitaxel" post="in the adjuvant setting in this cohort. Improving endocrine"/>
   <result pre="DCIS who had undergone lumpectomy and radiation therapy to either" exact="tamoxifen" post="or anastrozole. The authors reported a significant improvement in"/>
   <result pre="improvement in 10-year breast cancer-free interval favoring the group receiving" exact="anastrozole" post="(hazard ratio [HR] = 0.73, 93.5% vs. 89.2%, P"/>
   <result pre="III CALGB 40503 trial that looked at the addition of" exact="bevacizumab" post="to letrozole as first-line endocrine therapy. In this multicenter"/>
   <result pre="40503 trial that looked at the addition of bevacizumab to" exact="letrozole" post="as first-line endocrine therapy. In this multicenter trial that"/>
   <result pre="metastatic breast cancer, the authors reported that the addition of" exact="bevacizumab" post="to letrozole improved progression-free survival (HR = 0.74, 95%"/>
   <result pre="cancer, the authors reported that the addition of bevacizumab to" exact="letrozole" post="improved progression-free survival (HR = 0.74, 95% confidence interval"/>
   <result pre="95% confidence interval [CI]: 0.58-0.95, P = 0.016) compared to" exact="letrozole" post="alone. Furthermore, no significant difference was observed with regards"/>
   <result pre="4/6 inhibitor, has recently received FDA approval in combination with" exact="letrozole" post="as first-line therapy for hormone receptor-positive metastatic breast cancer."/>
   <result pre="phase III PALOMA-3 trial that looked at the addition of" exact="palbociclib" post="to fulvestrant among pre- and post-menopausal women with hormone"/>
   <result pre="PALOMA-3 trial that looked at the addition of palbociclib to" exact="fulvestrant" post="among pre- and post-menopausal women with hormone receptor-positive metastatic"/>
   <result pre="Median progression-free survival was significantly improved with the addition of" exact="palbociclib" post="from 3.8 months to 9.2 months (HR = 0.42,"/>
   <result pre="0.001). Most common side effects reported with the addition of" exact="palbociclib" post="included neutropenia, leukopenia, anemia, thrombocytopenia, and fatigue. These two"/>
   <result pre="abstracts raised several important questions that have clinical implications. Does" exact="bevacizumab" post="has a role among women with metastatic hormone receptor-positive"/>
   <result pre="hormone receptor-positive breast cancer? In an endocrine resistant population, should" exact="everolimus" post="or palbociclib be the agent of choice? What toxicities"/>
   <result pre="breast cancer? In an endocrine resistant population, should everolimus or" exact="palbociclib" post="be the agent of choice? What toxicities will be"/>
   <result pre="of choice? What toxicities will be observed among patients taking" exact="everolimus" post="following progression on palbociclib? Improving anti-human epidermal growth factor"/>
   <result pre="that randomized women with HER2 positive metastatic breast cancer to" exact="trastuzumab" post="and taxane, TDM-1 plus placebo or TDM-1 plus pertuzumab."/>
   <result pre="respectively. Although noninferiority of the TDM-1 containing arms compared to" exact="trastuzumab" post="and taxane was demonstrated, superiority was not observed. The"/>
   <result pre="The CLEOPATRA trial has clearly shown that the addition of" exact="pertuzumab" post="to trastuzumab and taxane improves prognostic outcome. The addition"/>
   <result pre="trial has clearly shown that the addition of pertuzumab to" exact="trastuzumab" post="and taxane improves prognostic outcome. The addition of pertuzumab"/>
   <result pre="to trastuzumab and taxane improves prognostic outcome. The addition of" exact="pertuzumab" post="to TDM-1 did not improve prognostic outcome over trastuzumab"/>
   <result pre="of pertuzumab to TDM-1 did not improve prognostic outcome over" exact="trastuzumab" post="and taxane as demonstrated by MARIANNE, suggesting that we"/>
   <result pre="trials have shown that the addition of 1 year of" exact="trastuzumab" post="significantly improves prognostic outcome among women with early stage"/>
   <result pre="not reported significant benefit when giving 2 years of adjuvant" exact="trastuzumab" post="compared to 1 year. Chan et al.[ 7] reported"/>
   <result pre="I-III HER2-positive breast cancer who had completed adjuvant chemotherapy and" exact="trastuzumab" post="to receive either 1 year of neratinib (a pan"/>
   <result pre="adjuvant chemotherapy and trastuzumab to receive either 1 year of" exact="neratinib" post="(a pan HER tyrosine kinase inhibitor) or 1 year"/>
   <result pre="significant improvement in invasive disease-free survival favoring the group receiving" exact="neratinib" post="(93.9% vs. 91.6%, HR = 0.67, 95% CI: 0.50-0.91,"/>
   <result pre="ASCO 2015, the investigators presented results looking at efficacy of" exact="enzalutamide" post="among triple receptor-negative tumors that expressed androgen receptors. Among"/>
   <result pre="study that looked at the efficacy of the anti-pd-1 inhibitor" exact="nivolumab" post="among patients with advanced hepatocellular carcinoma whose Child–Pugh score"/>
   <result pre="survival was estimated at 62%. These results are encouraging with" exact="nivolumab" post="currently being investigated in this setting in an expansion"/>
   <result pre="liver metastases to received first line mFOLFOX6 with or without" exact="bevacizumab" post="and with or without selective internal radiation therapy (SIRT)."/>
   <result pre="phase II HERACLES trial that looked at the efficacy of" exact="trastuzumab" post="and lapatinib among 25 patients HER2 amplified metastatic colorectal"/>
   <result pre="HERACLES trial that looked at the efficacy of trastuzumab and" exact="lapatinib" post="among 25 patients HER2 amplified metastatic colorectal cancer that"/>
   <result pre="whose disease has progressed following anthracycline (A), taxane (T) and" exact="capecitabine" post="(C): The BEACON study J Clin Oncol 2015 33"/>
   <result pre="Daniel BR Ackerman MA et al. TITAN: Ixabepilone versus weekly" exact="paclitaxel" post="following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple-negative breast cancer"/>
   <result pre="al. Primary results, NRG oncology/NSABP B-35: A clinical trial of" exact="anastrozole" post="(A) versus tamoxifen (tam) in postmenopausal patients with DCIS"/>
   <result pre="NRG oncology/NSABP B-35: A clinical trial of anastrozole (A) versus" exact="tamoxifen" post="(tam) in postmenopausal patients with DCIS undergoing lumpectomy plus"/>
   <result pre="F et al. Phase III trial evaluating the addition of" exact="bevacizumab" post="to letrozole as first-line endocrine therapy for treatment of"/>
   <result pre="al. Phase III trial evaluating the addition of bevacizumab to" exact="letrozole" post="as first-line endocrine therapy for treatment of hormone-receptor positive"/>
   <result pre="et al. Phase III, randomized study of trastuzumabemtansine (T-DM1) ±" exact="pertuzumab" post="(P) vstrastuzumab + taxane (HT) for first-line treatment of"/>
   <result pre="H Harvey VJ et al. Neratinib after adjuvant chemotherapy and" exact="trastuzumab" post="in HER2-positive early breast cancer: Primary analysis at 2"/>
   <result pre="A et al. Results from a phase 2 study of" exact="enzalutamide" post="(ENZA), an androgen receptor (AR) inhibitor, in advanced AR+"/>
   <result pre="W et al. Phase I/II safety and antitumor activity of" exact="nivolumab" post="in patients with advanced hepatocellular carcinoma (HCC): CA209-040 J"/>
   <result pre="al. SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 ±" exact="bevacizumab" post="(bev) versus mFOLFOX6 + selective internal radiation therapy (SIRT)"/>
   <result pre="Trusolino L Martino C Bencardino K et al. Trastuzumab and" exact="lapatinib" post="in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4745781/results/search/inn/results.xml">
   <result pre="November 14, 2014, the Food and Drug Administration (FDA) approved" exact="bevacizumab" post="in combination with chemotherapy for the treatment of patients"/>
   <result pre="receptors, has been reported to augment the antitumoral properties of" exact="gemcitabine" post="[ 14]. Interestingly, preclinical studies have shown that combination"/>
   <result pre="[ 14]. Interestingly, preclinical studies have shown that combination of" exact="trastuzumab" post="and pertuzumab may be more efficacious than treatment with"/>
   <result pre="Interestingly, preclinical studies have shown that combination of trastuzumab and" exact="pertuzumab" post="may be more efficacious than treatment with single antibodies"/>
   <result pre="other drugs currently used for the targeting of HER2, including" exact="trastuzumab" post="or pertuzumab, or the small molecule HER2 inhibitor lapatinib."/>
   <result pre="four ovarian cancer cell lines were treated with trastuzumab, pertuzumab," exact="lapatinib" post="or the antibody-drug conjugate trastuzumab-emtansine (T-DM1) [ 19]. Control"/>
   <result pre="cultures were counted after 7 days of treatment. Addition of" exact="trastuzumab" post="or pertuzumab did not affect the proliferation of the"/>
   <result pre="counted after 7 days of treatment. Addition of trastuzumab or" exact="pertuzumab" post="did not affect the proliferation of the four ovarian"/>
   <result pre="less sensitive resulted to be the A2780. In SKOV3 cells" exact="lapatinib" post="slightly reduced proliferation, while in OVCAR8 and A2780 the"/>
   <result pre="and A2780 the effect of that drug was marginal. Interestingly," exact="lapatinib" post="substantially inhibited the proliferation of IGROV1 cells, even though"/>
   <result pre="ovarian cancer cell lines. Cells were treated with 1 μM" exact="lapatinib" post="and 50 nM of the rest of the indicated"/>
   <result pre="control mice ( n = 5) and those treated with" exact="trastuzumab" post="and T-DM1 ( n = 5 per group) with"/>
   <result pre="trastuzumab, P = 0.504; Control vs T-DM1, P = 0.0001;" exact="trastuzumab" post="vs T-DM1, P = 0.004. P values were calculated"/>
   <result pre="T-DM1 with chemotherapeutic agents used in ovarian cancer (carboplatin, cisplatin," exact="docetaxel" post="and vinorelbine). SKOV3 cells were treated with the indicated"/>
   <result pre="standard of care drugs Part of the antitumoral effect of" exact="trastuzumab" post="is due to antibody-dependent cellular toxicity immunological mechanisms ["/>
   <result pre="of this, in vivo experiments comparing the antitumoral action of" exact="trastuzumab" post="and T-DM1 were performed using mice injected with SKOV3"/>
   <result pre="their sensitivity to T-DM1 in vitro. These studies showed that" exact="trastuzumab" post="slowed tumor growth in vivo when compared to the"/>
   <result pre="72 days after discontinuation of the treatments (Figure 3D). Biochemically," exact="trastuzumab" post="and T-DM1 did not affect the total level of"/>
   <result pre="investigated. To this end, combinations of T-DM1 with cisplatin, carboplatin," exact="docetaxel" post="or vinorelbine were tested in the SKOV3 and A2780"/>
   <result pre="this end, combinations of T-DM1 with cisplatin, carboplatin, docetaxel or" exact="vinorelbine" post="were tested in the SKOV3 and A2780 cells and"/>
   <result pre="the Chou-Talalay algorithm [ 21]. Synergistic effects of T-DM1 with" exact="docetaxel" post="and vinorelbine were observed (Figure 3E and Supplementary Figure"/>
   <result pre="algorithm [ 21]. Synergistic effects of T-DM1 with docetaxel and" exact="vinorelbine" post="were observed (Figure 3E and Supplementary Figure 2). T-DM1"/>
   <result pre="to their proliferation. These results raise the question of why" exact="lapatinib" post="affected proliferation of IGROV1 while HER2 knockdown did not."/>
   <result pre="of IGROV1 while HER2 knockdown did not. This effect of" exact="lapatinib" post="on IGROV1 cells may be explained by an off-target"/>
   <result pre="agents on ovarian cancer cell lines showed limited efficacy of" exact="trastuzumab" post="or pertuzumab, in line with a previously published in"/>
   <result pre="previously published in vivo study [ 15]. In contrast, the" exact="trastuzumab" post="derivative T-DM1 showed strong antitumoral properties both in vitro"/>
   <result pre="reported in breast cancer [ 24]. Interestingly, T-DM1 synergized with" exact="docetaxel" post="and vinorelbine. It is therefore possible that drugs altering"/>
   <result pre="levels of p27. This effect may be due to the" exact="trastuzumab" post="part of the compound, as this antibody has been"/>
   <result pre="this protein. Because of the much better effect of the" exact="trastuzumab" post="derivative T-DM1 with respect to other clinically available drugs"/>
   <result pre="from GE Healthcare Life Sciences (Piscataway, NJ, USA). Carboplatin and" exact="cisplatin" post="were from Pfizer (Madrid, Spain). Docetaxel was from Hospira"/>
   <result pre="in Andorra. Trastuzumab was purchased from a local pharmacy and" exact="pertuzumab" post="was obtained from Genentech (San Francisco, CA). Other generic"/>
   <result pre="glucose concentration (4,500 mg/L) and antibiotics (penicillin at 100 mU/mL," exact="streptomycin" post="at 100 μg/mL) and supplemented with 10% FBS. Knockdown"/>
   <result pre="whether the combination of T-DM1 with chemotherapeutic agents (carboplatin, cisplatin," exact="docetaxel" post="and vinorelbine) was synergistic, additive or antagonist, we used"/>
   <result pre="with PBS, cells were fixed and permeabilized by ice-cold 70%" exact="ethanol" post="overnight. Cells were centrifuged, resuspended in 500 μL of"/>
   <result pre="(with equal average tumour volumes) (vehicle (PBS) n = 5," exact="trastuzumab" post="n = 5, and T-DM1 n = 5). Mice"/>
   <result pre="(day 0 and day 7) at the first week with" exact="trastuzumab" post="(15 mg/kg) and T-DM1 (15 mg/kg) intravenously. Tumour diameters"/>
   <result pre="= width 2 × length/2. Mice treated with vehicle and" exact="trastuzumab" post="were sacrificed on day 28. Mice treated with T-DM1"/>
   <result pre="The combination of the tyrosine kinase receptor inhibitor SU6668 with" exact="paclitaxel" post="affects ascites formation and tumor spread in ovarian carcinoma"/>
   <result pre="Boente M Birrer MJ Liang SX et al. Incorporation of" exact="bevacizumab" post="in the primary treatment of ovarian cancer N Engl"/>
   <result pre="J Kimmig R et al. A phase 3 trial of" exact="bevacizumab" post="in ovarian cancer N Engl J Med 2011 365"/>
   <result pre="Klein-Szanto AJ Miner Z Vanderhyden BC Phase II evaluation of" exact="imatinib" post="mesylate in the treatment of recurrent or persistent epithelial"/>
   <result pre="A Kelsey S Sliwkowski MX et al. Clinical activity of" exact="gemcitabine" post="plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer,"/>
   <result pre="S Sliwkowski MX et al. Clinical activity of gemcitabine plus" exact="pertuzumab" post="in platinum-resistant ovarian cancer, fallopian tube cancer, or primary"/>
   <result pre="Harrison DJ Langdon SP Defining the molecular response to trastuzumab," exact="pertuzumab" post="and combination therapy in ovarian cancer Br J Cancer"/>
   <result pre="Computerized quantitation of synergism and antagonism of taxol, topotecan, and" exact="cisplatin" post="against human teratocarcinoma cell growth: a rational approach to"/>
   <result pre="PA Hart LS Dicker DT Humphreys R El-Deiry WS Off-target" exact="lapatinib" post="activity sensitizes colon cancer cells through TRAIL death receptor"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4747990/results/search/inn/results.xml">
   <result pre="patients with moderate emetic risk, 5HT 3 receptor antagonists and" exact="dexamethasone" post="were recommended, whereas for those receiving chemotherapy with low"/>
   <result pre="recommended, whereas for those receiving chemotherapy with low emetic risk" exact="dexamethasone" post="only is recommended. Patients receiving high-emetic-risk radiation therapy should"/>
   <result pre="Carmustine (&amp;gt; 250 mg/m 2 ) Dacarbazine Mechlorethamine Doxorubicin +" exact="cyclophosphamide" post="Streptozocin Epirubicin + cyclophosphamide Moderate emetic risk (emetic frequency"/>
   <result pre="2 ) Dacarbazine Mechlorethamine Doxorubicin + cyclophosphamide Streptozocin Epirubicin +" exact="cyclophosphamide" post="Moderate emetic risk (emetic frequency 30–90 %) Actinomycin D"/>
   <result pre="Gemcitabine Pentostatin Interferon α (5–10 million IU/m 2) Ranimusutine Liposomal" exact="doxorubicin" post="Topotecan Methotrexate (50–250 mg/m 2) Amifostine (&amp;lt; 300 mg)"/>
   <result pre="Although the 2009 NCCN guidelines indicate that high and low-dose" exact="cisplatin" post="regimens have high and moderate emetic risk, respectively, the"/>
   <result pre="risk, respectively, the 2008 MASCC and 2006 ASCO guidelines categorized" exact="cisplatin" post="as a drug of high emetic risk irrespective of"/>
   <result pre="emetic risk irrespective of dosage [ 8, 9]. Accordingly, all" exact="cisplatin" post="regimens, including those administered over several days were regarded"/>
   <result pre="frequently used as adjuvant treatments with tegafur-uracil and/or leucovorin and" exact="capecitabine" post="for colorectal cancer, S-1 for gastric cancer, and tegafur-uracil"/>
   <result pre="receptor antagonist (aprepitant), serotonin (5-hydroxytryptamine: 5HT 3) receptor antagonist, and" exact="dexamethasone" post="is recommended for acute emesis during highly emetic cancer"/>
   <result pre="Recommendation (Grade A): regimens containing 5HT 3 receptor antagonists and" exact="dexamethasone" post="are basically recommended for acute emesis during moderately emetic"/>
   <result pre="receptor antagonist to regimens of 5HT 3 receptor antagonist and" exact="dexamethasone" post="are considered. Acute onset of nausea and vomiting occurs"/>
   <result pre="highly emetic cancer agents, and suggests no additional effects of" exact="dexamethasone" post="after day 2. Upon issue of the 1st guideline,"/>
   <result pre="after day 2. Upon issue of the 1st guideline, oral" exact="aprepitant" post="was the only NK1 receptor antagonist available for clinical"/>
   <result pre="we immediately modified the diagram and included additional information about" exact="fosaprepitant" post="as a minor revision of the guideline, with careful"/>
   <result pre="High emetic risk: in the absence of aprepitant, 13.2–16.4 mg" exact="dexamethasone" post="should be given on day 1; b moderate emetic"/>
   <result pre="c low emetic risk; d minimum emetic risk. Asterisk, optional" exact="fosaprepitant" post="was added to the diagrams in a revised edition"/>
   <result pre="are necessary according to specific conditions of each patient. Intravenous" exact="dexamethasone" post="contains 3.3 mg/mL dexamethasone out of a total 4"/>
   <result pre="specific conditions of each patient. Intravenous dexamethasone contains 3.3 mg/mL" exact="dexamethasone" post="out of a total 4 mg/mL dexamethasone sodium phosphate"/>
   <result pre="contains 3.3 mg/mL dexamethasone out of a total 4 mg/mL" exact="dexamethasone" post="sodium phosphate CQ5. How should delayed nausea and vomiting"/>
   <result pre="A): a combined regimen of NK1 receptor antagonist (aprepitant) and" exact="dexamethasone" post="is recommended for treatment of delayed emesis during highly"/>
   <result pre="highly emetic cancer chemotherapy. Recommendation (Grade A): single administration of" exact="dexamethasone" post="is basically recommended for delayed emesis during moderately emetic"/>
   <result pre="moderately emetic cancer chemotherapy. However, regimens of NK1 antagonist and/or" exact="dexamethasone" post="are considered. Delayed onset of nausea and vomiting occurs"/>
   <result pre="preventing delayed emesis (Fig. 1). In specific cases in which" exact="dexamethasone" post="should be restricted, 2–4 days of 5HT3 antagonist is"/>
   <result pre="3 receptors with antagonistic agents. It has been proved that" exact="palonosetron" post="is not inferior to granisetron in the acute phase"/>
   <result pre="It has been proved that palonosetron is not inferior to" exact="granisetron" post="in the acute phase and is superior to granisetron"/>
   <result pre="to granisetron in the acute phase and is superior to" exact="granisetron" post="in the delayed phase [ 11]. CQ7. What is"/>
   <result pre="evidence of mechanisms. Although several classes of corticosteroid are available," exact="dexamethasone" post="and methylprednisolone are most frequently used as antiemetics, with"/>
   <result pre="mechanisms. Although several classes of corticosteroid are available, dexamethasone and" exact="methylprednisolone" post="are most frequently used as antiemetics, with strong evidence"/>
   <result pre="their effects [ 13, 14]. In particular, oral and intravenous" exact="dexamethasone" post="(4–20 mg/day) has been approved as antiemetic treatment during"/>
   <result pre="during cancer chemotherapy in Japan. However, the efficacy of high-dose" exact="dexamethasone" post="has not been compared with that of 20-mg treatments"/>
   <result pre="from that of the primary antiemetic agent. Among these, the" exact="dopamine" post="antagonists metoclopramide, butyrophenone, corticosteroid, and lorazepam may be considered"/>
   <result pre="agent. Among these, the dopamine antagonists metoclopramide, butyrophenone, corticosteroid, and" exact="lorazepam" post="may be considered for breakthrough emesis, despite poor evidence"/>
   <result pre="of antiemetic treatments for patients with advanced cancer showed that" exact="metoclopramide" post="is superior to placebo and equivalent to ondansetron, although"/>
   <result pre="51 advanced cancer patients showed no significant effects of additional" exact="dexamethasone" post="for nausea after failure of antiemetic response to metoclopramide"/>
   <result pre="additional dexamethasone for nausea after failure of antiemetic response to" exact="metoclopramide" post="[ 17]. Some reports recommend antiemetic prophylaxis using agents"/>
   <result pre="chemotherapy be managed? Recommendation (Grade B): during low emetic chemotherapy," exact="dexamethasone" post="should be considered according to chemotherapeutic regimen and patient"/>
   <result pre="regimen and patient background. Recommendation (Grade C1): routine usage of" exact="dexamethasone" post="is not recommended for minimum emetic chemotherapy. Prophylactic antiemetic"/>
   <result pre="ASCO and 2008 MASCC guidelines recommended administration of 4–8 mg" exact="dexamethasone" post="[ 13, 18], and include prochlorperazine [ 19] and"/>
   <result pre="administration of 4–8 mg dexamethasone [ 13, 18], and include" exact="prochlorperazine" post="[ 19] and metoclopramide as optional antiemetics. CQ10. How"/>
   <result pre="dexamethasone [ 13, 18], and include prochlorperazine [ 19] and" exact="metoclopramide" post="as optional antiemetics. CQ10. How is nausea and vomiting"/>
   <result pre="is nausea and vomiting managed for such regimens as several" exact="cisplatin" post="treatments daily? Recommendation (Grade B): a triple antiemetic regimen"/>
   <result pre="a triple antiemetic regimen of 5HT 3 antagonist, dexamethasone, and" exact="aprepitant" post="is recommended for acute nausea and vomiting during more"/>
   <result pre="vomiting during more typical chemotherapeutic regimens. A double regimen of" exact="dexamethasone" post="and aprepitant is recommended for delayed nausea and vomiting,"/>
   <result pre="more typical chemotherapeutic regimens. A double regimen of dexamethasone and" exact="aprepitant" post="is recommended for delayed nausea and vomiting, even during"/>
   <result pre="for delayed nausea and vomiting, even during regimens of several" exact="cisplatin" post="treatments daily. It is widely accepted that cisplatin is"/>
   <result pre="of several cisplatin treatments daily. It is widely accepted that" exact="cisplatin" post="is a highly emetic chemotherapeutic agent, and it is"/>
   <result pre="2 for treatment of a variety of malignancies. However, different" exact="cisplatin" post="regimens have been established with reasonable evidence, including several"/>
   <result pre="cisplatin regimens have been established with reasonable evidence, including several" exact="cisplatin" post="treatments daily at &amp;lt;50 mg/m 2 for oncologic tumors"/>
   <result pre="cholangiocarcinomas, bladder cancers, and germinomas [ 20, 21], and continuous" exact="cisplatin" post="injections at 100 mg/m 2 over 4 days for"/>
   <result pre="The 2009 NCCN and 2008 MASCC guidelines recommended treatments with" exact="lorazepam" post="[ 27] for anticipatory nausea and vomiting, and alprazolam"/>
   <result pre="with lorazepam [ 27] for anticipatory nausea and vomiting, and" exact="alprazolam" post="[ 28] for anticipatory nausea. CQ12. How are emetic"/>
   <result pre="pharmacokinetic interactions observed? Recommendation (Grade B): it is essential that" exact="aprepitant" post="is used carefully to avoid interactions with co-administered drugs,"/>
   <result pre="according to patient conditions and disease backgrounds is critical. Because" exact="aprepitant" post="induces and inhibits the cytochrome P450 enzymes 3A4 (CYP3A4)"/>
   <result pre="were not adjusted for several chemotherapeutic agents used concurrently with" exact="aprepitant" post="in phase III trials, these drugs should be used"/>
   <result pre="drugs should be used with caution [ 40, 41] because" exact="aprepitant" post="interacts with several non-chemotherapeutic drugs, including warfarin, dexamethasone, and"/>
   <result pre="non-chemotherapeutic drugs, including warfarin, dexamethasone, and methylprednisolone. Concurrent use of" exact="aprepitant" post="temporarily reduces prothrombin time–international normalized ratio (PT–INR) for patients"/>
   <result pre="patients [ 42]. Aprepitant also increases AUCs of the corticosteroids" exact="dexamethasone" post="and methylprednisolone, necessitating appropriate reductions of corticosteroid doses (CQ7)"/>
   <result pre="Moreover, concurrent use of the CYP3A4 inhibitors ketoconazole, itraconazole, and" exact="erythromycin" post="may increase aprepitant AUCs, whereas the CYP3A4 inducers carbamazepine,"/>
   <result pre="of the CYP3A4 inhibitors ketoconazole, itraconazole, and erythromycin may increase" exact="aprepitant" post="AUCs, whereas the CYP3A4 inducers carbamazepine, rifampicin, and phenytoin"/>
   <result pre="increase aprepitant AUCs, whereas the CYP3A4 inducers carbamazepine, rifampicin, and" exact="phenytoin" post="may reduce plasma levels of aprepitant. CQ19. How are"/>
   <result pre="Group for Antiemetic Research Dexamethasone alone or in combination with" exact="ondansetron" post="for the prevention of delayed nausea and vomiting induced"/>
   <result pre="Saito M Aogi K Sekine I et al. Palonosetron plus" exact="dexamethasone" post="versus granisetron plus dexamethasone for prevention of nausea and"/>
   <result pre="Aogi K Sekine I et al. Palonosetron plus dexamethasone versus" exact="granisetron" post="plus dexamethasone for prevention of nausea and vomiting during"/>
   <result pre="Sekine I et al. Palonosetron plus dexamethasone versus granisetron plus" exact="dexamethasone" post="for prevention of nausea and vomiting during chemotherapy: a"/>
   <result pre="115 124 10.1016/S1470-2045(08)70313-9 19135415 12. Aapro MS Alberts DS High-dose" exact="dexamethasone" post="for prevention of cisplatin-induced vomiting Cancer Chemother Pharmacol 1981"/>
   <result pre="6122510 13. Ioannidis JP Hesketh PJ Lau J Contribution of" exact="dexamethasone" post="to control chemotherapy-induced nausea and vomiting; a meta-analysis of"/>
   <result pre="Moyano JR Sala R et al. Dexamethasone in addition to" exact="metoclopramide" post="for chronic nausea in patients with advanced cancer: a"/>
   <result pre="HS, Palmer DD et al (2009) Gemcitabine with or without" exact="cisplatin" post="in patients with advanced or metastatic biliary tract cancer"/>
   <result pre="disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or" exact="etoposide" post="N Engl J Med 1987 316 1435 1440 10.1056/NEJM198706043162302"/>
   <result pre="IA Khan WA Qazilbash M et al. Clinical efficacy of" exact="lorazepam" post="in prophylaxis of anticipatory, acute, and delayed nausea and"/>
   <result pre="chemotherapy: a double-blind, placebo-controlled study of assessing the usefulness of" exact="alprazolam" post="J Clin Oncol 1993 11 1384 1390 8315437 29."/>
   <result pre="randomized, parallel-group study on the efficacy and safety of oral" exact="granisetron" post="and oral ondansetron in the prophylaxis of nausea and"/>
   <result pre="on the efficacy and safety of oral granisetron and oral" exact="ondansetron" post="in the prophylaxis of nausea and vomiting in patients"/>
   <result pre="Basurto C et al. Antiemetic activity of high doses of" exact="metoclopramide" post="combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer"/>
   <result pre="al. Antiemetic activity of high doses of metoclopramide combined with" exact="methylprednisolone" post="versus metoclopramide alone in cisplatin-treated cancer patients: a randomized"/>
   <result pre="activity of high doses of metoclopramide combined with methylprednisolone versus" exact="metoclopramide" post="alone in cisplatin-treated cancer patients: a randomized double-blind trial"/>
   <result pre="Hasler SB Hirt A Luethy AR et al. Safety of" exact="ondansetron" post="loading doses in children with cancer Support Care Cancer"/>
   <result pre="Talley NJ Meineche-Schmidt V Pare P et al. Efficacy of" exact="omeprazole" post="in functional dyspepsia: double-blind, randomized, placebo-controlled trials Aliment Pharmacol"/>
   <result pre="Soares HP Caparroz C et al. Granisetron is equivalent to" exact="ondansetron" post="for prophylaxis of chemotherapy-induced nausea and vomiting: results of"/>
   <result pre="Goldberg MR et al. Effects of the neurokinin1 receptor antagonist" exact="aprepitant" post="on the pharmacokinetics of dexamethasone and methylprednisolone Clin Pharmacol"/>
   <result pre="of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of" exact="dexamethasone" post="and methylprednisolone Clin Pharmacol Ther 2003 74 17 24"/>
   <result pre="neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and" exact="methylprednisolone" post="Clin Pharmacol Ther 2003 74 17 24 10.1016/S0009-9236(03)00066-3 12844131"/>
   <result pre="PJ Grunberg SM Gralla RJ et al. The oral neurokinin-1antagonist" exact="aprepitant" post="for the prevention of chemotherapy-induced nausea and vomiting: a"/>
   <result pre="Carides AD et al. Addition of the neurokinin-1 receptor antagonist" exact="aprepitant" post="to standard antiemetic therapy improves control of chemotherapy induced"/>
   <result pre="M Van Hecken A Oeyen M et al. Effect of" exact="aprepitant" post="on the pharmacokinetics and pharmacodynamics of warfarin Eur J"/>
   <result pre="al. Effect of aprepitant on the pharmacokinetics and pharmacodynamics of" exact="warfarin" post="Eur J Clin Pharmacol 2005 61 341 346 10.1007/s00228-005-0907-8"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4750533/results/search/inn/results.xml">
   <result pre="Akt. The discovery process of Akt inhibitors has evolved from" exact="adenosine" post="triphosphate (ATP)-competitive agents to alternative approaches employing allosteric sites"/>
   <result pre="uses repeated cycles of client protein binding, the hydrolysis of" exact="adenosine" post="triphosphate (ATP) and interaction with its co-chaperones, such as"/>
   <result pre="22). mTOR is a downstream member of the PI3K/Akt and" exact="adenosine" post="monophosphate-activated protein kinase pathways, and is a key regulator"/>
   <result pre="under investigation as anticancer therapies, such as the proteasome inhibitor," exact="bortezomib" post="( 34), and the natural lignans, deoxypodophyllotoxin ( 35)"/>
   <result pre="cancer cells. AZD5363 significantly enhanced the antitumor activity of docetaxel," exact="lapatinib" post="and trastuzumab in breast cancer xenografts. The activity of"/>
   <result pre="AZD5363 significantly enhanced the antitumor activity of docetaxel, lapatinib and" exact="trastuzumab" post="in breast cancer xenografts. The activity of AZD5363 in"/>
   <result pre="a phase Ib clinical study, the combination of ipatasertib with" exact="paclitaxel" post="was well-tolerated and a phase II study designed to"/>
   <result pre="selective than A-674563. The both derivatives increased the efficacy of" exact="paclitaxel" post="in a prostate carcinoma cell xenograft model ( 65)."/>
   <result pre="77). A phase I/II study on afuresertib in combination with" exact="bortezomib" post="and dexamethasone in patients with relapsed or refractory myeloma"/>
   <result pre="phase I/II study on afuresertib in combination with bortezomib and" exact="dexamethasone" post="in patients with relapsed or refractory myeloma showed an"/>
   <result pre="It is was tested clinically alone or in combination with" exact="trametinib" post="(MEK inhibitor) in various types of cancer ( 74)."/>
   <result pre="demonstrated significant synergy when combined with doxorubicin, camptothecin (topoisomerase inhibitors)," exact="gemcitabine" post="and 5-fluorouracil (antimetabolites), carboplatin (DNA cross-linker), erlotinib (EGFR) and"/>
   <result pre="combined with doxorubicin, camptothecin (topoisomerase inhibitors), gemcitabine and 5-fluorouracil (antimetabolites)," exact="carboplatin" post="(DNA cross-linker), erlotinib (EGFR) and lapatinib (dual EGFR/HER2 inhibitor)"/>
   <result pre="camptothecin (topoisomerase inhibitors), gemcitabine and 5-fluorouracil (antimetabolites), carboplatin (DNA cross-linker)," exact="erlotinib" post="(EGFR) and lapatinib (dual EGFR/HER2 inhibitor) in lung NCI-H460"/>
   <result pre="gemcitabine and 5-fluorouracil (antimetabolites), carboplatin (DNA cross-linker), erlotinib (EGFR) and" exact="lapatinib" post="(dual EGFR/HER2 inhibitor) in lung NCI-H460 or ovarian A2780"/>
   <result pre="MK-2206 alone or in addition to HER inhibitors, such as" exact="trastuzumab" post="or lapatinib, in various types of breast cancer ("/>
   <result pre="both in vivo and in vitro models. Cells treated with" exact="edelfosine" post="exhibited a marked and rapid decrease in p-Akt Ser473"/>
   <result pre="is dose-limiting and limits its clinical use ( 97). The" exact="glycerol" post="moiety in ALP has proven to be not essential"/>
   <result pre="for cutaneous breast cancer ( 100). The clinical use of" exact="miltefosine" post="is restricted to topical application due to hemolytic toxicity"/>
   <result pre="leishmaniasis ( 101). The replacement of the choline moiety of" exact="miltefosine" post="with a piperidine scaffold resulted in D-21266 (perifosine), a"/>
   <result pre="development for the treatment of colorectal cancer in combination with" exact="capecitabine" post="and of multiple myeloma in combination with bortezomib and"/>
   <result pre="combination with capecitabine and of multiple myeloma in combination with" exact="bortezomib" post="and dexamethasone or in combination with lenalidomide and dexamethasone"/>
   <result pre="capecitabine and of multiple myeloma in combination with bortezomib and" exact="dexamethasone" post="or in combination with lenalidomide and dexamethasone ( 102)."/>
   <result pre="in combination with bortezomib and dexamethasone or in combination with" exact="lenalidomide" post="and dexamethasone ( 102). Perifosine has been tested in"/>
   <result pre="with bortezomib and dexamethasone or in combination with lenalidomide and" exact="dexamethasone" post="( 102). Perifosine has been tested in combination with"/>
   <result pre="tested in combination with sorafenib, sunitinib, paclitaxel, docetaxel, lenalinomide or" exact="gemcitabine" post="in various other types of cancer ( 91). Erucylphosphocholine"/>
   <result pre="Erucylphosphocholine (ErPC) is a long chain and unsaturated homologue of" exact="miltefosine" post="which causes it to associate in aqueous environments as"/>
   <result pre="domain structure led to the development of compound PH-316, a" exact="sulfadiazine" post="derivative ( Fig. 8), which inhibited Akt and HT-29"/>
   <result pre="mice following oral administration. It showed synergic antitumor activity with" exact="paclitaxel" post="and gemcitabine in a Panc-1 tumors, with erlotinib in"/>
   <result pre="oral administration. It showed synergic antitumor activity with paclitaxel and" exact="gemcitabine" post="in a Panc-1 tumors, with erlotinib in a non-small-cell"/>
   <result pre="activity with paclitaxel and gemcitabine in a Panc-1 tumors, with" exact="erlotinib" post="in a non-small-cell lung cancers and with paclitaxel in"/>
   <result pre="tumors, with erlotinib in a non-small-cell lung cancers and with" exact="paclitaxel" post="in breast cancer ( 116). Thiourea derivatives High-throughput fluorescence"/>
   <result pre="( Fig. 9) that is metabolically activated inside cells by" exact="adenosine" post="kinase to its monophosphate active analog, TCN-P ( 121)."/>
   <result pre="to tumor inhibition by trastuzumab, and loss of PTEN predicts" exact="trastuzumab" post="resistance in patients Cancer Cell 6 117 127 2004"/>
   <result pre="Takahashi H Tsukuda K Ogasawara Y Shimizu N Proteasome inhibitor" exact="bortezomib" post="increases PTEN expression and enhances trastuzumab-induced growth inhibition in"/>
   <result pre="ipatasertib (Ipat, GDC-0068), an inhibitor of Akt, in combination with" exact="paclitaxel" post="(Pac) as front-line treatment for patients (pts) with metastatic"/>
   <result pre="of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or" exact="erlotinib" post="in patients with advanced solid tumors J Hematol Oncol"/>
   <result pre="LA et al. Biomarker-driven phase 2 study of MK-2206 and" exact="selumetinib" post="(AZD6244, ARRY-142886) in patients with colorectal cancer Invest New"/>
   <result pre="C van Glabbeke M Mouridsen H Phase II study of" exact="miltefosine" post="(hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult"/>
   <result pre="A phase Ib study of the Akt inhibitor GDC-0068 with" exact="docetaxel" post="(D) or mFOLFOX-6 (F) in patients (pts) with advanced"/>
   <result pre="derivative (MK-2206)  Alkylphospholipids Edelfosine (1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine, ET-18-OCH 3) ilmofosine (BM 41.440)," exact="miltefosine" post="(hexadecylphosphocholine, HePC), perifosine (D-21266), erucylphosphocholine (ErPC), erufosine (ErPC3, erucylphosphohomocholine"/>
   <result pre="Phase I/phase II clinical trials Afuresertib (GSK2110183) in combination with" exact="bortezomib" post="or dexamethasone Relapsed or refractory multiple myeloma Phase I/Phase"/>
   <result pre="II clinical trials Afuresertib (GSK2110183) in combination with bortezomib or" exact="dexamethasone" post="Relapsed or refractory multiple myeloma Phase I/Phase II clinical"/>
   <result pre="Phase I/phase II clinical trials Uprosertib (GSK2141795) in combination with" exact="trametinib" post="Relapsed or refractory multiple myeloma Phase I/phase II clinical"/>
   <result pre="cancer Phase I/phase II clinical trials MK-2206 in combination with" exact="gefitinib" post="or erlotinib Advanced non-small-cell lung carcinoma Phase I/phase II"/>
   <result pre="I/phase II clinical trials MK-2206 in combination with gefitinib or" exact="erlotinib" post="Advanced non-small-cell lung carcinoma Phase I/phase II clinical trials"/>
   <result pre="to hemolytic toxicity after intravenous injection MK-2206 in combination with" exact="selumetinib" post="Colorectal carcinoma Unsatisfactory clinical results Similar toxicity as for"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4751719/results/search/inn/results.xml">
   <result pre="transition (QIAGEN Hannover GmbH Germany). The expression of estrogen receptor," exact="progesterone" post="receptor, and the resistance marker excision repair cross-complementing rodent"/>
   <result pre="examined. Regarding DTCs, we and others have reported that bisphosphonates," exact="zoledronic acid," post="and clodronate contribute to the eradication of DTCs, even"/>
   <result pre="we and others have reported that bisphosphonates, zoledronic acid, and" exact="clodronate" post="contribute to the eradication of DTCs, even years after"/>
   <result pre="the Treat CTC trial investigators are evaluating the effectiveness of" exact="trastuzumab" post="in eliminating persisting CTCs in patients with an HER2-negative"/>
   <result pre="in primary BC has demonstrated a discordant estrogen receptor (ER)," exact="progesterone" post="receptor (PR), and/or HER2 receptor status between the primary"/>
   <result pre="that the residual breast tumor tissue cell populations surviving after" exact="letrozole" post="or docetaxel treatment were enriched for subpopulations of cells"/>
   <result pre="residual breast tumor tissue cell populations surviving after letrozole or" exact="docetaxel" post="treatment were enriched for subpopulations of cells with both"/>
   <result pre="NACT neoadjuvant chemotherapy, OS overall survival, PFS progression-free survival, PR" exact="progesterone" post="receptor, slCTC stem cell–like circulating tumor cell Data are"/>
   <result pre="those with hormone-responsive tumors (tamoxifen or an aromatase inhibitor), and" exact="trastuzumab" post="therapy was completed for at least 1 year in"/>
   <result pre="in patients with HER2 positivity [ 51, 52]. Additional oral" exact="clodronate" post="therapy (2 × 520 mg per day for at least 2"/>
   <result pre="tumor cell, DTC disseminated tumor cell, ER estrogen receptor, PR" exact="progesterone" post="receptor, slCTC stem cell–like circulating tumor cell Table 4"/>
   <result pre="tumor cell, DTC disseminated tumor cell, ER estrogen receptor, PR" exact="progesterone" post="receptor, slCTC stem cell–like circulating tumor cell In 92"/>
   <result pre="demonstrated by Naume et al., who administered six cycles of" exact="docetaxel" post="as secondary treatment in DTC-positive patients after first-line therapy"/>
   <result pre="adjuvant BC studies, where we demonstrated that the intake of" exact="clodronate" post="in case of DTC positivity was able to eradicate"/>
   <result pre="even years after the first diagnosis [ 26, 72]. Thus," exact="clodronate" post="intake was also offered to DTC-positive patients in this"/>
   <result pre="that the residual breast tumor tissue cell populations surviving after" exact="letrozole" post="or docetaxel were enriched for subpopulations of cells with"/>
   <result pre="residual breast tumor tissue cell populations surviving after letrozole or" exact="docetaxel" post="were enriched for subpopulations of cells with both tumor-initiating"/>
   <result pre="cells are attractive targets for these therapies. One example is" exact="everolimus" post="(RAD001), an oral inhibitor of mammalian target of rapamycin"/>
   <result pre="vitro and in vivo, and combination treatment with RAD001 and" exact="docetaxel" post="or trastuzumab has been reported to be effective in"/>
   <result pre="in vivo, and combination treatment with RAD001 and docetaxel or" exact="trastuzumab" post="has been reported to be effective in refractory metastatic"/>
   <result pre="of mammospheres and increased propensity for tumor formation. In addition," exact="lapatinib" post="did not lead to an increase in these tumorigenic"/>
   <result pre="recently published study suggested that the clinical efficacy of adjuvant" exact="trastuzumab" post="may relate to the ability of this agent to"/>
   <result pre="DTCs were not associated with worse outcomes, probably due to" exact="clodronate" post="intake as a secondary treatment option for the eradication"/>
   <result pre="3-kinase pNR pathological no response pPR pathological partial response PR" exact="progesterone" post="receptor RT-PCR reverse transcription polymerase chain reaction slCTC stem"/>
   <result pre="TNM tumor, node, metastasis stage TWIST1 Twist-related protein 1 ZOL" exact="zoledronic acid" post="Competing interests The authors declare that they have no"/>
   <result pre="Schoberth A Schindlbeck C Strobl B et al. Effect of" exact="zoledronate" post="on persisting isolated tumour cells in patients with early"/>
   <result pre="Goldnau C Oberhoff C Kimmig R Kasimir-Bauer S Effect of" exact="ibandronate" post="on disseminated tumor cells in the bone marrow of"/>
   <result pre="Janni W Lück HJ Becker S et al. Influence of" exact="zoledronic acid" post="on disseminated tumor cells in primary breast cancer patients"/>
   <result pre="Janni W Krawczyk N Lueck HJ et al. Influence of" exact="zoledronic acid" post="on disseminated tumor cells in bone marrow and survival:"/>
   <result pre="E Di Cosimo S Swaby RF et al. Lapatinib with" exact="trastuzumab" post="for HER2-positive early breast cancer (NeoALTTO): survival outcomes of"/>
   <result pre="Eidtmann H Kaufmann M Blohmer JU et al. Lapatinib versus" exact="trastuzumab" post="in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44):"/>
   <result pre="tumor cell (DTC) status after DTC-guided secondary adjuvant treatment With" exact="docetaxel" post="in early breast cancer J Clin Oncol. 2014 32"/>
   <result pre="the absence of HER2 amplification: implications for efficacy of adjuvant" exact="trastuzumab" post="Cancer Res. 2013 73 1635 46 10.1158/0008-5472.CAN-12-3349 23442322 84."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4752991/results/search/inn/results.xml">
   <result pre="increased expression of markers of EMT, and increased resistance to" exact="tamoxifen" post="therapy [ 37]. The complex and diverse ways in"/>
   <result pre="also had translational implications by showing a suppressive role for" exact="lapatinib" post="(a HER2 inhibitor) on FOXM1 expression at the protein,"/>
   <result pre="data showed a role for FOXM1 in the development of" exact="trastuzumab" post="(a HER2 antibody) resistance [ 62]. This is particularly"/>
   <result pre="HER2 antibody) resistance [ 62]. This is particularly important because" exact="trastuzumab" post="resistance may develop quickly and represents a challenge in"/>
   <result pre="[ 63]. BBC cells lack hormone estrogen receptors (ER) and" exact="progesterone" post="receptors (PR) and express genes that are usually seen"/>
   <result pre="cancer malignancy [ 79]. FOXM1 was found to contribute to" exact="cisplatin" post="(a platinum agent) resistance in breast cancer cells. The"/>
   <result pre="[ 80]. FOXM1 overexpression was implicated in the resistance to" exact="trastuzumab" post="(a HER2 monoclonal antibody) and paclitaxel (a microtubule stabilizing"/>
   <result pre="in the resistance to trastuzumab (a HER2 monoclonal antibody) and" exact="paclitaxel" post="(a microtubule stabilizing agent). Treatment with a siRNA targeting"/>
   <result pre="improved therapeutic sensitivity to these agents [ 81]. FOXM1 caused" exact="doxorubicin" post="resistance in breast cancer by enhancing DNA repair. The"/>
   <result pre="NF-kappa-B1 (NF κB1) interacted with FOXM1 in the presence of" exact="doxorubicin" post="to protect breast cancer cells from DNA damage ["/>
   <result pre="by de Olano et al. showed that the mechanism of" exact="epirubicin" post="resistance was mediated by activation of mitogen-activated protein kinase-activated"/>
   <result pre="normal formation of mitotic spindle and thus could interfere with" exact="paclitaxel" post="activity. Nestal de Moraes et al. [ 43] demonstrated"/>
   <result pre="al. [ 43] demonstrated that resistance to epirubicin, docetaxel, and" exact="paclitaxel" post="was associated with activation of XIAP and survivin by"/>
   <result pre="M. M. Raychaudhuri P. FoxM1 mediates resistance to herceptin and" exact="paclitaxel" post="Cancer Research 2010 70 12 5054 5063 10.1158/0008-5472.CAN-10-0545 20530690"/>
   <result pre="Peck B. Monteiro L. J. et al. FOXM1 confers acquired" exact="cisplatin" post="resistance in breast cancer cells Molecular Cancer Research 2010"/>
   <result pre="M. M. Raychaudhuri P. FoxM1 mediates resistance to herceptin and" exact="paclitaxel" post="Cancer Research 2010 70 12 5054 5063 10.1158/0008-5472.can-10-0545 20530690"/>
   <result pre="and p53 regulate FOXM1 expression via E2F in breast cancer" exact="epirubicin" post="treatment and resistance Molecular Cancer Therapeutics 2011 10 6"/>
   <result pre="The p38 MAPK-MK2 axis regulates E2F1 and FOXM1 expression after" exact="epirubicin" post="treatment Molecular Cancer Research 2012 10 9 1189 1202"/>
   <result pre="al. FOXM1 targets NBS1 to regulate DNA damage-induced senescence and" exact="epirubicin" post="resistance Oncogene 2014 33 32 4144 4155 10.1038/onc.2013.457 24141789"/>
   <result pre="FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer" exact="paclitaxel" post="resistance Oncogene 2015 10.1038/onc.2015.152 87 Gartel A. L. A"/>
   <result pre="epithelial-mesenchymal transition; TGF- β: transforming growth factor-beta; uPA: urokinase; uPAR:" exact="urokinase" post="receptor; MMP-2: matrix metallopeptidase-2; MMP-9: matrix metallopeptidase-9; VEGF: vascular"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4754120/results/search/inn/results.xml">
   <result pre="and breast cancer. Pamela Goodwin discussed the potential use of" exact="metformin" post="to improve breast cancer outcomes. Obesity is associated with"/>
   <result pre="(NCIC MA.32) was set up to examine the impact of" exact="metformin" post="in early breast cancer survivors. Subjects were randomly assigned"/>
   <result pre="in early breast cancer survivors. Subjects were randomly assigned to" exact="metformin" post="or a placebo for five years. Baseline weight and"/>
   <result pre="evidence of clinically significant disease. Aromatase inhibitors (AIs), tamoxifen, and" exact="fulvestrant" post="all target the oestrogen receptor and provide effective therapy"/>
   <result pre="to new treatment options. These include the cell cycle inhibitor" exact="palbociclib" post="and the combination of an mTOR inhibitor, everolimus. These"/>
   <result pre="OS over 50 months of follow-up with the addition of" exact="pertuzumab" post="to the trastuzumab and docetaxel arm in the first-line"/>
   <result pre="months of follow-up with the addition of pertuzumab to the" exact="trastuzumab" post="and docetaxel arm in the first-line treatment of women"/>
   <result pre="follow-up with the addition of pertuzumab to the trastuzumab and" exact="docetaxel" post="arm in the first-line treatment of women with HER-2"/>
   <result pre="pertuzumab-containing regimen. The (Advanced Breast Cancer 3) (ABC3) consensus states" exact="trastuzumab" post="with pertuzumab and a taxane is the preferred therapy"/>
   <result pre="The (Advanced Breast Cancer 3) (ABC3) consensus states trastuzumab with" exact="pertuzumab" post="and a taxane is the preferred therapy at the"/>
   <result pre="that included a taxane and at least two HER-2-targeted agents;" exact="trastuzumab" post="and lapatinib. Median survival was significantly longer in patients"/>
   <result pre="combination; PFS of 6.9 months in the arm buparlisib plus" exact="fulvestrant" post="compared to 3.2 in the fulvestrant alone arm. Further"/>
   <result pre="the arm buparlisib plus fulvestrant compared to 3.2 in the" exact="fulvestrant" post="alone arm. Further patients with the mutant PIK3CA also"/>
   <result pre="patients with the mutant PIK3CA also had better buparlisib plus" exact="fulvestrant" post="when compared with those who received fulvestrant but only"/>
   <result pre="better buparlisib plus fulvestrant when compared with those who received" exact="fulvestrant" post="but only slightly better (seven months) than the whole"/>
   <result pre="independent of oestrogen for growth and no longer respond to" exact="tamoxifen" post="and AIs. The group of Chandarlapaty wanted to ask"/>
   <result pre="open question. Early Breast Cancer The first trial examining adjuvant" exact="denosumab" post="(Xgeva, Amgen) as a treatment for breast cancer was"/>
   <result pre="The phase 3 ABCSG-18 clinical trial ( Figure 2) compares" exact="denosumab" post="with placebo in combination with adjuvant AI therapy in"/>
   <result pre="endocrine therapy who are at high risk for fracture. Adjuvant" exact="denosumab" post="increased DFS in AI-treated postmenopausal women with early HR+"/>
   <result pre="3). No differences in adverse events (AEs), serious AEs with" exact="denosumab" post="versus placebo was seen. No patient experienced necrosis of"/>
   <result pre="safety profile, and reduction in fractures, the authors conclude that" exact="denosumab" post="should be made available to postmenopausal patients with HR+"/>
   <result pre="from the Create-X trial, presented by Dr Toi, found that" exact="capecitabine" post="improved outcomes for breast cancer patients with residual disease"/>
   <result pre="of follow-up, DFS was significantly improved by the addition of" exact="capecitabine" post="in the adjuvant setting. OS was improved in patients"/>
   <result pre="node positive disease following neoadjuvant chemotherapy. Patients who were assigned" exact="capecitabine" post="had a 30% reduced risk of disease recurrence compared"/>
   <result pre="women with ductal carcinoma in situ (DCIS) treated with either" exact="tamoxifen" post="or the AI anastrozole. In this multicentre, randomised, placebo-controlled"/>
   <result pre="trial, it was found that the women in both the" exact="anastrozole" post="and tamoxifen groups had similar overall efficacy, with slightly"/>
   <result pre="was found that the women in both the anastrozole and" exact="tamoxifen" post="groups had similar overall efficacy, with slightly better outcomes"/>
   <result pre="dramatically different. More strokes and fractures were seen in the" exact="anastrozole" post="arm, but these women tended to have less endometrial,"/>
   <result pre="ovarian, and skin cancers compared with those who took tamoxifen;" exact="tamoxifen" post="is known to cause gynaecological cancers. However, among those"/>
   <result pre="is known to cause gynaecological cancers. However, among those receiving" exact="tamoxifen" post="had more thromboembolic events and gynaecological complications. So in"/>
   <result pre="in summary postmenopausal women with DCIS had similar outcomes with" exact="tamoxifen" post="or the AI anastrozole. The clinician’s choice should take"/>
   <result pre="but she focused on PRO. This trial compared anastrazole to" exact="tamoxifen" post="in postmenopausal women with DCIS. Just over 3000 postmenopausal"/>
   <result pre="postmenopausal women were enrolled and the primary endpoint indicated that" exact="anastrozole" post="was slightly but significantly better than tamoxifen in terms"/>
   <result pre="endpoint indicated that anastrozole was slightly but significantly better than" exact="tamoxifen" post="in terms of breast cancer-free interval, and was more"/>
   <result pre="antihypertensive agents for the prevention of cardiac damage associated with" exact="trastuzumab" post="treatment. The MANTICORE researchers assessed whether one year of"/>
   <result pre="assessed whether one year of treatment with the ACE inhibitor" exact="perindopril" post="or the beta-blocker bisoprolol can prevent the left ventricular"/>
   <result pre="of treatment with the ACE inhibitor perindopril or the beta-blocker" exact="bisoprolol" post="can prevent the left ventricular remodelling (measured with MRI)"/>
   <result pre="ventricular remodelling (measured with MRI) associated with one year of" exact="trastuzumab" post="therapy. In this trial, 99 patients received either the"/>
   <result pre="enzyme (ACE) inhibitor. The study found that women taking either" exact="perindopril" post="or bisoprolol had fewer signs of heart weakening than"/>
   <result pre="inhibitor. The study found that women taking either perindopril or" exact="bisoprolol" post="had fewer signs of heart weakening than the women"/>
   <result pre="breast cancer, with high expression of the oestrogen (ER) and" exact="progesterone" post="receptors (PR), and low Ki67 index and low HER-2."/>
   <result pre="been reduced by a shRNA. After treating the mice with" exact="tamoxifen" post="the mice with high levels of APOBEC3B developed tamoxifen"/>
   <result pre="with tamoxifen the mice with high levels of APOBEC3B developed" exact="tamoxifen" post="resistance significantly more rapidly than those with the reduced"/>
   <result pre="with high levels of APOBEC3B progressed significantly sooner after starting" exact="tamoxifen" post="therapy than those with low levels of APOBEC3B. So"/>
   <result pre="So in summary, increased levels of APOBEC3B can significantly reduce" exact="tamoxifen" post="responses, suggesting that APOBEC3B drives resistance to tamoxifen. Harris"/>
   <result pre="mutations’ suggesting that it is these mutations that probably drive" exact="tamoxifen" post="resistance. Cyclin-dependent kianses (CDKs) have been known to be"/>
   <result pre="breast cancer models were most sensitive to growth inhibition with" exact="palbociclib" post="and identified a synergistic interaction in inhibiting proliferation in"/>
   <result pre="identified a synergistic interaction in inhibiting proliferation in combination with" exact="tamoxifen" post="[ 1]. Sensitive ER+ breast cancer cell lines treated"/>
   <result pre="hypothesis for the phase II Paloma-1/ TRIO 18 study of" exact="palbociclib" post="+letrozole versus letrozole alone [ 2]. A significant improvement"/>
   <result pre="phase II Paloma-1/ TRIO 18 study of palbociclib +letrozole versus" exact="letrozole" post="alone [ 2]. A significant improvement in PFS was"/>
   <result pre="observed with the combination and resulted in the approval of" exact="palbociclib" post="plus letrozole as first line therapy for advanced postmenopausal"/>
   <result pre="the combination and resulted in the approval of palbociclib plus" exact="letrozole" post="as first line therapy for advanced postmenopausal ER+ breast"/>
   <result pre="more advanced settings a benefit was seen in combination with" exact="fulvestrant" post="[ 3]. Currently there are several other CDK 4/6"/>
   <result pre="19874578 2. Finn et al. The cyclin-dependent kinase 4/6 inhibitor" exact="palbociclib" post="in combination with letrozole versus letrozole alone as first-line"/>
   <result pre="al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with" exact="letrozole" post="versus letrozole alone as first-line treatment of oestrogen receptor-positive,"/>
   <result pre="cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus" exact="letrozole" post="alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4758093/results/search/inn/results.xml">
   <result pre="safety of Lapatinib administered beyond disease progression and combined with" exact="vinorelbine" post="in HER-2/ neu– positive advanced breast cancer: results of"/>
   <result pre="chemotherapy for metastatic breast cancer (MBC) and acts synergistically with" exact="trastuzumab" post="in HER-2/ neu positive disease. The present study was"/>
   <result pre="was set out to evaluate the efficacy and safety of" exact="vinorelbine" post="when combined with lapatinib, an anti-HER2 tyrosine-kinase inhibitor, as"/>
   <result pre="as late-line regimen administered beyond previous disease progression on prior" exact="lapatinib" post="in patients with HER-2/ neu- positive MBC. Methods The"/>
   <result pre="multicenter phase II trial. Patients had to be pretreated with" exact="lapatinib" post="plus chemotherapy, and received lapatinib at a daily dose"/>
   <result pre="had to be pretreated with lapatinib plus chemotherapy, and received" exact="lapatinib" post="at a daily dose of 1250 mg in combination"/>
   <result pre="at a daily dose of 1250 mg in combination with" exact="vinorelbine" post="20 mg/m 2 i.v. on days 1 and 8"/>
   <result pre="accrual. Results A total number of nine patients were included;" exact="lapatinib" post="administered beyond disease progression combined with vinorelbine resulted in"/>
   <result pre="patients were included; lapatinib administered beyond disease progression combined with" exact="vinorelbine" post="resulted in a median PFS of 7.7 months (95"/>
   <result pre="patients had primary disease progression. In two patients, modification of" exact="vinorelbine" post="dose due to toxicity became necessary; no dose modification"/>
   <result pre="AE Conclusion In this heavily pretreated patient population, combination of" exact="vinorelbine" post="plus lapatinib showed encouraging activity and was characterized by"/>
   <result pre="In this heavily pretreated patient population, combination of vinorelbine plus" exact="lapatinib" post="showed encouraging activity and was characterized by an acceptable"/>
   <result pre="by an acceptable safety profile. Despite the low patient number," exact="lapatinib" post="plus vinorelbine may constitute a potential treatment option in"/>
   <result pre="acceptable safety profile. Despite the low patient number, lapatinib plus" exact="vinorelbine" post="may constitute a potential treatment option in heavily pretreated"/>
   <result pre="(OS) as compared to chemotherapy alone. The varying interaction of" exact="trastuzumab" post="with different chemotherapeutic drugs has been subject of various"/>
   <result pre="5]. Of note, synergy was suggested for the combination of" exact="trastuzumab" post="and vinorelbine, [ 6] which is popular due to"/>
   <result pre="in conjunction with limited toxicity. Despite high activity, resistance to" exact="trastuzumab" post="will eventually occur during the course of treatment in"/>
   <result pre="various alternative anti-HER2 compounds including tyrosine-kinase inhibitors (TKIs) such as" exact="lapatinib" post="and second-generation antibodies such as pertuzumab or T-DM1. As"/>
   <result pre="inhibitors (TKIs) such as lapatinib and second-generation antibodies such as" exact="pertuzumab" post="or T-DM1. As member of the 4-anilinoquinazoline classes of"/>
   <result pre="T-DM1. As member of the 4-anilinoquinazoline classes of kinase inhibitors," exact="lapatinib" post="reacts with the ATP binding site of EGFR, and"/>
   <result pre="prior trastuzumab-based therapy or as first-line treatment in combination with" exact="letrozole" post="in luminal B/HER-2/ neu positive disease [ 8]. Treatment"/>
   <result pre="breast cancer, a prolongation of PFS by the continuation of" exact="trastuzumab" post="beyond progression under the proviso of a change of"/>
   <result pre="chemotherapy for metastatic breast cancer (MBC) and acts synergistically with" exact="trastuzumab" post="in HER-2/ neu positive disease. Based upon these considerations,"/>
   <result pre="considerations, it seemed reasonable to hypothesize that the combination of" exact="lapatinib" post="plus vinorelbine could also result in significant anti-tumor activity"/>
   <result pre="seemed reasonable to hypothesize that the combination of lapatinib plus" exact="vinorelbine" post="could also result in significant anti-tumor activity in the"/>
   <result pre="treatment in patients with HER-2/ neu positive MBC pretreated with" exact="trastuzumab" post="and lapatinib. Indeed, encouraging activity of lapatinib plus vinorelbine"/>
   <result pre="MBC pretreated with trastuzumab and lapatinib. Indeed, encouraging activity of" exact="lapatinib" post="plus vinorelbine combination therapy has been already demonstrated in"/>
   <result pre="with trastuzumab and lapatinib. Indeed, encouraging activity of lapatinib plus" exact="vinorelbine" post="combination therapy has been already demonstrated in two phase"/>
   <result pre="phase II trials [ 13, 14] while the concept of" exact="lapatinib" post="beyond disease progression was not investigated henceforth. Thus, the"/>
   <result pre="phase II trial was to assess activity and safety of" exact="lapatinib" post="plus vinorelbine in HER-2/ neu positive patients with MBC"/>
   <result pre="trial was to assess activity and safety of lapatinib plus" exact="vinorelbine" post="in HER-2/ neu positive patients with MBC who had"/>
   <result pre="4 countries. All eligible patients with MBC were pretreated with" exact="lapatinib" post="in combination with various cytotoxic drugs excluding vinorelbine. Lapatinib"/>
   <result pre="PFS in heavily pretreated MBC patients receiving the combination of" exact="lapatinib" post="and vinorelbine with a descriptive intent only. Patient population"/>
   <result pre="heavily pretreated MBC patients receiving the combination of lapatinib and" exact="vinorelbine" post="with a descriptive intent only. Patient population Eligible patients"/>
   <result pre="neoadjuvant or adjuvant setting, whereas all patients had received prior" exact="capecitabine" post="and seven taxanes (six patients docetaxel, one patient paclitaxel)"/>
   <result pre="docetaxel, one patient paclitaxel) for MBC. One patient received prior" exact="lapatinib" post="as third-line treatment for metastatic disease, which was not"/>
   <result pre="this study. The relationship to study drug was balanced between" exact="lapatinib" post="and vinorelbine (18.8 % related to lapatinib, 19.7 %"/>
   <result pre="The relationship to study drug was balanced between lapatinib and" exact="vinorelbine" post="(18.8 % related to lapatinib, 19.7 % related to"/>
   <result pre="vinorelbine (18.8 % related to lapatinib, 19.7 % related to" exact="vinorelbine" post="and 15.4 % related to both). The majority of"/>
   <result pre="Adverse events in this study were consistent with the known" exact="lapatinib" post="and vinorelbine safety profiles. Three serious adverse events have"/>
   <result pre="in this study were consistent with the known lapatinib and" exact="vinorelbine" post="safety profiles. Three serious adverse events have been reported"/>
   <result pre="in the focus of the present report, available drugs include" exact="trastuzumab" post="and lapatinib and, recently added, pertuzumab [ 15] and"/>
   <result pre="focus of the present report, available drugs include trastuzumab and" exact="lapatinib" post="and, recently added, pertuzumab [ 15] and T-DM1 ["/>
   <result pre="report, available drugs include trastuzumab and lapatinib and, recently added," exact="pertuzumab" post="[ 15] and T-DM1 [ 16]. Of note, resistance"/>
   <result pre="resistance to trastuzumab-based treatment can be partially overcome by maintaining" exact="trastuzumab" post="beyond disease progression [ 12] while switching chemotherapy, which"/>
   <result pre="12] while switching chemotherapy, which is known to interact with" exact="trastuzumab" post="in a divergent manner according to the used substance"/>
   <result pre="to the used substance [ 5]. Ultimately, however, activity of" exact="trastuzumab" post="is lost requiring alternative treatment approaches. It was this"/>
   <result pre="HER-2/ neu positive MBC were planned to be treated with" exact="lapatinib" post="beyond progression with the addition of vinorelbine. The latter"/>
   <result pre="backbone due to first, its previously described synergistic activity with" exact="trastuzumab" post="[ 6] and second, the fact that many patients"/>
   <result pre="with HER-2/ neu positive disease would be ultimately treated with" exact="lapatinib" post="and capecitabine [ 17] without any evidence-based further treatment"/>
   <result pre="neu positive disease would be ultimately treated with lapatinib and" exact="capecitabine" post="[ 17] without any evidence-based further treatment option. With"/>
   <result pre="results from phase I trials testing for the combination of" exact="lapatinib" post="and vinorelbine available [ 18, 19], the present data"/>
   <result pre="phase I trials testing for the combination of lapatinib and" exact="vinorelbine" post="available [ 18, 19], the present data in a"/>
   <result pre="present data in a heavily pretreated patient population show that" exact="lapatinib" post="plus vinorelbine constitutes another safe and moderately efficacious treatment"/>
   <result pre="in a heavily pretreated patient population show that lapatinib plus" exact="vinorelbine" post="constitutes another safe and moderately efficacious treatment option for"/>
   <result pre="heavily pretreated population at late disease stage, the combination of" exact="lapatinib" post="and vinorelbine resulted in a median PFS of 7.7"/>
   <result pre="population at late disease stage, the combination of lapatinib and" exact="vinorelbine" post="resulted in a median PFS of 7.7 months (95"/>
   <result pre="regards to PFS are similar to PFS data from the" exact="lapatinib" post="registration trial; in this prospective randomized phase III trial,"/>
   <result pre="in this prospective randomized phase III trial, the combination of" exact="lapatinib" post="plus capecitabine yielded 8.4 months median PFS [ 17]."/>
   <result pre="prospective randomized phase III trial, the combination of lapatinib plus" exact="capecitabine" post="yielded 8.4 months median PFS [ 17]. Thus, our"/>
   <result pre="a population of women with MBC who had received both," exact="lapatinib" post="and capecitabine previously. Although naturally limited by the small"/>
   <result pre="of women with MBC who had received both, lapatinib and" exact="capecitabine" post="previously. Although naturally limited by the small number of"/>
   <result pre="the present study indicate that similar to trastuzumab, administration of" exact="lapatinib" post="in multiple-lines may constitute a meaningful treatment option in"/>
   <result pre="may constitute a meaningful treatment option in selected patients and" exact="vinorelbine" post="is valuable cytotoxic combination partner for lapatinib. Since the"/>
   <result pre="was set out to evaluate the efficacy and safety of" exact="vinorelbine" post="when combined with lapatinib, an anti-HER2 tyrosine-kinase inhibitor, as"/>
   <result pre="as late-line regimen administered beyond previous disease progression on prior" exact="lapatinib" post="in patients with HER-2/ neu- positive MBC. In this"/>
   <result pre="In this heavily pretreated patient breast cancer population, combination of" exact="vinorelbine" post="plus lapatinib showed encouraging activity and was characterized by"/>
   <result pre="heavily pretreated patient breast cancer population, combination of vinorelbine plus" exact="lapatinib" post="showed encouraging activity and was characterized by an acceptable"/>
   <result pre="by an acceptable safety profile. Despite the low patient number," exact="lapatinib" post="plus vinorelbine may constitute a potential treatment option in"/>
   <result pre="acceptable safety profile. Despite the low patient number, lapatinib plus" exact="vinorelbine" post="may constitute a potential treatment option in heavily pretreated"/>
   <result pre="Agrapart V Ananthakrishnan R Staroslawska E Safety and efficacy of" exact="neratinib" post="(HKI-272) plus vinorelbine in the treatment of patients with"/>
   <result pre="R Staroslawska E Safety and efficacy of neratinib (HKI-272) plus" exact="vinorelbine" post="in the treatment of patients with ErbB2-positive metastatic breast"/>
   <result pre="C Beryt M Pietras R Slamon DJ Rational combinations of" exact="trastuzumab" post="with chemotherapeutic drugs used in the treatment of breast"/>
   <result pre="J Matulonis U Bunnell CA et al. Clinical activity of" exact="trastuzumab" post="and vinorelbine in women with HER2-overexpressing metastatic breast cancer"/>
   <result pre="U Bunnell CA et al. Clinical activity of trastuzumab and" exact="vinorelbine" post="in women with HER2-overexpressing metastatic breast cancer J Clin"/>
   <result pre="S Townsend A Kotasek D Phase II, open-label trial of" exact="lapatinib" post="and vinorelbine in women with previously treated HER2-positive metastatic"/>
   <result pre="A Kotasek D Phase II, open-label trial of lapatinib and" exact="vinorelbine" post="in women with previously treated HER2-positive metastatic breast cancer"/>
   <result pre="A phase II, randomized, multicenter study evaluating the combination of" exact="lapatinib" post="and vinorelbine in women with ErbB2 overexpressing metastatic breast"/>
   <result pre="II, randomized, multicenter study evaluating the combination of lapatinib and" exact="vinorelbine" post="in women with ErbB2 overexpressing metastatic breast cancer Breast"/>
   <result pre="Pedrini JL Pienkowski T Knott A et al. Pertuzumab plus" exact="trastuzumab" post="plus docetaxel for metastatic breast cancer N Engl J"/>
   <result pre="Pienkowski T Knott A et al. Pertuzumab plus trastuzumab plus" exact="docetaxel" post="for metastatic breast cancer N Engl J Med 2012"/>
   <result pre="Crown J Chan A Kaufman B et al. Lapatinib plus" exact="capecitabine" post="for HER2-positive advanced breast cancer N Engl J Med"/>
   <result pre="AM Phase I study of continuous and intermittent schedules of" exact="lapatinib" post="in combination with vinorelbine in solid tumors Ann Oncol"/>
   <result pre="of continuous and intermittent schedules of lapatinib in combination with" exact="vinorelbine" post="in solid tumors Ann Oncol 2012 23 4 1023"/>
   <result pre="Cottura E Tresca P et al. Phase I study of" exact="lapatinib" post="plus vinorelbine in patients with locally advanced or metastatic"/>
   <result pre="Tresca P et al. Phase I study of lapatinib plus" exact="vinorelbine" post="in patients with locally advanced or metastatic breast cancer"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4758788/results/search/inn/results.xml">
   <result pre="shorter survival time. 4, 5 Although HER-2-targeted agents such as" exact="trastuzumab" post="have dramatically improved prognosis of patients with HER-2 overexpression,"/>
   <result pre="FISH along with a lack of both estrogen receptor and" exact="progesterone" post="receptor were regarded as having HER-2-enriched subtype breast cancer."/>
   <result pre="MAPK signaling pathway could promote proliferation and angiogenesis. HER-2-targeted drugs," exact="trastuzumab" post="and lapatinib, may exert their action through MAPK signaling"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4759568/results/search/inn/results.xml">
   <result pre="TN subtypes, we have found seven exclusive subtype-related pathways, including" exact="glycine" post="serine and threonine metabolism pathway for Luminal B, glycerolipid"/>
   <result pre="cancer subtypes, we have found seven exclusive subtype-related pathways, including" exact="glycine" post="serine and threonine metabolism pathway for Luminal B, glycerolipid"/>
   <result pre="In clinical trial (June, 2015) triciribine phosphate, combined with paclitaxel," exact="doxorubicin" post="hydrochloride, and cyclophosphamide, used as a treatment to patients"/>
   <result pre="and AKR1C2 in breast cancer and their potential effect on" exact="progesterone" post="signaling . Cancer research 64, 7610– 7617 10.1158/0008-5472.can-04-1608 ("/>
   <result pre="Antonov A. , Agostini M. &amp;amp; Melino G. Serine and" exact="glycine" post="metabolism in cancer. Trends in biochemical sciences 39, 191–"/>
   <result pre="( 2015). 24747696 Lubecka-Pietruszewska K. et al. Clofarabine, a novel" exact="adenosine" post="analogue, reactivates DNA methylation-silenced tumour suppressor genes and inhibits"/>
   <result pre="2015). 25220225 Crivellari D. et al. Innovative schedule of oral" exact="idarubicin" post="in elderly patients with metastatic breast cancer: comprehensive results"/>
   <result pre="e71508 10.1371/journal.pone.0071508 ( 2013). 24013655 Yuan P. et al. Oral" exact="etoposide" post="monotherapy is effective for metastatic breast cancer with heavy"/>
   <result pre="al. A phase II study of the histone deacetylase inhibitor" exact="vorinostat" post="combined with tamoxifen for the treatment of patients with"/>
   <result pre="II study of the histone deacetylase inhibitor vorinostat combined with" exact="tamoxifen" post="for the treatment of patients with hormone therapy-resistant breast"/>
   <result pre="tyrosine metabolism 0.006883 TPO;ADH1C;MAOB;ADH1A ecm receptor interaction 0.007472 COL5A1;COL5A2;LAMA3;COL4A6;SPP1 *" exact="glycine" post="serine and threonine metabolism 0.024788 DMGDH;SDS;MAOB 3 chloroacrylic acid"/>
   <result pre="IV 1-benzhydryl-4-[(5-methyl-4-nitroisoxazol-3-yl)carbonyl]piperazine X 2-Chlor-N-(1-phenyl-3-propyl-1H-pyrazol-5-yl)acetamid X 4-{2-[(6-Chloro-4-quinazolinyl)amino]ethyl}phenol X Ampicillin X X" exact="clofarabine" post="X X EMF-sumo1-12 X X X etoposide X X"/>
   <result pre="Ampicillin X X clofarabine X X EMF-sumo1-12 X X X" exact="etoposide" post="X X gemcitabine X X X HBEG X idarubicin"/>
   <result pre="clofarabine X X EMF-sumo1-12 X X X etoposide X X" exact="gemcitabine" post="X X X HBEG X idarubicin X X X"/>
   <result pre="X etoposide X X gemcitabine X X X HBEG X" exact="idarubicin" post="X X X X INCA-6 X X vanoxerine X"/>
   <result pre="HBEG X idarubicin X X X X INCA-6 X X" exact="vanoxerine" post="X kinetin-riboside X L755507 X N-[2-(allyloxy)benzyl]-N-1,3-benzodioxol-5-yl-2-chloroacetamide X SA-792541 X"/>
   <result pre="SCH 79797 dihydrochloride X Selamectin X X X Sepantronium X" exact="teniposide" post="X 3-(3-Benzoyl-6-chloro-4,5-dihydroxy-1-benzofuran-7-yl)-2,4-pentanedione X AG-592 X Artesunate X CD-437 X"/>
   <result pre="3-(3-Benzoyl-6-chloro-4,5-dihydroxy-1-benzofuran-7-yl)-2,4-pentanedione X AG-592 X Artesunate X CD-437 X chrysenequinone X" exact="cladribine" post="X cyclosporin-a X IKK-2-inhibitor-V X ingenol X menadione X"/>
   <result pre="cyclosporin-a X IKK-2-inhibitor-V X ingenol X menadione X N-[(5-Fluoro-8-hydroxy-7-quinolinyl)(2-thienyl)methyl]acetamide X" exact="niclosamide" post="X X palbociclib X Pevonedistat X pyrvinium-pamoate X X"/>
   <result pre="X ingenol X menadione X N-[(5-Fluoro-8-hydroxy-7-quinolinyl)(2-thienyl)methyl]acetamide X niclosamide X X" exact="palbociclib" post="X Pevonedistat X pyrvinium-pamoate X X X RO-28-1675 X"/>
   <result pre="triciribine X wortmannin X 4-(4-Methoxyphenoxy)-2-(4-methylphenyl)-5-(2-thienyl)-3(2H)-pyridazinone X 6-(1,3-Benzodioxol-5-yl)-N-(cyclopentylmethyl)-4-quinazolinamine X BIBR-1532 X" exact="ixazomib" post="X methyl-2,5-dihydroxycinnamate X X mifepristone X milrinone X N’-[(E)-(2,3-Dihydroxyphenyl)methylene]-2-hydroxybenzohydrazide"/>
   <result pre="X 6-(1,3-Benzodioxol-5-yl)-N-(cyclopentylmethyl)-4-quinazolinamine X BIBR-1532 X ixazomib X methyl-2,5-dihydroxycinnamate X X" exact="mifepristone" post="X milrinone X N’-[(E)-(2,3-Dihydroxyphenyl)methylene]-2-hydroxybenzohydrazide X N-[5-(4-Morpholinylsulfonyl)-2-(1-pyrrolidinyl)phenyl]-4,5,6,7-tetrahydro-1-benzothiophene-2-carboxamide X paroxetine X"/>
   <result pre="X BIBR-1532 X ixazomib X methyl-2,5-dihydroxycinnamate X X mifepristone X" exact="milrinone" post="X N’-[(E)-(2,3-Dihydroxyphenyl)methylene]-2-hydroxybenzohydrazide X N-[5-(4-Morpholinylsulfonyl)-2-(1-pyrrolidinyl)phenyl]-4,5,6,7-tetrahydro-1-benzothiophene-2-carboxamide X paroxetine X ruxolitinib X"/>
   <result pre="X X mifepristone X milrinone X N’-[(E)-(2,3-Dihydroxyphenyl)methylene]-2-hydroxybenzohydrazide X N-[5-(4-Morpholinylsulfonyl)-2-(1-pyrrolidinyl)phenyl]-4,5,6,7-tetrahydro-1-benzothiophene-2-carboxamide X" exact="paroxetine" post="X ruxolitinib X SA-1478088 X SCH-79797 X SKF-83959 X"/>
   <result pre="mifepristone X milrinone X N’-[(E)-(2,3-Dihydroxyphenyl)methylene]-2-hydroxybenzohydrazide X N-[5-(4-Morpholinylsulfonyl)-2-(1-pyrrolidinyl)phenyl]-4,5,6,7-tetrahydro-1-benzothiophene-2-carboxamide X paroxetine X" exact="ruxolitinib" post="X SA-1478088 X SCH-79797 X SKF-83959 X 2-Dichloromethyl-4-ethylsulfanyl-6-phenyl-[1,3,5]triazine X"/>
   <result pre="2-Dichloromethyl-4-ethylsulfanyl-6-phenyl-[1,3,5]triazine X 4-{[5-(1-Naphthyl)-1,3,4-oxadiazol-2-yl]sulfanyl}-2-butyn-1-yl X BAS-02859604 X calmidazolium X homoharringtonine X" exact="irinotecan" post="X KM-03949SC X quizartinib X rhodomyrtoxin-b X TPCA-1 X"/>
   <result pre="BAS-02859604 X calmidazolium X homoharringtonine X irinotecan X KM-03949SC X" exact="quizartinib" post="X rhodomyrtoxin-b X TPCA-1 X trichostatin-a X Table 6"/>
   <result pre="X 5-[(Benzyloxy)methyl]-7-(1-piperidinylmethyl)-8-quinolinol X X 6-(2,3-Dihydro-1,4-benzodioxin-6-yl)-N-(3-methylbenzyl)-4-quinazolinamine X CD-437 X X X" exact="chlorambucil" post="X X cladribine X X etoposide X X X"/>
   <result pre="X 6-(2,3-Dihydro-1,4-benzodioxin-6-yl)-N-(3-methylbenzyl)-4-quinazolinamine X CD-437 X X X chlorambucil X X" exact="cladribine" post="X X etoposide X X X X gemcitabine X"/>
   <result pre="CD-437 X X X chlorambucil X X cladribine X X" exact="etoposide" post="X X X X gemcitabine X X heliomycin X"/>
   <result pre="X X cladribine X X etoposide X X X X" exact="gemcitabine" post="X X heliomycin X ingenol X X L-690488 X"/>
   <result pre="X X heliomycin X ingenol X X L-690488 X X" exact="lonidamine" post="X methylene-blue X X N-[(5-Bromo-8-hydroxy-7-quinolinyl)(2-thienyl)methyl]acetamide X N-[(5-Fluoro-8-hydroxy-7-quinolinyl)(2-thienyl)methyl]acetamide X X"/>
   <result pre="methylene-blue X X N-[(5-Bromo-8-hydroxy-7-quinolinyl)(2-thienyl)methyl]acetamide X N-[(5-Fluoro-8-hydroxy-7-quinolinyl)(2-thienyl)methyl]acetamide X X PAC-1 X" exact="palbociclib" post="X X tunicamycin X vorinostat X X wortmannin X"/>
   <result pre="N-[(5-Fluoro-8-hydroxy-7-quinolinyl)(2-thienyl)methyl]acetamide X X PAC-1 X palbociclib X X tunicamycin X" exact="vorinostat" post="X X wortmannin X X X X 4-(keto-methyl-oxido-sulfuraniumyl)-3-nitro-benzoic X"/>
   <result pre="X wortmannin X X X X 4-(keto-methyl-oxido-sulfuraniumyl)-3-nitro-benzoic X benzamide X" exact="benzydamine" post="X diphenyleneiodonium X menadione X NM-PP1 X NVP-BEZ235 X"/>
   <result pre="RO-28-1675 X serdemetan X ZM-241385 X aminopurvalanol-a X barasertib X" exact="cytarabine" post="X X dasatinib X entinostat X fluticasone X KIN001-055"/>
   <result pre="X ZM-241385 X aminopurvalanol-a X barasertib X cytarabine X X" exact="dasatinib" post="X entinostat X fluticasone X KIN001-055 X purvalanol-a X"/>
   <result pre="X barasertib X cytarabine X X dasatinib X entinostat X" exact="fluticasone" post="X KIN001-055 X purvalanol-a X pyrvinium-pamoate X X SIB-1893"/>
   <result pre="X X WZ-4002 X (4E)-2-(4-Methoxyphenyl)-4-[(4-methoxyphenyl)imino]-4H-chromen-6-ol X 5-[(Benzyloxy)methyl]-7-(1-pyrrolidinylmethyl)-8-quinolinol X chrysenequinone X" exact="clobetasol" post="X cyclosporin-a X idarubicin X K784-3187 X PLX-4720 X"/>
   <result pre="(4E)-2-(4-Methoxyphenyl)-4-[(4-methoxyphenyl)imino]-4H-chromen-6-ol X 5-[(Benzyloxy)methyl]-7-(1-pyrrolidinylmethyl)-8-quinolinol X chrysenequinone X clobetasol X cyclosporin-a X" exact="idarubicin" post="X K784-3187 X PLX-4720 X teniposide X WAY-170523 X"/>
   <result pre="clobetasol X cyclosporin-a X idarubicin X K784-3187 X PLX-4720 X" exact="teniposide" post="X WAY-170523 X withaferin-a X WYE-125132 X Table 7"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4763414/results/search/inn/results.xml">
   <result pre="ERBB2 overexpression is the therapeutic target for the monoclonal antibodies" exact="trastuzumab" post="and pertuzumab and the tyrosine kinase inhibitor lapatinib ["/>
   <result pre="is the therapeutic target for the monoclonal antibodies trastuzumab and" exact="pertuzumab" post="and the tyrosine kinase inhibitor lapatinib [ 8– 11]."/>
   <result pre="monoclonal antibodies trastuzumab and pertuzumab and the tyrosine kinase inhibitor" exact="lapatinib" post="[ 8– 11]. In addition to the known role"/>
   <result pre="28] and nuclear grade) and immunohistochemical (IHC) findings (ER and" exact="progesterone" post="receptor [PgR] expression and ERBB2 overexpression). ER and PgR"/>
   <result pre="RTK have successfully been used as cancer drugs, for example" exact="cetuximab" post="[ 33] and panitumumab [ 34] for EGFR overexpression,"/>
   <result pre="used as cancer drugs, for example cetuximab [ 33] and" exact="panitumumab" post="[ 34] for EGFR overexpression, and afatinib [ 35]"/>
   <result pre="[ 33] and panitumumab [ 34] for EGFR overexpression, and" exact="afatinib" post="[ 35] and dacomitinib as pan-HER inhibitors. In the"/>
   <result pre="[ 35] and dacomitinib as pan-HER inhibitors. In the clinic," exact="trastuzumab" post="[ 8], pertuzumab [ 10], lapatinib [ 11], and"/>
   <result pre="dacomitinib as pan-HER inhibitors. In the clinic, trastuzumab [ 8]," exact="pertuzumab" post="[ 10], lapatinib [ 11], and TDM-1[ 36] have"/>
   <result pre="inhibitors. In the clinic, trastuzumab [ 8], pertuzumab [ 10]," exact="lapatinib" post="[ 11], and TDM-1[ 36] have been used in"/>
   <result pre="cell survival via the Mek/Erk pathway [ 37, 38] and" exact="lapatinib" post="inhibited the interaction of ERBB4 with EGFR and ERBB2"/>
   <result pre="interaction of ERBB4 with EGFR and ERBB2 [ 39]. Therefore," exact="lapatinib" post="or a MEK inhibitor might be an effective therapeutic"/>
   <result pre="Pedrini JL Pienkowski T Knott A et al. Pertuzumab plus" exact="trastuzumab" post="plus docetaxel for metastatic breast cancer N Engl J"/>
   <result pre="Pienkowski T Knott A et al. Pertuzumab plus trastuzumab plus" exact="docetaxel" post="for metastatic breast cancer N Engl J Med 2012"/>
   <result pre="Crown J Chan A Kaufman B et al. Lapatinib plus" exact="capecitabine" post="for HER2-positive advanced breast cancer N Engl J Med"/>
   <result pre="II study of the anti-epidermal growth factor receptor monoclonal antibody" exact="cetuximab" post="with cisplatin versus cisplatin alone in patients with metastatic"/>
   <result pre="of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with" exact="cisplatin" post="versus cisplatin alone in patients with metastatic triple-negative breast"/>
   <result pre="anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus" exact="cisplatin" post="alone in patients with metastatic triple-negative breast cancer J"/>
   <result pre="T Peretz T A phase 1/2 of a combination of" exact="cetuximab" post="and taxane for &quot;triple negative&quot; breast cancer patients Breast"/>
   <result pre="Arance A Mukhopadhyay P et al. Ixabepilone alone or with" exact="cetuximab" post="as first-line treatment for advanced/metastatic triple-negative breast cancer Clin"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4763476/results/search/inn/results.xml">
   <result pre="compared with previous standards [ 9, 15– 18]. In particular," exact="trastuzumab" post="increases the clinical benefit of first-line chemotherapy in cases"/>
   <result pre="biological subtype determined using immunohistochemistry (IHC) for estrogen receptor (ER)," exact="progesterone" post="receptor (PgR), and human epidermal growth factor receptor type"/>
   <result pre="hormone therapy was similar over time periods. The anthracyclines and" exact="vinorelbine" post="were used less commonly in the later time period,"/>
   <result pre="P &amp;lt; 0.001). Another trend was the increased use of" exact="eribulin" post="for MBC in the later time period ( P"/>
   <result pre="2010s, several clinical trials for HER2-targeting agents beyond trastuzumab, including" exact="lapatinib" post="[ 27], pertuzumab [ 28], and the antibody drug"/>
   <result pre="trials for HER2-targeting agents beyond trastuzumab, including lapatinib [ 27]," exact="pertuzumab" post="[ 28], and the antibody drug conjugate ado-trastuzumab emtansine"/>
   <result pre="for MBC [ 30]. The combination of the mTOR inhibitor" exact="everolimus" post="with the aromatase inhibitor exemestane has increased efficacy in"/>
   <result pre="combination of the mTOR inhibitor everolimus with the aromatase inhibitor" exact="exemestane" post="has increased efficacy in patients with ER+ MBC ["/>
   <result pre="Gorbunova V , Mrsic-Krmpotic Z , et al. Doxorubicin and" exact="paclitaxel" post="versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for"/>
   <result pre=", et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and" exact="cyclophosphamide" post="as first-line therapy for women with metastatic breast cancer:"/>
   <result pre="a dose effect and improved efficacy and tolerability compared with" exact="megestrol" post="acetate . J Clin Oncol. 1998; 16: 453– 461."/>
   <result pre="et al. Anastrozole, a potent and selective aromatase inhibitor, versus" exact="megestrol" post="acetate in postmenopausal women with advanced breast cancer: results"/>
   <result pre=", Zilembo N , et al. Exemestane is superior to" exact="megestrol" post="acetate after tamoxifen failure in postmenopausal women with advanced"/>
   <result pre=", et al. Exemestane is superior to megestrol acetate after" exact="tamoxifen" post="failure in postmenopausal women with advanced breast cancer: results"/>
   <result pre="JP , Cervantes G , et al. Superior survival with" exact="capecitabine" post="plus docetaxel combination therapy in anthracycline-pretreated patients with advanced"/>
   <result pre="Cervantes G , et al. Superior survival with capecitabine plus" exact="docetaxel" post="combination therapy in anthracycline-pretreated patients with advanced breast cancer:"/>
   <result pre="Lower E , et al. Randomized phase III study of" exact="docetaxel" post="compared with paclitaxel in metastatic breast cancer . J"/>
   <result pre="et al. Randomized phase III study of docetaxel compared with" exact="paclitaxel" post="in metastatic breast cancer . J Clin Oncol. 2005;"/>
   <result pre="B , Imwalle B , Geyer CE . Lapatinib plus" exact="capecitabine" post="in women with HER-2-positive advanced breast cancer: final survival"/>
   <result pre="V , Campone M , et al. Pertuzumab, trastuzumab, and" exact="docetaxel" post="for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4764922/results/search/inn/results.xml">
   <result pre="led to the development of targeted anti-ERBB2 antibodies, such as" exact="trastuzumab" post="(Herceptin) that has become the standard care for patients"/>
   <result pre="to induce extracellular matrix (ECM) proteolysis through the activation of" exact="urokinase" post="plasminogen activator, lysosomal cathepsins and multi-domain zinc-dependent endopeptidases or"/>
   <result pre="transformation by ERBB2 can affect ER signalling as it induces" exact="tamoxifen" post="resistance 46. Co-amplification of TOM1L1 and ERBB2 significantly reduces"/>
   <result pre="of cancers were ER+ (≥10 fmol mg −1 of protein) and 71.9%" exact="progesterone" post="receptor positive (PR+). Array-CGH Array-CGH data corresponded to the"/>
   <result pre="Stable cell lines were obtained by selection with 0.5–1 μg ml −1" exact="puromycin" post="or 200 μg ml −1 hygromycin B. Cell culture reagents were"/>
   <result pre="brief, 1,000 cells were plated in medium containing 2.4 mg ml −1" exact="methylcellulose" post="in a well of a 96-well plate with round"/>
   <result pre="10 mM Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM EDTA, 75 U ml −1" exact="aprotinin" post="and 1 mM vanadate. Immunoprecipitations were done using 800 μg–1 mg protein"/>
   <result pre="904 ( 2007). 17618273 Zhang D. et al. Activity of" exact="lapatinib" post="is independent of EGFR expression level in HER2-overexpressing breast"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4769490/results/search/inn/results.xml">
   <result pre="properties including the presence of the estrogen receptor (ER), the" exact="progesterone" post="receptor (PR), human epidermal growth factor receptor 2 (Her2;"/>
   <result pre="been achieved during the last years by combining Her2 inhibitors" exact="trastuzumab" post="(Herceptin®, Genentech, South San Francisco, CA, USA), lapatinib (Tykerb®,"/>
   <result pre="Her2 inhibitors trastuzumab (Herceptin®, Genentech, South San Francisco, CA, USA)," exact="lapatinib" post="(Tykerb®, GlaxoSmithKline, Philadelphia, PA, USA; Tyverb®, GlaxoSmithKline, London, UK),"/>
   <result pre="(Tykerb®, GlaxoSmithKline, Philadelphia, PA, USA; Tyverb®, GlaxoSmithKline, London, UK), and" exact="pertuzumab" post="(Perjeta®, Genentech, South San Francisco, CA, USA) with chemotherapeutic"/>
   <result pre="easily as they reach the rest of the body, with" exact="lapatinib" post="in combination with capecitabine and T-DM1 monotherapy being a"/>
   <result pre="the rest of the body, with lapatinib in combination with" exact="capecitabine" post="and T-DM1 monotherapy being a possible exception [ 12]."/>
   <result pre="in that it contains two polypeptide sequences enriched in proline," exact="glutamic acid," post="serine, and threonine (PEST) [ 15]. PEST regions are"/>
   <result pre="Importantly, Mcl-1 mediates resistance against widely used anticancer therapies including" exact="paclitaxel" post="[ 26] and gemcitabine [ 27] as well as"/>
   <result pre="against widely used anticancer therapies including paclitaxel [ 26] and" exact="gemcitabine" post="[ 27] as well as early clinical BH3 mimetic"/>
   <result pre="drugs that block Bcl-2 and Bcl-xL [ 21, 28]. Moreover," exact="trastuzumab" post="sensitizes Her2-overexpressing cells to apoptosis by reducing anti-apoptotic Mcl-1"/>
   <result pre="Germany); cobalt (II) chloride hexahydrate from Sigma Aldrich (Schnelldorf, Germany);" exact="trastuzumab" post="(Herceptin®) from Roche (San Francisco, CA, USA); and ZVAD"/>
   <result pre="PAA Laboratories, Cölbe, Germany), 1 % penicillin/streptomycin and 2 mM " exact="l-glutamine" post="(all from Gibco, Life Technologies). MDA MB 453, MDA"/>
   <result pre="heat-inactivated FBS, 1 % penicillin/streptomycin, 2.5 mg insulin, 5 mg" exact="hydrocortisone" post="(Sigma), 8 μl cholera toxin, and 10 μg human"/>
   <result pre="maintain an atmosphere of 0.5– 1 % oxygen, 5 %" exact="carbon dioxide," post="and 37 °C. Small interfering RNAs and cell transfection"/>
   <result pre="(V = 4/3 πr 3). Isobologram analysis The interaction between EU-5346 and" exact="trastuzumab" post="was analyzed using the CompuSyn software program (ComboSyn, Inc.,"/>
   <result pre="cells but not Her2-negative BC cells with the Her2 inhibitors" exact="trastuzumab" post="(Fig. 2e) and lapatinib (Fig. 2f) under hypoxic conditions"/>
   <result pre="BC cells with the Her2 inhibitors trastuzumab (Fig. 2e) and" exact="lapatinib" post="(Fig. 2f) under hypoxic conditions induced marked downregulation of"/>
   <result pre="levels. BC cells were treated with the indicated doses of" exact="trastuzumab" post="e or lapatinib f for 2 days and then"/>
   <result pre="were treated with the indicated doses of trastuzumab e or" exact="lapatinib" post="f for 2 days and then exposed to hypoxia"/>
   <result pre="extracts were immunoprecipitated ( IP) with either Mcl-1 antibody or" exact="trastuzumab" post="and analyzed by immunoblotting with indicated antibodies. Nonspecific protein"/>
   <result pre="activity increases Her2 ubiquitination and degradation. Synergistic effects of combining" exact="trastuzumab" post="with Mcl-1-targeting approaches in trastuzumab-sensitive Her2-positive BC cells In"/>
   <result pre="SKBR3 (data not shown) cells. Moreover, the combination therapy of" exact="trastuzumab" post="with EU-5346 synergistically triggered cell death in BT-474 (Fig."/>
   <result pre="to the Chou-Talalay method. Fig. 5 Synergistic effects of combining" exact="trastuzumab" post="with Mcl-1-targeting approaches in trastuzumab-sensitive Her2-positive BC cells. a"/>
   <result pre="representative of three independent experiments. b Synergistic effects of combining" exact="trastuzumab" post="with siMCL1 in Her2-positive BC cells. BT-474 cells (5.5 × 10"/>
   <result pre="Data represent mean ± SD ( right). c Synergistic growth inhibition of" exact="trastuzumab" post="and EU-5346 in trastuzumab-sensitive Her2-positive BC cells under hypoxic"/>
   <result pre="BC cells under hypoxic conditions. BT-474 cells were pretreated with" exact="trastuzumab" post="or dimethyl sulfoxide (DMSO) for 24 hours under normoxic"/>
   <result pre="under hypoxic conditions. BT-474 cells were pretreated with trastuzumab or" exact="dimethyl sulfoxide" post="(DMSO) for 24 hours under normoxic conditions followed by"/>
   <result pre="BC cells All Her2-positive BC patients eventually develop resistance to" exact="trastuzumab" post="and other Her2 inhibitors. The precise mechanism of resistance"/>
   <result pre="in contrast to BT-474 cells no synergistic effects of combining" exact="trastuzumab" post="with siMCL1 (Fig. 6d) or EU-5346 (data not shown)"/>
   <result pre="both trastuzumab-sensitive (BT-474) and trastuzumab-resistant (HCC-1954) BC cells. d Combining" exact="trastuzumab" post="with siMCL1 in Her2 inhibitor-resistant Her2-positive BC cells does"/>
   <result pre="to about 18 months with multimodal therapies [ 45]. Although" exact="trastuzumab" post="is effective for systemic BC, its efficacy in brain"/>
   <result pre="46]. Moreover, the incidence of brain metastatic disease after adjuvant" exact="trastuzumab" post="is increasing with the improved management of systemic disease"/>
   <result pre="7b). Importantly, similar to maternal JIMT-1 cells, EU-5346 but not" exact="trastuzumab" post="and lapatinib induced cell death in brain-primed JIMT-1 BR3"/>
   <result pre="similar to maternal JIMT-1 cells, EU-5346 but not trastuzumab and" exact="lapatinib" post="induced cell death in brain-primed JIMT-1 BR3 cells, as"/>
   <result pre="factor, kD kilodalton, L lapatinib, Mcl-1 myeloid cell leukemia-1, T" exact="trastuzumab" post="Discussion The present study demonstrates a critical role of"/>
   <result pre="hypoxic conditions. Under normoxic conditions, Her2 regulates Mcl-1 upregulation. Conversely," exact="trastuzumab" post="treatment reduces Mcl-1 levels and renders cells sensitive to"/>
   <result pre="death also in BC cell lines resistant against Her2 inhibitors," exact="trastuzumab" post="and lapatinib in particular (Fig. 8); as well as"/>
   <result pre="in BC cell lines resistant against Her2 inhibitors, trastuzumab and" exact="lapatinib" post="in particular (Fig. 8); as well as in brain-primed"/>
   <result pre="as well as angiogenesis [ 60, 61]. The Her2 inhibitor" exact="trastuzumab" post="[ 62] binds to the C-terminal portion of Her2."/>
   <result pre="binds to the C-terminal portion of Her2. Another Her2 inhibitor," exact="lapatinib" post="[ 63], binds to the ATP binding site of"/>
   <result pre="binding site of Her2, but also Her1. Similar to siHER2," exact="trastuzumab" post="and lapatinib inhibit downstream signaling events, induce apoptosis, and"/>
   <result pre="of Her2, but also Her1. Similar to siHER2, trastuzumab and" exact="lapatinib" post="inhibit downstream signaling events, induce apoptosis, and inhibit proliferation"/>
   <result pre="Mcl-1 mediates inherent resistance against widely used anticancer therapies including" exact="paclitaxel" post="[ 26] and gemcitabine [ 27], as well as"/>
   <result pre="against widely used anticancer therapies including paclitaxel [ 26] and" exact="gemcitabine" post="[ 27], as well as BH3 mimetics. Moreover, Mcl-1"/>
   <result pre="in combination with ABT-199, and navitoclax, as well as with" exact="paclitaxel" post="and gemcitabine. Finally, our own and other data demonstrate"/>
   <result pre="MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide PARP Poly (ADP-ribose) polymerase PEST Proline," exact="glutamic acid," post="serine, and threonine PI Propidium iodide PR Progesterone receptor"/>
   <result pre="C Stemmler H-J et al. Multicenter phase II study of" exact="lapatinib" post="in patients with brain metastases from HER2-positive breast cancer"/>
   <result pre="Shen J-J et al. Inducing apoptosis and enhancing chemosensitivity to" exact="gemcitabine" post="via RNA interference targeting Mcl-1 gene in pancreatic carcinoma"/>
   <result pre="Profound prevention of experimental brain metastases of breast cancer by" exact="temozolomide" post="in an MGMT-dependent manner Clin Cancer Res. 2014 20"/>
   <result pre="Nau MM et al. Down-regulation of the erbB-2 receptor by" exact="trastuzumab" post="(herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4770148/results/search/inn/results.xml">
   <result pre="al., 2012); these include antibodies directed against HER2, such as" exact="trastuzumab" post="and pertuzumab, and small molecule tyrosine kinase inhibitors that"/>
   <result pre="(PI3K) pathway has been identified as a key determinant of" exact="trastuzumab" post="sensitivity and has been associated with poorer overall survival"/>
   <result pre="al., 2010; Nagata et al., 2004), although the impact on" exact="lapatinib" post="resistance remains unclear ( Xia et al., 2007). Here,"/>
   <result pre="response of individual tumours to treatment, we found that although" exact="paclitaxel" post="slowed tumour growth, it did not result in tumour"/>
   <result pre="PI3K pathway has been identified as a key determinant of" exact="trastuzumab" post="sensitivity and has been associated with poorer overall survival"/>
   <result pre="al., 2010; Nagata et al., 2004), although the impact on" exact="lapatinib" post="resistance remains unclear ( Xia et al., 2007). Like"/>
   <result pre="clinical trials are currently underway to evaluate the use of" exact="trastuzumab" post="and/or lapatinib with Akt inhibitors. One of the major"/>
   <result pre="are currently underway to evaluate the use of trastuzumab and/or" exact="lapatinib" post="with Akt inhibitors. One of the major advantages of"/>
   <result pre="treatments. To date, major advances in overcoming clinical resistance to" exact="trastuzumab" post="have focused on alternative strategies for targeting HER2 signalling,"/>
   <result pre="effective. Several in vitro studies have shown that resistance to" exact="lapatinib" post="and trastuzumab is associated with induction of EMT ("/>
   <result pre="in vitro studies have shown that resistance to lapatinib and" exact="trastuzumab" post="is associated with induction of EMT ( Creedon et"/>
   <result pre="factors that drive EMT was causally related to de novo" exact="trastuzumab" post="resistance ( Oliveras-Ferraros et al., 2012). One of the"/>
   <result pre="were dosed weekly with vehicle (cremaphor EL:ethanol, 1:1, v:v) or" exact="paclitaxel" post="(10 mg/kg) suspended in cremaphor EL:ethanol by intraperitoneal injection. Immunohistochemistry"/>
   <result pre="lysed in 1% Triton X-100, 50 mM HEPES (pH 7.4), 150 mM" exact="sodium chloride," post="1.5 mM magnesium chloride, 1 mM EGTA, 100 mM sodium fluoride, 10 mM"/>
   <result pre="approach identifies the PI3K pathway as a major determinant of" exact="trastuzumab" post="resistance in breast cancer . Cancer Cell 12, 395-"/>
   <result pre="( 2010). PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with" exact="trastuzumab" post="response and survival in patients with HER2-positive metastatic breast"/>
   <result pre="( 2013). Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to" exact="lapatinib" post="in HER2-positive gastric cancer . Oncogene 33, 3334- 3341."/>
   <result pre="al. ( 2012). Activation of an IL6 inflammatory loop mediates" exact="trastuzumab" post="resistance in HER2+ breast cancer by expanding the cancer"/>
   <result pre="to tumor inhibition by trastuzumab, and loss of PTEN predicts" exact="trastuzumab" post="resistance in patients . Cancer Cell 6, 117- 127."/>
   <result pre="A. ( 2012). Epithelial-to-mesenchymal transition (EMT) confers primary resistance to" exact="trastuzumab" post="(Herceptin) . Cell Cycle 11, 4020- 4032. 10.4161/cc.22225 22992620"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4772532/results/search/inn/results.xml">
   <result pre="peptide hormonal control: (i) cyclical production of ovarian estrogen and" exact="progesterone" post="accelerates ductal growth and branching during puberty, (ii) prolactin"/>
   <result pre="procedures. Three primarily investigated receptors are the estrogen receptor (ER)," exact="progesterone" post="receptor (PR), and human epidermal growth factor receptor 2"/>
   <result pre="cells respond to biological agents such as the monoclonal antibody" exact="trastuzumab" post="used in combination with conventional chemotherapy [ 16]. Cells"/>
   <result pre="glucose to pyruvate via glycolysis in the cytosol and to" exact="carbon dioxide" post="in the mitochondria via oxidative phosphorylation; under anaerobic conditions,"/>
   <result pre="combinations used to treat BC are listed below: AC -" exact="doxorubicin" post="(Adriamycin) and cyclophosphamide (Cytoxan, Procytox) AC – Taxol: doxorubicin"/>
   <result pre="treat BC are listed below: AC - doxorubicin (Adriamycin) and" exact="cyclophosphamide" post="(Cytoxan, Procytox) AC – Taxol: doxorubicin and cyclophosphamide, followed"/>
   <result pre="- doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan, Procytox) AC – Taxol:" exact="doxorubicin" post="and cyclophosphamide, followed by paclitaxel (Taxol) TC - docetaxel"/>
   <result pre="(Cytoxan, Procytox) AC – Taxol: doxorubicin and cyclophosphamide, followed by" exact="paclitaxel" post="(Taxol) TC - docetaxel (Taxotere) and cyclophosphamide TAC (or"/>
   <result pre="Taxol: doxorubicin and cyclophosphamide, followed by paclitaxel (Taxol) TC -" exact="docetaxel" post="(Taxotere) and cyclophosphamide TAC (or DAC): docetaxel, doxorubicin and"/>
   <result pre="cyclophosphamide, followed by paclitaxel (Taxol) TC - docetaxel (Taxotere) and" exact="cyclophosphamide" post="TAC (or DAC): docetaxel, doxorubicin and cyclophosphamide FAC (or"/>
   <result pre="TC - docetaxel (Taxotere) and cyclophosphamide TAC (or DAC): docetaxel," exact="doxorubicin" post="and cyclophosphamide FAC (or CAF): cyclophosphamide (orally), doxorubicin and"/>
   <result pre="docetaxel (Taxotere) and cyclophosphamide TAC (or DAC): docetaxel, doxorubicin and" exact="cyclophosphamide" post="FAC (or CAF): cyclophosphamide (orally), doxorubicin and 5-fluorouracil (Adrucil,"/>
   <result pre="TAC (or DAC): docetaxel, doxorubicin and cyclophosphamide FAC (or CAF):" exact="cyclophosphamide" post="(orally), doxorubicin and 5-fluorouracil (Adrucil, 5-FU) CEF: cyclophosphamide (orally),"/>
   <result pre="DAC): docetaxel, doxorubicin and cyclophosphamide FAC (or CAF): cyclophosphamide (orally)," exact="doxorubicin" post="and 5-fluorouracil (Adrucil, 5-FU) CEF: cyclophosphamide (orally), epirubicin (Pharmorubicin)"/>
   <result pre="(or CAF): cyclophosphamide (orally), doxorubicin and 5-fluorouracil (Adrucil, 5-FU) CEF:" exact="cyclophosphamide" post="(orally), epirubicin (Pharmorubicin) and 5-fluorouracil FEC: cyclophosphamide, epirubicin and"/>
   <result pre="cyclophosphamide (orally), doxorubicin and 5-fluorouracil (Adrucil, 5-FU) CEF: cyclophosphamide (orally)," exact="epirubicin" post="(Pharmorubicin) and 5-fluorouracil FEC: cyclophosphamide, epirubicin and 5-fluorouracil FEC"/>
   <result pre="5-FU) CEF: cyclophosphamide (orally), epirubicin (Pharmorubicin) and 5-fluorouracil FEC: cyclophosphamide," exact="epirubicin" post="and 5-fluorouracil FEC – T: cyclophosphamide, epirubicin and 5-fluorouracil,"/>
   <result pre="5-fluorouracil FEC: cyclophosphamide, epirubicin and 5-fluorouracil FEC – T: cyclophosphamide," exact="epirubicin" post="and 5-fluorouracil, followed by docetaxel CMF – IV: cyclophosphamide"/>
   <result pre="5-fluorouracil FEC – T: cyclophosphamide, epirubicin and 5-fluorouracil, followed by" exact="docetaxel" post="CMF – IV: cyclophosphamide (intravenous), methotrexate and 5-fluorouracil CMF"/>
   <result pre="cyclophosphamide, epirubicin and 5-fluorouracil, followed by docetaxel CMF – IV:" exact="cyclophosphamide" post="(intravenous), methotrexate and 5-fluorouracil CMF – PO: cyclophosphamide (orally),"/>
   <result pre="and 5-fluorouracil, followed by docetaxel CMF – IV: cyclophosphamide (intravenous)," exact="methotrexate" post="and 5-fluorouracil CMF – PO: cyclophosphamide (orally), methotrexate and"/>
   <result pre="– IV: cyclophosphamide (intravenous), methotrexate and 5-fluorouracil CMF – PO:" exact="cyclophosphamide" post="(orally), methotrexate and 5-fluorouracil Taxol – FAC: paclitaxel, then"/>
   <result pre="cyclophosphamide (intravenous), methotrexate and 5-fluorouracil CMF – PO: cyclophosphamide (orally)," exact="methotrexate" post="and 5-fluorouracil Taxol – FAC: paclitaxel, then followed by"/>
   <result pre="and 5-fluorouracil Taxol – FAC: paclitaxel, then followed by cyclophosphamide," exact="doxorubicin" post="and 5-fluorouracil Doxorubicin and docetaxel EC – GCSF: epirubicin"/>
   <result pre="paclitaxel, then followed by cyclophosphamide, doxorubicin and 5-fluorouracil Doxorubicin and" exact="docetaxel" post="EC – GCSF: epirubicin and cyclophosphamide, with filgrastim Docetaxel"/>
   <result pre="cyclophosphamide, doxorubicin and 5-fluorouracil Doxorubicin and docetaxel EC – GCSF:" exact="epirubicin" post="and cyclophosphamide, with filgrastim Docetaxel and carboplatin (Paraplatin, Paraplatin"/>
   <result pre="Doxorubicin and docetaxel EC – GCSF: epirubicin and cyclophosphamide, with" exact="filgrastim" post="Docetaxel and carboplatin (Paraplatin, Paraplatin AQ) Gemcitabine (Gemzar) and"/>
   <result pre="EC – GCSF: epirubicin and cyclophosphamide, with filgrastim Docetaxel and" exact="carboplatin" post="(Paraplatin, Paraplatin AQ) Gemcitabine (Gemzar) and docetaxel Gemcitabine and"/>
   <result pre="filgrastim Docetaxel and carboplatin (Paraplatin, Paraplatin AQ) Gemcitabine (Gemzar) and" exact="docetaxel" post="Gemcitabine and paclitaxel Capecitabine (Xeloda) and docetaxel Certain chemotherapy"/>
   <result pre="carboplatin (Paraplatin, Paraplatin AQ) Gemcitabine (Gemzar) and docetaxel Gemcitabine and" exact="paclitaxel" post="Capecitabine (Xeloda) and docetaxel Certain chemotherapy drugs may be"/>
   <result pre="Gemcitabine (Gemzar) and docetaxel Gemcitabine and paclitaxel Capecitabine (Xeloda) and" exact="docetaxel" post="Certain chemotherapy drugs may be used alone to treat"/>
   <result pre="- targeting the Her2/neu receptor Megace (Megestrol Acetate) - a" exact="progesterone" post="receptor agonist Mitomycin (Mutamycin) - a DNA cross-linker Nolvadex"/>
   <result pre="approved by the U.S. Food and Drug Administration (FDA) are" exact="goserelin" post="(Zoladex®) and leuprolide (Lupron®). (ii) Blocking estrogen production: Aromatase"/>
   <result pre="U.S. Food and Drug Administration (FDA) are goserelin (Zoladex®) and" exact="leuprolide" post="(Lupron®). (ii) Blocking estrogen production: Aromatase is the enzyme"/>
   <result pre="(ii) Blocking estrogen production: Aromatase is the enzyme that converts" exact="testosterone" post="to estradiol, which is found in the body’s muscle,"/>
   <result pre="Examples of aromatase inhibitors (AIs) approved by the FDA are" exact="anastrozole" post="(Arimidex®) and letrozole (Femara®), both of which temporarily inactivate"/>
   <result pre="inhibitors (AIs) approved by the FDA are anastrozole (Arimidex®) and" exact="letrozole" post="(Femara®), both of which temporarily inactivate aromatase, and exemestane"/>
   <result pre="and letrozole (Femara®), both of which temporarily inactivate aromatase, and" exact="exemestane" post="(Aromasin®), which permanently inactivates aromatase. Diaby et al. ["/>
   <result pre="estrogen receptors. Examples of SERMs approved by the FDA are" exact="tamoxifen" post="(Nolvadex®), raloxifene (Evista®), and toremifene (Fareston®). Tamoxifen has been"/>
   <result pre="Examples of SERMs approved by the FDA are tamoxifen (Nolvadex®)," exact="raloxifene" post="(Evista®), and toremifene (Fareston®). Tamoxifen has been used for"/>
   <result pre="approved by the FDA are tamoxifen (Nolvadex®), raloxifene (Evista®), and" exact="toremifene" post="(Fareston®). Tamoxifen has been used for more than 30"/>
   <result pre="as estrogen agonists according to the tissues considered. For example," exact="raloxifene" post="acts to prevent bone loss and to improve lipid"/>
   <result pre="inducing breast and uterine cancers. Other anti-estrogen drugs, such as" exact="fulvestrant" post="(Faslodex®) compete for estrogen receptor as estrogen antagonist. Upon"/>
   <result pre="of premenopausal and postmenopausal women with ER+ early-stage BC, while" exact="anastrozole" post="and letrozole have been approved in postmenopausal women. A"/>
   <result pre="and postmenopausal women with ER+ early-stage BC, while anastrozole and" exact="letrozole" post="have been approved in postmenopausal women. A third AI"/>
   <result pre="women who received adjuvant hormone therapy are advised to take" exact="tamoxifen" post="every day during 5 years in order to reduce"/>
   <result pre="the treatment of HR+ metastatic BCs. Investigations have shown that" exact="tamoxifen" post="is effective in treating women with metastatic BCs; toremifene"/>
   <result pre="that tamoxifen is effective in treating women with metastatic BCs;" exact="toremifene" post="is also approved for this use. Fulvestrant can be"/>
   <result pre="Turner et al. [ 111] showed that the combination of" exact="palbociclib" post="(a CDK4 and CDK6 inhibitor) and fulvestrant to treat"/>
   <result pre="the combination of palbociclib (a CDK4 and CDK6 inhibitor) and" exact="fulvestrant" post="to treat advanced BCs has a better outcome than"/>
   <result pre="fulvestrant to treat advanced BCs has a better outcome than" exact="fulvestrant" post="used alone. Anastrozole and letrozole can be given to"/>
   <result pre="has a better outcome than fulvestrant used alone. Anastrozole and" exact="letrozole" post="can be given to postmenopausal women as initial therapy"/>
   <result pre="postmenopausal women with advanced BCs whose disease has worsened after" exact="tamoxifen" post="treatment. The use of hormone therapy to treat BC"/>
   <result pre="(bevacizumab, pertuzumab, trastuzumab), (ii) chemotherapy (doxorubicin, cyclophosphamide, paclitaxel, carboplatin, capecitabine," exact="doxorubicin" post="hydrochloride, filgrastim), and (iii) nanoparticles to improve BC treatment"/>
   <result pre="% of all therapies [ 193– 195]. As outlined above," exact="tamoxifen" post="is an anti-estrogenic drug used as adjuvant in the"/>
   <result pre="which brings out key roles of CYP2D6 and CYP3A4\5 in" exact="tamoxifen" post="bioactivation [ 199]. FDA recommends CYP2D6 genotyping upon tamoxifen"/>
   <result pre="in tamoxifen bioactivation [ 199]. FDA recommends CYP2D6 genotyping upon" exact="tamoxifen" post="administration in postmenopausal and premenopausal women [ 197, 201]"/>
   <result pre="endoxifen plasma concentration. Although the relationship between genetic polymorphisms and" exact="tamoxifen" post="pharmacokinetics or pharmacodynamics is well understood, the variability in"/>
   <result pre="observed inter-study heterogeneity, such as differences in the quantification of" exact="tamoxifen" post="and its metabolites, co-medications, administered dose, time on treatment,"/>
   <result pre="next generation sequencing PM precision medicine PPI protein-protein interaction PR" exact="progesterone" post="receptor SC stem cell T thymine TAM tumor-associated macrophages"/>
   <result pre="AD Effects of pharmacogenetics on the pharmacokinetics and pharmacodynamics of" exact="tamoxifen" post="Clin Pharmacokinet 2015 54 8 797 810 10.1007/s40262-015-0273-3 25940823"/>
   <result pre="Z Ward BA Soukhova NV Flockhart DA Comprehensive evaluation of" exact="tamoxifen" post="sequential biotransformation by the human cytochrome P450 system in"/>
   <result pre="Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of" exact="tamoxifen" post="Breast Cancer Res Treat 2004 85 2 151 159"/>
   <result pre="I Yu C Kasai Y Kemeny M et al. Increasing" exact="tamoxifen" post="dose in breast cancer patients based on CYP2D6 genotypes"/>
  </snippets>
 </snippetsTree>
</projectSnippetsTree>
